0001564590-22-006713.txt : 20220224 0001564590-22-006713.hdr.sgml : 20220224 20220224161705 ACCESSION NUMBER: 0001564590-22-006713 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 111 CONFORMED PERIOD OF REPORT: 20211231 FILED AS OF DATE: 20220224 DATE AS OF CHANGE: 20220224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Schrodinger, Inc. CENTRAL INDEX KEY: 0001490978 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 954284541 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39206 FILM NUMBER: 22671196 BUSINESS ADDRESS: STREET 1: 1540 BROADWAY STREET 2: 24TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 BUSINESS PHONE: 503-299-1150 MAIL ADDRESS: STREET 1: 1540 BROADWAY STREET 2: 24TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10036 10-K 1 sdgr-10k_20211231.htm 10-K sdgr-10k_20211231.htm
false FY --12-31 0001490978 true true true true true true true true P3Y true P30D 0 2023-06-30 0 P4Y7M28D P4Y5M26D P6Y18D P7Y8M1D P6Y9M 0001490978 2021-01-01 2021-12-31 xbrli:shares 0001490978 us-gaap:CommonStockMember 2022-02-18 0001490978 sdgr:LimitedCommonStockMember 2022-02-18 iso4217:USD 0001490978 2021-06-30 0001490978 2021-12-31 0001490978 2020-12-31 0001490978 sdgr:UnallocatedCommonStockMember 2021-12-31 0001490978 sdgr:UnallocatedCommonStockMember 2020-12-31 0001490978 sdgr:LimitedCommonStockMember 2021-12-31 0001490978 sdgr:LimitedCommonStockMember 2020-12-31 iso4217:USD xbrli:shares 0001490978 sdgr:SoftwareProductsAndServicesMember 2021-01-01 2021-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember 2020-01-01 2020-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember 2019-01-01 2019-12-31 0001490978 sdgr:DrugDiscoveryMember 2021-01-01 2021-12-31 0001490978 sdgr:DrugDiscoveryMember 2020-01-01 2020-12-31 0001490978 sdgr:DrugDiscoveryMember 2019-01-01 2019-12-31 0001490978 2020-01-01 2020-12-31 0001490978 2019-01-01 2019-12-31 0001490978 us-gaap:SeriesEPreferredStockMember 2018-12-31 0001490978 us-gaap:SeriesDPreferredStockMember 2018-12-31 0001490978 us-gaap:SeriesCPreferredStockMember 2018-12-31 0001490978 us-gaap:SeriesBPreferredStockMember 2018-12-31 0001490978 us-gaap:SeriesAPreferredStockMember 2018-12-31 0001490978 us-gaap:CommonStockMember 2018-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001490978 us-gaap:RetainedEarningsMember 2018-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001490978 2018-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001490978 us-gaap:SeriesEPreferredStockMember 2019-01-01 2019-12-31 0001490978 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001490978 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0001490978 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001490978 us-gaap:SeriesEPreferredStockMember 2019-12-31 0001490978 us-gaap:SeriesDPreferredStockMember 2019-12-31 0001490978 us-gaap:SeriesCPreferredStockMember 2019-12-31 0001490978 us-gaap:SeriesBPreferredStockMember 2019-12-31 0001490978 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001490978 us-gaap:CommonStockMember 2019-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001490978 us-gaap:RetainedEarningsMember 2019-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001490978 us-gaap:NoncontrollingInterestMember 2019-12-31 0001490978 2019-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001490978 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001490978 us-gaap:CommonStockMember us-gaap:IPOMember 2020-01-01 2020-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2020-01-01 2020-12-31 0001490978 us-gaap:IPOMember 2020-01-01 2020-12-31 0001490978 us-gaap:CommonStockMember sdgr:FollowOnOfferingMember 2020-01-01 2020-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember sdgr:FollowOnOfferingMember 2020-01-01 2020-12-31 0001490978 sdgr:FollowOnOfferingMember 2020-01-01 2020-12-31 0001490978 us-gaap:SeriesEPreferredStockMember 2020-01-01 2020-12-31 0001490978 us-gaap:SeriesDPreferredStockMember 2020-01-01 2020-12-31 0001490978 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-12-31 0001490978 us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-12-31 0001490978 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-12-31 0001490978 sdgr:LimitedCommonStockMember 2020-01-01 2020-12-31 0001490978 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001490978 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001490978 us-gaap:CommonStockMember 2020-12-31 0001490978 sdgr:LimitedCommonStockMember 2020-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001490978 us-gaap:RetainedEarningsMember 2020-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001490978 us-gaap:NoncontrollingInterestMember 2020-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001490978 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001490978 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001490978 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001490978 us-gaap:CommonStockMember 2021-12-31 0001490978 sdgr:LimitedCommonStockMember 2021-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001490978 us-gaap:RetainedEarningsMember 2021-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001490978 us-gaap:NoncontrollingInterestMember 2021-12-31 0001490978 us-gaap:CommonStockMember us-gaap:IPOMember 2020-02-10 2020-02-10 0001490978 us-gaap:CommonStockMember us-gaap:IPOMember 2020-02-10 0001490978 us-gaap:CommonStockMember 2020-02-10 2020-02-10 0001490978 us-gaap:ConvertiblePreferredStockMember 2020-02-10 2020-02-10 0001490978 us-gaap:ConvertiblePreferredStockMember 2020-02-09 2020-02-09 0001490978 sdgr:LimitedCommonStockMember 2020-02-09 2020-02-09 0001490978 us-gaap:CommonStockMember sdgr:FollowOnPublicOfferingMember 2020-08-17 2020-08-17 0001490978 us-gaap:CommonStockMember sdgr:FollowOnPublicOfferingMember 2020-08-17 0001490978 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2020-08-17 2020-08-17 0001490978 us-gaap:CommonStockMember 2020-08-17 2020-08-17 0001490978 us-gaap:AccountingStandardsUpdate202001Member 2021-03-31 0001490978 us-gaap:AccountingStandardsUpdate201815Member 2021-12-31 0001490978 us-gaap:AccountingStandardsUpdate201613Member 2021-01-01 0001490978 sdgr:AccountingStandardsUpdate202108Member 2021-12-31 0001490978 srt:MinimumMember 2021-01-01 2021-12-31 0001490978 srt:MaximumMember 2021-01-01 2021-12-31 sdgr:Customer 0001490978 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2021-01-01 2021-12-31 0001490978 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember 2020-01-01 2020-12-31 xbrli:pure 0001490978 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember sdgr:CustomerAMember 2021-01-01 2021-12-31 0001490978 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember sdgr:CustomerAMember 2020-01-01 2020-12-31 0001490978 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember sdgr:CustomerBMember 2021-01-01 2021-12-31 0001490978 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember sdgr:CustomerBMember 2020-01-01 2020-12-31 0001490978 us-gaap:CustomerConcentrationRiskMember us-gaap:AccountsReceivableMember sdgr:CustomerCMember 2021-01-01 2021-12-31 0001490978 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2021-01-01 2021-12-31 0001490978 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2020-01-01 2020-12-31 0001490978 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-12-31 0001490978 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember sdgr:CustomerAMember 2021-01-01 2021-12-31 0001490978 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember sdgr:CustomerAMember 2020-01-01 2020-12-31 0001490978 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember sdgr:CustomerAMember 2019-01-01 2019-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-12-31 0001490978 sdgr:DrugDiscoveryMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-12-31 0001490978 sdgr:DrugDiscoveryMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-12-31 0001490978 sdgr:DrugDiscoveryMember us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-12-31 0001490978 sdgr:DrugDiscoveryMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0001490978 sdgr:DrugDiscoveryMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0001490978 sdgr:DrugDiscoveryMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-12-31 0001490978 sdgr:OnPremiseSoftwareMember 2022-01-01 2021-12-31 0001490978 sdgr:OnPremiseSoftwareMember 2021-01-01 2021-12-31 0001490978 sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember 2021-01-01 2021-12-31 0001490978 srt:MaximumMember sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember 2021-01-01 2021-12-31 0001490978 sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember sdgr:FirstAnniversaryMember 2020-04-01 2020-06-30 0001490978 sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember sdgr:FirstAnniversaryMember 2021-04-01 2021-06-30 0001490978 sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember sdgr:SecondAnniversaryMember 2021-01-01 2021-12-31 0001490978 sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember 2021-12-31 0001490978 sdgr:OnPremiseSoftwareMember 2020-01-01 2020-12-31 0001490978 sdgr:OnPremiseSoftwareMember 2019-01-01 2019-12-31 0001490978 sdgr:HostedSoftwareMember 2021-01-01 2021-12-31 0001490978 sdgr:HostedSoftwareMember 2020-01-01 2020-12-31 0001490978 sdgr:HostedSoftwareMember 2019-01-01 2019-12-31 0001490978 us-gaap:MaintenanceMember 2021-01-01 2021-12-31 0001490978 us-gaap:MaintenanceMember 2020-01-01 2020-12-31 0001490978 us-gaap:MaintenanceMember 2019-01-01 2019-12-31 0001490978 sdgr:ProfessionalServicesMember 2021-01-01 2021-12-31 0001490978 sdgr:ProfessionalServicesMember 2020-01-01 2020-12-31 0001490978 sdgr:ProfessionalServicesMember 2019-01-01 2019-12-31 0001490978 sdgr:RevenueFromContractWithCustomerBeforeSoftwareContributionMember 2021-01-01 2021-12-31 0001490978 sdgr:RevenueFromContractWithCustomerBeforeSoftwareContributionMember 2020-01-01 2020-12-31 0001490978 sdgr:RevenueFromContractWithCustomerBeforeSoftwareContributionMember 2019-01-01 2019-12-31 0001490978 sdgr:SoftwareContributionMember 2021-01-01 2021-12-31 0001490978 sdgr:SoftwareContributionMember 2020-01-01 2020-12-31 0001490978 sdgr:DrugDiscoveryServicesMember 2021-01-01 2021-12-31 0001490978 sdgr:DrugDiscoveryServicesMember 2020-01-01 2020-12-31 0001490978 sdgr:DrugDiscoveryServicesMember 2019-01-01 2019-12-31 0001490978 sdgr:DrugDiscoveryContributionMember 2021-12-31 0001490978 sdgr:DrugDiscoveryServicesRevenueFromContractsWithCustomersMember 2021-01-01 2021-12-31 0001490978 sdgr:DrugDiscoveryServicesRevenueFromContractsWithCustomersMember 2020-01-01 2020-12-31 0001490978 sdgr:DrugDiscoveryServicesRevenueFromContractsWithCustomersMember 2019-01-01 2019-12-31 0001490978 sdgr:DrugDiscoveryContributionMember 2021-01-01 2021-12-31 0001490978 sdgr:CollaborationAndLicenseAgreementMember sdgr:BristolMyersSquibbMember 2020-11-22 2020-11-22 0001490978 sdgr:CollaborationAndLicenseAgreementMember sdgr:BristolMyersSquibbMember 2020-11-22 0001490978 sdgr:CollaborationAndLicenseAgreementMember sdgr:BristolMyersSquibbMember sdgr:OncologyProductMember 2020-11-22 0001490978 sdgr:CollaborationAndLicenseAgreementMember sdgr:BristolMyersSquibbMember sdgr:NeurologyAndImmunologyProductMember 2020-11-22 sdgr:Program 0001490978 sdgr:CollaborationAndLicenseAgreementMember sdgr:BristolMyersSquibbMember 2021-01-01 2021-12-31 0001490978 sdgr:CollaborationAndLicenseAgreementMember sdgr:BristolMyersSquibbMember 2020-01-01 2020-12-31 0001490978 sdgr:CollaborationAndLicenseAgreementMember sdgr:BristolMyersSquibbMember 2021-12-31 0001490978 sdgr:CollaborationAndLicenseAgreementMember sdgr:BristolMyersSquibbMember 2020-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember 2021-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember 2020-12-31 0001490978 sdgr:DrugDiscoveryMember 2021-12-31 0001490978 sdgr:DrugDiscoveryMember 2020-12-31 0001490978 us-gaap:ComputerEquipmentMember 2021-12-31 0001490978 us-gaap:ComputerEquipmentMember 2020-12-31 0001490978 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001490978 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001490978 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001490978 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001490978 us-gaap:SecuritiesAssetsMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001490978 us-gaap:SecuritiesAssetsMember 2021-12-31 0001490978 us-gaap:EquityMethodInvestmentsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001490978 us-gaap:EquityMethodInvestmentsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001490978 us-gaap:EquityMethodInvestmentsMember 2021-12-31 0001490978 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001490978 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001490978 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001490978 us-gaap:SecuritiesAssetsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001490978 us-gaap:SecuritiesAssetsMember 2020-12-31 0001490978 us-gaap:EquityMethodInvestmentsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001490978 us-gaap:EquityMethodInvestmentsMember 2020-12-31 0001490978 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001490978 us-gaap:FairValueInputsLevel2Member 2020-12-31 sdgr:OperatingLease sdgr:SquareFoot 0001490978 sdgr:OfficeLeaseAgreementMember 2021-11-01 2021-11-01 0001490978 sdgr:OfficeLeaseAgreementMember 2021-11-01 0001490978 sdgr:OfficeLeaseAgreementMember 2021-11-30 2021-11-30 0001490978 sdgr:OfficeLeaseAgreementMember 2021-11-30 0001490978 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001490978 us-gaap:DomesticCountryMember 2021-12-31 0001490978 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001490978 sdgr:VotingCommonStockMember 2021-12-31 sdgr:Vote 0001490978 sdgr:VotingCommonStockMember 2021-01-01 2021-12-31 0001490978 sdgr:LimitedCommonStockMember 2021-01-01 2021-12-31 0001490978 sdgr:TwoThousandTenStockPlanMember 2021-12-31 0001490978 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-12-31 0001490978 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-01 2021-12-31 0001490978 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-01-01 2021-12-31 0001490978 sdgr:SharebasedCompensationAwardTrancheFourMember 2021-01-01 2021-12-31 0001490978 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001490978 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001490978 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001490978 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001490978 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001490978 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001490978 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0001490978 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-12-31 0001490978 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-12-31 0001490978 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001490978 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001490978 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001490978 sdgr:FaxianTherapeuticsLLCJointVentureMember us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2019-04-30 0001490978 sdgr:FaxianTherapeuticsLLCJointVentureMember us-gaap:CoVenturerMember 2019-04-30 0001490978 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001490978 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001490978 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001490978 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001490978 sdgr:NimbusTherapeuticsLLCMember 2021-12-31 0001490978 sdgr:NimbusTherapeuticsLLCMember 2020-12-31 0001490978 sdgr:NimbusTherapeuticsLLCMember 2021-01-01 2021-12-31 0001490978 sdgr:NimbusTherapeuticsLLCMember 2020-01-01 2020-12-31 0001490978 sdgr:NimbusTherapeuticsLLCMember 2019-01-01 2019-12-31 0001490978 sdgr:MorphicHoldingIncMember 2021-01-01 2021-12-31 0001490978 sdgr:MorphicHoldingIncMember 2020-01-01 2020-12-31 0001490978 sdgr:MorphicHoldingIncMember 2019-01-01 2019-12-31 0001490978 sdgr:MorphicHoldingIncMember 2021-12-31 0001490978 sdgr:MorphicHoldingIncMember 2020-12-31 0001490978 sdgr:PetraPharmaCorporationMember 2021-05-01 2021-05-31 0001490978 sdgr:PetraPharmaCorporationMember 2021-05-31 0001490978 sdgr:RavennaTherapeuticsMember 2021-01-01 2021-12-31 0001490978 sdgr:RavennaTherapeuticsMember 2021-12-31 0001490978 sdgr:RavennaTherapeuticsMember 2020-12-31 0001490978 sdgr:RavennaTherapeuticsMember 2020-01-01 2020-12-31 0001490978 sdgr:RavennaTherapeuticsMember 2019-01-01 2019-12-31 0001490978 sdgr:RelayTherapeuticsIncMember 2021-01-01 2021-01-31 0001490978 sdgr:RelayTherapeuticsIncMember 2021-01-01 2021-12-31 0001490978 sdgr:RelayTherapeuticsIncMember 2020-01-01 2020-12-31 0001490978 sdgr:RelayTherapeuticsIncMember 2019-01-01 2019-12-31 0001490978 sdgr:AjaxTherapeuticsIncMember us-gaap:SeriesBPreferredStockMember 2021-05-01 2021-05-31 0001490978 sdgr:AjaxTherapeuticsIncMember 2021-12-31 0001490978 sdgr:AjaxTherapeuticsIncMember 2020-12-31 0001490978 sdgr:ShouTiIncMember us-gaap:SeriesBPreferredStockMember 2021-07-01 2021-07-31 0001490978 sdgr:ShouTiIncMember 2021-12-31 0001490978 sdgr:ShouTiIncMember 2020-12-31 0001490978 sdgr:ShouTiIncMember 2021-01-01 2021-12-31 0001490978 sdgr:DavidEShawMember 2021-01-01 2021-12-31 0001490978 sdgr:DavidEShawMember 2020-01-01 2020-12-31 0001490978 sdgr:DavidEShawMember 2019-01-01 2019-12-31 0001490978 sdgr:DavidEShawMember 2021-12-31 0001490978 sdgr:DavidEShawMember 2020-12-31 0001490978 sdgr:MembersOfBoardOfDirectorsMember 2021-01-01 2021-12-31 0001490978 sdgr:MembersOfBoardOfDirectorsMember 2020-01-01 2020-12-31 0001490978 sdgr:MembersOfBoardOfDirectorsMember 2019-01-01 2019-12-31 0001490978 sdgr:BillAndMelindaGatesFoundationTrustMember 2021-01-01 2021-12-31 0001490978 sdgr:BillAndMelindaGatesFoundationTrustMember 2020-01-01 2020-12-31 0001490978 sdgr:BillAndMelindaGatesFoundationTrustMember 2019-01-01 2019-12-31 0001490978 sdgr:BillAndMelindaGatesFoundationTrustMember 2021-12-31 0001490978 sdgr:BillAndMelindaGatesFoundationTrustMember 2020-12-31 0001490978 sdgr:BillAndMelindaGatesFoundationTrustMember sdgr:DrugDiscoveryContributionMember 2021-10-01 2021-12-31 0001490978 sdgr:BillAndMelindaGatesFoundationTrustMember sdgr:DrugDiscoveryContributionMember 2021-12-31 0001490978 sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember 2020-12-31 0001490978 sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember srt:MinimumMember 2021-12-31 0001490978 sdgr:ShouTiIncMember 2021-01-01 2021-12-31 sdgr:segment 0001490978 us-gaap:OperatingSegmentsMember sdgr:SoftwareSegmentMember 2021-01-01 2021-12-31 0001490978 us-gaap:OperatingSegmentsMember sdgr:SoftwareSegmentMember 2020-01-01 2020-12-31 0001490978 us-gaap:OperatingSegmentsMember sdgr:SoftwareSegmentMember 2019-01-01 2019-12-31 0001490978 us-gaap:OperatingSegmentsMember sdgr:DrugDiscoverySegmentMember 2021-01-01 2021-12-31 0001490978 us-gaap:OperatingSegmentsMember sdgr:DrugDiscoverySegmentMember 2020-01-01 2020-12-31 0001490978 us-gaap:OperatingSegmentsMember sdgr:DrugDiscoverySegmentMember 2019-01-01 2019-12-31 0001490978 country:US 2021-01-01 2021-12-31 0001490978 country:US 2020-01-01 2020-12-31 0001490978 country:US 2019-01-01 2019-12-31 0001490978 srt:EuropeMember 2021-01-01 2021-12-31 0001490978 srt:EuropeMember 2020-01-01 2020-12-31 0001490978 srt:EuropeMember 2019-01-01 2019-12-31 0001490978 country:JP 2021-01-01 2021-12-31 0001490978 country:JP 2020-01-01 2020-12-31 0001490978 country:JP 2019-01-01 2019-12-31 0001490978 us-gaap:NonUsMember 2021-01-01 2021-12-31 0001490978 us-gaap:NonUsMember 2020-01-01 2020-12-31 0001490978 us-gaap:NonUsMember 2019-01-01 2019-12-31 0001490978 us-gaap:SubsequentEventMember sdgr:XTALBioStructuresIncorporationMember 2022-01-14 2022-01-14

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-K

 

(Mark One)

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2021

OR

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM                      TO                     

Commission File Number 001-39206

 

Schrodinger, Inc.

(Exact name of Registrant as specified in its Charter)

 

 

Delaware

95-4284541

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

1540 Broadway, 24th Floor

New York, NY

10036

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (212) 295-5800

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

Common stock, par value $0.01 per share

 

SDGR

 

The Nasdaq Stock Market LLC

Securities registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐

Indicate by check mark if the Registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.  Yes ☐ No ☒

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐

Indicate by check mark whether the Registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files).  Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

☒

  

Accelerated filer

 

☐

 

 

 

 

Non-accelerated filer

 

☐

  

Smaller reporting company

 

☐

 

 

 

 

 

 

 

Emerging growth company

 

☐

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐ No ☒

As of June 30, 2021, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the voting and non-voting common equity held by non-affiliates of the registrant was $3,519,898,945 based upon the closing sale price of the registrant’s common stock on that date.

As of February 18, 2022, the registrant had 61,873,343 shares of common stock and 9,164,193 shares of limited common stock outstanding.

DOCUMENTS INCORPORATED BY REFERENCE

The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2022 Annual Meeting of Stockholders within 120 days of the end of the registrant’s fiscal year ended December 31, 2021. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.

 

Auditor Firm Id:

185

Auditor Name:

KPMG LLP

Auditor Location:

Portland, OR

 

 

 

 

 

Table of Contents

 

 

 

 

Page

PART I

 

 

 

Item 1.

Business

 

6

Item 1A.

Risk Factors

 

51

Item 1B.

Unresolved Staff Comments

 

87

Item 2.

Properties

 

87

Item 3.

Legal Proceedings

 

87

Item 4.

Mine Safety Disclosures

 

87

 

 

 

 

PART II

 

 

 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

 

88

Item 6.

[Reserved]

 

89

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

 

90

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

 

112

Item 8.

Financial Statements and Supplementary Data

 

112

Item 9.

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

 

113

Item 9A.

Controls and Procedures

 

113

Item 9B.

Other Information

 

114

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

 

114

 

 

 

 

PART III

 

 

 

Item 10.

Directors, Executive Officers and Corporate Governance

 

115

Item 11.

Executive Compensation

 

115

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

115

Item 13.

Certain Relationships and Related Transactions, and Director Independence

 

115

Item 14.

Principal Accountant Fees and Services

 

115

 

 

 

 

PART IV

 

 

 

Item 15.

Exhibits and Financial Statement Schedules

 

116

Item 16.

Form 10-K Summary

 

119

 

 

 

 

 

Table of Contents

 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA

This Annual Report on Form 10-K, or this Annual Report, contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act and Section 21E of the Securities Exchange Act of 1934, as amended, that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this Annual Report, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” or the negative of these words or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The forward-looking statements in this Annual Report include, among other things, statements about:

 

•

the potential advantages of our physics-based computational platform;

 

•

our strategic plans to accelerate the growth of our software business;

 

•

our research and development efforts for our internal drug discovery programs and our computational platform;

 

•

the initiation, timing, progress, and results of our internal drug discovery programs or the drug discovery programs of our collaborators;

 

•

our plans to submit investigational new drug applications to the U.S. Food and Drug Administration for our internal drug discovery programs;

 

•

our plans to discover and develop product candidates and to maximize their commercial potential by advancing such product candidates ourselves or in collaboration with others;

 

•

our plans to leverage the synergies between our businesses;

 

•

the timing of, the ability to submit applications for and the ability to obtain and maintain regulatory approvals for any product candidates we or one of our collaborators may develop;

 

•

our drug discovery collaborations and our estimates or expectations regarding any milestone or other payments we may receive from such collaborations, including pursuant to our collaboration with Bristol-Myers Squibb Company;

 

•

our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with our cash, cash equivalents, and marketable securities;

 

•

the potential advantages of our drug discovery programs;

 

•

the rate and degree of market acceptance of our software solutions;

 

•

the potential continued impact of the COVID-19 pandemic on our business, operations, liquidity and prospects;

 

•

the rate and degree of market acceptance and clinical utility of our products;

 

•

our estimates regarding the potential market opportunity for our software solutions and any product candidate we or any of our collaborators may in the future develop;

 

•

our marketing capabilities and strategy;

 

•

our intellectual property position;

 

•

our ability to identify technologies with significant commercial potential that are consistent with our commercial objectives;

 

•

our expectations related to the use of our cash, cash equivalents, and marketable securities;

 

•

our expectations related to the key drivers of our performance;

 

•

the impact of government laws and regulations;

 

•

our competitive position and expectations regarding developments and projections relating to our competitors and any competing products, technologies, or therapies that are or become available;

 

•

our ability to maintain and establish collaborations or obtain additional funding; and

 

•

our reliance on key personnel and our ability to identify, recruit, and retain skilled personnel.

2

Table of Contents

 

 

We may not actually achieve the plans, intentions, or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions, and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report, particularly in “Risk Factor Summary” below and “Risk Factors”, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Moreover, we operate in a competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures, or investments we may make or enter into.

You should read this Annual Report and the documents that we file with the Securities and Exchange Commission, or the SEC, with the understanding that our actual future results may be materially different from what we expect. The forward-looking statements contained in this Annual Report are made as of the date of this Annual Report, and we do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this Annual Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements.

This Annual Report includes statistical and other industry and market data that we obtained from industry publications and research, surveys, and studies conducted by third parties as well as our own estimates of potential market opportunities. All of the market data used in this Annual Report involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data. Industry publications and third-party research, surveys, and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. Our estimates of the potential market opportunities for our product candidates include several key assumptions based on our industry knowledge, industry publications, third-party research, and other surveys, which may be based on a small sample size and may fail to accurately reflect market opportunities. While we believe that our internal assumptions are reasonable, no independent source has verified such assumptions.

Unless the context otherwise requires, we use the terms “company,” “we,” “us” and “our” in this Annual Report to refer to Schrödinger, Inc. and its consolidated subsidiaries.

3

Table of Contents

 

RISK FACTOR SUMMARY

Our business is subject to a number of risks of which you should be aware before making an investment decision. Below we summarize what we believe are the principal risk factors but these risks are not the only ones we face, and you should carefully review and consider the full discussion of our risk factors in the section titled “Risk Factors”, together with the other information in this Annual Report.

 

•

We have a history of significant operating losses, and we expect to incur losses over the next several years.

 

•

If we are unable to increase sales of our software, or if we and our current and future collaborators are unable to successfully develop and commercialize drug products, our revenues may be insufficient for us to achieve or maintain profitability.

 

•

Our quarterly and annual results may fluctuate significantly, which could adversely impact the value of our common stock.

 

•

If our existing customers do not renew their licenses, do not buy additional solutions from us, or renew at lower prices, our business and operating results will suffer.

 

•

A significant portion of our revenues are generated by sales to life sciences industry customers, and factors that adversely affect this industry could also adversely affect our software sales.

 

•

The markets in which we participate are highly competitive, and if we do not compete effectively, our business and operating results could be adversely affected.

 

•

We may never realize a return on our investment of resources and cash in our drug discovery collaborations.

 

•

Although we believe that our computational platform has the potential to identify more promising molecules than traditional methods and to accelerate drug discovery, our focus on using our platform technology to discover and design molecules with therapeutic potential may not result in the discovery and development of commercially viable products for us or our collaborators.

 

•

As a company, we do not have any experience in clinical development and have not advanced any product candidate into clinical development.

 

•

We may not be successful in our efforts to identify, discover or develop product candidates and may fail to capitalize on programs, collaborations, or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.

 

•

Conducting successful clinical trials requires the enrollment of a sufficient number of patients, and suitable patients may be difficult to identify and recruit.

 

•

A widespread outbreak of an illness or other health issue, such as the COVID-19 pandemic, could negatively affect various aspects of our business and make it more difficult to meet our obligations to our customers, and could result in reduced demand from our customers as well as delays in our drug discovery and development programs.

 

•

If we fail to comply with our obligations under our existing license agreements with Columbia University, under any of our other intellectual property licenses, or under any future intellectual property licenses, or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.

 

•

If we are unable to obtain, maintain, enforce, and protect patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.

 

•

Our internal information technology systems, or those of our third-party vendors, contractors, or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our services, compromise sensitive information related to our business, or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.

 

•

Our future success depends on our ability to retain key executives and to attract, retain, and motivate qualified personnel.

 

•

We are pursuing multiple business strategies and expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our multiple business units and our growth, which could disrupt our operations.

4

Table of Contents

 

 

•

Our executive officers, directors, and principal stockholders, if they choose to act together, have the ability to influence all matters submitted to stockholders for approval.

 

•

Our actual operating results may differ significantly from our guidance.

5

Table of Contents

 

 

PART I

Item 1. Business.

Overview

We are transforming the way therapeutics and materials are discovered.

Our differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly, at lower cost, and with, we believe, a higher likelihood of success compared to traditional methods. Our software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Our multidisciplinary drug discovery team also leverages our software platform to advance collaborative drug discovery and development programs and our own pipeline of novel therapeutics to address unmet medical needs.

Traditional drug discovery and development efforts have become increasingly complex, lengthy, capital-intensive, and are prone to high failure rates. Traditional drug discovery relies upon many rounds of costly and time-consuming manual molecule design, chemical synthesis, and experimental testing. One of the primary reasons for long timelines, high costs, and high failure rates in drug discovery is that predicting properties of molecules in advance of chemical synthesis is extremely complex and not amenable to traditional approaches.

Over the past several decades and with the concerted efforts of hundreds of our scientists and software engineers, we have developed a physics-based computational platform that is capable of predicting critical properties of molecules with a high degree of accuracy. This key capability enables drug discovery teams to design and selectively synthesize molecules with more optimal properties, reducing the average time and costs required to identify a development candidate and increasing the probability that a drug discovery program will enter clinical development. Furthermore, we believe that development candidates with more optimized property profiles will have a higher probability of success in clinical development. Additionally, since the physics underlying the properties of drug molecules and materials is the same, we have been able to extend our computational platform to materials science applications in fields such as aerospace, energy, semiconductors, and electronic displays.

We offer our customers a variety of software solutions that accelerate all stages of molecule discovery, design, and optimization. In 2021, all of the top 20 pharmaceutical companies, measured by 2020 revenue, licensed our solutions, accounting for $42.0 million, or 37%, of our software revenue in 2021. The widespread adoption of our software, supported by our global team of sales, technical, and scientific personnel, has driven steady growth in our software revenue. Biopharmaceutical companies are increasingly adopting our software at a larger scale, and we anticipate this scaling-up will drive future revenue growth. Our ability to expand within our customer base is demonstrated by the increasing number of our customers with an annual contract value, or ACV, in excess of $100,000. We had 190, 153, and 131 such customers, which represented 80%, 79%, and 78% of our total ACV, for the years ended December 31, 2021, 2020, and 2019, respectively. In addition, our customer retention rate for our customers with an ACV over $100,000 for the year ended December 31, 2021 was 98% and was 96% or higher for each of the previous eight fiscal years. We believe the growth in the number of our customers demonstrates that companies are increasingly recognizing the power and efficiency of our platform while the retention in this group is indicative of the continued value of our platform. See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Key Factors Affecting Our Performance” for additional information regarding ACV and customer retention rate.

We also leverage our platform and capabilities across a portfolio of collaborative and internal drug discovery programs spanning a wide range of disease targets and indications. Our drug discovery group is comprised of a multidisciplinary team of over 100 experts in protein science, biochemistry, biophysics, medicinal and computational chemistry, and discovery scientists with expertise in preclinical and early clinical development. During the year ended December 31, 2021, we collaborated on more than 20 drug discovery programs with more than ten different biopharmaceutical companies. These collaborations generate drug discovery revenue, including upfront payments, research funding payments, and discovery and development milestones, and have the potential to produce additional milestone payments, option fees, and future royalties.

Furthermore, in mid-2018, we launched a pipeline of internal, wholly-owned programs with the goal of rapidly advancing the discovery of best-in-class and first-in-class therapies. Our initial programs are focused on discovering and developing inhibitors for targets in DNA damage response pathways and genetically defined cancers. Since then, we have expanded into other therapeutic areas, including in the areas of immunology and neurology. We continue to advance multiple internal programs through investigational new drug, or IND, -enabling studies. We expect to submit an IND application to the U.S. Food and Drug Administration, or FDA, for our MALT1 program in the first half of 2022, and subject to receiving regulatory clearance, we expect to initiate a Phase 1 clinical trial of our MALT1 inhibitor in patients with relapsed and resistant lymphoma in the second half of 2022. We also plan to submit IND applications to the FDA for our CDC7 program in early 2023 and our WEE1 program in 2023, subject to

6

Table of Contents

 

favorable data from IND-enabling studies. In addition, we plan to initiate a Phase 1 clinical trial of our CDC7 inhibitor in 2023, subject to receipt of regulatory clearance. While our revenue-generating collaborations are an important component of our business, our strategy is to pursue an increasing number of wholly-owned programs and strategically evaluate on a program-by-program basis entering into clinical development ourselves, entering into collaborations, or out-licensing programs to maximize commercial opportunities.

As part of this strategy, in November 2020, we entered into an exclusive, worldwide collaboration and license agreement with Bristol-Myers Squibb Company, or BMS, pursuant to which we and BMS agreed to collaborate in the discovery, research and development of small molecule compounds for biological targets in the oncology, neurology and immunology therapeutic areas. The initial collaboration targets included HIF-2 alpha and SOS1/KRAS, which were two of our internal pipeline programs. In November 2021, we and BMS mutually agreed to replace the HIF-2 alpha target with another precision oncology target. Following the replacement election, all rights to the HIF-2 alpha target program reverted to us. Under the terms of the agreement, we received a $55.0 million upfront payment from BMS, and we are eligible to receive up to $2.7 billion in total milestones from BMS across all potential targets, as well as a tiered percentage royalty on net sales of each product commercialized by BMS ranging from mid-single digits to low-double digits, subject to certain specified reductions. See “—Collaboration Agreement with Bristol-Myers Squibb Company” for additional information relating to this agreement.

We generated revenue of $137.9 million, $108.1 million, and $85.5 million in 2021, 2020, and 2019, respectively, representing year-over-year growth of 28% and 26%, respectively. Our net loss was $101.2 million, $26.6 million, and $25.7 million for the years ended December 31, 2021, 2020, and 2019, respectively.

Strategy

Our mission is to improve human health and quality of life by transforming the way therapeutics and materials are discovered. Our physics-based approach and differentiated software solutions enable the discovery of novel molecules for drug development and materials applications more rapidly, at lower cost, and with, we believe, a higher likelihood of success compared to traditional methods.

 

•

Advancing the science that underlies our computational platform: We have emerged as the leader in the field of physics-based computational drug discovery, and we believe our computational platform is far ahead of that of our nearest competitors.   We intend to maintain our industry-leading position by introducing new capabilities and refining our software to further strengthen our technology and advance the science underlying our platform.

 

•

Growing and expanding our software business: We have experienced steady growth in our software revenues, achieving $113.2 million in revenue in 2021, an increase of 22% compared to 2020, primarily driven by broad adoption of our software solutions by the biopharmaceutical industry and the expansion of our materials science business.

 

▪

Life science software business: In 2021, all of the top 20 pharmaceutical companies, measured by 2020 revenue, licensed our solutions, accounting for $42.0 million, or 37%, of our software revenue in 2021. However, we estimate that many of our largest customers are currently purchasing only enough software to optimally enable only a small portion of their drug discovery projects, which typically represents a small fraction of their drug discovery projects. Our ability to expand within our customer base is demonstrated by the increasing number of our customers with an ACV of over $100,000. We had 190, 153, and 131 such customers for the years ended December 31, 2021, 2020, and 2019, respectively. In addition, we had 15, 16, and 10 customers for the years ended December 31, 2021, 2020, and 2019, respectively, with an ACV of over $1.0 million. We intend to leverage our existing relationships with our customers to drive larger-scale adoption of our solutions. Further, we believe there remains a large opportunity for growth as there are thousands of biopharmaceutical companies that could benefit from our solutions.

 

▪

Materials science software business: Beyond drug discovery, our solutions can be leveraged for broad application to address industrial challenges in molecule design, including in the fields of aerospace, energy, semiconductors and electronic displays. We intend to continue growing this business through increased brand awareness and a build-out of industry-specific functionality.

 

•

Accelerating growth of our drug discovery business: We also apply our computational platform across a diversified portfolio of drug discovery programs through collaborations with biopharmaceutical companies, and through our own efforts on internal programs. Our collaborations generate revenues through upfront payments, research funding, preclinical and clinical milestones as well as the potential for option fees, commercial milestones, and future royalties. We also benefit from equity positions in certain of our collaborators

 

▪

We are actively working with our collaborators to discover novel therapies. We also intend to add new collaborations that offer scientific synergies and favorable economic terms.

7

Table of Contents

 

 

▪

We plan to progress our existing internal programs, including our MALT1, CDC7 and WEE1 inhibitor programs, and continue to add new programs that leverage our computational platform. As we progress these programs, we will strategically evaluate on a program-by-program basis entering into preclinical and clinical development ourselves, entering into collaborations, or out-licensing programs to maximize commercial opportunities.

 

•

Leveraging the synergies between our businesses: We believe that there are significant synergies within our business. We leverage the feedback that we receive from our software customers, collaborators, and internal drug discovery experts to improve the functionality of our platform, which we believe supports increased customer adoption of our solutions and more rapid advancement of our collaborative and internal drug discovery programs. In addition, the success of our collaborators in advancing drug discovery programs provides significant validation of our platform and approach, which we believe increases the attractiveness of our platform to customers, helps us establish new collaborations, and validates the potential of our own internal drug discovery programs.

 

Central to our ability to pursue these distinct lines of business is a firewall policy consisting of a set of well-established protocols and technology measures designed to ensure that the intellectual property of our software customers and drug discovery collaborators remains confidential and segregated.

Industry Overview

Traditional drug discovery and development efforts have become increasingly complex, lengthy, capital-intensive, and are prone to high failure rates. Traditional drug discovery involves experimental screening of existing libraries of molecules to find molecules with detectable activity, or “hit molecules,” followed by many rounds of chemical synthesis to attempt to optimize those hit molecules to a development candidate that can be advanced into clinical development. Efforts to optimize initial hit molecules for a drug discovery project involve costly and iterative synthesis and testing of molecules seeking to identify a molecule with the required property profile. The optimal profile has the acceptable balance of properties such as potency, selectivity, solubility, bioavailability, half-life, permeability, drug-drug interaction potential, synthesizability, and toxicity. These properties are often inversely correlated, meaning that optimizing one property often de-optimizes others. The challenge of optimizing hit molecules is amplified by the limited number of molecules that can be feasibly tested across these properties with traditional methods. As a result, this optimization process often fails to yield a molecule with a satisfactory property profile to be a development candidate, which is why many drug discovery programs fail to advance into clinical development.

The traditional approach to drug discovery takes too long, is too prone to failure, and is too costly. Successfully reaching an IND application filing requires on average five to six years, and the average success rates suggest two out of three projects will fail. Accounting for such failures, the industry average cost to complete a successful IND filing is $35 million.

A typical drug discovery project only has the budget and time to synthesize and assay fewer than 10,000 molecules, because the cost and timelines associated with interrogating a greater number of molecules is impractical. This small sampling of molecules

8

Table of Contents

 

represents a minuscule fraction of the total number of molecules that could potentially be synthesized. Exploring such a limited number of molecules reduces the likelihood of identifying molecules with the desired property profile, which we believe leads to development candidates with higher failure rates.

Being able to predict molecular properties before initiating costly and time-consuming experimental synthesis would accelerate drug discovery, reduce costs, and increase the probability of success. If it were possible to accurately predict critical properties of molecules, fewer molecules would have to be experimentally synthesized and tested. As a result, larger pools of molecules could be analyzed allowing for more selective synthesis of molecules, leading to higher-quality molecules. In addition, with predictive computational methods, better selections of molecules would be synthesized through exploration of larger portions of chemical space, leading to higher-quality molecules that would in turn have a higher probability of progressing through clinical development and obtaining regulatory approval for commercial sale.

There have been many attempts to improve the efficiency of the drug discovery process by using computational methods to predict properties of molecules. One of the primary computational methods that many companies have attempted to deploy is machine learning, often referred to as artificial intelligence, or AI. One of the main benefits of machine learning is its ability to rapidly process data at scale. However, machine learning on its own has significant limitations and has therefore had a limited impact on improving the efficiency of the drug discovery process. Machine learning requires input data, referred to as a training set, to build a predictive model. This model is expected to accurately predict properties of molecules similar to the training set, but cannot extrapolate to molecules that are not similar to the training set. Accordingly, since the number of possible molecules that could be synthesized is effectively infinite, machine learning can only cover a minuscule fraction of the total number of molecules that could potentially be synthesized.

The other primary computational method that has been attempted involves using fundamental, “first-principles” physics-based methods, which require a deep and thorough understanding of the specific property to be computed. However, physics-based methods are difficult to develop and can be slow compared to machine learning. Further, to apply such methods to design molecules that will bind with high affinity to a particular protein target, the three-dimensional structure of that protein must be generated with sufficient atomic detail to enable application of these physics-based approaches, which is referred to as being “structurally enabled,” and such structures have been historically difficult to obtain. Another factor preventing computational chemistry from realizing its promise has been limited compute speed. However, despite all of these challenges, physics-based methods have a significant advantage over machine learning in that they do not require a training set and can, in principle, compute properties for any molecule.

Our Platform

Over the past several decades and with the concerted effort of hundreds of our scientists and software engineers, we have developed a computational platform that is capable of predicting critical properties of molecules with a high degree of accuracy. We have built our platform on a foundation of rigorous, physics-based methods, combined with the rapid data processing and scaling advantages of machine learning, that together provide a significant advantage over traditional methods. We believe that physics-based simulation is at a strategic inflection point as a result of the increased availability of massive computing power, combined with a more sophisticated understanding of models and algorithms and the growing availability of high-resolution protein structures.

We have demonstrated that our software platform can have a transformative impact on the drug discovery process by:

 

•

reducing the average time and cost required to identify a development candidate; and

 

•

increasing the probability of drug discovery programs entering clinical development.

Based on our collaborative drug discovery efforts to date, we believe that the development candidates discovered using our platform have a higher probability of successfully progressing through clinical development than the industry average.

9

Table of Contents

 

As shown below, we achieve these outcomes by tightly integrating our predictive physics-based methods, which have a high degree of accuracy, with machine learning, which is highly scalable. In addition, our platform enables real-time collaboration on drug discovery projects to inform decision-making and fully benefit from the predictive capabilities of our computational platform.

 

Our computational platform provides the following significant technological advantages over traditional approaches to drug discovery, all of which enable shortening timelines, decreasing costs, and increasing the probability of success of drug discovery efforts:

 

•

Speed. Our platform is able to evaluate molecules in hours rather than the weeks that it typically takes to synthesize and assay molecules in the laboratory.

 

•

Scale. Our platform can explicitly evaluate billions of molecules per day, whereas traditionally operated discovery projects only synthesize approximately one thousand molecules per year, thereby increasing the probability that we find a novel molecule with the desired property profile.

 

•

Quality. In a peer-reviewed study, our platform was tested against traditional methods for selecting tight-binding molecules and resulted in an eight-fold increase in the number of molecules with the desired affinity.

10

Table of Contents

 

The figure below compares the optimization process of drug discovery using traditional methods and our approach.

 

Our computational platform includes a broad array of proprietary capabilities:

 

•

Faster Lead Discovery: the ability to rapidly identify potent molecules suitable to initiate hit-to-lead and lead optimization efforts via solutions for virtual screening of extremely large libraries of molecules, as well as physics-based replacement of the central core of a molecule, known as scaffold hopping, to identify novel, highly potent molecules unavailable in library collections;

 

•

Accurate Property Prediction: the ability to assess key properties of drug-like molecules using physics-based calculations with accuracy comparable to that of experimental laboratory assays, to facilitate optimization of drug properties, including drug potency, selectivity, and bioavailability;

 

•

Large-Scale Molecule Exploration: the ability to computationally ideate and explore novel, high-quality drug-like molecules for consideration by discovery project teams utilizing computational enumeration and generative machine learning techniques that are trained and constructed to yield molecules that are synthetically feasible;

 

•

Large-Scale Molecule Evaluation: the ability to scale our calculations of key drug properties to ultra-large idea sets of billions of molecules to enable more rapid and successful identification of high-quality drug candidate molecules; and

 

•

Integrated Data Management and Visualization: the ability to generate, access, and analyze the data derived from complex calculations integrated with assay data through a powerful and user-friendly graphical interface.

Recognition of our scientific advances has come through customer adoption, and in citations of publications in peer reviewed journals. For example, the initial paper describing our ligand-protein docking program, Glide, published in 2004 is one of the most cited papers in the history of the Journal of Medicinal Chemistry, a premier journal in its field. Glide continues to be broadly used as a

11

Table of Contents

 

hit-finding technology throughout the biopharmaceutical industry by our customers. We have made many similar scientific advances in fields including druggability assessment, affinity calculation, protein structure refinement, and molecule ideation and design. These advances were achieved by our team of hundreds of Ph.D.-level scientists and software engineers with extensive input from our Scientific Advisory Board, or SAB, which includes thought leaders in computational chemistry, physics-based simulations, statistical mechanics, and machine learning.

Our computational platform is also applicable to new problems of interest and new fields of study. Since the underlying physics that drives a biologic to bind to its target is no different than the physics that drives a small drug molecule to bind to a protein, we have been able to successfully apply these technologies to the discovery of biologics. Similarly, the physics underlying the properties of materials is no different than the physics underlying the properties of drug molecules. Therefore, we have successfully applied our computational platform to materials science applications, including in the fields of aerospace, energy, semiconductors, and electronic displays.

Software Business

Overview

We are the leading provider of computational software solutions for drug discovery to the biopharmaceutical industry. In 2021, all of the top 20 pharmaceutical companies, measured by 2020 revenue, licensed our solutions, accounting for $42.0 million, or 37%, of our software revenue in 2021. Additionally, in 2021, our software was used by researchers around the world at more than 1,710 academic institutions. The widespread adoption of our software is supported by an approximately 150-person global team of sales, technical, and scientific personnel. Our direct sales operations span across the United States, Europe, Japan, India, and South Korea, and we have sales distributors in other important markets, including China.

We have a diverse and large existing customer base, ranging from startup biotechnology companies to the largest global pharmaceutical companies as well as an increasing number of materials science customers. Our ten largest software customers represented approximately 33% of our software revenue in 2021, including one customer that makes up 14% of total revenue. We continue to expand our customer base as we promote the education and recognition of the potential of our computational platform across industries. As of December 31, 2021, we had 1,647 active customers, which we define as the number of customers who had an ACV of at least $1,000 in a given fiscal year.

We believe there is a significant opportunity to expand the adoption of our platform within our growing customer base. Biopharmaceutical companies are increasingly adopting our software at a larger scale, and we anticipate that this scaling-up will drive future revenue growth. Our ability to expand within our customer base is demonstrated by the increasing number of our customers with an ACV over $100,000. We had 190, 153, and 131 such customers for the years ended December 31, 2021, 2020, and 2019, respectively. In addition, we had 15, 16, and 10 customers for the years ended December 31, 2021, 2020, and 2019, respectively, with an ACV of over $1.0 million. For the year ended December 31, 2021, our top 10 customers, measured by ACV, accounted for $34.1 million of our total ACV compared to $28.5 million for the year ended December 31, 2020. We believe biopharmaceutical companies are increasingly recognizing and applying the power and efficiency of our platform.

12

Table of Contents

 

Furthermore, we believe our sales and marketing approach and the quality of our software solutions help us cultivate long-standing relationships and reoccurring sales. This is demonstrated by the length of our key relationships, with the average tenure of our 10 largest customers in 2021 being over 17 years. Furthermore, our ability to expand our customer relationships over time is exemplified by our ability to retain our customers with an ACV over $100,000. For the year ended December 31, 2021, our year-over-year customer retention rate for our customers with an ACV over $100,000 was 98% and was 96% or higher for each of the previous eight fiscal years. We believe the continued expansion of our customer base coupled with our ability to expand our customers’ use of our software will continue to drive revenue growth. The figure below shows the different ways in which we are accelerating our growth.

See “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Key Factors Affecting Our Performance” for additional information regarding ACV and customer retention rate.

Our Software Solutions for Drug Discovery

We offer our customers a variety of software solutions that accelerate all stages of molecule discovery, design, and optimization pursuant to agreements with terms typically for one year. Our licenses give our customers the ability to execute a certain number of calculations across specified software solutions. Certain of our key software solutions are highlighted below, along with the particular stage of drug discovery in which they are employed.

 

•

Target Identification and Validation: the identification and evaluation of a protein target that might be worthwhile to pursue as the subject of a drug discovery campaign.

 

o

WaterMap characterizes the locations and energetics of water molecules occupying the binding site of, or solvating, a target protein. From this analysis, one can infer the druggability of a protein, as well as uncover opportunities to significantly increase binding affinity by exploiting the water structure in the binding site.

 

o

SiteMap allows binding site identification and evaluation to help locate potential protein binding sites, including allosteric sites, and predict the approximate druggability of those sites.

 

o

GlideEM, PrimeX and Phenix/OPLS4 enable optimization of intermediate quality experimental protein structures to a quality sufficient to drive structure-based drug discovery.

 

 

•

Hit Discovery: the identification of hit molecules.

 

o

FEP+ is our free energy calculation software. In hit discovery, this software can be used to replace the central core of earlier known tight binding molecules to identify novel, highly potent molecules unavailable in library collections. Often these molecules have much higher binding affinity and have a better property profile than typical hit molecules. FEP+ can also be used to calculate absolute binding affinities, which enables the software to evaluate and triage diverse molecules sharing no common peripheral features in a hit discovery context.

 

o

Glide is our virtual screening program that is used to screen libraries of molecules to find hit molecules likely to bind a particular protein target in a specific conformation.

 

o

WScore is our next-generation virtual screening program that utilizes a more accurate and robust description of protein-ligand interaction solvation effects. This and other novel features enable WScore to more reliably find hit molecules for challenging protein targets when screening libraries of molecules.

 

o

Shape uses the three-dimensional structure and shape of earlier known hit molecules to find new hits when screening libraries of molecules.

13

Table of Contents

 

 

o

AutoQSAR/DeepChem uses modern machine-learning methods trained to earlier known hit molecules to find novel hits when screening libraries of molecules.

 

o

Induced Fit Docking can computationally predict the binding mode of molecules to a binding site of a protein, including predicting how the conformation of the protein binding site may reorganize upon binding the molecule.

 

 

•

Hit to Lead and Lead Optimization: Hit to lead is the stage at which small molecule hits are evaluated and undergo limited optimization to identify promising lead molecules. Lead optimization improves on the property profile of lead molecules by designing new analogs with improved potency, reduced off-target activities, and favorable physicochemical/metabolic properties.

 

o

FEP+ is our free energy calculation software. In the hit to lead and lead optimization phases of drug discovery, FEP+ is used to predict the binding affinity of ligands to proteins with accuracy approaching that of physical experiments. It allows precise rank-ordering of large libraries of virtual molecules so that only the most potent molecules are synthesized in a program, which can save time and reduce cost. FEP+ can also be used to calculate the binding selectivity, solubility, and mutational resistance profiles of molecules, which are key properties for the optimization of bioavailability, toxicology, and efficacy.

 

o

AutoQSAR/DeepChem uses modern machine-learning methods to produce predictive quantitative structure-activity relationship, or QSAR, models. This allows more accurate methods, such as FEP+, to be applied at a much greater scale but with less accuracy to much larger sets of molecules than would otherwise be possible and enables predictive QSAR models of other properties to be developed and deployed on drug discovery projects.

 

o

PathFinder is an enumeration tool that enables the rapid exploration of synthetically tractable ligands. When PathFinder is deployed in conjunction with multiparameter optimization, machine learning, and FEP+ simulations, it provides a streamlined approach to create and evaluate large sets of synthetically tractable, lead-like, potent ligands.

 

 

•

Software Solutions Used Throughout the Drug Discovery Process:

 

o

LiveDesign is our user-friendly enterprise informatics solution that enables interactive and collaborative molecule design, aggregation and sharing of data, and end-to-end discovery project coordination between chemists, modelers, and biologists.

 

o

Maestro is our user-friendly modeling environment, which allows expert modelers to utilize our advanced modeling solutions.

Furthermore, in January 2022, we acquired XTAL BioStructures, Inc., a company that provides structural biology services, including biophysical methods, protein production and purification, and X-ray crystallography, which we believe will expand our offerings to include an advanced and differentiated service that provides customers access to protein structures that have been computationally validated and are ready for structure-based virtual screening and lead optimization.

Our Software Solutions for Materials Science

We also sell software licenses to customers engaged in molecule design for industrial purposes. The software solutions for our materials science customers leverage much of the same technology as our software for biopharmaceutical companies. In addition, similar to traditional drug discovery efforts, traditional approaches to discovering new molecules in these fields also suffer from long timelines, and it can take as long as 10 to 20 years to bring new materials to the market. We are focused on leveraging our technology to transform the way new materials are discovered, and we believe that materials science industries are only beginning to recognize the potential of computational methods. We are continuing to build a team of subject matter experts to further drive adoption of our computational platform in each of the following areas in which we currently operate:

 

•

mobile electronics and displays—organic electronics (OLED);

 

•

aerospace and defense—polymers, composites;

 

•

microelectronics—semiconductors, thin film processing;

 

•

oil and gas—catalysis, reactivity;

 

•

energy—alternative energy, batteries; and

 

•

consumer packaged goods—soft matter, formulations.

14

Table of Contents

 

 

As part of our ongoing efforts to further advance our software solutions for materials science applications, in June 2020, we entered into a three-year agreement with Gates Ventures, LLC to develop and apply atomistic simulations methods to improve battery performance.

Drug Discovery Business

Overview

We are using our computational platform in both collaborative and internal drug discovery programs. Traditional drug discovery and development efforts have become increasingly complex, lengthy, capital-intensive, and are prone to high failure rates. Decreasing returns on investments in drug research and development have created a significant opportunity for us to leverage our computational platform to design and discover new medicines. In drug discovery stages, our platform can reduce the time and cost required to identify a development candidate with a more optimized property profile as compared to traditional methods. We believe that these candidates with more optimized property profiles will have a higher probability of success in clinical development.

The figure below illustrates the advantages in time, cost, and molecule quality of our computational drug design approach over traditional drug discovery approaches.

 

The figures below show the number of collaborative programs we have worked on in each given year, as well as the amount of drug discovery revenue we have generated for the periods presented. While our revenue-generating collaborations are an important component of our business, our strategy is also to pursue an increasing number of internal programs and strategically evaluate on a program-by-program basis entering into preclinical and clinical development ourselves, entering into collaboration, or out-licensing programs to maximize commercial opportunities. As part of this strategy, in November 2020, we entered into an exclusive, worldwide collaboration and license agreement with BMS pursuant to which we and BMS agreed to collaborate in the discovery, research and clinical development of small molecule compounds for biological targets in the oncology, neurology and immunology therapeutic areas. Furthermore, in August 2021, we entered into a global discovery, development and commercialization collaboration with Zai Lab Limited focused on a novel program in oncology targeting DNA damage response. These programs are not included in the number of collaborative programs described below. See “—Our Pipeline” for a further discussion of these programs.

Furthermore, collaborative programs which we did not actively work on in a given year, but for which we are still eligible to receive potential milestone payments and royalties, are not included in the number of collaborative programs below. For the year ended December 31, 2021, we had seven such programs compared to nine and two for the years ended December 31, 2020, and 2019, respectively.

Our drug discovery revenue consists of revenue generated from collaborations through the combination of upfront payments, research funding payments, discovery and development milestones, and other fees, as well as any revenue generated from our pipeline of internal drug discovery programs, including revenue generated from our collaboration with BMS. As part of the BMS collaboration in November 2020, we received an upfront payment of $55.0 million. Approximately $13.7 million and $1.0 million of the upfront payment were included in our drug discovery revenue for the years ended December 31, 2021 and 2020, with the remainder recorded as deferred revenue as of December 31, 2021.

15

Table of Contents

 

Our Drug Discovery Collaborations

Over the last decade, leveraging our platform and expertise, we have steadily grown our portfolio of collaborations with biopharmaceutical companies that have provided us with significant income and have the potential to produce additional milestone payments, option fees, and future royalties. These programs pursue design of clinical candidates across a wide range of therapeutic target protein classes and indications. Many of these programs are pursuing novel molecules for targets where a low-dose small molecule inhibitor or activator with optimal drug-like properties has been difficult to achieve or where selectivity for the target of interest has been difficult to achieve relative to other proteins. We have steadily grown our pipeline of collaborations by selectively entering into drug discovery collaborations with high potential from a large number of opportunities. Among the key factors that we use to select collaborators are whether the targets are well-validated, have high therapeutic potential, and are amenable to the strengths of our computational platform, and whether or not the collaborator brings complementary capabilities, all of which we believe contribute to an increased probability of success.

Through access to the maximum potential scale of our computational platform and our drug discovery and software development teams, our collaborators receive the following key benefits:

 

•

Immediate utilization of our platform: Ability to immediately and efficiently leverage the full benefits of our computational platform, without the need for training or ramp-up time, thereby enabling accelerated drug discovery.

 

•

Access to massive compute power: Ability to run our computational software at scale, thereby avoiding the time and cost needed to build such computational infrastructure on their own.

 

•

Early access to cutting-edge functionality: Real-time access to emerging solutions as they are being developed.

 

•

Target exclusivity: Under our collaboration agreements, we agree to design drugs for a particular protein target or targets using our computational platform and knowhow exclusively for the collaborator.

Collaboration Agreements

We have entered into a number of collaborations with biopharmaceutical companies under which our collaborators are pursuing research in a number of therapeutics areas, including without limitation, various programs in oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immune-oncology, cardiopulmonary disease and tuberculosis. Our current collaborators include Ajax Therapeutics, Inc., Bright Angel Therapeutics Inc., Morphic Holding, Inc., or Morphic, Nimbus Therapeutics, LLC, Sanofi S.A., ShouTi Inc., TB Alliance and Takeda Pharmaceuticals Company Limited, or Takeda. With the exception of Takeda, where we retain all intellectual property rights until Takeda exercises its option to acquire a program, all of the programs being pursued under these collaborations are fully owned and controlled by each respective collaborator. Our opportunity to receive potential revenues from any of these programs is generally limited to research funding payments, development, regulatory, and commercial milestones, option fees to license projects and royalties on commercial sales, if any. We are not responsible for advancing their preclinical or clinical development or their commercialization, if approved.

16

Table of Contents

 

Equity Stakes. We have received equity consideration in certain of our collaborators, and from time to time, we have also made additional equity investments in certain of these collaborators. As noted above, all of these programs are fully owned and controlled by each respective collaborator, with the exception of Faxian, which is a 50/50 joint venture. The following table presents our equity stakes on an issued and outstanding basis as of December 31, 2021:

 

Company

 

Ownership %

 

Ajax Therapeutics, Inc.

 

6.3%

 

Bright Angel Therapeutics Inc.

 

33.3%

 

Faxian Therapeutics, LLC (JV)

 

50.0%

 

Morphic Holding, Inc. (1)

 

2.3%

 

Nimbus Therapeutics, LLC (2)

 

5.5%

 

Ravenna Pharmaceuticals, Inc.

 

3.1%

 

ShouTi, Inc.

 

4.5%

 

 

 

(1)

Based on the number of shares of common stock outstanding as of November 1, 2021, as reported on Morphic’s Quarterly Report on Form 10-Q for the period ended September 30, 2021, as filed with the SEC on November 4, 2021.

 

(2)

On a fully diluted basis

Financial Rights. In addition to our equity stakes in certain of our collaborators, we also have rights to various payments on a collaborator-by-collaborator agreement basis including research funding payments, discovery, development, and commercial milestones, potential option fees to license projects, and potential royalties in the single-digit range. Under certain of our collaboration agreements, we are also eligible to receive a percentage of our collaborators’ sublicense revenue.

Many of our collaborative programs are currently still in the discovery stages. Generally, the size of the payments we are eligible to receive from a collaborative program increases as the program advances. As a result of the broader validation of our platform, we intend to pursue an increasing number of wholly-owned programs, and we will continue evaluating new collaborative programs that fit our selection criteria and where the collaborator’s particular expertise has the potential to create substantial value. Importantly, our current collaboration agreements typically also contemplate additional program targets being added, allowing our collaborators to potentially increase the number of programs under our current collaboration agreements.

However, because these collaborations are not under our control, we cannot predict whether or when we might achieve any event-based increases in research funding payments, milestone payments, royalty or other payments under these collaborations or estimate the full amount of such payments, and we may never receive any such payments. For a further discussion of the risks we face with respect to receipt of any of these payments, please refer to “Risk Factors—Risks Related to Drug Discovery—We may never realize a return on our investment of resources and cash in our drug discovery collaborations”.

How We Work with Our Collaborators. Generally, our existing collaboration agreements provide that we agree to design drugs for a particular target or targets using our computational platform and knowhow exclusively for the collaborator. With the exception of Takeda, where we retain all intellectual property rights until Takeda exercises its option to acquire a program, the collaborator retains the intellectual property related to any molecules developed under the collaboration. Generally, our collaborators are not contractually required to provide us with, nor do we expect generally to receive, access to nonpublic information regarding key developments related to the advancement of these collaboration programs, such as clinical trial results, including safety and efficacy data, regulatory communications, or commercialization plans and strategies. To the extent we do receive such information, our collaboration agreements generally require us to maintain the confidentiality of information we receive under the collaboration.

As our collaboration strategy has evolved, we are seeking to take more direct control and responsibility for all aspects of a drug discovery project and own a higher percentage of the value generated in the completed programs. For example, under our collaboration with Takeda, after mutual agreement on the target(s) of interest, our drug discovery group conducts all drug discovery research and pharmacology activities through the development candidate stage. Takeda has the option to acquire the program at either the lead optimization stage or development candidate stage and to develop and commercialize product candidate(s) from the program. Importantly, under the collaboration with Takeda, we control the drug discovery process and retain all intellectual property rights to any product candidates that are discovered under the program until Takeda exercises its option to acquire the program. The collaboration with Takeda anticipates drug discovery research on up to six targets. Three programs have been initiated to date in schizophrenia, oncology, and neurodegenerative disease with multiple milestone payments achieved. Two of these programs continue to advance while the program in schizophrenia is no longer an active collaboration and all rights to this program will continue to be retained by us.

17

Table of Contents

 

Our Pipeline

In mid-2018, we launched a pipeline of internal, wholly-owned programs with the goal of rapidly advancing the discovery of best-in-class and first-in-class therapies. Our initial programs are focused on discovering and developing inhibitors for targets in DNA damage response pathways and genetically defined cancers. Since then, we have expanded into other therapeutic areas, including in the areas of immunology and neurology. We continue to advance multiple internal programs through investigational new drug, or IND, -enabling studies. We expect to submit an IND application to the FDA for our MALT1 program in the first half of 2022, and subject to receiving regulatory clearance, we expect to initiate a Phase 1 clinical trial of our MALT1 inhibitor in patients with relapsed and resistant lymphoma in the second half of 2022. We also plan to submit IND applications to the FDA for our CDC7 program in early 2023 and our WEE1 program in 2023, subject to favorable data from IND-enabling studies. In addition, we plan to initiate a Phase 1 clinical trial of our CDC7 inhibitor in 2023, subject to receipt of regulatory clearance. Our strategy is to pursue an increasing number of wholly-owned programs and strategically evaluate on a program-by-program basis entering into preclinical and clinical development ourselves, entering into collaborations, or out-licensing programs to maximize commercial opportunities.

As part of this strategy, in November 2020, we entered into an exclusive, worldwide collaboration and license agreement with BMS pursuant to which we and BMS agreed to collaborate in the discovery, research and development of small molecule compounds for biological targets in the oncology, neurology and immunology therapeutic areas. The initial collaboration targets included HIF-2 alpha and SOS1/KRAS, which were two of our internal pipeline programs. In November 2021, the Company and BMS mutually agreed to replace the HIF-2 alpha target with another precision oncology target. Following the replacement election, all rights to the HIF-2 alpha target program reverted to us. Under the terms of the agreement, we received a $55.0 million upfront payment from BMS, and we are eligible to receive up to $2.7 billion in total milestones from BMS across all potential targets, as well as a tiered percentage royalty on net sales of each product commercialized by BMS ranging from mid-single digits to low-double digits, subject to certain specified reductions. See “—Collaboration Agreement with Bristol-Myers Squibb Company” for additional information relating to this agreement.

Furthermore, in August 2021, we entered into a global discovery, development and commercialization collaboration with Zai Lab Limited focused on a novel program in oncology targeting DNA damage response. Under the terms of the agreement, we are entitled to receive an upfront payment, and if we elect to co-fund clinical development of a product candidate under the collaboration, we will be entitled to receive 50% of any profits from the commercialization of an approved therapeutic in the United States. We are also eligible to receive up to approximately $338 million in preclinical, clinical, regulatory and sales-based milestone payments from Zai Lab Limited for any product candidate developed under the collaboration, and we are entitled to receive tiered royalties on net sales outside the United States.

18

Table of Contents

 

The following is a summary of our drug discovery programs:

 

 

Our Approach to Target Selection

Our selection of targets is based on an extensive analysis of human targets and drug discovery programs. We analyze targets using automated methods at scale. The key steps we take in prioritizing programs involve:

 

•

Structural and modeling enablement. We use our computational platform to analyze protein structure quality as well as druggability of binding sites across thousands of target proteins in parallel. For a subset of high-quality structures of interest, we confirm amenability to our computational platform.

 

•

Evaluation of therapeutic potential. Our selection of targets is strongly influenced by the level of validation of the target, including analysis of human genetics and prior clinical data.

 

•

Identification of unsolved design challenges. We determine whether there are property profile challenges that could be solved by the application of our computational platform and provide a clinically meaningful differentiated, best-in-class or first-in-class product opportunity.

 

•

Assessment of potential value of pathways and mechanisms. We evaluate industry and commercial interest as well as the clinical utility with the aim of prioritizing programs with high commercial and therapeutic potential.

Using this comprehensive analysis, we have identified a large number of protein targets that we believe are amenable to our technology. We continue to evaluate a number of additional targets using this analysis methodology.

MALT1 Inhibitor Program

We are developing novel MALT1 inhibitors for the treatment of patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia who are resistant to or have relapsed on Bruton’s tyrosine kinase, or BTK, inhibitors, a currently-approved therapy for lymphoma patients. Constant activation of nuclear factor-kappa B, or NF-κB, a key signaling molecule in B cells, is a hallmark of several subtypes of lymphoma. MALT1 is a key mediator of the NF-κB signaling pathway, the main driver of a subset of B-cell lymphomas and functions by forming a complex with CARMA1 (Caspase recruitment domain-containing protein 11 also known as CARD-containing MAGUK protein 1) and BCL10 (B-cell lymphoma/leukemia 10) to mediate antigen receptor-induced lymphocyte activation. MALT1 is considered a potential therapeutic target for several subtypes of non-Hodgkin’s lymphomas.

Activated B-cell, or ABC, a subtype of diffuse large B-cell lymphoma, or ABC-DLBCL, is the most common type of aggressive non-Hodgkin’s B-cell lymphoma. ABC-DLBCL is associated with a number of mutations that trigger a constitutively active NF-κB signaling pathway, which often is mediated by increased MALT1 protease activity. Among these mutations is a gain of function mutation or amplification of MALT1, which has also been identified in ABC-DLBCL patients.

19

Table of Contents

 

Our program utilizes our physics-based software platform to enable the identification and advancement of multiple novel series from hit finding to lead optimization. Combining multi-parameter optimization, FEP+, and machine learning, we were able to prioritize tight-binding compounds with drug-like properties, and identify multiple novel and distinct chemical series which showed strong anti-tumor activity, ultimately enabling development candidate selections in our MALT1 inhibitor program in under two years.

As shown in the figures below, in preclinical studies, one of our MALT1 inhibitors, Compound 1, showed anti-tumor activity in a MALT1 enzymatic assay and strong anti-proliferative effect in cell viability in a BTK inhibitor resistant OCI-LY3 B-cell non-Hodgkin’s lymphoma cell line, when compared to ibrutinib, a covalent BTK inhibitor.

 

    

 

As shown in the figures below, in preclinical studies, Compound 1 also demonstrated strong anti-tumor activities as a single agent in BTK inhibitor resistant OCI-LY3 cells and in BTK sensitive OCI-LY10 B-cell non-Hodgkin’s lymphoma in vivo cell-line derived xenograft (CDX) models.

 

        

 

TPGS = D-alpha-tocopheryl polyethylene glycol succinate, a solvent used in co-administration for drug dosing in animals; TID = three times a day dosing; SDD = spray dried dispersion

 

In addition, Compound 1 demonstrated strong anti-tumor activities in combination with ibrutinib in the BTK inhibitor sensitive in vivo models, such as the ABC-DLBCL patient-derived xenograft (PDX) model LY2298 and the OCI-LY10 CDX model.

20

Table of Contents

 

Beyond ABC-DLBCL disease models, Compound 1 also demonstrated single agent anti-tumor activity in an in vivo mantle cell lymphoma REC-1 CDX model. Compound 1 also showed strong combination effects with venetoclax (an inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL2)) on inhibition of cancer cell viability in the OCI-LY10 CDX model.

 

 

QD = once per day dosing; BID = twice a day dosing

 

These data suggest that targeting MALT1 may expand therapeutic options for patients with selected B-cell lymphomas, such as ABC-DLBCL, with the possibility of expanding into other B-cell lymphomas such as mantle cell lymphoma. Furthermore, these small molecule MALT1 inhibitors demonstrated potential in combination with BTK inhibitors to overcome drug-induced resistance to BTK inhibitors in patients with relapsed/refractory B-cell lymphomas. Taken together, we believe the data present an opportunity to move a potential best-in-class MALT1 inhibitor into clinical trials, subject to the submission of our IND application and clearance from the FDA, and strongly underscore the therapeutic potential of our MALT1 inhibitors. We expect to submit an IND application to the FDA for our MALT1 program in the first half of 2022, and subject to receiving regulatory clearance, we expect to initiate a Phase 1 clinical trial of our MALT1 inhibitor in patients with relapsed and resistant lymphoma in the second half of 2022.

CDC7 Kinase Inhibitor Program

We are developing tight-binding, selective, novel small molecule inhibitors of CDC7 for the treatment of advanced solid and liquid tumors. CDC7 is a serine/threonine protein kinase that has been shown to play important roles in DNA replication initiation and in response to replication stress and DNA damage. CDC7 levels are high in certain tumors, and are thought to be linked to these cancer cells’ proliferative capacity and ability to bypass normal DNA damage responses.

CDC7 phosphorylates and activates the enzymes responsible for DNA replication initiation and proteins involved in replication stress response. Disruption of CDC7 activity in cancer cells leads to delayed DNA replication, increased replication stress, cell cycle abnormalities, and cell death.

The antiproliferative potential of CDC7 inhibition was validated by a third party in Phase 1 clinical trials of a CDC7 inhibitor in which responses were observed in patients, including those with bladder and pancreatic cancer. Prior to this positive result, existing CDC7 inhibitors were not sufficiently tight-binding, lacked selectivity, and demonstrated poor pharmacokinetic properties.

In order to maximize the anti-cancer activities of CDC7 inhibitors, very tight-binding inhibitors are required to achieve durable clinical impact as monotherapy or in the context of clinical combinations. Using our computational platform, we have identified multiple tight-binding, selective, and novel CDC7 inhibitor series.

As shown in the figures below, our advanced preclinical molecules, compound 1 (Cpd-1) and compound 2 (Cpd-2), demonstrated inhibition of recombinant human CDC7 in a biochemical kinase assay and inhibition of the phosphorylation of the serine in position 53, or S53, of the protein MCM2, or pMCM2, a downstream substrate of CDC7, in a Colo205 colorectal cancer cell line.


21

Table of Contents

 

Dose-dependent inhibition of CDC7 by Compound-1 (Cpd-1)

or Cpd-2 in a biochemical kinase (ADP-Glo) assay

 

 

Inhibition of phosphorylation of MCM2 (CDC7 substrate) at S53 by CDC7

inhibitors in Colo205 cells measured by MSD (Meso Scale Discovery) assay

 

 

Furthermore, Cpd-1 showed tumor growth inhibition resulting in tumor regression in the Colo205 colorectal cancer CDX model at doses that did not result in significant body weight loss. Cpd-1 also showed a dose-dependent increase in plasma drug concentration and a dose-dependent decrease in intratumoral pMCM2 in the Colo205 CDX model. In mouse models of acute myeloid leukemia, Cpd-1 also showed strong anti-tumor activity at doses that did not result in significant body weight loss.

 

22

Table of Contents

 

 

 

As also shown in the figures below, a combination of our advanced preclinical molecule, compound 4 (Cpd-4), with venetoclax (an inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL2)), olaparib (an FDA-approved PARP inhibitor marketed as LYNPARZA by AstraZeneca), ceralasertib (an ataxia telangiectasia and RAD-3relate, or ATR, inhibitor), or adavosertib (a WEE1 inhibitor) showed synergistic effect on inhibition of cancer cell viability in the indicated cancer cell lines, which are the acute myeloid leukemia cell line, or MV-4-11, the lung cancer cell line, or H460, and the Colo205 colorectal cancer cell line.

 

All competitor data is internally generated by contract research organizations, using commercially available tools or synthesized by third-party research chemists using publicly available structure information.

 

WEE1 Kinase Inhibitor Program

WEE1 is a gatekeeper checkpoint kinase that prevents cellular progression through the cell cycle allowing time for DNA repair before cell division takes place. Inhibition of WEE1 allows for accumulation of DNA damage, triggering DNA breakage and

23

Table of Contents

 

apoptosis in tumor cells. We are therefore developing tight-binding, selective WEE1 inhibitors with optimized physicochemical properties that we believe will be well suited for combinations with DNA damage response inhibitors such as PARP and ATR inhibitors and other targeted therapies for the treatment of ovarian, colorectal, breast, and other solid tumors.

A WEE1 inhibitor currently being investigated in Phase 2 clinical trials by a third party has shown clinically meaningful tumor regression with partial responses and stable disease in ovarian and uterine cancer, and is being studied in combinations with chemotherapy, PARP inhibitors, and immunotherapy.

A prior third party WEE1 inhibitor that has advanced to clinical trials may have off-target effects resulting from inhibition of other kinases, and inactivation of a liver enzyme, CYP3A4, which is responsible for elimination of drug and drug metabolites from the body, making dosing and combinations more challenging. We believe our computational platform can be used to identify tight-binding molecules with optimized drug-like properties that exhibit neither of these liabilities.

As shown in the figure below, we have identified WEE1 inhibitor lead molecules that are tight-binding and highly selective, and have exhibited a favorable drug-like property profile, including no observable inactivation of CYP3A4. We have benchmarked our compounds against AZD-1775, a WEE1 inhibitor being advanced by AstraZeneca, and Zn-C3, a WEE1 inhibitor being advanced by Zentalis Pharmaceuticals, and our lead molecules have shown comparable binding affinity against WEE1, as measured by Kd, a measure of binding affinity.

Our compounds have also shown comparable effects on the viability of the A427 non-small cell lung cancer cell line and the OVCAR3 high grade serous ovarian cancer cell line.  The selectivity of our WEE1 inhibitors was evaluated by profiling one of our lead compounds at 1 uM across a panel of over 450 kinases.  Our WEE1 inhibitor showed high selectivity for WEE1 in this assay panel, binding significantly, with a greater than 90% inhibition relative to control, to only eight other kinases.  

Furthermore, time-dependent inhibition, or TDI, of the enzyme CYP3A4 often results in clinically significant drug-drug interactions, or DDI.  In vitro, our compound showed no measurable TDI of CYP3A4, which we believe might lead to a lower potential liability for DDI if our WEE1 inhibitors were used in combination with other agents. We are pursuing in vitro and in vivo WEE1 and PARP inhibitor combination studies and studies in patient-derived tumor mouse models and other combinations, which we believe may have implications for future clinical combination trials.

All competitor data is internally generated by contract research organizations, using commercially available tools or synthesized by third-party research chemists using publicly available structure information.

 

SOS1/KRAS Inhibitor Program

In collaboration with BMS, we are developing a SOS1/KRAS protein-protein interaction inhibitor for the treatment of KRAS-driven cancers. SOS1, or Son of sevenless-1, is involved in the activation and regulation of KRAS. Oncogenic mutant KRAS

24

Table of Contents

 

stimulates the growth of some of the most intractable tumors, such as lung, pancreatic, and colon cancer. Strategies to disrupt the persistently active Ras pathway have focused on targeting Cys12 of the oncogenic mutant KRAS G12C with covalent inhibitors. Disruption of the SOS1/KRAS interaction has emerged as an alternative approach based on third party preclinical data. Our initial efforts suggest that we can leverage our computational platform to identify a novel development candidate for this target.

Pursuant to our collaboration and license agreement with BMS, once we have discovered or identified a SOS1/KRAS protein-protein interaction inhibitor that meets specified, mutually-agreed criteria (or upon BMS’s selection), BMS will be solely responsible for the further preclinical and clinical development, manufacturing and commercialization of such candidate at its own expense. See “—Collaboration Agreement with Bristol-Myers Squibb Company” for additional information relating to this agreement.

Other and Future Programs

We have identified a large number of protein targets that we believe are amenable to our computational platform, which creates a large and growing inventory of targets that we can potentially advance into discovery programs. Our drug discovery group also intends to pursue targets with strong biological validation and therapeutic potential that currently lack protein structures of sufficient quality to permit the use of our computational platform for drug discovery. We are actively pursuing strategic alliances with collaborators that have the ability to generate high-quality protein structures for these targets, which will enable us to initiate discovery efforts. For example, as part of these efforts, in 2020 we entered into strategic partnerships with Viva Biotech to access new x-ray crystal structures as well as with Thermo Fisher Scientific to obtain structures of protein complexes leveraging cryo-EM technology. Furthermore, in January 2022, we acquired XTAL BioStructures, Inc., a company that provides structural biology services, including biophysical methods, protein production and purification, and X-ray crystallography, which we believe will augment our ability to produce high quality target structures for our drug discovery programs.

Our initial programs are focused on discovering and developing inhibitors for targets in DNA damage response pathways and genetically defined cancers. Genomic instability of malignant cells leads to genetic mutations that can drive resistance to kinase inhibitors, creating the need for second and third generation drugs targeting the same disease. Our computational platform has been shown to be capable of predicting the impact that mutations in the kinase domain have on drug binding, potency, and drug sensitivity. Use of our platform to assess and evaluate the impact of clinical mutations on drug potency can be a powerful tool for drug discovery. We believe that deploying our platform at scale with access to genomic profiling data for patients puts us in a strong position to predict the impact of active-site resistance mutations with clinically relevant accuracy to optimize the design of molecules that are robust against common resistant mutations.

In addition to our programs highlighted above, we are also progressing a number of undisclosed programs in the areas of oncology, immunology, and neurology. We are pursuing certain of these programs on our own and certain of these programs are being advanced in collaboration with BMS pursuant to our collaboration agreement described above, as well as under a separate collaboration agreement with BMS that we entered into in August 2021 to discover, develop and commercialize bifunctional protein degraders. All of these programs are currently in the discovery stage, and we have not yet identified a development candidate for any of these programs.

Technical Details of Our Key Technologies

Calculation of key drug properties using physics-based methods

Over the past several decades and with the concerted effort of hundreds of our scientists and software engineers, we have developed a physics-based computational platform that is capable of predicting the binding affinity of a drug molecule with a high degree of accuracy. The binding affinity of a drug molecule to a target protein is the key driving force of its in vivo efficacy. Specifically, when a drug binds to a target protein, the affinity with which it binds directly affects the extent to which it will modulate the function of the protein. Therefore, the ability to predict the binding affinity of a drug molecule to a target protein with a high degree of accuracy can significantly accelerate discovery of new efficacious medicines.

Accurately calculating the binding affinity of a drug molecule to a protein is enormously complex and requires a full characterization of all the physical contributions to the binding. These contributions include the deformation and/or rigidification of the small molecule into the bound conformation (ΔG(1) in the figure below) and the rigidification of the protein in the bound conformation (ΔG(2)), the removal of waters surrounding the molecule (ΔG(3)) and the removal of waters within the protein binding site (ΔG(4)), and finally the interactions achieved between the molecule and protein when binding to form the protein-molecule complex (ΔG(5)).

25

Table of Contents

 

 

 


26

Table of Contents

 

 

We have developed a solution to consistently assess all of these contributions to binding with a high degree of accuracy, building on a method called “free energy perturbation.” Free energy perturbation perturbs, or transforms, an initial molecule into another molecule of interest and evaluates how that transformation changes binding affinity to a particular protein target. Our solution for conducting these calculations is called FEP+. FEP+ is enabled by the following differentiated constituent technologies:

 

•

classical molecular mechanics force field with broad coverage of drug-like molecules with a high degree of accuracy;

 

•

an automated workflow allowing for force field coverage to be extended on the fly utilizing our accurate quantum mechanics software;

 

•

computationally efficient molecular dynamics engine that runs on graphic processing units;

 

•

efficient, enhanced sampling methods that allow the calculation to be converged with reduced simulation times;

 

•

automated atom-mapping and interaction-mapping assignment; and

 

•

ability to scale these calculations to leverage large cloud computing environments.

All of these constituent technologies are necessary to achieve the accuracy, scalability and applicability of our free energy perturbation implementation.

In a notable peer-reviewed study including approximately 3,000 molecules across approximately 90 distinct projects, FEP+ exhibited an error profile that indicates its affinity predictions approach the accuracy of running a laboratory experiment. FEP+ is also able to perform these computations more rapidly than experimental assays. Computational assessment of a molecule utilizing FEP+ requires approximately only a few hours. In comparison, it often takes weeks to synthesize a drug-like molecule and assay its binding affinity for the target of interest in a laboratory. As a result, our FEP+ solution can be used to explore very large numbers of molecules to identify drug candidates much more rapidly than would be possible solely using experimental approaches.

In a peer-reviewed article published in collaboration with a large biopharmaceutical company, the ability of FEP+ to prioritize molecules for synthesis expected to bind more tightly than an initial hit was compared with several other industry-standard approaches. We found that FEP+ succeeded in prioritizing the synthesis of molecules with improved binding affinity with eight times greater success than any other technique tested. This evidence supports the essential role that FEP+ can play in advancing drug discovery programs.

Enumeration of extremely large libraries of molecules

We have developed methods to enumerate extremely large libraries of molecules with our PathFinder software solution, thereby allowing our software customers, our drug discovery collaborators, and our internal drug discovery team to explore a much larger portion of chemical space than is possible through manual design. The chemical enumeration technology we have developed incorporates the most commonly used chemical reactions and can, in a fully automated fashion, computationally explore billions of alterations of a molecule of interest.

Scaling accurate physics-based calculations to extremely large libraries of molecules

Although FEP+ calculations have been shown to be accurate, it is not possible to apply these calculations to billions of molecules given the current availability of computing resources. To address this problem, we developed an approach that leverages the accuracy of FEP+, but allows for exploration of billions of molecules rapidly by leveraging machine learning. We have succeeded in integrating our physics-based molecule scoring with highly computationally efficient modern machine-learning methods. This combined approach allows us to apply our physics-based calculations to much larger sets of molecules than would otherwise be computationally tractable. This allows us to both increase the speed and likelihood of identifying clinically viable molecules.

Advances in deep learning, a type of machine learning, in the past several years have required very large data sets as input to train the model. In a drug discovery program, the experimental data is typically sparse and expensive to procure, which is particularly problematic given that relevant drug-like chemical space is effectively infinitely large, estimated to be 10^60 molecules. For this reason, we believe that it would be extremely difficult to realize competitive advantage in a drug discovery program by using a platform exclusively based on machine learning or deep learning. Instead, we have developed an approach to integrate physics-based and machine-learning based scoring methodologies that allows the machine learning model to interactively prioritize additional molecules for physics-based analyses, known as active learning. Active learning retains the computational efficiency of machine learning while also taking advantage of the accuracy of the physics-based method. One can evaluate the utility of any particular prediction method with regard to both its accuracy and its computational efficiency. Modern machine learning methods, such as deep

27

Table of Contents

 

learning, do provide a small improvement over conventional machine learning methods. However, for much of its history, conventional molecular simulations were much less computationally efficient than machine learning but not that much more accurate.

In developing FEP+, we were able to resolve deficiencies in early attempts to develop physics-based methods. FEP+ calculations are much more accurate than either conventional machine learning or modern machine learning when scoring molecules structurally distinct from the training set data. In addition, by integrating FEP+ with our machine learning implementation, which we refer to as AutoQSAR/DeepChem, we developed a solution that we refer to as Active Learning FEP+. Active Learning FEP+ combines the accuracy of free energy calculations with the speed of machine learning calculations and can be used to explore up to billions of molecules within a day. By further combining this functionality with our ability to enumerate large sets of molecules provided by PathFinder and our ability to build and manage complex workflows utilizing cloud resources, we are able to deploy these capabilities at scale to advance projects.

Active Learning FEP+ is depicted in the figure below.

 

 

FEP+ is used to build a local model for a large library of molecules instead of relying on experimental data to provide the training set for the machine learning model. That machine learning model is then used to filter the large library of molecules down to a number that is small enough to be able to prioritize with FEP+. The result is that we can prioritize one billion molecules in as little as a day, rather than one million days.

Rapid identification of novel active hit molecules suitable to initiate hit-to-lead and lead optimization efforts

Several hit-finding technologies we have developed are routinely used to identify active hit molecules to initiate small molecule drug discovery programs. In our hit-finding campaigns, we and our software customers typically utilize:

 

•

modern machine learning models trained to the two-dimensional structures of known active molecules using our software solution, AutoQSAR/DeepChem;

 

•

shape-based methods trained to the known or computationally deduced three-dimensional bioactive conformations of known active molecules using our software solution, Shape;

 

•

structure-based docking methods that evaluate the number and kind of interactions possible utilizing a static atomistic representation of the experimentally determined three-dimensional structure of the target protein receptor using our software solutions, Glide and WScore; and

 

•

free energy calculations using our software solution FEP+, which provides a fully dynamic atomistic representation of the target protein receptor.

These four approaches are complementary to each other, and their integrated use has led to successful hit-finding campaigns for dozens of protein targets in our collaborative and internal drug discovery programs. There are also numerous reports in the literature and in patents of our software customers utilizing some combination of these approaches to identify hit molecules.

AutoQSAR/DeepChem is trained to find known active molecules in a search through a molecule library and operates solely on the two-dimensional structure of the molecule. From this training process, AutoQSAR/DeepChem learns to identify substructures in the molecules that may lead to activity. Then when applied to large libraries of molecules, these methods can identify molecules with

28

Table of Contents

 

measurable activity against the target protein. These methods are highly efficient and can be used to screen billions of molecules in less than one day. However, one significant limitation is that machine learning methods cannot extrapolate into chemical space that differs from the training set and therefore, this method tends to identify molecules similar to already known molecules.

Shape is used to identify molecules with a similar shape to known active molecules. It has been shown that molecules with similar three-dimensional shapes can have similar activities. While the hit rates and computational efficiencies of Shape and AutoQSAR/DeepChem are generally comparable, the hit molecules returned by these techniques tend to be distinct and complementary rather than redundant. This allows results from Shape to augment the AutoQSAR/DeepChem results while still being efficient for screening a large library.

Glide and WScore use knowledge of three-dimensional structure of the binding site of the protein of interest, rather than the structure of active molecules, to evaluate the likelihood of a small molecule to bind a protein target. Glide and WScore evaluate molecules based on the number and kind of contacts made between the molecule and protein. These methods are much more computationally expensive than AutoQSAR/DeepChem or Shape. However, they can be more readily applied to targets for which there is little or no earlier reported active molecules.

The fourth computational method we routinely use to identify hit molecules to initiate drug discovery programs is the FEP+ solution described above. When used in this context, FEP+ can be used to completely replace the core moiety of an earlier known molecule to yield a novel molecule with similar binding potency. This approach is much more computationally intensive than previous methods, but is also much more accurate. Utilizing this approach on multiple programs, we have been able to identify novel nanomolar or picomolar inhibitors in the first few months of project chemistry that have property profiles typical of molecules only observed in the later hit-to-lead phases of drug discovery.  Our FEP+ solution also supports the calculation of absolute binding affinities, which enables the software to evaluate and triage diverse molecules sharing no common peripheral features in a hit discovery context.

Computational analysis of the energetic properties of water molecules occupying molecule binding sites in proteins

Subtle structural variations in molecules can have a profound impact on binding affinity to the protein target. The effects of these structural variations can be explained by a detailed examination of the thermodynamics of binding, including the free energy changes resulting from displacing water molecules in the binding site. Our computational software solution WaterMap maps the locations and energetic properties of water molecules that occupy protein binding sites, provides insight into the properties of the binding site, and quantitatively describes the water-mediated forces driving the binding of small molecules. Further, such an analysis can be used to assess the propensity of drug-like molecules to bind to the protein target with high affinity. WaterMap presents the computed results graphically for easy visualization of the water molecules occupying a binding site and their energetic properties. This makes interpretation of binding affinity data more intuitive and provides insights to possible design routes to improve potency and selectivity.

Competition

Software Business

The overall market for molecular discovery and design software is global, rapidly evolving, competitive, and subject to changing technology and shifting customer focus. The solutions and applications offered by our competitors vary in size, breadth, and scope.

We believe the principal competitive factors in our market include, among other things, accuracy of computations, level of customer satisfaction and functionality, ease of use, breadth and depth of solution and application functionality, brand awareness and reputation, modern and adaptive technology platform, integration, security, scalability and reliability of applications, total cost, ability to innovate and respond to customer needs rapidly, and ability to integrate with legacy enterprise infrastructures and third-party applications.

We believe that we compete favorably on the basis of these factors and that the effort and investment required to develop a computational, physics-based platform similar to ours will hinder new entrants that are unable to invest the necessary capital and time, and lack the breadth and depth of technical expertise required to develop competing technology. Our ability to remain competitive will largely depend on our ability to continue to improve our computational platform and demonstrate success in our drug discovery efforts.

29

Table of Contents

 

Our software solutions face competition from commercial competitors in the business of selling or providing simulation and modeling software to biopharmaceutical companies. These competitors include BIOVIA, a brand of Dassault Systèmes SE, or BIOVIA, Chemical Computing Group (US) Inc., Cresset Biomolecular Discovery Limited, OpenEye Scientific Software, Inc., Optibrium Limited, Cyrus Biotechnology, Inc., Molsoft LLC, Insilico Medicine, Inc., Iktos, XtalPi Inc., and Simulations Plus, Inc.

We also have competitors in materials science, such as BIOVIA and Materials Design, Inc., and in enterprise software for the life sciences, such as BIOVIA, Certara USA, Inc., ChemAxon, PerkinElmer, Inc., and Dotmatics, Inc. In some cases, these competitors are well-established providers of these solutions and have long-standing relationships with many of our current and potential customers, including large biopharmaceutical companies. In addition, there are academic consortia that develop physics-based simulation programs for life sciences and materials applications. In life sciences, the most prominent academic simulation packages include AMBER, CHARMm, GROMACS, GROMOS, OpenMM, and OpenFF. These packages are primarily maintained and developed by graduate students and post-doctoral researchers, often without the intent for commercialization.

We also face competition from solutions that biopharmaceutical companies develop internally, smaller companies that offer products and services directed at more specific markets than we target, enabling these competitors to focus a greater proportion of their efforts and resources on these markets, as well as a large number of companies that have been founded with the goal of applying machine learning technologies to drug discovery.

Drug Discovery Business

The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and strong emphasis on proprietary and novel products and product candidates. While we believe that our computational platform, technology, knowledge, experience, and scientific resources provide us with competitive advantages, our drug discovery business faces potential competition from many sources, including major pharmaceutical, specialty biopharmaceutical companies, technology companies, academic institutions and government agencies, and public and private research institutions. Any product candidates that we or one of our collaborators successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future.

The key competitive factors affecting the success of the product candidates we develop, if approved, are likely to be their efficacy, safety, convenience and price, the level of generic competition and the availability of coverage and adequate reimbursement from third-party payors. If any of our product candidates are approved and successfully commercialized, it is likely that we will face increased competition as a result of other companies pursuing development of products to address similar diseases.

In particular, there is intense competition in the fields of oncology we are pursuing. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying new product candidates.

Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than our products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from the FDA or other comparable foreign regulatory authorities or in discovering, developing and commercializing products in our field before we do.

30

Table of Contents

 

Collaboration Agreement with Bristol-Myers Squibb Company

In November 2020, we entered into an exclusive, worldwide collaboration and license agreement with BMS, pursuant to which we and BMS agreed to collaborate in the discovery, research and preclinical development of small molecule compounds (other than protein-degrader compounds) for biological targets in the oncology, neurology and immunology therapeutic areas.

Under the agreement, during a limited research term, we will be responsible, at our own cost and expense, for the discovery of small molecule compounds (other than protein-degrader compounds) directed to five specified biological targets pursuant to a mutually agreed research plan for each such target. The initial collaboration targets included HIF-2 alpha and SOS1/KRAS, which were two of our early-stage programs. In November 2021, we and BMS mutually agreed to replace the HIF-2 alpha target with another precision oncology target. Following the replacement election, all rights to the HIF-2 alpha target program reverted to us. Once we have discovered or identified a compound for a target that meets specified, mutually-agreed criteria or upon BMS selection of a compound as a development candidate, BMS will be solely responsible for the further preclinical and clinical development, manufacturing and commercialization of such candidate at its own cost and expense. The research term will end on the earlier of four years or until we have delivered a candidate for each specified target. We may elect to extend the research term for a limited period of time to deliver a candidate for a given target. In addition, the parties may mutually agree to extend the initial research term for an additional year. Under the agreement, BMS has agreed to use commercially reasonable efforts to develop, seek and obtain regulatory approval for, and commercialize at least one product that contains a licensed compound for each target in each of the United States, Japan and the European Union. The research component of the collaboration will be overseen by a joint steering committee comprised of an equal number of representatives from each of us and BMS. In addition to the initial specified targets, the parties have also agreed on a list of four reserved targets. BMS may replace one of the initial specified targets with a reserved target during a limited substitution period in the research term.

Pursuant to the agreement, for a given target, we have granted to BMS an exclusive license, with the right to grant sublicenses, under certain patent rights, know-how and materials controlled by us to clinically develop, manufacture, use, sell, offer for sale, export and import and otherwise exploit, and have others do the same, any compound, molecule or product for such target throughout the world.

Under the terms of the agreement, BMS paid us an initial upfront fee payment of $55 million. We are also entitled to receive up to $2.7 billion in total milestones across all potential targets. Such milestones consist of up to $585 million in total milestones per oncology target, including $360 million in the aggregate for certain specified research, development and regulatory milestones and $225 million in the aggregate for certain specified commercial milestones, as well as up to $482 million in total milestones per neurology and immunology target, including $257 million in the aggregate for certain specified research, development and regulatory milestones and $225 million in the aggregate for certain specified commercial milestones.

We are also entitled to a tiered percentage royalty on annual global net sales of licensed products ranging from mid-single digits to low-double digits, subject to certain specified reductions. Royalties are payable by BMS on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim of certain specified patent rights covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country.

The agreement excludes any activities relating to protein-degrader compounds. However, under the terms of the agreement, for a limited period of time after the execution of the agreement, we and BMS agreed to negotiate a separate definitive agreement pursuant to which we will agree to license to BMS the right to conduct research, development and commercialization activities with respect to degrader compounds for the targets under the agreement. In August 2021, we and BMS entered into a definitive agreement to discover, develop and commercialize bifunctional protein degraders consistent with the terms and conditions described in the initial collaboration agreement.

On a target-by-target basis, during the term of the agreement for a given target, we are prohibited from clinically developing or commercializing, ourselves or with a third party, any nucleic acid, antibody, biologic, compound, small molecule or other molecule, or any product that contains the foregoing, that specifically modulates as its primary mechanism of action such target, or is designed to specifically modulate such target. Such prohibition encompasses both the initial specified targets listed as of the effective date of the agreement and those targets on the reserved target list for the limited substitution period.

Unless earlier terminated, the agreement will expire on a licensed product-by-licensed product and country-by-country basis on the expiration of the applicable royalty term for such licensed product in such country and in its entirety upon expiration of the last royalty term for the last licensed product. Either party may terminate the agreement earlier upon an uncured material breach of the agreement by the other party on a target-by-target basis, or upon the occurrence of certain events of insolvency of the other party.

31

Table of Contents

 

Additionally, BMS may terminate the agreement for any or no reason, in its entirety or on a target-by-target basis, upon specified written notice to us. BMS may also terminate the agreement on a target-by-target basis for safety reasons. We may terminate the agreement on a target-by-target basis to the extent BMS commences or participates in challenging certain patents licensed by us to BMS under the agreement.

In the event that BMS terminates the Agreement at will, or if we terminate for a breach, insolvency or patent challenge by BMS, we are entitled to certain reversionary rights with respect to certain compounds and products for the applicable terminated target(s).

In the event that BMS has the right to terminate the agreement, in whole or with respect to a particular target, upon our uncured material breach or an event of insolvency with respect to us, then in lieu of so terminating, BMS has the right to elect to the have the agreement continue in full force and effect; provided that all royalties and milestones thereafter payable by BMS to us with respect to such applicable target(s) shall be reduced by 50%.

License Agreements with Columbia University

We have entered into several license agreements with Columbia University, or the Columbia License Agreements. The Columbia License Agreements establish our rights and obligations with respect to certain patents, software code, technology, and improvements thereto that we license from Columbia University and that are used in, and integrated into, our software solutions, and our physics-based computational platform. Our rights and obligations under, and the terms and conditions of, the Columbia License Agreements that we consider material to the operation of our business are described more fully below.

On November 1, 2008, we entered into an amendment, or the Royalty Amendment, to certain Columbia License Agreements, including each of the agreements described below. The Royalty Amendment simplified the royalties payable under each agreement on gross revenues generated from the use of any product which contains any code or software, or is covered by any patent, that we license from Columbia University, or a Licensed Product, in connection with a services agreement. We also pay royalties under the Columbia License Agreements on gross revenues generated from the sale, licensing or renting of our Licensed Products, which we calculate on a product-by-product basis. In the event that one or more Licensed Products are sold together with other products for a single aggregate license fee, we have agreed to pay to Columbia University the applicable royalty on the gross revenues attributable to each Licensed Product based on the relative list prices of each product covered by such license fee.

For a description of the royalties payable by us to Columbia University in connection with our services agreements, see “—Services Royalty Amendment” below.

PS-GVB License Agreement

On May 5, 1994, we entered into a license agreement, or the 1994 Columbia Agreement, with Columbia University, which was amended on September 9, 2004 and November 1, 2008. The technology licensed under the 1994 Columbia Agreement is incorporated into our Jaguar quantum mechanical program, which we market and distribute as part of our physics-based computational platform. The 1994 Columbia Agreement grants us a worldwide, exclusive, license to the software code developed by Columbia University and incorporated into the electronic structure software program PS-GVB v1.0, or the PS-GVB Code, and all improvement to the PS-GVB v1.0 software program and PS-GVB Code developed by Columbia University, or the PS-GVB Improvements, including all PS-GVB Code and PS-GVB Improvements that are incorporated into any new products, new releases, and new versions related to the software, or the New PS-GVB Module Code, in each case, to reproduce, use, execute, copy, operate, sublicense, and distribute in connection with the marketing and sale of our products and services, to develop improvements thereto, and to conduct research and backup disaster recovery. We may only sublicense the PS-GVB Code, the PS-GVB Improvements, and the New PS-GVB Module Code, or the Licensed PS-GVB Software, to the extent they are incorporated into a product that is sold directly by us or that is distributed on our behalf. Under the 1994 Columbia Agreement, Columbia University retains the right to conduct, and to permit other academic and non-profit research institutions to conduct, research using the Licensed PS-GVB Software.

As consideration for entering into the 1994 Columbia Agreement, we have agreed to pay royalties to Columbia University in the low-single digit to low-double digit percentages based upon the contribution of Columbia University generated code to the applicable PS-GVB v1.0 software program on our, and our affiliates’, gross revenues from the sale, licensing, or renting of the PS-GVB v1.0 software program, including any improvements and modifications thereto, regardless of whether such improvement or modification is marketed as a new version, new release, or new product, excluding any sales to Columbia University and any revenue generated under services agreements.

The 1994 Columbia Agreement and the licenses granted thereunder may be terminated by us or Columbia University only upon the other party’s material breach of the agreement and such party’s failure to cure such breach. Upon termination, any third party that

32

Table of Contents

 

has licensed the Licensed PS-GVB Software from us will retain the right to use such software, and we will have the perpetual right to continue to provide support to any such third parties in connection with their use of such software.

Fast Multipole RESPA License Agreement

On July 15, 1998, we entered into a license agreement, or the 1998 Columbia Agreement, with Columbia University, which was amended on September 4, 2004, and November 1, 2008. The 1998 Columbia Agreement grants us a worldwide, non-exclusive, license to the Fast Multipole RESPA code developed at Columbia University, or the RESPA Code, which was incorporated into the IMPACT software program used in our Glide ligand-protein docking program, PrimeX protein modelling program, QSite QM/MM program, and Combglide automated library generation program, and all improvements to the IMPACT software program, including any new versions and new releases thereof, that are developed by Columbia University, or the IMPACT Improvements, in each case, to reproduce, use, execute, copy, compile, operate, sublicense, and distribute in connection with the marketing and sale of our products and services, to develop improvements thereto, and to conduct research and backup disaster recovery. We may sublicense the RESPA Code and the IMPACT Improvements, or the Licensed IMPACT Software, to the extent it is incorporated into a product that is sold directly by us or that is distributed on our behalf. Under the 1998 Columbia Agreement, Columbia University retains the right to conduct, and to permit other academic and non-profit research institutions to conduct, research using the Licensed IMPACT Software.

As consideration for entering into the 1998 Columbia Agreement, we have agreed to pay royalties to Columbia University in the low-single digit to low-double digit percentages based upon the contribution of Columbia University generated code to the applicable IMPACT software program on our, and our affiliates’, gross revenues from the sale, licensing, or renting of the IMPACT software program, including any improvements and modifications thereto and any new versions and new releases thereof, excluding any sales to Columbia University and revenue generated under services agreements.

The 1998 Columbia Agreement and the licenses granted thereunder may be terminated by us or Columbia University only upon the other party’s material breach of the agreement and such party’s failure to cure such breach. Upon termination, any third party that has licensed software from us subject to the 1998 Columbia Agreement will retain the right to use such software, and we will have the perpetual right to continue to provide support to any such third parties in connection with their use of such software.

Protein Folding License Agreement

In September 2001, we entered into a license agreement, or the 2001 Columbia Agreement, with Columbia University, which was amended on September 9, 2004 and November 1, 2008. The technology licensed under the 2001 Columbia Agreement is incorporated into our Prime protein modelling program, which we market and distribute as part of our physics-based computational platform. The 2001 Columbia Agreement grants us a worldwide, exclusive license to the protein folding code developed by Columbia University, or the Folding Code; all improvements to the Folding Code and to any of our products, software, or code that incorporates any part of the Folding Code, including any improvements thereto and new versions or new releases thereof, that are developed by Columbia University, or the Folding Code Improvements; and the issued patent covering the Folding Code, or the Folding Code Patent, in each case, to reproduce, use, execute, copy, compile, operate, sublicense, and distribute in connection with the marketing and sale of our products and services, to develop improvements thereto, and to conduct research and backup disaster recovery. We may sublicense the Folding Code, the Folding Code Improvements and the Folding Code Patent, or the Licensed Folding Code Software, to the extent it is incorporated into a product that is sold directly by us or that is distributed on our behalf. Under the 2001 Columbia Agreement, Columbia University retains the right to conduct, and to permit other academic and non-profit research institutions to conduct, research using the Licensed Folding Code Software.

As consideration for entering into the 2001 Columbia Agreement, we paid Columbia University a one-time, nominal license fee. In addition, we have paid royalties to Columbia University in low-single digit to low-double digit percentages based upon the contribution of Columbia University generated code to the applicable product, software program, or code on our, and our affiliates’, gross revenues from the sale, licensing, or renting of any commercial product, software program, or code incorporating the Licensed Folding Code Software, excluding any sales to Columbia University and revenues generated under services agreements. Our obligation to pay any royalty under the 2001 Columbia Agreement, including any royalty paid pursuant to the Royalty Amendment, terminated with the expiration of the last to expire patent licensed under the 2001 Columbia Agreement in January 2014.

The 2001 Columbia Agreement and the licenses granted thereunder may be terminated by Columbia University only upon our material breach of the agreement and our failure to cure such breach. Upon termination, any third party that has licensed software from us subject to the 2001 Columbia Agreement will retain the right to use such software, and we will have the perpetual right to continue to provide support to any such third parties in connection with their use of such software.

33

Table of Contents

 

PLOP License Agreement

On June 19, 2003, we entered into a license agreement, or the 2003 Columbia Agreement, with Columbia University, which was amended on November 1, 2008. The technology licensed under the 2003 Columbia Agreement is incorporated into our Prime and PrimeX protein modelling programs and our Membrane Permeability model, which we market and distribute as part of our physics-based computational platform. The 2003 Columbia Agreement grants us a worldwide, exclusive license to the protein local optimization program software code, or the PLOP Code, developed at Columbia University and the University of California and all software code comprising improvements to the PLOP Code that are developed by Columbia University or the University of California, or the PLOP Improvements, in each case, to reproduce, use, execute, copy, compile, operate, sublicense, and distribute in connection with the marketing and sale of our products and services, to develop improvements thereto, and to conduct research and backup disaster recovery. Pursuant to an interinstitutional agreement between Columbia University and the University of California, the University of California granted Columbia University the sole right to license the PLOP Code and PLOP Improvements and has agreed not to license the PLOP Code or PLOP Improvements to any third party for as long as the interinstitutional agreement remains in effect. We may sublicense the PLOP Code and PLOP Improvements to the extent they are incorporated into a product that is sold directly by us or that is distributed on our behalf. We are restricted from distributing the PLOP Code and PLOP Improvements source code without the prior written consent of Columbia University.

Columbia University and the University of California retain the right to use, and to permit other academic and non-profit research institutions to use, the PLOP Code and PLOP Improvements for teaching and academic research purposes.

As consideration for entering into the 2003 Columbia Agreement, we paid Columbia University a one-time, nominal license fee. In addition, we have agreed to pay royalties to Columbia University in low-single digit to low-double digit percentages based upon the contribution of Columbia University generated code to the applicable product, software program, or code on our, and our affiliates’, gross revenues from the sale, licensing, leasing, or renting any commercial product, software program, or code incorporating the PLOP Code or any PLOP Improvements, excluding any sales to Columbia University or the University of California and revenues generated under services agreements. Our obligation to pay any royalty under the 2003 Columbia Agreement, including any royalty paid pursuant to the Royalty Amendment, will terminate on June 19, 2023.

Columbia University is responsible for the copyright registration of the PLOP Code and PLOP Improvements. We are responsible for paying all reasonable copyright registration and attorney fees in connection with such copyright registrations.

The 2003 Columbia Agreement and the licenses granted thereunder may be terminated by us or Columbia University only upon the other party’s material breach of the agreement and such party’s failure to cure such breach. Upon termination, any third party that has licensed software from us subject to the 2003 Columbia Agreement will retain the right to use such software, and we will have the perpetual right to continue to provide support to any such third parties in connection with their use of such software.

Water Site Analysis License

On May 27, 2008, we entered into a software and patent license agreement, or the 2008 Columbia Agreement, with Columbia University, which was amended on November 1, 2008. The 2008 Columbia Agreement grants us a worldwide license, exclusive in the field of computational chemistry software and related services, to (a) certain software that implements the water site analysis method, or the Water Site Software; (b) all patent rights covering the Water Site Software, or the Water Site Patents; and (c) any products that incorporate or include the Water Site Software, or that is covered by the Water Site Patents, or the Water Site Products, in each case, to reproduce, modify, distribute, and perform and display in connection with the development, marketing, and sale of our products and services, to conduct research using the Water Site Software, and to conduct backup disaster recovery. Our Water Site Products include our WaterMap Core program, which we market and distribute as part of our physics-based computational platform. We are restricted from distributing the Water Site Software source code without the prior written consent of Columbia University. Under the 2008 Columbia Agreement, Columbia University retains the right to use, and to permit other entities and individuals to use, the Water Site Software and Water Site Patents for academic and non-commercial educational purposes in the field of computational chemistry software and related services.

As consideration for entering into the 2008 Columbia Agreement, we paid Columbia University a one-time, nominal license fee. In addition, we have agreed to pay royalties to Columbia University in low-double digit percentages on our, and our affiliates’, gross revenues from the sale, licensing, leasing, or renting of any Water Site Product, excluding any sales to Columbia University and revenues generated under services agreement. The royalties under the 2008 Columbia Agreement are paid on a product-by-product basis and vary based on whether or not the gross revenues are generated in countries of manufacture or sale in which the Water Site Product is covered by a Water Site Patent. In the event that there are multiple royalties payable on a single product, we are required to (i) pay the higher of the two royalties, if there are no more than two royalties payable on the particular Water Site Product or

34

Table of Contents

 

(ii) negotiate in good faith with Columbia University on a single royalty, if there are more than two royalties payable on the particular Water Site Product. In the event that we take action against Columbia University with respect to the validity or enforceability of any Water Site Patents, excluding any defensive actions or claims, the royalties paid under the 2008 Columbia Agreement will increase by a specified amount. Our obligation to pay any royalty under the 2008 Columbia Agreement, including any royalty paid pursuant to the Royalty Amendment, will terminate on May 27, 2028.

Columbia University is responsible for the prosecution and maintenance of the Water Site Patents in the jurisdictions that we specify. If we decide to discontinue the prosecution or maintenance of any Water Site Patent in any jurisdiction, but Columbia University objects to such discontinuation, our license to use such Water Site Patent will terminate in that jurisdiction; provided that, if we are using the Water Site Patent or Water Site Software in the jurisdiction at issue, Columbia University is obligated to discuss in good faith whether the licenses should instead be non-exclusive. Columbia University is also responsible for the enforcement of the Water Site Patent at its own expense and in its sole judgment; provided that, if we provide Columbia University with evidence of infringement of a Water Site Patent by a third party, and Columbia University fails to take appropriate enforcement action, we may initiate legal proceedings against the alleged infringer. We are responsible for reimbursing Columbia University for their reasonable expenses in connection with prosecuting and maintaining the Water Site Patents.

Unless terminated earlier, the 2008 Columbia Agreement will expire on a product by product and country by country basis upon the later of (i) the expiration of the last issued Water Site Patent, (ii) fifteen years from the date of the first commercial sale of a Water Site Product in a given country, and (iii) the expiration of the Water Site Software copyright. Columbia University may terminate the 2008 Columbia Agreement if we fail to cure a material breach, become subject to a voluntary or involuntary petition for bankruptcy or any other proceeding relating to insolvency, receivership or liquidation, or initiate any proceeding or assert any claim challenging the validity or enforceability of the Water Site Patents. Upon termination, any third party that has licensed a Water Site Product from us will retain the right to use such product, subject to the terms of their existing license agreement with us, and we will have the right to continue to provide support to any such third parties for the duration of their license agreement.

Services Royalty Amendment

On November 1, 2008, we entered into the Royalty Amendment with Columbia University, which amended and simplified our royalty obligations under each of the Columbia License Agreements described in each of the foregoing sections. Pursuant to the Royalty Amendment, we have agreed to pay royalties to Columbia University in mid-single digit percentages on the service fees generated from services (excluding certain gross revenue, including revenue generated under agreements with Columbia University) that we, or our affiliates, perform using one or more Licensed Products under an agreement with a third party. Upon termination of any of the Columbia License Agreements for any reason other than our material breach, we will have the right to continue to use the Licensed Products to provide services under existing third-party service agreements, until the expiration or termination of such agreements.

Intellectual Property

We strive to protect and enhance the proprietary technology, inventions, and improvements that are commercially important to the development of our business, including by seeking, maintaining, and defending patent rights, whether developed internally or jointly, or licensed from third parties. We also rely on trade secrets, know-how, continuing technological innovation, collaboration opportunities, and in-licensing opportunities to develop, strengthen, and maintain our proprietary position in our field.

It is important to our future commercial success to obtain and maintain patent and other proprietary protection for commercially important technology, inventions, and know-how related to our business; defend and enforce our intellectual property rights, in particular our patent, trademark, and copyright rights; preserve the confidentiality of our trade secrets; and operate without infringing, misappropriating, or violating the valid and enforceable patents and proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell, or importing any products we develop may depend on the extent to which we have rights under valid and enforceable patents or trade secrets that cover these activities.

The patent positions of companies like ours are generally uncertain and can involve complex legal, scientific, and factual issues. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. We also cannot ensure that patents will issue with respect to any patent applications that we or our licensors may file in the future, nor can we ensure that any of our owned or licensed patents or future patents will be commercially useful in protecting our software, technology, computational platform, and any product candidates we develop. In addition, the coverage claimed in a patent application may be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any products we develop will be protected or remain protectable by enforceable patents. Moreover, any patents that we

35

Table of Contents

 

hold or may hold may be challenged, circumvented or invalidated by third parties. See “Risk Factors—Risks Related to Our Intellectual Property” for a more comprehensive description of risks related to our intellectual property.

Our strategy is to file patent applications directed to our key software and our key programs in an effort to secure our intellectual property positions vis-a-vis this software and these programs. The patent portfolio for our software business includes at least 12 published patent families. As of February 4, 2022, we owned or held exclusive license rights to approximately 55 patents and patent applications, including at least eight issued or allowed U.S. cases, five pending U.S. non-provisional patent applications, 11 issued or allowed non-U.S. cases, including six granted European patents which have been validated among multiple individual European Patent Convention nations and five non-European patents, and nine pending foreign patent applications relating to our computational platform. While we believe that the specific and generic claims contained in our wholly-owned and licensed pending U.S. and non-U.S. applications provide protection for various aspects of our computational platform, third parties may nevertheless challenge such claims. Any patents that are issued or that may issue from these families are expected to expire between 2026 and 2038, absent any adjustments or extensions.

As of February 4, 2022, there were two published patent families related to our internal drug discovery business, and several of our drug discovery collaborators have filed patent applications related to our collaborations that include employees of ours as inventors, including over 100 compound patents and patent applications since 2010. We do not own any intellectual property rights related to these inventions. As of February 4, 2022, there are six pending wholly-owned provisional applications, six pending international patent applications, and two pending non-U.S. patent applications related to our internal drug discovery business.

Prosecution is a lengthy process, during which the scope of the claims initially submitted for examination by the U.S. Patent and Trademark Office may be significantly narrowed before issuance, if issued at all. We expect this may be the case with respect to some of our pending patent applications.

The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application, absent any adjustments or extensions.

In addition, in the United States, the term of a patent covering an FDA-approved drug may, in certain cases, be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984 as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years, but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents we may obtain in the future may be entitled to patent term extensions. If our use of product candidates or the product candidate itself receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved use or product candidate. We also intend to seek patent term extensions in any jurisdictions where available, however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and even if granted, the length of such extensions.

In addition to patent protection, as of February 4, 2022, we had approximately 49 copyright registrations covering our proprietary software code, and we rely upon unpatented trade secrets and confidential know-how and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and confidential know-how are difficult to protect. We seek to protect our proprietary information, in part, using confidentiality agreements with any collaborators, scientific advisors, service providers, employees, and consultants and invention assignment agreements with our employees. We also have agreements requiring assignment of inventions with selected consultants, scientific advisors, and collaborators. These agreements may not provide meaningful protection. These agreements may also be breached, and we may not have an adequate remedy for any such breach. In addition, our trade secrets and/or confidential know-how may become known or be independently developed by a third party, or misused by any collaborator to whom we disclose such information. Despite any measures taken to protect our intellectual property, unauthorized parties may attempt to copy aspects of our products or to obtain or use information that we regard as proprietary. Although we take steps to protect our proprietary information, third parties may independently develop the same or similar proprietary information or may otherwise gain access to our proprietary information. As a result, we may be unable to meaningfully protect our trade secrets and proprietary information. See “Risk Factors—Risks Related to Our Intellectual Property” for a more comprehensive description of risks related to our intellectual property.

We also own numerous trademarks registered in the United States and foreign jurisdictions, including “Schrödinger” and “LiveDesign”. We pursue additional trademark registrations to the extent we believe doing so would be beneficial to our competitive position.

36

Table of Contents

 

Sales and Marketing

Software Business

We commercialize our software solutions in various jurisdictions around the world through our software sales organization. We have sales operations in the United States, Europe, Japan, India, and South Korea and we also have established distribution channels in other important markets, including China. These efforts are led by our approximately 150 person global team of sales, technical, and scientific personnel. Our marketing strategy leverages our strong base of scientific publications to support the continued growth of our computational platform into computational chemistry markets across industries and academia worldwide.

Drug Discovery Business

We have not established a commercial organization or developed distribution capabilities given the current stage of development of our internal, wholly-owned drug discovery programs. We plan to enter into agreements with biopharmaceutical companies that contribute to our ability to efficiently advance development candidates that we discover internally using our computational platform through to commercialization. We expect to utilize a variety of types of collaboration, distribution, and other arrangements with one or more of these third parties to develop and ultimately commercialize our development candidates. Over time, we may also create a commercial organization for drug product sales if and as we advance the development of any product candidates that we determine to commercialize ourselves.

Manufacturing

We do not own or operate manufacturing facilities for the production of any product candidates, nor do we have plans to develop our own manufacturing operations. We rely and expect to continue to rely on third-party contract manufacturers for all of our required raw materials, drug substance, and finished drug product for the preclinical and clinical development of any development candidates we develop ourselves.

Government Regulation and Product Approvals

Government authorities in the United States at the federal, state and local level, and in other countries and jurisdictions, including the European Union, extensively regulate, among other things, the research, development, testing, manufacture, pricing, reimbursement, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, post-approval monitoring and reporting, and import and export of biopharmaceutical products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.

Approval and Regulation of Drugs in the United States

In the United States, drug products are approved and regulated under the Federal Food, Drug and Cosmetic Act, or FDCA, and applicable implementing regulations and guidance. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for such products, and for their regulatory approval, is typically referred to as a sponsor. The failure of a sponsor to comply with the applicable regulatory requirements at any time during the product development process, including non-clinical testing, clinical testing, the approval process or post-approval process, may result in delays to the conduct of a study, regulatory review and approval, and/or administrative or judicial sanctions.

A sponsor seeking approval to market and distribute a new drug in the United States generally must satisfactorily complete each of the following steps before the product candidate will be approved by the FDA:

 

•

preclinical testing including laboratory tests, animal studies, and formulation studies, which must be performed in accordance with the FDA’s good laboratory practice, or GLP, regulations and standards;

 

•

design of a clinical protocol and submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin;

 

•

approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated;

 

•

performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication, in accordance with current good clinical practices, or GCP;

37

Table of Contents

 

 

•

preparation and submission to the FDA of a new drug application, or NDA, for a drug product which includes not only the results of the clinical trials, but also detailed information on the chemistry, manufacture and quality controls for the product candidate and proposed labeling for one or more proposed indication(s);

 

•

review of the product candidate by an FDA advisory committee, where appropriate or if applicable;

 

•

satisfactory completion of an FDA inspection of the manufacturing facility or facilities, including those of third parties, at which the product candidate or components thereof are manufactured to assess compliance with current good manufacturing practices, or cGMP, requirements and to assure that the facilities, methods, and controls are adequate to preserve the product’s identity, strength, quality, and purity;

 

•

satisfactory completion of any FDA audits of the non-clinical and clinical trial sites to assure compliance with GCP and the integrity of clinical data in support of the NDA;

 

•

payment of user fees and securing FDA approval of the NDA to allow marketing of the new drug product; and

 

•

compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct any post- approval studies required by the FDA.

Preclinical Studies

Before a sponsor begins testing a product candidate with potential therapeutic value in humans, the product candidate enters the preclinical testing stage, including in vitro and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. Preclinical tests include laboratory evaluations of product chemistry, formulation, and stability, as well as other studies to evaluate, among other things, the toxicity of the product candidate. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the United States Department of Agriculture’s Animal Welfare Act, if applicable. The results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, are submitted to the FDA as part of an IND. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity and long-term toxicity studies may continue after the IND is submitted.

The IND and IRB Processes

Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their voluntary informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the inclusion and exclusion criteria, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.

An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an investigational clinical trial and a request for FDA authorization to administer such investigational product to humans. Such authorization must be secured prior to interstate shipment and administration of any product candidate that is not the subject of an approved NDA. In support of a request for an IND, sponsors must submit a protocol for each clinical trial, and any subsequent protocol amendments must be submitted to the FDA as part of the IND. The FDA requires a 30-day waiting period after the filing of each IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. At any time during this 30-day period, the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical hold or partial clinical hold. In these cases, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials, or parts of the trial, can begin.

Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. Clinical holds are imposed by the FDA whenever there is concern for patient safety and may be a result of new data, findings, or developments in clinical, nonclinical, and/or chemistry, manufacturing, and controls, or CMC. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol may not be allowed to proceed, while other protocols may be allowed. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold.

38

Table of Contents

 

Following issuance of a clinical hold or partial clinical hold, a clinical trial may only resume after the FDA has so notified the sponsor. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the clinical trial can proceed.

A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that such studies are conducted in accordance with GCP, including review and approval by an independent ethics committee, or IEC, and informed consent from subjects, if the data from such a foreign study is to be used in support of a marketing application.

In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB’s requirements or if the product candidate has been associated with unexpected serious harm to patients.

Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or committee. This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk. Other reasons for suspension or termination may be made by us based on evolving business objectives and/or the competitive environment.

Expanded Access

Expanded access, sometimes called “compassionate use,” is the use of investigational new products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational products for patients who may benefit from investigational therapies. FDA regulations allow access to investigational products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational product under a treatment protocol or Treatment IND Application.

When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational product for the requested treatment will not interfere with the initiation, conduct or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.

There is no obligation for a sponsor to make its investigational products available for expanded access; however, as required by amendments to the FDCA included in the 21st Century Cures Act passed in 2016, if a sponsor has a policy regarding how it responds to expanded access requests with respect to product candidates in development to treat serious diseases or conditions, it must make that policy publicly available. Sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 trial for a covered investigational product; or 15 days after the investigational product receives designation from the FDA as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy.

Human Clinical Trials in Support of an NDA

Clinical trials involve the administration of the investigational product candidate to human subjects under the supervision of a qualified investigator in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written clinical trial protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated.

39

Table of Contents

 

Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may also be required after approval.

Phase 1 clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion, and pharmacodynamics in healthy humans or in patients. During Phase 1 clinical trials, information about the investigational drug product’s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials.

Phase 2 clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. Phase 2 clinical trials are well controlled, closely monitored and conducted in a limited patient population. A Phase 2 trial may be further subdivided to Phase 2a and Phase 2b trials. A Phase 2a trial is typically an exploratory (non-pivotal) study that has clinical efficacy, pharmacodynamics, or biological activity as the primary endpoint. A Phase 2b trial is a definite dose range finding study with efficacy as the primary endpoint.

Phase 3 clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy, and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 clinical trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve, and, if approved, how to appropriately label a drug. Such Phase 3 studies are referred to as “pivotal.”

A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company’s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.

In some cases, the FDA may approve an NDA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate’s safety and effectiveness after approval. Such post-approval trials are typically referred to as Phase 4 clinical trials. These studies are used to gain additional experience from the treatment of a larger number of patients in the intended treatment group and to further document a clinical benefit in the case of drugs approved under Accelerated Approval regulations. Failure to exhibit due diligence with regard to conducting Phase 4 clinical trials could result in withdrawal of approval for products.

Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other studies or animal or in vitro testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the case of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the clinical data submitted.

In August 2018, the FDA released a draft guidance entitled “Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,” which outlines how sponsors can utilize an adaptive trial design in the early stages of oncology product development (i.e., the first-in-human clinical trial) to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to product development and reduce developmental costs and time.

Sponsors of clinical trials are required to register and disclose certain clinical trial information on a public registry (clinicaltrials.gov) maintained by the U.S. National Institutes of Health.  In particular, information related to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. The failure to submit clinical trial information to clinicaltrials.gov, as required, is a prohibited act under the FDCA with violations subject to potential civil monetary penalties of up to $10,000 for each day the violation continues.

40

Table of Contents

 

Concurrent with clinical trials, companies often complete additional animal studies. They must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.

Pediatric Studies

Under the Pediatric Research Equity Act, or PREA, applications and certain types of supplements to applications must contain data that are adequate to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The sponsor must submit an initial Pediatric Study Plan within 60 days of an end-of-phase 2 meeting or as may be agreed between the sponsor and the FDA. Those plans must contain an outline of the proposed pediatric study or studies the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information.

The FDA may, on its own initiative or at the request of the sponsor, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The law now requires the FDA to send a PREA Non-Compliance letter to sponsors who have failed to submit their pediatric assessments required under PREA, have failed to seek or obtain a deferral or deferral extension or have failed to request approval for a required pediatric formulation.

Expedited Review Programs

The FDA is authorized to expedite the review of applications in several ways. None of these expedited programs changes the standards for approval but they may help expedite the development or approval process of product candidates.

 

•

Fast Track designation. The sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND.  Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review.

 

•

Breakthrough therapy designation. To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review.

 

•

Priority review. A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review.

 

•

Accelerated approval. Drug products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials.

41

Table of Contents

 

 

•

Regenerative advanced therapy. With passage of the 21st Century Cures Act, or the Cures Act, in December 2016, Congress authorized the FDA to accelerate review and approval of products designated as regenerative advanced therapies. A product is eligible for this designation if it is a regenerative medicine therapy that is intended to treat, modify, reverse or cure a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the product candidate has the potential to address unmet medical needs for such disease or condition. The benefits of a regenerative advanced therapy designation include early interactions with the FDA to expedite development and review, benefits available to breakthrough therapies, potential eligibility for priority review and accelerated approval based on surrogate or intermediate endpoints.

Filing and Review of an NDA

In order to obtain approval to market a drug product in the United States, a NDA must be submitted to the FDA that provides sufficient data establishing the safety and efficacy of the proposed drug product for its intended indication. The application includes all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product’s chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by independent investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the drug product to the satisfaction of the FDA.

The NDA is a vehicle through which sponsors formally propose that the FDA approve a new product for marketing and sale in the United States for one or more indications. Every new drug product candidate must be the subject of an approved NDA before it may be commercialized in the United States. Biologic License Applications, or BLAs, are submitted for licensure of biologic products under the Public Health Service Act. Under federal law, the submission of most NDAs is subject to an application user fee. The sponsor of an approved NDA is also subject to an annual program fee. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation, an exception from the program fee when the program does not engage in manufacturing the drug during a particular fiscal year and a waiver for certain small businesses.

The FDA conducts a preliminary review of the application within 60 calendar days of its receipt, and must inform the sponsor within that period of time whether the application is sufficiently complete to permit substantive review. In the event that FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF, determination to the sponsor. The FDA may request additional information rather than accept the application for filing and, the application may be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing.

Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Under that agreement, 90% of applications seeking approval of New Molecular Entities, or NMEs, are meant to be reviewed within ten months from the date on which the FDA accepts the application for filing, and 90% of applications for NMEs that have been designated for Priority Review are meant to be reviewed within six months of the filing date. For applications seeking approval of products that are not NMEs, the ten-month and six-month review periods run from the date that the FDA receives the application. The review process and the Prescription Drug User Fee Act, or PDUFA, goal date may be extended by the FDA for three additional months to consider new information or clarification provided by the sponsor to address an outstanding deficiency identified by the FDA following the original submission.

In connection with its review of an application, the FDA typically will inspect the facility or facilities where the product is being or will be manufactured. These pre-approval inspections may cover all facilities associated with an NDA submission, including component manufacturing, finished product manufacturing, and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP and the integrity of the data in the application.

In addition, as a condition of approval, the FDA may require a sponsor to develop a REMS. A REMS uses risk-minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, the seriousness of the disease, the expected benefit of the product, the expected duration of treatment, the seriousness of known or potential adverse events, and whether the product is a new molecular entity.

The FDA may also refer an application for a novel product to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that review,

42

Table of Contents

 

evaluate and provide a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but the FDA considers such recommendations carefully when making decisions.

The FDA’s Decision on an NDA

The FDA reviews an application to determine, among other things, whether the product is safe and whether it is effective for its intended use(s), with the latter determination being made on the basis of substantial evidence.  The FDA has interpreted this evidentiary standard to require at least two adequate and well-controlled clinical investigations to establish effectiveness of a new product. Under certain circumstances, however, the FDA has indicated that a single trial with certain characteristics and additional information may satisfy this standard.  Ultimately, the FDA will determine whether the expected benefits of the drug product outweigh its potential risks to patients, and the agency will issue either a complete response letter, or CRL, or an approval letter.  

A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trials and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the sponsor will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional six-month extension to respond.  

If the FDA approves a new product, it may limit the approved indications for use of the product, require that contraindications, warnings, or precautions be included in the product labeling, or require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug’s safety after approval. The agency may also require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including a REMS, to help ensure that the benefits of the product outweigh the potential risks. REMS programs can include medication guides, communication plans for health care professionals, and elements to assure safe use, or ETASU. ETASU can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring, and the use of patent registries. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. The FDA may require a REMS before or after approval if it becomes aware of a serious risk associated with use of the product. The requirement for a REMS can materially affect the potential market and profitability of a product. After approval, many types of changes to the approved product, such as adding new indications, changing manufacturing processes, and adding labeling claims, are subject to further testing requirements and FDA review and approval.

Post-Approval Requirements

Following approval of a new prescription product, the manufacturer, the approved product and the product’s manufacturing locations are subject to pervasive and continuing regulation by the FDA, governing, among other things, monitoring and record-keeping activities, reporting of adverse experiences with the product and product problems to the FDA, product sampling and distribution, manufacturing and promotion and advertising. Although physicians may prescribe legally available products for unapproved uses or patient populations (i.e., “off-label uses”), manufacturers may not market or promote such uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a drug product.

If a company is found to have promoted off-label uses, it may become subject to administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes products, as well as adverse public relations and reputational harm. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.  

Patent Term Restoration and Extension

A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch- Waxman Act, which permits a patent restoration of up to five years for patent term lost during the FDA regulatory review. The restoration period granted on a patent covering a product is typically one-half the time between the effective date of the IND and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. Patent term restoration cannot

43

Table of Contents

 

be used to extend the remaining term of a patent past a total of 14 years from the product’s approval date. Only one patent applicable to an approved product is eligible for the extension, and only those claims covering the approved product, a method for using it, or a method for manufacturing it, may be extended. Additionally, the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The United States Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA.

Healthcare Compliance

In the United States, biopharmaceutical manufacturers and their products are subject to extensive regulation at the federal and state level, such as laws intended to prevent fraud and abuse in the healthcare industry.  Healthcare providers and third-party payors play a primary role in the recommendation and prescription of pharmaceutical products that are granted marketing approval. Arrangements with providers, consultants, third-party payors, and customers are subject to broadly applicable fraud and abuse, anti-kickback, false claims laws, reporting of payments to healthcare providers and patient privacy laws and regulations and other healthcare laws and regulations that may constrain our business and/or financial arrangements. Restrictions under applicable federal and state healthcare laws and regulations, including certain laws and regulations applicable only if we have marketed products, include the following:

 

•

federal false claims, false statements and civil monetary penalties laws prohibiting, among other things, any person from knowingly presenting, or causing to be presented, a false claim for payment of government funds or knowingly making, or causing to be made, a false statement to get a false claim paid;

 

•

federal healthcare program anti-kickback law, which prohibits, among other things, persons from offering, soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual for, or the purchasing or ordering of, a good or service for which payment may be made under federal healthcare programs such as Medicare and Medicaid;

 

•

the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, in addition to privacy protections applicable to healthcare providers and other entities, prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;

 

•

federal laws that require pharmaceutical manufacturers to report certain calculated product prices to the government or provide certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government healthcare programs;

 

•

federal Open Payments (or federal “sunshine” law), which requires pharmaceutical and medical device companies to monitor and report certain financial interactions with certain healthcare providers to the Center for Medicare & Medicaid Services, or CMS, within the U.S. Department of Health and Human Services for re-disclosure to the public, as well as ownership and investment interests held by certain healthcare providers and their immediate family members;

 

•

federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers;

 

•

analogous state laws and regulations, including: state anti-kickback and false claims laws; state laws requiring pharmaceutical companies to comply with specific compliance standards, restrict financial interactions between pharmaceutical companies and healthcare providers or require pharmaceutical companies to report information related to payments to health care providers or marketing expenditures; and state laws governing privacy, security and breaches of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts; and

 

•

laws and regulations prohibiting bribery and corruption such as the FCPA, which, among other things, prohibits U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations or foreign government-owned or affiliated entities, candidates for foreign public office, and foreign political parties or officials thereof.

Violations of these laws are punishable by criminal and/or civil sanctions, including, in some instances, exclusion from participation in federal and state health care programs, such as Medicare and Medicaid.  Ensuring compliance is time consuming and costly.  Similar healthcare laws and regulations exist in the EU and other jurisdictions, including reporting requirements detailing interactions with and payments to healthcare providers and laws governing the privacy and security of personal information.]

44

Table of Contents

 

Privacy Requirements

Privacy and data security requirements are either in place or underway in the United States. There are a broad variety of data protection laws that may be applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns based on general consumer protection laws. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act of 2018, or the CCPA, which became effective on January 1, 2020, requires companies that process information on California residents to make new disclosures to consumers about their data collection, use and sharing practices, allow consumers to opt out of certain data sharing with third parties and provide a new cause of action for data breaches. Many other states are considering similar legislation, and a broad range of legislative measures also have been introduced at the federal level.

Pharmaceutical Insurance Coverage and Health Care Reform

In the United States and markets in other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payers to reimburse all or part of the associated health care costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Thus, even if a product candidate of ours or one of our collaborators is approved, sales of the product will depend, in part, on the extent to which third-party payers, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations provide coverage and establish adequate reimbursement levels for the product. The process for determining whether a payer will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payer will pay for the product once coverage is approved. Third-party payers are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs.

Third-party payers may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication.

In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payer not to cover a product could reduce market acceptance once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payer’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payer’s determination to provide coverage for a product does not assure that other payers will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payer to payer.

In international markets, reimbursement and health care payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. In some countries, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a product. To obtain coverage and adequate reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product to other available therapies.

The containment of health care costs also has become a priority of federal, state, and foreign governments and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on coverage, reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company’s revenue generated from the sale of any approved products including those that we are our collaborators may develop. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future.

Review and Approval of Medicinal Products in the European Union

In order to market any product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety, and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales, and distribution of products. Whether or not it obtains FDA approval for a product, a

45

Table of Contents

 

sponsor will need to obtain the necessary approvals by the comparable non-U.S. regulatory authorities before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. Specifically, however, the process governing approval of medicinal products in the European Union generally follows the same lines as in the United States. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the European Union.

Clinical Trial Approval

On January 31, 2022, the new Clinical Trials Regulation (EU) No 536/2014 became effective in the European Union and replaced the prior Clinical Trials Directive 2001/20/EC. The new regulation aims at simplifying and streamlining the authorization, conduct and transparency of clinical trials in the European Union. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial to be conducted in more than one Member State of the European Union, or EU Member State, will only be required to submit a single application for approval. The submission will be made through the Clinical Trials Information System, a new clinical trials portal overseen by the EMA and available to clinical trial sponsors, competent authorities of the EU Member States and the public.

The new regulation did not change the preexisting requirement that a sponsor must obtain prior approval from the competent national authority of the EU Member State in which the clinical trial is to be conducted. If the clinical trial is conducted in different EU Member States, the competent authorities in each of these EU Member States must provide their approval for the conduct of the clinical trial. Furthermore, the sponsor may only start a clinical trial at a specific study site after the applicable ethics committee has issued a favorable opinion.

Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the EU at the EudraCT website: https://eudract.ema.europa.eu.

PRIME Designation in the European Union

In March 2016, the European Medicines Agency, or EMA, launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated agency contact and rapporteur from the Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies are appointed early in PRIME scheme facilitating increased understanding of the product at EMA’s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies.

Marketing Authorization

To obtain a marketing authorization for a product under European Union regulatory systems, a sponsor must submit an MAA either under a centralized procedure administered by the EMA, or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure, national procedure or mutual recognition procedure). A marketing authorization may be granted only to a sponsor established in the European Union. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the European Union, sponsors have to demonstrate compliance with all measures included in an EMA-approved Paediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted (1) a product-specific waiver, (2) a class waiver, or (3) a deferral for one or more of the measures included in the PIP.

The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid across the European Economic Area (i.e. the European Union as well as Iceland, Liechtenstein and Norway). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products, and products

46

Table of Contents

 

with a new active substance indicated for the treatment of certain diseases. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. The centralized procedure may at the request of the sponsor also be used in certain other cases.

Under the centralized procedure, the CHMP is responsible for conducting the initial assessment of a product and for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the European Union, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the sponsor in response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 15 calendar days of receipt of a final opinion from the CHMP, the European Commission must prepare a draft decision concerning an application for marketing authorization. This draft decision must take the opinion and any relevant provisions of European Union law into account. Before arriving at a final decision on an application for centralized authorization of a medicinal product the European Commission must consult the Standing Committee on Medicinal Products for Human Use, or the Standing Committee. The Standing Committee is composed of representatives of the EU Member States and chaired by a non-voting European Commission representative. The European Parliament also has a related “droit de regard”. The European Parliament’s role is to ensure that the European Commission has not exceeded its powers in deciding to grant or refuse to grant a marketing authorization.

The European Commission may grant a so-called “marketing authorization under exceptional circumstances”. Such authorization is intended for products for which the sponsor can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the sponsor cannot reasonably be expected to provide comprehensive evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization under exceptional circumstances may be granted subject to certain specific obligations, which may include the following:

 

•

the sponsor must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the benefit/risk profile;

 

•

the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an authorized person; and

 

•

the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects.

A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk- benefit balance in an annual reassessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of a marketing authorization of a medicinal product under exceptional circumstances, however, follows the same rules as a “normal” marketing authorization. Thus, a marketing authorization under exceptional circumstances is granted for an initial five years, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal.

The European Commission may also grant a so-called “conditional marketing authorization” prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization. Such conditional marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products), if (i) the risk-benefit balance of the product candidate is positive, (ii) it is likely that the sponsor will be in a position to provide the required comprehensive clinical trial data, (iii) the product fulfills an unmet medical need, and (iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization.

47

Table of Contents

 

The European Union medicines rules expressly permit the EU Member States to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal product containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. While the products we have in development do not make use of embryonic stem cells, it is possible that the national laws in certain EU Member States may prohibit or restrict us from commercializing our products, even if they have been granted a European Union marketing authorization.

Unlike the centralized authorization procedure, the decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference EU Member State prepares a draft assessment and drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose decision is binding on all EU Member States.

The mutual recognition procedure similarly is based on the acceptance by the competent authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of other EU Member States. The holder of a national marketing authorization may submit an application to the competent authority of an EU Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State.

As in the United States, information about clinical trials in support of a marketing application must be submitted within specific timeframes to the European Union (EudraCT) website: https://eudract.ema.europa.eu/ and other countries.

Regulatory Data Protection in the European Union

In the European Union, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No 726/2004 repeats this entitlement for medicinal products authorized in accordance the centralized authorization procedure. Data exclusivity prevents sponsors for authorization of generics of these innovative products from referencing the innovator’s data to assess a generic (abridged) application for a period of eight years. During an additional two-year period of market exclusivity, a generic marketing authorization application can be submitted and authorized, and the innovator’s data may be referenced, but no generic medicinal product can be placed on the European Union market until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be a new chemical entity so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests, and clinical trials.

Periods of Authorization and Renewals

A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety, and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five- year period of marketing authorization. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the European Union market (in case of centralized procedure) or on the market of the authorizing EU Member State within three years after authorization ceases to be valid (the so-called sunset clause).

Brexit and the Regulatory Framework in the United Kingdom

The United Kingdom’s withdrawal from the European Union took place on January 31, 2020. The European Union and the United Kingdom reached an agreement on their new partnership in the Trade and Cooperation Agreement, or the Agreement, which was applied provisionally beginning on January 1, 2021 and which entered into force on May 1, 2021. The Agreement focuses primarily on free trade by ensuring no tariffs or quotas on trade in goods, including healthcare products such as medicinal products.

48

Table of Contents

 

Thereafter, the European Union and the United Kingdom will form two separate markets governed by two distinct regulatory and legal regimes. As such, the Agreement seeks to minimize barriers to trade in goods while accepting that border checks will become inevitable as a consequence that the United Kingdom is no longer part of the single market. As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency, or the MHRA, became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law whereas Northern Ireland continues to be subject to EU rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law the body of EU law instruments governing medicinal products that pre-existed prior to the United Kingdom’s withdrawal from the European Union.

Furthermore, while the Data Protection Act of 2018 in the United Kingdom that “implements” and complements the European Union’s GDPR is now effective in the United Kingdom, it is still unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under GDPR. The Trade and Cooperation Agreement provides for a transitional period during which the United Kingdom will be treated like an European Union member state in relation to processing and transfers of personal data for four months from January 1, 2021.  This may be extended by two further months. After such period, the United Kingdom will be a “third country” under the GDPR unless the European Commission adopts an adequacy decision in respect of transfers of personal data to the United Kingdom. The United Kingdom has already determined that it considers all of the European Union and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the European and EEA remain unaffected.

Pricing Decisions for Approved Products

In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain reimbursement or pricing approval. For example, EU Member States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the European Union have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic, and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between low-priced and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries. 

General Data Protection Regulation

Many countries outside of the United States maintain rigorous laws governing the privacy and security of personal information. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA, is subject to the GDPR, which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, and it imposes heightened requirements on companies that process health and other sensitive data, such as requiring in many situations that a company obtain the consent of the individuals to whom the sensitive personal data relate before processing such data. Examples of obligations imposed by the GDPR on companies processing personal data that fall within the scope of the GDPR include providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, appointing a data protection officer, providing notification of data breaches and taking certain measures when engaging third-party processors.

The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the United States, and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to €20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance. In July 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-U.S. Privacy Shield framework, one of the mechanisms used

49

Table of Contents

 

to legitimize the transfer of personal data from the EEA to the United States.  The CJEU decision also drew into question the long-term viability of an alternative means of data transfer, the standard contractual clauses, for transfers of personal data from the EEA to the United States.  Following the withdrawal of the U.K. from the EU, the U.K. Data Protection Act 2018 applies to the processing of personal data that takes place in the U.K. and includes parallel obligations to those set forth by GDPR.

Human Capital

As of February 14, 2022, we had 664 full-time employees, including a total of 289 employees with Ph.D. degrees. Of these full-time employees, 477 of these employees are located in the United States and 187 of these employees are located in our offices outside of the United States. Additionally, as of February 14, 2022, 32% of our full-time employees self-identified as female or non-binary, or chose not to disclose their gender and 38% of our executive team self-identified as female, and 37% of our new hires since January 1, 2021 self-identify as female or non-binary, or have chosen not to disclose their gender. Our employees are our greatest asset and we strive to create a work environment that is inclusive, challenging and rewarding.

We are committed to embedding a long-term, formal Environmental, Social and Governance, or ESG, strategy within our business, and we recently created a new leadership role dedicated to Corporate Sustainability and ESG. We expect to complete a formal sustainability materiality assessment in the first half of 2022, serving as the foundation of our comprehensive, long-term, Corporate Sustainability strategy.

Further, our vision for Diversity, Equity and Inclusion, or DEI, is focused on developing a culture of transparency and accountability, active inclusion, and a growth mindset. We have focused our recruiting efforts on diversifying our candidate pipeline by participating in conferences and engaging with student networks that promote racial and gender diversity in the science and technology industries. Further, we utilize a structured interviewing model when assessing candidates to provide for consistency and equity in the hiring process across candidates and to help reduce unconscious bias.

Given our DEI aspirations, in 2021 we created our first DEI Council, a cross functional learning and listening body that allows our executive leadership team, employee volunteers, and Employee Resource Group, or ERG, leaders to listen to feedback from all levels of the company. ERG membership directly engages one third of our employees, however, these forums provide an environment for community support, professional development, and educational opportunities for our entire employee population. Through our ERG leadership program, ERG leaders are paired with an executive sponsor to guide them throughout their tenure, they have the opportunity to hone skills such as negotiation, influence, and public speaking. Our commitment to offering employee programs also extends to our investments in learning and development, or L&D, and in 2022, we launched a global L&D initiative with the Neuroleadership Institute designed to build active listening and bias mitigation skills. 

We consider the intellectual capital of our employees to be an essential driver of our business and key to our future prospects. Though the biotechnology industry is historically competitive for talent, we have maintained high employee retention rates. For the year ended December 31, 2021, our employee retention rate was 96.5%.

Given our financial resources, our industry-leading position in the field of physics-based computational drug discovery and materials science research and our developing internal drug discovery programs, we believe that we will continue to be able to fill positions and grow our headcount in support of our software, drug discovery and materials science businesses.

We are committed to providing our employees with compensation that meets the expectations of the market and industry norms. We monitor our compensation programs closely using comprehensive industry surveys and data to guide us, and we provide what we consider to be a competitive mix of incentives, including competitive salaries and bonuses, a 401(k) retirement plan with an employer matching contribution, health and welfare benefits and participation in our equity programs. We routinely review our compensation practices and analyze the equity of our compensation decisions for all employees. None of our employees is subject to a collective bargaining agreement or represented by a trade or labor union. We consider our relations with our employees to be good.

We believe our company culture is one that aims to support each individual fully, not just their contribution as an employee. The COVID-19 pandemic has resulted in the creation of a more fluid and flexible work environment to allow individuals to meet their needs and those of their family members while contributing to our success. In the current virtual world, we have moved from regular onsite wellness activities to those that can be enjoyed virtually, including meditation, yoga and other fitness classes, as well as art classes for employees and their families.

Our company culture also encourages engagement, both among our employees and within the communities we live and work. In the advancement of these efforts, internally, we have established a new mentorship program, updated our management training programs to include mental health and wellness trainings, and refreshed our annual review process to encourage more real-time feedback between employees and managers to set and achieve personal performance goals. In engaging with our external community, we host a student internship program, including in partnership with a non-profit educational group that supports underserved local high school students who have demonstrated the knowledge, character, and skills to achieve their aspirations. In addition, our ERGs sponsor a summer camp for a local non-profit organization dedicated to providing underserved students with hands-on science and

50

Table of Contents

 

engineering educational and mentorship experiences. To further our community engagement efforts, each of our U.S.-based employees is provided with a paid full day each year to volunteer in their local community.

The health and safety of our onsite employees has been an even greater focus for us since the onset of the COVID-19 pandemic. In early March 2020, we issued a global work from home policy to ensure the health of our employees and local communities while continuing to advance our business objectives. Beginning in June 2020, we began limited re-openings of certain of our offices in the United States and abroad. Our office re-openings are being conducted on a limited basis and are voluntary for all of our employees. We believe we are well-equipped to work remotely, engage with our customers and continue to advance our business

Our Corporate Information

Our principal executive offices are located at 1540 Broadway, 24th Floor, New York, New York 10036, and our telephone number is (212) 295-5800. Our website address is http://www.schrodinger.com. The information contained on, or that can be accessed through, our website is not incorporated by reference into this Annual Report or in any other report or document we file with the SEC, and any reference to our website address is intended to be an inactive textual reference only.

We own or have rights to trademarks, service marks, and trade names that we use in connection with the operation of our business, including our corporate name, logos and website names. Other trademarks, service marks, and trade names appearing in this Annual Report are the property of their respective owners. Solely for convenience, some of the trademarks, service marks, and trade names referred to in this Annual Report are listed without the ® and ™ symbols.

Available Information

We make available free of charge through our website our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We make these reports available through our website as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the SEC. We also make available, free of charge on our website, the reports filed with the SEC by our executive officers, directors and 10% stockholders pursuant to Section 16 under the Exchange Act as soon as reasonably practicable after copies of those filings are provided to us by those persons. The information contained on, or that can be access through, our website is not a part of or incorporated by reference in this Annual Report.

Item 1A. Risk Factors.

You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report and our other public filings with the SEC. The risks described below are not the only risks facing our company. The occurrence of any of the following risks, or of additional risks and uncertainties not presently known to us or that we currently believe to be immaterial, could cause our business, prospects, operating results, and financial condition to suffer materially.

Risks Related to Our Financial Position and Need for Additional Capital

We have a history of significant operating losses, and we expect to incur losses over the next several years.

We have a history of significant operating losses. Our net loss for the years ended December 31, 2021, 2020, and 2019 was $101.2 million, $26.6 million, and $25.7 million, respectively. As of December 31, 2021, we had an accumulated deficit of $230.0 million.

51

Table of Contents

 

We anticipate that our operating expenses will increase substantially in the foreseeable future as we continue to invest in our internal drug discovery programs, sales and marketing infrastructure, and our computational platform. We are still in the early stages of development of our own drug discovery programs. We continue to advance multiple internal programs through investigational new drug, or IND, -enabling studies, and we expect to submit an IND application to the U.S. Food and Drug Administration, or FDA, for our MALT1 program in the first half of 2022, and subject to receiving regulatory clearance, we expect to initiate a Phase 1 clinical trial of our MALT1 inhibitor in patients with relapsed and resistant lymphoma in the second half of 2022. We also plan to submit IND applications to the FDA for our CDC7 program in early 2023 and our WEE1 program in 2023, subject to favorable data from IND-enabling studies. In addition, we plan to initiate a Phase 1 clinical trial of our CDC7 inhibitor in 2023, subject to receipt of regulatory clearance. We have no drug products licensed for commercial sale and have not generated any revenue from our own drug product sales to date. We expect to continue to incur significant expenses and operating losses over the next several years. Our operating expenses and net income or loss may fluctuate significantly from quarter to quarter and year to year. We anticipate that our expenses will increase substantially as we:

 

•

continue to invest in and develop our computational platform and software solutions;

 

•

continue our research and development efforts for our internal drug discovery programs;

 

•

conduct preclinical studies and initiate and conduct clinical trials for any of our product candidates;

 

•

maintain, expand, enforce, defend, and protect our intellectual property;

 

•

hire additional software engineers, programmers, sales and marketing, and other personnel to support our software business;

 

•

hire additional clinical, quality control, and other scientific personnel; and

 

•

add operational, financial, and management information systems and personnel to support our operations as a public company.

If we are unable to increase sales of our software, or if we and our current and future collaborators are unable to successfully develop and commercialize drug products, our revenues may be insufficient for us to achieve or maintain profitability.

To achieve and maintain profitability, we must succeed in significantly increasing our software sales, or we and our current or future collaborators must succeed in developing, and eventually commercializing, a drug product or drug products that generate significant revenue. We currently generate revenues primarily from the sales of our software solutions and expect to continue to derive most of our revenue from sales of our software until such time as our or our collaborators’ drug development and commercialization efforts are successful, if ever. As such, increasing sales of our software to existing customers and successfully marketing our software to new customers are critical to our success. Demand for our software solutions may be affected by a number of factors, including continued market acceptance by the biopharmaceutical industry, market adoption of our software solutions beyond the biopharmaceutical industry including for material science applications, the ability of our platform to identify more promising molecules and accelerate and lower the costs of discovery as compared to traditional methods, timing of development and release of new offerings by our competitors, technological change, and the rate of growth in our target markets. If we are unable to continue to meet the demands of our customers, our business operations, financial results, and growth prospects will be adversely affected.

Achieving success in drug development will require us or our current or future collaborators to be effective in a range of challenging activities, including completing preclinical testing and clinical trials of product candidates, obtaining regulatory approval for these product candidates and manufacturing, marketing, and selling any products for which we or they may obtain regulatory approval. We and most of our current drug discovery collaborators are only in the preliminary stages of most of these activities. We and they may never succeed in these activities and, even if we do, we may never generate revenues that are significant enough to achieve and sustain profitability, or even if our collaborators do, we may not receive option fees, milestone payments, or royalties from them that are significant enough for us to achieve and sustain profitability. Because of the intense competition in the market for our software solutions and the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict when, or if, we will be able to achieve or sustain profitability.

Even if we achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, increase sales of our software, develop a pipeline of product candidates, enter into collaborations, or even continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment.

52

Table of Contents

 

In addition, although we have experienced revenue growth in recent periods, we may not be able to sustain revenue growth consistent with our recent history or at all. Our total revenues increased by 28% from $108.1 million in the fiscal year ended December 31, 2020 to $137.9 million in the fiscal year ended December 31, 2021, and by 26% from $85.5 million in the fiscal year ended December 31, 2019 to $108.1 million in the fiscal year ended December 31, 2020. You should not consider our revenue growth in recent periods as indicative of our future performance. As we grow our business, our revenue growth rates may slow in future periods.

Our quarterly and annual results may fluctuate significantly, which could adversely impact the value of our common stock.

Our results of operations, including our revenues, gross margin, profitability, and cash flows, have historically varied from period to period, and we expect that they will continue to do so. As a result, period-to-period comparisons of our operating results may not be meaningful, and our quarterly and annual results should not be relied upon as an indication of future performance. Our quarterly and annual financial results may fluctuate as a result of a variety of factors, many of which are outside of our control. Factors that may cause fluctuations in our quarterly and annual financial results include, without limitation, those listed elsewhere in this “Risk Factors” section and those listed below:

 

•

customer renewal rates and the timing and terms of customer renewals, including the seasonality of customer renewals of our on-premise software arrangements, for which revenue historically has been recognized at a single point in time in the first and fourth quarter of each fiscal year;

 

•

our ability to attract new customers for our software;

 

•

the addition or loss of large customers, including through acquisitions or consolidations of such customers;

 

•

the amount and timing of operating expenses related to the maintenance and expansion of our business, operations, and infrastructure;

 

•

network outages or security breaches;

 

•

general economic, industry, and market conditions, including within the life sciences industry;

 

•

our ability to collect receivables from our customers;

 

•

the amount of software purchased by our customers, including the mix of on-premise and hosted software sold during a period;

 

•

variations in the timing of the sales of our software, which may be difficult to predict;

 

•

changes in the pricing of our solutions and in our pricing policies or those of our competitors;

 

•

the timing and success of the introduction of new software solutions by us or our competitors or any other change in the competitive dynamics of our industry, including consolidation among competitors, customers, or strategic collaborators;

 

•

changes in the fair value of or receipt of distributions or proceeds on account of the equity interests we hold in our drug discovery collaborators, such as Morphic Holding, Inc.;

 

•

the success of our drug discovery collaborators in developing and commercializing drug products for which we are entitled to receive milestone payments or royalties and the timing of receipt of such payments, if any, such as under our collaboration agreement with Bristol-Myers Squibb Company, or BMS; and

 

•

the timing of expenses related to our drug discovery programs, the development or acquisition of technologies or businesses and potential future charges for impairment of goodwill from acquired companies.

In addition, because we recognize revenues from our hosted software solutions ratably over the life of the contract, a significant upturn or downturn in sales of our hosted software solutions may not be reflected immediately in our operating results. As a result of these factors, we believe that period-to-period comparisons of our operating results are not a good indication of our future performance and that our interim financial results are not necessarily indicative of results for a full year or for any subsequent interim period.

We may require additional capital to fund our operations. If we are unable to raise additional capital on terms acceptable to us or at all or generate cash flows necessary to maintain or expand our operations, we may not be able to compete successfully, which would harm our business, operations, and financial condition.

We expect to devote substantial financial resources to our ongoing and planned activities, including the development of drug discovery programs and continued investment in our computational platform. We expect our expenses to increase substantially in connection with our ongoing and planned activities, particularly as we advance our internal drug discovery programs, initiate or progress preclinical and IND-enabling studies, submit IND applications, initiate and progress clinical trials and invest in the further

53

Table of Contents

 

development of our platform. In addition, if we determine to complete clinical development and seek regulatory approval on our own, we expect to incur significant additional expenses. Furthermore, we incur additional costs associated with operating as a public company, as compared to when we were a private company.

Our current drug discovery collaborators, from whom we are entitled to receive milestone payments upon achievement of various development, regulatory, and commercial milestones as well as royalties on commercial sales, if any, under the collaboration agreements that we have entered into with them, face numerous risks in the development of drugs, including the conduct of preclinical and clinical testing, obtaining regulatory approval, and achieving product sales. In addition, the amounts we are entitled to receive upon the achievement of such milestones tend to be smaller for near-term development milestones and increase if and as a collaborative product candidate advances through regulatory development to commercialization and will vary depending on the level of commercial success achieved, if any. We do not anticipate receiving significant milestone payments from many of our drug discovery collaborators for several years, if at all, and our drug discovery collaborators may never achieve milestones that result in significant cash payments to us. Accordingly, we may need to obtain substantial additional capital to fund our continuing operations.

As of December 31, 2021, we had cash, cash equivalents, restricted cash, and marketable securities of $579.5 million. We believe that our existing cash, cash equivalents, and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 24 months. However, we have based this estimate on assumptions that may prove to be wrong, and our operating plans may change as a result of many factors currently unknown to us. As a result, we could deplete our capital resources sooner than we currently expect.

Our future capital requirements will depend on many factors, including:

 

•

the growth of our software revenue;

 

•

the timing and extent of spending to support research and development efforts;

 

•

the continued expansion of software sales and marketing activities;

 

•

the timing and receipt of payments from our collaborations as well as spending to support, advance, and broaden our internal drug discovery programs; and

 

•

the timing and receipt of any distributions or proceeds we may receive from our equity stakes in our drug discovery collaborators and partners.

In the event that we require additional financing, we may not be able to raise such financing on terms acceptable to us or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. If we are unable to raise additional capital on terms acceptable to us or at all or generate cash flows necessary to maintain or expand our operations and invest in our computational platform, we may not be able to compete successfully, which would harm our business, operations, and financial condition.

Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or drug programs.

To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders’ ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights as common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, selling or licensing our assets, making product acquisitions, making capital expenditures, or declaring dividends.

If we raise additional funds through collaborations, strategic alliances or marketing, distribution, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or product candidates or grant licenses on terms that may not be favorable to us or agree to exploit a drug development target exclusively for one of our collaborators when we may prefer to pursue the drug development target for ourselves.

If our estimates or judgments relating to our critical accounting policies prove to be incorrect or financial reporting standards or interpretations change, our results of operations could be adversely affected.

The preparation of financial statements in conformity with generally accepted accounting principles in the United States, or U.S. GAAP, requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances. The results of these estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Significant assumptions and estimates used in preparing our consolidated financial statements include determining the allocation of the transaction price and

54

Table of Contents

 

measurement of progress, including (1) the constraint on variable consideration, (2) the allocation of the transaction price to the performance obligations using their standalone selling price basis, and (3) the appropriate input or output based method to recognize collaboration revenue and the extent of progress to date, and the expected stock price volatility and the calculation of expected term of the award estimates used in the calculation of stock-based compensation.

Our results of operations may be adversely affected if our assumptions change or if actual circumstances differ from those in our assumptions, which could cause our results of operations to fall below the expectations of securities analysts and investors, resulting in a decline in the trading price of our common stock.

Additionally, we regularly monitor our compliance with applicable financial reporting standards and review new pronouncements and drafts thereof that are relevant to us. As a result of new standards, changes to existing standards and changes in their interpretation, we might be required to change our accounting policies, alter our operational policies, and implement new or enhance existing systems so that they reflect new or amended financial reporting standards, or we may be required to restate our published financial statements. Such changes to existing standards or changes in their interpretation may have an adverse effect on our reputation, business, financial position, and profit.

Risks Related to Our Software

If our existing customers do not renew their licenses, do not buy additional solutions from us, or renew at lower prices, our business and operating results will suffer.

We expect to continue to derive a significant portion of our software revenues from renewal of existing license agreements. As a result, maintaining the renewal rate of our existing customers and selling additional software solutions to them is critical to our future operating results. Factors that may affect the renewal rate for our customers and our ability to sell additional solutions to them include:

 

•

the price, performance, and functionality of our software solutions;

 

•

the availability, price, performance, and functionality of competing software solutions;

 

•

the effectiveness of our professional services;

 

•

our ability to develop or acquire complementary software solutions, applications, and services;

 

•

the success of competitive products or technologies;

 

•

the stability, performance, and security of our technological infrastructure; and

 

•

the business environment of our customers.

We deliver our software through either (i) a product license that permits our customers to install the software solution directly on their own in-house hardware and use it for a specified term, or (ii) a subscription that allows our customers to access the cloud-based software solution on their own hardware without taking control of the licenses. Our customers have no obligation to renew their product licenses or subscriptions for our software solutions after the license term expires, which is typically after one year, and many of our contracts may be terminated or reduced in scope either immediately or upon notice. In addition, our customers may negotiate terms less advantageous to us upon renewal, which may reduce our revenues from these customers. Factors that are not within our control may contribute to a reduction in our software revenues. For instance, our customers may reduce the number of their employees who are engaged in research and who would have use of our software, which would result in a corresponding reduction in the number of user licenses needed for some of our solutions and thus a lower aggregate renewal fee. The loss, reduction in scope, or delay of a large contract, or the loss or delay of multiple contracts, could materially adversely affect our business.

Our future operating results also depend, in part, on our ability to sell new software solutions and licenses to our existing customers. For example, the willingness of existing customers to license our software will depend on our ability to scale and adapt our existing software solutions to meet the performance and other requirements of our customers, which we may not do successfully. If our customers fail to renew their agreements, renew their agreements upon less favorable terms or at lower fee levels, or fail to purchase new software solutions and licenses from us, our revenues may decline and our future revenues may be constrained.

55

Table of Contents

 

Our software sales cycle can vary and be long and unpredictable.

The timing of sales of our software solutions is difficult to forecast because of the length and unpredictability of our sales cycle. We sell our solutions primarily to biopharmaceutical companies, and our sales cycles can be as long as nine to twelve months or longer. Further, the length of time that potential customers devote to their testing and evaluation, contract negotiation, and budgeting processes varies significantly, depending on the size of the organization and the nature of their needs. In addition, we might devote substantial time and effort to a particular unsuccessful sales effort, and as a result, we could lose other sales opportunities or incur expenses that are not offset by an increase in revenue, which could harm our business.

A significant portion of our revenues are generated by sales to life sciences industry customers, and factors that adversely affect this industry could also adversely affect our software sales.

A significant portion of our current software sales are to customers in the life sciences industry, in particular the biopharmaceutical industry. Demand for our software solutions could be affected by factors that adversely affect the life sciences industry. The life sciences industry is highly regulated and competitive and has experienced periods of considerable consolidation. Consolidation among our customers could cause us to lose customers, decrease the available market for our solutions, and adversely affect our business. In addition, changes in regulations that make investment in the life sciences industry less attractive or drug development more expensive could adversely impact the demand for our software solutions. For these reasons and others, selling software to life sciences companies can be competitive, expensive, and time consuming, often requiring significant upfront time and expense without any assurance that we will successfully complete a software sale. Accordingly, our operating results and our ability to efficiently provide our solutions to life sciences companies and to grow or maintain our customer base could be adversely affected as a result of factors that affect the life sciences industry generally.

We also intend to continue leveraging our solutions for broad application to industrial challenges in molecule design, including in the fields of aerospace, energy, semiconductors, and electronic displays. However, we believe the materials science industry is in the very early stages of recognizing the potential of computational methods for molecular discovery, and there can be no assurance that the industry will adopt computational methods such as our platform. Any factor adversely affecting our ability to market our software solutions to customers outside of the life sciences industry, including in these new fields, could increase our dependence on the life sciences industry and adversely affect the growth rate of our revenues, operating results, and business.

The markets in which we participate are competitive, and if we do not compete effectively, our business and operating results could be adversely affected.

The overall market for molecular discovery and design software is global, rapidly evolving, competitive, and subject to changing technology and shifting customer focus. Our software solutions face competition from commercial competitors in the business of selling or providing simulation and modeling software to biopharmaceutical companies. These competitors include BIOVIA, a brand of Dassault Systèmes SE, or BIOVIA, Chemical Computing Group (US) Inc., Cresset Biomolecular Discovery Limited, OpenEye Scientific Software, Inc., Optibrium Limited, Cyrus Biotechnology, Inc., Molsoft LLC, Insilico Medicine, Inc., Iktos; XtalPi Inc., and Simulations Plus, Inc.

We also have competitors in materials science, such as BIOVIA and Materials Design, Inc., and in enterprise software for the life sciences, such as BIOVIA, Certara USA, Inc., ChemAxon; PerkinElmer, Inc., and Dotmatics, Inc. In some cases, these competitors are well-established providers of these solutions and have long-standing relationships with many of our current and potential customers, including large biopharmaceutical companies. In addition, there are academic consortia that develop physics-based simulation programs for life sciences and materials applications. In life sciences, the most prominent academic simulation packages include AMBER, CHARMm, GROMACS, GROMOS, OpenMM, and OpenFF. These packages are primarily maintained and developed by graduate students and post-doctoral researchers, often without the intent for commercialization.

We also face competition from solutions that biopharmaceutical companies develop internally and from smaller companies that offer products and services directed at more specific markets than we target, enabling these smaller competitors to focus a greater proportion of their efforts and resources on these markets, as well as a large number of companies that have been founded with the goal of applying machine learning technologies to drug discovery.

Many of our competitors are able to devote greater resources to the development, promotion, and sale of their software solutions and services. It is possible that our focus on internal drug discovery will result in loss of management focus and resources relating to our software business, thereby resulting in decreasing revenues from our software business. Furthermore, third parties with greater available resources and the ability to initiate or withstand substantial price competition could acquire our current or potential competitors. Our competitors may also establish cooperative relationships among themselves or with third parties that may further enhance their product offerings or resources. If our competitors’ products, services, or technologies become more accepted than our

56

Table of Contents

 

solutions, if our competitors are successful in bringing their products or services to market earlier than ours, if our competitors are able to respond more quickly and effectively to new or changing opportunities, technologies, or customer requirements, or if their products or services are more technologically capable than ours, then our software revenues could be adversely affected.

We may be required to decrease our prices or modify our pricing practices in order to attract new customers or retain existing customers due to increased competition. Pricing pressures and increased competition could result in reduced sales, reduced margins, losses, or a failure to maintain or improve our competitive market position, any of which could adversely affect our business.

We have invested and expect to continue to invest in research and development efforts that further enhance our computational platform. Such investments may affect our operating results, and, if the return on these investments is lower or develops more slowly than we expect, our revenue and operating results may suffer.

We have invested and expect to continue to invest in research and development efforts that further enhance our computational platform, often in response to our customers’ requirements. These investments may involve significant time, risks, and uncertainties, including the risk that the expenses associated with these investments may affect our margins and operating results and that such investments may not generate sufficient revenues to offset liabilities assumed and expenses associated with these new investments. The software industry changes rapidly as a result of technological and product developments, which may render our solutions less desirable. We believe that we must continue to invest a significant amount of time and resources in our platform and software solutions to maintain and improve our competitive position. If we do not achieve the benefits anticipated from these investments, if the achievement of these benefits is delayed, or if a slowdown in general computing power impacts the rate at which we expect our physics-based simulations to increase in power and domain applicability, our revenue and operating results may be adversely affected.

If we are unable to collect receivables from our customers, our operating results may be adversely affected.

While the majority of our current customers are well-established, large companies and universities, we also provide software solutions to smaller companies. Our financial success depends upon the creditworthiness and ultimate collection of amounts due from our customers, including our smaller customers with fewer financial resources. If we are not able to collect amounts due from our customers, we may be required to write-off significant accounts receivable and recognize bad debt expenses, which could materially and adversely affect our operating results.

Defects or disruptions in our solutions could result in diminishing demand for our solutions, a reduction in our revenues, and subject us to substantial liability.

Our software business and the level of customer acceptance of our software depend upon the continuous, effective, and reliable operation of our software and related tools and functions. Our software solutions are inherently complex and may contain defects or errors. Errors may result from our own technology or from the interface of our software solutions with legacy systems and data, which we did not develop. The risk of errors is particularly significant when a new software solution is first introduced or when new versions or enhancements of existing software solutions are released. We have from time to time found defects in our software, and new errors in our existing software may be detected in the future. Any errors, defects, disruptions, or other performance problems with our software could hurt our reputation and may damage our customers’ businesses. If that occurs, our customers may delay or withhold payment to us, cancel their agreements with us, elect not to renew, make service credit claims, warranty claims, or other claims against us, and we could lose future sales. The occurrence of any of these events could result in diminishing demand for our software, a reduction of our revenues, an increase in collection cycles for accounts receivable, require us to increase our warranty provisions, or incur the expense of litigation or substantial liability.

We rely upon third-party providers of cloud-based infrastructure to host our software solutions. Any disruption in the operations of these third-party providers, limitations on capacity, or interference with our use could adversely affect our business, financial condition, and results of operations.

We outsource substantially all of the infrastructure relating to our hosted software solutions to third-party hosting services. Customers of our hosted software solutions need to be able to access our computational platform at any time, without interruption or degradation of performance, and we provide them with service-level commitments with respect to uptime. Our hosted software solutions depend on protecting the virtual cloud infrastructure hosted by third-party hosting services by maintaining its configuration, architecture, features, and interconnection specifications, as well as the information stored in these virtual data centers, which is transmitted by third-party internet service providers. Any limitation on the capacity of our third-party hosting services could impede our ability to onboard new customers or expand the usage of our existing customers, which could adversely affect our business, financial condition, and results of operations. In addition, any incident affecting our third-party hosting services’ infrastructure that may be caused by cyber-attacks, natural disasters, fire, flood, severe storm, earthquake, power loss, telecommunications failures,

57

Table of Contents

 

terrorist or other attacks, and other similar events beyond our control could negatively affect our cloud-based solutions. A prolonged service disruption affecting our cloud-based solutions for any of the foregoing reasons would negatively impact our ability to serve our customers and could damage our reputation with current and potential customers, expose us to liability, cause us to lose customers, or otherwise harm our business. We may also incur significant costs for using alternative equipment or taking other actions in preparation for, or in reaction to, events that damage the third-party hosting services we use.

In the event that our service agreements with our third-party hosting services are terminated, or there is a lapse of service, elimination of services or features that we utilize, interruption of internet service provider connectivity, or damage to such facilities, we could experience interruptions in access to our platform as well as significant delays and additional expense in arranging or creating new facilities and services and/or re-architecting our hosted software solutions for deployment on a different cloud infrastructure service provider, which could adversely affect our business, financial condition, and results of operations.

If our security measures are breached or unauthorized access to customer data is otherwise obtained, our solutions may be perceived as not being secure, customers may reduce the use of or stop using our solutions, and we may incur significant liabilities.

Our solutions involve the collection, analysis, and storage of our customers’ proprietary information and sensitive proprietary data related to the discovery efforts of our customers. As a result, unauthorized access or security breaches, as a result of third-party action, employee error, malfeasance, or otherwise could result in the loss of information, litigation, indemnity obligations, damage to our reputation, and other liability. Because the techniques used to obtain unauthorized access or sabotage systems change frequently and generally are not identified until they are launched against a target, we may be unable to anticipate these techniques or to implement adequate preventative measures. In addition, if our employees fail to adhere to practices we have established to maintain a firewall between our internal drug discovery team and our teams that work with software customers, or if the technical solutions we have adopted to maintain the firewall malfunction, our customers and collaborators may lose confidence in our ability to maintain the confidentiality of their intellectual property, we may have trouble attracting new customers and collaborators, we may be subject to breach of contract claims by our customers and collaborators, and we may suffer reputational and other harm as a result. Any or all of these issues could adversely affect our ability to attract new customers, cause existing customers to elect to not renew their licenses, result in reputational damage or subject us to third-party lawsuits or other action or liability, which could adversely affect our operating results. Our insurance may not be adequate to cover losses associated with such events, and in any case, such insurance may not cover all of the types of costs, expenses, and losses we could incur to respond to and remediate a security breach.

Any failure to offer high-quality technical support services could adversely affect our relationships with our customers and our operating results.

Our customers depend on our support organization to resolve technical issues relating to our solutions, as our software requires expert usage to fully exploit its capabilities. Certain of our customers also rely on us to troubleshoot problems with the performance of the software, introduce new features requested for specific customer projects, inform them about the best way to set up and analyze various types of simulations and illustrate our techniques for drug discovery using examples from publicly available data sets. We may be unable to respond quickly enough to accommodate short-term increases in customer demand for these support services. Increased customer demand for our services, without corresponding revenues, could increase costs and adversely affect our operating results. In addition, our sales process is highly dependent on the reputation of our solutions and business and on positive recommendations from our existing customers. Any failure to offer high-quality technical support, or a market perception that we do not offer high-quality support, could adversely affect our reputation, our ability to sell our solutions to existing and prospective customers and our business and operating results.

Our solutions utilize third party open source software, and any failure to comply with the terms of one or more of these open source software licenses could adversely affect our business or our ability to sell our software solutions, subject us to litigation, or create potential liability.

Our solutions include software licensed by third parties under any one or more open source licenses, including the GNU General Public License, the GNU Lesser General Public License, the Affero General Public License, the BSD License, the MIT License, the Apache License, and others, and we expect to continue to incorporate open source software in our solutions in the future. Moreover, we cannot ensure that we have effectively monitored our use of open source software or that we are in compliance with the terms of the applicable open source licenses or our current policies and procedures. There have been claims against companies that use open source software in their products and services asserting that the use of such open source software infringes the claimants’ intellectual property rights. As a result, we and our customers could be subject to suits by third parties claiming that what we believe to be licensed open source software infringes such third parties’ intellectual property rights, and we may be required to indemnify our customers against such claims. Additionally, if an author or other third party that distributes such open source software were to allege

58

Table of Contents

 

that we had not complied with the conditions of one or more of these licenses, we or our customers could be required to incur significant legal expenses defending against such allegations and could be subject to significant damages, enjoined from the sale of our solutions that contain the open source software and required to comply with onerous conditions or restrictions on these solutions, which could disrupt the distribution and sale of these solutions. Litigation could be costly for us to defend, have a negative effect on our business, financial condition, and results of operations, or require us to devote additional research and development resources to change our solutions.

Use of open source software may entail greater risks than use of third party commercial software, as open source licensors generally do not provide warranties or other contractual protections regarding infringement claims or the quality of the code, including with respect to security vulnerabilities. In addition, certain open source licenses require that source code for software programs that interact with such open source software be made available to the public at no cost and that any modifications or derivative works to such open source software continue to be licensed under the same terms as the open source software license. The terms of various open source licenses have not been interpreted by courts in the relevant jurisdictions, and there is a risk that such licenses could be construed in a manner that imposes unanticipated conditions or restrictions on our ability to market our solutions. By the terms of certain open source licenses, we could be required to release the source code of our proprietary software, and to make our proprietary software available under open source licenses, if we combine our proprietary software with open source software in a certain manner. In the event that portions of our proprietary software are determined to be subject to an open source license, we could be required to publicly release the affected portions of our source code, re-engineer all or a portion of our solutions, or otherwise be limited in the licensing of our solutions, each of which could reduce or eliminate the value of our solutions. Disclosing our proprietary source code could allow our competitors to create similar products with lower development effort and time and ultimately could result in a loss of sales. Any of these events could create liability for us and damage our reputation, which could have a material adverse effect on our revenue, business, results of operations, and financial condition and the market price of our shares.

Risks Related to Drug Discovery

We may never realize a return on our investment of resources and cash in our drug discovery collaborations.

We use our computational platform to provide drug discovery services to collaborators who are engaged in drug discovery and development. These collaborators include start-up companies, pre-commercial biotechnology companies, and large-scale pharmaceutical companies. When we engage in drug discovery with these collaborators, we typically provide access to our platform and platform experts who assist the drug discovery collaborator in identifying molecules that have activity against one or more specified protein targets. We historically have not received significant initial cash consideration for these services, except for the upfront payment of $55.0 million we received from BMS upon entry into our collaboration agreement with BMS. However, we have received equity consideration in certain of our collaborators and/or the right to receive option fees, cash milestone payments upon the achievement of specified development, regulatory, and commercial sales milestones for the drug discovery targets, and potential royalties. From time to time, we have also made additional equity investments in our drug discovery collaborators.

We may never realize return on our investment of resources and cash in our drug discovery collaborations. Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. Our drug discovery collaborators may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of any product candidates. In addition, our ability to realize return from our drug discovery collaborations is subject to the following risks:

 

•

drug discovery collaborators have significant discretion in determining the amount and timing of efforts and resources that they will apply to our collaborations and may not perform their obligations as expected;

 

•

drug discovery collaborators may not pursue development or commercialization of any product candidates for which we are entitled to option fees, milestone payments, or royalties or may elect not to continue or renew development or commercialization programs based on results of clinical trials or other studies, changes in the collaborator’s strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;

 

•

drug discovery collaborators may delay clinical trials for which we are entitled to milestone payments;

 

•

we may not have access to, or may be restricted from disclosing, certain information regarding our collaborators’ product candidates being developed or commercialized and, consequently, may have limited ability to inform our stockholders about the status of, and likelihood of achieving, milestone payments or royalties under such collaborations;

 

•

drug discovery collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with any product candidates and products for which we are entitled to milestone payments or royalties if the

59

Table of Contents

 

 

collaborator believes that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive;

 

•

product candidates discovered in drug discovery collaborations with us may be viewed by our collaborators as competitive with their own product candidates or products, which may cause our collaborators to cease to devote resources to the commercialization of any such product candidates;

 

•

existing drug discovery collaborators and potential future drug discovery collaborators may begin to perceive us to be a competitor more generally, particularly as we advance our internal drug discovery programs, and therefore may be unwilling to continue existing collaborations with us or to enter into new collaborations with us;

 

•

a drug discovery collaborator may fail to comply with applicable regulatory requirements regarding the development, manufacture, distribution, or marketing of a product candidate or product, which may impact our ability to receive milestone payments;

 

•

disagreements with drug discovery collaborators, including disagreements over intellectual property or proprietary rights, contract interpretation, or the preferred course of development, might cause delays or terminations of the research, development, or commercialization of product candidates for which we are eligible to receive milestone payments, or might result in litigation or arbitration;

 

•

drug discovery collaborators may not properly obtain, maintain, enforce, defend or protect our intellectual property or proprietary rights or may use our proprietary information in such a way as to potentially lead to disputes or legal proceedings that could jeopardize or invalidate our or their intellectual property or proprietary information or expose us and them to potential litigation;

 

•

drug discovery collaborators may infringe, misappropriate, or otherwise violate the intellectual property or proprietary rights of third parties, which may expose us to litigation and potential liability;

 

•

drug discovery collaborators could suffer from operational delays as a result of global health impacts, such as the COVID-19 pandemic; and

 

•

drug discovery collaborations may be terminated prior to our receipt of any significant value from the collaboration.

Our drug discovery collaborations may not lead to development or commercialization of product candidates that results in our receipt of option fees, milestone payments, or royalties in a timely manner, or at all. If any drug discovery collaborations that we enter into do not result in the successful development and commercialization of drug products that result in option fees, milestone payments, or royalties to us, we may not receive return on the resources we have invested in the drug discovery collaboration. Moreover, even if a drug discovery collaboration initially leads to the achievement of milestones that result in payments to us, it may not continue to do so.

We also rely on collaborators for the development and potential commercialization of product candidates we discover internally when we believe it will help maximize the commercial value of the product candidate. For example, under our collaboration agreement with BMS, after mutual agreement on the targets(s) of interest, our drug discovery group will be responsible for the discovery of development candidates. Once a development candidate meeting specified criteria for a target has been identified, BMS will be solely responsible for the development, manufacturing and commercialization of such development candidate. Even if we successfully identify one or more development candidates for BMS to develop and commercialize under our collaboration agreement, BMS may not achieve the research, development, regulatory and sales milestones for those development candidates that result in additional payments to us.

60

Table of Contents

 

We may never realize a return on our equity investments in our drug discovery collaborators.

We may never realize a return on our equity investments in our drug discovery collaborators. None of the drug discovery collaborators in which we hold equity generate revenue from commercial sales of drug products. They are therefore dependent on the availability of capital on favorable terms to continue their operations. In addition, if the drug discovery collaborators in which we hold equity raise additional capital, our ownership interest in and degree of control over these drug discovery collaborators will be diluted, unless we have sufficient resources and choose to invest in them further or successfully negotiate contractual anti-dilution protections for our equity investment. The financial success of our equity investment in any collaborator will likely be dependent on a liquidity event, such as a public offering, acquisition, or other favorable market event reflecting appreciation in the value of the equity we hold. The capital markets for public offerings and acquisitions are dynamic, and the likelihood of liquidity events for the companies in which we hold equity interests could significantly worsen. Further, valuations of privately held companies are inherently complex due to the lack of readily available market data. If we determine that any of our investments in such companies have experienced a decline in value, we may be required to record an impairment, which could negatively impact our financial results. The fair value of our equity interests in public companies, such as Morphic, may fluctuate significantly in future periods since we determine the fair value of such equity interests based on the market value of such companies’ common stock as of a given reporting date. All of the equity we hold in our drug discovery collaborators is subject to a risk of partial or total loss of our investment.

Our drug discovery collaborators have significant discretion in determining when to make announcements, if any, about the status of our collaborations, including about clinical developments and timelines for advancing collaborative programs, and the price of our common stock may decline as a result of announcements of unexpected results or developments.

Our drug discovery collaborators have significant discretion in determining when to make announcements about the status of our collaborations, including about preclinical and clinical developments and timelines for advancing the collaborative programs. While as a general matter we intend to periodically report on the status of our collaborations, our drug discovery collaborators, and in particular, our privately-held collaborators, may wish to report such information more or less frequently than we intend to or may not wish to report such information at all. The price of our common stock may decline as a result of the public announcement of unexpected results or developments in our collaborations, or as a result of our collaborators withholding such information.

Although we believe that our computational platform has the potential to identify more promising molecules than traditional methods and to accelerate drug discovery, our focus on using our platform technology to discover and design molecules with therapeutic potential may not result in the discovery and development of commercially viable products for us or our collaborators.

Our scientific approach focuses on using our platform technology to conduct “computational assays” that leverage our deep understanding of physics-based modeling and theoretical chemistry to design molecules and predict their key properties without conducting time-consuming and expensive physical experiments. Our computational platform underpins our software solutions, our drug discovery collaborations and our own internal drug discovery programs.

While the results of certain of our drug discovery collaborators suggest that our platform is capable of accelerating drug discovery and identifying high quality product candidates, these results do not assure future success for our drug discovery collaborators or for us with our internal drug discovery programs.

Even if we or our drug discovery collaborators are able to develop product candidates that demonstrate potential in preclinical studies, we or they may not succeed in demonstrating safety and efficacy of product candidates in human clinical trials. For example, in collaboration with us, Nimbus Therapeutics, LLC, or Nimbus, was able to identify a unique series of acetyl-CoA carboxylase, or ACC, allosteric protein-protein interaction inhibitors with favorable pharmaceutical properties that inhibit the activity of the ACC enzyme. Nimbus achieved proof of concept in a Phase 1b clinical trial of its ACC inhibitor, firsocostat, and later sold the program to Gilead Sciences, Inc., or Gilead Sciences, in a transaction valued at approximately $1.2 billion, comprised of an upfront payment and earn outs. Of this amount, $601.3 million has been paid to Nimbus to date, and we received a total of $46.0 million in cash distributions in 2016 and 2017. In December 2019, Gilead Sciences announced topline results from its Phase 2 clinical trial which included firsocostat, both as a monotherapy and in combination with other investigational therapies for advanced fibrosis due to nonalcoholic steatohepatitis, in which the primary endpoint was not met. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their product candidates.

61

Table of Contents

 

We may not be successful in our efforts to identify, discover or develop product candidates and may fail to capitalize on programs, collaborations, or product candidates that may present a greater commercial opportunity or for which there is a greater likelihood of success.

Research programs to identify new product candidates require substantial technical, financial, and human resources. As an organization, we have selected our first development candidates, which are for our MALT1 and CDC7 inhibitor programs, and advanced the programs into IND-enabling studies. We have not yet advanced any other programs into IND-enabling studies, and we may fail to identify potential product candidates for clinical development. Similarly, a key element of our business plan is to expand the use of our computational platform through an increase in software sales and drug discovery collaborations. A failure to demonstrate the utility of our platform by successfully using it ourselves to discover internal product candidates could harm our business prospects.

Because we have limited resources, we focus our research programs on protein targets where we believe our computational assays are a good substitute for experimental assays, where we believe it is theoretically possible to discover a molecule with properties that are required for the molecule to become a drug and where we believe there is a meaningful commercial opportunity, among other factors. The focus of our initial internal drug discovery programs was in the area of oncology, and we have only recently begun expanding into other therapeutic areas, including neurology and immunology. We may forego or delay pursuit of opportunities with certain programs, collaborations, or product candidates or for indications that later prove to have greater commercial potential. However, the development of any product candidate we pursue may ultimately prove to be unsuccessful or less successful than another potential product candidate that we might have chosen to pursue on a more aggressive basis with our capital resources. If we do not accurately evaluate the commercial potential for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaboration, partnership, licensing, or other arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. Alternatively, we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a collaboration.

Our research programs may show initial promise in identifying potential product candidates internally or with collaborators, yet fail to yield product candidates for clinical development for a number of reasons, including:

 

•

our research methodology or that of any collaborator may be unsuccessful in identifying potential product candidates that are successful in clinical development;

 

•

potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the product candidates unmarketable or unlikely to receive marketing approval;

 

•

our current or future collaborators may change their development profiles for potential product candidates or abandon a therapeutic area; or

 

•

new competitive developments may render our product candidates obsolete or noncompetitive.  

If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which would have a material adverse effect on our business.

We rely on contract research organizations to synthesize any molecules with therapeutic potential that we discover. If such organizations do not meet our supply requirements, or if such organizations do not otherwise perform satisfactorily, development of any product candidate we may develop may be delayed.

We rely and expect to continue to rely on third parties to synthesize any molecules with therapeutic potential that we discover. Reliance on third parties may expose us to different risks than if we were to synthesize molecules ourselves. Our reliance on these third parties will reduce our control over these activities but will not relieve us of our responsibilities. If these third parties do not successfully carry out their contractual duties, meet expected deadlines, or synthesize molecules in accordance with regulatory requirements, if there are disagreements between us and such parties or if such parties are unable to expand capacities, we may not be able to fulfill, or may be delayed in producing sufficient product candidates to meet, our supply requirements, and we may not be able to complete, or may be delayed in completing, the necessary preclinical studies to enable us to progress viable product candidates for IND, submissions and we will not be able to, or may be delayed in our efforts to, successfully develop and commercialize such product candidates. These facilities may also be affected by natural disasters, such as floods or fire, or geopolitical developments or public health pandemics, such as COVID-19, or such facilities could face production issues, such as contamination or regulatory concerns following a regulatory inspection of such facility. In such instances, we may need to locate an appropriate replacement third-

62

Table of Contents

 

party facility and establish a contractual relationship, which may not be readily available or on acceptable terms, which would cause additional delay and increased expense, and may have a material adverse effect on our business.

We or any third party may also encounter shortages in the raw materials or active pharmaceutical ingredient, or API, necessary to synthesize any molecule we may discover in the quantities needed for preclinical studies or clinical trials, as a result of capacity constraints or delays or disruptions in the market for the raw materials or API. Even if raw materials or API are available, we may be unable to obtain sufficient quantities at an acceptable cost or quality. The failure by us or the third parties to obtain the raw materials or API necessary to synthesize sufficient quantities of any molecule we may discover could delay, prevent, or impair our development efforts and may have a material adverse effect on our business.

If we are not able to establish or maintain collaborations to develop and commercialize any of the product candidates we discover internally, we may have to alter our development and commercialization plans for those product candidates and our business could be adversely affected.

We expect to rely on future collaborators for the development and potential commercialization of product candidates we discover internally when we believe it will help maximize the commercial value of the product candidate. We face significant competition in seeking appropriate collaborators for these activities, and a number of more established companies may also be pursuing such collaborations. These established companies may have a competitive advantage over us due to their size, financial resources, and greater clinical development and commercialization expertise. Whether we reach a definitive agreement for such collaborations will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration, and the proposed collaborator’s evaluation of a number of factors. Those factors may include the design or results of preclinical studies and clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large biopharmaceutical companies that have resulted in a reduced number of potential future collaborators.

If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop any product candidates or bring them to market.

63

Table of Contents

 

As a company, we do not have any experience in clinical development and have not advanced any product candidates into clinical development.

We only began conducting our own internal drug discovery efforts in mid-2018. We have selected our first development candidates, which are for our MALT1 and CDC7 inhibitor programs, and advanced the programs into IND-enabling studies. As a company, we do not have any experience in clinical development and have not advanced any product candidates into clinical development. We expect to submit an investigational new drug, or IND, application to the FDA, for our MALT1 program in the first half of 2022, and subject to receiving regulatory clearance, we expect to initiate our first clinical trial in the second half of 2022. We also plan to submit IND applications to the FDA for our CDC7 program in early 2023 and our WEE1 program in 2023, subject to favorable data from IND-enabling studies. In addition, we plan to initiate a Phase 1 clinical trial of our CDC7 inhibitor in 2023, subject to receipt of regulatory clearance. Our lack of experience in conducting clinical development activities may adversely impact the likelihood that we will be successful in advancing our programs. Further, any predictions you make about the future success or viability of our internal drug discovery programs may not be as accurate as they could be if we had a history of conducting clinical trials and developing our own product candidates.

In addition, as our internal drug discovery business grows, we may encounter unforeseen expenses, difficulties, complications, delays, and other known and unknown factors. Our internal drug discovery business may need to transition to a business capable of supporting clinical development activities. We may not be successful in such a transition.

Conducting successful clinical trials requires the enrollment of a sufficient number of patients, and suitable patients may be difficult to identify and recruit.

Conducting successful clinical trials requires the enrollment of a sufficient number of patients, and suitable patients may be difficult to identify and recruit. Identifying and qualifying patients to participate in future clinical trials for any other product candidate we develop is critical to our success. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the severity of disease; size of the patient population; the nature of the trial protocol; the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects; the availability of clinical trial investigators with appropriate competencies and experience; support staff; the number of ongoing clinical trials in the same indication that compete for the same patients; proximity of patients to clinical sites; availability of trial sites; ability to comply with the eligibility and exclusion criteria for participation in the clinical trial; ability to obtain and maintain patient consents; patient compliance; the ability to monitor patients during and after treatment; and the impact of the ongoing COVID-19 pandemic. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our product candidates. Patients may also not participate in our clinical trials if they choose to participate in contemporaneous clinical trials of competitive products.

Our inability to locate and enroll a sufficient number of patients for our clinical trials would result in significant delays, could require us to abandon one or more clinical trials altogether and could delay or prevent our receipt of necessary regulatory approvals. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing.

We plan to rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, which may prevent or delay our ability to seek or obtain marketing approval for or commercialize our product candidates or otherwise harm our business.

We plan to rely on third-party clinical research organizations, in addition to other third parties such as research collaboratives, clinical data management organizations, medical institutions and clinical investigators, to conduct our future clinical trials. These contract research organizations and other third parties will play a significant role in the conduct and timing of these trials and subsequent collection and analysis of data. These third-party arrangements might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, our product development activities might be delayed.

Our reliance on third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, and legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our responsibility to comply with any such standards. We and these third parties are required to comply with current good clinical practices, or cGCP, which are regulations and guidelines enforced by the FDA for all of our products in clinical development. Regulatory authorities in Europe and other jurisdictions have similar requirements. Regulatory authorities enforce these cGCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply

64

Table of Contents

 

with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you a given regulatory authority will determine that any of our clinical trials comply with cGCP regulations. We also are required to register ongoing clinical trials and post the results of completed clinical trials on a U.S. government-sponsored database, clinicaltrials.gov, within certain timeframes. Failure to do so can result in fines, adverse publicity and civil and criminal sanctions.

Furthermore, third parties on whom we rely may also have relationships with other entities, some of which may be our competitors. In addition, these third parties are not our employees, and except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our on-going clinical, nonclinical and preclinical programs. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised, our clinical trials may be extended, delayed or terminated and we may not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our medicines.

If we and any current or future collaborators are unable to successfully complete clinical development, obtain regulatory approval for, or commercialize any product candidates, or experience delays in doing so, our business may be materially harmed.

We are early in our development efforts. Our most advanced development candidates are in IND-enabling studies, and we have not advanced any product candidate into clinical development. Our ability to generate product revenues, which we do not expect will occur for many years, if ever, will depend heavily on the successful development and eventual commercialization of our product candidates. The success of our and any current or future collaborators’ development and commercialization programs will depend on several factors, including the following:

 

•

successful completion of necessary preclinical studies to enable the initiation of clinical trials;

 

•

successful enrollment of patients in, and the completion of, the clinical trials;

 

•

acceptance by the FDA or other regulatory agencies of regulatory filings for any product candidates we and our current or future collaborators may develop;

 

•

expanding and maintaining a workforce of experienced scientists and others to continue to develop any product candidates;

 

•

obtaining and maintaining intellectual property protection and regulatory exclusivity for any product candidates we and our current or future collaborators may develop;

 

•

making arrangements with third-party manufacturers for, or establishing, clinical and commercial manufacturing capabilities;

 

•

establishing sales, marketing, and distribution capabilities for drug products and successfully launching commercial sales, if and when approved;

 

•

acceptance of any product candidates we and our current or future collaborators may develop, if and when approved, by patients, the medical community, and third-party payors;

 

•

effectively competing with other therapies;

 

•

obtaining and maintaining coverage, adequate pricing, and adequate reimbursement from third-party payors, including government payors;

 

•

patients’ willingness to pay out-of-pocket in the absence of coverage and/or adequate reimbursement from third-party payors;

 

•

ongoing or future restrictions resulting from the COVID-19 pandemic and its collateral consequences may result in internal and external operational delays and limitations; and

 

•

maintaining a continued acceptable safety profile following receipt of any regulatory approvals.

Many of these factors are beyond our control, including clinical outcomes, the regulatory review process, potential threats to our intellectual property rights, and the manufacturing, marketing, and sales efforts of any current or future collaborator. Clinical drug development involves a lengthy and expensive process, with an uncertain outcome. If we or our current or future collaborators are unable to develop, receive marketing approval for, and successfully commercialize any product candidates, or if we or they experience delays as a result of any of these factors or otherwise, we may need to spend significant additional time and resources, which would adversely affect our business, prospects, financial condition, and results of operations.

65

Table of Contents

 

We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do, thus rendering our products non-competitive, obsolete or reducing the size of our market.

We face competition with respect to our and our collaborators’ product candidates from biopharmaceutical and biotechnology companies. The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary and novel products and product candidates. Our competitors have developed, are developing or may develop products, product candidates and processes competitive with our product candidates. Any product candidates that we successfully develop and commercialize, internally or with our collaborators, will compete with existing therapies and new therapies that may become available in the future.

In particular, there is intense competition in the fields of oncology we are pursuing. We have competitors both in the United States and internationally, including major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies, emerging and start-up companies, universities and other research institutions. We also compete with these organizations to recruit management, scientists and clinical development personnel, which could negatively affect our level of expertise and our ability to execute our business plan. We will also face competition in establishing clinical trial sites, enrolling subjects for clinical trials and in identifying new product candidates.

Large pharmaceutical and biotechnology companies, in particular, have extensive experience in clinical testing, obtaining regulatory approvals, recruiting patients and manufacturing biotechnology products. These companies also have significantly greater research and marketing capabilities than we do and may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical and biotechnology companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than our products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies, as well as in acquiring technologies complementary to, or necessary for, our programs. As a result of all of these factors, our competitors may succeed in obtaining approval from the FDA or other comparable foreign regulatory authorities or in discovering, developing and commercializing products in our field before we do.

Risks Related to Our Operations

Doing business internationally creates operational and financial risks for our business.

For the fiscal year ended December 31, 2021, sales to customers outside of the United States accounted for approximately 34% of our total revenues. Operating in international markets requires significant resources and management attention and subjects us to regulatory, economic, and political risks that are different from those in the United States. We have limited operating experience in some international markets, and we cannot assure you that our expansion efforts into other international markets will be successful. Our experience in the United States and other international markets in which we already have a presence may not be relevant to our ability to expand in other markets. Our international expansion efforts may not be successful in creating further demand for our solutions outside of the United States or in effectively selling our solutions in the international markets we enter. In addition, we face risks in doing business internationally that could adversely affect our business, including:

 

•

the need to localize and adapt our solutions for specific countries, including translation into foreign languages;

 

•

data privacy laws which require that customer data be stored and processed in a designated territory or handled in a manner that differs significantly from how we typically handle customer data;

 

•

difficulties in staffing and managing foreign operations, including employee laws and regulations;

 

•

different pricing environments, longer sales cycles, and longer accounts receivable payment cycles and collections issues;

 

•

new and different sources of competition;

 

•

weaker protection for intellectual property and other legal rights than in the United States and practical difficulties in enforcing intellectual property and other rights outside of the United States;

 

•

laws and business practices favoring local competitors;

 

•

compliance challenges related to the complexity of multiple, conflicting, and changing governmental laws and regulations, including employment, tax, reimbursement and pricing, privacy and data protection, and anti-bribery laws and regulations;

66

Table of Contents

 

 

•

increased financial accounting and reporting burdens and complexities;

 

•

restrictions on the transfer of funds;

 

•

changes in diplomatic and trade relationships, including new tariffs, trade protection measures, import or export licensing requirements, trade embargoes, and other trade barriers;

 

•

changes in social, political, and economic conditions or in laws, regulations, and policies governing foreign trade, manufacturing, development, and investment both domestically as well as in the other countries and jurisdictions;

 

•

adverse tax consequences, including the potential for required withholding taxes;

 

•

global health pandemics, such as COVID-19; and

 

•

unstable regional, economic and political conditions.

Our international agreements may provide for payment denominated in local currencies and our local operating costs are denominated in local currencies. Therefore, fluctuations in the value of the U.S. dollar and foreign currencies may impact our operating results when translated into U.S. dollars. We do not currently engage in currency hedging activities to limit the risk of exchange rate fluctuations.

Additionally, we could face heightened risks as a result of the recent withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit. Since the regulatory framework for pharmaceutical products in the United Kingdom covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived from European Union directives and regulations, the consequences of Brexit and the future regulatory regime that applies to products and the approval of product candidates in the United Kingdom remains unclear.

A widespread outbreak of an illness or other health issue, such as the COVID-19 pandemic, could negatively affect various aspects of our business and make it more difficult to meet our obligations to our customers, and could result in reduced demand from our customers as well as delays in our drug discovery and development programs.

Our business and operations could be adversely affected by health epidemics, including the ongoing COVID-19 pandemic, impacting the markets and industries in which we and our customers and collaborators operate.

The COVID-19 pandemic has been declared a national emergency. In response to the COVID-19 pandemic, state, local, federal, and foreign governments have put in place, and others in the future may put in place, quarantines, executive orders, shelter-in-place orders, and similar government orders and restrictions in order to control the spread of the disease. Such orders or restrictions, or the perception that such orders or restrictions could occur, have resulted in business closures, work stoppages, slowdowns and delays, work-from-home policies, travel restrictions, and cancellation or postponement of events, among other effects that could negatively impact productivity and disrupt our operations and those of our customers and collaborators. In early March 2020, we implemented a work-from-home policy for all of our employees. Beginning in June 2020, we began limited re-openings of certain of our offices in the United States and abroad. Our re-openings are being conducted on a limited basis and are voluntary for all of our employees. We have continued to phase-in the re-opening of our offices as our management and federal, state, or local authorities advise, and we may take further actions that alter our operations as may be required by federal, state, or local authorities, or which we determine are in our best interests. While most of our operations can be performed remotely, there is no guarantee that we will continue to be as effective while working remotely because our team is dispersed, many employees may have additional personal needs to attend to (such as looking after children as a result of school closures or family who become sick), and employees may become sick themselves and be unable to work. Decreased effectiveness of our team could adversely affect our results due to our inability to meet in person with potential or current customers and collaborators, or other decreases in productivity that could seriously harm our business.

The full extent of the future impact will depend on many factors outside of our control, including, without limitation, the extent, trajectory and duration of the pandemic, the development, availability and distribution of effective treatments and vaccines, the imposition of protective public safety measures, the emergence of new strains and variants of COVID-19 and the effectiveness of vaccines against such strains and variants, and the impact of the pandemic on the global economy. For instance, if certain of our customers experience downturns or uncertainty in their own business operations and revenue because of the economic effects resulting from the spread of COVID-19, they may decrease their spending, which may result in decreased software revenue. Furthermore, as a result of the restrictions related to COVID-19, our sales force has limited in-person interactions, and their ability to attend events that promote and expand knowledge of our company and platform, including industry conferences and events has been hampered.

67

Table of Contents

 

In addition, as a result of the COVID-19 pandemic, we may experience delays in the progress of certain of our and our collaborators’ drug discovery and development programs, particularly those that are in preclinical studies and clinical trials or that are preparing to enter clinical trials. Such delays may result in disruptions in current and future IND-enabling studies and clinical trials, manufacturing disruptions, trial site disruptions and impact the ability to obtain necessary institutional review board, or IRB, institutional biosafety committee, or IBC, or other necessary site approvals. For example, our contract manufacturing organizations, or CMOs, and our contract research organizations, or CROs, have experienced reductions in the capacity to undertake research-scale production and have experienced delays in executing preclinical studies, including our IND-enabling studies for our CDC7 program. We now expect to submit the IND application to the FDA for our CDC7 program in early 2023 and to initiate a Phase 1 clinical trial in 2023. These reductions and delays may persist in the future, and we, together with our CMOs and CROs, are closely monitoring the impact of the COVID-19 pandemic on these operations. Furthermore, if our collaborators experience similar delays with their drug discovery and development programs, that could delay our achievement of milestones and related revenue.

Inadequate funding or disruptions at the FDA and other agencies may also slow the time necessary for new product candidates to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.

The global impact of COVID-19 continues to rapidly evolve, and we will continue to monitor the situation closely. The ultimate impact of the COVID-19 pandemic or a similar health epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, operations, or the global economy as a whole. While the spread of COVID-19 may eventually be contained or mitigated, there is no guarantee that a future outbreak of this or any other widespread epidemics will not occur, or that the global economy will recover, either of which could seriously harm our business.

If we fail to manage our technical operations infrastructure, our existing customers, and our internal drug discovery team, may experience service outages, and our new customers may experience delays in the deployment of our solutions.

We have experienced significant growth in the number of users and data that our operations infrastructure supports. We seek to maintain sufficient excess capacity in our operations infrastructure to meet the needs of all of our customers and to support our internal drug discovery programs. We also seek to maintain excess capacity to facilitate the rapid provision of new customer deployments and the expansion of existing customer deployments. In addition, we need to properly manage our technological operations infrastructure in order to support version control, changes in hardware and software parameters and the evolution of our solutions. However, the provision of new hosting infrastructure requires adequate lead-time. We have experienced, and may in the future experience, website disruptions, outages, and other performance problems. These types of problems may be caused by a variety of factors, including infrastructure changes, human or software errors, viruses, security attacks, fraud, spikes in usage, and denial of service issues. In some instances, we may not be able to identify the cause or causes of these performance problems within an acceptable period of time. If we do not accurately predict our infrastructure requirements, our existing customers may experience service outages that may subject us to financial penalties, financial liabilities, and customer losses. If our operations infrastructure fails to keep pace with increased sales and usage, customers and our internal drug discovery team may experience delays in the deployment of our solutions as we seek to obtain additional capacity, which could adversely affect our reputation and adversely affect our revenues.

Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition.

Changes in tax law may adversely affect our business or financial condition.  The Tax Cuts and Jobs Act, or the 2017 Tax Act, as amended by the Coronavirus Aid, Relief, and Economic Security Act, or CARES Act, significantly revises the Internal Revenue Code of 1986, as amended, or the Code. The 2017 Tax Act, among other things, contains significant changes to corporate taxation, including a reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable income (except for certain small businesses), the limitation of the deduction for net operating losses, or NOLs, to 80% of current-year taxable income and elimination of NOL carrybacks, in each case, for losses arising in taxable years beginning after December 31, 2017 (though any such NOLs may be carried forward indefinitely and such NOLs arising in taxable years beginning before January 1, 2021 are generally eligible to be carried back up to five years), the imposition of a one-time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, the elimination of U.S. tax on foreign earnings (subject to certain important exceptions), the allowance of immediate deductions for certain new investments instead of deductions for depreciation expense over time, and the modification or repeal of many business deductions and credits.

68

Table of Contents

 

In addition to the CARES Act, as part of Congress’s response to the COVID-19 pandemic, economic relief legislation has been enacted in 2020 and 2021 containing tax provisions. Regulatory guidance under the 2017 Tax Act and such additional legislation is and continues to be forthcoming, and such guidance could ultimately increase or lessen the impact of these laws on our business and financial condition. Also, as a result of the changes in the U.S. presidential administration and control of the U.S. Senate in 2021, additional tax legislation may be enacted; any such additional legislation could have an impact on our company. In addition, it is uncertain if and to what extent various states will conform to the 2017 Tax Act and additional tax legislation.

Our ability to use our NOLs and research and development tax credit carryforwards to offset future taxable income may be subject to certain limitations.

As of December 31, 2021, we had federal NOLs of approximately $283.3 million and state NOLs of approximately $148.1 million, which, if not utilized, generally begin to expire in 2022. As of December 31, 2021, we also had federal research and development tax credit carryforwards of approximately $15.5 million and state research and development tax credit carryforwards of approximately $1.0 million. Unused credits began to expire in 2021 and generally expire over time if they remain unused. These NOLs and research and development tax credit carryforwards could expire unused and be unavailable to offset future income tax liabilities.

In addition, under Section 382 of the Code, and corresponding provisions of state law, a corporation that undergoes an “ownership change,” generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and research and development tax credit carryforwards to offset future taxable income. We have performed an analysis through March 31, 2021 and determined that such an ownership change has occurred. As a result of such ownership change or future ownership changes, our ability to use our NOLs and research and development tax credit carryforwards may be materially limited.

There is also a risk that due to regulatory changes, such as suspension of the use of NOLs, or other unforeseen reasons, our existing NOLs could expire or otherwise become unavailable to offset future income tax liabilities.  As described above in “Changes in tax laws or in their implementation or interpretation could adversely affect our business and financial condition,” the 2017 Tax Act as amended by the CARES Act, includes changes to U.S. federal tax rates and rules governing NOL carryforwards that may significantly impact our ability to utilize NOLs to offset taxable income in the future.  In addition, state NOLs generated in one state cannot be used to offset income generated in another state. For these reasons, we may be unable to use a material portion of our NOLs and other tax attributes.

Our international operations subject us to potentially adverse tax consequences.

We report our taxable income in various jurisdictions worldwide based upon our business operations in those jurisdictions. These jurisdictions include Germany, Japan, India and South Korea. The international nature and organization of our business activities are subject to complex transfer pricing regulations administered by taxing authorities in various jurisdictions. The relevant taxing authorities may disagree with our determinations as to the income and expenses attributable to specific jurisdictions. If such a disagreement were to occur, and our position were not sustained, we could be required to pay additional taxes, interest, and penalties, which could result in one-time tax charges, higher effective tax rates, reduced cash flows, and lower overall profitability of our operations.

Taxing authorities may successfully assert that we should have collected or in the future should collect sales and use, value added, or similar taxes, and we could be subject to tax liabilities with respect to past or future sales, which could adversely affect our results of operations.

We do not collect sales and use, value added, and similar taxes in all jurisdictions in which we have sales, based on our belief that such taxes are not applicable or that we are not required to collect such taxes with respect to the jurisdiction. Sales and use, value added, and similar tax laws and rates vary greatly by jurisdiction. Certain jurisdictions in which we do not collect such taxes may assert that such taxes are applicable, which could result in tax assessments, penalties, and interest, and we may be required to collect such taxes in the future. Such tax assessments, penalties, and interest or future requirements may adversely affect our results of operations.

Unanticipated changes in our effective tax rate could harm our future results.

We are subject to income taxes in the United States and various foreign jurisdictions, and our domestic and international tax liabilities are subject to the allocation of expenses in differing jurisdictions. Forecasting our estimated annual effective tax rate is complex and subject to uncertainty, and there may be material differences between our forecasted and actual tax rates. Our effective

69

Table of Contents

 

tax rate could be adversely affected by changes in the mix of earnings and losses in countries with differing statutory tax rates, certain non-deductible expenses as a result of acquisitions, the valuation of deferred tax assets and liabilities, and changes in federal, state, or international tax laws and accounting principles. Increases in our effective tax rate would reduce our profitability or in some cases increase our losses.

In addition, we may be subject to income tax audits by many tax jurisdictions throughout the world. Although we believe our income tax liabilities are reasonably estimated and accounted for in accordance with applicable laws and principles, an adverse resolution of one or more uncertain tax positions in any period could have a material impact on the results of operations for that period.

We have recently acquired, and we may again in the future acquire, companies or technologies, which could divert our management’s attention, result in additional dilution to our stockholders, and otherwise disrupt our operations and adversely affect our operating results.

We have recently acquired, and we may again in the future seek to acquire or invest in, businesses, solutions, or technologies that we believe could complement or expand our solutions, enhance our technical capabilities, or otherwise offer growth opportunities. For example, in January 2022, we acquired XTAL BioStructures, Inc., or XTAL, a company that provides structural biology services, including biophysical methods, protein production and purification, and X-ray crystallography, which will augment our ability to produce high quality target structures for our drug discovery programs. The pursuit of potential acquisitions may divert the attention of management and cause us to incur various expenses in identifying, investigating, and pursuing suitable acquisitions, whether or not they are consummated.

In addition, other than our acquisition of XTAL, we have limited experience in acquiring other businesses. If we acquire additional businesses, we may not be able to integrate the acquired personnel, operations, and technologies successfully, effectively manage the combined business following the acquisition or preserve the operational synergies between our business units that we believe currently exist. We cannot assure you that following any acquisition we would achieve the expected synergies to justify the transaction, due to a number of factors, including:

 

•

inability to integrate or benefit from acquired technologies or services in a profitable manner;

 

•

unanticipated costs or liabilities associated with the acquisition;

 

•

incurrence of acquisition-related costs;

 

•

difficulty integrating the accounting systems, operations, and personnel of the acquired business;

 

•

difficulties and additional expenses associated with supporting legacy products and hosting infrastructure of the acquired business;

 

•

difficulty converting the customers of the acquired business onto our solutions and contract terms, including disparities in the revenues, licensing, support, or professional services model of the acquired company;

 

•

diversion of management’s attention from other business concerns;

 

•

adverse effects to our existing business relationships with business partners and customers as a result of the acquisition;

 

•

the potential loss of key employees;

 

•

use of resources that are needed in other parts of our business; and

 

•

use of substantial portions of our available cash to consummate the acquisition.

In addition, a significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually. In the future, if our acquisitions do not yield expected returns, we may be required to take charges to our operating results based on this impairment assessment process, which could adversely affect our results of operations.

Acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our operating results, business, and financial position may suffer.

70

Table of Contents

 

Our operations may be interrupted by the occurrence of a natural disaster or other catastrophic event at our primary facilities.

Our operations are primarily conducted at our facilities in New York, New York and Portland, Oregon and our internal hosting facility located in Clifton, New Jersey. The occurrence of natural disasters or other catastrophic events could disrupt our operations. Any natural disaster or catastrophic event in our facilities or the areas in which they are located could have a significant negative impact on our operations.

Risks Related to Our Intellectual Property

If we fail to comply with our obligations under our existing license agreements with Columbia University, under any of our other intellectual property licenses, or under any future intellectual property licenses, or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.

We are party to a number of license agreements pursuant to which we have been granted exclusive and non-exclusive worldwide licenses to certain patents, software code, and software programs to, among other things, reproduce, use, execute, copy, operate, sublicense, and distribute the licensed technology in connection with the marketing and sale of our software solutions and to develop improvements thereto. In particular, the technology that we license from Columbia University pursuant to our license agreements with them are used in and incorporated into a number of our software solutions which we market and license to our customers. For further information regarding our license agreements with Columbia University, see “Business—License Agreements with Columbia University”. Our license agreements with Columbia University and other licensors impose, and we expect that future licenses will impose, specified royalty and other obligations on us.

In spite of our best efforts, our current or any future licensors might conclude that we have materially breached our license agreements with them and might therefore terminate the license agreements, thereby delaying our ability to market and sell our existing software solutions and develop and commercialize new software solutions that utilize technology covered by these license agreements. If these in-licenses are terminated, or if the underlying intellectual property fails to provide the intended exclusivity, competitors could market, products and technologies similar to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.

Disputes may arise regarding intellectual property subject to a licensing agreement, including:

 

•

the scope of rights granted under the license agreement and other interpretation related issues;

 

•

the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;

 

•

the sublicensing of patent and other rights under any collaborative development relationships;

 

•

the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our current or future licensors and us and our collaborators; and

 

•

the priority of invention of patented technology.

In addition, license agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement. For example, our counterparties have in the past and may in the future dispute the amounts owed to them pursuant to payment obligations. If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may experience delays in the development and commercialization of new software solutions and in our ability to market and sell existing software solutions, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.

Our obligations under our existing or future drug discovery collaboration agreements may limit our intellectual property rights that are important to our business. Further, if we fail to comply with our obligations under our existing or future collaboration agreements, or otherwise experience disruptions to our business relationships with our prior, current, or future collaborators, we could lose intellectual property rights that are important to our business.

We are party to collaboration agreements with biopharmaceutical companies, pursuant to which we provide drug discovery services but have no ownership rights, or only co-ownership rights, to certain intellectual property generated through the

71

Table of Contents

 

collaborations. We are also party to a collaboration agreement with BMS for the development and potential commercialization of product candidates we discover internally, which also provides for co-ownership rights to certain intellectual property generated through the collaboration in certain scenarios. We may enter into additional collaboration agreements in the future, pursuant to which we may have no ownership rights, or only co-ownership rights, to certain intellectual property generated through the future collaborations. If we are unable to obtain ownership or license of such intellectual property generated through our prior, current, or future collaborations and overlapping with, or related to, our own proprietary technology or product candidates, then our business, financial condition, results of operations, and prospects could be materially harmed.

Our existing collaboration agreements contain certain exclusivity obligations that require us to design compounds exclusively for our collaborators with respect to certain specific targets over a specified time period. Our future collaboration agreements may grant similar exclusivity rights to future collaborators with respect to target(s) that are the subject of such collaborations. Existing or future collaboration agreements may also impose diligence obligations on us. For example, existing or future collaboration agreements may impose restrictions on us from pursuing the drug development targets for ourselves or for our other current or future collaborators, thereby removing our ability to develop and commercialize, or to jointly develop and commercialize with other current or future collaborators, product candidates, and technology related to the drug development targets. Under our collaboration with BMS, for example, we are prohibited from developing and commercializing product candidates anywhere in the world that are directed at the targets specified under the agreement, until the earlier of such target ceasing to be included under the agreement or the expiration of the last to expire royalty term for the program related to the target. In spite of our best efforts, our prior, current, or future collaborators might conclude that we have materially breached our collaboration agreements. If these collaboration agreements are terminated, or if the underlying intellectual property, to the extent we have ownership or license of, fails to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products and technology identical to ours. This could have a material adverse effect on our competitive position, business, financial condition, results of operations, and prospects.

Disputes may arise regarding intellectual property subject to a collaboration agreement, including:

 

•

the scope of ownership or license granted under the collaboration agreement and other interpretation related issues;

 

•

the extent to which our technology and product candidates infringe on intellectual property that generated through the collaboration to of which we do not have ownership or license under the collaboration agreement;

 

•

the assignment or sublicense of intellectual property rights and other rights under the collaboration agreement;

 

•

our diligence obligations under the collaboration agreement and what activities satisfy those diligence obligations; and

 

•

the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by us and our current or future collaborators.

In addition, collaboration agreements are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property, or increase what we believe to be our obligations under the relevant agreements, either of which could have a material adverse effect on our business, financial condition, results of operations, and prospects. Moreover, if disputes over intellectual property that we have owned, co-owned, or in-licensed under the collaboration agreements prevent or impair our ability to maintain our current collaboration arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected technology or product candidates, which could have a material adverse effect on our business, financial condition, results of operations, and prospects.

If we are unable to obtain, maintain, enforce, and protect patent protection for our technology and product candidates or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully develop and commercialize our technology and product candidates may be adversely affected.

Our success depends in large part on our ability to obtain and maintain protection of the intellectual property we may own solely and jointly with others or may license from others, particularly patents, in the United States and other countries with respect to any proprietary technology and product candidates we develop. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our technology and any product candidates we may develop that are important to our business and by in-licensing intellectual property related to our technology and product candidates. If we are unable to obtain or maintain patent protection with respect to any proprietary technology or product candidate, our business, financial condition, results of operations, and prospects could be materially harmed.

72

Table of Contents

 

The patent prosecution process is expensive, time-consuming, and complex, and we may not be able to file, prosecute, maintain, defend, or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing, and prosecution of patent applications, or to maintain, enforce, and defend the patents, covering technology that we co-own with third parties or license from third parties. Therefore, these co-owned and in-licensed patents and applications may not be prepared, filed, prosecuted, maintained, defended, and enforced in a manner consistent with the best interests of our business.

The patent position of software and biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has in recent years been the subject of much litigation. In addition, the scope of patent protection outside of the United States is uncertain and laws of non-U.S. countries may not protect our rights to the same extent as the laws of the United States or vice versa. With respect to both owned and in-licensed patent rights, we cannot predict whether the patent applications we, our collaborators, and our licensor are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient protection from competitors. Further, we may not be aware of all third-party intellectual property rights or prior art potentially relating to our computational platform, technology, and any product candidates we may develop. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing of the priority application, or in some cases not published at all. Therefore, neither we nor our collaborators, or our licensor can know with certainty whether either we, our collaborators, or our licensor were the first to make the inventions claimed in the patents and patent applications we own or in-license now or in the future, or that either we, our collaborators, or our licensor were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability, and commercial value of our owned, co-owned, and in-licensed patent rights are highly uncertain. Moreover, our owned, co-owned, and in-licensed pending and future patent applications may not result in patents being issued that protect our technology and product candidates, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our owned, co-owned, or in-licensed current or future patents and our ability to obtain, protect, maintain, defend, and enforce our patent rights, narrow the scope of our patent protection and, more generally, could affect the value of, or narrow the scope of, our patent rights. For example, recent Supreme Court decisions have served to curtail the scope of subject matter eligible for patent protection in the United States, and many software patents have since been invalidated on the basis that they are directed to abstract ideas.

In order to pursue protection based on our pending provisional patent applications, we will need to file Patent Cooperation Treaty applications, non-U.S. applications, and/or U.S. non-provisional patent applications prior to applicable deadlines. Even then, as highlighted above, patents may never issue from our patent applications, or the scope of any patent may not be sufficient to provide a competitive advantage.

Moreover, we, our collaborators, or our licensor may be subject to a third-party preissuance submission of prior art to the U.S. Patent and Trademark Office, or USPTO, or become involved in opposition, derivation, revocation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights or allow third parties to commercialize our technology or product candidates and compete directly with us, without payment to us. If the breadth or strength of protection provided by our owned, co-owned, or in-licensed current or future patents and patent applications is threatened, regardless of the outcome, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future technology or product candidates.

Additionally, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Even if our owned, co-owned, and in-licensed current and future patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us, or otherwise provide us with any competitive advantage. The issuance of a patent is not conclusive as to its inventorship, scope, validity, or enforceability, and our owned and in-licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Such proceedings also may result in substantial cost and require significant time from our management and employees, even if the eventual outcome is favorable to us. In particular, given the amount of time required for the development, testing, and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. Furthermore, our competitors may be able to circumvent our owned, co-owned, or in-licensed current or future patents by developing similar or alternative technologies or products in a non-infringing manner. As a result, our owned, co-owned, and in-licensed current or future patent portfolio may not

73

Table of Contents

 

provide us with sufficient rights to exclude others from commercializing technology and products similar or identical to any of our technology and product candidates.

Changes to patent laws in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.

Changes in either the patent laws or interpretation of patent laws in the United States, including patent reform legislation such as the Leahy-Smith America Invents Act, or the Leahy-Smith Act, could increase the uncertainties and costs surrounding the prosecution of our owned and in-licensed patent applications and the maintenance, enforcement or defense of our owned and in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted, redefine prior art, provide more efficient and cost-effective avenues for competitors to challenge the validity of patents, and enable third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent at USPTO-administered post-grant proceedings, including post-grant review, inter partes review, and derivation proceedings. Assuming that other requirements for patentability are met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. After March 2013, under the Leahy-Smith Act, the United States transitioned to a first-to-file system in which, assuming that the other statutory requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent the claimed invention. As such, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.

In addition, the patent positions of companies in the development and commercialization of software, biologics and pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our patent rights and our ability to protect, defend and enforce our patent rights in the future.

A number of recent cases decided by the U.S. Supreme Court have involved questions of when claims reciting abstract ideas, laws of nature, natural phenomena and/or natural products are eligible for a patent, regardless of whether the claimed subject matter is otherwise novel and inventive. These cases include Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 12-398 (2013) or Myriad; Alice Corp. v. CLS Bank International, 573 U.S. 13-298 (2014); and Mayo Collaborative Services v. Prometheus Laboratories, Inc., or Prometheus, 566 U.S. 10-1150 (2012). In response to these cases, federal courts have held numerous patents invalid as claiming subject matter ineligible for patent protection. Moreover, the USPTO has issued guidance to the examining corps on how to apply these cases during examination. The full impact of these decisions is not yet known.

In addition to increasing uncertainty with regard to our ability to obtain future patents, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on these and other decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change or be interpreted in unpredictable ways that would weaken our ability to obtain new patents or to enforce any patents that may issue to us in the future. In addition, these events may adversely affect our ability to defend any patents that may issue in procedures in the USPTO or in courts.

74

Table of Contents

 

We, our prior, existing, or future collaborators, and our existing or future licensors, may become involved in lawsuits to protect or enforce our patent or other intellectual property rights, which could be expensive, time-consuming and unsuccessful.

Competitors and other third parties may infringe, misappropriate, or otherwise violate our, our prior, current and future collaborators’, or our current and future licensors’ issued patents or other intellectual property. As a result, we, our prior, current, or future collaborators, or our current or future licensor may need to file infringement, misappropriation, or other intellectual property related claims, which can be expensive and time-consuming. Any claims we assert against perceived infringers could provoke such parties to assert counterclaims against us alleging that we infringe, misappropriate, or otherwise violate their intellectual property. In addition, in a patent infringement proceeding, such parties could assert that the patents we, our collaborators, or our licensors have asserted are invalid or unenforceable. In patent litigation in the United States, defenses alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. Third parties may institute such claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in non-U.S. jurisdictions (e.g., opposition proceedings). The outcome following legal assertions of invalidity and unenforceability is unpredictable.

An adverse result in any such proceeding could put one or more of our owned, co-owned, or in-licensed current or future patents at risk of being invalidated or interpreted narrowly and could put any of our owned, co-owned, or in-licensed current or future patent applications at risk of not yielding an issued patent. A court may also refuse to stop the third party from using the technology at issue in a proceeding on the grounds that our owned, co-owned, or in-licensed current or future patents do not cover such technology. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information or trade secrets could be compromised by disclosure during this type of litigation. Any of the foregoing could allow such third parties to develop and commercialize competing technologies and products in a non-infringing manner and have a material adverse impact on our business, financial condition, results of operations, and prospects.

Interference or derivation proceedings provoked by third parties, or brought by us or by our collaborators or licensor, or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to conduct clinical trials, continue our research programs, license necessary technology from third parties, or enter into development collaborations that would help us bring any product candidates to market.

Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business.

Our commercial success depends upon our ability and the ability of our collaborators and licensor to develop, manufacture, market and sell any product candidates we may develop and for our collaborators, licensor, customers and partners to use our proprietary technologies without infringing, misappropriating or otherwise violating the intellectual property and proprietary rights of third parties. There is considerable patent and other intellectual property litigation in the software, pharmaceutical, and biotechnology industries. We may become party to, or threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our technology and product candidates, including interference proceedings, post grant review, inter partes review, and derivation proceedings before the USPTO and similar proceedings in non-U.S. jurisdictions such as oppositions before the European Patent Office. Numerous U.S. and non-U.S. issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our technologies or product candidates that we may identify may be subject to claims of infringement of the patent rights of third parties.

The legal threshold for initiating litigation or contested proceedings is low, so that even lawsuits or proceedings with a low probability of success might be initiated and require significant resources to defend. Litigation and contested proceedings can also be expensive and time-consuming, and our adversaries in these proceedings may have the ability to dedicate substantially greater resources to prosecuting these legal actions than we can. The risks of being involved in such litigation and proceedings may increase if and as any product candidates near commercialization and as we gain the greater visibility associated with being a public company.

75

Table of Contents

 

Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of merit. We may not be aware of all such intellectual property rights potentially relating to our technology and product candidates and their uses, or we may incorrectly conclude that third-party intellectual property is invalid or that our activities and product candidates do not infringe such intellectual property. Thus, we do not know with certainty that our technology and product candidates, or our development and commercialization thereof, do not and will not infringe, misappropriate or otherwise violate any third party’s intellectual property.

Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations or methods, such as methods of manufacture or methods for treatment, related to the discovery, use or manufacture of the product candidates that we may identify or related to our technologies. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that the product candidates that we may identify may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. Moreover, as noted above, there may be existing patents that we are not aware of or that we have incorrectly concluded are invalid or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction to cover, for example, the manufacturing process of the product candidates that we may identify, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize the product candidates that we may identify. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products, be forced to indemnify our customers, licensor, or collaborators or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.

We may choose to take a license or, if we are found to infringe, misappropriate or otherwise violate a third party’s intellectual property rights, we could also be required to obtain a license from such third party to continue developing, manufacturing and marketing our technology and product candidates. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us and could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product. A finding of infringement could prevent us from commercializing any product candidates or force us to cease some of our business operations, which could materially harm our business. In addition, we may be forced to redesign any product candidates, seek new regulatory approvals and indemnify third parties pursuant to contractual agreements. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar material adverse effect on our business, financial condition, results of operations and prospects.

We may be subject to claims by third parties asserting that our employees, consultants, or contractors have wrongfully used or disclosed confidential information of third parties, or we have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property.

Certain of our employees, consultants, and contractors were previously employed at universities or other software or biopharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual’s current or former employer. Litigation may be necessary to defend against these claims.

In addition, while it is our policy to require that our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Our intellectual property assignment agreements with them may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations, and prospects.

76

Table of Contents

 

If we fail in prosecuting or defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could have a material adverse effect on our competitive business position and prospects. Such intellectual property rights could be awarded to a third party, and we could be required to obtain a license from such third party to commercialize our technology or products, which license may not be available on commercially reasonable terms, or at all, or such license may be non-exclusive. Even if we are successful in prosecuting or defending against such claims, litigation could result in substantial costs and be a distraction to our management and employees.

If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed.

In addition to seeking patents for any product candidates and technology, we also rely on trade secrets and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information, to maintain our competitive position. We seek to protect our trade secrets and other proprietary technology, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors, collaborators, and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants, but we cannot guarantee that we have entered into such agreements with each party that may have or has had access to our trade secrets or proprietary technology. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive, and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor or other third party, our competitive position may be materially and adversely harmed.

Risks Related to Regulatory and Other Legal Compliance Matters

Even if we complete the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time consuming and uncertain and may prevent us from obtaining approvals for the commercialization of some or all of our product candidates. As a result, we cannot predict when or if, and in which territories, we will obtain marketing approval to commercialize a product candidate.

The research, testing, manufacturing, labeling, approval, selling, marketing, promotion and distribution of products are subject to extensive regulation by the FDA and comparable foreign regulatory authorities. We are not permitted to market our product candidates in the United States or in other countries until we receive approval of an NDA from the FDA or marketing approval from applicable regulatory authorities outside the United States. Our product candidates are in various stages of development and are subject to the risks of failure inherent in development. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. We have no experience as a company in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs to assist us in this process.

The process of obtaining marketing approvals, both in the United States and abroad, is lengthy, expensive and uncertain. It may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information, including manufacturing information, to regulatory authorities for each therapeutic indication to establish the product candidate’s safety and efficacy. The FDA or other regulatory authorities may determine that our product candidates are not safe and effective, only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use.

In addition, changes in marketing approval policies during the development period, changes in or the enactment or promulgation of additional statutes, regulations or guidance or changes in regulatory review for each submitted product application, may cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable.

In order to market and sell our products in the European Union and other foreign jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may file for marketing approvals but not receive necessary approvals to commercialize our products in any market.

77

Table of Contents

 

We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review designations in the US, and PRIME Designation in the European Union, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.

We may seek certain designations for one or more of our product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.

The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product’s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective.

We may also seek a priority review designation for one or more of our product candidates. If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months.

These designations are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for these designations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualifies for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.

In the EU, we may seek PRIME designation for our product candidates in the future. PRIME is a voluntary program aimed at enhancing the EMA’s role to reinforce scientific and regulatory support in order to optimize development and enable accelerated assessment of new medicines that are of major public health interest with the potential to address unmet medical needs. The program focuses on medicines that target conditions for which there exists no satisfactory method of treatment in the EU or even if such a method exists, it may offer a major therapeutic advantage over existing treatments. PRIME is limited to medicines under development and not authorized in the EU and the applicant intends to apply for an initial marketing authorization application through the centralized procedure. To be accepted for PRIME, a product candidate must meet the eligibility criteria in respect of its major public health interest and therapeutic innovation based on information that is capable of substantiating the claims. The benefits of a PRIME designation include the appointment of a CHMP rapporteur to provide continued support and help to build knowledge ahead of a marketing authorization application, early dialogue and scientific advice at key development milestones, and the potential to qualify products for accelerated review, meaning reduction in the review time for an opinion on approvability to be issued earlier in the application process. PRIME enables an applicant to request parallel EMA scientific advice and health technology assessment advice to facilitate timely market access. Even if we receive PRIME designation for any of our product candidates, the designation may not result in a materially faster development process, review or approval compared to conventional EMA procedures. Further, obtaining PRIME designation does not assure or increase the likelihood of EMA’s grant of a marketing authorization.

Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition, or results of operations.

The regulatory framework for the collection, use, safeguarding, sharing, transfer, and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data and employee data, is subject to the European Union General Data Protection Regulation, or the GDPR, which took effect across all member states of the European Economic Area, or EEA, in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR would increase our obligations with respect to any clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the European Union, including the United States and, as a result, increases the scrutiny that such rules should apply to transfers of personal data from any clinical trial sites located in the EEA to the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal

78

Table of Contents

 

information and/or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20 million Euros, whichever is greater, and confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric, or health data.

Given the breadth and depth of changes in data protection obligations, preparing for and complying with the GDPR’s requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors, or consultants that process or transfer personal data collected in the European Union. The GDPR and other changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation, and significant fines and penalties against us, and could have a material adverse effect on our business, financial condition, or results of operations.

Similar privacy and data security requirements are either in place or underway in the United States. There are a broad variety of data protection laws that may be applicable to our activities, and a range of enforcement agencies at both the state and federal levels that can review companies for privacy and data security concerns. The Federal Trade Commission and state Attorneys General all are aggressive in reviewing privacy and data security protections for consumers. New laws also are being considered at both the state and federal levels. For example, the California Consumer Privacy Act, or CCPA, which went into effect on January 1, 2020, is creating similar risks and obligations as those created by GDPR. Because of this, we may need to engage in additional activities (e.g., data mapping) to identify the personal information we are collecting and the purposes for which such information is collected. In addition, we will need to ensure that our policies recognize the rights granted to consumers (as that phrase is broadly defined in the CCPA and can include business contact information), including granting consumers the right to opt-out of the sale of their personal information. Many other states are considering similar legislation. A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with current and any future federal and state laws regarding privacy and security of personal information could expose us to fines and penalties. We also face a threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business.

We, and the collaborators who use our computational platform, may be subject to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations. Failure to comply with such laws and regulations, may result in substantial penalties.

We, and the collaborators who use our computational platform, may be subject to broadly applicable healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute our software solutions and any products for which we obtain marketing approval. Such healthcare laws and regulations include, but are not limited to, the federal health care Anti-Kickback Statute; federal civil and criminal false claims laws, such as the federal False Claims Act; the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA; the Federal Food, Drug, and Cosmetic Act; the federal Physician Payments Sunshine Act; and analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws and transparency laws.

Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other healthcare laws and regulations. Violations of applicable healthcare laws and regulations may result in significant civil, criminal, and administrative penalties, damages, disgorgement, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements, and/or oversight if a corporate integrity agreement or similar agreement is executed to resolve allegations of non-compliance with these laws and the curtailment or restructuring of operations. In addition, violations may also result in reputational harm, diminished profits, and future earnings.

We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws, and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures, and legal expenses, be precluded from developing, manufacturing, and selling certain products outside the United States or be required to develop and implement costly compliance programs, which could adversely affect our business, results of operations and financial condition.

Our operations are subject to anti-corruption laws, including the U.K. Bribery Act 2010, or Bribery Act, the U.S. Foreign Corrupt Practices Act, or FCPA, and other anti-corruption laws that apply in countries where we do business and may do business in

79

Table of Contents

 

the future. The Bribery Act, FCPA, and these other laws generally prohibit us, our officers, and our employees and intermediaries from bribing, being bribed, or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. Compliance with the FCPA, in particular, is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the biopharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.

We may in the future operate in jurisdictions that pose a high risk of potential Bribery Act or FCPA violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the Bribery Act, FCPA, or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. If we further expand our operations outside of the United States, we will need to dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate.

We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United Kingdom and the United States, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements, and currency exchange regulations, collectively referred to as the Trade Control laws. In addition, various laws, regulations, and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.

There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the Bribery Act, the FCPA, or other legal requirements, including Trade Control laws. If we are not in compliance with the Bribery Act, the FCPA, and other anti-corruption laws or Trade Control laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations, and liquidity. The U.S. Securities and Exchange Commission, or SEC, also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA’s accounting provisions. Any investigation of any potential violations of the Bribery Act, the FCPA, other anti-corruption laws or Trade Control laws by the United Kingdom, U.S., or other authorities could also have an adverse impact on our reputation, our business, results of operations, and financial condition.

Our employees, independent contractors, consultants, and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading laws, which could cause significant liability for us and harm our reputation.

We are exposed to the risk of fraud or other misconduct by our employees, independent contractors, consultants, and vendors. Misconduct by these partners could include intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately, or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. This could include violations of HIPAA, other U.S. federal and state law, and requirements of non-U.S. jurisdictions, including the European Union Data Protection Directive. We are also exposed to risks in connection with any insider trading violations by employees or others affiliated with us. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws, standards, regulations, guidance, or codes of conduct. Furthermore, our employees may, from time to time, bring lawsuits against us for employment issues, including injury, discrimination, wage and hour disputes, sexual harassment, hostile work environment, or other employment issues. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.

80

Table of Contents

 

Our internal information technology systems, or those of our third-party vendors, contractors, or consultants, may fail or suffer security breaches, loss or leakage of data, and other disruptions, which could result in a material disruption of our services, compromise sensitive information related to our business, or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.

We are increasingly dependent upon information technology systems, infrastructure, and data to operate our business. In the ordinary course of business, we collect, store, and transmit confidential information (including but not limited to intellectual property, proprietary business information, and personal information). It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such confidential information. We also have outsourced elements of our operations to third parties, and as a result we manage a number of third-party vendors and other contractors and consultants who have access to our confidential information.

Despite the implementation of security measures, given the size and complexity of our internal information technology systems and those of our third-party vendors and other contractors and consultants, and the increasing amounts of confidential information that they maintain, our information technology systems are potentially vulnerable to breakdown or other damage or interruption from service interruptions, system malfunction, natural disasters, terrorism, war, and telecommunication and electrical failures, as well as security breaches from inadvertent or intentional actions by our employees, third-party vendors, contractors, consultants, business partners, and/or other third parties, or from cyber-attacks by malicious third parties (including the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering, and other means to affect service reliability and threaten the confidentiality, integrity, and availability of information), which may compromise our system infrastructure, or that of our third-party vendors and other contractors and consultants or lead to data leakage. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity, and sophistication of attempted attacks and intrusions from around the world have increased. We may not be able to anticipate all types of security threats, and we may not be able to implement preventive measures effective against all such security threats. For example, third parties have in the past and may in the future illegally pirate our software and make that software publicly available on peer-to-peer file sharing networks or otherwise. The techniques used by cyber criminals change frequently, may not be recognized until launched, and can originate from a wide variety of sources, including outside groups such as external service providers, organized crime affiliates, terrorist organizations, or hostile foreign governments or agencies. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or those of our third-party vendors and other contractors and consultants, or inappropriate disclosure of confidential or proprietary information, we could incur liability and reputational damage and the further development and commercialization of our software could be delayed. The costs related to significant security breaches or disruptions could be material and exceed the limits of the cybersecurity insurance we maintain against such risks. If the information technology systems of our third-party vendors and other contractors and consultants become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.

While we have not experienced any significant system failure, accident, or security breach to date, and believe that our data protection efforts and our investment in information technology reduce the likelihood of such incidents in the future, we cannot assure you that our data protection efforts and our investment in information technology will prevent significant breakdowns, data leakages, breaches in our systems, or those of our third-party vendors and other contractors and consultants, or other cyber incidents that could have a material adverse effect upon our reputation, business, operations, or financial condition. For example, if such an event were to occur and cause interruptions in our operations, or those of our third-party vendors and other contractors and consultants, it could result in a material disruption of our programs and the development of our services and technologies could be delayed. Furthermore, significant disruptions of our internal information technology systems or those of our third-party vendors and other contractors and consultants, or security breaches could result in the loss, misappropriation, and/or unauthorized access, use, or disclosure of, or the prevention of access to, confidential information (including trade secrets or other intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. For example, any such event that leads to unauthorized access, use, or disclosure of personal information, including personal information regarding our customers or employees, could harm our reputation directly, compel us to comply with federal and/or state breach notification laws and foreign law equivalents, subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damages that could potentially have an adverse effect on our business. Further, sophisticated cyber attackers (including foreign adversaries engaged in industrial espionage) are skilled at adapting to existing security technology and developing new methods of gaining access to organizations’ sensitive business data, which could result in the loss of sensitive information, including trade secrets. Additionally, actual, potential, or anticipated attacks may cause us to incur increasing costs, including costs to deploy additional personnel and protection technologies, train employees, and engage third-party experts and consultants.

81

Table of Contents

 

Risks Related to Employee Matters and Managing Growth

Our future success depends on our ability to retain key executives and to attract, retain, and motivate qualified personnel.

We are highly dependent on the research and development, clinical, financial, operational, scientific, software engineering, and other business expertise of our executive officers, as well as the other principal members of our management, scientific, clinical, and software engineering teams. Although we have entered into employment agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain “key person” insurance for any of our executives or other employees.

The loss of the services of our executive officers or other key employees could impede the achievement of our development and sales goals in our software business and the achievement of our research, development, and commercialization objectives in our drug discovery business. In either case, the loss of the services of our executive officers or other key employees could seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals with the breadth of skills and experience required to successfully develop, gain regulatory approval of, and commercialize products in the life sciences industry.

Recruiting and retaining qualified scientific, clinical, manufacturing, accounting, legal, and sales and marketing personnel, as well as software engineers and computational chemists, will also be critical to our success. In the technology industry, there is substantial and continuous competition for engineers with high levels of expertise in designing, developing, and managing software and related services, as well as competition for sales executives, data scientists, and operations personnel. Competition to hire these individuals is intense, and we may be unable to hire, train, retain, or motivate these key personnel on acceptable terms given the competition among numerous biopharmaceutical and technology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors to assist us in formulating our research and development and commercialization strategy and advancing our computational platform. Our consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high quality personnel, our ability to pursue our growth strategy will be limited and our business would be adversely affected.

We are pursuing multiple business strategies and expect to expand our development and regulatory capabilities, and as a result, we may encounter difficulties in managing our multiple business units and our growth, which could disrupt our operations.

Currently, we are pursuing multiple business strategies simultaneously, including activities in research and development, software sales, and collaborative and internal drug discovery. We believe pursuing these multiple business strategies offers financial and operational synergies, but these diversified operations place increased demands on our limited resources. Furthermore, we have recently experienced, and we expect to continue to experience, significant growth in the number of our employees and the scope of our operations, particularly in the areas of drug development, clinical and regulatory affairs. To manage our multiple business units and our ongoing and anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and our management team’s limited attention and limited experience in managing a company with such ongoing and anticipated growth, we may not be able to effectively manage our multiple business units and the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations has led to and may continue to lead to significant costs and may divert our management and business development resources. In addition, in order to meet our obligations as a public company and to support our anticipated long-term growth, we will need to increase our general and administrative capabilities. Our management, personnel, and systems may not be adequate to support this future growth. Any inability to manage our multiple business units and growth could delay the execution of our business plans or disrupt our operations and the synergies we believe currently exist between our business units. In addition, adverse developments in one of these business units may disrupt these synergies.

Risks Related to Ownership of Our Common Stock

An active trading market for our common stock may not be sustained.

Our shares of common stock began trading on the Nasdaq Global Select Market on February 6, 2020. Prior to February 6, 2020, there was no public market for our common stock, and we cannot assure you that an active trading market for our shares will be sustained. As a result, it may be difficult for our stockholders to sell their shares without depressing the market price of our common stock, or at all.

82

Table of Contents

 

Our executive officers, directors, and principal stockholders, if they choose to act together, have the ability to influence all matters submitted to stockholders for approval.

As of February 18, 2022, our executive officers and directors and our stockholders who beneficially owned more than 5% of our outstanding common stock, in the aggregate, beneficially owned shares representing approximately 19.8% of our common stock and all of our limited common stock, or, if the holder of our limited common stock exercised its right to convert each share of its limited common stock for one share of our common stock, approximately 30.1% of our common stock. As a result, if these stockholders were to choose to act together, they would be able to influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, would influence the election of directors and approval of any merger, consolidation, or sale of all or substantially all of our assets.

This concentration of ownership control may:

 

•

delay, defer, or prevent a change in control;

 

•

entrench our management and board of directors; or

 

•

delay or prevent a merger, consolidation, takeover, or other business combination involving us that other stockholders may desire.

This concentration of ownership may also adversely affect the market price of our common stock.

The price of our common stock is volatile and fluctuates substantially, which could result in substantial losses for our stockholders.

Our stock price has been, and is likely to continue to be volatile. Since our initial public offering in February 2020 and through February 18, 2022, the intraday price of our common stock has fluctuated from a low of $24.37 to a high of $117.00. As a result of volatility, our stockholders may not be able to sell their common stock at or above the price paid for the shares. The market price for our common stock may be influenced by many factors, including:

 

•

our investment in, and the success of, our software solutions;

 

•

the success of our research and development efforts for our internal drug discovery programs;

 

•

initiation and progress of preclinical studies and clinical trials for any product candidates that we may develop;

 

•

results of or developments in preclinical studies and clinical trials of any product candidates we may develop or those of our competitors or potential collaborators;

 

•

the success of our drug discovery collaborators and any milestone or other payments we receive from such collaborators;

 

•

the success of competitive products or technologies;

 

•

regulatory or legal developments in the United States and other countries;

 

•

the recruitment or departure of key personnel;

 

•

variations in our financial results or the financial results of companies that are perceived to be similar to us;

 

•

guidance or announcements by us with respect to our anticipated financial or operational performance;

 

•

sales of common stock by us, our executive officers, directors or principal stockholders, or others, or the anticipation of such sales;

 

•

market conditions in the biopharmaceutical sector;

 

•

general economic, industry, and market conditions;

 

•

the societal and economic impact of public health epidemics, such as the ongoing COVID-19 pandemic; and

 

•

the other factors described in this “Risk Factors” section.

In the past, following periods of volatility in the market price of a company’s securities, securities class-action litigation has often been instituted against that company. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation, or adverse changes to our offerings or business practices. Such litigation may also cause us to incur other substantial costs to defend such claims and divert management’s attention and resources.

83

Table of Contents

 

Our actual operating results may differ significantly from our guidance.

We have released, and may in the future release, guidance in our annual or quarterly earnings conference calls, annual or quarterly earnings releases, or otherwise, regarding our future performance that represents our management’s estimates as of the date of such guidance. Our guidance, which includes forward-looking statements, is based on projections prepared by our management. Neither our registered public accountants nor any other independent expert or outside party compiles or examines the projections. Accordingly, no such person expresses any opinion or any other form of assurance with respect to the projections.

Projections are based upon a number of assumptions and estimates that, while presented with numerical specificity, are inherently subject to significant business, economic, and competitive uncertainties and contingencies, many of which are beyond our control and are based upon specific assumptions with respect to future business decisions, some of which will change. The principal reason that we have released, and would continue to release, guidance is to provide a basis for our management to discuss our business outlook with analysts and investors. We do not accept any responsibility for any projections or reports published by any such third parties.

Guidance is necessarily speculative in nature, and it can be expected that some or all of the assumptions underlying any guidance furnished by us will not materialize or will vary significantly from actual results. Accordingly, our guidance is only an estimate of what management believes is realizable as of the date of release. Actual results may vary from our guidance and the variations may be material.

We and our collaborators may not achieve projected discovery and development milestones and other anticipated key events in the time frames that we or they announce, which could have an adverse impact on our business and could cause our stock price to decline.

From time to time, we expect that we will make public statements regarding the expected timing of certain milestones and key events, such as the commencement and completion of preclinical and IND-enabling studies in our internal drug discovery programs as well developments and milestones under our collaborations. Morphic has also made public statements regarding its expectations for the development of programs under collaboration with us and they and other collaborators may in the future make additional statements about their goals and expectations for collaborations with us. The actual timing of these events can vary dramatically due to a number of factors such as delays or failures in our or our current and future collaborators’ drug discovery and development programs, including as a result of COVID-19, the amount of time, effort, and resources committed by us and our current and future collaborators, and the numerous uncertainties inherent in the development of drugs. As a result, there can be no assurance that our or our current and future collaborators’ programs will advance or be completed in the time frames we or they announce or expect. If we or any collaborators fail to achieve one or more of these milestones or other key events as planned, our business could be materially adversely affected and the price of our common stock could decline.

If securities analysts do not publish or cease publishing research or reports or publish misleading, inaccurate or unfavorable research about our business or if they publish negative evaluations of our stock, the price and trading volume of our stock could decline.

The market price and trading volume for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. We do not have control over these analysts. There can be no assurance that existing analysts will continue to cover us or that new analysts will begin to cover us. There is also no assurance that any covering analyst will provide favorable coverage. Although we have obtained analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock or publish inaccurate or unfavorable research about our business, or provides more favorable relative recommendations about our competitors, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price and trading volume to decline.

We have broad discretion in the use of our cash, cash equivalents, and marketable securities and may not use them effectively.

Our management will have broad discretion in the application of our cash, cash equivalents, and marketable securities and could use such funds in ways that do not improve our results of operations or enhance the value of our common stock or in ways that our stockholders may not agree with. The failure by our management to apply these funds effectively could harm our business, financial condition, results of operations, and prospects and could cause the price of our common stock to decline.

Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.

We have never declared or paid cash dividends on our common stock. We currently intend to retain all of our future earnings to fund the development and expansion of our business. Any determination to pay dividends in the future will be at the discretion of our board of directors. As a result, capital appreciation of our common stock, if any, will be the sole source of gain for our stockholders for the foreseeable future.

84

Table of Contents

 

Sales of a substantial number of shares of our common stock in the public market could cause the market price of our common stock to drop significantly, even if our business is doing well.

Sales of a substantial number of shares of our common stock in the public market, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock, impair our ability to raise capital through the sale of additional equity securities, and make it more difficult for our stockholders to sell their common stock at a time and price that they deem appropriate. As of February 18, 2022, we had outstanding 61,873,343 shares of common stock and 9,164,193 shares of limited common stock. All of our outstanding shares of common stock, including shares of common stock issuable upon the conversion of shares of our limited common stock, are available for sale in the public market, subject only to the restrictions of Rule 144 under the Securities Act in the case of our affiliates. In addition, certain of our executive officers, directors and affiliated stockholders have entered or may enter into Rule 10b5-1 plans providing for sales of shares of our common stock from time to time. Under a Rule 10b5-1 plan, a broker executes trades pursuant to parameters established by the executive officer, director or affiliated stockholder when entering into the plan, without further direction from the executive officer, director or affiliated stockholder. A Rule 10b5-1 plan may be amended or terminated in some circumstances. Our executive officers, directors and affiliated stockholders also may buy or sell additional shares outside of a Rule 10b5-1 plan when they are not in possession of material, nonpublic information.

We have also filed a universal shelf registration statement on Form S-3 which allows us to offer and sell an indeterminate number of shares of common stock, preferred stock, depositary shares or warrants, or an indeterminate principal amount of debt securities, from time to time pursuant to one or more offerings at prices and terms to be determined at the time of the sale.   Moreover, certain holders of our common stock and our limited common stock have rights, subject to specified conditions, to include their shares in registration statements that we may file for ourselves or other stockholders and may require us to file Form S-3 registration statements covering their shares.

We also have filed registration statements on Forms S-8 to register shares of common stock that we may issue under our equity compensation plans. Shares registered under the registration statement on Form S-8 are available for sale in the public market upon issuance, subject to volume limitations applicable to affiliates, vesting arrangements and exercise of options.

We have incurred and will continue to incur increased costs as a result of operating as a public company, and our management has devoted and will continue to be required to devote substantial time to new compliance initiatives and corporate governance practices.

As a public company, we have incurred and will continue to incur significant legal, accounting, and other expenses that we did not incur as a private company, which we expect to further increase now that we are no longer an emerging growth company. The Exchange Act, Sarbanes-Oxley Act of 2002, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq, and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote and will need to continue to devote a substantial amount of time and resources to these compliance initiatives, potentially at the expense of other business concerns, which could harm our business, financial condition, results of operations, and prospects. Moreover, these rules and regulations will increase our legal and financial compliance costs, and will make some activities more time-consuming and costly compared to when we were a private company.

We are evaluating these rules and regulations, and cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.

As a result of becoming a public company, we are obligated to develop and maintain proper and effective internal control over financial reporting. Any failure to maintain the adequacy of these internal controls may adversely affect investor confidence in our company and, as a result, the value of our common stock.

Pursuant to Section 404 of the Sarbanes-Oxley Act, we are required to furnish a report by our management on our internal control over financial reporting on an annual basis. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. Pursuant to Section 404, we are also required to have our independent registered public accounting firm issue an opinion on the effectiveness of our internal control over financial reporting on an annual basis beginning with this Annual Report.

During our evaluation of our internal control, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable to assert that our internal control over financial reporting is effective. In addition, if we have an unremediated material weakness, we would receive an adverse opinion regarding our internal control over financial reporting from our independent registered public accounting firm. We cannot assure you that there will not be material weaknesses or significant

85

Table of Contents

 

deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, or results of operations. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness in our internal control over financial reporting, we could lose investor confidence in the accuracy and completeness of our financial reports, the market price of shares of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC, or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.

Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.

As a public company, we are subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error or fraud may occur and not be detected.

Provisions in our corporate charter documents and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current directors and members of management.

Provisions in our certificate of incorporation and our bylaws may discourage, delay, or prevent a merger, acquisition, or other change in control of our company that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions:

 

•

establish a classified board of directors such that only one of three classes of directors is elected each year;

 

•

allow the authorized number of our directors to be changed only by resolution of our board of directors;

 

•

limit the manner in which stockholders can remove directors from our board of directors;

 

•

establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors;

 

•

require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent;

 

•

limit who may call stockholder meetings to the board of directors or to the secretary at the request of the holders of at least 25% of the outstanding shares of our common stock and limited common stock; and

 

•

authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a “poison pill” that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors.

86

Table of Contents

 

Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or the DGCL, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

Our certificate of incorporation designates the state courts in the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could discourage lawsuits against the company and our directors, officers, and employees.

Our certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) will be the sole and exclusive forum for: (1) any derivative action or proceeding brought on our behalf, (2) any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, employees or stockholders to our company or our stockholders, (3) any action asserting a claim arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (4) any action asserting a claim arising pursuant to any provision of our certificate of incorporation or bylaws (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. These choice of forum provisions will not apply to suits brought to enforce a duty or liability created by the Securities Act of 1933, as amended, the Exchange Act or any other claim for which federal courts have exclusive jurisdiction.

This exclusive forum provision may limit the ability of our stockholders to bring a claim in a judicial forum that such stockholders find favorable for disputes with us or our directors, officers, or employees, which may discourage such lawsuits against us and our directors, officers, and employees. Alternatively, if a court were to find the choice of forum provision contained in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could materially adversely affect our business, financial condition, and operating results.

Item 1B. Unresolved Staff Comments.

None.

Item 2. Properties.

Our principal facilities consist of office space. We occupy approximately 109,000 square feet of office space in New York, New York under a lease that currently expires in December 2037. We also occupy approximately 35,000 square feet of office space in Portland, Oregon under a lease that currently expires in September 2026, and we lease additional office space at our other office locations around the world. We believe our facilities are adequate and suitable for our current needs and that should it be needed, suitable additional or alternative space will be available to accommodate our operations.

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently subject to any material legal proceedings.

Item 4. Mine Safety Disclosures.

Not applicable.

87

Table of Contents

 

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

Our common stock has been publicly traded on the Nasdaq Global Select Market under the symbol “SDGR” since February 6, 2020. Prior to that date, there was no public market for our common stock. Our limited common stock is not listed or traded on any stock exchange.

Performance Graph

The following performance graph related information shall not be deemed to be “soliciting material” or to be “filed” with the Securities and Exchange Commission for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities under that Section, nor shall such information be incorporated by reference into any future filing under the Exchange Act or the Securities Act of 1933, as amended, or the Securities Act, except to the extent that we specifically incorporate it by reference into such filing.

The following graph compares the cumulative total return on our common stock with the cumulative total return of the Nasdaq composite and the Nasdaq Biotechnology Index from February 6, 2020 (the first date that shares of our common stock were publicly traded on the Nasdaq Global Select Market) through December 31, 2021. The graph assumes an investment of $100 on February 6, 2020, in each of the foregoing indices and in our common stock. Data for each of the indices and our common stock assumes that all dividends were reinvested on the day of issuance, if any. The comparisons are not intended to forecast or be indicative of future performance of our common stock.

 

 

Holders of Record

As of February 18, 2022, there were approximately 120 holders of record of our common stock and one holder of record of our limited common stock. The actual number of stockholders is greater than this number of holders of record and includes stockholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.

88

Table of Contents

 

Dividends

We have never declared or paid cash dividends on our common stock or our limited common stock. We currently intend to retain all available funds and any future earnings to fund the development and expansion of our business and we do not anticipate paying any cash dividends in the foreseeable future. Any future determination to declare and pay dividends will be made at the discretion of our board of directors and will depend on then-existing conditions, including our results of operations, financial condition, contractual restrictions, capital requirements, business prospects, and other factors our board of directors may deem relevant.

Use of Proceeds

On February 5, 2020, our registration statement on Form S-1, as amended (File No. 333-235890) was declared effective by the SEC in connection with our initial public offering of common stock, pursuant to which we issued and sold on February 10, 2020, 13,664,704 shares of our common stock at a public offering price of $17.00 per share, including 1,782,352 additional shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares, for total gross proceeds of $232.3 million. On February 10, 2020, we received net proceeds of $209.6 million, after deducting $16.3 million in underwriting discounts and commissions and $6.4 million in estimated offering expenses borne by us.

There has been no material change in the planned use of proceeds from our initial public offering from that described in the final prospectus related to the offering, dated February 5, 2020, as filed with the SEC on February 6, 2020.

Recent Sales of Unregistered Securities

Not applicable.

Issuer Purchases of Equity Securities

Not applicable.

Item 6. [Reserved.]

 

89

Table of Contents

 

 

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes appearing elsewhere in this Annual Report. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in “Risk Factors” of this Annual Report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis. For further information regarding our forward-looking statements, see “Cautionary Note Regarding Forward-Looking Statements” in this Annual Report.

Overview

We are transforming the way therapeutics and materials are discovered. Our differentiated, physics-based software platform enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly, at lower cost, and with, we believe, a higher likelihood of success compared to traditional methods. Our software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories around the world. Our multidisciplinary drug discovery team also leverages our software platform to advance collaborative drug discovery and development programs and our own pipeline of novel therapeutics to address unmet medical needs.

Since our founding, we have been primarily focused on developing our computational platform, which is capable of predicting critical properties of molecules with a high degree of accuracy, as well as advancing drug discovery programs both with our collaborators and internally. We have devoted substantially all of our resources to introducing new capabilities and refining our software, conducting research and development activities, recruiting skilled personnel, and providing general and administrative support for these operations.

We are using our computational platform for both collaborative and internal drug discovery programs. Over the last decade, we have entered into a number of collaborations with biopharmaceutical companies that have provided us with significant income and have the potential to produce additional milestone payments, option fees, and future royalties. Furthermore, in mid-2018, we launched a pipeline of internal, wholly-owned programs. We continue to advance multiple internal programs through investigational new drug, or IND, -enabling studies. We expect to submit an IND application to the U.S. Food and Drug Administration, or FDA, for our MALT1 program in the first half of 2022, subject to receiving regulatory clearance, we expect to initiate a Phase 1 clinical trial of our MALT1 inhibitor in patients with relapsed and resistant lymphoma in the second half of 2022. We also plan to submit IND applications to the FDA for our CDC7 program in early 2023 and our WEE1 program in 2023, subject to favorable data from IND-enabling studies. In addition, we plan to initiate a Phase 1 clinical trial of our CDC7 inhibitor in 2023, subject to receipt of regulatory clearance.

We have funded our operations to date principally from the sale of our equity securities, including our initial public offering and our follow-on public offering, and to a lesser extent, from sales of our software solutions and from upfront payments, research funding and milestone payments from our drug discovery collaborations, and from distributions on account of, or proceeds from the sale of, our equity stakes in our collaborators.

We currently conduct our operations through two reportable segments: software and drug discovery. The software segment is focused on selling our software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development.

Our software segment generates revenue from software product licenses, hosted software subscriptions, software maintenance, professional services, and contributions. The revenue we generate through our software solutions from each of our customers varies largely depending on the number of software licenses our customers purchase from us. The licenses that our customers purchase from us provide them the ability to perform a certain number of calculations used in the design of molecules for drug discovery or materials science. We deliver our software through either (i) a product license that permits our customers to install the software solution directly on their own in-house hardware and use it for a specified term, or (ii) a subscription that allows our customers to access our cloud-based software solution on their own hardware without taking control of licenses.

We currently generate drug discovery revenue from our collaborations, including upfront payments, research funding payments and discovery and development milestones. In the future, we may also derive drug discovery revenue from our collaborations from option fees, the achievement of commercial milestones, and royalties on commercial drug sales. In addition to revenue from our

90

Table of Contents

 

collaborations, we may also derive drug discovery revenue from collaborating on or out-licensing our internal drug discovery programs when we believe it will help maximize the commercial potential of the program. In November 2020, we entered into an exclusive, worldwide collaboration and license agreement with Bristol-Myers Squibb Company, or BMS, pursuant to which we and BMS agreed to collaborate in the discovery, research and development of small molecule compounds for biological targets in the oncology, neurology and immunology therapeutic areas. The initial collaboration targets included HIF-2 alpha and SOS1/KRAS, which were two of our internal pipeline programs. In November 2021, we and BMS mutually agreed to replace the HIF-2 alpha target with another precision oncology target. Following the replacement election, all rights to the HIF-2 alpha target program reverted to us. Under the terms of the agreement, we received an upfront payment of $55.0 million, and we are eligible to receive up to $2.7 billion in total milestone payments across all potential targets, as well as a tiered percentage royalty on net sales of each product commercialized by BMS ranging from mid-single digits to low-double digits, subject to certain specified reductions. See “Business—Collaboration Agreement with Bristol-Myers Squibb Company” for additional information relating to this agreement.

In August 2021, we entered into a global discovery, development and commercialization collaboration with Zai Lab Limited focused on a novel program in oncology targeting DNA damage response. Under the terms of the agreement, we are entitled to receive an upfront payment to help fund our share of research costs, and if we elect to co-fund clinical development of a product candidate under the collaboration, we will be entitled to receive 50% of any profits from the commercialization of an approved therapeutic in the United States. We are also eligible to receive up to approximately $338 million in preclinical, clinical, regulatory and sales-based milestone payments from Zai Lab Limited for any product candidate developed under the collaboration, and we are entitled to receive tiered royalties on net sales outside the United States.

We generated revenue of $137.9 million, $108.1 million, and $85.5 million in 2021, 2020, and 2019, respectively, representing year-over-year growth of 28% and 26%, respectively. Our net loss was $101.2 million, $26.6 million, and $25.7 million for the years ended December 31, 2021, 2020, and 2019, respectively.

Business Impact of COVID-19 Pandemic

In order to safeguard the health of our employees in light of the COVID-19 pandemic, in early March 2020 we implemented a company-wide work-from-home policy. Beginning in June 2020, we began limited re-openings of certain of our offices in the United States and abroad. Our re-openings are being conducted on a limited basis and are voluntary for all of our employees. We have continued to phase-in the re-opening of our offices as our management and federal, state, or local authorities advise, and we may take further actions that alter our operations as may be required by federal, state, or local authorities, or which we determine are in our best interests.

We did not see material impacts to our business from the COVID-19 pandemic during 2021. While we do not expect the COVID-19 pandemic to have future material impacts on our business, the full extent of the future impact will depend on many factors outside of our control, including, without limitation, the extent, trajectory and duration of the COVID-19 pandemic, the development, availability and distribution of effective treatments and vaccines, the imposition of protective public safety measures, the emergence of new strains and variants of COVID-19 and the effectiveness of vaccines against such strains and variants, and the impact of the COVID-19 pandemic on the global economy. For instance, with respect to our software business, some of our customers may experience increasing budgetary pressures as a result of downturns or uncertainty in their respective businesses, which may cause them to delay or reduce purchases. In addition, due to the restrictions related to COVID-19, our sales force has limited in-person interactions, and their ability to attend events that promote and expand knowledge of our company and platform, including industry conferences and events, has been hampered. Relative to our and our collaborators’ drug discovery programs, the COVID-19 pandemic could delay the progress of certain programs, particularly ones that are in preclinical studies and clinical trials. Such COVID-19-related delays may result in disruptions in current and future IND-enabling studies and clinical trials, manufacturing disruptions, trial site disruptions and impact the ability to obtain necessary institutional review board, or IRB, institutional biosafety committee, or IBC, or other necessary site approvals. For example, our contract manufacturing organizations, or CMOs, and our contract research organizations, or CROs, have experienced reductions in the capacity to undertake research-scale production and delays in executing some preclinical studies, including our IND-enabling studies for our CDC7 program. We now expect to submit the IND application to the FDA for our CDC7 program in early 2023 and to initiate a Phase 1 clinical trial in 2023. Such reductions could cause disruptions related to our current and future IND-enabling studies and clinical trials arising from delays in preclinical studies, manufacturing disruptions, and the ability to obtain necessary institutional review board, or IRB, institutional biosafety committee, or IBC, or other necessary site approvals, as well as other delays at clinical trial sites. We, together with our CMOs and CROs, are closely monitoring the impact of the COVID-19 pandemic on these operations. Furthermore, if our collaborators experience similar delays with their drug discovery and development programs, that could delay our achievement of milestones and related revenue. While there remains uncertainty about the extent of the effect of the COVID-19 pandemic, we do not envision a long-term impact from the COVID-19 pandemic on our ability to execute on our strategy.

91

Table of Contents

 

Management is actively monitoring the COVID-19 pandemic and its possible effects on our financial condition, liquidity, operations, customers, contractors, and workforce. For additional information on risks posed by the COVID-19 pandemic, please see “Risk Factors – Risks Related to Our Operations – A widespread outbreak of an illness or other health issue, such as the COVID-19 pandemic, could negatively affect various aspects of our business and make it more difficult to meet our obligations to our customers, and could result in reduced demand from our customers as well as delays in our drug discovery and development programs,” included elsewhere in this Annual Report.

In response to the COVID-19 pandemic, we have joined a multi-company philanthropic effort to discover and develop novel small-molecule antiviral therapeutics to address COVID-19. The intent of the alliance, which to date also includes Takeda Pharmaceutical Company Limited, Novartis AG, Alphabet, Inc., Gilead Sciences, Inc., and WuXi AppTec, Inc., is to make any discoveries from this alliance available to the public. There is no expectation that this effort will generate revenue for any of the companies involved in the alliance, including us.

Key Factors Affecting Our Performance

Ability to drive additional revenue from our software solutions from existing customers

Our large existing base of customers represents a significant opportunity for us to expand our revenue through increased utilization of our software. The revenue that we generate through our software solutions from each of our customers varies depending on the number of licenses for each software solution that each customer purchases from us. Accordingly, we work with our customers to improve their experience and increase the utility of our platform in order to expand the scale at which they deploy our platform in their business. Biopharmaceutical companies are increasingly adopting our software at a larger scale, and we anticipate that this scaling-up will drive future revenue growth. Our ability to expand within our customer base is demonstrated by the increasing number of our customers with an annual contract value, or ACV, of over $100,000. We had 190, 153, and 131 of these customers for the years ended December 31, 2021, 2020, and 2019, respectively. This subset of customers represented approximately 80%, 79%, and 78% of our total ACV for the years ended December 31, 2021, 2020, and 2019, respectively. In addition, we had 15, 16, and 10 customers with an ACV of over $1.0 million for the years ended December 31, 2021, 2020, and 2019, respectively.

With respect to contracts that have a duration of one year or less, or contracts of more than one year in duration that are billed annually, we define ACV as the contract value billed during the applicable period. For contracts with a duration of more than one year that are billed upfront, ACV in each period represents the total billed contract value divided by the term. ACV should be viewed independently of revenue and does not represent revenue calculated in accordance with generally accepted accounting principles in the United States, or U.S. GAAP, on an annualized basis, as it is an operating metric that can be impacted by contract execution start and end dates and renewal rates. ACV is not intended to be a replacement for, or forecast of, revenue. Our ACV was $112.1 million, $92.1 million, and $75.6 million for the years ended December 31, 2021, 2020, and 2019, respectively.

Another important driver of our ability to expand our customer relationships is the retention of our customers with an ACV over $100,000. For the year ended December 31, 2021, our year-over-year customer retention rate for such customers was 98% and was 96% or higher for each of the previous eight fiscal years. We calculate year-over-year customer retention for our customers with an ACV over $100,000 by starting with the number of such customers we had in the previous fiscal year. We then calculate how many of these customers were active customers in the current fiscal year. We then divide this number by the number of customers with an ACV over $100,000 we had in the previous fiscal year to arrive at the year-over-year customer retention rate for such customers. We intend to leverage our existing relationships with our customers to drive larger-scale adoption of our software solutions. If we are unable to continue to increase revenue from existing customers, our financial performance will be adversely impacted.

Ability to increase our customer base for our software solutions

We believe that we have significant opportunity to continue to increase the number of customers who use our solutions. We had 1,647, 1,463, and 1,266 active customers for the years ended December 31, 2021, 2020, and 2019, respectively. We define the number of active customers as the number of customers who had an ACV of at least $1,000 in the fiscal year. We use $1,000 as a threshold for defining our active customers as this amount will generally exclude customers who only license our PyMOL software, which is our open-source molecular visualization system broadly available at low cost.

While we have significantly penetrated the pharmaceutical industry, with all of the top 20 pharmaceutical companies, measured by 2020 revenue, licensing our software in 2021, our strategy is to grow our customer base. We believe there remains a large opportunity for growth as there are thousands of biopharmaceutical companies that could benefit from our solutions. Additionally, since the physics underlying the properties of drug molecules and materials is the same, we have been able to extend our computational platform to materials science applications in fields such as aerospace, energy, semiconductors, and electronic displays.

92

Table of Contents

 

We sell our software solutions to a growing number of materials science customers, and we believe materials science industries are only beginning to recognize the potential of computational methods. We continue to promote the education and recognition of our computational platform across industries. As part of our strategy, we have driven the adoption of our software by researchers, and we had more than 1,714 academic institutions across the world using our software in 2021. We believe that by introducing the benefits of our computational software at the academic stage, we will drive brand awareness and expand the use of our platform to industries that have historically relied on traditional methods for discovery of molecules. Our ability to continue to grow our customer base is dependent upon our ability to educate the market and support the business through investment in our sales and marketing efforts and the ongoing enhancement of our software solutions.

Advancement of our collaborations

We have entered into a number of collaborations with various biopharmaceutical companies to advance drug discovery. We will seek to enter into additional collaboration agreements, driven by the synergies we expect to achieve between our platform and the capabilities and expertise of our potential collaborators. We believe that our collaborations will be a significant driver of value for us in the form of equity stakes, research fees, preclinical, clinical, and commercial milestone payments, and option fees, as well as royalties on any potential future sales of products, if approved. We continue to work with our current collaborators to advance existing programs through discovery research stages and initiate additional programs. However, we do not generally exercise control over the development programs of our collaborators and often rely on decisions of the management of such companies with respect to clinical development and commercialization. Our ability to continue to derive value from our collaborations will be driven by both our capability to make progress in these programs as well as whether our collaborators successfully advance such programs beyond the discovery stage.

Ability to develop and expand our internal proprietary drug discovery pipeline

We are advancing our pipeline of internal drug discovery programs through extensive application of our software platform. Our initial programs are focused on discovering and developing inhibitors for targets in DNA damage response pathways and genetically defined cancers. Since then, we have expanded into other therapeutic areas, including in the areas of immunology and neurology. We continue to advance multiple internal programs through investigational new drug, or IND, -enabling studies. We expect to submit an IND application for our MALT1 program in the first half of 2022, and subject to receiving regulatory clearance, we expect to initiate a Phase 1 clinical trial of our MALT1 inhibitor in patients with relapsed and resistant lymphoma in the second half of 2022. We also plan to submit IND applications to the FDA for our CDC7 program in early 2023 and our WEE1 program in 2023, subject to favorable data from IND-enabling studies. In addition, we plan to initiate a Phase 1 clinical trial of our CDC7 inhibitor in 2023, subject to receipt of regulatory clearance. As we progress these programs, we will strategically evaluate on a program-by-program basis entering into preclinical and clinical development ourselves, entering into collaborations, or out-licensing programs to maximize commercial opportunities. As part of this strategy, in November 2020, we entered into an exclusive, worldwide collaboration and license agreement with BMS pursuant to which we and BMS agreed to collaborate in the discovery, research and development of small molecule compounds for biological targets in the oncology, neurology and immunology therapeutic areas. Furthermore, in August 2021, we entered into a global discovery, development and commercialization collaboration with Zai Lab Limited focused on a novel program in oncology targeting DNA damage response. We will need to continue to devote substantial resources to develop and expand our internal pipeline. Our ability to advance and build value in our internal drug discovery programs will impact our financial performance, especially as we increasingly shift our focus to these programs.

Components of Results of Operations

Software Products and Services Revenue

Our software business generates revenue from five sources: (i) on-premise software license fees, (ii) hosted software subscription fees, (iii) software maintenance fees, (iv) professional services fees, and (v) contributions.

On-premise software. Our on-premise software license arrangements grant customers the right to use our software on their own in-house servers or their own cloud instances for a specified term, typically for one year. We recognize revenue for on-premise software license fees upfront, either upon delivery of the license or the effective date of the agreement, whichever is later.

Hosted software. Hosted software revenue consists primarily of fees to provide our customers with hosted licenses, which allows these customers to access our cloud-based software solution on their own hardware without taking control of the licenses, and is recognized ratably over the term of the arrangement, which is typically one year. When a customer enters into a hosted arrangement for which revenue is recognized over time, the amount paid upfront that is not recognized in the current period is included in deferred revenue in our statement of financial position until the period in which it is recognized.

93

Table of Contents

 

Software maintenance. Software maintenance includes technical support, updates, and upgrades related to our on-premise software licenses. Software maintenance revenue is recognized ratably over the term of the arrangement. Software maintenance activities are performed in connection with the use of our on-premise software, and may fluctuate from period to period.

Professional services. Professional services, such as training, technical setup, installation or modeling services, where we use our software to perform tasks such as virtual screening and homology modeling on behalf of our customers, generally are not related to the core functionality of our software and are recognized as revenue when resources are consumed. Since each professional services agreement represents a unique, ad hoc engagement, professional services revenue may fluctuate from period to period.

Software contribution revenue. Contribution revenue consists of funds received under a non-reciprocal agreement with Gates Ventures, LLC entered into June 2020. The agreement is an unconditional non-exchange contribution without restrictions and the initial contribution was invoiced upon execution of the agreement. Revenue was recognized upon execution of the agreement and on the first anniversary of the agreement when invoiced, in accordance with Accounting Standard Codification, or ASC Topic 958, Not-for-Profit Entities as the agreement is not an exchange transaction. Additional revenue is expected to be recognized on the second anniversary of the agreement.

Drug Discovery Revenue

Drug discovery services. We currently generate drug discovery revenue from discovery collaboration arrangements, including research funding payments and discovery and development milestones. We expect our drug discovery revenue to trend higher over time as collaboration arrangements advance and we receive additional revenue from research funding payments, the achievement of discovery, development, and commercial milestones, option fees, and royalties on commercial drug sales. The majority of our current collaborations are in the discovery stage. Milestone payments typically increase in magnitude as a program advances. In addition to revenue from our collaborations, we may also derive drug discovery revenue from entering into collaborations or out-licensing our internal drug discovery programs when we believe it will help maximize the commercial potential of the program. For example, in November 2020, we entered into an exclusive, worldwide collaboration and license agreement with BMS, pursuant to which we received an upfront payment of $55.0 million from BMS, of which approximately $13.7 million and $1.0 million were included in our drug discovery revenue for the years ended December 31, 2021 and 2020, respectively. However, we expect that our revenue will fluctuate from period to period due to the inherently uncertain nature of the timing of milestone achievement and our dependence on the program decisions of our collaborators.

Drug discovery contribution revenue. Contribution revenue consists of funds received under an agreement with the Bill and Melinda Gates Foundation on a cost reimbursement basis, to perform services aimed at accelerating drug discovery in women’s health. Revenue is recognized as conditions are met in accordance with ASC Topic 958, Not-for-Profit Entities.

Cost of Revenues

Software products and services. Cost of revenues for software includes personnel-related expenses (comprised of salaries, benefits, and stock-based compensation) for employees directly involved in the delivery of software solutions, maintenance and professional services, royalties paid for products sold and services performed using third-party licensed software functionality, and allocated overhead (facilities and information technology support) costs. Pursuant to various third-party arrangements, we license technology that is used in our software. These arrangements require us to pay royalties based on sales volume, and such royalty payments represented 7.1%, 6.3%, and 6.7% of software revenues in the years ended December 31, 2021, 2020, and 2019, respectively.

Drug discovery. Costs of revenue for drug discovery includes personnel-related expenses and costs of third-party contract research organizations, or CROs, that support discovery activities in our collaborations, royalties paid for services performed using third-party licensed software functionality, and allocated compute capacity and overhead costs. While we have incurred costs associated with discovery efforts since late 2017, we have recognized and expect to continue to recognize revenues in the future if and when milestones are achieved. Generally, drug discovery costs of revenue for collaborations are incurred in advance of the revenue milestone achievement.

Royalty payments to third-parties represented 4.6%, 11.2%, and 6.7% of drug discovery revenues in the years ended December 31, 2021, 2020, and 2019, respectively. We expect our drug discovery costs of revenue to trend higher over time as our discovery collaborations advance.

94

Table of Contents

 

Gross Profit and Gross Margin

Gross profit represents revenue less cost of revenues. Gross margin is gross profit expressed as a percentage of revenue. Our software products and services gross margin may fluctuate from period to period as our revenue fluctuates, and as a result of changes in sales mix between on-premise and hosted software solutions. For example, the cost of royalties due for sales of our hosted software arrangements are recognized upfront, whereas the associated revenue is recognized over the term of the underlying agreement. Currently, gross margin is not meaningful for measuring the operating results of our drug discovery business.

Research and Development Expense

Research and development expense accounts for a significant portion of our operating expenses. We recognize research and development expense as incurred. Research and development expense consists of internal drug discovery and development program costs and costs incurred for continuous development of the technology and science that supports our computational platform, primarily:

 

•

personnel-related expenses, including salaries, benefits, bonuses, and stock-based compensation for employees engaged in research and development functions;

 

•

expenses incurred under agreements with third-party CROs and consultants involved in our internal discovery and development programs; and

 

•

allocated compute capacity on our internal discovery and development programs and overhead (facilities and information technology support) costs.

We expect our research and development expense to increase substantially in absolute dollars for the foreseeable future as we continue to invest in activities related to discovery and development of our internal drug discovery programs, in advancing our platform, and as we incur expenses associated with hiring additional personnel directly involved in such efforts. At this time, we do not know, nor can we reasonably estimate, the nature, timing, or costs of the efforts that will be necessary to complete the development of any of our internal drug discovery programs. Since our internal drug discovery efforts are in the early stages, currently we do not track research and development expense on a program-by-program basis.

Sales and Marketing Expense

Sales and marketing expense consists primarily of personnel-related costs for our sales and marketing staff and application scientists supporting our sales efforts, including salaries, benefits, bonuses, and stock-based compensation. Other sales and marketing costs include promotional events that promote and expand knowledge of our company and platform, including industry conferences and events and our annual user group meetings in the United States and Europe, advertising, and allocated overhead costs. Due to the inherent scientific complexity of our software solutions, a high level of scientific expertise is needed to support our sales and marketing efforts. We plan to make focused investments in sales and marketing over the foreseeable future to foster the growth of our business as we aim to expand software sales to existing customers and increase our customer base.

General and Administrative Expense

General and administrative expense consists of personnel-related expenses associated with our executive, legal, finance, human resources, information technology, and other administrative functions, including salaries, benefits, bonuses, and stock-based compensation. General and administrative expense also includes professional fees for external legal, accounting and other consulting services, allocated overhead costs, and other general operating expenses.

We expect to increase the size of our general and administrative staff to support the anticipated growth of our business. We expect to continue to incur additional expenses as a result of operating as a public company, including costs to comply with the rules and regulations applicable to companies listed on a U.S. securities exchange and costs related to compliance and reporting obligations pursuant to the rules and regulations of the Securities and Exchange Commission, or SEC. In addition, as a public company, we expect to continue to incur increased expenses such as insurance and professional services. As a result, we expect the dollar amount of our general and administrative expense to increase for the foreseeable future.

(Loss) Gain on Equity Investments

(Loss) gain on equity investments consists of realized gains in the form of cash distributions received from our equity investments offset by realized losses on the sale of equity.

95

Table of Contents

 

Change in Fair Value

Fair value gains and losses consist of adjustments to the fair value of our equity investments, including Nimbus Therapeutics, Inc., or Nimbus, ShouTi Inc., or ShouTi, Relay Therapeutics, Inc., or Relay, and Morphic Holding, Inc., or Morphic. We remeasure our investments at each period end.

In January 2021, we disposed of our equity stake in Relay for aggregate consideration of $15.7 million.

We expect that fair value gains and losses will fluctuate significantly in future periods.

Interest Income

Interest income consists of interest earned on our cash equivalents and marketable securities.

Income Tax Expense (Benefit)

Income tax expense (benefit) consists of U.S. federal and state income taxes and income taxes in certain foreign jurisdictions in which we conduct business. We maintain a full valuation allowance on our federal and state deferred tax assets as we have concluded that it is not more likely than not that the deferred tax assets will be realized.

96

Table of Contents

 

Results of Operations

Comparison of the years ended December 31, 2021, 2020, and 2019

The following table summarizes our results of operations data for the years ended December 31, 2021, 2020, and 2019:

 

 

Year Ended December 31,

 

 

 

 

 

 

2021 vs. 2020

 

 

 

 

 

 

2020 vs. 2019

 

 

 

2021

 

 

2020

 

 

Change

 

 

%

 

 

2019

 

 

Change

 

 

%

 

 

 

(in thousands)

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Software products and services

 

$

113,236

 

 

$

92,530

 

 

$

20,706

 

 

22%

 

 

$

66,735

 

 

$

25,795

 

 

39%

 

Drug discovery

 

 

24,695

 

 

 

15,565

 

 

 

9,130

 

 

59%

 

 

 

18,808

 

 

 

(3,243

)

 

-17%

 

Total revenues

 

 

137,931

 

 

 

108,095

 

 

 

29,836

 

 

28%

 

 

 

85,543

 

 

 

22,552

 

 

26%

 

Cost of revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Software products and services

 

 

26,495

 

 

 

18,003

 

 

 

8,492

 

 

47%

 

 

 

13,646

 

 

 

4,357

 

 

32%

 

Drug discovery

 

 

45,816

 

 

 

26,620

 

 

 

19,196

 

 

72%

 

 

 

22,804

 

 

 

3,816

 

 

17%

 

Total cost of revenues

 

 

72,311

 

 

 

44,623

 

 

 

27,688

 

 

62%

 

 

 

36,450

 

 

 

8,173

 

 

22%

 

Gross profit

 

 

65,620

 

 

 

63,472

 

 

 

2,148

 

 

3%

 

 

 

49,093

 

 

 

14,379

 

 

29%

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

90,904

 

 

 

64,695

 

 

 

26,209

 

 

41%

 

 

 

39,404

 

 

 

25,291

 

 

64%

 

Sales and marketing

 

 

22,150

 

 

 

17,795

 

 

 

4,355

 

 

24%

 

 

 

21,364

 

 

 

(3,569

)

 

-17%

 

General and administrative

 

 

64,009

 

 

 

41,898

 

 

 

22,111

 

 

53%

 

 

 

27,040

 

 

 

14,858

 

 

55%

 

Total operating expenses

 

 

177,063

 

 

 

124,388

 

 

 

52,675

 

 

42%

 

 

 

87,808

 

 

 

36,580

 

 

42%

 

Loss from operations

 

 

(111,443

)

 

 

(60,916

)

 

 

(50,527

)

 

83%

 

 

 

(38,715

)

 

 

(22,201

)

 

57%

 

Other income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(Loss) gain on equity investments

 

 

(1,781

)

 

 

4,108

 

 

 

(5,889

)

 

 

 

 

 

 

943

 

 

 

3,165

 

 

 

 

 

Change in fair value

 

 

11,359

 

 

 

28,263

 

 

 

(16,904

)

 

 

 

 

 

 

9,922

 

 

 

18,341

 

 

 

 

 

Interest income

 

 

1,057

 

 

 

2,253

 

 

 

(1,196

)

 

 

 

 

 

 

1,878

 

 

 

375

 

 

 

 

 

Total other income

 

 

10,635

 

 

 

34,624

 

 

 

(23,989

)

 

 

 

 

 

 

12,743

 

 

 

21,881

 

 

 

 

 

Loss before income taxes

 

 

(100,808

)

 

 

(26,292

)

 

 

(74,516

)

 

 

 

 

 

 

(25,972

)

 

 

(320

)

 

 

 

 

Income tax expense (benefit)

 

 

411

 

 

 

345

 

 

 

66

 

 

 

 

 

 

 

(291

)

 

 

636

 

 

 

 

 

Net loss

 

 

(101,219

)

 

 

(26,637

)

 

 

(74,582

)

 

 

 

 

 

 

(25,681

)

 

 

(956

)

 

 

 

 

Net loss attributable to noncontrolling interest

 

 

(826

)

 

 

(2,174

)

 

 

1,348

 

 

 

 

 

 

 

(1,110

)

 

 

(1,064

)

 

 

 

 

Net loss attributable to Schrödinger stockholders

 

$

(100,393

)

 

$

(24,463

)

 

$

(75,930

)

 

 

 

 

 

$

(24,571

)

 

$

108

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

97

Table of Contents

 

 

Revenues

 

 

Year Ended December 31,

 

 

 

 

 

 

2021 vs. 2020

 

 

 

 

 

 

2020 vs. 2019

 

 

 

2021

 

 

2020

 

 

Change

 

 

%

 

 

2019

 

 

Change

 

 

%

 

 

 

(in thousands)

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Software

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

On-premise software

 

$

74,598

 

 

$

58,311

 

 

$

16,287

 

 

28%

 

 

$

42,647

 

 

$

15,664

 

 

37%

 

Hosted software

 

 

11,076

 

 

 

9,192

 

 

 

1,884

 

 

20%

 

 

 

7,418

 

 

 

1,774

 

 

24%

 

Software maintenance

 

 

17,294

 

 

 

14,465

 

 

 

2,829

 

 

20%

 

 

 

11,643

 

 

 

2,822

 

 

24%

 

Professional services

 

 

9,268

 

 

 

9,562

 

 

 

(294

)

 

-3%

 

 

 

5,027

 

 

 

4,535

 

 

90%

 

Software contribution

 

 

1,000

 

 

 

1,000

 

 

 

—

 

 

0%

 

 

 

—

 

 

 

1,000

 

 

 

—

 

Total software products and services

 

 

113,236

 

 

 

92,530

 

 

 

20,706

 

 

22%

 

 

 

66,735

 

 

 

25,795

 

 

39%

 

Drug Discovery

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Drug discovery services

 

 

24,584

 

 

 

15,565

 

 

 

9,019

 

 

58%

 

 

 

18,808

 

 

 

(3,243

)

 

-17%

 

Drug discovery contribution

 

 

111

 

 

 

-

 

 

 

111

 

 

 

—

 

 

 

—

 

 

 

—

 

 

 

—

 

Total drug discovery

 

 

24,695

 

 

 

15,565

 

 

 

9,130

 

 

59%

 

 

 

18,808

 

 

 

(3,243

)

 

-17%

 

Total revenues

 

$

137,931

 

 

$

108,095

 

 

$

29,836

 

 

28%

 

 

$

85,543

 

 

$

22,552

 

 

26%

 

Software Products and Services Revenue

On-premise software. The increase in revenues for on-premise software was primarily attributable to existing and new customer growth, and an increase in multi-year arrangements during the year ended December 31, 2021 as compared to the year ended December 31, 2020 and during the year ended December 31, 2020 as compared to the year ended December 31, 2019.

Hosted software. The increase in revenues for hosted software was primarily due to increased spend from existing hosted customers, as well as new customers purchasing hosted software subscriptions, for which revenue is recognized ratably over time.

Software maintenance. The increase in revenues for software maintenance was primarily due to the increase in on-premise software sales in current and previous years. Software maintenance revenue is recognized over time.

Professional services. The decrease in revenues from professional services during the year ended December 31, 2021 as compared to the year ended December 31, 2020 was primarily due to the completion of a significant technology service project in 2020 that resulted in an increase to recurring on-premise software revenue upon renewal, as well as the timing of technology and modeling service projects.

The increase in revenues from professional services during the year ended December 31, 2020 as compared to the year ended December 31, 2019 was primarily due to revenue from significant technology service projects that began in late 2019, as well as an increased number of modeling service contracts.

Software contribution revenue. Contribution revenue during the year ended December 31, 2021 and the year ended December 31, 2020 was due to funds received under an agreement with Gates Ventures, LLC, which began in June 2020.

Drug Discovery Revenue

Drug discovery services. The increase in revenues for drug discovery services during the year ended December 31, 2021 as compared to the year ended December 31, 2020 was primarily due to the BMS collaboration services that began in November 2020, the timing and amount of collaboration milestones achieved, as well as research funding received during 2021 as compared to 2020. We expect that our revenue will fluctuate from period to period due to the inherently uncertain nature of the timing of milestone achievement and our dependence on the program decisions of our collaborators.

The decrease in revenues for drug discovery services during the year ended December 31, 2020 as compared to the year ended December 31, 2019 was primarily due to the timing and amount of collaboration milestones achieved during 2020 as compared to 2019.

98

Table of Contents

 

Drug discovery contribution revenue. Contribution revenue during the year ended December 31, 2021 was due to services performed under an agreement with the Bill and Melinda Gates Foundation, aimed at accelerating drug discovery in women’s health, which began in November 2021.

Cost of Revenues

 

 

 

Year Ended December 31,

 

 

 

 

 

 

2021 vs. 2020

 

 

 

 

 

 

2020 vs. 2019

 

 

 

2021

 

 

2020

 

 

Change

 

 

%

 

 

2019

 

 

Change

 

 

%

 

 

 

(in thousands)

 

Cost of revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Software products and services

 

$

26,495

 

 

$

18,003

 

 

$

8,492

 

 

47%

 

 

$

13,646

 

 

$

4,357

 

 

32%

 

Gross margin

 

 

77

%

 

 

81

%

 

 

 

 

 

 

 

 

 

 

80

%

 

 

 

 

 

 

 

 

Drug discovery

 

 

45,816

 

 

 

26,620

 

 

 

19,196

 

 

72%

 

 

 

22,804

 

 

 

3,816

 

 

17%

 

Software products and services. The increase in cost of revenues for software products and services during the year ended December 31, 2021 as compared to the year ended December 31, 2020 was attributable to increases of approximately $5.5 million in personnel-related expense, approximately $2.3 million in royalty expense due to higher sales levels, and approximately $0.7 million in other expenses.

The increase in cost of revenues for software products and services during the year ended December 31, 2020 as compared to the year ended December 31, 2019 was attributable to increases of approximately $2.6 million in personnel-related expense, approximately $1.5 million in royalty expense due to higher sales levels, and approximately $0.4 million in other expenses, offset by a decrease of approximately $0.2 million in travel and entertainment expense due to COVID-19.

Software products and services gross margin. The decrease in software gross margin during the year ended December 31, 2021 as compared to the year ended December 31, 2020 reflects our investment to support the rollout of large-scale deployments of our platform, as well as an increase in royalty fees. The increase in software gross margin during the year ended December 31, 2020 as compared to the year ended December 31, 2019 was primarily attributable to sales mix.

Drug discovery. The increase in cost of revenues for drug discovery during the year ended December 31, 2021 as compared to the year ended December 31, 2020 was attributable to increases of approximately $12.6 million in third-party CRO costs associated with the expansion and progression of collaboration drug discovery programs, including the BMS collaboration, approximately $6.7 million in personnel-related expense, and approximately $0.3 million in royalty expense, offset by a decrease of approximately $0.3 million in cloud computing expenses and approximately $0.1 million in other expenses.

The increase in cost of revenues for drug discovery during the year ended December 31, 2020 as compared to the year ended December 31, 2019 was attributable to increases of approximately $3.3 million in personnel-related expense, approximately $0.7 million in cloud computing expenses, and approximately $0.4 million in royalty expense, offset by a decrease of approximately $0.6 million in third-party CRO costs to support collaborations.

Research and Development Expense

 

 

 

Year Ended December 31,

 

 

 

 

 

 

2021 vs. 2020

 

 

 

 

 

 

2020 vs. 2019

 

 

 

2021

 

 

2020

 

 

Change

 

 

%

 

 

2019

 

 

Change

 

 

%

 

 

 

(in thousands)

 

Research and development

 

$

90,904

 

 

$

64,695

 

 

$

26,209

 

 

41%

 

 

$

39,404

 

 

$

25,291

 

 

64%

 

The increase in research and development expense during the year ended December 31, 2021 as compared to the year ended December 31, 2020 was attributable to increases of approximately $16.3 million in personnel-related expense, approximately $6.0 million in CRO costs associated with the expansion and progression of internal drug discovery programs, approximately $3.0 million in cloud computing expenses, and approximately $0.9 million in other expenses.

99

Table of Contents

 

The increase in research and development expense during the year ended December 31, 2020 as compared to the year ended December 31, 2019 was attributable to increases of approximately $11.7 million in personnel-related expense, approximately $10.1 million in CRO costs associated with the expansion and progression of internal drug discovery programs, approximately $2.3 million in cloud computing expenses, and approximately $1.1 million in other expenses.

Sales and Marketing Expense

 

 

 

Year Ended December 31,

 

 

 

 

 

 

2021 vs. 2020

 

 

 

 

 

 

2020 vs. 2019

 

 

 

2021

 

 

2020

 

 

Change

 

 

%

 

 

2019

 

 

Change

 

 

%

 

 

 

(in thousands)

 

Sales and marketing

 

$

22,150

 

 

$

17,795

 

 

$

4,355

 

 

24%

 

 

$

21,364

 

 

$

(3,569

)

 

-17%

 

The increase in sales and marketing expense during the year ended December 31, 2021 as compared to the year ended December 31, 2020 was attributable to increases of approximately $3.6 million in personnel-related expense, approximately $0.4 million in travel and entertainment expenses, and approximately $0.4 million in other expenses.

The decrease in sales and marketing expense during the year ended December 31, 2020 as compared to the year ended December 31, 2019 was attributable to a decrease of approximately $2.7 million in personnel-related expense and a decrease of approximately $1.2 million in travel and entertainment expenses due to COVID-19, partially offset by an increase of $0.3 million in other expenses.

General and Administrative Expense

 

 

 

Year Ended December 31,

 

 

 

 

 

 

2021 vs. 2020

 

 

 

 

 

 

2020 vs. 2019

 

 

 

2021

 

 

2020

 

 

Change

 

 

%

 

 

2019

 

 

Change

 

 

%

 

 

 

(in thousands)

 

General and administrative

 

$

64,009

 

 

$

41,898

 

 

$

22,111

 

 

53%

 

 

$

27,040

 

 

$

14,858

 

 

55%

 

The increase in general and administrative expense during the year ended December 31, 2021 as compared to the year ended December 31, 2020 was attributable to increases of approximately $16.5 million of personnel-related expense, approximately $5.1 million in other expenses, primarily reflecting costs necessary to build and maintain a public company infrastructure, and approximately $0.5 million in non-comparable costs related to the disposal of our equity stake in Relay.

The increase in general and administrative expense during the year ended December 31, 2020 as compared to the year ended December 31, 2019 was attributable to an increase of approximately $10.5 million of personnel-related expense, and an increase of approximately $7.5 million in other expenses, primarily reflecting costs necessary to build a public company infrastructure, partially offset by a $3.3 million reduction for non-comparable items recognized during 2019.

(Loss) Gain on Equity Investments

 

 

 

Year Ended December 31,

 

 

 

 

 

 

 

 

 

 

 

2021 vs. 2020

 

 

 

 

 

 

2020 vs. 2019

 

 

 

2021

 

 

2020

 

 

Change

 

 

2019

 

 

Change

 

 

 

(in thousands)

 

(Loss) gain on equity investments

 

$

(1,781

)

 

$

4,108

 

 

$

(5,889

)

 

$

943

 

 

$

3,165

 

The loss on equity investments during the year ended December 31, 2021 was primarily due to the realized loss on the disposal of our equity stake in Relay. The gain on equity investments during the year ended December 31, 2020 represents realized gains in the form of a cash distribution received from the Petra Pharma Corporation, or Petra, merger in May 2020 on account of our equity stake in Petra. The gain on equity investments during the year ended December 31, 2019 represents realized gains in the form of a cash distribution received from our Nimbus investment.

100

Table of Contents

 

Change in Fair Value

 

 

 

Year Ended December 31,

 

 

 

 

 

 

 

 

 

 

 

2021 vs. 2020

 

 

 

 

 

 

2020 vs. 2019

 

 

 

2021

 

 

2020

 

 

Change

 

 

2019

 

 

Change

 

 

 

(in thousands)

 

Change in fair value

 

$

11,359

 

 

$

28,263

 

 

$

(16,904

)

 

$

9,922

 

 

$

18,341

 

The change in fair value during the year ended December 31, 2021 was primarily due to a gain on our investment in Morphic. The change in fair value during the year ended December 31, 2020 was due to a gain on our investment in Relay of $17.6 million and a gain on our investment in Morphic of $13.7 million, offset by a loss on our investment in Nimbus of $3.0 million. The change in fair value during the year ended December 31, 2019 was due to a $14.1 million gain on our investment in Morphic, offset by a $4.2 million loss on our investment in Nimbus.

Interest Income

 

 

 

Year Ended December 31,

 

 

 

 

 

 

 

 

 

 

 

2021 vs. 2020

 

 

 

 

 

 

2020 vs. 2019

 

 

 

2021

 

 

2020

 

 

Change

 

 

2019

 

 

Change

 

 

 

(in thousands)

 

Interest income

 

$

1,057

 

 

$

2,253

 

 

$

(1,196

)

 

$

1,878

 

 

$

375

 

The decrease in interest income during the year ended December 31, 2021 as compared to the year ended December 31, 2020 was attributable to an overall decline in interest rates on our investment portfolio.

The increase in interest income during the year ended December 31, 2020 as compared to the year ended December 31, 2019 was attributable to increased earnings on our investment portfolio balance, which increased significantly year-over-year due to the investment of proceeds from our initial public offering in February 2020 and our follow-on public offering in August 2020, partially offset by a significant reduction in interest rates year-over-year.

Income Tax Expense (Benefit)

 

 

 

Year Ended December 31,

 

 

 

 

 

 

 

 

 

 

 

2021 vs. 2020

 

 

 

 

 

 

2020 vs. 2019

 

 

 

2021

 

 

2020

 

 

Change

 

 

2019

 

 

Change

 

 

 

(in thousands)

 

Income tax expense (benefit)

 

$

411

 

 

$

345

 

 

$

66

 

 

$

(291

)

 

$

636

 

Due to the full valuation allowance on our U.S. federal and state deferred tax assets, income tax expense (benefit) represents our income tax obligations in certain states and taxes in foreign jurisdictions in which we conduct business. The income tax benefit during the year ended December 31, 2019 is due to alternative minimum tax credits previously utilized that are refundable under the Tax Cuts and Jobs Act of 2017.

At December 31, 2021, we had federal and state net operating loss carryforwards of approximately $283.3 million and $148.1 million, respectively. These carryforwards, with the exception of federal net operating losses generated post 2017, will expire between 2022 and 2041 if not used by us to reduce income taxes payable in future periods. Utilization of post-2017 federal net operating loss carryforwards is limited to 80% of taxable income generated in a given tax year and carry forward indefinitely. At December 31, 2021, we had federal and state research and development tax credit carryforwards of approximately $15.5 million and $1.0 million, respectively. These carryforwards will expire between 2022 and 2041 if not used by us to reduce income taxes payable in future periods.

As required by ASC Topic 740, Income Taxes, our management has evaluated the positive and negative evidence bearing upon the realizability of our deferred tax assets, which are composed principally of net operating loss carryforwards and research and development credit carryforwards. Management has determined that it is more likely than not that we will not realize the benefits of our federal and state deferred tax assets and, as a result, a valuation allowance of $95.3 million, $58.2 million, and $35.3 million has been established at December 31, 2021, 2020, and 2019, respectively. The change in the valuation allowance for the years ended December 31, 2021, 2020, and 2019 was $37.1 million, $22.9 million, and $7.7 million, respectively. We recorded income tax

101

Table of Contents

 

expense of $0.4 million and $0.3 million for the years ended December 31, 2021 and 2020, respectively. We recorded an income tax benefit of $0.3 million for the year ended December 31, 2019.

 

 

102

Table of Contents

 

 

Quarterly Results of Operations

The following tables summarize our selected unaudited quarterly results of operations data for each of the eight quarters in the period ended December 31, 2021. The information for each of these quarters has been prepared on the same basis as our audited annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal, recurring nature that are necessary for the fair statement of the results of operations for these periods. This data should be read in conjunction with our audited consolidated financial statements included elsewhere in this Annual Report. Historical results are not necessarily indicative of the results that may be expected for the full fiscal year or any other period.

 

 

 

Three Months Ended

 

 

 

December 31,

 

 

September 30,

 

 

June 30,

 

 

March 31,

 

 

December 31,

 

 

September 30,

 

 

June 30,

 

 

March 31,

 

 

 

2021

 

 

2021

 

 

2021

 

 

2021

 

 

2020

 

 

2020

 

 

2020

 

 

2020

 

 

 

(in thousands)

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Software products and services

 

$

38,564

 

 

$

24,280

 

 

$

24,052

 

 

$

26,340

 

 

$

24,957

 

 

$

22,861

 

 

$

20,900

 

 

$

23,812

 

Drug discovery

 

 

7,606

 

 

 

5,570

 

 

 

5,732

 

 

 

5,787

 

 

 

8,075

 

 

 

2,936

 

 

 

2,192

 

 

 

2,362

 

Total revenues

 

 

46,170

 

 

 

29,850

 

 

 

29,784

 

 

 

32,127

 

 

 

33,032

 

 

 

25,797

 

 

 

23,092

 

 

 

26,174

 

Cost of revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Software products and services(1)

 

 

8,337

 

 

 

6,611

 

 

 

5,641

 

 

 

5,906

 

 

 

5,806

 

 

 

4,334

 

 

 

3,862

 

 

 

4,001

 

Drug discovery(1)

 

 

11,472

 

 

 

12,124

 

 

 

12,163

 

 

 

10,057

 

 

 

8,234

 

 

 

6,191

 

 

 

5,647

 

 

 

6,548

 

Total cost of revenues

 

 

19,809

 

 

 

18,735

 

 

 

17,804

 

 

 

15,963

 

 

 

14,040

 

 

 

10,525

 

 

 

9,509

 

 

 

10,549

 

Gross profit

 

 

26,361

 

 

 

11,115

 

 

 

11,980

 

 

 

16,164

 

 

 

18,992

 

 

 

15,272

 

 

 

13,583

 

 

 

15,625

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development(1)

 

 

25,145

 

 

 

23,219

 

 

 

21,092

 

 

 

21,448

 

 

 

17,319

 

 

 

17,019

 

 

 

16,657

 

 

 

13,700

 

Sales and marketing(1)

 

 

5,975

 

 

 

5,556

 

 

 

5,380

 

 

 

5,239

 

 

 

4,675

 

 

 

3,969

 

 

 

4,362

 

 

 

4,789

 

General and administrative(1)

 

 

17,756

 

 

 

17,014

 

 

 

15,850

 

 

 

13,389

 

 

 

13,582

 

 

 

9,729

 

 

 

9,651

 

 

 

8,936

 

Total operating expenses

 

 

48,876

 

 

 

45,789

 

 

 

42,322

 

 

 

40,076

 

 

 

35,576

 

 

 

30,717

 

 

 

30,670

 

 

 

27,425

 

Loss from operations

 

 

(22,515

)

 

 

(34,674

)

 

 

(30,342

)

 

 

(23,912

)

 

 

(16,584

)

 

 

(15,445

)

 

 

(17,087

)

 

 

(11,800

)

Other (expense) income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(Loss) gain on equity investment

 

 

—

 

 

 

—

 

 

 

—

 

 

 

(1,781

)

 

 

(48

)

 

 

—

 

 

 

4,156

 

 

 

—

 

Change in fair value

 

 

(7,920

)

 

 

(627

)

 

 

(4,918

)

 

 

24,824

 

 

 

4,750

 

 

 

18,233

 

 

 

8,359

 

 

 

(3,079

)

Interest (expense) income

 

 

(6

)

 

 

286

 

 

 

357

 

 

 

420

 

 

 

521

 

 

 

463

 

 

 

570

 

 

 

699

 

Total other (expense) income

 

 

(7,926

)

 

 

(341

)

 

 

(4,561

)

 

 

23,463

 

 

 

5,223

 

 

 

18,696

 

 

 

13,085

 

 

 

(2,380

)

(Loss) income before income taxes

 

 

(30,441

)

 

 

(35,015

)

 

 

(34,903

)

 

 

(449

)

 

 

(11,361

)

 

 

3,251

 

 

 

(4,002

)

 

 

(14,180

)

Income tax expense (benefit)

 

 

274

 

 

 

(4

)

 

 

67

 

 

 

74

 

 

 

225

 

 

 

(35

)

 

 

64

 

 

 

91

 

Net (loss) income

 

 

(30,715

)

 

 

(35,011

)

 

 

(34,970

)

 

 

(523

)

 

 

(11,586

)

 

 

3,286

 

 

 

(4,066

)

 

 

(14,271

)

Net loss attributable to

noncontrolling interest

 

 

(2

)

 

 

(4

)

 

 

(326

)

 

 

(494

)

 

 

(447

)

 

 

(566

)

 

 

(716

)

 

 

(445

)

Net (loss) income

attributable to Schrodinger

stockholders

 

$

(30,713

)

 

$

(35,007

)

 

$

(34,644

)

 

$

(29

)

 

$

(11,139

)

 

$

3,852

 

 

$

(3,350

)

 

$

(13,826

)

 

 

(1)

Includes stock-based compensation as indicated in the table located further below.

103

Table of Contents

 

 

Revenues:

 

 

 

Three Months Ended

 

 

 

December 31,

 

 

September 30,

 

 

June 30,

 

 

March 31,

 

 

December 31,

 

 

September 30,

 

 

June 30,

 

 

March 31,

 

 

 

2021

 

 

2021

 

 

2021

 

 

2021

 

 

2020

 

 

2020

 

 

2020

 

 

2020

 

 

 

(in thousands)

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Software

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

On-premise software

 

$

27,295

 

 

$

15,496

 

 

$

14,452

 

 

$

17,355

 

 

$

16,542

 

 

$

15,064

 

 

$

11,105

 

 

$

15,600

 

Hosted software

 

 

3,088

 

 

 

2,684

 

 

 

2,704

 

 

 

2,600

 

 

 

2,373

 

 

 

2,374

 

 

 

2,312

 

 

 

2,133

 

Software maintenance

 

 

4,612

 

 

 

4,401

 

 

 

4,176

 

 

 

4,105

 

 

 

3,841

 

 

 

3,536

 

 

 

3,551

 

 

 

3,537

 

Professional services

 

 

3,569

 

 

 

1,699

 

 

 

1,720

 

 

 

2,280

 

 

 

2,201

 

 

 

1,887

 

 

 

2,932

 

 

 

2,542

 

Revenue from contracts

   with customers

 

 

38,564

 

 

 

24,280

 

 

 

23,052

 

 

 

26,340

 

 

 

24,957

 

 

 

22,861

 

 

 

19,900

 

 

 

23,812

 

Software contribution

 

 

-

 

 

 

-

 

 

 

1,000

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

1,000

 

 

 

-

 

Total software products

   and services revenue

 

 

38,564

 

 

 

24,280

 

 

 

24,052

 

 

 

26,340

 

 

 

24,957

 

 

 

22,861

 

 

 

20,900

 

 

 

23,812

 

Drug discovery

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Drug discovery services

 

 

7,495

 

 

 

5,570

 

 

 

5,732

 

 

 

5,787

 

 

 

8,075

 

 

 

2,936

 

 

 

2,192

 

 

 

2,362

 

Drug discovery contribution

 

 

111

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

 

 

-

 

Total drug discovery

 

 

7,606

 

 

 

5,570

 

 

 

5,732

 

 

 

5,787

 

 

 

8,075

 

 

 

2,936

 

 

 

2,192

 

 

 

2,362

 

Total revenues

 

$

46,170

 

 

$

29,850

 

 

$

29,784

 

 

$

32,127

 

 

$

33,032

 

 

$

25,797

 

 

$

23,092

 

 

$

26,174

 

Deferred Revenue:

 

 

 

As of

 

 

 

December 31,

 

 

September 30,

 

 

June 30,

 

 

March 31,

 

 

December 31,

 

 

September 30,

 

 

June 30,

 

 

March 31,

 

 

 

2021

 

 

2021

 

 

2021

 

 

2021

 

 

2020

 

 

2020

 

 

2020

 

 

2020

 

 

 

(in thousands)

 

Deferred revenue

 

$

85,432

 

 

$

76,318

 

 

$

78,526

 

 

$

78,115

 

 

$

86,567

 

 

$

21,659

 

 

$

25,117

 

 

$

23,835

 

Gross Margin:

 

 

 

Three Months Ended

 

 

 

December 31,

 

 

September 30,

 

 

June 30,

 

 

March 31,

 

 

December 31,

 

 

September 30,

 

 

June 30,

 

 

March 31,

 

 

 

2021

 

 

2021

 

 

2021

 

 

2021

 

 

2020

 

 

2020

 

 

2020

 

 

2020

 

Software products and services

   gross margin

 

 

78

%

 

 

73

%

 

 

77

%

 

 

78

%

 

 

77

%

 

 

81

%

 

 

82

%

 

 

83

%

Stock-Based Compensation:

 

 

 

Three Months Ended

 

 

 

December 31,

 

 

September 30,

 

 

June 30,

 

 

March 31,

 

 

December 31,

 

 

September 30,

 

 

June 30,

 

 

March 31,

 

 

 

2021

 

 

2021

 

 

2021

 

 

2021

 

 

2020

 

 

2020

 

 

2020

 

 

2020

 

 

 

(in thousands)

 

Stock-based compensation:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Software products and

   services

 

$

389

 

 

$

396

 

 

$

382

 

 

$

229

 

 

$

152

 

 

$

169

 

 

$

124

 

 

$

85

 

Drug discovery

 

 

626

 

 

 

669

 

 

 

738

 

 

 

428

 

 

 

276

 

 

 

230

 

 

 

181

 

 

 

168

 

Research and development

 

 

2,157

 

 

 

2,130

 

 

 

1,925

 

 

 

1,228

 

 

 

863

 

 

 

857

 

 

 

822

 

 

 

508

 

Sales and marketing

 

 

331

 

 

 

370

 

 

 

362

 

 

 

218

 

 

 

141

 

 

 

165

 

 

 

116

 

 

 

93

 

General and administrative

 

 

3,953

 

 

 

4,087

 

 

 

3,609

 

 

 

2,263

 

 

 

1,571

 

 

 

1,617

 

 

 

1,486

 

 

 

921

 

Total stock-based

   compensation expense

 

$

7,456

 

 

$

7,652

 

 

$

7,016

 

 

$

4,366

 

 

$

3,003

 

 

$

3,038

 

 

$

2,729

 

 

$

1,775

 

104

Table of Contents

 

 

Depreciation:

 

 

 

Three Months Ended

 

 

 

December 31,

 

 

September 30,

 

 

June 30,

 

 

March 31,

 

 

December 31,

 

 

September 30,

 

 

June 30,

 

 

March 31,

 

 

 

2021

 

 

2021

 

 

2021

 

 

2021

 

 

2020

 

 

2020

 

 

2020

 

 

2020

 

 

 

(in thousands)

 

Depreciation:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cost of revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Software products and

   services

 

$

61

 

 

$

56

 

 

$

68

 

 

$

86

 

 

$

67

 

 

$

62

 

 

$

48

 

 

$

43

 

Drug discovery

 

 

82

 

 

 

106

 

 

 

167

 

 

 

232

 

 

 

226

 

 

 

213

 

 

 

205

 

 

 

193

 

Research and development

 

 

212

 

 

 

163

 

 

 

195

 

 

 

247

 

 

 

222

 

 

 

212

 

 

 

200

 

 

 

176

 

Sales and marketing

 

 

65

 

 

 

59

 

 

 

57

 

 

 

66

 

 

 

39

 

 

 

30

 

 

 

39

 

 

 

34

 

General and administrative

 

 

232

 

 

 

197

 

 

 

240

 

 

 

256

 

 

 

457

 

 

 

372

 

 

 

388

 

 

 

432

 

Total depreciation

     expense

 

$

652

 

 

$

581

 

 

$

727

 

 

$

887

 

 

$

1,011

 

 

$

889

 

 

$

880

 

 

$

878

 

Quarterly Revenue Trends

On-premise software revenue is subject to seasonality that generally favors the first and fourth quarter of each year, primarily due to the timing of customer renewals for on-premise software arrangements, for which revenue is recognized at a single point in time. Hosted software revenue grew more steadily in the periods presented, as existing customers and new customers increased their spend on hosted solutions, for which revenue is recognized over time. As a result, a portion of the software products and services revenue we reported in each period was attributable to sales we made in prior periods. Software maintenance revenue is related to on-premise software sales and also is recognized ratably over the term of the underlying agreement. Therefore, increases or decreases in customer sales, customer expansion, or renewals in a period may not be immediately reflected in revenue for the period. Our professional services arrangements are typically project-based and, therefore, fluctuated based on individual customer needs and ongoing project support. Drug discovery revenue fluctuated from period to period based on the achievement of specific collaboration milestones, including advancement of BMS collaborative services. The majority of our current collaborations are in the discovery stage. Milestone payments typically increase in magnitude as a program advances.

Quarterly Deferred Revenue Trends

Deferred revenue consists of the unearned portion of customer billings, which is recognized as revenue in accordance with our revenue recognition policy, as well as the unearned portion of unbilled collaboration milestones that are deemed probable in advance of actual achievement. Deferred revenue balances have fluctuated based on the timing of sales, shifts in product mix, fluctuations to the number and size of milestones that were deemed probable in advance of actual achievement, and the measurement of progress toward completion for service projects.

Quarterly Gross Margin Trends

Our software products and services gross margin experienced fluctuations over the periods presented due to increased headcount and the product mix for software and services, as the cost of royalties due on sales of our hosted software is recognized upfront, while the associated revenue is recognized over the term of the related agreement. Currently, gross margin is not meaningful for measuring the operating results of our drug discovery business.

Quarterly Operating Expense Trends

Operating expenses generally increased during the periods presented due to increased headcount and personnel-related expenses involved in research and development, sales and marketing, general and administrative activities, and CRO costs related to our internal drug discovery programs. These increases in headcount across our operations have supported the overall growth and management of our business. CRO cost increases were driven by the expansion and progression of our internal drug discovery programs.

105

Table of Contents

 

Quarterly Other (Expense) Income Trends

Other (expense) income during the periods presented consisted primarily of fair value gains and losses related to our equity investments in Nimbus, Morphic, ShouTi and Relay, a loss on the disposal of our equity stake in Relay, a gain from the Petra merger, and, to a lesser degree, interest income.

 

106

Table of Contents

 

 

Segment Information

The following tables summarize segment information for the years ended December 31, 2021, 2020, and 2019. See Note 15 in our audited consolidated financial statements for additional information regarding our segments.

Segment gross profit is derived by deducting operational expenditures, with the exception of research and development, sales and marketing, and general and administrative activities, from U.S. GAAP revenue. Operational expenditures are expenditures made that are directly attributable to the reportable segment. In many cases, these expenditures are allocated to the segments based on headcount. The reportable segment expenditures include compensation, supplies, and services from contract research organizations.

Certain cost items are not allocated to our reportable segments. These cost items primarily consist of compensation and general operational expenses associated with our research and development, sales and marketing, and general and administrative activities. These costs are incurred by both segments and, due to the integrated nature of our software and drug discovery segments, any allocation methodology would be arbitrary and provide no meaningful analysis. Additionally, we report assets on a consolidated basis and do not allocate assets to our reportable segments for purposes of assessing segment performance or allocating resources.

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

 

 

(in thousands)

 

Segment revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Software

 

$

113,236

 

 

$

92,530

 

 

$

66,735

 

Drug discovery

 

 

24,695

 

 

 

15,565

 

 

 

18,808

 

Total segment revenues

 

$

137,931

 

 

$

108,095

 

 

$

85,543

 

Segment gross profit:

 

 

 

 

 

 

 

 

 

 

 

 

Software

 

$

86,741

 

 

$

74,527

 

 

$

53,089

 

Drug discovery

 

 

(21,121

)

 

 

(11,055

)

 

 

(3,996

)

Total segment gross profit

 

 

65,620

 

 

 

63,472

 

 

 

49,093

 

Unallocated (expense) income:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

(90,904

)

 

 

(64,695

)

 

 

(39,404

)

Sales and marketing

 

 

(22,150

)

 

 

(17,795

)

 

 

(21,364

)

General and administrative

 

 

(64,009

)

 

 

(41,898

)

 

 

(27,040

)

(Loss) gain on equity investment

 

 

(1,781

)

 

 

4,108

 

 

 

943

 

Change in fair value

 

 

11,359

 

 

 

28,263

 

 

 

9,922

 

Interest

 

 

1,057

 

 

 

2,253

 

 

 

1,878

 

Income taxes

 

 

(411

)

 

 

(345

)

 

 

291

 

Consolidated net loss

 

$

(101,219

)

 

$

(26,637

)

 

$

(25,681

)

Liquidity, Capital Resources and Funding Requirements

We have a history of significant operating losses, and incurred negative cash flows from operations since inception through December 31, 2019, and again in the year ended December 31, 2021. As of December 31, 2021, we had an accumulated deficit of $230.0 million.

We have funded our operations to date principally from the sale our equity securities, including our initial public offering and our follow-on public offering, and to a lesser extent, from sales of our software solutions and from upfront payments, research funding and milestone payments from our drug discovery collaborations, and from distributions on account of, or proceeds from the sale of, our equity stakes in our collaborators. Our operating cash flows are impacted by the magnitude and timing of our software sales and by the magnitude and timing of our drug discovery milestone achievements and research funding fees.

As of December 31, 2021, we had cash, cash equivalents and marketable securities of $579.5 million.

107

Table of Contents

 

On February 10, 2020, we closed our initial public offering of our common stock, in which we sold 13,664,704 shares of common stock at a public offering price of $17.00 per share, resulting in net proceeds to us of $209.6 million, after deducting underwriting discounts and commissions and offering expenses borne by us.

On August 17, 2020, we closed a follow-on public offering, in which we sold 5,250,000 shares of common stock at a public offering price of $66.00 per share, resulting in net proceeds to us of $325.6 million, after deducting underwriting discounts and commissions and offering expenses borne by us.

On March 4, 2021, we filed a universal shelf registration statement on Form S-3 which allows us to offer and sell an indeterminate number of shares of common stock, preferred stock, depositary shares or warrants, or an indeterminate principal amount of debt securities, from time to time pursuant to one or more offerings at prices and terms to be determined at the time of the sale. As of December 31, 2021, no securities had been sold under the Form S-3.

We believe our existing cash, cash equivalents and marketable securities will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 24 months. Our future capital requirements will depend on many factors, including the growth of our software revenue, the timing and extent of spending to support research and development efforts, the continued expansion of software sales and marketing activities, the timing and receipt of milestone payments from our collaborations, as well as spending to support, advance, and broaden our internal programs. Furthermore, our capital requirements will also change depending on the timing and receipt of any distributions we may receive from our equity stakes in our drug discovery collaborators and partners. The potential for these distributions, and the amounts which we may be entitled to receive, are difficult to predict due to the inherent uncertainty of the events which may trigger such distributions.

We plan to utilize the existing cash, cash equivalents and marketable securities on hand primarily to fund our software and drug discovery activities. With respect to our internal programs, as part of our strategy we may choose to enter into collaborations or pursue out-licensing arrangements when we believe it will help maximize the commercial value of any such program.

We may be required to seek additional equity or debt financing. In the event that we require additional financing, we may not be able to raise such financing on terms acceptable to us or at all. If we are unable to raise additional capital or generate cash flows necessary to maintain or expand our operations and invest in our platform, we may not be able to compete successfully, which would harm our business, operations and financial condition. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans.

Our contractual obligations as of December 31, 2021 include operating lease obligations of $132.2 million, consisting of our continuing rent obligations through December 2037, primarily for our principal offices located in New York, New York and Portland, Oregon, which expire in December 2037 and September 2026, respectively. In addition, see Note 6 – Commitments and Contingencies to our consolidated financial statements appearing in Item 8 of this Annual Report for information relating to executed leases that have not yet commenced.

In December 2020, we entered into a five-year agreement with a third-party cloud provider for compute power. The agreement contains a minimum payment obligation, which totals $60 million over the five years after the date we entered into the agreement. There is no annual commitment.

We enter into agreements in the normal course of business with CRO vendors for research and preclinical studies, professional consultants for expert advice, and other vendors for various products and services. These contracts do not contain any minimum purchase commitments and are cancelable at any time by us, generally upon 30 days prior written notice, and therefore we believe that our non-cancelable obligations under these agreements are not material. We have also agreed to pay volume-based royalties to third-parties for use of software functionality under various licensing and related agreements.


108

Table of Contents

 

 

Cash Flows

The following table presents a summary of our cash flows for the periods shown:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

 

 

(in thousands)

 

Net cash (used in) provided by operating activities

 

$

(70,669

)

 

$

16,757

 

 

$

(26,059

)

Net cash used in investing activities

 

 

(16,812

)

 

 

(381,721

)

 

 

(53,855

)

Net cash provided by financing activities

 

 

7,952

 

 

 

541,274

 

 

 

28,684

 

Net (decrease) increase in cash and cash equivalents and restricted cash

 

$

(79,529

)

 

$

176,310

 

 

$

(51,230

)

Operating activities

During the year ended December 31, 2021, operating activities used approximately $70.7 million in cash primarily resulting from net loss of $101.2 million, which included an $11.4 million non-cash gain from changes in fair value, $26.5 million in stock-based compensation costs and $9.0 million of other non-cash operating expenses included in net loss, including depreciation and investment accretion costs, and a $1.8 million loss on equity investment that is classified as an investing activity. Changes in our operating assets and liabilities provided cash of approximately $4.7 million.

During the year ended December 31, 2020, operating activities provided approximately $16.8 million of cash. Cash provided by operating activities increased primarily from changes in our operating assets and liabilities, which provided cash of approximately $59.2 million primarily due to an increase of $59.7 million in deferred revenue, of which approximately $54.0 million is related to our agreement with BMS, and $12.5 million of non-cash operating expenses included in net loss, including depreciation and stock-based compensation costs. These increases are partially offset by our net loss of $26.6 million and $28.3 million non-cash gain from changes in fair value.

During the year ended December 31, 2019, operating activities used approximately $26.1 million of cash, primarily resulting from net loss of $25.7 million, which included a $9.9 million non-cash gain from changes in fair value and a $0.9 million gain on equity investment that is classified as an investing activity, partially offset by $6.2 million of non-cash operating expenses included in net loss, including depreciation and stock-based compensation costs. Changes in our operating assets and liabilities provided cash of approximately $4.2 million.

Investing activities

During the year ended December 31, 2021, investing activities used approximately $16.8 million of cash, consisting of $22.1 million used for purchases of marketable securities, net of maturities, $7.2 million used for purchases of property and equipment and $3.7 million used to make equity investments in Ajax Therapeutics, Inc. and ShouTi, partially offset by $15.7 million provided by the sale of our equity stake in Relay and $0.4 million provided by the distribution of funds from Petra in connection with the Petra merger.

During the year ended December 31, 2020, investing activities used approximately $381.7 million of cash, primarily for purchases of marketable securities.

During the year ended December 31, 2019, investing activities used approximately $53.9 million of cash, primarily for purchases of marketable securities.

Financing activities

During the year ended December 31, 2021, financing activities provided approximately $8.0 million of cash, primarily attributable to proceeds from stock option exercises.

During the year ended December 31, 2020, financing activities provided approximately $541.3 million of cash, primarily attributable to proceeds from issuances of our common stock in our initial public and follow-on offerings.

During the year ended December 31, 2019, financing activities provided approximately $28.7 million of cash, primarily attributable to proceeds from issuances of our Series E preferred stock.

109

Table of Contents

 

Seasonality

Generally, the first and fourth quarter of each year have typically been our largest quarters for software products and services revenue, primarily due to the timing of customer renewals of on-premise software arrangements, for which revenue is recognized at a single point in time. Seasonality has been a less significant factor for our hosted software arrangements, for which revenue is recognized ratably over time. Seasonality has not been a factor for our drug discovery revenues. Historical seasonality may not be indicative of future periods.

Critical Accounting Policies and Significant Judgments and Critical Accounting Estimates

Critical accounting policies are those that are both most important to the portrayal of a company's financial condition and results, and that require management's most difficult, subjective, and complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. Our management’s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these consolidated financial statements requires us to make judgments and estimates that affect the reported amounts of assets, liabilities, revenues, and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and the accompanying notes. We base our estimates on historical experience, known trends and events, and our beliefs of what could occur in the future considering available information. Actual results may differ from these estimates under different assumptions or conditions. On an ongoing basis, we evaluate our judgments and estimates in light of changes in circumstances, facts, and experience. The effects of material revisions in estimates, if any, are reflected in the consolidated financial statements prospectively from the date of change in estimates.

While our significant accounting policies are described in more detail in Note 2 – Significant Accounting Policies to our consolidated financial statements appearing in Item 8 of this Annual Report, we believe the following critical accounting estimates used in the preparation of our consolidated financial statements require the most difficult, subjective and complex judgments and estimates and have had, or are reasonably likely to have a material impact on our financial condition or results of operations.

Revenue

We recognize revenue in accordance with ASC 606, Revenue from Contracts with Customers, except for contracts that are within the scope of other standards, such as contribution grants and collaboration arrangements. In accordance with ASC 606, we recognize revenue when our customer obtains control of promised goods or services, in an amount that reflects the consideration which we expect to receive in exchange for those goods or services. To determine revenue recognition for arrangements that we determine are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as we satisfy a performance obligation.

Significant management judgment is applied to determine the allocation of the transaction price and measurement of progress, including (1) the constraint on variable consideration, (2) the allocation of the transaction price to the performance obligations using their standalone selling price, or SSP, basis, and (3) the appropriate input or output based method to recognize collaboration revenue and the extent of progress to date.

Variable consideration: Our revenue may include upfront payments for the performance of services in the future, which have both fixed and variable consideration. We include the unconstrained amount of estimated variable consideration in the transaction price. The amount included in the transaction price is constrained to the amount for which it is probable that a significant reversal of cumulative revenue recognized will not occur. At the end of each subsequent reporting period, we re-evaluate the estimated variable consideration included in the transaction price and any related constraint and, if necessary, adjust our estimate of the overall transaction price.

Research and development, regulatory or commercial milestones in our collaboration agreements may include some, but not necessarily all, of the following types of events:

 

•

completion of preclinical research and development work leading to selection of product candidates;

 

•

initiation of Phase 1, Phase 2, and Phase 3 clinical trials;

 

•

filing of regulatory applications for marketing approval in the United States, Europe or Japan;

 

•

marketing approval in major markets, such as the United States, Europe, or Japan;

 

•

commercial milestones and/or commercial royalties; and

110

Table of Contents

 

 

 

•

achievement of certain other technical, scientific, or development criteria.

At the inception of each arrangement that includes research, development, or regulatory milestone payments, we evaluate whether the milestones are considered probable of being reached and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the associated milestone value is included in the transaction price. Milestone payments that are not within our control or that of the licensee, such as regulatory approvals, are not considered probable of being achieved until those approvals are received. The transaction price is then allocated to each performance obligation on an SSP basis, for which we recognize revenue as or when the performance obligations under the contract are satisfied. At the end of each subsequent reporting period, we re-evaluate the probability of achievement of such development milestones and any related constraint, and if necessary, adjust our estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which may affect license, collaboration, and other revenues and earnings in the period of adjustment. The process of successfully achieving the criteria for the milestone payments is highly uncertain. Consequently, there is a risk that we may not earn all of the milestone payments from each of our collaborators. We recognized $6.3 million, $11.9 million, and $12.1 million from drug discovery milestones for the years ended December 31, 2021, 2020, and 2019, respectively.

Software performance obligations and transaction price allocation: At contract inception, we assess the goods or services promised within each contract that falls under the scope of ASC 606 to identify distinct performance obligations, which requires significant judgment based on the nature of each transaction. We allocate the transaction price to each distinct performance obligation on an SSP basis. We determine the SSP using information that includes historical discounting practices, market conditions, cost-plus analysis, and other observable inputs. We typically have more than one SSP for individual performance obligations due to the stratification of those items by classes of customers and circumstances. In these instances, we may use information such as the size and geographic region of the customer in determining the SSP. We may also estimate SSP based on management judgment by considering available data such as internal cost and margin objectives, pricing strategies, market/competitive conditions, historical profitability data, as well as other observable inputs. We establish SSP ranges for our products and services and reassesses them periodically. The determination of SSP required significant management judgment.

Collaboration agreement transaction price allocation and measurement of progress: At the inception of each arrangement, we utilize judgment to assess the nature of the performance obligations to determine whether they are distinct or a single combined performance obligation. We allocate the transaction price to each performance obligation based on the relative SSP of each performance obligation at inception, which will be determined based on each performance obligation’s estimated SSP. We determine the SSP at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant judgment is used to determine the inputs for total costs to perform the research activities, which may include the length of time required, the internal hours expected to be incurred on the services and the number and costs of various studies that will be performed by third-parties to complete the research plan. Revenue is recognized on a proportional performance basis over the period of service, using input-based measurements to estimate the performance. Changes to these assumptions may have a material effect on the amount and timing of revenue recognized. We recognized revenue of $14.6 million, $1.0 million, and zero related to collaboration agreements with proportional performance measurement for the years ended December 31, 2021, 2020, and 2019, respectively.

Stock-Based Compensation

Compensation expense related to stock-based transactions, including employee, consultant, and non-employee director stock option awards, is measured and recognized in the consolidated financial statements based on fair value. The fair value of each option award is estimated on the grant date using the Black Scholes option-pricing model. Expense is recognized on a straight-line basis over the vesting period of the award. Forfeitures are accounted for in the period in which the awards are forfeited.

We estimate the fair value of our option awards to employees, directors and non-employees using the Black-Scholes option pricing model, which requires the input of subjective assumptions, including the expected stock price volatility and the calculation of expected term of the award. Due to the lack of complete company-specific historical and implied volatility data for the full expected term of the stock-based awards, we base our estimate of expected volatility on a representative group of publicly traded companies. For these analyses, we selected companies with comparable characteristics to our own, including enterprise value, risk profiles, position within the industry and with historical share price information sufficient to meet the expected life of the stock-based awards. We compute historical volatility data using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. We will continue to apply this process until a sufficient amount of historical information regarding the volatility of our own stock price becomes available. We have estimated the expected term of our employee stock option using historical exercise data.  

Our weighted average volatility was, 59%, 60% and 57% for the years ended December 31, 2021, 2020, and 2019, respectively, and our expected term was 4.66, 4.49 and 6.05 for the years ended December 31, 2021, 2020, and 2019, respectively.

111

Table of Contents

 

We will continue to use judgment in evaluating the assumptions related to our stock-based compensation on a prospective basis. As we continue to accumulate additional data related to our common stock, we may have refinements to our estimates, which could materially impact our future stock-based compensation expense.

Recent Accounting Pronouncements

See Note 2 to our consolidated financial statements appearing elsewhere in this Annual Report for a discussion of recently issued accounting pronouncements.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

Our primary exposure to market risk is interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our investments, including cash equivalents and marketable securities, are in the form of U.S. Treasury and corporate bonds and a money market fund that is invested in U.S. Treasury and corporate bonds. Due to the nature of these investments, an immediate 10% change in interest rates would not have a material effect on the fair market value of this investment portfolio.

We are also exposed to market risk related to changes in foreign currency exchange rates. We maintain bank accounts denominated in Japanese yen, British pound sterling, Indian rupee, and Korean Republic won to accommodate deposits of amounts due from certain customers. We also contract with certain vendors that are located outside of the United States whose invoices are denominated in foreign currencies. We are subject to fluctuations in foreign currency rates in connection with these arrangements. We do not currently hedge our foreign currency exchange rate risk. Our cash balances and outstanding vendor invoices denominated in foreign currencies were not material as of December 31, 2021, 2020, and 2019, and our market risk associated with foreign currency exchange rates was deemed insignificant. An immediate 10% change in foreign exchange rates would not have a material effect on our consolidated financial statements.

Inflation generally affects us by increasing our cost of labor and target development costs. We do not believe that inflation had a material effect on our business, financial condition, or results of operations for the years ended December 31, 2021, 2020, and 2019.

Item 8. Financial Statements and Supplementary Data.

 

112

Table of Contents

 

 

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

 

 


F-1

Table of Contents

 

 

Report of Independent Registered Public Accounting Firm

 

To the Stockholders and Board of Directors
Schrödinger, Inc.:

Opinion on the Consolidated Financial Statements

We have audited the accompanying consolidated balance sheets of Schrödinger, Inc. and subsidiaries (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, 2021, in conformity with U.S. generally accepted accounting principles.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company’s internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated February 24, 2022 expressed an unqualified opinion on the effectiveness of the Company’s internal control over financial reporting.

Basis for Opinion

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

Estimation of total costs to perform for Bristol-Myers Squibb Company collaboration and license agreement

As discussed in Note 3(c) to the consolidated financial statements, the Company recorded revenue of $13.7 million during the year ended December 31, 2021 related to the Bristol-Myers Squibb Company (“BMS”) collaboration and license agreement on a proportional performance basis. The Company measures progress towards completion at the end of each reporting period based on measuring proportional performance. The proportional performance is determined using input-based measurements of total costs of research activities incurred for the agreement relative to the total estimate of costs of research activities for the agreement.

We identified the estimation of total costs to perform research activities for the BMS collaboration and license agreement as a critical audit matter. There was subjective auditor judgment in evaluating the Company’s estimate of total costs to perform research activities.

F-2

Table of Contents

 

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company’s process to account for the BMS collaboration and license agreement, including controls related to the determination of total costs to perform research activities. We evaluated the Company’s estimate of costs to be incurred by:

— Comparing the estimated length of time required to complete the research plan to both industry publications and actual time incurred to complete the various phases for a selection of the Company’s other research programs

— Comparing the estimated internal employee hours and external contract research organizations costs to be incurred by phase to other research programs completed by the Company

—Attending the quarterly forecast review meetings to evaluate factors impacting total costs to perform research activities

— Inspecting minutes of Joint Steering Committee meetings between the Company and BMS to evaluate factors impacting total costs to perform research activities and compared it with the outcome of the inquiries stated above

Identification of performance obligations in complex or unusual software revenue arrangements

As discussed in Note 3(a) to the consolidated financial statements, the Company reported on-premise software revenue of $74.6 million and hosted software revenue of $11.1 million for the year ended December 31, 2021. As discussed in Note 3(d), the Company’s contracts with customers often include promises to transfer multiple software products and services, including training, professional services, technical support services, and rights to unspecified updates. At contract inception, the Company assesses the products and services promised within each contract to identify distinct performance obligations that should be accounted for separately.

We identified the determination of distinct performance obligations in complex or unusual software revenue arrangements as a critical audit matter. There was subjective auditor judgment in evaluating whether promised products and services in complex or unusual software revenue arrangements are separate performance obligations or inputs into a combined performance obligation.

The following are the primary procedures we performed to address this critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the software revenue process, including controls related to the determination of distinct performance obligations. For a selection of complex or unusual software revenue arrangements, we evaluated whether the performance obligations identified by the Company were capable of being distinct in the context of the contract by obtaining an understanding of the Company’s product and service offerings, obtaining and inspecting contracts, and evaluating the application of the revenue recognition accounting guidance for the selected contract.

/s/ KPMG LLP

We have served as the Company’s auditor since 2010.

Portland, Oregon
February 24, 2022


F-3

Table of Contents

 

 

Report of Independent Registered Public Accounting Firm

 

To the Stockholders and Board of Directors
Schrödinger, Inc.:

Opinion on Internal Control Over Financial Reporting

We have audited Schrödinger, Inc. and subsidiaries' (the Company) internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2021, based on criteria established in Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of the Company as of December 31, 2021 and 2020, the related consolidated statements of operations, comprehensive loss, convertible preferred stock and stockholders’ equity (deficit), and cash flows for each of the years in the three-year period ended December 31, 2021, and the related notes (collectively, the consolidated financial statements), and our report dated February 24, 2022 expressed an unqualified opinion on those consolidated financial statements.

Basis for Opinion

The Company’s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Annual Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company’s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.

Definition and Limitations of Internal Control Over Financial Reporting

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ KPMG LLP

We have served as the Company’s auditor since 2010.

Portland, Oregon
February 24, 2022

F-4

Table of Contents

 

SCHRÖDINGER, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(in thousands, except for share and per share amounts)

 

Assets

 

December 31, 2021

 

 

December 31, 2020

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

120,267

 

 

$

202,296

 

Restricted cash

 

 

3,000

 

 

 

500

 

Marketable securities

 

 

456,212

 

 

 

440,395

 

Accounts receivable, net of allowance for doubtful accounts of $108 and $60

 

 

31,744

 

 

 

31,423

 

Unbilled and other receivables, net for allowance for unbilled receivables of $30 and $0

 

 

8,807

 

 

 

3,955

 

Prepaid expenses

 

 

5,030

 

 

 

4,409

 

Total current assets

 

 

625,060

 

 

 

682,978

 

Property and equipment, net

 

 

10,025

 

 

 

5,140

 

Equity investments

 

 

43,167

 

 

 

45,664

 

Right of use assets

 

 

75,384

 

 

 

10,129

 

Other assets

 

 

2,851

 

 

 

2,352

 

Total assets

 

$

756,487

 

 

$

746,263

 

Liabilities and Stockholders’ Equity

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

8,079

 

 

$

8,398

 

Accrued payroll, taxes, and benefits

 

 

18,405

 

 

 

12,000

 

Deferred revenue

 

 

55,368

 

 

 

45,403

 

Lease liabilities

 

 

2,042

 

 

 

4,543

 

Other accrued liabilities

 

 

7,317

 

 

 

2,861

 

Total current liabilities

 

 

91,211

 

 

 

73,205

 

Deferred revenue, long-term

 

 

30,064

 

 

 

41,164

 

Lease liabilities, long-term

 

 

77,827

 

 

 

7,221

 

Other liabilities, long-term

 

 

300

 

 

 

654

 

Total liabilities

 

 

199,402

 

 

 

122,244

 

Commitments and contingencies (Note 6)

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Preferred stock, $0.01 par value. Authorized 10,000,000 shares; zero shares issued and

   outstanding at December 31, 2021 and December 31, 2020, respectively

 

 

—

 

 

 

—

 

Common stock, $0.01 par value. Authorized 500,000,000 shares;

   61,834,515 and 60,713,534 shares issued and outstanding at December 31, 2021

   and December 31, 2020, respectively

 

 

618

 

 

 

607

 

Limited common stock, $0.01 par value. Authorized 100,000,000 shares;

   9,164,193 shares issued and outstanding at December 31, 2021 and

   December 31, 2020, respectively

 

 

92

 

 

 

92

 

Additional paid-in capital

 

 

786,964

 

 

 

752,558

 

Accumulated deficit

 

 

(229,952

)

 

 

(129,559

)

Accumulated other comprehensive (loss) income

 

 

(651

)

 

 

317

 

Total stockholders’ equity of Schrödinger stockholders

 

 

557,071

 

 

 

624,015

 

Noncontrolling interest

 

 

14

 

 

 

4

 

Total stockholders’ equity

 

 

557,085

 

 

 

624,019

 

Total liabilities and stockholders’ equity

 

$

756,487

 

 

$

746,263

 

 

See accompanying notes to consolidated financial statements.

F-5

Table of Contents

 

SCHRÖDINGER, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

(in thousands, except for share and per share amounts)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Software products and services

 

$

113,236

 

 

$

92,530

 

 

$

66,735

 

Drug discovery

 

 

24,695

 

 

 

15,565

 

 

 

18,808

 

Total revenues

 

 

137,931

 

 

 

108,095

 

 

 

85,543

 

Cost of revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Software products and services

 

 

26,495

 

 

 

18,003

 

 

 

13,646

 

Drug discovery

 

 

45,816

 

 

 

26,620

 

 

 

22,804

 

Total cost of revenues

 

 

72,311

 

 

 

44,623

 

 

 

36,450

 

Gross profit

 

 

65,620

 

 

 

63,472

 

 

 

49,093

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

90,904

 

 

 

64,695

 

 

 

39,404

 

Sales and marketing

 

 

22,150

 

 

 

17,795

 

 

 

21,364

 

General and administrative

 

 

64,009

 

 

 

41,898

 

 

 

27,040

 

Total operating expenses

 

 

177,063

 

 

 

124,388

 

 

 

87,808

 

Loss from operations

 

 

(111,443

)

 

 

(60,916

)

 

 

(38,715

)

Other income:

 

 

 

 

 

 

 

 

 

 

 

 

(Loss) gain on equity investments

 

 

(1,781

)

 

 

4,108

 

 

 

943

 

Change in fair value

 

 

11,359

 

 

 

28,263

 

 

 

9,922

 

Interest income

 

 

1,057

 

 

 

2,253

 

 

 

1,878

 

Total other income

 

 

10,635

 

 

 

34,624

 

 

 

12,743

 

Loss before income taxes

 

 

(100,808

)

 

 

(26,292

)

 

 

(25,972

)

Income tax expense (benefit)

 

 

411

 

 

 

345

 

 

 

(291

)

Net loss

 

 

(101,219

)

 

 

(26,637

)

 

 

(25,681

)

Net loss attributable to noncontrolling interest

 

 

(826

)

 

 

(2,174

)

 

 

(1,110

)

Net loss attributable to Schrödinger common and

   limited common stockholders

 

$

(100,393

)

 

$

(24,463

)

 

$

(24,571

)

Net loss per share attributable to Schrödinger

   common and limited common stockholders, basic and diluted:

 

$

(1.42

)

 

$

(0.41

)

 

$

(4.09

)

Weighted average shares used to compute net loss

   per share attributable to Schrödinger common and

   limited common stockholders, basic and diluted:

 

 

70,594,950

 

 

 

60,024,658

 

 

 

6,004,500

 

 

See accompanying notes to consolidated financial statements.

F-6

Table of Contents

 

SCHRÖDINGER, INC. AND SUBSIDIARIES

Consolidated Statements of Comprehensive Loss

(in thousands)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Net loss attributable to Schrödinger common and

   limited common stockholders

 

$

(100,393

)

 

$

(24,463

)

 

$

(24,571

)

Changes in market value of investments, net of tax:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized (loss) gain on marketable securities

 

 

(968

)

 

 

301

 

 

 

25

 

Comprehensive loss

 

$

(101,361

)

 

$

(24,162

)

 

$

(24,546

)

 

See accompanying notes to consolidated financial statements.

 

F-7

Table of Contents

 

 

 

SCHRÖDINGER, INC. AND SUBSIDIARIES

Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(in thousands, except for share amounts)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated

 

 

 

 

 

 

 

 

Series E preferred

stock

 

Series D preferred

stock

 

Series C preferred

stock

 

Series B preferred

stock

 

Series A preferred

stock

 

 

Common stock

 

Limited common

stock

 

Additional

paid-in

 

Accumulated

 

other

comprehensive

 

Non

controlling

 

Total

stockholders’

 

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

Shares

 

Amount

 

 

Shares

 

Amount

 

Shares

 

Amount

 

capital

 

deficit

 

loss (income)

 

interest

 

equity (deficit)

 

Balance at December 31, 2018

 

53,669,659

 

$

79,377

 

 

39,540,611

 

$

22,000

 

 

47,242,235

 

$

19,844

 

 

29,468,101

 

$

9,840

 

 

134,704,785

 

$

30,626

 

 

 

5,906,976

 

$

59

 

 

—

 

$

—

 

$

8,915

 

$

(80,525

)

$

(9

)

$

—

 

$

(71,560

)

Change in unrealized

   loss on marketable

   securities

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

25

 

 

—

 

 

25

 

Issuances of Series E

   preferred stock, net

   of issuance costs

   of $127

 

20,126,118

 

 

29,893

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

Issuances of common

   stock upon stock

   option exercise

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

214,845

 

 

2

 

 

 

 

 

 

 

 

547

 

 

—

 

 

—

 

 

—

 

 

549

 

Stock-based compensation

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

2,193

 

 

—

 

 

—

 

 

—

 

 

2,193

 

Contributions by

   noncontrolling interest

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

1,151

 

 

1,151

 

Net loss

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

(24,571

)

 

—

 

 

(1,110

)

 

(25,681

)

Balance at December 31, 2019

 

73,795,777

 

 

109,270

 

 

39,540,611

 

 

22,000

 

 

47,242,235

 

 

19,844

 

 

29,468,101

 

 

9,840

 

 

134,704,785

 

 

30,626

 

 

 

6,121,821

 

 

61

 

 

—

 

 

—

 

 

11,655

 

 

(105,096

)

 

16

 

 

41

 

 

(93,323

)

Change in unrealized

   loss on marketable

   securities

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

301

 

 

—

 

 

301

 

Issuances of common

   stock upon stock

   option exercise

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

1,398,177

 

 

14

 

 

—

 

 

—

 

 

4,169

 

 

—

 

 

—

 

 

—

 

 

4,183

 

Stock-based compensation

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

10,545

 

 

—

 

 

—

 

 

—

 

 

10,545

 

Issuances of common

   stock upon initial

   public offering, net

  of issuance costs

   of $22,667

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

13,664,704

 

 

136

 

 

—

 

 

—

 

 

209,497

 

 

—

 

 

—

 

 

—

 

 

209,633

 

Issuances of common

   stock upon follow-on

   offering, net of

   issuance costs of

   $20,901

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

5,250,000

 

 

53

 

 

—

 

 

—

 

 

325,547

 

 

—

 

 

—

 

 

—

 

 

325,600

 

Conversion of

   convertible

   preferred stock into

   common stock

 

(73,795,777

)

 

(109,270

)

 

(17,844,124

)

 

(9,928

)

 

—

 

 

—

 

 

—

 

 

—

 

 

(134,704,785

)

 

(30,626

)

 

 

30,278,832

 

 

303

 

 

—

 

 

—

 

 

149,521

 

 

—

 

 

—

 

 

—

 

 

149,824

 

Exchange of

   convertible

   preferred stock into

   limited common

   stock

 

—

 

 

—

 

 

(21,696,487

)

 

(12,072

)

 

(47,242,235

)

 

(19,844

)

 

(29,468,101

)

 

(9,840

)

 

—

 

 

—

 

 

 

—

 

 

—

 

 

13,164,193

 

 

132

 

 

41,624

 

 

—

 

 

—

 

 

—

 

 

41,756

 

Conversion of limited

   common stock into

   common stock

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

4,000,000

 

 

40

 

 

(4,000,000

)

 

(40

)

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

Contributions by

   non-controlling interest

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

 

 

—

 

 

—

 

 

2,137

 

 

2,137

 

Net loss

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

(24,463

)

 

—

 

 

(2,174

)

 

(26,637

)

Balance at December 31, 2020

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

60,713,534

 

 

607

 

 

9,164,193

 

 

92

 

 

752,558

 

 

(129,559

)

 

317

 

 

4

 

 

624,019

 


F-8

Table of Contents

 

 

Change in unrealized

   loss on marketable

   securities

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

(968

)

 

—

 

 

(968

)

Issuances of common

   stock upon stock

   option exercise

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

1,120,981

 

 

11

 

 

—

 

 

—

 

 

7,916

 

 

—

 

 

—

 

 

—

 

 

7,927

 

Stock-based compensation

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

26,490

 

 

—

 

 

—

 

 

—

 

 

26,490

 

Contributions by

   non-controlling interest

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

 

 

—

 

 

—

 

 

836

 

 

836

 

Net loss

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

 

—

 

 

—

 

 

—

 

 

—

 

 

—

 

 

(100,393

)

 

—

 

 

(826

)

 

(101,219

)

Balance at December 31, 2021

 

—

 

$

—

 

 

—

 

$

—

 

 

—

 

$

—

 

 

—

 

$

—

 

 

—

 

$

—

 

 

 

61,834,515

 

$

618

 

 

9,164,193

 

$

92

 

$

786,964

 

$

(229,952

)

$

(651

)

$

14

 

$

557,085

 

 

See accompanying notes to consolidated financial statements.

 

F-9

Table of Contents

 

 

SCHRÖDINGER, INC. AND SUBSIDIARIES

 

Consolidated Statements of Cash Flows

(in thousands)

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cash flows from operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

$

(101,219

)

 

$

(26,637

)

 

$

(25,681

)

Adjustments to reconcile net loss to net cash (used in) provided by

 

 

 

 

 

 

 

 

 

 

 

 

operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

Loss (gain) on equity investments

 

 

1,781

 

 

 

(4,108

)

 

 

(943

)

Noncash revenue from equity investments

 

 

(107

)

 

 

(397

)

 

 

(186

)

Fair value adjustments

 

 

(11,359

)

 

 

(28,263

)

 

 

(9,922

)

Depreciation

 

 

2,847

 

 

 

3,658

 

 

 

3,640

 

Stock-based compensation

 

 

26,490

 

 

 

10,545

 

 

 

2,193

 

Noncash research and development expenses

 

 

811

 

 

 

2,137

 

 

 

1,051

 

Noncash investment accretion

 

 

5,270

 

 

 

646

 

 

 

(506

)

Loss on disposal of property and equipment

 

 

140

 

 

 

—

 

 

 

—

 

Decrease (increase) in assets:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable, net

 

 

(321

)

 

 

(12,747

)

 

 

(5,038

)

Unbilled and other receivables

 

 

(5,187

)

 

 

3,468

 

 

 

(1,556

)

Reduction in the carrying amount of right of use assets

 

 

5,799

 

 

 

5,342

 

 

 

4,177

 

Prepaid expenses and other assets

 

 

(1,121

)

 

 

187

 

 

 

410

 

(Decrease) increase in liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

 

(411

)

 

 

4,882

 

 

 

(294

)

Accrued payroll, taxes, and benefits

 

 

6,405

 

 

 

4,966

 

 

 

2,948

 

Deferred revenue

 

 

(1,028

)

 

 

59,705

 

 

 

6,715

 

Lease liabilities

 

 

(2,949

)

 

 

(5,417

)

 

 

(4,025

)

Other accrued liabilities

 

 

3,490

 

 

 

(1,210

)

 

 

958

 

Net cash (used in) provided by operating activities

 

 

(70,669

)

 

 

16,757

 

 

 

(26,059

)

Cash flows from investing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Purchases of property and equipment

 

 

(7,167

)

 

 

(2,538

)

 

 

(1,836

)

Purchases of equity investments

 

 

(3,700

)

 

 

(2,869

)

 

 

—

 

Distribution from equity investment

 

 

375

 

 

 

4,582

 

 

 

943

 

Proceeds from sale of equity investments

 

 

15,735

 

 

 

—

 

 

 

—

 

Purchases of marketable securities

 

 

(414,802

)

 

 

(519,668

)

 

 

(110,187

)

Proceeds from sale and maturity of marketable securities

 

 

392,747

 

 

 

138,772

 

 

 

57,225

 

Net cash used in investing activities

 

 

(16,812

)

 

 

(381,721

)

 

 

(53,855

)

Cash flows from financing activities:

 

 

 

 

 

 

 

 

 

 

 

 

Issuances of common stock upon initial public offering, net

 

 

—

 

 

 

211,491

 

 

 

—

 

Issuances of common stock upon follow-on public offering, net

 

 

—

 

 

 

325,600

 

 

 

—

 

Issuances of Series E preferred stock, net

 

 

—

 

 

 

—

 

 

 

29,893

 

Issuances of common stock upon stock option exercise

 

 

7,927

 

 

 

4,183

 

 

 

549

 

Contribution by noncontrolling interest

 

 

25

 

 

 

—

 

 

 

100

 

Deferred offering costs

 

 

—

 

 

 

—

 

 

 

(1,858

)

Net cash provided by financing activities

 

 

7,952

 

 

 

541,274

 

 

 

28,684

 

Net (decrease) increase in cash and cash equivalents and restricted cash

 

 

(79,529

)

 

 

176,310

 

 

 

(51,230

)

Cash and cash equivalents and restricted cash, beginning of year

 

 

202,796

 

 

 

26,486

 

 

 

77,716

 

Cash and cash equivalents and restricted cash, end of year

 

$

123,267

 

 

$

202,796

 

 

$

26,486

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Supplemental disclosure of cash flow and noncash information

 

 

 

 

 

 

 

 

 

 

 

 

Cash paid for income taxes

 

$

448

 

 

$

381

 

 

$

139

 

Supplemental disclosure of non-cash investing and financing activities

 

 

 

 

 

 

 

 

 

 

 

 

Accrued deferred offering costs

 

 

—

 

 

 

—

 

 

 

2,142

 

Purchases of property and equipment in accounts payable

 

 

705

 

 

 

8

 

 

 

90

 

Acquisitions of right of use assets in exchange for lease obligations

 

 

71,054

 

 

 

2,709

 

 

 

464

 

Right of use assets recognized on adoption

 

 

—

 

 

 

—

 

 

 

16,475

 

Reclassification of deferred financing costs to additional paid-in capital

 

 

—

 

 

 

1,858

 

 

 

—

 

 

See accompanying notes to consolidated financial statements.

F-10

Table of Contents

SCHRÖDINGER, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements

For the years ended December 31, 2021, 2020, and 2019

(in thousands, except for share and per share amounts)

(1)

Description of Business

Schrödinger, Inc. (the “Company”) has developed a differentiated, physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly, at lower cost, and with, the Company believes, a higher likelihood of success compared to traditional methods. The Company sells its software to biopharmaceutical and industrial companies, academic institutions, and government laboratories. The Company also applies its computational platform to a broad pipeline of drug discovery and development programs in collaboration with biopharmaceutical companies. In addition, the Company uses its platform to advance a pipeline of internal drug discovery programs.

On February 10, 2020, the Company completed an initial public offering (“IPO”), in which the Company issued and sold 11,882,352 shares of its common stock at a public offering price of $17.00 per share.  The underwriters fully exercised their option to purchase an additional 1,782,352 shares of the Company’s common stock at the public offering price less underwriting discounts. The Company raised $209.6 million in net proceeds after deducting underwriting discounts and commissions and offering expenses payable by the Company.

Immediately prior to the closing of the IPO, preferred stockholders voluntarily exchanged 98,406,823 shares of preferred stock for an aggregate of 13,164,193 shares of limited common stock.  In addition, upon the closing of the IPO, the remaining 226,344,686 shares of preferred stock automatically converted into an aggregate of 30,278,832 shares of common stock.

On August 17, 2020, the Company completed a follow-on public offering, in which the Company issued and sold 4,500,000 shares of its common stock at a public offering price of $66.00 per share. The underwriters fully exercised their option to purchase an additional 750,000 shares of the Company’s common stock at the public offering price less underwriting discounts. The Company raised $325.6 million in net proceeds after deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, a stockholder of the Company sold 500,000 shares of common stock. The Company did not receive any proceeds from the sale of shares of common stock by the selling stockholder.

(2)

Significant Accounting Policies

(a)

Recently Issued Accounting Pronouncements

In January 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) —Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, which clarifies the accounting related to equity investments and derivatives. This guidance was effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption was permitted. The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Topic 350) – Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. This standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for annual periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021, with early adoption permitted. The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.

F-11

Table of Contents

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU No. 2016-13 replaces the existing incurred loss impairment model with an expected loss model which requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes generally result in earlier recognition of credit losses.  The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.

In October 2021, the FASB issues ASU No. 2021-08, Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires the measurement and recognition of contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standard Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606). This update replaces the existing guidance requiring contract assets and contract liabilities to be measured and recognized at fair value. The standard is effective on a prospective basis for annual periods beginning after December 15, 2022, including interim periods within the fiscal year, with early adoption permitted. The Company plans to early adopt this new standard effective January 1, 2022 and does not expect a material impact on its consolidated financial statements.

(b)

Basis of Presentation and Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the assumptions used in the allocation of revenue, estimates regarding the progress of completing performance obligations under collaboration agreements, and the valuation of stock-based compensation. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements.

(c)

Principles of Consolidation

The Company’s consolidated financial statements include the accounts of Schrödinger, Inc., its wholly owned subsidiaries, and its variable interest entity. All intercompany balances and transactions have been eliminated in consolidation. The functional currency for foreign entities is the United States dollar. The Company accounts for investments over which it has significant influence, but not a controlling financial interest, using the equity method.

(d)

Cash and Cash Equivalents and Marketable Securities and Restricted Cash

Included in cash and cash equivalents were cash equivalents of $90,477 and $185,614 as of December 31, 2021 and 2020, respectively, which consisted of money market funds and certificates of deposit, and are stated at cost, which approximates market value. The Company classifies all highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company classifies all marketable securities, which consist of fixed income securities, as available for sale securities.

At times, cash balances held at financial institutions were in excess of the Federal Deposit Insurance Corporation’s insured limits; however, the Company primarily places its cash with high-credit quality financial institutions.

Restricted cash consists of letters of credit held with the Company’s financial institution related to facility leases and is classified as current in the Company’s balance sheets based on the maturity of the underlying letters of credit.

F-12

Table of Contents

(e)

Accounts Receivable

Accounts receivable are stated at original invoice amount less an allowance for doubtful accounts. Management estimates the allowance for doubtful accounts by evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Account balances are considered delinquent if payment is not received by the due date. Accounts receivable are written off when deemed uncollectible. Recovery of accounts receivable previously written off is recorded when received. Changes in the balance of accounts deemed uncollectible were deemed immaterial as of December 31, 2021 and 2020. Interest is not charged on accounts receivable.

(f)

Fair Value of Financial Instruments

The carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities.

(g)

Property and Equipment

Property and equipment are stated at cost. The Company did not capitalize any interest during 2021 and 2020. Maintenance and repairs are expensed as incurred.

Depreciation is calculated using the straight‑line method over the estimated useful lives of the assets, which range from 3 to 7 years. Amortization of leasehold improvements is calculated using the straight‑line method over the remaining life of the lease or the useful life of the asset, whichever is shorter.

Property and equipment are reviewed for impairment as discussed below under Accounting for the Impairment of Long‑Lived Assets.

(h)

Accounting for the Impairment of Long‑Lived Assets

Long-lived assets, such as property and equipment subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that carrying value exceeds fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, depending on the nature of the asset. No impairment was identified for the years ended December 31, 2021, 2020, and 2019.

(i)

Warranties

The Company typically warrants that its products will perform in a manner consistent with the product specifications provided to the customer for a period of 30 days. Historically, the Company has not been required to make payments under these obligations. Therefore, no liabilities for such obligations are presented in the consolidated financial statements.

(j)

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade receivables.

The Company does not require customers to provide collateral to support accounts receivable. If deemed necessary, credit reviews of significant new customers may be performed prior to extending credit. The determination of a customer’s ability to pay requires judgment, and failure to collect from a customer can adversely affect revenue, cash flows, and results of operations.

F-13

Table of Contents

As of December 31, 2021, three customers accounted for 17%, 15%, and 11% of total accounts receivable, respectively. As of December 31, 2020, two customers accounted for 17% and 14% of total accounts receivable, respectively. For the year ended December 31, 2021, one customer accounted for 14% of total revenues. For the year ended December 31, 2020, no customer accounted for more than 10% of total revenues. For the year ended December 31, 2019, one customer accounted for 12% of total revenues.

(k)

Royalties

Royalties represent a component of cost of revenues and consist of royalties paid to owners of intellectual property used in or bundled with the Company’s software. Generally, royalties are incurred and recorded at the time a customer enters into a binding purchase agreement, although some royalty agreements are based instead on cash collections. Royalty expense was $9,826, $7,663, and $7,352 for the years ended December 31, 2021, 2020, and 2019, respectively.

(l)

Software Development Costs

Costs to develop new software products and substantial enhancements to existing software products are expensed as incurred. Historically, the Company has not capitalized any software development costs because the software development process was essentially completed concurrent with the establishment of technological feasibility.

(m)

Research and Development and Advertising

Research and development and advertising costs are expensed as incurred. The Company did not incur any significant advertising costs in 2021, 2020, or 2019.

(n)

Stock‑Based Compensation

The Company calculates stock‑based compensation expense utilizing fair value–based methodologies and recognizes expense over the vesting period of such awards.

(o)

Commissions

Commissions represent a component of sales and marketing expense and consist of the variable compensation paid to the Company’s sales representatives. Generally, sales commissions are earned and recorded as expense at the time that a customer has entered into a binding purchase agreement. Commissions paid to sales representatives are recoverable only in the case that the Company cannot collect against any invoiced fee associated with a sales order. Commission expense was $1,829, $1,362, and $754 in 2021, 2020, and 2019, respectively.

(p)

Income Taxes

The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of the assets and liabilities. Deferred tax assets are reduced by a valuation allowance when it is estimated to become more likely than not that a portion of the deferred tax assets will not be realized. Accordingly, the Company currently maintains a full valuation allowance against existing net deferred tax assets.

The Company recognizes the effect of income tax positions only if such positions are deemed “more likely than not” capable of being sustained. Interest and penalties accrued on unrecognized tax benefits are included within income tax expense in the consolidated financial statements.

(q)

Comprehensive Loss

Comprehensive loss includes net loss and changes in equity related to changes in unrealized gains or losses on marketable securities.

F-14

Table of Contents

(r)

Equity Investments

In the normal course of business, the Company has entered, and may continue to enter, into collaboration agreements with private companies to perform drug design services for such companies in exchange for equity ownership stakes in such companies. If it is determined that the Company has control over the investee, the investee is consolidated in the financial statements. If the investee is consolidated with the Company and less than 100% of the equity is owned by the Company, the Company will present non-controlling interest to represent the portion of the investee owned by other investors. If it is determined that the Company does not have control over the investee, the Company evaluates the investment for the ability to exercise significant influence.

Equity investments over which the Company has significant influence may be accounted for under equity method accounting in accordance with ASC Topic 323, Equity Method and Joint Ventures. If it is determined that the Company does not have significant influence over the investee, and there is no readily determinable fair value for the investment, the equity investment may be accounted for at cost minus impairment in accordance with ASC Topic 321, Equity Securities.

For further information regarding the Company’s equity investments, see Note 5, Fair Value Measurements, Note 10, Noncontrolling Interest, and Note 12, Equity Investments.

(s)

Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders

The outstanding equity of the Company consists of common stock and limited common stock. Under the Company’s certificate of incorporation, the rights of the holders of common stock and limited common stock are identical, except with respect to voting and conversion. Holders of limited common stock are precluded from voting such shares in any election of directors or on the removal of directors. Limited common stock may be converted into common stock at any time at the option of the stockholder.

Undistributed earnings allocated to the participating securities are subtracted from net income in determining net (loss) income attributable to common and limited common stockholders. Basic net (loss) income per share is computed by dividing net (loss) income attributable to common and limited common stockholders by the weighted-average number of shares of common and limited common stock outstanding during the period.

For the calculation of diluted net income, net income attributable to common and limited common stockholders for basic net income is adjusted by the effect of dilutive securities, including awards under the Company’s equity compensation plans. Diluted net income per share attributable to common and limited common stockholders is computed by dividing the resulting net income attributable to common and limited common stockholders by the weighted-average number of fully diluted shares of common and limited common stock outstanding.

(3)

Revenue Recognition

Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for promised goods or services. The Company’s performance obligations are satisfied either over time or at a point in time.

The following table illustrates the timing of the Company’s revenue recognition:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Software products and services – point in time

 

 

55.5

%

 

 

55.0

%

 

 

49.9

%

Software products and services – over time

 

 

26.6

 

 

 

30.6

 

 

 

28.1

 

Drug Discovery – point in time

 

 

3.3

 

 

 

6.7

 

 

 

8.6

 

Drug Discovery – over time

 

 

14.6

 

 

 

7.7

 

 

 

13.4

 

F-15

Table of Contents

 

(a)

Software

The Company enters into contracts that can include various combinations of licenses, products and services, some of which are distinct and are accounted for as separate performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price of the contract to each performance obligation on a relative standalone selling price (“SSP”) basis. Revenue is recognized net of any sale and value-added taxes collected from customers and subsequently remitted to governmental authorities.

The Company’s software business derives revenue from five sources: (i) on-premise software license fees, (ii) hosted software subscription fees, (iii) software maintenance fees, (iv) professional services fees, and (v) contributions.

On-premise software. The Company’s on-premise software license arrangements grant customers the right to use its software on their own in-house servers or their own cloud instances for a specified term, typically for one year. The Company recognizes revenue for on-premise software license fees upfront, either upon delivery of the license or the effective date of the agreement, whichever is later. In instances where the timing of delivery differs from the timing of invoicing, the Company considers whether a significant financing component exists. The Company has elected the practical expedient to not assess for significant financing where the term is less than one year. The Company’s updates and upgrades are not integral to maintaining the utility of the software licenses. Payments typically are received upfront or annually.

Hosted software. Hosted software revenue consists primarily of fees to provide the Company’s customers with hosted licenses, which allows these customers to access the Company’s cloud-based software solution on their own hardware without taking control of licenses.  Hosted software is recognized ratably over the term of the arrangement.

Software maintenance. Software maintenance includes technical support, updates, and upgrades. Software maintenance revenue is considered to be a separate performance obligation and is recognized ratably over the term of the arrangement.

Professional services. Professional services, such as training, technical support, installation, or assisting customers with modeling, generally are not related to the core functionality of the Company’s software and are recognized as revenue when resources are consumed. The Company has historically estimated project status with relative accuracy, although a number of internal and external factors can affect such estimates, including labor rates, utilization and efficiency variances. Payments for services are due in advance or upon consumption of resources.

F-16

Table of Contents

Software contribution revenue. Software contribution revenue consists of funds received under a non-reciprocal agreement with Gates Ventures, LLC.  The agreement is an unconditional non-exchange contribution without restrictions and the initial contribution was invoiced upon execution of the agreement.  Revenue was recognized upon execution of the agreement and on the first anniversary of the agreement when invoiced in accordance with ASC Topic 958, Not-for-Profit Entities as the agreement is not an exchange transaction.

The agreement with Gates Ventures, LLC covers the period from June 23, 2020 through June 22, 2023 for total consideration of up to $3,000. The Company received $1,000 in connection with its entry into the agreement in the second quarter of 2020, and $1,000 in the second quarter of 2021 on the first anniversary of its entry into the agreement. The Company is also entitled to receive an additional $1,000 payment on or around the second anniversary of the agreement, subject to the Company providing certain progress reports to the Trustees of Columbia University in the City of New York. As of December 31, 2021, the Company had no deferred revenue balance related to this agreement.

The following table presents the revenue recognized from the sources of software products and services revenue:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

On-premise software

 

$

74,598

 

 

$

58,311

 

 

$

42,647

 

Hosted software

 

 

11,076

 

 

 

9,192

 

 

 

7,418

 

Software maintenance

 

 

17,294

 

 

 

14,465

 

 

 

11,643

 

Professional services

 

 

9,268

 

 

 

9,562

 

 

 

5,027

 

Revenue from contracts with customers

 

 

112,236

 

 

 

91,530

 

 

 

66,735

 

Software contribution

 

 

1,000

 

 

 

1,000

 

 

 

—

 

Total software revenue

 

$

113,236

 

 

$

92,530

 

 

$

66,735

 

(b)

Drug Discovery

Drug discovery services. Revenue from drug discovery and collaboration services contracts is recognized either over time, typically by using costs incurred or hours expended to measure progress, or at a point in time based on the achievement of milestones. Payments for services are generally due upon achieving milestones stated in a contract, upfront at the start of a contract, or upon consumption of resources. Services may at times include variable consideration and milestone payments. The Company has estimated the amount of consideration that is variable using the most likely amount method. The Company evaluates milestones on a case-by-case basis, including whether there are factors outside the Company’s control that could result in a significant reversal of revenue, and the likelihood and magnitude of a potential reversal. If achievement of a milestone is not considered probable, the Company constrains (reduces) variable consideration to exclude the milestone payment until it is probable to be achieved. As of December 31, 2021, 2020, and 2019, milestones not yet achieved that were determined to be probable of achievement totaled $2,250, $250, and $1,500, respectively, and $2,250, $85, and $1,500 of those milestones were recognized as revenue for the years ended December 31, 2021, 2020, and 2019.

Drug discovery contribution revenue. Drug discovery contribution revenue consists of funds received under an agreement with Bill and Melinda Gates Foundation on a cost reimbursement basis, to perform services aimed at accelerating drug discovery in women’s health, which began in November 2021. Revenue is recognized as conditions are met in accordance with ASC Topic 958, Not-for-Profit Entities. As of December 31, 2021, there was a $1,129 deferred revenue balance related to this agreement.

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Drug discovery services revenue from contracts with customers

 

$

24,584

 

 

$

15,565

 

 

$

18,808

 

Drug discovery contribution

 

 

111

 

 

 

—

 

 

 

—

 

Total drug discovery revenue

 

$

24,695

 

 

$

15,565

 

 

$

18,808

 

F-17

Table of Contents

 

(c)

Collaboration and License Agreement

On November 22, 2020, the Company entered into an exclusive, worldwide collaboration and license agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company and BMS have agreed to collaborate in the discovery, research and preclinical development of new small molecule compounds for disease indications in oncology, neurology, and immunology therapeutics areas. The Company will be responsible, at its own cost and expense, for the discovery of small molecule compounds directed to five specified biological targets pursuant to a mutually agreed research plan for each such target. The initial targets included HIF-2 alpha and SOS1/KRAS, which were two of the Company’s internal programs. In November 2021, the Company and BMS mutually agreed to replace the HIF-2 alpha target with another precision oncology target. Following the replacement election, all rights to the HIF-2 alpha target program reverted to us. Once a development candidate meeting specified criteria for a target under the agreement has been identified by the Company, BMS will be solely responsible for the further development, manufacturing and commercialization of such development candidate at its own cost and expense.

Under the terms of the agreement, BMS paid the Company an initial upfront fee payment of $55,000. The Company also is entitled to receive up to $2,700,000 in total milestone payments across all potential targets, consisting of: a) up to $585,000 in milestone payments per oncology target, including $360,000 in the aggregate for the achievement of certain specified research, development, and regulatory milestones and $225,000 in the aggregate for the achievement of certain specified commercial milestones; and b) up to $482,000 in milestone payments per neurology and immunology target, including $257,000 in the aggregate for the achievement of certain specified research, development, and regulatory milestones and $225,000 in the aggregate for the achievement of certain specified commercial milestones.

The Company is also entitled to a tiered percentage royalty on annual net sales ranging from mid-single digits to low-double digits, subject to certain specified reductions. Royalties are payable by BMS on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country.

The Company assessed the collaboration and license agreement in accordance with ASC 606 and concluded that BMS is a customer based on the agreement structure. At inception, the Company identified one performance obligation for each of the five programs under the agreement, which includes research activities for each program and a license grant for the underlying intellectual property. The Company determined that the license grant for intellectual property is not separable from the research activities, as the research activities are expected to significantly modify or enhance the license grant over the period of service, and therefore are not distinct in the context of the contract.

The Company determined that the transaction price at the onset of the agreement is $55,000. Additional consideration to be paid to the Company upon the achievement of future milestone payments were excluded from the transaction price as they represent milestone payments that are not considered probable as of the inception date such that there is not a significant risk of revenue reversal.

The Company has allocated the transaction price of $55,000 to each performance obligation based on the SSP of each performance obligation at inception, which was determined based on each performance obligation’s estimated standalone selling price. The Company determined the estimated standalone selling price at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to perform the research activities included the length of time required, the internal hours expected to be incurred on the services and the number and costs of various studies that will be performed to complete the research plan.

Revenue associated with the research activities is recognized on a proportional performance basis over the period of service for research activities, using input-based measurements of total costs of research incurred to estimate the proportion performed. Progress towards completion is remeasured at the end of each reporting period.

F-18

Table of Contents

During the years ended December 31, 2021 and 2020, the Company recognized $13,749 and $988, respectively, associated with the agreement based on the research activities performed. As of December 31, 2021 and 2020, there was $40,263 and $54,012 of deferred revenue related to the agreement, which was classified as either current or non-current in the consolidated balance sheet based on the period the services are expected to be performed. There was no outstanding receivable for this collaboration as of December 31, 2021.

(d)

Significant Judgments

Significant judgments and estimates are required under ASC Topic 606. Due to the complexity of certain contracts, the actual revenue recognition treatment required under Topic 606 for the Company’s arrangements may be dependent on contract-specific terms and may vary in some instances.

The Company’s contracts with customers often include promises to transfer multiple software products and services, including training, professional services, technical support services, and rights to unspecified updates. Determining whether licenses and services are distinct performance obligations that should be accounted for separately, or are not distinct and therefore should be accounted for together, requires significant judgment. In some arrangements, such as most of the Company’s term-based software license arrangements, the Company has concluded that the licenses and associated services are distinct from each other. In other arrangements, including collaboration services arrangements, the licenses and certain services may not be distinct from each other. The Company’s time-based software arrangements may include multiple software licenses and a right to updates or upgrades to the licensed software products, and technical support. The Company has concluded that such promised goods and services are separate distinct performance obligations.

The Company is required to estimate the total consideration expected to be received from contracts with customers, including any variable consideration. Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is allocated to each separate performance obligation on a SSP basis.

Judgment is required to determine the SSP for each distinct performance obligation. The Company rarely licenses or sells products on a standalone basis, so the Company is required to estimate the range of SSPs for each performance obligation. In instances where the SSP is not directly observable because the Company does not sell the license, product, or service separately, the Company determines the SSP using information that includes historical discounting practices, market conditions, cost-plus analysis, and other observable inputs. The Company typically has more than one SSP for individual performance obligations due to the stratification of those items by classes of customers and circumstances. In these instances, the Company may use information such as the size and geographic region of the customer in determining the SSP. Professional service revenue is recognized as costs and hours are incurred, and judgment is required in estimating both the project status and the costs incurred or hours expended.

If a group of agreements are so closely related to each other that they are, in effect, part of a single arrangement, such agreements are deemed to be one arrangement for revenue recognition purposes. The Company exercises significant judgment to evaluate the relevant facts and circumstances in determining whether the separate agreements should be accounted for separately or as, in substance, a single arrangement. The Company’s judgments about whether a group of contracts comprises a single arrangement can affect the allocation of consideration to the distinct performance obligations, which could have an effect on results of operations for the periods involved.

Judgment is required to determine the total costs to perform research activities, which include the length of time required, the internal hours expected to be incurred on the services, and the number and costs of various studies that may be performed by third-parties to complete the research plan.

Generally, the Company has not experienced significant returns or refunds to customers.

The Company’s estimates related to revenue recognition require significant judgment and a change in these estimates could have an effect on the Company’s results of operations during the periods involved.

F-19

Table of Contents

(e)

Contract Balances

The timing of revenue recognition may differ from the timing of invoicing to customers and these timing differences result in receivables, contract assets, or contract liabilities (deferred revenue) on the consolidated balance sheets. The Company records a contract asset when revenue is recognized prior to invoicing. A deferred revenue liability is recorded when revenue is expected to be recognized subsequent to invoicing. For the Company’s time-based software agreements, customers are generally invoiced at the beginning of the arrangement for the entire term, though when the term spans multiple years the customers may be invoiced on an annual basis. For certain drug discovery agreements where the milestones are deemed probable in a period prior to when the milestone is achieved, the Company records a contract asset for the full value of the milestone.

Contract assets are included in unbilled and other receivables within the consolidated balance sheets and are transferred to receivables when the Company invoices the customer.

Contract balances were as follows:

 

 

As of

December 31,

 

 

As of

December 31,

 

 

 

2021

 

 

2020

 

Contract assets

 

$

8,271

 

 

$

3,589

 

Deferred revenue, short-term:

 

 

 

 

 

 

 

 

Software products and services

 

 

32,945

 

 

 

28,218

 

Drug discovery

 

 

22,423

 

 

 

17,185

 

Deferred revenue, long-term:

 

 

 

 

 

 

 

 

Software products and services

 

 

3,938

 

 

 

1,976

 

Drug discovery

 

 

26,126

 

 

 

39,188

 

For the years ended December 31, 2021 and 2020, respectively, the Company recognized $42,127 and $24,921 of revenue that was included in deferred revenue at the end of the preceding period. All other deferred revenue activity is due to the timing of invoices in relation to the timing of revenue, as described above. The Company expects to recognize as revenue approximately 65% of its December 31, 2021 deferred revenue balance in the next 12 months and the remainder thereafter. Additionally, contracted but unsatisfied performance obligations that had not yet been billed to the customer or included in deferred revenue were $26,694 as of December 31, 2021.

Payment terms and conditions vary by contract type, although terms typically require payment within 30 to 60 days. In instances where the timing of revenue recognition differs from that of invoicing, the Company has determined that its contracts generally do not include a significant financing component. The primary purpose of invoicing terms is to provide customers with simplified and predictable ways of purchasing the Company’s products and services, not to facilitate financing arrangements.

(f)

Deferred Sales Commissions

The Company has applied the practical expedient for sales commission expense, as any material compensation paid to sales representatives to obtain a contract relates to a period of one year or less. Therefore, the Company has not capitalized any costs related to sales commissions.

(4)

Property and Equipment

Property and equipment consisted of the following:

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

Computers and equipment

 

$

16,059

 

 

$

12,718

 

Leasehold improvements

 

 

2,276

 

 

 

4,385

 

Furniture and fixtures

 

 

4,045

 

 

 

1,839

 

 

 

 

22,380

 

 

 

18,942

 

Less accumulated depreciation

 

 

(12,355

)

 

 

(13,802

)

 

 

$

10,025

 

 

$

5,140

 

F-20

Table of Contents

 

Depreciation expense for 2021, 2020, and 2019 was $2,847, $3,658, and $3,625, respectively, and is included within cost of revenues and research and development, sales and marketing, and general and administrative expenses within the consolidated statements of operations.

(5)

Fair Value Measurements

Various inputs are used in determining the fair value of the Company’s financial assets and liabilities. These inputs are summarized into the following three broad categories:

Level 1 – quoted prices in active markets for identical securities

Level 2 – other significant observable inputs, including quoted prices for similar securities, interest rates, credit risk, etc.

Level 3 – significant unobservable inputs, including the Company’s own assumptions in determining fair value

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. Marketable securities, which consist primarily of corporate and U.S. government agency bonds, are classified as available for sale and fair value does not differ significantly from carrying value as of December 31, 2021 and 2020. The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2021:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities

 

$

—

 

 

$

456,212

 

 

$

—

 

 

$

456,212

 

Equity investments

 

 

39,561

 

 

 

—

 

 

 

1,887

 

 

 

41,448

 

Total

 

$

39,561

 

 

$

456,212

 

 

$

1,887

 

 

$

497,660

 

The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2020:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities

 

$

—

 

 

$

440,395

 

 

$

—

 

 

$

440,395

 

Equity investments

 

 

45,570

 

 

 

—

 

 

 

—

 

 

 

45,570

 

Total

 

$

45,570

 

 

$

440,395

 

 

$

—

 

 

$

485,965

 

Fair value of the Company’s investments in Nimbus Therapeutics, LLC (“Nimbus”) and ShouTi Inc. (“ShouTi”), classified as Level 3 in the fair value hierarchy, was determined under the hypothetical liquidated book value method (“HLBV method”), as further described in Note 12, Equity Investments. Significant unobservable inputs used under the HLBV method include Nimbus’ and ShouTi’s annual financial statements and the Company’s respective liquidation priorities. The following table sets forth changes in fair value of the Company’s Level 3 investments:

 

 

 

Amount

 

As of December 31, 2019

 

$

108

 

Cash contributions

 

 

2,869

 

Unrealized loss

 

 

(2,977

)

As of December 31, 2020

 

 

-

 

Cash contributions

 

 

2,000

 

Unrealized loss

 

 

(113

)

As of December 31, 2021

 

$

1,887

 

F-21

Table of Contents

Unrealized gains and losses arising from changes in fair value of the Company’s equity investments are classified within change in fair value in the consolidated statements of operations. During the years ended December 31, 2021 and 2020, there were no transfers between Level 1, Level 2 and Level 3 investments. See Note 12, Equity Investments, for further information.

(6)

Commitments and Contingencies

(a)

Leases

The Company leases office space under operating leases that expire at various dates through 2037. The Company has elected the package of practical expedients under the transition guidance of ASC Topic 842, Leases, to exclude short-term leases from the balance sheet and to combine lease and non-lease components.

Upon inception of a lease, the Company determines if an arrangement is a lease, if it includes options to extend or terminate the lease, and if it is reasonably certain that the Company will exercise the options. Lease cost, representing lease payments over the term of the lease and any capitalizable direct costs less any incentives received, is recognized on a straight-line basis over the lease term as lease expense.

In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date if the rate implicit in the lease is not readily determinable. Upon execution of a new lease, the Company performs an analysis to determine its incremental borrowing rate using its current borrowing rate, adjusted for various factors including level of collateralization and lease term. As of December 31, 2021, the remaining weighted average lease term was 15 years.

During the year ended December 31, 2021, the accounting commencement began for two new leases, which increased the right-of-use (“ROU”) assets and lease liabilities by $71,054. ROU assets and lease liabilities were equal as no lease costs or incentives were associated with acquiring the leases.

On November 1, 2021, the Company entered into an office lease agreement for 16,727 square feet of office space located at One Main Street, Cambridge, Massachusetts. Under the terms of the agreement, the Company will pay base rent of approximately $135 per month with a 3% annual rental escalation. The Company estimates that the lease commencement date will occur during the three months ending June 30, 2022 and continue to the end of the lease, which is 10 years after commencement.

On November 30, 2021, the Company entered into an office lease agreement for 19,753 square feet of office space located at Salarpuria Sattva, Knowledge City, Hyderabad, India. Under the terms of the agreement, the Company will pay base rent of approximately $20 per month from commencement to handover date and $29 per month from handover date to termination of the lease. The Company estimates that the lease handover and commencement dates will occur during the three months ending March 31, 2022 and continue to the end of the lease in June 2023.

Variable and short-term lease costs were immaterial for the year ended December 31, 2021. Additional details of the Company’s operating leases are presented in the following table:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Operating lease costs

 

$

7,627

 

 

$

5,895

 

 

$

5,181

 

Cash paid for operating leases

 

 

4,561

 

 

 

6,050

 

 

 

5,108

 

 

F-22

Table of Contents

 

Maturities of operating lease liabilities as of December 31, 2021 under noncancelable operating leases were as follows:

 

Year ending December 31:

 

 

 

 

2022

 

$

2,087

 

2023

 

 

8,809

 

2024

 

 

9,632

 

2025

 

 

9,241

 

2026

 

 

8,758

 

Thereafter

 

 

93,656

 

Total future minimum lease payments

 

 

132,183

 

Less: imputed interest

 

 

(52,314

)

Present value of future minimum lease payments

 

 

79,869

 

Less: current portion of operating leases payments

 

 

(2,042

)

Lease liabilities, long-term

 

$

77,827

 

(b)

Legal Matters

From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. While the results of such litigation cannot be predicted with certainty, management believes that the final outcome of such matters is not likely to have a material adverse effect on the Company’s financial position or results of operations or cash flows.

(7)

Income Taxes

Income tax expense is comprised of the following:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Current:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

—

 

 

$

—

 

 

$

583

 

State

 

 

67

 

 

 

178

 

 

 

(95

)

Foreign

 

 

344

 

 

 

167

 

 

 

(779

)

Current income tax expense (benefit)

 

 

411

 

 

 

345

 

 

 

(291

)

Deferred:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

 

—

 

 

 

—

 

 

 

—

 

State

 

 

—

 

 

 

—

 

 

 

—

 

Deferred income tax expense (benefit)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

$

411

 

 

$

345

 

 

$

(291

)

Components of loss before income taxes by tax jurisdiction were as follows:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

United States

 

$

(101,341

)

 

$

(24,567

)

 

$

(25,385

)

Foreign

 

 

1,359

 

 

 

449

 

 

 

523

 

Loss before income taxes

 

$

(99,982

)

 

$

(24,118

)

 

$

(24,862

)

Reconciliation of income tax expense at the applicable statutory income tax rates to the effective income tax rate is as follows:

F-23

Table of Contents

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Statutory federal income tax rate

 

 

21.0

%

 

 

21.0

%

 

 

21.0

%

State taxes, net of federal benefits

 

 

4.9

 

 

 

14.2

 

 

 

4.2

 

Withholding tax

 

 

—

 

 

 

—

 

 

 

(2.3

)

Section 162(m) limitation

 

 

(5.2

)

 

 

(12.8

)

 

 

—

 

Stock compensation

 

 

12.4

 

 

 

68.5

 

 

 

0.2

 

Return-to-provision adjustments

 

 

(1.7

)

 

 

(1.3

)

 

 

3.2

 

Research and development credit

 

 

6.3

 

 

 

6.2

 

 

 

5.2

 

Tax contingencies, net of reversals

 

 

(0.7

)

 

 

(0.6

)

 

 

(0.5

)

Change in valuation allowance

 

 

(37.2

)

 

 

(95.0

)

 

 

(31.3

)

Other

 

 

(0.2

)

 

 

(1.6

)

 

 

(0.6

)

Effective income tax rate

 

 

(0.4

)%

 

 

(1.4

)%

 

 

(0.9

)%

The income tax expense for the years ended December 31, 2021 and December 31, 2020 primarily related to state taxes and taxes in foreign jurisdictions. Income tax benefit for the year ended December 31, 2019 primarily related to alternative minimum tax credits previously utilized that are refundable under the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”).

The total change in valuation allowance for the year ended December 31, 2021 was $37,149, which primarily was due to the generation of net operating losses.

Tax effects of temporary differences that give rise to significant portions of deferred income tax assets and deferred income tax liabilities were as follows:

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Deferred income tax assets:

 

 

 

 

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

67,985

 

 

$

51,498

 

 

$

26,119

 

Accrued expenses

 

 

10,309

 

 

 

7,918

 

 

 

6,164

 

Deferred Revenue

 

 

10,632

 

 

 

394

 

 

 

500

 

Lease Liabilities

 

 

18,773

 

 

 

2,165

 

 

 

433

 

Credits

 

 

14,559

 

 

 

8,752

 

 

 

7,468

 

Gross deferred tax assets

 

 

122,258

 

 

 

70,727

 

 

 

40,684

 

Less valuation allowance

 

 

(95,304

)

 

 

(58,155

)

 

 

(35,251

)

Net deferred tax assets

 

 

26,954

 

 

 

12,572

 

 

 

5,433

 

Deferred income tax liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain on equity investments

 

 

(8,545

)

 

 

(10,185

)

 

 

(1,984

)

Prepaid expenses

 

 

(969

)

 

 

(889

)

 

 

(441

)

Depreciation and amortization

 

 

(17,440

)

 

 

(1,498

)

 

 

(3,008

)

Net deferred income tax assets

 

$

—

 

 

$

—

 

 

$

—

 

As of December 31, 2021, the Company had federal and state net operating loss (“NOL”) carryforwards of $283,314 and $148,130, respectively. These carryforwards, with the exception of federal NOLs generated post 2017, will expire between 2022 and 2041 if not used by the Company to reduce income taxes payable in future periods. Utilization of post 2017 federal NOL carryforwards are limited to 80% of taxable income generated in a given year and carry forward indefinitely. As of December 31, 2021, the Company had federal and state research and development tax credit carryforwards of $15,459 and $977, respectively. These carryforwards will expire between 2022 and 2041 if not used by the Company to reduce income taxes payable in future periods.

Pursuant to Internal Revenue Code Sections 382 and 383, the utilization of NOLs and other tax attributes may be substantially limited due to cumulative changes in ownership greater than 50% that may have occurred or could occur during applicable testing periods. The Company has performed an analysis through March 31, 2021 and

F-24

Table of Contents

determined that such an ownership change has occurred. There was no material impact to the financial statements due to this ownership change.

The Company has not recognized a deferred tax liability for the undistributed earnings of its foreign operations as the Company considers these earnings to be indefinitely reinvested.

In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the 2017 Tax Act. With the enactment of the CARES Act, the Company has not recognized a quantitative or qualitative impact for the years ended December 31, 2021, 2020, and 2019.

The Company classifies interest and penalties related to unrecognized tax benefits within income tax expense in the consolidated statement of operations. Following is a reconciliation of total gross unrecognized tax benefits:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Balance, January 1

 

$

1,046

 

 

$

902

 

 

$

781

 

Additions for tax positions taken in prior years

 

 

282

 

 

 

25

 

 

 

24

 

Reductions for tax positions taken in prior years

 

 

(20

)

 

 

(16

)

 

 

(12

)

Additions for tax positions related to the current year

 

 

394

 

 

 

135

 

 

 

109

 

Balance, December 31

 

$

1,702

 

 

$

1,046

 

 

$

902

 

 

The Company does not anticipate any significant increases or decreases in its uncertain tax positions within the next 12 months.

The Company and its subsidiaries file U.S. federal income tax returns and various state, local and foreign income tax returns. As of December 31, 2021, the Company’s statutes of limitations are open for all federal and state years tax returns filed after the years ended December 31, 2016 and 2015, respectively. Net operating loss and credit carryforwards for all years are subject to examination and adjustments for the three years following the year in which the carryforwards are utilized. The Company is not currently under Internal Revenue Service or state examination.

(8)

Stockholders’ Equity (Deficit)

(a)

Common Stock

As of December 31, 2021, the Company had authorized 500,000,000 shares of common stock with a par value of $0.01 per share. Holders of common stock are entitled to one vote per share, to receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company’s preferred stock, if any.

Common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.

(b)

Limited Common Stock

As of December 31, 2021, the Company had authorized 100,000,000 shares of limited common stock with a par value of $0.01 per share.

F-25

Table of Contents

Holders of limited common stock are entitled to one vote per share, however, the holders of limited common stock shall not be entitled to vote such shares in any election of directors or on the removal of directors. Holders of limited common stock are entitled to receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company’s preferred stock, if any.  Holders of the Company’s limited common stock have the right to convert each share of limited common stock into one share of the Company’s common stock.

Limited common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the limited common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.

(c)

Preferred Stock

As of December 31, 2021, the Company had authorized 10,000,000 shares of undesignated preferred stock with a par value of $0.01 per share.  The Company’s board of directors has the discretion to determine the rights, preferences, privileges, and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges, and liquidation preferences, of each series of preferred stock.

(9)

Stock-Based Compensation

Stock Incentive Plans

As of December 31, 2021, the Company’s stock incentive plans included the 2010 Stock Plan (the “2010 Plan”), the 2020 Equity Incentive Plan (the “2020 Plan”), and the 2021 Inducement Equity Incentive Plan (the "2021 Plan”) (together, the “Plans”). The 2020 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to employees, directors, consultants or advisors.

The 2021 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to persons who were not previously an employee or director of the Company or who are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to such person’s entry into employment with the Company and in accordance with the requirements of the Nasdaq Stock Market Rule 5635(c)(4). Neither consultants nor advisors are eligible to participate in the 2021 Plan.

The 2010 Plan provided for the granting of incentive stock options and nonstatutory stock options to employees, directors, consultants, or advisors. As of the effective date of the 2020 Plan, no further awards will be made under the 2010 Plan. Any options or awards outstanding under the 2010 Plan remain outstanding and effective. Shares of common stock subject to outstanding awards granted under the 2010 Plan that expire, terminate, or are otherwise surrendered, cancelled, forfeited, or repurchased by the Company are available for issuance under the 2020 Plan.

Stock Options

Stock options must be granted at an exercise price not less than 100% of the fair market value per share at the grant date. The board of directors or compensation committee determines the exercise price of the Company’s stock options based on the closing price of the common stock as reported on the Nasdaq Global Select Market on the day of the grant. The maximum contractual term of options granted under the Plans is typically 10 years, options generally vest over four years with 25% of the shares underlying the option vesting at the end of the first year and the remaining vesting monthly over the following three years.

During 2021, 2020, and 2019, 1,120,981, 1,398,177, and 214,845 options under the Plans were exercised for total proceeds of $7,927, $4,183, and $549, respectively.

The fair value of each option award is determined on the date of grant using the Black Scholes Merton option-pricing model. The calculation of fair value includes several assumptions that require management’s judgment. The expected terms of options granted to employees during 2021, 2020, and 2019 were calculated using an average of historical exercises. Estimated volatility for 2021, 2020, and 2019 incorporates a calculated volatility derived from the historical closing prices of shares of common stock of similar entities whose share prices were publicly available

F-26

Table of Contents

for the expected term of the option. The risk-free interest rate is based on the U.S. Treasury constant maturities in effect at the time of grant for the expected term of the option. The Company accounts for forfeitures as they occur, as such, the Company does not estimate forfeitures at the time of grant.

As of December 31, 2021, there were 2,283,037 shares available for grant under the Plans. Following are the weighted average valuation assumptions used for options:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Valuation assumptions

 

 

 

 

 

 

 

 

 

 

 

 

Expected dividend yield

 

 

—

%

 

 

—

%

 

 

—

%

Expected volatility

 

 

59

%

 

 

60

%

 

 

57

%

Expected term (years)

 

 

4.66

 

 

 

4.49

 

 

 

6.05

 

Risk-free interest rate

 

 

0.71

%

 

 

1.46

%

 

 

2.33

%

 

The following table presents classification of stock-based compensation expense within the consolidated statements of operations:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cost of sales

 

$

3,858

 

 

$

1,384

 

 

$

376

 

Research and development

 

 

7,440

 

 

 

3,050

 

 

 

460

 

Sales and marketing

 

 

1,281

 

 

 

516

 

 

 

311

 

General and administrative

 

 

13,911

 

 

 

5,595

 

 

 

1,046

 

Total stock-based compensation

 

$

26,490

 

 

$

10,545

 

 

$

2,193

 

Stock option activity was as follows:

 

 

 

Number of

shares

 

 

Weighted

average

exercise

price

 

 

Weighted

average

remaining

contractual

term (years)

 

 

Aggregate

intrinsic

value

 

Beginning, January 1, 2021

 

 

7,257,460

 

 

$

12.14

 

 

 

 

 

 

 

 

 

Granted

 

 

1,696,327

 

 

93.13

 

 

 

 

 

 

 

 

 

Exercised

 

 

(1,120,981

)

 

 

7.00

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(149,346

)

 

 

41.47

 

 

 

 

 

 

 

 

 

Expired

 

 

(3,119

)

 

 

1.70

 

 

 

 

 

 

 

 

 

Balance, December 31, 2021

 

 

7,680,341

 

 

 

30.19

 

 

 

7.67

 

 

$

35,584

 

Exercisable, December 31, 2021

 

 

3,473,716

 

 

 

10.83

 

 

 

6.75

 

 

$

83,306

 

The weighted average grant date fair value per share of options granted during 2021, 2020, and 2019 was $45.07, $9.55, and $2.93, respectively. The intrinsic value of options exercised during 2021, 2020, and 2019 was $71,308, $87,946, and $546, respectively.

As of December 31, 2021, there was $78,355 of unrecognized compensation cost related to unvested stock options granted under the Plans, which is expected to be recognized over a weighted average period of 2.87 years. The fair value of shares vested during 2021, 2020, and 2019 was $19,080, $3,153, and $1,734, respectively.

(10)

Noncontrolling Interest

The Company reviews each legal entity formed by parties related to the Company to determine whether or not the Company has a variable interest in the entity and whether or not the entity would meet the definition of a variable interest entity (“VIE”) in accordance with ASC Topic 810, Consolidation. If the entity is a VIE, the

F-27

Table of Contents

Company assesses whether or not the Company is the primary beneficiary of that VIE based on a number of factors, including (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to any contractual agreements and (iii) which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines it is the primary beneficiary of a VIE, the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements at the time that determination is made. The Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs on a quarterly basis. If the Company were to determine that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, it would deconsolidate the VIE in the period that the determination is made.

If the Company determines it is the primary beneficiary of a VIE that meets the definition of a business, the Company measures the assets, liabilities and noncontrolling interests of the newly consolidated entity at fair value in accordance with ASC Topic 805, Business Combinations at the date the reporting entity first becomes the primary beneficiary.

In October 2018, Faxian Therapeutics, LLC (“Faxian”) was formed in the United States. In April 2019, upon consummation of the joint venture, the Company and WuXi AppTech ("WuXi"), each received a 50% equity interest in the entity in exchange for their contributions to the entity. The Company determined that Faxian was a VIE and concluded that it is the primary beneficiary of the VIE. As such, the Company has consolidated Faxian's results into the consolidated financial statements, and eliminated WuXi's ownership as a non-controlling interest.

(11)

Net Loss per Share Attributable to Common and Limited Common Stockholders

The following table presents the calculation of basic and diluted net loss per share attributable to common and limited common stockholders for the years presented (in thousands, except for share and per share data):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to Schrödinger common

   and limited common stockholders

 

$

(100,393

)

 

$

(24,463

)

 

$

(24,571

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used to compute net

   loss per share attributable to Schrödinger common

   and limited common stockholders, basic and diluted:

 

 

70,594,950

 

 

 

60,024,658

 

 

 

6,004,500

 

Net loss per share attributable to Schrödinger common

   and limited common stockholders, basic and diluted:

 

$

(1.42

)

 

$

(0.41

)

 

$

(4.09

)

 

Since the Company was in a loss position for all years presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Convertible preferred stock

 

 

—

 

 

 

—

 

 

 

42,734,884

 

Shares subject to outstanding common stock options

 

 

7,680,341

 

 

 

7,257,460

 

 

 

4,805,562

 

 

 

 

7,680,341

 

 

 

7,257,460

 

 

 

47,540,446

 

 

F-28

Table of Contents

 

(12)

Equity Investments

(a)

Nimbus

The Company provides collaboration services for Nimbus under the terms of a master services agreement executed on May 18, 2010, as amended. Collaboration agreements are separate from the transaction that resulted in equity ownership and related fees are paid in cash to the Company. As Nimbus is a limited liability company and the Company is not a passive investor due to its collaboration with Nimbus on a number of drug discovery targets, the Company's management determined that it has significant influence over the entity and therefore accounts for the investment as an equity method investment.

The Company has concluded that the carrying value of its equity investment in Nimbus should reflect its contractual rights to substantive profits. The Company further determined that the HLBV method for valuing contractual rights to substantive profits provides the best representation of its financial position in Nimbus.

The HLBV method is a balance sheet-oriented approach to equity method accounting. Under the HLBV method, the Company determines its share of earnings or losses by comparing its claim on the book value at the beginning and end of each reporting period. This claim is calculated as the amount that the Company would receive (or be obligated to pay) if the investee were to liquidate all of its assets at recorded amounts, determined as of the balance sheet date in accordance with U.S. GAAP, and distribute the resulting cash to creditors and investors in accordance with their respective priorities.

The carrying value of the Nimbus investment was zero as of December 31, 2021 and December 31, 2020. The Company has no obligation to fund Nimbus losses in excess of its initial investment. The Company reported losses of zero, $2,977, and $4,180 on the Nimbus investment during 2021, 2020, and 2019, respectively.

(b)

Morphic

The Company accounts for its investment in Morphic Holding, Inc. (“Morphic”) at fair value based on the share price of Morphic’s common stock at the measurement date.

During 2021, 2020, and 2019 the Company reported gains of $11,548, $13,685, and $14,102 on the Morphic investment, respectively. As of December 31, 2021 and December 31, 2020, the carrying value of the Company’s investment in Morphic was $39,561 and $28,013, respectively.

(c)

Petra

Prior to May 2020, the Company had concluded that its equity investment in Petra Pharma Corporation (“Petra”) should be valued as a non-marketable equity security as the Company did not exercise significant influence over Petra.

During May 2020, Petra entered into a merger agreement with a third party. In connection with the merger, the Company received $4,582 of merger consideration in exchange for the Company’s shares of Petra common stock and is eligible to receive potential earn-outs tied to the achievement of specified development, regulatory, and commercial milestones. The Company is also eligible to receive $361 in escrow payments. During 2021, the Company received escrow payments of $335.

(d)

Ravenna

In connection with the Petra merger, the Company received 2,676,191 shares of common stock of Ravenna Pharmaceuticals, Inc. (“Ravenna”). The Company concluded that its equity investment in Ravenna should be valued as a non-marketable equity security as the Company does not exercise significant influence over Ravenna. As of each of December 31, 2021 and December 31, 2020, the carrying value of the Company’s investment in Ravenna was $19 and $94, respectively. The Company reported losses of $75, zero, and zero on the Ravenna investment during 2021, 2020, and 2019, respectively.

F-29

Table of Contents

(e)

Relay

In July 2020, Relay successfully completed an initial public offering. The Company accounts for its investment in Relay at fair value based on the share price of Relay’s common stock at the measurement date. In January 2021, the Company disposed of its equity stake in Relay for aggregate consideration of $15,735, resulting in a loss of $1,821 for 2021. The Company reported a gain of $17,556 on the Relay investment for the year ended December 31, 2020. There was no gain or loss on the Relay investment for 2019, as Relay was not a public company during this period.

(f)

Ajax

In May 2021, the Company purchased 631,377 shares of Series B preferred stock of Ajax Therapeutics, Inc. (“Ajax”) for $1,700 in cash. The Company has concluded that its equity investment in Ajax should be valued as a non-marketable equity security as the Company does not exercise significant influence over Ajax. As of December 31, 2021 and December 31, 2020, the carrying value of the Company’s investment in Ajax was $1,700 and zero, respectively.

(g)

ShouTi

In July 2021, the Company purchased 494,035 shares of Series B preferred stock of ShouTi for $2,000 in cash. As ShouTi is structured as a company limited by shares, incorporated under the laws of the Cayman Islands and the Company is not a passive investor due to its collaboration with ShouTi on a number of drug discovery targets, the Company’s management determined that it has significant influence over the entity and therefore accounts for the investment as an equity method investment.

The Company has determined that the HLBV method for valuing contractual rights to substantive profits provides the best representation of its financial position in ShouTi. The carrying value of ShouTi was $1,887 and zero as of December 31, 2021 and December 31, 2020, respectively. The Company has no obligation to fund ShouTi losses in excess of its initial investment. The Company recorded a loss of $113 on the ShouTi investment during the year ended December 31, 2021.

(13)

Employee Benefit Plan

The Company offers a 401(k) employee savings plan to its U.S.‑based employees. The Company made discretionary matching contributions equal to 100% of the first 4.0% of compensation contributed by employees for the years ended December 31, 2021, 2020, and 2019. Matching contributions during 2021, 2020, and 2019 were $2,592, $1,748, and $1,492, respectively.

(14)

Related Party Transactions

(a)

D. E. Shaw

For the years ended December 31, 2021, 2020, and 2019, the Company licensed technology and purchased services for $7,940, $7,281, and $5,190, respectively, from companies controlled by David E. Shaw and/or affiliates of companies controlled by David E. Shaw (the “D. E. Shaw entities”), stockholders of the Company. In addition, D. E. Shaw entities purchased certain products and services from, and provided cost reimbursements to, the Company totaling $318, $226, and $195 for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021 and 2020, the Company had net payables of $2,637 and $3,464, respectively, to D.E. Shaw entities.

(b)

Board Member

For the years ended December 31, 2021, 2020, and 2019, the Company paid consulting fees of $390, $364, and $361, respectively, to a member of its board of directors.

F-30

Table of Contents

(c)

Bill and Melinda Gates Foundation

For the years ended December 31, 2021, 2020, and 2019, the Bill & Melinda Gates Foundation, an entity under common control with Bill and Melinda Gates Foundation Trust, a stockholder of the Company, issued a grant under which it agreed to pay the Company directly for certain licenses and services provided to a specified group of third-party organizations. Revenue recognized for services provided by the Company under this grant were $1,160, $2,094, and $1,065 for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021 and 2020, the Company had net receivables of $165 and $543, respectively, due from the Bill & Melinda Gates Foundation.

In the fourth quarter of 2021, the Company recognized $111 in drug discovery contribution revenue related to funds received under an agreement with the Bill & Melinda Gates Foundation, aimed at accelerating drug discovery in women’s health. As of December 31, 2021, the Company had no receivables due under this agreement from the Bill & Melinda Gates Foundation.

The Company received $1,000 in contribution revenue in connection with its entry into an agreement with Gates Ventures, LLC in the second quarter of 2020, and $1,000 in contribution revenue in the second quarter of 2021 on the first anniversary of its entry into the agreement. Gates Ventures, LLC is an entity under control of William H. Gates III, who may be deemed to be the beneficial owner of more than 5% of the Company’s voting securities. As of December 31, 2021 and 2020, the Company had no net receivables due from Gates Ventures, LLC.

(d)

ShouTi

During the year ended December 31, 2021, the Company entered into multiple software agreements with ShouTi and its subsidiary for approximately $650. The Company recognized revenue of approximately $129 in the aggregate related to these agreements during the year ended December 31, 2021.

(15)

Segment Reporting

The Company has determined that its chief executive officer (“CEO”) is its chief operating decision maker (“CODM”). The Company’s CEO evaluates the financial performance of the Company based on two reportable segments: Software and Drug Discovery. The Software segment is focused on licensing the Company’s software to transform molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. 

The CODM reviews segment performance and allocates resources based upon segment revenue and segment gross profit of the Software and Drug Discovery reportable segments.  Segment gross profit is derived by deducting operational expenditures, with the exception of research and development, sales and marketing, and general and administrative activities from U.S. GAAP revenue. Operational expenditures are expenditures made that are directly attributable to the reportable segment. These expenditures are allocated to the segments based on headcount. The reportable segment expenditures include compensation, supplies, and services from contract research organizations.

Certain cost items are not allocated to the Company’s reportable segments. These cost items primarily consist of compensation and general operational expenses associated with the Company’s research and development, sales and marketing, and general and administrative.  These costs are incurred by both segments and due to the integrated nature of the Company’s Software and Drug Discovery segments, any allocation methodology would be arbitrary and provide no meaningful analysis.

F-31

Table of Contents

All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is financial information with respect to the Company’s reportable segments for the periods presented:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Segment revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Software

 

$

113,236

 

 

$

92,530

 

 

$

66,735

 

Drug discovery

 

 

24,695

 

 

 

15,565

 

 

 

18,808

 

Total segment revenues

 

$

137,931

 

 

$

108,095

 

 

$

85,543

 

Segment gross profit:

 

 

 

 

 

 

 

 

 

 

 

 

Software

 

$

86,741

 

 

$

74,527

 

 

$

53,089

 

Drug discovery

 

 

(21,121

)

 

 

(11,055

)

 

 

(3,996

)

Total segment gross profit

 

 

65,620

 

 

 

63,472

 

 

 

49,093

 

Unallocated:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

(90,904

)

 

 

(64,695

)

 

 

(39,404

)

Sales and marketing

 

 

(22,150

)

 

 

(17,795

)

 

 

(21,364

)

General and administrative

 

 

(64,009

)

 

 

(41,898

)

 

 

(27,040

)

(Loss) gain on equity investments

 

 

(1,781

)

 

 

4,108

 

 

 

943

 

Change in fair value

 

 

11,359

 

 

 

28,263

 

 

 

9,922

 

Interest income

 

 

1,057

 

 

 

2,253

 

 

 

1,878

 

Income tax (expense) benefit

 

 

(411

)

 

 

(345

)

 

 

291

 

Consolidated net loss

 

$

(101,219

)

 

$

(26,637

)

 

$

(25,681

)

The following table sets forth revenues by geographic area for the years ended December 31, 2021, 2020, and 2019:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

United States

 

$

90,398

 

 

$

60,737

 

 

$

47,622

 

Europe

 

 

27,810

 

 

 

24,370

 

 

 

17,504

 

Japan

 

 

8,565

 

 

 

14,558

 

 

 

14,367

 

Rest of World

 

 

11,158

 

 

 

8,430

 

 

 

6,050

 

 

 

$

137,931

 

 

$

108,095

 

 

$

85,543

 

 

(16)

Subsequent Events

On January 14, 2022, we acquired 117,840 shares of XTAL BioStructures, Inc. for $6.5 million, a company that provides structural biology services, including biophysical methods, protein production and purification, and X-ray crystallography, which includes $6.0 million in upfront purchase price, plus an adjustment for working capital, less cash acquired.

 

F-32

Table of Contents

 

Item 9. Changes in and Disagreements With Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our principal executive officer and principal financial officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of December 31, 2021. The term “disclosure controls and procedures,” means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on such evaluation of our disclosure controls and procedures as of December 31, 2021, our principal executive officer and principal financial officer have concluded that as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

Management’s Annual Report on Internal Control Over Financial Reporting and Attestation Report of Registered Public Accounting Firm

Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act). Our internal control over financial reporting is a process designed under the supervision of our principal executive officer and principal financial officer, and effected by our board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Management assessed our internal control over financial reporting as of December 31, 2021. Management based its assessment on criteria established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 Framework). Based on the results of its evaluation, management concluded that our internal control over financial reporting was effective as of December 31, 2021. Our independent registered public accounting firm, KPMG, LLP, has issued an attestation report on the effectiveness of our internal control over financial reporting, which is included in Item 8 of this Annual Report.

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the fourth quarter of 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Inherent Limitations on Effectiveness of Controls

Our management, including our principal executive officer and principal financial officer, do not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two

113

 

Table of Contents

or more people or by management override of the controls. The design of any system of controls is also based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions, over time, controls may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

Item 9B. Other Information

None.

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not Applicable.

114

 

Table of Contents

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

The information required by this Item 10 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2022 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December 31, 2021 pursuant to General Instruction G(3) of Form 10-K.

We have adopted a written code of business conduct and ethics that applies to our directors, officers, and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We have posted a current copy of the code on our website, www.schrodinger.com. In addition, we intend to post on our website all disclosures that are required by law or Nasdaq listing standards concerning any amendments to, or waivers from, any provision of the code. Our website is not incorporated by reference into this Annual Report and you should not consider any information contained in or accessible from our website to be a part of this Annual Report.

Item 11. Executive Compensation.

The information required by this Item 11 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2022 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December 31, 2021 pursuant to General Instruction G(3) of Form 10-K.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

The information required by this Item 12 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2022 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December 31, 2021 pursuant to General Instruction G(3) of Form 10-K.

The information required by this Item 13 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2022 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December 31, 2021 pursuant to General Instruction G(3) of Form 10-K.

Item 14. Principal Accountant Fees and Services.

The information required by this Item 14 is incorporated herein by reference from the information that will be contained in our proxy statement related to the 2022 Annual Meeting of Stockholders, which we intend to file with the Securities and Exchange Commission within 120 days of the end of our fiscal year ended December 31, 2021 pursuant to General Instruction G(3) of Form 10-K.

115

 

Table of Contents

PART IV

Item 15. Exhibits and Financial Statement Schedules.

 

(1)

Financial Statements

The following documents are included on pages F-2 through F-9 attached hereto and are filed as part of this Annual Report.

 

 

 

(2)

Financial Statement Schedules

All financial statement schedules have been omitted because they are not applicable, not required, or the information required is shown in the consolidated financial statements or the notes thereto.

 

(3)

Exhibits

The exhibits filed as part of this Annual Report are listed below.

 

Exhibit

Number

 

Description of Exhibit

 

 

Form

File No.

Exhibit

Filing Date

Filed Herewith

 

 

 

 

 

 

 

 

 

3.1

 

Restated Certificate of Incorporation

 

8-K

001-39206

3.1

2/10/2020

 

 

 

 

 

 

 

 

 

 

3.2

 

Amended and Restated Bylaws

 

8-K

001-39206

3.2

2/10/2020

 

 

 

 

 

 

 

 

 

 

4.1

 

Specimen Stock Certificate evidencing the shares of common stock

 

S-1/A

333-235890

4.1

1/27/2020

 

 

 

 

 

 

 

 

 

 

4.2

 

Amended and Restated Share Exchange Agreement, dated January 24, 2020, by and between the Registrant and Bill & Melinda Gates Foundation Trust

 

S-1/A

333-235890

4.2

1/27/2020

 

 

 

 

 

 

 

 

 

 

4.3

 

Description of Securities Registered Under Section 12 of the Exchange Act

 

10-K

001-39206

4.3

3/4/2021

 

 

 

 

 

 

 

 

 

 

10.1 

 

Amended and Restated Investors’ Rights Agreement, dated as of November 9, 2018, by and among the Registrant and the other parties thereto, as amended

 

S-1/A

333-235890

10.1

1/27/2020

 

 

 

 

 

 

 

 

 

 

10.2+

 

2010 Stock Plan, as amended

 

S-1

333-235890

10.2

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.3+

 

Form of Notice of Stock Option Grant and Stock Option Agreement under 2010 Stock Plan

 

S-1

333-235890

10.3

1/10/2020

 

116

 

Table of Contents

 

 

 

 

 

 

 

 

 

10.4+

 

2020 Equity Incentive Plan

 

S-1/A

333-235890

10.4

1/27/2020

 

 

 

 

 

 

 

 

 

 

10.5+

 

Form of Stock Option Agreement and Form of Restricted Stock Unit Agreement for U.S. Participants under the 2020 Equity Incentive Plan

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

10.6+

 

Form of Restricted Stock Unit Agreement for Non-U.S. Participants under the 2020 Equity Incentive Plan

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

10.7+

 

2020 Employee Stock Purchase Plan

 

S-1/A

333-235890

10.6

1/27/2020

 

 

 

 

 

 

 

 

 

 

10.8+

 

Second Amended and Restated Director Compensation Policy

 

10-K

001-39206

10.7

3/4/2021

 

 

 

 

 

 

 

 

 

 

10.9+

 

Senior Executive Incentive Compensation Plan

 

S-1

333-235890

10.8

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.10+

 

Amended and Restated Executive Severance and Change in Control Benefits Plan

 

10-Q

001-39206

10.3

8/12/2021

 

 

 

 

 

 

 

 

 

 

10.11+

 

Employment Agreement, dated May 11, 2010, by and between the Registrant and Ramy Farid

 

S-1

333-235890

10.10

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.12+

 

Employment Agreement, dated November 14, 2018, by and between the Registrant and Joel Lebowitz

 

S-1

333-235890

10.11

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.13+

 

Employment Agreement, dated May 14, 2018, by and between the Registrant and Karen Akinsanya

 

S-1

333-235890

10.14

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.14+

 

Employment Agreement, dated April 27, 2010, by and between the Registrant and Yvonne Tran

 

S-1

333-235890

10.16

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.15+

 

Employment Agreement, dated September 11, 2006, by and between the Registrant and Patrick Lorton

 

S-1

333-235890

10.17

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.16+

 

Employment Agreement, dated March 9, 2009, by and between the Registrant and Robert Abel

 

S-1

333-235890

10.19

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.17+

 

Consultant Agreement, dated July 1, 1999, between the Registrant and Richard A. Friesner, as amended

 

10-Q

001-39206

10.4

8/12/2021

 

 

 

 

 

 

 

 

 

 

10.18+

 

Form of Indemnification Agreement between the Registrant and each of its Executive Officers and Directors

 

S-1

333-235890

10.21

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.19

 

Office Lease Agreement, dated April 5, 2021, by and between the Registrant and SPUSV5 1540 Broadway, LLC

 

8-K

001-39206

10.1

4/8/2021

 

 

 

 

 

 

 

 

 

 

10.20

 

Lease, dated August  6, 2008, between One Main Place Portland – Oregon, Inc., Landlord, and Registrant, Tenant, as amended

 

S-1

333-235890

10.23

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.21

 

Office Lease Amendment, dated May 6, 2021, by and between Registrant and MADISON-OFC ONE MAIN PLACE OR LLC

 

10-Q

001-39206

10.2

8/12/2021

 

 

 

 

 

 

 

 

 

 

10.22†

 

Agreement, dated as of May  5, 1994, between The Trustees of Columbia University in the City of New York and Registrant, as amended

 

S-1

333-235890

10.24

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.23†

 

Agreement, dated as of July  15, 1998, between The Trustees of Columbia University in the City of New York and Registrant, as amended

 

S-1

333-235890

10.25

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.24†

 

Agreement, dated as of September 2001, between The Trustees of Columbia University in the City of New York and Schrödinger, LLC, as amended

 

S-1

333-235890

10.26

1/10/2020

 

117

 

Table of Contents

10.25†

 

Agreement, dated as of June  19, 2003, between The Trustees of Columbia University in the City of New York and Schrödinger, LLC

 

S-1

333-235890

10.27

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.26†

 

Software and Patent License Agreement, dated May  27, 2008, between The Trustees of Columbia University in the City of New York and Schrödinger, LLC

 

S-1

333-235890

10.28

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.27†

 

Services Royalty Amendment, dated November  1, 2008, by and between The Trustees of Columbia University in the City of New York and Schrödinger, LLC

 

S-1

333-235890

10.29

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.28†

 

Services Agreement, dated June  25, 2013, between D.E. Shaw India Software Private Limited and Schrödinger, LLC, as amended

 

S-1

333-235890

10.30

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.29†

 

License and Software Development Agreement, dated March 14, 2013, by and between D. E.  Shaw Research LLC and Schrödinger, LLC

 

S-1

333-235890

10.31

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.30†

 

Amended and Restated License and Software Development Agreement, dated May  20, 2014, by and between D. E. Shaw Research, LLC and Schrödinger, LLC

 

S-1

333-235890

10.32

1/10/2020

 

 

 

 

 

 

 

 

 

 

10.31+

 

Global Bonus Plan

 

S-1/A

333-235890

10.33

1/27/2020

 

 

 

 

 

 

 

 

 

 

10.32†

 

Independent Contractor Agreement, dated June 23, 2020, by and between the Registrant and Gates Ventures, LLC

 

10-Q

001-39206

10.2

8/10/2020

 

 

 

 

 

 

 

 

 

 

10.33

 

Stock Option Agreement for Non-U.S. Participants under the 2020 Equity Incentive Plan

 

10-Q

001-39206

10.2

11/12/2020

 

 

 

 

 

 

 

 

 

 

10.34†

 

Collaboration and License Agreement, dated November 22, 2020, by and between the Registrant and Bristol-Myers Squibb Company

 

10-K

001-39206

10.37

3/4/2021

 

 

 

 

 

 

 

 

 

 

10.35+

 

2021 Inducement Equity Incentive Plan

 

10-K

001-39206

10.38

3/4/2021

 

 

 

 

 

 

 

 

 

 

10.36+

 

Nonstatutory Stock Option Agreement under 2021 Inducement Equity Incentive Plan

 

10-K

001-39206

10.39

3/4/2021

 

 

 

 

 

 

 

 

 

 

10.37+

 

Restricted Stock Unit Agreement for U.S. Participants under 2021 Inducement Equity Incentive Plan

 

10-K

001-39206

10.40

3/4/2021

 

 

 

 

 

 

 

 

 

 

10.38+

 

Restricted Stock Unit Agreement for Non-U.S. Participants under 2021 Inducement Equity Incentive Plan

 

10-K

001-39206

10.41

3/4/2021

 

 

 

 

 

 

 

 

 

 

21.1

 

Subsidiaries of the Registrant

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

23.1

 

Consent of KPMG LLP, independent registered public accounting firm

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

31.1

 

Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

31.2

 

Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

32.1#

 

Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

X

118

 

Table of Contents

 

 

 

 

 

 

 

 

 

32.2#

 

Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

 

 

 

 

X

 

 

 

 

 

 

 

 

 

101.INS

 

Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

 

 

 

 

 

X

101.SCH

 

Inline XBRL Taxonomy Extension Schema Document.

 

 

 

 

 

X

101.CAL

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

 

 

 

 

 

X

101.DEF

 

Inline XBRL Taxonomy Extension Definition Linkbase Document.

 

 

 

 

 

X

101.LAB

 

Inline XBRL Taxonomy Extension Label Linkbase Document.

 

 

 

 

 

X

101.PRE

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

 

 

 

 

 

X

104

 

Cover page formatted as Inline XBRL and contained in Exhibit 101.

 

 

 

 

 

X

 

†

 

Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

 

 

 

 

 

 

#

 

The certifications attached as Exhibits 32.1 and 32.2 that accompany this Annual Report, are deemed furnished and not filed with the Securities and Exchange Commission and are not to be incorporated by reference into any filing of Schrödinger, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report, irrespective of any general incorporation language contained in such filing.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

+

 

Management contract or compensatory plan or arrangement filed in response to Item 15(a)(3) of the Instructions to the Annual Report on Form 10-K.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Item 16. Form 10-K Summary

None.

119

 

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

SCHRÖDINGER, INC.

 

 

 

 

Date:  February 24, 2022

 

By:

 /s/ Ramy Farid

 

 

 

 

 

 

 

Ramy Farid, Ph.D.

 

 

 

President and Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the Registrant in the capacities and on the dates indicated.

 

Name

 

Title

 

Date

 

 

 

 

 

/s/ Ramy Farid

 

President and Chief Executive Officer, Director

 

February 24, 2022

Ramy Farid, Ph.D.

 

(Principal Executive Officer)

 

 

 

 

 

 

 

/s/ Joel Lebowitz

 

Chief Financial Officer

 

February 24, 2022

Joel Lebowitz

 

(Principal Financial Officer)

 

 

 

 

 

 

 

/s/ Jenny Herman

 

Senior Vice President, Finance and Corporate Controller

 

February 24, 2022

Jenny Herman

 

(Principal Accounting Officer)

 

 

 

 

 

 

 

/s/ Michael Lynton

 

Chairman of the Board

 

February 24, 2022

Michael Lynton

 

 

 

 

 

 

 

 

 

/s/ Jeffrey Chodakewitz

 

Director

 

February 24, 2022

Jeffrey Chodakewitz, M.D.

 

 

 

 

 

 

 

 

 

/s/ Richard Friesner

 

Director

 

February 24, 2022

Richard Friesner, Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Gary Ginsberg

 

Director

 

February 24, 2022

Gary Ginsberg

 

 

 

 

 

 

 

 

 

/s/ Rosana Kapeller-Libermann

 

Director

 

February 24, 2022

Rosana Kapeller-Libermann, M.D., Ph.D.

 

 

 

 

 

 

 

 

 

/s/ Gary Sender

 

Director

 

February 24, 2022

Gary Sender

 

 

 

 

 

 

 

 

 

/s/ Nancy Thornberry

 

Director

 

February 24, 2022

Nancy Thornberry

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

120

 

 EX-10.5 2 sdgr-ex105_247.htm EX-10.5 sdgr-ex105_247.htm

Exhibit 10.5

Schrödinger, Inc.

STOCK OPTION AGREEMENT

Schrödinger, Inc. (the “Company”) hereby grants the following stock option pursuant to its 2020 Equity Incentive Plan. The terms and conditions attached hereto are also a part hereof.

Notice of Grant

 

 

 

 

Name of optionee (the “Participant”):

  

 

Grant Date:

  

 

Incentive Stock Option or Nonstatutory Stock Option:

  

 

Number of shares of the Company’s Common Stock subject to this option (“Shares”):

  

 

Option exercise price per Share:1

  

 

Number, if any, of Shares that vest immediately on the grant date:

  

 

Shares that are subject to vesting schedule:

  

 

Vesting Start Date:

  

 

Final Exercise Date: 2

  

 

Vesting Schedule:

 

 

 

 

Vesting Date:

  

Number of Options that Vest:

 

  

 

 

  

 

 

All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.

This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.

 

 

 

 

 

 

 

 

 

 

            

 

Schrödinger, Inc.

Signature of Participant

 

 

 

 

 

 

 

 

 

 

By:

 

 

Street Address

 

 

 

 

 

 

Name of Officer

Title:

City/State/Zip Code

 

 

 

 

 

1 

This must be at least 100% of the Grant Date Fair Market Value (as defined in the Plan) of the Common Stock on the date of grant (110% in the case of a Participant that owns more than 10% of the total combined voting power of all classes of stock of the Company or its parent or subsidiary (a “10% Shareholder”)) for the option to qualify as an incentive stock option (an “ISO”) under Section 422 of the Code.

 

2 

The Final Exercise Date must be no more than 10 years (5 years in the case of a 10% Shareholder) from the date of grant for the option to qualify as an ISO. The correct approach to calculate the final exercise date is to use the day immediately prior to the date ten years out from the date of the stock option award grant (5 years in the case of a 10% stockholder).

 

 


 

 

Schrödinger, Inc.

Stock Option Agreement

Incorporated Terms and Conditions

 

1.

Grant of Option.

This agreement evidences the grant by the Company, on the grant date (the “Grant Date”) set forth in the Notice of Grant that forms part of this agreement (the “Notice of Grant”), to the Participant of an option to purchase, in whole or in part, on the terms provided herein and in the Company’s 2020 Equity Incentive Plan (the “Plan”), the number of Shares set forth in the Notice of Grant of common stock, $0.01 par value per share, of the Company (“Common Stock”), at the exercise price per Share set forth in the Notice of Grant. Unless earlier terminated, this option shall expire at 5:00 p.m., Eastern time, on the Final Exercise Date set forth in the Notice of Grant (the “Final Exercise Date”).

The option evidenced by this agreement is intended to be an incentive stock option as defined in Section 422 of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”) to the maximum extent permitted by law, solely to the extent designated as an incentive stock option in the Notice of Grant. Except as otherwise indicated by the context, the term “Participant”, as used in this option, shall be deemed to include any person who acquires the right to exercise this option validly under its terms.

 

2.

Vesting Schedule.

This option will become exercisable (“vest”) in accordance with the vesting schedule set forth in the Notice of Grant.

The right of exercise shall be cumulative so that to the extent the option is not exercised in any period to the maximum extent permissible it shall continue to be exercisable, in whole or in part, with respect to all Shares for which it is vested until the earlier of the Final Exercise Date or the termination of this option under Section 3 hereof or the Plan.

 

3.

Exercise of Option.

(a) Form of Exercise. Each election to exercise this option shall be in writing, in the form of the Stock Option Exercise Notice attached as Annex A, signed by the Participant, and received by the Company at its principal office, accompanied by this agreement, or in such other form (which may be electronic or through a third party equity plan administrator) as is approved by the Company, together with payment in full in the manner provided in the Plan. The Participant may purchase less than the number of shares covered hereby, provided that no partial exercise of this option may be for any fractional share.

(b) Continuous Relationship with the Company Required. Except as otherwise provided in this Section 3, this option may not be exercised unless the Participant, at the time he or she exercises this option, is, and has been at all times since the Grant Date, an employee, director or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants, or advisors of which are eligible to receive option grants under the Plan (an “Eligible Participant”).

 

(c) Termination of Relationship with the Company. If the Participant ceases to be an Eligible Participant for any reason, then, except as provided in paragraphs (d) and (e) below, the right to exercise this option shall terminate three months after such cessation (but in no event after the Final Exercise Date), provided that this option shall be exercisable only to the extent that the Participant was entitled to exercise this option on the date of such cessation. Notwithstanding the foregoing, if the Participant, prior to the Final Exercise Date, violates the restrictive covenants (including, without limitation, the non-competition, non-solicitation, or confidentiality provisions) of any employment contract, any non-competition, non-solicitation, confidentiality or assignment agreement to which the Participant is a party, or any other agreement between the Participant and the Company, the right to exercise this option shall terminate immediately upon such violation.

(d) Exercise Period Upon Death or Disability. If the Participant dies or becomes disabled (within the meaning of Section 22(e)(3) of the Code) prior to the Final Exercise Date while he or she is an Eligible Participant and the Company has not terminated such relationship for “cause” as specified in paragraph (e) below, this option shall be exercisable, within the period of one year following the date of death or disability of the Participant, by the Participant (or in the case of death by an authorized transferee), provided that this option shall be exercisable only to the extent that this option was exercisable by the Participant on the date of his or her death or disability, and further provided that this option shall not be exercisable after the Final Exercise Date.

(e) Termination for Cause. If, prior to the Final Exercise Date, the Participant’s employment or other relationship with the Company is terminated by the Company for Cause (as defined in below), the right to exercise this option shall terminate immediately upon the effective date of such termination of employment or other relationship. If, prior to the Final Exercise Date, the Participant is given notice by the Company of the termination of his or her employment or other relationship by the Company for Cause, and the effective date of such employment or other relationship termination is subsequent to the date of delivery of such notice, the right to exercise this option shall be suspended from the time of the delivery of such notice until the earlier of (i) such time as it is determined or otherwise agreed that the Participant’s employment or other relationship shall not be terminated for Cause as provided in such notice or (ii) the effective date of such termination of employment or other relationship (in which case the right to exercise this option shall, pursuant to the preceding sentence, terminate upon the effective date of such termination of employment or other relationship). If the Participant is party to an employment, consulting or severance agreement with the Company which agreement, plan or arrangement contains a definition of “cause” for termination of employment, “Cause” shall have the meaning ascribed to such term in such agreement, plan or arrangement. Otherwise, “Cause” shall mean willful misconduct by the Participant or willful failure by the Participant to perform his or her responsibilities to the Company (including, without limitation, breach by the Participant of any provision of any employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Participant and the Company), as determined by the Company, which determination shall be conclusive. The Participant’s employment shall be considered to have been terminated for Cause if the Company determines, within 30 days after the Participant’s resignation, that termination for Cause was warranted.

 

 

4.

Tax Matters.

(a) Withholding. No Shares will be issued pursuant to the exercise of this option unless and until the Participant pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this option.

(b) Disqualifying Disposition. If this option is an incentive stock option and the Participant disposes of Shares acquired upon exercise of this option within two years from the Grant Date or one year after such Shares were acquired pursuant to exercise of this option, the Participant shall notify the Company in writing of such disposition.

 

5.

Transfer Restrictions; Clawback.

(a) This option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Participant, either voluntarily or by operation of law, except by will or the laws of descent and distribution, and, during the lifetime of the Participant, this option shall be exercisable only by the Participant.

(b) In accepting this option, the Participant agrees to be bound by any clawback policy that the Company has in place or may adopt in the future.

 

6.

Provisions of the Plan.

This option is subject to the provisions of the Plan (including the provisions relating to amendments to the Plan), a copy of which is furnished to the Participant with this option.

[Remainder of Page Intentionally Left Blank]

 


 

 

ANNEX A

Schrödinger, Inc.

Stock Option Exercise Notice

Schrödinger, Inc.

120 West 45th Street

17th Floor

New York, NY 10036-4041

Dear Sir or Madam:

I,                 (the “Participant”), hereby irrevocably exercise the right to purchase shares of the Common Stock, $0.01 par value per share (the “Shares”), of Schrödinger, Inc. (the “Company”) at $                 per share pursuant to the Company’s 2020 Equity Incentive Plan and a stock option agreement with the Company dated (the “Option Agreement”). Enclosed herewith is a payment of $                , the aggregate purchase price for the Shares. The certificate for the Shares should be registered in my name as it appears below or, if so indicated below, jointly in my name and the name of the person designated below, with right of survivorship.

 

 

 

 

 

 

Dated:                                                                      

 

 

 

 

 

 

 

 

 

 

 

 

Signature

 

 

 

 

Print Name:

 

 

 

 

 

 

 

Address:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Name and address of persons in whose name the Shares are to be jointly registered (if applicable):

 

 

 

 

 

 

 

 

 

 

 

 


 

Schrödinger, Inc.

 

Restricted Stock Unit Agreement

Schrödinger, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2020 Equity Incentive Plan.  The terms and conditions attached hereto are also a part hereof.

 

Notice of Grant

Name of recipient (the “Participant”):

 

Grant Date:

 

Number of restricted stock units (“RSUs”) granted:

 

Number, if any, of RSUs that vest immediately on the grant date:

 

RSUs that are subject to vesting schedule:

 

Vesting Start Date:

 

 

Vesting Schedule:

Vesting Date:

Number of RSUs that Vest:

 

 

 

 

All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.

 

This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.

 

Schrödinger, Inc.


Signature of Participant

 


Street Address

By:

Name of Officer

Title:


City/State/Zip Code

 


Schrödinger, Inc.

 

Restricted Stock Unit Agreement

Incorporated Terms and Conditions

 

1.Award of Restricted Stock Units. In consideration of services rendered and to be rendered to the Company, by the Participant, the Company has granted to the Participant, subject to the terms and conditions set forth in this Restricted Stock Unit Agreement (this “Agreement”) and in the Company’s 2020 Equity Incentive Plan (the “Plan”), an award with respect to the number of restricted stock units (the “RSUs”) set forth in the Notice of Grant that forms part of this Agreement (the “Notice of Grant”).  Each RSU represents the right to receive one share of common stock, $0.01 par value per share, of the Company (the “Common Stock”) upon vesting of the RSU, subject to the terms and conditions set forth herein.  

2.Vesting.  The RSUs shall vest in accordance with the Vesting Schedule set forth in the Notice of Grant (the “Vesting Schedule”).  Any fractional shares resulting from the application of any percentages used in the Vesting Schedule shall be rounded down to the nearest whole number of RSUs.  As soon as practicable after the vesting of the RSU, the Company will deliver to the Participant, for each RSU that becomes vested, one share of Common Stock, subject to the payment of any taxes pursuant to Section 7.  The Common Stock will be delivered to the Participant as soon as practicable following each vesting date, but in any event within 30 days of such date.  

3.Forfeiture of Unvested RSUs Upon Cessation of Service.  In the event that the Participant ceases to be an Eligible Participant (as defined below) for any reason or no reason, with or without cause, all of the RSUs that are unvested as of the time of such cessation shall be forfeited immediately and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation.  The Participant shall have no further rights with respect to the unvested RSUs or any Common Stock that may have been issuable with respect thereto.  The Participant shall be an “Eligible Participant” if he or she is an employee, director or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants or advisors of which are eligible to receive awards of RSUs under the Plan.

4.Restrictions on Transfer.  The Participant shall not sell, assign, transfer, pledge, hypothecate, encumber or otherwise dispose of, by operation of law or otherwise (collectively “transfer”) any RSUs, or any interest therein. The Company shall not be required to treat as the owner of any RSUs or issue any Common Stock to any transferee to whom such RSUs have been transferred in violation of any of the provisions of this Agreement.

5.Rights as a Stockholder.  The Participant shall have no rights as a stockholder of the Company with respect to any shares of Common Stock that may be issuable with respect to the RSUs until the issuance of the shares of Common Stock to the Participant following the vesting of the RSUs.  

6.Provisions of the Plan.  This Agreement is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.  

7.Tax Matters.  

(a)Acknowledgments; No Section 83(b) Election.  The Participant acknowledges that he or she is responsible for obtaining the advice of the Participant’s own tax advisors with respect to the award of RSUs and the Participant is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with respect to the tax consequences relating to the RSUs.  The Participant understands that the Participant (and not the Company) shall be responsible for the Participant’s tax liability that may arise in connection with the acquisition, vesting and/or disposition of the RSUs.  The Participant acknowledges that no election under Section 83(b) of the Internal Revenue Code of 1986, as amended, (the “Code”) is available with respect to RSUs.  

(b)Withholding.  The Participant acknowledges that, regardless of any action taken by the Company, the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to the Participant’s participation in the Plan and legally applicable or

deemed applicable to the Participant (“Tax-Related Items”), is and remains the Participant’s responsibility and may exceed the amount actually withheld by the Company.  The Participant acknowledges and agrees that prior to the relevant taxable or tax withholding event and at such time as the Participant is not aware of any material nonpublic information about the Company or the Common Stock and the Participant is not subject to any restriction on trading activities with respect to the Common Stock pursuant to any Company insider trading or other policy, the Participant shall execute the instructions set forth in Schedule A attached hereto (the “Automatic Sale Instructions”) as the means of satisfying the withholding obligations for Tax-Related Items (the “Sell-to-Cover Withholding”).  Further, the Participant agrees to pay to the Company, including through withholding from the Participant’s wages or other cash compensation paid to the Participant by the Company, any amount of Tax-Related Items that the Company may be required to withhold or account for as a result of the Participant’s participation in the Plan that cannot be satisfied by the Sell-to-Cover Withholding.  If the Participant fails to comply with his or her obligations in connection with the Tax-Related Items, the Company may refuse to issue or deliver the shares or the proceeds of the sale of shares of Common Stock.  

8.Miscellaneous.

(a)Section 409A.  The RSUs awarded pursuant to this Agreement are intended to be exempt from or comply with the requirements of Section 409A of the Code and the Treasury Regulations issued thereunder (“Section 409A”).  The delivery of shares of Common Stock on the vesting of the RSUs may not be accelerated or deferred unless permitted or required by Section 409A.

(b)Participant’s Acknowledgements.  The Participant acknowledges that he or she:  (i) has read this Agreement; (ii) has been represented in the preparation, negotiation and execution of this Agreement by legal counsel of the Participant’s own choice or has voluntarily declined to seek such counsel; (iii) understands the terms and consequences of this Agreement; (iv) is fully aware of the legal and binding effect of this Agreement; and (v) agrees that in accepting this award, he or she will be bound by any clawback policy that the Company may adopt in the future.

 

 

 

 

 


 

Schedule A

Automatic Sale Instructions

 

The undersigned hereby consents and agrees that any taxes due on a vesting date as a result of the vesting of RSUs on such date shall be paid through an automatic sale of shares as follows:

(a)Upon any vesting of RSUs pursuant to Section 2 hereof, the Company shall arrange for the sale of such number of shares of Common Stock issuable with respect to the RSUs that vest pursuant to Section 2 as is sufficient to generate net proceeds sufficient to satisfy the Company’s minimum statutory withholding obligations with respect to the income recognized by the Participant upon the vesting of the RSUs (based on minimum statutory withholding rates for all tax purposes, including payroll and social security taxes, that are applicable to such income), and the net proceeds of such sale shall be delivered to the Company in satisfaction of such tax withholding obligations.

(b)The Participant hereby appoints the Chief Executive Officer, the Chief Financial Officer and the Chief Legal Officer (or a person holding a similar title), and any of them acting alone and with full power of substitution, to serve as his or her attorneys in fact to arrange for the sale of the Participant’s Common Stock in accordance with this Schedule A.  The Participant agrees to execute and deliver such documents, instruments and certificates as may reasonably be required in connection with the sale of the shares pursuant to this Schedule A.

(c)The Participant represents to the Company that, as of the date hereof, he or she is not aware of any material nonpublic information about the Company or the Common Stock and is not subject to any restriction on trading activities with respect to the Common Stock pursuant to any Company insider trading policy or other policy.  The Participant and the Company have structured this Agreement, including this Schedule A, to constitute a “binding contract” relating to the sale of Common Stock, consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act.

The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made.

 

 

 

_______________________________

 

Participant Name:  ________________

 

Date:  __________________________

 

 

 

 EX-10.6 3 sdgr-ex106_246.htm EX-10.6 sdgr-ex106_246.htm

Exhibit 10.6

Schrödinger, Inc.

 

Restricted Stock Unit Agreement FOR NON-U.S. PARTICIPANTS

Schrödinger, Inc. (the “Company”) hereby grants the following restricted stock units pursuant to its 2020 Equity Incentive Plan.  The terms and conditions attached hereto are also a part thereof.

 

Notice of Grant

Name of recipient (the “Participant”):

 

Grant Date:

 

Number of restricted stock units (“RSUs”) granted:

 

Number, if any, of RSUs that vest immediately on the grant date:

 

RSUs that are subject to vesting schedule:

 

Vesting Start Date:

 

 

Vesting Schedule:

Vesting Date:

Number of RSUs that Vest:

 

 

 

 

All vesting is dependent on the Participant remaining an Eligible Participant, as provided herein.

 

This grant of RSUs satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.

 

Schrödinger, Inc.


Signature of Participant

 


Street Address

By:

Name of Officer

Title:


City/State/Zip Code

 


1

402562279-v3\NA_DMS

Schrödinger, Inc.

 

Restricted Stock Unit Agreement for Non-U.S. Participants

Incorporated Terms and Conditions

 

1.Award of Restricted Stock Units.  The Company hereby grants to the Participant, subject to the terms and conditions set forth in this Restricted Stock Unit Agreement for Non-U.S. Participants, including any additional terms and conditions for the Participant’s country included in the appendix attached hereto (this “Agreement”) and in the Company’s 2020 Equity Incentive Plan (the “Plan”), an award with respect to the number of restricted stock units (the “RSUs”) set forth in the Notice of Grant that forms part of this Agreement (the “Notice of Grant”).  Each RSU represents the right to receive one share of common stock, $0.01 par value per share, of the Company (the “Common Stock”) upon vesting of the RSU, subject to the terms and conditions set forth herein.  

2.Vesting.  The RSUs shall vest in accordance with the Vesting Schedule set forth in the Notice of Grant (the “Vesting Schedule”).  Any fractional shares resulting from the application of any percentages used in the Vesting Schedule shall be rounded down to the nearest whole number of RSUs.  As soon as practicable after the vesting of the RSU, the Company will deliver to the Participant, for each RSU that becomes vested, one share of Common Stock, subject to the payment of any taxes pursuant to Section 7.  The Common Stock will be delivered to the Participant as soon as practicable following each vesting date, but in any event within 30 days of such date.  

3.Forfeiture of Unvested RSUs Upon Cessation of Service.  In the event that the Participant ceases to be an Eligible Participant (as defined below) for any reason or no reason, with or without cause, all of the RSUs that are unvested as of the time of such cessation shall be forfeited immediately and automatically to the Company, without the payment of any consideration to the Participant, effective as of such cessation.  The Participant shall have no further rights with respect to the unvested RSUs or any Common Stock that may have been issuable with respect thereto.  The Participant shall be an “Eligible Participant” if he or she is an employee, director or officer of, or consultant or advisor to, the Company or any other entity the employees, officers, directors, consultants or advisors of which are eligible to receive awards of RSUs under the Plan.  

For purposes of the RSUs, the Participant’s status as an Eligible Participant will be considered terminated as of the date the Participant is no longer actively providing services to the Company, the Employer or any of the other affiliates of the Company (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where the Participant is employed or engaged or the terms of the Participant’s employment or service agreement, if any), and unless otherwise expressly provided in this Agreement or determined by the Company, the Participant’s right to vest in the RSUs under the Plan, if any, will terminate as of such date and will not be extended by any notice period (e.g., the period of service would not include any contractual notice period or any period of “garden leave” or similar period mandated under employment laws in the jurisdiction where the participant is employed or providing services or the terms of the Participant’s employment or service agreement, if any); the Committee shall have the exclusive discretion to determine when

2

the Participant is no longer actively providing services for purposes of the RSU grant (including whether the Participant may still be considered to be providing services while on a leave of absence).

4.Restrictions on Transfer.  The Participant shall not sell, assign, transfer, pledge, hypothecate, encumber or otherwise dispose of, by operation of law or otherwise (collectively “transfer”) any RSUs, or any interest therein. The Company shall not be required to treat as the owner of any RSUs or issue any Common Stock to any transferee to whom such RSUs have been transferred in violation of any of the provisions of this Agreement.

5.Rights as a Stockholder.  The Participant shall have no rights as a stockholder of the Company with respect to any shares of Common Stock that may be issuable with respect to the RSUs until the issuance of the shares of Common Stock to the Participant following the vesting of the RSUs.  

6.Provisions of the Plan.  This Agreement is subject to the provisions of the Plan, a copy of which is furnished to the Participant with this Agreement.  

 

7.Nature of Grant.  In accepting the grant, the Participant acknowledges, understands and agrees that:

(a)the Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended or terminated by the Company at any time, to the extent permitted by the Plan;

(b)the grant of the RSUs is exceptional, voluntary and occasional and does not create any contractual or other right to receive future grants of RSUs, or benefits in lieu of RSUs, even if RSUs have been granted in the past;

(c)all decisions with respect to future RSUs or other grants, if any, will be at the sole discretion of the Company;

(d)the RSU grant and participation in the Plan shall not create a right to employment or other service relationship with the Company;

(e)the RSU grant and participation in the Plan shall not be interpreted as forming or amending an employment or service contract with the Company or the Employer, and shall not interfere with the ability of the Company, the Employer or any affiliate of the Company, as applicable, to terminate the Participant’s employment relationship (if any);

(f)the Participant is voluntarily participating in the Plan;

(g)the RSUs and the shares of Common Stock subject to the RSUs, and the income from and value of same, are not intended to replace any pension rights or compensation;

(h)the RSUs and the shares of Common Stock subject to the RSUs, and the income and value of same, are not part of normal or expected compensation for purposes of,

3

including but not limited to, calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, holiday pay, long-service awards, pension or retirement or welfare benefits or similar payments;

(i)unless otherwise agreed with the Company in writing, the RSUs and the shares of Common Stock subject to the RSUs, and the income and value of same, are not granted as consideration for, or in connection with, the service the Participant may provide as a director of a subsidiary of the Company;

(j)the future value of the underlying shares of Common Stock is unknown, indeterminable and cannot be predicted with certainty;

(k)no claim or entitlement to compensation or damages shall arise from forfeiture of the RSUs resulting from the termination of the Participant’s employment or other service relationship (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where the Participant is employed or engaged or the terms of the Participant’s employment agreement, if any); and

(l)neither the Company, the Employer nor any other subsidiary or affiliate of the Company shall be liable for any foreign exchange rate fluctuation between the Participant’s local currency and the United States Dollar that may affect the value of the RSU or of any amounts due to me pursuant to the settlement of the RSU or the subsequent sale of any shares of Common Stock acquired upon settlement.

 

8.Tax Matters.  

(a)Acknowledgments; Responsibility for Taxes.  The Participant acknowledges that, regardless of any action taken by the Company or, if different, the Participant’s employer (the “Employer”), the ultimate liability for all income tax, social insurance, payroll tax, fringe benefits tax, payment on account or other tax-related items related to the Participant’s participation in the Plan and legally applicable or deemed applicable to the Participant (“Tax-Related Items”), is and remains the Participant’s responsibility and may exceed the amount actually withheld by the Company or the Employer.  The Participant further acknowledges that the Company and/or the Employer: (i) make no representations or undertakings regarding the treatment of any Tax-Related Items in connection with any aspect of this award of RSUs; and (ii) do not commit to and are under no obligation to structure the terms of the grant or any aspect of the RSUs to reduce or eliminate the Participant’s liability for Tax-Related Items or achieve any particular tax result.  Further, if the Participant is subject to Tax-Related Items in more than one jurisdiction, the Participant acknowledges that the Company and/or the Employer (or former employer, as applicable) may be required to withhold or account for Tax-Related Items in more than one jurisdiction.

(b)Withholding.  Prior to the relevant taxable or tax withholding event and at such time as the Participant is not aware of any material nonpublic information about the Company or the Common Stock and the Participant is not subject to any restriction on trading activities with respect to the Common Stock pursuant to any Company insider trading or other policy, the Participant shall execute the instructions set forth in Schedule A attached hereto (the

4

“Automatic Sale Instructions”) as the means of satisfying the withholding obligations for Tax-Related Items (the “Sell-to-Cover Withholding”). In the event the Sell-to-Cover Withholding results in over-withholding, the Participant may receive a refund of any over-withheld amount in cash and will have no entitlement to the stock equivalent, or if not refunded, the Participant may seek a refund from the local tax authorities.  In the event of under-withholding, the Participant may be required to pay any additional Tax-Related Items directly to the applicable tax authority, to the Company or to the Employer. The Participant agrees to pay to the Company or the Employer, as applicable, including through withholding from the Participant’s wages or other cash compensation paid to the Participant by the Company and/or the Employer, any amount of Tax-Related Items that the Company or the Employer may be required to withhold or account for as a result of the Participant’s participation in the Plan that cannot be satisfied by the Sell-to-Cover Withholding.  If the Participant fails to comply with his or her obligations in connection with the Tax-Related Items, the Company may refuse to issue or deliver the shares or the proceeds of the sale of shares of Common Stock.  

9.Data Privacy.  If the Participant would like to participate in the Plan, the Participant will need to review the information provided in this Section 9 and declare with its signature under this Agreement consent to processing of Participant’s personal data for such processing activities requiring consent.

If the Participant is based in the EEA+ (as defined below), the Participant has the right to withdraw his or her consent for such processing activities at any time and declares that he or she has read the transparency document on the website of the Company or, if different, the Participant’s Employer. The withdrawal of consent does not affect the lawfulness of processing based on consent before its withdrawal. Other processing activities (e.g., the transfer of personal data to tax authorities) are based on other legal grounds, e.g., a legal obligation to which the controller is subject, or a legitimate interest pursued by the controller or by a third party. For such processing activities consent is not needed or given by the Participant.

  

(a)EEA+ Controller and Representative. If the Participant is based in the European Union (“EU”), the European Economic Area, or the United Kingdom (collectively “EEA+”), the Participant should note that the Company, with its registered address at 1540 Broadway, 24th Floor, New York, New York 10036, United States of America, is the controller responsible for the processing of the Participant’s personal data in connection with the Agreement and the Plan. The Company’s representative in the EEA+ by means of Art. 27 GDPR is Prof. Dr. h.c. Heiko Jonny Maniero, DGD Deutsche Gesellschaft für Datenschutz GmbH, Fraunhoferring 3, 85238 Petershausen. The representative can be reached by email at heiko.maniero@dg-datenschutz.de.

(b)Data Collection and Usage. The Company collects, uses and otherwise processes certain personal data about the Participant, including, but not limited to, the Participant’s name, home address and telephone number, email address, date of birth, social insurance number, passport or other identification number (e.g., resident registration number), salary, nationality, job title, any shares of stock or directorships held in the Company, details of all options or any other entitlement to shares of stock awarded, canceled, exercised, vested, unvested or outstanding in the Participant’s favor, which the Company receives from the Participant, Participant’s Employer or otherwise in connection with this Agreement or the Plan (“Data”), for

5

the purposes of implementing, administering and managing the Plan and allocating shares of Common Stock pursuant to the Plan.

If the Participant is based in the EEA+, the legal basis, where required, for the processing of Data by the Company is: (i) the consent of the Participant; or (ii) the necessity of the data processing for the Company to (1) perform its contractual obligations under this Agreement, (2) comply with legal obligations established in the EEA+, or (3) pursue the legitimate interest of complying with legal obligations established outside of the EEA+.

If the Participant is based outside of the EEA+, the legal basis, where required, for the processing of Data by the Company is the Participant’s consent, as further described below.

(c)Stock Plan Administration Service Providers. The Company grants access to Data to TD Ameritrade, Inc., an independent service provider, which is assisting the Company with the implementation, administration and management of the Plan (“Broker”). In the future, the Company may select a different service provider and share Data with such other provider serving in a similar manner. Broker will open an account for the Participant to receive and trade shares of Common Stock acquired under the Plan. The Participant may be asked to agree on separate terms and data processing practices with Broker, with such agreement being a condition of participating in the Plan.

(d)International Data Transfers. In the event the Participant resides, works or is otherwise located outside of the U.S., Data will be transferred from the Participant’s country to the U.S., where the Company and its service providers are based. The Participant understands and acknowledges that the U.S. might not provide a level of protection of personal data equivalent to the level of protection in the Participant’s country.

If the Participant is based in the EEA+, the legal basis, where required, for the transfer of Data from the EEA+ to the Company and for the access to Data granted by the Company to Broker or, as the case may be, a different service provider of the Company in the U.S. is to satisfy the Company’s contractual obligations under the terms of this Agreement and/or its use of the standard data protection clauses adopted by the EU Commission.

If the Participant is based outside of the EEA+, the Company’s legal basis, where required, for the transfer of Data from the Participant’s country to the Company and for the access to Data granted by the Company to Broker or, as the case may be, a different service provider of the Company is the Participant’s consent, as further described below.

(e)Data Retention. The Company will hold and use the Data only as long as is necessary to implement, administer and manage the Participant’s participation in the Plan, or as required to comply with legal or regulatory obligations, including under tax and security laws.

(f)Data Subject Rights. The Participant may have a number of rights under data privacy laws in his or her jurisdiction. Depending on where the Participant is based and subject to the conditions set out in applicable law, such rights may include the right to request from the Company access to and rectification, erasure or portability of Data, to restrict or object to the processing of Data, lodge a complaint with a supervisory authority and/or to receive a list with the names and addresses of any potential recipients of Data. To receive additional information

6

regarding these rights or to exercise these rights, the Participant can contact the Company’s data privacy representative at heiko.maniero@dg-datenschutz.de.

(g)Necessary Disclosure of Personal Data. The Participant understands that providing the Company with Data is necessary for the performance of the Agreement and that the Participant’s refusal to provide Data would make it impossible for the Company to perform its contractual obligations and may affect the Participant’s ability to participate in the Plan.

(h)Voluntariness and Consequences of Consent Denial or Withdrawal. Participation in the Plan is voluntary and the Participant is providing any consents referred to herein on a purely voluntary basis. The Participant understands that he or she may withdraw any such consent at any time with future effect for any or no reason. If the Participant does not consent, or if the Participant later seeks to withdraw his or her consent, the Participant’s salary from or employment and career with the Employer will not be affected; the only consequence of refusing or withdrawing the Participant’s consent is that the Company would not be able to grant the options or other awards to the Participant or administer or maintain the options. For more information on the consequences of refusal to consent or withdrawal of consent, the Participant should contact the Company’s data privacy representative at heiko.maniero@dg-datenschutz.de.

If the Participant is based outside of the EEA+, by accepting the options and indicating consent via the Company’s online acceptance procedure, the Participant explicitly declares his or her consent to the entirety of the Data processing operations described in this Section 9 including, without limitation, access to Data provided by the Company to Broker or, as the case may be, a different service provider of the Company in the U.S.

10.Miscellaneous.

(a)Section 409A.  The RSUs awarded pursuant to this Agreement are intended to be exempt from or comply with the requirements of Section 409A of the Code and the Treasury Regulations issued thereunder (“Section 409A”).  The delivery of shares of Common Stock on the vesting of the RSUs may not be accelerated or deferred unless permitted or required by Section 409A.

(b)No Advice Regarding Grant.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding participation in the Plan, or the acquisition or sale of the underlying shares of Common Stock.  The Participant understands and agrees that he or she should consult with his or her own personal tax, legal and financial advisors regarding participation in the Plan before taking any action related to the Plan.

(c)Governing Law and Venue.  The provisions of this Agreement shall be governed by and interpreted in accordance with the laws of the State of Delaware, excluding choice-of-law principles of the law of such state that would require the application of the laws of a jurisdiction other than the State of Delaware. For purposes of litigating any dispute that arises directly or indirectly from the relationship of the parties evidenced by this grant or this Agreement, the parties hereby submit to the exclusive jurisdiction of the State of New York and agree that such litigation shall be conducted only in the courts of New York County, New York,

7

or the federal courts for the United States for the Southern District of New York, and no other courts, where this grant is made and/or to be performed.

(d)Entire Agreement; Enforcement of Rights.  This Agreement, together with the Plan, sets forth the entire agreement and understanding of the parties relating to the subject matter herein and supersedes all prior discussions, agreements, commitments, or negotiations between the parties. No adverse modification or amendment of this Agreement, nor any waiver of any rights under this Agreement, will be effective unless in writing and signed by the parties to this Agreement (which may be electronic). The failure by either party to enforce any rights under this Agreement will not be construed as a waiver of any rights of such party.

(e)Severability.  If one or more provisions of this Agreement are held to be unenforceable under applicable laws, the parties agree to renegotiate such provision in good faith.  In the event that the parties cannot reach a mutually agreeable and enforceable replacement for such provision, then (a) such provision shall be excluded from this Agreement, (b) the balance of this Agreement shall be interpreted as if such provision were so excluded, and (c) the balance of this Agreement shall be enforceable in accordance with its terms.

(f)Consent to Electronic Delivery and Participation.  The Company may, in its sole discretion, decide to deliver any documents related to current or future participation in the Plan by electronic means.  The Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through an on-line or electronic system established and maintained by the Company or a third party designated by the Company.  

(g)Language.  The Participant acknowledges that the Participant is proficient in the English language and, accordingly, understands the provisions of this Agreement and the Plan.  If the Participant has received this Agreement, or any other document related to the RSUs and/or the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.

(h)Compliance with Law. Notwithstanding any other provision of the Plan or this Agreement, unless there is an exemption from any registration, qualification or other legal requirement applicable to the shares of Common Stock, the Company shall not be required to deliver any shares issuable upon settlement of the RSU prior to the completion of any registration or qualification of the shares under any local, state, federal or foreign securities or exchange control law or under rulings or regulations of the U.S. Securities and Exchange Commission (“SEC”) or of any other governmental regulatory body, or prior to obtaining any approval or other clearance from any local, state, federal or foreign governmental agency, which registration, qualification or approval the Company shall, in its absolute discretion, deem necessary or advisable.  The Participant understands that the Company is under no obligation to register or qualify the shares with the SEC or any state or foreign securities commission or to seek approval or clearance from any governmental authority for the issuance or sale of the shares.  Further, the Participant agrees that the Company shall have unilateral authority to amend the Agreement without the Participant’s consent to the extent necessary to comply with securities or other laws applicable to issuance of shares.

8

(i)Country-Specific Provisions.  The RSUs shall be subject to any special terms and conditions set forth in the Appendix for the Participant’s country.  Moreover, if the Participant relocates to one of the countries included in the Appendix, the special terms and conditions for such country will apply to the Participant to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Appendix constitutes part of this Agreement.

(j)Imposition of Other Requirements.  The Company reserves the right to impose other requirements on Participant’s participation in the Plan, on the RSUs, and on any shares of Common Stock issued upon the vesting of the RSUs, to the extent the Company determines it is necessary or advisable for legal or administrative reasons, and to require the Participant to accept any additional agreements or undertakings that may be necessary to accomplish the foregoing.

(k)Insider Trading/Market Abuse Laws.  The Participant may be subject to insider trading restrictions and/or market abuse laws in applicable jurisdictions, including, but not limited to, the United States and the Participant’s country, which may affect the Participant’s ability to accept, acquire, sell, or otherwise dispose of shares of Common Stock, rights to shares of Common Stock (e.g., RSUs), or rights linked to the value of shares of Common Stock under the Plan during such times as the Participant is considered to have “inside information” regarding the Company (as defined by the laws in the applicable jurisdictions).  Insider trading laws and regulations may prohibit the cancellation or amendment of orders the Participant placed before the Participant possessed inside information.  Furthermore, the Participant could be prohibited from (i) disclosing the inside information to any third party, which may include fellow employees and (ii) “tipping” third parties or causing them otherwise to buy or sell securities.  Any restrictions under these laws or regulations are separate from and in addition to any restrictions that may be imposed under the Company’s trading policy.  Neither the Company nor any of its affiliates will be responsible for such restrictions or liable for the failure on the Participant’s part to know and abide by such restrictions.  The Participant should consult with his or her own personal advisor regarding compliance with such restrictions.  

(l)Participant’s Acknowledgements.  The Participant acknowledges that he or she: (i) has read this Agreement; (ii) has been represented in the preparation, negotiation and execution of this Agreement by legal counsel of the Participant’s own choice or has voluntarily declined to seek such counsel; (iii) understands the terms and consequences of this Agreement; (iv) is fully aware of the legal and binding effect of this Agreement; and (v) agrees that in accepting this award, to the extent permitted by law, he or she will be bound by any clawback policy that the Company may adopt in the future.


9

Schrödinger, Inc.

 

COUNTRY-SPECIFIC APPENDIX TO

RESTRICTED STOCK UNIT AGREEMENT FOR NON-U.S. PARTICIPANTS

Capitalized terms used but not defined in this Country-Specific Appendix (the “Appendix”) shall have the same meanings assigned to them in the Plan or the Agreement.

Terms and Conditions

This Appendix, which is part of the Agreement, includes additional terms and conditions that govern the RSUs if the Participant works and/or resides in one of the countries listed below.  If the Participant is a citizen or resident of a country other than the one in which he or she is currently working (or is considered as such for local law purposes), or if the Participant transfers employment or residency to a different country after receiving the RSUs, the Company will, in its discretion, determine the extent to which the terms and conditions contained herein will be applicable to the recipient.  

Notifications

This Appendix also includes information regarding certain other issues about which the Participant should be aware with respect to participation in the Plan.  The information is based on the securities, exchange control and other laws in effect in the respective countries as of August 2021.  Such laws are often complex and change frequently.  As a result, the recipient should not rely on the information noted herein as the only source of information relating to the consequences of participation in the Plan because the information may be out-of-date when the RSUs vest and/or when the Participant sells any shares of Common Stock acquired under the Plan.

In addition, the information contained herein is general in nature and may not apply to the Participant’s particular situation.  As a result, the Company is not in a position to assure the Participant of any particular result.  Accordingly, the Participant is strongly advised to seek appropriate professional advice as to how the relevant laws in the recipient’s country may apply to his or her situation.

If the Participant is a citizen or resident of a country other than the one in which he or she is currently working (or is considered as such for local law purposes), or transfers employment/residency to a different country after receiving the RSUs, the notifications contained in this Appendix may not be applicable to the Participant in the same manner.  


10

AUSTRALIA

 

Notifications

 

Tax Conditions.  Subdivision 83A-C of the Income Tax Assessment Act 1997 (Cth) applies to the RSUs granted under the Plan, such that the RSU grant is intended to be subject to deferred taxation.  

 

Securities Law Information.  This grant of RSUs is intended to comply with the provisions of the Corporations Act 2001, ASIC Regulatory Guide 49 and ASIC Class Order CO 14/1000. Additional details are set forth in the Australian Offer Document provided herewith.

 

Exchange Control Information.  If the Participant is an Australian resident, exchange control reporting is required for cash transactions exceeding AUD10,000 and international fund transfers.  If an Australian bank is assisting with the transaction, the bank will file the report on the Participant’s behalf.  If there is no Australian bank involved with the transfer, the Participant will be required to file the report.

 

FRANCE

Terms and Conditions

 

Consent to Receive Information in English.  By accepting the RSUs, the Participant confirms that he or she has read and understood the Plan and the Agreement, including all terms and conditions included therein, which were provided in the English language.  The Participant accepts the terms of those documents accordingly.

En acceptant les RSUs, le Titulaire de les RSUs confirme avoir lu et compris le Plan et le Contrat y relatifs, incluant tous leurs termes et conditions, qui ont été transmis en langue anglaise. Le Titulaire de les RSUs accepte les dispositions de ces documents en connaissance de cause.

Notifications

Tax Information.  The RSUs are not intended to qualify for special tax and social security treatment applicable to restricted stock units granted under Section L.225-197-1 to L.225-197-6 of the French Commercial Code, as amended.

Foreign Asset/Account Reporting Information.  If the Participant holds cash or shares of Common Stock outside of France, the Participant must declare all foreign bank and brokerage accounts (including any accounts that were opened or closed during the tax year) on an annual basis, on form No. 3916, together with his or her income tax return.  It is the Participant’s responsibility to comply with French foreign asset and account reporting requirements, and neither the Company nor the Employer will be liable for any resulting fines or penalties.

11

GERMANY

Notifications

 

Exchange Control Information.  If the Participant remits funds in excess of €12,500 out of or into Germany, such cross-border payment must be reported monthly to the German Federal Bank (Bundesbank).  The Participant is responsible for the reporting obligation and should file the report (“Allgemeine Meldeportal Statistik”) electronically by the fifth day of the month following the month in which the payment is made. A copy of the report can be accessed via the Bundesbank’s website at www.bundesbank.de and is available in both German and English.

Foreign Asset/Account Reporting Information.  If the acquisition of shares of Common Stock under the Plan leads to a “qualified participation” at any point during the calendar year, the Participant will need to report the acquisition when he or she files his or her tax return for the relevant year.  A qualified participation is attained if (i) the value of the shares of Common Stock acquired exceeds €150,000 or (ii) in the unlikely event the Participant holds shares of Common Stock exceeding 10% of the Company’s total Common Stock. The Participant is responsible for complying with this reporting obligation and should confer with his or her personal tax advisor to determine his or her obligations in this regard.

 

INDIA

Notifications

 

Exchange Control Information. Indian residents are required to repatriate the proceeds from the sale of shares of Common Stock to India within specified timeframes. The Participant must retain the foreign inward remittance certificate received from the bank where the foreign currency is deposited in the event that the Reserve Bank of India or the Employer requests proof of repatriation.  It is the Participant’s responsibility to comply with these requirements. Neither the Company nor the Employer will be liable for any fines or penalties resulting from the Participant’s failure to comply with any applicable laws.

 

Foreign Asset/Account Reporting Information. Indian residents are required to declare any foreign bank accounts and any foreign financial assets (including shares of Common Stock held outside of India) in their annual tax returns.  The Participant is responsible for complying with this reporting obligation and should confer with his or her personal tax advisor to determine his or her obligations in this regard.

Ireland

Notifications

Director Notification Obligation. If the Participant is a director, shadow director, or secretary of an Irish affiliate, the Participant is required to notify such Irish affiliate in writing if the Participant receives or disposes of an interest in the Company representing more than 1% of the Company’s voting share capital (e.g., RSUs, shares of Common Stock, etc.), if the Participant becomes aware of the event giving rise to such notification requirement, or if the Participant

12

becomes a director, shadow director, or secretary of an Irish affiliate if such an interest exists at the time. This notification requirement also applies with respect to the interests of a spouse or children under the age of 18 (whose interests will be attributed to the director, shadow director, or secretary).

 

Japan

Notifications

Foreign Asset / Account Reporting Information. The Participant will be required to report details of any assets held outside of Japan as of December 31st to the extent such assets have a total net fair market value exceeding ¥50 million.  Such report will be due by March 15th each year.  The Participant is responsible for complying with this reporting obligation and should confer with their personal tax advisor to determine the Participant’s obligations in this regard.

 

SOUTH KOREA

 

Notifications

Foreign Asset / Account Reporting Information. The Participant must declare all foreign financial accounts (e.g., non-Korean bank accounts, brokerage accounts) to the Korean tax authority and file a report with respect to such accounts in June of the following year if the monthly balance of such accounts exceeds KRW 500 million (or an equivalent amount in foreign currency) on any month-end date during a calendar year. The Participant is responsible for complying with this reporting obligation and should confer with their personal tax advisor to determine the Participant’s obligations in this regard.

 

United Kingdom

 

Terms and Conditions

Tax Matters.  The following provision supplements Section 8 of the Agreement:

Without limitation to Section 8 of the Agreement, the Participant agrees that the Participant is liable for all Tax-Related Items and hereby covenants to pay all such Tax-Related Items, as and when requested by the Company or the Employer or by Her Majesty’s Revenue and Customs (“HMRC”) (or any other tax authority or any other relevant authority).  The Participant also agrees to indemnify and keep indemnified the Company and the Employer against any Tax-Related Items that they are required to pay or withhold or have paid or will pay to HMRC (or any other tax authority or any other relevant authority) on the Participant’s behalf.  

Notwithstanding the foregoing, if the Participant is a director or an executive officer of the Company (within the meaning of such terms for purposes of Section 13(k) of the Exchange Act), the Participant acknowledges that the Participant may not be able to indemnify the Company or the Employer for the amount of any income tax not collected from or paid by the Participant, as it may be considered a loan.  In this case, the amount of any income tax not collected within 90 days of the end of the U.K. tax year in which the event giving rise to the Tax-Related Item(s)

13

occurs may constitute an additional benefit to the Participant on which additional income tax and National Insurance contributions (“NICs”) may be payable.  The Participant will be responsible for reporting and paying any income tax due on this additional benefit directly to HMRC under the self-assessment regime and for reimbursing the Company or the Employer (as appropriate) for the value of any employee NICs due on this additional benefit, which the Company or the Employer may recover from the Participant by any of the means referred to in the Plan or Section 8 of the Agreement.


14

Schedule A

 

Automatic Sale Instructions

 

The undersigned hereby consents and agrees that any taxes due on a vesting date as a result of the vesting of RSUs on such date shall be paid through an automatic sale of shares as follows:

 

(a)Upon any vesting of RSUs pursuant to Section 2 hereof, the Company shall arrange for the sale of such number of shares of Common Stock issuable with respect to the RSUs that vest pursuant to Section 2 as is sufficient to generate net proceeds sufficient to satisfy the Company’s minimum statutory withholding obligations (or, for Participants outside the United States, applicable statutory withholding obligations) with respect to the income recognized by the Participant upon the vesting of the RSUs (based on minimum statutory withholding rates (or, for Participants outside the United States, applicable statutory withholding rates) for all tax purposes, including payroll and social security taxes, that are applicable to such income), and the net proceeds of such sale shall be delivered to the Company in satisfaction of such tax withholding obligations.  

(b)The Participant hereby appoints the Chief Executive Officer, the Chief Financial Officer and the Chief Legal Officer (or a person holding a similar title), and any of them acting alone and with full power of substitution, to serve as his or her attorneys in fact to arrange for the sale of the Participant’s Common Stock in accordance with this Schedule A.  The Participant agrees to execute and deliver such documents, instruments and certificates as may reasonably be required in connection with the sale of the shares pursuant to this Schedule A.

(c)The Participant represents to the Company that, as of the date hereof, he or she is not aware of any material nonpublic information about the Company or the Common Stock and is not subject to any restriction on trading activities with respect to the Common Stock pursuant to any Company insider trading policy or other policy.  The Participant and the Company have structured this Agreement, including this Schedule A, to constitute a “binding contract” relating to the sale of Common Stock, consistent with the affirmative defense to liability under Section 10(b) of the Securities Exchange Act of 1934 under Rule 10b5-1(c) promulgated under such Act.

The Company shall not deliver any shares of Common Stock to the Participant until it is satisfied that all required withholdings have been made.

 

 

 

_______________________________

 

 

Participant Name:  ________________

 

Date:  __________________________

 

 

15

 EX-21.1 4 sdgr-ex211_9.htm EX-21.1 sdgr-ex211_9.htm

Exhibit 21.1

List of Subsidiaries

 

 

 

 

Name                                                                          

  

Jurisdiction of Incorporation

Schrödinger, LLC

  

Delaware

Schrödinger GmbH

  

Germany

Synaptic Science LLC

  

Delaware

Schrödinger, KK

  

Japan

Reo Discovery Limited

  

Ireland

Faxian Therapeutics, LLC

  

Delaware

Schrödinger Technologies Ltd           United Kingdom                                                     Schrödinger India Private Limited                                           India                                                                                               Schrodinger Korea LLC                          South Korea

XTAL BioStructures, Inc.                          Massachusetts

 

 

 EX-23.1 5 sdgr-ex231_7.htm EX-23.1 sdgr-ex231_7.htm

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

The Board of Directors
Schrödinger, Inc.:

We consent to the incorporation by reference in the registration statements (No. 333-236297 and 333-253864) on Form S-8 and in the registration statement (No. 333-253865) on Form S-3 of our reports dated February 24, 2022, with respect to the consolidated financial statements of Schrödinger, Inc. and the effectiveness of internal control over financial reporting.

 

/s/ KPMG LLP

Portland, Oregon
February 24, 2022

 

 EX-31.1 6 sdgr-ex311_12.htm EX-31.1 sdgr-ex311_12.htm

 

EXHIBIT 31.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Ramy Farid, certify that:

 

 

1.

I have reviewed this Annual Report on Form 10-K of Schrödinger, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 24, 2022

 


/s/ Ramy Farid

 President and Chief Executive Officer (Principal Executive Officer)

 

 

 EX-31.2 7 sdgr-ex312_11.htm EX-31.2 sdgr-ex312_11.htm

 

EXHIBIT 31.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES

EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

 

I, Joel Lebowitz, certify that:

 

 

1.

I have reviewed this Annual Report on Form 10-K of Schrödinger, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

a.

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

 

b.

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: February 24, 2022

 


/s/ Joel Lebowitz

 Chief Financial Officer (Principal Financial Officer)

 

 

 EX-32.1 8 sdgr-ex321_8.htm EX-32.1 sdgr-ex321_8.htm

Exhibit 32.1

 

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Schrödinger, Inc. (the “Company”) hereby certifies, to his knowledge, that:

 

 

(i)

the accompanying Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

 

 

(ii)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: February 24, 2022

 


/s/ Ramy Farid

 President and Chief Executive Officer (Principal Executive Officer)

 

 

 EX-32.2 9 sdgr-ex322_10.htm EX-32.2 sdgr-ex322_10.htm

Exhibit 32.2

 

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

 

Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Schrödinger, Inc. (the “Company”) hereby certifies, to his knowledge, that:

 

 

(i)

the accompanying Annual Report on Form 10-K of the Company for the fiscal year ended December 31, 2021 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

 

 

(ii)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

 

Date: February 24, 2022

 


/s/ Joel Lebowitz

 Chief Financial Officer (Principal Financial Officer)

 

 

 GRAPHIC 10 g0na1tfcz5u2000015.jpg GRAPHIC begin 644 g0na1tfcz5u2000015.jpg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�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g0na1tfcz5u2000019.jpg GRAPHIC begin 644 g0na1tfcz5u2000019.jpg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Ʈ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end GRAPHIC 12 g0na1tfcz5u2000003.jpg GRAPHIC begin 644 g0na1tfcz5u2000003.jpg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end GRAPHIC 13 g0na1tfcz5u2000001.jpg GRAPHIC begin 644 g0na1tfcz5u2000001.jpg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g0na1tfcz5u2000010.jpg GRAPHIC begin 644 g0na1tfcz5u2000010.jpg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end GRAPHIC 15 g0na1tfcz5u2000002.jpg GRAPHIC begin 644 g0na1tfcz5u2000002.jpg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g0na1tfcz5u2000014.jpg GRAPHIC begin 644 g0na1tfcz5u2000014.jpg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end GRAPHIC 17 g0na1tfcz5u2000004.jpg GRAPHIC begin 644 g0na1tfcz5u2000004.jpg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g0na1tfcz5u2000013.jpg GRAPHIC begin 644 g0na1tfcz5u2000013.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ I, M^U+7G6HK?67CC6);S4=2?3GTEI!Y"X\D[L;8P!]['XT >B9/I0*\)BEN[SPQ M+)'JFIV-K)?HXMY8[B1H4"'"NXPWS'DX. :[*/Q#XBT7PCI>H-I=JEJ5BCEC MGGD\Y2S;<\@^H/)S0!Z+12*YKR+4KJX'A3PO;3S:S'JDEO\TZ^;LM_GYD<*,L_& #0! M[=17DNGMJ\?Q'D>&2YOI)7D&RX2:*.V41C8QYV,I^F>:[3P]K>K7FN:GI6K0 M6D,K"]U3P9K%CIS$7D]JZ18.,DCI^/3\: M3V&MRI9_$/PI?ZLFF6NLPRW,DGE)M#;7?^Z&Q@GVS73UYAX*\6:-#X:TCPV= M,O[?5H(5@EM6L)!Y4BCF0N1M SSG.:\[\.7]U=Z?X;?3;_Q#/XE_M$*Z.TIM M_LN\[NOR%<>^>OM5=;"Z7/H+7=:M?#VB76K7N_[-:IOD\M)U?3][Z8-#%I$ FQ_M _=CKVZYI+8&:.F>+="UG5[G2M-U*&ZN[9- M\J1'<%&Z'GT-;5>.:!XGT-OC7?7-J9DLKRPBLK9A8RHIE#CY<;!M'N<#W MKV.CH'4**** "BBB@ HHHH ***,B@ HK&U_Q1I'AB".?6+P6T4C%48HS9/X MTGA_Q7HOBB*671[T7*1$!R$9<9^H% &U13&FB7[TB#ZL*B-_9K]Z[@'UD% % MBBJC:KIR*6>_M5 &23,H_K4<>N:3+$)8]3LVC;HPG7!_6@"_15'^VM*_Z"=G M_P!_U_QJW%-%/&)(9$D0]&1@0?Q% #Z*** "BBB@ HHHH **HZOJ<>CZ7-?2 MPS3+$N?+A0N[>P KD)_B?:0Z;I]XNF7$BW-J;R95=08(0VW)SU.>PH [VN2T M;_DHOB/_ *XVW\C45C\1;"]UL6/V66&UDDEBBO9' 1WC4%QCJ >IIOAJ^M- M0\?>(Y[*YBN(3#;@/$X9+Z M&OAB[\:^,&\=C3FU)+K; NIE=J6V/E,>_@#W'- 'LX((!!!!Z$4M>+:AXGN( MO$VL:1IOC&WT/1;+3+>XTX&*-]X\L$!2_)!R">IZ8Q1'XZU[58_"-O>ZY#X= MCU"PDNKB^:%/WCJV HW_ "C(&: /7=.U6PU>*:73[J.X2&5H)&C.=KKU4^XI MUSJ=A9S1PW5];02R?<26559OH">:\E^&>L:U9>%+V32=$/B S:S=&:6&ZCMP MOW,-ASR&R3@=,5%\4/\ A&]9OSX>@L]-C\27PC>[O[IE'V",8/,A/7'&U>M' M8#VFBJ6D1PPZ-916]S]JA2!%2?=N\P !L]\U=H8!1110 4444 %%%(3@4 + M14*W4#S-"LT;2J,L@8;A]14M "TC,J*68@*HR2>PKR_1OBO=:E\2[CPO-H;V M]O&[H)V8AEV_Q,#Q@UZ+)J5@@Q+>VRCONE7_ !H QH/B#X2N;Q+2'7[)[AWV M+&).2WI72U\_>'[J_B^.VH27::/'8A?WCYC"+"/]64/][I7MA\2Z%C_D,Z?_ M .!*?XT :F12UXO8:/<6WQ4E\1S>/-/DTMI&?R/M@W,IZ(5SC KU$>*?#^/^ M0WI__@2G^- &OFBO(=%\:^,M5^+$VF0PVMQH"2$%X=K*L79]X/4^E>O4 %%% M% !1110 4452U35K#1;,W>I7<5K "%WR' R>U %VN=U7P?9:QJ=W>7,LN+JP M-B\:X "DYW ^M:.DZYIFNP/-IEY'=1(VUFCS@'TK1H X(?"^V$7F_P!L7G]I M"82+>[$W !/+"[<8QM.*K>,O#&E:/X(M8X+2)Y;26VBCN'0&3 D'\77UKT:N M1^)/_(HM_P!?=O\ ^C%H ZU/N+]*6D3[B_2EH 1E#HRL,AA@U0T31-/\/:7% MINF0&&TB)*(7+8RM>:%E:U3>(E[Y?[JG\:7PK:_$N;P_;PZO? MZ?9SC.Z62$S3D=LC(7-=]96%IIMJMM96T5O @PJ1*% JQ@4 >0?$SPKX@G\+ MM!%J>N:S=3MCRH(XUB7'/S* #@_6H_A;X$C?PXUOXBTW58;N)^D\S1H0>@4* MW05[)BB@#S[Q9\*]*U?P[<6>D(MA?M@QW!=VQ@]#ST-0^!OA38:#H7V?78K7 M5+UI"YE="P4=E&:]'HH XSQ#\,O#FMZ%=:=#86]C+,N$N((AN0@YS5+P7\)M M#\+:4]M>10:I<.^]IIX!\OL @44 <=XF^'.AZYX>O-.M;"SL9YDQ'<16 MZAD.QN=2-Z\LOF84$(G&, &NWHQ0 4444 %%%% !117.ZA MXY\/:9J3Z==7^+I" \:1,^TGH"0#B@#>GB$\$D39"NI4D>A&*XVX^&FE7%C8 M6OVJ\C2TM_LK;&7,\6[<5;CU],5VJL& (Z$9I"ZJ<$@?4T PKKPZDX MR,_6N4T;_DHOB/\ ZXVW\C0!UM4+W1-*U*5);[3;2YDC^Z\T*N1^)%7Z* .8 M'@72&\3:CK5U#'=&]BAC-O-$K1Q^6, KD=:V[O2=.U"&*&\L+:XCB(,:2Q*P M3'3 (XJY10!!:V=K9(Z6MO% KN9&$:!0S'J3CO5&\\,Z%J%RUS>:/8W$[_>D ME@5F/U)%:M% $=O;PVEO';V\210QJ%2-%PJ@= !V%2444 %%%% !1110 9K# MUKQ3IVCS+:,9+K4'&8[.U3S)6_ =![G%5Y$AD_?RA6[-_#W]Z]"_X0@W/.I^(=:O2>J_:?)3\D KK** .5C^' M/A5)#*VDK-*PPSS2N['ZDFK0\#^%P,?V!8'/',(-=!10!QD/PI\$PW"SIX?M MQ(K;AEF(S]"<5O?\(QH.?^0+I_\ X#)_A6K10!F_\(]HG_0(L/\ P'3_ H_ MX1W1/^@18?\ @.G^%:5% %6UTVQL2QM+*WMRWWC%$%S^56J** "BBB@ HHHH M *XGXG!&T&S4-,+LWL?V00A,F7G'+_*!UZUVQZ5YM\3[V:.."PE,TEI>%5"1 MZ;]I","?F)R.?04 :GP[O;FXL-0M[^:=[ZUN?+GCF6/]V=H( ,8PPKJ]0@BN M=.N(I_,,31G<(V*MCV(YS7&?"Z%[;1KRW$$L<,=Q^Z>2R^S&3(&3MR2>>YKO M>U 'BT^C7L'@BUNGO=3LS?7OVB2,B:;RHP&V1G!W*.F3ZUH:Z_B"3X>:8T]M M:VUF7MO-BE:1IPWF#U]>#SS7K-%2SL?Y?6N;\=^-G\$ M:?'?2:7)>6K$B21)538>PP>23[>E8OAO4+CXGS6VM7=D]IH=F^Z"V=PWVB8? MQMCC:O8>M %ZS\-_\)JQU?Q5:![1U(LM,E^["A_C?U:AK\D[PZI+>VDB1V\LL%KB3'\6X]!],T >\PL&B1AGE0>>M<9XY\.1Z_ MJ>C6_P!AD?S9\7%TA8>3$OS$<'C<>*[.+)C4MUVC/UJ2@#RBST;5;;XDS7-G M;73M)+*'FO+<^5 @0!"CAOF';'7Z5O>$X]1C\=>(EU2>WGN?*M\O!&47&#C@ MDUW-CL#J]_D*QY%O'_%*?IV]36SJ^IVVC:5<:C=MMA@0LWJ?0#W)XK%\(:5 M'OACX:\.:NNKVMM))J(7!GED+$ ML?O-CID\_G79XHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ]*\R^ M*%WI,/DV[HG]HW+(C221RNL463\V$ZX->F]J\R^)]]I-F88Y+I5U*X9(]LEU M)&L<>3\Y"<_E0!<^%3Q_V5J<,21-%#=;5N(XY(Q.-H^;:Y)'I7;ZA?1:;IMU M?3 ^5;Q-*^.N ,UR'PT6)='N_*OK6['G_>MKB24#@<$OR*["^M!?6$]J9)(Q M*A3?&?F7/<>] '$6WQ3MKO38;J'2+AYKB;RH+=9HRSX4N2>?EP!WJ+QEXETO M6? UK-!=1+)=36TL=N[@28,@_AZ^M6&^&%J[-WMHRUK-;1),Z R8$@_BZT >A)]Q?I2TB?<7Z4M !111 M0 4444 %%%% !1161XCUV+P_I,EXZ&64D1V\"_>FD/"J/QH \_\ BWIE]XSG MLO">D0VTUR ;J:65ROV8#A2<I)(ZYJ]X4T.;2K2:ZU!Q+JU^_G7DO\ M=D'^RHX%=#0 445G3Z[I5M%<2S: MC;1QVS[)F>4 (WH?0T :-%9?_"2:*-.74#JUF+-VVK/YR["WIGUIP\0:09;: M(:I:&2Z&8%\YH-5[S5+&PF@BN[R&"2X;9$LCA3(?09 MZF@"W15.WU2QN[NXM+>\AEN+":Q);WFLW5W8Z*\*PR1K8V[:*&25>,[V/([]*][N-GDR>8,Q[3N M '48YKP>\;2-1\13M;Q+96<3HEMYFEW,C2J.Y.1CGCI0![S#GRUR #M&0.U< MIXP\:OX7OK*V2Q687"L[S22%(X@"!RP4XZ]ZZR+_ %:_[HK%U_PI8^(V4WDU MVBA#')'!,465">#FG> M%=3LM7\=^(KO3[E+BW,5N!(AXR :T[#P-HVG:U_:=NDP=6=XX6DS%&S@!F5> MQ( JKH:)'\1/$:HJJ/)M^%&.QH Z^BBB@ HHHH **** "BBB@ I#TI:PO%>M MOHVD?Z*HDU&Z<6]G%_>E;H?H.I^E 'G2>/;'QW\2[/PRUM<16-C-)(RL,_:) M8_N[AV4')^H%>Q#I7/>&?"=AX?LXRD$3Z@RYN+PH/,E<\L2>O4UT/:@ HKC_ M !GXKN/#%[I(CC22"X:;SP1\VU(R_P OOD51TC7O%,]A:ZQ=-I4EE>6KSI:Q M;EF0A25"G/S]L]* .^HKR&W^(WB/RTLKR&WM]8N98(XK>:V>,0B0GYSS\PX[ M8YJ];?%@6VGQ_P!HZ=YEVLDD4K0W$:(2C%<@.P.#0!ZA17F,'Q$U.Y\01LEM M;KI#:C%IQC/,VYTW;]P.,#TJQXL\C45YC_P +/>]\5W%CID4$MC'9S/"V[,D\Z8X49ZT%NT3H",]R<@^M '<45YI>_%99=$GN+'3+BWN)+&2[LGN0I24( M<'(!R.:RM*^*NK:IK7AS3EMK=6N&\K4_E.8Y#G 7GC@9H ]@HHHH **** "B MBB@ /2N"^)EX(])BCM[I(KE9D:9$GCBE,7.<,W3FN]/2N \;:Q!97S63VFFW M4MS!MC5T#3QL1W!Z#H4X ]J[7/ M%<+\,[>XMM,O8[FXC:3S06@$!C>(XYW94=?\FNIUUHTT*^:4731B%MPM<^:> M.BX[T :.X5R/Q(.?"#?]?=O_ .C%KS>*RO+OPS*V=9T^&2_24V@MII?)4(0J MDDACN/+$<9K=UT>(O^%?:8;F"SM;0/;>= XD,ZMY@[DX]#@T >LK]Q?I2TB? M<7Z4M !1110 4444 %%%-=U1&=F"JHR23@ 4 1W5S!9V[W%S*D4*#CVDF5NY%) M6[EZ$*!_ .>>YKN?!_A]_"_A:QT>2[>[>V3:97[\YX]AVH W:*** "O(+OPI MK<7BB[UAM*:]LXM8-S]CW+F=#'M#J#P2#V->OTF!0!Y/K.@7.JZ7#.WA*YLH MQ?O.MO831K+RN%D=2,9SV!K&/@[Q5*Z)>Z:)KN[2TVW<>P+:>6Q+9QT.,=.I MKW+%)@4 >57?P\\3LEZPUF.02Q2JD8GGR2RD 89MO?TJ7P=I>L:3=7MV^ASV MD5U!;V8@4H"K*N&E.#TS^->H8HP* /$=,\+:YIZ!YO"_VHV%C-;R1.R[;^1Y M0R'KR!C))JO-X1URYTV"YDT2^BNGN9)KSR4C5@S1[5$29*A!T.>:]VP*,"@# MSNZT77U^&VA:9;I+;7T,MNMPMI+M*1@_-S].M$QK@UW3".VE-W6I:AXP>,V]S7&GPE' M*M]US%D$].H)^E 'L\7^K4]MHI);B& J)9HXRYPH=@-Q]!26_P#J(_F9OD'S M,.3QWKSWXDZ7<:K?6-O;Z!?' MYW_//>-WY5R^C?\ )1O$?_7&V_D:Y?3_ WJT'Q >^M+*YA\Z20S7=Y''(J) ML 0QL.<_[)K<\)V][;>.O$4=_>B\G\JW)E$0CXP>,"@#N:*** "BBB@ HHHH M ***AN?^/:7]]Y/R']YQ\G'7GTH ?)(D,3RR,%C0%F8G@ 5Q_AY&\3ZZ_BBX M1A90@P:7&P_A_BEQ_M=O:O&?#OBCQ#XK^(!\+:MXDG?1Y)G24$HOFHO1236K10!S MTG@K09-;_MB@# G\%^'+F]^V/I-L)O*>'OI71T4 %%%% !1110 4444 !Z5E7OAS2-1U M&&_N[&*:ZAQLD8].HHH *Y'XD_\BBW_ %]V_P#Z M,6KWB?Q./#JV:)9R7EU>2&.&%'"YVJ68DGI@"N7\8>*=)UGP1:/#=Q)/=RVT ML=L[@28,@_A_ T >CK]Q?I2TB?<7Z4M !17 ?$_XAW7@&TL9;72C>M=.5+,2 M$3&...YSQ5K3?B18W^FVT_\ 9>K_ &B6,,\$=D[;">V< &@#M,T9KR;QY=>. M?%%K:P>$M.U33%1RTTDY6$OZ @R23Z50TN6_^)NGV]] M')1N%HK_ +VZQ_?8=$SV'6MRU\!Z#$'>]M3J=S(,27&H'SG;\^ /88KHH8(K M>)(H8UCC0;51!@*/0"@!+>WBM($@@C2.&-0J(@P% ["I:** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** $(!R",YZU7M=/L[$.+2UA@#G M,&4"L^YU+4/&H>PT3?:Z,V4N-3=,&5>ZP@]<_ MWNGI7E/@_P"%GB6Q\?0ZMKN@PW5FTK-(KS)@$_Q%>AQUQ7T6BJB!54*HX P M * ,/3?!?AO2DMOLFBV226X'ER^2I<$=]V,Y]ZWJ** "BBB@ HHHH **** " MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH P_$7AFV\1QVWFW$]M/ M:R&2&: @,I(*GKQ@@D5S?C30M.TCP);VUM;1_P"C36T<G7I7/:-_P E%\1_]<+;^1H ZVBBB@!BQ1H[.J*&;[S HWD_E@Q310[XMQ]<'/'4\4 "V M_C?:/^)EHG3_ )])/_BZ7[-XX_Z"6A_^ DG_ ,75/X8ZS?:WX2$^I3337B7, ML./^@EH?_@))_\ %T?9O''_ M $$M#_\ 23_ .+KJ** .7^S>./^@EH?_@))_P#%T?9O''_02T/_ ,!)/_BZ MZBB@#A=;N_'6D:<;M)](NF\Q$\N*TDS\S 9^_P!LY_"M+[-XWS_R$M#_ / 2 M3_XNL?XCZW?Z9<:;!!J#Z=:S+.\EP@&2Z)E$R0>I_.NM\.W5S?>'--N[Q=MS M-;(\HQC#%03Q0!E?9O''_02T/_P$D_\ BZ/LWCC_ *"6A_\ @))_\77444 < MO]F\./^@EH?_@))_\ %UU%% '+_9O&_P#T$M$_\!)/_BZE\,W^LW5S MJMKK*0>99SK''+!$R)*I7.1DGOQ702'",=VW /)[>]>=^!]>N-6\5ZE%%K[: ME80H5(FV*S2;N3&HY" <<]: /1Z*** "BBB@!KYVG!P>QKS'Q9X>\3:G);VM MQI]IJT;L?M%Y"J0R+%G(B3<3CIRU>H44 >8V/A'5[?QN]]:6TEC#-)(UQ=/< M)+N4H%38N,JPQ]..]6K#P=KT?BK5;A_$>I1PRQQ!+D)%F4@'((V]J[ZY,Z6T MC6\:R3!241VVACV!/:O+O$#>.+OQ/H-Q:BE&CBQL+#E %H>%]8P/^*QU7_OW#_\ $T?\(OJ__0XZK_W[A_\ B:A^'$4L/A.- M9GN"YF=C'.CKY63G8N_DJ.Q-=?0!RW_"+ZO_ -#CJO\ W[A_^)H_X1?5_P#H M<=5_[]P__$UU-% '+?\ "+ZO_P!#CJO_ '[A_P#B:/\ A%]7_P"AQU7_ +]P M_P#Q-=310!RW_"+ZO_T..J_]^X?_ (FC_A%]7_Z''5?^_"S.+DPN(B/[^#C]: .0TKP_P"*+C[;_:'BC4H/+NG2WVQQ?/$,;6/R]3S6 MC_PB^K_]#CJO_?N'_P")KGOAA;ZA#>7AFAOXK;[) LHN]WS70W>81N_#D<5Z M50!RW_"+ZO\ ]#CJO_?N'_XFC_A%]7_Z''5?^_FK]P=>G M>@!:*** "BBB@ HHHH *0TM% #$B2-=L:*HSG"C%/HHH **** "BBB@ HHHH M KFRM3-YQMH3+G.\QC=GUS4_04M(: ,&P\8Z)>Z9'J#WD=I#),\*?:G$99D8 MJ<9//(J]<:]I%I.L-QJ=G#*RAE1YE!(/0]:\]'PPU&VCA:WO-/GF$=S"Z7,+*Y?M:?61G:^[Y![$4 >NZG MXFM-+U?3]-EAGDFO0S(8U!5%7&YF)/ &:@U7QMH.EZ/>:E]NBNHK10TJ6LBR M. 3@< UB^*=+OKGQ;HU8\WPGF;3K:UAN[2+R M].2SD*Q$>8PD#EC^6* -^3XG:$+S3+2%+JXGU&U^TP)%&"=N"0#SP>#Q71:# MK=MXAT:WU2T6189P=JR+AA@D'(^HKSC3_A;/X>U%-7%X;O[+.\L<"1DOY.Q@ ML:^^6)KL?AY8W>G>";"VO;=[>X7>6BD'S+ER1G\#0!TA:SI=G/ M&ODWOFF2=GP(@B[B?>NAK \0>$[#Q)(AJ M%6M&^'[/HL<6KL8KO^RSI<@M MY-R^7G.X$CK3Y?A1HD]W![C<3;F7:VTJ1CUKNJX71?!MWHOBG39(=ATK3K&2VCD:3,KEVW GRAPHIC 19 g0na1tfcz5u2000008.jpg GRAPHIC begin 644 g0na1tfcz5u2000008.jpg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g0na1tfcz5u2000009.jpg GRAPHIC begin 644 g0na1tfcz5u2000009.jpg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end GRAPHIC 21 g0na1tfcz5u2000017.jpg GRAPHIC begin 644 g0na1tfcz5u2000017.jpg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Ċ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®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g0na1tfcz5u2000012.jpg GRAPHIC begin 644 g0na1tfcz5u2000012.jpg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end GRAPHIC 23 g0na1tfcz5u2000007.jpg GRAPHIC begin 644 g0na1tfcz5u2000007.jpg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g0na1tfcz5u2000016.jpg GRAPHIC begin 644 g0na1tfcz5u2000016.jpg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�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end GRAPHIC 25 g0na1tfcz5u2000018.jpg GRAPHIC begin 644 g0na1tfcz5u2000018.jpg M_]C_X 02D9)1@ ! 0$ #_VP!# ," @@(" @(" @(" @(" @(" @( M" @(" @(" @(" @(" @(" @(" @(" @(" H(" @("0D)" @+#0H(#0@("0C_ MVP!# 0,$! 8%!@H&!@H-#0H.#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T- M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0W_P 1" $Y ET# 2( A$! Q$!_\0 M'0 ! $% 0$! '+_ .\++^R6O^"N ML?Q]Q7-LJ-&DKAS%H0N9RW&L. _+H5XK?HES4EW$&:W<9?[!,_"[C^&V_IJ? M81GX9N6L,5ZO7VT+VE+S_)5C'*L9F1*YN)L] 8;[ M!,_"[G^&V_IJ?8)GX7<_PVW]-69JPM[\#(Q$H(ER,'$3Z)4!:_8)GX7<_P - MM_35X\/L.">+&D< P1"3VX+3*5GZBEQZ_P 4UGZP6'^+=?7!_EK>@,[2E* 4 MI2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4JE5H!2E* M 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4 MH#6N!/O"R_LEO_@A6L\%,B[NGW^F=DEJ3:&?61*#T\0[M+D'EMGNY+GS]U.<3EE M5BKM:WD8DC;ENXDM4JD35:K,L^*C_F,0ZK#3]\=-1"-/B:=<=+_'M]&W-W\7 MZ*W#%\5!"C(K-C%B*R()EJM4A.DMK7WG_#K0KQ6(A,R9/F#>($*I2.X. M][!C+GN^[^A3_,K>>)\=FW6)B(%),4J(8S:'4P]';9MM_P"ZM9N.8)?(!DN< MF&+YTB72>B!H/:\/<\5OL5;E0,@\&V%_(G,&8% =R!R!%]\GF!]YWC^C9;4[ MV6?ML^]I;6&(B2\B9/8:,;FR(K\31N?=+FL]3Y;V7@]]7I=+N7=WN_];=>.)87>B-Q"@;+&NUP M<.#2/W*'H+Z2G_6?_#\:LUBG$S.C@T16!Q="F0EVE9$#]B>_VO#_ &-6Z^-F MR8P*Q)DEM:-[N->\:S,&=&W)\W_M=5 >)X)>B=Q(:X)AM,3E@$/;MEK7H^3[ MT#]C\G58PR].#B)N4KB'RL#8F7Z]%O"-; 8WN]S?;'?=?5N?)5;XIQVT@&%B MM>3K,'3+]+!([I:V D-OO%^FKKV9\_XZR%CQNS,)E.I<"C6R6=[J?KT: 6K; M9\'R/IQ0%[Q,JZG1MPV>[;G"&)7D_N]LSW/37GN?'U>Q=GU6EG@EPI%Y(01L M=<$81+/?!8&:\V=W[2=ON?V->G#W'$NEL$M<;=LJXC;>#-0OW.P?=IVV=W_U M\.*=S#:0+,%KAAF ,6;#VEZ[JT1VSZ-N;NV_ZGZZ@-KX/6^$#TC5NP;,]7$6S M/HG,0"FT5;B#,2G2H"Q/FI+[_#[E#V!AJMW?&/;M/";B_,&!G_JBEH[KY6X9 M\C63XTY@W,V;Q=;Q:$ZP;=6S$W6\6E9V^X#^Z3MM[]?A;R?$[ZK=)B.I@372 MHHMN\O:C;;MLANTIS_K:CIL3N)+UTJ(.).94+NB>>L$8>&* M;\06K<"TMK1^O1^1AY5F. >8;;MC09;2H@4#1,2XRUM,GJ^%4;N6O MQ:\TVMN/+MUI),5\ZZB.>9EP,DJWM>D%'V4=,NN-H5A8WAV^@-%LZO+SF)=]'6JY$[W$B?BFX"! M2L5JM;XT3VV,2O;5K6I7M6_HW:-!ZV;2V;@;36R[:[OSS63P?G&FY@8MTMN'RYH2I+;9@CL @S.7])Z M+*XAZ/"=XS-KSPZHZ+#4P)4JFBM%M.9*R!TRERB1=V=DU9[6L6WPV9AU+8U? M=1?+W9SGT&>>,L]._P!-Z;.)"X/<;-QB9Y'<6R=*$8G<6X=N\N$Z_0A2EJS] M"?-U46-B5Q-9T"M.NN+0)=B]9LV[MBMN0 .\%Z6,7KW/#7/P^U_VUC^#.:(W MDHCHUQ;]*M3N[:7[/>H6: /J6UVCQT3WO7WE+1<2!JIJJ(L(YBL0S$)>BY8B MWQ E3=9IE2E&%OZ ;N[MIW.]VD^?K^.MC3S-"61W#XMRNSLHN^YVIN ,T>AN M[VWT@.B[NSXWT7?4TSVY3>Z5&V)\Y4*MDW,I>07&'GB "$!N;2RM(T>)XGW< M'5]&W\5?1\S('4!VUP%SOJMU6F:38TW)-X&#%MV=O;6]C=UW5T=OG[G>:>)Y MJQ MZ4I2A(4I2@*94KYK0><=\:[!\K-@'J0.M1FMHP=S;K/0P.L.[.B[B+8VF_4J M&^(<7^PS5MW[JXM21>-?;M85RU46J=_>0QO>Y?ZMM-="=VX5EM?#0>=+I!LS M8EN!T;C=Y"2M@B6; .B'O)MM<72 M=8)=MV6TOO3!7>N2W+O=J8K$JYQ70H3#K972GMOM ]\(V+1VVQAL79-:#-Q MBU;6S,>TW4^:FCB-3 FRONHW$&"KN$L2R-0,C241.DO_ /=>/+_[PLO[):_X M*ZST45B#+=@:=RVO6,M0-I290;P%A#I)JEO-:V''OM6 3-;E6N\+<.]&3"8+ M7 &PAG3IT@;&, /V>NMBJ3QVXFKZJ9TSJ):8 M[%,*6X8$Q@A@A/*?1ZJ^@P\('3 ! Z=&4#&G3[GF]"LA2@,:&$*B B%A$+]" M- =W]7[E$X8H(@16 C'F@0 1&LE2@+!U@!C($ D,^>)'4)5]HL0&!@0&('J& M(CT:O*4!C780J9$B6$D'H3(!J'\SJZJN>ACEE C'Y(JYI0&L8+PF"28<29&V M $SD@SG1N?)K5U]X?>^+-9,,'3 [<*7 99:- :?X*RE* L+6P 2(Q !(_/,! MI(OSZLO^6P_P".LK2@-4M. [1>W (6,*N+BY"!C2(ONMW?/\K=]W\RL=::CWFMQ3OHH=)B+/:8"V_Z(=@*R%*JN+12E* 4I2@%*4H#2 MKSEE9LD2->N0OOL@&M?1'L>@P9GN[G2&&W=]M[3.O8^7JI@)WKO>6QK NIN.][P-LU^;:VML [K9 MVN[6WQ>^J/[?F.\K99_92T,KDK6'F"TZ,+%^YK-@;GA[B^BJZ7YG,[S/PJ]\ M*XVOKAX6J;M*Z:M %OJ1;6C^[]EN*N'LM6M\+NVQU-\&WICY$>BFQWG M+ZQ%Z19<.%C6HN MSNC^ZWV&WMN,&3NW#5+0C=^K562N^6]O,P0%<*9G=:B0 MQBS(;MQO>!?BW&&U7M4^SF,ISBQ_%]Y!KQ#<"6Q@^HU[?="735K>[Y7;5]\[ M6][/:K.MX_O,VHM[VWN8AF%@%_"P( *^NF(>DP6W:8Q2P!JOKU;GTTV5O(AM M)6N^'ELA(GJF$,!JNT?I@$@&L_7]/_K*K7"N"4(Z)MP7W':G9HS+T4'T?7!^ M_P#>J/W?CJ,#XFQ270,7BH \6/#(^Y0(A4NU8_?G_P")W%_4]OPJL.,^@WK+0/OBY3XVWX5IO.[SV/<[U6FV.VXG[6YUUH 8TX;C$8;<+N(^S&$BFT? 'L6[_L1D:0ZMO:8 MP]IGRR]WQ*^K;F?2MF'5,O((MBLUKEYZ%6IFAFR ?GH7WOB_!G-9C'.!$/(RG6#9-#8 M]4QBZU[EUQ!>DY 7;ENZ5ARK[2"=K:;K7N 'T??A MXO>]BI1JIF;KR"JIJ_"/!H6F]I)QE<-Z0YC6[A,;LVZ/V?=H7W2HA75/QUME M4BJU!BT4I2O0*4I0"M?X@P)5VD[=\22F:8,8,UEEKU^FN5,#T/@F*V"E :9@ M_+:S1NR*9,G!H)<2"W$RN+DY?88=<.82$ZK(WW2UWQH6NV]E;L8W:=O;71_KJO7#'R M,>ZWM-TQ+ESA8]'4Q>F"$;1:Q?JZ8,D6DGKV]!_\ 748KQA[KNTA;6WMLG$A)%TP%CVCPG$X>G6M M:5L6IFQWORS]KV-8;ASCK%S23"9!.Z%K>B(ES;2XWD PP1]C;3;8E9O^Y'.< MUVVK:WN^FWD2Z_$EV[Y<69OZ5*V2[=4_JN+C:EZUK4#MC+:GI9LU[!KN8;;K:Q9]RF83V)[JM?L.-Q0 MY)3?MN+(HN08]J0TB_19L0D#M[9.ON^D?M>Z\ZMF-07Q'B$)&["#A[\)X?Z2 MTPVB7N7-_P!+/[V=ML5N=[W+MGZ(5I'*;$'N0PKE@/R>T;=@ M$902(!?69]&M%7$[FY&ZE.U,;?G9#%E_9+7_!76&YM\6Q9V-P<-A3 MS2T+7JU%-QMGMZ ^&?\ K\I=P-0YI\V[FV>RULUIEBD;[&M+T=?N!6)Y9\[; MAB+T[K;=T6UZ5!KC3^Q/\='-(@?$K#M=AFWV_%\1GA?6UEM26XMNXD%8VW$?*2O %EPV]6DUGW5 MF"=0N#^7NU,'([RB$XQ)*V&6KH'7 &>X+ [OK _UZY5XDY2RTH1EVOS SK&.XXMA*0 M)PZH]++6678W/@^B[WZKO?-6W.7-HI6LXKQ2"]41,$P=$Z>V.H3-89@?F/TP M\U4'BI>TMS9@-TR ([1$1QN9 &W';G; Y_10&STK54\8VQ1J!T%&80)#!EN2 MSMAMA'B;D ?AQZC/BKZ^W%,269#MZ52LQG5N:P8SL '7ZE ;12M>#BRWDLH< M,SF(YQZ.H]O0&OP]R=P.K/UXKRO.*5"@,[2E* 4JE,Z K M2J5\F>5 *5A,3XF!7IS$15UA6- Z,P*)_%0GI-;<9/*JTI0@*53.E 5I2E * M4I0"E*4 I2E 670 [78'M^GV?2_/K[3;B,1 Q$1'5$1%7$G357EP/$4#'FB( M^#S5Y)M "-(B(CY\H'2-7.=8/BG%@4 R3!6)&(2+;$"RS$9RG.,X]&N>N;_E)VN'CIL2&XN8GT8+4O\ ;G\'[ZEW@?C6;NVM M7D$!%RL#ZIU")&&>BJ5F5FM5C8S9;40PK-(MJL;=T0,]6D=7FSRKY&S&"D]( MZIC*9R[15=U6KC7'@"8CS1'5&5>]4SKXED4!Z4JF=* K2E* 4I2@%*4H!2E* M 52JTH!5,JK2@%*4H!2E* 4I2@%*4H!2E* 4I2@%*4H#7N7_ -X67]DM?\%= M:QS7Y?,OAMV6[ 7<6K"-.#X ME"KDB,GVPG>&B=H2$S9H0'RGAUA PO$;93KT2BUPUC%-4NX9VKDSV]!H1XOK M[M=J\2\LK&])9W5JBX)7H$Q8%I_?[/Z.L)SFYV MJHQR.EW=<;9I*5ECVMMY_(Y@P3$E73C=;A<7-W(B42 ;@](U]YK#;KJ[E+P. M5C:"MDYN;.^[L]D6F =@/Q*VZACD!PVQ%\J+>W?;I%!!>[H&L2/V8?6;FC_B MUU'7BW6[C7RXIJ-I\3#XY@,7*MHRF!F1G. 2?F^8U;E_[/\ ULU<%)@8'-DY M$9:C/44[B=@^W]76SU6IE)I \M$;A-DV3)1EE.SV1UH/Q-O=]@OVL_\ EFAX M?7&Q':R0PFAU^L8,7V_YYUG:4!IX<"J"%[9L DK0"F#($4"@'K7XB]KPWL^# M_P!;>[Y;(.(SD]0]J#D4L[7>:SVV+MD)+M,?OF>C:VO$,_95N]* Q6#X5" M%PL/1&.SU '^XM:EUE:4H!6"P_Q;KZX/\M;UG:P6'^+=?7!_EK>@,[2E4H#3 M^-N. M SF>NHEMO*27+=&KKS^.O7RA\*:P"@,\ZY/MN6]U+(.!+//SUI*J>2 M.2U3ZAD.3T512M),VX_1?AOB$+E<&,_EJWXRO"!4D&><16A\ATF"8@^K(>O. MI&Q7&[80G=,(&>SUS6RC9I(SA*N..GJF5=R*<3\?\[W TES,YP52?Y/?&QW$ M]93$U=\;>3K98@W>M6#)^EE6V\L>2Y6XVMK4U5IPMS1L[LM"FQN>Y/I5NCY:9/B?%)6$S% M13AO/$8?M3.?7YIJ7L:5!!,%&<5S+SIY2E!1=VLZ6KG5,1[0:P9FD751 MTT_T9MMW>=.X;C LB)CX:OXBHMY.<21=6P%,2+1ZCCYU2>)]=9:-7CUIN&VULAAJ!=N6G5RBY+0N6 M3J:#?4[?R='>2%B#+^[R:H$RTG+9.LB,6'K]"MHY=>2.^UQ6V>VY!BK>=Z0@ M#$M?LZYV..HUKC[/5U61_L[16R^S_,Z[U5!7E?\ ![[S""A R9H\!+!>K1)EVF"L^[/ZNMKL.6."7FF\7: MV;Y+M"\5@6JMRQ#$4VJI)A@E2X](YTC%8%+1-"UUQV>?>IUS2%85CMW&:JM0 M;Q'Y5-DN=-JME[/PR'=*']=E9OEISZMK]FP0';W$CF*V3J$_JSK:G!FZ<78^ M-I;.N2B9%($91'XO5K@;B_F+CES=K;=.N[);6AH6O6A:U:_4^4K] >($:U&. MG5GI[/Q]NHH\H9UJ>%W$&,DS1W, !DW5ZFBL2HC9UVL=)DE=#3RVR1W7;+_ MD7#DRA:>^-H:0 I9.HOS]=;/E\=0!Y,18JZV$\3"04$!T>&1I>7SV5/Y3^^L MB-KE--60Z,S)=<>U*4J9B"E*4 I2E *5YF<1&E11PQY1F'7+(5J-)E.D-T-(E^O4KT I4?\= M%E_9+7_!76PT JF55I0'@5?034/^4ES7;A-B+D").QH+<8PK/ M+\=9!J3?:5H#N9(KU0RW9JAMR P&@M2K=BP,_$^D#NJRWVWCM7+Y2[;MI;'J M:F[&>YMAN?,]KLT!M-*T,N/UC)0=N\)"2#KV2DFAMGLAMMF<^V'7X5?.)\.K#$N80#-N0ZA"0&X=G > RSOWA^OG:T!OU*U[ASB2'B10# D M2TS#(#/T-?J5L- *P6'^+=?7!_EK>L[6"P_Q;KZX/\M;T!F:K6 XCXD%(YS. M4UJ%AS@43(7)1.W]E;F M80(,41ZYTZA774'E*T'UP"JW5E!R]@.I]R4/819GIF M3FLCS+5HUK !LS!&/ZI%736"L5?VPL'+(O]TJ_. MK@;"L[9S_@MF#U_65U%Y*',681-L19Q+STY_LZG^UJ:K9M/::VIR*II,6;Q< MGCA7@J+[H0NT0@KI%QGJZ0I!L7=LT? M3 C:\^]![N57=GQ-?2Q$N&Q1 M#S 1M&O,;L5>_K\-EQ]"I.7TU8JZY4O=LJ.99E=OMW#:.A^:[4E/:0 Q8:SZ2U:^\/=[N/4C\>4RD\ M+[F![W%U6:X M0PI@3=/?&EMT_=E>H"VE "T(#7]6O=^M8V@-HDJI,37/O,+RQL/LGE;K!UV: MRTL)>@5B7N:SRJ1.67.2TQ6WBX1K$8+08,#3MG[AUC+-&S6JVXV,V5U4,2S2 M1NJL;M?X:+,IG."CS&,Z2&M9XVQD<-LKFZB),UAJS*=1$7AA6SXA?"D"8PH$ M @B,Y]48KB#G1Y8LWH/L[2V'HK.SOL(]TNWZ:P]G6QIZ:2;[:FK9E7D7-GP] M>8J3',(WLD=9YSV!#Z.L/@/#P"UB3*!C01!G[Z_4K8^ O!MIN;4BVI#MG'N M5&_$^/&MT&4>;66>=56-=:3)Z\EO%""^N;2"F4RG>R]43 U__4K"^4EQ:=SB M#+.)G:M ]#U2:P-S767\CMR#*ZN9N4$]W86B&!NBI?K[=?'E,SV MZTCC#'I(8!QM6EJMA;:F_6KV9W;-U.WO+[W).SL_*NKV MP[E"X MU3B3S7:O5< ,HMM1-!FO6;-KM=[TQC.[C[HNKA[&N^K50&_P!?% J(^?O/M."( B#>N7:A0C5IU?// MZ.I1QM(UJ@T_RFN-'0Q.'JDE P):XP+21#/8 /WU$&/J?:;>YHKAG[8K2N9O =SA)E;W ZT27C9()UCI6NN0_2V/R5\Q,5I'*SF.G%;1=T MC.!GJ(9](2]<#_'6\36[5KEN4^=2Q-#(T]=?WV\_J: \>*N&$7BMJX2#5S.K0P-0 MZJUG@#DU8X8;F6R86;I#7VS+/1Z !N,G*MH#A!7OW7]]O?ZFJGPDKW[J/^W7 MG]34--;KBY:B18VC5MK%]B%BMHR+!$PG3JB8U#V.W6/O.$+9DS!)7,%)'(Y> MD3,MR3^LT!_!7K]J2O>NO[[>?U-/M25[UU_?;S^IJ92?#N$[NO[[>?U-/M25[UU_?; MS^IH#VO.'D'JU+ M]=?WV\_J:?:DKWKK^^WG]30%0X9M^QW(=CK"=/S]S_$[RO.WX.M0]%" MXS_%\QB_C^3]=?WV\_J:?:DKWKK^^WG]30%_AN$+3$PL8&)G M.%<6W&^ M!Q,^G7Z-<<<)A>()CYIK15<,C27*?4O3V<4<-*T,R[B8. M.,/N19EZ563B)-:@US.DPRG+YE3;Q)AI65LN?,$]G]:HBXS<%ZG+*)E<24EYV'.HBK0O]"UU :XSA1U64YY49?S*RV&\O8N;N!$]8]H.$#.B,BF.T<5S ME%E;4&YFN\SO:/.%K:=J5=TK6P9:=?_ &FLCT6Z^61_=C_J:Q># M6=RE*TPM!0L ""EQCJT?,Z-62WKKY)']X/\ IJN-:85'#)A+'0P-\IUZX7*U MD, M>R82QL[?=^?/-7G_ "^?$N(FZRN=F)"X%#1T27:6W1_UWE53Q"TF-1$! M%P)B'49M6L92MF\<[:?E.I7M=OJRC>:G/X9@XJ&8C,B*>K,M>?I:JZ2\C'BS)U[90)'K6+@B![(EX=3%QAY*&%W%PRX*W9F MV=9[+-L=7U=;KRHY-6>%+9T9.@F3J.9/<9^9KK10T31S77'U7-_5=-6Y?A3* MNXM^?8Q&"7J9: ,9:F 9GIUGH] *_-3#70$%!AG,Q\/JUU+CU\[&,1;)%G&Z M:D+F>RL0.M,YJF M<_1TUMO,OEN*4B9&![R]75ZM8KR>^%;2;9IW1[1'J,/_ ZQ/&>,2&8DV!JGM#72O$'-RYQ8+9)$2P%*A>N.S MN/T=YKKVX X/PXK%C!8 G$=B([6Y7WPQP&+4ON <"S5VM$EXE3KZK6VV\1'' M::SQ_P D"$ 68;9,TDHXK3;SR=;Y+!7=.4E9U66Y_5T$;1PMM8BKF=BML M@+6PM\MI(:YC/TB]\Z]O)CM#/&D.5V4VHM;_E6X>G"DV>&8>N+6W?J:_;[).V_0 S\5E:6DRG]GHKLU MUO\ F=[0YZM?3KEL:_5DYNYU/A7./#',V5WML;/UG:'#M/*UN;A MNLA-0C#&A$2DR+NV,7Z?2%>Y\59#HMU\LC^['_4U86=N]6L1!1C+&G$RTQ+O M#W/0VF^_5_O77R:/YY_TU7FM,([AX;PR/NE;:E;<=[ M])_-O\(PS1FR9DW'XC-/^X'7V%*^3_[V9T!GIKA'RY-+K^T8EH,A:#4T%SJ) M1:]?;_CKICRB>+CL\/[K,67#1MQ./9[F9G_L"N?N&^5SXAE1), TDHQ+./6KJCABY/%R 7.@(V]42SW*@?B?AL8N$ MI (@6,ZYCU?E*GWB&SLEVB2MS+?R[<>[6[S.>.9592F-64A?F[PP$,$((>HS M'7ZI5\>3_P ?W.$WA.$3FV8MH,#U2/1W9_S*R*;]#+D0N\LX+4&OT:E7CS ; M((3%L>N"@-?S:H]TT=/IV\B>GNN,)P]PQ<8LTV%.XXM1S,E6I7_D\.O7LBT* M >L>W$^B6W4D<0X/.&BIMM.-N V"L&W!A,MC7"PG40_GU+'(SD[A-S9V]VW#TE<1)!)R$9%H/T]'A_[ M*XR'T\\L=!VFJE=F;@>?D2<*N1AK6N@A&Z>3D@7R6A80?[7+. MNDX"K:VM8"($8B(CXJN8KLXX]-54X"OJFJJAIF[CTI2E7&"*4I0"E*4 I2E M*53.F= 5I5,Z9T!2E?.Y%>72A^,?XJ6XD+U+FE?.JJT)E:52JT I2E *4I0" ME*4 I2E *4I0%*MW*&.N8BO:M>XOO]M<%YHH31;FM+3BJSM[I!VQS$:XZOFE M7.:> 66AL$AF9'5G'O5N?&R;ABR8@\CCM17OR3YG1B0E:WR]-RKLYS[0:PUD MW6L;ALN94UEW6\SFWBHYW99$93!5M>#\86]PC04Q$Q&GJ]6MSY\\CGB)NLPU MKGSA'I!4.GJKIJW-5: M&VTYC+,C6HD:-G-ML,-M)ZS,C+XY]$:]<5QY2URI6D#@?RQ72 M'+KDM;A&_=M)QQ'87'9&M5')J+<8%;1>WFT5:XSODY< 0$E=OZV3X8>[6V\\ MN6@WR9RC.?AK4+/FB"'[/4,9Z8B/5J1[/CP#*!$HF*INCF6TS(J:HH'6=2$N M6/+=]H>GKTYUT[P_;2*XS\\U]VEF!1!1$5DLJG!#IK:8N95[5DFHW(]*4I62 M:@L0MQB2F!B)(LYF(]+U.W\=7U*4!YYU69JDU!W-KF+?G>!A6$Z!N27O/N&1 MJ&W5YO0^4J#%L,.,C6D86%[87;7VRF-M6L)H$F-1)(_4,*PN'<"7N),DK M@&6]K$:WW#XT]T'I[>Y5_P 2<;<0<.O4Z^N8Q"S:>3(F.T/YGR=='<7IG$<) M?%L77GI:7W%/)M^1%?#UY<[T!AX,,B]D$:M52GP9 MB3F3 '.Q.O0S,O#+VE=+76$V?#>&O:FQ(=I?>-'O&L^>;*XA/C\I:UXS$2UA M-F/K*W69YK&SKM.:R/T^^80R-@VY>!T!<\,607:PALN7.G<=,5:3SRG9:B5]!_1S4=\N.=1XMC=P@FRNS1!!;6X3IWML]MAL^4^JJ:N(>+D6#K4"+*+ MINR(9^M[]4W)(OQ-IHU.7SJZ[7YG*7!'DJ8^I\CTD;-,]DVJ;J(A_,KLC@_A M@+*W5;+DI!0:8DRU$7SSK/"45\E^.(_?7L-.L?$KS+-I\P:Z8N:4I60:DL^B MCJD],:IC+/+M:?L)5G?+OX9<70;P1(DIW5NR]GN>@=3*@K>TO<045S>;6;$,/2H=?H=W\I6M>6%S'Z.%OA0V^R!@#HZ@$=* MS] /X*ZF;,UCI+;3@LOROW%:M/=WF%X2L$O RNWD B'86OVA?GUEN$L*P\DO MWB(&#';46 MY3(SC*GR^:QRTP7 KG$+H+)11G,%,LGT5J#UZ[/X-X6796RK9?H*#3G/K%ZY MUJO*;DTG#!(M4ON6QDQY1I[/N+#V:ZDRLLT0I2E *5A\8Q]*=&\T%0UHI7)E MIUM9Z !\^:M\?XLMK7+?<(2?H!GJ8?U:P[TZ V"E:PGC:U)2WB]4K:1@LH/L MD2Y9K'/S=U"V;OR6VSS933#..[1VB%W 'N&(!EZQ,!C #^6L_P""@-GI2E 4 MJV]^'X2AA)C$&%OL#TNCK\0*MACU&M,::;37J M>N)^46QSS1A5@[$(5.ECQG;1J^8SKSK%3A7$ES!7%SB"L)5,]A #=(_/9-8 M?C_CW[&Z<)PE8JA(CO-@=1#_ .Y]+42<9WU\X@.Z>Q\#ZC9[.FKVE6/@IB+3 MR2;I&_L)P=@O$2!BXM<55B8CVC0:@'6/S-NKAWE1K9;K"VMS;B;2VILI$^Z; MZ^Y]'%0]AN(OPEZKA!3$=DS")[+E,]^NBN*K:QP]=WC@I'?K7D\$\-L* M%!B]X#,](LFX,1U?GL5M5$N-8Q<7EU!7+381#KZY[/[-=;[CW+<%V:[F3"89 MZD>D-5^\=6_#;_*36@1NVXW[#N,[SA]PHQ)IW>'.^]K[3J)1>X^I/X.YV8;? M'M6]TLF_ N>R1?F:\LZY)X9\KL[)463;9=XA1Z0G#>(5S*%# M88HH-U+%=G\PP8OQ%UE21JUK2K:S=Y3C%-#CL:Y? Z@":^ZB'D)S'=>J?;W8 MZ;VQ9L/^?[AU+E:R2/&-K6-C%)J+HU%YC'+.LI2@5K3G3#77%DX[6Z&2&?!=ZK!K)\/<'Z;F'@.4S\53/B6"J< M.E@P4?!G7QAV!"OJCKC\=8^B;=:]M.T]S= A$E\7740\?8C;6^;A$!/TIR]$ MJEW%;'<"1^'X*ACB'@:6R:FQG$^:O)[K=I9E;1X2?48]N">=%E?@2)R6V/4K M4^-N"5LDM19?HK3\*Y)NL[N#$I()FIV=R]-ZHR.(G+X:IA9FVR&?F\,$#+)2 MM?Y*F/AC)D: SRFOA/DVD1[A7 Q/XAU5*'"O "K6(RF3*/A MF*SSF;VNN.9.:G)RYEVXO."K-\KN";J#&#U?CKJ*XL /THB:^;?#0#T1B*UR MTBK)<=/)GSR4^BRC"K;0 C\45?4I6Q.4%*4H!2E4H#S9'57/7,C$'8/BOV5V M&.LWH"WN94.HD$OPST?)UT&95XDF"B8*(F)\\31EN4OADTVW+.';4/U?RE=+>W$Z M5_P5EUC$1E'5$53''W8\C-J:W4C6&-;44CCCCDUA=V<-N;!+G%.F"D=)%^>Q M=:]QSS4L>'5)6:0A9%I6BU !)8^_MY^'6Q\\N(+BTPY]U:B)M3 F S&KUX6? M_/4%8SY+-[?JF]N;[7=L#7ID.Z'YF58\[8K]M=QMLLCBF9<*Z;Z7A^/_ ' G MBUQRSQ_#6Q;L@TO403/K 7SPKBP.5:U7C;9J%PU+-$S'HD7OU)WD26%PF]Q) M!P4*5H$Q]47ZZWGGGR@N>E%B%DN70T?NA0>*)!ZX?*5*/ZRJS*8M=@V6U+0T MTFPC#CGET=C*SU0)Y"U9KGT:ZKY5<2E?8;;7!^FP-)_G !K%8?M*Z\X+X8&RM46P3F*0T9^]\^LPT6+=<;C\_\ FQR>O\)O MVFA5P5L;":BX1!EIW/4/;\-E;]Y.W"6)7M\%_?A=$NU MB+B#[QK.Q[3V:J[ M<8J)ZIB)I Q'FK7+1VM=<=I/ZJEFIO;M&EUEE_ZGCAMM(+ )G.8C*:OJI5:V M)Q I2E *4I0"E*I0&-O\/!PR+!$AGJF)C4)5JF$P &5H)ZP./24==!5C<=P5=PEJ M&1F#0(#_ #3J9%)6C:Y?S.(>5?*M=Q)0L4K+1J*9[-;%RNQ0\/Q5"US.W<." MW<$>B6YZ]?.-\KL5P]A NW?<+STK;;QJU!\_;\.MWY*6EJ5FTT-;LJV>W;>%W M=PJY-C6J;XVXK]$KWM^"XU&0@/FS.=(U:?;7;?A%O_."@(<&[)PA.(1<=>&7 MY#M(,;G1=WNPQW1-O=7<)MC1N]SW.^VKVSO7,)5OK:Q3,3M3L&7"=M^Q: NX MNSV]M/W-V-I3=K_6/J:WS&^)+<08X&VQ/4ENWF8$7H:]'GW.\8L,X^';J]PY M\-+,UP%TJ-!Q.6J 9[AY=Y;MV_T[?RBNH#9*4KY*@(YYQQ%1#R?XJ798BLH MR-1=F8/UBJ;N*K \3)SE(TKCM% 1V1K75M)H36KQ-I$URD;8)>'>G:VBX)C& M2I7YH?\ VZ["Y[\"'=X0RWMXS8F%&N/>V/4K@/B=-S9W,';.>D@#5!K,QTUT M=Y/OE4LFSNEX@4N?:+$TL]=XF>WH/Z3<]I22@98M96/=3=:0S@Y79 M,#[/ZE:%BO$EQ?%,FP]O/NU0?9$:F?BRR;BC2N7+ 2GKR4O2(_\ U*AW$N"; MJW(M"38K5U&N-6GYC*Y+,]14N7B?3/1YLN[+RTX2P$#NEVS(F0?V!] MY9>S.I>Y4<5)P[%;&W:Z0E#MIC#'2HA9N>O^O6'Y4< -!WV0O E*K8"-0'Z3 M"T>G4?\ $-X+C8TIS)ADHLUJI&CVJJG]K4R4]UUKF1JM4JM4&0*4I0"E*4 I2E *4I0"E*4 MI2E *L;S#0/SQU_'5]2@,,> KFPZWM[:(G$+T-;+@NT1%[0_P#?[JH0 MXVX&=>YW5R3&,(=.^=3)SVLYN;;#L5MXEB(0(,R[6V#.\ _W]U^FM+O^:\E9 M#:S(Z!G5$Y=JK]9TF9[MQY!&NFJKQ('P'@\3OD6XS,SKU'G72V-A=80))AD: M'!JF(G5V:BZYX6=:S;W[8$(O-0("2TMTAZ^CY.I+3PDR[M#NC=$[?9T'/:JV MKK?M6=QODYT1XVP! LS^#UJC7&+]UE< MFVW;HRTEHU>E^I6RX)SFFX<)F10X.U.?:K*J8Y5@5KMI0K+<2QAO$[<,!UJ] M$0; T]Y'_)5EPES(!*;A6 \L23;1 M?+@"!9]H#G47\%:1L,'VL7FG\86UPQ9 1,4HX_-(A^96WX1Y(=@*TWEYBWW& MT!,0D 03 \31N;E6N,8QB'OG\FNI$YFX$EMUP_@L1#Y00 MG2VX\Q5&/7%K:62]O!,.,2-F6D M;@U^@"ZZA6$1$1\$598/@BK=8J0L%K#S Z1&LA-;*:2ZU5VJII(8VN:21KF M8]Z4I51F"E*4 I2E *4I0"E*4 I2E *4I0"E*4 I5,Z9T!6E>>Y3I>TKYU57.A,K2E* 4I2@%*4H!5A?X<#0,&#!+.-)C/HD-7]* YHO>'< M0P!K(M$'B.$NG5-OZ3;;Y@?1U98+QKA'3+8&X$ZV;U73F(<*V7%*]JZ@['%[(=# MT77IRW\BRVL[@+BZN9O95.I2Y7MKU>H9]XW77,S4<\=0S*?:Z+U!E MDO6Y)^\&OMA^C_P ZJIK]/ZG(JSGV MGN&]E?88_AZS^UZPN;VZTQB%W&A*([1"7LP_\5M;MR Y93;)Z==ZCQ&\C=>Q MOIAK]3YE2!CG -K!J?'G' M:,.2#WZ]!.4F2$=6WN3Z9_1JC-C)_P"_S5]8]Q_;VUW96C-9G[G=A-?/,+AF;H+=>@36-THW ?HDC0P&?\]1UAG*J_P!VS:Y@FZUO= -U M:C'#D89B=I:.9\I<.N;O=;]9]%4%5?U,EF;J2MQ5Q*%K;7-U,:XM4-=(1/:G M;"6:?TZ*S6[&>6<9^?*N>_\ 17=%:FE5DNU;]BKRTN7"Q)?9"Z>C;7VP[UB] MW[IZ5=;+NN.KOGUE;GE=<%B1O*''JOE7"[E9V BJW6"\TF;+9M_ZAJZ,GN6J M9XJ=U]2T\/(CJ-XDV])&(84VT7IDINGDF)CU""U?<=O^142 MV' =R%L(#AP=,0=FQU[#+83Q([3$;2[9.OQ=R[6@V_=>S"FSM^;OJOF<'8@Z M3:0=$8>(7-PO-H-)"F8$=@AG=^TZ3/A*^"HVJ2N8F0'Q.>4Q.7GRK$<.\2#< M 11V9AUTG3,_@MRRW,OWAG4=7S;0S,D,MYE"E'!LL-IS0/TP7A]LG<_M5 MUWW>>%%8C#^6SP865@I5Q.+MNXQ.&),NB_9!C]'X5N-M_N7HW@Y,\7V5>::_ MB+F)T!\=<1,9QYXS]&OO<_'4#X9RQN8E =&4EZXN0O<0W0@L2A]L] 3W>=RS M=N&!=-Z7$;/1^[EWGCRQK@:^O- /LX6J%8/;F!W"2W.B8FB[N_#9/=]' ]KS M-;\DGS2T\/(:C>)/721RSSC+X\ZQ. 8Z-Q#2',-I[K&P*I%EE;KW@0S:M1(O$_.NP MM0F,W.6N/I# :]]XY;[->TAMG-&_PHAC$4&VSF'^+;^8WSUAL5YFVX M&Q>5RW9G)YVMKS?<398QAX6NV9!+&:+E4'^T7W=8[5B_\ L<6,ZDR2>IN:C7J1_4K8ZY8O>$K)I%?8!<)&^1&]HMR[+P]HEB*FWE'S"'$K) M=S Z#]!J_DVAZ85.2..W4A:Y3'5IHY-&H6UC?:4K5N)^,[>T)$/.1FX>%NO( M=7;/W^KL+^DS]>*QS+-II6FXKQPI3=H0=Z2UL2:V@",]PWK9WBP5.VJ9R\5BOE: VRE:-A?-"T> M6A)D<]+981.@]N;@+7I>333J>.*>4 ][V6^$V!7^U.EEQ)[2-7 MS#JVP_@[B.]F77-^.&Q,]BUMP!ND?GLJ6N#."K>Q0"+<(!8Q^M)>^=;%_MJ] MIT3;&IAK3O)NE8@/%> ^(;,=ZVQ7IA#VIM[A0#N?,"?@JU=Y3K'I4BSM3/%6 MR0':F)Z4$'IFSZ.N@YC.*U[#>!+95TZ]!0Q<. 8<1Z6BBSICS4-2R?PVM4B M1?)/%+^1+%L1/;B,^CV?=#J_/K*W/DGX=(Y R\6?JL"Y/4-38$U4ZC[R3#CC M:36C3NW'.&$\P;O 73:XH3+JS/KM;R -A?5LJ4. NVEZHTZB]P_P 56W13ZT*DJL)ETVMQ-C')J+&69- YFZN 8 M8;2^UMZ#T:#/PEU7E?<98MQ$?KBY&6?N9,KGKRB^2AX9<3>!),MKLS.9GU7L M[PP/ZZO,XFDCM:/M1#=>CJ"FKIFCJFY/L^1*O*WRQXN+T;6Z1%NEQZ$,W-6D MC] '?CJ6?*$X/*\P\]H=;4F#PB/2+1Z?_#K\^.'\..ZO+:WMXF7->K1$>KV_ M3_8U^J]FO(8B9SK4Y=/),K:AT?J[*Z;+JA5I^Y#BOA7FB5NAJ1TY,C2><=H: MW+R:.'V/OSOM,PA*B")R[+&L^3J=\7Y08:]FZVR03)G.2T>E^?6U8;AP* 5K M 0 .H0"-(C6W."+RJTI0"E*4!J?'_%,65EE#X@%BU\C;OTVRCS@#N\E]QZ$^?V4;OA]<;)Q3PX%W;7%JR9$ M+E#;[C'XQSQM MEVUP\57)[5JR]2LD.3TE"_70QBO#C6O=F?"4S=\/KK)XCS4ME$,'#PRA9LF; M9VFV!A[8'==W]SY_C\%7>MR7UUC_ /1%N+8JYNWW 3:/L;?.$K-2KH-MAF8> M/<;:P[WS?#M==>6)\D%N=#W&LW,A07)G96S=>SUK-'2%NZ/W?=>VC+Z3OJEL M&XR3N9Z *%&36M-UY"5VUFXBTV)K6\/:]:M8=[W.[[.*W'"<87<)4]1:U.6# M5E[P,"& ?Z8K7L'Y?@FX&X@RF0F_+3,=G_\ $7H>?\O8_P!^:S/"G#PVMM;V MHS)#;I4D2GTB%8:(JIK22_(SU*4J),5\S7U5E>7,+ C+S")3->X$6QZ8$)S3^VJ9\-PT$K!0# Z &/5&HC\G.PEH7N(LZW7 MMTTLY]52^[6%2VW% BJ9ZZC_ (\XP;*R-,SU?%4#\R.9!]*B(*=. M=2+@_'Z9M9#5$E(_#6M]RLERG;ID[4ZQR,MUQ'^">4M=V[]IQQIF?A&IMXDQ M6RO;*6G 24QYI[5,:K1M1/<[V[N^;9=E>#L-&+P!0+(79635,E MI:FE=7[UW; >?X1&P#6_VNLNSBB3<'*B774W:+B5+C5I4N>WKJ^GCODPP;B8-5)8C6\BO _*^YQ%RL5Q M8V"4&+;6R M*K<6\YK*PB)NKA*8TZH7)ZGZ?JUUL7!_'5K MB"1?:N!JY^&)[0E[IA54M1@[6F7#E\D,6HRO:W>;&,>;\45$G-/GW:8;.AQF M;]62K9'BL^>?R:Z\^,_*

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end GRAPHIC 26 g0na1tfcz5u2000005.jpg GRAPHIC begin 644 g0na1tfcz5u2000005.jpg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end GRAPHIC 27 g0na1tfcz5u2000006.jpg GRAPHIC begin 644 g0na1tfcz5u2000006.jpg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end GRAPHIC 28 g0na1tfcz5u2000020.jpg GRAPHIC begin 644 g0na1tfcz5u2000020.jpg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g0na1tfcz5u2000011.jpg GRAPHIC begin 644 g0na1tfcz5u2000011.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRWXD>*]47QCH'@;1[ MN2PDU4JUW>1#]ZD+,5Q&?X6^5SGJ,#!%>I5Y]\0/!%]J^MZ/XKT+R7UG1V#" MVF;:MU&#N\L-T5LY )X^;DC&: ,?XD2W_P -].T[Q+H6IZE(J7*VUW9WU]+< MQ7$; MG]ZS;6R@&5Q]X_B>*?&NH:_P",?#O@S0+R73H]6MUNKN]C \Y86C9] MB$_<;:I.[J"5QT.;GC70-?\ B5!IVBR:3<:)I<+?A]?P^*M#\7^%(8);W28U@?3Y9/+%Q$H*@*_16VL5YXZ'M@@'0 MWWA6]LH[)]!UC5D>.]MFNHKF^>X%Q"LJ^8"92Q3Y=Q^0KNY!!R,<);_:C^T+ M<: =6UDZ5':BX6U.J7!4/L5L_?R1DGY>G;&*]-M-3UB_N(D_L"?38@09I;Z: M%B1Z1K$[Y/;+%0,Y^;I7G\&A^)%^.,WBUO#5Z-+EMQ; _:+;>#M5=Q7S?N\9 M]<=L\4 >K7-NEW:R6\C2JDB[6,4K1N![,I#*?<$&O(O@M<7NJ:OXGEU#5-4O M#87GDVRW&H32(B$N,;68J>@Y()KT9=!M-*E;4;4:S=W$09EMSJT\@D)!& DL MOE]^-V /;%>>?#72/$_@V[\12ZCX4U&5=2NQ/#]GN;1BJY;[VZ88/S#IF@#M M/B#X>U+7_#,ZZ+J=_8:M I>U>UNY(0YX)1@K -D# )Z$Y]<\!X)\62^+/AW% MX=BNKQ?$YG-M,SWLXEC .XW#/OW@!<_+D N N "!7I?AR?6WTR^O=:T^6WNY M;B22*Q$Z2-'& %1 P;;D[<]0,L>E<%X)T#Q#HWQ1\0ZY=^&;NWT_5W/E,)[8 MF++[BSA93[D[=QH T/BD^M^$_AJ;C0-=N+9+(*DSS@W%Q/0#C /OBJ.N^$M3\6?"C3]*EL'L-8T MT0210W,L;*\L2!3AD9AM8%@"<'U H ?HVKW&B?%Z[\'K0B[N'G M>*4<-AW);:0,X)P".,9-3?%OQQ>>#/#D TI5.JZC+Y%L[@$1<.0.H% %FV\%W=IH^(_$VM-KGEL? M[0EO'D3S3G)\AB8MF3@+LR!T(/S5YUX_;5](\0?#VU.K:Q;3:DT4&IQQ:I.% MD*F%&&%? /+9*XR23DGFO2M-UOQ3/I\$%YX3FM]3*[99I+N VH8=6RKF3!'( M&SJ0,@?-7'_$KP[XDU_QGX5O=-T*XNK?1;D37$ZS6\:S#=$Q\M6E#?P,,-CG MN1S0!'K.MZE\.OBEH>GQZE>WOA_7&$;6U[.T[6\A8)N21R7 !*G!)'+>Q%#X MBQ:UX!\5:;XJM]2UN^\--.OVS3VU*UFE1[BXEX;&],AU.^;Q6NI:C)!>_O+2 MT&I2O;HA!^8INV[FSDKC:O R,GK:\E^%FE>,O!]U=:%?Z'=OX=>9GL[F6YM MS);Y/1D60\'J0N<')PM!= X0LH8\A<\FO!X;F2^T#6 M[OQ'=31ZK::+:RZ87D*.&,60Z#NQDX/Y5:N;BXDTO6]3OIG3Q?;ZO;Q64?F$ M.$)BVJJ=U92^>.Y]* /<**\Y\::SX\\-V.IZS;OHCZ7:G?'&Z2>:4) &>V>: M]$C8M&K'J0": '4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111 M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!6O=/LM M1A$-]:0740.X)/&'7/K@U"VA:0UK%;-I5B;>%MT41MTVH?4#& ?I5^B@"K<: M987<\,]S8VTTL/\ JGDB5F3_ '21Q^%#Z;82WR7LEE;/=H,).T2F11[-C(JU M10!Q?Q:_Y)=KO_7%?_0UKL8O]3'_ +HKCOBU_P DNUW_ *XK_P"AK78Q?ZF/ M_=% #Z**Y+Q;\0]#\(V?FW,WVB?S/+%O 07SUY]*:3>P'6T5S7A;QSHOBRPB MN+*X6.61BIMY2!(".O%6O$7B%?#W]GRS6[/:W-TMM+,&QY.[A6([C.!^-#36 MX&W17-3>,[&V\0W^G3XBMK"*,S73L-OF/RL8'4G'-5KKX@:3::]:VDD\(L+B MQ:[6\W_+P^W;C\_RI ==17/+XLLDOM46[FMX;.R$!2X\T'S/,7<..WMZU&GC M*QDU^.R1XS8MIKWYO"^%4+($(/YG\J .EHJCIFL:?K,+RZ?=1SHC;6VGE3[B MLBZ\7I;^-['PV+"X/VD/NNV&V-2L9?:/[QP.W2@#I:*X;_A8JJZ73Z3<#2)K MJ2SM[Q6!,DJY'W.H!92 :=IGQ"75((HX=.H^%88[J'13>V;,D;2B=4*NS;0,'W(YJC<^-]9MM0_L]_#H^V1 MV;7DT9O$ 5 Q& >A/% '=45PEM\17UHPQ^&]$N-1D-M'_L=-BT23^TKBT^UO;SW"1;!N*[ Q.&;(/ H [2BN2\8^*]2\+6 M*W\>B&[LPL8ED%PJE'=P@7!Z\D<^]5;OQW=Z6UQ#J>BM;W4&DW&IM&LRN-L3 M ;BN.L/&MW]HTE=9T9["WU8JEI<+,LB%V70VRN<*96QDTXWO MH!D>%_!.B>%+"*VL;5'D0EC<2J#(2>IW5H>(='BU_P /WNES'"W$156_NMU5 MOP(!JS8ZE9:G"TMC=17$:G:6C;(!HU#4;+2;&2]U"YBMK:,9>61L 4.]]0// M1\-M0;P[9?:+V*XUN*_-_8H!!7/3(/K6M2 \M@^&NJV\:3+ M=6CW-L^GS0HX)CD:W@,3!O8Y)!]A5[7/ 6I>)&F>]N+2V:?2GLV%N#M60W"R MKQW7"X/KDUZ)10!Q&@Z'J^@7D^X@ >]6=?T?7 M+[Q?HNIV:69M--,AQ+(P=_,0HW0=@U6YOI?+B:5(0V"?F=@JC\214>J:[I>BM;+J-[%;O:.W@DGF8)'&I=V/0 #)-96A>*-(\2"4Z5=?:!$ 6.Q@.>G4 MH0I%<64^Y%4HNT,C+TXZCVK&O? 'B"X\,V>B/< MZ7>JL#1O=74;F:!V8G?&PYX!&/H*]/HH YCQ/X:N=8\$#0K>Y!G4V_[Z8_>\ MN1&)/N0IJCXJ\'WNNZK?75O/"B3Z#GZG%IUQ<[ M;J5XHU0*3\TF[8">V=C?E6M0!PEKX6UW4)-!AUR:RBL=&>.:..U+,TTL:[4) M)Z =<5W=8FO>+M$\,M$-7O1;>:I92R$C Z\@<=:BMO&WA^[C1XM07#QRR+N4 MJ2L8!<\CL&% '045@:5XU\/:UA-/G\3Z-;:NFES:A M"EXY51&3T9ON@GH">PH P?BU_P DNUW_ *XK_P"AK78Q?ZF/_=%<=\6?^27: M[_UQ7_T-:[&+_4Q_[HH ?7"^-O"&H:WY#V-Q)*1(69)Y0%0$?P\5W5%7";@[ MH#C?!/A:^T.U;[=<2))YA8112 QL,=QC^M+\0=-O+NVTB]MK-K^+3K]+FXLE M )F0 C@'J1G.*[&BE.;F[L#SK7=7NO$.GP36.DZO;:?'>1C4&$)AFFAPV0O\ M6 V,X[=*P+71];O[^.&?^UTTQJRL,J01Z@ MTM2!X3JL6O:3X8N+M[C5(S<^'H)[N1YFR+O[0@./[K;21@8XK3DM=8::]DL( M];7PTU]:&XB=W\]T"/YQ3/S!=WE9QZ'%>O7-K!>V[V]S"DT+_>1QD'G-2T > M1:6==TO6K*_EMM8DT7S;Z*TB;<\JQNL7E;QUY99-I/(!K.M=%U^YT21KLZNM MS;>&8GA"SNI^UJ\IYYY;IUZBO;J* /%=3L-8U">4ZE::K/J?V^RE@9=WV=;< M>66X'RY#;\YYSBNJ^)T%N]OILJ:?)<7Z7D#K)% 79(ED#/SV_K7?LRJ,LP S MC)-!( R2!]: .?N-6LM@^M=VJ*F[:H7<Q^M M 'G&J:9K&IZ)IFL64)35-2U^*]4S(2((@CK#O'7 0(2/5C7/ZK-J"6.DV$DN MJ17L=G=OJ(DFD+13AT!N!L^\,[BH^[BO=JS[_2M*U66,7]I;7$D?W/,4$COC MZ4 (M$\(:/9Z9>Q M76FO:RW-W/"8UMQ&HW $]2<8P*]6I@EC/213]#2B1"VT.I;T!YH =1110 44 M44 %%%% !1110 5S6M>*KC1[^*V.AWEPDTJPQ2QLNUW()QR?8UTMLIY+JSBFFMGMI'&6BD(W+['%6***0!1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117.ZEXY\. M:5=-:W.IQ_:%^]%&"[+]0.E '15YC\1+"[G\1K.(=1BMGTF:V2XT^W\UY)'/ M^J<8.%Q@]NIYKMM'\5:)K[M'INH0SRH,M$#AQ^!YK8H \8.FZGI^DZY8WN@7 M$EWK6D6UO:);PF1(Y%A\LQEOX-K?-S]:=-HFJVVBZUX7EL+N?5M0U6&YM[Y8 M28_+#1'>9/X=@1ACV'K7LM% 'D_Q5\)R1^$M>U@Z_JK+M$GV,RCR>77Y<8Z5 MZK#Q!&/]D?RKCOBU_P DNUW_ *XK_P"AK78Q?ZF/_=% #ZX[QCK&NZ3ITQMH MH&\YO+A,6YI%X^]C&.*[&BKA)1E=JY$XN2LG8YCPIJNLZOI]O<7,-O'&/DE# M%A)D=\$8YK/^)-W+;V&DP/=2V>EW5^D.H7,3;62(@\;OX03@$UV]1W%O#=P/ M!)+S4FTFWGL%FMVO5>[\DLDWD!"I5=W&=V#R:] M!A\-Z';V$EC#I%BEI* Q MZ]_6I*/,9_B-XAM-(EO918N]QHL6K6ZB,@0[IE0HW/S##=>*NW/CC7+/5I]$ M:YT^>5KRT@CU)(R(H1,CL0PSR1Y>!R,[Q79ZQX1TC6-'ETV2V2"-X%M@\*@, MD2L&"#VR!Q5N/P]HT6GRV$>E62VDIW20B!=CGU(QR: .(TCQYJ,OB6+2K^6R M,$<5Z4_AW19+2WM'TFR:WMVW0Q&!2J'U Q3UT/2DC>--/MU1X/L[*( MQ@Q6>(?$^H^(;.5S<6MK9V^K6,*V>#Y[DF-R^[/3YNF.0#71_ M$^%D@TB_&ISP"'4+=!;K(%1]T@!9NYP/PKK9/#NBRW(N9-*LVG 51*85+ +] MWG&>,4_4M"TK6#&=2T^WNC'G9YR!MN?2@ U"6SN]+OHVU 01+&5FGBE"M",< MG/8XKS"QTV+6M,UTZ+JD=CI%XD$%J+JY),A1\O*>O6O2H?#FDP0WT( MLXFBOF#7$;*"KX !'H *AA\'^&[>.:.'0]/1)@!(HMUPP'3/% '*>'M4&D> M"O%#6-G!#/H[3@/'*\L4SK'N# LE '!Z=XUUJ]\6W-K)-91:?:7-PMV&C_P!5%%T(?=\S M'N,?+6!J^K7VA7N@>*&LI[F]OTU&_:W!/R(8XQ$&'HD83/T:NT_X5AH MZ::YM_-DF6WD"XW2!@V7 #L/G;@G'/>NNDLK66>&:2WB:2!66)BHR@888#TR M * /-=1\9>(HM7M=,L;S3KB9[2UF618UB"QRRR3./[S.26/ZT >.Z18067PV\*ZI TRWE[J5LMQ*9F M)D'G$8Y/L*=##IJ^"_$NL2WLD&LV^IW?V69+AO,#!_D4+GD$\8Q7L"Z1IRV< M%FME +:WVELX2>ZAB8C(620*2/QJ>N0^ M(NF6%SX5O+J>QMI;A!&JRR1*SJ/,' )&<GPF&RM8+:(MN*0QA%SZX'>II)$AC:25U1%&2S' %(!U>8_$KQ[ MI&@:YHUC<":2>UNDO)EC7.Q,$?F<_I732>);O5Y6MO#-J+G!VO?SY6WC^AZN M?85Q7C/X:66H:EH]YJ>I7=S?WMXEMV^I M6$%[:N)()T$D;#N#5BJ]A96^FV$%E:ILMX$$<:^@%6*@84444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R8D02%=V=IQ MM'/3M7 Z?IVK>'];L[AKQ6L[F1VN=]ND*I'C(+MU,FZO0:\]^)MN;J\\.PK9 M0WS-<2XMKJ;RH'^3JS>H["@#L[>/2KN[^WVR6DUR@*>?&%+ 'J-PYJ_7)>!+ M%K&QO%;1M-TO=*#LL+CSE?CJQ[&NMH **** .+^+7_)+M=_ZXK_Z&M=C%_J8 M_P#=%<=\6O\ DEVN_P#7%?\ T-:[&+_4Q_[HH ?69J.K"RAD*PR,ZG RN%_. MM.FO&DJ%'4,K#!!'6JBTGJ3-2:M%V*5AJ:WL4;>5(K,.)-.%G>^8FR0 M2Q31-MDB<=&4]C2DTWH$4TO>=S&_M/5_"ML#K]Y'JTMU,L-E%:6^R1Y""2N, MXQ@9S5=OB59;U@BTN_EO09UFM54;XFAVEP>W1@1ZU:/@2&6VVW6LZI --L[M;S[1=2W96X\Z9V&9FF #,W'4!1C%(HH_ M\+1TI;*YNY;*]CBCLTOXMR&&.R9!Y MDIE#%".V,(V?3::HZ[\-(;KPZUGIERZW4>E1Z7"T[?+Y:RJ^XX'WOEK0;X>V M,IFN;C4+Z;4WGBG6_9QYD;1 A O&, ,W&.=QH FTSQW8:GJL.F+;7,-XWVA9 M8I%P87AV%E/U$BD'WK-_X6CI[6D=S%IE_-&=.34I"B@^5"S,"3SU&T\5;'P[ ML8Y8;J'4;^+4$EFEEO%<>9,90H<-QC&$4# XQ2VWPYTJUT^>SCN+KRYM*&E$ MEAD1 L0>GWOG- &9XB^(#^24T*"=EBOK6WEOC&#$/,9"5^NUA]"16EXZUO7= M%_LV735MDLY+R&&YED^9SO<+M5?QZTU_AOIS.RI?WT=J\\-R]LKC8TL04!NF M>=@S6IXG\+KXGAMX9=1N[6*&190L&WYG4@J3D'H10!K:A%=3Z?/%97"VURRX MCF9-X0^N.]>;QZOXS2W\2?9M0CU3[$8[:WDBL\?ORP\P@9^8*I/XUW>G:9>V MO]H"YU*:<7#YA)QF$;0../7FJ]MX6@L/#<6CV%[=6HC;?]IC8>:SDY+$D8)) M/- &7X>\2/'X5U74=1U![Z;33(;E?LWD/%L7<4*YZXY_&JTGQ0LH4EDFT?4H MT@CBN)F:,?NX9#A)#ST)SQ[&MJV\(64&A:IIC3W$K:IYAN[EV'F2,Z[2>F!@ M8 X[55N_ .F7EK?023W(6]L8+&0JPR$B)*D<=>>: &6OC^RO/$,>D0V-XQDN M9;9)@HVEH_OD]P!ZGK6!<>/KBPUC3=2OKR.'0;Z2^>)-GS-#"J+&0>Y9MS#U M#"F0^ /$2:W?3Q:C#9K>33M/=Q-O9XY V%5"/E(RO.?X:ZO4_ VBZLFEPW4) M-MIUM+;0P#[NQT5.?UZ+5+C26.E7R6-ROSF22+S!@#D8S7#ZEX U\Z['=V&HK(T5M#;V][<2 M?O(@A8DLNTAR=W7BN[TO3[JVL+B"]O'NGEFE<,W5$9CM4?04 ><@5/;>(/%DF@ZWXC34K62'3;VXC^PO; M[0\<3=-^E:&LUP;;39TGB8L-S,KEAGCIDU17X<6GE75H^ MK:BVFW5R]S/9;U".S-N() SMSVS0!UFG7BZCIEK>HI5;B%90IZ@, /NCO52]\8:)93>1]L%Q<9QY%JIE?\ES1JV!NUR'Q)U*SL/!MTMU MKZ M1#K%[K,$\UF=I@6'9&JN0/EY)SG'6JBM=1,]"N?&-F[+;Z*C:M>2*&5+8Y10 M>A9^BBHH_#5WJ\BW'B:Z%PH.5L("5@3_ 'N[GZ\5+X%\+#P?X5MM*,J33*2\ MTJK@,Q.>/8=*Z2DVEL,9'''#$L<2*D:C"JHP /85SGBW_C\\.?\ 85C_ /06 MKIJY[5_#$NKWL5P^LWL*P3":&*,)M1@, \C/26Z"O0*\ MU\9:AI^OWMBMA?Z.;K3+B3SK;5250Y7'W3U]C0!I?#6PM[#3K]+=]"8-,"?[ M'W[/N_Q;CU_I7<5PW@;5;9;FXTN1M#%XY\U4T=#LV@ $N<8S7\RXATYFGOY$;$6%'W=W\3 M#DX%=:%U/QAR_G:;H1Z+]V>Z'O\ W%/YFM'7+.VT_P #ZK:V<"001Z?.$C08 M _=M51]UB.&^&?P_EC\*QGQ(T\JR/YEO9_:6\N.,@$94'!).3@^M>FV6G66G M1>596D%M'_=AC"C]*@T+_D7]._Z]H_\ T$5H4I2;8PKFO'W_ ")=_P#]L_\ MT8M=+7-^*M#U;7K9K.TU&"VLY$42*\)9BP;.0<^PI+<#I**I:7%J,-H5U.YA MN+C>2'BCV#;V&/SJ[2 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ KC_'-[H^G0V[7N@1ZM=S;S'%Y: MD[4&78D] !785P/Q0BCOK/3=-737N[RZE<02+>?9?*PN6_>>XXQWH W_ W> MZ7+-?6.G:?'9&T,>]4C50P= ZD8]C4WB'Q':^'H;?S5,UU=2B&VMT(#2,>O7 MH .2:Q/AQIEQI>E7<5UIL=I*TH)D%_\ :WF^4#+-CC'0#TJ#QEX3N]7UZ/4H M=/L]3C^PO9BWNY"HA9F)\P?G@]^!B@#0UCQS;:3>WD L+JZ33X4FU":'!6V5 MN1G)RW'/':H[CX@V$-W-LM+B73;:XCM;C44QY44C[< \Y(&]02.F:YX>!O$6 MFZ=J.FV4]M>)K&GPV=U=3R$- Z1^4SXQE@5Y'?(I\O@+5H;#4?#5I]G;1=2O MH[M[MY")8E!1G3;CDDQ\'_:]J -'XL7UF?AMKMN+J S>4H\OS!NSO7C%=S#_ M *F/_=%>9_%;PAX?C\$Z]K*:5 -2*"3[1@[MQ=-FN\PI M$G.T(Y!)/U6O6:J5D]!(*QO$>FZGJVG265A>06T<\3Q3&6(N2K#''(P>36S1 M4(9D:!8ZGIUDMMJ-Y!6T5P[26MW=BW23Y< Y)&2#S7H->?>.=>T>X\FS MC;PY?W%O*PEAU.X"^5QV]Z +GPXBM(M.OA::18Z:IF&Y+.\^T!SMZDY.#[5V MM<%\,[:)(M8NH9-'5;FX1OLVE/OCAP@')]3UKO: "BBB@#B_BU_R2[7?^N*_ M^AK78Q?ZF/\ W17'?%K_ ))=KO\ UQ7_ -#6NQB_U,?^Z* 'T444 %%%% !1 M110 4444 %%%% !1110 4444 %07EG!J%I):W*%X9!AE#%<]^H(-3U7OKV#3 M=/N+ZZ?9;V\;2R-Z*!DT L:?HEA++J-_>O=6XG(5 M%0JH+,?;;G ]:]#TKPTMM=_VEJDYU#52/]K8EG'_ $U8?='^R/QKIX;>&TM5M[:)(H8UVI&BX51Z 5+5 M+4]-CU6U^SRS7$*[@VZ"0HWYU-QF3X%_Y%&V_P"NUQ_Z.>NCK$T3PO9>'V/V M*:\*8($6LJ8SO"8!7/I774 %%%% '% M_%K_ ))=KO\ UQ7_ -#6NQB_U,?^Z*X[XM?\DNUW_KBO_H:UV,7^IC_W10 ^ MBBB@ HHHH **** "BBB@ HHHH ***:Z++&T;C*L"I'J#0 T3PDX$J$G_ &A4 ME<#I7A?1H_'VI0I9 1VT$$D*^8^$8[LGK["NFUGQ%:Z0R6ZH]UJ$W^ILX!F1 M_P# >YXIM=@-*[N[>QM9+F[F2&",9>21L "N4G.H>.()+:))+#P_*I62:1<3 M7:GJ$4_<4C^(\GM5JT\/76J74>H^)G2:1#N@L(SF"W/J?[[>YX';UK?O;V#3 MK.2[N7V0Q#+-@G'..U/;8#SKX;>!-'T'7-;OK8323VMV]E"TK9V1[4;\SGK7 MIM<-X-U_3IM6UBV25_-O-2DF@#1L-Z>6O()'^R?RKN:)7OJ)!1114C"BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD=6N?#G@_7+6]N+"UMYM6N& M6:_; *N%R"S'GG&.*ZZN"^)LD3)H]E33KV"Z2,[7:%PP4^AQ5RN"^&4D2PZQ9VTUE>6UM<*L>H6=NL2 MW&4!.0O!*],BM#QUXMF\.Z9-'ID4=QJQMY+A(G/RQQH,L[^W&!ZDT =;17GF MH^,M<+:M/ID5H;?1+.*YNUE!S<%H_,94(^[A>_/-0R_$#4I;2_\ $-I%;?V! MIU[':31.#YT@)0.X/08,G [X- &K\6O^27:[_P!<5_\ 0UKL8O\ 4Q_[HKRK MXJ^.M"E\):]H"S7']H!1%M^S/MW!U)^;&.W7->JP\P1G_9'\J 'T444 %%%% M !1110 4444 %%<1>6^OKXNM=,C\1RI!=6\]S_Q[H2FQXP%'MB0_E7:H"J*& M;<0,$^M-JP#JBN)X[6WDGE8+'&I9B3@<5B7_ (JA2[;3])MWU341]Z*$_)%[ MR/T4?K4$7AFYU25;KQ-=B[(.Y+&'*V\?U'5S[G\J+=P/(M$^)FM:W\1IH+*& MWMSJKK:+)M+F%%SA\=SBO;]&\/V>BJ[QEY[R;F>[F.Z24^Y[#V'%8&CZ/IMM M\2=9E@L+>*1+6 JR1@%27MOYUU:);JX#1A9-V0 M1^E7Z&K.P!56YU&RLY ES=11,1D!V XJU7+^-;K2X-)DCNY+=;J0+Y0D W$! MAG%.$>:5@.CM[J"[C\RWE25 <;D.1FI:J:=<6%Q9B;3GA:W)/S18VD]^E227 MEM$,R7$2 ?WG I-:V GK(O\ Q#;:=="WF@N2S,%4I$2&)[ T^7Q'H\)P^HP9 M] V3^E>?>+_'-Q'K4,-BL3V]NR3HSH02V#^G-:TJ4INUA-GJ%M.+JV294= X MSM=<$?45+5#1+V34M$L[V8*))H@[!>F35^LFK.PPHHHI %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5P'Q0U![6TTNTDOD MLK"[G9+B7[(MR_"Y4+&IQQ7?UPOQ'66,:1>VLFHQ75O,YCDL;/[0PRN" M".P- $OPVFMY-)NX[769M2ABE 7S+!;41:K=:G::B+R^O[J:"=4(O;06[QY4' '<=\UV M= '$7/PX@99X+'4Y[*TO;:.UOX40-YZ(-HPQ.5)7@GGBI+CX>6TMQ<0Q7\L. MC75S'=W.FK&"LDB;<8;J%)121WQ79T4 <7\6?^27:[_UQ7_T-:[&+_4Q_P"Z M*X[XM?\ )+M=_P"N*_\ H:UV,7^IC_W10 ^BBB@ HHHH **** "BBN;U+Q#/ M<7KZ1X?C2YOQQ-.W^IM1ZL>[>BCFFE<#A?$'Q4T;3/B="CV]S+'I\,]E-)&H M/[QVC/ ZG!C(/UKM/[/USQ)\VJROI6G'I96S_OI!_P!-)!]WZ+^=LU):"$7+7#R6Y"8(CV@<'MWKM6NK=/ MO3QK]7%5.#B[ 2U6O;Z&P@\Z??LSCY%+'\A4;ZQIL?W[ZW'UD%8VO^,K'2]* MDN;26*ZF5E C#=1L G)C('!QU/O6C7G7@SQC= M7D+Z?%I;S-$&<&-O[SD\YZ#FNK\O7[S[\MM81GL@\Q_\*JI2Y96>@KFP[I&N MYV55'=CBN#\?>+!::>EMI=U!(TV^.< ;L*1CKZ\UTJ>&[-VWWLD]\_\ TWD) M7_OD8%5O$T&E0Z+);2V:%FBD^SI'#D!]O&,#@]*=/E4UU PO!/B76M2TF4'3 MQ=F&01HZ.L:J HX.3DFNF\[Q%+]VTL(!_P!-)F8_H*;X8.G#35CL(/)954S# MRRN6Q[]>E;=%22YG9 8WV/7Y?]9JEM"/2*VW'\R:XOQWX6U2X6&]^V&ZC@0A MVEVKMR0!@"O3:Q?$%EJ>HVSVEI]F$,BC.. M,=*[2BE";B[@5=.6V33X$LXS';JN(T((P/QYJU114, HHHH **** "BBB@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR77/'EI ME:AX@N]$FTZ_:.-K*W9S+'M&-QP1U)KUJLS3-#M-*N-0GM][/?W)N9=YSAR M./0<4 <[\.GT>XMM2N]-U>]U6>:9?M5S=H58D+A0 0. *[6D Z #Z4M !11 M10!Q?Q:_Y)=KO_7%?_0UKL8O]3'_ +HKCOBU_P DNUW_ *XK_P"AK78Q?ZF/ M_=% #Z*** "BBB@"![VUC#-(\8Z;#?Z?%+<13>??E+<,2C(0-W]X\@XKK--TB7Q+;6UQJ$*VFA(JM9 MZ5'@!U_A:7'Z(./7-7RZ7$3-?:AXN=H=)DDLM&!Q)?XQ)<>HB'8?[7Y5T6FZ M99Z19)9V,"PPIV'4GN2>Y/J:M*JH@1%"JHP !@ 51OM9LK!A'++OG;[L,0WN MWT I:O1#.1OI/%!\<6-PFG:<6CM+F.-3=-\R%XN3QP>!Q[FN[0L8U+@!\#< M<@&O"]7&MS>);J1(K^-I)Y&B0ELJF[D<=NG3VKUW[+X@8_-J=F@_V;4G^;5M M5I**6HDS9ILA(B8A@I .">@K(.FZPWWM;&5$<$?R\^I/)% M='45S";BW>(320EAC?$0&'TSFLE.ST&>:>$_ C1:S<37DTXDBDFD:=']VQMQ_P!LQ5/7=/T6;2G@U-8H;5V7)&$Y!R.1]*V:1E5AAE!' MH16:DT[C.,\"6.B6L+26,@-[('$J[R3M#G;Q],5VE-6-%.510?84ZG.7-*X! M1114 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q?Q:_P"2 M7:[_ -<5_P#0UKL8O]3'_NBN.^+7_)+M=_ZXK_Z&M=C%_J8_]T4 /HHHH *Q M];\00Z28[:*)KO49^(+2+[SGU/\ =4=R:IZIX@GFO7TC0(TN+]?]=.W^IM1Z MN>Y_V153318Z/+*MBLVL:Q-_Q\7/4D^A;HJ^PJE%L#S/Q=X7T2^\4V5SXB\0 M1)J-Y<;=0BA8!;= A*J">>P&3ZUZU9ZQIEAIUI8Z6TFH>7$JQ+!\Y*@<$GH* M\O\ %WA^:^\32SW45FL]R^TA8V(! ]<A#]DUC4_^/RX%A;G_ )8VYS(1[OT'X5?L=+LM-4BU@5&;[SGE MV^K'DU>1GD551225S.$U)NW06D90Z,C#*L M,$4M%9FAE1>&M'AF6:.R19%((8,V>/QK5HHIMM[@%%%%( HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X_QV;FWL_M::W=V> M(FCM;.S0>9I)KL*Y[7_!>D^)+^VO;\W8GMD*0M!<-'LSU(QT M)]: .(O-4\236_B&:[U:2ROO#VFP2B*#;Y4T>Z)65AC)9MY(/TKN;CP)H-W]G^T6\TGE0I Y:=O MWZ)]T2\_/@^M3W'@W1+K6!J*XL+9O\ 7W,I57Q_=0YP/=CT[5G_ !<\#>(/%?B.TN-)L?-BAMMAD:10 M"2Q.,>W]:['X=>%AHOA*TMM2TJ&*_B+!V<*[-SD'/;K^E;I04;LE\W0HZ:+% M;1;2-;FXMUY%IIT3[&/7)[G(KH;>?61$L.G:%;V4&./M$H&/^ KFNBZ# M HJ743Z"Y9=6>,^*O^$H'B(8:ZF,3;D:WC94#$<[,^W>O0=/T?4)K&"7_A(- M157C!"O&@8<=#D9S6U+8+-*)&GG!!RH#X"_2K*+L15W,V!C+'DUI4K\T4DMC M*%)J3YGIZF.-!N"/GUW4S]'0?^RTA\.;OO:OJ9_[; ?TK;HK'VDC7V<3QV_T MSQ'#XO\ MME!/(L+GR?/G#%D& J' MHP^E:!M+8DDV\1)Z_(*@U'2[35+<0W,>=IS&ZG:T9]5/8UM4K*HDI+8QIT94 MVVGN7:*YL:E?^'W$6KDW-CG"7Z+RGM(!_,5T,4L<\2RQ.KQL,JRG((K"4''7 MH;QFI>H^BBBI*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH M**** "BBB@ HHHH **** "BBB@#B_BU_R2[7?^N*_P#H:UV,7^IC_P!T5QWQ M:_Y)=KO_ %Q7_P!#6NQB_P!3'_NB@!]%%% !1110 4444 %%%% !1110 CHL MB%'4,K#!!&0:YF?2+[0I6N]!.^W)W2V#GY3[H?X373TC9VG'7'%7";B1."EZ MG)6/C^PN[V6UEB:UDB WB9@,'N/J*USXGT?M>*WT4FN=LO =M;:]_:1CN68N M7PTZGD]<^U=7_95N/N&1/HU;5%13]TPI.LU[Q3/BK21_RVD/^[$Q_I4%YXFL M)+.0)/=P9'^N6V8[??D5JBQ9?N774I$BD0JS!!D U$ M?9W_ *_R+DZEOZ_S.3\.^,+>ZU&X^U:W,R13,(HVA $D>.&)'3G/Z5VD.MZ7 M<'$5_ Q]-XS7$^&?"T.D:Q]KMG>210T?ELW$@(^GXUUTT>ES'%]I\<;'_GK$ M,?G6M>,.?W3*A4DX>\:JR(_W'5OH7MO80>="9E_D:R?$5I-H6ASW5GJ.HO(!MBA.)0S'IG(SBL8PC*229O*9> IM:O+>:PDNI;-H*'.*M5PG@Y=;O=&5);J2QF@Q&4>T W =#GOQ70_V;K/\ T'/_ M "6'^-$Z:C)J_P#7W!"HY13L;5!( R:Q?[-UG_H.?^2P_P :YSQ?9>*381VM MAY_E2A34I6YD.51Q5^5G>T5S.ES>*Y-.AFN8[(S%?G MAE#1L"/<9'O5O^UM5@'^DZ'*WJUO*KC\N#2=-IVNAJHK7L;=%8O_ D]A&=M MTEU:'OY\#*/SQBG2>*-&1K<+?0N;B41)L;/)]:7LY]@]I'N;%%%%06%%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 <7\6O^27:[_P!<5_\ 0UKL8O\ 4Q_[HKCOBU_R2[7?^N*_ M^AK78Q?ZF/\ W10 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M0@$8(!![&EHH J-IUN6W1AH7_O1';^G2HISJ%I"SQLET%'W6&UOTZUH452D^ MNI#IKIH8VEZG?75L6DM&D(; =2%!_.KWVB[_ .?%O^_BU: & ![4M.4DW= M(F,))6>S9V(^\& )_ U8^W./O6=P/HN?Y5HV#4+6XC5 MTF3##."<&IPZ-T93]#4?V.V*A3;Q$ 8'R"HSIMH?^6('^Z2*7NE+GZV+5(-1BNVOVM#&NU%BB7KG.<]S71_V=&/N2SI])/\ &L[4=(O)Y(3#=NRJ MW\9^[[UI2ERRO&5C.K=QLXW-FWC>*WCCDD,KHH4N1C=CO4E-C4K&JLVY@,%O M6G5BS=;!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %1F>%9A"94$K#(0L,G\*DKQ;6_+SXFDEQ_PEBZ M]"-,)SYPBW1>6$_V"F_../O9H [7XM?\DNUW_KBO_H:UV,7^IC_W17!>+?"G MC'Q-;:CI@UW3(=)NSA8C:MYBID$ MGKQZ5,NE?$A5"CQ'HF ,?\ '@W_ ,50 M!W5%>6>*KWXB^%]$_M*77=&F7SXH=BV+ Y=PN?O=LUM?V7\2?^ACT3_P ;_X MJ@#N:*X;^R_B3_T,>B?^ #?_ !5']E_$G_H8]$_\ &_^*H [FBO*]9OOB+H^ ML:'ISZ[HTC:KE;?]E_$G_H8]$_\ !O_ (J@#N:*X;^R M_B3_ -#'HG_@ W_Q5']E_$G_ *&/1/\ P ;_ .*H [FBO++F]^(MOXOL/#YU MW1C)=VTMP)18MA0A QC=WS6U_9?Q)_Z&/1/_ ;_P"*H [FBN&_LOXD_P#0 MQZ)_X -_\51_9?Q)_P"ACT3_ , &_P#BJ .YHKRNTOOB+=^+]2T :[HRR65O M%.TIL6PP?/&-W;%;?]E_$G_H8]$_\ &_^*H [FBN&_LOXD_]#'HG_@ W_P 5 M1_9?Q)_Z&/1/_ !O_BJ .YHKRSP_>_$77IM8CCUW1HO[-U"2Q;=8L=Y4*=P^ M;I\WZ5M?V7\2?^ACT3_P ;_XJ@#N:*X;^R_B3_T,>B?^ #?_ !5(VF_$E49C MXCT3@9_X\&_^*H [JBO+?"UW\1?$V@Q:I%KNC0K))(FQK%B1M8K_ 'O:MG^R M_B3_ -#'HG_@ W_Q5 'B?^ #?_%5B^+;WXB^%?#5UK,N MNZ-,D!C!C2Q8$[G5?[W^U0!ZG17#?V7\2?\ H8]$_P# !O\ XJC^R_B3_P!# M'HG_ ( -_P#%4 =S17#?V7\2?^ACT3_P ;_XJL77KSXBZ'U 'J=%<-_9?Q)_Z&/1/_ ;_P"*K3T*R\8V^I;]U:-MW&#DGIUH Z:BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH MH **** "BBB@ HHHH **** "BBB@ HHHH *A:SMGNDNGMX6N$&U92@+J/0'J M*FHH **** .>\4ZOH-E%#9:U']H\X^:ENL9D)"$'?@=@<'-;5E>VVHV4-Y:3 M+-;SH'CD4Y#*>AKD_$%MJ.G>,H=>M--FU&"33I+%XX2-\;%U96P>QQ@_A6IX M)TBYT+P;ING7@47,49,BH(O$/AO3-2MQJPWW- MF/M"N(BWV8-\N\D?=!Z5TR.LB*Z$%6&01W%<#\0+;5=4M;O2K/1KJ3SXT-O= MVTBA7A M^$[>TO5"7#/),\8.1'O@^#-,N=4NC':07$ M_FRE5YEE; SCN<#\A6]7F'C/PSKWB/3;K5+;8V=/,-MIUQ"?,A8_?(YQO/3/ M85Z5;"=;6%;ED:<(!(R#"EL%)GTK[ M+=6L<4H3]W:MY>]R#PW3DM795RE_9WVO^*]-2:WDBT:PC%X^_CSIS]Q"/]GE MC[XKJZ "N:U#Q9X?.H2:)>2[_,<6LNZ,F+>XXC9NF2.U=+7G&M3:CJ?C*"SN M?#FH'1+.Z257@1<7$P/$CG/"+U]3B@#J]/U_0_[;;PQ83)]KLX S01CB- <8 MSZCCBMRN!6"YA^+BWT.BW,=B;!K5[A8P$,ID+ECZ@CO7?4 %MX M?NL7"S3-"!+$?*EEC.XH&Z$@KG\*ZBO-?.U?6/&*-=Z!?VEI92.NF$1J84D8 M%3<2<]>3@>Y/>@#MHO$.F3^(YM BN ^H00?:)(U'W5R!R?7D<>]:E><^&?"> MNZ#XTM9KB:VN+;[#.+F[6(AYI'D1CN)/WB0#Z +BO1J &NZQ1M([!44%F)[ M5R8\7>%-9??/*I^Q(;V)[B,J-J\&1,]0/6NJG?9;ROY9EVH3Y:C);CI^->3F MWU[Q$-9GN?#MU:ZG-8R6U@DZ+]G@BR/DSGEV]>G H ]#T3Q/IFOR3164CB:% M5=XI4*,%;[K8/8^M;->?> -&O[#7+^ZDLKVWLI+2&('4) \S2)D'!_N ?K7H M- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%-D8K$S#J M37D'A[XB^(9]/\-ZG?7>EWB:O=BVDL8(RDT(+,-_4Y VY.?6@#V&BN2M/B/X M?N[J*)9+B.&=G2WNI(&6&3G(% 'J=%<=-\3/#]O<+#*UTN!'Y[F!MMN7Q MM$A_A/(X[5>NO&VEV>MQ:7<)=QM-,+>.=H&\EI",A0_3)H Z.BO/M*^*5I-8 MZO>ZG8WEK;65^UJLGD-@C>$4'_:R>1VJY_PM'P^LCI,E_"89DAN3):LHMF<@ M)YG]T-D8H [6BN5F^(>@0:V^F/+,6CN!:R7 B)A28]$+],Y(%16WQ)T*ZOH+ M5%O!Y]R]I'*UNPC:9208]W3<<<4 =?17(>"?&K>*K"_N9;"XM1;7$J O&0I1 M6P.3_%ZCM69H_CY8=$M[G5&GN;[5)9Y[.UM8"[1P*Q R!V &2?>@#T*BO/\ M0_B(%\&V.K:S#7I\4!S@8[T =317+>']9O+CQ5KFE7;%XXE@N[4LNUEBE7[A'J&5JZF@ H MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "BBB@!KKOC9?4$5R7@OP'8>%?#EK820VT]]'&Z27B1 .X9F/7KT('X5U]% M'G5C\.=0MXM'TZXU6"72=%G:>QC\G]XS?-L\P]"!N[=:AC^&5\^DZU:3:I!# M]OBC2*"VC801.C;M^TG@GN!Q7I=% %"UMKPZ(MK?31/=F$QR21*0I.,9 -T4 _#V8^(M0O[*:Q:VU&99[ MB*\@:1E88#;<'&"!WZ57O?AQJ5]XA6_N-8CEABU6/4(=ZL714;(B'.T*!TXK MT>B@#SR?X>ZC+9:OIXU.#[%>ZJ-3BS&=Z-YHD92>XXP*GUGX?7&J1>*T74$3 M^W)[25,H3Y7D[,@^N=E=Y10!P$7P\FM-?N[BVEL)-/N[\WTB7,#/*C,0SJIS MC!(XR.*=!\/KB'3]*MCJ"$V.N-JI.P_,I9FV?7YNM=[10!RWA3PQ>>'H-3LI M[R&XL;FYEN(0J$.OF,20QZ'K7,Z-X)UVW_L^X@N8K*\TL7&GCSDWI/;,^Y7& M.AY_2O3Z* /+V^%^JC2;/3EUN.2WBMYH98Y$;86=B?, !'S#..>*27X?NWB3 MPG:E9'MM,L@M]<*,1S^6CQGXAUF[A,,4WDVMLI M/+1Q@DO^+,WY5T]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1 M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%% 4% !1110 4444 %%%% !1110!_]D! end EX-101.SCH 30 sdgr-20211231.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Consolidated Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Consolidated Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Consolidated Statements of Operations link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Consolidated Statements of Comprehensive Loss link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100070 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Description of Business link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Significant Accounting Policies link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Revenue Recognition link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Property and Equipment link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - Fair Value Measurements link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Income Taxes link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Stockholders' Equity (Deficit) link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Noncontrolling Interest link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Net Loss per Share Attributable to Common and Limited Stockholders link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - Equity Investments link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - Employee Benefit Plan link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Segment Reporting link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Subsequent Events link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Revenue Recognition (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Property and Equipment (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - Fair Value Measurements (Tables) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - Commitments and Contingencies (Tables) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - Income Taxes (Tables) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Net Loss per Share Attributable to Common and Limited Stockholders (Tables) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Segment Reporting (Tables) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Description of Business - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Significant Accounting Policies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Revenue Recognition - Schedule of Timing of Revenue Recognition (Details) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Revenue Recognition - Additional Information (Details 1) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Revenue Recognition - Additional Information (Details 1) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - Revenue Recognition - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Revenue Recognition - Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue (Details) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Revenue Recognition - Schedule of Drug Revenue Recognition (Details) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Property and Equipment - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value (Details) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Investments (Details) link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Fair Value Measurements - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Commitments And Contingencies - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Commitments And Contingencies - Summary of Operating Leases (Details) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Commitments And Contingencies - Summary of Maturities of Operating Lease Liabilities Under Noncancelable Operating Leases (Details) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Commitments And Contingencies - Summary of Maturities of Operating Lease Liabilities Under Noncancelable Operating Leases (Details)2 link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Income Taxes - Summary of Income Tax Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction (Details) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate (Details) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Income Taxes - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities (Details) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Income Taxes - Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits (Details) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100580 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Valuation Assumptions Used for Options (Details) link:calculationLink link:presentationLink link:definitionLink 100590 - Disclosure - Stock-Based Compensation - Summary of Classification of Stock Based Compensation Expense (Details) link:calculationLink link:presentationLink link:definitionLink 100600 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) link:calculationLink link:presentationLink link:definitionLink 100610 - Disclosure - Noncontrolling Interest - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100620 - Disclosure - Net Loss per Share Attributable to Common and Limited Stockholders - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders (Details) link:calculationLink link:presentationLink link:definitionLink 100630 - Disclosure - Net Loss per Share Attributable to Common and Limited Stockholders - Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive (Details) link:calculationLink link:presentationLink link:definitionLink 100640 - Disclosure - Equity Investments - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100650 - Disclosure - Employee Benefit Plan - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100660 - Disclosure - Related Party Transactions - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100670 - Disclosure - Segment Reporting - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink 100680 - Disclosure - Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details) link:calculationLink link:presentationLink link:definitionLink 100690 - Disclosure - Segment Reporting - Schedule of Revenues by Geographic Area (Details) link:calculationLink link:presentationLink link:definitionLink 100700 - Disclosure - Subsequent Events - Additional Information (Details) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 31 sdgr-20211231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 32 sdgr-20211231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 33 sdgr-20211231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Cover [Abstract] Document and entity information. Document and entity information. Document And Entity Information [Table] Document And Entity Information [Table] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Common Stock Common Stock [Member] Limited common stock. Limited Common Stock Limited Common Stock [Member] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Document Type Document Type Amendment Flag Amendment Flag Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Document Period End Date Document Period End Date Current Fiscal Year End Date Current Fiscal Year End Date Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity File Number Entity File Number Entity Well-known Seasoned Issuer Entity Well Known Seasoned Issuer Entity Voluntary Filers Entity Voluntary Filers Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Security12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Document Annual Report Document Annual Report Document Transition Report Document Transition Report ICFR Auditor Attestation Flag Icfr Auditor Attestation Flag Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Entity Public Float Entity Public Float Auditor Name Auditor Name Auditor Location Auditor Location Auditor Firm ID Auditor Firm Id Unbilled and other receivables current. Statement Of Financial Position [Abstract] Statement [Table] Statement [Table] Unallocated common stock. Common Stock Unallocated Common Stock [Member] Statement [Line Items] Statement [Line Items] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Restricted cash Restricted Cash Current Marketable securities Marketable Securities Current Accounts receivable, net of allowance for doubtful accounts of $108 and $60 Accounts Receivable Net Current Unbilled and other receivables, net for allowance for unbilled receivables of $30 and $0 Unbilled And Other Receivables Current Prepaid expenses Prepaid Expense Current Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Equity investments Equity Method Investments Right of use assets Operating Lease Right Of Use Asset Other assets Other Assets Noncurrent Total assets Assets Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued payroll, taxes, and benefits Accrued Payroll Taxes Current Deferred revenue Deferred Revenue Current Lease liabilities Operating Lease Liability Current Other accrued liabilities Other Accrued Liabilities Current Total current liabilities Liabilities Current Deferred revenue, long-term Deferred Revenue Noncurrent Lease liabilities, long-term Operating Lease Liability Noncurrent Other liabilities, long-term Other Liabilities Noncurrent Total liabilities Liabilities Commitments and contingencies (Note 6) Commitments And Contingencies Stockholders’ equity: Stockholders Equity [Abstract] Preferred stock Preferred Stock Value Common stock Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Accumulated other comprehensive (loss) income Accumulated Other Comprehensive Income Loss Net Of Tax Total stockholders’ equity of Schrödinger stockholders Stockholders Equity Noncontrolling interest Minority Interest Total stockholders’ equity Stockholders Equity Including Portion Attributable To Noncontrolling Interest Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Allowance for unbilled receivables current. Allowance for doubtful accounts receivable Allowance For Doubtful Accounts Receivable Current Allowance for unbilled receivable Allowance For Unbilled Receivables Current Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Income Statement [Abstract] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] Software products and services. Software Products and Services Software Products And Services [Member] Drug discovery. Drug Discovery Drug Discovery [Member] Revenues: Revenues [Abstract] Total revenues Revenue From Contract With Customer Excluding Assessed Tax Cost of revenues: Cost Of Revenue [Abstract] Total cost of revenues Cost Of Revenue Gross profit Gross Profit Operating expenses: Operating Expenses [Abstract] Research and development Research And Development Expense Sales and marketing Selling And Marketing Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Other income: Nonoperating Income Expense [Abstract] (Loss) gain on equity investments Income Loss From Equity Method Investments Change in fair value Increase Decrease In Equity Securities Fv Ni Interest income Investment Income Interest Total other income Nonoperating Income Expense Loss before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax expense (benefit) Income Tax Expense Benefit Net loss Profit Loss Net loss attributable to noncontrolling interest Net Income Loss Attributable To Noncontrolling Interest Net loss attributable to Schrödinger common and limited common stockholders Net Income Loss Net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted: Earnings Per Share Basic And Diluted Weighted average shares used to compute net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted: Weighted Average Number Of Share Outstanding Basic And Diluted Statement Of Income And Comprehensive Income [Abstract] Net loss attributable to Schrödinger common and limited common stockholders Changes in market value of investments, net of tax: Other Comprehensive Income Available For Sale Securities Adjustment Net Of Tax Period Increase Decrease [Abstract] Unrealized (loss) gain on marketable securities Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Temporary equity stock issued during period shares new issues. Temporary equity stock issued during period shares conversion of convertible securities. Temporary equity stock issued during period value conversion of convertible securities. Exchange of convertible preferred stock into limited common stock, value. Temporary equity, exchange of convertible preferred stock into limited common stock, shares. Temporary equity exchange of convertible preferred stock into limited common stock, value. Exchange of convertible preferred stock into limited common stock, shares. Conversion of limited common stock Into common stock shares. Conversion amount of limited common stock into common stock. Statement Of Stockholders Equity [Abstract] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Additional Paid-In Capital Additional Paid In Capital [Member] Accumulated Deficit Retained Earnings [Member] Accumulated Other Comprehensive Loss (Income) Accumulated Other Comprehensive Income [Member] Non Controlling Interest Noncontrolling Interest [Member] Series E Preferred Stock Series E Preferred Stock [Member] Series D Preferred Stock Series D Preferred Stock [Member] Series C Preferred Stock Series C Preferred Stock [Member] Series B Preferred Stock Series B Preferred Stock [Member] Series A Preferred Stock Series A Preferred Stock [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Initial Public Offering I P O [Member] Follow on offering. Follow-on Offering Follow On Offering [Member] Beginning Balance Convertible preferred stock, Beginning Balance, Shares Temporary Equity Shares Outstanding Convertible preferred stock, Beginning Balance Temporary Equity Carrying Amount Attributable To Parent Beginning Balance, Shares Shares Outstanding Change in unrealized loss on marketable securities Issuances of Series E preferred stock, net of issuance costs Temporary Equity Stock Issued During Period Value New Issues Issuance of Series E preferred stock net of issuance costs, Shares Temporary Equity Stock Issued During Period Shares New Issues Issuances of common stock upon stock option exercise Stock Issued During Period Value Stock Options Exercised Issuances of common stock upon stock option exercise, Shares Stock Issued During Period Shares Stock Options Exercised Stock-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Issuances of common stock upon public offering, net of issuance costs Stock Issued During Period Value New Issues Issuances of common stock upon public offering, net of issuance costs, Shares Stock Issued During Period Shares New Issues Conversion of convertible preferred stock into common stock Stock Issued During Period Value Conversion Of Convertible Securities Conversion of convertible preferred stock into common stock, Shares Stock Issued During Period Shares Conversion Of Convertible Securities Temporary equity, conversion of convertible preferred stock into common stock Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities Temporary equity, conversion of convertible preferred stock into common stock, Shares Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities Exchange of convertible preferred stock into limited common stock Exchange Of Convertible Preferred Stock Into Limited Common Stock Value Exchange of convertible preferred stock into limited common stock, Shares Exchange Of Convertible Preferred Stock Into Limited Common Stock Shares Temporary equity, exchange of convertible preferred stock into limited common stock Temporary Equity Exchange Of Convertible Preferred Stock Into Limited Common Stock Value Temporary equity, exchange of convertible preferred stock into limited common stock, Shares Temporary Equity Exchange Of Convertible Preferred Stock Into Limited Common Stock Shares Conversion of limited common stock into common stock Conversion Of Stock Amount Converted1 Conversion of limited common stock into common stock, Shares Conversion Of Limited Common Stock Into Common Stock Shares Conversion of limited common stock into common stock Conversion Amount Of Limited Common Stock Into Common Stock Conversion of limited common stock into common stock, Shares Conversion Of Stock Shares Converted1 Contributions by noncontrolling interest Noncontrolling Interest Increase From Subsidiary Equity Issuance Net loss Ending Balance Convertible preferred stock, Ending Balance, Shares Convertible preferred stock, Ending Balance Ending Balance, Shares Temporary equity stock issued during period value of issuance costs. Common stock issuance costs Payments Of Stock Issuance Costs Issuance of preferred stock value of issuance costs Temporary Equity Stock Issued During Period Value Of Issuance Costs Noncash revenue from equity investments. Research and development noncash expense. Investment accretion noncash expense. Increase decrease in unbilled and other receivables. Increase (decrease) in reduction in the carrying amount of right of use assets. Increase decrease in operating lease liabilities. Proceeds From Issuance Upon Follow On Public Offering Net. Noncash Or part noncash acquisitions of right of use assets in exchange for lease obligations. Noncash Or part noncash right of use assets recognized on adoption. Noncash or part noncash reclassification of deferred financing costs to additional paid in capital. Statement Of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash (used in) provided by Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Loss (gain) on equity investments Noncash revenue from equity investments Noncash Revenue From Equity Investments Fair value adjustments Depreciation Depreciation Depletion And Amortization Stock-based compensation Share Based Compensation Noncash research and development expenses Research And Development Noncash Expense Noncash investment accretion Investment Accretion Noncash Expense Loss on disposal of property and equipment Gain Loss On Sale Of Property Plant Equipment Decrease (increase) in assets: Increase Decrease In Operating Assets [Abstract] Accounts receivable, net Increase Decrease In Accounts Receivable Unbilled and other receivables Increase Decrease In Unbilled And Other Receivables Reduction in the carrying amount of right of use assets Increase Decrease In Reduction In The Carrying Amount Of Right Of Use Assets Prepaid expenses and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets (Decrease) increase in liabilities: Increase Decrease In Operating Liabilities [Abstract] Accounts payable Increase Decrease In Accounts Payable Accrued payroll, taxes, and benefits Increase Decrease In Employee Related Liabilities Deferred revenue Increase Decrease In Deferred Revenue Lease liabilities Increase Decrease In Operating Lease Liabilities Other accrued liabilities Increase Decrease In Other Accrued Liabilities Net cash (used in) provided by operating activities Net Cash Provided By Used In Operating Activities Cash flows from investing activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of property and equipment Payments To Acquire Property Plant And Equipment Purchases of equity investments Payments To Acquire Equity Method Investments Distribution from equity investment Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital Proceeds from sale of equity investments Proceeds From Sale Of Equity Method Investments Purchases of marketable securities Payments To Acquire Marketable Securities Proceeds from sale and maturity of marketable securities Proceeds From Sale And Maturity Of Marketable Securities Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash flows from financing activities: Net Cash Provided By Used In Financing Activities [Abstract] Issuances of common stock upon initial public offering, net Proceeds From Issuance Initial Public Offering Issuances of common stock upon follow-on public offering, net Proceeds From Issuance Upon Follow On Public Offering Net Issuances of Series E preferred stock, net Proceeds From Issuance Of Preferred Stock And Preference Stock Issuances of common stock upon stock option exercise Proceeds From Stock Options Exercised Contribution by noncontrolling interest Proceeds From Minority Shareholders Deferred offering costs Payments Of Financing Costs Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net (decrease) increase in cash and cash equivalents and restricted cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect Cash and cash equivalents and restricted cash, beginning of year Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash and cash equivalents and restricted cash, end of year Supplemental disclosure of cash flow and noncash information Supplemental Cash Flow Information [Abstract] Cash paid for income taxes Income Taxes Paid Net Supplemental disclosure of non-cash investing and financing activities Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Accrued deferred offering costs Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction Purchases of property and equipment in accounts payable Capital Expenditures Incurred But Not Yet Paid Acquisitions of right of use assets in exchange for lease obligations Noncash Or Part Noncash Acquisitions Of Right Of Use Assets In Exchange For Lease Obligations Right of use assets recognized on adoption Noncash Or Part Noncash Right Of Use Assets Recognized On Adoption Reclassification of deferred financing costs to additional paid-in capital Noncash Or Part Noncash Reclassification Of Deferred Financing Costs To Additional Paid In Capital Documents Incorporated by Reference Documents Incorporated By Reference [Text Block] Organization Consolidation And Presentation Of Financial Statements [Abstract] Description of Business Business Description And Basis Of Presentation [Text Block] Accounting Policies [Abstract] Significant Accounting Policies Significant Accounting Policies [Text Block] Revenue From Contract With Customer [Abstract] Revenue Recognition Revenue From Contract With Customer [Text Block] Property Plant And Equipment [Abstract] Property and Equipment Property Plant And Equipment Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Commitments And Contingencies Disclosure [Abstract] Commitments and Contingencies Commitments And Contingencies Disclosure [Text Block] Income Tax Disclosure [Abstract] Income Taxes Income Tax Disclosure [Text Block] Equity [Abstract] Stockholders' Equity (Deficit) Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Stock-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Noncontrolling Interest [Abstract] Noncontrolling Interest Minority Interest Disclosure [Text Block] Earnings Per Share [Abstract] Net Loss per Share Attributable to Common and Limited Stockholders Earnings Per Share [Text Block] Equity Method Investments And Joint Ventures [Abstract] Equity Investments Equity Method Investments Disclosure [Text Block] Compensation And Retirement Disclosure [Abstract] Employee Benefit Plan Pension And Other Postretirement Benefits Disclosure [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Segment Reporting [Abstract] Segment Reporting Segment Reporting Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Recently Issued Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Basis of presentation and use of estimates. Basis of Presentation and Use of Estimates Basis Of Presentation And Use Of Estimates Policy [Text Block] Principles of Consolidation Consolidation Policy [Text Block] Cash and cash equivalents and marketable securities and restricted cash policy. Cash and Cash Equivalents and Marketable Securities and Restricted Cash Cash And Cash Equivalents And Marketable Securities And Restricted Cash Policy [Text Block] Accounts Receivable Trade And Other Accounts Receivable Policy Fair Value of Financial Instruments Fair Value Of Financial Instruments Policy Property and Equipment Property Plant And Equipment Policy [Text Block] Accounting for the Impairment of Long Lived Assets Impairment Or Disposal Of Long Lived Assets Including Intangible Assets Policy Policy [Text Block] Warranties Standard Product Warranty Policy Concentrations Concentration Risk Credit Risk Royalties policy. Royalties Royalties Policy [Text Block] Software development costs policy. Software Development Costs Software Development Costs Policy [Text Block] Research and development and advertising policy. Research and Development and Advertising Research And Development And Advertising Policy [Text Block] Stock-Based Compensation Share Based Compensation Option And Incentive Plans Policy Commissions Commissions Policy Income Taxes Income Tax Policy [Text Block] Comprehensive Loss Comprehensive Income Policy Policy [Text Block] Equity Investments Equity Method Investments Policy Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders Earnings Per Share Policy [Text Block] Schedule of Timing of Revenue Recognition Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Table [Text Block] Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue Disaggregation Of Revenue Table [Text Block] Drug discovery revenue. Drug Discovery Revenue Drug Discovery Revenue Table [Text Block] Schedule of Contract Balances Contract With Customer Asset And Liability Table [Text Block] Summary of Property and Equipment Property Plant And Equipment [Text Block] Schedule of Assets and Liabilities Measured at Fair Value Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block] Summary of Changes in Fair Value of Level 3 Investments Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Text Block] Summary of Operating Leases Lease Cost Table [Text Block] Summary of Maturities of Operating Lease Liabilities Under Noncancelable Operating Leases Lessee Operating Lease Liability Maturity Table [Text Block] Summary of Income Tax Expense Schedule Of Components Of Income Tax Expense Benefit Table [Text Block] Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block] Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block] Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities Schedule Of Deferred Tax Assets And Liabilities Table [Text Block] Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block] Summary of Weighted Average Valuation Assumptions Used for Options Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block] Summary of Classification of Stock Based Compensation Expense Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block] Summary of Stock Option Activity Schedule Of Share Based Compensation Stock Options Activity Table [Text Block] Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders Schedule Of Earnings Per Share Basic And Diluted Table [Text Block] Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block] Summary of Financial Information with Respect to Reportable Segments Schedule Of Segment Reporting Information By Segment [Text Block] Schedule of Revenues by Geographic Area Revenue From External Customers By Geographic Areas Table [Text Block] Organization, consolidation and presentation of financial statements. Organization, consolidation and presentation of financial statements. Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Preferred Stock Convertible Preferred Stock [Member] Follow on public offering. Follow-on-Public Offering Follow On Public Offering [Member] Underwriter Over Allotment Option [Member] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Issued and sold shares Offering price per share Net proceeds from issuance of common stock Proceeds From Issuance Of Common Stock Stock issued during period shares sold by selling stockholders. Proceeds from issuance of common stock by stockholder. Issued and sold shares by selling stockholder Stock Issued During Period Shares Sold By Selling Stockholders Proceeds from sale of common stock by stockholder Proceeds From Issuance Of Common Stock By Stockholder Significant accounting policies. Significant accounting policies. Significant Accounting Policies [Table] Significant Accounting Policies [Table] Accounting Standards Update Adjustments For New Accounting Pronouncements [Axis] Accounting Standards Update Type Of Adoption [Member] ASU - 2020-01 Accounting Standards Update202001 [Member] 2018-15 Accounting Standards Update201815 [Member] ASU - 2016-13 Accounting Standards Update201613 [Member] Accounting standards update 202108. ASU - 2021-08 Accounting Standards Update202108 [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum Minimum [Member] Maximum Maximum [Member] Concentration Risk Type Concentration Risk By Type [Axis] Concentration Risk Type Concentration Risk Type [Domain] Customer Concentration Risk Customer Concentration Risk [Member] Concentration Risk Benchmark Concentration Risk By Benchmark [Axis] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Accounts Receivable Accounts Receivable [Member] Revenue Benchmark Sales Revenue Net [Member] Customer Major Customers [Axis] Customer Name Of Major Customer [Domain] Customer A. Customer A Customer A [Member] Customer B. Customer B Customer B [Member] Customer C. Customer C Customer C [Member] Significant Accounting Policies [Line Items] Significant Accounting Policies [Line Items] Change in accounting principle, accounting standards update, adopted Change In Accounting Principle Accounting Standards Update Adopted Change in accounting principle, accounting standards update, adoption date Change In Accounting Principle Accounting Standards Update Adoption Date Change in accounting principle, accounting standards update, immaterial effect Change In Accounting Principle Accounting Standards Update Immaterial Effect Cash equivalents Cash Equivalents At Carrying Value Interest costs capitalized Interest Costs Capitalized Estimated useful lives of assets Property Plant And Equipment Useful Life Impairment of long-lived assets Impairment Of Long Lived Assets Held For Use Concentration risk number of customers. Concentration risk, number of customers Concentration Risk Number Of Customers Concentration risk, percentage Concentration Risk Percentage1 Royalty expense Royalty Expense Commission expense. Commission expense Commission Expense Equity method investment, ownership percentage Equity Method Investment Ownership Percentage Timing of revenue recognition, percentage. Disaggregation Of Revenue [Table] Disaggregation Of Revenue [Table] Timing of Transfer of Good or Service Timing Of Transfer Of Good Or Service [Axis] Timing of Transfer of Good or Service Timing Of Transfer Of Good Or Service [Domain] Point in Time Transferred At Point In Time [Member] Over Time Transferred Over Time [Member] Disaggregation Of Revenue [Line Items] Disaggregation Of Revenue [Line Items] Timing of revenue recognition Timing Of Revenue Recognition Percentage Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table] On premise software. On Premise Software On Premise Software [Member] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Revenue, remaining performance obligation, expected timing of satisfaction, period Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Agreement with Gates Ventures, Limited Liability Company. Agreement with Gates Ventures, LLC Agreement With Gates Ventures Limited Liability Company [Member] Contract with Customer, Duration Contract With Customer Duration [Axis] Contract with Customer, Duration Contract With Customer Duration [Domain] First anniversary. First Anniversary First Anniversary [Member] Second anniversary. Second Anniversary Second Anniversary [Member] Drug discovery member. Drug Discovery Services Drug Discovery Services [Member] Drug discovery contribution. Drug Discovery Contribution Drug Discovery Contribution [Member] Collaboration and license agreement. Collaboration and License Agreement Collaboration And License Agreement [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Bristol-Myers Squibb. BMS Bristol Myers Squibb [Member] Oncology product. Oncology Product Oncology Product [Member] Neurology and immunology product. Neurology and Immunology Product Neurology And Immunology Product [Member] Revenue, practical expedient, financing component [true false] Revenue Practical Expedient Financing Component Software contribution revenue related to agreement cover period start date. Software contribution revenue related to agreement cover period end date. Software contribution revenue recognition amount. Software contribution revenue yet to be earned. Software contribution revenue recognized. Software contribution revenue related to agreement cover period start date Software Contribution Revenue Related To Agreement Cover Period Start Date Software contribution revenue related to agreement cover period end date Software Contribution Revenue Related To Agreement Cover Period End Date Software contribution revenue recognition amount Software Contribution Revenue Recognition Amount Software contribution revenue recognition Software Contribution Revenue Recognized Additional revenue entitled to receive Software Contribution Revenue Yet To Be Earned Deferred revenue Contract With Customer Liability Hosted software. Hosted Software Hosted Software [Member] Software Maintenance Maintenance [Member] Professional services. Professional Services Professional Services [Member] Revenue from contract with customer before software contribution. Revenue From Contract With Customer Before Software Contribution Revenue From Contract With Customer Before Software Contribution [Member] Software contribution. Software Contribution Software Contribution [Member] Total software revenue Milestone payment yet to be achieved. Revenue recognized for milestone payment. Milestone payment yet to be achieved Milestone Payment Yet To Be Achieved Revenue recognized with milestones Revenue Recognized For Milestone Payment Revenue recognized for drug discovery. Drug discovery services revenue from contracts with customers. Drug Discovery Services Revenue from Contracts with Customers Drug Discovery Services Revenue From Contracts With Customers [Member] Total drug discovery revenue Revenue Recognized For Drug Discovery Upfront payment received. Maximum milestone payments to be received. Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones. Milestone payments to be received upon achievement of certain specified commercial milestones. Upfront fee received Upfront Payment Received Maximum milestone payments to be received Maximum Milestone Payments To Be Received Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones Milestone Payments To Be Received Upon Achievement Of Certain Specified Research Development And Regulatory Milestones Milestone payments to be received upon achievement of certain specified commercial milestones Milestone Payments To Be Received Upon Achievement Of Certain Specified Commercial Milestones Collaborative agreement number of programs. Number of programs under agreement Collaborative Agreement Number Of Programs Collaboration and license agreement transaction price. Transaction price Collaboration And License Agreement Transaction Price Receivable from collaboration. Deferred revenue, revenue recognized Contract With Customer Liability Revenue Recognized Deferred revenue Deferred Revenue Receivable from collaboration Receivable From Collaboration Contract assets Contract With Customer Asset Net Deferred revenue, short-term: Deferred Revenue And Credits Current [Abstract] Deferred revenue, long-term: Deferred Revenue And Credits Noncurrent [Abstract] Percentage of revenue expected to be recognized Revenue Remaining Performance Obligation Percentage Unsatisfied performance obligation Revenue Remaining Performance Obligation Contract with customers, payment terms. Contract with customers, payment terms Contract With Customers Payment Terms Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Long-Lived Tangible Asset Property Plant And Equipment By Type [Axis] Long-Lived Tangible Asset Property Plant And Equipment Type [Domain] Computers and Equipment Computer Equipment [Member] Leasehold Improvements Leasehold Improvements [Member] Furniture and Fixtures Furniture And Fixtures [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Computers and equipment Property Plant And Equipment Gross Less accumulated depreciation Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property Plant And Equipment Net Depreciation expense Depreciation Fair Value By Balance Sheet Grouping [Table] Fair Value By Balance Sheet Grouping [Table] Asset Class Fair Value By Asset Class [Axis] Asset Class Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain] Marketable Securities Securities Assets [Member] Equity Investments Equity Method Investments [Member] Fair Value Hierarchy and NAV Fair Value By Fair Value Hierarchy Level [Axis] Fair Value Hierarchy and NAV Fair Value Measurements Fair Value Hierarchy [Domain] Level 1 Fair Value Inputs Level1 [Member] Level 2 Fair Value Inputs Level2 [Member] Level 3 Fair Value Inputs Level3 [Member] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items] Total Assets Assets Fair Value Disclosure Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, cash contributions. Beginning balance Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value Cash contributions Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Cash Contributions Unrealized loss Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss Ending balance Fair value, assets, Level 1 to Level 2 transfers, amount Fair Value Assets Level1 To Level2 Transfers Amount Fair value, assets, Level 2 to Level 1 transfers, amount Fair Value Assets Level2 To Level1 Transfers Amount Fair value, asset transfers into Level 3 Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3 Operating lease expiration year. Lessee Lease Description [Table] Lessee Lease Description [Table] Office Lease Agreement. Office Lease Agreement Office Lease Agreement [Member] Lessee Lease Description [Line Items] Lessee Lease Description [Line Items] Operating lease expiration year Operating Lease Expiration Year Operating lease, weighted average lease term Operating Lease Weighted Average Remaining Lease Term1 Number of new operating leases. Increase in operating lease right of use asset. Increase in operating lease liabilities. Number of new operating lease Number Of New Operating Leases Increase in right-of-use assets Increase In Operating Lease Right Of Use Asset Increase in lease liabilities Increase In Operating Lease Liabilities Lease costs Lease Cost Area leased. Percentage of annual rental escalation. Lease expiration period. Base rent per month. Area leased Area Leased Base rent per month Base Rent Per Month Percentage of annual rental escalation Percentage Of Annual Rental Escalation Lease expiration period Lease Expiration Period Base rent per month from commencement to handover date. Base rent per month from handover to termination date. Base rent per month from commencement to handover date Base Rent Per Month From Commencement To Handover Date Base rent per month from handover to termination date Base Rent Per Month From Handover To Termination Date Lease expiration date Lease Expiration Date1 Operating lease costs Operating Lease Cost Cash paid for operating leases Operating Lease Payments 2022 Lessee Operating Lease Liability Payments Due Next Twelve Months 2023 Lessee Operating Lease Liability Payments Due Year Two 2024 Lessee Operating Lease Liability Payments Due Year Three 2025 Lessee Operating Lease Liability Payments Due Year Four 2026 Lessee Operating Lease Liability Payments Due Year Five Thereafter Lessee Operating Lease Liability Payments Due After Year Five Total future minimum lease payments Lessee Operating Lease Liability Payments Due Less: imputed interest Lessee Operating Lease Liability Undiscounted Excess Amount Present value of future minimum lease payments Operating Lease Liability Less: current portion of operating leases payments Current: Current Income Tax Expense Benefit Continuing Operations [Abstract] Federal Current Federal Tax Expense Benefit State Current State And Local Tax Expense Benefit Foreign Current Foreign Tax Expense Benefit Current income tax expense (benefit) Current Income Tax Expense Benefit Deferred: Deferred Income Tax Expense Benefit Continuing Operations [Abstract] Federal Deferred Federal Income Tax Expense Benefit State Deferred State And Local Income Tax Expense Benefit Deferred income tax expense (benefit) Deferred Federal State And Local Tax Expense Benefit Income Tax Expense (Benefit), Total United States Income Loss From Continuing Operations Before Income Taxes Domestic Foreign Income Loss From Continuing Operations Before Income Taxes Foreign Loss before income taxes Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments Effective income tax rate reconciliation withholding taxes. Effective income tax rate reconciliation, section 162 limitation. Effective income tax rate reconciliation return-to-provision adjustments. Statutory federal income tax rate Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate State taxes, net of federal benefits Effective Income Tax Rate Reconciliation State And Local Income Taxes Withholding tax Effective Income Tax Rate Reconciliation Withholding Taxes Section 162(m) limitation Effective Income Tax Rate Reconciliation Section162 Limitation Stock compensation Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost Return-to-provision adjustments Effective Income Tax Rate Reconciliation Return To Provision Adjustments Research and development credit Effective Income Tax Rate Reconciliation Tax Credits Research Tax contingencies, net of reversals Effective Income Tax Rate Reconciliation Tax Contingencies Change in valuation allowance Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance Other Effective Income Tax Rate Reconciliation Other Adjustments Effective income tax rate Effective Income Tax Rate Continuing Operations Income Tax Contingency [Table] Income Tax Contingency [Table] Income Tax Authority Income Tax Authority [Axis] Income Tax Authority Income Tax Authority [Domain] Federal Domestic Country [Member] State State And Local Jurisdiction [Member] Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Change in valuation allowance Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance Deferred tax assets lease liabilities. Deferred tax liabilities, depreciation and amortization. Deferred income tax assets: Deferred Tax Assets Net Of Valuation Allowance [Abstract] Net operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards Accrued expenses Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities Deferred Revenue Deferred Tax Assets Deferred Income Lease Liabilities Deferred Tax Assets Lease Liabilities Credits Deferred Tax Assets Tax Credit Carryforwards Gross deferred tax assets Deferred Tax Assets Gross Less valuation allowance Deferred Tax Assets Valuation Allowance Net deferred tax assets Deferred Tax Assets Net Deferred income tax liabilities: Deferred Tax Liabilities [Abstract] Unrealized gain on equity investments Deferred Tax Liabilities Unrealized Gains On Trading Securities Prepaid expenses Deferred Tax Liabilities Prepaid Expenses Depreciation and amortization Deferred Tax Liabilities Depreciation And Amortization Net deferred income tax assets Deferred Tax Assets Liabilities Net Operating loss carryforwards, expiration year. NOL carryforwards, percentage of taxable income limitation on use. Federal net operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards Domestic State net operating loss carryforwards Deferred Tax Assets Operating Loss Carryforwards State And Local Operating loss carryforwards, expiration year Operating Loss Carryforwards Expiration Year NOL carryforwards, percentage of taxable income limitation on use N O L Carryforwards Percentage Of Taxable Income Limitation On Use Research and development tax credit carryforwards Deferred Tax Assets Tax Credit Carryforwards Research Balance, January 1 Unrecognized Tax Benefits Additions for tax positions taken in prior years Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions Reductions for tax positions taken in prior years Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions Additions for tax positions related to the current year Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions Balance, December 31 Income tax examination, description Income Tax Examination Description Number of votes for common share. Common stock, description. Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Voting common stock. Voting Common Stock Voting Common Stock [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Number of votes for common share Number Of Votes For Common Share Common stock, description Common Stock Description Right to exchange each share of limited common stock to common stock. Right to exchange limited common stock to common stock, share Right To Exchange Each Share Of Limited Common Stock To Common Stock Maximum percentage of stock options must be granted at exercise price of fair market value. Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand ten stock plan. 2010 Plan Two Thousand Ten Stock Plan [Member] Vesting Vesting [Axis] Vesting Vesting [Domain] Tranche One Share Based Compensation Award Tranche One [Member] Tranche Two Share Based Compensation Award Tranche Two [Member] Tranche Three Share Based Compensation Award Tranche Three [Member] Share-based compensation award tranche four. Tranche Four Sharebased Compensation Award Tranche Four [Member] Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-based compensation arrangement by share-based payment award, number of shares available for grant Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Maximum percentage of stock options must be granted at exercise price of fair market value Maximum Percentage Of Stock Options Must Be Granted At Exercise Price Of Fair Market Value Share-based compensation arrangement by share-based payment award, options granted, contractual term Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period Share-based compensation arrangement by share-based payment award, award vesting period Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 Share-based compensation arrangement by share-based payment award, award vesting rights, percentage Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage Valuation assumptions Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract] Expected dividend yield Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate Expected volatility Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Expected term (years) Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 Risk-free interest rate Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Cost of Sales Cost Of Sales [Member] Research and Development Research And Development Expense [Member] Sales and Marketing Selling And Marketing Expense [Member] General and Administrative General And Administrative Expense [Member] Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items] Total stock-based compensation Allocated Share Based Compensation Expense Number of shares Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward Beginning, January 1, 2021 Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross Exercised Forfeited Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Expired Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period Balance, December 31, 2021 Exercisable, December 31, 2021 Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Weighted average exercise price Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward Beginning, January 1, 2021 Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Granted Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price Exercised Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price Forfeited Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price Expired Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price Balance, December 31, 2021 Exercisable, December 31, 2021 Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price Share-based compensation arrangement by share-based payment award, weighted average remaining contractual term. Weighted average remaining contractual term (years) Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Remaining Contractual Term [Abstract] Balance, December 31, 2021 Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 Exercisable, December 31, 2021 Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 Share-based compensation arrangement by share-based payment award, aggregate intrinsic value. Aggregate intrinsic value Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract] Balance, December 31, 2021 Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value Exercisable, December 31, 2021 Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 Weighted average per share grant date fair value of options granted Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value Intrinsic value of options exercised Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value Unrecognized compensation cost related to unvested stock options granted Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options Expected to be recognized over a weighted average period Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 Share-based compensation arrangement by share-based payment award, options, vested in period, fair value Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 Minority Interest [Table] Minority Interest [Table] Ownership Ownership [Axis] Ownership Ownership [Domain] Faxian Therapeutics, LLC joint venture. Faxian Faxian Therapeutics L L C Joint Venture [Member] Consolidated Entities Consolidated Entities [Axis] Consolidated Entities Consolidated Entities [Domain] Variable Interest Entity, Primary Beneficiary Variable Interest Entity Primary Beneficiary [Member] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] WuXi AppTech Co Venturer [Member] Minority Interest [Line Items] Minority Interest [Line Items] Equity interest percentage Minority Interest Ownership Percentage By Noncontrolling Owners Numerator: Net Income Loss [Abstract] Denominator: Weighted Average Number Of Shares Outstanding [Abstract] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Convertible Preferred Stock Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Shares Subject to Outstanding Common Stock Options Employee Stock Option [Member] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of earnings per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Schedule Of Equity Method Investments [Table] Schedule Of Equity Method Investments [Table] Investment, Name Schedule Of Equity Method Investment Equity Method Investee Name [Axis] Investment, Name Equity Method Investee Name [Domain] Nimbus Therapeutics LLC. Nimbus Therapeutics, LLC Nimbus Therapeutics L L C [Member] Morphic holding Inc. Morphic Holding, Inc. Morphic Holding Inc [Member] Petra pharma corporation. Petra Pharma Corporation Petra Pharma Corporation [Member] Ravenna therapeutics. Ravenna Therapeutics Ravenna Therapeutics [Member] Relay therapeutics, inc. Relay Therapeutics, Inc Relay Therapeutics Inc [Member] Ajax Therapeutics, Inc. Ajax Therapeutics, Inc Ajax Therapeutics Inc [Member] ShouTi, Inc. ShouTi Shou Ti Inc [Member] Schedule of Equity Method Investments [Line Items] Schedule Of Equity Method Investments [Line Items] Equity investments gains (losses) Escrow payments receivable. Escrow payments received. Escrow payments receivable Escrow Payments Receivable Escrow payments received Escrow Payments Received Common shares received in connection with merger. Non marketable equity securities. Common shares received in connection with merger Common Shares Received In Connection With Merger Carrying value of non-marketable equity securities Non Marketable Equity Securities Loss on sale of equity method investments Equity Method Investment Realized Gain Loss On Disposal Number of preferred shares purchased. Number of preferred shares purchased Number Of Preferred Shares Purchased Cash payments to purchase of shares Plan name Description Of Defined Contribution Pension And Other Postretirement Plans Discretionary matching contributions Defined Contribution Plan Employer Matching Contribution Percent Discretionary matching contributed by employees Defined Contribution Plan Employer Matching Contribution Percent Of Match Matching contributions Defined Contribution Plan Cost Recognized Purchase of services and license technology from related party. Reimbursements received from related parties for sales of products and services provided. Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] David E Shaw. D. E. Shaw Entities David E Shaw [Member] Members of board of directors. Member of Board of Directors Members Of Board Of Directors [Member] Bill and Melinda gates foundation trust. BMGFT Bill And Melinda Gates Foundation Trust [Member] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Purchase of services and license technology from related party Purchase Of Services And License Technology From Related Party Reimbursements received from related parties for sales of products and services provided Reimbursements Received From Related Parties For Sales Of Products And Services Provided Net receivables (payables) Related Party Transaction Due From To Related Party Payment of consulting fees. Payment of consulting fees Payment Of Consulting Fees Revenue recognized Drug discovery revenue recognized Percentage of voting securities. Contributions revenue recognized. Contributions Revenue Recognized Contributions Revenue Recognized Percentage of voting securities Percentage Of Voting Securities Software sales transactions amount Related Party Transaction Amounts Of Transaction Revenue from related parties Revenue From Related Parties Number of reportable segments Number Of Reportable Segments Unallocated. Schedule Of Segment Reporting Information By Segment [Table] Schedule Of Segment Reporting Information By Segment [Table] Consolidation Items Consolidation Items [Axis] Consolidation Items Consolidation Items [Domain] Operating Segments Operating Segments [Member] Segments Statement Business Segments [Axis] Segments Segment [Domain] Software Segment. Software Segment Software Segment [Member] Drug Discovery Segment. Drug Discovery Segment Drug Discovery Segment [Member] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Segment revenues: Segment Reporting Information Revenue [Abstract] Segment gross profit: Gross Profit [Abstract] Total segment gross profit Unallocated: Unallocated [Abstract] Research and development Sales and marketing General and administrative Income tax (expense) benefit Schedule Of Revenues From External Customers And Long Lived Assets [Table] Schedule Of Revenues From External Customers And Long Lived Assets [Table] Geographical Statement Geographical [Axis] Geographical Segment Geographical [Domain] United States UNITED STATES Europe Europe [Member] Japan JAPAN Rest of World Non Us [Member] Revenues From External Customers And Long Lived Assets [Line Items] Revenues From External Customers And Long Lived Assets [Line Items] Revenues Number of shares acquired. Purchase price including upfront purchase price, adjustment for working capital, less cash acquired. Subsequent Event [Table] Subsequent Event [Table] Subsequent Event Type Subsequent Event Type [Axis] Subsequent Event Type Subsequent Event Type [Domain] Subsequent Event Subsequent Event [Member] Business Acquisition Business Acquisition [Axis] Business Acquisition, Acquiree Business Acquisition Acquiree [Domain] XTAL BioStructures, Incorporation. XTAL BioStructures, Inc X T A L Bio Structures Incorporation [Member] Subsequent Event [Line Items] Subsequent Event [Line Items] Number of shares acquired Number Of Shares Acquired Payments to acquire businesses, et of cash acquired Payments To Acquire Businesses Net Of Cash Acquired Purchase price including upfront purchase price, adjustment for working capital, less cash acquired Purchase Price Including Upfront Purchase Price Adjustment For Working Capital Less Cash Acquired EX-101.PRE 34 sdgr-20211231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 35 R1.htm IDEA: XBRL DOCUMENT v3.22.0.1
Document and Entity Information - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Feb. 18, 2022
Jun. 30, 2021
Document And Entity Information [Line Items]      
Document Type 10-K    
Amendment Flag false    
Document Fiscal Year Focus 2021    
Document Fiscal Period Focus FY    
Document Period End Date Dec. 31, 2021    
Current Fiscal Year End Date --12-31    
Entity Registrant Name Schrodinger, Inc.    
Entity Central Index Key 0001490978    
Entity Tax Identification Number 95-4284541    
Entity File Number 001-39206    
Entity Well-known Seasoned Issuer Yes    
Entity Voluntary Filers No    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Large Accelerated Filer    
Entity Small Business false    
Entity Emerging Growth Company false    
Entity Shell Company false    
Entity Incorporation, State or Country Code DE    
Entity Address, Address Line One 1540 Broadway    
Entity Address, Address Line Two 24th Floor    
Entity Address, City or Town New York    
Entity Address, State or Province NY    
Entity Address, Postal Zip Code 10036    
City Area Code 212    
Local Phone Number 295-5800    
Title of 12(b) Security Common stock, par value $0.01 per share    
Trading Symbol SDGR    
Security Exchange Name NASDAQ    
Document Annual Report true    
Document Transition Report false    
ICFR Auditor Attestation Flag true    
Entity Public Float     $ 3,519,898,945
Auditor Name KPMG LLP    
Auditor Location Portland, OR    
Auditor Firm ID 185    
Documents Incorporated by Reference The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2022 Annual Meeting of Stockholders within 120 days of the end of the registrant’s fiscal year ended December 31, 2021. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein.    
Common Stock      
Document And Entity Information [Line Items]      
Entity Common Stock, Shares Outstanding   61,873,343  
Limited Common Stock      
Document And Entity Information [Line Items]      
Entity Common Stock, Shares Outstanding   9,164,193  

XML 36 R2.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Current assets:    
Cash and cash equivalents $ 120,267 $ 202,296
Restricted cash 3,000 500
Marketable securities 456,212 440,395
Accounts receivable, net of allowance for doubtful accounts of $108 and $60 31,744 31,423
Unbilled and other receivables, net for allowance for unbilled receivables of $30 and $0 8,807 3,955
Prepaid expenses 5,030 4,409
Total current assets 625,060 682,978
Property and equipment, net 10,025 5,140
Equity investments 43,167 45,664
Right of use assets 75,384 10,129
Other assets 2,851 2,352
Total assets 756,487 746,263
Current liabilities:    
Accounts payable 8,079 8,398
Accrued payroll, taxes, and benefits 18,405 12,000
Deferred revenue 55,368 45,403
Lease liabilities 2,042 4,543
Other accrued liabilities 7,317 2,861
Total current liabilities 91,211 73,205
Deferred revenue, long-term 30,064 41,164
Lease liabilities, long-term 77,827 7,221
Other liabilities, long-term 300 654
Total liabilities 199,402 122,244
Commitments and contingencies (Note 6)
Stockholders’ equity:    
Preferred stock
Additional paid-in capital 786,964 752,558
Accumulated deficit (229,952) (129,559)
Accumulated other comprehensive (loss) income (651) 317
Total stockholders’ equity of Schrödinger stockholders 557,071 624,015
Noncontrolling interest 14 4
Total stockholders’ equity 557,085 624,019
Total liabilities and stockholders’ equity 756,487 746,263
Common Stock    
Stockholders’ equity:    
Common stock 618 607
Limited Common Stock    
Stockholders’ equity:    
Common stock $ 92 $ 92
XML 37 R3.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Balance Sheets (Parenthetical) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Allowance for doubtful accounts receivable $ 108 $ 60
Allowance for unbilled receivable $ 30 $ 0
Preferred stock, par value $ 0.01 $ 0.01
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 500,000,000 500,000,000
Common stock, shares issued 61,834,515 60,713,534
Common stock, shares outstanding 61,834,515 60,713,534
Limited Common Stock    
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 100,000,000 100,000,000
Common stock, shares issued 9,164,193 9,164,193
Common stock, shares outstanding 9,164,193 9,164,193
XML 38 R4.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenues:      
Total revenues $ 137,931 $ 108,095 $ 85,543
Cost of revenues:      
Total cost of revenues 72,311 44,623 36,450
Gross profit 65,620 63,472 49,093
Operating expenses:      
Research and development 90,904 64,695 39,404
Sales and marketing 22,150 17,795 21,364
General and administrative 64,009 41,898 27,040
Total operating expenses 177,063 124,388 87,808
Loss from operations (111,443) (60,916) (38,715)
Other income:      
(Loss) gain on equity investments (1,781) 4,108 943
Change in fair value 11,359 28,263 9,922
Interest income 1,057 2,253 1,878
Total other income 10,635 34,624 12,743
Loss before income taxes (100,808) (26,292) (25,972)
Income tax expense (benefit) 411 345 (291)
Net loss (101,219) (26,637) (25,681)
Net loss attributable to noncontrolling interest (826) (2,174) (1,110)
Net loss attributable to Schrödinger common and limited common stockholders $ (100,393) $ (24,463) $ (24,571)
Net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted: $ (1.42) $ (0.41) $ (4.09)
Weighted average shares used to compute net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted: 70,594,950 60,024,658 6,004,500
Software Products and Services      
Revenues:      
Total revenues $ 113,236 $ 92,530 $ 66,735
Cost of revenues:      
Total cost of revenues 26,495 18,003 13,646
Drug Discovery      
Revenues:      
Total revenues 24,695 15,565 18,808
Cost of revenues:      
Total cost of revenues $ 45,816 $ 26,620 $ 22,804
XML 39 R5.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Statement Of Income And Comprehensive Income [Abstract]      
Net loss attributable to Schrödinger common and limited common stockholders $ (100,393) $ (24,463) $ (24,571)
Changes in market value of investments, net of tax:      
Unrealized (loss) gain on marketable securities (968) 301 25
Comprehensive loss $ (101,361) $ (24,162) $ (24,546)
XML 40 R6.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)
$ in Thousands
Total
Initial Public Offering
Follow-on Offering
Series E Preferred Stock
Series D Preferred Stock
Series C Preferred Stock
Series B Preferred Stock
Series A Preferred Stock
Common Stock
Common Stock
Initial Public Offering
Common Stock
Follow-on Offering
Limited Common Stock
Additional Paid-In Capital
Additional Paid-In Capital
Initial Public Offering
Additional Paid-In Capital
Follow-on Offering
Accumulated Deficit
Accumulated Other Comprehensive Loss (Income)
Non Controlling Interest
Beginning Balance at Dec. 31, 2018 $ (71,560)               $ 59       $ 8,915     $ (80,525) $ (9)  
Convertible preferred stock, Beginning Balance, Shares at Dec. 31, 2018       53,669,659 39,540,611 47,242,235 29,468,101 134,704,785                    
Convertible preferred stock, Beginning Balance at Dec. 31, 2018       $ 79,377 $ 22,000 $ 19,844 $ 9,840 $ 30,626                    
Beginning Balance, Shares at Dec. 31, 2018                 5,906,976                  
Change in unrealized loss on marketable securities 25                               25  
Issuances of Series E preferred stock, net of issuance costs       $ 29,893                            
Issuance of Series E preferred stock net of issuance costs, Shares       20,126,118                            
Issuances of common stock upon stock option exercise $ 549               $ 2       547          
Issuances of common stock upon stock option exercise, Shares 214,845               214,845                  
Stock-based compensation $ 2,193                       2,193          
Contributions by noncontrolling interest 1,151                                 $ 1,151
Net loss (25,681)                             (24,571)   (1,110)
Ending Balance at Dec. 31, 2019 (93,323)               $ 61       11,655     (105,096) 16 41
Convertible preferred stock, Ending Balance, Shares at Dec. 31, 2019       73,795,777 39,540,611 47,242,235 29,468,101 134,704,785                    
Convertible preferred stock, Ending Balance at Dec. 31, 2019       $ 109,270 $ 22,000 $ 19,844 $ 9,840 $ 30,626                    
Ending Balance, Shares at Dec. 31, 2019                 6,121,821                  
Change in unrealized loss on marketable securities 301                               301  
Issuances of common stock upon stock option exercise $ 4,183               $ 14       4,169          
Issuances of common stock upon stock option exercise, Shares 1,398,177               1,398,177                  
Stock-based compensation $ 10,545                       10,545          
Issuances of common stock upon public offering, net of issuance costs   $ 209,633 $ 325,600             $ 136 $ 53     $ 209,497 $ 325,547      
Issuances of common stock upon public offering, net of issuance costs, Shares                   13,664,704 5,250,000              
Conversion of convertible preferred stock into common stock 149,824               $ 303       149,521          
Conversion of convertible preferred stock into common stock, Shares                 30,278,832                  
Temporary equity, conversion of convertible preferred stock into common stock       $ (109,270) $ (9,928)     $ (30,626)                    
Temporary equity, conversion of convertible preferred stock into common stock, Shares       (73,795,777) (17,844,124)     (134,704,785)                    
Exchange of convertible preferred stock into limited common stock 41,756                     $ 132 41,624          
Exchange of convertible preferred stock into limited common stock, Shares                       13,164,193            
Temporary equity, exchange of convertible preferred stock into limited common stock         $ (12,072) $ (19,844) $ (9,840)                      
Temporary equity, exchange of convertible preferred stock into limited common stock, Shares         (21,696,487) (47,242,235) (29,468,101)                      
Conversion of limited common stock into common stock                 $ 40                  
Conversion of limited common stock into common stock, Shares                       (4,000,000)            
Conversion of limited common stock into common stock                       $ (40)            
Conversion of limited common stock into common stock, Shares                 4,000,000                  
Contributions by noncontrolling interest 2,137                                 2,137
Net loss (26,637)                             (24,463)   (2,174)
Ending Balance at Dec. 31, 2020 624,019               $ 607     $ 92 752,558     (129,559) 317 4
Ending Balance, Shares at Dec. 31, 2020                 60,713,534     9,164,193            
Change in unrealized loss on marketable securities (968)                               (968)  
Issuances of common stock upon stock option exercise $ 7,927               $ 11       7,916          
Issuances of common stock upon stock option exercise, Shares 1,120,981               1,120,981                  
Stock-based compensation $ 26,490                       26,490          
Contributions by noncontrolling interest 836                                 836
Net loss (101,219)                             (100,393)   (826)
Ending Balance at Dec. 31, 2021 $ 557,085               $ 618     $ 92 $ 786,964     $ (229,952) $ (651) $ 14
Ending Balance, Shares at Dec. 31, 2021                 61,834,515     9,164,193            
XML 41 R7.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Initial Public Offering | Common Stock    
Common stock issuance costs $ 22,667  
Follow-on Offering | Common Stock    
Common stock issuance costs $ 20,901  
Series E Preferred Stock    
Issuance of preferred stock value of issuance costs   $ 127
XML 42 R8.htm IDEA: XBRL DOCUMENT v3.22.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Cash flows from operating activities:      
Net loss $ (101,219) $ (26,637) $ (25,681)
Adjustments to reconcile net loss to net cash (used in) provided by      
Loss (gain) on equity investments 1,781 (4,108) (943)
Noncash revenue from equity investments (107) (397) (186)
Fair value adjustments (11,359) (28,263) (9,922)
Depreciation 2,847 3,658 3,640
Stock-based compensation 26,490 10,545 2,193
Noncash research and development expenses 811 2,137 1,051
Noncash investment accretion 5,270 646 (506)
Loss on disposal of property and equipment 140    
Decrease (increase) in assets:      
Accounts receivable, net (321) (12,747) (5,038)
Unbilled and other receivables (5,187) 3,468 (1,556)
Reduction in the carrying amount of right of use assets 5,799 5,342 4,177
Prepaid expenses and other assets (1,121) 187 410
(Decrease) increase in liabilities:      
Accounts payable (411) 4,882 (294)
Accrued payroll, taxes, and benefits 6,405 4,966 2,948
Deferred revenue (1,028) 59,705 6,715
Lease liabilities (2,949) (5,417) (4,025)
Other accrued liabilities 3,490 (1,210) 958
Net cash (used in) provided by operating activities (70,669) 16,757 (26,059)
Cash flows from investing activities:      
Purchases of property and equipment (7,167) (2,538) (1,836)
Purchases of equity investments (3,700) (2,869)  
Distribution from equity investment 375 4,582 943
Proceeds from sale of equity investments 15,735    
Purchases of marketable securities (414,802) (519,668) (110,187)
Proceeds from sale and maturity of marketable securities 392,747 138,772 57,225
Net cash used in investing activities (16,812) (381,721) (53,855)
Cash flows from financing activities:      
Issuances of common stock upon initial public offering, net   211,491  
Issuances of common stock upon follow-on public offering, net   325,600  
Issuances of Series E preferred stock, net     29,893
Issuances of common stock upon stock option exercise 7,927 4,183 549
Contribution by noncontrolling interest 25   100
Deferred offering costs     (1,858)
Net cash provided by financing activities 7,952 541,274 28,684
Net (decrease) increase in cash and cash equivalents and restricted cash (79,529) 176,310 (51,230)
Cash and cash equivalents and restricted cash, beginning of year 202,796 26,486 77,716
Cash and cash equivalents and restricted cash, end of year 123,267 202,796 26,486
Supplemental disclosure of cash flow and noncash information      
Cash paid for income taxes 448 381 139
Supplemental disclosure of non-cash investing and financing activities      
Accrued deferred offering costs     2,142
Purchases of property and equipment in accounts payable 705 8 90
Acquisitions of right of use assets in exchange for lease obligations $ 71,054 2,709 464
Right of use assets recognized on adoption     $ 16,475
Reclassification of deferred financing costs to additional paid-in capital   $ 1,858  
XML 43 R9.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of Business
 12 Months Ended
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Abstract]  
Description of Business

(1)

Description of Business

Schrödinger, Inc. (the “Company”) has developed a differentiated, physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly, at lower cost, and with, the Company believes, a higher likelihood of success compared to traditional methods. The Company sells its software to biopharmaceutical and industrial companies, academic institutions, and government laboratories. The Company also applies its computational platform to a broad pipeline of drug discovery and development programs in collaboration with biopharmaceutical companies. In addition, the Company uses its platform to advance a pipeline of internal drug discovery programs.

On February 10, 2020, the Company completed an initial public offering (“IPO”), in which the Company issued and sold 11,882,352 shares of its common stock at a public offering price of $17.00 per share.  The underwriters fully exercised their option to purchase an additional 1,782,352 shares of the Company’s common stock at the public offering price less underwriting discounts. The Company raised $209.6 million in net proceeds after deducting underwriting discounts and commissions and offering expenses payable by the Company.

Immediately prior to the closing of the IPO, preferred stockholders voluntarily exchanged 98,406,823 shares of preferred stock for an aggregate of 13,164,193 shares of limited common stock.  In addition, upon the closing of the IPO, the remaining 226,344,686 shares of preferred stock automatically converted into an aggregate of 30,278,832 shares of common stock.

On August 17, 2020, the Company completed a follow-on public offering, in which the Company issued and sold 4,500,000 shares of its common stock at a public offering price of $66.00 per share. The underwriters fully exercised their option to purchase an additional 750,000 shares of the Company’s common stock at the public offering price less underwriting discounts. The Company raised $325.6 million in net proceeds after deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, a stockholder of the Company sold 500,000 shares of common stock. The Company did not receive any proceeds from the sale of shares of common stock by the selling stockholder.
XML 44 R10.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Significant Accounting Policies

(2)

Significant Accounting Policies

(a)

Recently Issued Accounting Pronouncements

In January 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) —Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, which clarifies the accounting related to equity investments and derivatives. This guidance was effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption was permitted. The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Topic 350) – Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. This standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for annual periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021, with early adoption permitted. The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU No. 2016-13 replaces the existing incurred loss impairment model with an expected loss model which requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes generally result in earlier recognition of credit losses.  The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.

In October 2021, the FASB issues ASU No. 2021-08, Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires the measurement and recognition of contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standard Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606). This update replaces the existing guidance requiring contract assets and contract liabilities to be measured and recognized at fair value. The standard is effective on a prospective basis for annual periods beginning after December 15, 2022, including interim periods within the fiscal year, with early adoption permitted. The Company plans to early adopt this new standard effective January 1, 2022 and does not expect a material impact on its consolidated financial statements.

(b)

Basis of Presentation and Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the assumptions used in the allocation of revenue, estimates regarding the progress of completing performance obligations under collaboration agreements, and the valuation of stock-based compensation. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements.

(c)

Principles of Consolidation

The Company’s consolidated financial statements include the accounts of Schrödinger, Inc., its wholly owned subsidiaries, and its variable interest entity. All intercompany balances and transactions have been eliminated in consolidation. The functional currency for foreign entities is the United States dollar. The Company accounts for investments over which it has significant influence, but not a controlling financial interest, using the equity method.

(d)

Cash and Cash Equivalents and Marketable Securities and Restricted Cash

Included in cash and cash equivalents were cash equivalents of $90,477 and $185,614 as of December 31, 2021 and 2020, respectively, which consisted of money market funds and certificates of deposit, and are stated at cost, which approximates market value. The Company classifies all highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company classifies all marketable securities, which consist of fixed income securities, as available for sale securities.

At times, cash balances held at financial institutions were in excess of the Federal Deposit Insurance Corporation’s insured limits; however, the Company primarily places its cash with high-credit quality financial institutions.

Restricted cash consists of letters of credit held with the Company’s financial institution related to facility leases and is classified as current in the Company’s balance sheets based on the maturity of the underlying letters of credit.

(e)

Accounts Receivable

Accounts receivable are stated at original invoice amount less an allowance for doubtful accounts. Management estimates the allowance for doubtful accounts by evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Account balances are considered delinquent if payment is not received by the due date. Accounts receivable are written off when deemed uncollectible. Recovery of accounts receivable previously written off is recorded when received. Changes in the balance of accounts deemed uncollectible were deemed immaterial as of December 31, 2021 and 2020. Interest is not charged on accounts receivable.

(f)

Fair Value of Financial Instruments

The carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities.

(g)

Property and Equipment

Property and equipment are stated at cost. The Company did not capitalize any interest during 2021 and 2020. Maintenance and repairs are expensed as incurred.

Depreciation is calculated using the straight‑line method over the estimated useful lives of the assets, which range from 3 to 7 years. Amortization of leasehold improvements is calculated using the straight‑line method over the remaining life of the lease or the useful life of the asset, whichever is shorter.

Property and equipment are reviewed for impairment as discussed below under Accounting for the Impairment of Long‑Lived Assets.

(h)

Accounting for the Impairment of Long‑Lived Assets

Long-lived assets, such as property and equipment subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that carrying value exceeds fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, depending on the nature of the asset. No impairment was identified for the years ended December 31, 2021, 2020, and 2019.

(i)

Warranties

The Company typically warrants that its products will perform in a manner consistent with the product specifications provided to the customer for a period of 30 days. Historically, the Company has not been required to make payments under these obligations. Therefore, no liabilities for such obligations are presented in the consolidated financial statements.

(j)

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade receivables.

The Company does not require customers to provide collateral to support accounts receivable. If deemed necessary, credit reviews of significant new customers may be performed prior to extending credit. The determination of a customer’s ability to pay requires judgment, and failure to collect from a customer can adversely affect revenue, cash flows, and results of operations.

As of December 31, 2021, three customers accounted for 17%, 15%, and 11% of total accounts receivable, respectively. As of December 31, 2020, two customers accounted for 17% and 14% of total accounts receivable, respectively. For the year ended December 31, 2021, one customer accounted for 14% of total revenues. For the year ended December 31, 2020, no customer accounted for more than 10% of total revenues. For the year ended December 31, 2019, one customer accounted for 12% of total revenues.

(k)

Royalties

Royalties represent a component of cost of revenues and consist of royalties paid to owners of intellectual property used in or bundled with the Company’s software. Generally, royalties are incurred and recorded at the time a customer enters into a binding purchase agreement, although some royalty agreements are based instead on cash collections. Royalty expense was $9,826, $7,663, and $7,352 for the years ended December 31, 2021, 2020, and 2019, respectively.

(l)

Software Development Costs

Costs to develop new software products and substantial enhancements to existing software products are expensed as incurred. Historically, the Company has not capitalized any software development costs because the software development process was essentially completed concurrent with the establishment of technological feasibility.

(m)

Research and Development and Advertising

Research and development and advertising costs are expensed as incurred. The Company did not incur any significant advertising costs in 2021, 2020, or 2019.

(n)

Stock‑Based Compensation

The Company calculates stock‑based compensation expense utilizing fair value–based methodologies and recognizes expense over the vesting period of such awards.

(o)

Commissions

Commissions represent a component of sales and marketing expense and consist of the variable compensation paid to the Company’s sales representatives. Generally, sales commissions are earned and recorded as expense at the time that a customer has entered into a binding purchase agreement. Commissions paid to sales representatives are recoverable only in the case that the Company cannot collect against any invoiced fee associated with a sales order. Commission expense was $1,829, $1,362, and $754 in 2021, 2020, and 2019, respectively.

(p)

Income Taxes

The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of the assets and liabilities. Deferred tax assets are reduced by a valuation allowance when it is estimated to become more likely than not that a portion of the deferred tax assets will not be realized. Accordingly, the Company currently maintains a full valuation allowance against existing net deferred tax assets.

The Company recognizes the effect of income tax positions only if such positions are deemed “more likely than not” capable of being sustained. Interest and penalties accrued on unrecognized tax benefits are included within income tax expense in the consolidated financial statements.

(q)

Comprehensive Loss

Comprehensive loss includes net loss and changes in equity related to changes in unrealized gains or losses on marketable securities.

(r)

Equity Investments

In the normal course of business, the Company has entered, and may continue to enter, into collaboration agreements with private companies to perform drug design services for such companies in exchange for equity ownership stakes in such companies. If it is determined that the Company has control over the investee, the investee is consolidated in the financial statements. If the investee is consolidated with the Company and less than 100% of the equity is owned by the Company, the Company will present non-controlling interest to represent the portion of the investee owned by other investors. If it is determined that the Company does not have control over the investee, the Company evaluates the investment for the ability to exercise significant influence.

Equity investments over which the Company has significant influence may be accounted for under equity method accounting in accordance with ASC Topic 323, Equity Method and Joint Ventures. If it is determined that the Company does not have significant influence over the investee, and there is no readily determinable fair value for the investment, the equity investment may be accounted for at cost minus impairment in accordance with ASC Topic 321, Equity Securities.

For further information regarding the Company’s equity investments, see Note 5, Fair Value Measurements, Note 10, Noncontrolling Interest, and Note 12, Equity Investments.

(s)

Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders

The outstanding equity of the Company consists of common stock and limited common stock. Under the Company’s certificate of incorporation, the rights of the holders of common stock and limited common stock are identical, except with respect to voting and conversion. Holders of limited common stock are precluded from voting such shares in any election of directors or on the removal of directors. Limited common stock may be converted into common stock at any time at the option of the stockholder.

Undistributed earnings allocated to the participating securities are subtracted from net income in determining net (loss) income attributable to common and limited common stockholders. Basic net (loss) income per share is computed by dividing net (loss) income attributable to common and limited common stockholders by the weighted-average number of shares of common and limited common stock outstanding during the period.

For the calculation of diluted net income, net income attributable to common and limited common stockholders for basic net income is adjusted by the effect of dilutive securities, including awards under the Company’s equity compensation plans. Diluted net income per share attributable to common and limited common stockholders is computed by dividing the resulting net income attributable to common and limited common stockholders by the weighted-average number of fully diluted shares of common and limited common stock outstanding.
XML 45 R11.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition
 12 Months Ended
Dec. 31, 2021
Revenue From Contract With Customer [Abstract]  
Revenue Recognition

(3)

Revenue Recognition

Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for promised goods or services. The Company’s performance obligations are satisfied either over time or at a point in time.

The following table illustrates the timing of the Company’s revenue recognition:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Software products and services – point in time

 

 

55.5

%

 

 

55.0

%

 

 

49.9

%

Software products and services – over time

 

 

26.6

 

 

 

30.6

 

 

 

28.1

 

Drug Discovery – point in time

 

 

3.3

 

 

 

6.7

 

 

 

8.6

 

Drug Discovery – over time

 

 

14.6

 

 

 

7.7

 

 

 

13.4

 

 

(a)

Software

The Company enters into contracts that can include various combinations of licenses, products and services, some of which are distinct and are accounted for as separate performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price of the contract to each performance obligation on a relative standalone selling price (“SSP”) basis. Revenue is recognized net of any sale and value-added taxes collected from customers and subsequently remitted to governmental authorities.

The Company’s software business derives revenue from five sources: (i) on-premise software license fees, (ii) hosted software subscription fees, (iii) software maintenance fees, (iv) professional services fees, and (v) contributions.

On-premise software. The Company’s on-premise software license arrangements grant customers the right to use its software on their own in-house servers or their own cloud instances for a specified term, typically for one year. The Company recognizes revenue for on-premise software license fees upfront, either upon delivery of the license or the effective date of the agreement, whichever is later. In instances where the timing of delivery differs from the timing of invoicing, the Company considers whether a significant financing component exists. The Company has elected the practical expedient to not assess for significant financing where the term is less than one year. The Company’s updates and upgrades are not integral to maintaining the utility of the software licenses. Payments typically are received upfront or annually.

Hosted software. Hosted software revenue consists primarily of fees to provide the Company’s customers with hosted licenses, which allows these customers to access the Company’s cloud-based software solution on their own hardware without taking control of licenses.  Hosted software is recognized ratably over the term of the arrangement.

Software maintenance. Software maintenance includes technical support, updates, and upgrades. Software maintenance revenue is considered to be a separate performance obligation and is recognized ratably over the term of the arrangement.

Professional services. Professional services, such as training, technical support, installation, or assisting customers with modeling, generally are not related to the core functionality of the Company’s software and are recognized as revenue when resources are consumed. The Company has historically estimated project status with relative accuracy, although a number of internal and external factors can affect such estimates, including labor rates, utilization and efficiency variances. Payments for services are due in advance or upon consumption of resources.

Software contribution revenue. Software contribution revenue consists of funds received under a non-reciprocal agreement with Gates Ventures, LLC.  The agreement is an unconditional non-exchange contribution without restrictions and the initial contribution was invoiced upon execution of the agreement.  Revenue was recognized upon execution of the agreement and on the first anniversary of the agreement when invoiced in accordance with ASC Topic 958, Not-for-Profit Entities as the agreement is not an exchange transaction.

The agreement with Gates Ventures, LLC covers the period from June 23, 2020 through June 22, 2023 for total consideration of up to $3,000. The Company received $1,000 in connection with its entry into the agreement in the second quarter of 2020, and $1,000 in the second quarter of 2021 on the first anniversary of its entry into the agreement. The Company is also entitled to receive an additional $1,000 payment on or around the second anniversary of the agreement, subject to the Company providing certain progress reports to the Trustees of Columbia University in the City of New York. As of December 31, 2021, the Company had no deferred revenue balance related to this agreement.

The following table presents the revenue recognized from the sources of software products and services revenue:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

On-premise software

 

$

74,598

 

 

$

58,311

 

 

$

42,647

 

Hosted software

 

 

11,076

 

 

 

9,192

 

 

 

7,418

 

Software maintenance

 

 

17,294

 

 

 

14,465

 

 

 

11,643

 

Professional services

 

 

9,268

 

 

 

9,562

 

 

 

5,027

 

Revenue from contracts with customers

 

 

112,236

 

 

 

91,530

 

 

 

66,735

 

Software contribution

 

 

1,000

 

 

 

1,000

 

 

 

—

 

Total software revenue

 

$

113,236

 

 

$

92,530

 

 

$

66,735

 

(b)

Drug Discovery

Drug discovery services. Revenue from drug discovery and collaboration services contracts is recognized either over time, typically by using costs incurred or hours expended to measure progress, or at a point in time based on the achievement of milestones. Payments for services are generally due upon achieving milestones stated in a contract, upfront at the start of a contract, or upon consumption of resources. Services may at times include variable consideration and milestone payments. The Company has estimated the amount of consideration that is variable using the most likely amount method. The Company evaluates milestones on a case-by-case basis, including whether there are factors outside the Company’s control that could result in a significant reversal of revenue, and the likelihood and magnitude of a potential reversal. If achievement of a milestone is not considered probable, the Company constrains (reduces) variable consideration to exclude the milestone payment until it is probable to be achieved. As of December 31, 2021, 2020, and 2019, milestones not yet achieved that were determined to be probable of achievement totaled $2,250, $250, and $1,500, respectively, and $2,250, $85, and $1,500 of those milestones were recognized as revenue for the years ended December 31, 2021, 2020, and 2019.

Drug discovery contribution revenue. Drug discovery contribution revenue consists of funds received under an agreement with Bill and Melinda Gates Foundation on a cost reimbursement basis, to perform services aimed at accelerating drug discovery in women’s health, which began in November 2021. Revenue is recognized as conditions are met in accordance with ASC Topic 958, Not-for-Profit Entities. As of December 31, 2021, there was a $1,129 deferred revenue balance related to this agreement.

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Drug discovery services revenue from contracts with customers

 

$

24,584

 

 

$

15,565

 

 

$

18,808

 

Drug discovery contribution

 

 

111

 

 

 

—

 

 

 

—

 

Total drug discovery revenue

 

$

24,695

 

 

$

15,565

 

 

$

18,808

 

 

(c)

Collaboration and License Agreement

On November 22, 2020, the Company entered into an exclusive, worldwide collaboration and license agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company and BMS have agreed to collaborate in the discovery, research and preclinical development of new small molecule compounds for disease indications in oncology, neurology, and immunology therapeutics areas. The Company will be responsible, at its own cost and expense, for the discovery of small molecule compounds directed to five specified biological targets pursuant to a mutually agreed research plan for each such target. The initial targets included HIF-2 alpha and SOS1/KRAS, which were two of the Company’s internal programs. In November 2021, the Company and BMS mutually agreed to replace the HIF-2 alpha target with another precision oncology target. Following the replacement election, all rights to the HIF-2 alpha target program reverted to us. Once a development candidate meeting specified criteria for a target under the agreement has been identified by the Company, BMS will be solely responsible for the further development, manufacturing and commercialization of such development candidate at its own cost and expense.

Under the terms of the agreement, BMS paid the Company an initial upfront fee payment of $55,000. The Company also is entitled to receive up to $2,700,000 in total milestone payments across all potential targets, consisting of: a) up to $585,000 in milestone payments per oncology target, including $360,000 in the aggregate for the achievement of certain specified research, development, and regulatory milestones and $225,000 in the aggregate for the achievement of certain specified commercial milestones; and b) up to $482,000 in milestone payments per neurology and immunology target, including $257,000 in the aggregate for the achievement of certain specified research, development, and regulatory milestones and $225,000 in the aggregate for the achievement of certain specified commercial milestones.

The Company is also entitled to a tiered percentage royalty on annual net sales ranging from mid-single digits to low-double digits, subject to certain specified reductions. Royalties are payable by BMS on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country.

The Company assessed the collaboration and license agreement in accordance with ASC 606 and concluded that BMS is a customer based on the agreement structure. At inception, the Company identified one performance obligation for each of the five programs under the agreement, which includes research activities for each program and a license grant for the underlying intellectual property. The Company determined that the license grant for intellectual property is not separable from the research activities, as the research activities are expected to significantly modify or enhance the license grant over the period of service, and therefore are not distinct in the context of the contract.

The Company determined that the transaction price at the onset of the agreement is $55,000. Additional consideration to be paid to the Company upon the achievement of future milestone payments were excluded from the transaction price as they represent milestone payments that are not considered probable as of the inception date such that there is not a significant risk of revenue reversal.

The Company has allocated the transaction price of $55,000 to each performance obligation based on the SSP of each performance obligation at inception, which was determined based on each performance obligation’s estimated standalone selling price. The Company determined the estimated standalone selling price at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to perform the research activities included the length of time required, the internal hours expected to be incurred on the services and the number and costs of various studies that will be performed to complete the research plan.

Revenue associated with the research activities is recognized on a proportional performance basis over the period of service for research activities, using input-based measurements of total costs of research incurred to estimate the proportion performed. Progress towards completion is remeasured at the end of each reporting period.

During the years ended December 31, 2021 and 2020, the Company recognized $13,749 and $988, respectively, associated with the agreement based on the research activities performed. As of December 31, 2021 and 2020, there was $40,263 and $54,012 of deferred revenue related to the agreement, which was classified as either current or non-current in the consolidated balance sheet based on the period the services are expected to be performed. There was no outstanding receivable for this collaboration as of December 31, 2021.

(d)

Significant Judgments

Significant judgments and estimates are required under ASC Topic 606. Due to the complexity of certain contracts, the actual revenue recognition treatment required under Topic 606 for the Company’s arrangements may be dependent on contract-specific terms and may vary in some instances.

The Company’s contracts with customers often include promises to transfer multiple software products and services, including training, professional services, technical support services, and rights to unspecified updates. Determining whether licenses and services are distinct performance obligations that should be accounted for separately, or are not distinct and therefore should be accounted for together, requires significant judgment. In some arrangements, such as most of the Company’s term-based software license arrangements, the Company has concluded that the licenses and associated services are distinct from each other. In other arrangements, including collaboration services arrangements, the licenses and certain services may not be distinct from each other. The Company’s time-based software arrangements may include multiple software licenses and a right to updates or upgrades to the licensed software products, and technical support. The Company has concluded that such promised goods and services are separate distinct performance obligations.

The Company is required to estimate the total consideration expected to be received from contracts with customers, including any variable consideration. Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is allocated to each separate performance obligation on a SSP basis.

Judgment is required to determine the SSP for each distinct performance obligation. The Company rarely licenses or sells products on a standalone basis, so the Company is required to estimate the range of SSPs for each performance obligation. In instances where the SSP is not directly observable because the Company does not sell the license, product, or service separately, the Company determines the SSP using information that includes historical discounting practices, market conditions, cost-plus analysis, and other observable inputs. The Company typically has more than one SSP for individual performance obligations due to the stratification of those items by classes of customers and circumstances. In these instances, the Company may use information such as the size and geographic region of the customer in determining the SSP. Professional service revenue is recognized as costs and hours are incurred, and judgment is required in estimating both the project status and the costs incurred or hours expended.

If a group of agreements are so closely related to each other that they are, in effect, part of a single arrangement, such agreements are deemed to be one arrangement for revenue recognition purposes. The Company exercises significant judgment to evaluate the relevant facts and circumstances in determining whether the separate agreements should be accounted for separately or as, in substance, a single arrangement. The Company’s judgments about whether a group of contracts comprises a single arrangement can affect the allocation of consideration to the distinct performance obligations, which could have an effect on results of operations for the periods involved.

Judgment is required to determine the total costs to perform research activities, which include the length of time required, the internal hours expected to be incurred on the services, and the number and costs of various studies that may be performed by third-parties to complete the research plan.

Generally, the Company has not experienced significant returns or refunds to customers.

The Company’s estimates related to revenue recognition require significant judgment and a change in these estimates could have an effect on the Company’s results of operations during the periods involved.

(e)

Contract Balances

The timing of revenue recognition may differ from the timing of invoicing to customers and these timing differences result in receivables, contract assets, or contract liabilities (deferred revenue) on the consolidated balance sheets. The Company records a contract asset when revenue is recognized prior to invoicing. A deferred revenue liability is recorded when revenue is expected to be recognized subsequent to invoicing. For the Company’s time-based software agreements, customers are generally invoiced at the beginning of the arrangement for the entire term, though when the term spans multiple years the customers may be invoiced on an annual basis. For certain drug discovery agreements where the milestones are deemed probable in a period prior to when the milestone is achieved, the Company records a contract asset for the full value of the milestone.

Contract assets are included in unbilled and other receivables within the consolidated balance sheets and are transferred to receivables when the Company invoices the customer.

Contract balances were as follows:

 

 

As of

December 31,

 

 

As of

December 31,

 

 

 

2021

 

 

2020

 

Contract assets

 

$

8,271

 

 

$

3,589

 

Deferred revenue, short-term:

 

 

 

 

 

 

 

 

Software products and services

 

 

32,945

 

 

 

28,218

 

Drug discovery

 

 

22,423

 

 

 

17,185

 

Deferred revenue, long-term:

 

 

 

 

 

 

 

 

Software products and services

 

 

3,938

 

 

 

1,976

 

Drug discovery

 

 

26,126

 

 

 

39,188

 

For the years ended December 31, 2021 and 2020, respectively, the Company recognized $42,127 and $24,921 of revenue that was included in deferred revenue at the end of the preceding period. All other deferred revenue activity is due to the timing of invoices in relation to the timing of revenue, as described above. The Company expects to recognize as revenue approximately 65% of its December 31, 2021 deferred revenue balance in the next 12 months and the remainder thereafter. Additionally, contracted but unsatisfied performance obligations that had not yet been billed to the customer or included in deferred revenue were $26,694 as of December 31, 2021.

Payment terms and conditions vary by contract type, although terms typically require payment within 30 to 60 days. In instances where the timing of revenue recognition differs from that of invoicing, the Company has determined that its contracts generally do not include a significant financing component. The primary purpose of invoicing terms is to provide customers with simplified and predictable ways of purchasing the Company’s products and services, not to facilitate financing arrangements.

(f)

Deferred Sales Commissions

The Company has applied the practical expedient for sales commission expense, as any material compensation paid to sales representatives to obtain a contract relates to a period of one year or less. Therefore, the Company has not capitalized any costs related to sales commissions.
XML 46 R12.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment
 12 Months Ended
Dec. 31, 2021
Property Plant And Equipment [Abstract]  
Property and Equipment

(4)

Property and Equipment

Property and equipment consisted of the following:

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

Computers and equipment

 

$

16,059

 

 

$

12,718

 

Leasehold improvements

 

 

2,276

 

 

 

4,385

 

Furniture and fixtures

 

 

4,045

 

 

 

1,839

 

 

 

 

22,380

 

 

 

18,942

 

Less accumulated depreciation

 

 

(12,355

)

 

 

(13,802

)

 

 

$

10,025

 

 

$

5,140

 

 

Depreciation expense for 2021, 2020, and 2019 was $2,847, $3,658, and $3,625, respectively, and is included within cost of revenues and research and development, sales and marketing, and general and administrative expenses within the consolidated statements of operations.
XML 47 R13.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Fair Value Measurements

(5)

Fair Value Measurements

Various inputs are used in determining the fair value of the Company’s financial assets and liabilities. These inputs are summarized into the following three broad categories:

Level 1 – quoted prices in active markets for identical securities

Level 2 – other significant observable inputs, including quoted prices for similar securities, interest rates, credit risk, etc.

Level 3 – significant unobservable inputs, including the Company’s own assumptions in determining fair value

The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. Marketable securities, which consist primarily of corporate and U.S. government agency bonds, are classified as available for sale and fair value does not differ significantly from carrying value as of December 31, 2021 and 2020. The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2021:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities

 

$

—

 

 

$

456,212

 

 

$

—

 

 

$

456,212

 

Equity investments

 

 

39,561

 

 

 

—

 

 

 

1,887

 

 

 

41,448

 

Total

 

$

39,561

 

 

$

456,212

 

 

$

1,887

 

 

$

497,660

 

The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2020:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities

 

$

—

 

 

$

440,395

 

 

$

—

 

 

$

440,395

 

Equity investments

 

 

45,570

 

 

 

—

 

 

 

—

 

 

 

45,570

 

Total

 

$

45,570

 

 

$

440,395

 

 

$

—

 

 

$

485,965

 

Fair value of the Company’s investments in Nimbus Therapeutics, LLC (“Nimbus”) and ShouTi Inc. (“ShouTi”), classified as Level 3 in the fair value hierarchy, was determined under the hypothetical liquidated book value method (“HLBV method”), as further described in Note 12, Equity Investments. Significant unobservable inputs used under the HLBV method include Nimbus’ and ShouTi’s annual financial statements and the Company’s respective liquidation priorities. The following table sets forth changes in fair value of the Company’s Level 3 investments:

 

 

 

Amount

 

As of December 31, 2019

 

$

108

 

Cash contributions

 

 

2,869

 

Unrealized loss

 

 

(2,977

)

As of December 31, 2020

 

 

-

 

Cash contributions

 

 

2,000

 

Unrealized loss

 

 

(113

)

As of December 31, 2021

 

$

1,887

 

Unrealized gains and losses arising from changes in fair value of the Company’s equity investments are classified within change in fair value in the consolidated statements of operations. During the years ended December 31, 2021 and 2020, there were no transfers between Level 1, Level 2 and Level 3 investments. See Note 12, Equity Investments, for further information.
XML 48 R14.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies
 12 Months Ended
Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]  
Commitments and Contingencies

(6)

Commitments and Contingencies

(a)

Leases

The Company leases office space under operating leases that expire at various dates through 2037. The Company has elected the package of practical expedients under the transition guidance of ASC Topic 842, Leases, to exclude short-term leases from the balance sheet and to combine lease and non-lease components.

Upon inception of a lease, the Company determines if an arrangement is a lease, if it includes options to extend or terminate the lease, and if it is reasonably certain that the Company will exercise the options. Lease cost, representing lease payments over the term of the lease and any capitalizable direct costs less any incentives received, is recognized on a straight-line basis over the lease term as lease expense.

In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date if the rate implicit in the lease is not readily determinable. Upon execution of a new lease, the Company performs an analysis to determine its incremental borrowing rate using its current borrowing rate, adjusted for various factors including level of collateralization and lease term. As of December 31, 2021, the remaining weighted average lease term was 15 years.

During the year ended December 31, 2021, the accounting commencement began for two new leases, which increased the right-of-use (“ROU”) assets and lease liabilities by $71,054. ROU assets and lease liabilities were equal as no lease costs or incentives were associated with acquiring the leases.

On November 1, 2021, the Company entered into an office lease agreement for 16,727 square feet of office space located at One Main Street, Cambridge, Massachusetts. Under the terms of the agreement, the Company will pay base rent of approximately $135 per month with a 3% annual rental escalation. The Company estimates that the lease commencement date will occur during the three months ending June 30, 2022 and continue to the end of the lease, which is 10 years after commencement.

On November 30, 2021, the Company entered into an office lease agreement for 19,753 square feet of office space located at Salarpuria Sattva, Knowledge City, Hyderabad, India. Under the terms of the agreement, the Company will pay base rent of approximately $20 per month from commencement to handover date and $29 per month from handover date to termination of the lease. The Company estimates that the lease handover and commencement dates will occur during the three months ending March 31, 2022 and continue to the end of the lease in June 2023.

Variable and short-term lease costs were immaterial for the year ended December 31, 2021. Additional details of the Company’s operating leases are presented in the following table:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Operating lease costs

 

$

7,627

 

 

$

5,895

 

 

$

5,181

 

Cash paid for operating leases

 

 

4,561

 

 

 

6,050

 

 

 

5,108

 

 

 

Maturities of operating lease liabilities as of December 31, 2021 under noncancelable operating leases were as follows:

 

Year ending December 31:

 

 

 

 

2022

 

$

2,087

 

2023

 

 

8,809

 

2024

 

 

9,632

 

2025

 

 

9,241

 

2026

 

 

8,758

 

Thereafter

 

 

93,656

 

Total future minimum lease payments

 

 

132,183

 

Less: imputed interest

 

 

(52,314

)

Present value of future minimum lease payments

 

 

79,869

 

Less: current portion of operating leases payments

 

 

(2,042

)

Lease liabilities, long-term

 

$

77,827

 

(b)

Legal Matters

From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. While the results of such litigation cannot be predicted with certainty, management believes that the final outcome of such matters is not likely to have a material adverse effect on the Company’s financial position or results of operations or cash flows.
XML 49 R15.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Income Taxes

(7)

Income Taxes

Income tax expense is comprised of the following:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Current:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

—

 

 

$

—

 

 

$

583

 

State

 

 

67

 

 

 

178

 

 

 

(95

)

Foreign

 

 

344

 

 

 

167

 

 

 

(779

)

Current income tax expense (benefit)

 

 

411

 

 

 

345

 

 

 

(291

)

Deferred:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

 

—

 

 

 

—

 

 

 

—

 

State

 

 

—

 

 

 

—

 

 

 

—

 

Deferred income tax expense (benefit)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

$

411

 

 

$

345

 

 

$

(291

)

Components of loss before income taxes by tax jurisdiction were as follows:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

United States

 

$

(101,341

)

 

$

(24,567

)

 

$

(25,385

)

Foreign

 

 

1,359

 

 

 

449

 

 

 

523

 

Loss before income taxes

 

$

(99,982

)

 

$

(24,118

)

 

$

(24,862

)

Reconciliation of income tax expense at the applicable statutory income tax rates to the effective income tax rate is as follows:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Statutory federal income tax rate

 

 

21.0

%

 

 

21.0

%

 

 

21.0

%

State taxes, net of federal benefits

 

 

4.9

 

 

 

14.2

 

 

 

4.2

 

Withholding tax

 

 

—

 

 

 

—

 

 

 

(2.3

)

Section 162(m) limitation

 

 

(5.2

)

 

 

(12.8

)

 

 

—

 

Stock compensation

 

 

12.4

 

 

 

68.5

 

 

 

0.2

 

Return-to-provision adjustments

 

 

(1.7

)

 

 

(1.3

)

 

 

3.2

 

Research and development credit

 

 

6.3

 

 

 

6.2

 

 

 

5.2

 

Tax contingencies, net of reversals

 

 

(0.7

)

 

 

(0.6

)

 

 

(0.5

)

Change in valuation allowance

 

 

(37.2

)

 

 

(95.0

)

 

 

(31.3

)

Other

 

 

(0.2

)

 

 

(1.6

)

 

 

(0.6

)

Effective income tax rate

 

 

(0.4

)%

 

 

(1.4

)%

 

 

(0.9

)%

The income tax expense for the years ended December 31, 2021 and December 31, 2020 primarily related to state taxes and taxes in foreign jurisdictions. Income tax benefit for the year ended December 31, 2019 primarily related to alternative minimum tax credits previously utilized that are refundable under the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”).

The total change in valuation allowance for the year ended December 31, 2021 was $37,149, which primarily was due to the generation of net operating losses.

Tax effects of temporary differences that give rise to significant portions of deferred income tax assets and deferred income tax liabilities were as follows:

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Deferred income tax assets:

 

 

 

 

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

67,985

 

 

$

51,498

 

 

$

26,119

 

Accrued expenses

 

 

10,309

 

 

 

7,918

 

 

 

6,164

 

Deferred Revenue

 

 

10,632

 

 

 

394

 

 

 

500

 

Lease Liabilities

 

 

18,773

 

 

 

2,165

 

 

 

433

 

Credits

 

 

14,559

 

 

 

8,752

 

 

 

7,468

 

Gross deferred tax assets

 

 

122,258

 

 

 

70,727

 

 

 

40,684

 

Less valuation allowance

 

 

(95,304

)

 

 

(58,155

)

 

 

(35,251

)

Net deferred tax assets

 

 

26,954

 

 

 

12,572

 

 

 

5,433

 

Deferred income tax liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain on equity investments

 

 

(8,545

)

 

 

(10,185

)

 

 

(1,984

)

Prepaid expenses

 

 

(969

)

 

 

(889

)

 

 

(441

)

Depreciation and amortization

 

 

(17,440

)

 

 

(1,498

)

 

 

(3,008

)

Net deferred income tax assets

 

$

—

 

 

$

—

 

 

$

—

 

As of December 31, 2021, the Company had federal and state net operating loss (“NOL”) carryforwards of $283,314 and $148,130, respectively. These carryforwards, with the exception of federal NOLs generated post 2017, will expire between 2022 and 2041 if not used by the Company to reduce income taxes payable in future periods. Utilization of post 2017 federal NOL carryforwards are limited to 80% of taxable income generated in a given year and carry forward indefinitely. As of December 31, 2021, the Company had federal and state research and development tax credit carryforwards of $15,459 and $977, respectively. These carryforwards will expire between 2022 and 2041 if not used by the Company to reduce income taxes payable in future periods.

Pursuant to Internal Revenue Code Sections 382 and 383, the utilization of NOLs and other tax attributes may be substantially limited due to cumulative changes in ownership greater than 50% that may have occurred or could occur during applicable testing periods. The Company has performed an analysis through March 31, 2021 and

determined that such an ownership change has occurred. There was no material impact to the financial statements due to this ownership change.

The Company has not recognized a deferred tax liability for the undistributed earnings of its foreign operations as the Company considers these earnings to be indefinitely reinvested.

In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the 2017 Tax Act. With the enactment of the CARES Act, the Company has not recognized a quantitative or qualitative impact for the years ended December 31, 2021, 2020, and 2019.

The Company classifies interest and penalties related to unrecognized tax benefits within income tax expense in the consolidated statement of operations. Following is a reconciliation of total gross unrecognized tax benefits:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Balance, January 1

 

$

1,046

 

 

$

902

 

 

$

781

 

Additions for tax positions taken in prior years

 

 

282

 

 

 

25

 

 

 

24

 

Reductions for tax positions taken in prior years

 

 

(20

)

 

 

(16

)

 

 

(12

)

Additions for tax positions related to the current year

 

 

394

 

 

 

135

 

 

 

109

 

Balance, December 31

 

$

1,702

 

 

$

1,046

 

 

$

902

 

 

The Company does not anticipate any significant increases or decreases in its uncertain tax positions within the next 12 months.

The Company and its subsidiaries file U.S. federal income tax returns and various state, local and foreign income tax returns. As of December 31, 2021, the Company’s statutes of limitations are open for all federal and state years tax returns filed after the years ended December 31, 2016 and 2015, respectively. Net operating loss and credit carryforwards for all years are subject to examination and adjustments for the three years following the year in which the carryforwards are utilized. The Company is not currently under Internal Revenue Service or state examination.
XML 50 R16.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders' Equity (Deficit)
 12 Months Ended
Dec. 31, 2021
Equity [Abstract]  
Stockholders' Equity (Deficit)

(8)

Stockholders’ Equity (Deficit)

(a)

Common Stock

As of December 31, 2021, the Company had authorized 500,000,000 shares of common stock with a par value of $0.01 per share. Holders of common stock are entitled to one vote per share, to receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company’s preferred stock, if any.

Common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.

(b)

Limited Common Stock

As of December 31, 2021, the Company had authorized 100,000,000 shares of limited common stock with a par value of $0.01 per share.

Holders of limited common stock are entitled to one vote per share, however, the holders of limited common stock shall not be entitled to vote such shares in any election of directors or on the removal of directors. Holders of limited common stock are entitled to receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company’s preferred stock, if any.  Holders of the Company’s limited common stock have the right to convert each share of limited common stock into one share of the Company’s common stock.

Limited common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the limited common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.

(c)

Preferred Stock

As of December 31, 2021, the Company had authorized 10,000,000 shares of undesignated preferred stock with a par value of $0.01 per share.  The Company’s board of directors has the discretion to determine the rights, preferences, privileges, and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges, and liquidation preferences, of each series of preferred stock.
XML 51 R17.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation
 12 Months Ended
Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Stock-Based Compensation

(9)

Stock-Based Compensation

Stock Incentive Plans

As of December 31, 2021, the Company’s stock incentive plans included the 2010 Stock Plan (the “2010 Plan”), the 2020 Equity Incentive Plan (the “2020 Plan”), and the 2021 Inducement Equity Incentive Plan (the "2021 Plan”) (together, the “Plans”). The 2020 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to employees, directors, consultants or advisors.

The 2021 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to persons who were not previously an employee or director of the Company or who are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to such person’s entry into employment with the Company and in accordance with the requirements of the Nasdaq Stock Market Rule 5635(c)(4). Neither consultants nor advisors are eligible to participate in the 2021 Plan.

The 2010 Plan provided for the granting of incentive stock options and nonstatutory stock options to employees, directors, consultants, or advisors. As of the effective date of the 2020 Plan, no further awards will be made under the 2010 Plan. Any options or awards outstanding under the 2010 Plan remain outstanding and effective. Shares of common stock subject to outstanding awards granted under the 2010 Plan that expire, terminate, or are otherwise surrendered, cancelled, forfeited, or repurchased by the Company are available for issuance under the 2020 Plan.

Stock Options

Stock options must be granted at an exercise price not less than 100% of the fair market value per share at the grant date. The board of directors or compensation committee determines the exercise price of the Company’s stock options based on the closing price of the common stock as reported on the Nasdaq Global Select Market on the day of the grant. The maximum contractual term of options granted under the Plans is typically 10 years, options generally vest over four years with 25% of the shares underlying the option vesting at the end of the first year and the remaining vesting monthly over the following three years.

During 2021, 2020, and 2019, 1,120,981, 1,398,177, and 214,845 options under the Plans were exercised for total proceeds of $7,927, $4,183, and $549, respectively.

The fair value of each option award is determined on the date of grant using the Black Scholes Merton option-pricing model. The calculation of fair value includes several assumptions that require management’s judgment. The expected terms of options granted to employees during 2021, 2020, and 2019 were calculated using an average of historical exercises. Estimated volatility for 2021, 2020, and 2019 incorporates a calculated volatility derived from the historical closing prices of shares of common stock of similar entities whose share prices were publicly available

for the expected term of the option. The risk-free interest rate is based on the U.S. Treasury constant maturities in effect at the time of grant for the expected term of the option. The Company accounts for forfeitures as they occur, as such, the Company does not estimate forfeitures at the time of grant.

As of December 31, 2021, there were 2,283,037 shares available for grant under the Plans. Following are the weighted average valuation assumptions used for options:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Valuation assumptions

 

 

 

 

 

 

 

 

 

 

 

 

Expected dividend yield

 

 

—

%

 

 

—

%

 

 

—

%

Expected volatility

 

 

59

%

 

 

60

%

 

 

57

%

Expected term (years)

 

 

4.66

 

 

 

4.49

 

 

 

6.05

 

Risk-free interest rate

 

 

0.71

%

 

 

1.46

%

 

 

2.33

%

 

The following table presents classification of stock-based compensation expense within the consolidated statements of operations:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cost of sales

 

$

3,858

 

 

$

1,384

 

 

$

376

 

Research and development

 

 

7,440

 

 

 

3,050

 

 

 

460

 

Sales and marketing

 

 

1,281

 

 

 

516

 

 

 

311

 

General and administrative

 

 

13,911

 

 

 

5,595

 

 

 

1,046

 

Total stock-based compensation

 

$

26,490

 

 

$

10,545

 

 

$

2,193

 

Stock option activity was as follows:

 

 

 

Number of

shares

 

 

Weighted

average

exercise

price

 

 

Weighted

average

remaining

contractual

term (years)

 

 

Aggregate

intrinsic

value

 

Beginning, January 1, 2021

 

 

7,257,460

 

 

$

12.14

 

 

 

 

 

 

 

 

 

Granted

 

 

1,696,327

 

 

93.13

 

 

 

 

 

 

 

 

 

Exercised

 

 

(1,120,981

)

 

 

7.00

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(149,346

)

 

 

41.47

 

 

 

 

 

 

 

 

 

Expired

 

 

(3,119

)

 

 

1.70

 

 

 

 

 

 

 

 

 

Balance, December 31, 2021

 

 

7,680,341

 

 

 

30.19

 

 

 

7.67

 

 

$

35,584

 

Exercisable, December 31, 2021

 

 

3,473,716

 

 

 

10.83

 

 

 

6.75

 

 

$

83,306

 

The weighted average grant date fair value per share of options granted during 2021, 2020, and 2019 was $45.07, $9.55, and $2.93, respectively. The intrinsic value of options exercised during 2021, 2020, and 2019 was $71,308, $87,946, and $546, respectively.

As of December 31, 2021, there was $78,355 of unrecognized compensation cost related to unvested stock options granted under the Plans, which is expected to be recognized over a weighted average period of 2.87 years. The fair value of shares vested during 2021, 2020, and 2019 was $19,080, $3,153, and $1,734, respectively.
XML 52 R18.htm IDEA: XBRL DOCUMENT v3.22.0.1
Noncontrolling Interest
 12 Months Ended
Dec. 31, 2021
Noncontrolling Interest [Abstract]  
Noncontrolling Interest

(10)

Noncontrolling Interest

The Company reviews each legal entity formed by parties related to the Company to determine whether or not the Company has a variable interest in the entity and whether or not the entity would meet the definition of a variable interest entity (“VIE”) in accordance with ASC Topic 810, Consolidation. If the entity is a VIE, the

Company assesses whether or not the Company is the primary beneficiary of that VIE based on a number of factors, including (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to any contractual agreements and (iii) which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines it is the primary beneficiary of a VIE, the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements at the time that determination is made. The Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs on a quarterly basis. If the Company were to determine that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, it would deconsolidate the VIE in the period that the determination is made.

If the Company determines it is the primary beneficiary of a VIE that meets the definition of a business, the Company measures the assets, liabilities and noncontrolling interests of the newly consolidated entity at fair value in accordance with ASC Topic 805, Business Combinations at the date the reporting entity first becomes the primary beneficiary.

In October 2018, Faxian Therapeutics, LLC (“Faxian”) was formed in the United States. In April 2019, upon consummation of the joint venture, the Company and WuXi AppTech ("WuXi"), each received a 50% equity interest in the entity in exchange for their contributions to the entity. The Company determined that Faxian was a VIE and concluded that it is the primary beneficiary of the VIE. As such, the Company has consolidated Faxian's results into the consolidated financial statements, and eliminated WuXi's ownership as a non-controlling interest.
XML 53 R19.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss per Share Attributable to Common and Limited Stockholders
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Net Loss per Share Attributable to Common and Limited Stockholders

(11)

Net Loss per Share Attributable to Common and Limited Common Stockholders

The following table presents the calculation of basic and diluted net loss per share attributable to common and limited common stockholders for the years presented (in thousands, except for share and per share data):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to Schrödinger common

   and limited common stockholders

 

$

(100,393

)

 

$

(24,463

)

 

$

(24,571

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used to compute net

   loss per share attributable to Schrödinger common

   and limited common stockholders, basic and diluted:

 

 

70,594,950

 

 

 

60,024,658

 

 

 

6,004,500

 

Net loss per share attributable to Schrödinger common

   and limited common stockholders, basic and diluted:

 

$

(1.42

)

 

$

(0.41

)

 

$

(4.09

)

 

Since the Company was in a loss position for all years presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Convertible preferred stock

 

 

—

 

 

 

—

 

 

 

42,734,884

 

Shares subject to outstanding common stock options

 

 

7,680,341

 

 

 

7,257,460

 

 

 

4,805,562

 

 

 

 

7,680,341

 

 

 

7,257,460

 

 

 

47,540,446

 

 

 
XML 54 R20.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Investments
 12 Months Ended
Dec. 31, 2021
Equity Method Investments And Joint Ventures [Abstract]  
Equity Investments

(12)

Equity Investments

(a)

Nimbus

The Company provides collaboration services for Nimbus under the terms of a master services agreement executed on May 18, 2010, as amended. Collaboration agreements are separate from the transaction that resulted in equity ownership and related fees are paid in cash to the Company. As Nimbus is a limited liability company and the Company is not a passive investor due to its collaboration with Nimbus on a number of drug discovery targets, the Company's management determined that it has significant influence over the entity and therefore accounts for the investment as an equity method investment.

The Company has concluded that the carrying value of its equity investment in Nimbus should reflect its contractual rights to substantive profits. The Company further determined that the HLBV method for valuing contractual rights to substantive profits provides the best representation of its financial position in Nimbus.

The HLBV method is a balance sheet-oriented approach to equity method accounting. Under the HLBV method, the Company determines its share of earnings or losses by comparing its claim on the book value at the beginning and end of each reporting period. This claim is calculated as the amount that the Company would receive (or be obligated to pay) if the investee were to liquidate all of its assets at recorded amounts, determined as of the balance sheet date in accordance with U.S. GAAP, and distribute the resulting cash to creditors and investors in accordance with their respective priorities.

The carrying value of the Nimbus investment was zero as of December 31, 2021 and December 31, 2020. The Company has no obligation to fund Nimbus losses in excess of its initial investment. The Company reported losses of zero, $2,977, and $4,180 on the Nimbus investment during 2021, 2020, and 2019, respectively.

(b)

Morphic

The Company accounts for its investment in Morphic Holding, Inc. (“Morphic”) at fair value based on the share price of Morphic’s common stock at the measurement date.

During 2021, 2020, and 2019 the Company reported gains of $11,548, $13,685, and $14,102 on the Morphic investment, respectively. As of December 31, 2021 and December 31, 2020, the carrying value of the Company’s investment in Morphic was $39,561 and $28,013, respectively.

(c)

Petra

Prior to May 2020, the Company had concluded that its equity investment in Petra Pharma Corporation (“Petra”) should be valued as a non-marketable equity security as the Company did not exercise significant influence over Petra.

During May 2020, Petra entered into a merger agreement with a third party. In connection with the merger, the Company received $4,582 of merger consideration in exchange for the Company’s shares of Petra common stock and is eligible to receive potential earn-outs tied to the achievement of specified development, regulatory, and commercial milestones. The Company is also eligible to receive $361 in escrow payments. During 2021, the Company received escrow payments of $335.

(d)

Ravenna

In connection with the Petra merger, the Company received 2,676,191 shares of common stock of Ravenna Pharmaceuticals, Inc. (“Ravenna”). The Company concluded that its equity investment in Ravenna should be valued as a non-marketable equity security as the Company does not exercise significant influence over Ravenna. As of each of December 31, 2021 and December 31, 2020, the carrying value of the Company’s investment in Ravenna was $19 and $94, respectively. The Company reported losses of $75, zero, and zero on the Ravenna investment during 2021, 2020, and 2019, respectively.

(e)

Relay

In July 2020, Relay successfully completed an initial public offering. The Company accounts for its investment in Relay at fair value based on the share price of Relay’s common stock at the measurement date. In January 2021, the Company disposed of its equity stake in Relay for aggregate consideration of $15,735, resulting in a loss of $1,821 for 2021. The Company reported a gain of $17,556 on the Relay investment for the year ended December 31, 2020. There was no gain or loss on the Relay investment for 2019, as Relay was not a public company during this period.

(f)

Ajax

In May 2021, the Company purchased 631,377 shares of Series B preferred stock of Ajax Therapeutics, Inc. (“Ajax”) for $1,700 in cash. The Company has concluded that its equity investment in Ajax should be valued as a non-marketable equity security as the Company does not exercise significant influence over Ajax. As of December 31, 2021 and December 31, 2020, the carrying value of the Company’s investment in Ajax was $1,700 and zero, respectively.

(g)

ShouTi

In July 2021, the Company purchased 494,035 shares of Series B preferred stock of ShouTi for $2,000 in cash. As ShouTi is structured as a company limited by shares, incorporated under the laws of the Cayman Islands and the Company is not a passive investor due to its collaboration with ShouTi on a number of drug discovery targets, the Company’s management determined that it has significant influence over the entity and therefore accounts for the investment as an equity method investment.

The Company has determined that the HLBV method for valuing contractual rights to substantive profits provides the best representation of its financial position in ShouTi. The carrying value of ShouTi was $1,887 and zero as of December 31, 2021 and December 31, 2020, respectively. The Company has no obligation to fund ShouTi losses in excess of its initial investment. The Company recorded a loss of $113 on the ShouTi investment during the year ended December 31, 2021.
XML 55 R21.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plan
 12 Months Ended
Dec. 31, 2021
Compensation And Retirement Disclosure [Abstract]  
Employee Benefit Plan

(13)

Employee Benefit Plan

The Company offers a 401(k) employee savings plan to its U.S.‑based employees. The Company made discretionary matching contributions equal to 100% of the first 4.0% of compensation contributed by employees for the years ended December 31, 2021, 2020, and 2019. Matching contributions during 2021, 2020, and 2019 were $2,592, $1,748, and $1,492, respectively.
XML 56 R22.htm IDEA: XBRL DOCUMENT v3.22.0.1
Related Party Transactions
 12 Months Ended
Dec. 31, 2021
Related Party Transactions [Abstract]  
Related Party Transactions

(14)

Related Party Transactions

(a)

D. E. Shaw

For the years ended December 31, 2021, 2020, and 2019, the Company licensed technology and purchased services for $7,940, $7,281, and $5,190, respectively, from companies controlled by David E. Shaw and/or affiliates of companies controlled by David E. Shaw (the “D. E. Shaw entities”), stockholders of the Company. In addition, D. E. Shaw entities purchased certain products and services from, and provided cost reimbursements to, the Company totaling $318, $226, and $195 for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021 and 2020, the Company had net payables of $2,637 and $3,464, respectively, to D.E. Shaw entities.

(b)

Board Member

For the years ended December 31, 2021, 2020, and 2019, the Company paid consulting fees of $390, $364, and $361, respectively, to a member of its board of directors.

(c)

Bill and Melinda Gates Foundation

For the years ended December 31, 2021, 2020, and 2019, the Bill & Melinda Gates Foundation, an entity under common control with Bill and Melinda Gates Foundation Trust, a stockholder of the Company, issued a grant under which it agreed to pay the Company directly for certain licenses and services provided to a specified group of third-party organizations. Revenue recognized for services provided by the Company under this grant were $1,160, $2,094, and $1,065 for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021 and 2020, the Company had net receivables of $165 and $543, respectively, due from the Bill & Melinda Gates Foundation.

In the fourth quarter of 2021, the Company recognized $111 in drug discovery contribution revenue related to funds received under an agreement with the Bill & Melinda Gates Foundation, aimed at accelerating drug discovery in women’s health. As of December 31, 2021, the Company had no receivables due under this agreement from the Bill & Melinda Gates Foundation.

The Company received $1,000 in contribution revenue in connection with its entry into an agreement with Gates Ventures, LLC in the second quarter of 2020, and $1,000 in contribution revenue in the second quarter of 2021 on the first anniversary of its entry into the agreement. Gates Ventures, LLC is an entity under control of William H. Gates III, who may be deemed to be the beneficial owner of more than 5% of the Company’s voting securities. As of December 31, 2021 and 2020, the Company had no net receivables due from Gates Ventures, LLC.

(d)

ShouTi

During the year ended December 31, 2021, the Company entered into multiple software agreements with ShouTi and its subsidiary for approximately $650. The Company recognized revenue of approximately $129 in the aggregate related to these agreements during the year ended December 31, 2021.
XML 57 R23.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Reporting
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Segment Reporting

(15)

Segment Reporting

The Company has determined that its chief executive officer (“CEO”) is its chief operating decision maker (“CODM”). The Company’s CEO evaluates the financial performance of the Company based on two reportable segments: Software and Drug Discovery. The Software segment is focused on licensing the Company’s software to transform molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. 

The CODM reviews segment performance and allocates resources based upon segment revenue and segment gross profit of the Software and Drug Discovery reportable segments.  Segment gross profit is derived by deducting operational expenditures, with the exception of research and development, sales and marketing, and general and administrative activities from U.S. GAAP revenue. Operational expenditures are expenditures made that are directly attributable to the reportable segment. These expenditures are allocated to the segments based on headcount. The reportable segment expenditures include compensation, supplies, and services from contract research organizations.

Certain cost items are not allocated to the Company’s reportable segments. These cost items primarily consist of compensation and general operational expenses associated with the Company’s research and development, sales and marketing, and general and administrative.  These costs are incurred by both segments and due to the integrated nature of the Company’s Software and Drug Discovery segments, any allocation methodology would be arbitrary and provide no meaningful analysis.

All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is financial information with respect to the Company’s reportable segments for the periods presented:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Segment revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Software

 

$

113,236

 

 

$

92,530

 

 

$

66,735

 

Drug discovery

 

 

24,695

 

 

 

15,565

 

 

 

18,808

 

Total segment revenues

 

$

137,931

 

 

$

108,095

 

 

$

85,543

 

Segment gross profit:

 

 

 

 

 

 

 

 

 

 

 

 

Software

 

$

86,741

 

 

$

74,527

 

 

$

53,089

 

Drug discovery

 

 

(21,121

)

 

 

(11,055

)

 

 

(3,996

)

Total segment gross profit

 

 

65,620

 

 

 

63,472

 

 

 

49,093

 

Unallocated:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

(90,904

)

 

 

(64,695

)

 

 

(39,404

)

Sales and marketing

 

 

(22,150

)

 

 

(17,795

)

 

 

(21,364

)

General and administrative

 

 

(64,009

)

 

 

(41,898

)

 

 

(27,040

)

(Loss) gain on equity investments

 

 

(1,781

)

 

 

4,108

 

 

 

943

 

Change in fair value

 

 

11,359

 

 

 

28,263

 

 

 

9,922

 

Interest income

 

 

1,057

 

 

 

2,253

 

 

 

1,878

 

Income tax (expense) benefit

 

 

(411

)

 

 

(345

)

 

 

291

 

Consolidated net loss

 

$

(101,219

)

 

$

(26,637

)

 

$

(25,681

)

The following table sets forth revenues by geographic area for the years ended December 31, 2021, 2020, and 2019:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

United States

 

$

90,398

 

 

$

60,737

 

 

$

47,622

 

Europe

 

 

27,810

 

 

 

24,370

 

 

 

17,504

 

Japan

 

 

8,565

 

 

 

14,558

 

 

 

14,367

 

Rest of World

 

 

11,158

 

 

 

8,430

 

 

 

6,050

 

 

 

$

137,931

 

 

$

108,095

 

 

$

85,543

 

 
XML 58 R24.htm IDEA: XBRL DOCUMENT v3.22.0.1
Subsequent Events
 12 Months Ended
Dec. 31, 2021
Subsequent Events [Abstract]  
Subsequent Events

(16)

Subsequent Events

On January 14, 2022, we acquired 117,840 shares of XTAL BioStructures, Inc. for $6.5 million, a company that provides structural biology services, including biophysical methods, protein production and purification, and X-ray crystallography, which includes $6.0 million in upfront purchase price, plus an adjustment for working capital, less cash acquired.
XML 59 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies (Policies)
 12 Months Ended
Dec. 31, 2021
Accounting Policies [Abstract]  
Recently Issued Accounting Pronouncements

(a)

Recently Issued Accounting Pronouncements

In January 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2020-01, Investments—Equity Securities (Topic 321), Investments—Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) —Clarifying the Interactions between Topic 321, Topic 323, and Topic 815, which clarifies the accounting related to equity investments and derivatives. This guidance was effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption was permitted. The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.

In August 2018, the FASB issued ASU No. 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Topic 350) – Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract. This standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for annual periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021, with early adoption permitted. The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.

In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments-Credit Losses (Topic 326) – Measurement of Credit Losses on Financial Instruments, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU No. 2016-13 replaces the existing incurred loss impairment model with an expected loss model which requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes generally result in earlier recognition of credit losses.  The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.

In October 2021, the FASB issues ASU No. 2021-08, Business Combinations (Topic 805) – Accounting for Contract Assets and Contract Liabilities from Contracts with Customers, which requires the measurement and recognition of contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standard Codification (“ASC”) 606, Revenue from Contracts with Customers (Topic 606). This update replaces the existing guidance requiring contract assets and contract liabilities to be measured and recognized at fair value. The standard is effective on a prospective basis for annual periods beginning after December 15, 2022, including interim periods within the fiscal year, with early adoption permitted. The Company plans to early adopt this new standard effective January 1, 2022 and does not expect a material impact on its consolidated financial statements.
Basis of Presentation and Use of Estimates

(b)

Basis of Presentation and Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the assumptions used in the allocation of revenue, estimates regarding the progress of completing performance obligations under collaboration agreements, and the valuation of stock-based compensation. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements.
Principles of Consolidation

(c)

Principles of Consolidation

The Company’s consolidated financial statements include the accounts of Schrödinger, Inc., its wholly owned subsidiaries, and its variable interest entity. All intercompany balances and transactions have been eliminated in consolidation. The functional currency for foreign entities is the United States dollar. The Company accounts for investments over which it has significant influence, but not a controlling financial interest, using the equity method.
Cash and Cash Equivalents and Marketable Securities and Restricted Cash

(d)

Cash and Cash Equivalents and Marketable Securities and Restricted Cash

Included in cash and cash equivalents were cash equivalents of $90,477 and $185,614 as of December 31, 2021 and 2020, respectively, which consisted of money market funds and certificates of deposit, and are stated at cost, which approximates market value. The Company classifies all highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company classifies all marketable securities, which consist of fixed income securities, as available for sale securities.

At times, cash balances held at financial institutions were in excess of the Federal Deposit Insurance Corporation’s insured limits; however, the Company primarily places its cash with high-credit quality financial institutions.

Restricted cash consists of letters of credit held with the Company’s financial institution related to facility leases and is classified as current in the Company’s balance sheets based on the maturity of the underlying letters of credit.
Accounts Receivable

(e)

Accounts Receivable

Accounts receivable are stated at original invoice amount less an allowance for doubtful accounts. Management estimates the allowance for doubtful accounts by evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Account balances are considered delinquent if payment is not received by the due date. Accounts receivable are written off when deemed uncollectible. Recovery of accounts receivable previously written off is recorded when received. Changes in the balance of accounts deemed uncollectible were deemed immaterial as of December 31, 2021 and 2020. Interest is not charged on accounts receivable.
Fair Value of Financial Instruments

(f)

Fair Value of Financial Instruments

The carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities.
Property and Equipment

(g)

Property and Equipment

Property and equipment are stated at cost. The Company did not capitalize any interest during 2021 and 2020. Maintenance and repairs are expensed as incurred.

Depreciation is calculated using the straight‑line method over the estimated useful lives of the assets, which range from 3 to 7 years. Amortization of leasehold improvements is calculated using the straight‑line method over the remaining life of the lease or the useful life of the asset, whichever is shorter.

Property and equipment are reviewed for impairment as discussed below under Accounting for the Impairment of Long‑Lived Assets.

Accounting for the Impairment of Long Lived Assets

(h)

Accounting for the Impairment of Long‑Lived Assets

Long-lived assets, such as property and equipment subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that carrying value exceeds fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, depending on the nature of the asset. No impairment was identified for the years ended December 31, 2021, 2020, and 2019.
Warranties

(i)

Warranties

The Company typically warrants that its products will perform in a manner consistent with the product specifications provided to the customer for a period of 30 days. Historically, the Company has not been required to make payments under these obligations. Therefore, no liabilities for such obligations are presented in the consolidated financial statements.
Concentrations

(j)

Concentrations

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade receivables.

The Company does not require customers to provide collateral to support accounts receivable. If deemed necessary, credit reviews of significant new customers may be performed prior to extending credit. The determination of a customer’s ability to pay requires judgment, and failure to collect from a customer can adversely affect revenue, cash flows, and results of operations.

As of December 31, 2021, three customers accounted for 17%, 15%, and 11% of total accounts receivable, respectively. As of December 31, 2020, two customers accounted for 17% and 14% of total accounts receivable, respectively. For the year ended December 31, 2021, one customer accounted for 14% of total revenues. For the year ended December 31, 2020, no customer accounted for more than 10% of total revenues. For the year ended December 31, 2019, one customer accounted for 12% of total revenues.
Royalties

(k)

Royalties

Royalties represent a component of cost of revenues and consist of royalties paid to owners of intellectual property used in or bundled with the Company’s software. Generally, royalties are incurred and recorded at the time a customer enters into a binding purchase agreement, although some royalty agreements are based instead on cash collections. Royalty expense was $9,826, $7,663, and $7,352 for the years ended December 31, 2021, 2020, and 2019, respectively.
Software Development Costs

(l)

Software Development Costs

Costs to develop new software products and substantial enhancements to existing software products are expensed as incurred. Historically, the Company has not capitalized any software development costs because the software development process was essentially completed concurrent with the establishment of technological feasibility.
Research and Development and Advertising

(m)

Research and Development and Advertising

Research and development and advertising costs are expensed as incurred. The Company did not incur any significant advertising costs in 2021, 2020, or 2019.
Stock-Based Compensation

(n)

Stock‑Based Compensation

The Company calculates stock‑based compensation expense utilizing fair value–based methodologies and recognizes expense over the vesting period of such awards.
Commissions

(o)

Commissions

Commissions represent a component of sales and marketing expense and consist of the variable compensation paid to the Company’s sales representatives. Generally, sales commissions are earned and recorded as expense at the time that a customer has entered into a binding purchase agreement. Commissions paid to sales representatives are recoverable only in the case that the Company cannot collect against any invoiced fee associated with a sales order. Commission expense was $1,829, $1,362, and $754 in 2021, 2020, and 2019, respectively.
Income Taxes

(p)

Income Taxes

The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of the assets and liabilities. Deferred tax assets are reduced by a valuation allowance when it is estimated to become more likely than not that a portion of the deferred tax assets will not be realized. Accordingly, the Company currently maintains a full valuation allowance against existing net deferred tax assets.

The Company recognizes the effect of income tax positions only if such positions are deemed “more likely than not” capable of being sustained. Interest and penalties accrued on unrecognized tax benefits are included within income tax expense in the consolidated financial statements.
Comprehensive Loss

(q)

Comprehensive Loss

Comprehensive loss includes net loss and changes in equity related to changes in unrealized gains or losses on marketable securities.
Equity Investments

(r)

Equity Investments

In the normal course of business, the Company has entered, and may continue to enter, into collaboration agreements with private companies to perform drug design services for such companies in exchange for equity ownership stakes in such companies. If it is determined that the Company has control over the investee, the investee is consolidated in the financial statements. If the investee is consolidated with the Company and less than 100% of the equity is owned by the Company, the Company will present non-controlling interest to represent the portion of the investee owned by other investors. If it is determined that the Company does not have control over the investee, the Company evaluates the investment for the ability to exercise significant influence.

Equity investments over which the Company has significant influence may be accounted for under equity method accounting in accordance with ASC Topic 323, Equity Method and Joint Ventures. If it is determined that the Company does not have significant influence over the investee, and there is no readily determinable fair value for the investment, the equity investment may be accounted for at cost minus impairment in accordance with ASC Topic 321, Equity Securities.

For further information regarding the Company’s equity investments, see Note 5, Fair Value Measurements, Note 10, Noncontrolling Interest, and Note 12, Equity Investments.

Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders

(s)

Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders

The outstanding equity of the Company consists of common stock and limited common stock. Under the Company’s certificate of incorporation, the rights of the holders of common stock and limited common stock are identical, except with respect to voting and conversion. Holders of limited common stock are precluded from voting such shares in any election of directors or on the removal of directors. Limited common stock may be converted into common stock at any time at the option of the stockholder.

Undistributed earnings allocated to the participating securities are subtracted from net income in determining net (loss) income attributable to common and limited common stockholders. Basic net (loss) income per share is computed by dividing net (loss) income attributable to common and limited common stockholders by the weighted-average number of shares of common and limited common stock outstanding during the period.

For the calculation of diluted net income, net income attributable to common and limited common stockholders for basic net income is adjusted by the effect of dilutive securities, including awards under the Company’s equity compensation plans. Diluted net income per share attributable to common and limited common stockholders is computed by dividing the resulting net income attributable to common and limited common stockholders by the weighted-average number of fully diluted shares of common and limited common stock outstanding.
XML 60 R26.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition (Tables)
 12 Months Ended
Dec. 31, 2021
Revenue From Contract With Customer [Abstract]  
Schedule of Timing of Revenue Recognition

The following table illustrates the timing of the Company’s revenue recognition:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Software products and services – point in time

 

 

55.5

%

 

 

55.0

%

 

 

49.9

%

Software products and services – over time

 

 

26.6

 

 

 

30.6

 

 

 

28.1

 

Drug Discovery – point in time

 

 

3.3

 

 

 

6.7

 

 

 

8.6

 

Drug Discovery – over time

 

 

14.6

 

 

 

7.7

 

 

 

13.4

 
Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue

The following table presents the revenue recognized from the sources of software products and services revenue:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

On-premise software

 

$

74,598

 

 

$

58,311

 

 

$

42,647

 

Hosted software

 

 

11,076

 

 

 

9,192

 

 

 

7,418

 

Software maintenance

 

 

17,294

 

 

 

14,465

 

 

 

11,643

 

Professional services

 

 

9,268

 

 

 

9,562

 

 

 

5,027

 

Revenue from contracts with customers

 

 

112,236

 

 

 

91,530

 

 

 

66,735

 

Software contribution

 

 

1,000

 

 

 

1,000

 

 

 

—

 

Total software revenue

 

$

113,236

 

 

$

92,530

 

 

$

66,735

 
Drug Discovery Revenue

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Drug discovery services revenue from contracts with customers

 

$

24,584

 

 

$

15,565

 

 

$

18,808

 

Drug discovery contribution

 

 

111

 

 

 

—

 

 

 

—

 

Total drug discovery revenue

 

$

24,695

 

 

$

15,565

 

 

$

18,808

 
Schedule of Contract Balances

Contract balances were as follows:

 

 

As of

December 31,

 

 

As of

December 31,

 

 

 

2021

 

 

2020

 

Contract assets

 

$

8,271

 

 

$

3,589

 

Deferred revenue, short-term:

 

 

 

 

 

 

 

 

Software products and services

 

 

32,945

 

 

 

28,218

 

Drug discovery

 

 

22,423

 

 

 

17,185

 

Deferred revenue, long-term:

 

 

 

 

 

 

 

 

Software products and services

 

 

3,938

 

 

 

1,976

 

Drug discovery

 

 

26,126

 

 

 

39,188

 
XML 61 R27.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment (Tables)
 12 Months Ended
Dec. 31, 2021
Property Plant And Equipment [Abstract]  
Summary of Property and Equipment

Property and equipment consisted of the following:

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

Computers and equipment

 

$

16,059

 

 

$

12,718

 

Leasehold improvements

 

 

2,276

 

 

 

4,385

 

Furniture and fixtures

 

 

4,045

 

 

 

1,839

 

 

 

 

22,380

 

 

 

18,942

 

Less accumulated depreciation

 

 

(12,355

)

 

 

(13,802

)

 

 

$

10,025

 

 

$

5,140

 
XML 62 R28.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements (Tables)
 12 Months Ended
Dec. 31, 2021
Fair Value Disclosures [Abstract]  
Schedule of Assets and Liabilities Measured at Fair Value The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2021:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities

 

$

—

 

 

$

456,212

 

 

$

—

 

 

$

456,212

 

Equity investments

 

 

39,561

 

 

 

—

 

 

 

1,887

 

 

 

41,448

 

Total

 

$

39,561

 

 

$

456,212

 

 

$

1,887

 

 

$

497,660

 

The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2020:

 

 

 

Level 1

 

 

Level 2

 

 

Level 3

 

 

Total

 

Assets:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Marketable securities

 

$

—

 

 

$

440,395

 

 

$

—

 

 

$

440,395

 

Equity investments

 

 

45,570

 

 

 

—

 

 

 

—

 

 

 

45,570

 

Total

 

$

45,570

 

 

$

440,395

 

 

$

—

 

 

$

485,965

 
Summary of Changes in Fair Value of Level 3 Investments The following table sets forth changes in fair value of the Company’s Level 3 investments:

 

 

 

Amount

 

As of December 31, 2019

 

$

108

 

Cash contributions

 

 

2,869

 

Unrealized loss

 

 

(2,977

)

As of December 31, 2020

 

 

-

 

Cash contributions

 

 

2,000

 

Unrealized loss

 

 

(113

)

As of December 31, 2021

 

$

1,887

 
XML 63 R29.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments and Contingencies (Tables)
 12 Months Ended
Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]  
Summary of Operating Leases Additional details of the Company’s operating leases are presented in the following table:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Operating lease costs

 

$

7,627

 

 

$

5,895

 

 

$

5,181

 

Cash paid for operating leases

 

 

4,561

 

 

 

6,050

 

 

 

5,108

 

 

 
Summary of Maturities of Operating Lease Liabilities Under Noncancelable Operating Leases

Maturities of operating lease liabilities as of December 31, 2021 under noncancelable operating leases were as follows:

 

Year ending December 31:

 

 

 

 

2022

 

$

2,087

 

2023

 

 

8,809

 

2024

 

 

9,632

 

2025

 

 

9,241

 

2026

 

 

8,758

 

Thereafter

 

 

93,656

 

Total future minimum lease payments

 

 

132,183

 

Less: imputed interest

 

 

(52,314

)

Present value of future minimum lease payments

 

 

79,869

 

Less: current portion of operating leases payments

 

 

(2,042

)

Lease liabilities, long-term

 

$

77,827

 
XML 64 R30.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2021
Income Tax Disclosure [Abstract]  
Summary of Income Tax Expense

Income tax expense is comprised of the following:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Current:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

$

—

 

 

$

—

 

 

$

583

 

State

 

 

67

 

 

 

178

 

 

 

(95

)

Foreign

 

 

344

 

 

 

167

 

 

 

(779

)

Current income tax expense (benefit)

 

 

411

 

 

 

345

 

 

 

(291

)

Deferred:

 

 

 

 

 

 

 

 

 

 

 

 

Federal

 

 

—

 

 

 

—

 

 

 

—

 

State

 

 

—

 

 

 

—

 

 

 

—

 

Deferred income tax expense (benefit)

 

 

—

 

 

 

—

 

 

 

—

 

 

 

$

411

 

 

$

345

 

 

$

(291

)
Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction

Components of loss before income taxes by tax jurisdiction were as follows:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

United States

 

$

(101,341

)

 

$

(24,567

)

 

$

(25,385

)

Foreign

 

 

1,359

 

 

 

449

 

 

 

523

 

Loss before income taxes

 

$

(99,982

)

 

$

(24,118

)

 

$

(24,862

)
Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate

Reconciliation of income tax expense at the applicable statutory income tax rates to the effective income tax rate is as follows:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Statutory federal income tax rate

 

 

21.0

%

 

 

21.0

%

 

 

21.0

%

State taxes, net of federal benefits

 

 

4.9

 

 

 

14.2

 

 

 

4.2

 

Withholding tax

 

 

—

 

 

 

—

 

 

 

(2.3

)

Section 162(m) limitation

 

 

(5.2

)

 

 

(12.8

)

 

 

—

 

Stock compensation

 

 

12.4

 

 

 

68.5

 

 

 

0.2

 

Return-to-provision adjustments

 

 

(1.7

)

 

 

(1.3

)

 

 

3.2

 

Research and development credit

 

 

6.3

 

 

 

6.2

 

 

 

5.2

 

Tax contingencies, net of reversals

 

 

(0.7

)

 

 

(0.6

)

 

 

(0.5

)

Change in valuation allowance

 

 

(37.2

)

 

 

(95.0

)

 

 

(31.3

)

Other

 

 

(0.2

)

 

 

(1.6

)

 

 

(0.6

)

Effective income tax rate

 

 

(0.4

)%

 

 

(1.4

)%

 

 

(0.9

)%
Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities

Tax effects of temporary differences that give rise to significant portions of deferred income tax assets and deferred income tax liabilities were as follows:

 

 

 

As of December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Deferred income tax assets:

 

 

 

 

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

67,985

 

 

$

51,498

 

 

$

26,119

 

Accrued expenses

 

 

10,309

 

 

 

7,918

 

 

 

6,164

 

Deferred Revenue

 

 

10,632

 

 

 

394

 

 

 

500

 

Lease Liabilities

 

 

18,773

 

 

 

2,165

 

 

 

433

 

Credits

 

 

14,559

 

 

 

8,752

 

 

 

7,468

 

Gross deferred tax assets

 

 

122,258

 

 

 

70,727

 

 

 

40,684

 

Less valuation allowance

 

 

(95,304

)

 

 

(58,155

)

 

 

(35,251

)

Net deferred tax assets

 

 

26,954

 

 

 

12,572

 

 

 

5,433

 

Deferred income tax liabilities:

 

 

 

 

 

 

 

 

 

 

 

 

Unrealized gain on equity investments

 

 

(8,545

)

 

 

(10,185

)

 

 

(1,984

)

Prepaid expenses

 

 

(969

)

 

 

(889

)

 

 

(441

)

Depreciation and amortization

 

 

(17,440

)

 

 

(1,498

)

 

 

(3,008

)

Net deferred income tax assets

 

$

—

 

 

$

—

 

 

$

—

 
Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits

The Company classifies interest and penalties related to unrecognized tax benefits within income tax expense in the consolidated statement of operations. Following is a reconciliation of total gross unrecognized tax benefits:

 

 

 

Year ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Balance, January 1

 

$

1,046

 

 

$

902

 

 

$

781

 

Additions for tax positions taken in prior years

 

 

282

 

 

 

25

 

 

 

24

 

Reductions for tax positions taken in prior years

 

 

(20

)

 

 

(16

)

 

 

(12

)

Additions for tax positions related to the current year

 

 

394

 

 

 

135

 

 

 

109

 

Balance, December 31

 

$

1,702

 

 

$

1,046

 

 

$

902

 
XML 65 R31.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation (Tables)
 12 Months Ended
Dec. 31, 2021
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]  
Summary of Weighted Average Valuation Assumptions Used for Options Following are the weighted average valuation assumptions used for options:

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Valuation assumptions

 

 

 

 

 

 

 

 

 

 

 

 

Expected dividend yield

 

 

—

%

 

 

—

%

 

 

—

%

Expected volatility

 

 

59

%

 

 

60

%

 

 

57

%

Expected term (years)

 

 

4.66

 

 

 

4.49

 

 

 

6.05

 

Risk-free interest rate

 

 

0.71

%

 

 

1.46

%

 

 

2.33

%

 
Summary of Classification of Stock Based Compensation Expense

The following table presents classification of stock-based compensation expense within the consolidated statements of operations:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Cost of sales

 

$

3,858

 

 

$

1,384

 

 

$

376

 

Research and development

 

 

7,440

 

 

 

3,050

 

 

 

460

 

Sales and marketing

 

 

1,281

 

 

 

516

 

 

 

311

 

General and administrative

 

 

13,911

 

 

 

5,595

 

 

 

1,046

 

Total stock-based compensation

 

$

26,490

 

 

$

10,545

 

 

$

2,193

 
Summary of Stock Option Activity

Stock option activity was as follows:

 

 

 

Number of

shares

 

 

Weighted

average

exercise

price

 

 

Weighted

average

remaining

contractual

term (years)

 

 

Aggregate

intrinsic

value

 

Beginning, January 1, 2021

 

 

7,257,460

 

 

$

12.14

 

 

 

 

 

 

 

 

 

Granted

 

 

1,696,327

 

 

93.13

 

 

 

 

 

 

 

 

 

Exercised

 

 

(1,120,981

)

 

 

7.00

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(149,346

)

 

 

41.47

 

 

 

 

 

 

 

 

 

Expired

 

 

(3,119

)

 

 

1.70

 

 

 

 

 

 

 

 

 

Balance, December 31, 2021

 

 

7,680,341

 

 

 

30.19

 

 

 

7.67

 

 

$

35,584

 

Exercisable, December 31, 2021

 

 

3,473,716

 

 

 

10.83

 

 

 

6.75

 

 

$

83,306

 
XML 66 R32.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss per Share Attributable to Common and Limited Stockholders (Tables)
 12 Months Ended
Dec. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders

The following table presents the calculation of basic and diluted net loss per share attributable to common and limited common stockholders for the years presented (in thousands, except for share and per share data):

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Numerator:

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to Schrödinger common

   and limited common stockholders

 

$

(100,393

)

 

$

(24,463

)

 

$

(24,571

)

Denominator:

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares used to compute net

   loss per share attributable to Schrödinger common

   and limited common stockholders, basic and diluted:

 

 

70,594,950

 

 

 

60,024,658

 

 

 

6,004,500

 

Net loss per share attributable to Schrödinger common

   and limited common stockholders, basic and diluted:

 

$

(1.42

)

 

$

(0.41

)

 

$

(4.09

)
Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive

Since the Company was in a loss position for all years presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Convertible preferred stock

 

 

—

 

 

 

—

 

 

 

42,734,884

 

Shares subject to outstanding common stock options

 

 

7,680,341

 

 

 

7,257,460

 

 

 

4,805,562

 

 

 

 

7,680,341

 

 

 

7,257,460

 

 

 

47,540,446

 
XML 67 R33.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Reporting (Tables)
 12 Months Ended
Dec. 31, 2021
Segment Reporting [Abstract]  
Summary of Financial Information with Respect to Reportable Segments

All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is financial information with respect to the Company’s reportable segments for the periods presented:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

Segment revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Software

 

$

113,236

 

 

$

92,530

 

 

$

66,735

 

Drug discovery

 

 

24,695

 

 

 

15,565

 

 

 

18,808

 

Total segment revenues

 

$

137,931

 

 

$

108,095

 

 

$

85,543

 

Segment gross profit:

 

 

 

 

 

 

 

 

 

 

 

 

Software

 

$

86,741

 

 

$

74,527

 

 

$

53,089

 

Drug discovery

 

 

(21,121

)

 

 

(11,055

)

 

 

(3,996

)

Total segment gross profit

 

 

65,620

 

 

 

63,472

 

 

 

49,093

 

Unallocated:

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

(90,904

)

 

 

(64,695

)

 

 

(39,404

)

Sales and marketing

 

 

(22,150

)

 

 

(17,795

)

 

 

(21,364

)

General and administrative

 

 

(64,009

)

 

 

(41,898

)

 

 

(27,040

)

(Loss) gain on equity investments

 

 

(1,781

)

 

 

4,108

 

 

 

943

 

Change in fair value

 

 

11,359

 

 

 

28,263

 

 

 

9,922

 

Interest income

 

 

1,057

 

 

 

2,253

 

 

 

1,878

 

Income tax (expense) benefit

 

 

(411

)

 

 

(345

)

 

 

291

 

Consolidated net loss

 

$

(101,219

)

 

$

(26,637

)

 

$

(25,681

)
Schedule of Revenues by Geographic Area

The following table sets forth revenues by geographic area for the years ended December 31, 2021, 2020, and 2019:

 

 

 

Year Ended December 31,

 

 

 

2021

 

 

2020

 

 

2019

 

United States

 

$

90,398

 

 

$

60,737

 

 

$

47,622

 

Europe

 

 

27,810

 

 

 

24,370

 

 

 

17,504

 

Japan

 

 

8,565

 

 

 

14,558

 

 

 

14,367

 

Rest of World

 

 

11,158

 

 

 

8,430

 

 

 

6,050

 

 

 

$

137,931

 

 

$

108,095

 

 

$

85,543

 

 
XML 68 R34.htm IDEA: XBRL DOCUMENT v3.22.0.1
Description of Business - Additional Information (Details) - USD ($)
 12 Months Ended
Aug. 17, 2020
Feb. 10, 2020
Feb. 09, 2020
Dec. 31, 2020
Dec. 31, 2021
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Offering price per share       $ 0.01 $ 0.01
Preferred Stock          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Conversion of convertible preferred stock into common stock, Shares   226,344,686      
Temporary equity, exchange of convertible preferred stock into limited common stock, Shares     98,406,823    
Limited Common Stock          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Offering price per share       $ 0.01 $ 0.01
Exchange of convertible preferred stock into limited common stock, Shares     13,164,193    
Common Stock          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Issued and sold shares   1,782,352      
Net proceeds from issuance of common stock $ 325,600,000 $ 209,600,000      
Conversion of convertible preferred stock into common stock, Shares   30,278,832   30,278,832  
Issued and sold shares by selling stockholder 500,000        
Proceeds from sale of common stock by stockholder $ 0        
Common Stock | Initial Public Offering          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Issued and sold shares   11,882,352   13,664,704  
Offering price per share   $ 17.00      
Common Stock | Follow-on-Public Offering          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Issued and sold shares 4,500,000        
Offering price per share $ 66.00        
Common Stock | Underwriter          
Organization Consolidation And Presentation Of Financial Statements [Line Items]          
Issued and sold shares 750,000        
XML 69 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Significant Accounting Policies - Additional Information (Details)
 12 Months Ended
Dec. 31, 2021
USD ($)
Customer
Dec. 31, 2020
USD ($)
Customer
Dec. 31, 2019
USD ($)
Customer
Mar. 31, 2021
Jan. 01, 2021
Significant Accounting Policies [Line Items]          
Cash equivalents $ 90,477,000 $ 185,614,000      
Interest costs capitalized 0 0      
Impairment of long-lived assets 0 0 $ 0    
Royalty expense 9,826,000 7,663,000 7,352,000    
Commission expense $ 1,829,000 $ 1,362,000 $ 754,000    
Equity method investment, ownership percentage 100.00%        
Customer Concentration Risk | Accounts Receivable          
Significant Accounting Policies [Line Items]          
Concentration risk, number of customers | Customer 3 2      
Customer Concentration Risk | Accounts Receivable | Customer A          
Significant Accounting Policies [Line Items]          
Concentration risk, percentage 17.00% 17.00%      
Customer Concentration Risk | Accounts Receivable | Customer B          
Significant Accounting Policies [Line Items]          
Concentration risk, percentage 15.00% 14.00%      
Customer Concentration Risk | Accounts Receivable | Customer C          
Significant Accounting Policies [Line Items]          
Concentration risk, percentage 11.00%        
Customer Concentration Risk | Revenue Benchmark          
Significant Accounting Policies [Line Items]          
Concentration risk, number of customers | Customer 1 0 1    
Customer Concentration Risk | Revenue Benchmark | Customer A          
Significant Accounting Policies [Line Items]          
Concentration risk, percentage 14.00% 10.00% 12.00%    
Minimum          
Significant Accounting Policies [Line Items]          
Estimated useful lives of assets 3 years        
Maximum          
Significant Accounting Policies [Line Items]          
Estimated useful lives of assets 7 years        
ASU - 2020-01          
Significant Accounting Policies [Line Items]          
Change in accounting principle, accounting standards update, adopted       true  
Change in accounting principle, accounting standards update, adoption date       Jan. 01, 2021  
Change in accounting principle, accounting standards update, immaterial effect       true  
2018-15          
Significant Accounting Policies [Line Items]          
Change in accounting principle, accounting standards update, adopted true        
Change in accounting principle, accounting standards update, adoption date Jan. 01, 2021        
Change in accounting principle, accounting standards update, immaterial effect true        
ASU - 2016-13          
Significant Accounting Policies [Line Items]          
Change in accounting principle, accounting standards update, adopted         true
Change in accounting principle, accounting standards update, adoption date         Jan. 01, 2021
Change in accounting principle, accounting standards update, immaterial effect         true
ASU - 2021-08          
Significant Accounting Policies [Line Items]          
Change in accounting principle, accounting standards update, adopted true        
Change in accounting principle, accounting standards update, adoption date Jan. 01, 2022        
Change in accounting principle, accounting standards update, immaterial effect true        
XML 70 R36.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition - Schedule of Timing of Revenue Recognition (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Software Products and Services | Point in Time      
Disaggregation Of Revenue [Line Items]      
Timing of revenue recognition 55.50% 55.00% 49.90%
Software Products and Services | Over Time      
Disaggregation Of Revenue [Line Items]      
Timing of revenue recognition 26.60% 30.60% 28.10%
Drug Discovery | Point in Time      
Disaggregation Of Revenue [Line Items]      
Timing of revenue recognition 3.30% 6.70% 8.60%
Drug Discovery | Over Time      
Disaggregation Of Revenue [Line Items]      
Timing of revenue recognition 14.60% 7.70% 13.40%
XML 71 R37.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition - Additional Information (Details 1)
Dec. 31, 2021
On Premise Software | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01  
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]  
Revenue, remaining performance obligation, expected timing of satisfaction, period 1 year
XML 72 R38.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition - Additional Information (Details)
 3 Months Ended 12 Months Ended
Nov. 22, 2020
USD ($)
Program
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Deferred revenue, revenue recognized       $ 42,127,000 $ 24,921,000  
Percentage of revenue expected to be recognized       65.00%    
Unsatisfied performance obligation       $ 26,694,000    
Agreement with Gates Ventures, LLC            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Software contribution revenue related to agreement cover period start date       Jun. 23, 2020    
Software contribution revenue related to agreement cover period end date       Jun. 22, 2023    
Deferred revenue       $ 0    
Agreement with Gates Ventures, LLC | First Anniversary            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Software contribution revenue recognition   $ 1,000,000 $ 1,000,000      
Agreement with Gates Ventures, LLC | Second Anniversary            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Additional revenue entitled to receive       1,000,000    
Collaboration and License Agreement | BMS            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Upfront fee received $ 55,000,000          
Maximum milestone payments to be received $ 2,700,000,000          
Number of programs under agreement | Program 5          
Transaction price $ 55,000,000          
Deferred revenue, revenue recognized       13,749,000 988,000  
Deferred revenue       40,263,000 54,012,000  
Receivable from collaboration       $ 0    
Maximum            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Contract with customers, payment terms       60 days    
Maximum | Agreement with Gates Ventures, LLC            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Software contribution revenue recognition amount       $ 3,000,000    
Minimum            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Contract with customers, payment terms       30 days    
On Premise Software            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Revenue, practical expedient, financing component [true false]       true    
Drug Discovery Services            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Milestone payment yet to be achieved       $ 2,250,000 250,000 $ 1,500,000
Revenue recognized with milestones       2,250,000 $ 85,000 $ 1,500,000
Drug Discovery Contribution            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Deferred revenue       $ 1,129,000    
Oncology Product | Collaboration and License Agreement | BMS            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Maximum milestone payments to be received 585,000,000          
Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones 360,000,000          
Milestone payments to be received upon achievement of certain specified commercial milestones 225,000,000          
Neurology and Immunology Product | Collaboration and License Agreement | BMS            
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]            
Maximum milestone payments to be received 482,000,000          
Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones 257,000,000          
Milestone payments to be received upon achievement of certain specified commercial milestones $ 225,000,000          
XML 73 R39.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition - Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disaggregation Of Revenue [Line Items]      
Total software revenue $ 137,931 $ 108,095 $ 85,543
On Premise Software      
Disaggregation Of Revenue [Line Items]      
Total software revenue 74,598 58,311 42,647
Hosted Software      
Disaggregation Of Revenue [Line Items]      
Total software revenue 11,076 9,192 7,418
Software Maintenance      
Disaggregation Of Revenue [Line Items]      
Total software revenue 17,294 14,465 11,643
Professional Services      
Disaggregation Of Revenue [Line Items]      
Total software revenue 9,268 9,562 5,027
Revenue From Contract With Customer Before Software Contribution      
Disaggregation Of Revenue [Line Items]      
Total software revenue 112,236 91,530 66,735
Software Contribution      
Disaggregation Of Revenue [Line Items]      
Total software revenue 1,000 1,000  
Software Products and Services      
Disaggregation Of Revenue [Line Items]      
Total software revenue $ 113,236 $ 92,530 $ 66,735
XML 74 R40.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition - Schedule of Drug Revenue Recognition (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Disaggregation Of Revenue [Line Items]      
Total drug discovery revenue $ 24,695 $ 15,565 $ 18,808
Drug Discovery Services Revenue from Contracts with Customers      
Disaggregation Of Revenue [Line Items]      
Total drug discovery revenue 24,584 $ 15,565 $ 18,808
Drug Discovery Contribution      
Disaggregation Of Revenue [Line Items]      
Total drug discovery revenue $ 111    
XML 75 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Revenue Recognition - Schedule of Contract Balances (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Disaggregation Of Revenue [Line Items]    
Contract assets $ 8,271 $ 3,589
Deferred revenue, short-term:    
Deferred revenue 55,368 45,403
Deferred revenue, long-term:    
Deferred revenue, long-term 30,064 41,164
Software Products and Services    
Deferred revenue, short-term:    
Deferred revenue 32,945 28,218
Deferred revenue, long-term:    
Deferred revenue, long-term 3,938 1,976
Drug Discovery    
Deferred revenue, short-term:    
Deferred revenue 22,423 17,185
Deferred revenue, long-term:    
Deferred revenue, long-term $ 26,126 $ 39,188
XML 76 R42.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment - Summary of Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Property Plant And Equipment [Line Items]    
Computers and equipment $ 22,380 $ 18,942
Less accumulated depreciation (12,355) (13,802)
Property Plant And Equipment Net 10,025 5,140
Computers and Equipment    
Property Plant And Equipment [Line Items]    
Computers and equipment 16,059 12,718
Leasehold Improvements    
Property Plant And Equipment [Line Items]    
Computers and equipment 2,276 4,385
Furniture and Fixtures    
Property Plant And Equipment [Line Items]    
Computers and equipment $ 4,045 $ 1,839
XML 77 R43.htm IDEA: XBRL DOCUMENT v3.22.0.1
Property and Equipment - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Property Plant And Equipment [Abstract]      
Depreciation expense $ 2,847 $ 3,658 $ 3,625
XML 78 R44.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Total Assets $ 497,660 $ 485,965
Level 1    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Total Assets 39,561 45,570
Level 2    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Total Assets 456,212 440,395
Level 3    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Total Assets 1,887  
Marketable Securities    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Total Assets 456,212 440,395
Marketable Securities | Level 2    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Total Assets 456,212 440,395
Equity Investments    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Total Assets 41,448 45,570
Equity Investments | Level 1    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Total Assets 39,561 $ 45,570
Equity Investments | Level 3    
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]    
Total Assets $ 1,887  
XML 79 R45.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Investments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Fair Value Disclosures [Abstract]    
Beginning balance   $ 108
Cash contributions $ 2,000 2,869
Unrealized loss (113) $ (2,977)
Ending balance $ 1,887  
XML 80 R46.htm IDEA: XBRL DOCUMENT v3.22.0.1
Fair Value Measurements - Additional Information (Details) - USD ($)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Fair Value Disclosures [Abstract]    
Fair value, assets, Level 1 to Level 2 transfers, amount $ 0 $ 0
Fair value, assets, Level 2 to Level 1 transfers, amount 0 0
Fair value, asset transfers into Level 3 $ 0 $ 0
XML 81 R47.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments And Contingencies - Additional Information (Details)
 12 Months Ended
Nov. 30, 2021
USD ($)
SquareFoot
Nov. 01, 2021
USD ($)
SquareFoot
Dec. 31, 2021
USD ($)
OperatingLease
Lessee Lease Description [Line Items]      
Operating lease expiration year     2037
Operating lease, weighted average lease term     15 years
Number of new operating lease | OperatingLease     2
Increase in right-of-use assets     $ 71,054,000
Increase in lease liabilities     71,054,000
Lease costs     $ 0
Office Lease Agreement      
Lessee Lease Description [Line Items]      
Area leased | SquareFoot 19,753 16,727  
Base rent per month   $ 135,000  
Percentage of annual rental escalation   3.00%  
Lease expiration period   10 years  
Base rent per month from commencement to handover date $ 20,000    
Base rent per month from handover to termination date $ 29,000    
Lease expiration date Jun. 30, 2023    
XML 82 R48.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments And Contingencies - Summary of Operating Leases (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]      
Operating lease costs $ 7,627 $ 5,895 $ 5,181
Cash paid for operating leases $ 4,561 $ 6,050 $ 5,108
XML 83 R49.htm IDEA: XBRL DOCUMENT v3.22.0.1
Commitments And Contingencies - Summary of Maturities of Operating Lease Liabilities Under Noncancelable Operating Leases (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]    
2022 $ 2,087  
2023 8,809  
2024 9,632  
2025 9,241  
2026 8,758  
Thereafter 93,656  
Total future minimum lease payments 132,183  
Less: imputed interest (52,314)  
Present value of future minimum lease payments 79,869  
Less: current portion of operating leases payments (2,042) $ (4,543)
Lease liabilities, long-term $ 77,827 $ 7,221
XML 84 R50.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Summary of Income Tax Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Current:      
Federal     $ 583
State $ 67 $ 178 (95)
Foreign 344 167 (779)
Current income tax expense (benefit) 411 345 (291)
Deferred:      
Income Tax Expense (Benefit), Total $ 411 $ 345 $ (291)
XML 85 R51.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
United States $ (101,341) $ (24,567) $ (25,385)
Foreign 1,359 449 523
Loss before income taxes $ (99,982) $ (24,118) $ (24,862)
XML 86 R52.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
Statutory federal income tax rate 21.00% 21.00% 21.00%
State taxes, net of federal benefits 4.90% 14.20% 4.20%
Withholding tax     (2.30%)
Section 162(m) limitation (5.20%) (12.80%)  
Stock compensation 12.40% 68.50% 0.20%
Return-to-provision adjustments (1.70%) (1.30%) 3.20%
Research and development credit 6.30% 6.20% 5.20%
Tax contingencies, net of reversals (0.70%) (0.60%) (0.50%)
Change in valuation allowance (37.20%) (95.00%) (31.30%)
Other (0.20%) (1.60%) (0.60%)
Effective income tax rate (0.40%) (1.40%) (0.90%)
XML 87 R53.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Additional Information (Details)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
USD ($)
Income Tax Contingency [Line Items]  
Change in valuation allowance $ 37,149
Federal net operating loss carryforwards 283,314
State net operating loss carryforwards $ 148,130
Income tax examination, description As of December 31, 2021, the Company’s statutes of limitations are open for all federal and state years tax returns filed after the years ended December 31, 2016 and 2015, respectively. Net operating loss and credit carryforwards for all years are subject to examination and adjustments for the three years following the year in which the carryforwards are utilized. The Company is not currently under Internal Revenue Service or state examination.
Minimum  
Income Tax Contingency [Line Items]  
Operating loss carryforwards, expiration year 2022
Maximum  
Income Tax Contingency [Line Items]  
Operating loss carryforwards, expiration year 2041
Federal  
Income Tax Contingency [Line Items]  
NOL carryforwards, percentage of taxable income limitation on use 80.00%
Research and development tax credit carryforwards $ 15,459
State  
Income Tax Contingency [Line Items]  
Research and development tax credit carryforwards $ 977
XML 88 R54.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Deferred income tax assets:      
Net operating loss carryforwards $ 67,985 $ 51,498 $ 26,119
Accrued expenses 10,309 7,918 6,164
Deferred Revenue 10,632 394 500
Lease Liabilities 18,773 2,165 433
Credits 14,559 8,752 7,468
Gross deferred tax assets 122,258 70,727 40,684
Less valuation allowance (95,304) (58,155) (35,251)
Net deferred tax assets 26,954 12,572 5,433
Deferred income tax liabilities:      
Unrealized gain on equity investments (8,545) (10,185) (1,984)
Prepaid expenses (969) (889) (441)
Depreciation and amortization $ (17,440) $ (1,498) $ (3,008)
XML 89 R55.htm IDEA: XBRL DOCUMENT v3.22.0.1
Income Taxes - Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Income Tax Disclosure [Abstract]      
Balance, January 1 $ 1,046 $ 902 $ 781
Additions for tax positions taken in prior years 282 25 24
Reductions for tax positions taken in prior years (20) (16) (12)
Additions for tax positions related to the current year 394 135 109
Balance, December 31 $ 1,702 $ 1,046 $ 902
XML 90 R56.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stockholders' Equity (Deficit) - Additional Information (Details)
 12 Months Ended
Dec. 31, 2021
Vote
$ / shares
shares
Dec. 31, 2020
$ / shares
shares
Class Of Stock [Line Items]    
Common stock, shares authorized 500,000,000 500,000,000
Common stock, par value | $ / shares $ 0.01 $ 0.01
Preferred stock, shares authorized 10,000,000 10,000,000
Preferred stock, par value | $ / shares $ 0.01 $ 0.01
Voting Common Stock    
Class Of Stock [Line Items]    
Common stock, shares authorized 500,000,000  
Common stock, par value | $ / shares $ 0.01  
Number of votes for common share | Vote 1  
Common stock, description Common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.  
Limited Common Stock    
Class Of Stock [Line Items]    
Common stock, shares authorized 100,000,000 100,000,000
Common stock, par value | $ / shares $ 0.01 $ 0.01
Number of votes for common share | Vote 1  
Common stock, description Holders of limited common stock are entitled to one vote per share, however, the holders of limited common stock shall not be entitled to vote such shares in any election of directors or on the removal of directors. Holders of limited common stock are entitled to receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company’s preferred stock, if any.  Holders of the Company’s limited common stock have the right to convert each share of limited common stock into one share of the Company’s common stock.  
Right to exchange limited common stock to common stock, share 1  
XML 91 R57.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]      
Share-based compensation arrangement by share-based payment award, number of shares available for grant 2,283,037    
Maximum percentage of stock options must be granted at exercise price of fair market value 100.00%    
Share-based compensation arrangement by share-based payment award, award vesting period 4 years    
Issuances of common stock upon stock option exercise, Shares 1,120,981 1,398,177 214,845
Issuances of common stock upon stock option exercise $ 7,927 $ 4,183 $ 549
Weighted average per share grant date fair value of options granted $ 45.07 $ 9.55 $ 2.93
Intrinsic value of options exercised $ 71,308 $ 87,946 $ 546
Unrecognized compensation cost related to unvested stock options granted $ 78,355    
Expected to be recognized over a weighted average period 2 years 10 months 13 days    
Share-based compensation arrangement by share-based payment award, options, vested in period, fair value $ 19,080 $ 3,153 $ 1,734
Tranche One      
Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]      
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage 25.00%    
Tranche Two      
Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]      
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage 25.00%    
Tranche Three      
Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]      
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage 25.00%    
Tranche Four      
Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]      
Share-based compensation arrangement by share-based payment award, award vesting rights, percentage 25.00%    
2010 Plan      
Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]      
Share-based compensation arrangement by share-based payment award, number of shares available for grant 0    
Maximum      
Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]      
Share-based compensation arrangement by share-based payment award, options granted, contractual term 10 years    
XML 92 R58.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation - Summary of Weighted Average Valuation Assumptions Used for Options (Details)
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Valuation assumptions      
Expected volatility 59.00% 60.00% 57.00%
Expected term (years) 4 years 7 months 28 days 4 years 5 months 26 days 6 years 18 days
Risk-free interest rate 0.71% 1.46% 2.33%
XML 93 R59.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation - Summary of Classification of Stock Based Compensation Expense (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation $ 26,490 $ 10,545 $ 2,193
Cost of Sales      
Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation 3,858 1,384 376
Research and Development      
Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation 7,440 3,050 460
Sales and Marketing      
Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation 1,281 516 311
General and Administrative      
Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]      
Total stock-based compensation $ 13,911 $ 5,595 $ 1,046
XML 94 R60.htm IDEA: XBRL DOCUMENT v3.22.0.1
Stock-Based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Number of shares      
Beginning, January 1, 2021 7,257,460    
Granted 1,696,327    
Exercised (1,120,981) (1,398,177) (214,845)
Forfeited (149,346)    
Expired (3,119)    
Balance, December 31, 2021 7,680,341 7,257,460  
Exercisable, December 31, 2021 3,473,716    
Weighted average exercise price      
Beginning, January 1, 2021 $ 12.14    
Granted 93.13    
Exercised 7.00    
Forfeited 41.47    
Expired 1.70    
Balance, December 31, 2021 30.19 $ 12.14  
Exercisable, December 31, 2021 $ 10.83    
Weighted average remaining contractual term (years)      
Balance, December 31, 2021 7 years 8 months 1 day    
Exercisable, December 31, 2021 6 years 9 months    
Aggregate intrinsic value      
Balance, December 31, 2021 $ 35,584    
Exercisable, December 31, 2021 $ 83,306    
XML 95 R61.htm IDEA: XBRL DOCUMENT v3.22.0.1
Noncontrolling Interest - Additional Information (Details) - Faxian
Apr. 30, 2019
WuXi AppTech  
Minority Interest [Line Items]  
Equity interest percentage 50.00%
Variable Interest Entity, Primary Beneficiary  
Minority Interest [Line Items]  
Equity interest percentage 50.00%
XML 96 R62.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss per Share Attributable to Common and Limited Stockholders - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Numerator:      
Net loss attributable to Schrödinger common and limited common stockholders $ (100,393) $ (24,463) $ (24,571)
Denominator:      
Weighted average shares used to compute net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted: 70,594,950 60,024,658 6,004,500
Net loss per share attributable to Schrödinger common and limited common stockholders, basic and diluted: $ (1.42) $ (0.41) $ (4.09)
XML 97 R63.htm IDEA: XBRL DOCUMENT v3.22.0.1
Net Loss per Share Attributable to Common and Limited Stockholders - Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive (Details) - shares
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share 7,680,341 7,257,460 47,540,446
Shares Subject to Outstanding Common Stock Options      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share 7,680,341 7,257,460 4,805,562
Convertible Preferred Stock      
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]      
Antidilutive securities excluded from computation of earnings per share     42,734,884
XML 98 R64.htm IDEA: XBRL DOCUMENT v3.22.0.1
Equity Investments - Additional Information (Details) - USD ($)
 1 Months Ended 12 Months Ended
Jul. 31, 2021
May 31, 2021
Jan. 31, 2021
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Schedule of Equity Method Investments [Line Items]            
Equity investments       $ 43,167,000 $ 45,664,000  
Equity investments gains (losses)       (1,781,000) 4,108,000 $ 943,000
Distribution from equity investment       375,000 4,582,000 943,000
Proceeds from sale of equity investments       15,735,000    
Cash payments to purchase of shares       3,700,000 2,869,000  
Nimbus Therapeutics, LLC            
Schedule of Equity Method Investments [Line Items]            
Equity investments       0 0  
Equity investments gains (losses)       0 (2,977,000) (4,180,000)
Morphic Holding, Inc.            
Schedule of Equity Method Investments [Line Items]            
Equity investments       39,561,000 28,013,000  
Equity investments gains (losses)       11,548,000 13,685,000 14,102,000
Petra Pharma Corporation            
Schedule of Equity Method Investments [Line Items]            
Distribution from equity investment   $ 4,582,000        
Escrow payments receivable   361,000        
Escrow payments received   $ 335,000        
Ravenna Therapeutics            
Schedule of Equity Method Investments [Line Items]            
Equity investments gains (losses)       $ (75,000) 0 0
Common shares received in connection with merger       2,676,191    
Carrying value of non-marketable equity securities       $ 19,000 94,000  
Relay Therapeutics, Inc            
Schedule of Equity Method Investments [Line Items]            
Equity investments gains (losses)         17,556,000 $ 0
Proceeds from sale of equity investments     $ 15,735,000      
Loss on sale of equity method investments       1,821,000    
Ajax Therapeutics, Inc            
Schedule of Equity Method Investments [Line Items]            
Equity investments       1,700,000 0  
Ajax Therapeutics, Inc | Series B Preferred Stock            
Schedule of Equity Method Investments [Line Items]            
Number of preferred shares purchased   631,377        
Cash payments to purchase of shares   $ 1,700,000        
ShouTi            
Schedule of Equity Method Investments [Line Items]            
Equity investments       1,887,000 $ 0  
Equity investments gains (losses)       $ (113,000)    
ShouTi | Series B Preferred Stock            
Schedule of Equity Method Investments [Line Items]            
Number of preferred shares purchased 494,035          
Cash payments to purchase of shares $ 2,000,000          
XML 99 R65.htm IDEA: XBRL DOCUMENT v3.22.0.1
Employee Benefit Plan - Additional Information (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Compensation And Retirement Disclosure [Abstract]      
Plan name 401(k) employee savings plan to its U.S.‑based employees    
Discretionary matching contributions 100.00%    
Discretionary matching contributed by employees 4.00%    
Matching contributions $ 2,592 $ 1,748 $ 1,492
XML 100 R66.htm IDEA: XBRL DOCUMENT v3.22.0.1
Related Party Transactions - Additional Information (Details) - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2021
Jun. 30, 2021
Jun. 30, 2020
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Related Party Transaction [Line Items]            
Revenue recognized       $ 137,931,000 $ 108,095,000 $ 85,543,000
Drug discovery revenue recognized       24,695,000 15,565,000 18,808,000
Agreement with Gates Ventures, LLC            
Related Party Transaction [Line Items]            
Net receivables (payables) $ 0     $ 0 0  
Agreement with Gates Ventures, LLC | First Anniversary            
Related Party Transaction [Line Items]            
Contributions Revenue Recognized   $ 1,000,000 $ 1,000,000      
Agreement with Gates Ventures, LLC | Minimum            
Related Party Transaction [Line Items]            
Percentage of voting securities 5.00%     5.00%    
Drug Discovery Contribution            
Related Party Transaction [Line Items]            
Drug discovery revenue recognized       $ 111,000    
D. E. Shaw Entities            
Related Party Transaction [Line Items]            
Purchase of services and license technology from related party       7,940,000 7,281,000 5,190,000
Reimbursements received from related parties for sales of products and services provided       318,000 226,000 195,000
Net receivables (payables) $ (2,637,000)     (2,637,000) (3,464,000)  
Member of Board of Directors            
Related Party Transaction [Line Items]            
Payment of consulting fees       390,000 364,000 361,000
BMGFT            
Related Party Transaction [Line Items]            
Net receivables (payables) 165,000     165,000 543,000  
Revenue recognized       1,160,000 $ 2,094,000 $ 1,065,000
BMGFT | Drug Discovery Contribution            
Related Party Transaction [Line Items]            
Net receivables (payables) 0     0    
Drug discovery revenue recognized $ 111,000          
ShouTi            
Related Party Transaction [Line Items]            
Software sales transactions amount       650,000    
Revenue from related parties       $ 129,000    
XML 101 R67.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Reporting - Additional Information (Details)
 12 Months Ended
Dec. 31, 2021
segment
Segment Reporting [Abstract]  
Number of reportable segments 2
XML 102 R68.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Segment revenues:      
Total revenues $ 137,931 $ 108,095 $ 85,543
Segment gross profit:      
Total segment gross profit 65,620 63,472 49,093
Unallocated:      
Research and development (90,904) (64,695) (39,404)
Sales and marketing (22,150) (17,795) (21,364)
General and administrative (64,009) (41,898) (27,040)
(Loss) gain on equity investments (1,781) 4,108 943
Change in fair value 11,359 28,263 9,922
Interest income 1,057 2,253 1,878
Income tax (expense) benefit (411) (345) 291
Net loss (101,219) (26,637) (25,681)
Operating Segments | Software Segment      
Segment revenues:      
Total revenues 113,236 92,530 66,735
Segment gross profit:      
Total segment gross profit 86,741 74,527 53,089
Operating Segments | Drug Discovery Segment      
Segment revenues:      
Total revenues 24,695 15,565 18,808
Segment gross profit:      
Total segment gross profit $ (21,121) $ (11,055) $ (3,996)
XML 103 R69.htm IDEA: XBRL DOCUMENT v3.22.0.1
Segment Reporting - Schedule of Revenues by Geographic Area (Details) - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Dec. 31, 2019
Revenues From External Customers And Long Lived Assets [Line Items]      
Revenues $ 137,931 $ 108,095 $ 85,543
United States      
Revenues From External Customers And Long Lived Assets [Line Items]      
Revenues 90,398 60,737 47,622
Europe      
Revenues From External Customers And Long Lived Assets [Line Items]      
Revenues 27,810 24,370 17,504
Japan      
Revenues From External Customers And Long Lived Assets [Line Items]      
Revenues 8,565 14,558 14,367
Rest of World      
Revenues From External Customers And Long Lived Assets [Line Items]      
Revenues $ 11,158 $ 8,430 $ 6,050
XML 104 R70.htm IDEA: XBRL DOCUMENT v3.22.0.1
Subsequent Events - Additional Information (Details) - Subsequent Event - XTAL BioStructures, Inc
$ in Millions
Jan. 14, 2022
USD ($)
shares
Subsequent Event [Line Items]  
Number of shares acquired | shares 117,840
Payments to acquire businesses, et of cash acquired $ 6.5
Purchase price including upfront purchase price, adjustment for working capital, less cash acquired $ 6.0
XML 105 sdgr-10k_20211231_htm.xml IDEA: XBRL DOCUMENT 0001490978 2021-01-01 2021-12-31 0001490978 us-gaap:CommonStockMember 2022-02-18 0001490978 sdgr:LimitedCommonStockMember 2022-02-18 0001490978 2021-06-30 0001490978 2021-12-31 0001490978 2020-12-31 0001490978 sdgr:UnallocatedCommonStockMember 2021-12-31 0001490978 sdgr:UnallocatedCommonStockMember 2020-12-31 0001490978 sdgr:LimitedCommonStockMember 2021-12-31 0001490978 sdgr:LimitedCommonStockMember 2020-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember 2021-01-01 2021-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember 2020-01-01 2020-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember 2019-01-01 2019-12-31 0001490978 sdgr:DrugDiscoveryMember 2021-01-01 2021-12-31 0001490978 sdgr:DrugDiscoveryMember 2020-01-01 2020-12-31 0001490978 sdgr:DrugDiscoveryMember 2019-01-01 2019-12-31 0001490978 2020-01-01 2020-12-31 0001490978 2019-01-01 2019-12-31 0001490978 us-gaap:SeriesEPreferredStockMember 2018-12-31 0001490978 us-gaap:SeriesDPreferredStockMember 2018-12-31 0001490978 us-gaap:SeriesCPreferredStockMember 2018-12-31 0001490978 us-gaap:SeriesBPreferredStockMember 2018-12-31 0001490978 us-gaap:SeriesAPreferredStockMember 2018-12-31 0001490978 us-gaap:CommonStockMember 2018-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001490978 us-gaap:RetainedEarningsMember 2018-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001490978 2018-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001490978 us-gaap:SeriesEPreferredStockMember 2019-01-01 2019-12-31 0001490978 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001490978 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-12-31 0001490978 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001490978 us-gaap:SeriesEPreferredStockMember 2019-12-31 0001490978 us-gaap:SeriesDPreferredStockMember 2019-12-31 0001490978 us-gaap:SeriesCPreferredStockMember 2019-12-31 0001490978 us-gaap:SeriesBPreferredStockMember 2019-12-31 0001490978 us-gaap:SeriesAPreferredStockMember 2019-12-31 0001490978 us-gaap:CommonStockMember 2019-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001490978 us-gaap:RetainedEarningsMember 2019-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001490978 us-gaap:NoncontrollingInterestMember 2019-12-31 0001490978 2019-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001490978 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001490978 us-gaap:CommonStockMember us-gaap:IPOMember 2020-01-01 2020-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2020-01-01 2020-12-31 0001490978 us-gaap:IPOMember 2020-01-01 2020-12-31 0001490978 us-gaap:CommonStockMember sdgr:FollowOnOfferingMember 2020-01-01 2020-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember sdgr:FollowOnOfferingMember 2020-01-01 2020-12-31 0001490978 sdgr:FollowOnOfferingMember 2020-01-01 2020-12-31 0001490978 us-gaap:SeriesEPreferredStockMember 2020-01-01 2020-12-31 0001490978 us-gaap:SeriesDPreferredStockMember 2020-01-01 2020-12-31 0001490978 us-gaap:SeriesAPreferredStockMember 2020-01-01 2020-12-31 0001490978 us-gaap:SeriesCPreferredStockMember 2020-01-01 2020-12-31 0001490978 us-gaap:SeriesBPreferredStockMember 2020-01-01 2020-12-31 0001490978 sdgr:LimitedCommonStockMember 2020-01-01 2020-12-31 0001490978 us-gaap:NoncontrollingInterestMember 2020-01-01 2020-12-31 0001490978 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001490978 us-gaap:CommonStockMember 2020-12-31 0001490978 sdgr:LimitedCommonStockMember 2020-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001490978 us-gaap:RetainedEarningsMember 2020-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001490978 us-gaap:NoncontrollingInterestMember 2020-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001490978 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001490978 us-gaap:NoncontrollingInterestMember 2021-01-01 2021-12-31 0001490978 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001490978 us-gaap:CommonStockMember 2021-12-31 0001490978 sdgr:LimitedCommonStockMember 2021-12-31 0001490978 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001490978 us-gaap:RetainedEarningsMember 2021-12-31 0001490978 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001490978 us-gaap:NoncontrollingInterestMember 2021-12-31 0001490978 us-gaap:CommonStockMember us-gaap:IPOMember 2020-02-10 2020-02-10 0001490978 us-gaap:CommonStockMember us-gaap:IPOMember 2020-02-10 0001490978 us-gaap:CommonStockMember 2020-02-10 2020-02-10 0001490978 us-gaap:ConvertiblePreferredStockMember 2020-02-10 2020-02-10 0001490978 us-gaap:ConvertiblePreferredStockMember 2020-02-09 2020-02-09 0001490978 sdgr:LimitedCommonStockMember 2020-02-09 2020-02-09 0001490978 us-gaap:CommonStockMember sdgr:FollowOnPublicOfferingMember 2020-08-17 2020-08-17 0001490978 us-gaap:CommonStockMember sdgr:FollowOnPublicOfferingMember 2020-08-17 0001490978 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2020-08-17 2020-08-17 0001490978 us-gaap:CommonStockMember 2020-08-17 2020-08-17 0001490978 us-gaap:AccountingStandardsUpdate202001Member 2021-03-31 0001490978 us-gaap:AccountingStandardsUpdate201815Member 2021-12-31 0001490978 us-gaap:AccountingStandardsUpdate201613Member 2021-01-01 0001490978 sdgr:AccountingStandardsUpdate202108Member 2021-12-31 0001490978 srt:MinimumMember 2021-01-01 2021-12-31 0001490978 srt:MaximumMember 2021-01-01 2021-12-31 0001490978 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001490978 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001490978 sdgr:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001490978 sdgr:CustomerAMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001490978 sdgr:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001490978 sdgr:CustomerBMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001490978 sdgr:CustomerCMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001490978 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001490978 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001490978 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001490978 sdgr:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2021-01-01 2021-12-31 0001490978 sdgr:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001490978 sdgr:CustomerAMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-12-31 0001490978 sdgr:DrugDiscoveryMember us-gaap:TransferredAtPointInTimeMember 2021-01-01 2021-12-31 0001490978 sdgr:DrugDiscoveryMember us-gaap:TransferredAtPointInTimeMember 2020-01-01 2020-12-31 0001490978 sdgr:DrugDiscoveryMember us-gaap:TransferredAtPointInTimeMember 2019-01-01 2019-12-31 0001490978 sdgr:DrugDiscoveryMember us-gaap:TransferredOverTimeMember 2021-01-01 2021-12-31 0001490978 sdgr:DrugDiscoveryMember us-gaap:TransferredOverTimeMember 2020-01-01 2020-12-31 0001490978 sdgr:DrugDiscoveryMember us-gaap:TransferredOverTimeMember 2019-01-01 2019-12-31 0001490978 sdgr:OnPremiseSoftwareMember 2022-01-01 2021-12-31 0001490978 sdgr:OnPremiseSoftwareMember 2021-01-01 2021-12-31 0001490978 sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember 2021-01-01 2021-12-31 0001490978 srt:MaximumMember sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember 2021-01-01 2021-12-31 0001490978 sdgr:FirstAnniversaryMember sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember 2020-04-01 2020-06-30 0001490978 sdgr:FirstAnniversaryMember sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember 2021-04-01 2021-06-30 0001490978 sdgr:SecondAnniversaryMember sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember 2021-01-01 2021-12-31 0001490978 sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember 2021-12-31 0001490978 sdgr:OnPremiseSoftwareMember 2020-01-01 2020-12-31 0001490978 sdgr:OnPremiseSoftwareMember 2019-01-01 2019-12-31 0001490978 sdgr:HostedSoftwareMember 2021-01-01 2021-12-31 0001490978 sdgr:HostedSoftwareMember 2020-01-01 2020-12-31 0001490978 sdgr:HostedSoftwareMember 2019-01-01 2019-12-31 0001490978 us-gaap:MaintenanceMember 2021-01-01 2021-12-31 0001490978 us-gaap:MaintenanceMember 2020-01-01 2020-12-31 0001490978 us-gaap:MaintenanceMember 2019-01-01 2019-12-31 0001490978 sdgr:ProfessionalServicesMember 2021-01-01 2021-12-31 0001490978 sdgr:ProfessionalServicesMember 2020-01-01 2020-12-31 0001490978 sdgr:ProfessionalServicesMember 2019-01-01 2019-12-31 0001490978 sdgr:RevenueFromContractWithCustomerBeforeSoftwareContributionMember 2021-01-01 2021-12-31 0001490978 sdgr:RevenueFromContractWithCustomerBeforeSoftwareContributionMember 2020-01-01 2020-12-31 0001490978 sdgr:RevenueFromContractWithCustomerBeforeSoftwareContributionMember 2019-01-01 2019-12-31 0001490978 sdgr:SoftwareContributionMember 2021-01-01 2021-12-31 0001490978 sdgr:SoftwareContributionMember 2020-01-01 2020-12-31 0001490978 sdgr:DrugDiscoveryServicesMember 2021-01-01 2021-12-31 0001490978 sdgr:DrugDiscoveryServicesMember 2020-01-01 2020-12-31 0001490978 sdgr:DrugDiscoveryServicesMember 2019-01-01 2019-12-31 0001490978 sdgr:DrugDiscoveryContributionMember 2021-12-31 0001490978 sdgr:DrugDiscoveryServicesRevenueFromContractsWithCustomersMember 2021-01-01 2021-12-31 0001490978 sdgr:DrugDiscoveryServicesRevenueFromContractsWithCustomersMember 2020-01-01 2020-12-31 0001490978 sdgr:DrugDiscoveryServicesRevenueFromContractsWithCustomersMember 2019-01-01 2019-12-31 0001490978 sdgr:DrugDiscoveryContributionMember 2021-01-01 2021-12-31 0001490978 sdgr:BristolMyersSquibbMember sdgr:CollaborationAndLicenseAgreementMember 2020-11-22 2020-11-22 0001490978 sdgr:BristolMyersSquibbMember sdgr:CollaborationAndLicenseAgreementMember 2020-11-22 0001490978 sdgr:BristolMyersSquibbMember sdgr:OncologyProductMember sdgr:CollaborationAndLicenseAgreementMember 2020-11-22 0001490978 sdgr:BristolMyersSquibbMember sdgr:NeurologyAndImmunologyProductMember sdgr:CollaborationAndLicenseAgreementMember 2020-11-22 0001490978 sdgr:BristolMyersSquibbMember sdgr:CollaborationAndLicenseAgreementMember 2021-01-01 2021-12-31 0001490978 sdgr:BristolMyersSquibbMember sdgr:CollaborationAndLicenseAgreementMember 2020-01-01 2020-12-31 0001490978 sdgr:BristolMyersSquibbMember sdgr:CollaborationAndLicenseAgreementMember 2021-12-31 0001490978 sdgr:BristolMyersSquibbMember sdgr:CollaborationAndLicenseAgreementMember 2020-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember 2021-12-31 0001490978 sdgr:SoftwareProductsAndServicesMember 2020-12-31 0001490978 sdgr:DrugDiscoveryMember 2021-12-31 0001490978 sdgr:DrugDiscoveryMember 2020-12-31 0001490978 us-gaap:ComputerEquipmentMember 2021-12-31 0001490978 us-gaap:ComputerEquipmentMember 2020-12-31 0001490978 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001490978 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001490978 us-gaap:FurnitureAndFixturesMember 2021-12-31 0001490978 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001490978 us-gaap:SecuritiesAssetsMember us-gaap:FairValueInputsLevel2Member 2021-12-31 0001490978 us-gaap:SecuritiesAssetsMember 2021-12-31 0001490978 us-gaap:EquityMethodInvestmentsMember us-gaap:FairValueInputsLevel1Member 2021-12-31 0001490978 us-gaap:EquityMethodInvestmentsMember us-gaap:FairValueInputsLevel3Member 2021-12-31 0001490978 us-gaap:EquityMethodInvestmentsMember 2021-12-31 0001490978 us-gaap:FairValueInputsLevel1Member 2021-12-31 0001490978 us-gaap:FairValueInputsLevel2Member 2021-12-31 0001490978 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001490978 us-gaap:SecuritiesAssetsMember us-gaap:FairValueInputsLevel2Member 2020-12-31 0001490978 us-gaap:SecuritiesAssetsMember 2020-12-31 0001490978 us-gaap:EquityMethodInvestmentsMember us-gaap:FairValueInputsLevel1Member 2020-12-31 0001490978 us-gaap:EquityMethodInvestmentsMember 2020-12-31 0001490978 us-gaap:FairValueInputsLevel1Member 2020-12-31 0001490978 us-gaap:FairValueInputsLevel2Member 2020-12-31 0001490978 sdgr:OfficeLeaseAgreementMember 2021-11-01 2021-11-01 0001490978 sdgr:OfficeLeaseAgreementMember 2021-11-01 0001490978 sdgr:OfficeLeaseAgreementMember 2021-11-30 2021-11-30 0001490978 sdgr:OfficeLeaseAgreementMember 2021-11-30 0001490978 us-gaap:DomesticCountryMember 2021-01-01 2021-12-31 0001490978 us-gaap:DomesticCountryMember 2021-12-31 0001490978 us-gaap:StateAndLocalJurisdictionMember 2021-12-31 0001490978 sdgr:VotingCommonStockMember 2021-12-31 0001490978 sdgr:VotingCommonStockMember 2021-01-01 2021-12-31 0001490978 sdgr:LimitedCommonStockMember 2021-01-01 2021-12-31 0001490978 sdgr:TwoThousandTenStockPlanMember 2021-12-31 0001490978 us-gaap:ShareBasedCompensationAwardTrancheOneMember 2021-01-01 2021-12-31 0001490978 us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-01 2021-12-31 0001490978 us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2021-01-01 2021-12-31 0001490978 sdgr:SharebasedCompensationAwardTrancheFourMember 2021-01-01 2021-12-31 0001490978 us-gaap:CostOfSalesMember 2021-01-01 2021-12-31 0001490978 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001490978 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001490978 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001490978 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001490978 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001490978 us-gaap:SellingAndMarketingExpenseMember 2021-01-01 2021-12-31 0001490978 us-gaap:SellingAndMarketingExpenseMember 2020-01-01 2020-12-31 0001490978 us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-12-31 0001490978 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001490978 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001490978 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001490978 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember sdgr:FaxianTherapeuticsLLCJointVentureMember 2019-04-30 0001490978 sdgr:FaxianTherapeuticsLLCJointVentureMember us-gaap:CoVenturerMember 2019-04-30 0001490978 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001490978 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001490978 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001490978 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001490978 sdgr:NimbusTherapeuticsLLCMember 2021-12-31 0001490978 sdgr:NimbusTherapeuticsLLCMember 2020-12-31 0001490978 sdgr:NimbusTherapeuticsLLCMember 2021-01-01 2021-12-31 0001490978 sdgr:NimbusTherapeuticsLLCMember 2020-01-01 2020-12-31 0001490978 sdgr:NimbusTherapeuticsLLCMember 2019-01-01 2019-12-31 0001490978 sdgr:MorphicHoldingIncMember 2021-01-01 2021-12-31 0001490978 sdgr:MorphicHoldingIncMember 2020-01-01 2020-12-31 0001490978 sdgr:MorphicHoldingIncMember 2019-01-01 2019-12-31 0001490978 sdgr:MorphicHoldingIncMember 2021-12-31 0001490978 sdgr:MorphicHoldingIncMember 2020-12-31 0001490978 sdgr:PetraPharmaCorporationMember 2021-05-01 2021-05-31 0001490978 sdgr:PetraPharmaCorporationMember 2021-05-31 0001490978 sdgr:RavennaTherapeuticsMember 2021-01-01 2021-12-31 0001490978 sdgr:RavennaTherapeuticsMember 2021-12-31 0001490978 sdgr:RavennaTherapeuticsMember 2020-12-31 0001490978 sdgr:RavennaTherapeuticsMember 2020-01-01 2020-12-31 0001490978 sdgr:RavennaTherapeuticsMember 2019-01-01 2019-12-31 0001490978 sdgr:RelayTherapeuticsIncMember 2021-01-01 2021-01-31 0001490978 sdgr:RelayTherapeuticsIncMember 2021-01-01 2021-12-31 0001490978 sdgr:RelayTherapeuticsIncMember 2020-01-01 2020-12-31 0001490978 sdgr:RelayTherapeuticsIncMember 2019-01-01 2019-12-31 0001490978 sdgr:AjaxTherapeuticsIncMember us-gaap:SeriesBPreferredStockMember 2021-05-01 2021-05-31 0001490978 sdgr:AjaxTherapeuticsIncMember 2021-12-31 0001490978 sdgr:AjaxTherapeuticsIncMember 2020-12-31 0001490978 sdgr:ShouTiIncMember us-gaap:SeriesBPreferredStockMember 2021-07-01 2021-07-31 0001490978 sdgr:ShouTiIncMember 2021-12-31 0001490978 sdgr:ShouTiIncMember 2020-12-31 0001490978 sdgr:ShouTiIncMember 2021-01-01 2021-12-31 0001490978 sdgr:DavidEShawMember 2021-01-01 2021-12-31 0001490978 sdgr:DavidEShawMember 2020-01-01 2020-12-31 0001490978 sdgr:DavidEShawMember 2019-01-01 2019-12-31 0001490978 sdgr:DavidEShawMember 2021-12-31 0001490978 sdgr:DavidEShawMember 2020-12-31 0001490978 sdgr:MembersOfBoardOfDirectorsMember 2021-01-01 2021-12-31 0001490978 sdgr:MembersOfBoardOfDirectorsMember 2020-01-01 2020-12-31 0001490978 sdgr:MembersOfBoardOfDirectorsMember 2019-01-01 2019-12-31 0001490978 sdgr:BillAndMelindaGatesFoundationTrustMember 2021-01-01 2021-12-31 0001490978 sdgr:BillAndMelindaGatesFoundationTrustMember 2020-01-01 2020-12-31 0001490978 sdgr:BillAndMelindaGatesFoundationTrustMember 2019-01-01 2019-12-31 0001490978 sdgr:BillAndMelindaGatesFoundationTrustMember 2021-12-31 0001490978 sdgr:BillAndMelindaGatesFoundationTrustMember 2020-12-31 0001490978 sdgr:DrugDiscoveryContributionMember sdgr:BillAndMelindaGatesFoundationTrustMember 2021-10-01 2021-12-31 0001490978 sdgr:DrugDiscoveryContributionMember sdgr:BillAndMelindaGatesFoundationTrustMember 2021-12-31 0001490978 sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember 2020-12-31 0001490978 srt:MinimumMember sdgr:AgreementWithGatesVenturesLimitedLiabilityCompanyMember 2021-12-31 0001490978 sdgr:ShouTiIncMember 2021-01-01 2021-12-31 0001490978 us-gaap:OperatingSegmentsMember sdgr:SoftwareSegmentMember 2021-01-01 2021-12-31 0001490978 us-gaap:OperatingSegmentsMember sdgr:SoftwareSegmentMember 2020-01-01 2020-12-31 0001490978 us-gaap:OperatingSegmentsMember sdgr:SoftwareSegmentMember 2019-01-01 2019-12-31 0001490978 us-gaap:OperatingSegmentsMember sdgr:DrugDiscoverySegmentMember 2021-01-01 2021-12-31 0001490978 us-gaap:OperatingSegmentsMember sdgr:DrugDiscoverySegmentMember 2020-01-01 2020-12-31 0001490978 us-gaap:OperatingSegmentsMember sdgr:DrugDiscoverySegmentMember 2019-01-01 2019-12-31 0001490978 country:US 2021-01-01 2021-12-31 0001490978 country:US 2020-01-01 2020-12-31 0001490978 country:US 2019-01-01 2019-12-31 0001490978 srt:EuropeMember 2021-01-01 2021-12-31 0001490978 srt:EuropeMember 2020-01-01 2020-12-31 0001490978 srt:EuropeMember 2019-01-01 2019-12-31 0001490978 country:JP 2021-01-01 2021-12-31 0001490978 country:JP 2020-01-01 2020-12-31 0001490978 country:JP 2019-01-01 2019-12-31 0001490978 us-gaap:NonUsMember 2021-01-01 2021-12-31 0001490978 us-gaap:NonUsMember 2020-01-01 2020-12-31 0001490978 us-gaap:NonUsMember 2019-01-01 2019-12-31 0001490978 sdgr:XTALBioStructuresIncorporationMember us-gaap:SubsequentEventMember 2022-01-14 2022-01-14 shares iso4217:USD iso4217:USD shares sdgr:Customer pure sdgr:Program sdgr:OperatingLease sdgr:SquareFoot sdgr:Vote sdgr:segment false FY --12-31 0001490978 true true true true true true true true P3Y true P30D 0 2023-06-30 0 P4Y7M28D P4Y5M26D P6Y18D P7Y8M1D P6Y9M 10-K true 2021-12-31 2021 false 001-39206 Schrodinger, Inc. DE 95-4284541 1540 Broadway 24th Floor New York NY 10036 212 295-5800 Common stock, par value $0.01 per share SDGR NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false 3519898945000 61873343 9164193 The registrant intends to file a definitive proxy statement pursuant to Regulation 14A relating to the 2022 Annual Meeting of Stockholders within 120 days of the end of the registrant’s fiscal year ended December 31, 2021. Portions of such definitive proxy statement are incorporated by reference into Part III of this Annual Report on Form 10-K to the extent stated herein. 185 KPMG LLP Portland, OR 120267000 202296000 3000000 500000 456212000 440395000 108000 60000 31744000 31423000 30000 0 8807000 3955000 5030000 4409000 625060000 682978000 10025000 5140000 43167000 45664000 75384000 10129000 2851000 2352000 756487000 746263000 8079000 8398000 18405000 12000000 55368000 45403000 2042000 4543000 7317000 2861000 91211000 73205000 30064000 41164000 77827000 7221000 300000 654000 199402000 122244000 0.01 0.01 10000000 10000000 0 0 0 0 0.01 0.01 500000000 500000000 61834515 61834515 60713534 60713534 618000 607000 0.01 0.01 100000000 100000000 9164193 9164193 9164193 9164193 92000 92000 786964000 752558000 -229952000 -129559000 -651000 317000 557071000 624015000 14000 4000 557085000 624019000 756487000 746263000 113236000 92530000 66735000 24695000 15565000 18808000 137931000 108095000 85543000 26495000 18003000 13646000 45816000 26620000 22804000 72311000 44623000 36450000 65620000 63472000 49093000 90904000 64695000 39404000 22150000 17795000 21364000 64009000 41898000 27040000 177063000 124388000 87808000 -111443000 -60916000 -38715000 -1781000 4108000 943000 11359000 28263000 9922000 1057000 2253000 1878000 10635000 34624000 12743000 -100808000 -26292000 -25972000 411000 345000 -291000 -101219000 -26637000 -25681000 -826000 -2174000 -1110000 -100393000 -24463000 -24571000 -1.42 -0.41 -4.09 70594950 60024658 6004500 -100393000 -24463000 -24571000 -968000 301000 25000 -101361000 -24162000 -24546000 53669659 79377000 39540611 22000000 47242235 19844000 29468101 9840000 134704785 30626000 5906976 59000 8915000 -80525000 -9000 -71560000 25000 25000 127000 20126118 29893000 214845 2000 547000 549000 2193000 2193000 1151000 1151000 -24571000 -1110000 -25681000 73795777 109270000 39540611 22000000 47242235 19844000 29468101 9840000 134704785 30626000 6121821 61000 11655000 -105096000 16000 41000 -93323000 301000 301000 1398177 14000 4169000 4183000 10545000 10545000 22667000 13664704 136000 209497000 209633000 20901000 5250000 53000 325547000 325600000 -73795777 -109270000 -17844124 -9928000 -134704785 -30626000 30278832 303000 149521000 149824000 -21696487 -12072000 -47242235 -19844000 -29468101 -9840000 13164193 132000 41624000 41756000 4000000 40000 -4000000 -40000 2137000 2137000 -24463000 -2174000 -26637000 60713534 607000 9164193 92000 752558000 -129559000 317000 4000 624019000 -968000 -968000 1120981 11000 7916000 7927000 26490000 26490000 836000 836000 -100393000 -826000 -101219000 61834515 618000 9164193 92000 786964000 -229952000 -651000 14000 557085000 -101219000 -26637000 -25681000 -1781000 4108000 943000 107000 397000 186000 11359000 28263000 9922000 2847000 3658000 3640000 26490000 10545000 2193000 811000 2137000 1051000 -5270000 -646000 506000 -140000 321000 12747000 5038000 5187000 -3468000 1556000 -5799000 -5342000 -4177000 1121000 -187000 -410000 -411000 4882000 -294000 6405000 4966000 2948000 -1028000 59705000 6715000 -2949000 -5417000 -4025000 3490000 -1210000 958000 -70669000 16757000 -26059000 7167000 2538000 1836000 3700000 2869000 375000 4582000 943000 15735000 414802000 519668000 110187000 392747000 138772000 57225000 -16812000 -381721000 -53855000 211491000 325600000 29893000 7927000 4183000 549000 25000 100000 1858000 7952000 541274000 28684000 -79529000 176310000 -51230000 202796000 26486000 77716000 123267000 202796000 26486000 448000 381000 139000 2142000 705000 8000 90000 71054000 2709000 464000 16475000 1858000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(1</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Description of Business</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Schrödinger, Inc. (the “Company”) has developed a differentiated, physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly, at lower cost, and with, the Company believes, a higher likelihood of success compared to traditional methods. The Company sells its software to biopharmaceutical and industrial companies, academic institutions, and government laboratories. The Company also applies its computational platform to a broad pipeline of drug discovery and development programs in collaboration with biopharmaceutical companies. In addition, the Company uses its platform to advance a pipeline of internal drug discovery programs.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On February 10, 2020, the Company completed an initial public offering (“IPO”), in which the Company issued and sold 11,882,352 shares of its common stock at a public offering price of $17.00 per share.  The underwriters fully exercised their option to purchase an additional 1,782,352 shares of the Company’s common stock at the public offering price less underwriting discounts. The Company raised $209.6 million in net proceeds after deducting underwriting discounts and commissions and offering expenses payable by the Company.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Immediately prior to the closing of the IPO, preferred stockholders voluntarily exchanged 98,406,823 shares of preferred stock for an aggregate of 13,164,193 shares of limited common stock.  In addition, upon the closing of the IPO, the remaining 226,344,686 shares of preferred stock automatically converted into an aggregate of 30,278,832 shares of common stock. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On August 17, 2020, the Company completed a follow-on public offering, in which the Company issued and sold 4,500,000 shares of its common stock at a public offering price of $66.00 per share. The underwriters fully exercised their option to purchase an additional 750,000 shares of the Company’s common stock at the public offering price less underwriting discounts. The Company raised $325.6 million in net proceeds after deducting underwriting discounts and commissions and offering expenses payable by the Company. In addition, a stockholder of the Company sold 500,000 shares of common stock. The Company did not receive any proceeds from the sale of shares of common stock by the selling stockholder.</p> 11882352 17.00 1782352 209600000 98406823 13164193 226344686 30278832 4500000 66.00 750000 325600000 500000 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(2)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Significant Accounting Policies</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Recently Issued Accounting Pronouncements</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2020-01, <span style="font-style:italic;">Investments—Equity Securities</span> (Topic 321), <span style="font-style:italic;">Investments—Equity Method and Joint Ventures </span>(Topic 323),<span style="font-style:italic;"> and Derivatives and Hedging </span>(Topic 815)<span style="font-style:italic;"> —Clarifying the Interactions between Topic 321, Topic 323, and Topic 815</span>, which clarifies the accounting related to equity investments and derivatives. This guidance was effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption was permitted. The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No. 2018-15, <span style="font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software</span> (Topic 350) – <span style="font-style:italic;">Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract</span>. This standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for annual periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021, with early adoption permitted. The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments-Credit Losses</span> (Topic 326) – <span style="font-style:italic;">Measurement of Credit Losses on Financial Instruments</span>, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU No. 2016-13 replaces the existing incurred loss impairment model with an expected loss model which requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes generally result in earlier recognition of credit losses.  The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2021, the FASB issues ASU No. 2021-08, <span style="font-style:italic;">Business Combinations </span>(Topic 805) – <span style="font-style:italic;">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span>, which requires the measurement and recognition of contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standard Codification (“ASC”) 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span> (Topic 606). This update replaces the existing guidance requiring contract assets and contract liabilities to be measured and recognized at fair value. The standard is effective on a prospective basis for annual periods beginning after December 15, 2022, including interim periods within the fiscal year, with early adoption permitted. The Company plans to early adopt this new standard effective January 1, 2022 and does not expect a material impact on its consolidated financial statements.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Basis of Presentation and Use of Estimates</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the assumptions used in the allocation of revenue, estimates regarding the progress of completing performance obligations under collaboration agreements, and the valuation of stock-based compensation. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">c</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Principles of Consolidation</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s consolidated financial statements include the accounts of Schrödinger, Inc., its wholly owned subsidiaries, and its variable interest entity. All intercompany balances and transactions have been eliminated in consolidation. The functional currency for foreign entities is the United States dollar. The Company accounts for investments over which it has significant influence, but not a controlling financial interest, using the equity method.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">d</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Cash and Cash Equivalents and Marketable Securities and Restricted Cash</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in cash and cash equivalents were cash equivalents of $90,477 and $185,614 as of December 31, 2021 and 2020, respectively, which consisted of money market funds and certificates of deposit, and are stated at cost, which approximates market value. The Company classifies all highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company classifies all marketable securities, which consist of fixed income securities, as available for sale securities.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At times, cash balances held at financial institutions were in excess of the Federal Deposit Insurance Corporation’s insured limits; however, the Company primarily places its cash with high-credit quality financial institutions.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash consists of letters of credit held with the Company’s financial institution related to facility leases and is classified as current in the Company’s balance sheets based on the maturity of the underlying letters of credit.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">e</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Accounts Receivable</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable are stated at original invoice amount less an allowance for doubtful accounts. Management estimates the allowance for doubtful accounts by evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Account balances are considered delinquent if payment is not received by the due date. Accounts receivable are written off when deemed uncollectible. Recovery of accounts receivable previously written off is recorded when received. Changes in the balance of accounts deemed uncollectible were deemed immaterial as of December 31, 2021 and 2020. Interest is not charged on accounts receivable.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">f</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Fair Value of Financial Instruments</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">g</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Property and Equipment</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost. The Company did not capitalize any interest during 2021 and 2020. Maintenance and repairs are expensed as incurred.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation is calculated using the straight‑line method over the estimated useful lives of the assets, which range from 3 to 7 years. Amortization of leasehold improvements is calculated using the straight‑line method over the remaining life of the lease or the useful life of the asset, whichever is shorter.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are reviewed for impairment as discussed below under Accounting for the Impairment of Long‑Lived Assets. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">h</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accounting for the Impairment of Long‑Lived Assets</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets, such as property and equipment subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that carrying value exceeds fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, depending on the nature of the asset. No impairment was identified for the years ended December 31, 2021, 2020, and 2019.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">i</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Warranties</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company typically warrants that its products will perform in a manner consistent with the product specifications provided to the customer for a period of 30 days. Historically, the Company has not been required to make payments under these obligations. Therefore, no liabilities for such obligations are presented in the consolidated financial statements.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">j</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Concentrations</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade receivables.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not require customers to provide collateral to support accounts receivable. If deemed necessary, credit reviews of significant new customers may be performed prior to extending credit. The determination of a customer’s ability to pay requires judgment, and failure to collect from a customer can adversely affect revenue, cash flows, and results of operations. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, three customers accounted for 17%, 15%, and 11% of total accounts receivable, respectively. As of December 31, 2020, two customers accounted for 17% and 14% of total accounts receivable, respectively. For the year ended December 31, 2021, one customer accounted for 14% of total revenues. For the year ended December 31, 2020, no customer accounted for more than 10% of total revenues. For the year ended December 31, 2019, one customer accounted for 12% of total revenues.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">k</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Royalties</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties represent a component of cost of revenues and consist of royalties paid to owners of intellectual property used in or bundled with the Company’s software. Generally, royalties are incurred and recorded at the time a customer enters into a binding purchase agreement, although some royalty agreements are based instead on cash collections. Royalty expense was $9,826, $7,663, and $7,352 for the years ended December 31, 2021, 2020, and 2019, respectively.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">l</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Software Development Costs</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs to develop new software products and substantial enhancements to existing software products are expensed as incurred. Historically, the Company has not capitalized any software development costs because the software development process was essentially completed concurrent with the establishment of technological feasibility.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">m</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Research and Development and Advertising</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development and advertising costs are expensed as incurred. The Company did not incur any significant advertising costs in 2021, 2020, or 2019.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">n</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock‑Based Compensation</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company calculates stock‑based compensation expense utilizing fair value–based methodologies and recognizes expense over the vesting period of such awards.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">o</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commissions</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commissions represent a component of sales and marketing expense and consist of the variable compensation paid to the Company’s sales representatives. Generally, sales commissions are earned and recorded as expense at the time that a customer has entered into a binding purchase agreement. Commissions paid to sales representatives are recoverable only in the case that the Company cannot collect against any invoiced fee associated with a sales order. Commission expense was $1,829, $1,362, and $754 in 2021, 2020, and 2019, respectively.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">p</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Income Taxes<span style="font-weight:normal;font-style:normal;"> </span></p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of the assets and liabilities. Deferred tax assets are reduced by a valuation allowance when it is estimated to become more likely than not that a portion of the deferred tax assets will not be realized. Accordingly, the Company currently maintains a full valuation allowance against existing net deferred tax assets.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the effect of income tax positions only if such positions are deemed “more likely than not” capable of being sustained. Interest and penalties accrued on unrecognized tax benefits are included within income tax expense in the consolidated financial statements.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">q</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Comprehensive Loss</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss and changes in equity related to changes in unrealized gains or losses on marketable securities.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">r</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Equity Investments</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company has entered, and may continue to enter, into collaboration agreements with private companies to perform drug design services for such companies in exchange for equity ownership stakes in such companies. If it is determined that the Company has control over the investee, the investee is consolidated in the financial statements. If the investee is consolidated with the Company and less than 100% of the equity is owned by the Company, the Company will present non-controlling interest to represent the portion of the investee owned by other investors. If it is determined that the Company does not have control over the investee, the Company evaluates the investment for the ability to exercise significant influence. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments over which the Company has significant influence may be accounted for under equity method accounting in accordance with ASC Topic 323, Equity Method and Joint Ventures. If it is determined that the Company does not have significant influence over the investee, and there is no readily determinable fair value for the investment, the equity investment may be accounted for at cost minus impairment in accordance with ASC Topic 321, Equity Securities.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further information regarding the Company’s equity investments, see Note 5, Fair Value Measurements, Note 10, Noncontrolling Interest, and Note 12, Equity Investments. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">s</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outstanding equity of the Company consists of common stock and limited common stock. Under the Company’s certificate of incorporation, the rights of the holders of common stock and limited common stock are identical, except with respect to voting and conversion. Holders of limited common stock are precluded from voting such shares in any election of directors or on the removal of directors. Limited common stock may be converted into common stock at any time at the option of the stockholder.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Undistributed earnings allocated to the participating securities are subtracted from net income in determining net (loss) income attributable to common and limited common stockholders. Basic net (loss) income per share is computed by dividing net (loss) income attributable to common and limited common stockholders by the weighted-average number of shares of common and limited common stock outstanding during the period.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the calculation of diluted net income, net income attributable to common and limited common stockholders for basic net income is adjusted by the effect of dilutive securities, including awards under the Company’s equity compensation plans. Diluted net income per share attributable to common and limited common stockholders is computed by dividing the resulting net income attributable to common and limited common stockholders by the weighted-average number of fully diluted shares of common and limited common stock outstanding.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Recently Issued Accounting Pronouncements</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2020, the Financial Accounting Standards Board (“FASB”) issued Accounting Standard Update (“ASU”) No. 2020-01, <span style="font-style:italic;">Investments—Equity Securities</span> (Topic 321), <span style="font-style:italic;">Investments—Equity Method and Joint Ventures </span>(Topic 323),<span style="font-style:italic;"> and Derivatives and Hedging </span>(Topic 815)<span style="font-style:italic;"> —Clarifying the Interactions between Topic 321, Topic 323, and Topic 815</span>, which clarifies the accounting related to equity investments and derivatives. This guidance was effective for the Company in the first quarter of 2021 on a prospective basis, and early adoption was permitted. The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2018, the FASB issued ASU No. 2018-15, <span style="font-style:italic;">Intangibles-Goodwill and Other-Internal-Use Software</span> (Topic 350) – <span style="font-style:italic;">Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract</span>. This standard aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for annual periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021, with early adoption permitted. The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2016, the FASB issued ASU No. 2016-13, <span style="font-style:italic;">Financial Instruments-Credit Losses</span> (Topic 326) – <span style="font-style:italic;">Measurement of Credit Losses on Financial Instruments</span>, which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. ASU No. 2016-13 replaces the existing incurred loss impairment model with an expected loss model which requires the use of forward-looking information to calculate credit loss estimates. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to certain available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes generally result in earlier recognition of credit losses.  The Company adopted this new standard effective January 1, 2021 with no material impact on its consolidated financial statements.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2021, the FASB issues ASU No. 2021-08, <span style="font-style:italic;">Business Combinations </span>(Topic 805) – <span style="font-style:italic;">Accounting for Contract Assets and Contract Liabilities from Contracts with Customers</span>, which requires the measurement and recognition of contract assets and contract liabilities acquired in a business combination in accordance with Accounting Standard Codification (“ASC”) 606, <span style="font-style:italic;">Revenue from Contracts with Customers</span> (Topic 606). This update replaces the existing guidance requiring contract assets and contract liabilities to be measured and recognized at fair value. The standard is effective on a prospective basis for annual periods beginning after December 15, 2022, including interim periods within the fiscal year, with early adoption permitted. The Company plans to early adopt this new standard effective January 1, 2022 and does not expect a material impact on its consolidated financial statements.</p> 2021-01-01 2021-01-01 2021-01-01 2022-01-01 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Basis of Presentation and Use of Estimates</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the assumptions used in the allocation of revenue, estimates regarding the progress of completing performance obligations under collaboration agreements, and the valuation of stock-based compensation. Actual results could differ from those estimates, and such differences may be material to the consolidated financial statements.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">c</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Principles of Consolidation</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s consolidated financial statements include the accounts of Schrödinger, Inc., its wholly owned subsidiaries, and its variable interest entity. All intercompany balances and transactions have been eliminated in consolidation. The functional currency for foreign entities is the United States dollar. The Company accounts for investments over which it has significant influence, but not a controlling financial interest, using the equity method.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">d</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Cash and Cash Equivalents and Marketable Securities and Restricted Cash</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Included in cash and cash equivalents were cash equivalents of $90,477 and $185,614 as of December 31, 2021 and 2020, respectively, which consisted of money market funds and certificates of deposit, and are stated at cost, which approximates market value. The Company classifies all highly liquid investments with an original maturity of 90 days or less to be cash equivalents. The Company classifies all marketable securities, which consist of fixed income securities, as available for sale securities.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At times, cash balances held at financial institutions were in excess of the Federal Deposit Insurance Corporation’s insured limits; however, the Company primarily places its cash with high-credit quality financial institutions.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Restricted cash consists of letters of credit held with the Company’s financial institution related to facility leases and is classified as current in the Company’s balance sheets based on the maturity of the underlying letters of credit.</p> 90477000 185614000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">e</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Accounts Receivable</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable are stated at original invoice amount less an allowance for doubtful accounts. Management estimates the allowance for doubtful accounts by evaluating individual customer receivables and considering a customer’s financial condition, credit history, and current economic conditions. Account balances are considered delinquent if payment is not received by the due date. Accounts receivable are written off when deemed uncollectible. Recovery of accounts receivable previously written off is recorded when received. Changes in the balance of accounts deemed uncollectible were deemed immaterial as of December 31, 2021 and 2020. Interest is not charged on accounts receivable.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">f</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Fair Value of Financial Instruments</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying values of cash and cash equivalents, accounts receivable, accounts payable, and accrued liabilities approximate fair value due to their short maturities.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">g</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Property and Equipment</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost. The Company did not capitalize any interest during 2021 and 2020. Maintenance and repairs are expensed as incurred.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation is calculated using the straight‑line method over the estimated useful lives of the assets, which range from 3 to 7 years. Amortization of leasehold improvements is calculated using the straight‑line method over the remaining life of the lease or the useful life of the asset, whichever is shorter.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are reviewed for impairment as discussed below under Accounting for the Impairment of Long‑Lived Assets. </p> P7Y <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">h</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Accounting for the Impairment of Long‑Lived Assets</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-lived assets, such as property and equipment subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require a long-lived asset or asset group be tested for potential impairment, the Company first compares undiscounted cash flows expected to be generated by that asset or asset group to its carrying value. If the carrying value of the long-lived asset or asset group is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that carrying value exceeds fair value. Fair value is determined using various valuation techniques, including discounted cash flow models, quoted market values, and third-party independent appraisals, depending on the nature of the asset. No impairment was identified for the years ended December 31, 2021, 2020, and 2019.</p> 0 0 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">i</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Warranties</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company typically warrants that its products will perform in a manner consistent with the product specifications provided to the customer for a period of 30 days. Historically, the Company has not been required to make payments under these obligations. Therefore, no liabilities for such obligations are presented in the consolidated financial statements.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">j</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Concentrations</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of trade receivables.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not require customers to provide collateral to support accounts receivable. If deemed necessary, credit reviews of significant new customers may be performed prior to extending credit. The determination of a customer’s ability to pay requires judgment, and failure to collect from a customer can adversely affect revenue, cash flows, and results of operations. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, three customers accounted for 17%, 15%, and 11% of total accounts receivable, respectively. As of December 31, 2020, two customers accounted for 17% and 14% of total accounts receivable, respectively. For the year ended December 31, 2021, one customer accounted for 14% of total revenues. For the year ended December 31, 2020, no customer accounted for more than 10% of total revenues. For the year ended December 31, 2019, one customer accounted for 12% of total revenues.</p> 3 0.17 0.15 0.11 2 0.17 0.14 1 0.14 0 0.10 1 0.12 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">k</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Royalties</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalties represent a component of cost of revenues and consist of royalties paid to owners of intellectual property used in or bundled with the Company’s software. Generally, royalties are incurred and recorded at the time a customer enters into a binding purchase agreement, although some royalty agreements are based instead on cash collections. Royalty expense was $9,826, $7,663, and $7,352 for the years ended December 31, 2021, 2020, and 2019, respectively.</p> 9826000 7663000 7352000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">l</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Software Development Costs</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Costs to develop new software products and substantial enhancements to existing software products are expensed as incurred. Historically, the Company has not capitalized any software development costs because the software development process was essentially completed concurrent with the establishment of technological feasibility.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">m</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Research and Development and Advertising</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development and advertising costs are expensed as incurred. The Company did not incur any significant advertising costs in 2021, 2020, or 2019.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">n</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock‑Based Compensation</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company calculates stock‑based compensation expense utilizing fair value–based methodologies and recognizes expense over the vesting period of such awards.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">o</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Commissions</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commissions represent a component of sales and marketing expense and consist of the variable compensation paid to the Company’s sales representatives. Generally, sales commissions are earned and recorded as expense at the time that a customer has entered into a binding purchase agreement. Commissions paid to sales representatives are recoverable only in the case that the Company cannot collect against any invoiced fee associated with a sales order. Commission expense was $1,829, $1,362, and $754 in 2021, 2020, and 2019, respectively.</p> 1829000 1362000 754000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">p</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Income Taxes<span style="font-weight:normal;font-style:normal;"> </span></p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company records deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the financial statement carrying amounts and the tax basis of the assets and liabilities. Deferred tax assets are reduced by a valuation allowance when it is estimated to become more likely than not that a portion of the deferred tax assets will not be realized. Accordingly, the Company currently maintains a full valuation allowance against existing net deferred tax assets.</p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company recognizes the effect of income tax positions only if such positions are deemed “more likely than not” capable of being sustained. Interest and penalties accrued on unrecognized tax benefits are included within income tax expense in the consolidated financial statements.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">q</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Comprehensive Loss</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss includes net loss and changes in equity related to changes in unrealized gains or losses on marketable securities.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">r</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Equity Investments</p></td></tr></table></div> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the normal course of business, the Company has entered, and may continue to enter, into collaboration agreements with private companies to perform drug design services for such companies in exchange for equity ownership stakes in such companies. If it is determined that the Company has control over the investee, the investee is consolidated in the financial statements. If the investee is consolidated with the Company and less than 100% of the equity is owned by the Company, the Company will present non-controlling interest to represent the portion of the investee owned by other investors. If it is determined that the Company does not have control over the investee, the Company evaluates the investment for the ability to exercise significant influence. </p> <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments over which the Company has significant influence may be accounted for under equity method accounting in accordance with ASC Topic 323, Equity Method and Joint Ventures. If it is determined that the Company does not have significant influence over the investee, and there is no readily determinable fair value for the investment, the equity investment may be accounted for at cost minus impairment in accordance with ASC Topic 321, Equity Securities.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For further information regarding the Company’s equity investments, see Note 5, Fair Value Measurements, Note 10, Noncontrolling Interest, and Note 12, Equity Investments. </p> 1 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">s</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The outstanding equity of the Company consists of common stock and limited common stock. Under the Company’s certificate of incorporation, the rights of the holders of common stock and limited common stock are identical, except with respect to voting and conversion. Holders of limited common stock are precluded from voting such shares in any election of directors or on the removal of directors. Limited common stock may be converted into common stock at any time at the option of the stockholder.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Undistributed earnings allocated to the participating securities are subtracted from net income in determining net (loss) income attributable to common and limited common stockholders. Basic net (loss) income per share is computed by dividing net (loss) income attributable to common and limited common stockholders by the weighted-average number of shares of common and limited common stock outstanding during the period.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the calculation of diluted net income, net income attributable to common and limited common stockholders for basic net income is adjusted by the effect of dilutive securities, including awards under the Company’s equity compensation plans. Diluted net income per share attributable to common and limited common stockholders is computed by dividing the resulting net income attributable to common and limited common stockholders by the weighted-average number of fully diluted shares of common and limited common stock outstanding.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;">Revenue Recognition</span></p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue is recognized upon transfer of control of promised products or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for promised goods or services. The Company’s performance obligations are satisfied either over time or at a point in time. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table illustrates the timing of the Company’s revenue recognition:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software products and services – point in time</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software products and services – over time</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug Discovery – point in time</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug Discovery – over time</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Software</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company enters into contracts that can include various combinations of licenses, products and services, some of which are distinct and are accounted for as separate performance obligations. For contracts with multiple performance obligations, the Company allocates the transaction price of the contract to each performance obligation on a relative standalone selling price (“SSP”) basis. Revenue is recognized net of any sale and value-added taxes collected from customers and subsequently remitted to governmental authorities.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s software business derives revenue from five sources: (i) on-premise software license fees, (ii) hosted software subscription fees, (iii) software maintenance fees, (iv) professional services fees, and (v) contributions.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">On-premise software.<span style="font-style:normal;"> The Company’s on-premise software license arrangements grant customers the right to use its software on their own in-house servers or their own cloud instances for a specified term, typically for one year. The Company recognizes revenue for on-premise software license fees upfront, either upon delivery of the license or the effective date of the agreement, whichever is later. In instances where the timing of delivery differs from the timing of invoicing, the Company considers whether a significant financing component exists. The Company has elected the practical expedient to not assess for significant financing where the term is less than one year. The Company’s updates and upgrades are not integral to maintaining the utility of the software licenses. Payments typically are received upfront or annually.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Hosted software.<span style="font-style:normal;"> Hosted software revenue consists primarily of fees to provide the Company’s customers with hosted licenses, which allows these customers to access the Company’s cloud-based software solution on their own hardware without taking control of licenses.  Hosted software is recognized ratably over the term of the arrangement.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Software maintenance<span style="font-style:normal;">. Software maintenance includes technical support, updates, and upgrades. Software maintenance revenue is considered to be a separate performance obligation and is recognized ratably over the term of the arrangement.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Professional services<span style="font-style:normal;">. Professional services, such as training, technical support, installation, or assisting customers with modeling, generally are not related to the core functionality of the Company’s software and are recognized as revenue when resources are consumed. The Company has historically estimated project status with relative accuracy, although a number of internal and external factors can affect such estimates, including labor rates, utilization and efficiency variances. Payments for services are due in advance or upon consumption of resources.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Software c</span><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ontribution</span><span style="font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> revenue</span><span style="Background-color:#FFFFFF;color:#222222;">. </span><span style="Background-color:#FFFFFF;color:#222222;font-style:normal;">Software </span><span style="font-style:normal;">c</span><span style="font-style:normal;">ontribution</span><span style="font-style:normal;"> revenue consists of funds received under a non-reciprocal agreement with Gates Ventures, LLC.  The agreement is an unconditional non-exchange contribution without restrictions and the initial contribution was invoiced upon execution of the agreement.  </span><span style="Background-color:#FFFFFF;color:#000000;font-style:normal;">Revenue was recognized upon execution of the agreement </span><span style="Background-color:#FFFFFF;color:#000000;font-style:normal;">and on the first anniversary of the agreement </span><span style="Background-color:#FFFFFF;color:#000000;font-style:normal;">when invoiced in accordance with</span><span style="Background-color:#FFFFFF;color:#000000;font-style:normal;"> ASC</span><span style="Background-color:#FFFFFF;color:#000000;font-style:normal;"> Topic 958, </span><span style="Background-color:#FFFFFF;color:#000000;">Not-for-Profit Entities</span><span style="Background-color:#FFFFFF;color:#000000;font-style:normal;"> as the agreement is not an exchange transaction.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement with Gates Ventures, LLC covers the period from June 23, 2020 through June 22, 2023 for total consideration of up to $3,000. The Company received $1,000 in connection with its entry into the agreement in the second quarter of 2020, and $1,000 in the second quarter of 2021 on the first anniversary of its entry into the agreement. The Company is also entitled to receive an additional $1,000 payment on or around the second anniversary of the agreement, subject to the Company providing certain progress reports to the Trustees of Columbia University in the City of New York. As of December 31, 2021, the Company had no deferred revenue balance related to this agreement.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the revenue recognized from the sources of software products and services revenue:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On-premise software</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,598</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,311</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,647</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hosted software</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,076</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,192</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,418</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software maintenance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,294</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,465</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,643</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,268</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,562</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,027</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from contracts with customers</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,236</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,530</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,735</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software contribution</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total software revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,236</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,530</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,735</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">b</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Drug Discovery</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Drug discovery<span style="font-style:normal;"> </span>services. <span style="font-style:normal;">Revenue from drug discovery and collaboration services contracts is recognized either over time, typically by using costs incurred or hours expended to measure progress, or at a point in time based on the achievement of milestones. Payments for services are generally due upon achieving milestones stated in a contract, upfront at the start of a contract, or upon consumption of resources. Services may at times include variable consideration and milestone payments. The Company has estimated the amount of consideration that is variable using the most likely amount method. The Company evaluates milestones on a case-by-case basis, including whether there are factors outside the Company’s control that could result in a significant reversal of revenue, and the likelihood and magnitude of a potential reversal. If achievement of a milestone is not considered probable, the Company constrains (reduces) variable consideration to exclude the milestone payment until it is probable to be achieved. As of December 31, 2021, 2020, and 2019, milestones not yet achieved that were determined to be probable of achievement totaled $2,250, $250, and $1,500, respectively, and $2,250, $85, and $1,500 of those milestones were recognized as revenue for the years ended December 31, 2021, 2020, and 2019.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Drug discovery contribution revenue<span style="Background-color:#FFFFFF;color:#222222;">. </span><span style="Background-color:#FFFFFF;color:#222222;font-style:normal;">Drug discovery </span><span style="font-style:normal;">contribution revenue consists of funds received under an agreement with Bill and Melinda Gates Foundation on a cost reimbursement basis, to perform services aimed at accelerating drug discovery in women’s health, which began in November 2021. Revenue is recognized as conditions are met in accordance with ASC Topic 958, </span><span style="Background-color:#FFFFFF;color:#000000;">Not-for-Profit Entities. </span><span style="font-style:normal;">As of December 31, 2021, there was a $1,129 deferred revenue balance related to this agreement.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:5.24%;text-indent:-5.24%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug discovery services revenue from contracts with customers</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,584</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,565</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,808</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug discovery contribution</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total drug discovery revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,695</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,565</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,808</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">c</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Collaboration and License Agreement</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 22, 2020, the Company entered into an exclusive, worldwide collaboration and license agreement with Bristol-Myers Squibb Company (“BMS”), pursuant to which the Company and BMS have agreed to collaborate in the discovery, research and preclinical development of new small molecule compounds for disease indications in oncology, neurology, and immunology therapeutics areas. The Company will be responsible, at its own cost and expense, for the discovery of small molecule compounds directed to five specified biological targets pursuant to a mutually agreed research plan for each such target. The initial targets included HIF-2 alpha and SOS1/KRAS, which were two of the Company’s internal programs. In November 2021, the Company and BMS mutually agreed to replace the HIF-2 alpha target with another precision oncology target. Following the replacement election, all rights to the HIF-2 alpha target program reverted to us. Once a development candidate meeting specified criteria for a target under the agreement has been identified by the Company, BMS will be solely responsible for the further development, manufacturing and commercialization of such development candidate at its own cost and expense.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the agreement, BMS paid the Company an initial upfront fee payment of $55,000. The Company also is entitled to receive up to $2,700,000 in total milestone payments across all potential targets, consisting of: a) up to $585,000 in milestone payments per oncology target, including $360,000 in the aggregate for the achievement of certain specified research, development, and regulatory milestones and $225,000 in the aggregate for the achievement of certain specified commercial milestones; and b) up to $482,000 in milestone payments per neurology and immunology target, including $257,000 in the aggregate for the achievement of certain specified research, development, and regulatory milestones and $225,000 in the aggregate for the achievement of certain specified commercial milestones.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also entitled to a tiered percentage royalty on annual net sales ranging from mid-single digits to low-double digits, subject to certain specified reductions. Royalties are payable by BMS on a licensed product-by-licensed product and country-by-country basis until the later of the expiration of the last valid claim covering the licensed product in such country, expiration of all applicable regulatory exclusivities in such country for such licensed product and the tenth anniversary of the first commercial sale of such licensed product in such country.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company assessed the collaboration and license agreement in accordance with ASC 606 and concluded that BMS is a customer based on the agreement structure. At inception, the Company identified one performance obligation for each of the five programs under the agreement, which includes research activities for each program and a license grant for the underlying intellectual property. The Company determined that the license grant for intellectual property is not separable from the research activities, as the research activities are expected to significantly modify or enhance the license grant over the period of service, and therefore are not distinct in the context of the contract.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company determined that the transaction price at the onset of the agreement is $55,000. Additional consideration to be paid to the Company upon the achievement of future milestone payments were excluded from the transaction price as they represent milestone payments that are not considered probable as of the inception date such that there is not a significant risk of revenue reversal.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has allocated the transaction price of $55,000 to each performance obligation based on the SSP of each performance obligation at inception, which was determined based on each performance obligation’s estimated standalone selling price. The Company determined the estimated standalone selling price at contract inception of the research activities based on internal estimates of the costs to perform the services, inclusive of a reasonable profit margin. Significant inputs used to determine the total costs to perform the research activities included the length of time required, the internal hours expected to be incurred on the services and the number and costs of various studies that will be performed to complete the research plan.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue associated with the research activities is recognized on a proportional performance basis over the period of service for research activities, using input-based measurements of total costs of research incurred to estimate the proportion performed. Progress towards completion is remeasured at the end of each reporting period.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the years ended December 31, 2021 and 2020, the Company recognized $13,749 and $988, respectively, associated with the agreement based on the research activities performed. As of December 31, 2021 and 2020, there was $40,263 and $54,012 of deferred revenue related to the agreement, which was classified as either current or non-current in the consolidated balance sheet based on the period the services are expected to be performed. There was no<span style="color:#FF0000;"> </span>outstanding receivable for this collaboration as of December 31, 2021.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">d</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Significant Judgments </p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant judgments and estimates are required under ASC Topic 606. Due to the complexity of certain contracts, the actual revenue recognition treatment required under Topic 606 for the Company’s arrangements may be dependent on contract-specific terms and may vary in some instances.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s contracts with customers often include promises to transfer multiple software products and services, including training, professional services, technical support services, and rights to unspecified updates. Determining whether licenses and services are distinct performance obligations that should be accounted for separately, or are not distinct and therefore should be accounted for together, requires significant judgment. In some arrangements, such as most of the Company’s term-based software license arrangements, the Company has concluded that the licenses and associated services are distinct from each other. In other arrangements, including collaboration services arrangements, the licenses and certain services may not be distinct from each other. The Company’s time-based software arrangements may include multiple software licenses and a right to updates or upgrades to the licensed software products, and technical support. The Company has concluded that such promised goods and services are separate distinct performance obligations.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is required to estimate the total consideration expected to be received from contracts with customers, including any variable consideration. Once the estimated transaction price is established, amounts are allocated to the performance obligations that have been identified. The transaction price is allocated to each separate performance obligation on a SSP basis.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Judgment is required to determine the SSP for each distinct performance obligation. The Company rarely licenses or sells products on a standalone basis, so the Company is required to estimate the range of SSPs for each performance obligation. In instances where the SSP is not directly observable because the Company does not sell the license, product, or service separately, the Company determines the SSP using information that includes historical discounting practices, market conditions, cost-plus analysis, and other observable inputs. The Company typically has more than one SSP for individual performance obligations due to the stratification of those items by classes of customers and circumstances. In these instances, the Company may use information such as the size and geographic region of the customer in determining the SSP. Professional service revenue is recognized as costs and hours are incurred, and judgment is required in estimating both the project status and the costs incurred or hours expended.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a group of agreements are so closely related to each other that they are, in effect, part of a single arrangement, such agreements are deemed to be one arrangement for revenue recognition purposes. The Company exercises significant judgment to evaluate the relevant facts and circumstances in determining whether the separate agreements should be accounted for separately or as, in substance, a single arrangement. The Company’s judgments about whether a group of contracts comprises a single arrangement can affect the allocation of consideration to the distinct performance obligations, which could have an effect on results of operations for the periods involved.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Judgment is required to determine the total costs to perform research activities, which include the length of time required, the internal hours expected to be incurred on the services, and the number and costs of various studies that may be performed by third-parties to complete the research plan.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Generally, the Company has not experienced significant returns or refunds to customers.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s estimates related to revenue recognition require significant judgment and a change in these estimates could have an effect on the Company’s results of operations during the periods involved.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">e</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"/><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"/><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"/><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contract Balances</span></p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The timing of revenue recognition may differ from the timing of invoicing to customers and these timing differences result in receivables, contract assets, or contract liabilities (deferred revenue) on the consolidated balance sheets. The Company records a contract asset when revenue is recognized prior to invoicing. A deferred revenue liability is recorded when revenue is expected to be recognized subsequent to invoicing. For the Company’s time-based software agreements, customers are generally invoiced at the beginning of the arrangement for the entire term, though when the term spans multiple years the customers may be invoiced on an annual basis. For certain drug discovery agreements where the milestones are deemed probable in a period prior to when the milestone is achieved, the Company records a contract asset for the full value of the milestone.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract assets are included in unbilled and other receivables within the consolidated balance sheets and are transferred to receivables when the Company invoices the customer.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract balances were as follows:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,271</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,589</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, short-term:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software products and services</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,945</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,218</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug discovery</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,423</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,185</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, long-term:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software products and services</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,938</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,976</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug discovery</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,126</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,188</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021 and 2020, respectively, the Company recognized $42,127<span style="color:#FF0000;"> </span>and $24,921 of revenue that was included in deferred revenue at the end of the preceding period. All other deferred revenue activity is due to the timing of invoices in relation to the timing of revenue, as described above. The Company expects to recognize as revenue approximately 65% of its December 31, 2021 deferred revenue balance in the next 12 months and the remainder thereafter. Additionally, contracted but unsatisfied performance obligations that had not yet been billed to the customer or included in deferred revenue were $26,694<span style="color:#FF0000;"> </span>as of December 31, 2021.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment terms and conditions vary by contract type, although terms typically require payment within 30 to 60 days. In instances where the timing of revenue recognition differs from that of invoicing, the Company has determined that its contracts generally do not include a significant financing component. The primary purpose of invoicing terms is to provide customers with simplified and predictable ways of purchasing the Company’s products and services, not to facilitate financing arrangements.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">f</span><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Deferred Sales Commissions</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has applied the practical expedient for sales commission expense, as any material compensation paid to sales representatives to obtain a contract relates to a period of one year or less. Therefore, the Company has not capitalized any costs related to sales commissions.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table illustrates the timing of the Company’s revenue recognition:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software products and services – point in time</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49.9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software products and services – over time</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28.1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug Discovery – point in time</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.7</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.6</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug Discovery – over time</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.4</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 0.555 0.550 0.499 0.266 0.306 0.281 0.033 0.067 0.086 0.146 0.077 0.134 P1Y 2020-06-23 2023-06-22 3000000 1000000 1000000 1000000 0 <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents the revenue recognized from the sources of software products and services revenue:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On-premise software</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,598</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,311</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,647</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hosted software</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,076</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,192</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,418</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software maintenance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,294</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,465</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,643</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Professional services</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,268</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,562</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,027</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue from contracts with customers</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,236</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,530</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,735</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software contribution</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,000</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total software revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,236</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,530</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,735</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 74598000 58311000 42647000 11076000 9192000 7418000 17294000 14465000 11643000 9268000 9562000 5027000 112236000 91530000 66735000 1000000 1000000 113236000 92530000 66735000 2250000 250000 1500000 2250000 85000 1500000 1129000 <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug discovery services revenue from contracts with customers</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,584</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,565</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,808</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug discovery contribution</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">111</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total drug discovery revenue</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,695</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,565</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,808</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 24584000 15565000 18808000 111000 24695000 15565000 18808000 55000000 2700000000 585000000 360000000 225000000 482000000 257000000 225000000 5 55000000 55000000 13749000 988000 40263000 54012000 0 <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract balances were as follows:</p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contract assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,271</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,589</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, short-term:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software products and services</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32,945</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,218</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug discovery</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,423</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,185</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue, long-term:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software products and services</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,938</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,976</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug discovery</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,126</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,188</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 8271000 3589000 32945000 28218000 22423000 17185000 3938000 1976000 26126000 39188000 42127000 24921000 0.65 26694000 P60D <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(4)</span></p></td> <td valign="top"> <p style="margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Property and Equipment</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,059</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,718</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,276</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,385</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,045</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,839</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,942</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,355</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,802</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,140</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.22%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation expense for 2021, 2020, and 2019 was $2,847, $3,658, and <span style="color:#000000;">$3,625</span>, respectively, and is included within cost of revenues and research and development, sales and marketing, and general and administrative expenses within the consolidated statements of operations.</p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consisted of the following:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="6" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.4%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computers and equipment</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,059</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,718</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,276</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,385</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,045</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,839</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,380</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,942</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,355</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,802</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,025</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,140</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 16059000 12718000 2276000 4385000 4045000 1839000 22380000 18942000 12355000 13802000 10025000 5140000 2847000 3658000 3625000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(5)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Fair Value Measurements<span style="font-weight:normal;"> </span></p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Various inputs are used in determining the fair value of the Company’s financial assets and liabilities. These inputs are summarized into the following three broad categories:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1 – quoted prices in active markets for identical securities</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2 – other significant observable inputs, including quoted prices for similar securities, interest rates, credit risk, etc.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;margin-left:5.24%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3 – significant unobservable inputs, including the Company’s own assumptions in determining fair value</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The inputs or methodology used for valuing securities are not necessarily an indication of the risk associated with investing in those securities. Marketable securities, which consist primarily of corporate and U.S. government agency bonds, are classified as available for sale and fair value does not differ significantly from carrying value as of December 31, 2021 and 2020. The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2021:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">456,212</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">456,212</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,561</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,887</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,448</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,561</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">456,212</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,887</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">497,660</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2020:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440,395</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440,395</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,570</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,570</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,570</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440,395</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">485,965</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fair value of the Company’s investments in Nimbus Therapeutics, LLC (“Nimbus”) and ShouTi Inc. (“ShouTi”), classified as Level 3 in the fair value hierarchy, was determined under the hypothetical liquidated book value method (“HLBV method”), as further described in Note 12, Equity Investments. Significant unobservable inputs used under the HLBV method include Nimbus’ and ShouTi’s annual financial statements and the Company’s respective liquidation priorities. The following table sets forth changes in fair value of the Company’s Level 3 investments:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash contributions</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,869</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,977</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash contributions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(113</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,887</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gains and losses arising from changes in fair value of the Company’s equity investments are classified within change in fair value in the consolidated statements of operations. During the years ended </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2021 and 2020</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, there were </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">no</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> transfers between Level 1, Level 2 and Level 3 investments. See Note 12, Equity Investments, for further information</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</span></p> The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2021: <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">456,212</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">456,212</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,561</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,887</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41,448</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,561</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">456,212</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,887</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">497,660</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents information about the Company’s assets and liabilities measured at fair value as of December 31, 2020:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440,395</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440,395</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Equity investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,570</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,570</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,570</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">440,395</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">485,965</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 456212000 456212000 39561000 1887000 41448000 39561000 456212000 1887000 497660000 440395000 440395000 45570000 45570000 45570000 440395000 485965000 The following table sets forth changes in fair value of the Company’s Level 3 investments: <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.84%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2019</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash contributions</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,869</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,977</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash contributions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.9%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,000</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized loss</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(113</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.9%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,887</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 108000 2869000 -2977000 2000000 -113000 1887000 0 0 0 0 0 0 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(6)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Commitments and Contingencies</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Leases</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company leases office space under operating leases that expire at various dates through 2037. The Company has elected the package of practical expedients under the transition guidance of ASC Topic 842, <span style="font-style:italic;">Leases</span>, to exclude short-term leases from the balance sheet and to combine lease and non-lease components.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon inception of a lease, the Company determines if an arrangement is a lease, if it includes options to extend or terminate the lease, and if it is reasonably certain that the Company will exercise the options. Lease cost, representing lease payments over the term of the lease and any capitalizable direct costs less any incentives received, is recognized on a straight-line basis over the lease term as lease expense.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In determining the present value of lease payments, the Company uses its incremental borrowing rate based on the information available at the lease commencement date if the rate implicit in the lease is not readily determinable. Upon execution of a new lease, the Company performs an analysis to determine its incremental borrowing rate using its current borrowing rate, adjusted for various factors including level of collateralization and lease term. As of December 31, 2021, the remaining weighted average lease term was 15 years.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, the accounting commencement began for two new leases, which increased the right-of-use (“ROU”) assets and lease liabilities by $71,054. ROU assets and lease liabilities were equal as no lease costs or incentives were associated with acquiring the leases.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 1, 2021, the Company entered into an office lease agreement for 16,727 square feet of office space located at One Main Street, Cambridge, Massachusetts. Under the terms of the agreement, the Company will pay base rent of approximately $135 per month with a 3% annual rental escalation. The Company estimates that the lease commencement date will occur during the three months ending June 30, 2022 and continue to the end of the lease, which is 10 years after commencement.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On November 30, 2021, the Company entered into an office lease agreement for 19,753 square feet of office space located at Salarpuria Sattva, Knowledge City, Hyderabad, India. Under the terms of the agreement, the Company will pay base rent of approximately $20 per month from commencement to handover date and $29 per month from handover date to termination of the lease. The Company estimates that the lease handover and commencement dates will occur during the three months ending March 31, 2022 and continue to the end of the lease in <span style="-sec-ix-hidden:F_000698">June 2023</span>.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Variable and short-term lease costs were immaterial for the year ended December 31, 2021. Additional details of the Company’s operating leases are presented in the following table:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,627</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,895</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,181</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for operating leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,561</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,050</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,108</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of operating lease liabilities as of December 31, 2021 under noncancelable operating leases were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,087</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,809</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,632</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,241</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,758</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,656</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,183</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of future minimum lease payments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,869</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion of operating leases payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,042</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities, long-term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,827</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(b)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:8pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Legal Matters</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">From time to time, the Company may become involved in routine litigation arising in the ordinary course of business. While the results of such litigation cannot be predicted with certainty, management believes that the final outcome of such matters is not likely to have a material adverse effect on the Company’s financial position or results of operations or cash flows.</p> 2037 P15Y 2 71054000 71054000 0 16727 135000 0.03 P10Y 19753 20000 29000 Additional details of the Company’s operating leases are presented in the following table: <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.06%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.48%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease costs</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,627</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,895</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,181</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.48%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash paid for operating leases</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,561</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,050</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.38%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,108</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> 7627000 5895000 5181000 4561000 6050000 5108000 <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of operating lease liabilities as of December 31, 2021 under noncancelable operating leases were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ending December 31:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,087</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,809</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2024</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,632</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2025</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,241</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2026</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,758</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93,656</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total future minimum lease payments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">132,183</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: imputed interest</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(52,314</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.3%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of future minimum lease payments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.88%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79,869</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less: current portion of operating leases payments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,042</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.3%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease liabilities, long-term</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.88%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,827</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 2087000 8809000 9632000 9241000 8758000 93656000 132183000 52314000 79869000 2042000 77827000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(7)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Income Taxes</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense is comprised of the following:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">583</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(779</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current income tax expense (benefit)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">411</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(291</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax expense (benefit)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">411</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(291</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of loss before income taxes by tax jurisdiction were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(101,341</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,567</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,385</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,359</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(99,982</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,118</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,862</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of income tax expense at the applicable statutory income tax rates to the effective income tax rate is as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory federal income tax rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal benefits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Withholding tax</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 162(m) limitation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Return-to-provision adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax contingencies, net of reversals</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37.2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31.3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The income tax expense for the years ended December 31, 2021 and December 31, 2020 primarily related to state taxes and taxes in foreign jurisdictions. <span style="color:#000000;">Income tax benefit for the year ended December 31, 2019 primarily related to alternative minimum tax credits previously utilized that are refundable under the Tax Cuts and Jobs Act of 2017 (the “2017 Tax Act”).</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The total change in valuation allowance for the year ended December 31, 2021 was $37,149, which primarily was due to the generation of net operating losses.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax effects of temporary differences that give rise to significant portions of deferred income tax assets and deferred income tax liabilities were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,985</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,498</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,119</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,309</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,918</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,164</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,632</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease Liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,773</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,165</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">433</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,559</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,752</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,468</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,258</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,727</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,684</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,304</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,155</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,251</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,954</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,572</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,433</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax liabilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on equity investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,545</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,185</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,984</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(969</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(889</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,498</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,008</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred income tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company had federal and state net operating loss (“NOL”) carryforwards of $283,314 and $148,130, respectively. These carryforwards, with the exception of federal NOLs generated post 2017, will expire between 2022 and 2041 if not used by the Company to reduce income taxes payable in future periods. Utilization of post 2017 federal NOL carryforwards are limited to 80% of taxable income generated in a given year and carry forward indefinitely. As of December 31, 2021, the Company had federal and state research and development tax credit carryforwards of $15,459 and $977, respectively. These carryforwards will expire between 2022 and 2041 if not used by the Company to reduce income taxes payable in future periods.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Internal Revenue Code Sections 382 and 383, the utilization of NOLs and other tax attributes may be substantially limited due to cumulative changes in ownership greater than 50% that may have occurred or could occur during applicable testing periods. The Company has performed an analysis through March 31, 2021 and </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determined that such an ownership change has occurred. There was no material impact to the financial statements due to this ownership change.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not recognized a deferred tax liability for the undistributed earnings of its foreign operations as the Company considers these earnings to be indefinitely reinvested.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In response to the COVID-19 pandemic, the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”) was signed into law in March 2020. The CARES Act lifts certain deduction limitations originally imposed by the 2017 Tax Act. With the enactment of the CARES Act, the Company has not recognized a quantitative or qualitative impact for the years ended December 31, 2021, 2020, and 2019.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies interest and penalties related to unrecognized tax benefits within income tax expense in the consolidated statement of operations. Following is a reconciliation of total gross unrecognized tax benefits:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, January 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,046</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">902</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions taken in prior years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">282</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions for tax positions taken in prior years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions related to the current year</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,702</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,046</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">902</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company does not anticipate any significant increases or decreases in its uncertain tax positions within the next 12 months.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company and its subsidiaries file U.S. federal income tax returns and various state, local and foreign income tax returns. As of December 31, 2021, the Company’s statutes of limitations are open for all federal and state years tax returns filed after the years ended December 31, 2016 and 2015, respectively. Net operating loss and credit carryforwards for all years are subject to examination and adjustments for the three years following the year in which the carryforwards are utilized. The Company is not currently under Internal Revenue Service or state examination.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense is comprised of the following:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">583</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">167</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(779</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current income tax expense (benefit)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">411</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(291</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax expense (benefit)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">411</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">345</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(291</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> 583000 67000 178000 -95000 344000 167000 -779000 411000 345000 -291000 411000 345000 -291000 <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Components of loss before income taxes by tax jurisdiction were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(101,341</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,567</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,385</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Foreign</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,359</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">449</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">523</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(99,982</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,118</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,862</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> -101341000 -24567000 -25385000 1359000 449000 523000 -99982000 -24118000 -24862000 <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reconciliation of income tax expense at the applicable statutory income tax rates to the effective income tax rate is as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Statutory federal income tax rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net of federal benefits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.9</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Withholding tax</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2.3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Section 162(m) limitation</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12.8</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68.5</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Return-to-provision adjustments</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.3</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development credit</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax contingencies, net of reversals</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.7</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.5</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(37.2</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95.0</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(31.3</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.2</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.6</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective income tax rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.4</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.9</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)%</p></td> </tr> </table></div> 0.210 0.210 0.210 0.049 0.142 0.042 -0.023 -0.052 -0.128 0.124 0.685 0.002 -0.017 -0.013 0.032 0.063 0.062 0.052 0.007 0.006 0.005 -0.372 -0.950 -0.313 -0.002 -0.016 -0.006 -0.004 -0.014 -0.009 37149000 <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax effects of temporary differences that give rise to significant portions of deferred income tax assets and deferred income tax liabilities were as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax assets:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,985</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51,498</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,119</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued expenses</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,309</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,918</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,164</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred Revenue</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,632</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease Liabilities</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,773</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,165</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">433</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Credits</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,559</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,752</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,468</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gross deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">122,258</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,727</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40,684</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less valuation allowance</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(95,304</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(58,155</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(35,251</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,954</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,572</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,433</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income tax liabilities:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unrealized gain on equity investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,545</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(10,185</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,984</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(969</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(889</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(441</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,440</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,498</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,008</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred income tax assets</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 67985000 51498000 26119000 10309000 7918000 6164000 10632000 394000 500000 18773000 2165000 433000 14559000 8752000 7468000 122258000 70727000 40684000 95304000 58155000 35251000 26954000 12572000 5433000 8545000 10185000 1984000 969000 889000 441000 17440000 1498000 3008000 283314000 148130000 2022 2041 0.80 15459000 977000 <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company classifies interest and penalties related to unrecognized tax benefits within income tax expense in the consolidated statement of operations. Following is a reconciliation of total gross unrecognized tax benefits:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.12%;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.78%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, January 1</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,046</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">902</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">781</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions taken in prior years</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">282</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.5%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions for tax positions taken in prior years</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions related to the current year</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">394</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">135</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.5%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,702</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,046</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">902</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 1046000 902000 781000 282000 25000 24000 20000 16000 12000 394000 135000 109000 1702000 1046000 902000 As of December 31, 2021, the Company’s statutes of limitations are open for all federal and state years tax returns filed after the years ended December 31, 2016 and 2015, respectively. Net operating loss and credit carryforwards for all years are subject to examination and adjustments for the three years following the year in which the carryforwards are utilized. The Company is not currently under Internal Revenue Service or state examination. <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(8)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stockholders’ Equity (Deficit)</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Common Stock </p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company had authorized 500,000,000 shares of common stock with a par value of $0.01 per share. Holders of common stock are entitled to one vote per share, to receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company’s preferred stock, if any.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(b)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Limited Common Stock </p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company had authorized 100,000,000 shares of limited common stock with a par value of $0.01 per share. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Holders of limited common stock are entitled to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> vote per share, however, the holders of limited common stock </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> not </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">entitled to vote such shares in any election of directors or on the removal of directors. Holders of limited common stock are entitled to receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">stockholders, subject to preferential amounts owed to holders of the Company’s preferred stock</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, if any</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.  Holders of the Company’s limited common stock have the right to </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">convert</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> each share of limited common stock </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">into</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">one</span><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> share of the Company’s common stock.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Limited common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the limited common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(c)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Preferred Stock </p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company had authorized 10,000,000 shares of undesignated preferred stock with a par value of $0.01 per share.  The Company’s board of directors has the discretion to determine the rights, preferences, privileges, and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges, and liquidation preferences, of each series of preferred stock.</p> 500000000 0.01 1 Common stockholders have no preemptive or other subscription rights and there are no redemption or sinking fund provisions with respect to such shares. The rights, preferences and privileges of holders of the common stock are subject to and may be adversely affected by the right of the holders of shares of any series of preferred stock that the Company may designate and issue in the future. 100000000 0.01 Holders of limited common stock are entitled to one vote per share, however, the holders of limited common stock shall not be entitled to vote such shares in any election of directors or on the removal of directors. Holders of limited common stock are entitled to receive dividends, if and when declared by the board of directors, and upon liquidation or dissolution, to receive a portion of the assets available for distributions to stockholders, subject to preferential amounts owed to holders of the Company’s preferred stock, if any.  Holders of the Company’s limited common stock have the right to convert each share of limited common stock into one share of the Company’s common stock. 1 1 10000000 0.01 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(9)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Stock-Based Compensation</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Incentive Plans </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, the Company’s stock incentive plans included the 2010 Stock Plan (the “2010 Plan”), the 2020 Equity Incentive Plan (the “2020 Plan”), and the 2021 Inducement Equity Incentive Plan (the "2021 Plan”) (together, the “Plans”). The 2020 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to employees, directors, consultants or advisors. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2021 Plan provides for the award of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other stock-based awards to persons who were not previously an employee or director of the Company or who are commencing employment with the Company following a bona fide period of non-employment, in either case, as an inducement material to such person’s entry into employment with the Company and in accordance with the requirements of the Nasdaq Stock Market Rule 5635(c)(4). Neither consultants nor advisors are eligible to participate in the 2021 Plan.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The 2010 Plan provided for the granting of incentive stock options and nonstatutory stock options to employees, directors, consultants, or advisors. As of the effective date of the 2020 Plan, no further awards will be made under the 2010 Plan. Any options or awards outstanding under the 2010 Plan remain outstanding and effective. Shares of common stock subject to outstanding awards granted under the 2010 Plan that expire, terminate, or are otherwise surrendered, cancelled, forfeited, or repurchased by the Company are available for issuance under the 2020 Plan. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Stock Options</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock options must be granted at an exercise price not less than 100% of the fair market value per share at the grant date. The board of directors or compensation committee determines the exercise price of the Company’s stock options based on the closing price of the common stock as reported on the Nasdaq Global Select Market on the day of the grant. The maximum contractual term of options granted under the Plans is typically 10 years, options generally vest over four years with <span>25%</span> of the shares underlying the option vesting at the end of the first year and the remaining vesting monthly over the following three years.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2021, 2020, and 2019, 1,120,981, 1,398,177, and <span style="color:#000000;">214,845</span> options under the Plans were exercised for total proceeds of $<span style="color:#000000;">7,927</span>, $4,183, and <span style="color:#000000;">$549,</span> respectively.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value of each option award is determined on the date of grant using the Black Scholes Merton option-pricing model. The calculation of fair value includes several assumptions that require management’s judgment. The expected terms of options granted to employees during 2021, 2020, and 2019 were calculated using an average of historical exercises. Estimated volatility for 2021, 2020, and 2019 incorporates a calculated volatility derived from the historical closing prices of shares of common stock of similar entities whose share prices were publicly available </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">for the expected term of the option. The risk-free interest rate is based on the U.S. Treasury constant maturities in effect at the time of grant for the expected term of the option. The Company accounts for forfeitures as they occur, as such, the Company does not estimate forfeitures at the time of grant.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, there were 2,283,037 shares available for grant under the Plans. Following are the weighted average valuation assumptions used for options:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation assumptions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000854">4.66</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000855">4.49</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000856">6.05</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.71</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.46</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.33</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents classification of stock-based compensation expense within the consolidated statements of operations:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,858</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,384</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">376</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,440</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,050</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,281</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">516</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,911</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,595</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,046</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,490</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,545</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,193</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity was as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term (years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning, January 1, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,257,460</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,696,327</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93.13</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,120,981</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.00</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149,346</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.47</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,119</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.70</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,680,341</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.19</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000889">7.67</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,584</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable, December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,473,716</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.83</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000890">6.75</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,306</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted average grant date fair value per share of options granted during 2021, 2020, and 2019 was $<span style="color:#000000;">45.07</span>, $9.55, and $2.93, <span style="Background-color:#FFFFFF;color:#000000;">respectively</span>. The intrinsic value of options exercised during 2021, 2020, and 2019 was $71,308, $87,946, and $546, respectively. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2021, there was $78,355<span style="color:#FF0000;"> </span>of unrecognized compensation cost related to unvested stock options granted under the Plans, which is expected to be recognized over a weighted average period of 2.87 years. The fair value of shares vested during 2021, 2020, and 2019 was $<span style="color:#000000;">19,080</span>, $3,153, and <span style="color:#000000;">$1,734,</span> respectively.</p> 0 1 P10Y P4Y 0.25 0.25 0.25 0.25 1120981 1398177 214845 7927000 4183000 549000 2283037 Following are the weighted average valuation assumptions used for options: <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.3%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:55.16%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.52%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.26%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation assumptions</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected term (years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000854">4.66</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000855">4.49</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000856">6.05</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.16%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.71</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.52%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.46</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.26%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.33</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:5.24%;font-size:10pt;"> </p> 0.59 0.60 0.57 0.0071 0.0146 0.0233 <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table presents classification of stock-based compensation expense within the consolidated statements of operations:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.16%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of sales</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,858</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,384</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">376</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,440</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,050</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">460</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.72%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,281</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">516</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">311</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,911</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,595</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,046</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.72%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,490</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,545</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.16%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,193</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 3858000 1384000 376000 7440000 3050000 460000 1281000 516000 311000 13911000 5595000 1046000 26490000 10545000 2193000 <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock option activity was as follows:</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">shares</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">exercise</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">price</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">average</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">remaining</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">contractual</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">term (years)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">intrinsic</p> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning, January 1, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,257,460</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.14</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,696,327</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.2%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93.13</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,120,981</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.00</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(149,346</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.47</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,119</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.70</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.2%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.36%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balance, December 31, 2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,680,341</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30.19</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000889">7.67</span></p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.2%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.2%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,584</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.36%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercisable, December 31, 2021</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,473,716</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.83</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="-sec-ix-hidden:F_000890">6.75</span></p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.2%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.2%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83,306</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 7257460 12.14 1696327 93.13 1120981 7.00 149346 41.47 3119 1.70 7680341 30.19 35584000 3473716 10.83 83306000 45.07 9.55 2.93 71308000 87946000 546000 78355000 P2Y10M13D 19080000 3153000 1734000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(10)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Noncontrolling Interest</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company reviews each legal entity formed by parties related to the Company to determine whether or not the Company has a variable interest in the entity and whether or not the entity would meet the definition of a variable interest entity (“VIE”) in accordance with ASC Topic 810, </span><span style="font-style:italic;Background-color:#FFFFFF;">Consolidation</span><span style="Background-color:#FFFFFF;">. If the entity is a VIE, the </span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">Company assesses whether or not the Company is the primary beneficiary of that VIE based on a number of factors, including (i) which party has the power to direct the activities that most significantly affect the VIE’s economic performance, (ii) the parties’ contractual rights and responsibilities pursuant to any contractual agreements and (iii) which party has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company determines it is the primary beneficiary of a VIE, the Company consolidates the financial statements of the VIE into the Company’s consolidated financial statements at the time that determination is made. The Company evaluates whether it continues to be the primary beneficiary of any consolidated VIEs on a quarterly basis. If the Company were to determine that it is no longer the primary beneficiary of a consolidated VIE, or no longer has a variable interest in the VIE, it would deconsolidate the VIE in the period that the determination is made.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">If the Company determines it is the primary beneficiary of a VIE that meets the definition of a business, the Company measures the assets, liabilities and noncontrolling interests of the newly consolidated entity at fair value in accordance with ASC Topic 805, </span><span style="font-style:italic;Background-color:#FFFFFF;">Business Combinations</span><span style="Background-color:#FFFFFF;"> at the date the reporting entity first becomes the primary beneficiary.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2018, Faxian Therapeutics, LLC (“Faxian”) was formed in the United States. In April 2019, upon consummation of the joint venture, the Company and WuXi AppTech ("WuXi"), each received a 50% equity interest in the entity in exchange for their contributions to the entity. The Company determined that Faxian was a VIE and concluded that it is the primary beneficiary of the VIE. As such, the Company has consolidated Faxian's results into the consolidated financial statements, and eliminated WuXi's ownership as a non-controlling interest.</p> 0.50 0.50 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(11)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Net Loss per Share Attributable to Common and Limited Common Stockholders</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The</span><span style="color:#000000;"> following table presents the calculation of basic and diluted net loss per share attributable to common and limited common stockholders for the years presented (in thousands, except for share and per share data): </span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to Schrödinger common</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   and limited common stockholders</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100,393</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,463</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,571</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares used to compute net</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   loss per share attributable to Schrödinger common</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   and limited common stockholders, basic and diluted:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,594,950</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,024,658</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,004,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to Schrödinger common</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   and limited common stockholders, basic and diluted:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.42</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.41</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.09</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company was in a loss position for all years presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,734,884</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares subject to outstanding common stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,680,341</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,257,460</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,805,562</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,680,341</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,257,460</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,540,446</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The</span><span style="color:#000000;"> following table presents the calculation of basic and diluted net loss per share attributable to common and limited common stockholders for the years presented (in thousands, except for share and per share data): </span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Numerator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss attributable to Schrödinger common</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   and limited common stockholders</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(100,393</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,463</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,571</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Denominator:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Weighted average shares used to compute net</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   loss per share attributable to Schrödinger common</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   and limited common stockholders, basic and diluted:</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,594,950</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,024,658</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,004,500</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share attributable to Schrödinger common</p> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">   and limited common stockholders, basic and diluted:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.42</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.41</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4.09</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> -100393000 -24463000 -24571000 70594950 60024658 6004500 -1.42 -0.41 -4.09 <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the Company was in a loss position for all years presented, basic net loss per share is the same as diluted net loss per share as the inclusion of all potential common shares outstanding would have been anti-dilutive. Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</p> <p style="margin-top:2pt;margin-bottom:0pt;text-indent:5.24%;font-family:Times New Roman;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:39.88%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.84%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.92%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42,734,884</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares subject to outstanding common stock options</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,680,341</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,257,460</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,805,562</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.92%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,680,341</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,257,460</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.84%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,540,446</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> 42734884 7680341 7257460 4805562 7680341 7257460 47540446 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(12</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Equity <span style="font-family:Calibri;">Investments</span></p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nimbus</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company provides collaboration services for Nimbus under the terms of a master services agreement executed on May 18, 2010, as amended. Collaboration agreements are separate from the transaction that resulted in equity ownership and related fees are paid in cash to the Company. As Nimbus is a limited liability company and the Company is not a passive investor due to its collaboration with Nimbus on a number of drug discovery targets, the Company's management determined that it has significant influence over the entity and therefore accounts for the investment as an equity method investment.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The Company has concluded that the carrying value of its equity investment in Nimbus should reflect its contractual rights to substantive profits. The Company further determined that the HLBV method for valuing contractual rights to substantive profits provides the best representation of its financial position in Nimbus.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><span style="Background-color:#FFFFFF;">The HLBV method is a balance sheet-oriented approach to equity method accounting. Under the HLBV method, the Company determines its share of earnings or losses by comparing its claim on the book value at the beginning and end of each reporting period. This claim is calculated as the amount that the Company would receive (or be obligated to pay) if the investee were to liquidate all of its assets at recorded amounts, determined as of the balance sheet date in accordance with U.S. GAAP, and distribute the resulting cash to creditors and investors in accordance with their respective priorities.</span></p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying value of the Nimbus investment was zero as of December 31, 2021 and December 31, 2020. The Company has no obligation to fund Nimbus losses in excess of its initial investment. The Company reported losses of zero, $2,977, and $4,180 on the Nimbus investment during 2021, 2020, and 2019, respectively.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(b)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Morphic</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The <span style="Background-color:#FFFFFF;">Company</span> accounts for its investment in Morphic Holding, Inc. (“Morphic”) at fair value based on the share price of Morphic’s common stock at the measurement date.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2021, 2020, and 2019 the Company reported gains of $11,548, $13,685, and $14,102 on the Morphic investment, respectively. As of December 31, 2021 and December 31, 2020, the carrying value of the Company’s investment in Morphic was $39,561 and $28,013, respectively.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(c)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Petra</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prior to May 2020, the Company had concluded that its equity investment in Petra Pharma Corporation (“Petra”) should be valued as a non-marketable <span style="Background-color:#FFFFFF;color:#000000;">equity</span> security as the Company did not exercise significant influence over Petra.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During May 2020, Petra entered into a merger agreement with a third party. In connection with the merger, the Company received $4,582 of merger consideration in exchange for the Company’s shares of Petra common stock and is eligible to receive potential earn-outs tied to the <span style="Background-color:#FFFFFF;color:#000000;">achievement</span> of specified development, regulatory, and commercial milestones. The Company is also eligible to receive $361 in escrow payments. During 2021, the Company received escrow payments of $335.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(d)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Ravenna</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the Petra merger, the Company received 2,676,191 shares of common stock of Ravenna Pharmaceuticals, Inc. (“Ravenna”). The Company concluded that its equity investment in Ravenna should be valued as a non-marketable equity security as the Company does not exercise significant influence over Ravenna. As of each of December 31, 2021 and December 31, 2020, the carrying value of the Company’s investment in Ravenna was $19 and $94, respectively. The Company reported losses of $75, zero, and zero on the Ravenna investment during 2021, 2020, and 2019, respectively.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(e)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Relay</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2020, Relay successfully completed an initial public offering. The Company accounts for its investment in Relay at fair value based on the share price of Relay’s common stock at the measurement date. In January 2021, the Company disposed of its equity stake in Relay for aggregate consideration of $15,735, resulting in a loss of $1,821 for 2021. <span style="color:#000000;">The Company reported a gain of $17,556 on the Relay investment for the year ended December 31, 2020. </span>There was no gain or loss on the Relay investment for 2019, as Relay was not a public company during this period. </p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(f)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Ajax</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2021, the Company purchased 631,377 shares of Series B preferred stock of Ajax Therapeutics, Inc. (“Ajax”) for $1,700 in cash. The Company has concluded that its equity investment in Ajax should be valued as a non-marketable equity security as the Company does not exercise significant influence over Ajax. As of December 31, 2021 and December 31, 2020, the carrying value of the Company’s investment in Ajax was $1,700 and zero, respectively.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(g)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ShouTi</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In July 2021, the Company purchased 494,035 shares of Series B preferred stock of ShouTi for $2,000 in cash. As ShouTi is structured as a company limited by shares, incorporated under the laws of the Cayman Islands and the Company is not a passive investor due to its collaboration with ShouTi on a number of drug discovery targets, the Company’s management determined that it has significant influence over the entity and therefore accounts for the investment as an equity method investment. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that the HLBV method for valuing contractual rights to substantive profits provides the best representation of its financial position in ShouTi. The carrying value of ShouTi was $1,887<span style="color:#FF0000;"> </span>and zero as of December 31, 2021 and December 31, 2020, respectively. The Company has no obligation to fund ShouTi losses in excess of its initial investment. The Company recorded a loss of $113 on the ShouTi investment during the year ended December 31, 2021.</p> 0 0 0 -2977000 -4180000 11548000 13685000 14102000 39561000 28013000 4582000 361000 335000 2676191 19000 94000 -75000 0 0 15735000 -1821000 17556000 0 631377 1700000 1700000 0 494035 2000000 1887000 0 -113000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(13</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Employee Benefit Plan</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company offers a 401(k) employee savings plan to its U.S.‑based employees. The Company made discretionary matching contributions equal to 100% of the first 4.0% of compensation contributed by employees for the years ended December 31, 2021, 2020, and 2019. Matching contributions during 2021, 2020, and 2019 were $2,592, $1,748, and $1,492, respectively.</p> 401(k) employee savings plan to its U.S.‑based employees 1 0.040 2592000 1748000 1492000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(14)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>Related Party Transactions</p></td></tr></table></div> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(a)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">D. E. Shaw</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021, 2020, and 2019, the Company licensed technology and purchased services for $7,940, $7,281, and $5,190, respectively, from companies controlled by David E. Shaw and/or affiliates of companies controlled by David E. Shaw (the “D. E. Shaw entities”), stockholders of the Company. In addition, D. E. Shaw entities purchased certain products and services from, and provided cost reimbursements to, the Company totaling $318, $226, and $195 for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021 and 2020, the Company had net payables of $2,637 and $3,464, respectively, to D.E. Shaw entities.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(b)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Board Member</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021, 2020, and 2019, the Company paid consulting fees of $390, $364, and $361, respectively, to a member of its board of directors.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(c)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;font-style:normal;"/>Bill and Melinda Gates Foundation</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the years ended December 31, 2021, 2020, and 2019, the Bill &amp; Melinda Gates Foundation, an entity under common control with Bill and Melinda Gates Foundation Trust, a stockholder of the Company, issued a grant under which it agreed to pay the Company directly for certain licenses and services provided to a specified group of third-party organizations. Revenue recognized for services provided by the Company under this grant were $1,160, $2,094, and $1,065 for the years ended December 31, 2021, 2020, and 2019, respectively. As of December 31, 2021 and 2020, the Company had net receivables of $165 and $543, respectively, due from the Bill &amp; Melinda Gates Foundation.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the fourth quarter of 2021, the Company recognized $111 in drug discovery contribution revenue related to funds received under an agreement with the Bill &amp; Melinda Gates Foundation, aimed at accelerating drug discovery in women’s health. As of December 31, 2021, the Company had no receivables due under this agreement from the Bill &amp; Melinda Gates Foundation.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company received $1,000 in contribution revenue in connection with its entry into an agreement with Gates Ventures, LLC in the second quarter of 2020, and $1,000 in contribution revenue in the second quarter of 2021 on the first anniversary of its entry into the agreement. Gates Ventures, LLC is an entity under control of William H. Gates III, who may be deemed to be the beneficial owner of more than 5% of the Company’s voting securities. As of December 31, 2021 and 2020, the Company had no net receivables due from Gates Ventures, LLC.</p> <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(d)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:italic;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">ShouTi</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the year ended December 31, 2021, the Company entered into multiple software agreements with ShouTi and its subsidiary for approximately $650. The Company recognized revenue of approximately $129 in the aggregate related to these agreements during the year ended December 31, 2021.</p> 7940000 7281000 5190000 318000 226000 195000 -2637000 -3464000 390000 364000 361000 1160000 2094000 1065000 165000 543000 111000 0 1000000 1000000 0.05 0 0 650000 129000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(15</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Segment Reporting</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has determined that its chief executive officer (“CEO”) is its chief operating decision maker (“CODM”). The Company’s CEO evaluates the financial performance of the Company based on two reportable segments: Software and Drug Discovery. The Software segment is focused on licensing the Company’s software to transform molecular discovery. The Drug Discovery segment is focused on building a portfolio of preclinical and clinical drug programs, internally and through collaborations. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The CODM reviews segment performance and allocates resources based upon segment revenue and segment gross profit of the Software and Drug Discovery reportable segments.  Segment gross profit is derived by deducting operational expenditures, with the exception of research and development, sales and marketing, and general and administrative activities from U.S. GAAP revenue. Operational expenditures are expenditures made that are directly attributable to the reportable segment. These expenditures are allocated to the segments based on headcount. The reportable segment expenditures include compensation, supplies, and services from contract research organizations.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain cost items are not allocated to the Company’s reportable segments. These cost items primarily consist of compensation and general operational expenses associated with the Company’s research and development, sales and marketing, and general and administrative.  These costs are incurred by both segments and due to the integrated nature of the Company’s Software and Drug Discovery segments, any allocation methodology would be arbitrary and provide no meaningful analysis.</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is financial information with respect to the Company’s reportable segments for the periods presented:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment revenues:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,236</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,530</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,735</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug discovery</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,695</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,565</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,808</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment revenues</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,931</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,095</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,543</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment gross profit:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,741</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,527</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,089</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug discovery</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,121</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,055</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,996</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment gross profit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,620</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,472</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,093</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unallocated:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90,904</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,695</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,404</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,150</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,795</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,364</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,009</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,898</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,040</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Loss) gain on equity investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,781</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,108</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,359</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,263</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,922</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,057</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,253</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,878</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax (expense) benefit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(411</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(345</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated net loss</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(101,219</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,637</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,681</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth <span style="font-family:Calibri;">revenues</span> by geographic area for the years ended December 31, 2021, 2020, and 2019:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,398</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,737</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,622</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,370</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,504</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,565</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,558</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,367</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rest of World</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,158</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,430</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,050</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,931</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,543</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> 2 <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All segment revenue is earned in the United States and there are no intersegment revenues. Additionally, the Company reports assets on a consolidated basis and does not allocate assets to its reportable segments for purposes of assessing segment performance or allocating resources. Presented below is financial information with respect to the Company’s reportable segments for the periods presented:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.04%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment revenues:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,236</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,530</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66,735</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug discovery</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,695</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,565</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,808</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment revenues</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,931</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,095</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,543</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Segment gross profit:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Software</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,741</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74,527</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,089</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Drug discovery</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,121</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(11,055</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,996</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total segment gross profit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,620</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,472</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,093</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Unallocated:</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(90,904</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,695</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(39,404</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(22,150</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(17,795</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(21,364</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(64,009</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(41,898</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(27,040</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Loss) gain on equity investments</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,781</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,108</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">943</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,359</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,263</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,922</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.64%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest income</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,057</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,253</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.3%;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,878</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax (expense) benefit</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(411</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(345</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">291</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.64%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Consolidated net loss</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(101,219</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,637</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.3%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25,681</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td> </tr> </table></div> 113236000 92530000 66735000 24695000 15565000 18808000 137931000 108095000 85543000 86741000 74527000 53089000 -21121000 -11055000 -3996000 65620000 63472000 49093000 90904000 64695000 39404000 22150000 17795000 21364000 64009000 41898000 27040000 -1781000 4108000 943000 11359000 28263000 9922000 1057000 2253000 1878000 411000 345000 -291000 -101219000 -26637000 -25681000 <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth <span style="font-family:Calibri;">revenues</span> by geographic area for the years ended December 31, 2021, 2020, and 2019:</p> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin:auto;border-collapse:collapse; width:100%;"> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="10" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.1%; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-top:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td colspan="2" style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;" valign="bottom"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United States</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90,398</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60,737</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,622</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Europe</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,810</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,370</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,504</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:45.6%;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Japan</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,565</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.28%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,558</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.18%;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,367</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:solid 0.75pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rest of World</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,158</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,430</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:solid 0.75pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,050</p></td> <td style="background-color:#FFFFFF;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> <tr> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:45.6%; border-bottom:double 2.5pt transparent;" valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137,931</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.28%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108,095</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.18%; border-bottom:double 2.5pt transparent;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;" valign="bottom"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,543</p></td> <td style="background-color:#CFF0FC;padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;" valign="bottom"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </p></td> </tr> </table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"> </p> 90398000 60737000 47622000 27810000 24370000 17504000 8565000 14558000 14367000 11158000 8430000 6050000 137931000 108095000 85543000 <div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:5.24%;white-space:nowrap" valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(16</span><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">)</span></p></td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Subsequent Events</p></td></tr></table></div> <p style="text-align:justify;margin-bottom:0pt;margin-top:6pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 14, 2022, we acquired <span style="color:#000000;">117,840</span> shares of <span style="color:#000000;">XTAL BioStructures, Inc. </span>for $6.5 million,<span style="font-size:12pt;"> </span>a company that provides structural biology services, including biophysical methods, protein production and purification, and X-ray crystallography, which includes $6.0 million in upfront purchase price, plus an adjustment for working capital, less cash acquired.</p> 117840 6500000 6000000.0 EXCEL 106 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 107 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 108 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 109 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.0.1 html 282 474 1 false 97 0 false 10 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Consolidated Balance Sheets Sheet http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Consolidated Statements of Operations Sheet http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 100040 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Sheet http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) Statements 6 false false R7.htm 100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) Sheet http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical) Statements 7 false false R8.htm 100070 - Statement - Consolidated Statements of Cash Flows Sheet http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 8 false false R9.htm 100080 - Disclosure - Description of Business Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusiness Description of Business Notes 9 false false R10.htm 100090 - Disclosure - Significant Accounting Policies Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies Significant Accounting Policies Notes 10 false false R11.htm 100100 - Disclosure - Revenue Recognition Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognition Revenue Recognition Notes 11 false false R12.htm 100110 - Disclosure - Property and Equipment Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment Property and Equipment Notes 12 false false R13.htm 100120 - Disclosure - Fair Value Measurements Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 100130 - Disclosure - Commitments and Contingencies Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 14 false false R15.htm 100140 - Disclosure - Income Taxes Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxes Income Taxes Notes 15 false false R16.htm 100150 - Disclosure - Stockholders' Equity (Deficit) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficit Stockholders' Equity (Deficit) Notes 16 false false R17.htm 100160 - Disclosure - Stock-Based Compensation Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 17 false false R18.htm 100170 - Disclosure - Noncontrolling Interest Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterest Noncontrolling Interest Notes 18 false false R19.htm 100180 - Disclosure - Net Loss per Share Attributable to Common and Limited Stockholders Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholders Net Loss per Share Attributable to Common and Limited Stockholders Notes 19 false false R20.htm 100190 - Disclosure - Equity Investments Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestments Equity Investments Notes 20 false false R21.htm 100200 - Disclosure - Employee Benefit Plan Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlan Employee Benefit Plan Notes 21 false false R22.htm 100210 - Disclosure - Related Party Transactions Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 22 false false R23.htm 100220 - Disclosure - Segment Reporting Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReporting Segment Reporting Notes 23 false false R24.htm 100230 - Disclosure - Subsequent Events Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEvents Subsequent Events Notes 24 false false R25.htm 100240 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies Significant Accounting Policies (Policies) Policies http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies 25 false false R26.htm 100250 - Disclosure - Revenue Recognition (Tables) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognition 26 false false R27.htm 100260 - Disclosure - Property and Equipment (Tables) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables Property and Equipment (Tables) Tables http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment 27 false false R28.htm 100270 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurements 28 false false R29.htm 100280 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies 29 false false R30.htm 100290 - Disclosure - Income Taxes (Tables) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxes 30 false false R31.htm 100300 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensation 31 false false R32.htm 100310 - Disclosure - Net Loss per Share Attributable to Common and Limited Stockholders (Tables) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersTables Net Loss per Share Attributable to Common and Limited Stockholders (Tables) Tables http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholders 32 false false R33.htm 100320 - Disclosure - Segment Reporting (Tables) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingTables Segment Reporting (Tables) Tables http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReporting 33 false false R34.htm 100330 - Disclosure - Description of Business - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails Description of Business - Additional Information (Details) Details 34 false false R35.htm 100340 - Disclosure - Significant Accounting Policies - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails Significant Accounting Policies - Additional Information (Details) Details 35 false false R36.htm 100350 - Disclosure - Revenue Recognition - Schedule of Timing of Revenue Recognition (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfTimingOfRevenueRecognitionDetails Revenue Recognition - Schedule of Timing of Revenue Recognition (Details) Details 36 false false R37.htm 100360 - Disclosure - Revenue Recognition - Additional Information (Details 1) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails1 Revenue Recognition - Additional Information (Details 1) Details 37 false false R38.htm 100370 - Disclosure - Revenue Recognition - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails Revenue Recognition - Additional Information (Details) Details 38 false false R39.htm 100380 - Disclosure - Revenue Recognition - Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails Revenue Recognition - Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue (Details) Details 39 false false R40.htm 100390 - Disclosure - Revenue Recognition - Schedule of Drug Revenue Recognition (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDrugRevenueRecognitionDetails Revenue Recognition - Schedule of Drug Revenue Recognition (Details) Details 40 false false R41.htm 100400 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfContractBalancesDetails Revenue Recognition - Schedule of Contract Balances (Details) Details 41 false false R42.htm 100410 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails Property and Equipment - Summary of Property and Equipment (Details) Details 42 false false R43.htm 100420 - Disclosure - Property and Equipment - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails Property and Equipment - Additional Information (Details) Details 43 false false R44.htm 100430 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value (Details) Details 44 false false R45.htm 100440 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Investments (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3InvestmentsDetails Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Investments (Details) Details 45 false false R46.htm 100450 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 46 false false R47.htm 100460 - Disclosure - Commitments And Contingencies - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails Commitments And Contingencies - Additional Information (Details) Details 47 false false R48.htm 100470 - Disclosure - Commitments And Contingencies - Summary of Operating Leases (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeasesDetails Commitments And Contingencies - Summary of Operating Leases (Details) Details 48 false false R49.htm 100480 - Disclosure - Commitments And Contingencies - Summary of Maturities of Operating Lease Liabilities Under Noncancelable Operating Leases (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails Commitments And Contingencies - Summary of Maturities of Operating Lease Liabilities Under Noncancelable Operating Leases (Details) Details 49 false false R50.htm 100500 - Disclosure - Income Taxes - Summary of Income Tax Expense (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails Income Taxes - Summary of Income Tax Expense (Details) Details 50 false false R51.htm 100510 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByTaxJurisdictionDetails Income Taxes - Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction (Details) Details 51 false false R52.htm 100520 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails Income Taxes - Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate (Details) Details 52 false false R53.htm 100530 - Disclosure - Income Taxes - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails Income Taxes - Additional Information (Details) Details 53 false false R54.htm 100540 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails Income Taxes - Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities (Details) Details 54 false false R55.htm 100550 - Disclosure - Income Taxes - Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalGrossUnrecognizedTaxBenefitsDetails Income Taxes - Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits (Details) Details 55 false false R56.htm 100560 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails Stockholders' Equity (Deficit) - Additional Information (Details) Details http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficit 56 false false R57.htm 100570 - Disclosure - Stock-Based Compensation - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails Stock-Based Compensation - Additional Information (Details) Details 57 false false R58.htm 100580 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Valuation Assumptions Used for Options (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageValuationAssumptionsUsedForOptionsDetails Stock-Based Compensation - Summary of Weighted Average Valuation Assumptions Used for Options (Details) Details 58 false false R59.htm 100590 - Disclosure - Stock-Based Compensation - Summary of Classification of Stock Based Compensation Expense (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfClassificationOfStockBasedCompensationExpenseDetails Stock-Based Compensation - Summary of Classification of Stock Based Compensation Expense (Details) Details 59 false false R60.htm 100600 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails Stock-Based Compensation - Stock Option Activity (Details) Details 60 false false R61.htm 100610 - Disclosure - Noncontrolling Interest - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails Noncontrolling Interest - Additional Information (Details) Details 61 false false R62.htm 100620 - Disclosure - Net Loss per Share Attributable to Common and Limited Stockholders - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonAndLimitedStockholdersDetails Net Loss per Share Attributable to Common and Limited Stockholders - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders (Details) Details 62 false false R63.htm 100630 - Disclosure - Net Loss per Share Attributable to Common and Limited Stockholders - Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsAntiDilutiveDetails Net Loss per Share Attributable to Common and Limited Stockholders - Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive (Details) Details 63 false false R64.htm 100640 - Disclosure - Equity Investments - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails Equity Investments - Additional Information (Details) Details 64 false false R65.htm 100650 - Disclosure - Employee Benefit Plan - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails Employee Benefit Plan - Additional Information (Details) Details 65 false false R66.htm 100660 - Disclosure - Related Party Transactions - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails Related Party Transactions - Additional Information (Details) Details 66 false false R67.htm 100670 - Disclosure - Segment Reporting - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails Segment Reporting - Additional Information (Details) Details 67 false false R68.htm 100680 - Disclosure - Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details) Details 68 false false R69.htm 100690 - Disclosure - Segment Reporting - Schedule of Revenues by Geographic Area (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingScheduleOfRevenuesByGeographicAreaDetails Segment Reporting - Schedule of Revenues by Geographic Area (Details) Details 69 false false R70.htm 100700 - Disclosure - Subsequent Events - Additional Information (Details) Sheet http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails Subsequent Events - Additional Information (Details) Details 70 false false All Reports Book All Reports sdgr-10k_20211231.htm sdgr-20211231.xsd sdgr-20211231_cal.xml sdgr-20211231_def.xml sdgr-20211231_lab.xml sdgr-20211231_pre.xml sdgr-ex105_247.htm sdgr-ex106_246.htm sdgr-ex211_9.htm sdgr-ex231_7.htm sdgr-ex311_12.htm sdgr-ex312_11.htm sdgr-ex321_8.htm sdgr-ex322_10.htm g0na1tfcz5u2000001.jpg g0na1tfcz5u2000002.jpg g0na1tfcz5u2000003.jpg g0na1tfcz5u2000004.jpg g0na1tfcz5u2000005.jpg g0na1tfcz5u2000006.jpg g0na1tfcz5u2000007.jpg g0na1tfcz5u2000008.jpg g0na1tfcz5u2000009.jpg g0na1tfcz5u2000010.jpg g0na1tfcz5u2000011.jpg g0na1tfcz5u2000012.jpg g0na1tfcz5u2000013.jpg g0na1tfcz5u2000014.jpg g0na1tfcz5u2000015.jpg g0na1tfcz5u2000016.jpg g0na1tfcz5u2000017.jpg g0na1tfcz5u2000018.jpg g0na1tfcz5u2000019.jpg g0na1tfcz5u2000020.jpg http://fasb.org/us-gaap/2021-01-31 http://xbrl.sec.gov/dei/2021q4 true true JSON 112 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sdgr-10k_20211231.htm": { "axisCustom": 0, "axisStandard": 31, "contextCount": 282, "dts": { "calculationLink": { "local": [ "sdgr-20211231_cal.xml" ] }, "definitionLink": { "local": [ "sdgr-20211231_def.xml" ] }, "inline": { "local": [ "sdgr-10k_20211231.htm" ] }, "labelLink": { "local": [ "sdgr-20211231_lab.xml" ] }, "presentationLink": { "local": [ "sdgr-20211231_pre.xml" ] }, "schema": { "local": [ "sdgr-20211231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "https://xbrl.sec.gov/naics/2021/naics-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd" ] } }, "elementCount": 642, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2021-01-31": 22, "http://www.schrodinger.com/20211231": 1, "http://xbrl.sec.gov/dei/2021q4": 4, "total": 27 }, "keyCustom": 83, "keyStandard": 391, "memberCustom": 43, "memberStandard": 51, "nsprefix": "sdgr", "nsuri": "http://www.schrodinger.com/20211231", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100090 - Disclosure - Significant Accounting Policies", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies", "shortName": "Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100100 - Disclosure - Revenue Recognition", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognition", "shortName": "Revenue Recognition", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100110 - Disclosure - Property and Equipment", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment", "shortName": "Property and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100120 - Disclosure - Fair Value Measurements", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurements", "shortName": "Fair Value Measurements", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100130 - Disclosure - Commitments and Contingencies", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100140 - Disclosure - Income Taxes", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxes", "shortName": "Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100150 - Disclosure - Stockholders' Equity (Deficit)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficit", "shortName": "Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100160 - Disclosure - Stock-Based Compensation", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100170 - Disclosure - Noncontrolling Interest", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterest", "shortName": "Noncontrolling Interest", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100180 - Disclosure - Net Loss per Share Attributable to Common and Limited Stockholders", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholders", "shortName": "Net Loss per Share Attributable to Common and Limited Stockholders", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100010 - Statement - Consolidated Balance Sheets", "role": "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100190 - Disclosure - Equity Investments", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestments", "shortName": "Equity Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100200 - Disclosure - Employee Benefit Plan", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlan", "shortName": "Employee Benefit Plan", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100210 - Disclosure - Related Party Transactions", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions", "shortName": "Related Party Transactions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100220 - Disclosure - Segment Reporting", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReporting", "shortName": "Segment Reporting", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100230 - Disclosure - Subsequent Events", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEvents", "shortName": "Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100240 - Disclosure - Significant Accounting Policies (Policies)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100250 - Disclosure - Revenue Recognition (Tables)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionTables", "shortName": "Revenue Recognition (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100260 - Disclosure - Property and Equipment (Tables)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables", "shortName": "Property and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100270 - Disclosure - Fair Value Measurements (Tables)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables", "shortName": "Fair Value Measurements (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100280 - Disclosure - Commitments and Contingencies (Tables)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables", "shortName": "Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100290 - Disclosure - Income Taxes (Tables)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables", "shortName": "Income Taxes (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100300 - Disclosure - Stock-Based Compensation (Tables)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100310 - Disclosure - Net Loss per Share Attributable to Common and Limited Stockholders (Tables)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersTables", "shortName": "Net Loss per Share Attributable to Common and Limited Stockholders (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100320 - Disclosure - Segment Reporting (Tables)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingTables", "shortName": "Segment Reporting (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "U_iso4217USD_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100330 - Disclosure - Description of Business - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "shortName": "Description of Business - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_us-gaapStatementClassOfStockAxis_us-gaapConvertiblePreferredStockMember_20200210_20200210", "decimals": "INF", "lang": null, "name": "us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "p", "sdgr:CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100340 - Disclosure - Significant Accounting Policies - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "sdgr:CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_srtProductOrServiceAxis_sdgrSoftwareProductsAndServicesMember_us-gaapTimingOfTransferOfGoodOrServiceAxis_us-gaapTransferredAtPointInTimeMember_20210101_20211231", "decimals": "3", "first": true, "lang": null, "name": "sdgr:TimingOfRevenueRecognitionPercentage", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100350 - Disclosure - Revenue Recognition - Schedule of Timing of Revenue Recognition (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfTimingOfRevenueRecognitionDetails", "shortName": "Revenue Recognition - Schedule of Timing of Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "us-gaap:RevenueFromContractWithCustomerTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_srtProductOrServiceAxis_sdgrSoftwareProductsAndServicesMember_us-gaapTimingOfTransferOfGoodOrServiceAxis_us-gaapTransferredAtPointInTimeMember_20210101_20211231", "decimals": "3", "first": true, "lang": null, "name": "sdgr:TimingOfRevenueRecognitionPercentage", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_srtProductOrServiceAxis_sdgrOnPremiseSoftwareMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100360 - Disclosure - Revenue Recognition - Additional Information (Details 1)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails1", "shortName": "Revenue Recognition - Additional Information (Details 1)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_srtProductOrServiceAxis_sdgrOnPremiseSoftwareMember_us-gaapRevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2022-01-01_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100370 - Disclosure - Revenue Recognition - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "shortName": "Revenue Recognition - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100380 - Disclosure - Revenue Recognition - Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails", "shortName": "Revenue Recognition - Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_srtProductOrServiceAxis_sdgrOnPremiseSoftwareMember_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100030 - Statement - Consolidated Statements of Operations", "role": "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:CostOfRevenue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "sdgr:DrugDiscoveryRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "sdgr:RevenueRecognizedForDrugDiscovery", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100390 - Disclosure - Revenue Recognition - Schedule of Drug Revenue Recognition (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDrugRevenueRecognitionDetails", "shortName": "Revenue Recognition - Schedule of Drug Revenue Recognition (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "sdgr:DrugDiscoveryRevenueTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_srtProductOrServiceAxis_sdgrDrugDiscoveryServicesRevenueFromContractsWithCustomersMember_20210101_20211231", "decimals": "-3", "lang": null, "name": "sdgr:RevenueRecognizedForDrugDiscovery", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100400 - Disclosure - Revenue Recognition - Schedule of Contract Balances (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfContractBalancesDetails", "shortName": "Revenue Recognition - Schedule of Contract Balances (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ContractWithCustomerAssetNet", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100410 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails", "shortName": "Property and Equipment - Summary of Property and Equipment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100420 - Disclosure - Property and Equipment - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails", "shortName": "Property and Equipment - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100430 - Disclosure - Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails", "shortName": "Fair Value Measurements - Schedule of Assets and Liabilities Measured at Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AssetsFairValueDisclosure", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100440 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Investments (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3InvestmentsDetails", "shortName": "Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:FairValueDisclosuresTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100450 - Disclosure - Fair Value Measurements - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails", "shortName": "Fair Value Measurements - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:FairValueAssetsLevel1ToLevel2TransfersAmount", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "sdgr:OperatingLeaseExpirationYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100460 - Disclosure - Commitments And Contingencies - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "shortName": "Commitments And Contingencies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "sdgr:OperatingLeaseExpirationYear", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100470 - Disclosure - Commitments And Contingencies - Summary of Operating Leases (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeasesDetails", "shortName": "Commitments And Contingencies - Summary of Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100480 - Disclosure - Commitments And Contingencies - Summary of Maturities of Operating Lease Liabilities Under Noncancelable Operating Leases (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails", "shortName": "Commitments And Contingencies - Summary of Maturities of Operating Lease Liabilities Under Noncancelable Operating Leases (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100040 - Statement - Consolidated Statements of Comprehensive Loss", "role": "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:ComprehensiveIncomeNetOfTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100500 - Disclosure - Income Taxes - Summary of Income Tax Expense (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails", "shortName": "Income Taxes - Summary of Income Tax Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20190101_20191231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CurrentFederalTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100510 - Disclosure - Income Taxes - Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByTaxJurisdictionDetails", "shortName": "Income Taxes - Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100520 - Disclosure - Income Taxes - Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails", "shortName": "Income Taxes - Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "3", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100530 - Disclosure - Income Taxes - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "shortName": "Income Taxes - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100540 - Disclosure - Income Taxes - Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails", "shortName": "Income Taxes - Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100550 - Disclosure - Income Taxes - Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalGrossUnrecognizedTaxBenefitsDetails", "shortName": "Income Taxes - Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20181231", "decimals": "-3", "lang": null, "name": "us-gaap:UnrecognizedTaxBenefits", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100560 - Disclosure - Stockholders' Equity (Deficit) - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "shortName": "Stockholders' Equity (Deficit) - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_us-gaapStatementClassOfStockAxis_sdgrVotingCommonStockMember_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100570 - Disclosure - Stock-Based Compensation - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "shortName": "Stock-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100580 - Disclosure - Stock-Based Compensation - Summary of Weighted Average Valuation Assumptions Used for Options (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageValuationAssumptionsUsedForOptionsDetails", "shortName": "Stock-Based Compensation - Summary of Weighted Average Valuation Assumptions Used for Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100590 - Disclosure - Stock-Based Compensation - Summary of Classification of Stock Based Compensation Expense (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfClassificationOfStockBasedCompensationExpenseDetails", "shortName": "Stock-Based Compensation - Summary of Classification of Stock Based Compensation Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100050 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20181231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20201231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100600 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "shortName": "Stock-Based Compensation - Stock Option Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_srtOwnershipAxis_sdgrFaxianTherapeuticsLLCJointVentureMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapCoVenturerMember_20190430", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100610 - Disclosure - Noncontrolling Interest - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails", "shortName": "Noncontrolling Interest - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_srtOwnershipAxis_sdgrFaxianTherapeuticsLLCJointVentureMember_us-gaapRelatedPartyTransactionsByRelatedPartyAxis_us-gaapCoVenturerMember_20190430", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners", "reportCount": 1, "unique": true, "unitRef": "U_xbrlipure", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100620 - Disclosure - Net Loss per Share Attributable to Common and Limited Stockholders - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonAndLimitedStockholdersDetails", "shortName": "Net Loss per Share Attributable to Common and Limited Stockholders - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R63": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100630 - Disclosure - Net Loss per Share Attributable to Common and Limited Stockholders - Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsAntiDilutiveDetails", "shortName": "Net Loss per Share Attributable to Common and Limited Stockholders - Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100640 - Disclosure - Equity Investments - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails", "shortName": "Equity Investments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:EquityMethodInvestmentsDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_srtScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_sdgrNimbusTherapeuticsLLCMember_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:EquityMethodInvestments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100650 - Disclosure - Employee Benefit Plan - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails", "shortName": "Employee Benefit Plan - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100660 - Disclosure - Related Party Transactions - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "shortName": "Related Party Transactions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:RelatedPartyTransactionDueFromToRelatedParty", "p", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_us-gaapTypeOfArrangementAxis_sdgrAgreementWithGatesVenturesLimitedLiabilityCompanyMember_20201231", "decimals": "INF", "lang": null, "name": "us-gaap:RelatedPartyTransactionDueFromToRelatedParty", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_sdgrsegment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100670 - Disclosure - Segment Reporting - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails", "shortName": "Segment Reporting - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "U_sdgrsegment", "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100680 - Disclosure - Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails", "shortName": "Segment Reporting - Summary of Financial Information with Respect to Reportable Segments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_srtConsolidationItemsAxis_us-gaapOperatingSegmentsMember_us-gaapStatementBusinessSegmentsAxis_sdgrSoftwareSegmentMember_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100690 - Disclosure - Segment Reporting - Schedule of Revenues by Geographic Area (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingScheduleOfRevenuesByGeographicAreaDetails", "shortName": "Segment Reporting - Schedule of Revenues by Geographic Area (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_srtStatementGeographicalAxis_countryUS_20210101_20211231", "decimals": "-3", "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100060 - Statement - Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "shortName": "Consolidated Statements of Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_us-gaapIPOMember_20200101_20201231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:PaymentsOfStockIssuanceCosts", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_us-gaapBusinessAcquisitionAxis_sdgrXTALBioStructuresIncorporationMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220114_20220114", "decimals": "INF", "first": true, "lang": null, "name": "sdgr:NumberOfSharesAcquired", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100700 - Disclosure - Subsequent Events - Additional Information (Details)", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails", "shortName": "Subsequent Events - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_us-gaapBusinessAcquisitionAxis_sdgrXTALBioStructuresIncorporationMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20220114_20220114", "decimals": "INF", "first": true, "lang": null, "name": "sdgr:NumberOfSharesAcquired", "reportCount": 1, "unique": true, "unitRef": "U_xbrlishares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "U_iso4217USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "100070 - Statement - Consolidated Statements of Cash Flows", "role": "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": "-3", "lang": null, "name": "sdgr:NoncashRevenueFromEquityInvestments", "reportCount": 1, "unique": true, "unitRef": "U_iso4217USD", "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "100080 - Disclosure - Description of Business", "role": "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusiness", "shortName": "Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "sdgr-10k_20211231.htm", "contextRef": "C_0001490978_20210101_20211231", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 97, "tag": { "country_JP": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "JAPAN", "terseLabel": "Japan" } } }, "localname": "JP", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingScheduleOfRevenuesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "country_US": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "UNITED STATES", "terseLabel": "United States" } } }, "localname": "US", "nsuri": "http://xbrl.sec.gov/country/2021", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingScheduleOfRevenuesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm Id", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r637" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r632" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated By Reference [Text Block]", "terseLabel": "Documents Incorporated by Reference" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line1", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line2", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r639" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float", "terseLabel": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r631" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r640" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well Known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r634", "r635", "r636" ], "lang": { "en-us": { "role": { "label": "Icfr Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r630" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security12b Title", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r633" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "sdgr_AccountingStandardsUpdate202108Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accounting standards update 202108.", "label": "Accounting Standards Update202108 [Member]", "terseLabel": "ASU - 2021-08" } } }, "localname": "AccountingStandardsUpdate202108Member", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_AgreementWithGatesVenturesLimitedLiabilityCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreement with Gates Ventures, Limited Liability Company.", "label": "Agreement With Gates Ventures Limited Liability Company [Member]", "terseLabel": "Agreement with Gates Ventures, LLC" } } }, "localname": "AgreementWithGatesVenturesLimitedLiabilityCompanyMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_AjaxTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ajax Therapeutics, Inc.", "label": "Ajax Therapeutics Inc [Member]", "terseLabel": "Ajax Therapeutics, Inc" } } }, "localname": "AjaxTherapeuticsIncMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_AllowanceForUnbilledReceivablesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Allowance for unbilled receivables current.", "label": "Allowance For Unbilled Receivables Current", "terseLabel": "Allowance for unbilled receivable" } } }, "localname": "AllowanceForUnbilledReceivablesCurrent", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "sdgr_AreaLeased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area leased.", "label": "Area Leased", "terseLabel": "Area leased" } } }, "localname": "AreaLeased", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "sdgr_BaseRentPerMonth": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Base rent per month.", "label": "Base Rent Per Month", "terseLabel": "Base rent per month" } } }, "localname": "BaseRentPerMonth", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_BaseRentPerMonthFromCommencementToHandoverDate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Base rent per month from commencement to handover date.", "label": "Base Rent Per Month From Commencement To Handover Date", "terseLabel": "Base rent per month from commencement to handover date" } } }, "localname": "BaseRentPerMonthFromCommencementToHandoverDate", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_BaseRentPerMonthFromHandoverToTerminationDate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Base rent per month from handover to termination date.", "label": "Base Rent Per Month From Handover To Termination Date", "terseLabel": "Base rent per month from handover to termination date" } } }, "localname": "BaseRentPerMonthFromHandoverToTerminationDate", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_BasisOfPresentationAndUseOfEstimatesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Basis of presentation and use of estimates.", "label": "Basis Of Presentation And Use Of Estimates Policy [Text Block]", "terseLabel": "Basis of Presentation and Use of Estimates" } } }, "localname": "BasisOfPresentationAndUseOfEstimatesPolicyTextBlock", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "sdgr_BillAndMelindaGatesFoundationTrustMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bill and Melinda gates foundation trust.", "label": "Bill And Melinda Gates Foundation Trust [Member]", "terseLabel": "BMGFT" } } }, "localname": "BillAndMelindaGatesFoundationTrustMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_BristolMyersSquibbMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bristol-Myers Squibb.", "label": "Bristol Myers Squibb [Member]", "terseLabel": "BMS" } } }, "localname": "BristolMyersSquibbMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents and marketable securities and restricted cash policy.", "label": "Cash And Cash Equivalents And Marketable Securities And Restricted Cash Policy [Text Block]", "terseLabel": "Cash and Cash Equivalents and Marketable Securities and Restricted Cash" } } }, "localname": "CashAndCashEquivalentsAndMarketableSecuritiesAndRestrictedCashPolicyTextBlock", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "sdgr_CollaborationAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration and license agreement.", "label": "Collaboration And License Agreement [Member]", "terseLabel": "Collaboration and License Agreement" } } }, "localname": "CollaborationAndLicenseAgreementMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_CollaborationAndLicenseAgreementTransactionPrice": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Collaboration and license agreement transaction price.", "label": "Collaboration And License Agreement Transaction Price", "terseLabel": "Transaction price" } } }, "localname": "CollaborationAndLicenseAgreementTransactionPrice", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_CollaborativeAgreementNumberOfPrograms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative agreement number of programs.", "label": "Collaborative Agreement Number Of Programs", "terseLabel": "Number of programs under agreement" } } }, "localname": "CollaborativeAgreementNumberOfPrograms", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "sdgr_CommissionExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Commission expense.", "label": "Commission Expense", "terseLabel": "Commission expense" } } }, "localname": "CommissionExpense", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_CommonSharesReceivedInConnectionWithMerger": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common shares received in connection with merger.", "label": "Common Shares Received In Connection With Merger", "terseLabel": "Common shares received in connection with merger" } } }, "localname": "CommonSharesReceivedInConnectionWithMerger", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "sdgr_CommonStockDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common stock, description.", "label": "Common Stock Description", "terseLabel": "Common stock, description" } } }, "localname": "CommonStockDescription", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sdgr_ConcentrationRiskNumberOfCustomers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Concentration risk number of customers.", "label": "Concentration Risk Number Of Customers", "terseLabel": "Concentration risk, number of customers" } } }, "localname": "ConcentrationRiskNumberOfCustomers", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "sdgr_ContractWithCustomersPaymentTerms": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contract with customers, payment terms.", "label": "Contract With Customers Payment Terms", "terseLabel": "Contract with customers, payment terms" } } }, "localname": "ContractWithCustomersPaymentTerms", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "sdgr_ContributionsRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Contributions revenue recognized.", "label": "Contributions Revenue Recognized", "terseLabel": "Contributions Revenue Recognized" } } }, "localname": "ContributionsRevenueRecognized", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_ConversionAmountOfLimitedCommonStockIntoCommonStock": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Conversion amount of limited common stock into common stock.", "label": "Conversion Amount Of Limited Common Stock Into Common Stock", "terseLabel": "Conversion of limited common stock into common stock" } } }, "localname": "ConversionAmountOfLimitedCommonStockIntoCommonStock", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "sdgr_ConversionOfLimitedCommonStockIntoCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion of limited common stock Into common stock shares.", "label": "Conversion Of Limited Common Stock Into Common Stock Shares", "terseLabel": "Conversion of limited common stock into common stock, Shares" } } }, "localname": "ConversionOfLimitedCommonStockIntoCommonStockShares", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "sdgr_CustomerAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer A.", "label": "Customer A [Member]", "terseLabel": "Customer A" } } }, "localname": "CustomerAMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_CustomerBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer B.", "label": "Customer B [Member]", "terseLabel": "Customer B" } } }, "localname": "CustomerBMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_CustomerCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer C.", "label": "Customer C [Member]", "terseLabel": "Customer C" } } }, "localname": "CustomerCMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_DavidEShawMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "David E Shaw.", "label": "David E Shaw [Member]", "terseLabel": "D. E. Shaw Entities" } } }, "localname": "DavidEShawMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_DeferredTaxAssetsLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails": { "order": 10100.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deferred tax assets lease liabilities.", "label": "Deferred Tax Assets Lease Liabilities", "terseLabel": "Lease Liabilities" } } }, "localname": "DeferredTaxAssetsLeaseLiabilities", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_DeferredTaxLiabilitiesDepreciationAndAmortization": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails": { "order": 10040.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred tax liabilities, depreciation and amortization.", "label": "Deferred Tax Liabilities Depreciation And Amortization", "negatedLabel": "Depreciation and amortization" } } }, "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_DocumentAndEntityInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Document and entity information.", "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "localname": "DocumentAndEntityInformationLineItems", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "sdgr_DocumentAndEntityInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Document and entity information.", "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "localname": "DocumentAndEntityInformationTable", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stringItemType" }, "sdgr_DrugDiscoveryContributionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Drug discovery contribution.", "label": "Drug Discovery Contribution [Member]", "terseLabel": "Drug Discovery Contribution" } } }, "localname": "DrugDiscoveryContributionMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDrugRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "sdgr_DrugDiscoveryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Drug discovery.", "label": "Drug Discovery [Member]", "terseLabel": "Drug Discovery" } } }, "localname": "DrugDiscoveryMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfContractBalancesDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfTimingOfRevenueRecognitionDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "sdgr_DrugDiscoveryRevenueTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Drug discovery revenue.", "label": "Drug Discovery Revenue Table [Text Block]", "terseLabel": "Drug Discovery Revenue" } } }, "localname": "DrugDiscoveryRevenueTableTextBlock", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "sdgr_DrugDiscoverySegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Drug Discovery Segment.", "label": "Drug Discovery Segment [Member]", "terseLabel": "Drug Discovery Segment" } } }, "localname": "DrugDiscoverySegmentMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "sdgr_DrugDiscoveryServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Drug discovery member.", "label": "Drug Discovery Services [Member]", "terseLabel": "Drug Discovery Services" } } }, "localname": "DrugDiscoveryServicesMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_DrugDiscoveryServicesRevenueFromContractsWithCustomersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Drug discovery services revenue from contracts with customers.", "label": "Drug Discovery Services Revenue From Contracts With Customers [Member]", "terseLabel": "Drug Discovery Services Revenue from Contracts with Customers" } } }, "localname": "DrugDiscoveryServicesRevenueFromContractsWithCustomersMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDrugRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "sdgr_EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails": { "order": 10060.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation return-to-provision adjustments.", "label": "Effective Income Tax Rate Reconciliation Return To Provision Adjustments", "terseLabel": "Return-to-provision adjustments" } } }, "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAdjustments", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "sdgr_EffectiveIncomeTaxRateReconciliationSection162Limitation": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails": { "order": 10040.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation, section 162 limitation.", "label": "Effective Income Tax Rate Reconciliation Section162 Limitation", "terseLabel": "Section 162(m) limitation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationSection162Limitation", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "sdgr_EffectiveIncomeTaxRateReconciliationWithholdingTaxes": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails": { "order": 10030.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Effective income tax rate reconciliation withholding taxes.", "label": "Effective Income Tax Rate Reconciliation Withholding Taxes", "terseLabel": "Withholding tax" } } }, "localname": "EffectiveIncomeTaxRateReconciliationWithholdingTaxes", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "sdgr_EscrowPaymentsReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Escrow payments receivable.", "label": "Escrow Payments Receivable", "terseLabel": "Escrow payments receivable" } } }, "localname": "EscrowPaymentsReceivable", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_EscrowPaymentsReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Escrow payments received.", "label": "Escrow Payments Received", "terseLabel": "Escrow payments received" } } }, "localname": "EscrowPaymentsReceived", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_ExchangeOfConvertiblePreferredStockIntoLimitedCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exchange of convertible preferred stock into limited common stock, shares.", "label": "Exchange Of Convertible Preferred Stock Into Limited Common Stock Shares", "terseLabel": "Exchange of convertible preferred stock into limited common stock, Shares" } } }, "localname": "ExchangeOfConvertiblePreferredStockIntoLimitedCommonStockShares", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "sdgr_ExchangeOfConvertiblePreferredStockIntoLimitedCommonStockValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exchange of convertible preferred stock into limited common stock, value.", "label": "Exchange Of Convertible Preferred Stock Into Limited Common Stock Value", "terseLabel": "Exchange of convertible preferred stock into limited common stock" } } }, "localname": "ExchangeOfConvertiblePreferredStockIntoLimitedCommonStockValue", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "sdgr_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetCashContributions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset, cash contributions.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Cash Contributions", "terseLabel": "Cash contributions" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetCashContributions", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_FaxianTherapeuticsLLCJointVentureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Faxian Therapeutics, LLC joint venture.", "label": "Faxian Therapeutics L L C Joint Venture [Member]", "terseLabel": "Faxian" } } }, "localname": "FaxianTherapeuticsLLCJointVentureMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_FirstAnniversaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First anniversary.", "label": "First Anniversary [Member]", "terseLabel": "First Anniversary" } } }, "localname": "FirstAnniversaryMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_FollowOnOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow on offering.", "label": "Follow On Offering [Member]", "terseLabel": "Follow-on Offering" } } }, "localname": "FollowOnOfferingMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "sdgr_FollowOnPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Follow on public offering.", "label": "Follow On Public Offering [Member]", "terseLabel": "Follow-on-Public Offering" } } }, "localname": "FollowOnPublicOfferingMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_HostedSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hosted software.", "label": "Hosted Software [Member]", "terseLabel": "Hosted Software" } } }, "localname": "HostedSoftwareMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails" ], "xbrltype": "domainItemType" }, "sdgr_IncreaseDecreaseInOperatingLeaseLiabilities": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10320.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease liabilities.", "label": "Increase Decrease In Operating Lease Liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiabilities", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sdgr_IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssets": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10270.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in reduction in the carrying amount of right of use assets.", "label": "Increase Decrease In Reduction In The Carrying Amount Of Right Of Use Assets", "negatedLabel": "Reduction in the carrying amount of right of use assets" } } }, "localname": "IncreaseDecreaseInReductionInTheCarryingAmountOfRightOfUseAssets", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sdgr_IncreaseDecreaseInUnbilledAndOtherReceivables": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10260.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in unbilled and other receivables.", "label": "Increase Decrease In Unbilled And Other Receivables", "negatedLabel": "Unbilled and other receivables" } } }, "localname": "IncreaseDecreaseInUnbilledAndOtherReceivables", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sdgr_IncreaseInOperatingLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase in operating lease liabilities.", "label": "Increase In Operating Lease Liabilities", "terseLabel": "Increase in lease liabilities" } } }, "localname": "IncreaseInOperatingLeaseLiabilities", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_IncreaseInOperatingLeaseRightOfUseAsset": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase in operating lease right of use asset.", "label": "Increase In Operating Lease Right Of Use Asset", "terseLabel": "Increase in right-of-use assets" } } }, "localname": "IncreaseInOperatingLeaseRightOfUseAsset", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_InvestmentAccretionNoncashExpense": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10230.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment accretion noncash expense.", "label": "Investment Accretion Noncash Expense", "negatedLabel": "Noncash investment accretion" } } }, "localname": "InvestmentAccretionNoncashExpense", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sdgr_LeaseExpirationPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease expiration period.", "label": "Lease Expiration Period", "terseLabel": "Lease expiration period" } } }, "localname": "LeaseExpirationPeriod", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "sdgr_LimitedCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Limited common stock.", "label": "Limited Common Stock [Member]", "terseLabel": "Limited Common Stock" } } }, "localname": "LimitedCommonStockMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "sdgr_MaximumMilestonePaymentsToBeReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Maximum milestone payments to be received.", "label": "Maximum Milestone Payments To Be Received", "terseLabel": "Maximum milestone payments to be received" } } }, "localname": "MaximumMilestonePaymentsToBeReceived", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of stock options must be granted at exercise price of fair market value.", "label": "Maximum Percentage Of Stock Options Must Be Granted At Exercise Price Of Fair Market Value", "terseLabel": "Maximum percentage of stock options must be granted at exercise price of fair market value" } } }, "localname": "MaximumPercentageOfStockOptionsMustBeGrantedAtExercisePriceOfFairMarketValue", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "sdgr_MembersOfBoardOfDirectorsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Members of board of directors.", "label": "Members Of Board Of Directors [Member]", "terseLabel": "Member of Board of Directors" } } }, "localname": "MembersOfBoardOfDirectorsMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_MilestonePaymentYetToBeAchieved": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payment yet to be achieved.", "label": "Milestone Payment Yet To Be Achieved", "terseLabel": "Milestone payment yet to be achieved" } } }, "localname": "MilestonePaymentYetToBeAchieved", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_MilestonePaymentsToBeReceivedUponAchievementOfCertainSpecifiedCommercialMilestones": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Milestone payments to be received upon achievement of certain specified commercial milestones.", "label": "Milestone Payments To Be Received Upon Achievement Of Certain Specified Commercial Milestones", "terseLabel": "Milestone payments to be received upon achievement of certain specified commercial milestones" } } }, "localname": "MilestonePaymentsToBeReceivedUponAchievementOfCertainSpecifiedCommercialMilestones", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_MilestonePaymentsToBeReceivedUponAchievementOfCertainSpecifiedResearchDevelopmentAndRegulatoryMilestones": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones.", "label": "Milestone Payments To Be Received Upon Achievement Of Certain Specified Research Development And Regulatory Milestones", "terseLabel": "Milestone payments to be received upon achievement of certain specified research, development, and regulatory milestones" } } }, "localname": "MilestonePaymentsToBeReceivedUponAchievementOfCertainSpecifiedResearchDevelopmentAndRegulatoryMilestones", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_MorphicHoldingIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Morphic holding Inc.", "label": "Morphic Holding Inc [Member]", "terseLabel": "Morphic Holding, Inc." } } }, "localname": "MorphicHoldingIncMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_NOLCarryforwardsPercentageOfTaxableIncomeLimitationOnUse": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "NOL carryforwards, percentage of taxable income limitation on use.", "label": "N O L Carryforwards Percentage Of Taxable Income Limitation On Use", "terseLabel": "NOL carryforwards, percentage of taxable income limitation on use" } } }, "localname": "NOLCarryforwardsPercentageOfTaxableIncomeLimitationOnUse", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "sdgr_NeurologyAndImmunologyProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Neurology and immunology product.", "label": "Neurology And Immunology Product [Member]", "terseLabel": "Neurology and Immunology Product" } } }, "localname": "NeurologyAndImmunologyProductMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_NimbusTherapeuticsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nimbus Therapeutics LLC.", "label": "Nimbus Therapeutics L L C [Member]", "terseLabel": "Nimbus Therapeutics, LLC" } } }, "localname": "NimbusTherapeuticsLLCMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_NonMarketableEquitySecurities": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non marketable equity securities.", "label": "Non Marketable Equity Securities", "terseLabel": "Carrying value of non-marketable equity securities" } } }, "localname": "NonMarketableEquitySecurities", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsInExchangeForLeaseObligations": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash Or part noncash acquisitions of right of use assets in exchange for lease obligations.", "label": "Noncash Or Part Noncash Acquisitions Of Right Of Use Assets In Exchange For Lease Obligations", "terseLabel": "Acquisitions of right of use assets in exchange for lease obligations" } } }, "localname": "NoncashOrPartNoncashAcquisitionsOfRightOfUseAssetsInExchangeForLeaseObligations", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sdgr_NoncashOrPartNoncashReclassificationOfDeferredFinancingCostsToAdditionalPaidInCapital": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash or part noncash reclassification of deferred financing costs to additional paid in capital.", "label": "Noncash Or Part Noncash Reclassification Of Deferred Financing Costs To Additional Paid In Capital", "terseLabel": "Reclassification of deferred financing costs to additional paid-in capital" } } }, "localname": "NoncashOrPartNoncashReclassificationOfDeferredFinancingCostsToAdditionalPaidInCapital", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sdgr_NoncashOrPartNoncashRightOfUseAssetsRecognizedOnAdoption": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncash Or part noncash right of use assets recognized on adoption.", "label": "Noncash Or Part Noncash Right Of Use Assets Recognized On Adoption", "terseLabel": "Right of use assets recognized on adoption" } } }, "localname": "NoncashOrPartNoncashRightOfUseAssetsRecognizedOnAdoption", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sdgr_NoncashRevenueFromEquityInvestments": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10180.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Noncash revenue from equity investments.", "label": "Noncash Revenue From Equity Investments", "negatedLabel": "Noncash revenue from equity investments" } } }, "localname": "NoncashRevenueFromEquityInvestments", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sdgr_NumberOfNewOperatingLeases": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of new operating leases.", "label": "Number Of New Operating Leases", "terseLabel": "Number of new operating lease" } } }, "localname": "NumberOfNewOperatingLeases", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "sdgr_NumberOfPreferredSharesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of preferred shares purchased.", "label": "Number Of Preferred Shares Purchased", "terseLabel": "Number of preferred shares purchased" } } }, "localname": "NumberOfPreferredSharesPurchased", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "sdgr_NumberOfSharesAcquired": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares acquired.", "label": "Number Of Shares Acquired", "terseLabel": "Number of shares acquired" } } }, "localname": "NumberOfSharesAcquired", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "sdgr_NumberOfVotesForCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of votes for common share.", "label": "Number Of Votes For Common Share", "terseLabel": "Number of votes for common share" } } }, "localname": "NumberOfVotesForCommonShare", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "sdgr_OfficeLeaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office Lease Agreement.", "label": "Office Lease Agreement [Member]", "terseLabel": "Office Lease Agreement" } } }, "localname": "OfficeLeaseAgreementMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_OnPremiseSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "On premise software.", "label": "On Premise Software [Member]", "terseLabel": "On Premise Software" } } }, "localname": "OnPremiseSoftwareMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails1", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails" ], "xbrltype": "domainItemType" }, "sdgr_OncologyProductMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Oncology product.", "label": "Oncology Product [Member]", "terseLabel": "Oncology Product" } } }, "localname": "OncologyProductMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_OperatingLeaseExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating lease expiration year.", "label": "Operating Lease Expiration Year", "terseLabel": "Operating lease expiration year" } } }, "localname": "OperatingLeaseExpirationYear", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "sdgr_OperatingLossCarryforwardsExpirationYear": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating loss carryforwards, expiration year.", "label": "Operating Loss Carryforwards Expiration Year", "terseLabel": "Operating loss carryforwards, expiration year" } } }, "localname": "OperatingLossCarryforwardsExpirationYear", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "gYearItemType" }, "sdgr_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization, consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sdgr_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Organization, consolidation and presentation of financial statements.", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sdgr_PaymentOfConsultingFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment of consulting fees.", "label": "Payment Of Consulting Fees", "terseLabel": "Payment of consulting fees" } } }, "localname": "PaymentOfConsultingFees", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_PercentageOfAnnualRentalEscalation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of annual rental escalation.", "label": "Percentage Of Annual Rental Escalation", "terseLabel": "Percentage of annual rental escalation" } } }, "localname": "PercentageOfAnnualRentalEscalation", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "sdgr_PercentageOfVotingSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of voting securities.", "label": "Percentage Of Voting Securities", "terseLabel": "Percentage of voting securities" } } }, "localname": "PercentageOfVotingSecurities", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "sdgr_PetraPharmaCorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Petra pharma corporation.", "label": "Petra Pharma Corporation [Member]", "terseLabel": "Petra Pharma Corporation" } } }, "localname": "PetraPharmaCorporationMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_ProceedsFromIssuanceOfCommonStockByStockholder": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of common stock by stockholder.", "label": "Proceeds From Issuance Of Common Stock By Stockholder", "terseLabel": "Proceeds from sale of common stock by stockholder" } } }, "localname": "ProceedsFromIssuanceOfCommonStockByStockholder", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_ProceedsFromIssuanceUponFollowOnPublicOfferingNet": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10050.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Issuance Upon Follow On Public Offering Net.", "label": "Proceeds From Issuance Upon Follow On Public Offering Net", "terseLabel": "Issuances of common stock upon follow-on public offering, net" } } }, "localname": "ProceedsFromIssuanceUponFollowOnPublicOfferingNet", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sdgr_ProfessionalServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Professional services.", "label": "Professional Services [Member]", "terseLabel": "Professional Services" } } }, "localname": "ProfessionalServicesMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails" ], "xbrltype": "domainItemType" }, "sdgr_PurchaseOfServicesAndLicenseTechnologyFromRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Purchase of services and license technology from related party.", "label": "Purchase Of Services And License Technology From Related Party", "terseLabel": "Purchase of services and license technology from related party" } } }, "localname": "PurchaseOfServicesAndLicenseTechnologyFromRelatedParty", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_PurchasePriceIncludingUpfrontPurchasePriceAdjustmentForWorkingCapitalLessCashAcquired": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Purchase price including upfront purchase price, adjustment for working capital, less cash acquired.", "label": "Purchase Price Including Upfront Purchase Price Adjustment For Working Capital Less Cash Acquired", "terseLabel": "Purchase price including upfront purchase price, adjustment for working capital, less cash acquired" } } }, "localname": "PurchasePriceIncludingUpfrontPurchasePriceAdjustmentForWorkingCapitalLessCashAcquired", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_RavennaTherapeuticsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ravenna therapeutics.", "label": "Ravenna Therapeutics [Member]", "terseLabel": "Ravenna Therapeutics" } } }, "localname": "RavennaTherapeuticsMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_ReceivableFromCollaboration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivable from collaboration.", "label": "Receivable From Collaboration", "terseLabel": "Receivable from collaboration" } } }, "localname": "ReceivableFromCollaboration", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_ReimbursementsReceivedFromRelatedPartiesForSalesOfProductsAndServicesProvided": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reimbursements received from related parties for sales of products and services provided.", "label": "Reimbursements Received From Related Parties For Sales Of Products And Services Provided", "terseLabel": "Reimbursements received from related parties for sales of products and services provided" } } }, "localname": "ReimbursementsReceivedFromRelatedPartiesForSalesOfProductsAndServicesProvided", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_RelayTherapeuticsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Relay therapeutics, inc.", "label": "Relay Therapeutics Inc [Member]", "terseLabel": "Relay Therapeutics, Inc" } } }, "localname": "RelayTherapeuticsIncMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_ResearchAndDevelopmentAndAdvertisingPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development and advertising policy.", "label": "Research And Development And Advertising Policy [Text Block]", "terseLabel": "Research and Development and Advertising" } } }, "localname": "ResearchAndDevelopmentAndAdvertisingPolicyTextBlock", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "sdgr_ResearchAndDevelopmentNoncashExpense": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10220.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research and development noncash expense.", "label": "Research And Development Noncash Expense", "terseLabel": "Noncash research and development expenses" } } }, "localname": "ResearchAndDevelopmentNoncashExpense", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "sdgr_RevenueFromContractWithCustomerBeforeSoftwareContributionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue from contract with customer before software contribution.", "label": "Revenue From Contract With Customer Before Software Contribution [Member]", "terseLabel": "Revenue From Contract With Customer Before Software Contribution" } } }, "localname": "RevenueFromContractWithCustomerBeforeSoftwareContributionMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails" ], "xbrltype": "domainItemType" }, "sdgr_RevenueRecognizedForDrugDiscovery": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue recognized for drug discovery.", "label": "Revenue Recognized For Drug Discovery", "terseLabel": "Total drug discovery revenue", "verboseLabel": "Drug discovery revenue recognized" } } }, "localname": "RevenueRecognizedForDrugDiscovery", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDrugRevenueRecognitionDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_RevenueRecognizedForMilestonePayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue recognized for milestone payment.", "label": "Revenue Recognized For Milestone Payment", "terseLabel": "Revenue recognized with milestones" } } }, "localname": "RevenueRecognizedForMilestonePayment", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_RightToExchangeEachShareOfLimitedCommonStockToCommonStock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right to exchange each share of limited common stock to common stock.", "label": "Right To Exchange Each Share Of Limited Common Stock To Common Stock", "terseLabel": "Right to exchange limited common stock to common stock, share" } } }, "localname": "RightToExchangeEachShareOfLimitedCommonStockToCommonStock", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "sdgr_RoyaltiesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalties policy.", "label": "Royalties Policy [Text Block]", "terseLabel": "Royalties" } } }, "localname": "RoyaltiesPolicyTextBlock", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "sdgr_SecondAnniversaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second anniversary.", "label": "Second Anniversary [Member]", "terseLabel": "Second Anniversary" } } }, "localname": "SecondAnniversaryMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, aggregate intrinsic value.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value [Abstract]", "terseLabel": "Aggregate intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueAbstract", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "sdgr_ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation arrangement by share-based payment award, weighted average remaining contractual term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted average remaining contractual term (years)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAverageRemainingContractualTermAbstract", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "sdgr_SharebasedCompensationAwardTrancheFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based compensation award tranche four.", "label": "Sharebased Compensation Award Tranche Four [Member]", "terseLabel": "Tranche Four" } } }, "localname": "SharebasedCompensationAwardTrancheFourMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_ShouTiIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ShouTi, Inc.", "label": "Shou Ti Inc [Member]", "terseLabel": "ShouTi" } } }, "localname": "ShouTiIncMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_SignificantAccountingPoliciesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Line Items]", "terseLabel": "Significant Accounting Policies [Line Items]" } } }, "localname": "SignificantAccountingPoliciesLineItems", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sdgr_SignificantAccountingPoliciesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Significant accounting policies.", "label": "Significant Accounting Policies [Table]", "terseLabel": "Significant Accounting Policies [Table]" } } }, "localname": "SignificantAccountingPoliciesTable", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "sdgr_SoftwareContributionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Software contribution.", "label": "Software Contribution [Member]", "terseLabel": "Software Contribution" } } }, "localname": "SoftwareContributionMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails" ], "xbrltype": "domainItemType" }, "sdgr_SoftwareContributionRevenueRecognitionAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Software contribution revenue recognition amount.", "label": "Software Contribution Revenue Recognition Amount", "terseLabel": "Software contribution revenue recognition amount" } } }, "localname": "SoftwareContributionRevenueRecognitionAmount", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_SoftwareContributionRevenueRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Software contribution revenue recognized.", "label": "Software Contribution Revenue Recognized", "terseLabel": "Software contribution revenue recognition" } } }, "localname": "SoftwareContributionRevenueRecognized", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_SoftwareContributionRevenueRelatedToAgreementCoverPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Software contribution revenue related to agreement cover period end date.", "label": "Software Contribution Revenue Related To Agreement Cover Period End Date", "terseLabel": "Software contribution revenue related to agreement cover period end date" } } }, "localname": "SoftwareContributionRevenueRelatedToAgreementCoverPeriodEndDate", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "sdgr_SoftwareContributionRevenueRelatedToAgreementCoverPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Software contribution revenue related to agreement cover period start date.", "label": "Software Contribution Revenue Related To Agreement Cover Period Start Date", "terseLabel": "Software contribution revenue related to agreement cover period start date" } } }, "localname": "SoftwareContributionRevenueRelatedToAgreementCoverPeriodStartDate", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "sdgr_SoftwareContributionRevenueYetToBeEarned": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Software contribution revenue yet to be earned.", "label": "Software Contribution Revenue Yet To Be Earned", "terseLabel": "Additional revenue entitled to receive" } } }, "localname": "SoftwareContributionRevenueYetToBeEarned", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_SoftwareDevelopmentCostsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Software development costs policy.", "label": "Software Development Costs Policy [Text Block]", "terseLabel": "Software Development Costs" } } }, "localname": "SoftwareDevelopmentCostsPolicyTextBlock", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "sdgr_SoftwareProductsAndServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Software products and services.", "label": "Software Products And Services [Member]", "terseLabel": "Software Products and Services" } } }, "localname": "SoftwareProductsAndServicesMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfContractBalancesDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfTimingOfRevenueRecognitionDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "sdgr_SoftwareSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Software Segment.", "label": "Software Segment [Member]", "terseLabel": "Software Segment" } } }, "localname": "SoftwareSegmentMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "sdgr_StockIssuedDuringPeriodSharesSoldBySellingStockholders": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock issued during period shares sold by selling stockholders.", "label": "Stock Issued During Period Shares Sold By Selling Stockholders", "verboseLabel": "Issued and sold shares by selling stockholder" } } }, "localname": "StockIssuedDuringPeriodSharesSoldBySellingStockholders", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "sdgr_TemporaryEquityExchangeOfConvertiblePreferredStockIntoLimitedCommonStockShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity, exchange of convertible preferred stock into limited common stock, shares.", "label": "Temporary Equity Exchange Of Convertible Preferred Stock Into Limited Common Stock Shares", "terseLabel": "Temporary equity, exchange of convertible preferred stock into limited common stock, Shares" } } }, "localname": "TemporaryEquityExchangeOfConvertiblePreferredStockIntoLimitedCommonStockShares", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "sdgr_TemporaryEquityExchangeOfConvertiblePreferredStockIntoLimitedCommonStockValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity exchange of convertible preferred stock into limited common stock, value.", "label": "Temporary Equity Exchange Of Convertible Preferred Stock Into Limited Common Stock Value", "terseLabel": "Temporary equity, exchange of convertible preferred stock into limited common stock" } } }, "localname": "TemporaryEquityExchangeOfConvertiblePreferredStockIntoLimitedCommonStockValue", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "sdgr_TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period shares conversion of convertible securities.", "label": "Temporary Equity Stock Issued During Period Shares Conversion Of Convertible Securities", "terseLabel": "Temporary equity, conversion of convertible preferred stock into common stock, Shares" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "sdgr_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period shares new issues.", "label": "Temporary Equity Stock Issued During Period Shares New Issues", "terseLabel": "Issuance of Series E preferred stock net of issuance costs, Shares" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "sdgr_TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period value conversion of convertible securities.", "label": "Temporary Equity Stock Issued During Period Value Conversion Of Convertible Securities", "terseLabel": "Temporary equity, conversion of convertible preferred stock into common stock" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "sdgr_TemporaryEquityStockIssuedDuringPeriodValueOfIssuanceCosts": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Temporary equity stock issued during period value of issuance costs.", "label": "Temporary Equity Stock Issued During Period Value Of Issuance Costs", "terseLabel": "Issuance of preferred stock value of issuance costs" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueOfIssuanceCosts", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "sdgr_TimingOfRevenueRecognitionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Timing of revenue recognition, percentage.", "label": "Timing Of Revenue Recognition Percentage", "terseLabel": "Timing of revenue recognition" } } }, "localname": "TimingOfRevenueRecognitionPercentage", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfTimingOfRevenueRecognitionDetails" ], "xbrltype": "percentItemType" }, "sdgr_TwoThousandTenStockPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two thousand ten stock plan.", "label": "Two Thousand Ten Stock Plan [Member]", "terseLabel": "2010 Plan" } } }, "localname": "TwoThousandTenStockPlanMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_UnallocatedAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unallocated.", "label": "Unallocated [Abstract]", "terseLabel": "Unallocated:" } } }, "localname": "UnallocatedAbstract", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "sdgr_UnallocatedCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Unallocated common stock.", "label": "Unallocated Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "UnallocatedCommonStockMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "domainItemType" }, "sdgr_UnbilledAndOtherReceivablesCurrent": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10290.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Unbilled and other receivables current.", "label": "Unbilled And Other Receivables Current", "terseLabel": "Unbilled and other receivables, net for allowance for unbilled receivables of $30 and $0" } } }, "localname": "UnbilledAndOtherReceivablesCurrent", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "sdgr_UpfrontPaymentReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Upfront payment received.", "label": "Upfront Payment Received", "terseLabel": "Upfront fee received" } } }, "localname": "UpfrontPaymentReceived", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "sdgr_VotingCommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Voting common stock.", "label": "Voting Common Stock [Member]", "terseLabel": "Voting Common Stock" } } }, "localname": "VotingCommonStockMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "sdgr_XTALBioStructuresIncorporationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "XTAL BioStructures, Incorporation.", "label": "X T A L Bio Structures Incorporation [Member]", "terseLabel": "XTAL BioStructures, Inc" } } }, "localname": "XTALBioStructuresIncorporationMember", "nsuri": "http://www.schrodinger.com/20211231", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r117", "r253", "r258", "r266", "r450", "r451", "r459", "r460", "r531", "r626" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r117", "r253", "r258", "r266", "r450", "r451", "r459", "r460", "r531", "r626" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidationItemsAxis": { "auth_ref": [ "r117", "r161", "r174", "r175", "r176", "r177", "r179", "r181", "r185", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r261", "r263", "r265", "r266" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Axis]", "terseLabel": "Consolidation Items" } } }, "localname": "ConsolidationItemsAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidationItemsDomain": { "auth_ref": [ "r117", "r161", "r174", "r175", "r176", "r177", "r179", "r181", "r185", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r261", "r263", "r265", "r266" ], "lang": { "en-us": { "role": { "label": "Consolidation Items [Domain]", "terseLabel": "Consolidation Items" } } }, "localname": "ConsolidationItemsDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r52", "r54", "r115", "r116", "r269", "r280" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investee Name [Domain]", "terseLabel": "Investment, Name" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_EuropeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Europe [Member]", "terseLabel": "Europe" } } }, "localname": "EuropeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingScheduleOfRevenuesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r192", "r318", "r324", "r595" ], "lang": { "en-us": { "role": { "label": "Major Customers [Axis]", "terseLabel": "Customer" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r268", "r279", "r351", "r353", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r592", "r596", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r268", "r279", "r351", "r353", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r592", "r596", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r192", "r318", "r324", "r595" ], "lang": { "en-us": { "role": { "label": "Name Of Major Customer [Domain]", "terseLabel": "Customer" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r187", "r318", "r322", "r549", "r591", "r593" ], "lang": { "en-us": { "role": { "label": "Product Or Service [Axis]", "terseLabel": "Product and Service" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails1", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfContractBalancesDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDrugRevenueRecognitionDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfTimingOfRevenueRecognitionDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r187", "r318", "r322", "r549", "r591", "r593" ], "lang": { "en-us": { "role": { "label": "Products And Services [Domain]", "terseLabel": "Product and Service" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails1", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfContractBalancesDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDrugRevenueRecognitionDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfTimingOfRevenueRecognitionDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r268", "r279", "r330", "r351", "r353", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r592", "r596", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Range [Axis]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r268", "r279", "r330", "r351", "r353", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r592", "r596", "r627", "r628" ], "lang": { "en-us": { "role": { "label": "Range [Member]", "terseLabel": "Statistical Measurement" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r53", "r54", "r115", "r116", "r269", "r280" ], "lang": { "en-us": { "role": { "label": "Repurchase Agreement Counterparty Name [Domain]", "terseLabel": "Counterparty Name" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "label": "Schedule Of Equity Method Investment Equity Method Investee Name [Axis]", "terseLabel": "Investment, Name" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r188", "r189", "r318", "r323", "r594", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625" ], "lang": { "en-us": { "role": { "label": "Segment Geographical [Domain]", "terseLabel": "Geographical" } } }, "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingScheduleOfRevenuesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r188", "r189", "r318", "r323", "r594", "r611", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625" ], "lang": { "en-us": { "role": { "label": "Statement Geographical [Axis]", "terseLabel": "Geographical" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingScheduleOfRevenuesByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_AccountingStandardsUpdate201613Member": { "auth_ref": [ "r217" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments.", "label": "Accounting Standards Update201613 [Member]", "terseLabel": "ASU - 2016-13" } } }, "localname": "AccountingStandardsUpdate201613Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate201815Member": { "auth_ref": [ "r232", "r233" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2018-15 Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract (a consensus of the FASB Emerging Issues Task Force).", "label": "Accounting Standards Update201815 [Member]", "terseLabel": "2018-15" } } }, "localname": "AccountingStandardsUpdate201815Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingStandardsUpdate202001Member": { "auth_ref": [ "r496", "r497", "r498", "r499" ], "lang": { "en-us": { "role": { "documentation": "Accounting Standards Update 2020-01 Investments - Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815): Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the Emerging Issues Task Force).", "label": "Accounting Standards Update202001 [Member]", "terseLabel": "ASU - 2020-01" } } }, "localname": "AccountingStandardsUpdate202001Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r40", "r534" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10150.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r612" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r9", "r25", "r194", "r195" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10280.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable Net Current", "terseLabel": "Accounts receivable, net of allowance for doubtful accounts of $108 and $60" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedPayrollTaxesCurrent": { "auth_ref": [ "r16", "r43" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10160.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Payroll Taxes Current", "terseLabel": "Accrued payroll, taxes, and benefits" } } }, "localname": "AccruedPayrollTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r38", "r237" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails": { "order": 10020.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment", "negatedLabel": "Less accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r28", "r57", "r58", "r59", "r580", "r604", "r608" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10100.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income Loss Net Of Tax", "terseLabel": "Accumulated other comprehensive (loss) income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r56", "r59", "r66", "r67", "r68", "r119", "r120", "r121", "r457", "r599", "r600", "r645" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "Accumulated Other Comprehensive Income [Member]", "terseLabel": "Accumulated Other Comprehensive Loss (Income)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r26" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10080.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid In Capital Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r119", "r120", "r121", "r390", "r391", "r392", "r475" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid In Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r123", "r124", "r125", "r126", "r135", "r204", "r205", "r221", "r222", "r223", "r224", "r226", "r227", "r252", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r427", "r428", "r429", "r430", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r493", "r494", "r496", "r497", "r498", "r499", "r500", "r501", "r522", "r550", "r551", "r552", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r641", "r642", "r643", "r644", "r645" ], "lang": { "en-us": { "role": { "documentation": "Information by amendment to accounting standards.", "label": "Adjustments For New Accounting Pronouncements [Axis]", "terseLabel": "Accounting Standards Update" } } }, "localname": "AdjustmentsForNewAccountingPronouncementsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r355", "r356", "r396", "r397" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value", "terseLabel": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash (used in) provided by" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r356", "r382", "r395" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Allocated Share Based Compensation Expense", "terseLabel": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfClassificationOfStockBasedCompensationExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r32", "r200", "r228" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Allowance For Doubtful Accounts Receivable Current", "terseLabel": "Allowance for doubtful accounts receivable" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsAntiDilutiveDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsAntiDilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsAntiDilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities Name [Domain]", "terseLabel": "Antidilutive Securities, Name" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsAntiDilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Arrangements And Nonarrangement Transactions [Member]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r109", "r169", "r176", "r183", "r215", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r450", "r459", "r492", "r532", "r534", "r568", "r579" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r12", "r14", "r51", "r109", "r215", "r253", "r254", "r255", "r257", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r450", "r459", "r492", "r532", "r534" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10200.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r478" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets Fair Value Disclosure", "terseLabel": "Total Assets" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r350", "r352" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r350", "r352", "r443", "r444" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "auth_ref": [ "r7", "r118", "r155" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Business Description And Basis Of Presentation [Text Block]", "terseLabel": "Description of Business" } } }, "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r101", "r102", "r103" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred But Not Yet Paid", "terseLabel": "Purchases of property and equipment in accounts payable" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r8", "r34", "r99" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10250.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash And Cash Equivalents At Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r94", "r99", "r104" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents and restricted cash, end of year", "periodStartLabel": "Cash and cash equivalents and restricted cash, beginning of year" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r94", "r502" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashEquivalentsAtCarryingValue": { "auth_ref": [ "r34" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash Equivalents At Carrying Value", "terseLabel": "Cash equivalents" } } }, "localname": "CashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activities" } } }, "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted": { "auth_ref": [ "r0", "r1", "r119", "r120", "r122", "r204", "r205", "r218", "r219", "r220", "r221", "r222", "r252", "r386", "r387", "r388", "r427", "r466", "r467", "r468", "r493", "r495", "r496", "r497", "r500", "r501", "r511", "r522", "r550", "r551", "r597", "r598", "r641" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether accounting standards update was adopted.", "label": "Change In Accounting Principle Accounting Standards Update Adopted", "terseLabel": "Change in accounting principle, accounting standards update, adopted" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdopted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate": { "auth_ref": [ "r0", "r1", "r119", "r120", "r129", "r204", "r205", "r218", "r219", "r220", "r221", "r222", "r252", "r386", "r387", "r388", "r427", "r466", "r467", "r468", "r469", "r472", "r493", "r495", "r496", "r497", "r500", "r501", "r511", "r522", "r550", "r551", "r597", "r598", "r641" ], "lang": { "en-us": { "role": { "documentation": "Date accounting standards update was adopted, in YYYY-MM-DD format.", "label": "Change In Accounting Principle Accounting Standards Update Adoption Date", "terseLabel": "Change in accounting principle, accounting standards update, adoption date" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateAdoptionDate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect": { "auth_ref": [ "r123", "r134", "r206", "r225", "r393", "r431" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether effect from applying amendment to accounting standards is immaterial.", "label": "Change In Accounting Principle Accounting Standards Update Immaterial Effect", "terseLabel": "Change in accounting principle, accounting standards update, immaterial effect" } } }, "localname": "ChangeInAccountingPrincipleAccountingStandardsUpdateImmaterialEffect", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r107", "r109", "r136", "r137", "r138", "r140", "r142", "r148", "r149", "r150", "r215", "r253", "r258", "r259", "r260", "r266", "r267", "r277", "r278", "r282", "r286", "r492", "r638" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class Of Stock [Domain]", "terseLabel": "Class of Stock" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsAntiDilutiveDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class Of Stock [Line Items]", "terseLabel": "Class Of Stock [Line Items]" } } }, "localname": "ClassOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CoVenturerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other venturer from the perspective of the entity in the corporate joint venture.", "label": "Co Venturer [Member]", "terseLabel": "WuXi AppTech" } } }, "localname": "CoVenturerMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CommissionsPolicy": { "auth_ref": [ "r566", "r567" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fees earned by the broker dealer, acting as an agent in the buying and selling of securities and administrative efforts on behalf of customers and may include the timing of commission revenue recognition and presentation in the financial statements. Commissions earned are usually related to the broker dealer's customers' trading volume and the dollar amounts of the trades.", "label": "Commissions Policy", "terseLabel": "Commissions" } } }, "localname": "CommissionsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r46", "r249", "r571", "r585" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments And Contingencies", "terseLabel": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments And Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r246", "r247", "r248", "r250", "r613" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments And Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r119", "r120", "r475" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock Par Or Stated Value Per Share", "terseLabel": "Common stock, par value", "verboseLabel": "Offering price per share" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock Shares Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r24", "r293" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock Shares Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r24", "r534" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10060.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock Value", "terseLabel": "Common stock" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Compensation And Retirement Disclosure [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r61", "r63", "r64", "r73", "r575", "r588" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income Net Of Tax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income Policy Policy [Text Block]", "terseLabel": "Comprehensive Loss" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computers and Equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r153", "r154", "r192", "r490", "r491", "r612" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r153", "r154", "r192", "r490", "r491", "r609", "r612" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk By Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r153", "r154", "r192", "r490", "r491", "r609", "r612" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk By Type [Axis]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r151", "r578" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk Credit Risk", "terseLabel": "Concentrations" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r153", "r154", "r192", "r490", "r491" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk Percentage1", "terseLabel": "Concentration risk, percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r153", "r154", "r192", "r490", "r491", "r612" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r106", "r452" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation Policy [Text Block]", "terseLabel": "Principles of Consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.", "label": "Contract With Customer Asset And Liability Table [Text Block]", "terseLabel": "Schedule of Contract Balances" } } }, "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerAssetNet": { "auth_ref": [ "r303", "r305", "r319" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.", "label": "Contract With Customer Asset Net", "terseLabel": "Contract assets" } } }, "localname": "ContractWithCustomerAssetNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfContractBalancesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerDurationAxis": { "auth_ref": [ "r318", "r326" ], "lang": { "en-us": { "role": { "documentation": "Information by duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract With Customer Duration [Axis]", "terseLabel": "Contract with Customer, Duration" } } }, "localname": "ContractWithCustomerDurationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ContractWithCustomerDurationDomain": { "auth_ref": [ "r318", "r326" ], "lang": { "en-us": { "role": { "documentation": "Duration of contract with customer. Includes, but is not limited to, short-term and long-term contracts.", "label": "Contract With Customer Duration [Domain]", "terseLabel": "Contract with Customer, Duration" } } }, "localname": "ContractWithCustomerDurationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ContractWithCustomerLiability": { "auth_ref": [ "r303", "r304", "r319" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract With Customer Liability", "terseLabel": "Deferred revenue" } } }, "localname": "ContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "auth_ref": [ "r320" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.", "label": "Contract With Customer Liability Revenue Recognized", "terseLabel": "Deferred revenue, revenue recognized" } } }, "localname": "ContractWithCustomerLiabilityRevenueRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockAmountConverted1": { "auth_ref": [ "r101", "r102", "r103" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion Of Stock Amount Converted1", "terseLabel": "Conversion of limited common stock into common stock" } } }, "localname": "ConversionOfStockAmountConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockSharesConverted1": { "auth_ref": [ "r101", "r102", "r103" ], "lang": { "en-us": { "role": { "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion Of Stock Shares Converted1", "terseLabel": "Conversion of limited common stock into common stock, Shares" } } }, "localname": "ConversionOfStockSharesConverted1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ConvertiblePreferredStockMember": { "auth_ref": [ "r277", "r278", "r282" ], "lang": { "en-us": { "role": { "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.", "label": "Convertible Preferred Stock [Member]", "terseLabel": "Preferred Stock", "verboseLabel": "Convertible Preferred Stock" } } }, "localname": "ConvertiblePreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsAntiDilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r80", "r109", "r215", "r253", "r254", "r255", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r492" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10160.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost Of Revenue", "terseLabel": "Total cost of revenues" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost Of Revenue [Abstract]", "terseLabel": "Cost of revenues:" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfSalesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing cost of sales.", "label": "Cost Of Sales [Member]", "terseLabel": "Cost of Sales" } } }, "localname": "CostOfSalesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfClassificationOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "auth_ref": [ "r110", "r423", "r434" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails": { "order": 10050.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Federal Tax Expense Benefit", "terseLabel": "Federal" } } }, "localname": "CurrentFederalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "auth_ref": [ "r110", "r423" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails": { "order": 10070.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current Foreign Tax Expense Benefit", "terseLabel": "Foreign" } } }, "localname": "CurrentForeignTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "auth_ref": [ "r110", "r423", "r434", "r435" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails": { "order": 10010.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.", "label": "Current Income Tax Expense Benefit", "totalLabel": "Current income tax expense (benefit)" } } }, "localname": "CurrentIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Income Tax Expense Benefit Continuing Operations [Abstract]", "terseLabel": "Current:" } } }, "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "auth_ref": [ "r110", "r423", "r434" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails": { "order": 10060.0, "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Current State And Local Tax Expense Benefit", "terseLabel": "State" } } }, "localname": "CurrentStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r152", "r192" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction": { "auth_ref": [ "r101", "r102", "r103" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of debt issuance costs that were incurred during a noncash or partial noncash transaction.", "label": "Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction", "terseLabel": "Accrued deferred offering costs" } } }, "localname": "DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "auth_ref": [ "r110", "r424", "r434" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails": { "order": 10030.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal Income Tax Expense Benefit", "terseLabel": "Federal" } } }, "localname": "DeferredFederalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails": { "order": 10020.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Federal State And Local Tax Expense Benefit", "totalLabel": "Deferred income tax expense (benefit)" } } }, "localname": "DeferredFederalStateAndLocalTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense Benefit Continuing Operations [Abstract]", "terseLabel": "Deferred:" } } }, "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenue": { "auth_ref": [ "r33" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueAndCreditsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Revenue And Credits Current [Abstract]", "terseLabel": "Deferred revenue, short-term:" } } }, "localname": "DeferredRevenueAndCreditsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueAndCreditsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Revenue And Credits Noncurrent [Abstract]", "terseLabel": "Deferred revenue, long-term:" } } }, "localname": "DeferredRevenueAndCreditsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfContractBalancesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredRevenueCurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10170.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.", "label": "Deferred Revenue Current", "terseLabel": "Deferred revenue" } } }, "localname": "DeferredRevenueCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfContractBalancesDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredRevenueNoncurrent": { "auth_ref": [ "r33" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10120.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.", "label": "Deferred Revenue Noncurrent", "terseLabel": "Deferred revenue, long-term" } } }, "localname": "DeferredRevenueNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfContractBalancesDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "auth_ref": [ "r110", "r424", "r434" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails": { "order": 10040.0, "parentTag": "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred State And Local Income Tax Expense Benefit", "terseLabel": "State" } } }, "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsDeferredIncome": { "auth_ref": [ "r421", "r422" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails": { "order": 10090.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.", "label": "Deferred Tax Assets Deferred Income", "terseLabel": "Deferred Revenue" } } }, "localname": "DeferredTaxAssetsDeferredIncome", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsGross": { "auth_ref": [ "r415" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails": { "order": 10050.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Gross", "totalLabel": "Gross deferred tax assets" } } }, "localname": "DeferredTaxAssetsGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r417" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Deferred Tax Assets Liabilities Net", "totalLabel": "Net deferred income tax assets" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r417" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails": { "order": 10010.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets Net", "totalLabel": "Net deferred tax assets" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets Net Of Valuation Allowance [Abstract]", "terseLabel": "Deferred income tax assets:" } } }, "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r421", "r422" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails": { "order": 10070.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": { "auth_ref": [ "r421", "r422" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards Domestic", "terseLabel": "Federal net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": { "auth_ref": [ "r421", "r422" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.", "label": "Deferred Tax Assets Operating Loss Carryforwards State And Local", "terseLabel": "State net operating loss carryforwards" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "auth_ref": [ "r420", "r421", "r422" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails": { "order": 10110.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards", "terseLabel": "Credits" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "auth_ref": [ "r420", "r421", "r422" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.", "label": "Deferred Tax Assets Tax Credit Carryforwards Research", "terseLabel": "Research and development tax credit carryforwards" } } }, "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": { "auth_ref": [ "r421", "r422" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails": { "order": 10080.0, "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.", "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities", "terseLabel": "Accrued expenses" } } }, "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r416" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails": { "order": 10060.0, "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets Valuation Allowance", "negatedLabel": "Less valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities [Abstract]", "terseLabel": "Deferred income tax liabilities:" } } }, "localname": "DeferredTaxLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails": { "order": 10030.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.", "label": "Deferred Tax Liabilities Prepaid Expenses", "negatedLabel": "Prepaid expenses" } } }, "localname": "DeferredTaxLiabilitiesPrepaidExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities": { "auth_ref": [ "r421", "r422" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails": { "order": 10020.0, "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from unrealized gains on trading securities.", "label": "Deferred Tax Liabilities Unrealized Gains On Trading Securities", "negatedLabel": "Unrealized gain on equity investments" } } }, "localname": "DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfTaxEffectsOfTemporaryDifferencesThatGiveRiseToSignificantPortionsOfDeferredIncomeTaxAssetsAndDeferredIncomeTaxLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan Cost Recognized", "terseLabel": "Matching contributions" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan Employer Matching Contribution Percent", "terseLabel": "Discretionary matching contributions" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan Employer Matching Contribution Percent Of Match", "terseLabel": "Discretionary matching contributed by employees" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r97", "r235" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r97", "r164" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10200.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation Depletion And Amortization", "terseLabel": "Depreciation" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of defined contribution pension and other postretirement plans.", "label": "Description Of Defined Contribution Pension And Other Postretirement Plans", "terseLabel": "Plan name" } } }, "localname": "DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation Of Revenue [Line Items]", "terseLabel": "Disaggregation Of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfContractBalancesDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDrugRevenueRecognitionDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfTimingOfRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r318", "r322", "r323", "r324", "r325", "r326", "r327", "r328" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue [Table]", "terseLabel": "Disaggregation Of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfContractBalancesDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfDrugRevenueRecognitionDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfTimingOfRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation Of Revenue Table [Text Block]", "terseLabel": "Schedule of Revenue Recognized from the Sources of Software Products and Services Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r398" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_DomesticCountryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.", "label": "Domestic Country [Member]", "terseLabel": "Federal" } } }, "localname": "DomesticCountryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasicAndDiluted": { "auth_ref": [ "r141" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share Basic And Diluted", "terseLabel": "Net loss per share attributable to Schr\u00f6dinger common and limited common stockholders, basic and diluted:" } } }, "localname": "EarningsPerShareBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonAndLimitedStockholdersDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r143", "r144" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share Policy [Text Block]", "terseLabel": "Net (Loss) Income per Share Attributable to Common and Limited Common Stockholders" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r143", "r144", "r145", "r146" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss per Share Attributable to Common and Limited Stockholders" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholders" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r404" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Continuing Operations", "totalLabel": "Effective income tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r112", "r404", "r437" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails": { "order": 10010.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate", "terseLabel": "Statutory federal income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r404", "r437" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails": { "order": 10090.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "auth_ref": [ "r404", "r437" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails": { "order": 10050.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.", "label": "Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost", "terseLabel": "Stock compensation" } } }, "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r404", "r437" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails": { "order": 10100.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Effective Income Tax Rate Reconciliation Other Adjustments", "terseLabel": "Other" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r404", "r437" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails": { "order": 10020.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "Effective Income Tax Rate Reconciliation State And Local Income Taxes", "terseLabel": "State taxes, net of federal benefits" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxContingencies": { "auth_ref": [ "r404", "r437" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails": { "order": 10080.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": -1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax contingencies. Includes, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.", "label": "Effective Income Tax Rate Reconciliation Tax Contingencies", "negatedLabel": "Tax contingencies, net of reversals" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxContingencies", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": { "auth_ref": [ "r404", "r437" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails": { "order": 10070.0, "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.", "label": "Effective Income Tax Rate Reconciliation Tax Credits Research", "terseLabel": "Research and development credit" } } }, "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfIncomeTaxExpenseApplicableStatutoryIncomeTaxRatesToEffectiveIncomeTaxRateDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "terseLabel": "Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]", "verboseLabel": "Employee Service Share Based Compensation Allocation of Recognized Period Costs [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfClassificationOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r383" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options", "terseLabel": "Unrecognized compensation cost related to unvested stock options granted" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [ "r380" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Employee Stock Option [Member]", "terseLabel": "Shares Subject to Outstanding Common Stock Options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsAntiDilutiveDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r2", "r66", "r67", "r68", "r119", "r120", "r121", "r124", "r131", "r133", "r147", "r224", "r293", "r300", "r390", "r391", "r392", "r429", "r430", "r475", "r503", "r504", "r505", "r506", "r507", "r508", "r599", "r600", "r601", "r645" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r212" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity Method Investment Ownership Percentage", "terseLabel": "Equity method investment, ownership percentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": { "auth_ref": [ "r75", "r76", "r97" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.", "label": "Equity Method Investment Realized Gain Loss On Disposal", "negatedLabel": "Loss on sale of equity method investments" } } }, "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestments": { "auth_ref": [ "r35", "r170", "r211" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10220.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.", "label": "Equity Method Investments", "terseLabel": "Equity investments" } } }, "localname": "EquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity Method Investments And Joint Ventures [Abstract]" } } }, "localname": "EquityMethodInvestmentsAndJointVenturesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.", "label": "Equity Method Investments Disclosure [Text Block]", "terseLabel": "Equity Investments" } } }, "localname": "EquityMethodInvestmentsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestments" ], "xbrltype": "textBlockItemType" }, "us-gaap_EquityMethodInvestmentsMember": { "auth_ref": [ "r210" ], "lang": { "en-us": { "role": { "documentation": "Investment in the stock of an investee which is adjusted for the investor's share of the earnings or losses of the investee after the date of acquisition.", "label": "Equity Method Investments [Member]", "terseLabel": "Equity Investments" } } }, "localname": "EquityMethodInvestmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentsPolicy": { "auth_ref": [ "r35", "r93", "r213", "r492" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.", "label": "Equity Method Investments Policy", "terseLabel": "Equity Investments" } } }, "localname": "EquityMethodInvestmentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsLevel1ToLevel2TransfersAmount": { "auth_ref": [ "r480" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.", "label": "Fair Value Assets Level1 To Level2 Transfers Amount", "terseLabel": "Fair value, assets, Level 1 to Level 2 transfers, amount" } } }, "localname": "FairValueAssetsLevel1ToLevel2TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsLevel2ToLevel1TransfersAmount": { "auth_ref": [ "r480" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.", "label": "Fair Value Assets Level2 To Level1 Transfers Amount", "terseLabel": "Fair value, assets, Level 2 to Level 1 transfers, amount" } } }, "localname": "FairValueAssetsLevel2ToLevel1TransfersAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss": { "auth_ref": [ "r483" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3) and still held.", "label": "Fair Value Assets Measured On Recurring Basis Change In Unrealized Gain Loss", "terseLabel": "Unrealized loss" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisChangeInUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]", "terseLabel": "Asset Class" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r481", "r485" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]", "terseLabel": "Summary of Changes in Fair Value of Level 3 Investments" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]", "terseLabel": "Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]" } } }, "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r478", "r485" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Fair Value By Asset Class [Axis]", "terseLabel": "Asset Class" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "auth_ref": [ "r478", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.", "label": "Fair Value By Balance Sheet Grouping [Table]", "terseLabel": "Fair Value By Balance Sheet Grouping [Table]" } } }, "localname": "FairValueByBalanceSheetGroupingTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r270", "r272", "r273", "r331", "r333", "r334", "r335", "r336", "r337", "r338", "r346", "r479", "r538", "r539", "r540" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value By Fair Value Hierarchy Level [Axis]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurements" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r270", "r331", "r333", "r338", "r346", "r479", "r538" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value Inputs Level1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r270", "r272", "r273", "r331", "r333", "r338", "r346", "r479", "r539" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value Inputs Level2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r270", "r272", "r273", "r331", "r333", "r334", "r335", "r336", "r337", "r338", "r346", "r479", "r540" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Inputs Level3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": { "auth_ref": [ "r482" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3", "terseLabel": "Fair value, asset transfers into Level 3" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r481" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsSummaryOfChangesInFairValueOfLevel3InvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r270", "r272", "r273", "r331", "r333", "r334", "r335", "r336", "r337", "r338", "r346", "r538", "r539", "r540" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Measurements Fair Value Hierarchy [Domain]", "terseLabel": "Fair Value Hierarchy and NAV" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r486", "r487" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value Of Financial Instruments Policy", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture And Fixtures [Member]", "terseLabel": "Furniture and Fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r97" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10240.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain Loss On Sale Of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r82" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails": { "order": 10040.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10140.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General And Administrative Expense", "negatedLabel": "General and administrative", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General And Administrative Expense [Member]", "terseLabel": "General and Administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfClassificationOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r78", "r109", "r169", "r175", "r179", "r182", "r185", "r215", "r253", "r254", "r255", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r492" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails": { "order": 10010.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10100.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Total segment gross profit", "totalLabel": "Gross profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GrossProfitAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Gross Profit [Abstract]", "terseLabel": "Segment gross profit:" } } }, "localname": "GrossProfitAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IPOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First sale of stock by a private company to the public.", "label": "I P O [Member]", "terseLabel": "Initial Public Offering" } } }, "localname": "IPOMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": { "auth_ref": [ "r97", "r234", "r239" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).", "label": "Impairment Of Long Lived Assets Held For Use", "terseLabel": "Impairment of long-lived assets" } } }, "localname": "ImpairmentOfLongLivedAssetsHeldForUse", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment Or Disposal Of Long Lived Assets Including Intangible Assets Policy Policy [Text Block]", "terseLabel": "Accounting for the Impairment of Long Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": { "auth_ref": [ "r111", "r436" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByTaxJurisdictionDetails": { "order": 10010.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.", "label": "Income Loss From Continuing Operations Before Income Taxes Domestic", "terseLabel": "United States" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByTaxJurisdictionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r70", "r169", "r175", "r179", "r182", "r185", "r565", "r573", "r576", "r589" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10030.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": { "auth_ref": [ "r111", "r436" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByTaxJurisdictionDetails": { "order": 10020.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.", "label": "Income Loss From Continuing Operations Before Income Taxes Foreign", "terseLabel": "Foreign" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByTaxJurisdictionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r169", "r175", "r179", "r182", "r185" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByTaxJurisdictionDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.", "label": "Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments", "totalLabel": "Loss before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfComponentsOfLossBeforeIncomeTaxesByTaxJurisdictionDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "auth_ref": [ "r71", "r97", "r166", "r211", "r572", "r586" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails": { "order": 10050.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10170.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10070.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).", "label": "Income Loss From Equity Method Investments", "negatedLabel": "Loss (gain) on equity investments", "positiveTerseLabel": "Equity investments gains (losses)", "terseLabel": "(Loss) gain on equity investments" } } }, "localname": "IncomeLossFromEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r240", "r243" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfClassificationOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfClassificationOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r407" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]", "terseLabel": "Income Tax Authority" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r408", "r412", "r414", "r426" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r112", "r405", "r413", "r419", "r432", "r438", "r440", "r441", "r442" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationDescription": { "auth_ref": [ "r406" ], "lang": { "en-us": { "role": { "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.", "label": "Income Tax Examination Description", "terseLabel": "Income tax examination, description" } } }, "localname": "IncomeTaxExaminationDescription", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r113", "r132", "r133", "r167", "r403", "r433", "r439", "r590" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails": { "order": 10080.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10040.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense Benefit", "negatedLabel": "Income tax (expense) benefit", "terseLabel": "Income tax expense (benefit)", "totalLabel": "Income Tax Expense (Benefit), Total" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesSummaryOfIncomeTaxExpenseDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r65", "r401", "r402", "r413", "r414", "r418", "r425" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax Policy [Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r404" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r100" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income Taxes Paid Net", "terseLabel": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r96" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10290.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase Decrease In Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r96" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10250.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase Decrease In Accounts Receivable", "negatedLabel": "Accounts receivable, net" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredRevenue": { "auth_ref": [ "r96" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10310.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.", "label": "Increase Decrease In Deferred Revenue", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": { "auth_ref": [ "r96" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10300.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Increase Decrease In Employee Related Liabilities", "terseLabel": "Accrued payroll, taxes, and benefits" } } }, "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": { "auth_ref": [ "r91", "r209" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails": { "order": 10060.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10190.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10080.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Increase Decrease In Equity Securities Fv Ni", "negatedLabel": "Fair value adjustments", "terseLabel": "Change in fair value" } } }, "localname": "IncreaseDecreaseInEquitySecuritiesFvNi", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Assets [Abstract]", "terseLabel": "Decrease (increase) in assets:" } } }, "localname": "IncreaseDecreaseInOperatingAssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase Decrease In Operating Liabilities [Abstract]", "terseLabel": "(Decrease) increase in liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingLiabilitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccruedLiabilities": { "auth_ref": [ "r96" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10330.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in other expenses incurred but not yet paid.", "label": "Increase Decrease In Other Accrued Liabilities", "terseLabel": "Other accrued liabilities" } } }, "localname": "IncreaseDecreaseInOtherAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r96" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10280.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets", "negatedLabel": "Prepaid expenses and other assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestCostsCapitalized": { "auth_ref": [ "r510" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest capitalized during the period.", "label": "Interest Costs Capitalized", "terseLabel": "Interest costs capitalized" } } }, "localname": "InterestCostsCapitalized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r83", "r162" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails": { "order": 10070.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10090.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income Interest", "terseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r519", "r521" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease Cost", "terseLabel": "Lease costs" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r519" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease Cost Table [Text Block]", "terseLabel": "Summary of Operating Leases" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseExpirationDate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.", "label": "Lease Expiration Date1", "terseLabel": "Lease expiration date" } } }, "localname": "LeaseExpirationDate1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold Improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LesseeLeaseDescriptionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Lessee Lease Description [Line Items]", "terseLabel": "Lessee Lease Description [Line Items]" } } }, "localname": "LesseeLeaseDescriptionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeLeaseDescriptionTable": { "auth_ref": [ "r515" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about lessee's leases.", "label": "Lessee Lease Description [Table]", "terseLabel": "Lessee Lease Description [Table]" } } }, "localname": "LesseeLeaseDescriptionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r520" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee Operating Lease Liability Maturity Table [Text Block]", "terseLabel": "Summary of Maturities of Operating Lease Liabilities Under Noncancelable Operating Leases" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r520" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails2": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee Operating Lease Liability Payments Due", "totalLabel": "Total future minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "auth_ref": [ "r520" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": { "order": 10080.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due After Year Five", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r520" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": { "order": 10030.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months", "terseLabel": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": { "auth_ref": [ "r520" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": { "order": 10070.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Five", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r520" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": { "order": 10060.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Four", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r520" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": { "order": 10050.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Three", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r520" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": { "order": 10040.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee Operating Lease Liability Payments Due Year Two", "terseLabel": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r520" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails2": { "order": 10010.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee Operating Lease Liability Undiscounted Excess Amount", "negatedLabel": "Less: imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r41", "r109", "r177", "r215", "r253", "r254", "r255", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r451", "r459", "r460", "r492", "r532", "r533" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10010.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r31", "r109", "r215", "r492", "r534", "r570", "r583" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities And Stockholders Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r44", "r109", "r215", "r253", "r254", "r255", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r451", "r459", "r460", "r492", "r532", "r533", "r534" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10110.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MaintenanceMember": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Process of preserving asset, including, but not limited to, building, machinery and software.", "label": "Maintenance [Member]", "terseLabel": "Software Maintenance" } } }, "localname": "MaintenanceMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [ "r10", "r42" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10270.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable Securities Current", "terseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r50", "r109", "r215", "r253", "r258", "r259", "r260", "r266", "r267", "r492", "r569", "r582" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10040.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Minority Interest", "terseLabel": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestDisclosureTextBlock": { "auth_ref": [ "r465" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Minority Interest Disclosure [Text Block]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "MinorityInterestDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterest" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterestLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Minority Interest [Line Items]", "terseLabel": "Minority Interest [Line Items]" } } }, "localname": "MinorityInterestLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Minority Interest Ownership Percentage By Noncontrolling Owners", "terseLabel": "Equity interest percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestTable": { "auth_ref": [ "r50", "r79", "r447", "r458" ], "lang": { "en-us": { "role": { "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.", "label": "Minority Interest [Table]", "terseLabel": "Minority Interest [Table]" } } }, "localname": "MinorityInterestTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10030.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided By Used In Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10020.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided By Used In Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r94", "r95", "r98" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10010.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided By Used In Operating Activities", "totalLabel": "Net cash (used in) provided by operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided By Used In Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r6", "r60", "r62", "r68", "r72", "r98", "r109", "r123", "r127", "r128", "r129", "r130", "r132", "r133", "r139", "r169", "r175", "r179", "r182", "r185", "r215", "r253", "r254", "r255", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r477", "r492", "r574", "r587" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 10010.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income Loss", "terseLabel": "Net loss attributable to Schr\u00f6dinger common and limited common stockholders", "totalLabel": "Net loss attributable to Schr\u00f6dinger common and limited common stockholders" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonAndLimitedStockholdersDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Income Loss [Abstract]", "terseLabel": "Numerator:" } } }, "localname": "NetIncomeLossAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonAndLimitedStockholdersDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r60", "r62", "r68", "r132", "r133", "r454", "r463" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10020.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income Loss Attributable To Noncontrolling Interest", "terseLabel": "Net loss attributable to noncontrolling interest" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements Policy Policy [Text Block]", "terseLabel": "Recently Issued Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonUsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Countries excluding the United States of America (US).", "label": "Non Us [Member]", "terseLabel": "Rest of World" } } }, "localname": "NonUsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingScheduleOfRevenuesByGeographicAreaDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Noncontrolling Interest [Abstract]" } } }, "localname": "NoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": { "auth_ref": [ "r301", "r449", "r456" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.", "label": "Noncontrolling Interest Increase From Subsidiary Equity Issuance", "terseLabel": "Contributions by noncontrolling interest" } } }, "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r119", "r120", "r121", "r300", "r446" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non Controlling Interest" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r84" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10060.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income Expense", "totalLabel": "Total other income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income Expense [Abstract]", "terseLabel": "Other income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number Of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10110.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r169", "r175", "r179", "r182", "r185" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10050.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income Loss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r516", "r521" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease Cost", "terseLabel": "Operating lease costs" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r513" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails2": { "order": 10020.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease Liability", "totalLabel": "Present value of future minimum lease payments" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r513" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": { "order": 10010.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10180.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease Liability Current", "negatedLabel": "Less: current portion of operating leases payments", "terseLabel": "Lease liabilities" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r513" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails": { "order": 10020.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10130.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease Liability Noncurrent", "terseLabel": "Lease liabilities, long-term" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfMaturitiesOfOperatingLeaseLiabilitiesUnderNoncancelableOperatingLeasesDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r514", "r517" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease Payments", "terseLabel": "Cash paid for operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfOperatingLeasesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r512" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10230.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease Right Of Use Asset", "terseLabel": "Right of use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r518", "r521" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease Weighted Average Remaining Lease Term1", "terseLabel": "Operating lease, weighted average lease term" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OperatingSegmentsMember": { "auth_ref": [ "r174", "r175", "r176", "r177", "r179", "r185" ], "lang": { "en-us": { "role": { "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Operating Segments [Member]", "terseLabel": "Operating Segments" } } }, "localname": "OperatingSegmentsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r15", "r16", "r17", "r43" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10190.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities Current", "terseLabel": "Other accrued liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r39" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10240.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income Available For Sale Securities Adjustment Net Of Tax Period Increase Decrease [Abstract]", "terseLabel": "Changes in market value of investments, net of tax:" } } }, "localname": "OtherComprehensiveIncomeAvailableForSaleSecuritiesAdjustmentNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "auth_ref": [ "r55", "r57" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "order": 10020.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax", "terseLabel": "Unrealized (loss) gain on marketable securities", "verboseLabel": "Change in unrealized loss on marketable securities" } } }, "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLiabilitiesNoncurrent": { "auth_ref": [ "r45" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10140.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.", "label": "Other Liabilities Noncurrent", "terseLabel": "Other liabilities, long-term" } } }, "localname": "OtherLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OverAllotmentOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.", "label": "Over Allotment Option [Member]", "terseLabel": "Underwriter" } } }, "localname": "OverAllotmentOptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsOfFinancingCosts": { "auth_ref": [ "r90" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10090.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for loan and debt issuance costs.", "label": "Payments Of Financing Costs", "negatedLabel": "Deferred offering costs" } } }, "localname": "PaymentsOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfStockIssuanceCosts": { "auth_ref": [ "r90" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Payments Of Stock Issuance Costs", "terseLabel": "Common stock issuance costs" } } }, "localname": "PaymentsOfStockIssuanceCosts", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": { "auth_ref": [ "r86" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.", "label": "Payments To Acquire Businesses Net Of Cash Acquired", "terseLabel": "Payments to acquire businesses, et of cash acquired" } } }, "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireEquityMethodInvestments": { "auth_ref": [ "r86" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10110.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Payments To Acquire Equity Method Investments", "negatedLabel": "Purchases of equity investments", "terseLabel": "Cash payments to purchase of shares" } } }, "localname": "PaymentsToAcquireEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r207" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10140.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments To Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r87" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10100.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments To Acquire Property Plant And Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r330", "r332", "r338", "r339", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r354" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Pension And Other Postretirement Benefits Disclosure [Text Block]", "terseLabel": "Employee Benefit Plan" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEmployeeBenefitPlan" ], "xbrltype": "textBlockItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r357", "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r23", "r277" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock Par Or Stated Value Per Share", "terseLabel": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock Shares Authorized", "terseLabel": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r23", "r277" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock Shares Issued", "terseLabel": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r23", "r534" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10050.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred Stock Value", "terseLabel": "Preferred stock" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r11", "r13", "r229", "r230" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10300.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense Current", "terseLabel": "Prepaid expenses" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital": { "auth_ref": [ "r85", "r93" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10120.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of distribution received from equity method investee for return of investment, classified as investing activities. Excludes distribution for return on investment, classified as operating activities.", "label": "Proceeds From Equity Method Investment Dividends Or Distributions Return Of Capital", "terseLabel": "Distribution from equity investment" } } }, "localname": "ProceedsFromEquityMethodInvestmentDividendsOrDistributionsReturnOfCapital", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceInitialPublicOffering": { "auth_ref": [ "r88" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10040.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.", "label": "Proceeds From Issuance Initial Public Offering", "terseLabel": "Issuances of common stock upon initial public offering, net" } } }, "localname": "ProceedsFromIssuanceInitialPublicOffering", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r88" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds From Issuance Of Common Stock", "terseLabel": "Net proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": { "auth_ref": [ "r88" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10060.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.", "label": "Proceeds From Issuance Of Preferred Stock And Preference Stock", "terseLabel": "Issuances of Series E preferred stock, net" } } }, "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMinorityShareholders": { "auth_ref": [ "r89" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10080.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.", "label": "Proceeds From Minority Shareholders", "terseLabel": "Contribution by noncontrolling interest" } } }, "localname": "ProceedsFromMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10150.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.", "label": "Proceeds From Sale And Maturity Of Marketable Securities", "terseLabel": "Proceeds from sale and maturity of marketable securities" } } }, "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": { "auth_ref": [ "r85" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10130.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.", "label": "Proceeds From Sale Of Equity Method Investments", "terseLabel": "Proceeds from sale of equity investments" } } }, "localname": "ProceedsFromSaleOfEquityMethodInvestments", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockOptionsExercised": { "auth_ref": [ "r88", "r385" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10070.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.", "label": "Proceeds From Stock Options Exercised", "terseLabel": "Issuances of common stock upon stock option exercise" } } }, "localname": "ProceedsFromStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r6", "r60", "r62", "r68", "r92", "r109", "r123", "r132", "r133", "r169", "r175", "r179", "r182", "r185", "r215", "r253", "r254", "r255", "r258", "r259", "r260", "r262", "r264", "r266", "r267", "r448", "r453", "r455", "r463", "r464", "r477", "r492", "r576" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10160.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10010.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Profit Loss", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property Plant And Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r38", "r238" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Property Plant And Equipment By Type [Axis]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r242", "r614", "r615", "r616" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Disclosure [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipment" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r37", "r236" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails": { "order": 10010.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Gross", "terseLabel": "Computers and equipment" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property Plant And Equipment [Line Items]", "terseLabel": "Property Plant And Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r19", "r20", "r238", "r534", "r577", "r584" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10210.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property Plant And Equipment Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property Plant And Equipment Net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r36", "r238", "r614", "r615" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property Plant And Equipment Policy [Text Block]", "terseLabel": "Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r19", "r238" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property Plant And Equipment [Text Block]", "terseLabel": "Summary of Property and Equipment" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r19", "r236" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Property Plant And Equipment Type [Domain]", "terseLabel": "Long-Lived Tangible Asset" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property Plant And Equipment Useful Life", "terseLabel": "Estimated useful lives of assets" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r340", "r525", "r526" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r525", "r528" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "Related Party Transaction Amounts Of Transaction", "terseLabel": "Software sales transactions amount" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r114", "r256", "r258", "r259", "r265", "r266", "r267", "r526" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Related Party Transaction Due From To Related Party", "terseLabel": "Net receivables (payables)" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r340", "r525", "r528", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party Transactions By Related Party [Axis]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r523", "r524", "r526", "r529", "r530" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "Related Party Transactions" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r399", "r548", "r629" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails": { "order": 10020.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10120.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research And Development Expense", "negatedLabel": "Research and development", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research And Development Expense [Member]", "terseLabel": "Research and Development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfClassificationOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedCashCurrent": { "auth_ref": [ "r8", "r18", "r104" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10260.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.", "label": "Restricted Cash Current", "terseLabel": "Restricted cash" } } }, "localname": "RestrictedCashCurrent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r27", "r300", "r393", "r534", "r581", "r603", "r608" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10090.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings Accumulated Deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r2", "r119", "r120", "r121", "r124", "r131", "r133", "r224", "r390", "r391", "r392", "r429", "r430", "r475", "r599", "r601" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue From Contract With Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r160", "r161", "r174", "r180", "r181", "r187", "r188", "r192", "r317", "r318", "r549" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10150.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue From Contract With Customer Excluding Assessed Tax", "positiveLabel": "Revenues", "positiveTerseLabel": "Revenue recognized", "terseLabel": "Total revenues", "verboseLabel": "Total software revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfRevenueRecognizedFromSourcesOfSoftwareProductsAndServicesRevenueDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingScheduleOfRevenuesByGeographicAreaDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r306", "r307", "r308", "r309", "r310", "r311", "r314", "r315", "r321", "r329" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue From Contract With Customer [Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognition" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": { "auth_ref": [ "r190" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.", "label": "Revenue From External Customers By Geographic Areas Table [Text Block]", "terseLabel": "Schedule of Revenues by Geographic Area" } } }, "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromRelatedParties": { "auth_ref": [ "r77", "r256", "r258", "r259", "r265", "r266", "r267", "r610" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue From Related Parties", "terseLabel": "Revenue from related parties" } } }, "localname": "RevenueFromRelatedParties", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuePracticalExpedientFinancingComponent": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Indicates (true false) whether practical expedient was elected not to adjust consideration for effect of financing component when transfer and customer payment for product or service occurs within one year or less.", "label": "Revenue Practical Expedient Financing Component", "terseLabel": "Revenue, practical expedient, financing component [true false]" } } }, "localname": "RevenuePracticalExpedientFinancingComponent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "booleanItemType" }, "us-gaap_RevenueRemainingPerformanceObligation": { "auth_ref": [ "r312" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.", "label": "Revenue Remaining Performance Obligation", "terseLabel": "Unsatisfied performance obligation" } } }, "localname": "RevenueRemainingPerformanceObligation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]", "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1", "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails1" ], "xbrltype": "durationItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis]", "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]", "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails1" ], "xbrltype": "stringItemType" }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation.", "label": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Table [Text Block]", "terseLabel": "Schedule of Timing of Revenue Recognition" } } }, "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueRemainingPerformanceObligationPercentage": { "auth_ref": [ "r313" ], "lang": { "en-us": { "role": { "documentation": "Percentage of remaining performance obligation to total remaining performance obligation not recognized as revenue.", "label": "Revenue Remaining Performance Obligation Percentage", "terseLabel": "Percentage of revenue expected to be recognized" } } }, "localname": "RevenueRemainingPerformanceObligationPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Revenues From External Customers And Long Lived Assets [Line Items]", "terseLabel": "Revenues From External Customers And Long Lived Assets [Line Items]" } } }, "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingScheduleOfRevenuesByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RoyaltyExpense": { "auth_ref": [ "r81" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.", "label": "Royalty Expense", "terseLabel": "Royalty expense" } } }, "localname": "RoyaltyExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale Of Stock Name Of Transaction [Domain]", "terseLabel": "Sale of Stock" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r153", "r192" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Sales Revenue Net [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsAntiDilutiveDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]", "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Diluted Per Share Calculations Anti-dilutive" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r425" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]", "terseLabel": "Summary of Income Tax Expense" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "auth_ref": [ "r417" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.", "label": "Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]", "terseLabel": "Schedule of Tax Effects of Temporary Differences that Give Rise to Significant Portions of Deferred Income Tax Assets and Deferred Income Tax Liabilities" } } }, "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r142" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule Of Earnings Per Share Basic And Diluted Table [Text Block]", "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share Attributable to Common and Limited Stockholders" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r404" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]", "terseLabel": "Schedule of Reconciliation of Income Tax Expense Applicable Statutory Income Tax Rates to Effective Income Tax Rate" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r356", "r381", "r395" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfClassificationOfStockBasedCompensationExpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r356", "r381", "r395" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]", "terseLabel": "Summary of Classification of Stock Based Compensation Expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Schedule Of Equity Method Investments [Line Items]", "terseLabel": "Schedule of Equity Method Investments [Line Items]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEquityMethodInvestmentsTable": { "auth_ref": [ "r6", "r109", "r214", "r215", "r492" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.", "label": "Schedule Of Equity Method Investments [Table]", "terseLabel": "Schedule Of Equity Method Investments [Table]" } } }, "localname": "ScheduleOfEquityMethodInvestmentsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "auth_ref": [ "r478", "r479" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis Table [Text Block]", "terseLabel": "Schedule of Assets and Liabilities Measured at Fair Value" } } }, "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": { "auth_ref": [ "r110" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.", "label": "Schedule Of Income Before Income Tax Domestic And Foreign Table [Text Block]", "terseLabel": "Schedule of Components of Loss Before Income Taxes by Tax Jurisdiction" } } }, "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r38", "r238" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Schedule Of Property Plant And Equipment [Table]", "terseLabel": "Schedule Of Property Plant And Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r527", "r528" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule Of Related Party Transactions By Related Party [Table]", "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": { "auth_ref": [ "r69", "r191" ], "lang": { "en-us": { "role": { "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.", "label": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]", "terseLabel": "Schedule Of Revenues From External Customers And Long Lived Assets [Table]" } } }, "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingScheduleOfRevenuesByGeographicAreaDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r169", "r172", "r178", "r231" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule Of Segment Reporting Information By Segment [Table]", "terseLabel": "Schedule Of Segment Reporting Information By Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r169", "r172", "r178", "r231" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule Of Segment Reporting Information By Segment [Text Block]", "terseLabel": "Summary of Financial Information with Respect to Reportable Segments" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r362", "r369", "r372" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]", "terseLabel": "Summary of Stock Option Activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r375" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]", "terseLabel": "Summary of Weighted Average Valuation Assumptions Used for Options" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfStockByClassTable": { "auth_ref": [ "r47", "r107", "r148", "r149", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r282", "r286", "r291", "r294", "r295", "r296", "r297", "r298", "r299", "r300" ], "lang": { "en-us": { "role": { "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.", "label": "Schedule Of Stock By Class [Table]", "terseLabel": "Schedule Of Stock By Class [Table]" } } }, "localname": "ScheduleOfStockByClassTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": { "auth_ref": [ "r412", "r426" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the change in unrecognized tax benefits.", "label": "Schedule Of Unrecognized Tax Benefits Roll Forward Table [Text Block]", "terseLabel": "Schedule of Reconciliation of Total Gross Unrecognized Tax Benefits" } } }, "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuritiesAssetsMember": { "auth_ref": [ "r208" ], "lang": { "en-us": { "role": { "documentation": "A share, participation, or other interest in property or in an enterprise of the issuer or an obligation of the issuer that (a) either is represented by an instrument issued in bearer or registered form or, if not represented by an instrument, is registered in books maintained to record transfers by or on behalf of the issuer, (b) is of a type commonly dealt in on securities exchanges or markets or, when represented by an instrument, is commonly recognized in any area in which it is issued or dealt in as a medium for investment, and (c) either is one of a class or series or by its terms is divisible into a class or series of shares, participations, interest, or obligations.", "label": "Securities Assets [Member]", "terseLabel": "Marketable Securities" } } }, "localname": "SecuritiesAssetsMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureFairValueMeasurementsScheduleOfAssetsAndLiabilitiesMeasuredAtFairValueDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r156", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r174", "r175", "r176", "r177", "r179", "r180", "r181", "r182", "r183", "r185", "r192", "r244", "r245", "r591" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segment [Domain]", "terseLabel": "Segments" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r156", "r158", "r159", "r169", "r173", "r179", "r183", "r184", "r185", "r186", "r187", "r191", "r192", "r193" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Reporting" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReporting" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingInformationRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting Information Revenue [Abstract]", "terseLabel": "Segment revenues:" } } }, "localname": "SegmentReportingInformationRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails": { "order": 10030.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 }, "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations": { "order": 10130.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling And Marketing Expense", "negatedLabel": "Sales and marketing", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SellingAndMarketingExpenseMember": { "auth_ref": [ "r74" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing selling and marketing expense.", "label": "Selling And Marketing Expense [Member]", "terseLabel": "Sales and Marketing" } } }, "localname": "SellingAndMarketingExpenseMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfClassificationOfStockBasedCompensationExpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesAPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series A preferred stock or outstanding series A preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series A Preferred Stock [Member]", "terseLabel": "Series A Preferred Stock" } } }, "localname": "SeriesAPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesBPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series B Preferred Stock [Member]", "terseLabel": "Series B Preferred Stock" } } }, "localname": "SeriesBPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesCPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series C preferred stock or outstanding series C preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series C Preferred Stock [Member]", "terseLabel": "Series C Preferred Stock" } } }, "localname": "SeriesCPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesDPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series D preferred stock or outstanding series D preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series D Preferred Stock [Member]", "terseLabel": "Series D Preferred Stock" } } }, "localname": "SeriesDPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SeriesEPreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Outstanding nonredeemable series E preferred stock or outstanding series E preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.", "label": "Series E Preferred Stock [Member]", "terseLabel": "Series E Preferred Stock" } } }, "localname": "SeriesEPreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows": { "order": 10210.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share Based Compensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1", "terseLabel": "Share-based compensation arrangement by share-based payment award, award vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions And Methodology [Abstract]", "terseLabel": "Valuation assumptions" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageValuationAssumptionsUsedForOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r378" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate", "terseLabel": "Expected dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageValuationAssumptionsUsedForOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r377" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageValuationAssumptionsUsedForOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r379" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageValuationAssumptionsUsedForOptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant", "terseLabel": "Share-based compensation arrangement by share-based payment award, number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number", "periodEndLabel": "Exercisable, December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r365" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price", "periodEndLabel": "Exercisable, December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r371" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value", "terseLabel": "Intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": { "auth_ref": [ "r368" ], "lang": { "en-us": { "role": { "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period", "negatedLabel": "Expired" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period", "negatedLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r370" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average per share grant date fair value of options granted" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r384" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value", "terseLabel": "Balance, December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r364", "r384" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number", "periodStartLabel": "Beginning, January 1, 2021", "terseLabel": "Balance, December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Roll Forward", "terseLabel": "Number of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r363" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price", "periodStartLabel": "Beginning, January 1, 2021", "terseLabel": "Balance, December 31, 2021" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Rollforward", "terseLabel": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price", "terseLabel": "Exercised" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price", "terseLabel": "Expired" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price", "terseLabel": "Forfeited" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price", "terseLabel": "Granted" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche One [Member]", "terseLabel": "Tranche One" } } }, "localname": "ShareBasedCompensationAwardTrancheOneMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche Three [Member]", "terseLabel": "Tranche Three" } } }, "localname": "ShareBasedCompensationAwardTrancheThreeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.", "label": "Share Based Compensation Award Tranche Two [Member]", "terseLabel": "Tranche Two" } } }, "localname": "ShareBasedCompensationAwardTrancheTwoMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r357", "r360" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share Based Compensation Option And Incentive Plans Policy", "terseLabel": "Stock-Based Compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "auth_ref": [ "r358" ], "lang": { "en-us": { "role": { "documentation": "Percentage of vesting of award under share-based payment arrangement.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage", "terseLabel": "Share-based compensation arrangement by share-based payment award, award vesting rights, percentage" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r359" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period", "terseLabel": "Share-based compensation arrangement by share-based payment award, options granted, contractual term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r376", "r394" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1", "terseLabel": "Expected term (years)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationSummaryOfWeightedAverageValuationAssumptionsUsedForOptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r384" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1", "terseLabel": "Exercisable, December 31, 2021" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Exercisable, December 31, 2021" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r373" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2", "terseLabel": "Balance, December 31, 2021" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r374" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1", "terseLabel": "Expected to be recognized over a weighted average period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": { "auth_ref": [ "r361" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.", "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1", "terseLabel": "Share-based compensation arrangement by share-based payment award, options, vested in period, fair value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares Outstanding", "periodEndLabel": "Ending Balance, Shares", "periodStartLabel": "Beginning Balance, Shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r105", "r118" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Significant Accounting Policies" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StandardProductWarrantyPolicy": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for standard warranties including the methodology for measuring the liability.", "label": "Standard Product Warranty Policy", "terseLabel": "Warranties" } } }, "localname": "StandardProductWarrantyPolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StateAndLocalJurisdictionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.", "label": "State And Local Jurisdiction [Member]", "terseLabel": "State" } } }, "localname": "StateAndLocalJurisdictionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r5", "r156", "r160", "r161", "r162", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r170", "r171", "r174", "r175", "r176", "r177", "r179", "r180", "r181", "r182", "r183", "r185", "r192", "r231", "r241", "r244", "r245", "r591" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Statement Business Segments [Axis]", "terseLabel": "Segments" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSegmentReportingSummaryOfFinancialInformationWithRespectToReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r22", "r23", "r24", "r107", "r109", "r136", "r137", "r138", "r140", "r142", "r148", "r149", "r150", "r215", "r253", "r258", "r259", "r260", "r266", "r267", "r277", "r278", "r282", "r286", "r293", "r492", "r638" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Statement Class Of Stock [Axis]", "terseLabel": "Class of Stock" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureEquityInvestmentsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsAntiDilutiveDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficitAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DocumentDocumentAndEntityInformation", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r2", "r49", "r66", "r67", "r68", "r119", "r120", "r121", "r124", "r131", "r133", "r147", "r224", "r293", "r300", "r390", "r391", "r392", "r429", "r430", "r475", "r503", "r504", "r505", "r506", "r507", "r508", "r599", "r600", "r601", "r645" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Statement Equity Components [Axis]", "terseLabel": "Equity Components" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Income And Comprehensive Income [Abstract]" } } }, "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement Of Stockholders Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r119", "r120", "r121", "r147", "r549" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "auth_ref": [ "r48", "r271", "r293", "r294", "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.", "label": "Stock Issued During Period Shares Conversion Of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock into common stock, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r23", "r24", "r293", "r300" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Stock Issued During Period Shares New Issues", "terseLabel": "Issuances of common stock upon public offering, net of issuance costs, Shares", "verboseLabel": "Issued and sold shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r23", "r24", "r293", "r300", "r366" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Stock Issued During Period Shares Stock Options Exercised", "negatedLabel": "Exercised", "terseLabel": "Issuances of common stock upon stock option exercise, Shares" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "auth_ref": [ "r49", "r293", "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.", "label": "Stock Issued During Period Value Conversion Of Convertible Securities", "terseLabel": "Conversion of convertible preferred stock into common stock" } } }, "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r23", "r24", "r293", "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Stock Issued During Period Value New Issues", "terseLabel": "Issuances of common stock upon public offering, net of issuance costs" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "auth_ref": [ "r49", "r293", "r300" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the exercise of stock options.", "label": "Stock Issued During Period Value Stock Options Exercised", "terseLabel": "Issuances of common stock upon stock option exercise" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r24", "r29", "r30", "r109", "r202", "r215", "r492", "r534" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10030.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders Equity", "totalLabel": "Total stockholders\u2019 equity of Schr\u00f6dinger stockholders" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders Equity [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r2", "r3", "r67", "r109", "r119", "r120", "r121", "r124", "r131", "r215", "r224", "r300", "r390", "r391", "r392", "r429", "r430", "r446", "r447", "r462", "r475", "r492", "r503", "r504", "r508", "r600", "r601", "r645" ], "calculation": { "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets": { "order": 10020.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders Equity Including Portion Attributable To Noncontrolling Interest", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedBalanceSheets", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r108", "r278", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r292", "r300", "r302" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders Equity Note Disclosure [Text Block]", "terseLabel": "Stockholders' Equity (Deficit)" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockholdersEquityDeficit" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r509", "r536" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r509", "r536" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r509", "r536" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r509", "r536" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEventsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r535", "r537" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent Events" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Subsidiary Sale Of Stock [Axis]", "terseLabel": "Sale of Stock" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureDescriptionOfBusinessAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow and noncash information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": { "auth_ref": [ "r253", "r258", "r259", "r260", "r266", "r267" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Carrying Amount Attributable To Parent", "periodEndLabel": "Convertible preferred stock, Ending Balance", "periodStartLabel": "Convertible preferred stock, Beginning Balance" } } }, "localname": "TemporaryEquityCarryingAmountAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TemporaryEquitySharesOutstanding": { "auth_ref": [ "r21" ], "lang": { "en-us": { "role": { "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.", "label": "Temporary Equity Shares Outstanding", "periodEndLabel": "Convertible preferred stock, Ending Balance, Shares", "periodStartLabel": "Convertible preferred stock, Beginning Balance, Shares" } } }, "localname": "TemporaryEquitySharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of new stock classified as temporary equity issued during the period.", "label": "Temporary Equity Stock Issued During Period Value New Issues", "terseLabel": "Issuances of Series E preferred stock, net of issuance costs" } } }, "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfConvertiblePreferredStockAndStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceAxis": { "auth_ref": [ "r318", "r327" ], "lang": { "en-us": { "role": { "documentation": "Information by timing of transfer of good or service to customer.", "label": "Timing Of Transfer Of Good Or Service [Axis]", "terseLabel": "Timing of Transfer of Good or Service" } } }, "localname": "TimingOfTransferOfGoodOrServiceAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfTimingOfRevenueRecognitionDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TimingOfTransferOfGoodOrServiceDomain": { "auth_ref": [ "r318", "r327" ], "lang": { "en-us": { "role": { "documentation": "Timing of transfer of good or service to customer. Includes, but is not limited to, at point in time or over time.", "label": "Timing Of Transfer Of Good Or Service [Domain]", "terseLabel": "Timing of Transfer of Good or Service" } } }, "localname": "TimingOfTransferOfGoodOrServiceDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfTimingOfRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "auth_ref": [ "r196", "r197", "r198", "r199", "r201", "r203" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accounts receivable.", "label": "Trade And Other Accounts Receivable Policy", "terseLabel": "Accounts Receivable" } } }, "localname": "TradeAndOtherAccountsReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_TransferredAtPointInTimeMember": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred at point in time.", "label": "Transferred At Point In Time [Member]", "terseLabel": "Point in Time" } } }, "localname": "TransferredAtPointInTimeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfTimingOfRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransferredOverTimeMember": { "auth_ref": [ "r327" ], "lang": { "en-us": { "role": { "documentation": "Contract with customer in which good or service is transferred over time.", "label": "Transferred Over Time [Member]", "terseLabel": "Over Time" } } }, "localname": "TransferredOverTimeMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionScheduleOfTimingOfRevenueRecognitionDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfAdoptionMember": { "auth_ref": [ "r0", "r1", "r2", "r3", "r4", "r123", "r124", "r125", "r126", "r135", "r204", "r205", "r221", "r222", "r223", "r224", "r226", "r227", "r252", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r427", "r428", "r429", "r430", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r493", "r494", "r496", "r497", "r498", "r499", "r500", "r501", "r522", "r550", "r551", "r552", "r597", "r598", "r599", "r600", "r601", "r602", "r603", "r604", "r605", "r606", "r607", "r608", "r641", "r642", "r643", "r644", "r645" ], "lang": { "en-us": { "role": { "documentation": "Amendment to accounting standards.", "label": "Type Of Adoption [Member]", "terseLabel": "Accounting Standards Update" } } }, "localname": "TypeOfAdoptionMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r445" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Type Of Arrangement [Axis]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetails", "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureRevenueRecognitionAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_UnrecognizedTaxBenefits": { "auth_ref": [ "r400", "r409" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrecognized tax benefits.", "label": "Unrecognized Tax Benefits", "periodEndLabel": "Balance, December 31", "periodStartLabel": "Balance, January 1" } } }, "localname": "UnrecognizedTaxBenefits", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r410" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions", "negatedLabel": "Reductions for tax positions taken in prior years" } } }, "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": { "auth_ref": [ "r411" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.", "label": "Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions", "terseLabel": "Additions for tax positions related to the current year" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": { "auth_ref": [ "r410" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.", "label": "Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions", "terseLabel": "Additions for tax positions taken in prior years" } } }, "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureIncomeTaxesScheduleOfReconciliationOfTotalGrossUnrecognizedTaxBenefitsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r450", "r451", "r459", "r460", "r461" ], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Primary Beneficiary" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNoncontrollingInterestAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VestingAxis": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Information by vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Axis]", "terseLabel": "Vesting" } } }, "localname": "VestingAxis", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VestingDomain": { "auth_ref": [ "r384" ], "lang": { "en-us": { "role": { "documentation": "Vesting schedule of award under share-based payment arrangement.", "label": "Vesting [Domain]", "terseLabel": "Vesting" } } }, "localname": "VestingDomain", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).", "label": "Weighted Average Number Of Share Outstanding Basic And Diluted", "terseLabel": "Weighted average shares used to compute net loss per share attributable to Schr\u00f6dinger common and limited common stockholders, basic and diluted:" } } }, "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonAndLimitedStockholdersDetails", "http://www.schrodinger.com/20211231/taxonomy/role/StatementConsolidatedStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number Of Shares Outstanding [Abstract]", "terseLabel": "Denominator:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2021-01-31", "presentation": [ "http://www.schrodinger.com/20211231/taxonomy/role/DisclosureNetLossPerShareAttributableToCommonAndLimitedStockholdersScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonAndLimitedStockholdersDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 10 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690" }, "r118": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "http://asc.fasb.org/topic&trid=2122369" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(4)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31010-122693" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "http://asc.fasb.org/topic&trid=2144383" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592" }, "r155": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "http://asc.fasb.org/topic&trid=2134479" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8657-108599" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8721-108599" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8844-108599" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8981-108599" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599" }, "r193": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "http://asc.fasb.org/topic&trid=2134510" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e4975-111524" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "11B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=SL6953423-111524" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5212-111524" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5093-111524" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(d)(1)", "Topic": "310", "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r208": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "http://asc.fasb.org/topic&trid=2196928" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "321", "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=123583895&loc=d3e30768-111565" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(b)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r216": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "323", "URI": "http://asc.fasb.org/topic&trid=2196965" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL82887624-210437" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120254519-210437" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL120320025-210437" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(4)", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "http://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "350", "URI": "http://asc.fasb.org/extlink&oid=120431994&loc=SL118172731-207502" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r242": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "http://asc.fasb.org/topic&trid=2155823" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r248": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "http://asc.fasb.org/topic&trid=2144648" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "http://asc.fasb.org/topic&trid=2127136" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S65", "SubTopic": "10", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(CFRR 211.02)", "Topic": "480", "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r302": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "http://asc.fasb.org/topic&trid=2208762" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130569-203045" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046" }, "r329": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "http://asc.fasb.org/topic&trid=49130388" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(5))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.1)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.12)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948" }, "r354": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "http://asc.fasb.org/topic&trid=2235017" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b),(f)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(3)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(4)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.13)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.14)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.17)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(g)(2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907" }, "r398": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "http://asc.fasb.org/topic&trid=2228938" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "105", "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "10B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.2)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)(3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.3)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331" }, "r442": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "http://asc.fasb.org/topic&trid=2144680" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.24)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686" }, "r465": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "http://asc.fasb.org/topic&trid=2197479" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=121483254&loc=SL120254523-199619" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.28,29)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(1)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(2)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-30)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r483": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r494": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "825", "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.9)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "835", "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL120154346-209984" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848", "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313" }, "r530": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "http://asc.fasb.org/topic&trid=2122745" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r537": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "http://asc.fasb.org/topic&trid=2122774" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "926", "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447" }, "r563": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41256-110953" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41261-110953" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(f))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r576": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r585": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(10))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iii)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(iv)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(1)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07.1(c))", "Topic": "946", "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580" }, "r630": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r631": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r632": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r633": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r634": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r635": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r636": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r637": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r638": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402" }, "r639": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580" }, "r640": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "848" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "848" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "848" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(01)", "Topic": "848" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r7": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "http://asc.fasb.org/topic&trid=2122149" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(12))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1(e))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.19)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "210", "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "21D", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=SL94080555-108585" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585" } }, "version": "2.1" } ZIP 113 0001564590-22-006713-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-22-006713-xbrl.zip M4$L#!!0 ( !R"6%3L\B9+QT *1! 6 9S!N83%T9F-Z-74R,# P M,# Q+FIP9Y6[8W0E0+(*.=6(;'=NVDT[2L=W!B>UT;%L=V[:MCFW;UO3] MWGWSWILU/V;VCUI[K:I5NZJV=U5]+7]M U!D)*0E &!@8(#_P-<:0!0 0X. M\_\9X/ZK@86%A8&!1X2#0?R'P_S7)& 0D)!0WZ#@H*#@$!%A$/__PU"T*#04G)88)]2,E!?P/- *]>3@I MR([+'3YOP6^B)W*/:Z FV&,/PL)0+M^F&1[-U;;CS*8!2JTV[N:"*@.Y$&R4 M5KD0N];@]B06?CG+EC"O)K=E[^9C7.CFBL?*&YV#Z485OP+\("YZ7*M&:E=0R*9Y2HA6A)?J2#:=(;9#7[$Y MIK4,QTY4!AJ^Y830 .Z&-_&&0S2><:A6P$\#>/[)):]D;=^,8!HO'=N)A<;:%T,4# MW.NA>@8,$Z@''\>^MUO:5-OD#KU4H_94+%$\,_G":PPQ?6"8MFL-EBZG#3DX MY0S1MJ]2I1V;O9AFWE*/W!E"U!,<9R:?._U6 39#]X+V05"MQCM_PUP3CSP MS9B%3N0[O%:GZY\-G:)5*5 >RUI>1&S!RV]!!)W=*Z$YEG>R,F(A.9Q_YZ#1 MD=LN@TL=O5ZM][9?]Q/6\^YXK[N4^Q"Q;LJ]J_3N>0_4:U;XT':M6.R_-,:N M50P9*\D3 7?KC!O:Z\ELIYL3>^VI^*$CU]\8'90-]K5B"8V M9-4%1,V-<$>C41*%SC7L%^>W>U_$6YW!$[/N.7P$B,V7?Z*6DNXBEE48N2DZ M((,KH+GWWF*/-C.'!HZ&JZV:.P@DG>UDJTHZ/*PZGRVG'BN:/'DFE\^ZG.7D MBW:>H)$A7+NZ0"WJ:L?,-YK#W]G6*^#S" [8#L-Y27"TB<9Z;+XT\TBQ1V_6 MP3::D+:;YV2;1N3$9J!+R((7:8A,^FS \2:R# M05(R]]N2NL^XTMR%.@8.'"N\:51JHY8'$2$76FY83!4FK'8R'\$E.C2Q3(@T M*F4JVO%?GCF;K_M3 @W6LV_C^4340FJ-"M,I0^G5ZGHWT$>X\+UKT'LSX:A[ MTB*GZB/_XN?]3\7\WW3T?Z%<9CI5& EA+7V-S*V5^ 9XGGG2^3GJ@=ZLOF'U M,BJ,Q'J+)&.<5(WV-+/5%@4S%F+Y7$?-1K7#V1OIQ6=V&E@1&&UK5Z:YK<)' MQ3"GA+B(P_<:ME30G_%BSA/U*B1A_PL)9=:!G3-N6T89_Z F S>%#IU7O%.LM^ M 98W- JK[#3FV[: -5MI>8)SJ$LE]9B+&+?*3_3>E#-]+Q/&1N.T=1F/XBWY/**!#DO'>(Z\[*6(ND/8L?WPZNU=B=*/!%:>3/&8?0'J MOP 44H0,.T =A-\:1UAGYD]**7E*OJ)UH3JZ?0=%[GZ5JQ&/^NOQ E5VFLE) MP3OVIIL.&VJ\D_RML2/O"6X&[P?ETR4[Q#Y<7?N^L:,?"[[5BM\&6/XN[%\X M:43TV-93;T!%M4OB BKY+12&!#=;/ZY=+UY*FP_9B&93E=@. 0> (VDR<:"K31-]_ 4<4J$,P2 MB[D;2DU5@%6<.0DURER@BYB:-5-8W=M3Y](6VV3:!P.-VE](V2/D;J=@EFZTUE;V:SYT7.,2)J9Z:>UDI@ MWN8V:)7:] H:&PX":QR;+^"*X_Q?QB]'+TAE-YJJG>HOPV M92^H@+.:%O]J@$"HGPPMKJW03,^(2)((5?# O;KP6DDES*UJLJ^UDM LXU7J MM>&#J+=T.BVJ6'4:X-J:KV(X1 MZNX3[9X:>5V;PG&3[)T8M@1Y:G:M*0JO=/Z%/?@"9#Q:G=#R2G "W@&,&+A#Y.LCP=^LP),);1M0.FCZIRH3%!*);1<1V M)6=FNG?KEL_'&2/.8'UYF#-%D].P8EWSHFC_'FV6-@G;G>-@HC$KR&+?0#!P MJT')-U4P9C QLH_97P-=AKIAF'*RD+!CL=+>^KH9BL<[N!1Q]_SL/D5\;"?. M,('J^_^#D>!)92^6!ZM=*'0YI*L9KL3FGR]="+Y$[\TQ*=FZXH$AUNZ8)YJ/ MDADG^(YW0X^(.8<.O"9C,,92OA12,IJ:3&U3":0@X-D8[ M0WP69B\'1C/X@2FGT0*W* _&:N2JE:74P?/D,D#@3[7_R2I(,:%_J+ZX>[<] M_$KO<;QB1HV+R><*N W"9S/NRWPQ(ZMQ^_:+8$N#BVW:O>)'(WQ9<5L^MBL_ MI>"4,=*<-<7X5(#LI]W1%P 5_@?]TY0/?1+G_:'91[\6T.3D(A'.3M?9OC.6 MM%2Y0(KXWW['W) 3R7;VY[DM\;K=J%),<@X2#O@(C,8*9?/:=@>/"^.A#B76 M1G-[,ZWA>XV"[NYE& ]$?%+E.Y'&21O:8F$^%_UHU3$+9UM%4OI?VU6^ M;&RFSZR,@"T[\"IR/PVR.SJ8WI)=9GYN_]#+7&/8[:)&Y#FH<[= ,;C+^/A( M?7B8WGW^O,K2*;H-]U)8H<[E,3Z11\(FVA7I/2#R5NRR95-#53A2?94/M('5LS+L52-:7C03E9J5_X<#FWX"V M7,]4/X>I5;,/\4P,4H-^>,AA'Y\G!G./UFZ^='T!VC;T]!#WXGZG2"1%L!?/ MFH ,RO"8R:6 ,9+N)KP^(K6)07@10=\C>?>#NP,QM]+5_6\SH,KAO,]@2S#+ MXU$"9='N$S(=[W)6QKA[Q#&?*AA[JD&$ZD*+BBR1]=7,IQ <47]7CW71]&=2 M%C_BO&5,B=<-?^)OUX^M%ZF!,+++^16"_A[J/14T4&W%KO)(2JR?=!ZW9[Y!/-<- MN]4#2]PB:RB">=6*L-![82)^T*J#\7XFM%]R>HVU5:W8P$T8E836R>;^1SS0 MGP_3@EJN?_ ^IP8SWN#[[I3@*62.42 DF@GI2I7+@8B_&!_7'%"HT: M7=8 &+G/#12SA8>VWPM$1J4!+F_V;,/<:Y'[)8*R8G4?(*)+>OPF9$;LS4=2 MJ?HC%!$2Z\ZG%,$V1[/7Y"[-1XM(&CMZ,P73]4@@T!QEY]\*5&E^?(NUX\1) M#MM5ZK*_E>)[8XWIL(U*%BC3XZ&MHE-'KX1W)#NC7$*Z@:F$@D([#5SC>.ZF MU!NV->I@_9XQBDR-++8*<_DP\0+L0O)%O!,,*-4C9:T7C/9!:FAO=_&OY:5, M**G<9[/YW.O$@D_ZK?!?!@ +R8^L3'>Q_ AYS'5[0L QL*[&=:7ZA24E61__ MK<3L8G_ /JJ.KU\:=KR7]X29%&+,R2!UC@,%\NRR08",?T]75FV[R,B5O"E>*5\0N MTY01*I,*1UJ?GT,0S6Z0JC;L)Z+[;Z<=2T,V>1:AN-)-5&A_ 72[![UV"Y/F M5KI"/!*$(&RAEB"M7'O--!.W:=O"GKTK#VYP[OYMOJ-TK2>"/1V1D6GNWG1( MWR$9.$.H_<:SOXZ1WD?NI^&F?VUH!BA0"=:CP)>!F17TS&&]AT>P%T\FKQ0$ M8PGS&H,QOE3K"+1&4[;?QXO\E#/Y.J,CK(_\=JZS!CA20C#R6!:R_'YBDT!( M('.TMDGU>=S;!@:NORE!DEZ^CQUA[+[=^47^7<:>[ 17KX3KB_O$TQ@@O'$V M]C(W^9M*3HRL$?#C=UO.&"99?S/H%K7QC%^&M3T(:2@U&RM7S4)%;\4KW%#7A_2\FK:$Y[ M_9-@.J'8O6L5YSVUXV"F)%QCE)$>1$0[9U=*2\P27YJ+73-\<)*]&J06. *; M<)=UN_*I]>&GX-T"4:O[ 6)%4EG0'0S%FLNMF?ZS_J3E_=CMWL'G4%;%*:TM MFJ"K1;F-3AP5]^B#7$+BX>>KF)Z3>.-L)A*)UDTU2FC$7,]__!R-N$PIF$P< MW]:+R ;>+%T]<08S;WGT>KMFE+Z_4&[NY &RC+*";1'OUB]U'94$*03%5I+Y5;+[ M/T-#_SDU,+DLKR_ $?,8I^+ */8XSP/[$I+B2N+.T=&;XDF8[*;.\]&U"X[1 M@&YJ#$&L-S,OBF_]!=9A0'7FF*=L0)1[L'.=*Z2XRXX>85)^#S#3X,YH7.?A M)-(0'"7;=G^H293OT<'NUS"P_X":S1BOT>3RJH@Y^GIQJ/<2GS$?I69NO5/& M:9CW1SU)HJN$=$8[=1O7*T>M5]-VUS=#-7=V,L1I"+^>E3 #*5M)M8/<^9D_ M ;"ND-+57B\DR?LA\,Y%?=R6V7*+QBCH8#4.5NN5FZ[.BH?-':N]R64+U-8: M(Y4=DU)K\;&0P/7E&KS>58:=8H$(R^K,-#B)U75;U<;U5"/GO;WH1)'L'L0O M@'B'4S1*(QA\[I,'S;G-R[1J8_U1,K8-2L#00/\O-1(-9F9"%*;WG6!$HD@$ M_B,;^(V^]=3T.7AA,,2=U4Q.(CG/J-KCS ^]$RK(075[X9S88:OA)FV49"#_ M>UJ%J$'B/9I1!9?S/XS]L=UM KB7P3)P!D8\9@D+76(H![X)ZVX5'6NY!N'2!WI%2=$I-553[L:BP#F#^9'RS.3!6 M=9>MGI,HS MK7./EYN)B67N'X4)V8AD>F%&U)S!= #1P%1A,T!ZDH=:A9O1=9!R6<9OKF-, M#+VDL[08SD6\MNP[?@'L'T/>C&E1UR6Q5- ;PCO%W/7"T6$T!XSP1Z2?A>PR M"QG_XF9ZL4_"PT#4QU,UTW6Z>PJ6<*#15_:_$Z@5."U6H4C.]J)#33]QWBDI M6Y8J!#&G'WA*18S:LN&I$5(,Z*E"[-5,XVA2+:7L?@$67A([=C;QOC'U8 R" MP?C(D6[(WWRZ#B]612$5*A>BQP'^CP@1K+VU MQ3XY+3YQJU[@GOOM2A,YZ_WH&$/*&:0@G<8M.%0$8,O?Y373^ M8CZ.BR12K,2+='N/K]VVXNKWL7H&=;?\HEU7.M8C'$(E_"XI[W7!$!@Z=EO, MVML]5K;4/6H M["16#9)@,!''[,J6WPN.K]/JRU07&)OXUN M[=J_EY!7*NW"AZD5[55,\&+*X\X'#@>L)28UEARPS"0)-W(S/7BG.9<_26^@ MHX68SI&@$K&Q>F&GQ4R?UX>;N3_S>H&>8TIA34Q5F@8;2"8XZ3VREBX*5,'Y M4O=MQ)/(;\-&>-WPS>UGR1A#ZT*+TK"U%\LNP6D*>WW*,?NB'9PNM??B84IU M*NL_:3 L@[SNZ6=&NCG:N;(#29P9K-(S72Z%5964TS;_3^VS@C\ZQ((<\:-LM"0 MU]_D^.1P_?WR+[/RUA)\O;F?)S^=$PZC6[36./1!4K,%8GH0@3IYX$&1]B$ MM7;\2 [7\7J.\W@BMK7*9'E*"5.M>GJW4B.-9-4A\=T"P0.T^/J_R;:;8%LU M9K:7BIN*>S:%0:4+OLAAAM]1F3/)5V18HDNZYT]I;^M'G4K0-.Z2C+I-/Y'T M;GW17C$GC;TGUJ@T)QXJD5^54=X#ARE&&PN-;-DA:1\MW&;Y]]]V#24')HNQ_@E0S MR"8=?X.0D+F#Y3%!#EX[^V\/.]8(*U%-!VFY+8+C,;;-'Z,5?AK+S:?F#">G M$J5;FQ)VQ$=O])YE1X[APB3+O\:I(U0]-)M5_*ZQ>3H/%^P4'T\F8\N2_S;; M_\Y RD""3"3O)QMCRF@VT_:QU[&VTRV188ZEG.:^&.RHNMOT)AVYJ7#(A=3Z M&\<6S7Q\ER%JHPSAT=$^[*DUH5B8FK3QW%6_LH0%D_\L(D9;K]A-J++,*G@R M[>3[O<1B_SX%T&+3DA6#&S/$'4&__-[@M@=:D4!F*P63Y<^"CV MF?0?$RP06!=TV8V>)ST46?@"B#B*M.YO5$_6))8GBA<3A!8:O1?>((OU7VJ: MCPE76/3?K2(WO\O34FLI9DTQ-P9@$B:D@MDN;7X!OND&.<3]K,2*0.$&8KXJ M!(KI^?TG7H!K%"&&Y]O73H U:@Y&:H+T'&>Q=8!QYES%F_2]KT!4N+3$SVGD M8Z'*=.#?_+3Y5(%]'Q ==T=D96LO;PPW[S+N>\/R@\&[\3";).(,&'O88N@ M6.=C]Y?FC:^WZ%1RA?S/ @H2T"$43E/K.0) \&>"(KH$E<=D[#BT,DRTD,#> MEA1H;XNH4/@;D/V3J.[SE;#*\F^!)-;#A8]Y',-AT8'.(OKR#::R#>:2J,4[=[O;)PN3RB3R^ MH5>A'D "P85S+K[+R[KXHX\Y4PA5 0W:?1.A#2O]"X##C%VW$H';+UZ1H',_ MQ3.D<$E8[11+>/5,DV^?P6;$#"&TO:@O%L;R> 'IE[W5&Y7M8V'\-L=YV:U? M_J[XHU700B&?F5UD:$#JE=> .@#B^'60[\DGSDECYWM?S612J17290G$#^BU M3#:4MYRX]\ZR2.08,PBQ29C15&+TX$^Y)F(N)%_IY0T];7PA[D"[5-;4@'IP M9BHB%^FSF5?+;@_/K"KZ,(_&'N.P 41S\XSQSEC#)HT^O/33:<>.C3N15_&H MO08C%CYC-,GO#P-[:^2F+^&'-O1XT2119@:7MG(V%N,_&U"\MWI??.DJUX6C M;5O>< V8>XS-L\\;SC+?'!^RM MLEMOB3+__14<>GM@BGKU6"3+H=C\U&[N/L27F^U$Y3>V J%:Y9BM-^TS3+8+1?(5V6+II%7Y]*CX=B^G%Y$(Q MSL$LLT/C+S4VPU"U7#29/:2&IQ/V9K9I,#Q0R.$6):-6V[0??;;3J,^D8Z>V M0V,#3333"04M!@=.J"/P-FU]KW4R?YV"\] ,&7HQ;BW]9HO)'@^W$(TF%6@A-#08JA,_(!6IM9M)H!T_W M\I-KJ)*K-N_D"M)/^H7(DU0$.0E,FM[4IA4_)2,JXIY?&@24R?[QD)A+8AN@ M:NVCG WU> CU(-=2&PAZ*J[2D<8GR;_6'?. MA3I(_ZKFI6C!&B#W,#5VDKXWA(L\%%+SXU&[7$L,))&>O7/-^,./]6) ;_X= M-!<*0LZ=0B'(VL;'O!0I>IZ>Z5/8K[^2^ '[OO1GI5E50'N/VJB&PM6?Z7GC M.^F!:]",TA1DZFCS1JSXB 269V,%^#O*OM\B9X3-OKQUM0*0^(Q)"/"S MA=<3@'02OC80XJ&<.7W8]B&=9]?C0$_OW#M0; MJY(:L;@V(>G5@4(8<)MA4L!&O5AU4\;$G[_>S-.+,P7,QMC>JP!-! K'!EU* MQD$?F+TX&7=4)[I\TR/K-R95QFB=VJ2>"2E)(%XGSJ3&*P!QO1\Y+\1?"E*J M!8N,Q9T.80;#K%6[%)P'!@%R]:#PD$8T'.UAC(C?=MH1?'"<5ZEO43TNU/-7 M"@6B@@.0$W3ZS8U8EM.H.F&0KEWJEY*7O._^\/.)CJ?1+M=QJU>2S+,SQ:5_ M9I@FM:B3W6MUXG6O;MVG,N@B)^M:V=.K6L4-9_W>,([FU%O0%N95O5/^IC3/ MY63+#:OU]X_J923X+L^L6,C?H+/OKGD)HO5^I/E=7Y1IH M@X;4WD]=";CK&J.[29-80CM>WA_Q[EVZ'Y:4-R%M.G+Z!\4)O1ZV^'CT(BLE MOP V==8"/ D_'N*4U$K$6]&^_?I'+O>?!;G1LP=#M1L?+D6+ NODSO M(OH" M0/F>JJO )_J0)]$)//3&.#A;+M?">)[ J%#JZ\D@WVD//-:VN7SYSB%L MO0;\?OW&W)"VLI*54[JR6%KZ;D1S5+* 72G+!<+C2MAJ#$5'1S822IX6XS; M(B>$P&Z&Y%M;P)OTHKDU>JC MRUWA]'L;%@R?L%.0/E[*A"$>;5I50B!WC 5$[C1S_>X8VX7@>NL(Y#A]7<+F M)'MV@V%!8 6E\?EQ+]?)/.1\GOT,\ECX'%!2@B(I?39/TJZ =Y;R=JW2JD4@ MCX%Q$9,MSM_>=+SV&;C VG?Y*%L(L@^F_?7S43XT?N#9(ZBE4;#W)K**T(7W M3)>U;8UA^7TIW]GF-!4*DW4I4*M=LYP6M1H'V#Q(VUE_''G4NF4U^>E3:+>3 MC52L+[J ;]0'*!7>HY:5HIG(,#S+*2,?O;AQ$;+27K=PP59'33;[M9+WF(P5,I,T0L?%;9C-A.!NH^WUIY/!), M/KTK)]X5@.D+E=:L;<9*(QU0,\18DQR,O[?'L*:< M4W"!UXC[+JW@X(F(/0&92"ET!,XJJ!=Y>_::!5;ASG) JI$;IJ41T5\$6XO; MB9#D>@H;+:6(G..D=U-^KYP4OM8^4+]3U^ZF&%X%%0UFXW*AG4V\MA@LGWWW M&=1M:X!GA+FUAT)TOK@\?/[C76MF7(L.5<99D77 WF+"!(=-T3[=/=H11 #Z MK&HU2'4VG(G,!,,0/.<9+R*[A-6ON:.RO7&0\_9H*WX"J[C8Q8((C"%X)S/US+]]_*U[<<0P%S>U,7N:0LU)JXCAF'2@4=RM%^?4 M?R/KA[0-)OCK GG2YO48Y+%]E+/SGF*HQ*=C!U)*D<&PB==4PV\\FH60=,U' M?.)Y$L.\(EJM093CFX?5"KEB[!][&>U+F(SQF-(UIO*2W_((%D7KTY#P [.38T* M1Q'!N Y)L&V^ WX8ZK1P_:I>AJ3DTC1,L>IMQOF+TQ>R7OL%*+CX(!::8.1P'!$&SP(07_J 65Z81 MEBG%^ Y>JERF"B[G:/'9H_BNY'N/""HLXVX)H./?^%CX+=VMAO(%4%X]$V][ MGGS)JI?^ NS'W .7XI%(!_#"N:+3>KGFR9;:<*;LSKO6J:/M")LI-TI4,YY- MIK4%M=JXKWY,)9$>[&LE"OX"]VVI>_N8QE3/>)!XA+)K/L",FHGK#K&QS';1 M8'B$_Z!:&U-=&I+$]BB+-Z*\L7 HX\+(L'LZ;>->^H#SQ_!YH934*:@_A;M]^ M2$M'_ZW)V5Y+&,?8D?8%H,A6[@6G'#'"QUL!&Q(<39-@(#NRL-1L_(&@]'0P M$?]I1'3E'+!Y<(69.+H44&F@QK\.)R-+= 0C6_ ML1!A_"P,WNL(-^30?/JE-OGQ=[A>< ES[?,!O>SV($*RLBKN"\##E/( 64]( M=*3I93-A'SS SZ]M^N'FJM\K'BWCE-B[.RX!6BE-UCX,YWFD7>^WEC(!"S3[ MEKT?U-B;!LK".. 47=!1)J*@S/=_/:?ZS2\''.D?E0_876U)I MUMJN>X8.9]P&@U*3I!$#JT[YMSLAO?V1EF"RB(9"'6+/>2KJJ>R#J=TD$RJ[3SQ\?%N5ZT03I)P+ M74I@V&[:P?!J'"I V]EP]UTR:6!"ZS?0MN]:WPV0T M8,Z@8G/^:*;QR#/$(WJR\6U+_'C*H6X_]L4@5@++RWOXM?LMFQ[W?+;TY\\* M?O,H[#Z4'%D8XK>^*N5E5X:IRY- 84[/^H40Z*"+\7PGFNVUI>@-=)*!^K%>HX,-3K<'JIQ!O(2.:2Q0K'[G+\@LF+!'?FUZ,$;TLT!9O+RZN,[O#XCGWF% (N M*,:$S,JA^G+##7,QCU]US7)<_$0 #!4KCY/5(MI,;X- M^\3JM90_MGO'JG:^=*EZQ),TKD+6XS4S2TWR&TCR675,HZW-L-.V"N["6W\; M8#.HS'@K,[U:R&)FP^V'=*!YL8.!;B:1@M#)B_?Z:GF_%Y0AQ%BN71A6/#X1 MD_82&8A.G&S4QBL6QK@^O;8OD*_^:4"(8\@!U!2>!"88"11+ V"YR2!YGMIO M=7BVC0F&-&MY#7P5/>V.PR=$'4G2?E:SY):D:B51EN,$B^EDQX'.<2F5)E:$ M%J(:].\XU,.;&H=:<>8%G+PNXNFVDK,QC]TJMUE-H=C".5[(GF*_ $L--:'" M&[=FDQ^1S0->"2SV>&1\^X[Q>4:/NS#M V07*[2>_CZ28U@+@KDI?[L(=K;G M81%V)(^17:Z$FY]V'F#W4.QY4+_I1FF %[+!.&#SO M227YH2[Y10LEK]_PSLMD2GN%T7;T:5Z%>^E.JVD%HL M^"3K3)B628?_*BQ$! HIAR_%W #*D$Y3Y= MM,V4V\]]@F>&Z(ZOF;Q>P!6(DPH%_N?F7DP1\AO-55^JI%2]#N'O=*:40ZLK MP9"62G@+1^^=)_K6I+9,L(0^A=5\U(3VD,MUC2=4ASTSUOMG[B7@$(A!NT]3 M'1U:':-F;?6(CO"<1J=J)N;GVSA@"Z]CJ]4\V5MW[8&6BF,$Z ?)[$")%'Q[8K3AO?Z@#T MY@66+=VM<^5+^PW,.&5LN3U"]N2OQ"?F>F!=(M\R.$2L/HS"8R'SMT_@.ZYP MB>-0ZH_2W2'VG-X^5J,D>[/A<2?2!@06QR^ 9(U@0X*3@0 A<40K4UC[O)H3 M/[_78PLCJ6HWYFF"DU'W0>\3V"?9Y^^%]U4NYBJCAU7YU-/3)KF/7*^0=V5$ M.0&59VNW)E0-^,8N[.R&8AS)Y@04QC]I"GC9MKU9Z;8+QUJ>:43(!_"/%%@6 M5@0NDQT<*Z,OJW9=9YYTC=03#P[U",O0J)I%"\UYJX?XT=/ M0./ !H=E1IU);ODO -7^?,V1:'1+S7" @*)!/M;Q4:O@QC?D9$CX=?MI3-V% M0FT/'Z)?JC2JLN1_14A)MO_9259QY4* -EG\E':%8=5?G]?Z;@W=]YSQP(]^ M+\7YQC8R!@G5QHGD64<2:YT<'8PQ4SX1W+.D;$V70891PQLY]\-QVDFOK6(' MXP0%M$0JI#D%Y"(E;>/ EXE=C)4_NIA_MF!7&,]BRJ],@_]Z*,08[XZL@6;W ME(WW6T=_95)E55+O#\'V?::8^1N^946\8R2$9 :C7.3(N+TKH'T!$FM?K$%* MIXO*3B-%TTYF6FW#W'RD IBFC.'$O%^ P%HZJZP%C<.>"J/NW*/O<(*^GN\) MROP'T9HE'GC4OD,YTP^$X(35&//+!OX?V^&[+4JKI90Q28V,\.@ KLN6CY.6>C> M8B_9C[E"S:E&3-]UJAD=<9X5']LMSR.:T31F'Z"T']+-3LESN.00Q\5',:=4 M1U'?;\X"OP!.&U\ 8?$#'L:Y,$.2R?K G>^CG;49)E^ LQ_CD5QZ3N?H:--U M'V%O-YYAI?P,/N@'/Y<[%"U4G5OT=D?*?N9ELSD4_$?/?Y8E?0=/T-EBXO@& M2^@NZ:-"UO[H%$X0:GXCH$*U^OVC3X>3-QD2QFWR3>69RV.T1G9ZT-?)LI M(V;DX9%FA#+9M#A:%.#B1VQL4T%KL1VP#4WL,N. MUT%%AI!TADU3CR":9**QL'(.(E!5:'&9L!P5 %PEL4;0;L]/:$K9YFR<\O'# M&JK[<&7,@!XR<<=F8^ZW..M:$^SBB1U_.5Y"&>\W^NPHM:&V5JR)BTB]8&V\ M@.?O3@?V Q,SS0XNFW2;\='_.&0:/2$G"G(-Z:N(X8 \G MFZ:S5P30>E4'<"6S7MK3E>ZYX?YQGWCKHF2H4)&W3*M,E2H/DQ#Y,=;W"5U- M&<4I4WM@_.GPT^\?DSLL!Z5"0_R!*-]D2E78_OO*C8V4\#\6'AFNK":,[WS)+/#!78Q(16A3@&'%QI/BKJ[3H7TT11%-RIW=O\DXX5F^DREG MX!37KAL=-VW8 &U62O!XC/#6E[+HBO*]" (5 MUF0L+F7I'A[\&YR_CHHR)= MSA,'F2F\(_IIFT0N8;[M>0J![TCH$O6$0R(55N3NJSGT;3[%D?)X8K24OP_/ M&HFFV1A%I%?14_W3>;XKQC5]F?+(KMNPNA)> [=/^@JHFBQCNF+A@1[7BF,L M(V'>>.P_ODI,OEU39ZP2F1?M.U47K&\T*V M/UH">RB7W8O7X?($O#$4W;4];& D<.B1DT0KFB^-%,-("T$:+/">5"$Y!SO3 M*VW\C!Z0EEAN3\#O.]YM;B#X4UD]1D5OWF<;*%GR6*IMT4(14AL3ZO^;PQ.J M7OK/ZQER.>NW.[0)T577"\'NA"KX'@94[$U<8EQQ=RD74>H+L38.6"X(_K)' M-BN@5"^P+@UGXX%GGCRNP#KUS&5Q%(0[3"3=E(M443=^J!L1-/9G#";4;UZG M]%:<-B2H9Y>J[PN E:4CYA?:N)*[B80#TFBTA<>7H:7"Q-&ZM["$!'!\ <2V$S7\3Y+AI AG M*M%S"V^+5@QJ4+&2+O&LEG5#1:G';=T8"3M50MP1!:63]8O^C&7H\(\G$X+\ M.XKU1JVG,G]E:MD([07O0 DANXI!4?>TK[1HF*!=/E5F@@ZV$JK\712AQCI# MXD13$HA\D>L^D[=JS40VBGEN="-8*L=\4MC;2.GZ4Y/^A4:EB^$??:D_9&?) MO3< U9VQ>L#$X@Z 1V_&3FS5]W2)05E<>O_?#EX0[2B*!KE)CE-@(*# ,278 M!,_;#MIT3WMY[Z .)C%"?>!1V;C>.:\ ?+.3 %:IIQ^\\C MC*KSHC50K3FP]AO[ZH7U2V:M/6BW;QEU@OI4R=UG\*<>\PX"<+4XJ(SPLJ+P M/ .(C*U?80(1\ >(J M3%_!Z4(P]CN8FF@F>.TB+\YM)W(3J1#"]D7 [W)X3-3:O"8LY[61GJA$IL"C MKZW3T6)I"843LT5G\M"(OP 7HIF/';PS[V4#;CF(V#*[^$\<>S"QV8?B#QF^ M5*=)EBN8Y@WQ%*,1RJ0DP1ASP5PE]^-HZF214>>WID3N7!Z]Y39!"H$,9 WR MZ6@0"0KVSC8G!"E15H0X,II0MB__(F:$-,&IIA51G/HA>1P)^<6IU;SS+@>Z MZ4!W_8'O^[U\F:#3B$WD3Z(5.HF062=X9/3%B/$VG2X'U;WU@)WAR64%',$" MANN8\_>M2XVL36L17T[K6MMQ?*KWIF1NO[MNK[2*.7-?'W#?&L6[9%7UK&@\ MR@ND>0'[WG\'@V'%/N!-)W?7H)TU&7+#]^!> [^Q1MN\#X?RZ5E.W],*W>^_ M1#(R^YCU,/S ]V_ZA6@7+BM.,\RB+P#*]M9$.>9PZU:7PD+I_N?S_K]]^![F MR_,^(;E$@=I2?4G%U1&@,2.UF,QLBLQ&,[X NZ>#M7&08C6: X8H^\KQMHD2 M7)(Z1X+&;'B"89(V\&..G3I?OI-P*;E*47_QT3Y,XUN-&>WQJU,=51F MR^4*RY0Y_PN4M*^7KEQGE;?#2"9:#6B4RY+ M3L(Z+5W^UJJ?O?1OL59!NK,(F!"DQ4"DQB_KJ%:$51M]K@-;6CUO617'']LE M]U #%"X:@"<:0!&P+96H=S_ _WC37^/QT ^<*4D>0IAE&?Q6G M%;4^4M[>XX#-A1K73^'XGC,5;(KW %RT"X51";#'8>)URUI)+LP@';"8'3 V M0$T6#!_8*_F@*87Z$6I\=5L:$IP1\HO0U9&],]]_>:AFMO$:J6!$PC%-QK# -V0@A _;/3R6X6;BJZ@LZ(S,MKI=O M2 O9RX?:**N6H?AGUE="3?T#ZKD2]+)X=@35A+&F1.!FZVUPTW;D1Q60'GG$ M4NOQ.14!OX*G8@* TIVO 1*L]$EI3(HVP,PAD5]7 MG)RR'>T'PW49"6XD?/(-AX%/^15_@M<1*TSNLEHOWSEV1W N(U&)Q6Y: M'L.7\ V"G]\@EH/]8]IQ/'WE3#<&4M&+:!&8S,T5"'C)8-Y71N$]L_Q?NNV4 M(W:2*@NJ4%^[;4^92V_>#P\W4>3(%%A773*-N)'PC)?7*(\?0S88J;GZO+]C MYC'WGK5@DX$\00#0<8B;_+3]==E3E%W8. )WD$[T;64C-=-!;L0*JB%XG<#26F)@J6X9UNJ8K*N@3<=NKD'6:\;,IWY#SUKT M 0$""GB'1A_;LN?L9BQ5"[\C"8)N=[RN\!X]$YE("ZER3U[:FN?//%_NY?75 M%T:6)O8V1$Z$(LXXC>9=S!88.#.!J0.-7Z=+^HX[WO8<2K7B+(I=5S M01;HGJ:)S6_7[W\>OP"F&^\T)NHC*72.']T:J;J?K!L6,L[^M*@@UOHMF_'; M>QN0C5?5V#U>(G5'D5H5S"JY.'T5!_ZZG9:M,1AN?&&!BHE4 MEJK^5X"?"3.$1)O)VL9[S%J42_1$OH$D>L]>O=Z2E($$*J3-SP)%LO;+#V%? M>1::RHX.CT[!UX\-B7I.3$Q52:7[B\BV52U/GWH;(@EZ1\95#%UZAY"R?NTH MK;^UW;/X<9[\I1Y3O707=!$A%!W$R?;^=#)ND;_G_&[I_8.+!MC.S OJ>&?8@;YFA7%HO4A,-CB8'%A?%8RU1LRF@2]=MG-E#57MA"I M>;&&D%;W.M +9*-),F$2$P-3+OOYYU]81-<:,_BNY[M$"MRU'^>Q&1IP[F0FN# &8U<9=7/9612V@( MG\6<(;I;MOG'RJV9&D4*FLW?!HD.&Y,XG%S- MKV%#YSMVM/X3H2[",P/O/8^D[TQ\*.Q! '64'J#X'V8X%.P0S">40)9?G ,3 M^<]984 E>Y4EM09#S$AC[.8ZNIF82[U$\1V-__GH#@L^J0\\BE;?H7@4A9GY M@.'\VGR5E3/^\]'GW>:3_@LPY0F;@E.M6LM\])M[+H5TOWA:@7E[;X;-WP@9 MMCF!T4'J[5E>,^4O(*G*+WA%:EX]J"^ ML"'AW\]TPITNCE-EX'C/Q'Q&:R*Y%&7:PYQ] ME^#][==<;@F]16\6H94$LYN$)I]A7:D@]]KCH)=ZTRI-K]-0G+7>C2[3^5CA MM%5CZ2UNZ8V/JM-ZG,_2VUYA;%>MSRP.C*A//NQTXV M?^JGT"=*#E$ W5N\#PB2M>/9.CU=6J]Q 'J\5R)USC@AR%H5J7<,\94F M>H+FF$HO?1AT:Q_@)VU=NU),/;:KI**M4 :96_NF2+ L5"L$VKATO \T%*XDVU9Y$=94 (= M4 ))*/<=@!NO'_#D8GH8_UT;_+\E*5'(/OXL]5_^O<;A*UHU+SH%%7J ET'O MB4PZYU)A?C93S*1X%%+^)E#TS*G4'-$"MX%S4H>&2_=$34*%96Q]D30F=53W(=(J>.0%':%$N=VI/9+:ZF MI]]+TR?9T8D:KJJ*:>WUP\;0N;UB9M0ZV,C@VN5L($?O";-'_J/UIKT,H;P[ MISL]AA@=$",0![*W-]>'J M1J9)*GJ#+?=Z5IL34%3K]X[\ HSKBSEQUN+3GZOSYQ7!/TOPN$OKOPJX]0=6 MCI>6K?BF0GT!Z'7*'#3#%$?S+;X 7*PQ#^COD:HVHQ<8_(HPHOK<^(% M.CD/H*;'"7_SM]3H,^8^[GPM5]";,)XG-$Z\ON=YZ<_Q-''M(V82K*"*_-/1 M;IYT[9"7BIV^T;D:3P^N04V19GX>&&B1@I1J/E9^PK<$.C/D32UM#BC$M MTD.I(,@8!-TK\^.(?-0A/%Z* >O[__FG#N)KY?\"4$L#!!0 ( !R"6%0P M@C]M3X\ $B= 6 9S!N83%T9F-Z-74R,# P,# R+FIP9^R[=53#N%MS=@PT:W!T&'R2X0]#@@P[N$!R"0[#@[L$MN+O[YOG)\[Z[[YY[ M=O?^=<_=.C7S_?3I[U37G.Y3755=_3K_^AN +@>4!0)@8& _Z#7)8 $ X6 M%NE_F=[^]87\%AD)Z1WJ6R34/QCI+R$P'^UOO M([XN E#@_@C'@,, B *>U8J?CJDD_933OG'/E6%\KK,[&Y&:YWK$;ENOL)2Q MHZW'9[OL=4-D^/:ANF0I]1D/6?"I4 7-PH;9ESLWE"S:C<5P/I3Q%8 >;'25 M"7,V+*!W$R_^[@84G2[B)",!>LQ5J^[V=.DXZ+[572[FOOU2\=] +*8OQPO+[V9UJ6[M#Z_2_P02H.N_> MMD-=U+4()'6QX%?L=ZAS)"2"7>60?LKU-\ _LFK78YU!6[&>G_1I,"HE^S'K MC886PKBT\S@J^&_P?Y7Z/U>J[N@349TJ#:K/KF?ZL^Q;LTI\:#4B,$(16ZL2 M(S4=4YE,G M[F@%1:>;XD54Z?_RRQ^C3*EX#/RF(=Z&5 ;TCSRBGAX!US:4R0=:YLXWU*)1 ML@Z&KP#4Q/'?'&'^74&'_W^;E_^KU/^7E"+(+U1ZN"J\7T); 6_%0)G+ M4$ M1^QEEPX_J(A6E]_0A==9)O*ZWTF,O@+B@9]? 2&? Z?I#"<'FW5W38A#*>LK MW7M,4I>'2FJN5C <=C2 .*B%">#O(SW]1D[KSAILS95GI+W-VE<=WQI(=X0IOXDQF)\-(L:+ E.T! MO]%A!)+LFMWZ]TJM(V]6"ATE30E5D%IT")PD9Q19P/,0]G:?QN^RCVM$!IE$ MNT4/>OXT[VOS]!>$&2QW(L7:"ND__H]L&OFQW$"RV*VN/O[=!XQO),3E6&[L MX?W>/_#'!6:%,*/ ]"!I!_FKD-^#QKK]:6).H?TM;VU-D';=9[-G0=G-<-6V-Z!Y%LJ _#NX.6W]T@;Z*J MCGZ^]A*Q??\.ERI$*!A7A_!H6;0!#1 ^J;_Z^*;R%0#E=FPDBH]F2\YF2=Y+ M$VTS5KBRS4Q2HQ> M*\SZB?1,32+[VNU)W$Q3B3FJB3E:XK.UA"I-#O*+6\WVQPFFYZG5]OX/]X]7 M.5-[K7-\]"F-L?:?9=JQ^JXM1%?S*+!&'E;4+:7N#\4$,$$L-TBN'W+4+:9M MTN1A6^=U!ZF5D(=NOZ.VM$9TX8V(113,Y-7B/2C4/X2^ BS]7WZ@'M/+(?R? ML2MMEPG^>ESQ#C];6]EYNL$/92LN5=7B9=X6#( TPLG=L.LXT=JJI^1YDE]- M==[;:%D8Q8\RSD17I)T#8#^3W)J.Y<*PI0*%EDTA1:/"6![_O4IALCNIW'VJ MIT2Y]W8D?]:!FNA?ZT#H'^L HCW9[N5?V'BA?"A -9HP]7HUNTI^=B[-A)%P%Y.$,'H3%L58)_1Y'5$YUEUX_T9CIAR9ZK=JRD9S M:I"'([)[A2=AN05:XE)-!REW8ZFLER@[2$[^_)M5>"3NAX[N>[GIF96DIHLV M-),]9C KR,OC@X&Z;D6DF1R&[;Y$*JXA-S!\Q#O0" YPN+"BD!8: /@^HBW; M3;UP!(6($E='?IYWK.W]=F9=TQI2@N_&Q0]5. 0JH5(7@:*1%#;"[B[ZN[*4 M$JNFU%.3R*&)3QCP=/O$GYP77U;N@WV/]@WF*Y\C;XQT'^1UY!UGCUU,C=E;VG2Z3R!'S21[(:&G._;^5E5 MW9N%7=>^7[\"+$CV>&2Z=MU2HSS.?3=H[#2]S3/X]8T#[JMHEK6PWE9'F3\? MSFBV**4I*C=/T]*7$U#H_R39;FF _VH*;@^Z821[8K0TVY<9:L+!-E>IU$7S3/[R5O/F;ZCL8"VG3/_?<>\50:'/1B7^5,I56R4X?4VJ M5VS^?V(&_[*$M1\+&?$F+)(B1F$3"__)B*$#=PKC!6B=Y/Y'L% M4)-*E=PTV/TD'8,(L&M+$:?44&!$AK]5<#>/]M-V(']9K+$;1N<(/".V99-9 M9B6:QM)?O?8$2;IPX7*W80YY9^T)+B@C2I^$:MU @+:K[V#@LW7TT#-I]-W2XVM-M(( 5K"0;P$ ME70O'TZJ3DJ:)^P6IB'FPZOS9^?CY,M-83>B<+ \K!$GA7M;54+=U;_B\/5[ MV05!G'"W=F?GLZWE0^R#3/H-4$T8(3J['5IS84()2MH;.O;-Q+62W3: M6=?2COXENMZ8!+@R4[0D*G<2T8(.M_0%/$N;)!X]*(5:.\SSNJRS'@,*M9,RIH,[K5M^Y(?5AW0<)4SPI">34RGHI1FZ(Q]U]P2[?YHEY16B% MZR>6F1K@ AJZR8*Q5QP$#7^[O^5AZ/?0\_$5(**> M<"_X(U&]RKS-"N+"_6);\"LDHJ?,# .4R4J#29?"Q\]/ZPVR]D8E$D;E?>FKN:P#K% M?D03CD(#JJ@C_=^K"D/MO%3XFW;KIVXGU]85;19.U02_K\U\\67COBFDE";P ML>T M:J!U>G)*3SLV=3R/:6-KP#"ABMW!<6[WQIA/KOP]MXL8-TY1I[5QY,J MM/G@*6][ZXQ!26_):.LT7GAQX^;//M\NFS5&\'Q4\)H6M MU>#E\KB"=# +33Q@?^&SQE[U1N5YLX(Y0Y/MMO4+E@Y*QJ+ )-,?.:6B;NOW MEX1'\<]]P WG+T.^,=N9&C_FB-/UV->FMR@]OC \,YF] AB2UE2>B:HSA,RH MXOHX-BB+;#)10 *?:1R*E^L5L7VG$O,V_C(R4O>/\G\;&3^_J?]5(Z/=GCQA MD5C.C$CORM Z%],@9;)0PXQ9W?,Q7R7(@1[I&L@>_GNUK-Y-DX9)-YNQUT[SE,;Z\>]3[GD$YNXVAY"\? .?*R]4 U3D/F+><4S MD*N]ESX.VVF8(*IM;!CX03B;9$M*'_G"G36KZ6@8XP0]@B/63*5:@_0VUJ9T M/*:+]5R^[/O]5:6\2&(U9GN9+.*2AI^.#E0QNK'^%2"V)*Q?WZQ13DO@Z*N: MF&?^MQ-D N:.0 LN-S+2P)YJ,Y4(W?F^ ^0?#"<,VQ5$"W'&<%.G=6(K(M#@ MT\LU;V[ M8;9CUSA/HCF/5%1)-(_*=BDWDJO&_>=<6]E"@D<>/CYA5Y+\[5GMU(A@<>[# MG:DV73FLXWXM>'?A6,S_7VT^Z+]L#!/_6D#*/URK3&M6$8((.F$,4&H_47K++(G8PLZ;%=Q?IQ5R*28AJ^U5' F[[-6_ABF!L TY'%[*C8X'3?,.8@\ ML"=I^!*/>28O1]21/P \E^D]WLCDER5NHS=T/0@_\&_8D0L1X:)8F U68*(I MLAP8(0H>?_RF:>=Z5=_XD"RF?4 D#B3W9A.SQ*XL9LP]2WRQ4;G]=P MW6&W@+O\R#'<0,-DB-49E')#MGDK--3,_5SDEAEM/S_!C"SL%D1!D9*Z\@-FQ0KXP)=I._8N81X]^26?"I]Z?9?-F)9/8-:5SSJV M/)*BMA#(-M(09T>YR\L\-?XE* S@T1G)R558V1"\IU']#5KVC?0*#OFJVUPB$,A=X+B!)D*M4?DX.=ENK;BWU7$RK MVS3*M/A$@+\J NAX@]G:4+F5X3?;S*@<_4-OB+GGD[3N =2+;K(0"@S!P,+0 MZR&.WA2RT#N<;:@LVI6J3K<,'^S:CFLA?I*.W_%PV D@EKA_&;[I>TABWHR1 M*=1#8&3O=8H8R;5][D0949(43FY=%@RC,\L@$D5@.UQ>'D9#55/Y;CB-&^Y+D23@:#F6CQY0_'(Q8Z->5 4E36H4 %)X MT3TS+W=64C7>:'ZHS1 4RT49Z/,([,.09.*W[U.DX%_7JK83M(,&C"/47$CR M;,?]]%;>ICKMZQ.UB0Y4U)#4T*@:>U\\JN_:*$.*$Q;U):(?@5A",#CRA]#7 MD5U.1FFMXBXR:7S3(VM!LD_%7UVA'@\<+E2NLHNS/F9FG#F$NSNEU:T@O)O! MC8/)6MM16J]^Z!+Y";BF@&;9HLQS*.% 3>L'O;6D+#*N+ 3GKHDORXFK="+*)T!C49#TM]1JGMD ME':::1-NUU[ZQ.U8UG2?W.:&:>+8N1, "B[":O:-M23U!?+V!GUK2 M?$'<689+<6?:J+G9>\[HY5EYZ%*:LGFL#@&_BM'T+5/_[F9_ M UEA-64OD9RD1!GA-TEK?57<4P'Z/YZF[EQ.Y@!0-5H_4QC$!,;)U:[X%.00 M(3.1Y_:A([MRB<;#RBWS(H.5$G5(*?C?QLOK=.0;89G8/;^.(WDO0$ MEK$9N4_3:?)CI^2".8R=$_OA5GF$@TR-ZMFP=CI%?W"I,N8)<\^DYR8(C M:K*#>_MO\TD-=!YN9T.RZ7BD()ZY8[9JXV;)CGI9[-EL^(,K-(-D@H;>YHF5 M^(/1)RQX7&&5(+EIB"?D362IO6ZB)X1%MJ_L>HX'?@L:GV7VCB,5^P)%C#_8 MWXK'8ZC:#FT;'CYO,-)69VV"U4T[N&E9TWB#0Q7SJ(]5T,-GN=% /:D:-!AI MV5N'4YSKF$&.[4&XGDS6_PJXU.I+T8VSZ*WN0FJRE(K?R#(9P$/9\+[$R?9T M=>9F[Q,JJS,H*VCT!VOL;5W4";RSD(FS8R(A=L1V3NF+VGV/U8-KO.J,^CS. M"#?-VZO5<16D.W'4W3!$W8TH'@QP^<:)W5SSV:W<$ST_IERBT^R\U0EX+?#,"ZT"6UNHYG$FY^@PS+1H=X \&LC>N74,7X&7P[9 ?R M+82I-XN.*A Q*/M@A$9KTN?031PO"4E]3. # ;56)JC1C02J#*1FOK;JR! MW]^Z^\ZOTQ]L(*?(_;GN85$MF:#BF?V01XI I.L?L$)K. M0(NPD_)!*-HX$/@]0O \3L]-",W0+A-ON4SUNKPE=J=2H=#B>U):U\8_X[9V MQT)79HY2]J%,G/L*FVMY/9E*X"*M9,\IW%6I>LXS9U_F0Y^-^_2<48+;FOKV MC[".8ZQ7@$9VD<;P0UY%:/)+'">A:GV?%Y6HQXM]2K[<^9VH19&N+1:QN' % M2 TKR0NK0[V GM-L1#C_/=T0'&H.(:F52A%Q[9<708OO8U;$"F,.#USL MZ#Y*T"I.82ENSN[LY/3D-<9%"8GEBMT^ OGD;"A9T1 M MN/ MRT,RR9>Q8\E_73_6#55)] 21C5\+U)3G.W$W.J=MY<^(!N??"G,-0[3Z.\&+ M7AUA<;,N>/%8B3JCREA(*]Z.YWV/?>T%I0Z!+,H5IE^%%4=+V9VV/ MG=NWPIFSS;9@4GHSG;/-$:&F+04G4%-$OCTBZ'GUXGC&\*:]RA2;&O/+)^EJ M'6_\V6:L?NH0-6ACDRJ\QB.X?17 )EEA$+_FJNO MT7!-:87!(4*N],+C>;[7+T"Y!VV)@\)><>5KAI>Y$@L)3UK MO-3'1TF#O.54 [3+9^DH",>F8(/AC/&0MS)4@H_X:B[Q8I16HDGKYSZIY5$R M6B[:T3!E7Q8X8C6KSF6'4/?<-R'?:&@ P-<\6A&.LSBG5;P_&S\]_ M=_S)USIW4F8L[)PF%%]1Q,8V1$\=N) G?68*%>1DDXL0-]].=.C@TA'TGN&W M+J-WQ6S4^L;EK0A'LP5;OQ[/XL2O!H/13B1D/)>3W\8X2K@]58E(.P^/H<@[ M. :"7U84XNT(YF"M.VG_]BT-N0AJ$=_6=?C%3":\WQT.F:JMPE#AS8?;DR2& MWY,&>MVAE1XA857Z2OP:"NX^V[Y;+]SJ38M0CKQ4524.*TO5JQ93-3MFB@V$ M"C!(IWRC/E!Q$G*&F,701F2UR,9$)Z3"(Z1<.(*>/N@OH=KX8%0(&X(_%=,D M"=-:97BIG5SAH3I:?\S,5H<'6[P>O22D_>85T*11:5&EP:"&?\VGNR+M&L,# M2EI@W2-1#:G+^JC3:8P1Y+S&8;K*5MNM$FUOU"ZW9W63+JO*!%:._\#X@@9] MCT1@/0W![VYY]'7MF/RD(59+3>WBM/6=.'!3G? !*4;S$!S\=<>NSDTWM*7-%4-H+5?@^%?+SWFI%/B/H6/K1TUI=5E,65,GB#<95>.%EG0, [%3&;1E^^V[,"0@'@SG.BHMFK" M66$DY_Q[9Q$-+\/Z+?Q%&"ML$T$5BX*M/J+P+KDU_'$BK9WZBGGH"(H9X=O1 M&/'K4IVE5.K>G7Y\T,B=B&7,N;7ZJ5I,YB)&73P;_ VY=J%977=X,\HJR2O@ M7C#)^@!$-$=%QEB5WZ:CD^RVW;Q[^T2OI386J?>170]QF =GF1@"^MG9EDV6 M^=X$P3 54N#V?:N&*+]@7PPL$Q-O$@:R1POC<0ZYUS^HN X 6R,T.0U74V71 MI$0&L;_KA AOGLP+2"^78H .QSY!Z"0SLZES%QT36Y8%.V_%7I8..-N(>*D< MLE\!>IK]H"'<1GIW>M_MR_)HHOHTH,+GQ8'S\6XV*3_0_%'KFVW0_ID98 M)XV_'!$UGVJL*)RI/^ F\ F77^;)GKY\QR*JTX>T> MLRI8WOF\C5=FE#)[HC2:0OM=Z #^&_XK=?DF4R#GS\ZL3SYJ/&N0]86)GWQ( MK9PR(\B;&0AOG>**A9C7%;E;A:9'R&TM,)Z0_ST'=])%SV0V@9D"]01#*F%1 MU#V]RZ^A0^EJ=I**CT_\J'%01-%\Q$W/:XK(-U4W6UYTF.# M7(ECRMLI"T*8>?9EVPB./ZY+BO"NSJ!CY=?T :-]!I[4_7!EJEO L?:BI![Y M;UNMGQ&/7+G^*%24G&Q?.Y/.?$9G'6;4&<4M8/M=+A?C8#67&A3&&K=;:^OU*#4"+N)Z B:KXV3TL+HZ'A$J-L@FC)U5DTY&AP= F-^84"H'; M\\![MX#W0/^SV*R+7XT*%2QM(RE@EE'QGK"F85::3:'LHLY;O;62LG&@5RJ: MC?!8 DZ#1H:S@&1 =!3V8*6_%=/Q16\&AMNQTU^ZG8EH\:+%BI*0FQ$RJ]^RSE[,PZ M[!2%^@['Z7S[LD"R_6EI]O"PUT!3,S&5Y] $6_EWF?@<*@$$:?%%$'T'OVF+ ME:9K1:N:N47!T7@HE3E4/0C[6SAJ-XAT,I__J.FQ*('C.6\GQ) LVGB)4&96 MQALZ$7N6[.@'UX?%W^? X6YA"/;533N6/(\"[7B1\+I]TV+1VWX2G4C;DU9] M-$TG*=T%]#^%',ZDFJXV\-&U] M(.B$5<10;=AW*=?H>]#IC&?) K0B%:98,HRX@3L*TB6^'PQ>@PJ->;,RWLZ8 M[RM&ZLH-7-2 S!%&8XV!6AE5P]+GH8.P0Q_VDI=;G($B-\,N"=%-0^R1F7Y. M'6Z\( <"?_&]R:8[^%]NN,U#N^L.-LO]C&><(\FS%P?E1V#4 @_[B,ZX8&L/ M-8ED#_X^XW,SEDYL0Z?[TM'V'W$91:,:-T]\G'*:$#G;:2C_&T)I>,$$=RKZ MT&%]0Z9TLDM6OW+= U'%[CGX6A9_)&TPSY7]*:,@5>/9I0"#DJ$"3\ 223R7 ML.]+8H-@6/S#$I$QG]T",1DGR]/HCL."8>*D'L/'_"@GL[/:1ERS*"@<9TQI M>MQ)?\O*D6$$ZC.]'*KK#_E J>>O6ILX^0Z.F8V;(AWF7$WS( )_DYD["6MK M-()'/\Y21W%9A&J;O+6&')ZKQ]/"0@?#C'K,>CN]TR6QMNC*84U&[8&;X-PH MQ9[.W.S$M5O^\H[X*CM7C&N@?/V0NHO'/@^1;KFWS@_!SUCA09DQBE3W^6:G M_+%S.RME(FTM3_%1[;\2VXX@KX">B.GF;\%/ IGO!%J@K9[Y>UYP\K:?1Z)9 MF+ZT52BT'QH:3Z#ZX"C1Q%_2-%9B;-2R!J&.CG#%K#SA+P1M:)47)#,HJ\C9 MHV&JV4OZ@6I2H>+L+RIDD.NN*E%FFB6.(:?M9]6=:^\]KP/PU6+*\5(,K[^" MIR_[]BO R[=,@]8)#;N X!&IB9]JD MGLLK#H40A=X4]7EBV).L<\QNJJTN=E\$/ M2Y8BJCK7EJDN$J[U^]G$_O7-KFP0-+'095GU/Q^>K4^^ H)U2>-%!R4KP?]O M3\_>#&FH5%7(ULRCN()CU<@'S)JDU8_E1,-> 0FLE#/?2[3;"PF&.(:B^II: M#0J%5;%LK9U!67"FA!9P*!!6)#B#9.@E^Q=2:\]V:R?-W ?&7_>LLL3<&5B! M@["D:L@4([9EBCX--!=A[)>F\K?B9> R6F6U8Z:2[YEI>]U>3(HS8QV; <_P MI:"2RU*&Y=JD&TK0^@-RS)GB?5[0\ ME^B5]@-J9]AT/3L'HJ+$N7A#0 IA2(3T>Y_9FJ\=ZC4[)Z<:YFV9 MLP;B5)+ RRN.I"->VPS ]<4H19QH^A,&NE)8:9MH5_<,UU91F3,OF\7REB'- M/+3+)6$9.!)9$XYZXG?!,S&?NA'+71]CC;LMSNUI-$WH],:%5U('$0_P"/Z( MN[<%"4MX>>N'1DU3&]KH.H-^:Y M-7DV"T\U7;]T'W-UE]]1% X+W#KN>_C$T/.][N/9XEQ !65;D[Q#?L:!SK':>!@C\:"N>[7PJO/O7.,Q^GD M;MJ'5P#C<9NLC=!7)UWJY&UH=HY"8Q_8G&H+ZGA@U[ M[C..0V!U1GX;W>9>$*2RV0G:6/1 7GIM_H$K#U,]^2TY"*4B!#6NEITX<[I7 M8+ MTE[<+&->#:A:GAJ4EY-U[8].9R3PBZH42R[>-X<&* [=6[8@ 1CO-O;&I9:E MB#;DGTX/ &JB^JL'K0K&)K6?/'5$2W11T::*I4R,R*O, N#0)?M,'2.D;Y+> M-59M1FOU&Y1#VX]D55E)UFYD'6)=!=S@#,07[/KQT\X:NS!77"U>X MZ7[1,OGI:"(.&5^O;>_=TSUKB\Z70_C*,A/$7[VZBVZ';WBXE.QQ*61X42F2 M;UWSR4J> = 9,6'.D7;,JJ_XK'=DA:NWU[W0DZ_BBX?]".A*5)W;O;@L-AIUF##Q_(XB, MK^D6#'H@S7RX((5:9<3J00..^;\0XGV1#N!:M_C038MI!#_"HKR%E'&RF[HZ M5S>5*[ ZH=BL,[6>AVQHW):OQDF$;Q1VK<1QV[&II^N]Y&1@KSVS^2PT#1_L M$TV&A]K5]SM"-76#_ L!?+*5T^H-;0F$C&S'$UFY+<@KSL?T5"\GZX[]OS;!/X MA?8.=)-%G$^W6.75;@^$];!_Q2^ PXI. 59KA!]*EL*5)*OMW87;Z7K?UVKO M(V?V6>E^*CX,2T=V9[CM"-DL$.C^"IA8CU,&LW+#AF6H#]ES%X]!HHN^X!M3 M?O!*DH4VU0!N8U-$AN?)&EH+]\4U/K/J-CHYEC=7?[3XT=PG5HW%U2XB^KUN]():;0_)(:41WV/PRXC\HVG0WLMA^U:+3 M9H_)%9?4V_UY@L5>+WDNA8ZOI)>0C1XAV,JE*U-G<1H([-2ZWNTG0Y2;.M.= M1[_]-"&7Y69ZRQA%X:RY&;W$,B)/[Q?6/9FK#LT&:?@$@?%ZM ^?IXF#9*TC M.(@?QY9-AV+$9VJ+[?SH; =6W.@-=^-&B.MBG@HLG8D&&PG>#)2YWVJE<-7, MQ^"%TDTIYV,#QCP!%J>?TF"$9K$4TWNFG4.Z3^>@5$'IQ*A^QM0I:36XWR5,RYHJ7954:=#",B MO36$9A;DB@2@F8P5=K)B=#@H^KDD33(31^IM;40CW@Q;57KVJHD@>D%<>WMQ M#G-&KD+]YLK#C[7.%PL94<.C/Y='RK7/0-O#'?G'VQ71]!\+&?LTJRZBX7GR M?V,.Q@::W2[L*:R?Q9- AOL&LEAO?Y&63>^4]G#0,C0,]EZ8^;%*]:?DU=>73##J4T;#(W0'"KMVT??,T%P?62EH M,14A$[\\$FCB/,&$1-*RZD@J?*R91B!BD$[ME%>"WM7O% L1]%8"!+.U"YNC M*-^+#A8YY*UN_'S,D*MK]9\_\OFK!5_OA'5@F%8DF$\%X@,I]8@!(QKQRU'FRFN520O1$E/2]W2)Q(O_ M)1U9_5^3EGN\=?^0^H?9M7]F'CP4OAF=P9^VHZ1V0X6?+5&T0(AXF:ST[W-= M.4A8TXWTEUZ@MN%=35<9<7(;\=:\$M/SB_M&"*Q+5'*R6D?I-\[>49% MS^9%1/6LQ0^#M#U'%4?*WU25FXRM,+.'8J[*/=T?U#!DAX(,9SH:7@'"=E>\ M0%#)%G8@J/"MK%Y*2=_/%[Y70*UZ17N&;J75!(7\EFP/!6U0;"QH?4@NA M*9EY$D8W$/[$$^H:#BC])46>45:[C:P9]O/7E@WM2)+Z 1VRY3RZ\FTU D'$ M58L-R'5OJ=T]3W-.CCOTHS13ODD -G//Y>!FG-H-K.BEWEQ;-;A:+R[*]$I7 M6U,S;]EZA.Y3E+LLTB^Y?J[T!O[QOH@1IM,V3]'9<<+YAT(.4DU]9V0JX0,: M]=7&WO/^%88I//7>2!\=W'!+\]03'XXA1*3*SR]\\RQ*JS.I;TIU>RGR@T+, MXO4<@>,8L-.--Z1 2M:SRC=6>[F+&) ITQ-K;IRI[<%XWE_UUKJTV'.+\!2( MTUPJL8/UY: _<]%7!47%8)&45.*V7K<6AS<;V(QZ07A@U6 MN0&U\>8 2/NB#;\IUJXWR9]JS=W:R8'GMDS\BD^BI(IN$PCY6.\E*95DU4SJ MJF_5S_(!8MG78?H*<-7$+7^4D#'G$9'-6^CR3I+9$476Y&BS7@T:LLL9\D7@;?G\0 M@W\2TD<;_;3(JB18S^_)F.T@9L.VV#B]^[@67N2UNLM*:K0IYJ(Z_\XEI,$% M7/-[ 4V45X,#D_G)1R2BWB%XIW498MEC$F+QC-S8>U<@#S6+L;.F-7'V$?LNTWK8O@*D)J1L/9KB&:5IB(HW>LW+Z![D QP M[J>&[1-+X/RQG>S^QVYEKB#K5Z1<-=:Y'7X599SP&IW99RXOD+1"((YV1E)9 M5;W8[)SJO$GWLJ^T4SDPF#5+M5 K0;1 #L T[>*IWO*^RT@N+35PO=Y:XE7: M8"XJB"(I8N+Q,,%N,.4P2:,EML4_[UT]Y4TYG-2-GB9@?-MW&-R(.9G"8A89 MTA!MCO]='>]U%VSF^%#Z,L'$.CQL 9D IP'3I%/A]NT M=BM9=PA[7@$U3&N@-_N_;A+117<8>O]JG_YISTUS$YD6T218>F,[3)?,T%'( MELB3O0S5MD7P[L\MN?*:T=(D6SX2_^E+HJ-R W[IC'D:.,O[DO)Y$_MS^+Q? M2E_DDXVLG+)I4MI_E,#^1^F2,-%?I4NP3QDV6W^7+KGX_U6Z!+E0H>.O^]\H M7?HGF];**9MHUN&.)7U7%*NOHD]B%4-E%]SU_Y+E6G'],8 Q4"YVL[ ['LAG M>5?2 R3/]K=V71+ K:\$TD:=ORV$;&\'=?G@&3*C]]'A=@DA)J. M^Y)V-&P]2D&X6T\=QU:*X,A#[ #I/_]F=#VH5F8IL2FC[B@Y)RRH57CL?[W0 MT*+) H$5U,@ETHX<=G*:4:EE14E+Y]A/C"LAA,\%QF.6O5W5Y!__/+8&2/>5 MW%8ZF5IXR(%0]R9;=6-;64WMY-BE^; MZVA&'G%40'=SQ<6PH_'L98XT^J+NFX*?5]0$EJ;QK'%#H[[K%PI)Q5ZV= M$+3VC1F>@Y<.,A\"B%1F55,O,-%33(VB OMX,5\!J, 27Q6G,8U-W"O+*$<_ M7U=IL!_Q(Y7TIJ0]. _F:U) AO8^-.BG4GVDFF+QL!=))3/.5QA5L]*(6">73(9N:@3Q!R;ST7G%5 M>BMV36#Y47 ;2=&GQNTB1CKEY'GSH*O]!]1N%AL\I"-2(J)!+YRJ"S>=IJ"0G&:?(!5(-+%,[=_7S'Y\953L^ M-_Y*>S#2_CU452>0P<3)]8DF \&JVIR;O3YO1-_A9X\7^:GA!8W,D9UN5XQK M/-_Q^MME@A.MV"8A%(9,?O'5T"@J1LM MX5DOW7*TFOR^KY@QV NC4 !_58N 5 4DLS,P3L9'_%1>WGE5^)3Y )D76 >0 MBS,U@YEJ:IU62"EJS8I7GSP=@=R,' F6M-)9Z9P/*6.1=IC5&@5M/@L5@ZL$ M"]UCDL0Z+,X(T=(I%N156)R$^:N4=M>ST_J:G50+F@&!UR92*%L$6 W@%&YU M)\^I@[Z1BVA&Q8*:"(<__VU.@GL)42V ((3%4=HC,8?M*RT<;P0LNA4'I4 8V*2*\6VQA\']%0C-:1+S"K8 _OK2YQENC M:5=DD?=*87#RG8-.M%%:CT:61V_K,N*DB-M Q\4.,L3 \!,1>BFX]!:1E59+2JA^:4KMI(03 H[Y#A$61CP9)?S1403AN$9Y2G'S9KO#&K),U!=&ZQ= MK!#MH!--+KF?,Q(;I%Q/&C-BC>=6XOJT*^7JNE;X(<1")OX-U5L:1+QF_)UZ M,FH)RN7GR!;O?7G5\GPRE20^L^_T*J@$LX69[#UFUL:"/1PK![%'F(4<[68DX^C#DG MC,OJ98H 5>1F:Y(4QN:"/;'*!VY\.@F^0<6&0"S.B;*X8H@ET:S#(X2&8D:K ME6,=KF4,0RCBP'?O"^-W"&*D30?P99S,SZ<]O_CR/@UJWEJ?1_G*V*L10[=9 M2]4,=:]]L]\*A3$3!PXI3'*%W7(&?O<,YCG>K\8 9G20?IN]:3"64.'0_]Y/ MH0T!"L^QD*'=O/&792F^]4Z,IH% +BR=Z"L8: L61P.0\UU2Q;$^C3(TDT2W M\(UT^AY=7J@K:3TL86V,)+/(_-DCZ#_&V%/IYH#FOX#8G#-:6\NT"TMF4TW' M5,[TWDF6MLBY%L_%C#,AP]&-V_2%67)C+(N#1BS)ZFBMAQOG#-)9=4V0#.7% M]2G6&&2 OYOO;7Z*'*&-M.\C)>_DV7X;N6//Q)5BH&:VUCG$L*3^7JZNE[@0 M'H070?":>6=M:)/@95.>M%(IPJ13;FJC[$+-\Y_H:JR^VK M'/-.PW1&W=. E]F;K+:(' 4]@&@)N[XRA/6D9._I.7T9DB8_.6*\ MS[=S>@K(9^S;SV?[79NO/9V>DNRE7&E,;&CS!<8"V,=MK<490Y<=@"WV:&A1 MZ=(7X;7CRA7"_*,)Y$>.S6L:G5F;B<$HC>@I/,?NWJ7?FRQGI?D:5?.S![TEX MZ&(^PH^+-<\;I,QL1O./M%.=M/%CV5E:^"4X1>(>&*@PD\]&9Q,$>FZ'1 F M,#=Z4\914]W/>2[_K.W8A8:<$1YL)6O$JY[^:D?NT=.\&:>H$D5Z1W?,9'4L M=4)3G3,=Z@J0X::<>;UBTWXDP'5NI2 M?64S_K421^DK JV4:^POF9/5"-4%WA?SW0Q\#L?2BO3-[6XA^U!MGW*GR^- 0RD'12]30)T^/4]>?T1*W+F>GI>M2 M,(.GI1E1:!D7IU =N?7[R\@&5[T8U-F2WPMA#L4(_D_.VYK+_VM,T*7XZ3]N M#/\_W!1-UO L>3;XC"2.$8H0SSN@A6TG;91*O64^KDG!7\,)/;V;GU,]&+'4 MG@[$?_(HT='-33P4F8I():@Y5OU$N.F&C;43"+P,'S./5CU,=EA2>30"$E') M$I+C0***WP$GL?!P"91KJ?I'MG?=O3L>VZ[W$BL,,O-_O@L["Y9PS(ZJQ)^? MPWDAP,&*:7==TF/_I9GA^WA/Q>BBCBM2?HRHVTH-@N<[B7>6U;ZD;J[55O#T M6$?WI$H8W4G"VVG_(R\->IVNWI<1F1BN>MML"/^NU8H+%)H+V$5'?^IWA,H!/.UD\@>4=AW]8* M\Y*S][X:">\,+*'04W*2^7#$9U.N5"$B @(WD??!*F@.,B&:$16,)#L^K4+E MQY/2G1/RZMNU.NRQ@>_8CSEP^9%4B?/A?HXT"(D/D/2L%BE1>M;I"I9$?J+^ MR94(-XS>ZY-*G< 'P,->7()'[-@^,W;OO[OFV:0((CI24)W14S,@8"8_E8*1C@F<7(]O>W;N']@:9I0_L_3!?:FDD&9)" MO,/]578#7N7 UZ9(]P-G^-BB%-J\A9,-3: MEN>2A#WGG99$>;'TM66C\?X M3O'Z&+WQFQ\CT3?XLU 0(OU@4?7QZS%_#!2.?4>3-Y-#JE]8E9;M#'DRX70"V3!'/+ M=%^S$H>^^>'N0C!/7Z$U9SFY:*$IN5261<1\O7L!4/&IRIV-+Q7/V>?$W G MHM>5LRI24$598&SF,>40J&,F%36E6+/=X_*U4AQ*/N%!P]I#(+M:%0U?OR4_ MA4/1A%ERA=%!;N;82F>$D;B+O8 H?I=[ M/[SR?K%Q3K-[LND\[;]Q]]91;7_;OF@H%(<2K+@$=T)P*<4=BCL%@CL$IT"+ MM $"P1U*L>(4]^+!*>Y2W-U;VM[?WN?L?!GKCS766/F. MK"33/FO.SZR(0U.RKCR8O3+68 ME=_1*\O2;LU $I(J#893^+Y=..[9B>IW3CG;!K$\+GT&S7:KYO"J"E98OR?= M2HR(*2LEJ$61QLTDIJX3>%G;/@1[#^0@$W\_O9U7')[$:E/&(RB;?XEFZB96 M:5Z1[LOM&?G8,1F1FK(?C71H#)>/B%#.LX2]1J23(.[NUD[*&NHTU)O5D)VA M8YKS8:F3O[#J([EC,705(J[K23]@ MO!W.P>"Q(LQL*MIM%=:K*"JZW57(JHUI%CS2/__IM&@FM4KG@:7N>8Y@C/R) M0N8045XFY5@7+'=16\6^Y:WVKL K'$_/"/\^LJBC4L+&&VWVN>!\T4N64<%" MRHD>'>68TJ?Z^->OO8Y^$*+OY7-B@Q MHN^) C81%W\ AXMRP^M^1TZ9!5E"2&:Y^'M4K4 2C_:#65,^6-@@)3.W?HI=^:V'*IZ=S4X4Z47F M<7B-T6@B"2R=)\WNX6AFID@H:2NM\^-=N00X8&IPUJQ?FU:&I2BX@= XBU<= MFA;>CX.5JTG(#[?9NI(=WZ;/;23'K+!E/+Y+QGE+WE')G=82U\.!GQ#_&Y8& M/EXTG&*Q.XQHT+5WXA-=_M&6R$:Q#Y3 3/#I JI:QM;)WQ?0D[2<9Z_TQ$BX MG38&UN3J.C[-U^EW4?+Y2F+!FA#A)2&:#LF56G.=7_5=J2AK\OXL!]4@5\_# MWNHD)Q:BC1P:W%U?DN+;4=V3L!YG>F5JHHSF3XQA/73 M> >9[$%]!2A6;'_E=XS\#='+-_S,[GJQH^6687.%2C[,#6H] DD ZXR=<"?J M:/;J_"NB^:6R=T\BY1FJ>%;:L]-@BZU%63@7]R"A/H(/ N(4T:.\]9J>='/ JOK"G%,(*PX.=#2L. ,$IIO^R)=%$S)! M_3RQT3?V@\-@K89=9=Q;)NX[1:M$>7O^"#N,+HQ."'*TZP7^EVG1& ]M 6W)X\D6-.X97\ <_C)AJ? M5-] (D1RY?QQ96U-M>5 _R[J_'OJJNA%@,[PK-#GYV]IL<##(]RO$.PZ5OA= M[*.R7H.KQ&*>=SQMG->SO/ *+G%)>Z%>&-6-QYHBY:@GW:54M R"B67X9BE, MJRFU^,A(-655O6HZ KZ,T*.KE''JBTX-X*XK,'-4/D"D/,.CY%11R4G+RFJE MY%M(.RXYK6Y0$G6OLQ[&7VDFIK+AP_O0E96 1.\!(R/=WVCKVEF)-!P<]JMU MC&2EE1*D96XX2'TQ?O6:7<#L_O8CMABYNL6326C"0#3:64!37>ZZP41@?F*F MZ!=_B+_N]I=(SQA,%3P3*ZOQW7S+DCM]/"VGS M\8Z5M*?X\' *SFK1!#^$3LO_970;LBS5ZW808_#%;RP)3\"RB5#L\QS::NA# MCWGWV-;38>UJ'M4?:12ET$C]"M=+^Q:B-VMTU*#CSJ0SO6K5&UU[K2 U7@:$ M8C%YPA#LG'>%8M&K)=?6)-&XT:%'&%O=$H7Z#J58X7'6W6PHK>'T<47:MK'F?FM\A0%K$@P0KS"<4%-WE5Q1H=J78 ML@+;9 =7#R+;<> [*]]]-:'EJ+=X4RF&'3\E:)N=1$GY<^#%RD=EH8ZZQA^0TL0VNE((WU@E@Z0FR+">#U-'L-?]S%UFSVIT[8 M=I&NET^-&"*%+QQE]&HG54RD>H// M'/F"OO^8^=KRV1ELE?MJ@9PY2=,A]\8["9V$44F,_FU T?V#L0SQ*XOZ,F&[ MMIT\17D$.)]H4S"\%FJU)MG>8+UCCV\[,)YLZ#92^[G5L;@:4&##;R__12M[N[M8DI]\%>'& /-S -N^'@X'?O;3=6@OHRR M6X2QE8Z?5).G\"O-4KV=\$K'D>XAD*"=$G=M=XBQ\F7C2U%9X..:A84E_?1K M7]^ZG8X$YDQ14]P)7O4WM5)32NE3[!8A>TU/CU)"S)_6DS0,QCGEYU]R\O' M#+.NI4V+D(0T#EO4V7B23UFAS&W40QFIY!Z>67SU>VJZJS1SW(O?O/KBT ;P MWO8R-Z7;HV00WZ 4W6Z7[^7W @P+4L,F.SO-K 3$@&-Z>N8EI=/Z00V9EWUO M%:B!KD\3V?(ELARZ61XU_P @KV*IYK7E2 %QY$"0;&3F *%:M-\+]J&W-#2* M%'W::V7TDM!A;Q-)[2E@0UYTMC#!MOG*=L/\) M]?_/.5SO3+C8-HA_QX<^Y0KZYY1=I+XH8%UO21PY#*EH(EL1D#V_21\WT)"F M9Q)IL1QN/8N2V0_<9-0&Z@_#X6EEU0JZ-O,V"-W(>)HC0>)8SDUKDLLSHP<1 M=UX^GPX1LRSW*@*^Z992TOQTBE&;G^*PK0JOCG'J >P/!O14_FUW80=GK\Q' M SDM8@(-5W49YR11$=\0@!="Z6B%V5-2GR$9I/8ABG@#7]PU?4^^EO7]@@TZ MVRF[>'(K5P/2=P(@H\96<2]9,0DWSIC!N#&30S*P>>RX>9;]DM+@9?(\JI;I MRQ&.'JNB+2AV+[:7(EO-'P!0]&6$/,./-]]*A.,."A=>9C&BTYZ_DPFD%JMU).23II@0RG:19X-TTW=:G 1 MS/W&O-$" R]D(?RRO!;VHA&\(VW7SX-]BD8=EJJ#,E&?N;*;37);HP_F,H@A M3(+H5EK\8]B>8B:DOJ:#U4'3;OCH%O*=B64=PE,JB6-4E#+/!*0^4[YW^DM@ MS)3[X@EWZ@,KD]IX]&8D_$_DTR\&2&NU@ _R0>-3[Q+!G7^I5T#4B QL?;V*/X,& MOEO&R3NC=U"6D#F2NH%BCD=+<&452[B$W]'P^F/[VM\)K4):.$]*JI!'?P5" M-,"^@7-EHAFXH@H,L1<. 1B(CH)/IW/X0L(G??ID0:"R,A ;9Z5!J_3GJV)) M9"P- 1Q=D,48(\BF90'S[CL4LX#.P!K6WN1M4+4TISMF+Q\8"V]$B,4%,K6T M-\NSD?Q()C]?BY/7^[MXF37L#5(=L,LRO.4&R7UX)A1'DT9Z]D8["2 J.@P^ M75]U>ET0. ;^7&$=H9W>?*GHLCL,H1A%4015X5Y;)'RJIL\-FRDRN-W-^&9< M"Y+#-V0 ,'$P T_Z"DR^R""3H((#9I,A@$'Q3KMA6$DZ8HO9BIX/BV53!T3\!U!7W"#N6-73 M^R;OW)NCQ],VEG9P)Q0_=?T MTG: 4OGG\ U15E>EA@?O69: W_FMQ=NA)!]Z(1#ZH1O9!9V' MLJZY_CI!#JRP9@V=,8!*1BP8:AZ[N'(K#2D^:PP;K*HOY8'J?_L/!:WOVUAO M5\.J;.-_&F6?Q*FQ$T1X1Q#.N(8WD/96^=>_XB#0M\0 MQ7G'LH6P5!KO&>H/P.?IEQY0/B?/?GMTRHA>9&31%*;>!TQ!W^:I2H7 ]&+M MNK!LZ$ -W]I6)X<8EQ74VH,JEJP+?U27\NUFQ6G%DE;V9DWFNC'_-O=%$RG_XK^T=Y MXK_(=\_;_2\8VDWL?P':9#HJ>6(*K.(P^TD\(DMV&]+6^P/7SC9OJJ[OI-%G M'**OG;\PM>G[]76>E+GQZ4'=2=9(';:=8*AH1\:Z;)R1J""-(DP1-9LTO^ M#U8PG(POT1'Z.YVV-X:#4P'[+C(T_@,\1?:X.F)[(59:^/+=:]1 BXOG7&YG M>Y6QR*(DZQ=3 KB0S<9YYV=!Z[E[]._>/4A]\XG-/IDAQS?76CRF>HKF'\]" M^#1H9:4@@_!ZYX"+KT)"S^/4@B# MB^D4A2,W$SU)H:%NY$0VH\,/$J>5"DF?A=_-[%" A 5UR<6 ?<)!.;1M>W5^ MJ06C"[P_6'PJ.SQ(M:UH,82\RX75Y\'ZCX8#T6(4+ZH#?+#<)F=[8WC1O3!$ M#=S.^4:#!I6^RU.2@P%T+2%4@6UO#5 MGT$7KD'N7@_5C8>3)DL#N4 \:BMAF?2K0E]AF[1M*^NZ*!J_8[. HMW$PQ^3 M'?8:]<])B10<4*+5 L,<8*Y"#"^!@52I#+E =YSA#E+B97H#C][4"FC*ID0A M(YU2?)P89H%AQYF^X>FZ[_K]/,V8;D] MA_!?'LL!/4>\E(.$O_M"0G'MN:/ MIL3Z5J%*T""W0XNZ"J>C7&:?X4;<8'NUO>9/"E*_^^$3DR53P:1GQ( "OJ=$ MN?9# =11>QU&*(;;*Q?SS?6UO!F'KY^?W,2K6/."3(@+;>T[&2IT[0 1Z#C) M:@F4-;JI1=!9;T'Q0<64*EV/#P2?(2\/Z"08<5(R]EKS>>;ZVNNS\[!,4U]C MMM#]?OY!.FS/?/2J8R3MFSG[CXD&G.ZUP8D)KYW!]S3RPLS^](R0J+JL%6F? MD;V\CT.S[4H*+D+03,Q.H5@KNODO<#=@5$0G6*0\E,=G^[",>G)P-XED<-KN M$V*ZO@(/@+2J@QB5"(-<3.!=<[%YUI@,[X#,Y7OP;TQC\?,R_HN(X)EP7OMO MKUGGCB/I,&Q\U6VBP*,T H6;WF^^BF+1!&0XQZ8EEV0$BTRH%AV& 3$G)2*L MG,C*O5MX/*E"_,3V38#/ 21\0,U6>("#[.+KWX)S7W:[DU_PN^F$,UA MQ?"!W=47IV8Q_,?+_HQQ2" 5GI=PE=53>!HGDPVN27QD$/P _01;#GA8?696 M[N.^MP!B?&G?>*D$RV9[O=2,T.[\ V#1I1J?>H"C]V2*#FXID;Y[ Q^JR+2,:SB(J0(RKL76JUA+$]?AMY5D.%/P!4<7W>.[F9FUR!^DI* M,,$.0_IGR'LVVD+9'22$.R #V6FO@5>Z@!=)9&LM"'J2-VXEF(_ET+N3 -%^ MH?,C=RJ,AL>TSR4B):),L:/?6G378\&PCL>BBRB:54JI]MI)#_6_EB?\W[.E MO-QT"J%805(-V_:-*0JX%"/I),?=1?BR]UL_IZ@8_?C6@!^?/7B>\)?=LPD: M=IWNCKW_MFYGM-Y&OOS#063)L8?>)C/:Q/5:S;'?8H4,*W M&QE.5L$US&+,((XB\4MK#[&B_%EX=EPR=-,0\CA-"Q_5[P%R04I-!QQ3#>\TM' M/(/XC+M5CVI$^:BY\+!E+H9'\7MJ*^-@*0UX9L\ZT-,B%N17UW-_GG5FY:TZ MK$4-P#<9V7]F=RA@]OZB MG3)#R_3G@=^#0?7<O9EP*8YM%(+:TVHLN-@#LB-PMCQD.N4<[82]8%U? M#60Z2\>I1)=_X[]V'O^&"Y:V:&%(G.V_3*,O M"_.T<3IE$-"#>DD^XS#:"5JYX5A,E06>Z>L E6HO7T^:/"R5O/7U BK><.6D M,(\Y&OGM B-&>,]M0Y;+T#Z1/S8D8&A//(%K+\5I&-H(P#)-&CX\0F2$EMM4&$D M-/1WX!C#-&549&:DHRQ\TF\=:M?7DK WV6L$3:)05 MRI;)Y1QG_8@R19O3W]4YVWEU_Z:>A/]23S.\G0TZ$)[?C09?3-#)*DB(S%X- MO6ED%8%MC_[EMIU$'95587YAU8"L1ZA@I\H5BDMDNQAYMKMO(5OM:K865TJ? MF^BB4\0AJ40PZS:Z($LZU. Q40IU]!^%IT5G;Z[):5/*_!E!DM9L0)I)\"ZD M#W]\G<$=A#!\3&3Q')RY?FXI3VF$P&,JP]XE=Z!FI0%J3A_0W.N7KR;V60:WY M:8K;W9?OLQ;.>HO01Q3@"G M*/VE61!(>X<]A(U,A^YX2D5,:9L04IV'E56P M!6K,"I-GJMD*)(C69)@'']3-:VOM]:@1P>^/&?EC&+=H\M %499$K,PU'PK# M62UOS4.7ZR:A(Z:>!^ \69:4?J-#]2:1R#?%2SBDE=HR@0T>9&GX,H'XN]2J M#*QHB%%*(#8\Y[IJ1 DG!B4\[%C67G3$C#WS5;M=ESVRL[\.$Y#TP6.]^2K M3:5?.9_ MN?9[%WQQUR%(+:%F0)#B,"+Y/J7 VR$?^,3O@\ I,'<@#YZ&S%K0JYS]5";* MW.NQQLWH$E20WC5 F_V6U9B$/\1V>:\DMJDRH"9;N1]#1TVI9UB[XR1.1DT\ M[&[7'5,&&+.NL'C[:)JYF8+3A^1F,):>S,9"TSP72\16]%Q,RVH="14)<9WW M=. ^>JX83JN^(8*;<1P@.NYS:KD@:-[)BF+QV=E7UU%1<2<6W<=20GWE. JL M,=TKFQ7J%](.L[&2/$MG'V7*8 ?">]_+@,_ZLUH&U^:*5Z=PAB4'3CLJ*Y8P2[BH/)G$1W?N (I] M8YEZ2-!]HXLVYC$C:2@@(=9C[?YT]/L9)01"(6/W8A.T;NK*/,DPC"=K$]@0 M!UVX33CFLG@Q@6!Z#@%SRJAB<__2EF$D19*L5/=L0D07[3U^*F4'9'C1Y5RN MZYC:*T6\J4"M)]K1^/%21[^8#(UU=92AJJLGYX]^#R7#CN$8;%Y=5F,8##V2 M=*E4N9'#&2.V9)]1-HCM$8M0QPJ,1P2AY'7 %C]OUWTT#V0*)UVI\/D%)'TM ML2\L[=@D"$7*3[?6VJM-5J?^G2J:BOI_FUI ^[_GH%[[*RJ"_,\HU! M$:]:(7IV2;W8R^LPY,;E'X#]D.Z3Q&W],Y8;@P63W8 ,HOXPHPN[EG"TF5'6 M\^PU*% TG WQ!Y""D3\W.R/W"49Q-&ZE')2I W[8L,:W@2[\1/WE"KJ=5OE, ML+ *ND1 M'BX@PM),#H5AA- ;Y5'M,I[I]UWQFU#+/EYR]2_\9Z:7D_X_OR7E M91S013XQ?7_Y";C9GWJ>W@42S-X"P\.]OL#3S(-GBUX4']]8ID]*.I!+JFO3 M](;HKA7ZT\DD8%]PT)2GEOO4;S. #M+ M!JR.30+=]BSI-J5/@2Y)E12U%'%0'#O5=B=U#4=C02B;8ROK'.^%N)3^4&'K M+R3% %5-G(UAO7W@$/9(C)WD6Q+_-Q6.P?-L=Q-JE1VF_?&[DHA L?"A=CO^ M&O2^).ZHV)@UDWG>SQ4_494DBZE@/%\8#C8#S$7X":N;X?"ZN6CK_ #/A#]D MZF6V$AFXV&@+G+[(1;OBF6(AS/#@_EIX+3*FJDDJP88.")5/;U9@5.]A,JL8 MI8-BQKRU47RQZ>7EMR^<2?#)AJ:T;ALAF\#38XVO->K0Q\I$$I!*NQ$8$(!E M:LXT6Z]B(T?J+OM]&!8!Q:)H-Q: Y!:,G$@E'DAV6% MC> W#AP8I>93FW5N<#QB#]=6DPQ@Z"6T>:^HPMVC39"PCMBRG ^ _0'X['T- M,UO5[99CG.#MBQSO3G?)_@.@34!RB>SP5B)APTVOQWAR8ZDIV) );7-BW0&QYT.5NV5S\CX- T7$;T M^ M.P&2;7N"II0'?SJ4U\X9UO3%]+>06L(66UR.;;7HF5[)&LQ*")7PV:#4U<_T M_G!'WPFMXUAS.72Z[DA@!+IU1_1=1Q4ZA->>UA E/6]2.-/Q,7+P@@A^?NXS MGL3\6_5Z3]-9C^4[EQR7]*:6 _X#T#SFNG!24456_W$0!8D M1*IE7;,72*3('YW->"B73V0C:YOR6/#U3,@K5&B"W_;$=)^AI[QBU'_FR.-?@:;-,5B:K_NKMTQ=8I88(A3MDZX MC*U#'CIU&+Y#PKE4M C7:E1A)YANKZQLUSKX#T#\<6@RO)Q=[KL_(*K+\]P" M0TZE%?YA&[99'[XN1,8^VYG\ A'.Q3E/,LLT;CJ3C=+K1NNGC'A=;W>V@ZQ.-W-;4J;#BR1--0$2Z ML55@<]VX79W4@P*Y';_D.TJ!J"LR3GNVEYN22GAA<:2)HBCK\N;^$+SUX+NZ M>GL1KX 6]R2=L*)I@E=8C/D ,P7N!??D2\IM#H 2)H2KL!['!)RQ[M<"+Y1 M0,.T*LF^%F_H9U2WIEU\LSK 2%HQO-_B!%/%]OE8;A3>53(EU2MAL\4QJF-? M$RTL=<9(IN^U[C,;HV4 Q)S=@SYB-P6I@[3),?)@47;V)N\D'\BB \.$8"5W=C"[2;STQ/ P M=3\55IAI74+16TN9$DOT++RQ.RVG==3TO2[/ZFET_;&SM[W"B 5$F,A-G9FZ MG1B2$F-J@LUF*8N@<&*.MZVC4G_7H)1N9N4_B]Q5"OZV.,8Z''?X!Z"/M($( MF?FSI'!<\D<=>S+%4)W[EU6/4Z,8[R121(\,3M@Y]W]$?TA)WH%D)7J*Z1\[ M9Q]@4@ZZ,4RC$14X(3DW\MFIXT9 184- M)M=70L;*\*.[BU45,L,?'>9\/5276L'YRI!WEHCJ^+9]A -7KB)F M(-W%I>N<)"HMX1V%(.U03=1:AS=5_2R5AYJ4;:KI!).5#G!%\I.R >\+5@OW M@>!>#D.NI-T61QFCM(DOI,E$ MHYQ!35Y6$AX;[1_USGCL(P_=;U>_K/KMTB)VT*4WC18'?E4(J.<[9UH3H8%( M)^T\+-MG>6BW9+"!&U,"!GI%58&.V]VNDM.]T%US>$/N "^@AI!RI M8UM3-(UBN' )M/9QQVHJ3/I3)KLH>(!4=0<*KCPS7=D#'BI5+]U55Q62%OVS MN\/?1TE$FX:M!<6I6=%FIMKSZ+E'7T VDH^30]?R:YTU%DPN@68Z1XQYT%-W M?([?\R]COH; YSOC5#)WF,Q$-50Z"56J)9 T.#O7O2RY-OR>;L#'^!($&=]H M1XB<^TOY,%;2Q1N[,9ELE GV^/*W!)F910^L7N".+3W^ 0B\BIO'+S_(:OKKYQ<30&L+B1FZ'I,LU>Y6V;'_:?)PM??K__6KEKYM,[#\ JX*+ MVE^U6H?37R;O%T,6V6Z<0XWSD+=4TM1\R\R_*R4(Z&/33A)##?[>&^W_Z6J< MA"R@%#;Q60MC#YQQ9P-"WAO<0^7_]M*45]WY1\^1UIF:"+M\4E<0:%-=)7K/ M;]GDM/?IA+'CKDIMIT&AWK]Z=M/=U \"K']Q%M5_L>KT5R#Y+P[N)&.4-^'[ M_\[!__^\&MLFRU2Y_WCY.RQ?\4&?_C*K!I]M,_0^+@OUTP1I95^7Z%"KR!8_?K*IV>'Z-3^ $8QV\#>3J(I9EVQ,7Z<0ES-@RYZ'51I.F(![Q-: M=?1-$R'ZP?VS.6_[>YIM1\%*XXWS "\7.$*JMX!9&Z4.WG_@B^@2?<[0;]=/8 M)PO'ZTV,]E?&OIPW1%@.(?VED\M6?YDN";8%7CD5_:*\#24O3_Y:N$7U9JU= M@T5J_AP4?,1E6S W;?-6@"HZEG]!7N$D@2[MI)HDJ]RM"Y;PKN'$K_,YJZA; M_[7 (;2 5C_5XRV8P+7]B1NF)9)RK$?ZA;E<(.GACG'30> 9@3V!_\'J:U]B M,D =CYZP)*7JB+0(_;LT-??RS5Z$ FF4;PENSI?A$4EW]Y\1I5.>U6'9%J@B M_WLI4P/GI4+*$WO7'@K2]O&+0S!;9$%V[= M!C8O9A%2^JH&Y.$[7)P->Z7B@^DJC6]3E^I M/@LQOH2=[HHJOL8<>Y!RL.8]TF?4L8=6I-W3%5[9>>KBIZ- M.FYK#$AQK]A?:^5>M'-@&E)*AN_AD-I1JT[>'CZ/=Q#(]][AG/']O!4CD:SU MUT?166H]B6+',!7W,+E(?,%$+IGVM#)@891FR1TO%B/7*[B4A;R1^T[-2$/J M4OM!M8_RB]WWT>%O(T-CW:B1L01E>EZ5:VLYRD7_7([Q]K(,EG-[XP]) M$;7Y:&YD4LWJO#1"N4H[E8#;Z^%7;/SER_T7RP"!R_2FNU4?A0I:FT:-%GYG MP2TDAD8W+7KR$PDT4=V=^(2SE=/+*OX@!=.8QH.IOD=/):^8VD/S5U+D\SPY M_!G@;:;!W99C)WCOF+.$W[L^BHG]'$ZNHR+Z,MQ!_T&[407L;-;VO[ZGS*U. MP#*2A_CG08.TAO$*WS@Z>MXJR$ R&_JK]AD7/W2K^+HD M[&KN2J6A[@FH0--/^**^.9TDHY)D;C=CFV@0''=M7M@B]GS/Y=OTZX7Q[6"5 MANNOY8I'57SFQ./J3GMH1;)YH[NB$:R8A,?E7VS/_OK!JPX.JKCH364P&.B\ MNQ)0X#X!);0$W(V,+0-^[*G,BP)>T&J-MF%'B+#]#3B'/&R.LSFENIP#0;+* M%^W;2$<,?@'\, ZX?H'<*/$,_\' ML J=;W3N66)AI*Y85A@9C%]],+JFVPT"ZNQL5^('.$4W\]COT>;/\' M$.RRZ"04 S6/W@<$]V,K^(H=^!PP@, MX63B;_HI?F'IT6;TWE>X8&8ALU]3Y-=SBQ]H27C"Q7W+,@7X6(U'%VUVM,VB MLQ5#Z7$LO=9U>+6/;!*;=GI=9_U>]='+:9\H4;];>8(Q2@.K6/3TM]L:\BI= M@LB=UZ8R)7UY);4VW9W]*""D,;%A+S=]AM.O/&9J*GTEYI-B?YG 1R>-W>HC M>1JC*,D^==U3B$:$?EC_34J?)F5JPETXE51N0V0+>SL'ID?!X,"=.DSC.HDW MU22O>)@/_1'$4DP"7)_%/'=4H9?PT_TN/[YG.>4C9?3AO%_DBYA,*A((#OL' MHL:^%XS\GFKHT)G3@4_:HHUX45:RK).EH]1#'[AZ;^.*MX42ZBA])'QY4 :U M21]>7KL1'=\C&JSZ$,;ASC ,FO>Q [L]6H]9Z[2O?0FCA+M(B]XB!>JKDO-! MNW9X@#OI(Y2>KLI-F]VW.BU,F2J+?UDG,\=U)A/8YJ*P8T,!*=,A MP9;E8YE6^)]E2ID9)YQ,=Q)6MK ?Q]=;WX2V5Q9^,[$- S MHFEX&B\-SZD/^\PN@H9\-KZ(JH9\(GJF(\3(9RUV7RV-+;T%X:;Z;/Z'@:,! M4KI-EBW,-E]QX=P5;23] )UC.T++V4M1DH*>8F3E4,G6@?NSD M3'30UQ'A.$:*T O_M6\"E[,M:D?6K5'Z!JND(4@'@D]$Z8E:8 M4?[6@"],'&^LTSHT1Z&B4F&,JA"$_SDZ"5+W8]_S7=>W;_?/DD.A64U)KH&V MY%\IKBT4OGZFU7L,_GDA9\?)I5(OF< =S.)I,F.LUO:3QR9AN8,HX M2NK@A?1KO2#?@/(&D6 MB3&)IR9?^8HD1A^^KN_FKM+93?Q2U,1%O;=JK\D?MLIBJGK_DAWE1C10B_LL MB@GR2<2LS?>XL:$F7S%U4 -72$\XFT.KP^/TK;K[3Z=0^9(1;3$USH0FY0$R M>D>G5+6*(R>(B>3!7((M%M)+5$O0"T+=*M;T.-O8)&3BR-R46>TPX*B( "? MDS_'QZ">/?XQ\*-LR<3<^ QR?K?S!Z!!T,I!+2)_HJ+#/9M&+BAC'.=)^O8% MK#"-(6%AHHY#@.GB2J2IJD^M/(ZWU$:XOXZ!"RN'SH8I)WTY',#Z::PIX6?; MK??LCNJ ?T*3@H;KX$HV8YCS4R MO%ROVU28^Q4X:8@4'-=EF[-G^?MY1XM\68Q7X/3DG&#$QC61X]8'*#]-_ MF56H6*854C=XBS\Z/)Q$C_ED=0LF[*IVYBRHZ8":XA2%HPI6HI:EJ-)SKCCG MO6*T]^#\J$=Q+_GH&V08MG?4?@%AJ[$K[LS^ (J3%:376 E^;L6_T'\#* MSS^ N[\LR'=[D$53I0^/ :A VZ1*[3;?GVS>*H6JVN?W5Q[?MP-BP#&HV^O4 MT(-)K#W7(J>\FWC]+8:)[(^4G<>MOP!U=J+AS@M"/94',-'9AP?717766H0( M+WGY;=D?P$;*V3(OI \5%>%]=U"Z01V@^A$UE[ M)1XBJ&^&T?'F9KY1D,(]1""A.?M18W5SZY5XJW5Y%1_UEMO1ZP.]J\:BIFS$ MF'8GEMNLOAUG)0]'JG.EY6@ 89+1B MD[S,64VI(KDAG'9;LT64UV.>\5?U]&XYOQ3FX"!8P M^MWVZJ/I9R,%JGV(C6Q&U+VG M;1D?Q8XY@R\N=W9W$;8/K_;T;,0)&"[Q4:R"U&LS M#,T]OL_0?N:L.JS6T11X:>;DZ.\OIN;2$@*5$8#>ZVAY.DN(=21QDH M5O*\)U^LI8HP+'=E;R^[\[.:%3TO,&&U:E&B>>(5,M$#3OHI,[/UZN/U:M(? M +S_T6KF'*F;@83A"34>3 J23#FN\D'KQ$2TU?^ MVE&KY'%MU\VBI*1Y9VP=W>(.@8LD;24\TH<+;/JQ"+L_N.T>ID)&H8RL.'LA M5J](",G%[HG\S_&C)H8E]/BO(&0V9HG4/%@]&JF);P(%?L-^N>2]59[+V@$< MQP-C%1V:%%TR&-,E84JTD,5D^LIVP^B6:R8C%1S\,KNVQ66TL"Y C'*YVR.G@$G$ M6+)#R,:1%X%K-*'0'TG74Z-X%WO,L!J+A"XVD)$7Q,WTL2C!]@VI(SPBXMV( MI[^/H'I?!S\$L8OC%=\FC>[W1)%IT8"X*[QPTN#(0/"[D->\IJ1-*21I2<7U MG=]Z*B*=,-SP6,X-AV0QC^$AMW(EQPJO)F2^'U6I M]?(Q"Y')VC9T:#1Y)UPY\"T3X$B#*M*4J M;BR\K1@&FV#R:M,_O\J4#D;%>HX8ML22*-<1;L+50ZSYGXVVNPQ,FL:0R&P! M,/X2\_=^9*BQH.BM]L>MP4M74%DH+C9YW%&BRNR6)>"RPGZ0\'D&1IR=R79V M1!S/+M95_JHAJ6L0U4LE$+.BI'TF-H,<-8^9SM/MH*&T3(1E=,:;Z,+EH=JB ML)EKQ=A-0Q48G60V7[*?%29SB/)=MLP%[T.KLTP%@4X$$O$=YT1)(_I!&61; MDP\@[/ZX/4B-@LN8M;U8(NRHJTI2&$5RBF:!BP&9!5RKE&,2V(K4= 9N9\QI M2,Y?4>M5HID[R;;8X13,\<8*R*A^_BVQBM@>2/I=C,@3\W8ZG6J@D]&JMNQ( M$,W[H&%%2AO)7>^*R2OW;YW@Z!=Q-R[9*)!'RNI+O.-2G2*N95G2Q&) A M+TP':L-ERB7L F(=!"P4C5C8,\-@*P6^ZEZ6UB61"$.@2L;X;EG1ZI;/.XZ= MY', %R%P!0>#,7>ZC04NU\YD.1-4X>=J?L:BZG)"B%V8JSQ3\H ;QW]%'[]G M27$E\- ^6E,C%2KE_*ULOTJB\ QU*57(/L#0BP,?5TKG9M5^GI0B+NX ZIH; M+180VU8@VM* YCSG_L9H=)RH3$TX^O50V(_K\G8]V*?BQ&[IO;>=,(W@F\%V M@1=BF#U@"!\5/6SY#&OL]?+C#4?=C12&4_0,)!,%?$?)3!&&F(*@3^ SS6(% M^G5&NGURL,2\/X.:Q<503J*C3F0?*S^^V$@FPF,RF2YN0402X99C"ZS5,DLU M<5@HVM0!.JW\VC_VG/Z.<_X0\:7/4KN2-G-Q,"Z4FEP,W=]PET%L79K%&^1D M:<9?ZAT_0,,^V2.CPK!RLOTAFWD$!.VD^"'E ZKW$0.4""H2N3B(\@*4^3.5 M?WU5^7N.YRN%:YC1U5J J>"BW97#!\ZXM9V[\L9U9;1O+O77=.51>#4UY:H,"PZ#$^R%@4\2H5MDP&X_1M) "?@Q*=L.H\OW%)XO) M9'3H@B3J]0##1!9NF^_GL=?/9DF%K"9/QGQB*$_W5)YI<)$[N8@C5[;]V IS(!YINNZQUJX!3P9: M'[G)*>Y*>C[EUHFA0.BH,JFD,J918-&!5=50BJ_K_*:#[0V7]'M=T89[4XMJ M*QZK/F'HUV;+84.8/0L@ 4_X3= @$ M(%F1CY]#?3CGB,I5^YZ()LS_),EEL0B1!QGYP,L9__:%96_[B/X:GK5?8O'9 MK)Y(S@"(M*G4+ P\_ J,LC.FZ>IP4V 2YEOV>2,_L\WZB7@+2/=$47T1DU?/ MR\5?+EUA1.'LH42P:P[6C^M(I*%?-\>?'OT;Q@]<'["("RGX/&6,M+G.G)1D MK-^,C"4-)SB&K3_C03!ALFB?04*6,I>6,L+\I,P^R(/P^%W%3$"B!%TB'?"V M'AS*VC^ QK;+!BC9-MA0)$2&M$!.FJ,?':5(\O1Q][LWL'K/5Y'N>7?DW!I9 M=\V>1"3LD5Z:CX^+#])BMSM/D%!9&F>TPZW-; S!PXF&2 V,46_;=F(:&&A[ M"3RZ&/?HJ/ 3D!I772UDHR&"(FJ>B?U6^/^N; MZM@.OC_K3#X[.,B#.VC6V8[*,:&1$0[@^'/%665S,YU+2T7$CN-DN=-NZEM8 MJ*X>:6EIH'W2AKO)=IP$((H'8U&*MA75-$ MQ>#!FK=O;J('XM,0-N8?796OJV45P!01C(L?J-P(SZV=;Z60(Q;B+MMY91+" MR3C"%5VX8CU=+Q,88:L-[<_K8U)Y]@;,IE9_ZS/F5#T7@#Z9 [Q]DZ"H3SV^ M!=Y;0#+=2V/:?@MD-?!UO].K$/_R?E(97;&2-#Y:S CI)XBV35!QH/:AMO7C M&(8@"$@T"/<=EK'O9*RE'+2Q1US] ?A@, 2>)[^-LU:*8\Z\$^!L[@\A1X=( M#HP\U\2TQ3S.B#R@S'5AW"+F[O MUV[T37\'XB9.3)46)T"IE)DBGHK9/#7R$QMU?Y+0]\(R0:QIURZFP^07:#YB M_HG:RX1,^>@':]%437*X.S5=^ ;0:QL(H1RSX"DWP'=5[G)^7_8A2#;"0=&8 MC2&B![P51-$#]$_'+O5=VB8L9LP7H^_!C4/LFRZRLE)\ZPZB;()GRV_?3#AZ M#YCH? *7W/8&&--.$9(3JYA5*+U1;SY*%;3]N;DB\=OY4*TH$)9 )(#YR2E' MZ1USR\D>);(>,"I+LAV1%70SFU9Z'Z$&?]#LHR-4,%;L\P1U'%O=G@E)&RQKZ#8)[4/FK*",3"'YZZ'\"C 6T_5#=6M]/K8 M(T3D/:;IA;(Z!D(L-'X'[M4*-?!:O,Q7>(;M;3\DKLRUQ/A=8NL[%,6"NB1U M/P.Q\6FH<1.8*"!NB31"P.>1"@$6:G,&)EET0ELGU)(W4\*?/Y7A4.>RX119 M$[&QPS&;ET)>11HQ^LP]D3PLAVK8)[6/:?43%$&M(Z" MNHKH^/BQM&3Y=)+8Y3&$(N7S]QW.?O\(N];^22FMPOE_%785W#XQ7\R?9=Y3,E4*J_8U M"ZF;O(*"E@37X3A\IZ.#F-O]5N>?Y' M.^<5# ?#[O$5*7I+L"59UHK>=E?O&ZP@X458+6RL)4@(JY.0*%%62Q E>(,E MHJY$B_8JV15$$M%6B^C!ZD0+7^:9YYR\9MY9IX= M]%XGXC:EN2RF0" F WY?MW/%[VG9D\6-'3X"]QY*RNGERIZ2U_J@.J')@UP M0TI,NDE4B9+%=LD;"J[AJP,R;5*G@+36T5#9CZMXJ]M)D -$(--(')#_ =NN M_1 ;34MP'B4]><5A+"!UIR]UJLL<=.==3RM[!V(PW*;%S"?IQUNP(=$HN@N" M"FKY%C JXQY'1K,QOE=K=<)5U M_81T!Y&5S,6=T?XI:+F>$;I#?7/J];:I\WKOW M2T:.@2SG_OB@X9NP4T"T.\1R#<^[^;(+?H6&?4M:!R6_'T%4J":^U%"=-53L M;'9Q8L_YYQ10T5N:XI>;M8:WJE<-RJ?NC_[RMW#GK.XP 8UU64?[O%ICU)R( MZ917RL9--,IX:16_5[^IU-!#JV+M/-;D&^F\.\+,MY <&W<$+Z6^TOG9)'X* MX$W8[WPMS5&I3WRV**74D\=I6LMZ"KA)U]DG.5&OA++L:*,#KWQT_IU!EK26 ML-[<310N2MDT '?$^D;1PDAB$\1U'++2FFW]2K"Z7 7:_^_ *#--3+Q6 ;). M$AC6H407%=ZF/M%WO4N?B ])DRO';SSM]IQ#*611 ?T8FF2(H^Z65,6X5Q.J M^'#Z;:T6AZE'07PP"^8TAVN=\RS[+6GS1#)5+Z%B#WXQ M"C3K*AZ1)^,JOA8%7N2B%)GDGMN<31PXGT'"UBX$M7=->_=3T:[S\VW/Q97+ M!3T"H *UC7U$".@\1I#U0CL0_;C/,1K#>PK8J.1>T(:*AFA;WAA(ZP[X^,C+ M?93*NW^\U'6B".ZV^X[(&WT5V]_@9L0:9034E6-]D7F\6DY+)-+2'P0L!)?- M:#>(IA606&[8FH:]^E/7': 0;\VK;*72P2;Y%RVJRNM9; -6%5EK:J&9XOOS5\OD'-Z1_"\_HMH+(6VT? MO!:Y.@*Z+0F/-;].#GM\;O:9FQ*9&6J@]SR2P,!-E:7GO@@87S%P==^I370S M5D61U44[.2_ 9MRS%5B2^YG/I9'EH3\"KY:=_SC$\5>*OF=2Z97YH#.S6O_P MY?^AF%- T$GVPM<*+(WTREHRM_VMA8:Q@0CK4SQP#WFRV'4S7^NL(WWD2V;\ M)F>1@(.FJ,4=K["5*86VV$;\I0#)>*LYDV=S]LM:&K9FV7?OMG,.P$T#+C_3 M^OHYZ7,FAI 2R1M,)0@2WWJ'$R(O6&X8 %,Q*HKZJ1W>U[2*0%\MF0S-\9YD@\#!-_=K[EN;(516U"A5H'@X(G):Q6GEIPY2(WMSZ8I2!+-YD@T,(IB9O,NGQ MF-;K%%53X4[8#"_T,L@[%.0_-_G6X[8#G[\*3Y)T_('!I\N/"P1,>K[48752 MDXZ;EN##Q;6BU1:]X(OLX/X;YX,)TFQ;'' 8S_U>9>:W%*_$F MUD80#D\!&#YV[H?&B%N-FFID3Y-__FR96DD91&M2$K=[9'_NW7+\9X1U*C5!!,($1IM=J7+?OO[M<8F%#_); M8%A@F34OL!8\I3Y!/>QO3/X>^_=DSP M_"320>(EF4VGP"13BA_$8S4YQ!RL.3!]8HY<@>(>0Z\('C% 1YJ2Z4*R@"XT M,(67LBF4\F%A3WM]'\OFX06W&X[;TAUDB=#G>,:MB0.3@@\"'1N47>_9<4'@ M-C6$2PE<<"&@*"[>HKL'GE<.8HVX*R(R3UD=(YL,OWMO5;XKFWEAKC!D7@!O MA=A6A5T73Y@*R/-X ;$6MF6_&I4BGLJ0C+G8? V]G<,GDG8&D\.+!F4J>R+X(>V+1^R1"IMI,9\5;@6ZFP8'^-)VGM9&80Q MK)'82LA*4RE1QS'6!ZL,_BXTW;RQRQ4-IK[N:<]G2Q^K\SJCUE8CH@#<<#7]X[^@U3^_RKMA+ M:QA2D=T:YD31UVGU57+V2/JV0P];0\BN.N;L,P. O4R6N8_1(ZB8JTK^H?)J MF.E\KI/S2$[>)2*(GRU&PG'@NC*?Q"@2G_#B$CD%.7NS\5KOS[EQ5.J;_3(@ MKZ52(FD5)]RSD&DVNSEJ:O\K^4BP^+W+D(Q_;X#?(!QU4>VJCA9#^1P<:L8< MH.VU9LP2D[0BIU'<&CS9WA4JQ5P9#F&/$W/&S3A-8Z_1O]'U"=7%GD(\K""# M5-$(N W&$*Z@Z;.-58&Z!WLM-.VZWRVNPNOYJK+LW +,BHG/3++.A6H9&XX8 MCPTYX)\906?%V?% G^I,S#%00>?5&3J:,3O (T0RZ2]Y/_E\;W_NJP:BTVT;@UV< MMY64 JK@95;UVO/9XWKU:_N;OR=_\P_7UCKQ5$H**D7!QL4578*ZD=625Z"T MXYOC'>K@ZA2V M1K>>DQ;+D@S3DHBG@/M'GCZZ_W, ^'?]&VJJ%18V[_WW3WL$[,!B;)=QE;.@ MK5T5!>W/6U9I>_&!JRB]HK:>R:M.PXHLZ#G56D5"][9C\X M=_V[5?WH7#B/SC(R-\EPD_FD4$('\KYIQV@O)AT<=@.)ASLSP"V? NPO9&5L M#LO>5D-%+=9H1ON*B9IRW7,:K*++T?#[C\/-TZ._CIX(.PT2B/[JTB%9&*QF M%9K>4AO^=E:"OJV3WYWQD*)LUYS:WRZ-S(O&=TUH0[0MWP^EEC.PFM68Q\[J M-KK4 HI"X\24F]#RRMZ/,2VA+O;#Q#_P2/#S@_Z)ZW8L]=&])HT \BM[ZM&3 MDB9^N4Q>L=FIWR_G_*BA%%)Q5W]FBO*)VOM[,D 197!?V?ABAFB&4J!Q&8CA M:6>XKI$>;O PB;9YYJ@NO".A\$^?3@&O/^];#R-\?A$R+!ZA[.P4&J8JNDH3 M1QQH@SGFUFI\XS65('Z^,*Q3QLDW5?_#I6R-_YI"%<4&YU&8S5M0(E((SI^W M)?E@)0DR.6"+=(7_;2O_SY(NU?Z"RZZ"CU%5TOL#!$HJ(R\N*MP(AKX>1E2& M3K1PN@[9C2R]='MG$YMYW:VYRS2C<PO1ET138CB3 MNU!C]93/'@S@AW[A(9[&[AQ(N@_9CVTE&W5]R#/U\I!)>J7)UT,BG+_B!,GZ;7IHUS7-. *TW$K=K+]E_I_S/^8 M_Y]-D,G92119_BCE87\C[NX_=C>\#"^5S\'R9AI;-/5#R@R.ZNHHQIR[DL;< MI_1_ 5!+ P04 " <@EA4GIG^V\FN "?M0 %@ &C5U M,C P,# P,RYJ<&>$N@54'$'S+[I <'<(%H('A^":X![<69S X@Z+)"&X)<$A M0(+;XHN[!G=9-'B0Q67Q1_*][[U[S_G?<_NV"AH6+\=_R_U_]W\MC!X 0 M ^D,V0 %Z24 F1 )A1#IL0= P @/4/YK[;_RC-4-'1D% PDS">V.0$ &0D9 MY8F$A8K^I"XJZE,#@(1*1(R&3LA \I*/7P:#]ZV6MA4IO::EFT?(MX0I;6"%AX?LVI[MZ@T/WX<^:824[>NJIKXLPK*;^S%_-S:&W/TQ.H MD/Y;_C\%GAZ!]*3#$U.<\(F,#'CV[!GRTYNC_(=)](SXI182(0D?*L-;2U)Z MWC>:VB&=_#(6'[_^G#BV\JA9VSAA=,M]7 #@H#QU)D0A!$@!#C18[_\,Q/V. MI RE\(2F]UZHWX,O!,0E>Q\!N_-J8O38B2+OPC/,.2AZ<=MN:L?'<"]M^?#V1,],Y[LT M3^H7UT:-T @H"N\WCQ]B/>A2FD8%I+&^*EC':;M>!$XF%2MTB$)E% ?&6Y\' MMIGGM#H&7*F5-@*?5!TZ]/%4<-/-ZWBC<3F=.!GP?#PT?%,2F?$^]WUQOR 7 M5OKJ2;#K;,[=8OMIIJSU>5QB +2-2H7A*CR(;?+# AOM\FJ4UU!SZVF:XX]/ M.V98Y%SJ''41G[L]7G;@RE5S9;4++>P')@D[VB5Q5F$W.BK1B M"O_1;9OU$6*DFK@%$,L<*+O;DC18?DUQ>]_<=CU[%,X(MKT_*PE"3\S"&DC^ M0"R=Z>-IPBISIEN46"]@!AD>.KV=W-.*_5 M'RG>M1MOD*3^"L^X&JT4]U:H.-9UVB(>9&^E;.5?LQPF8BKYIONZ99 MALG>4ZX>OH\[83E=U>U&]/F3>L"!O)J:S/95[:[X3]LL*8;%YJ-, M9HFCL(9I1R+CYF CY;-QZ^CP$010DB4IK_"( 5+XV] MXJ!Y'[7SZ[69HZX&*18-QQ1I%L.-:'8!Q$P=*KZ930WZ?)FL4>^SGLDB493P M'SM7+N*SJC(31DCJ#EXIYWV5C]GM:"@[7+&C45>>WG/Q1DP7UR"=TC\3=OTJ MI./5I!AR)[/UODK]V--OIEXEF .D 5%>.N8/F@VR MF:8B'.L1D*R+:H[$YVO<+4'R[#OEL=]6^\@CQ*WD$KQK4\I_6E)_L!271ZHR M&6Q+&@L3R (#N:_2Z&(\OR[:\:U.Y@7Q3O+GE9=.&NVBCBS:_W/FO,)Z[79P M$J)?K?PO1W\P:^HG?//HR>%Y)ZU6<)XN'@'O1>U%%;V,E*^U%WPDUL?N3X&7 M(7D[+3'_&4AIF4JC%8HBV@N^$EN64FW##^-[]$=V1(:1,0-,8&"<7N4*ZJ5C MT=KU+OW,Z0ZTXA78]+K*X!&@$I%&7I>Y\,6F?X:!RBS[Z)WI8'#"RT= ;NG] MD,[AS'7S73%B__BT@L3%ETIS_*=BDL5TBZ? ++Y!,KDDW97^6./M:>]2EX4E M4==.D C!QEL%!)+74M [X*9]^Y]O4ITV 1MJ0?6_ R3%HDNSA3;;>),+4$W;.U!8^SLU(>% M;26,*7CW+!@J=F;?*3;4$QR4=O]S->-=:NT6654Y';E=B/U00N-KO9,3_%7; MX/=/ C>/G@-^]OK45OI5?>;9_O?V$.(7/X-.+3]_ER18Z@H?U*REE\@8!=*_.5+"% MNS/7CJ/N98"A6APJ00;6;A9-ZE_ZD\:?&^'9&C8*O+ZML*:YL#H56!R8*'>" MFF(N*F6W*MUYY!/@%Y1H\S\K[?=[21[21^W2$,2A]Y0)K.8+E.H*"U3Y(-Q [DB2R\OHEM* MCDDKDP=23&>W^_A8JSWU+JZB^2=%KR1,/5.653;%E48:0EC5IAEVKFY?%OM3-7]+'F6Y\ M^VORW>9^5KH(CEYY0EM.506.6H$[UX_>9;CQU6A2&.L^(N9)7!!"/&_- C-M M)X,+B^3TPTO02+G_^^F@A$FH5J2D[CP?(4VU=94<,^O(I*I(_.O>L8+^%K** MF9D2M$R[)Q5C:T?E%H^C W,EKV=9(NH7^(\RWYV)EUFN$GM3T3%PM+RH>JUA M/F"M)Z60#PF !@O\:8&[5!_9.P04'O^9#Z 43LR+WNG;?5DF^'K O..$%BE_ M)G<2-,!%ZLS5E21I/]%P;")? M._["UJNK:#PJQF/:8@F)$3Z#O(*KK@MTD\A_N^82N(H>-X(V2G*_A&;C.#JX M<\QN'-7''/6*RL)S_P&;SE3+3R1$&%[1L[3*DVA+1G=%7&?:3YGJA1Z%(YOU MAB2P=DZX)4$5!D40+84;[0NBB(PHXN2D/\BP1>.@ZKIKLVW1S@ M=ZER6RLT^28999K/POB;>)6!OA^"DN,J%F>G-L)2IS>34I'U M&;?3V?VB6TO@(4;N\"953YA+[4,HI08FAWIXO05$\?HN/2UXD@Y/,=^#JE@/_AIV.RH':XP/@)6 M;?XB5GE=>"#"T4\HHG_5;,$PN5;D7AXM!U8$M;?7L7OX1B'B.L04VB. PF$H M/O9[RX/*5#) :G]BI!S8ZMSL.Q_^GS%,[WQZ0K=:\'=D3]O9U642$_!9T39E MS*+93%T%,5GO[<<(E_YQUS-)N*"A:5F27YW:_@RY>3KN5E[[! MWT2NQ3)U-Y/:_*KS^$CJ28;>[Q=#. ZIPRH%ENXT8O87*EIBG^8Z6P]1JU<; M*[]'#QN*3).1E)S\4?EB>'O)%5T8Q9[I%*=W> M.'0R/+EZGJ \I?ZFM"E',)&,DI/ MO7HL:C"%2+00HLZK=*.;$D!%Q9-/2\:W$RT: 5U^(EO$#CJO7V MNC8]>K>?!QB:MEL279QTV1,ZI%'8C$_>XMSQD]BH*5#D%U #=I7TF$,;OB?E MNR8'-""%F\G>&"AF/R /!NS]4^F9O3N M7)()%'"4#HHQ[=G;F661G[_G#)YK_!4ZZ3KZ$"*Y!931$ \L"6A#M(1"8=J+=L6QT"GSA<>^I>K!(A*<& 79'#2[M*T:F,^(:= MC4,Y_#$EO/S^YN*VCGU6JOSO7035SFU"1.47%EEB?3>8(_U8M0@__NQ05,GLU='@]AWL4+W1 H(CHKO]A6% MX Y8ADH88JZU;TRSY#KP]Y+4_?XG-\Z.=0<^7%QCHWL]CA!Z_;T'[)Z-?B$1 M=H6M(,X09N5LRD2VIWG-MT(/X:3V7+H5+)/,"4O!AYA@7_9SLWKT(_KC0&:S M187UJ6_V:V*EV2Y_=JX^I;!X)T!VXKQ"W5+!/SVZ;. UR@[5:56IW]E.;2U" MB!QV8+*(R>&)@HNPK)R1P/628_4C6^,.4;W,D!074?6&TYVU_9M^9P[*PEV/ M*!^J""8,7VK[J7XRA*76KQ'"5,J)8T*6)99@5S)+ MK>$J2+N*MELO>T55.8\WN3P^PU9IWAN28CH>L;+[NW+*:)BBW"AS?6;\.^KE M7\-JN18L/AF_@L^F6[=N(&V(O[P41*%T,49G87CKPW MOX:,RO4_@)1*]$SX[7>$HGG$2H\-K MK]6$1\=/H/I,+B(L8^H;=O*]0KM*W\ !>Q%*//P)3/(MF!]R@]9F!82;,YP2 MH,,9,@W4+L0<9JJ5W3_K2;J^8A)^95S!]J>NLT_;]86)'?D9'I&[4RE%8J"( M\A0W2$FS8O?F=<82.7M[S!/./ +R!)(2OAVJUSJ;=!MV/FR4L?X?N2;%^)HI):*&"!B,N[ ME6@(<,$4%_5$76OXG#I/\=N#7L7O)T/!MH2+S'EKA7_Z;GQ8_XS+&HVY;\<- MY(ZA[ 'HOL^L?&.RV 1D@OE:MY 6S)_*X,FS36%:@^X=O'-?CS\WG?3X,VV& MGM G1O:,HL0RM5:U!RB*S$MNOK#&<4T'4="K^Q:@,V>4Q>ZBV?[9\_NVVSD5 M0L%(@Z51S!KNWK;W]#$IU#K5KJ)3L+SYM%ZG.PX3AWPM+*K(UL8]W#>CP>**6.1]-O#-(6.BZD/VI&%$ M.PUG!/;F\M>6]?*J=C&C,H@6K!_;PQ M:Z\I=IZA8HW_<)+%<2GZ.G&LV>@1<'+[=:?'N_'LV=+MQM!W;Z8JC>Z7:Q,& M(\?\[(V=EN7/#,LMG33%_!OR4$\QE>V1/7 M,>O>#;Q:")3RR&I5<$A;VNX3P^].(KWQCQ;\^C[YAP=U7_#9],\9'N\.U?8/ MGDF+]1G!?'AM89(LST:;A:O-1W3KBE1+G+S4,YMVKQ[B@GW9B.M5(H WO/>_ MR]/6CX-.J5<2N)U*K[3!)=W>.[Q4CP!YJ1:2KXL)/17W) \(O8>_2$,;S^U4 M8";_"-AR?P3(N=R>["]4WB5=<3,SAJ0P>BHFY6##MW"N;QX![BT5O7?:KZW' M-K1OQ+-+?[N9B9L1K^^VR'FWPD&+0KV*30#_NORSN\L;=KD A7F6/TA["W$? M:"'%[?#7^RJ=Y>I!6%.OY_TG6_^6N M#V&"[51&W]F\MY'H*+;1QFK*6J###@TJ.+\>\V[$X- MX&*LOLJ$VR=(WKFDXB!9%:=6>^##)AP]X@GJ/IZPV]+O/=DG+C+< MO,Z)F#M&MGIS[W8PWJ)9O:NN$%>L!I(87G.XIQ:R;A0")L>9A;^S[_SMY6)K M@(&X^*50?'BJ'?_WRTQ"5*K7R2IA<@6JDMV$">-7Q?F^Q75#[)&LW'\2^,<% MQ;":*:2%IDQ/DVU.A]7LAO W?)DTXLI M%KM/&V[#G1N.C9^;+KX+=UK\]JXGO5",OE/NINJIQN]=:+?-,4AF]($>RJ5R MB3K1IZ[C+C+3U+T0;Y7SW"J2?EI0O(Z MN<()O,-K4?=1.>0E) _]CEJ('\,,H! )[/H@F_M8' M.W1>A)^8'UWG/A/EZN][>C[90&ES/4^(:MDN^6I0=9BZ\C*Q"*]WMMYH)19- MXK\^Y\1S7U?&.$!(E4;ZF=.Q1^Y/*$'_?PW_@_=%:\-\=^B#EPV>.8^CN9[Y M:K7,F_C_2G]RA'\.(^N34DN/)3 LOQ :*. 5*&6O[1 -?\!HQ!B7%$D+**'' M52V$LT+Y:Z@6 K-H7I3-F%VKNJ-Z4DB;PD'S3B]F[*%P!X:A.WK%' ;.&P,GAUQ 6T&)L1?JT81O H,9@SH9@EG>O7TFJ G76XD\@UT5FY*\Y:X5+I:)VZC+_>6HBM-;%'RMYJ%25Z() M%%)T \85&A8F2'AE,>'U"=&2<:^73(@EASI[YRK*7T<:AAS_J2NC(^)#S4I M&\5]2]T*FZ[ XJ>R(ZV,."J0$EK1RP[#OS3K=M&1SZY451%H('T0\RXB+Q!" M@D+ =[IJ2BO1)VQ.X>&K>(3RSK43(LZ@<7_'<=1!^:SH !8IG5PJ1SXD0HVEM M.%_"#H<5A"N">$CN.BE2757OO@W(YR@2)J_LG" E^&64NFQ7\4F>K M$88=M^Z8RX"##_F#3XR<$II;7"&N+4OX'_&T:$/XJQX!VZ16* E@W'*0#=P1 M%LUB(-9^ F(![(P4)U]RM'[9N]DO*!B\$1RTW*7:3JOI M RT[$GTSW8OZ6+ M-+M6((9E">UM8;C[KSZ4JM1/X>OCI.81#9Q:_9$W,S?+A2V7X68M-+@M?EW8 M/(L2KZRNX1>1X!A*J!N]@FGKCHBQ5BX!A7JC'(_P:+(BV1\!))"O/"T&3F!C M8MCIRU9X1HYRN\DCX!' MG/-J6Y3W>#P+M9^<\O5C0_6ER+7=;89U:E_D C7A5_@0N8:>U,!4@\_N^^]#L3U MB0DKDSEKY,#&T(F\1\ Z-#XQ#"__MV_T&_,Z(W8##L+]G8K8N-./?5AS5*/V M1I>#AI_%2"?*RR,AV78:E#T5+J?E(\%V"8^ J$D_W_*7>D/';4'@&]]K+B+D2ZY5)8![!%Z(Q,^XG1M4NHXWD?+F)(0F6QQ!"%V1_"VUK7 M8U6;.&OJ:&@C\ 75X%8:DM?CXA)/"OOQP#KZ).3]UUJ#;&R;7F_+JXW=EXK! M=Y" ;_/#_K)).PP(Q)AM[$W(/46AE-B;N3)SN!Z1!,R[N+7VW\P\[T1J M3"M393K>L[W8+;JYBMJP[ WMNO[X@XOHXF/FLKS%V* /GA!5G!;1.5\P#6N' M"5G7.EU_CT7ON0;DERDFK-KF -VF>LE#J QG_U8TM&#\A)ZGRK9R-93EPSII MLF4-I7/5E[@L%S]E!@N5RJU?J* XL\I)&;64#B<07F93[C[#@QI*H+#YJ:_9 M9;L=-&,F]W>Y%$WT^KE_;3C%'NZGU?HRN3?T"*4 ,8NK8F:,A,J5+3!I1< @ M=6NB+ZA(K$UL7LKN?0DHU-+D[1S[XLTT$88D>,+(M9&,?37T $B>&R0 1]/^ M-_-PR=ZIGS!B_?@7?_30 CC!JY?:Q%7:K4=@(&<1(XFV+:GD56M/Q0:U9QM3T+^P MIRFIQ^?R_CBT9]/B("M_O9]*Z@SH5S@Z^0A(4+MEVARK(1[GRX%4:^G3D\44 M?\Q0/8>M"#8A*V)B&L MJ1;+&$4_Z*KYT:+C( L\:"?*W!YVN+CS4*] B^?6PY&&% MP P1T&Q\V9WT@/VJ;$FG]PX3R?+%D"EE5KMTTP'\?A"[VVCU"B0S3MZ(OUN2$^OHZ^OI$$";^C1_F MC/T#V\?Z]T8_9$=BP?ON7=)?1XJID[="DC?Z)U_%61%3=!,1[>$.V#*BM?0? M[NN295W##2=56;$Z1%JN[4T)6',J^=?>9)*&!=%5UYR-_T_!@B/+P&@#; :# M@%U;B\.0'=M,(8E.SC_BBP_VWK#4^-ND9JS ( NTE>.L.1D_-T"\Q%4!^G7. ME>G[/EUO]C5QJTV[EIQFVZT5=B89.M&&7D#+A%Y.O[R(7]!S98QV\:#:)FSD M\,#+!O848F%@]K$#0_ONG+1P,SYVS8DM;K3;9BWM&\VQ7T/4/B)W6_(U\_/= M?!89>W';Q/%[@\IHT]38J,WN6D2:>&& S/"U@7XO9LZ;XL2+5GQ[H#0OJW?K M6=(P9(:(B,$<'ZCI>&>T]@A@FN\-++%(@WS')J'.DQ.V\V^K\^__$3-Z9C;M4JQR)U>$T.--KOAON8\LQ\HLXKB?LRX MN%[=X=\H27\N8>344\6ZV_KIMT]KN* NZW*B9) *\.'FRU()?2W!,"-G=%!8 MXWL!A3EDG!:/BI&"1=?Z_EO0#!UE2'XR]!#*U^UFB?B0^;F[TN+4;+7Z$7#' M5NIK;HI[K;QQ4X.X\-C>K,[C63= ZQ+WQ6TPCCTS2_6)[/[9'H^_?00WCO\T M>+(56.:M*S+>'A/$6 26XJOYLH]I-C>4O&PR[3@,,N/K6^),>S5RQ;;'"#"% MF$/#9B&@WL3A$GPVJXT/ZWKUZ2=&+;! 4<21E%L!*S,VE_P+U:F!A8J:+.U\ MEP^\^.?:3P!/>G9DM:V@_6REU6NQKMW@E08HG'YWH3=K>.1/Q.6KM7D,2BUT M$)#>6%#KW#YAD-A\ IU0K*?Q.\NJ$1NYD_GH"?J1MEY69X?N.O-0U1=3BY7+ MO2W/P&Y?7$A7;I:FL7CC!"DGJ'(H0I3/L[\]>JUF7_L!5V2]DHJHRU9HW&+W MYT-8L,5%[0"_X[. 7H?/N1D)L/'O(L4Q^I*%>1*;>]GF(9%;V MK9=QQT+1 +0'@P'W4"YE_"%?P(7;?_W77"3UH;=33UZEG[ET&SPX6GE7KWC) MJ1*%BB I:JZ )F\1&VMPEENBJ=6AV)5:^=*8@\7-_ S@X84A+G?O$GOI56@8 M2_2R_3C.I<=&4"!0$A:[/ERK6%>;0K @BLU&N7G 50%)[4/ZP 5$C6[J39D( MCC09J^(9^,H 6.0U)>Q1N(DN+YB_GS,E#.4@X!(B$Q*J>%>[)\A#^2RF3-Q! MJO;6F(;>3Z$SS<^!$)Y<6*Q8Q0K0IV\P#FWT4YDNLCT55%SX,D[UE?E>%S^/ MA(@F;,6=MC,:I*A 98,,>I,6#YO>I^@\L.H60WNH(O5XZ':D.F+S_S$_9'J! M^5DT<-D3C8D_%M(]XH_&2L5KON%D3 ;:?OER6M35IS>(K,[8N$0@E-4M'JDQ M.?/H#*R#U\RVP)TSK9_!8>7.45A\$O"=?0'=\ $<2)I3/_9W8DHBG1/%RN/N MNW#9#B_:R"6M>$(%Q6&$T0?\E#&YM./YN8WTIS">3]UE.:-3W=TDXU^IB]M^N)0AW2O?DCS$E'"-/@T/Q-1L7T_N;U]P67S@T; M:)(S$]C;@^SG%YUZVIXRP;4.K*M]KW!M5AT@%E\C9C9299J]/=['*$JX1/ZS M&SYW7 CX.ARJQD(1<2AMG>O4$STU&'HWYK!GRH)%AH^=X0MD\U*OC$VS]AN2 M.#3Z8.CN)9$]/\[JR==: >+INQ/-3Q1M7]8CH#9T9 KHD]#F1B1F%Y)?%S/D M98YNYU2N,F=I4?_N1P2'2-\%^.J9!SCU?0/PS=99 6EI+'\%9V@^9>P,R%>& MNY7PH"J,W3 -O @1>!B3M>R7_57.!$KXRYM*JU>UIX[=JJX86"A-4;\U7A*> M4[+%/-Q*,)Y&+0Y5H*:!%KJ<#?K>Q>>Y"$"B[QA$*Z^\:GQ"27DQH%R)Q99 M7G/H[H2=B14ZK$X9="@9D)?N,-COC7T>-WAA]FPEVU_@NXSE[R'N M:N Z_P/^^J1GG^+J^MN6E8BI\I$\QZ^_R>2.%A01=@=_R.EZP6YG6E%*DFJ? M7<#7D+\O2^__\V$9N?6G*^J!@F.7J1;AQ7V^4(%RP^('4Y^+""C?+$7GGE%O MT @\A;M4$V'NN.8^VLJ_1Y 20$*6?5"&@S".U;_5:"7MJ.1,;E:_/(AW!.&@ MN\Q$,\=@!WK225=I2\E0!?F4F$H3G)9([)A7@ MU3%_3&\F?*UNL-F=GF7GH.E;J6QE209:J>KSL1IWYG]!?96HT M;X=E2OQ8J5C6"KLY&]PDB^9&QQCK[9T^?\0V*:_ND:VAS7)NKP J$X?BIF7S M8U3O7L0,LV_/?3/RA9>5!MQICT^?M&::Y&1K3@[JRDQ?R"\I7V('Y >1 M?@L/A;B&40\[\G..2 MFHD\'( X"W\$:-S:1W&0AL1D$*:,S,3)C>%D#:-T%]*D=T0S1=8[P&V_EHB0 M:UID)]-=ZE27CK!NCZZG5')J$&E77ZI49"#P1_S/?.F&-P/\@O6^WOKZB'L55W\%NB>9:M4:2R .+ZN':DYX7)+ MY4]^%P^ )](;&7)GS(BSD4F!8R.F4W=.RY(0*/:ZC;/09)D>TV>M4Z.[4$1,R":DT"^VC2 AD MUV()ZK]_\P(+>F;H/<@HF:1YZK;!?MRX!-G7/D1>J\)$Q[D\-QY&_EDRLT(V M(T:@5ODG#*?:97)8J9%?JMEHHGA]UZ[$0>D7:A+,BFKAQL]PDVRGIM1H; MKYE@Q&E;"^5+(SH(=X>4Y]%),?-QY5P5815^[/>V6+:08=16N^7LN5<-UTDB M IXC5F6!NK,5#$J-!BE@)-,T]ZK0PN2OV@F5N7N9UQNJODOG9MLV,5[-$U.ORA5KAH*"%1'.$ ML^9O/<31["L3U_Y0A-$TSD<>" @C"6$$ ^E\AT/#^@OT.+J&&Q^J/+MCA\5H M>KB#R"Y U'2D#97.=B=FU[(JDZ*8A'E'H(7AH6#9:KT#(J2/1GUZYDNBH2FJ M9X@847^<^OK>+JB&VB^L3C#F\1ZA][,[451*J;/TTF%_RNC/\I'&7/[6GR<'%>@=-MSYB$>F)_#Z9TZ+6.\WY7?GZRA#8VMP,X_S M*M(_^_@]-#9.F2+5LH"Y>ECRO!N^)#_EZ78ZA0FP5XQ:?H18%[Y%QL[^V0DTJ#_GY\<>7&MT#HQX]=DP*.^16'(X^G.2WAZ4'1WC7]L/UI"- ( M#"WR/$7>6RTQ!>Y/JL4O(FK,"]Z;#:$S&KQE*"X(7"2_Y!Q-U^03^L[]YGL_ M,=IEZX.85WM4&MO=-0:79P!7+]]CN/0:B?G$5Z!K8)H[F@99#J>%%4OTJ MM6\O&Q;#^_?&S0DXGQ(+9\ED(XVHO.K8E [#_B)9B3>72=\E0+AE0T71D_1C MAC)*\Q$PUPL9C0FL%TU12L=?_*=_X,W54_D5\3]%BZ>@\7&$)B.0M [*\#?A MF; 6[O<$=K\[+FZIA/9=MJ>G+GW!-JE>7/^Q\*45 G(KN+.*K7#Y=M%$V?1; MB-<@J;_LI8*A"+/>&I@[_(0&A=7OX9416,BRS7&.5C+6+E0&:H<"XV@R&T% TL M%BZ9!8]:(7L1Z/"H2M@&SB-@H=B4>07O8D25RN>D*^$AFN&.3)]8_O2LCQN\TSW9;%R53)T[ M]\ MOT? ITS;H8:%N(.7Z'R\'+7[RJ483>.19"V6G JWT*V6"(R!,%$ZZ5%+IAY M3!XH(T"\XR*?77)3N#OT##-BHG9?WL@U5AP"6JSI+]&YN!$-A,_\'KJ!TO54 MYBJ94) ;&D^\PC%EK #A.RA:C*]>N+%"6ZR23Q>2!_&TM[=?#M< M 0A:=I2C!%6Q&AB9:QS/VFDFE&B:S7Q\K@2Y(:I=I2EG[>&@W:@H+*(=_7X, MV:A0\.%&_KA9)-*],;? M!9]XOZ1EA:2KI5IL50!F;F=7BX-:796X>YM7U,:DB2H4OXBH,P/2R$W9 MP^"?3)#-_4*3AYG>T<29Q_?(6;2/0E@BT;&7E'O!_E#R7NNEN+M@.QW[:-J% M'V&MVG6%_8EZDBS-/Q(I5ZXV_%V[K1^&5D=F2_9M?'(:-4AVE\DE.WEN%0[V M_#>7G$!!BY=%M'CFJ\/>107LS)OZUYPSS_5E?U$B:,I1P)U.J_F*.)',7Z@QV >)""&D.S@O%3_/4H& _!ZXE=/?!D9#K*J,'HHU[6+NN!] L[;>:R=>%:K' MO+]'7#>\@6&.72+=]?M3?>" NA_1&Q2Z!SX#H!3:*IN\-Z%F5] 1G]\2%L.2 MF4X+U.#T%R+]\3J*"O M()N_5-E"+L0QAR%V'7Q]DKK0D%XRJQ\%8@*Q<3@] N2Z#W@M^P2Y6)APR3YU MI@>TJN_W%=/=\\]T;W0OWO^0>M7HD'FB%I<8RGDH0U#HH\;NA=6N\*=RZ'PE M!'WZ3_N-9?\CH!2&6+O622$Z;346?LB;. DB0'N7T+DR-6\(]]7;= MWH5$".$AWVOY!C!]3ODY?#3Q"&!9OKW9%4>G(*K+/)JCLATZ8P\_]MM&/&/G MJ.%)0,@CD>?%W)V#QYQR35.:X(6RO]A22QH#S]:*@,]B)^ZG# M75^ 24MZ?CLIOT:6M36;I^O47FHESI@4]\KM*T,I4J1Z*@)"6]*(;3B5N*@F MQ3.G[MB&RXA6JS*3[8Z^ Z2D4'M.U#V*'V+ #I(U7,'*A?O2U3(YV8X-QXV. M"/_5WL-='!QS[HZW?19NT]K/^,,T[++B<:F46-Z5DQ\LEJJF2DI8M%: =Y-B MYH:W]NQO$J^@)EPRWWJJ;4ZWZ:>0KM)VF3$_1'ZIOM(&B%&J:!?+Y1/SOF"Z M,+8VJ=ZR\TO<%]>=JW2MA\/UYBQ*Z8?M!F 34U%T.!_K#5 K?QRCMA33F2-XP=:V":EHV%ZTYEW%EH MC1NBP79$)M,">A0L4)R02Q:).L9KMOVVK5!'(A/98R%GXP2U0:N%YH4W W2> M42$U7&23[G=1J^1!ETKL4(WS")FFE,V'AB\)STXCKM(_+DZ?2$ #W/L;@&29 M)S;W#OJ(X0HH>D9XUJIW&_O&*AFWY"/@=K/B)$V?57&YNJ0>?\XRY7C?*[@I MCZTG3N1+/@P")YWG[BE.=<(ZY]==5$@I;&H(>@46^NYRAG!;+X[<8OJ]G2\'>8;;]15-35'_S< $^"<&DRK< ^^<>]Y!/AR=V$Y]0EE\LE%4 _5#==I[Z'*!L]=E?*L]:T$ M2T&T=ZN\JS;[0?M<.\XFG.FS:SEEV9U?O40\O]D1XE7@%=L^CST(&TAEY'NM M$..%Z0:DD]EW4/XNJ@;I&M' +Y(:J>"]'@O7:>T7X"L7SZ]9M*MB)X7TC2^F M<.<#*7VLPG:L# (M-X#6=_EEG1UN]!8?'W(F![&''@%'_HC=YN+/Y.PTM6= MGMF5'5G(NX\V/V @XXC%TCO'$A5G;YVDQ)K]!)=41;_LH K&,<,7-:FLG($R M%N36KSXM!):T% M5(R ^FQ_NAN^W,%^&5VT/&80] L@A*<6&8I;6X2A(S<)> MX1KU^H+X@&>RO@:.@GFWQDFY-JPC*+L-,K5!8WO%Q=4H51D>EE_SA3FFI1)8 MDY\[$]C%7Q0?E8J#O=S3&+O8PACS;0Q&B%$+WP0NXFLW%^GTTX)"HR^W]FYT M16'PFK=?")A[W7.C!?(]K<83SX[/]O0"Y!W;I/RTS78I).&]<23/YG-Z/=+/ M[5Z72?S,;LQ?[/H8EC3OJGK"0#S"M"F*>=.;"W.85(.LJJ6&A*-1.[YD%RU@ MI_$KQ\^ZU'5YKH1[AGNZTGBB-M?H6ZT#K]EU'@F%$W&V&?QZ!+AY35#A?N+5 M),NQ*!N\Z4WIQK=3%M3W_JJ ';$O;\B?TVN^S;]/^VE//Y1)3VS;BO)IQJ7X M08QVM$DF[0!6*UO6;6BV;/D(B'R7N>:\6RZ]I QWX%Z^U?#31_9U+2B^<_;K M*1=Q*DQ9H+M+Q^(W%[)BS>>"&S-P^DPSDW,W'^__X&6,A<^V&?M/)U,+<'!0 M>[B>1XQF"(8R@/&QO5QV,=\YX:2T-H;()B"._ASO;16UO)\U-''J9P/R;'.J MMRK_EF]&ZPV"W$IDS4A[P=0G LERZG\3'#+J;V3$MBE?EG'^6T9A4SV2:(M2 M^^\_#H)U$^RDOB7U9;>+MQG=SZB,6QDY,;I;1[[^IVJUYQ7 M150%T@S[N.4F_OG)7\Q3)>8]@76.&A*.0[,I<0F'3*]V@HS7S>%=@%]'P%WB.&2DK:K[LI@@]M5W,Y[ M\V*]*9>W)@U[46?8Q93N-KC\'!\+*,?V2MCE F-ML_T+WN?B=JL-D[+BEEG8 MH)9YX13K2=2X1 V5O(WBG?>PKPS$TJ\2,W*UX7J'P9.H,&1G_O%CP=C5[IR_ MV"]QM?4- WG2L%2.)QA?\<#++4V[9'#\/E;96]W\ULV:2]H[T:_ZIG.=JTG* MS;?DQ[I:-P1D1LM(AV6^*0.;/EH/'K@*NFETAG!^RX(9>$UG+-G]'D$88W.K M?FO?<9-:_X.8Z3S!H=+@/6UC"+'?%N,F#:NLH@GK$#I2X5)O#QMT4>=I/JFB MP(RTX1W9G0R,7WQM^26!49@H*].NK#$]: +]LO$1@%T!B\BIC29 MNL/]S=#OMXO>[6MSHBX,UA5D;PR< @4]2*\],2J7V_TW,3.>7RR6@"PR^-$C M]<=-.[%UY;GO2QZD45MBG(/,]/ M)D7KDS3\IQ&\9[2[>^)5"'QTA9EG,0)4=5]E^(Z/ Y&MGP2X7BU%>NDN 9[B;.!0F- MYDVD7%7W(I5)0=UQI*YI&='_Z8_?%$N-OV4J-;=5_0$\&%5RX& E0U5X,?2/ M. H4WC<#IP\/*4/K8 BHVXLWV/>1QD^X+WG173?_%8(K@/>3E3\8^* 1:-)$ M41QI<&"3/C<]DC%57M%5/:^(RC'PO:E'>D3#;V7ZI?JNQ5(TAP]'F6AG6JL\ M74W.HNLR1! Y8@/-&^WGI8@7T\=XTO#8A."HWXPOW\S@VVL&"$7BN=/P<8VG MY![NZ=<0<(--CK;;];DA;QCNDTX4[*4&SQX!4TS!,8.WS-\5 1'XR8(2 I3D M?M/34[?/$;#:["W[JVM;Y2'$<&GB4]KZZN^J*FEZP.4-"&M$$ASXFL[6V_8- M,MI.1Z/R0,KT@'H[ABTM2E!]J>*E.8(I6*OBBFUPDZ'O[EF@93%SDRYY8H\E M37;/H0G65=CD2%\;8S"7^D;RGAX(R-/H-VL%= DHS#.Y]"%JQZG[X[0&1&MW MPC0D$/QNEALW-.^X:$/$+7LG&F=AS&-I.-S!E3-2N'NZ)YDF1)>3YRLY]:O* M0/_K0P3D9[$4 KA2>&6 M@]P .ZHMM.@W=@EWMKI?^9 98D-G,>8V4O76]^-;I&Q7/92,/F8C[[="P";^ M;4E,QG6C)AGZZ">!X8?KQ(G 9A90UEDIK M#ONZ^:U9\61-)W?_.KMK?B7]9CW>S!]*FJIK2+?4*"U$W/ST[4:'KQO5;FI\ M3M!HHI*W<8 9^$(V*- *C^;3'+0A(-"2V^ ^'R417^)/&<^AN$O_9L5[\7]A M@3W@$? 4%R;^W[C0,1;:,(Y&QFXV5P<"0M6TD5@)HX@+3^E9"R;OX37G)X*1&N12-JK4)4!R:X,\]P/OYBM3JF_.; M; ']#VOM5 :0_IJ%PGHGRNQF"G^BA8 M/$-5>M>R+D;*3X,#6MAW>V1;6Q4N8]EH[6(XJZ@543:MN*77+/039#D"?6V. M]:@0K 4+5\1[95#_:DA-NH; XDST$: [4%[PIV,Z?2R$;'PH9?8J2=DJ2+W@ M(EUMC[2F-%7V++[E9@%+!:QN\ OCI&\HGHR/G$+6\PR%J(XW_,A+H^W*"[T4 M2!L3'?732BZ R$3N_'U#U[C[\<")_O*. *+]VJ6J0&.3ENH1 %S+]EI- N:N M-;3PQ]G6N%O@ /X4=:OR_>U M&A8IPTDK^FFZ91"AJTG&-RT"%Z*@Z.ZE:"3-NO++3DU2O*Z[EOD_C=R!\0&4?9F/B2R-_\V/;'/(+4<]% M%B\/?M*/1C]!6V28X<:W"TG.*=Y;9 )=AD8F:5QL-; 5)&6[\$L!:UK=A5Z+ M>JK5$H'K\,W%.A5;9(XW#<]GI4VU M!B5#E2ISH>$LQT_(;(,%B%UW:P:X7 6M.U-]\_G_;^FG\=^MGW7>; MU5+_][L,I^/.><)E&;&?'9F-P@M4Z?!7] ZS:*'FNQ_!9G/<4>=OI%$A(*,5 MD%: RCIV9LO&['.7\%K!-;<7D@P!C4W?Q_P, @29AU.JRM 6TJ(K%0[^"*'W MO#5"[\Q-[6=U']N9A27@*'Q@';QSCS/)!/JIWBK:SL/?*6KA1CITYJ /"?HX M5F3=>C3%UL<=:A=:JM3K&"('%;ALH G@FIJ,=N^BD9A[UR!?\M3K8,]>QE3$ MW?9ZOAY-'DW.L5=/Y%0 BEX/'[V:^@.V_%XG/+]^1J8YPLYL=6<4OD&5W5LN MN_-;RT N4+ZQB8-/T#?,'^H?M7BM2[7(%;^EX^+85!4_<$NVUE'GK;^DL3UQ M@][+^0BHF0Q:#Q:LT#1Y!+S*!=M,W)7$PE/T, ^%B-:Z;J58#EG.0/CCVPPN M]V]8#IG3\Y$>=.4OA\JZ059N]2)!_BFJ2YNWJ[''F"9![S_M/SO,,7=K[]!J M+WLQ&*MSHU2]HB_V^A45K1!*G/3>ML#6GK?402$FK7X&CSZT(M:B1S()JE$/ MY(_WT8+O=.0]$&C137B6!N\I 5W92H#2=S_%B^J\U3%%7SN:$<_/0XR^U?#S MB2+.?74AX$7-8/+2K";R007.1[N"5#9"W =VUE*V])H3>]4I+:U0^$/ M3)X&SNQD[1EV>?<]#TY.N!T;Y&>.!Q4-V2,%[6XU2;@,KD.6UYUG@;!) U%7@O&]V6'>.[MRWC_O)0-_:-EU& 9?.^DNQU[73L,GF6+1E'HZX MER,DUK=)BTC]H0W7]Z^N7?!]FHU:FH1M>:E>;-$(?3H-7Y\*PV]6:P+WS>(8 MO3"ZMTR)^$3\P"D@&"@&X=-.7Q+>:FWJ DK^R$B#P0@JM^0S6 H5J7OFMOF/ M\+69,.(7;^IK),)XPX!#_,WE"X(V\6KL0C>XJ/3L#V,7G28)#MS>:P4?V,.5G@) M32E0'?"HF0L+_5F"WN2,9R7\ZC/N'2\&K]P#U8^#J[V3_>4MN2]&=:I@9/YX M"?1?EFYJEJ>+8>"A AH\F&I$#=I42^8!]:\X^5:32"WG#_@P+1\( M.2>0M M8NE->&P/''KU-LLS0Z0,$VTWRK2Q..N_/+3++WFXQ$PZ%JT%!*RY'22K2_M. MIB2-&@>E=#=3GL#*7Q8S>K0I/\5JK6D4_I +S,BJGBGYG,^ [4:U3\ ^Y<+ M^C1$.6J_"V7&;+*W(DM2MBHPF\SZ%O6FGDQEVRWS?HD?7 M+=7(<%=[7_/1N1]#>[NC@Z9-HV3W7L)Q-_'6$F ;#H]RU6"KN\!.VA1SSS5] M8JJS-OG"4CB^]TU4.ZM570L_D5"._/A= ?^J@ZTB.%+^8YXQ8>T+DC@??SE6 MC6+ZPE(@^<^BI+!5]KS1E;74-I:GA'/L7 O;&,6.8RDJ,HZJ\ =K'JH56EUG MLO)[LY%0!&MOL%K&J,>G:V%X]RO]F?/Y[HZ:C'[ ,S>#B)'V?T!C;O$6Z1(2 MW@E0D+O^ Q,L)B\5X".6CC!#$^.J+T_VZ\VOV?H40(%&#SWN(V)I+-]FXD/2 M'QA6O8>8Y["HS?JZ(HV/*VF:,RHVVM9F$\4EPN5D\^RX-W[M#\QVN%)=?RCQ MFB*;I\2'S@_3(8P<)8F9A=AC$*!JM>^#.\\#_]59M53^=N75I24@RN#-=-T2 M^*3V0A;=&#?/MC&KV*K5$YJUN[L!UOBUC/6+0P^D] MVU.4R6/8JR_ZDO;:].G[FT)^QYQ4X58S@6!NE* JJ^0<64]I2D=-&@9F7N MHS\P;ED,*P1"CJL36;/JY*0Q"$;BE]#+%O<$JN(*G:"@S/N'$??#D@]SP1L= MRF79K N,A6+,P>XG.XT9/'9;\G!PO((GC]NUBJGT;]I1T=7M9-'< M?W7XBLCJOC_&."Z6;EAJ"1UL?-MM]8;R,S0VL!F"2L(#R@PNZ^6JW##.=/*S MF];SW[#WOMWM(YM\1["_W+(H!-$/-U^>?ZEBYLGBIA_06-BN5.9;R MKW/65,V[\!$DN*H8;K.RR/CYEZD:K0/["8XWMM-F=W+92%\J:+I%X\MK/?Q. MO_F.'UZLVY72*(QTW<'2LXEEL?[VDJ750YK=I)EES?:5 AAD.U2;E5[#P=V% M+QN)=)+>;')YZ^5:P#(-I/]NT#L-L42.QW5ERS^,7?;=2#MEV/$)[.<8ML>= M^J)FSOATJ/P^I,WEG*,:L5TK5!C2)VB8'-+AT\#K.[=,U9R&:9]GA# $6*F: M_F&QU#8L/YR^[):*(%6$Y9Y&^Z/[VD*<;-F40O''$UZWVR'A/16)]_$Z>MR/ M'Q'I,=,LK)_:NPQ ?H<8JCRL,YE7'N-_8 S/\X"!<$#W^!H&264/R/UZ+-J8 MJ@5C5'SP7(/N1=?/">#KBIFBO-R1):/JA5T]*26\[RC1/K7*8=FQ!,G]MMXF M^N?E39:WGZ(X)P_5! *0#;%,)_:HXROY!7 &3) ;7" M#.[IJB,136M!@<+;6>*>&4CU24M?D\F:RHZS*>S'2$^R1#8#-GD+?#^?#_&' MGL0X!C-\W>:QWJ5@Z] 'D=N@,H]&^^Q@5!IO';H-0B/1_?0 M;5:2]E[T <3 ,O_D!LBZ28"+]O^&OVWJ;UJ[R(Y!LYYQ"][9NC#7DGN@?D=, M;8P; =Y'EOR^]G.DHE]]7(CEMI5^3B 3UP9BE>U]_H^9RE;D<&OH B#Z99/& MM#:9-W72DO,O"ZWG$1'\SVEC\BXBI&\)CD,(\ A\%4P-NXR,2ZD1MG+=O2>S M#4-"P6MKIF'+S(LGL@NJ@OH?K70%#%@UO;L K;/N)\\@46(Q@6%#&^ETH2]0 M9=+,XSI1^6K62L 2]+X6%,="LY+2%$2&8$XVS M0"*B3/C>:ZT,+*J.]O7USR\-)* M-)X<+N^N672!RE0,R03&ONQ')N^9FYO;4^.O'6V=CWPTO[#RX44_V]T#FCI[ M'-/O W50R-VIO#9OO1)CZ?%8-R4T3&UYY#6$0]B1E#BEL#ZJ34M"]V%>W9I. MGIJE5VK0PW>=3KAN#&:^)T'+ALUB)/8IU\(;<2Q+\ "T57@LF>E7V?):2DH* M?ARO,MO=<4Z^=,GT$6/C=W ,8#)06?WJ',28I$Y2V""ZS&@Q?90^LVGJY0>X M2\I$/;SUROP#HZUM^]R]^IRLS^B4>&F,?-9=0Z0_9UP^JV"V/QJD88T:4)OX MIK%I/]]Y8/ ^(8J>?WZ[=-5* \TG64V&VC2:WNZ+']=7F;'1 ]31O"-SR2;+ MB0NV6L.B]]W;?/.62;_'8&4K!'E85?G3#(I;ZA[Y= KV_\"(M"H#1@JW8YQN M&=N>R)@?[\1K?-GF^]A%WU]W;CH\9#;>8#_-/&&8_7*""Q."D])TRR*+!)ZA M8"9@I:*6SQB8NS5)CY(@-VD5'@@J96ZK^5=-V?.N-*DV@*L,H]XG,TE;MYU+ M#0.9%;:]'G]TM3U(M_V!:4(K/2Q%6E7+J_QX4W$@UJWV U6?907%:9I[:.5I MF&.E_^P/#-Q 1Z-6&R!.P556].B\Q7IR3CTY%EIKAQWGWR7P5KED/\O1 .>:=[(TYUPH-F]T6GGO8:9;CZ;%9O MZ,8'_8T<8#T]PP6B75TN'FBI@H_\;+\'BL1C3/!A()HD72K'1L?*2MV636TJ M\F$TA ->EZ51?Z[*MATJ3/*72\\Z:G\:2*X2D4DN']^\O7EJ#3YY$N$LVIL* M0ETF)Z)4VZ 1L(F;_8"T[@/^ 5EKR2#ADXI;:.BVI#VI3_]4023B;>H0G3QA MYS;,IP*69I.U/9(X18OE*!CHCLV]Y<7[\',U@GCL!YSXX+..[ZGT=%+SY731S'HXY3%2M$(]@W&N&D! M6R_[USJ.[Q07RGM.[H=T2Z9+XU+=IY+5&!RG6CX-OEB:WQB&KMXHJ*?B'.Q= M*>OV+1D&-B''DEOF-2%S"D$=Y$3%9Y#Y.A;N6J,65!Z ("<>9:Q2%WS$,&W_ M;C-S^/I6]Z!AF53++>BV2_RIG3GGS0-)XMT#X\K0T](?F,R@S3M^P"VH=A E MU/"7#2;IO/&5>+4D S@#GW=FL, F.Y3J'^,Y-66X4=>O/MLM&$AZ__4@VU]9 MY)ZE:O.B'I[L+**>!#H5$#9-E;>GI>:P*J261SEV'E)8',R3]U.G,_X:[AQH M_4CZ9:4S]N712D0&NAQ+;SZ;7?SK+#3 "T5V$76XM', ?\1D=^&GZT@-K;F M8JY))0!#+?!I36TJ$D\:_D_,,]/:8V\;#)3=Z'> M3TGKKE'W6; MEF[]_?-MTJD0LW%E\5N1CKHLBJ,W6]",$QE\J+F5(%_8/+9L \*/#]X6EJATKQG>\); MZ4 =+OL#(Y!Y;26KX=?@,JX4[*+Q>^9DZ^DYCR4J53/?$U[;/\ZZ+O(.NH46= X(8#YPOQ*P- MBN.AOOFK*UQVSATSRC_;36:7?%BYD+Q#XWM.M'SDZFX+(GGNE*D[J:622^>F M!&D,;81[XG\(F]7*,7.!_TP.L^=.:KGD:(K=HWJ+NQ1UL/1"(OZ)1EZ1Q[&' M>5>+EG)>&;Z-M= S_B/>^Q'05M0G;Q/KA'W6?*[9XX9!81V)L+?^<7[+S6N M!:,F0E]*E7OPR4Q.K1])[12:[ H3Y'CN>%KJW:D*MR#\@2GD9RN9W#A\J7(^ MU.\I,>?NN:9;2.YU+\XR;NMS1EXV[9>RLH7%-]>3F,M^+VFFO+?"=7]]R^2$ M\7-9@LUH896@MOJ$"]*_QHRGW(_#W_W/O59SD=RD[=K,.R@86BP[P(;1_%=7 M/8^:&EQGN];G7E'-7N-6W#MUHFVDRN"G?.!;QBNO)TP5'QW(0:D+HC_Q.P>N M"'O9Y$Z]OJZ&H>9U=*JQ!+ZQ#JC/JW>%A$_$RS"-@3<0G98[2\3-4&, M38P>%'\'^)&[^TX\XM#"-$6+K#9B N^KB!Y?]=Q26>LEO[+X*\%$4BK^Z@4- M'$F\&K9A0Q73OH_HFVUS?V J9>K+V)+6#>QI?C8I11.CFVAM0H:#(GEZE M #H)LVKX;I7+,"6 MRH1&A'KM4G^2 Z_;QJ#E+(5;LH@Q^PPJ1 Y/B@CE7O4 M3:%7?^R='*SXEBQ Q5+/#/Q-VLSU9\64 :4V!J.E&JM18:UW!?8^')R\1>G< MT3QBZ849'VY$7J0=S$%/S\0N]8![B\V4SK72?HXVA;X6SJ])]76LF+$<>TFI M3SB!@N1#60](V_(AL@"HC)YO0@4YI)26 8")DQ)TL'.1-BD^1&DN)284>.L/ M3I*$OIM:+5>RL#,C\4T;HB3Q+3(N>$UJH^A73!]B6:-7UV MR?)YR7D.6Z5E8/%32+N,S#NAU;* U"&.E0#P,XMX3-JI@'X^M!G2Z=5<:9). M;4X.(\#VMRY4GAV;U,-%;C,JV3AMX$OLNDF0M6*;_YK="ES[;^T$7K2&)LDH M/>QH==VN?\-]N_Q']XSCI#QA@I:[GNA3_JT9KE=6["VA,[@+Q8+*%SU20(RJ M^&K Y$J^'LL-<2AU-R@39#2-!B<06> TI?]CKZ?8<;IFV"VF)H"# ME)+8;)CH5 5C?779_1W:)P@E6/P=@Y2>+-ZN+@^-I4SVH!QSZ<5L6Z4IOKUR M[1D'C$*%-$// D?NX%=-!">7CH%*YD%*LQG]]S-+=9(+2EE$:D1"/)/ M\>T:MLUZ7Y%%&3Y@=[N&TTL'Y4,>@2FZ*L_&R@&MMI@0K\&W5J 17 M/65+N^1/?4G7]D%:X1I8;R'RYE^C22,@LQB,<3XZUQ-6CN<,,E:Y=.^6U>0A M[=*1[T VBFZ^M0DLYB]QNI8*PAX[4W\/C>Z26=UUYEG)T(,,#WJM2!*#BCE4 M_G'&RF,VC-9M?E^X'&H"/IK1JJSD1BLTPRBU:'I=%1Q!/1>1I&D4#*-F"33: MB^"=675>9J? T%"MO/=$]\\@<&_FW93CNHCFPHC: M#B%TI5\ONS64?;5Y$JBN!H&$JC=412O&ATLA9$C*OZSR67.E:'D*Q@UIWS]- M=<\HN7P[Z%%Y[U/7[:FN+)%R/UN2'''7C#'2.[5U<Y^-, MKW7'Q'H;KCC9'_=H!>(;6K0BI<.6D$D2KD-M K_(.VZ@Z*ZCS/O.K^8 MLL,R,35E1W9,KO0)>5 ?=MP^FXW,B+8$H]$@&UY[<]SBA%.' MVL";$[(W]SZ/CGM)B8\UI1KXM M<-9B+=6#<%5I_1HY.GIQ Z\3T8W!!TA&-J0MW?#TPB/&W*UVH2QN!\M"'4/^G?Y?@XZ#*U@CM@:-6G:X/_@5Q=/9/F[@OI'&7PY&A>=L_9 M9<.H3)5:BE FY;F0 5/HD%@.N=*<%$4^2IKRFMT7(B RG8$+X:VEJ 2?!OPM MO^0N"34IB-/.!I,R-&;+M#L82?/2ISIM1)4B?441<]2%92U!'7Q=J9D.EUM= M8(+8B!4DYMX<%AID?J$E8Y\)'IHHL49> 0]^J.'N("N^\;.)SISX]@=&2U,[ M<=',": <..'RK1(]&5'-;'@R]3/RYXM?WS[-V;H"N,)508=:3^SV\A,.)2X9 M4I.P,F^S"[MVZA<%!TGOT19K]4KN<@M1]\SX&#1=I*Q(&0E"@#8?L#@'L(OWR+U^W4KK292'K& M8N"74A727Q$$:'$?A?P6CD!+R/,I-4W6["B[SF%&:-#N M*JL/[<1FI4\H@FH-@_W'3>F$.'F*#S\EH$FKWCW=?I.8"A(*^L0 MP[08%2HBM3X@B7=2D,1X(5;NZS#*;CIHAJA$AK64U!2I4&\\,I1.:,7E]]>. MT1Y19#)0X&*_-CEJ:R_"C2PY ME!2U3)?3:>$ER[?*+O",OQ&S9+G&+1-^+$S7\-,F],PP<8 M?"?'\KX=N!6IS4@&_N9IT/*4:6+\]4Y 8]WHKJU=-9WAP/@MXQ@LT CB+Y)9 MLKH)+C'9.-_84ND(_5JH_[^+R-(UKW4W9L$=5S,>;.H[M[I 1<"]HJ76[<[Y!9G+)GK# -;5V!/J3K/SMP( M"2-NW+?V,MWB)V40<]#:9_T:9[F,K*]*2&<.>*BL'!,W'0K!IMW-+3&<8_@8 MAM0&-*3P(SV@E+E\S_TB>7#67+B**[9C3P!N.G(ZK)W4B*820<[8K:2JPS$B M%X8I>5KV#)N4O4R:"Y7F/D7_D9O2X(="ZW&3"ZPETMD/&;>2T1]A/#>_N1^[ M:#C&VI^A,W[59%W[F$[E-OXV-X7$E!DIL+7AQG+W6Z]]23[QI"\PL%[-219C M;3MGL9;A%>5:$=30XK4=695\*=39 BRZZX.M M'J: MHS>52J@,#Y#CKZ[5C_$!U89VQME]H?YN1D_%,)GVA7MA?V#&!S'?9(#T3:,7- M:K8>&EH6;J?H/3JEY_=+?VTV98T1?\8M+S/]F/(]/[6-W09$S7#&5T4Z7'+$ MX\MG5EOLS$MM#=>[>&?HZ9>4_,"(62CT"7#1,3:[HC0P# M*.&[\HS(3M6-T.UO;!0 J^J6DN)?2_G;V]T]^$S"MX;VV&4-7X8=>*!=7\;' M06T*S\!\7":3NJW$R9&[X[T"EB3,:V.VTBG:F0$@+]]R#'^KH-:1^;?5LB%G MDR4ZJ>1FU_RT-GX[].,0KF]47*6+XN>B:-BBI7+)2-]_FIHY#V\K6B'6NPOH MI^+')LNT)[FO+-K4"GE=EY9E@]CKJY$(7JJ^XFC4^JP\G1H0&$3'O"*>"(.C]/ MT:W$Y;=>NBT!58E]*AGY)T&I:#F=7-900!5(;IAO.9-"597?OK_(KVAX:GGO MCF-;??J\2F6ZLO+YE[V-;8D!"#>!XD/KMTU<4("1^BF/-A^!8][J[Y)@L&%G M8T1_6C9FLQ7UX;O!B2>NO0-T>'AD;X1.H,HB._)K9']:/4B1EB=AR)J=+0:$ MW\0OL#<0%"W\214WM_A%1?$"_6K1_Q]7)G\#O^_7Z=70Z$^=5R=[,U^]-:T[ MGMQ $DWZ$I:V+>7WP+BZ1&\'%Q,K?(4M9*>3^.F2PP=N>E6:KA1 BE!*Y/?Y M[S<\VL+)B?U)0<3WO68S$\735U0060&VEC(RX(?E.3')B<)FY#Z]+_"PKQC" M6/R[1."3*AXH=EC?5-/H[[2_64#M2T+GWDM)BY[DGJ M0^4KK5)'_RR$W+'Z74]=@\;O6*CZD(09EM%3[A3'CKI"BX^0[$4U**4Y)C:8 MK.R]B66TIXEOD&("8AU-+1[3/-=VH>#W5-D[E:!K5GR67@N'.)%9#D>C9--] M])K8#)H_,"MJZ0C\^PX-+/57KSZR'7_=(]?:2Y&^&#!''Q_[ P.6:&!%[&%O M.O4[%AE.=.[PFYPR%Q';UC51,P?= M KATK*]8">PLR>S9*?SQ8PTZU]*S%ZB8$?*33&8FKT.GMTT;(08+:1TK5BA^ M^%=0BY@AWH*V-I,%YZ(CX'M)%T-4LG7]J.$R U)_J%IY[AX%27OXU,S$;="JLB7U J[J MCBPBQM)W!*Z.+;H!DGQ](#+K;G6K=FB2QVA-P0'[.TW0.X4*P2D<*7@J M9%]KN2-*=/E^IMH9'.<-\46UI5M,[@JW8 NMYN+1#IQ49 ;.MUSY>NRB1 M;4ASRL,2V^0LAU,AT]B.*XFX@=[FL'WH^)[Y0J]FAX+RSG?7D3.+?YH@\PJ' M,6T=["'D6;*R[*:D7%6"9-B9JUTGSI?G G2.I_"GQS5^S+5\A3+5J:=UE#JG MS."F1O27L2; =BQ2YF2Q/9OJKE%+,UNVN#GB<)]$*BM1RQ9P85\(B:V7T2 MFUJR;Y=MUD%K-8^?9*BB9R<1#-"?V3<@W4S/NP7VJNT#.+L+X*=TS+93 MLAM\W/-KHA%="V*R;E3."(U?S[G%3"2&YP4C.$I\8PS_ V/#CU9_9IP& G/9 MKI;&UI353$Q-&P4>"0M:]1T; /[#3#> M?A/S0:1HF?@\LVEWCS&L*<2604@\GQP('B1CU;VL0;14?".']?X84T_J!F6G M8G:56HICYW4_]D]BWN029-8V?HA$,3V%BZ4&;;<*4Z/\7=4&''I9?PMZ&Z"$ M1]+#/WXQE#5XROISH;;%X$^@!A:.K5M9F_OA)RAK+.'4O.V&FG/9L9X$B6'P M0(PEX,>$[M6/("#8RX Z7?PTHD\/S7G_]VFF6Y]%#/D;S8Q'7D>/6N&]@H;- M23[W@$&'U!1*HL3)EGB#-R2._+4+E=[/(N*\H6X3-)-QS0X/5;VFC.+P*(- M0]2Y5,H_A3]_^53#HER0CX3,>LF=(=% ><6*W5%W:L+XY2- <$%X6G?;.&3P MZ!YBNDNQP+F;*[[2:55I)@"+E*4P2#/\':O4,^BHY:C<[P"(7UD[0W2-O,B' M2C SWKE.$C$EG$^QRJU%Z+ML5X1>1^1O"WI"#;N;\9HZ!%T^C::.;-PLSEO$ MMC)_BQAF-UV:\%_NG'SM2U[%-7/7K'-:X]D8T[_<'(\4$=U^A5W^#6WHC/8M MJJP,]=+5\GD[N("LE\RY?MD K=U+%(48*L))=D?$:R4G4@!N,KX,;(BQO/R[7?&;D;J MQ02XI)G"RY1;X)2"QA*S1OW)DBJ/$//%59)$_K6"^QM32TK#=KR2*2)YXV-8 M3XJU;?!(V0.HYI!.(MU5^BB7_'/+(5"#]7@.QV:/8K*[R:#ZU\Z?85]K=HP&-]]]F;[W>!XR1T>(VQ%1-7\=(RB M7AV2!FT)R).=SW580_$RJ5*&$OH\2]5JG[G>JT("MW&A%_W][/_DG5"9LZTE M=:B)Q_*T[-%ZM20R^:KD776,@)LQI*>,&C!72Y/6.-<7PB6.:I@=<1S_CH"W M-.LJ\R&NT9"[R+_J/.(,.I7N<93B69W?F%P *WR8L*>#@M#:8Q0;4:U,3'[U0$B'& 4,@7@Q)R#]PU8.G&8W^4)R7^8/HX66PCI,X> ME=N">X/-R=LBAL2%%'^)X:;$+.W^Z^L4S?OO>1$?]E$%9V M*A%05ZNE!S/ZC:L.KMA!I&KB (%WR>RS1 CTH-F;^?&.[XU,?&Q^"[>CD;1D\JN$GK"J6%A#TI?&SP@Y95Q M":V7)%LRX:F =V71C M15\K#LI4Y/!"$)66%P*8;7_4C4= 0/-LCS#U_U4 _3F46#KI+[H_B.:0?4=IH!TQB+1"BR\KF4,CRY6?\U9&^ MCBIT&H&^=IJO#9M]8HEOP[0,8_/ZN5*ZZ3EK.M@&NG&12_TC CN(_A9SKIOW MY"GT]:H>U#&YK=VB,;.][PZ.*;_A4\.5 C^5V2E:6%"JH"/1NN#:D9?3RP>. MG"O.JV"I#'1+!PY&QJL;2R$S3 Y8(+,QGS2PUN-+P$[CU"U&5"IUF0F1:HWY: U<*$J]P^1[$9:H.4,FN9)>G.< R--MG M8MO0'3E41XPW@+* *I^Y?%Y$\Q@2.!@_0F/?A"K7Y\W5>TBYLR0^/.U>),H6 M8OB[I%7FIYU;9+G3U.2>1SQSX)#(*V9X,L/?1&9OWS!@+YL4!.&3VD+G)?$+ M1PXSHCHZLTNSP;!XZ0*BU7=E>>R!HZ*P'^ +A4T*7Q'-\9M=UERMYU_C6S+2 M..6XZOEV_((S@KE2J9R$!1-A):G 0/K*YSX6O!U#SM-%,J:>_MVT-/^*UH#; MV&@_-61M.RC=9'GO=[W$L(9JQ4*3]-0[L''M7.0?F(/I8MCGE4)%%[,N)?0! MO%D*@?!+,S-S]66'4F.$_LWU_[=CHG\/NU<5#.M6&.F?\"9;TS/&8XT!2RJ. M;9$_Q;GV([+FE,7K$)!#<]JR;EI'IE>B0J @CW \JVJP9#J: X2NS/L1M?N2 M5G3'D[[(O$W]JGQFU#STC8(W5Y.7D+R'!/]+$*5XE='JIC3&504MB;H0_CR5 M\Q*4\\K.1VGP%ML#_$":7ME?6_,(7X+G5-?=0X7 O2D3U:"=4/HBT9= ^RX3 MXOE85_O5AY[VER9A28^GZ7\Y1Z'KJO?3GI]5=+:PGVB'W4 M2C'7S:^G'XL?1-PTZ@RJH4*Z!(0$VA I:OA\* 1LS6JBB1H&JI/+#J7Z#]WQ MYNMCJ@=&XS].*"R9W-CSY^W^4D,\ST# \YR5>Y:G2I^?X8S9O?TZ5@WTUY4P MYPX8N[B7H0WTT$M@+B4Y6:"?R)IC)>"R%N\RL#:!LT+&#)I6_SQ)0)K;C6IU M;7CQ42_?I6-P*@LY^P.#-N\$E%J/LU@KM5X29HLMES]>'I=G M3-^A-FBD%G$VECY#>1IKE99'M.Y+5B_O0;$@7Y4?>6\OAZ[] MZ(($.1B<=#Q/E28O[ X WQ5=D3OL/D,U%=U_R9G_QXBC(FQN^8V 4].0@,PV M)"12&9"/B&!NSG]@I]21=)5I.$/]G9/!E29/&ID)I7I\:?M:R_5M1H]U*TWU M%\@!B0LX #ELY"0Z"\-N=F0_<6#J@:O/Z3(P?J:]O"7MHR8-5MGXAP174P/L MO-P6X[.&Z02R!M,#[AH=.N9W9FO$4SCV87.XV3@SA05V-44TO+\Z 58^AJ5U M4O#&Y @>/*QW.R>F5>ZB P18/-\L.H436X'C:(Q3(Y<;U:@FP.XE\GV9-]8>]"'[7*)C>!7CWYG!G2I]CZ2'WI>2!I MA1SS A$.&5[1'3N(VXHE6.9F9".KT6:4YLK45#.!31P<&'D85)AN]!@66Y)? M'N.3^A3S 7)L92+\UH@^/P:O11::^($%3O(R@+/T.%;1\/@5Z^]ECZ%Q?'U# M$R(I@4C)C3;:L.D[WO+'::2(C7 M@M==_'@.)_D')H^BPXDMH(84?7/066*W@%P@(&D;7D5(C5E:7"5&R1.YS8BN MITX=_Y@3P0H=^(4EP! 368KUP)6'/G/XI[7C8\6X&MN!+1+L 1%6E=I&/C<+ M02_8?#JRIBE^)%=U94HX]I#X6BY?4B[[&]ZZG2HFCU]BM/EF$=>E_V/7=^HE M W)- UVISQ>.N<@5!>*&05EI9?M*=6DE0]6]2[,7[7 C77U\'H^BQ M.6[@+)(1@G8-:==1IH, 6;F_7R/W#T-M)U 2&%;10$LVE M?:H4A;&R^%JKW2IF73@?):G;KCW*%R?J&T%"9+&R_+4+KW?5J_C8;($?)V!FM@;Y3P>F?E4V=YJY9R9,;. KL&IA$7WF2D 9Q.)Z25G'/+#D!1 =^ MFLU%?14[\@Q3VG%-AY'K4 Q'/(\MA#1?U.2PB MCB*!=4(CD:K[[W:EQC>@S=RVE0D\=+=1K;5XCR)H]MN=;I&'FBR/8+9?9Q;> M638T&U\-$9*"P[7%@ X1_%O-(];'*8L9RI@@WK,<#DV!(45B-AW8*(K\,S): MPF%7>M#,<=MO^Q*LA<=.E %JS@9#-2QX^4482H-&KMDG55H9:PKUJ2%/J9,+ MA]?G.5&BT5@A4A)'XNYY@U[=XRRJW5EYN7&[ID\#L-*L@?_O^)@G\Y??R' M![U(A*^>(:JGF 9N#TUU&(ZL8'3HV_R36&IYX%7CO+C>#F2><+^$J9A&U19L MM((S6:5WMN6P^Z&1SX5SMKLE&!&P".',.OA*>K-\<[)))^ ?-VPHU.>V)F+* M)"/DE"X-< NJ'5=/Z+@T-@AE34QCOOB)+$*RKU ,9M2AB!!:4HG7;>G$1C,1 M^0,#CE*%RU&D40#/[?G[F5TV79=DMQ"P^JH->!.-K?Z7N"3]Q8< M*O&PY[Y*-L?6UOP<AH' 2;(+FW9?D+5-]?"L:6,<6&YZM4Q*4Q=/SD.-:9%R^'JK M?Z'_NB.F;]D8#_Z;O3X-M,4>S1DD'VU2= D0(0R1E]XZ(&U ^QDG"$#@*BBJ M,J0A\[T35(&7PRNHRD/=BD7+^#WJ6"0%!G4UI@$Q/;?,H0"D\Z MX;VI_ZCI=7N02-A$J ).E0; YTV@"P[L#+R]2\1):RU$9/F!EADX7\J#^5O$ MC%[,F(W(^F3A(*JGD">3@DU+V&@8D$K,,AN+U5= @X4>)1^.+ XHL59LM5^2 M**]G\UGJ2WGGF"-F=>-!R44?0$#R.>:P-L<%IW'%*$\X3Z_55.0L/&>7O,'4 MWT7ZRRMK9.%*UX@M^HZ-R2JG],#E8:+T#V"L-C6B'W@9K9G,ARZL2(^(A&)3 MS95D%SOH%W=TWT?1Z(481FIWSIN6)3A9!@BDR1QV\,89E/1\4&DTD_4O9L]& M=5+O.EV05/T$##.N*@9IM%Q. BR8U-AS$009CC]?L5*_&'C/W!3'SF=2Q+IP MS#"0,$Z225;7H*IKT3+.1!LWB#L6D.QI'!1O!:9ZO]4L&_2&V?MLT;+Y84GX MD[)OZ-?"?T%9E7^7)@3_1[0KKV92NG/=)Z]F#,$&O[A/=AWE1263WH1C_H#Q ME>$T/0G2EPH/8DJ9[-. -7=S&;Z+NP=$?/=DD<7&WO;B\\X([C:,&%'^ 3'\KT;_[$H -#E")(8Z?IRT53B M,BVER"CE>)1:8*'^RBP^3U]4LF]S6"0CB/+=MO#4$:B!;ZZH+&'8G!D0:H]" M%KK^B,,(LY;_: 8G-;SZ0\P7M4"\ MV)H+/VW^HMQVSC4QN)U"B:FM((+'Y5/(..?A&33Y!#I&5H%Y&5^5 OBB*W#> M'HV6\SRE#?DD+\KB.ST!3.^C/B,5G:3L\2M)8J1JTR:8TVN4E4V M8B*1-U&%+(A#)3>HG>0M\?E*82M_Z44^<^]-2;;^3QAXF&\PHE]A4)+4>+^! MYW;>4;^'9H>\K%4Y[7_OQ,.E_+6K M:/Z77C-[WO!%E[GYLL/XLIA]^0^7)0BP3T*JB 2:[S MZE:X8Q4;OW)>7W2'H/UP8D\?N#W./TR M[[&YUM6 ^?GKZYR:=]^*.?WC'G"+?KIL^\$-EFES6YZ@#;53T@7+2IUXC>]?#"OM@[[_9YL M@/7])T/5QL>/ANQA24E@OG +-]AH[&'7A*4O*"BI.9U=)\"BKS^WWAMXV&%" MI)OH\8/\8A$V/XVJR';@Z+:@Q.>-G.\#KS57["4,K"?1H/Y->.*.=F,BW=3$ M1BTQ277@]]/01VF!U:S%(R"G\L3<'YA1$:_SF5:)<_OEPVL?.BNZ"">-B!S] ME!O7.-.=P ;Y=J 7>]+PE^E[60^QV@(O164N?24)_8E2(95:D4G61E+M'[5. M936P(_B:-HWQ;@2WK5KZ>\OY$)LDIX: M63V*V[GFG\BHYB*:W2V3I9HJ+LL,6QQ+=.C$4*I ':S)G])=O\MSL% M/S8W;P76V+!$#".1R<.@A;<;-9T?.!X@E853FX8;G9YU87EY,I@KBZM6Q.]9 MXW-H#T3\>6UDTO*R7.]B?DR?)2\."7J4U<8[1&"L;@5KW'33XJG',_5/Y/YF M#,;X U/J\@;V8-(J(37.9/',-2'/WFDAU+^A\%.Q])K_Z=MY=?R[;-!'^H0E M8\K#:\1C3LN248RYK\=VABRLZC@;8L3,?;5N4NDCY:T%*>^L;37$YA0JT3E5 MNN$ND2F*1/P3R5)2@ 8N[BLG>QM_L=22?V#;?X8G9T[/*PGY?X$GE-4$'65C M]<:Z[ILU8UX>#MO"KQ$A&BU=@M>DTNF=TX:)S$^TJK';:T5M"&*I#X"CA_G] MYC3WBU#/5_D:/@%A=Y!)SF:CI;#0TTS[&,5:>W[7^,>\E53)V%JT/S"NL3?; MJH&\SY!DW;8V_FUB?HUYM. M99+1)6,5<_.S96$CVA:X3V7B$*B.S5=:'993 #\*16(63DI:2KP^[,NOH]:% MK[2":CIBZK^:T5+\G3DF8ZSOZNA!,6LJ8-I5HN;'86[L?5?4RV6=!?'6NTS\ M>/MO%"@)7%N,:BN&%S2H5B9RGS@G/EOZMRWG>7).9N!6QA"Z&2*=7(868)&O MA3[0K3T50D&I> TEP9U4A5<=H.-?1I+4#S.-N5CDJ.%B+?7B25EMN0I:MQ!W MW=2:\# -W\/>&W.E)%VV51*],HDU;J/.Q(C#>+=*;H1+[9Y=1=+$EKB#3'N5 MTJ@Y88QAY>JM:66W@&>J^OS#,OZQ%RSZRX-DF-D+8)^,>SE8\4)SG__G!A8, MO_KEF=\O/D\WI#=[NO0&::I-=JINX\@8AR:O/0[-.RIWNX&VB31MH9)M;(V2 MSAI8:!/?W4 M:,7LR.UTV8TC< MOSVE; P%\[?Y#8_71TYJ*<_>A54.UUYNP^OJ[%#J#;Z?_T+A?T=4+^LSE<]V MRZ>741_0G+Y=-RY>\I]]5?Q[B4XR$V&"U'S=,*-Z++6V$OGW!@YB?.PHRD^6 M:I_D-?9R3FGGQ71Z\'"M.[GT&,A6?'R*_\!P +//%,23N.:LX#&I=M.FZ9+7 MSB1"Q4_/%:;292NUIG/+W8(P=):F%#P[)71,_'I/1FJW!ZLX&LIM/Z:3VD(] MD&=:-Y.@VHBG6H+)X#^3&ZZ M).6Z *MNI-]VM46N0_M392PP2#8?*Z947.\T0=TS$P4GX E()BZ2S'+AU#K\ M4B[(W87&Z3(T_Y,JJ[)J0Z^Z>4O7Z4^8!>^(P#AYX>]$PJ)L!M8?:4('JITU M&.&P$"IL:"XN/QYBE"AP\?Q?U_4LR"B\[ N]^L<3G+PPANZ_C!3^&E^:QTB& MK;R@!;#5V-VT@0J*=#EP_LF\H3%E7B*Y"!IG:&$=4&];>N+^-8^MTZJ[R4C2 M<=1)"@H9GZ.^;+546R"L-L!W),"W%BO9VUK;3IP\KAOH[5!E+ID%=>J^Z_G% M-@@$Q(\+NSM-_Z>6_IOPI/(?3?R4:/W_IK?&]E^F?G^S8U6J6]/#,GJ,'QWH M*X%"5N5BJ=BN01/-K-5S);*GYG:J=(X.-C= VB%9Z%YQY&'KRO=.>1?F7*IW MENX-\]KVEW#S3#_OTY>YPQ"_5^KO1%6)91*M_X1'&IWA-QXL(7'0DFLYTK5Q M;* 2(62TYK"@)-8"Y4JUAP&66VBUJ%(&)R.&H2&98 M:0Y8R:8*&DO9X1J15L?Z$<;<\,YBEH@FQ2I3]/*]K[0DJO?G%K3S.?--R&2X MEE]_&JVYERD,J\9- ]MC^$YP1>I5-P%F)&U*Q? J=6T'M"MVDZ8KJ?]]> #1D!I9@:,-Z?J710 MBC,0LD?8*..A,L:ORG K=,#']P#@7FW)01G F /&CQ.7J3B:X^6:/U444)6I MW8^)J0N0K]76L9_KL1<0C\KJ*$HF?E;M 7UW+W)\4M(D*P@$3!C-[YG0<*GG MTWD:G+FEI*07J(K@I:4L*)?X',S+ ]7U=&]:"'[]@8%Q-B\PWY2E:-FPA \F MFIBMG8LP$TZ1!VUR(J'\WM$.S&3ON6*=J@PO([&K55C%#IKFRD>>DAQU;^B5Z7<5_^3EDH!SP!# 5/:!8Q$ M4,G8G0^GOE9?/%8%#/]0><@8D \GQ?W=CP(ML@GL;6!,)8'#LTH9#J MQ*5S.V5@"WY;STFIBMRG\/%/O>&O^^$X1E.Z:%.\(=]1YX/%H&D:I15U?-Z571M4U(M\@G[W M-<7,K12L6@'X5O=?R$P[B^W!Q2*VK)%I\JICO(4K'? MDDVY\T"$@CTTZF@V[DN'H5SJHBE33&1<6M]WV4F.?+@J:6"VJMM!(O$O M!E7.+K-MF)G%BVO/J*2;?5/I0,BF) &KI&&=2#WIW:Z5((]HEB>)%R,$9AY] M/D2#256<4*H>Q:)OA\/O!\J6(;*VAF9Y45E.X3)WW6E.51^;L>T"PQ<:"Z9+ MOG) CC8XG6=N\^SRB3K:YG!P':L5E3U_<9LQ N%;^"[LZZ6 RC"#S^4%&+1' M6?>UUZRV+E^L]E3P@V+RU)1'R85#T@ALHV.;##XOLZLJ[A6'+3E>V]ZO,>OU MQQ3R:#XZ^WK#_WK_T ._9:D4Z>5VPTHFQOT#BT438Q7Y/E$^[8;:]6^O1R(G_3DC2*G$C_#J1]0 MKL9- >@2J5DL3_8F14=C#*8D..+$3KTJ,=JP?Y[#0__"8_^7U/3"4'[^!U71 M"WLQ0_1QVZST^5R2 C& <9+?J#7H4Q=ER[!VDG.7=/Y("%SJ.OB:M>$1*HB, M;W2.[#BERIR /^%U)R>KN:\Q^G24]S'79X$!(W*%K?#F2>5#J:JQ:/#N)B/# MT;#QJ,FR4HZMFX:%@(();&3JQJ:"4./^),H";ZK6$TK$ZW1A,TX?X'R7+GM; MMK!&W""NQ6W D6":_#2TK=]SKWGW'//?<]]WW\VFTEV M9C^SF^S,['SGI]WA"CIQ&-ODFK/$59J3AS\7EWT63HM(AHE\Q&O6=AC 5B&D M I.,]78GC@+>R<&XP72Z,K L'9[G6R,2E:^^[QYS@=*NKDJ M%"/-H9K2-ZL;U3W+<(ZPK#5)*:+OX-PMV!JJCKU.,(U7<7OQ M\J,4! A/2Q M)F;BZ>RSF"X,X=.FW2HH,+J49Y3GEF14N)OJJ">P(4&R MO._A)_E&3:F);F#%FYPR?W\WZ:"AW.8U1V4:KF]9XT+"FL4.B$A:F;''66+0 M07>%9.;D(/ZJ5_K8HG60ES@B="MEAS;]TQ,C@_ V$01127AYTM+&9HIIW8DH M_!Q16F!5!EV5>\:FVWLX\Q$Z[&5X1CTFR=]:TY3,AR+LI./-&3Y[9:L,YQ-= M^+D@RN M=]7%D2'9\>ZW%EV#"L5NQ#1^ 40%6KB:]MXAGD5RD]!9Z%D0-J+C%!&V@WM" MV!$,C%FB8&1:!OE:LP_D'FOB\J.S.^!;+ D:4 M$BZ.JB*Y6V,E=J0>6+L=6FK0K-\'DELBT%C.N]^(?G<:G?D91U7^\]:E@V(( MQ'2Y.\QC5E'\FD9<@,^RDSC'MKSZZT+*[E6(,78_7D3]:G5<16<5[+N3369O M[@N/@Y\YAB0,< ?I,&+=$0_[A%V>IV(/[.L?6;!M?ULF_(5M6Z36R?HU%>WP!^2Z9FN^V M3Z S@E7?Z15[[&EF9@Z8AL;4([1=N^P9A=5G1Y/+7W'=G( 8"77^\RT[V@G?4(MR7K9*ATK,?-ZT-;5,7EVL MBZL2A#1$?2K4A*A%G^-%Q[N9/W\UZCSQFJT'MI*96T@\9OO]:'0E:A)M%#75 M%M,+8URPQ'9W+SA W5/K/PS$?WXBJN;_5&-$6VS:M0"LA8DS>:F/[5+K0ZZ8 M'5"D>+CKG;RHFK1X!#P+GX!%"F5L'3+WUNP5E-2?5M;BX(UF'F[Z8+O2C_,: MVXQ^X)XWL"S"1/_T0E")9KKD%\#C%+]0_PQ_=SI2(8 '[9@^]97^J_9?@'(6 MN!7L\[N-ENUY1_^UPA[N![VA8E:>FF%;>Y'(&6577\POEV0G>1NZ^PW&0*) M-S#>>&JJMU'!D:[(]>$*]?HBVHU-QTL&V3#%!<:NEQRU^!J99[JJ1:.XY!DI MJ?1. WVF!00YD\9 MZ3EB29:R&\;YM,D9W7NX_.&*Y6YTZ@:UUA(!Z.<,2?WGAI\$?_?%##(;2A_4_$,B0L Z6RYZR#5_"&:C,J*BV MEKV_'2T0I'A87MA),+5FTE)KAH)LWT;0M^\*)>=0-Y2[[-^-AT[%>O=O).IP M:>N#\S_(?+')XO1 MNKPDF)F^7QFOC35YI7%2LYT>5(RN'N*/,J5"N.;=\DYYU5_!N6?@?3Y3(>K[ MF_ 8CF\Z&KG/_VP3P>OR+& AP:D?CQ1K;TDT= M-;W5N5HFX5F'X*B&SJ([S7(#ZWFP&;'CF S5:U%[]YNVF.#[35M=YL1;I.*8 M"4-EUI;8.$+&=[[C\AV\/$%$>:'W$)M7\+C06&5Q"MP94M$#5"4JU03SH,Z< MHQ\:_>4NI^(Y%A9]P:@.^6MN]*#IXKVYLZ4;71=O@V405F?QYT+'1&>HD=@IG86AR8QOS[,)ZNWUU(Q:.0ZSW1>#SE<" MQM%@R# &_K;;--R\Y_T#ZLZ=T'"=^[&1#;/KBQ-!K#WUMT:LU@8)V%!H*= 1^2YS0=^/ M\VSG&?(F?I_1@T6O \ D>!))6W/;:G;!_/.F-A/2KDO+-_O^TH2!0!_\'5YT MAV?J'208>SX_&[4#:K%0RP]^'M)ME+@Y'0F%P M[75];XF?#6FRSGJ+-33H=0:S(&3E-TABZ;>^%H2ZK@IC-5Q$BB_"HR:(E].= MWC0AT$"O.L_)\BPS4WO6D+>Q&0C>$'(.0,0_J?6S4C'E!4("CL8=6W B)AW, M=A,:!!K*H^T+RS?L\YIJ_-?&BVLHA1Z@ ]T/RC$TUOAZ174(S8XJKWCY.L[9 MU=D;1\".E$,3'!G2E>*1)=-^VVRMP?Y9.P-U7ZT3# 3!^-BM?)@AU\$2R3UF M>7P#Y]-)N?OJUL%$!.(2:E;AJ4#/?.-4RAU>VN"E?1_Q]F8'6^]' MM]B1P6IJ/'3AE%,&^+=S_:?8CV@"Q+./-8=L,-;5'T?M0EY0G@$WW:U!ZH)G MFOX7AP?^MDA-O?X9UP\22TNZL';3(IVO@AP0CH07H/*"5!S3=^KG)XZ4*>O8 MY,]E&.6BTN.]G4X-OO\8LKH-!FD9O^.*U27;Y V&%?LZ\6BB(3=$+BJ=.V9+TY3P5X*.R996[$>E"TBH5KSFD\R$ATC^ I'E$ZEH?DS5TWF]O8^T@T B_60L9MT;T>\Z"> M"_^7]PNJ+K9VAA^/C$Q,7!VS(]"&S54%MD)(Q7WNG;_O:\>ON;!3Q5LMMWHU M%9$;SM JJDP)?KZC0F4_\JJD8H^\OJG8:S:25.RPP$J+"G5V23^N4+>.SU1^ M\> //+DVFC['-Y4VP=_UB[M6!19'(6\+OHE&1 [_VFWH9$E];O+EV<\\:,UM MS9]@HZO1)LWK)7IVP.I*K3M'"/]FZ*F)H;B_>!0FYTZ M>B 5?C(+4J]=O.A&N)CL62(UY'\"C]\''WTGER/07PR2_2WZX!\Z#OE]UC_/ M]SN7PQ6_*XCYE[(,R$*PEZVAPW3%#F^'G/2/*W74/DJ69%1G>KK46NHV"JM& MJ+S%?2\86/B**LI+# WG2+<_+YQVN(Y0685^!.!O\BRU."<"2M&/ 9[AZ:W+[2/0VZ,+9!;H(2661R1%4:ZGK<@6N6P*R)VW'>K_\(&GQ@G MA44$,X??./L+YMSFV1]?GE9F2X=G;A;6R2JPS"SQS&[.].1."H^/D.7XZZI.S7?Z'C.JB]QE M_RAL$?;=H+:K]"HDVRBGS6L#UO:+RK5R+CU39=AV-,UAV,67,X'&.\'J,6[] MI;87(+2M#D8V>VV4E:1BV@1U'A<33AFG'@V\F@4N !JNW\#<9:E/0 M".#9W8QD)N,44&(I'R#X467GY4:1&6.6YS]"^JM8O.R7B4 M):7+10>_YBIYCOU2\=#8=TS\M#A@8O"CU[Q>!%D2I:M8>\860P"PMLB3C(_9?#-SA]H\5_KT7'5P?XP]7QVJ7.[P.M!ZM#:: MG^($P(J:QVLJ*P^>L#2X%AE(9A!H:J\HNRA5FX,RM2HN($9[J-,_IH^:B:>L M3M !!:DI"E1=PPC,;'E9G^#9WQ<0EC>9T;7?$A7B\L5%*/.0 M[4&]:YOWOY@O"VX\^\CQ"GD9DIJGA(^"0"57]Q T7KNI$[L5_QH!MGH[/GYD M71,,=UJV)\$E8*UN COO1./AB^W(OD+)_'YR.SEMBB?;5NK?:O(N[^!^#G$Y MK#BO=]RB4MKB]Z\G:#J38BE@+"4M66T<01SH1B+/$]>/&S[T[ \&,X?2*%[O96Z![3Y/;A'0TU>,0>LS8M')5JS>$AV&*9TA(B(Z/*E%JA7=,"!$-C%F5Z<_K3K+9U&KUXOX" M%/^VF#T"JEV1[2NGDIX!(6=ZY%CGJ[14"R8+&DW:&]KP2\)76Z$7.LVMOM00YAL\E[B-?JQHG?:A ML$T>3VBX$R#A;CQF(*+L"2C5L0W*2KEW^)9!;#^(AQ'"V$ZF[7%WU*61-\L(2F&BDV@0K\?KO";MO)B:E/?\J&KN MM_P$3SK3"'B-6ZR"UL7XY54:X[&=K.I#%7)7K% ]=/XZT*&%!QQ([A>_10(I MV!HPQ?^0'%E]?_M+^Z!)+G;8T;\1R[?4%[H]XV/6H>7#V4QV#= MWTSUDSNU0"MKAY<5O@36'M3XH7Q(]C&W5%T5K,W'5Y+W%-O76(786.G^3X Q M@G\%C/W#[>N%K*GC/3-[-#N@Z)L=+R\)>I\C+Z31#!1)6J/Z!:B(><]&'0S6 M^@4X+\@WF->2,V /$V_V)N,M73]"DFZG5@I*M$(1,];09H;,UIS72,)[!C1' ML3%>9 YNY5<5)D:\/%2UR5L\U#=''? /S!Z8/SFHGCS;X"*.K.#0/<26=G21 M*W-.[L&2Y_XA/[\!WHI'-'@Q0D8,&!E,?4OSD%S0QM9<7:ZN!V]>)UG]!7@^ M#(D4&.1+%N^T[#".LB0VHRB#%[<9)I1EHN9( M!%FNG#Q 5S^[%OOJ?2EX/5CND-L,J"-IG$XG79]G]LVZ"8_DDTMU:K&>4(RE ML:E[V!LJUIVH$_]XF5*&.%M78M8C GFN_/T78,5<,UMI]BVI4YR$UL<,#%K< MXT%W$C+_@_DW4KMMGD0%E],PS!+ ZD0BO;@C[=&2&7D8JN_557F2Z?I;M5^ MH=UK[_,[D0B@=]>6K*J>";(M@\Q-*NJT[3N3REUU[)28T=0.\T(F4GG'=XC) MPPJ62_C@WN7P\*!COF_S_K&V-\-X#]ND?_<^OP^])'_ MLV"*W'\/KBYP8V_K82RK?_-#ZT ,HG0N\V;L]*J0+DJ&/]LE'D681^##>F6F M_O#;^L5VWFB^,XP85Z>."LM8.AB,2K7=1R'KC;GXV2B3\JVD)A T1H\3'E:* MYPP34'V#QL$BJ 3L% DZ?CP*=ZJ9M1 S9VVV%%7;BD*C<\!FR,'\N;\@ L7I M*-_XT<)'C!?"QKZ**\N=2F:=GQUU,;UN'X1%%.\D.? M2PY,(7R<.9YKC,^7 MOV@G:435C:^PJ9V7C VK>Z@D;4!\E6I:0C7D\ZF?-%2PPQ1NR;/3[IUZ]%PE0G8A\A(2\[G3U/N20<',VK M'A$!+,B.")H<[A\610 R>_KL?G+GH93A,37BR(8.[9HC=P?#["7=8@)TMH^Y MP\KM&I:"JY+TI.[;N>U9+N76W%*Y*)AGA]]OR\I6_>UK*'))7)W ;01V" $Q M:A;-7U%YK(\_=4PK3W &F"U!HI=.T?4\==L"C4#RN) PE'%R;UD%5?8,GYUN M0@N2G//\']*G\?CN8'ZDS[8'YZ_X]%7 8$.E+^<9^M 5Y^_ U5MVGM-9YF?6 M"'4KX!\2-G"_!=DSY@"$I@93)XWG45CO+0)!\YA*K,?U?GR'[KLKGX>B^;>- M=3]%S!2?.B]$"$EGNFLF Z/">O9>FF9OY"T_VMC[Z+JX"HUA8(4] L/Y+362 MZ@]^RG!K=:=&B%\WZ=\NF+J.^RBM]NG6?55F=T8\U2E.O#Y079J#92YNW(BP M=<)SEX5]V=[FTM+C"M1^M@GH8Z+:><49XM%F]'6O2CP(YDGIT=#![A4%/I\U MH(QH@GRE_1%L/%7ZU0B/1]4@YXNJ(: IP!$8Z:>[=]P,][P92AK90N<%L:Z3 MI/HME5'N=7OL\G7%[V.7PSX3+]F9V[:FJ*W=\&V,(UH7J67 M"^E8/P>GWS014>66?M2]?5P/=R:<"ZOQ3DX91<7 -?6DD@]05R$OS@.KB]7" MI<+#)TP&1W-8%D"TJF",TJ)T^_H?$..=KNZ%)__V4?^)GR@B\=5+"_;5"R6Q MR4$+?L9;EVZN'^+>9+VU3*1S[Q%EHWHZ==H[]G>L[*M4#1[=>0Z6VB*B@9R[ M@7CY>[D$[IS\Q5(%!,:R?)JS-,6488S+48@E=.)H&-*-.$%4-E!@HXI"^[Q+ M8_;,#CIB#.\\/W46V6;]34^7E0.5!8J'V?M)L6*KK( M?%>KIV3!")J@$MZM_7DG1CB]D@K2^N/<8MEOQQYL$;(KY; M*.4]Q)=U?-4%4[Y5*:G0D&=?!I5\?QZ7'SRIEVO<^PM@/#I3DP4[%GW\.O;H MW$(;2(_L?,$(P==VUISE2[!RFIOG-A;7J6S_WF[[E?9!! J\/_F9]-21HRFR-E8[1MIB#]2J&F$H#:J#CTR:BL<:6-T&<;XA M[]A4J:5I5E&/@!!TXR?0P1]3O[6,IDSISU][,9K'59H7] ^^!7\R&OYY MXE6=ZMWOFH4UH,!OJ,P+:7SQ*6'KJ9!5%NML*\XK ;^0G,M0SC^G\"%RG;>- M.=!,-1B)N7@X29O.\?EJ.>WW,>EGK\'+O+M_,R4TM5;%(_5U/U"+Z?%SA5=?/1AMLF?M!^Z6[E&L.7L0^.(J_QS,O2-#LU)VQ@O>O#<^XWMU,B%U__6*!K3.2PU@WMJ*: M:\I!KSP]/SUVEEWK+,TN\>#9^2K+L\EZ'83_[..:XEBPUB?! /.Z2_:BNX#Z M4$06!?(C:M_;1T/5T\9? ,GG"R;(=>^^ULG#%;"?8<);%C"_#&=Y2!/X"P0MMBYCJ MK1V\[38T%=A=@AE>A$=@0B -"Y8O4NNQB$)\(R=A+8K'IY=YV)?#DJ3TM\&A MI*.-I2PE&<(W:=89\:_$9JX^%L_=!X@' M.";&DP=PZ>SIZ?D7<6Q])BNQ*YQO_>1D>R8QW*TFG+(G"&0!P&C]#>X;%MBVDWV@)%T>E?4'JOFFK/FN$ MLZ:_Y#7_)N)$8QR/Y53J%FHD9XP$ [MRE6EU[\L8)KX7-B,NZLT)N1$E)5FX M5[>9DD-E:M\J7_3QX/5?D-CB:? K,0\9CJ';!+94[TTZ2SE7UXY5N^WLZ36D MV'=0AO05;.N':43&*$=L:WO@URVC?IZ8$_CAG3 O=/BT#?WPRBNS7KR94@6# M]RYE,F 5SJ':98B;,U-$)>]I:W4O\0E[#4?-J+UF:LH54JG_UKC5FS#RF4+# MM!A/%9XA^8L$VY!&V[#,<8":=3)Q:6EDB"O+ 5A;("CF^6 MP4/M!9VE]8;"PG3W[E6M5V@[EN+5OB/AX-IQ+$P->7$<]O="+(XI$*O1XUG5J?\()/= M!KIY2\;GPTO&CX.=U*<.VE")>7:*,+2.*4$%-B.&PMHE<] QX5)%OXO@T1I# M625ND("]84AK.LW((EG$+>5I\8U>S?/,[+P+TRLS4I!+Q[9(WF[C+;/'QY!3 M65*K%EO-N/@3^\.,^^A+:'N5J/V*Z6=T-S +AR,ZJW:/@0BF]/ORB5*'\\#Q M-9=B8A@(:K\L;K"/;#_-IOY^/)5II#Z4J93ON,*^-:?+FS&"SB3EF0_OH,V' M1^02)[-\!U^7+9N?Q>I,,BA8/0-&0J>-DB8'C4@/O'P*DK]38%K/4@48/' M]WIH!BI,BO3"1CST8MC^GLN1GP/WE!>PM9LD*KTJC#^$]A,[3YJ9)32 MW"4FDKVRNQ8WU.>6@;M=WAJ:Z<$-P:W,1U2GK=^JB?@J3>IZ6>R?BF[C&$L^C2>2I$9GA>ZW8*AYZDC>]G6G 2T M&U!I,2"='Y$&+RV<>WG,/ ?[BYUPYMC%AD!9WD#4#(UGD&1Q.OT:!R_*^_TE MM0S<+Z*N#,GNDTI-7T?%47)/ V#5+9194%4T4\\5!B]*/* M:.2,%V_J,61$1*,???0UG27/WZ[41?"GSQ3U([QXEG!8;$&Y(6/N<\MOG'-G MWN;KFUAI9^$ +.%,N-D"_5BNIS@YSGCD@B8U>0:R'78E@6F6W!,:I&V.8M!( M_"2G-Y:X5-=,O+F$T],=QM2)_=!T@+$(7#RO8Y5F(TPWBM1KHDH940\DII]@IC_UR=5F]\?IH1TI?6/497L=6O8D// MEJZBO^1G1,8EJME.DE3^+FBW]>/A!+;> ORUZ/_*3YN3VJ?89\VJ3+(G--H[R(H MCX>**\F+WQ--*$Y-AY2O\_)C'^"5;X6Z_1?9JA]+/ CK-JAA/U3CU+P+9] W5@MXD0[QUX MB5K49\:RR$21=L1T(4.[@CF_J,WOL0E=O-*?DRCI0=3Q'K*E^*2BZ1?@A\E_ M',UCSN 4F#/S/L&5ZNX7@ 5?H_[XP*<=NO]X]$#A*F4'DS*\T.B_&3_Z^0M0 MOAI WW241CP'X7;"'N%ZQO!:]PQ(2/=>T'M:8TZJYMS^ M"5HDQ>E_.LN.A/';"SJUA#R^ULTA=/K*!^VY1Z4D13/37*10PS XC)"GRFYZ MUR)UR=[R]L\$[J2P]]XVIK[; MS,OBLM6KS1? W4A=CZ?$W#5P6O1QF\GJ3)XZ#=;=_@5X4U$-@;\?I"V35\=S M8JV98@E@9G+GBW0M:]__>>T.09-M(\A2P"DF7S2P^Z'&#K;T;U)G\UH!&4-4[1I9_ MS$?)?;=E"7@(87O:J\):/YGP?9M(Q>P.B7_=/>0TO=0QO=&^7_G3/U'?!V]H M=_+LELY6UX_<^V4'H:U:Q_8@MV6AO94;"57!S6;EQ-YCO)>!IY8)^[\DCKW2 M1?U;A6D"8_2_C("6Z3]IJP323 RVUCD+CO@L+\;+KK MK''I)7[\,?5X34LP5E;:7&VG4\VF26'(*H:.2G/*#$G20*U&6@G%/+RB&!X( MCP;'6-:J;#U3>6N/CI#;@(!: ADSAYPN23L%%"1;4_ :T]<)X X2O;6@_JB. M'E)/1PM Y%I!V^5]$KTCV%WTKFE25_6 SOT"Q)8D3 P1-.""B J=X>5.$GS M'V.FFCG;0+2Z#6.GM:2%SRFO,04=R*X7R7(VA9B%P*9</!SK<"S MVB;'+<+2T;]WC,=_%='!85R3!/-L1845#!)TYJ%CXG!K965%+C-<&[TZ/.L@ M6>HHEGM04>B86XNLWIMCM*.N14^-OP64H#,<*]MNV M=BLR.B<'[*AY>R["4G"]QO[?_OFW,F@]3-=LT(RD+=T'CJ+PR@%VTG]%6 M]M_5-=/-_^<(YE]XZ;\=!M*&YXUO9W@@@,XUO/+I0DY2OEKM9M3R#;;*R0]P MXCZ0C8@U/04P4 ^D^NU#]P0"9?G3PU3-IX)VYNAQOO', P&/YLO Q,)LQS5, MD*6BH0,-PZC'=EH-Q:1-[7%E4G._=WH[K(;BODHNAAW=SD[%HV!_SE9N;G'O M!@=:6SH_VL0]M O>QF#GT^#QCSTG?AJ^\YHV-541!LIW5''5D/FAJKP$,:F; MLI=%7])&,G(/0*1WOX8>5L%Y?@'"QT73=&C^!CGYDX^?_U^2[O];:2B"DK\@ M;@7(>AWG7S_P## Z.])1V#I^KL2UT1XM\>O-V3X:*TCATZX6&$ZJ7YP[E[\+ MJ!OK!Y:\<-$WDF$!BUD?9LPG1;-D5E2LAMLG)8J98#J!@KXD'"'H';&$VT+1 M*MTY([*U_!E1I6KSR0".L-I? +];G1CK'[F6?0@D2[203SI3"I+J+2_50J;4 ML]X4'^HV)D5W59I*_VT9_M,;BSR9&N+AI;AMAKNLY1G$:)?GIB.57\>)WC>7CY5$C4$ZL&-*TI MOF5XB;Q/S!V$"ICR:VGS554RJNG-B?Y647G"?P=&_:_8!Z-_@![^;)[_.MT_ M+TF6K6\V&HPYTS$@R0W!+B'&__4/0N'_B7ELVO2O)WQ7\PRB1XXY?]G MLIDG\('SJ0(>C=G$"3?J_!L+& 'IGZ^0_?E\1GKOS\@_B@JNZ"P(Y8J78BS[ MTC+J\%,2SI-@?J?)J#P^_W"*0'5'](? M+;9\KQQCX?TCX _WKH(0HU-7@=__*+]6_@]02P,$% @ '()85#20B?@S MH0 S[SSG]7M_[ MOWMOC_?^^\;H.:IV[5TUU]QK?6NM*=^NQX7'#0">LKR2/ ! 0'P%WE#B[.KP]ORXQ<;#0,7^=X?SE\,O +X.8 MO]Z/'P'XZ A22!^1$&@!B/@(2/@(CS# ,P " !$1Z??N_B9HZ*@8",@HB$B_ M?M;" R @ Y"0T#!041!04)%1D1 !OWJ"@D^ BD:(3D3#K>,&)28CI^5_DY(V MPZ?]*O7S#IV4)FR*AYY7H'&:A-3"TC-)1LLCF4':ZMV'70Q&P5\V*7[=['^^ M(P 5[9=-Q-_Z(XCK??#R?DV^XC)?[O1P1&@;3]JAL!'5G M<\%<].*=BD#,::O>QYXK^-\98,V(=OC(\[1PNTNFU=[;4 =Z"7$BW72M>Q=T MD#)MT&@6WM>-\@BHU>$F#+;FEQGRI[_]!D/S_+X'T'UI) M*+^#%/[?!*1_;;=_@?3_.TALH_ Z7XA;+&H>G:TEQJ%'G!5@F%L0=3P#31%. M7[88)GV2F5Y] E%+$ ,BQHUY&=G7WZ/.P1$.E6]\"&_PA( MJV]L;.9ZL3IX0.5@AO7VD*,(#*Z60Y#])\2X)LK1>?L4U%_EN!NM(];D@0Q] M4P-'\6Y WK.<>O)<9F02?UAZD<20VFL_,"L('N.=I[V$+0&-?Y\%R@M8YMZ8 M_\D2%;2;-%!XDI26N?3VYV&!D\>6#:/(=]:QRRLD"Y>(KW'Q%3L2Q$?-#4ST?X'"Q$/FF^!NIFZ3'&,H85Q<)BPWO#,V+TSN&Y2\L6K4Z4 MA#XIHV+OL(7&"2'585O4 C80IF1!IBO]DF0,1>,/-KX "D$!F]J6[PA1YF1I M =HDMG2E9B35AKZE,@HG#9J[O0CH=T!1=O[PA MO-^V(/FC1;(I @Q7"#;6*%.X)6B!&*1K0P*_\/+R= AW=H]KNT'YSS!9X9F)5T?YJ>:0C98\AVO+S-M].%0#V"I,]M1SW6G"#BT*W7 Y<126HR\T9=]OJ[%A9A7F0\,7 W1 MVU!\A=#!FQ#>-/OR0ALPN!(3&PU0M]VPK4@&,3MZ4?SFV=.RTQEL624G^296 ME-ZD[-UZHD/4IN^,2@W4%H^\F&Q<['!9=J:@9EA9I DXO$*%-G8E&ZJ[P.HY MNID[&$YOI+S!5<_F47JM>9?J%QPSPM*1 / 1%T:;4RS^A M'D?T^*>.YIH-4X ,%F:*$H.*#@RH M_=E.\S35WKCE[D=1S*D[9D'%Y3H%R$?CMX!/Q4 MX$9D+ZRC&-:@]'F#VULQ+!EO9+@B(TXKW_?T WQ4\<#*9X<3#MEIVG1]8W$U2# M#Z>JZ/$NWQOQU*1PD;\A-O)]G2#2:WT6/5B_HD!4%V;TD9,TY::9T??(L/)3 MF^**4$DP?8YK@1WABXJO /<7?N]91)WA[>F -N2^G%9#;G2BJ%I2%FFYGP@B99D 14 MP,_DBE<4-)XUP+7^"-B=>W$E>;9I9.G.1BLZ)42PC6PUW32(>A4UG;@R>">? MB%8FU%3*+4F;:T^YEL"XHHWIY\(DV$)"?(8]5?(VUWFO91$DG=KG3Q;980\Y+4K$=W5B-.'9TT$#DDB]% M*"H*;QXRA3NJN"G3G>\@\H ;D^7'Q?EAA&SF-YZ9BD6.X-XBM_&#S9*2-AXK M8CV')MHAG=M6>'/8G7>'.S3QU$P%HSO$]B$@2R*2I_H'&Q@>83F[F\5CQ_5C MBG(*M)11.<9)[PO=S3.7F8?8+YRGKNATE?:0\ 83D84[Z&QB9 #GXI7/82+N MJ:!$G@EQ\E ;ZA0*(4&9=- G'^[7RUPG7Q/M'>333923BH6?LK;QO'P$E/-^ MS7YX*<\\(5E1@_ YXQD;R?K/+_7+/@+X"9O\$9&I3)C-]ABB\_%VIB\M42U^ MD@WQ:I!,(H=-GR41JBW(_)_ 8-FGB M@DW(4&1\2/5.:,O#ET2F4+O<1RTN3R]Y8_8# M,H0[.PUZ![Y(X4\.$OV3R"CCT MKSMON&$C&IZ9BNQX6?J^JX+39Y&IJ,3&N\F/.3X"[K.&'@&\59GMF8U'/V=( M_-S+-*K$/L#?=_L^ H#M%X8G38YCPV/@,?C8V.HP..K7.U^0ELG[KV)B).(, M G$-NL*P+6C3DSV+)?L'%RXBP4;)-V%=1%3B3D.20V4 4I#3/,'"MRVW%Q3%-8<\O3/Q*N6JCYO7K>M MP6;J,/1XHH^ C->45TK+7!^TOR:J"]UA?(SF$OCJ#O*V&?$VL6_^=.CO>&$0 MTLTB#]VM@[*+IG H=6$-F?5G%;7(>R%]1; MT\Y7TFLT.,F,MKFMKD%4NL_D/G%C-4BD7_E12(C!M!:FGI'09)EZX!Q:&1S#:/#$359?D$Q2DXR])5,+16E5>C:E97?6I ML-(L-Y]6^;-=KB:/MUJ$)/&DQ!]LW%V_ZL_UNEO#3L+;L@QU6+4R-O*.#BC7 MJI21^R1Y;'D"TUT,>B/G?@TH(+6KJU-VR.N'!*(U.P/\J22!EQVR"H& %4D M6'8!(W-Q,2K\;C'=W[*>9^@:%YL)6TB%H-"G/"M3C4AKD@)NFS$4+3TA;(!F M14MV)2^3+\L)L7SM'?B[/,2 M\'9SG_;S[;MEL9S>_FQ.JV.X@N]6DEB2G^UZ*>VH:H6@E,17P)[#?B"AD6Z8 M[KT:)8'U@4P>36Q*@A-GS<]U@'I$!V#=QF4OM+J $6T[T.5B<)-%&>;)=]+R MPUNWC,S?"A72Y(W3;]]'5>OX6EB)ZTL*%!)BX>45! T"0CJ.#)J;2C1[!PX= M*MP\Y=G:P8-?VXMVKPV?.\%J#0<<,.;" MZMTR:N%BR;$RO2RR&>@TB5&K18F1+Y'L2,<'SFUR!!*204^7F:17O+DR.%-+ MM+<(MG112S,> 4OPJH^[E03U0.[08.DGE2Q&VCO'6N4L5:FG*UAD,/L4L0Y- M!B[L=I[P S3"V4? .(6ZLXE?N>.=@?PGQ[A8&V]]3T?AXCP_4E#R2H#]62IW ME"6CK+$V@F.(_H[%I"8&:.Q6%,C9R @BQQ60H$.6Y_O:0SI7)\\_(PB:;B:G MX42D*XS8;OU %W[5WETCHDC\Q;1Y[KC,4=NBV94V*^UE6+12]5K#,_LSC*9W M)"S/P+D[23!]28S5\TF.)AWO@395&:1&_MI&YW/YZ7X^U',I/N?CI6(F/,Y7 MF0.PCQCMSX%@Q?*:AYY'P%<*[D? '.G6=-X#EZH7!B]/3 M0VA@=Y=)T.2+>]W57"H^H&*?46LNFX=/..S/)- MDX:8VGN5]K0L?1&T_XPLF]%HW+S .NEX!+SPM==TJDLLOW\>_GWU$9#?6;!@ M,D!S/3C$4HOI5GZ-.U=]D,IT+QH7]$T_X;XFO+2TTV33L?Q%?^W4EFO;K@JQ M3[OGZ2U,2ZY.OF"^V+1&9$C7P)[RPE[O:W/@B@LDZ"$D86.WG)U^N$BT0HO% M313!9(4&"F)G'O+L5(D M+/ZBZLSYZM_2X?FK2N:_-/ZE\?^(QEUVU\L=O:$IQX?6=>##G1][?@O%;GZ/ M&4_\Q,W/=&CXMXVPB6[?F;3Q M_-:3LI-7PL1GET8OG 5'7P3FQ=@<#=[:G'QF/CRRF3Z"IUQ']EX)^I4N(S5# M+>8/3-\%E]8PCR!1MR&(!MTJ92Z>>WD[#L"R:W)S,Y<^WFYOGIFD$U=!TPH' M&0@G#M./)@F5J.OA=*\V!\B2FAU/R-_MR"ZM:]JGBO\O/;J:S&P"1D6BR;K5 ML+CZO!?! ;P7&ZSR,AUM,D=<<&S?]K7K!-&6?(IW?;\F&#L*\G545??0H!EE MZ39(32;,3%>0 :F?I BHMBO?W/T-!8V_S="!CP5.%L#V;?^]29N]2&^C\=;6 MZ$0.Z-\<]'SU7Z'C%'YA:__SWP9F?N5O.IGB_[[.V-]TVOY].W\"'%&W_^^L MJ?B)OZRI_\-&YE=*H%=_'=%_GTWT+XU_:?SO-"!+;7\PQ2.HOR_KFNXM;X,= M5:I:\J$O8LL)]X&D:&9/?;\\ KQAZ>IY' G?P_-R[GCA1:UR#LH3*@V)S[0H M<2TY"I]*?L'4"+U^-5;2GT_>B%)B@WH7;_5)-P *CZM5H:5$$C<46N01(A$S=4+/L M_MJ*H,60V8Y?R2I+JLZ]:S]QN6Z\+!E'3\A=OWJ7G00-(I0E0^Y)*":OA@&3 MVST"_2PK#T(KYB UUR 2LLJRA##6J1M$])\BFI.CKIQU$@B'^2%;^<3&^DS% M7+N^O:5<>.A\#I^SLI^A;R=A8-YF"Q#NZXCSP0G/(^3QBA]+&624-BW&U9+@ M#DJ1:PA%JM,F#&%VI8TVO/_R)&L&JA_+$!MM1P>KC)&48:I"EZ=_:G13LHJ3 MJ+]*PGSSS0HI2HO #R4BC$JE7I5_S?L#\KFO3I,ZSV[FZ2 /JMMLH@^IQV'3,[$4 M_5>F9W_+I^2EK(<:O>L 7AL<6(8_1(8%D@,:""@.TQ\]Y2S;S.,W:KS V'V M4DMZ+-J:"Y:CJZIA*+D5X"=:HWDQEUB$76.]68C5YV<^W/2!D<63@]=:M Q) MF@W&V[ZM,7UK\_(;(!QB'F)30E!DW.ZW(DG,)^MKX[5J9%D,9A/_QJV*&B A MC<4GR6S4X+=;M"TV9#+1.N2V.E&BE:1"5#V%12::9+)0:@FB\:)AM/F+?+.Q M<8ZT<89X'9@YP!>!Y ?:5<8Q!E*F9,;M;VVBN= X\O+2*>_TJL'_!8E^OFNM MIV#C,JY^.&-=@PW!523/LK.*9_D0(0RUK*NT 8_87J3(VE#8;AU@O//IT&YX MY2+/O5JANV-N."CZ4LH<^=QMCHZ9K,&.UDEU<>=X\;*=-K*EK4O)SC$G>;X1 M*5H WW"8&TZ^:)ZT+\4^%+L2&\*3+9@1]J[$:_PB((]W4##-"YW#_%0J:DC, M8X9B(=?AATRC# Z+G7A?%H6&48X.U%R6#4E!E[E8>*U?*-;QR/)4?-A"YTC% M\ND4DHI2_74EOFY\CHZIP9 MA5:3+<9P]--3*6Q9^3%Z.4ISZF/IL8GCQ0Y>WBM:UF"RF18O*YLEMM8J*Q_H M?/]FPRXPL!D2.V+4$H_00*1K^/0PZ.@)4;6SF]\TF*NJ7+<[&,^&=AHHG"E, M^ WD.)Q?$G4^#K\SN=-+4;!DEKT:8?6T\@MVFW6M XC;[L!+XCO O'VH8V-2 M5$G ;(& ].;_Y!S%C"V9E-2I-\[5*'/-A_! ##3$J1$7.RYY.WK.+4C<:;U( M;+Q![IQJ1*\CW,%]\54&24>ZLZ\KXXR(ZG!N&<1&<(G)MI)G^D$D#MQ$FGFN M'6VVS'OH/VO=$SZ&5'M3;:?9R4W&/#.6U@U#57@WL3!@/)'8.*9IW\HEB*?J M]W$17-)HAJ\,&Y,^E%:=^$TFIR\)6![+E$,[&!1P#$X/7G!Y$.SN[HYD,%8[H<934#X5A5B?=)W<[3A%=8 MNRDOU)7Y=C&. -_-SX":^7-C8S Z"ME M3$NKIK:Z0CJ_QJ_@(OM/_[6GMYK',RYE-2H$>D)?Z!+4G9$(8_;Q!>!K4H%% MH&^@;^-^RUB=MMRXG.CTN"1QQO*HDZ:='Z9M9@LO)CEWY^\+U,Y_Z$X&F&*S M">[,SWNT]WS'U*2:"(/34.H]C1._7*NR8_.SYZ_^)J@]M2T&ZHZKX;Q%$:*E MC:EBP/_/"+'N\KT1;ETG-JTV3";:\T1.C'BZ]O+P.;*SE5&\MC\06FO'I MKVBR)E!0C'C%6_,Z)7U2=1E*Z,1TRVN<#CY;9,G[.$P0J+NF<+MZ/DF(=K(^ M.\*^!LZ5BC"SGU_K-79^QD3NO?'^\ MA9ETE)%&5V4-*O1Q%$??J^-G^H+$820Y/>H\D",M\_D)P4SJ+H:T+FO?+=?2 MI:S9*__NW/<-6M4VINKDJ5NX=Y)04HS<93H"YP:;\6R)^"N M)67*HNZ!)YT)D2)U]F[6*M)1G+'7B/8NU,2JF[+W8^3WBIK&G*5GI-K>/#]>AM3*[Z[8N_Q/;D6BMC)#RYO7PZXK)K60",-AA*VP/P+ABQZ[!N MA16:/\[0!UTTG/##I?[B&=,J@R8\U^5YV_"%"RS-($<6F LEA :)L@EAE"P% M-':4+H*]E 4E =M$:(%FMBF3LJ&\4)O$CFZ##H&W!AU!.BE3 M[6F%1;W?-M,MMS$O=*\6^Q"RR#*+F V*46U5(G8)N9HU2;%W$EX%?0NDC"!O MD2*T/EF1U9_S-&Z3]I<47Q!3P1I8F6]R\![=&.NJ?9GWZ8G7$X*^,V_^(\/5 M\QM>-LPGC'G]G;.$_*/;%P:-;.J_$FF]#_^Y#.TB%<7A];MUOW3Z8J".H^I% M'T!;S$V&)4>3_,4IKFJ&X4<;>A/ZITIA$3*FZM.'N:(-KLZZ=<[/5 /8N/K% M_(;$&?I353T%7%)VLT&/@%E\7?&B&.( +.3!/%_'S^50MP48FX1HK 7O<.H\$E..H@5O0\U%V$A!O(R,)G"=FMQU^L MRMALYK+9U!K1%GJ=-]-R\::$>MG\5%ENJ/?Q7:884BXT01WF(/;;M:6@I8SH#QUA+P&[6SF' M>/UT!G?-R,KJ6 5TST+724,QQV_YKU:.ZQ[Z^@1'CXS$SWRXJM=3S$PF]A\! M*RP[ZXRXHV)I3*"@89/EF(815UDY)#W+_SVR[X0=-=[FA!75UVPDG+XAW$8T3E0595ID=QS?%/MM?_8D+/,@$E7-BZQ/,)B/ MI")+Q@9]C7%L 9ZCH.Z2S5O9 M?SU>=XIDT>=T:V$]<,69 V=N^P]#E,8[UR M),6*X2L&J<>[;YUEVC-Q1'HUXV6W0COLO$'>E(OG >U& E\#\HM?['5V%2Z* MS.5U+,25[#5;M2 )4Z#K@ZW)=MP(+ 1Q:?!B8Z69"A:;Y)'I=;">#;PW&#P3 M)2/.FCWZU,\=;3FE'S/B<\S)QZ-2)&2JUV:/R2-',216?:@=BHRM*3F-[4TB M_@C89-6>5%2L&#'+R- M_J0S\"S.-,TGC$!K4/]AH^=[*62AN/:KTK[])F72PJAM4(L0MTP^8R9#,6*>^OHN8;\\]U7AS,0>+:-]5-H>='*QF=_#QB/]=';E8.)$U9VE. M[H)DKB(;Z9KII!%4VN>;@4BZ/N6W!0(+O _8)UCJ#$2;#%9B(;83& ;;M&XD MW+&P:'+Q<[,$D!EI*%E?G8(6B_[AKTEBS\.=-2ZH20=;4,KQNV MJH^E$]Z566K\/[77V0-#5R<8.#ML$E MD]6<)GQE6S"X?+_ZSS-QW2;V2^>Q/2&^QOG/10$'@8R>)H/[FPNN"07 MO5;:W+ZM6]*)DY4S8UO4X_@'K\WID,K4B+0:"JOO-!GWUVT)Z,8>Z0N%E]>? M\,N.N]_.MUMKGK+-NIN0)C M'70>((\9(7:4Y+45^KB]S7TZ[(F;[NU-&W,KY=3,'FE88EZJ; MS,?:584E[&PIZ#K6_$CY3EJ8=<#T/5]B% 6A"NWQ(6 M35KHM""RXN2Q,UDM5[-96!Z6CQ2NMTTQEVBSRO8U4^5[^ M0RW;UQ#L5NVE$!4&G&7 &.(<^Y#8$AV8N:O)M.,ET7>%WM%\^@8Q+\W]F!N,MEY?!3H4H[T_IXQ63>.T06N:G'?].ZNRT:[2KG^=OKI>- M$XK2ON$32$>,5!7C$%O0Y* SH@!"C6K$EKY>'-7FMV1!6!-/-:7[J99@*H+N_D;,))Z42F4*"4$WU$^YXB M=#EFVGBQ(GZW8G>PT@JZ53]N[VN!6"=$[!Y1D2FG:)DT41_GLTF*]^E0EO'$ M98J(TL@I%G5Q0-JNP%$@0&0@^JHP+N<1$*(C5085>P?;)BKGY7O9VL?-9W"& M,P81[(D[V$HRA6V6VU9$X =W \>XM-/S%EC4(H37QGA:Y] WJ$>@O6PY91J< M[Q&G\P3;, E6 Q1-ARUID;D,_&_:%'!]";%T' J-J]R0U95CD9#;1/&ZRSTW MS#O3ZE\6*Y>FE8-D;/;D'%P2;P=NYI^ MJQN<+:4#SFB5C: \UL0(H=PIT"*6QF","=:"O:2(D37GS)'=&E-5?695NIC; M&;=^;(;3=]F$WT)D.A]W,1;#P^EB MWXSUI)M:L.)5*W='IY-SDS\.!415'8>+ BN%E[=U-T_M@40PXO@):K1*^-@! MG'AXO\^3/J10.QHS7@&;2W>3S^(Y932X-O&MT> /L3 /K"Z_0=DK!--519O.>?B>VW _0%]@8@E-4--J5W> M.9J"R/6H&X7$6:-+J 4G61+9T,[^4^3Q8-4%'Q%]L"195+:@.4G09;/I'$W' MBH!!09XAWVY6%9)NEO)LO.$1Q3YJB#2:D#[6'$G->/FO",L5C9;("X7:N,UGIMKP&U0MI//NC&?%"1XAZ4^TK2QI.JQ$0+@ MNWHO0-!F2K6B3UUL&[ZBZ#"V)7T\P?'1^5?A#CQ\ !Y-3W0U;;@@+5X_++E@ MSU5S.G59O"F+HX;191SJ>/Q<-+DWR4\0?% >=@[Y!H^0="K]Q&;Z\2-QBDQ)-F+GPGKPT>W8*;Y+7 M%#X^T8L1&Y_Y^B4NN,YMH[;ZZ0KLMF1^&?/=5L;M\N>8,M586?V="3PF$FYQ M2TXN()M?!QO8L.YY2BU8!O"4K4!W0B.]BY2HCYZO MCZ Z*(=MM?)^+][P$TXE'=DF393)0%%_0XYADD.6\F9?2&PBL?YH./VTDGU_ M&,?K?D?9&C6F-C_5W2? I6EO^;LN8C%A7VD52;#JY9[D1+VX) %_Q, M!0XH2YBQCZ/&]1JR3T">41D^W._[E ,@R69MO8PF./>8"[M> M#1W?>7!B:'!DSPM&1[3\EUW/,&?W^G>3;6^(*P"3+*'!N>4;8E!*M-33?#Q5 M)OP4[0Y:%B77X[\$CW"9C'EFP0A?R[U88Q;K!+WG[(;HD6*MG!!?&XA+^I5G MVO&DKPNX<[UWX[0UZ%[-K^GLQ3FJ@>TC8$CL$0 QX9]W[%YV6;,YPU$.R!;Y MB[=790+>X.T\L!D=:+;,?"M7K@16N7N)5S(42=3OGRGC *;O]"1_BP!^S<3Z MZYQ-CM\'-OJZ:C4"/[WP>D'0?N;]MQ*ISB%EO?'):@*LMIIY)4L4Y_R5;!WG M\_' Z6I[6M8KT_TV][#K8/]Z'PAI3%N=_=Q)>F^FOW&A> '5(15#^-:QPU)3 MQ^XI2)>(2DT\TK>2T2%]: ]JJYN+3^Q79_W_Q2_I,#FYV;LZ[:"1T%&F,_:[ M2$YI_$IXC$#$M*7RS,9AU+YQK<486*-\4$7U/1@VO>XB,<(J8(:WX*,; @D* M6.#SB)0YC!UNZZ,0'\LCQ2*TL)6Z:>]CEMD$$::M@]'D"E,AFR^LO'2UKA8J M5,*II)VRT!5JD'OONK\-0Z=[%V:5*#U>O3M^DVD'HFU@(UN*F[,0++%SWFSD M4*:>BFVNF&F@'IRP_C@$!*EBRUOW3:8($^Y.'S#KYUTV5#AL7JAAV"::BC,D M0@Q+8LT*,H=*3)9+(8JN8PI-H<+4WC6^X*-W&&(5:>/@#9CK-B+ M6SKL[3;ASI6^!.(QZ(P&$Y91$N@6XMOM\J#G\OJ[0=A4TFYIQ*=R%J1!K=ER MK-*-"%S-/SH4-D<46^B ,)=2M#V2 M: ;!QI^F;7WWT3(-1C;:T]E"]C51["E'\H[^(?-YF;?XMGF]UX&C,VE+=?RSF@73_4/+GJ9V;'T+A6EXV M]^&KK1V4YG5RE7AM$S5M<3\O. 1 M:"4Z+G;$EX 5-C7";C BX.ZC .XG)^HL#GR9/9*/WONE!R K1Y0&F_#BB4;? MRR.SSMG"H(6 XA($(N@(>>"9=S.)#>*[QTO=+/H.$QYR?0VF,[R2FK'U"S74 MHT0ATT- II1F=4(9H//$SUI'>OJ7#!*ZWO2]F.-NIS,0((@"LXH/BP/?4E/%R+D> M&4%N%!B2*IV$<)S1A1,Q!ORY2>EH/I=\L+T%FI>:KNA:.'PV21[[;-J!^YR] M-^\3MKL* L[+D 9PF)\0GCSPUU)-@79*:L(PGNO_Y:F\)4%-O9V MM$3;'OKA)@29W4C0 PH2P&!T]_*V&":+MI&5E:M[&)J)<"J)JAY2]P&.-V[S M:?0#C6FW\\J6%JS!X0=0Z7Y#6E<\B#[4_2OIS>"U/71CKB%ZMD*[+O8(E^(9 M\^L0U@7)S=8WYW$> ]NQ*!'A;73)=HL#3<.>;ZV<<)L1=\;BZ()T'P&K20'O M7^K1H071)(KB:FX))7)+&M;?DE^X%YEIT+"/$^652D=U(*X:!PH34KB6)*)O#R]&-8I:FX@[9/NC1<(=.7)9 M(]T%0/&+\[6Z5B!+D'EN[RX)B!9D(> ([JFJ6W;DS'EUJ$3QC2M"&PV>3XO' M9 -?7#SW^NVH]^3'[D 0P2, L^4;1TEN+H$M01_'ET> G/R1D9_IF(<1F="V M*;>DJ*(N&^J"JD3CA7Z=<@D)4)@X:K/.E*6.?1H'&-XEC@FV10O3>'#N= MH*&PX9JQ#?1:/WR=?F8]']&=-MW+3_)*;N?5LE9 M:G3B?J?UH58?(Y]R.TII1GN%$_2U#4\GQP:@67908L;;/^M5RJY]-EO[YZQ@>8.GRADK;1*.5:)_"VTR[-Y$\OE[V\8I); M6%_IC]AZJ=[[,&XP\EM-]4]%5.9=XFOFMSL!PK/^NH2I>@N%WY-.O^@O'Q TR3_K&.D^[H6V_*NMD- MH*TFIE*(IM"Z6+;254E4]NB[JB]@G!+OI;;S@+Q,4+6A,L@G8:F0^G&W\G!H M.>!GK;..F9FEPI-K>&[2OUOKFB+QS+P\MBCY7M:U<]+T\_PGN5GF4'QO+]*@ M$V^B-H7(2-F9FI5*R9M"*A;F&<=;F+[^I[&MI-5L@::,'5\'-PM.#;?E0^#K MNC;-K-#IEO%675737MX!HCYM6;HTWS?#8ZYN##[PW)P+&]!]<\(;/8ZMU..E M+H.M?E"3^-/3EQ!".T:T: YO\S.,-5?P\SETVK+/SU6^@LR=O:7:55J=.I5A MWZL,*97[ER%"MFHZV_7;V$']O##V%I3@YS?6N'Y1^=%C(L;1KW0B(7)/BSPY MU&RP/,H-#T/#MRWH/L'HO-Z5[@U.C"W$4D]\BK7BJ]4:V@_U&[!)3XD_[/)G M,"Y/,)JM%RAXJ_4$UQ6CF%QS8 *NE!>T+#76S:.C]#'I M5,%+1X@]I6A:FA,-?ZT+'*&0LZZ6 @*.Q#Y,*GI\HI?G3"(]:!\^XU[V<;1\ MY=CO=TT!IAS3VDR6048"%>B0F6)]^&**;AG/5+=@6K*QEN[UN/DX[4 MZL%)I>_,"*Y>>!0H@%@)+E*#>EOVGE^^BNK(;3\/0^/$"B]22%#O\MWAAOA^ MP^Z9AQ@$<72GO2(.VSFX9NG:Z10BZIN!;DB^2\!IY'^J?O5JXZA-5%CTJU5W M37%M 7E[L%;[7P/RRRN'OP_(&K\'56;HGRGFWP@%?8%(IOO,1E:._MW>I:B_ M<.9F;+-_>H&EG>]'2-^MSMCJ2'\/R-=MXC\D'Q;NE??[XN#%]>L,LLKG9_?S M1ZR#OW%AQU7IS!JV:!UH418^'5G7-3I32.$2PC'O5OZIAQ[755&W6:H MKRVD=CXO>&<5@=H" AT$PNVF\/4JK__,'>7(M[//,%OC[ 5<#T[%X=5RAG 2 M7)T=S(]:XZ^7@/(JW'/HD=$*[+;#R.%@R7QEVA1\"]'F-?!6TME&N;L(B-ZS M=L%>L]]9@ [E;N+)G$UJLGK!3I FFG MH?9J96LLV%?RPGVSBBQ870Y/7(^('2)MEY5T:TQ*PCS))3+B9K-EY;!.+E)M MDA@B.)RP$]A5(#>08W%TC2P^EW$'Q5DGCYC/#B,B8]0G&7YK':_YF,T"C7,[ MH9;"MP.@S]*K5#AW..!>4A&A)WG:";FO_.;[PXMS[-.Y/BVAR;0EO752_]'P M%&IA>?/:.X$$JMOE,XD');ZYF8J%/HMV"4]U\^":N\ R$G0"CMU"()FI)M#E M!%LW2HD5R$X#%7&X (4\N0PO!D8A%FEI;L(-!"B')ZLZ)0\4R9_S=N*)IN7@ M-7X_&N13TO *7)2XS50/W"7/$&W!]8:OF.0#%_,YJA=[BB81\>/PZP?=&\M! M8=5H0Z[O;6N(,BN2M-=_O/8^\PH46[]B"Z6X%/1@7_R&IFRYC>=@O$JTUGK- MWX8[]#A7=[1DPC,(C;OCD> SZ$&8'J M=P$J,P\3W?.P+HV5?2+B[L,!+4_;%J;#RH<+G\^L[34D.P]I9MTN3U^+MOAT MB,I8O.I&.;OI"OV1!4WK]>300YDIL/\FG":^S-F\_#WS7D;;ALFL0>V$8?-C MH?B''TX]OODP?@%WSQ]$:^>FE)B>]FXD@;G1D-X)_9B[ZPH3?")B$^5JE_2E M9O^M4PN#'L;NCMS91T"KOOSO-7WVN<-!VZK9CW"Q[)W>19ODDL/)6ZP.-R]A M=71P@?VA,5##3M#.=(TF%$@';:S MK*KPSA&DVL&G0XY!F6>2 BO#]=S*QNVJ)/:Y@ WI/M-H:;N[Z69]5V_;U%.]L#)$3C99=EQCKC"H&C="TUWT:=?K7 M?/6*QGN$M#98B#P2U1\")[Y]!PK)D,F S:!$D7S3(^ G9I'P*+@ K&I"*E6M?O(47,>Q M/5J-%-&.W>Q+T/%MD* 15(O[=3 WJN_?=?51"6O M(US22*;':,H@CP;SSBI+<8@K7="\O53 MN+8:^E@Z_>SF\-WG_=4!QP^CMU>/ &;"?_!R:DST!1]4IOD;/2F"##"+/K#; MM<[5!]^$0R*I[__VQX3P*E^I^U*1;]_U?Z[*95-<+^5=H($QM7=9YC7: MAZ[W@0OKS3/?,\0D=9&#*9^?>TV_[W ;BABN^RZS,.L:6>'>2E4Z4C>[QPL, M\J&:;#G^[ .JI&WQ_WC]MLCVC7YGLF',UL%/S4RGWSHSK( MN<& TOGYI(61OC8\Z1&@<8SYQQ#UT/W2Q/_N(ET%7?Q I',F".&FT_G30IO^ MSU/Q?)?5LM-Q:ZSG:VC0HQ^-:^3O9W[CS?0) [>8K ]U\ W9X3]8>P+6^$9J MJ^3:7KS6.\D>S%0[.N:8^+2@(_[.V(_)_.=>]2X^$8Y)]!\;QW2>J1=RRTNJE)^SUV.GR_\8_>!+]'0&&,<)V^/+'\(U'Y74U M!6GT_4A1?4=JMYJ>)4?9\>OK;MI]YSTS^Q[6"V=S,+B;4Q%)%"I_4F\(MN5I+GP@*2@(6)R*]4)>? M;'A+0JZ'JE]*G96]6&+?4/GL1M-D2?MF;6\>D0V:X'[7!W=)$=#B _N]1=\: M$?4?6!(;WY 4V2&4/.-YHA(U1 U-X1ZTU(0D<\UPEL2Z,]'"B9[5=Q:PF\). M^I_9=\Y%+5>[\@\;D9%7M'T!V:>(<0TI3W'U8IWE#NH1\IKS;JBSHN*,6I(T M?.]QM[6B%*Y&)7?O$DE:;R2E3B6OF1Q,50?R[R4+%; FADWS*JNJ[A'@^Z;Z M&B>A)%RS?J;T=AV3:)QI$&B)T&^*^E(F"!-.%1.L')NTBC0=>O+RC43#A-8J MX\5SPHC/<"3=!OF':I$9*4&AJ/)JF0,9T0$$):(D):+8%#'!Z&P^ 'N05Y]6UD5:NY0 MMI?U%8+B$=W0U:O0X M+/;H:SH[[V(6L]'2#A<;G!7/Q.1)LF9*^6#X^ERH=)P[?:N(0&IQ:=I%7N6; MYB&MG-@O5896R6A5-"K(//ASM%:L>_(KII JD6;HU9E'%IO%,R$BF<3;ENGZ>) ;V <,?4':<=*=1E+]8RM,"/FM/XC 7TLVCB&.%HY Z:\AO)MZQ/V7C M;:JEJT;4"_]"K'+\RV%>]]^-*/P0XUO[DF!S*_EEJ+2CU9J>?6A@[=G5W+!8<=0[1=1S.73T' M@1S7*S)U_@S8+&EM&+'!TW/O#K#["RJSDO9:M@O,V%XJK5MAY8.0 M?>-:K J]D/:@)MB9QT=\IP3'^G1.'DNP&?3%@[C3Q*-@D*K&#NE%J)Q M3 W'U:MT?ZW:VMF-#57W[@I,_4;7'1:L.4%N;Z9O 5-$!L,79% )Y '0>(Q[ MW*$T!W^FNAV8MHD+"3]=0Q+*RVL-7,7N6^3)3G_W(;NG_SUWTU.^;WSM/C5: M37[W:D\;'3:"'3Z_;]R?9)>#&+1_GR+%9(1YBXM7VU_]UBA:S]"E M:68D2TNCMHVF^P]&7H[SQKZ#%&Y.&-A;,'[# M%Y4TE*O)U;P(]>-#Y&W,U7' Y[YVY" M?IYWR1&&5W:/ /UXWV^!U>>C;?ZCVPM[E'J85%;NWS'9:!LE*$*S//#L1>>Q M"&'?'4P==6M9:,:TM>K$B L]<%T(%UVW]?&FZG(HK7IGSH5<5Y?E?0E?5PJN M47U?"W\7F7WF$6L].S UIX5KX#I9)>_[Y?ZNG421ZSGY0N* \GQV3B@3]D#\ MOF#>Q8>JD<4)U4LVHSIS1Y-D$4C-:H6Z3.75P6+[WH4B*G'(3OX!(WZ#LX7C M7>YB;ND I?.%_TE@K\SXC8&\EOW6P3[S$+#58KY.[.*GB0FKHN*GYR@+22B8 MRNI2.1&T'SV-)GV69?7S5EV>8K\('\!X$E.G@?/N?*I8[(K,\\#QP^3M59!8 M@]1]R=U?LB''84E'G\.(^\$.#.,?[N[T.:F*IUV%RGHE[_8^B'$&O=F%"$6P M86N1R7-LXZKNJ0)/4FMO00_"O-UF\)F,D;Q#EV5[_S$J:K8P<17WV91(X'4S ME25?K3KV4L,1F>9SJC34D) L4M8_*).9VJ)X33/+R#6%_EQ[@Q70_X4_?UE0\QW$FO)G%J,S^Z>;6NT86%RBP"P] MY4P8.'R^,IOSR\&XMW*4(NDIC54<_R/]C?&/++EVE388>GGXJAG7'68VWZ3\ M%5Q0N?]/_>/M5W#(^VMPF-#%Z9Y\K7\2.1CNK/3CQJ3L""O-P8TEOO^:6$^G M8_41 -WW;Y0@8P77K)T\Y&NO%I[V*M>'+D3.Z=@$K]V]>+GT >6OQ5$AZ\8_ MYS3_H/=B! 2/FL3WGN 1E?^>D_Y!\553O$CYJ;ZD0^CLOGCT]XEUVOZ_$NO_ M9Q)KE9T+^#D\GR/2:QSZTZ#9*3MH,]O[0S5%X\K#SZ!?6="+)_U6R1BN/_0= MB+_WNW4 7G*OB'S0B\=,LPE6)RN-H B;M/2E=S ;B!\O-,7]?-2E["<,RY%@ MK*$J*<^+$^GYQ QS*X#7CP">N>;N2>%:HC%^JZB@;K2=@$*J(TV])^\W^.R M#S@A$[EASFC@EE,QO5'\VNN\XWEZ*-ZOEL$%7\=-M(!ZKN3L.4IPU;V/YJ+; MS/&H/:YGJI+NLJDR3)&DI*[1\G7LI30_[BWS==!)7(FD%132;VH#:4F S"*P MNH 2L&)L7F%%WV]4E-MY$-K 9%2288/UTCG];EC$#2@!F2H['YONLZYSJO__TN'9]YUK/6O>YU MK_7\IF^T_*CO6W-I1]?&S5;YZ1>(CDHNGU@7)AEERQF&+C,UJ!^!LH8$=;"L M.ZTXFGFEMI_Q=-/Q94E(HPH_0]* .J^N$O^XQN8DW^'D,(^Q]!>I5-N7MVDI MAE(='CA8[_31Z:=-/O\,B>YTK\:17\4_') M7ORO*3ZV7W[#0,(U.N2/=S:?ASIK?HG(3:[35_Q7"4BTI?4/">@C)OQM[A\2 MT F_WB?Q+W](LV6,1GH-%*HS5Z(KQ4-#LM]@;8C9U/O81B>#9:'#[7WRKU[SN\%TW>O-J4)E[8SCB1U$'2D,CJA12NF!.%V^CGS2@RS* M*&8*])DB8Z^X;'F M(V^)BA]H[J68V+^%-3%>":M8Y*4+?E70.-J*NY!HI8@^'?)+M^OL.Q M4]%I_0F'1%6[WE4;QZGZ:CS45G=Q4^L=;A!]SFJ+JR+V:7*@V5Z<+/Y@UGR4_MGDQ]";I*:13=#,7:B+\]3'83^XW6B-Q^_9B? MKA',IZ_S&TC++:ZG>#;_(#FZP_]-^H77>. MYP1'-P4^=R>:?7T*6N F^T^M:_^G=;5_6Q?\.WOG5%Y%R-K@'V&!YWH5%G_, M!^IZ_8$UNN9,/]"V/W>D/@S(+'FB_"U]L:MEX:#BUO'%>.7V%>#H.VF_Z3X4 M=3"DJ$*62!#/&U@8OO?^/E9^-'YA_7PH&N9T"W_IOK%AXYO6R 4)"H7K5GS%M6_K/7P8W= ( MIM"V-F*(G+_35@'Y(SO7-/V1JH,PO21 ^KG&6EJOH-FKZCV!1DTV5_AC;69N MM$-!$R19?.J1.H MI']Z"ALO:R=.QW9B[^?J E#XUQAWSL;31,[JU[_>NGP\ MH'BUCPJMZ^L24[4^/>T<#CK+X W@86S<=0/KUUS&7Y"70YE;T[?AWXPYV^6F M$?CY%5SQZNH;7M\U"S%QL11>+6AR?Y6<.[M2_J_H4NX*+_7"Z"+2NF_67'"% MF3E7,#/+PQ+;]45;\VAVJV$6Z M_T1$@%<>"1%7A_,:W\G57>-?SRBU46+#^MK_B$VM1X_NYJ&"7E M:&7CX) P5/>"JG_C(_&1TZC1GTX;6%&TH__I=S=+\TK6#/DX?-C\;><)R?3" MX-R!WL-!'W>NF7*DR6<$MQDV!,J_OUC\0.&N@1=WW3\N$-C\XY8!^>G]9.Q[ M>6K)#7>V^ Y[Y[?%F)D#*^HH_XVIM[!^^\HWA0@=:FI-Z;?Y@E?Q?.7H!]K" MN=3B;8*?<7P%",7&L@?R^]P-K^\_NEWF:G+SK[&$5/?_M;&$_[D&'>'3GQR; MPY4[L@7B\C'_P.EG0=1F3JR[_9-HTZ1=P=$O8O1[8*@LRC7X.U*KMOPKY-.X M>-PU]0'^Q+^_#BG-HZ A[SN_XY): S"/C7_>_A#G.GX<9ZZFA=HIB:F][0[Q M.,*6%7/KZH:OH8&V(OUW@C*>"?K%,?$],2"03K?%*.+?NW"_FH@RKHP3)=ZM MK:KDVAKX@5;Z"9/2Y5I(4_M_J6K%(0SGN99.=P*^6HHZN)A77I&(>LSX]W^) M\M-.OT3Y2MQ7<+)ZQ$^?O:J%C RN7++DXRP<7[KS7U5)DM4\\#3TBHK"J M>_]7D"\*HO@HZK;O;2(ORYF0OPU%$4;W/KZG8VPQ9,5>4??'W6.K7V')WV25 MZMLBH*!@157T;[-A!W^R#AV-WT8)*>[W9]Q ;Z*BX-?BKDER/]G@8Q,G=6CD'N_B_LF.^VH=! MZ76%LSG1/3U Z_+FR[9W]BLA:\UMPF7-KNY;]W"+O/-JK7@ MFCC8&GC\?C4$L)F?]KZ.::O5X.B^V_2_PLMT<^O4BR#K< [1JB6=*]34PON- M,_L4B7WK7S]2-(5*9M[^\'VM !7[Q57;-QB)^;,:T5OYV\.#VN#5A@J4\O'M MZ+Y#PNC4:\9L=!U5K;/>-.&SY/5OMB[C!@T._RA=4SG^9,Z,W;>_6U4,RAZ3 M"8^]_8%6_^5?&6KLGX4;7O=_,;'\X:J/_O#;:4Z>1PM11=?7< R\KLL(;[<3 M!"*LN]P??_/D(?8G$7N>/YU69F;R;[3PFD#)/?RM>+A<$:EWTQO ;Q(4O,$Y M=53GA[HOF#FY7Z1>X?ZU)E$;^X\W8_B*#@;7C[&I+CP]I4)L'/R2?61FYE], M;>C@;^FBO?K 3/GD6^XL6>>^#1^-F)(\4WMOP@W_O6R-&EJ+S0 MB[$YHF$@9U[LH<^X[)'IU%T,'Q!CLLR:HE\OA? I87Q;^OK/O*?6^! 0J4#N M%#EP4]Z2DHF%D@F!9F]OCT @'H?;[]F;**695Z><%^S5CN],1DG9&I,KD;#$2Q0;'^'FD&U(I;+NTIGY\5CT^#W!1>!W_6& M[S[Z8$5R9^BH8)TK*P0B$SQR+L;;.SGU;OT)F98_09/C&/#4OV'_YQX+8C]J M8V6X&3)'R0+J\!-)Z' :5(B.C@Z3A435VS\(-H\.%GLSFM:$HH]C15D]L?IR M=W"$)E0$/FI0W0+3HYTAL MH\P0A=Z!W$TP#&;O[>W]%N:6[F4D&6Q[=._"X\ED-713G:\CMF!/9FUV]CF/ MRSS)H3)HS->-DWD[X"AL7C%,AI2DS^5T!TL.8V&8IQFJ-;K0T-#L.CDZVL#/ M*_MIPE_F!QI/ZTB;^7R=%,OR65'R:I%@+0:.P%KPW7%,OU J]6'W1P>_C%&U MM-!3G$Q6"^_SN"'I2XU+_5)'82P17T)::W2%>':T\IU=\U8I0<7P(H_7G4\> M.Z8?]7@YF?&736]@%9;%BUB*TMQ=[[C'F2*/0F44V=] C6(/"PXV#.:>[@\^ M_KG/6\9+[N1Z'^$>CSIR79S8"/.(@'G%+)F?%G7)S'QA\28_M?SW45BL M<#9SE%J UW;Q=!SF/TH ^Z1BX%Z:]RWN\'9]JOO#8CU+_FHLA0YR,LS<9P(1 M&6UDK71"0D+M[>T??I[\BR$=S\4#76+!(T7[(MN,!T$2,T+785'7GM\,L$G M" %E2[8%)@2"/88.,Y(;FET.#K,?-#14?E%G/M!:=,NRMLW")/3OF#8KE/@?GD^G19^^V'T:-3:2,T\8%\UK3\_ TY%Z MEU-[_Q>G]M^CD'8QPZU?#([2OTIS%J/5Z(;V=&5HY KE[[3V3A?/_4!KFOH= MDWE_K6[D146H2:[]*MGQN8) NYJFM46?J"W"C?XPNW;G8.&O5YE@7F+U+P\? M;_U *S9OZDNS&%0W.!W_1F>*%V::(4(TGO'AR!,?/" MGO=PZ[AX>EP0<5*E64E/<3Q9M8<2/* C,S,2K1FNALHD^_4##BO\LP>5\6G/ MOLR_9'R2NCQ(Z;C0(WS\"<]"LWVV*?&>("K(NJ[W=9*37\#I3W?X*X"XA=Z, MQ(JHA%$YJE;BM_8=N*%Z^GTI\]OSJ4 MVI7W9KCN@]V"-(2KP @R]H=1W$[;M'=]N3O2?Z>>M^VSWKP5325T>K/$#@$1N=+.8C? MIZ+633TIV>ZNF>(K'4?C04ICD83K""2T> MBY74@1ZGQKB@)$^V[I/@5\B=/<-X*(@S*%8'@J;BW(UDA2+Y7A,<'!R-CHZ- M'WP#[G-.#J=.YC5:@&GI%W64*YUOWDK[U!;/UX=F^<+2+/@]])LM[\+^E;5I48G' P M/QK3GTZ*D[^//?C@:Q/V&\43]*\UF: RP2<;O=,_T+[^.K27T5'%2'T=O3N, M\U\R'],__5 ^Y=XW/IT"0T3D=4D0Q+T^6A:C T,'3U&Y#>]0/T'02IU=O0WB M]!)VNY 773!LP4<$;RSCJ[RE:CXY2^[5,M7XM'_MV9>*4&-&97&$%MIF%\:% MHX8<965T8QUC:I>0 &O]>@W8^#N5K:_$^$N;HOAZLJ717Z5,X&=3%5^%-TA+;D1L>2?^;A\X8:(W@J M$5V?;J2"Y/)"E)([_?*:?P,P6S+S#5]'YL^<64?#(G@D/?.P^ <:<127#,]T MOOLQC(Q#XZUO-3TBAT MM%]B.V-G8>O@TFOK\)M1\@L7<>,3\5U6>VK\P9FY!DW(Y82XI7/,+34+[\_7T3@;?3!B^NZPG!IH/;1B!7!G6Y?2N*VZ/7P"PLSZ8?' M<9YUSCH:'W2R/?K655Q@TKR$GD8CG'-_M1_VRRT>=$1B+_<>]WSE2+3^DO&2 M^DEH,8AN2N&!FFY)HX4CKE7W3])GNA%E)&+D=:V;HWZOH9YS6M?] 1_1]6#'.S/0%8 M4*94\5WJ#;HN>-P)2+5K!H-Y[Q?SZ&HY7\[!C:1_5S&U#(K!1] +F^]DO[?[ MB4WDPJ& C6+(+\HV^7REKT:5;QM([_&&WUR7_6ISU M8&X#FI%2XMQ0G @[?M :&!LKI^FH\8V"Y\65@EURY_?V<']_W"BH:-,G&_.Q19:'BOY>(?]C4=YLN879:G !-K*@)H=QD]8G'GK4(P _&QV>H/--78FD_JRA]2 M7_4_OF=KE+6B(@7H6N<>EOR/OK'ZM.D.!8%\;S&AYYPL_0HW%71M%TO9_XEJ M[%U%+HTM!L^1]HJ@=Q;_/"EW_1G]W'_>4%#[QW813E,?CC'H3773Y[*W\@T1 M1(^)X%./DYKZ7J2,35G<4G\17?P?SY&/-.OY\#\D1(W'_]$WWRLV2;'6IO>. M8SJC-,FG%''3NE[).M#\-(QI6S_E4XH'&B[UQ6LC^W<_(X^&H.:TU_J+(9$:7FHC N M>#$9TN]G'R3FHG%>2%L?O 5[/1O86P07LL%.>I ;K;Z'@ Y^:!-*J+LW?@24 MVQKYYH+D.YS(]BJC]P6;B['A4Z?ZEJ9M&4=:GKKTN*DW;9%6ZR5"=14,\B/S M6O7#N$]"M$:(;U?O**[V0513J%V_*(>KLE6*;S4>S-2(4@(X"[DNN\PXH>[/ M=42_]%1S],(C"ST$/ Y=GW*2E4WG.,GS+.,IB%Q^M?73\I%C&]F+(1VT5167_\P;LO<;V^$YO(@+!4;8;^NX5]"@&^G5P5+V2W#D;3[V(+RL.4F,' M/Y,N,5AA="*2O*]0\^"^DS]/.)>NHV/'N?.@J#A)[M#@V]$FFS!+4=P7JL59 M#>T?B$I&%M5UXI:.FL\KM3K7V@T*RVX?-![>K8-15TK[53_!!Y1-&D]^%1M MA@'V;I!Y) YTY"9LD\Q63I&6=Y=&JD;TR T;;ZASK8]JW!>Q1'.7@\6YD86< M92?@M!*36+P$VZ=4ZAGT N>+I4 ]Q3AA-)%Y,\$9:&N1ZS;?,2-5NOG0<^*P M3 !$2;!=.XBDE!GY$9'TMD M8VP/S /8[_EP4-(P7%S\4'_Q(0D]K^BMD(H!';+&'+$FH=;V'VCY]=]K9NM= M\]NA8@U5:/.9 PHR.]0L+I]'31ZHR5.W6!'1%'DC8-CVWO1ZGA*E] Q%J6&^ M0#A0VV9D]7$<5V*M@*KPI5A# R Z>L@D$US@;9GV :PV\T[0H K^-J>:V;-1 M$>3>\)T5VB.,0+N5 ,#%'"KPTY( Q^\T[WXK@MFIWX^([WHC# M(TTA.M]UJI=*RNE=!/M84R(>*0!'U7G:AP@@1\26M(:LX51Q7');<>,]U&.X M8]3HCLDY&J]IAM V *#>KW*>DZLBHUI@<^5@OUR]4Y<+B(B_H&'PX!D)=0Q< M/6+(QHYU(UT,4DRV 2[S).62LBA<=DU.Q_%KL0XB()=]KBA"XT+C$%CQA.'N M*V,-2[ ]+(XZ-[IX(#L?@!!5?'G:"TNA%0<(*]NI 9"K_C*F'6/HJFQ\]ZB( MN&YE9*SV;/7=PBQ7QQ.K>?%%$#I3Q].\EE$N#^.N,RCR,FD;#13,4^4S@]3? M&%!LE6/+_,D#QE@*.(5K M"@>6;68MRRS60X0_?*;RE5$G]#>*#5?Q=D^.8:O2U]UHI MW1=.,K(/S3REL6)\0CO&GJW7&Z%\'U CF1%(D&1V^J#'A36@SPF*91Q3&VLZ M&? #K0'3?4.YTBOP-D4]Y7+32R+@>S_L]IAVP@IB)2TT&8K59XJ8.AWL&( [ M"DFFZ8)[[L )JO0HCZP(.@*LN!PA*+6+6*:O/&EO"9D:%P(6%NW[!#9G%[' MT.DFTLX44[B)7G[J,LSD\H8=]0,MB;G;&]7)0ZUIPB?"5&?8BC0DJ!+&_NH8 M= .OKE'HI!B;5TF(XN[ AC4DHH@:?B":XJSNP>B4J5,7B0KINI]SA[I*GJ&4 MI>18" .;<9#D-H3KMCI @38S>W'5<-_-JEWWM44UB=YW1MT&->>[%,W,\"8. MO&^B0A$/&F5<;&B&2%+>@N>4U@*.2>'*8Q95P[G M.FQQ$8EE429F9*@Y"H,@5.5U#W>;(K2CC&K".H1L^G4"^.?%:\1,:;3-@V^9 M<9@Q$EH3"0$BL:KQVQL>TA6LFL]GF$%X%-%FVGA!8BZY997DM*8FS$)5^JTN M;FNL)UMNK(<3:8\9 "\DM7@RJIJ1^\*ME: ;DCXN:^=;-1BI^^KX:1SL?M1- M&=F4];#!#;?0;+9Y8CD5W;-L(PHL7$HD(Y'9^DFMV2'68V7++&F:P,^V"?54P<='^J>C M[S&H_>T1++VT2#;?OEKET+>V:72N&JN(6B4F,A%W5PV_"&KC*,M5RK&E%C6G MUV*M7:TR]6>A MN[%FDR9&/SG>W*FC'J7.M$#CI3&+U[,OQ)$$,8_(B1YO&%*@K]4BI-D*I_%# MC>)D<3I+I:5S-CE*2T6L"U$V!?S)L) MJT,;(O)4H7H>3Z0DI4BMP-I?OJA$9\ M;R9IQ"^5Z7.LU*9H)0AMM6S(D\(NE%A]NY0&V]PG,M=-Z'!U9E"Y.HJDR4"^3H_2;EGE\[@ M>=P]TV)5*U).IB#8 D9 #_CQ]]WK)$W^^A=/4*$#SQ-/<]> M2GIG^&@)IE TNL>N5 *4>\) OM1;E/X=*FUW57E-/>9Z7N\VA)GU:M&X=8!Z M+0M;$S!Z=(VR/!'GBNL1@GN>E":4N&W9[F>7JQ](H53K52:[?H*$#A6&\2&O M190^D10GZX=Y=':*#PC&*(F2]O>;@K3IG#8#N,AL\YQUE'FRU4T MWT':Q?TD.S-?#2.RORT=+VR.1)1HQB\Z'$U5>; CXJ9)YK& 33@CZ"RX=D>+ MX89),._!A05H^\:J00Y?4?-F":5U#15EUZ"+L]WB:UHQQ?Q:W9'+=Y.V!+YV M*":R/9=V&-B/.]6Z E]"T91Z+?8I\(,",WKY0F9.;K:H?[;H3W#(ZA:M>+%D M''-.P"=[RZFXE]N0"^6$3TES%F5R852>& ,!8;!N,[PRSOAF2 KT)M[FG!RC MBQ5U(H7662]O50HL.#(:22 *E[3N5P0;F6)"QP X+9J05Y4O69.IY]R1";E,XGANQ2&YSV MA&,$O($S6%2.09K&P@J8K1(([. UR8-!IUT4)@,I'[9W;@Z[H=XAG G-?![. M;&(80J;9;K7ZC"=H',_Q:I:HC#!0VC".:"FQ(X;KLCU"V'44SH90[Q3Z /L< M"-@,TP MRLR1 [HWS,$<4;NJVX!R'CQ9GTAC&ZN:7/?<<'*;?H:[FUGM*;YHXNF%@T@@OSZ\%:PAUG(94/A(4<1@0MG-3 MT G?##GU;4(;Y[RO%]5':VC9F!\V[YY8C=0QD[#AXP*F =5 MG(]F?-VR/@IJ[EZ,C0CJ)7"G#P3&34JSNPFV1;\514>C@OEL(5#;PK\N MZ\QZ7)HL,JM3(N6X?EF_2H?+6.FD73 MFI\V&*6=?KZ"]$G+XN*)S8QBN&6]LS,[8DQDR,)= *]]$,D0F-+260N&<\<: MT@7K"B583I&3CLQ6M'Q^3M?K5%37(_H9MJ[&#M]ER"<# [$9MF9$PNN>G_O8 MOK(L5C\QZ(EBY/ZP/4,R:=O)HR>-_46BK:D6=AXF,!@:4>_;LO(#;3-A75;- M [=B6,RH=,7,W::%.,PQ4G :]]Q%D+Z>4WH:AO2M^./@@Y:.\WE>&;6\-P' M37%H0^JINP3Z!)TR:FK)4<6K+#N?T<$SY O2-I9NR1<8BZP4N.(&9!2B/&X MH0$RR!,3 @CV0Y[T"F>*5M"\D@MV7S5(,J:*>TG/X<&$W&K 7?'9[Z>D=<%P M-W4*,Q0[V@ US$5F--61U()27G58Y+:XQTQG7!M MJXI\1F.!B\[.%H3L!H$9/P<^4*"#RM$@B9;2_;6#0-L%H=HP?KM[<2]KXD%( MI6Y34*V&W?UJR*V!F.CIEB&P-!B/9#)/!9Y6K6DW TCV+2 M6LBY]YBN_0,BW-TS81V@UX[I=R'4[17DI[N8I@J-*9B1S/VG")QIV,3D"24--@89JV[# YA4!82H\:#J)PS MN(V\C=+MK5(!T/22C3%&MRKT4D/23V_!#I@7SI-WDV$'R$O\[D9?-6VV[AYE MXM@3\,L'8>P=Y@-AW&-.)I>;DXXTA5@(SK;LO"K>J?)Y&&]IOF03+*KCT-27 MA3&J!SGEKI+-GEK@&1L3+"6'U!#/;(#"X#[AZ%OOG5HG.-_KTU$_.!VS1/14 MOJ(^[ 6*QGWYF>K9RBOK;L#E_-[3X#MSW)]8_LNTVN+,S M,,:0%^'?T-5)&@VRE8;(]]>V;22-;>(/0SM6RM"*V3US[_M!G%/859#LM*U.2- MEH>8>KK=&NHB5^1Z>IQSCYWPYB0X5C')]DMENQ\*E]^BTGV\B6(\J@K7>9 M M0B9$1)OWBY_-K)8VM<*H? +DI>D$>:ID7/=1]];!Z %+J8Z$Z&W0481Z5]$9)(CC? A-1-C" M66RH($,]9)$"$KA;GU5"!XSKWWI0,GK 'J=3@KS=8N5GQS7Y--,NB,B@!MMU M8];(Q4_))XK34/C-G M5&,LJ+.(;IQW;[OGQBGKAZC%)ANA<,38.D=_N+?5!%+NIK(OI M='&UBBAW@/( 6@ VQ'UMKOKK8M=2[<:6'2^]#$O/^7(1G'B8;.L;9-TG%-") M@XHVK7/ZEE1@QW?V%A97R8(0#8#B; (V-1W?L'BCQD!G)X\UID8G8S)B7*BX M]8LC8AZH^(Q/INNS&8P>Y$S:!U^P>GC6>HPJQ3RZ2\JU+;OD.V1\W$ZJ^)#8 MIS]3T^,5WK@F5Z,G!J ?!@ZQK=2CB5.F_QC@"4.] 3MV8+/#]MZZO+#XB6+? M5LZ\GWRU.//"V)#,=C6F5W'=$-#>EEPT^?I48"F"A3VIB$3-."9!V;2Q&^NX M">:;&:U31Z:&83G\?L-AHU?)7URY/?3,2#QE9]>&B*7M\N' TWJO"#Z"!SOE7POL]@JBX%MSA)5MNI(JRFHHLVT!)[6 M_"H9SK%G0Q>06;Y.[K(:YS1OD/ T_)9H>&Z3^] SC5VG/G.NG.+$A1QV5Y:> MR!ZS1'5CQ7(BZCB5"UUZ:UW%"BN" 9,A*5^B*HPC\<8X7_MD+\Y^GXDWA= M^"!-'@GUC/%SM4\E=?JH38=6?]K/O.T=$ 5^X/W>O0QATA.F;=WWX;JM^@75 MAN]-B[X>?<+*M7\NE$@1G6]H2)8Z3>&OR#]: M=Z]W.]+H,(;1CF<,/O<)V\S-U.R6'."HA!#+-%?'&!%M55DS5A"D[YGBI1TN MQM&)J:)T=5\("7?LU$%-U'0 =88@L0OIER69J B<$LUEU^@-:B_UG\50W@@3 M3Q?_YTT/M\K36]8_T-[%:3(A8U]_B*OBC7E_YZ'0>I(12\&D?M:*Z7U1<4#N M=N/1R%T#:CM'.DM2A)<#V[ %]I14-QRL><<]1*1TL\3;TV 8H=KD)WL9M9NG"\Z5>&X MJQG/%\789O6T-^!OO<]^(!"GUROB2UB[P/1T6&!M9M^D%@30% L)9*O'N>>7 M9>LQ1V[C$-(;V 0[D@Y#>OB*Z^FQOQ"4#PUCI#;G-Y*5^S22$[5<97,YAX,? MPDNB-XW*WCHZ^H$61]AJEAC'*+C8717& G^O3M%!Z?B,9K#0?@H 71 30A<# M222D:]6_4S"9W?<.W^8^HY%'[51YH.@$&F,%0LXU7U]XU"HCL5U9D2=]W_@6 M_6C>C+YA/W.Q,;C72A[6ZW?2F$9P2.@-X[H)QL',SRE.GYW>9#&*YZ"D(/UR(\K.-(O!TV ?3#P#<#JW'[ MO!N43BI4C'&=1AMG/,(E31BS)F=QOJT_R?RQ'X-8]%W0CE9OMD"B#_43+JRD M$5]=1#X[][S (@_!+.U9;PUS:==@OJ/)NN>NZ9FKN>0+*C,W7_4\&JB#V_HH MC:Y$4Q:/C7#8\H9X;:\#+2"N?!@8L+B9MVR;9QJ[Q+94.+BV.$"?KO N#GBQ M;H27 \$'<"+5>3!A2K0=CSPQ)$E3C#^0GSK:6KJN:B(JE2-".Y1PATD1OBZ7 MTC8M=-VV(F(%"74TC'@S,)SA )'P**#&#JLF9Z(*7?NJ9#K0JAQ:.],2G@O/ M$COPS%#AE1/JMA'J,<]=:<+%E1,W]Z//_"RQ-+ XK/]\$-IYMWZ\5_A,LMFT M4I87DS%NRVL-UR?-.JVQF?D%2_%F MF!O%"P]A9HTM>$RFVF>3SYCS$;6<;<:XW8:%S[35:FW8_$R C9ZOC6L(-ZEY M&K' 2H T*B&N_7<;?@6FJDL"BZ['8]IDY;I.F%T=1EB-B5I3IAREQ-0CY1A\ MO/0Q8SWN3:Q9YI8JZQSN]-[46V]X@QN0G3BR$0RW^5@PR!G *<<;;F3ZS&W\ MPE$R<5@)!+QD*79RUI.MQ&U&7M01T%D0WQ-=O=0\,:R^6S#Y4J-*YSD!Y$:, MR1OF-"VLMLC(7GRIZ MT%AELL[\+G$A(KRX(2?_^+)/+DE"/T#@!QIWX%(VE1],;/F$2(3"0"\/>(/T12:?O2 MK83C,[!%S1&U2A)*E16&[L_MDL: .N*!$ZHZ6BZ5 M'N;K0^N[1++U]Y>9:E! DQ(^O5X P;:HDD(7TVN FHP&UOU2Z;#S9CKR3D2U MCDY=Z.R4Q%3>=E8Q["TE_%8Z@?3F+:?#_5"XNR,;@HL>B<71"Q9*7GGK,DX3 M5R/84X=_$:-,WDPTTN\:'7JCSVLS"A12),IEZLA@"(#%\2IL*.8>/.&4Y#OP M"9G(J9OK>=#QD2,^%- '3RD$ H].4]S0LR%*&+YQB>Q,WA];S#K>@IR*83B5 MSUN63&LF%SS2*7J+X$:9-412?@IK\M69X[F]] M*16>&%1 @X9TKY(*&(?) U*::AO$<-Z"4?8242NIE7R=K94+NYA27PP#ET(3 M0OJV6$UYYA!92H]THT$*;!,,B6\53(B.$9>U%W@>%6[CRN13PRBY]N-GU4"/ M 7NHWPELY+ $D%":/NL>LP@Q%UC?%@F#A$4.(\%XP KL=O05(4&&9(JJLG0=V>(XC?%8K--U)FDV=584UC\\ M+D@]VZ3#5Y%9Q @V(8U[[^&)9)4 "-VM43L_$/^P2?Y12RUG0+:HPE3:'D-/ MF4F!'J)2X1X0X:-<9#%0I.HK;X.Z#RACL1O#+Y9:8@?A*\@:1[!'D29T;:5H MJ C9.#3A$E.!V%TJ;)J1-7)3GA(&+ )Q*GF#=[VS(,K&"2)FB!R3<."B)8T? M*EE:L42Z%X%/*8GH8SYW'ZQ0#4VCG-GI=,PSSD*>Q203)Q7'9AF"HU3N1#&/ M:B/3O_&O+G]\QY[O"6B$ZQ53C+H(K,_#,V?" ^DB1XX,GN.C0'?4E2W!-I0C MQ1XC*D52!?T,'2ZVEKW)S-8XS@3WF?-DR>D\3M!FK$01A$-QPE9W+E^?' M![I.;)14K"0+"2%X)EMI?/3$3\GS!8+Z,E?J29@C0D0@'UIQ.D1$.F"$"#7*ICZ(F4NASXG9L"3ML.#(Z:/1Q9 ZTV&+P8%.CALSVF_E'N_T1B11. MS:N%Y,^H4.6A)E%D/F,A_/:Y"?M02M'GC$>8^UX2ZV*K^R>@SD!5?2Y5,XPH MX]#=-B>:RL;IODR)/G(@AC:#Z=)%_8GXT_ \UPVW)\FA,>*'$-4RY5MH2)9= M"E.EELC0-LRUW8UC)2;4:Y.%UH^="!@5UIZ"7I]0Y#$4XN,QG-_@L(Z=I,>! ML$&C'&Q@1K@J;-Q<2$S 222P,DLI%I)VH^!/W6D1$>T)X9(J2>HP]XVWDMBY MCZ-TN-]4BAHPR5R9#F^6]7JG-]X$6=:P4)?;=HUP^HP/=@'B2B/U(G'8G M@/=DH8NZ>T:.#Q@0.N.G>RD]\W!*4RK[KG,6UTZ]>R^U7L-702YS4RB('6:_ M+NTK'!IV]'TZ8W,CG0$+A[/?, 9 /WEJ9/0A"=AD%#9UY\A^9SM[AFF%'M5KM,XYSWL>4P]Z7^JF<*S\7-X4=G--U "2KALJTQ>L03[1*8*[I_ MW*6>#\)*S 9YSS&TJ1I)-2_#>",'(RG&>P:JNKVXM*AX7R4_QS]AQGDG3<_+ M>C;";%A)TUMT[=47%G\IDT1%9:YA[IU$<( 3*4\;J_6<]^A M[N"#[ILLFM!$5&K=B.V%=8!M>._.1T$V@+E-RIP$ 2;26@N10EL'H\.DB]^. M995&2.9K7)CSIH6#]D,19;.EV$EB*Z/NM7(;"Y(G7>GW8S&^[$J?3(F4;7VDYY@;F_*)IPW*9 M/8'=7,6L:)Q\!3TI2B*Y'80AV$,PB8L?(>W+UYA3^(Z@P5 \O? 585:J9-YA M>&KFO7: -CH2OBP>?QN'8%2^$9T.O<[N"&B<]_J(G[+DP1;+,^40F^;RNT-F M;N"2G)5N9Y?SKGTEQM>]Y/QV.3DK12ZA#]Q7NJ$;YU6J# P^*=01&X; U"\* M\S&A-#VLRFD4=%-1G,NFM4K@F^Q45-B^1$;,.:)/6E)/N MA6 F*HRIQ$ 4E MX^*0(0@T02'&^'7HTHP0E4MNY,+"7&8':K\W5$%/TW1K7 F=+;*B'[_?4B@! M2BJ8Y> 3M_4^QRO+5\9,)P#4MSNWG'>TW<,I*91C+SGKLI2[,==-XS*@*PF' MU&:B"=76D42GF>S1G]ZG\O^"&[E!9A@F4 JFI%%W*OIX,"/A>>-=%$1+7)3F MG=(&J:1K\;9TT(!L$\";RR,@GZTNP+;^>/!![?Q[A_#,W/7H&(/,B^5=/3!\ MWP]%-H %O%^\ K=-(:2N'+2<%N42,Y#(9XO UC@/,@PWUY%GG0U9SJT/\CN> M'UP26_AF$+I.%XRD13(QZ>&!;/OCW^&Z#-I'L]H=:A9RG_1W1_G>8_ X@ZA3 M]VD3*&SA+\RCHOIM.N^3-%D1-B'O';ZK)E,G?\^!H,9+A]PB/TU$'#@ _;W"XQ'X6'.- M97/JE'*@PCK#;. 3K2*> ;N,28UG(Y,BT90NE'5I5=Z17=O6+GD6OA#8[3U= MT_^Y'R+\W^S//E0LQKW/8\B&7.>&*FL220B\CV +!M/J9F0>55 X&!DY.EH MLHR2V3]TQKN,)9XU]PCY@18.K_G& _B!EEK;V%ALR!NUI%CC^30Z6I-BM* 9 M57^)75?E(((MOL*?PS[Z<9;BC/9V99Y[ML22L=&(P^/ZR4DN/N4&TX>O4NF' MYK/J5EO4=W$;.IM"_?O"]SFN/]'8&)EX,)OW?ENPF;W2NVKRLMOEO:N-%2C_ M\_!3,'>$[)H[W8.W%\U&ML6\=M6%^]299G(QBSQ4=Z+=X(:CJ;=T8 M[!G_KA)OU#?#P29H=)![OD#GA";6$\.7-\\3,PQHC@A)>K4U*9S;4U M&>/?[,Y"%E87NU_:RI^GE58=A>PT. &%MQH(*8=6*@KE\.&\$EL9H!]PDV\4V,/ >QJ]O<]\/,']_)\I4WN ME%H?E+'Z^8V+9>&-@U.KB. Q?*,=+3BP')ZW2HA 745XA=H#OV*7W>OOHRTF M]=OTSG2.$'[3ZKD0F*-]1=14#V-D(0F=_X7&OI9@S@B((+CG$2N2MZ9$R<;; MGZ]D&V0[4]+L!Z?L5K^8,0/*- D9[:6^.'VRT7+\Y*PFIFM/-$BA'^R.Y8XS M^F#Z2=-'=A+-VO'7NR/.687*]U9F1IJ7_M5)FBR7TYN#!2A+B$[I$_%%EGG/ M\NCSU,92JZ.A"Z^$@942&'$3K_ TI=M/G9NDR4*6"NF3%MJW;]01-'/)?U5+ MSH'W&G)%T=Q+W8B3%PO<309Y3Q(FW^FQ5HVZC0S"+5;DY&/_P]C<)U0NUBRJ)53BTF$3@UFM X&:!%GNWH,EJ@.U TG8:.^"7T:LCE^ M*NER\W&^6+:C21_!4#HT,M!\^D73>V,B4LT;,=868X^/$II/=K$;ZKY1;6#\D7IZ9(X0_E57>6_VM?/&\EN[-"TW M!&>C5K]A9W_3R"Z73UP?F)9@WL=ZLRI;]*WWP0$Q6X?:+)MA;'I[5U&P=0E3$Z^0Y8V&S[=.J=[J MH#5ELRP":;F:;#1ZH*S1YD?D]>R.;B+A ZAH&[J4WM*XQKI9-XHREX4P^;P< M6=1>6C39B,<(NBGU&-/&@D_ X$+H,'AL2L!/Y_53I,645EZN,/R2P>[Q3^<- ML/8VJLC."3S#=WUYC7U_BR33B%O3&X21O:$YXGR:K* R WTDP\='L)UDHDY M?*S]O3$Q]$((;Q,^KK8(K3V;>=>>5Q']D-=>0V7Z4$3QN]M'8;/]/5R$MUOL0>W^;@!-,5?35#16CHXH^1S M/F VW;Y&S^N#NU?VERHSAH&<'2;]:O M8 ,486(Y"3A^^VX E%HI4% /-G^0;;I;B %W8&=\"F'..%=@ MJU0QV]*@3PD_U'#9[=W=;2]4^T*, ]O0H\1Z_+(SO:K@&M<&KP^+5ZVK]:OY M\Z:2RF71YT;&#+W@Q@_(',OQ2=^L=2-4[B(LL*MG#OK3@0N)V0\>Y#MF/7-? MQ7&%?1*88*^0CKM5&%/9&&@V>WY ':/CF!PAVYTLL[:5,28(:;1_;X4%T,P9 M!Q_MX3M+7Y^';]?!;W35@Q^1T3P$\T@9XG+'8$+483$"Z";N3@NF:>[/[]N@ MLMAQ([?/&^L<@:]8EMWXQHUKO7QT#/),&U*FI@*[1S0PW 4T!>B3):B/-V,T M=O;6&[/4^4T@7#_0#F+I%ST=)S,5195IL"@<(NY$4VP( MOI:GYD,J%Z,)(< >Q?H6I[?CW>LA%\7X('61 M2^<&%8UE7L^0).F.@N\TXI./"8=!.W2;)#)5A\]*G465O!I'6#(?@I9P *;F M]VL,GV V_WO<5AP0)U-<\FR<&HLYSG=GO?3:S0H0'H/@P\X&W<36H\/DX,:/ MX,;>$S2 !T##DITZJNK9(:R='M20/3[YD ]+HX: JHA.2I4,&6R,/NDU(U1. MXXB5[[M9<'T<*VX,DI!FH*SXTS1=66<[#FSQA@#D\H/]D9GSW^SRMV":_OBA MQ5H$$31*IAW)@UE7816UIDM#U\?8MX;&=Z20Z4L 5FPI(4^_Y>0C4-%S'E@N34(U-'>X:?O%(=0]U'XOT*J^ MSOE.-O*\(=9,ERK 82M"ER_*\G]OQOWO;M/2[2T:;A%,(BE!GH:<=D+=S]8. ME[+-H]VFHI1A:K.F%O. !$MT($\R4D#@8$EGEQ:[#^]L]"1'$2!.HC&1=4$K+0CN;PLNXPP$JGL;Z^D9D>UY> M>#:=6K-4S,N31/A!PG]&5-[O;(;K=4;>BO-R"L/&!+\B8.IOD*IPA] @0:HZ M%3//M70SZ7O12T63P\A:B7VT M\!$P2XGJ^->X::K-4[O'3A6VFO0)3T/ND';,*!LB"8"2#M-3,FB)[<]0"Z.H M"(3(;ELTH!Y?Q+/ZLO3;]M">49CPJ+J>4%9^EN/,4RF>L8KYWFI&Y%H:/ZE, MMS-J:O;^IJHMY%6$"$5-Q?'N_MN21Q26/D[>Y!+C>+2.%['8\:?-BO]NH,B. M1UV*2F%, MJL9^L94^O-N(L"$6MBYNLYT/,X(5^%P(6=!(O<^F&.40JSI'FA MFS;%XYNT7@_0-W!X3&UQV=F6Z4A)L+Y)(H.79?'_G_*].ZBIOMLZ*")5>I,B MO5>IH2E@*-(1 H3>$CJ$*(0F2J^A!) FH/0.AM!1(:$3$.E5*8+4AR(*-J[O MO7=>_>;RS#?OG3OSS9WO_+7_..?,_NV]]MIKG9ES_X^5&_2;;_5TFH_^G2EJ M]6OCJSEV_O:V'$Z"^_[/>Z).'OW!?^MB!/[=Q&3\]SS,GTM/G,H:&;'!HDO4IDY?G90#9=5_P31XIYK05!0BJ.R>@ET8?@4*0 M/]B_]371-5OWYJE/PBPO TQN>YEI[F]#2]-\**C*!*A9UZ[ MM?$A@+FQ[_G52HPR_#518SID''DJE!8:^],/\[0A9](A4&QO. M3CX]Z;:6/:[A2.<0HS.ZJO%7HF I1:0U)[:R/0-@BGU5$EZ*%H(VZHU<)](_ M>=E6&:ANK7(Q\=3U*DB3+8DI4[4&'K)L*EYK,R=/TSGH!\XJ-;M@N739JRXW3A%#,- M"#ZZL4+A1F(FN&DJ+^;D[L[EV;+I@FQTXOQU(QD;D3-,A_X;1<7@74.U%T=2 MP<;IM^AS([723/3^JN@*4U17!*A%JKH7@A; \Q=33>6S]254AKB,V36V;JJ: MY8WK?%.P<5P3/#,K531XN2N2-D'\)IQ4T=1M6[M5WW5WMN;$DJ]*BN&#>*[4 M:RK7[FI7#ZN>RJY8>;=L <$GTV][2UY\E0K0GSD'##+#"*]*D)) D#S@5NQ" MFS?ZPL7N8?F%+;&)28S#CD$.EE7S0?;3>S\,/1$[);W^5;[1/A7%-7I@.]); M('UX="%LQHDEH""(1FL=Q-9@60G4YDJ"FAC*?\(02J?3DS3QQY)M0%[@"V-G>^"CJ:W?AK)@B8]8;D6W+[2D_<50A3#;\ MM;S:5+62Q$F'0P9" _BQ[X)IO1A_1T>QDA_IZVB5H\E2Q[)B?^MFT=EWQ\KQ-1\V;O MK#4F@F1IV/GBH;5B")(WD&= ])@,(Z4+!16QW_DK,T 0X>*5T6/9FY9 %Y99 MWB:?_7TJMM0L$[,0?M=]+'-2S,2L1Z?@.>">X9%?J^]WS&KPJ_&0R,CT\<9( MWHTQ/\)8H<+=0S;2LJ)']L3V;Q'+PC-PZZ2+9V1J_J$NIC]Q E=EF[!HP5, M[CQDE\)/7<,'6O:B8.< F) MQNED\7&>N/Y.][^TR'EZT%R*VK)CNWG1[N%R M[Q.WLH_%^A;SK_5*@1 A5@2BCH)5&0M%:YV+\TI9"%M$7+=TV93).$T.$E?U M82KPOSU T@>8B)F!]L@EZ!"9%QF1*945"*^+_<224P(%@SJE44* M9HL@[8B%&Q>2^+3\B0(9HTUP'86I_H?LJAZP0(NA(["&$IC7#9'/RB;+:\ I M#PM'DF$Z6-H>AO0M!; HEH8JU<:6^&U7AC8*P2HSIG!QR$>-!JX%;$5G,X\H M77AHF>)S+0=.%ASTE.G2C&HH8JOMS=QE%<+W1*5;RK04I6*K;_N6;MX^M%:] MN#3]?6WRB% +YG+^F0VD'+S1X^,T+'5>9T6Q.*9ZEDG8-1V<9+G[2(:,/OO3 MY2]P3KUNVS*,)^W*2H1BR'0;HZ%8LSW=P#,?#["36ZM)XZ!: %5O=/9UF$1* M_E7!P!/">]KMI[+E(Y.V!8?^)SAT0Y$F[0BH] 9R<^YHH^1"2K' Y:+^:!5SX5+FTZGCD>J MVY.7=%$320].9I+6XLK=4,YA$E"E._J$WMFFEAK#WP0?K3%G(K8(N0LMD<][S+KZ66H_$P(+-*M[8,E;K#1#Q*!L0W7[H48\(\+J5C@F[%,$$I M[5_N*0@+B(,'S?+,MR>FKCGC8$%<&*[N40UHVM(\JP[$Q,TVBM3(WM @Z?UZ MA7O@J@1#+4"VCP!A>USQ2F$PA 4D:\/V45*NU$-4_]-6A\*PTOS,A4">0HD/ M+F_9M)"P[P63-Q>@K6Y6ZM98T_"FDX\;PH1*\[LW*IB0-/11$\DR&=Z#E%#\%3&_5&DB5,WKN9<*5UW9I5_1 M$@HB,CO-Z$WLG+J42:'=O9_8SZH0-NZ3S1\NUI?46.L:O-!,1&]%!,L>L?\, M#*-3FB6L&4>71"1MU /_&,0I3W3+.-^@J4;7"]>M(TTBPVN&>$2=._W+83L6 M/R.:,?_364)92-Y,MY :@9$UMX.;#(C3AFFW>"Y-\/G"GPI1#K8<(T_[U7_M:+=\>M+5/EV67]GZU_!C)];1K:,GK\ [>OGY%[FK?\ M<*H2E.53[+'Z+&&\0RH'!)Z4&9!NZ$31YM$W2--0H#'WI6F:PPE98[]?5:?R MS[ &+E5GR*M'<4-#.-O]A]Z$'\2[A&;#]NW#J7KOPF4L776R5$<\80F'_U=+[IN_@0@PRMKK;X!IV MU6H:^R$AMQ4=XS7YXPJ"QY5'Y_-G!1[>J.(YDO&PB/VC6D$)7N&NKS;AOM4V M_0O@D'S;>'IM')RE97-L6R'?-O?8+L_+4[VI>*Z\4)IO0MXC/>BKN4AL!B<9 M$S.TU -]&^PV7G>HK4U)2\%8@M+]@*9A/=OK?CJ;CWR_J =L+=N=0[_\D'O MYXQ1\L$NPLJE69,S+@@GEX">H>Q/QA%06OY#%@-62YC0G+_&?E?XF&'VYW#X MZ.H[\$O-YIH-YM2!@@8_M5&8Z:NEGSS?OY\([5Q_@X L0HV9T@J5/0TX^$WS ME3/-?7E6ILKK5;*C*4[O]\OX0409I>;X%0$E,WC6*#XD FF0?T=W\!SP=BE% M,?\Z\Q [^(\[P8_([<4QJ^QJ8R).P!:)(I)_-ZX.-U4SO*^EC6#"+V@_=CH MZ=)L7<6T*P8&PF\>BO4\":\*83(HODTQZR8DL]&)"$\S0T//=!P/,K6%:E]= M=MM;NU(B^FDZG_3V5> "<&X)2[%.N62J]&VN]ASP_A!%P3>^RKY&4DCW@HC! M;)E-TA]_W$_+:DD?':N('1H??G)XI5@2# JX,)./\Y^]/[FHGP..WZI)'OG[ M&11GMQ6HG&QLFB6=&4=E5$D-"MP(+@DL=HXDZVXDRO8>%*M]/C7X'*MGP:13 MZI9K(A 6I-R1D!PXT0DY35OI!0Q1&9&5:A@*]2F5U;QM3'63&568G+=I0G_: MX/W^V>"/6?D#P&^\.Y0H?O!RO\0*RMS??(D%COJ[/W_LE.P$H;5.^(*1D^D MR9I&2HULN?-DD\3'OP(E6 MX;>^B=ZW^[Z6D/R@C<#AJTLW</CWDM"?2?66>M+A3F[^L8,J=MXH7P$Y-V6VGGK\\[GE3<4B];(2K M1\.(-S_PR84#9FGM.5<[,OLD8B)[DE;S:;\J6VY.3$)DSC2H:$5C U8Q!F=] MU0(R"BZVYA@BB>%8/ZB9$2!'$O)>,#3,1)64^W2:?TA^)#ZT"&7.S+8S9'4A M7E?*UYQ$9WSFG(U^%M,Y[J@=I1WUEE74I$7N=GR$2>K67&J5E;N89Y!S.GA: MXDJ]L8SJ^._1*G#*NS'G>[9HO3V#\[1"52)XZ#5NM=0UU8I(CI>P TN@ZQ'W-PG'BC70?8:RKL%67.Z M.UO?I&2=:&WY+ERKM2>I-0PUO=HS3"\1.M6PF9%P$-EG,ZI'URWF%;R:U8E. M9 ABT\L[Z$_,.^BF'F8LKE95RGYZG0;N,54F\'F+12> \]%<0A/MK+C^H:9+ MTQ;=28'F1%#HA73-+@V#]<;;A5NHR:LBCC\21I@<72"7'@$S.$(G-S8F"DM- M28&:C@2Y4*-8WR'S WM^K!VCG<,]O]*J:;M^C@\LK70J*6;NYX!.;Q5;B8T? M(:%%'U/GH DSA\U.+\G52CB8GHU7:?Q4 5.O#'(+_R9)SKV7Z=N]A<'4,QA M*UT,DV;(IPNF'3PGPM:+&O=H -0P5$@T(CS17+YE*(4Z0^+UH0%E@$,/1/EJ MK*-E?+\:!PV.ZZDH!A'$DY:_#(289-T<_/1UG1#M_?,';T<,HY4+%CKNG!+/ M\3RB5$V,RDR4NI(80\RD"CZYS9=DA9GVS5/]137_Q$_K'RR-:Q:;5E34#)M\ MLP2@/*ESD*A5$GFIUM]DMVCZV9UU*7L&)%SRKK LT5[Y<+F7\FXG%0O!Z6 V M2[=15/;@*]BE;H7!#YQ3.2RTJ#C+IFQZ,#8%=?"&9<@W3_WG\0O^#]*IBVJF MU]7#C#>FE'YE*S^YU^:NW=TVN]\?DF.':?,POWAM8[&9;PLO?XM=Q+XP]5SU M#?H&+J7UKK]P3O7K,DYO+*JM#^K6QW=M[OV]9KCY'Y(!_:\JACO6GA?-X81H MJ=K5+]1M-_^W)-B@8(*%&_>Z+67K/Z_V8%UGF;73)B7$S[+$71F<:V>)L[ZU M,2PW]V/'1*1UBL+;0^3T:86/IE.GE('L3779LFXQ.LN:F]I\_LKW+7U8$Y6E MMP,YHL[^XY"-O^3(V3_/"Y$^2-"2YA\)\SF]S^[X8Y[ZJ/G]^T^[M%IMN4&? M(B:*=?A$5...8G$U\J)@G5KGR3B.6*/7G3<]R 5/\C#$#Q8@R*FH M0#7W@GEZG]GBPB9 ;"1A-M(\ID434Z-"HH5%0:9E'<\'FAX*0'D-7G]_]3FW MBIGSN]2[;Q:^'(IBNA3YG]UOJS/5W3_2]ABMTH+XHD9YTO_DN(X0/CZX@[ ?^ MQO1OS80]^=R;>W!]XTX14;&\H_W16[*K/8EK8HD@%&+^LUGZ6B'PAY*P,7:S M8^_]BJ*6N.D'C5<>1.E^K4P.E40<0%S4 ;')7+YKVJ.D LUK\ASC+&JQEIGG M !$;G%R_/7.]*JP*OLJ0("0@XLV GF%US0([QNG4@ 0BG1.Y)QL[93+#%#?7 MDG6=9IK25U]TL_0<(M@8AO(/9792;"/I4Q?MI)/B,(BM!X@+2:!H 3S&19H< M5$0U,N[7L5K[B76P+,%L)FA:_X>N<[:('@8=5'^ZE+_QL=:-41Y_9K9RQ-YF M@6$W0*U85-\ALM>W#&!E-TX"PK\*(M=@#C"A$^5S &/[6Q]PQG+2U%GG=T0? M?X'P(OHW)%]U7Q_'M^?. M&\RWZPE!\K8EGCLOOB8KZ=ZZ%K%FZ%F9_M_];T.+?LX[UF:WPP:W6L&'M_U_Y[G\\04]M^+?N M2(I>G@X5]O>.9)^H#^4H>RF+R5#Q13!H)MX@*;X5Q-L ;% .5*CL(O_B99Q> MJ[-#)?* RQ'Z=!9%2R<-SYTJ$]*P2'L>*)!:++D*?*+GE7@Q6_GT )FU:!-O M)-]U*WO*,OD6O. 7$-20Q/79J:#]XT3B&T;6!>\?*^F#R;:U'#-MR=,)G0U& M'-!:@\)'X 1@7Y!KT[Y?7,^8734 C=Y8Y6DD-+_+]_>^MX;E0;+0+D1@_&%8@L"LT87V3JLPT+6?;&1H-;$0P3-%=5:HJ+ MZ;*3 O%X-Q"#)#1X:RSLK&G&_UF'9)<*28P*2Q<<_\$)H_("G"YB(H?TUO0 MQ@ A(V->K\MA*983WM(=].C!"N7)EKU8<'TDN%Q-^/**:_P3-8]9Q! (J;XF M >//<GV)J@DEQ).G8-4_HO ^R6LZB6:2SCTH7A9AE?,WG7";WWV9>CEO?4%0+3- MTF2/Y'Q3H3C2?EBHJGY=EM;NZY3)_U5.2@:_$U%1,^ZXW"LK/1=)YK;+R1'M M),A^>E^3,N)^'8&PGJ"%0'YPU[(<%IS80!4%C_BF/7&%_]>CQI6I(JWB6/#F-$70J]NT^K?<4]-S\] M&9?\&(.5I/P!AI),!WFQ74Q*-'O#JM$HSQO;Z2 ":R_PV#;;6$RB87.1G6(. M61;(P7<,ZUSV7*Y<'O:OQD74<5!5?5Z'/Q)>W;]L.Q^,=< 7E4R=Z(_Z4RM= M3BU=:8;?][#5OY$9YM "7FR8E4FY\2I^:&3"C,87G#&*@%!F4%3 GCX:P< Z1(SXRG(:? M[-@W_.5\+2+);&4S/4D9Q"3Q5N\*,K^:DE;+I/5*94ZY.TM.K/5C"C)@)/K1 M<81O"G6*AX2S?[=*H\H7']/'?>(V&Q9IV\'F=;\:M_,IE^WB!VP2SO9L9.=()0R)W[R#CH^B%5;%=F D3S9)"[P/1+)WA44V6;< MGB%K6**;;G''BS#&1GUTHF&W< ZJ6\1"@4.FGI>?G4)-XEY1F.2]MWZY?(T^ MRFE*PDST*JOM(ZZ0CRHOG"&PXJH4R&+[ZX= M/^M*2,Z%YYMM]X*QI((._@E8G=?.9"PZO8O)28/9\1B%K0>%WLT_#P9=^NJF M43N+?3L@.TM!% 9<-O9:%,2^IO)B/E#QCB.LWOR1[N QG-8B[X]FK?UGK/HK M'O!>4&EF@]_02J"&'AK[GC1E_=K9Q/54C8*X@N\!YG@.!5ICX>V/Q-%U!ON^ M3"C!)AFGZ]Y7@.MUZX37J-DHOYFH 55W)V>GY &K,1ZOG &90/;-,+;^7%"2!7Z/:,H->?GEP'%[+8%;M!;R]P@1G MASIN[MWCJ* 9JRK5*LC']G58I'-[[C,]'N)!T&=58^A=-LNGS_J!VHY//(=C MYE"[R/L/]3Q,>SG<0 E+MN&_.Y?R.[2! M?/8KKZ9[+Q1F'5=Z+72-L;C"3E)NU"M1<_HD)\RS4 :3-)>\Z53^;%@WRIO- M(G-T0]Y"#*S&:EY(KN2HLZ5O&(S23KHJMH*/NZP3OK79B*2B/2'5?U MM&H"%'NJL#I'+W]!O/6SAQUY/K25_H3<-;#'RWV8=B_*$=[%G29V(; MXX.8TQPC0G$]?0/M).+]'5YVP.[H/BUIE#>:PLTG:^"@[AXRE)>1*\:_E(D< MZ3"?6W!#M4!:;]3.'[>9"_%7[X5>K>6/&&&SH)=WM-"^ %?_B+6:77A51T/L M]2H ;L\N97ZN'PT&=K<7$(SN)#<=.J2ONUYN8]._4:(20>!2QW(N6% M9OC7#LZZLG6K/P9Q;,3UW3H99'.1\5L/G!Z=E_%:RLGJ5[E("[]8>#CF)93: M>"-A]XNL&U5[%)$?:\R#Z&G*;\\UX^R&6N3VE>!-*/\*\%[+%RHO 1$M?W,, MY,PV8MW2CCZAH_/1B%4,MYBD'7($$(&G RI^K2.4/CVR3?C $3E=9VB^X8DV MQ>\LIJO<(N=M@6[=7?&J9UCSH(%R.Y?3-/%6?FKSZT5]O/#C'9B_%HKOJ[X1 M5-G6Q:OJ6=:"UMP=]])\( M]?:9((,SLW"U;(W+=S/E,["J]DK);>E:"R M?'!0/".;BTS7%?YZE#-P-N!BUZAFM3XG(Z- M]C"9=3MI>CMQSWU,A_O)O@T M8%>/3C8)=B=._4I3>^?[XVNNJ3P\4<)5_Z]_?OB7K_.Y?P-02P,$% @ M'()85 _&)!YD@ Y*P !8 !G,&YA,71F8WHU=3(P,# P,#4N:G!G[+L% M6!W-LC8Z!/=@P2TX)$!PEQ#US]GG^N^_YKYUS[W-G/?7,ZIJNZJJ9Z>JWNGN@L]!5X*6,A+0$ ,# Q@] M_P#H B &("$@("+ (R$B(B(C(Z&@X:*CH:*B$6+C8.*2$I&3D1*1D%!0,]-1 MO'Y#14)"S\WPAO4=!P<'.1VO( ^; #,[!]L?2F"0D9'14-$(T-$)V"A)*-G^ MEP_H3P +"<8.]CLLS&O@!18,+!8,M L@!P 8>)@_#^#O!\P+6#AX!$0D9!34 MYPIU+X$7,+"P+^!@X>'AX)ZO^CU?!^"PX+$IWXDBX"@;([YVQF7[')N%1/6^ MJ@-/9>R4FMW$)0 9Y14^ 2$1#2T=/0,C!R<7-P\OG]@'<0E)*6D9535U#4TM M;1U3,W,+2RMK&U%Q\=\2$I.^)Z=DY^3FY1<4%A57 MU]36U3V=W;/SN_N+RZOKF] MN__#+Q@ %N:OXW_J%]:S7R_@X&#A$/_P"^:%YQ\5L.#@*=\A8(LJ(QH[X[QF M^XR$^SXVJZH#F8I=Y13/Q&4,Y14UQQK-V1^N_>G9?\ZQ@/]#GOW#L7_S:QY M@X5Y?GBP6( P<'-/7PK"6M'3LAX;M*=+W%;*/4*,)#?,4Z/8H<&;'"D3E\%P MF2/&U& H_4*0V/3U!@DP,*H BO44^U[YQ J*25!A._F '\ M0'ZV!Z#_@PKSFAL"M$Q2O'+B/.:PP9_,['""$(M^TL&.YSWK_4,W([U#V;%< M-O)ZTH K289N\.Q&<9J;0+3@[HL_&V+DCPA]^W:SL2F%QRA*5B".55V)+TX1 M4)T*I#>G*"*$(T,'WN(JB\#_%Q..^ V(B#[B&,*A!'N0>09Z##"! N4;4$#4 M9I?IG\L+F(]::8TG-][W).JXR@9[YZ+BN$HP_XKT1T.>'SNB(Q1X 05^1SE- M+=Z"("(>SW&,Y0EIYI7PK>W,XZ@F/83_\DFY0)2'D$/90/I20CT8#/^TH9OK M4 !70K[>>UZF4X:0:6W/+H^&$L>M(CR*9U&>$^B__GL@O#CG8<9STZOAUV"8 M&ZF=.%.\\3IR>:19!O8VH1;6MW;@7(S/2=!MFC/$Y9W], MRV"1N<#)/J_^U*[<#_Q.%(@?68WHU,W$E^\.T-DD(77,#].ETRC;3*"C%9 MB!@@N*<8]5;RD_ :\\.;%8MS.(B$Q*,EP67^TNY, SD6Q627\"ZL5.)4_F*+ MU#@#+.&HB()S^+H#1SM^9G#U[6M,]*:F8"K,!9UM2K2JX#Z&Q)%M @(*4X&4 M5R6C$%0H\(FC]83E%A6"O+)_?UQBZ8Q+9!A:[1,9PZM5)H9>)]%\VWO2J]X(ZL8I 4'/BCU' M:UP/)3&G"-*6'/Z;'+YHK[NFGW@:G1WS6PV=L[7Q^;UXX[81[IOB;+A:'];. M"P1?7!_TRCC?)A5#@?&D7866=I:G.DA!H3Q%,#(-Q==P7=@V>*>],^IT[!G# MI,Z9LUU7>W0/?=0LTT\?*SWQEGI )"9@VUSKM[0?""VB/I'=EC,J8NQ'G:8J MC,%7/,H9AT^9A0P9H$@%M=EM?,+TD06!KQI7[E+JA1B:XG7K)CCEL3?D?2<] M:SV3J;'M@>KZB?-Z#.>^@^'WRRPMX)2]6D5,?1L/C6H.%;W2LQ[2F6"L$I(V M3,)5,R,29[Z.5>0CWV> *" M[L42\3+7FES575A3BXW8CD9* ;-T<"1*+_9U6O/!H-4HF>ZY'ZE*7Z,&Z[Z% MTL!+'8K"81WI: HQ@>.5P75C;DQ1RF\R!YO2+:1B#0GI4V-&?I+YP$QPQA;< M*JI5AOQ:_Q"M77;%>U(QSP5#Q9:;&S2"#).&(52721>T(C7-J2H0=GPH .S3GM7%7$ND>YO:NWJ[ M%O%&3_<#VH0S_)UF:QZKQ]1GT9=S+=J>!7N>GCYMG]W-ID^P5^7BJ ,DD;@J M!44% N#-,C$,K;D@Y%-NK62P%>Q-HBI>'";R72'CAE2J5SS\A.SS!"_UPTTFL>I7LFS??CP.V MP4=80HD-HB0\]ZNL&[;2J2L/,5Y?DKCZ+H91Q_6>>=M$@Q5/TD4:P/0QGSB M4,X\\KH("+H:FQM[C"\1-V6OQ.-4#."-J.',%/7]/%!:\1)6GFSA79>EC3+) MV-#BOOZ\^6L ?]"\7S4!T9HT]$"UV!X*Z/9"D!Y8%)_ $)@:VW5P=WM-P[0; M:CHS_\[Y4;YWSE?\#DH2ACN"3\Z3EI'3QWF%\WM$]CU9OO3A\\OLU#&1JYC; MML'CEU+E=7X"#8'NQ(HU,K2)OD_*Z:_=M^2,9"#&(WR?WNDK1G!H"XBM^1XQ M$VHPY(N8>)#3NU,F"/URTKZ+[9AC-Y8TMKA\W?P,LW2=>.H3* M1TGO]8J77C)00*+^-*^+Z,OU$6ZUHC/F5S;>V8[SKDM"6,(=W"773AS)=7KW M(H[45I5I78*CK7@D?X[M5T,NJH(?@SH#6JTZ.EO-:Z*F\J MV03S="3J+[%(%&>CEL]/+]0OC;;LV=^A6QJV0J33I0'EA6A\MDLT3C'#CP:.\T$2;/?%H-,.W>,^Y M'>MN"G*T<-B4)M26"0;LS7F,7&=F-U$J"JU3VE+7F11?6B?*^LN'5H-K+C1X M68E=FMD_Y@9(4<1FZ@Q6IVI,^M/H"T(R$N7%0.$U7/8XVLBGBU4,=E'DHT#7L=KO&ZAUQT\/&;>EHN@P.(A!'K"Q)B+=& M-NB/$,=5BZ3_"_3\/T@I+.#;L0^&GF?_G> B S)@]A6Q]1F8_=[MA?F6::KP MS(SF74].-TD@R>J$-_+(%-O[$-^-\[J?D8KW5[ 1-[FC#A 7+F%4K!V*@B!- M]UD^7&L[4AHWXC599 @%A .X_\LD1NKFAL1U7:^=L)TO#(F<3MK<;HM\D:L; MG&\!7&5Q %>5-H7)BCK#6X7>5.6$JE)=G21.>I=!>5QK6FI.GP!!0_7K,Y3] M@:@LC@O\G6!B2KT<1K4;@_=V6FI;@F0D72V=QGA4IQ1XJ&8#%<9:^,VS!;M^ MUW5W+XT(/)0415;W(8IH7<)6$N"5*>LNZ2[UF-5G,'QEI[1:9$4K@#/SA'LI MCBIB5ON',7^1"CN\RI"($IOTD5Q#8\#Q,G^$=4X*,BZ;-#&"!F(6G),X(/TW MJ->?'[Z,3)OQ(9Q^LJ;O$$\-0YKZ$A>X9ZCJB^NIEM@_:T0K+:#\O"M:\._P M(1YN@\;UN1C)1#?QR,)K32>TJ "G'U<\<*L^2G#_9,6?EF #_11^UE9 =C@] MD/WU*X(T[('L?PWHU4GDG%D#^S0TOE! 'ZG\J#1+;-.@=ARA0PS9<(93H:ZV[LN2H<#OW!(2YC4M M3SB5N4'.R0E];PVIJA_PFS'(Y )&& 6GG +'W(JZ1,TR\IQY]TR75Q;B?)SH MKXMVI?!:W6WA-STPJ(-2M!\+X@@&7O F\4/SFU%]2(2 M+LUP,#;H4,IBY)3FY6>&J>P/+*."9]M^J_;Q1&F[F%WW[:G-+ZLW2 ^LTYD4 MSY'$3M^DPQ-MO[$C:CW(,-Q6]8+M[1EWT? M\M 1B NEC'-O?E?2#/LYG"YT*9W-JRR;?;21#:9.JVA?Y,GZ0=]CXMZL12CU MH+7-XUWQTG"QF+DE6^);MBHC15A$$HW.-YY<#;&#-)$QN.)3]NN,2C$2/_M* M#Z# ';QUYK$P)$A:S<7:&Q+9I*04F7'O7T3X_*HYN,!["I%#@:^D[8_/FZ]JS!,P"%/C9?DFEIP4%UBH,+P3UG&"#6(#O%O MHAQBF].P2T$1Y -U-K5$?GFUPQRLC%)+4E! 0#VE.1K](4*,B+$XYD1_)38N M@^YW[C3U.(Y&#=\72W3'[:B[RU[7H^>(U_6%[Z33][:V,57I(C<,[VW(=T.[ M 0(T'Z.=/7V:G9!+/XF^.0-K#]<%?#9OE?=YGCAQL[TJTKR%G* C4BHQT;56 MYNFUHX&@:F9*U9?[A3ZPT(5M3I17'&>!EM M*M.4V75VJ_EKOG1<3Z?7U:;29&:NZO M^F:'DH)^]OFN=T3#./3+)6,N98$Q,GF8@>XQF-8&I).E6;)/AO(IWHYOQWYY MKW],?L'N_-4Y@KRV[M;DM1_AXE07:.=?X^TL M;4*WY&[E& H$X]2EMQF"[HB%:,Y(#(CK:Q)E92/RP[X';TJR$F1+D-JU55LK\%R'8WO1\@3NEM# ]LQB92YQA^)G77Z5+Q-[;/7P M;6>3L;;4IDS5M6/J6R=JJKQ17JP]Z\-:",*&YY7+8.\;A9LVOPGBE#TPQ"FU M)E$=+18#F9@YJ1B^-:'@8A-Y\\7UJH@S>$; V!0C?)FL>7S=>]UW(;7(A#X\ MFB3T^AVSM![L)WA4W8_MLI ?E^U#5=8@^[S;WA[/F[C0LK*CP\W847-D6ANK M%G-W8IW1HEN?"\4)ATVM[.9$K=DBUR\7+TE^4']>@8M<+]I?QFF=+A:QZ),S?."ZZB"*8SF9 MH1TJ"CRRVVS^@TU>^ZP)_=OBK2O;,OX/8Y93U-64#KDXU.]ZNLPHWMZDPI%@ M($C(Z]6<82_M7S?;)7)SS>#,IOZJ^81FQ*-2"B.P.?T&M<1+57M:(!W[0+UR MTB%JDTV[Q7@C]AN"),9@CR9EL,^X(%!Q]TI NE3<[SE,$5KWXY3L73.7;T8*W4,1M;=&Z2E77&:G:T[X4FRP9U[8L>-5%]Y.K6FR5)F>Q:.7P'K?=4UV#M8 M"48>U54\B-$A/-W65O/U>7[. D2)04(I8\7-O,DTT2*N/\TAE-$23&F58W Z M$E6NY($8!WE200G76=NRKB\/'Y*GD/HI'.YC95>/&*\'N[C9YJV;$^-_I!H% M#$ V99-O_'8G^0^5FA!C,WC6BQSHJGY[!78)SU9KS7>8TQP]/9:1UC7W504S MYGU/= WTR;PK:WB0@3.&ICY9:% M==DK5D+N-L4S!I[^GSS#\D<>]Z"?C#/5^J#5=+**#6)[Q@.-P,,:!0XP9OUB M,];G.(^"AZX7_@D&Y$2*U^F\)QS$8'ENE03C>G"<&ITK6OYMQT#PT:T92N<$ M1[JBSJUAV4J_ ['.&2Z;GK?NIY]F"]AFJP N1EM^LR*6M6;#O$$$>BWQ\H)2 M78KZ8HX-U8O>^!'!XC)+RZW;5O]U1W?WG5L:QY:1D*[FAX]BS>,*$>Q:>2UR MB)E(LVC1^0Y-%)^$#%K<2D%HMRD/LK\YN>M/GZ:N\A)S?&[8A2G1 M7G/J460LV#98M-/J->&3_DN:)*N/9Q-KYJP0K-Q\" 782M/*Q@_.WQK>5A.8 M3L3+U:2JMDQF7QR5K1LEQP!)'@YX$I+K3O":4.#+,JJ\L'JJ9F5C)7A\7;N@ M[DWU*XD^#0E$-&0XCPZ2]::%420#<<3@.L+:II/AQ._UW/5<-_YR);_2^SHF MW\&]%+4C.=,AL@BGJIDZ,3YUS1D& ICLQ9389-V2:1+.1PIY5\UN1ABW\HYV MH #L_:3R'HCEEG8INJ;0L&R2KR*DW([J58]Z_!'R:ZF"XF/53E__NO>=>G&# MOWSD1R+6#I(O>ZJU/]O.SO3)6:*9V:5A/$YKAKCI'OA9K-4.4ZF,76I4>6U6 MMS5KX^U0V[\K])P%1A1$>$G498?ING)^00A/#ZRXN?GLN&*A@$U9W1#*.=OG M4']K_"UJ\] 12=A6ENKBN]&+ M#$#4N]#*>#U6\2ANG+L/*YJQ;,^\UKZN=6--/(Q#.U&U[H(;S8J*\86L=IB[ MDVL^KWOL^?[;/,@&E6XUR)8\7"<:F1%KO3&1!$R;J!IPA>HAM5" 59_ER18B MWO31VML]5[YHX=8&(H^7;:%;]=H[BDQX&LFUL0*DYQH^=NLWVKF"F7GO_)S, MB>+%6SZ'=G(,R1^8Z+*T6?"-]=&GBB]KC?"MOJ8O])(<+60L7[6O'J"6,74T M"P8=^JM/M>8Z#Z1^GO_IPL:&N:8H/NS(,JFS!Q+^759R&Z,^00U.9$'3UYN= M1Q]?1/W^K?IS(OV7K4I!Y_'4HML15%XWJ])#9G=DSM 46?$0JQ$\W>TW(LK! M(XIR1)MUY!@KR_JVOVT,\),T)YGSO\T:CG+8V^/*"8D&VV49BC31M?.6/?&_ MG\QJ.56+FS_2YU:((ZYI5?RVS3.)T7)>$)NB/&7['/QN87T$!:" F)CBV4?' MIQ*R*K-[]9XDHE&7.*EJEF\_O^X/3G[,=1L1-_**[T[Y D&98LX_[7XDTN_^ MELV?&,?ECO:%24#D6'W3)W81I;7L5N-"=ZI%FAB3=D9Y/*LNV.5GS#N=]R[L M:>B#"ZT:4Q4MZL5>*AM@I*ZN1S94PRML1"P6#SP&!*.>T-KTM=DM35UY6)FQ\8WYL< MN1"KG]+@M(^JW6J.C\UH]2JOD J0U7_5LVR^\$;C+*?<-0#W!4^Y#"GCW$N=SYHXF@W1O'Z;T3M55-(QW%3CEOM\YDB[8K0I5[OC4?]7WNM%/NC('> M'MG/.T9\Y\%W0)K;3;G$3"#^#MVVB:M@ MO3V>0(2@_B$@%SE*@7M-B'6F4]T3'TY^AV5YENU/\]\X4 M=Y&#[^9$"=\CC[8J-9\.[F503)4[" @7V4PW?WGNU<&RJ!LX'PX!,[<+)5.J MYV']0FQ"T7#T\;.]:VY\S[7P[+1G_72#)KYF#6?M*Y0?N- 'BS@=C 5+PF&T6.21$;9-V',( MZLJ.Y82?_UKW+IB 7_O:5X/&1>./EL:PN<%+>*)J0 KJ$J(YO1JWPIG=J\>W M?W/D_>:]BIS"CR -QV\XT4V\)$86*;=)A9F_GLCW/?B"GNJ3"O0,EV5>US=$ M]E-E#"#(NZ)OV()UK:Y(93L]ZW4$@D#CRUISV1H\&G&L+B5]HWJ>>%7KZ80M M8FM^8C+2'U3TNM1)0V!"F#+M/J=LUWD_2J\K8LJN39\N7G-S.XM9\K$G6&WM+U&]( MTBV44+ XMY>DR:V3VO>F=.H;1VA!,C(=RO>._BNRNLSU$[3]\Z7YX;4KXO(R MC 3_;9$\"FHL%KJX=F[8S)3T]0ID!_ 8RZ';'HM][2S9M"P!LQPVP7=F%%9S MN"+E#HJ75I#V"GVAFUG#F:O;I\&F&N/UX!39 WDQ^91.Y9K H[=VXV\"I.XZ MJ2K@S%[ZO+0Z'0UC_B@+Y]F?,VJ=/XP41QRVI3^.$_T"0^2@_R#&IV^,@Y-. MK26PTU/'5MIB^K?@T5FB-WNN54^LK/5?:W?>*&>GO "+Y]^(00-[FH MBNY^L]^"2/W,] 7A!IO8U@#QD')D9:\2FS!?^M&/1*_M.()EK4Y&?GH:,7?@ M>@1>I?(4$I.GMZBW-Z^?EWM#?F 6@"Z^9'I_^YPFW/KOYX_V303C"\MP5JLV=.&!43ZF-&*1+ <)R"=^, MZ11&QI:>H.G?@0A;0H'U@ZSQ2[ @L6+TKU]4>+7>\T%S9_'Q@]@^F3K !>;+ MVP;YJ18?BC;9.3=,3.%D?ET=:0Y']]DF)1&MIX>98FV#!1LNI67MH?@%A<\; ML1AB#+OB3GPJ7A$=E?LZ\NW!YE,Y&<>V$;J-=&'*CSU+89XOU2)7TTC"]UIP MLO6\7#ON/1(\SNJZ&'L468Z#+2TI?-%G'^EC.I\<;A#/0+INZ,+=B9X>]Y,U M/==E.8[7A:5X8VC.(']).A1> M\K!N5R'^L?*ML^&$X(PU^T=%[(5]>@PD*0)>4#>R8I?Z,SJ_%<\_$XP&DX7. M=W_S )EF#!#'T$K]M!_8NZ!WR,4;IJD&32<]+@7?V-Y#$@O$\[UJ5^;W;;EB M?1V+K3\11_'@>F-(J&4AVB(0=HS:A"B>N6\<>*08U*P=I-/*;KE:4XV2E% J M-Q;-^FOT\I2["*/MT_W2N=@5(G/$W->T"0-LSR^&B;Y*6?1CQ7'#!*ZDJ=NS M_ZK.)/#R5)OX2,H<8VM.G6F7LKW.E3SX80 3H_L;V5W_J$Q>$\O:PTA<9^_* MO"9^%$*8%\>3D/9Z6YNGN%2D;TVMI>L.[(\-IQ(#LC-]")@3W+\&7I 7.J;B MK-N0)RYA46YA&,#&A$V)^-6LD)?KY:L5O-[#U90".?8RBA-?8 3')5/QP)E6 M*,ILM_!FV3AY-<@W30AP>J^!>;I"5,-.U(^V:?S5HUF[_(X]@=J<\:>DK<*M MZ:6Y?;7_."?X+T@>?^G1*ON/*681S')0-Q0X1XZ @&.>X$M^_'/13OC,Q&6C M?6EGU_E9OV]!/[R\MCDZH@H%>4T%%85W4>:.6OG;_+IO MW0+RQ-%#C+A9@CA-)04JF2T3AI2G!M*P"DH,%U]SS-P0Q].M/TX7O;&@WPI6 MXNZYZ^@5ZU;/3@TW*XY3V$MRX&2P#.!YQ;,>3;="$(G5<%4477NX;FIKYQ#R MV##OFJEG27A3.L#HE^:+=[1O<,,LE,<1I]^D=>'&>HL8[=K+(59(<"A?FG@F MDQI!^7$+F6 #H:0#+HD]E[5\CV1-0F1T1S,ZL B0JD>/'GQ=]?@YC\62E"RH M8R9U.]QQRP5L@Y-LOZ6"=?3[-1YI2)DVWV# N)BU/=HQ$OOKM(L9DE6B87,S MD](\+9*7DJ_CBB8B=M^7J0A*0Z8HJQ]H\0-G-4C*$XX CFYLI>UU#273D25]?K0IR'_(VUG MWZNX1E]@^O1]Q_M?2"J(='0"D[A*67B5,J5;.<;BN.K)0?]KTW"X?VP7^,8$@T5 M%+?Q,AUUVRJ+H'_0&E/&9:2'44,#&";_K]MT0:!!]JJN>N:8L\C1L<*16B.: MW9/>O.']0K@$0$#8JY>!R D6QW6K=&_\=]/]_UF"X?AC426T[61#'!!J@@+X M4*"/EN7^6/CR57G /Y?+*J% =]A@-!3PS,SJ5A;'.\ZDMK%][ATX4*!>&0KL MOLXHG3$@_3HDR]DR0&4Z@UA8H+]DC5^#G/?@TM:M@J5*@N8SI0N^W?S\UM[D MG2Z50P>OI:.*;0I#8P_7[%%J>-K.<$Y;1OM6DU".M;$EOXZ$I7=U.SM6$"*) MV^9ZCKT0S0SD)^%C!0^M"[?I>:$[<6WS9&Y3**L&Q:?.# *H/R&_)X0KDU2 M,6]D2T0;@R= ;!KQ+CCI8?)KQQ(VY^UGHDYYJ&O?U0SOF::G:VZV1F-@".=X M#\M[(QA,GSC>(\^LNV"1K$VM]JX)D?"FET/<%[7#&7V2K:YDR$PSAC@V9J_O M2+5ONK.S)L)J4XV]$).!.&UUIR"/=C.C8>E5CGR!K<[H]',JIM]F+H\*$?-H M/X$",OF'_2Z'D>J!<4@\5"FI\DVR@A*H8;"X4=7OHVW&_/"'V.S;ON[P8TPA MGB&4U1?XNK&&J^39YIY Q$M*)*;H)H@I+9HB;J*BP:"(@W#AJO4T:1*-I-/F M(K-$\SM=TA@2BZ(H$\4CJ0J!.N27L[$8G_E,,M_V9&!+AOON6"":V8F@^(UX MES;9,%'E9$2FQL^TIU0_+CWVFTZ4J2H&>!N#O\ODI4B]"WVJBF[7R4TLO->; M@T^MZ63+(DR"R MBRC@7V>;<3)SQ>X_F"#(!4JZNZ%KK)NPHW[5(&P5YX3X_:P2!OD0AF2R?>Y5 MCIJM(Y\BM>Y=FR7A"/O>>$YC4Q4XP:(U8(^YDKO4:_[1R7O3HG0?/W;!YKPF MB[@,SA<_/;=")F+4WM'")N&M;@.C[?$%?6MKY#7.L V=9,.\5.QG#.1>XX[2 M^3I'EUAM@_<=$7+%N-&!:)B<<4*-(,VN4K)?]R<:_)^>^+>[Q_7]R+ MVI9:L+44EHDKT@>5/S(-AH,%[_J[]7&>BEE4[Y2O"UL5M]2LR@13WEU7L_C] M>U[.W(__$E99E]W/%]Y7>)0\<*MI'GC)&F7'?%29647?WE8Y%?D19,YSK:X> M0X$V:^':LB?=\_SE.>\?_01W#S$Z_;M.ME*J7Q+&@F2FK,'LI@\R*U/MC'^K M5NK#^!0I!ZE3FH6,-UPY#L0<,8$T'DO(P@4CQ0[4T?]6+/S;M:K=G-DNH?^; MJZ8U!X%9];LLF_ BQ%E,7]Y/CD2EVKSJX"'\N6_+/"%P/ ^2H#?*& BPL4N!EVF52^ MTC%^RM'MVP?]Q2/_NPE-2AW!:@&"XF_)U?/)YSE;H@L>? 8?1J' Q[&_;+!- MS&\)(U0Z+M8[4E)XQO:R?S3UOB%VZG_:E.I]&2MDK&S37?@_.EF'ZZ?Q'60U M?6Y/55TDTFY*Y<)URH1$ZXUM:;=-*%>JPTMM+<^*LX7]-;;A5?0JYZ MG5?"S^EU^/Y&+&V4650@$UH 4W@9G?P=608Q#M'8!:DXKH:DE++2TI*XN?7; MH5ZL'G!,>\-T2_/YO>]!OX.Y:[/$",PJQD\_IAS,X 3;!5D2K2$[UGY]_9JI MW0K*"_*'H[NQ;>&;A8ORS,,]T+O.ISK,39#WP:0F[)J\WKP-N7GR:+R3$YO_ MP?7CO;_ZBB:I#5L>LX:/EYZ<,^[=^C-\,W/[VT"I05NU,UJZE^B\K*L0OJ.0Y9IEV&_OYTIS5%07M\] J";39L#-\!.FT3CP\PIG MEGDIS5:74ZKL=S*M%*O'U1R7%SD".)'')"3D><2?\\3-R%^*C"VD^MJF)I>C M!?!0H1 C+6B'O0& ^XSUTKWF7)V41;M@+X-E0]H/R2*4E9@FKI.N(OB%Y99Z M9S"0KLGE\>G+;A(7"1:3>3R]%SQW#49DW##AK4*MI#5R)=;NSJ35@:X*]@I+SO3XE[ M1T;Q@RE'[^^LEC U%D7HXF!@3SE@*L1=K^<;YC!^6%P<4]N+9S4$86R;5BE, M]0,8!7' =GY\5_UO428]G:5.#A5)XH5O&O',3KGVU"\5LPZM=A&F\*+H0M?J MH[O0,S66*"^(?&(-8D>9?7'KA89 MMVN/CZG ]-7_68S^=QCUJLP=-973+*@W$0IX$XHQ/*+33#UU;X^Q1Q7=**LQ MQOQ4MV'TIO)=4'G*O?-V_/$,<#[\)4J$6K;"2,]&58W&U&(SU!Z&)R%-IDTD M35!3U6_BS3'/J$9%JL*L3D=CS1^$JZPF\A^ *.<_X]3N& C1<_[./C4@'/TD MK&8]Q51QM1*D7ZQI>-".W4>C+?57:,D:[/;+Y;4OR;!G8 M<>%]3@R_!QL)/[E5%-*X9F4W7A36UARX+.DLBQ.U%KX4 ).Z.']52G,=14R9 MGCBI8W@4+=)51'L]C9V*,AC7I!?-%;E301?CP\R-8Q.^0SVQ.OFH"2(=2X]C MLI)A5#@+HFY3')#\40P%K&T96-P.PAR8L^J;ZUZ"Y3Z$4QN?UV#H(F;X! :^ M-QYP=],4)@^;7#$0YV#M1J_XKD<Q39-B_M:$HW1%+>)1U' MBU! _+_I(S)QT1=?XV-Z&L,/??VNHX9A2D?C.L*NP1#Z![RO(WE"E_0U MWPZD-MTY%K0A:K!_YQA;[?Q[DF/]+C;;QC9.@DXL4-QF_U5QGX4*7H@A"-)J MKOF!.K?<62U_;V"(/KM:0)ZI<^TAF8J95,;4N.-A(X_KL/R#^E*4#U-:Z^0Q M7?NX*1?^=/B,J:N,$A-Z5._ )A2X+^:8? ;"<)4-AK2V16/3MG&R>"P9,G&( MA 3W*MN&,X./@YL>D.< W[>W6RIHJ8NUEU0@U]B0>+XD[8X=V1N-W(/)>VBC M.7G2-D::QL7:NI.P/4"T&CKF^OG"OI\.L8ZD3R]ZAG.W%&SOWZ-EPHTC:EAN4QP_#JU&L2W@: ^4K$G+?9$N >.ZU@/_G@R":C M3\3M.BKKE4'RO$'FIKR56H<[X,\Y\2.#&T-PK_2,8 _EW=4F&O.(G[N5W-MRUC;E.^-A$SBP=,!#6/5]@ZJ'0^8D>&$.UU5O*UYEND%2T%C M,:[: */,4*."VM8PZ<@^+[;5M-0L6V7?ZW2]C*3"?DM6.?RP47J^G4E-L:(E MP<1D9U=<\V6.-_CD1=>DBN,M [5Z- X[[6(X1)4N1TT#7KWJ%P7Z?+1WK_GS MJ, >Y"%7U^4::O.&'TWQW-@@<_/Z4/"4LG9XZ1H#)B@@2&D.D;S7 MX,JA2R]:&GRZ2V]GLY90N1YAL<7G$37.X6C=GM-II>MLKKC._YZWP(WU,>[A MGKSW;KMEONZ1TYLSOPXI3+:T2V*7/W#E]$![@[[XV\D4L7ECDD1UQ+P.*':/ M0\.AHK@_KV.;-M/5_:OB<1(E:%E0!-%\Y0Z_'2T MY#D>D,^K@'YSW4#N#"&,,4<,PKO$OL_XJP *X(G@'["H3#@<5Y2>O#E>"[ U M.@C[P5:" %OIWJNH4P>_,[ZLL=3"I\\B^,!O*"+]/%@\+O]Q@CWP)J$ M'YL5+$,M,C-5:]SUPVA+4X.M^3?Q.DJ)?3PVW]6T. 5$3L[I9,_K$MT2XL+L M% (=A(LLYM("ZQ%8M)=JGB78!SYJ3*BR17/90]P?=-R)>PMW8A6:IMP.Z.;< M0;:P)!^KAXJ]]R9_(Z#-@ZYQB7S1WW]H^B*3:6W+E7*XJ) G%_^;E^<-%9D\Y%ZGVH?H6KD1:1&^G*>L='+98.%A3"AG51Z M_16YE()\F^J5-W:_5C#?[,728F -%*GO>,+&Q\;T?$$K<%X[V)DXO@3;R]#; M,:-]L5BL#26)4R/]B17G:TGB.^'P2!^WLJCW@>,:GYH0?>IK\M@GU&_4T3\P M,"2\KTL\R2AJN342K[D3D["E72@3L$4.P\6PG3 17Y=+EEK'#;]YM\\50TU1 M&UK#0(^H(N'5ZX/OY)M \YLJ7J>^7=M#'+O\P2G0+O+3%T=[< S!Y66QXAH/ M9(6C*C_M]^B[Y*%K)NIBZ4%X%^< /]$>6YG1+C[UJR])E2L+=UC8U!8)(@I2 M=TT;/!O3Y0OZNLL_Z>HR&-8=8G""56_#@8$D4;]1#OSW_+%>#FL>,8RY^;]R M+;]*^$:W3:67['E*(\X7M*CZN7K;!$AES\E/61O8,ZAJH/1D*5##=ME3PS=B;/H9-#\V7N;ZFX MK@W&W9\EF$KBKV!3XW\QPI=TV5DD,DD=Z2W/A:D'H"$H-^()9+"YWFKD)7ZM MUW0>B?XNJ^Q8]1J)Q^X8<.*[?%&[^X,,_-WC'O=:/J^N==%LKN>T/1E+R.2= MBG/PZF/.=,/?HRGM'ULAE?_ 8S\09X37GZ$.W'.0UN^%!$S]UOSG@TYF*NXQRY4?/O?L;GYFXUD]%'?2I^B3[G([VLZAI58752 M5R]&MW/?(A$2.TG1G:VJ%]/#4S@24)VUYUI09HFRM09)@8-G^>A M3_&,2.WWF_'1P[5\ZI$D;)G1IDUW(U$3GTO8O0F\(O%7I',Q+"'93:TX^LMZ MBUU!0T[2#3:.<%A?P:$=/'#C="%)AS&6SH4&>O/?'VO#)92W/HG"O?P1Q\HJ MS5DC_DK4PV)N%PI8MN![XC?@QV<3;%C71X4[I\$#9JMF&5Z%%*+S,*,P:FCW\2EE MZTSD1[X1Q.0U0^^':.*<6"/(D,Q'73HC?:>?<+6821'^&)&?;]ZF1&Q]&5 ' M]\=)_P6_5Q@=X$[[B:HA-,X)4<7V]?Y>N>$8HJA2?.%CQ+<$/,]&?7W.P7N* M7<967$T9:2:J8!473V/UBL.<2;OE:0MW28JX+[ =B/?J*0QA_'CEI3G@N+E- M2X1E949[JO@ WNO-*>[?Z^<_M)@M@U;3=Z3QK7E=%D*H".YB;*:R$[[>)1M< MC_,_$);1O,%6H^]6I!+L5O4CG,M.=B?^!O[PKNY7L?D,;P>QQ]E"^&1V!(6* M59FI^:M,F_K38T9DDQ&7H:[-.#_I8N?=8-1D\T#5MC":[T.G%4F5<=[[R;T; M.K7*9LP6YO.[*Z:Q'S1GWD\15.N:>S#[6A*'[N3;\#MBBCG2%'%[LHG;#!D% MU1\IB<*1,"LB-D'JJL1)"C\>=AMB?'A%$'4U5]>08!Z,/EB'DO8YO8EJ-F4^ M.QR[,M71*3N<(93AK.=""@M!.IMGV?H%13]G>1A&IMW((0*"=HQ/V&B2>%,= MH]Y]*S:R2B>IYQ970I0U?9-+XC=:WQY(GQ5:5 M,JNQK9N\IN'P;E?(<4:L8>ASDC+NE'Q?-SE]VH%7I9ZR;1Y$&OS>DCK-K.],=V48ACW0XC#3'E\T#7O^U%_*TH;;;U(6;6E^Y:5/EM@M6+BI M_SK%=(WO.$1'+NYG+GUK6A];-@_S>@CLF]EZT^Q/6%PYMR(K5%BY6/I.UDD, M,<09UN:\@.IJ6%^><[6E(7%>32OGDVXUWRL:23F22/*1.!I%T]T0?*G)M,Q(\L7=,PI6>"F!IF8J:#1HUEYVQ- MX*=?S<@WI&>U-(5-FMA)-H7QP!*'"(MJ.-29U21HV%IWF16R/8(E_!K,KG: M*;4QARQ;8>9K[/JJHP^)BY5+2XW.(SS7^?JW_K)%Y02C"'3F+D<(>[B13@4" M+*2"P_C)&KG+%1>D7&4,]@H,1HT!3.9]*:Q!W^Q'O$W[CWJGRX:+2]D%WBWH M+=;*$*EB5_3'9KA(*/#^'!9WSQUV?GNJ^T7*D0IEM4>6 98045"P:'SO1MI5 MX#E&=S$#%Q]B'3M@B9-B1][-"-+?S%SMLRR!01W/F#D LZRS565Y>7VS]K7S M%GQ/9X8WU42!3COMDMG M%_S"?RW/^$,!6D[YV1ZG=VGJO:E%:7="_2;A],7L*$JHK.IP<4[ B0C\=\8 M:1[ LSQ59CRH."P?&)*$?;G82ELL3]M#5*_H4M MOY_4H*_S&Z2J])A7KN 8T;V4',_-IVI03975QY[S_GU- ?\$=+S?6=:N) HY M3DKU'?I)@6YEA?/?2@;-C4>-%Z& XDA3&9.BGZIR]!P;;AH84'9-V/OO*.\ZH5)OW];--*:3^/&.N#B^^81XXG[ MKI]8G%!_5]>!!(&"[ N9Z[#=)#Z^\@(N!FER/PJ6+$Y,'D>J#W*_N'[:2 E" MF0]MN*#0/K'WD4PO&B;*9\JWL0QT/)OD253QDU-@P=?NOC,94:6QJ:T1W?!*^EKV,Q*W\ZG_*FHG;?F6GCNQ>YF7"G MG; WT;7]OOSK;MN8,#0Y(6(U_["(RDF8E3S=;EXL85TNA[R.?[CQ<44,6A6>D^GH/XHC/R\/#-<8[IG=8"RC8KN\ M?EU;6.#T[S\"^N^#:8KU_K.!F#]UZ' H'Q'XXBV._-F VM]TC&7'6'7.EF_[=%*Q$DO=O"Y_ M_8;A)]U,M+RTN&R\>0\*K?A84Q/HB@V.%&%"'3(L_'@6#[GC;!>W*M'6ID(V M_I:^P"KT=RZ'7PKH;H/NZ=S6/]Q_Z1I_BFKQYP,'%+CH47S8'+NVA@([D9DW M_67W]-5BZT*+UR**,%R1A0)D-:4R_NJS(/83 M?4$\COUS(5O])%W,(ZJ^]-CNIX +B)_%#_\; *14(HHW=7J9!;SGEER6=YX1K*QZ%UR#^$8BH-0*.E*S<=Y>/A0DW,'4_)F-N6 M^'\)DE& M?SK/],\CTU1V^%;:XM+8G$@\EW& MDVC9/N,:K^@R>2Y&&L0BCHZ:L+:.@<+C[ MA0KIO%O[&4U+_?CC\[/2ARO/UFJMS7?U.W>?$,E96JV4U0E=P+$\KB6$KKH$ M.DA=Y\<9'P?6ZA/O%$G<=AD9,CA]$S+VM7)C0G&E)"00D,B[I*^&[<:-L)%A MHQ-L*EP9E/2%*PYZ1(G0/#9W3==<,L1N0^NR#MQ3P',1D1*CA8]2/U:TKCS>F*^W951LHW MX]J];SNK:Q6Z>C8=.PAV I_SGXB/E?)T\U3?&L48J#\']HWZ)Y>EA%O-2\V9 MQ@^:]IPV\>060P%#M@QRV1,H@.YX2_T*N^YWW(&KMPL7E>J<)*AKNTB1B6#% MKT^$F<3>6\[X$RDW1D(9KBP< S8:(P#/\TD""3HM@$YYTFR56OY+#\V^T^B[""UZ#:3R7@[85&_^]E']%V8*GRF!%N+:P\QV'_.(B!1M2KB+KCKYSMRM$0"V@I* MIED*W\GJ2CZGK5I.1SXK$:KE*RH++I3FOW!OK%46-W$+^D]\[I?KK9^MC*I22ORN:5C^_O@W*K# 0/@EYJW$9>;=Y7/$CX%P@'YQ MYT*!T0+(!]!9A>S!Y8/PP;87: [OH:+W,48XNQ46@M5*!_$3/J>" E'DIU%[ MPA=[4""6_-'J_DEH]/XNY%K<_^ ,"E"-[E:(0($OCM+/?4'Q,10*;$@^4ODH M/MZ#-B6A )%0NV(-I,WX*=:P^1'4=W'/]%MXC7@X)[DYP=[?@P=T)[N[62 ))8P&"NSN$X.X0@@5MW-W=Z7Y\]]YY M<[^9N7/GK;?>6F_6FC_.Z=6GJO>IJG-J[]]O5_7>"2]S//O^#10P$%L]=00% M5*< +71..LDOA"'_2:/S_]IF\O_&3?[SHG_QGYND4WFT5A_R(5RDILJ%4YG3 M?:7YG#]%*X)9>00#H8@L/V-A82&@+7Q"X]Y^7S:I([''KP]'$Z+_H+9=70B0 MD%9Y^2#3?U"%^Y^+_^TOTORQ$RH#H!8B#6#!T1':%,.! GJH\WN!-V+U]\FO M2+.T>LT&W'I1G/;Y$'SO M9\75>R$H8&$/,MX'!;!M=(Z(=D9 G+M?IM6AATX\L.?%"I7Z0P%TP$5# IQ>+IGX+488";EK$:L_%AN^J+S&KUZ& M]#/@EM_R/V[ZQ'/V%XA)/S E$(CYM!KV,I]G]ZII_HW =6_@=#L4D-#Y7!5[ M]*1R 6%ZZCV\ ^X\D=^3-4K[TOV]/"@ M152>/J4"04<>P"M-X#)YR8[Y"8O M] M_:1S'_&/!KU:XFRV$PI QHPX]C2I#

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¯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�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�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횫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�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

X2%XDHVUV;)>H$<6&[8Z:[X".HJ4,(YQS]F)EI$Q7SOV6OYG "-K_7M$,N8!L V\J!)WY)0[3>%U? M)"6,1M]FN_LI=6]I=%G_\DG'W]E(+O^H--R>=,R+,N/:Q&E$\L5WV^+[,R5C;!; M%7PZ>X?.AX=Q^IL1A=68%N);")R.DQPH1U>"R'JF0L/B:QD9M%XY0F] ;ESH M=.YKY'0J[DI;Q7<(4P-+;^4=@]5P-I@+%CM50O&-9N9ND.3M@0T;K=9 MN;4FSV_4NE)_S7([Y[-E*=3?)\$PQCM8ZFOB]5B>XE(5#\G]%X-R=0K6_1MR MZ?<:>TS[Y5G]G5W+B$2_HH+UM9RK_)_&K+\B.8K;H\V27CXY$E#^<>J3MWUX M[%'N,+W;25#SEP,+(KC/'KIG)2>&]L:>9@MG_9@--M&UMG8-G-S?!BO#I]+! MV)O($2I 87' VN[.@+_$:#G+MO(>/M33BCI,,JCH;Q%D07_5-!DU*[U3JOYF M-[0SG'S/-.F\7OYYQBW9*2I XK)N@W'1M/5ZA0I@C4"COE,9\=@+.]"N0IEI MH^91 _OU,E?VA\X>WS)%]M+/5)9]&ER]YG1PIG/4-3N6\0;WR7TV_$5:=Q$_ M6;P(N8XB!QN>9*Z76L$8A5*DLDGL0>S]A:E=3? Z#$QDOA"\NLU1&L&9W4_^RHF M+L9+X.BU >E:L,B8BCV7SP'1@8+['G-A>14V-2FRADI>Q8:1SM/%QR)S38(Z M1W<"=$5&I+V!L80]S-0#,L!?&A MA_\DVG?M44E)>P-F.O/EJ5OW[K6X0>?BAO4IK&O8.=342ULU I%XY6&O%?1-U, MM.'=8I0.:#%9K7?IUYF*[IRJ3EN-5_\N?'_\BQ+RJXT*A767 MYE">@V5$@5_>?GMRP^_)KL& \YWZXIK0&[5^+@7K0I9W,T2/;R8T=RX&/F$J M:J(<7:5E9)Q$[V;%7S;)7<3R(C''I1T]=( A?ULY[ >/UD MA>43\MHB5NF(GV\_87*1_7QI(TW^O9\5-[^\_]02.CT@:0 I$3]WXZ62R5SR M4%(2T=NY6-WATLM47>FHA?[^?0<:P\/F4XZ&XHQ"8&?]+*8K21QB- H02I1Q MRI"JK^CWZGEV%M_55"I?G.>,>>*Z!$RC>GLX-K2 >P.!.FK#5$-M/QC&V M(9Y.!,;_>]?>43BKP])%E<)7KO30_75Z=3_'7 M"NL6S@CR*5(\:(%V19(*C-1#"*(YY4XSH\A#7;A(^#/;0U0@3/_@RVH[/XQU MV="Q%6@.ZSWT6H[(X_&\/'+WMU=\'B'X4N*,%\T@8>AJ;P3F@=2IBL_>9VY-2IX[)7[04$+2N-&L MZ2XN/O>GJV6TZ7"KV0B\P=NJW+YC']3H4^@VO(E->X M[4FL6]M:&%'/+ZZE.H7$GD)A+J4E@AC&J910>?TT!T)^_L.+2U$SUE QKV3H MD;,-Q\HJTNV0CFP M89#3VUL:L^#'MN>K%;B6^!GR)Q8#GB;C(XPK#_*7,/EJ91[0O?"9K("%-$** M>T@G[/!W"9Y8L"DA?6HR#'14E3/GMN72Q&E"1.%2M?2[&7&A9&A:S%7CFI1. M9SV2T-ZCY1)PRHF/9ULE]T+)+^7/TM;]'0+K1@5B:-%AF HT85Y"2L6:I/@, ML!O1,!E+IY@L1_7S0V7IPDZ[V5-/OGJ GKX1D5J[&7+C="V>[L9LB->>#J7U44%%7@%S?QR_O M4&:@>ZDT!Z M14-0[54:T9DD;$R#'L.9U%END5S14D&"JKXX#TMOIW-Q3^18 MHVK\5G/L']M_=84*=:F6,&S:2_)9; ?.NIYTLF7 PI^3G(K&6APR"=97!G;6 MM.8?,/.;I]J_J?0HO7#J<(&UMI!PB)(\20_>($FA!Q$D=M?NTKS0@EQ,.>?T M'$E@;:4#U)A:%&NRE9.$,[ES4GUUJRS5H_1O>[IJ"@A/D!,&4#KB M:5B?.A>YD HXR(2!R[B>UO<(IN'X&JM]RM5B:F?FY-)-'(\M6^E?5R<.CZ4\ M*P9*PNX=@BXI4ZZ!IX9[XF!G")X?8 -@K(%,9&IT_JSK"&I&M [\M+"\N9XX>^=[B[N\L6W&A@ M.-NG+U>BQ,QOK%6PJ7+L0Z3E,R!UOG6:4O@\3T_!#24OAI)7(G[W75DOJ[O) M#Y&[220'(-1A@_"RGB;7$;8IB[AZM2#3P<*R'E8"GV;-P/6;M[49]LM);C6W MEDZJ=-^OJ4\W/SMX]1CS(S?9/3A-D28TM580XB@L5=,RL3"Y(?632U3@B!PJ M?$(5?I3@P:=FO"/N[2QX4PAC:^MZS5&:EXY/V8XN"M !$.T(#!5HRZ!9Y)-E MV CB.,H!'A903D:M'B&R+]F>'E*7])LU2#;MA4D$Z?=*B2;)Y;,.^S1]/W6!;FWN00\LEW)$M/^:D9+[15G3_JZOK_,C MA%FX'..8Q5NLW(>YX<@D3AQTV" ?-=:8E7+.RG!L,[;$R#35ZG;&@_D$PB.* ML_7FZ+XV7@J2!,*:N8Z"\>_)T3 >/_:6R9*-U5XX49^0TIPABM!!JZKK$M@D6G@YX?O1Q'XN\]?)S641PFRSWUF+FV MK][^R:G90Z[51 7IP#4A50=%[ET$X=3U8S1ZRY!#3GJ]-O6 !MSF6_/G6VF) M\8RAI!EF"'CR2S.T^?\<:[K?,_Y_7.N<\X_7-=08^7Y]&7Y6WRV MMO^GZ@SJKO;SODC![*WQI>DYV?Q4],CN>B+C7N0!UB6 M=)Q] 2'7 3N!4P TVF?5J&E)C_L*5&\-AT:I#Z^*4VJ*?"=?]? C?-+"@/N) MV=>F#Y[0Y*6!2'C8(^\F>*J1H*4!T ,H)3ZNI+DSI2F*9;7^!L='K[WIK^A MPGCA)C;?>/F!&6\#M^./HEV[,_*IGQF&ZCKQITNX9)TP\3$59(GT@HOU(Y:! M(^.:*>,#_8$UHIFNUMM*)>L9MJ4S4$ET(TB]90'5[M1]R!W8% ?=CI7;HDW- M,Z?A7C.,5[-U)+")&COQM9^_"VS:N8E$!-QX[B[DT.(=;RO,('@_#*RBJ"=1 M='6^V]P,J>\7N.9\B>HFS+P!6MU.VLI" XK.K.2GNFST,+X!+LN^&QURFW(SE=\5_+8F=,Y$0%PAVT7J>:K>D,O,#U VID/* M*VD.;&X6PQ&10+<"'1<0Z4=#/Z_9T-H40)3V&/*7KF9G/!&]^'3-?\C#]G#L MB8__7!"[=RK3X/:VZ_<2E9URN]34XH7## \0:Q7>YWV$_S:ZP*I'S2U >0"E M!?5*A@9XI%#<002:/@S,%-D:O9E7,V^WUL9',W4KBN,/';_X_)Q-TW3C<*5" M6]7XB_3RM.5#2C^M09-"P%2K9N7#NSL&B65LSNA*+*'^C;JV00'7>)3LC>'? M"7]*/[F]+\;YE38\?_,L(JKFANKQ\\*[$TQ)1P8_TQ XPH PH<#">^#^.&.A MC,+)*EQ 2R.F'!M3UUP^-:!O?+:6&.Y=7=+YU-@8()PZ'R+UYG.N\?I#??8+ MPRMDEFBGJWH9F<3OE^W:E5CEXKZREYWWWLTTU"_<+YR;8&C??M'P@82^V$%G M%9N;,0N7*?Z6ZL.9^JXIVA%;D_[5CP0RTS,R MG.L6+5P>K&]6;D]M& FS8D"R](YT$#57A#ZH +0R#/V7K)T&A@,NH0@7Z5/6 M$6V>2B*#BRM-8^4=B8&!;>\\Q(;NI:G5AS,_L5Z#EWZ6@=*@3"'=;O1?X>@P M5Y-"Y>C>0Q8]*8O4H3DV-NX^U4@MC3%C\+Z67Q$ZH^U[CGX]^6J M+6N&'6>:DJM/7 G7JK5X<#A'EW@S.+TVOX5JER-%4;S2 ]01SY6(=\1:"VV)4T2V"4V.QT2(6 M=HU1VH3-Z]/)[M*7S28BG[+>XN?(&@FN)*: J!NK GEJU?6>;#VF;4:<+8'( M^Z)I+?3T;3/-Z!CJX^,H_SZKKP7KH0:=@E8RW-SO%9WF'>W:P6AN15%MT"\N M+E4OV *J')0\[Y!*Y'=\?6E9!2*-W/AZ_FI BA5AEFNT1KQJIYS<9$\,*WH_ MA7HWY:)22202N\_=65)?M.*04NEP[C:Q%'A<;I<1,#6Q$N#2%/QR&7ZI^M=4 MUI^;3U=)6QBH[D>C?G#7/>"B;FQMD'#B#K)[C:"Q<]T)1J1G6VMF]K M=QP!8R>#?:IE)%35*H(A^4E;LBM^=6!5X>WLO!+GMY"K*Z=U0V\'.+!YN4"Q MZ )"^L( ].=:I.E$&3,QVR.DRZC%>2> >B)*+)(+T+R78\'!%H8]TY6F6VH: MJI8<^A[]"A%XH=D ]V#\]5^UJ.8'JL5R3T2V(AKIVU&GQS1I[HD&!?5N$7EQU)N_IUOXVSWD]Q^DR<>AH>(K1I4A%*@>A MVI;^C*:1HA5A^SP7]KP[I826''Z^OW0:"+,ZA8(_\3KC[584<I9\UK4=OJ!\GO#?]@H5FL-PH?IDX:9-U<$"NO-N%VX(GOJGC49EQZ:JC: M1MU1,,:B*3.311%)&[8P,H<73 #T8?9!5HKTINO8W M[P'%\ Y>L 8>;!&NG":BDY[BRA5S9Y4::\-$XTT,J2$'^FO4D33O0$_JH\KD#:'B@59.9.# M/%2RDCN8JIUBN MP>#4)ON$' U#:6 H %[V'UA9;/$5;)-YLI'JI-^R!74P&4,ITAFY94:[J]J, MX;^^]O #W_774RW)B&KAL^J*V:K_R43[_V1B3G[AO2*'@BU+1U2VLA;1ZHZG M1==6,]Q3QQ4>5EW1N/<+%:+-_(0B>(+YC^)#$0R@?CRJ<[9MF.A&J(07E9U6 M$H 6;K#0?O/ K8W>5-*==1QB(E61#A_L/R55/C"4 1O&=I!D$2@RK'U0,O(: MS;,HJ!@(^L(6&X^TK5IUOBXP.]!][4/NEE_)_9-'#I[4EY./?AL 1(#'[<'N ME$CWUJKO$;RTT:TZ9VYSKA3:-Z\[)?IZ9Z M1"B 5/HK>P+JLYEBQ,=ZQ^:*/ ^0YPP8459M:,%(V2($QO)S0Z8U5TV)?UJH MK_SAC0C)H6 ?Q2>D0U(AGNVP'F>F1#/#/@ K>P1Y'OD%+[BQ4Y]:T [ M^OI?/V)+J2J-?"TTHN \1:W:IV/IF'H5Z4::[)EX2CY/]6N6EW]3:4'A"G9O MX$,$O'3%U:.DDUWTWM.RUG5RDM@QXNX^??WGV6 3@0O-@E]D6IQU+O#N/+!V MY=HXG_-I=NMYZR]HONN?+-%O&0PFVG'+Z"ZK?A\2@(G;A]3NKJ_1N.DO@ \5 MKI.^,EQ#&X$/'O^IL>=&\ZVE"/)HF-0Z&2Q^QGV>%.>O%#(>""9@GH.@]G(? M0KVI(8@B.!@=0ZPMB+[ B?]@GH?Q(H87K@P_?GG)ND'GTP@40<>*VFN6IR[T M.FX+2IW7Q[3Q$AWL:+M,T79Z*3"MM38#,P7]]@!)P$G00G]BQS?5<'FTM/G9 MK%+2Q?;#Y8S*%;7%1L95TS?S'H:'N:3NL4!:?C3/C>#'4(E$U=4GWJZO V:J M78E?T(\D$8I-J6(YK$Q3KDMQX:,$^\(C\/O?JK$?.B M.Y_<])$(E=,?2;FE],0AP\\B#.Z/+W9K=C5X,L4=#V=*@8=^Q #0(!L, M2C/_$G@O3T"6L!=QVG-M;^-#J%_9E%;",84W"VT_]\;1T="Y^31 Y:^\Y/1E M&P!_A?JG,4-G,B\?L7HC$;-RL7JF"UWN:A1F"P=U8DKMY3N_ G8(RQI1Y$-H>-FT1>V%8H>S7F&S$;Q/6>2_#W'-I6!42QBQ MW"M%#@9#,?I98<_N<=>YK\PVEZ? M_D'YE!^2?&])V5#^H6-P!L'A_:S&9%=>@:F8R21A4J]^%DMJ5MX..5.NO3%+ M=ZT?7D4B "_VB<>L?W%\0(;%2_HRN/C#R.O >>KXQN*=4;8<@-S8=H)+Z3OR MJK^@J]=U?9[^IOXO4=.*/QEECZ\3I9A2'>@$P(2,296%,/W*@*DO1F>P JXD MUXOA>\.FMPF0RGBU.Y.$B=;!:%K M3-.(BX05P?QT:_TEO$LZLOO#@^3/DUR^TOZ\\B :))+3=8VE(4J')V@I8)*L M H.=LA](3"$2?1HT-Y@4(#J!YGE'XW@1:GO$3W-0/KL)6?C.?U>YE#35+B>, M93A%!]XM.,TE_G/Z2VW_O94[P9_\=VI_(ZMAW&*C!7H##F7V&?Z: ;D42PT/ M">O'\!G13'>'R%Y7I7NY*+41QN!DVM0(FUMY87-2D,UESM!!MN_Q$D!N_U8* M( 456Y<#P]NN 58LL57GAVZUV ]<5V=O_%/;\_.9ZMYQ#-F'S>VU#U$]]%? M0->ZVTA[(1\Q&[D?NH9*K'AS!O*%O-U.+-N5DK0^9]=0IA;OZ35.;PZ[/OG[ M<^I/.N/^WWK9.Y(#3%1#5FW#YH\+=!6@G6$'^+3I>.J/XR0F?TV((,5'-7CB M2M\12QN\2SYE_SIZ_ECZ2HF4=.?!70Q>E;K&/J%[%TV]QDO\G. X'*EH3IZG MG&YZ^##ENJ=$_H26DF>FMVB4EW*G=LG;2NO#=&2R#Y,_B,VM/4<"5+#M:,'& M#^2""^2$+OPACS,TWO:UJ)O^JL'%UZ'!57XC1CV*SW5[--_QBZ\E2[%G5L.M MOP0"J^Y#U MU:;&!NI:YVL>07H,M;6L0*TX&T;DPHXW934MR1W9R,=RWPD^R2V]?6; "3]4 M1H]B%;/%PS#(+6*PC$QXL3;B%FC,K?5QVR MQM =Z&6HZ4(0=P:F,M!L5K$H$U M>W%=K2?0%2F7%)OB7ILV?TWH/V5UX-6%_&C&!*P#PY14VH>1'67]J)[ HMD_(\\NB:@'\ZP1O[P5,4VY"Y<'G&I^6,B@CK?4?H>^25(%5( %<_2&XB9_(=I&W,F#4A"';D4?' M]B$^$=7&O2A1L!AQ*::O.5/CTYY^.3]6\^_]!(O4Y:=ND+ M1;<<>7V9)[K[!<&IO4U;87W9$MYYLTC;7JH/@94N^;G[RSX]:F0UMV[BZYXF MSHE5BW^ ?X:OG2#TARR$4P[-,X*X 8=KJ:;UC4>\QW985\U<>91,/TPKM+1^ MNOV^XEG<-.>@R8XU"E0H5&>HH">*8 R=:X;60=T-V];QJ3N.X>E!-]4*;ED:IAT)ICPE?97Y2U5$)O8H-;MS M#98,?9UW;QL_V=BH6D]9P +J?CW!S[6BJ3?QQ+:]7?>_K8,H@A;3N8:I6O\Y MFT>URU,#B[9OHDDWX0!,Y\N:W&QNK4/*7'^:30[>N\OSM&P=1&4.6>85((H& MID]=&5-8E7Z#YKQ>.(\2@;FM>$H#R:]M=>-JM W>I,_J[>3I"_:-G/U6)4I) M?$KFOO-.3YAE@^#X(L,+P,C2W%]F#U'9;\AH;B#$NFZXOEK5LBYF@,AM=<;^ MV)5K_,(_S[Q)-SLRTW?><&(9QA1V8W.&4]%LKE@&U!HD^1-ALURT\=<5+@%& M!X$2OU+ST&J$/5M\GG'+/+D])!@.T_4AM6 ]Y7]L4!W MA#:8KW=3SQ[P#IL[L=B__L>P4 M,'UTR2 (4, PA8+($TRA=CJ,.M@-Y;P20-X4,8-^1)X&.(.<5K?;D K8&UB^ M?,KK=?5_M+(=/I*_\^='HQ^QWJ"\"PSF8.OE<_N0R8 NI!(.: >+\ G$1=1A M_Z?8ET6B(0%[TIUUKA;>3X2[5=,\CD9SYP]9L]OP^)#<7/ MU82%O6HL)=7J4L+GKWEA7XFCS:C/B:Q?6#?GY"4QI>^;9=C&!@_"6R6?PX<7 M;Q2:"%OB9-)AKL6+#KP.MUAW,X.>!JI-VN;,>GB^=#N7$>R'CV/"9HB#W]E+ M.)5(&VH0 9V U "*:(=N-7QOD9U+.;$/@4UH&WRV%_NWKC9Z*=3IT2$K93NA M:YHN/R 7)\AHID "FXO$, 9KSPTC7>;]YN]0GY0+7Z ?-=IYK)R&M=)>8G-; M)B30R=JW%--)UT=^YXG?O?HI?$O^TVA)7)+KU:$M*[AL 0@PML3!;A1VD,)/ M]6)S\C!$$,_6RN;E<;(T&.70 II[)@IC]9UYZGU64ZP5VNZC3\J'LH0HFZ$" MSUD7+XLPW V4-?X#:CV#.D(_SLRK=[K[*WQCBDDG+,LB4YQ9UBWBJ),L_TKOVPP]-B0KCH*\,,L\ M35,L*K%23ZCIURG1R?-13M'FKKPULLNMR-EU36H4Y!0]8.3HR\P0F)K$S@MYZ;!%(U@NG,34FEY/8/S8"F1>D;"9R+@H]A!O=^9QG>ZUQ M0:VEEZ S=V\Y^40 1ORLC$#QF2I7@<'.@#=\KS*@\/Q2>E!! MM>OD8R1ZHA^=#,*3E2R@MOS%%E .G<53MS2X$+%S.90#<[\.XY0 JP7QPSER M ?_4G'CYOD4DP5YDJY+SIIN<2LRCX-A?,.I-%*"*(6P"BJ5Q9&LP9-J($UVR M:2B!GPQHNT8,3C CL [S=9A5H+[#_3QI\7>_WL!5U8?CFSAC2-<5S%*E,2QA M+X19\>.S][)3)MA%2%5 M]R*!$I"=YK'02 WV+ [DZC'1B'V(*PWUPD@NTG"HNAYU F%P$Y>T^<4UM+7X M3*6AQ-6O/5(4K;N4GYNZ_2[.A3'M\WXV5?YF<>Z:'66^GV@V'9Q/EIS( M=26ROL\OS>\XVV.UZQMSPC9QN?Y(;6O0@0?8)-2!Y>]&BFPBBFJ%DHD\Q0PC(LI1\LA1K!,=_=F2;M*Y'63N)BBE+'EM @2-O. M]YNPN+[W%;O5IZ]TVS:I\+2_F-5O;&O)[@9M/_KK;T:(X^_C 47G-M(1YL.1 M!C71SHOC=1B@W79(^WXPJ@01T2&J^J28.'@H'?ZB\?%I*;*I3V*9&4([\59H M[/O*"+T1F\B&?Q>0OEU%CUJT;*QFPC>TB#D:NKK-44Z5WM7-O]<*&;RT]OG- MY[@#S%- "@W='4[S>\L/!)#5O#J;%G]^$]"C:%4Z_W/J[F6>8-VLP/RMK??B MAL[;P: KLT!X>Q%* L[(4DS+D8,P$22''_X(F2:25;D&Y=SYU%".24NB/)[* MN9I<3.MHKE$;DW=._G3VI_+M ]K0N150:I;=HL+62^8T?JR19SI']R'\T !> MJ5](H>81K1S-50>$.<-F?(#>3RE41"FR SI?I^I\=*E[[(#^M@FHP-:#_CZ< M4T6"DOPL] $T[J*Q&U!$]\92=6-QY_N+"N.A?-/3U76K$Q<;.BS?WM-4^/E^ M_JY)GG'("H[[2,);"94F%EM[+%[$9NWU<-QH-0H+#??,WE:T3\_.,QMP#0JK MW['R3-N$MOJK]AH=B72C8KO1L:CC;$U U0$[;JA&DR,TR2;]CC(;C3WR3:(D M\U'?8I8\&?QBF668['3)O2 MT:?3=C$^R)Y+4Y,>=5;%-?0-) )%N 6=P\V*L*+QOD&QZ(^[;4&'_&3%V&<0 M[1T7O;$=Q6@W$1$9R%"#U?MJM5/AB?<$UQX9OO-[D%]IRNGP;))C3Y*:VJ#T M@JE,3N/KXYJRPB B3,=+L$[3M185?HT3@UQ8VEEK_AT)YTV\ MI+Y#,R'$'_/XX05R$#-#(P%&/XTPWX?8L8Q:I=IY$MK)U, $W")EP:D&WU*@ M;Z89X/:H/.2,BVK7H-OT/Q98U5TGCPR+@AG4&70]B2F2P^9Z0WU)CP6PU'8R MEBFHU"'+QSPRER:^NL<19QC,LT@TG4^1Z5J]]F#GQ=B-BI*?UQ1NG(#N3+5?- "9$)!I4-#.JX^-/6<@7Z=L8-H;#'VDWC3!K M>OU:\]+>PZG_ES@3MU9QL\3RD43720H,=\ M?]7G"_X((=E$#*3V0IXUG&>$E+U&/Q_I^9,XJ,WJXG:[<47D^\$35_BZCAG] M2YF;J$RJC"F4,DCU,&TQDQ"N677:E?KM%T$D]I>5[D.T\V_F(1F[WO#L1@LZ M&_> [86?JP)+^#XD#5\+I7A0\?3;@#9#VP\MT6)*TVV7D"DI=C5J4'C[(12S M)O+.>^A!U6OQLDPKG#RA#W[I#R8=S>;^.R3YT;#5C#]8B"PTA"S\'G1,=^06 M_+9QY)PM'%<\236[#%U8EJ4ZWN9E2KT!DZ#O>,478(W$%6+;OA/T;_N-9T5>+-?O+;G6 MO.VR(@K/"7HUG)F/OF!A.?YQ';T#VH >T%@7!+%>DLG%*D4J^)'J2)0+U+PN MV0_+%)Y*F%I\!IE7LB5G5F)L.>S6?-)(1QUQI4?XVY:4J3^U=_K9/:4,%A\" MXPX_U.8I3U.H#YYI?$GN]W+'IB&V:MQL1M0UYFW/6\BX=PE[S+UNP!Y*8KO@ MYWZA?F1\02JPLL[B']@F[)TH(/.FD@XR;8M6QY%:WZN]1D)5J_6N%ZO]I <( M]BM4FN/$I;*_WK#H"MC)8',2&.;^L 844R"-+-O%NF^A-,:THW)XUH^I>\.W M/6 RF3LL4%>.:S2*E@A.JOG9YW DZKS6N>VBTS$XV-+;$JBGLJ PO_P?1!^:@ 2F^O1/J3A*E(3\"B. MU(76[78FXF3\?"S'\AS8L_5I YVLK]ZPNM[(?R,_O-X.%>M$+DS0*L'BDXGJ M[F8*U;$''JW]\9B@.[K9 M=Y^X_D&(=^[]HC?J7]WO2_Z?##/ Y).*KO_%RFOWM-FKH##7!GH/9 MCKD4#!L51LHA9V6IUS"B[ E80VHLPX5IR"H.M8W&:5%)L;^A7"OV?B**$6LZ M0X6YWUTYPV/V=B4\V,7QU@H,*&IAK&^D>_3[FYO5G^]/9)49+8G83' MZ3UR=9 7+XJS#;G8KK@30%([O>N_AHRB>4R[BV@'C =ZGW1HU5-XC&D1N*:> MI8X/$?V1[S<1G,'36UQZ55'7P$-,)HOBFL#D=Z 7T0KR]V0[-@%E\TZ2 Z M>=>U]$W98&B)=;CO\BZ5.\\YWE2SW%LI3'\Y-HEUF_5R'W('$PVMQ;1CJ1R$ M HD@J%V^)Y#7V?39"LT/I#.?>;]E_]YX_?TK=T6.X0>E7 @31G6"L4_H *_, M3:AEW^^0^<;U/ZLX8T,.TX8G-[&.+-,$%/"5X'DHDD6TISM5,;AH27^SV:U'+ M0"E]@SA^Y,""2^-<<:M;_D_>I]N73-C'8AF7F<98=AM A-;"&A=0!^=[HUU M_/Z845E]9E7GR<$ OWM81'CQ"Q=+_3-7]*6^9D\/;9[1;Q-\!?UEHT;QD>.-(];J:HL.'68^+LP$-!](VPFJ_/@RHIBXS MJV*K49/BL?N0R]J,.H8RNQ=V%.\%>[[G0]B,\91)NTJ=R6S;M6M^[=A@R^=? M$M93L28JIQ$:MO"05^[\38.;?IBRV'=B^,!7\HN>PTD0%@HQI?IE'^+(2]-@TFR?,B^ %"V!($NU M"7CV%*3X+$!M6O;//_=_]S^Q $,0BIR11_7:&RG*G+MP;R8>POCY@;K RH-^S'")G4CDF0$05R:%,+)0DQ+6K4\<'. M<1W17//X4,D^-2/BA-M]7'Q0W?2ESF]VA+-'Q,4"'_6>]PRBU='O@?:5K$'K MECO1+]#UFQ0,.0@"6)D"=O/5*!BU[-GOR?IQG=I?#C.Z<=ZCZA?@#X,NPPWX M[W@/_.@^R?L9#^<%%+JC]R$!^Y!HZ%&GB M?]&QGJ_[4EN-=!$)+O6]@M4#":Y_%K!<"0,4S"D&M)>7&X GC'O(:1D=H(P: M/S"N:I5V\)?(D&]WAZH/7RJAH?)7NOARXL&R O[7S[\T4K_97(;J0>?>VBZA M"'A2 SK3 DITI0^3$!O89I7^M/E+;M)[SA11)A]]']+N6L84E*,_D.')'J+ M3]$42@MYBLR77=<^K!D$C>_(M9>T>W"*B2,?:5[I? 2> E,@/_(PZ^7?^R"] MW?/MJVP1H*]FM:DTNL;"=RV$S*VZ6:_6$*L,^QT=-'%OV10]1M M]C$\XS+[&^[X1VK0^DM&$**=?#^K:E(,>5-L^E[G8Y7OH&XZ_QV]!%M##T!/'D>+60C@IZL3Z6JC?0G.*;L!D MBO&435WLS8^MV<<[-!1:N:84C+SJ;6S",IQ0 M)M\'AVRV)&_W2>*D7S6$H#[L0YB" R2Z_3C*?^:N[ O>^6Q6F7:KUZUTT<9S M:3S2KFWTCK83' 6+49AOAWTVO(:?025!Q?X/:>N%+' &.C*_S,Y7P/C]?2QP M$#5'PB3?/FC+5-U,CCR0L2N!8[#>H.;>9.]#ZC#KB8S+R%X:TQ+%UTW[CL"B MDB3&WL%YV0)O9D->6,:>:E##%L[T8!Q8Z=#;K1QT/U:2MNV/=C?:@UD]ZD9S M&8"Q'##99S9$] 44X6C5@P84H##89JW. M/K/QFW(-D6,]JC8P8:&V@<'5TGG%;,M87_A-,M5JH1U,M-XFB;"YOQEF@ M9J?*4+D:@,$ ,E6 LR>>=)-VM%)J,/S$/YAGO7>"X5QMP/C)*;/@^ M3:\\FUY:J, D7#W8Z>ZS M6\G;URR5R_P.7MT5J0<8,.ZC"";X.X//H1P[,ZI=:)$&T7.1-T8C1>%MGSK@I[L?H,8DC@"TE=POY_/W\">0Q% MZ(/Q,$U (L,I1UL:;,]VF)U&V+I286G:0M$NR1)*\:'*RV/JQ5R\&[=CX!NV MAV)AK3MM3!L@F"R;+'N"&4"MZR;>O+@TA6T4R1,9S\=&;,N!&9"3+3%MJ1,=:8#\ MQ/I@$'F%LICW)5=Z.5;[$WFJ2=JIE[+I;E/Y]349E[S(OG_HN_.&!^J8# <5 MQA0*8?-\!Y9IITZ+AZ;:'@_U< M(QW<769_N%TD6EU\9T;M."08"W-A7@7K2"[R',!H%Y7A8?V#FD/CZT7*:1EN MC>S>$10VDG_^Z# 36NVID<'3"5@)?# -4JW*JWEF>DCM"\9*,&>LXZX2C(OL M%/>DZ74YY62FT SQ??'(RY=/9QX8YR;;9Z?(5\,IWB5-E]16428ZH)RP'_S! M7J-_&07)BYZ1PAN4'UQ%U:^FA5^I+&.8L# MQZ7-1F#A_4+._%:':<7?;27;M>S/(!:33)7E'\D=K$E-=LR*/EX<QN^](8\?U+-8YV(_'AJGIK;K.1?ZTBU'2MP'\!5E:^7@?L]0I3;MZ^EU\GT)'! M# 1CV MQ%@,]%&F-JR8D\S'* )I?&OV[\VJ.K5,@;PGF\@+OHT/W35F&]]NL&=G)>/V M(?Z<\B[FD?]V:W_[2]%CP&2ZRK2F+GQQ_4OTCY@#"44K%Y>?UTO;#)K%>]PR M+_FQ*A':^DV'+PO>#)_+\O)H.(3X$<#Y1@!.ADV2,:WHZ4C39I' M<+K _6V[!BHTKB%-R/V6JVF5R]==Y]H5$:R]FUM%N9I6Q8>3?PJRKMQA&3(/ M-#9]!&2IJ<-TXOS UA1Y,';NE5A^3[7OT])@6Q%WDN\6EJ0=Z_UFY 5#W7&D*$V]$J61D+O'*7)MIGI3X7&2YAJ# M7;'IC MCT+[U-35UYT2R?<$'G7+9WAD(7U1!#?478\(^A]6HI%RY#$J+'%'XUBDR>>& MA ZC0^/U,_8,BY!Y:?Z4&5Q62+"7(2_]TFVE'Z4G.H6:= _I;R^^*$^I-M-K MHC@LV2W9N=<7*6:DQRRFYL)Z1 -O_G%F2H8_+0BGY(#1N\;*P,\52=C&R-)C MJ$S^1&L+]$_$GLJKK7=V'5J]-;9BX:F5/E)_^?+XGQ_A\;!+;GBV'4.TF M48/03*$1>C@0Q= %=EU&H5YI1+138]HMP*ZB_M&50G_!U?+BEC-K$@WMW4MO MX$OR1U(<'Y9%4Z"UFTR1G(5EIF#>'"Z-(8TB7(9Z;1+EG$$R?)?34(F,D@0N MM.T-OJC?%%MI_-A#YR.VNTR[P?2.BW"J+3XY?K;B9];!#TA^YFE6+6KN,Y1J MAW^^#VF$_55=GJJL N@]WDG<0_R)R L+!3K;%C31Q$"U("1)"GO1K$1(]^C\ MUKS"/^YBWT[KGG)[ICK6/HR)HX_2'.7.-FE5O-^V$2AQVAMY?+>89)!5LC%9 M[1#QBIB5'S08.E3:X#X]Z[19--R].LB4@C-\L>O]X/'-T-3SR%9_JI&GV4-8 M"52[QD%7XC5)!Q\:#Y88^-/JIN(3N0#8;R?$Q,$G7M+!GT5)X'PQP-J$- M!ISQZ81-&LSCUU_/X9-P"L,MTC2-=E!O9Y>1*V6%$*A;GZT-7*.T:\CQDLWH M>O?)?@.>@:3F?Z)APYM,J2CPH'3']B'W>2<#"+)<2('570F=!L9-%X*W4D>U M5D^P: )29M5"?$Q;^OSZ]MD)9QU!_43*M/XA?^$^GU^#@!Z)KC"*?V +*#FG M!;4(_^L)Q,YCOTS. ^@Y#UV+CWDWQG=@ZVT)3D-:$5:AZ?,!:[^M7.ZD'M:\ M-OX)\NK3]B9PNC4A'A^(!I0P;;S<2"*I+JPP@J9+?XJ%GI## B3J/L1^I,'B M,5S?V.]B7!(0,SP;D4(K'NH_&S'!+6HX/H))J+;E_,C7&V4+?>/=)?<>?'H6Y2?R/K(32G71 $Z7K2LS>*'K?51L]]M+ M>%I@]5R!/TP*4;I KFF0*5I(2S0Z/;SLX> XNCD3V>V "I%_6%]<[%OU!;F3 M$OGR+XU $1SV(??2)JTZ_DZOW(>\G%6@B>3,DX@7%F:Z*JE=4S;4&79YT'OB MFFM)VX^7:_] P\N:6>]T@J'*7[59,4PG,+R"D.V@C#F..V5=C.Q%)T>TK<6\LF#YK*QR]0N,5?G,[Q.>!\> E?, CHO*0K4#/7&!Z@ M,*L77>\.+4'$ML-D0RV0$JLP(2-9DN]NHZLUKN0Q/02XLY.G^D2^[N4]-9[. M(JU;W-B32Q7:5,>'3^+,CULM%R@[TK/\FM(SV7UL_5A-X8QJ MI3S%]Q=.\C+/*X^GCMU](^4G MY"?D+Z WY)4B=,>.W_C=^W7ARY"G7%&1DQ^8?T#^W(_>2H(EXW?^E.Q#]"MG M\7//2. 'DV[L3K=!EIZU)\BV.4XA=+N0?U_B\(STI.X^8\K.ITDAXE@>BDWZ9Z/\ :,:IQV'$ 3_C["&YQ,:)\]3QW' MDV7Y5MABS6DWOAM:EWCZYHX]CV?;R[6.!,W'KT[VOC+NDTC7[WPZ ?M1[@%; MHTQ5MZ:/3[W9A_1ULT5!>'O[]U$Y6&HS Y%@0M"M=M)8$.=E*%.B>Q]RYC-U MD)49)+X/6;D[L1+$%"Z[,A%I"X(3C?6^7H/'-Q?_HJ'?BMQ8#2_S;1)!AU3X M3^R>^/>LB)-(HD+GMW[F^8[D[EK,0BR;TPIXU=:A*G[J8V::_6HL0.]L>5\3/MMZX\Q.(D1--B#G(QW?:R*N#/2KF? M0 =%?&PA"EP!N.O;@.)ERJ'X5NP#)$RJQ]\8&G>-B^10;FS$6]<5OQ(9%)!3 M7KR&,0/0H)&?08=\9/^0$<$!^@P9%$&?K1RI0BM+55/7TJ(MI[5 :WP3"Z=@ M7>,3NN,.:R*55:YOBF/+O/0^ELZ^'I:X$;\A$) F+;6_].)0NM&#;S M)A4\N>*$L?IA7\3U.G\XS\8A1\[_O-V4!W(.R4C!W-N8J?\US&Z638=2'^XR M2WS8G%G[$"^9E'U(V6\,Q',2G7TO:JJ8]YWX&(G8[^>I)I[W5K(11A6*^;=5)E1 M1[>XT:60*F]!YCIL5V@JY)Q]Z_^N#^A_C$+U[/R?+4B0)]W_8S8D)@O_?YHN M]K\>P\JY M/T5S"+H,+DZ;H5IE#";,1#X6)A:Z5'85W+*T@L5!(^!! 8F5I8TGSC%QCSK>L"K%.'D!:_S]T<*^VEY6.H??%BG-E:9P[/]2(RU MCAZM8//@N&$H@C5J;H8W$'G,4RI2MKF?/?S32-9Y%=4+6\W MQ62!(Y&"-A[15D,1D"&=.L^A7%^,0ZE18PQSLVU MX+Q'$!-YMM-%,HJB4-P[^,FC>0>,B.G$?_!Y_K=A+ #Y?9:S_NT^I$/F^$L+_"3R[Z?=U3MTZ:!J%?^(7\-[5_0?)K3W<^\GA1FP8EK]J?%=GI&O(]O"0 MWKUT9:_[%OP$)Z>3,3RH"R2J,2^@(-K%.XGI((&9%@B;TKR)9U4CC?)ZU-?O MWVMNHB)C*RUSPL/4PJZH:B\EW=1;;\>A R-YU3DMY(!@[!?J&+_"2"$GX7 M7# >JIH;^5T@TS9Q?>0!W.M6->7L U!X!2"\+K]_W7G<-TGH0#2L6[23-PXM MK(Z:6X4EH/FK<6*1QI^ $(XVRNE9U(L;"'/7' +?]-D3$K,P087"8?O'AEK6 MCZ0$]-;2UG'-(:YUY5)CQXPGQ.$E$.=S:5%9#436FLM&)'> D#,W>_0LH7LD*8&, M8?)!V5Q*\[ $3\C$[WT(H&+>82UG.1$I22[P[#-/^D]F^;N:%BPVHCF=IAK' M9^_%G?]R[,C3(*9T);5O/J@#'P^EVD:@XM$\S"PCU-*Z M^3>_HRXQ3WESP?Q?_Z+G6-^YOQ5H^KF)__) L&B@^! V;&;#15*TO(%F/"U+:4L_8&5WY,-PY=PJ$3F>"08,+%WD%*\ M23@)H('AQ1Y&">+]X>;MNDZY667QD0X5I$%RC\;ZAE=3?L4K'V9F7'R;C/+N>!\.:W1R MH@3+BU#;#_-W"]G%BYD>REU=VQ9E*)C9 N2*-TT?7 MWG*.UO?;;U]+AP>VZ2(>_ZFI6HKN""\^Z_4MA.]A233&Z%;2I][ZHJ2:,2-O MF<";A9::?CJ%,K>*Z_'I)./U=V@5<$/;8P482B%8E>?_=\6%BBYC%;9<@J;6 M!QTCSO:0@];[_D>:77B:IOAA\WB[3T.LJ:7M9GYP.9U *P61W=0 M!'N\C^USU(&6B&K_?<@''XI=E2D][?G3\I2YVNQYRH.=;+.40Y=FXK[5:L>U M&]EK E.?DO9,Z.I@LLPQ$:QHH^.^^Y"/2A060Q(Y=#&A$QH]SCD7Q(,8)'CR MCVOW*W41S3)+ITS4JK0SO_OKOCLVK%P#7WS]LS?[;+"[+<%V$HS*5O"[2"B" M)5N$/8VOMR6@!9&#Z(^\ZYN:[I':U+*4!^J_!_F!^.7K.?U6]X9VQ+R:XG9< MWBBV-B%RY1;CD^?NMCZXI (X>HI]+O<>*G%4'1 H<^SQS'N7$530;*%761TQ M'3]:W1=J4+/K%A+R1*')B &>WSL\W(T4+5NKC?DR>'!VNI,F2\>,K3.%X7=N MS]XOU(W^LK53>R+IH74A]@!WD40U\O87'#&0_87TL>T M=M3DX!<2]1J:Z-PA8B3^03@,]?D^QXFK77M;6:/.169%G7]JK>]I17 M?;H138F(]Y5]#A-!S96AJ0\Q;;;<"#39I\-#E.[*2L_EY9?E1^01B!MOYJ " M^Y VP<9YN&:?PRCD@C&D_GLB0'F\,(9 KJUK;^=7J5QSS*RP4=$LR!3\^11W;7TV;^J&1:]] M%M%JQC6L+F+WJ>Q2#M69/@X0&(9@T0PT/,^X$^G ^@>GB/R*/,:JC'0+(J-% M$ ;=;T5'#95+_9V)PU-^'SW]WFV)J97&Z/*$A/5JIFZ>ZK)&74910T290C4, M>A@ I1;1/:GJGU%D"[R_V[U6&JIC1EU_PZT=SS4;$O#>NJ3DG^VRYM'3VV$O MT$MQKQ8XT* TBP7C\:X'BE[)BI?LECW1#7U*>DCIG!>JI2^C0KV"!Q,P494-HDHQ/?J+L^&HB[ MP%2@CL*X(ZW+(GV B/=^KOU9@PFO[]9_'CE)XREI^$F,HK^A*[N&&J<]4CP> M'IM2]J)]+)Y7LT"RXL2MIYER!EM;&M.66V-=RJR2UJS9-DNK7,Y-/T66??I' M=L,?]&OT >A<(XQJQCL)I7/B6!E&QQ&#W29V&>3LUJ)9D@5UZE8,2@BQYC'D MTX@?UW:;;U[,WKR1B623\XMO2<8D_1ED\S3\UQ+RE527EM!BS=!DVM"4$K4V MD]!2.#T/=^!H6W>[\UX\.D*F+E1SDKO5F/^GB^B%TGV(UJ+!+F8U@A[[M]4" MV2F"/LA6GP9"Z#1E^P>]0#R:GIE_>4Q6\$GS4"Z(^^P,-CRZ/Z1K,$-P<*UX>=,HK5TF' M=]GM(L5ZF;W$SN(J VM+B4IY>FK?3!,)8_N5C?=]E_1GP>'/'NCI-]!%85EQ MZ-HNR%J'EG#YX";$4+TJ>"\,0X&(8J?FMHBR3QA0PY-;PD& ^P(TDSE:QT>4QZ2ZW8-'C^/2P:]2 D(ZD"#F MQ]QF?V7+T((2&O!<0,)UP.=.4/DO&;D1]=]1 =:?7.[/'&'G14GI.M5I()92 M;CUU+E/$?U2NK&0]+<*Z19P)@'_;ARPN[$.X]R%3-AQL[C50&96R*O#K]EB0 MZW9@.,&-W,.(O"XH%62NQ/!V'"]UMG6>Q+=J M)()]:?O=\$*)9X#K&#.&(M;M7?K#5'OL6_05@[LIJ?J&SEMUX$[_ N$WY/#? M\5N#DZ)?\'5A1>"G$ZQ29D HV>QM"*B7VKL:$Q]B?9,=W['[S:?SA'C:DU\G MYZZTWRA/[/6Q3$\NVQE3=S[3/4,/=M[-=?KT?^@EH;<(^.WQ.W/'TOK.IQN92OE4;Z\;ORN^?/!@ 7 *M,,SX[XW?=A*6HROJ>/5& M]%SE/D3R:J@![^Q*!L&[:E5&IJ$@\/0W=>QU6LM9R=UH@GML[LX^Y.]KIK=D M =4TRO9TY>7W\P08$R^3;9G%>"P$M[@$,UJ+;@@C!X']*'@\Z@D MG#SW4D/RDH(O4]9A@C36?J(MS? 3"-@ +4T9A4ON!9S'X*1 MY4:M#/3BF_S9"B -_(CFQ*DA*MGG*7F6VM:!O<-NW((2,0/JBL85G(:'8%.F7O]H43^[6GO<\6"V+GXR MF2]G:WP_\RYI*^5_-7+Y_]% >OP)Z-P"^H_)?Z. ;J>!,;KJ4>R\<0FIBB*T M(85H/BE_.ZYE&Y3B6_C)0?R(D8ZFU"RR]TB+/ME:AN$Y$7HTK=/U^D>U[)PR MDTN+?>8"]:FG$Y/>U:'7NGW[=;]U M[UOKKG??NN\E*_4OM7?5EWUJ?U5UJCX>2'WA]BLV+!Q28L)'JN01@W-2 I%F_>.*!7PH=JO-?XZ^+( M1/3LH?(BY>1.; %3L@':#HBLKC-TG, 1RKN?]K!RF_D0$]A:2G/9U6P[0E%[ M_@%B?;]K?;1@9/);U9!CMHG?6XR=.U']!=$1G3/:U63&T8.-0\&(1[87&2?> M,!S=232=3Z$O4\!3:&4$7VLP8,)GU[N;%04-7 .]!'] MY'Y]Y%SY-N4]I??V;_4X+N$&\2OG>B%W_QIWU$OP! A>$SL_;1\9:EKJA=@: M7,APAC(]2I:TX[Z7NH3U8F:+^7=U[.PQ?W*AT%5$@\/ETD+W@XM3BG'XZN9< M&H&"Z5CC]48,/XK"%X>>H>(:*.]';BF%P)K2QI:O5(7K\=VV\\!F6+;/O98; M>08-PRNC5H,X#\&MS6.&X#PDH,_08NZEJ7631Y-FVMX8:F-%VH[:GR!$5Z%Z MW6_4D7:?4F@[X),O:KG5WZM6NV.K6=3;JY:!]C^FJ1]N-\F30(#GM9^K[$98MKA!MD8&NP:<&UG9Z MKRM6:JT>F/+2U/1IU)M*2LK6&&K45WZSAL;<4*@L;)4HJ_(Q2Q#GSQ60A!7O MJ)NYSRHA3C4!\L!-^+T3ZRN]##Y<)[S*.;V+$)>AV[S]O<&E&3@?2L;JR90* M*7=WAA1T0O1BBE^-37JTJG9#-8F\E%B1.I)ZJ30#7]E_ MR*7Z@$W>+"?E!>*"$XRK4BU5@.B&(BL-U/7/&RB4EDNSQ7O6 P(%F%Y]QLH" MII9%1+ EW0\2X&;@U]R%#>(]#"$VSB):95!W;4?I@QY5<0,DHF>W3O+>#&A! M_3LG1T6L;MY_U(AB^&%-*2.K6QA')TV?XDA 9?44R6!;X;Y\TGP' EW:!<%% M9*L/7NII$O;ET;GIA9S;ZOZR!W4FR_M!B>9Y;(:$]I=">M2IGZXSZW-2O[AE MH-7#GAQP;,HFCUS:V,5GD&@T*S;9Z$B/8CUMEH!Z%']@^M/69CRB1]H (4.Y M1:]2;"42%>0#M;JI3#3%^Z2]G$/%*,PM\0_N#[^MU7*,,+LVU<>4LV1<@=XI M2-: IHQ 7*NB7.9T5/BJ:S^!Z4'1XE^N16C%S)?'H',:+68K4;(Q:H?AHIMLA)T!(&EVB\YX<- MCDTJ#;IEJ_9.O:>$5Z/VN[%A9C4UE1ZVC6+U3EL00V]0'(HL7F M+.WR'$#M ML+<\%9;9X&.#,+64M7?>TNMH44-/R(+"=)M?,?M6X70/5@$DC!O!"U0A$^!; MF%:3FF 0(=U9!X$2+#OV=L#MK4EUH]E\0O\#:0Q$;GAR M!H-!/\UZ'"K,D-_<*Q5BPSSP4>5[^@T50-R0A7[.KDAG^XMB)=XR/RW%;D_Y M/-MXI_F*:G^0%$&:X[-@X=5(-'$JBUS].8K2*VM+VU%?Q)2BJ>2GYWBFZ0:7$YPJACU]X.+,M.J) E?79*B U MM0+,?54Q29(E:2[GE]P*4>P+9,H<9NB'PM/ICF _4-?OJ\6.J8?(-N2G32N'EBF.F:7*NGW(W3I"E]#?* *6,]FP M!55B!AS4.]FB \7&UIPJ*?T^,\V/7''V$GF?DU;^?F'[O*IA^Q M14N&/-_U*&7QNNB@&!LF $3 >_WI(:SXYN.XL4V2 HRWMP!;B)Y9_G0T33*2 M>;9L&5$0^VUWO6.67>>:O+UUZDK>\=/M1+D,5EX2)#S JFNT4QG8I 6M-KA# MWB[2#0E/FZH&"=4E%D^N/91XM-OSDXGSZQ:E+ M1T2##9UXP68ET+'MQ"RBL+_185J+'X6 1_Y2,3)X)$'9H:DZMOO"1^(15H;' MSZV$%:A)J%N[XT*90, -B_2E;XCTRH+CJE.$-=V)X9H%#_[\3"^FS=((P*DFF-$":#L>4XJ-:AE"P46;M; YO)AI3&SVD<=D,!)22\[#YM3] MU'-$O5)\4#?2Y/76=<)P"'X7>&;9'M_JA\T\RX;=2YP;1$,*EBX=J)RQ*X\- M>O)CH+%B9=IM7L%C M5Y55VNZR@WX!\S:D++/QE$?CL1%I-145P8Z73#TUE',6TJWHRW-A2,8-H+4> M60[OM!9D6H(%U"$K&E_[VAB',;09S:P),TWC;$,8<8!DERI)W,&MWE1P:[HO ML[C^\C[ANEE_)!5=NSI.ZZ$_!HT8YYA\K!RFD5J\01!#B7GN+H5&ZR0-^+[P M[-LV<'=UFRV,P3-VR.*!H=,#&"&K67_S_CFRJ.&Q4+5A0W'H9_)+\JI&".,L MN&9:1WT6U9&]C53Z#G M647EX+.ZAHRE-QI6(24Q8D=-Z$]G5'06WDFEW\V20]F4V51+7>406EO7CX.% M[U-]=+\'8JQJ2$L[DT[XCJK.#J\.DN&@/^T2?9%5@=L?"G A5W3*=%H4MU&$V+/;FTY%OQG6U0=6%AURSI:[IO)X[\%#D<+_^ M1:03CJQ(O8P93ZM<*J,U(VEV?"D85(ZDW]E?"9O@ADQ4@'&_=^G&S77+SD61>_>ZPC8&8C,'=GXK,H M@E6\]OMEEOF9K(,OGILUM*?9>!E](>,SG3'#+^,=[=$%&@B[9

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�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�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�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

3[W\65+ M(?UH>__FICSI*+TC+&4LB'E<_+"P3[83*%;&YTX1WQ8_C,:JX+F1/R_PV6<5 M@A4P:KGN"!0%2$?'A#@CUT+WE"V(+J8%)?71/4QD+SNWY*VA;U_AQ%M#VT+? MB6F.'GNP.4]ZO*=!O75">KR7%!7JA-O/Y_2[J\\_-"3,8:VI$@&PEY9KBUBE M N/NCK+?H52B E<^ M8!5MK9%N^9F!4,6#3S)YKL%I? 0!DN8+/$5P31'M*4[]CQ9![<69\Y<8VA9A M#8NP&Z)648Z,EN-_5!4,5N8_@)A[(!-E@%V$>*TV$O2Y3@D^RR8[:R/ RJJZ MB?+6P+8%1)87S9D0B1;@TY-.5T#$2-";J5V$U1E$(\M!H^BJ Q6NG;'5NB2@ M.&=V=S+;0:X+>I'W)0H\.S?0VS]-"?3JO+WB=I*R.\;\7%V]LEXQA+.0D9T_ M2T-QRV00U=PQ).^OI>RI+PJYV2>^90MHH(]"?!0!X>AEALTU;(>:DUQRQ?[I MEZH3(@_>46J99B?&(WS2]F4JPLS:(L.SE#/+R;10+B\TP/I@WB(L:H 7.FH> MT6YPE^H_"[;3%*6+L*?L&XNPLV&FG;9H%T@([NK F-&49Z#Z*&@5D-GAXW8Z M7D$SC4F,R"V';G&G=8]DZ%DH8:5N5BLGQ\-_X")HV+"!- MYQ+_>Z: 74 CS P)-61]#@>W.I'IZ!_XN.LQ)#[9(/:$KR*'=YI?ZI!&7N9F MF\=W(,L#U/E!2H:Y$"5K2 KZN/9 J^?PIJ%CDO/(Y/$KZ#_9K0S(O7C*R^AH M9)A.7#VF?17I,<4Z_>%B\FK-^KT1MJDT&S4IWZ\]R3L#%:D/U#,Q2<1!@J;B>?:H(K6384KN.GQK M>UQQ&S'=E:Z[?-:)US?4C9R_ZA]B<5LU1#A;9+\L5?2(%C^\;^W'M],J24+\ M[5I]%=^\2KT$,%6QV[;-T)Y[$>V@@PN(5>2K>\MH6;ST"L_(,>$BS.XDS\<[ MP@H'83NY<9DJ-WLUL?;\ Z[XS*V1SY*S(:,P78HQ.J0:%7$OVD47 /V&491] MW:N>F:[$,&*L6QH =MM,'GH'=]BT_0_'<\X(H"F/$NB7P3P.[JLA_DUK6V*T M=^A07)[M\RB\0\L?4![2P_ -M41W <(HB-?YSOH:&@&;23/S_%E?/<<<%'5) MGD+-(7T-8:'M,+ M+(9'R.FJX+89NY7J)(\YW*IQN65R$BV0?T76=:$R6G8O-3 K,C0_+'0,\R[0 ML#H,C%*:%GC0?A(,3;8QK<&6O MLIDK(84_M9IP1D!UH>3T=H-=WM@14,,N)Y0@%V&YE)@EU4KVD*L&H7]$4Y0) MC!IY%OF=:NCDU^2(,TLH;OKB6<25%.XQPU9P_AHEW?ON0_(.>:=M?LV[-^<] MB5G/96'@YH/0O>K73CE-P!QKZA;3^OW63-=/]*F=VB5D:XVMV#\C5HG)P5GR M7:+)(S@XOB>19DEDG8\#1-8V0*Q\VO"T MJ7\.&1?%G)K$;E_;4JX<[Y%9#[V,(_,V]O)U* MB!*$I]41N=)80W^?0KLAK4#=T=U&*"GZ]="DM7U9>O.[Z)]IY9],OJ0:'8OU M1QQ#WIAJC.:R^*Y%V 9_7 ;0I6B#HMJ=[?3W)&^G,6N"P,VMW'L&UD.(ZW0$ M;AGU;JC+H^)"E7P""%&FLW#AAC=ASE^B;PN_!%4,4F_^A\)>%G1@87(*%BA\ MH"#K""K:TH21C4TOQ;S06K+#N"?-,:S\U-#K-0NIV;I#D[\8K%^TR/\>(91D MW.!^:,@_R%VNR:H)J&LZK1/%0+31,9UE^NA%.% K-CBX7N>[)W@?ABZ=C+8[+O8, MB&JE#81=D%NB$1!*Q;ZF"P%F5*[9LP([LEN'++JS0(6RF/2>O%0U$9GQIW+T MIH7S]H>_%-L6I\R8?RAX?RCFI&AYO^5?5Q#VE$#]/=H9$;3=Y]4_NE^2&:MU M>WH,* B'O=W&=-1A",1%F)F=T*W<\1WGA&ZW*N!@7W1J6[&SA61,8GT,2L\P MK[QS5N7(MAF/<0>,]&UPY?!T!GT)C4#,PP!8>.X";>IK^M%5H$.88L6UO?H2 M3*(^5/TMA&TOLZPO#8E,V M7E8R;<.^=#1E4W?26BUH>+^PN#?'001#H"AE&MO8G)UW72--^R!MT^,.YT\5 M1;;\;9O0-T[U!OZVE%4/U"(CQ<;:X;SV#.WVQ=J,.V\H%2)Z[3J95YA&=,#3 M3#!7#-Z4 $#0/K,B^AF_OEZBEH4D3[Z[WTEN,ADB1]$R2?-V) M4\*,E.)(3;[K-/PZS\T8YI<:_RAF%5!6C'](QK4Y6-Q4,BP2));!2;$5"9$V M6?SB"KRD"'AT(3 I/I:PG+=S7T[NU[L)8&XB@ZD.!GEIO2%G.!UA0G4FTY1= MF0^X/I_'TS;XP-%53[PJRIA;Z]F3#ED=TR]5 1<)3NBVMZ-1TCED:/B+QN>< M[/37FYMRC[Y+^-_YBF]]M:_OAI0(]3. <0C"@8%8V_E&U>@AP*V2M7M<7P@KIJT(E>[2Y=4I@I)SL_P5077 TW9F(:9/T-J*+Z2Z;7F M\+;LB(Q4)2.GLA$X6'W>8%%\$+U$[Z-OHBGNX=.4B%@E;2GV(7YA0-.D"G - M$W,8:Q$C&18C!E%0K]HKBMV46,2-8295Q_S=))M1<++=WM0^#<KQ'\TON?DUX> M][0DPYLFA*/NK/9[@F =A[A$AP<.-L0_E$,(E3W1]-3DVHE&;VY=UB5E "[B M6RBU8^>D+&RNL+KRG9$@)$T:OS=Q+7VU%7?.L.MJ@!G#:AOM*H.(Z6C$!\%5 MYV\A:>6DAN^@?TA!L:C=(M4B;#64Y;^[ENPXZD/WU,<;U1&S-C*CTNV>XXGB MSAB[/O1&,OQ0/6AQ1_7](X&88F)QI_(D4QTU!M,+P]<\^"T[?,F=WZ[5/OK9 M,GB9U1^;K^VV 5W5%[0PPUMYH]U5"E8YD^-LWG?.GU33NH6/@(15XRG%""N= M:\V^^^.?!\G94]Y5EY63E]=N.\]SO$#A.[\4]\M:";&>*:E%M()%F*4@'@YM MF]>M?2-$ /<,WAKX'^*C4G%N)\_#:B9L0K=5@ N"N-X1A M#QD&!^(R]O6Y1:.4F'R>J0JW;D)R(=+H4_FW/B(=L%1HCS'X#4"TBLD"8$8S M"CF!NS0'('H\<=05]2B+>T1C?=LELFP:&FL(!/B=6)7Z_$?39L)E7L#HY5K=Z?BD M:DBX2R6?J@<<#:OO: ]!DZKB-EJ.MV]X/F!ML)]ILV,ZHFW>F['<5(TUJ8]U M!Z34[Z%EY'IA24>.Y/PL.]N!W5: ^I<1$=*_Z2$VA 7O*YHY67_2W1/7ZQ1J M6$\SK Y6(N/;?-+B,P5XU%+H<&W\"]"EJ)3=2%=V$T\U_FXT)>1X5 M=T83.'^KO.$ M@A0L^"OTBIZ]\D&^@G:ABG(E1C*XX>R81A2,6DDW&)OFZY1N%3 Y(;Y/RUPYP MA@G"2'KV=-PSP;/ZT@,M?>NYOZAYTO M.X>Z(2%M)I?J F7WUE)"08;JO)&@5A5WF*?\&7*F)&I[PSC2_=QLC6,NLE:F MZ1*6A.?CJP.RF=[5-NJ..YQ>_;/_&8^'!KSS_C9;' PD+Q'D2M39F&C.]_." ;G&5%]#P=PW_%7";WXR:; "L(4- MR*3O))%6,2 YPFOFC=# MZOTFFM)7N*5H$VJW#W\;&"_,0.V!-BL15E&/#!X -3.]BARH-'];G]@(RLBM ME(V;6K\>M7YH[CTP6Z..;^N%R!#C@':#LT=^NZFP;%VQ$3@V&F3R910KX^!; M!B'ODP6:LU -T-R)LS68$WQ%N7Q;,E,8LPU@%^AL5 E>+.])(<;28 $-'>HE M-OB9,>ARF]GOXX"N&[.$_#M]J9'C^EJ\YG"=K\:FTTA)3G67QZ%BG^F@H MB%._T1+(55V1#6S-W0QXV_S(-HA^^:?B^5#7VP^@+ZJ,CD>^GKLZEM\"U7>Y -AJO!>>[)"5M#93VUO#F:/]Y5K)V9LT$U^*!MY<9 M8ET"=^2V"FZ*5S^^DA8MT-F=F5$T7*-XZ)]@8AGY3".DT.#O6BO>DP/;?L47 MH>'@UO*DS7COA2KZ*.BEKFQX1(Z-ZJ^=L0XR=-%5*\J0L;G);$MRGONIIB$, M$/8&+@M6;65I?Z"^PW$$65N@>!5<=O00=*%"YPL%7T@*:)BY@K;2N32 O\=8 MY1\N7'!,BB8YQW?$7K'TP*RZ\\^.F%X&$(D[A*Z/PUT M+YJ*6;4EUTD1!]OUPU1%>1QLZ:'J;V!8&R\8Q1C7EIOHLW@FVF2*'U!\51=4 M$35.W=[+PS\826#:L,X8Q]OU?.58-H:31*2D6Y1M*;$GD7G1RF%?FKGL4ZI9 M^J- 5=37#)DUAY_>H>S:<%.?!4B5@BR^->2S#_"Y_HT@VC6XX=H*OH04JJ>U MIPV_#P>&L"RHM#V-,Q\IR"'I]R2ID@(C!CSJ/*;MK7P>6;:NB?[P/VFN_[E@ M+.%^J+I*YP_(IS(?D._>-Q:G'3=4JB'U4EU#TR\08RL9RR%<>SWE7Z['^E$L MHCMRMAEC38X01HX\(UY:ZQ2ZMWQ&SE-:ZC%')[\4FY8?5>[.9'6B)W* M5WU=.;-NB!+EEIGW3U&W4=PYA!SUOII1^)H3$T47R;^(+J3&_GR+7".,%.7X M^_VT4-'O&U967XU/J]!VV):YTI4(R 6KLXG: W9F/J2^%C04-SE%5DT^Z-=K><])( M$':'\$72<-_HJMEX'$PVOA!A_,BA^5"(KLQ-(J',J,;QM(IW&7C33MWZ]&7A MQS]G1H,[D4?;T@IFA%!5T]WRVT<@D@*[)J@&>CXH]+Z;"EH+4R[N&*GX.^7* M!G@[!MK,U%F+5+@;Y:7@-^_R2P%#AJL43R@6T"KDUSSAV7(S_XT/(.M7 M9>L;;TE_ +KHY\J?BMW7JCX2AE[OQ1>_:.E'39]O<,(>;KZ5KC]ZA,OM)YF5 ME@[=';O-_8^MQF[=ANVZO1ASGFM&W0EC+1BM"V4_&&::145 WW6C_,-4>L*? M<8UB]Y*/H1F[]M=_=\ZW*F=N?=?V$(Z-U4(WN;H?U.=:G8EF$J)$(U M1C\O#8=.@K?W#<31NQ"F<\W8K=$>8Z^NWWPT./[M2-2>"RSR^4GLRUY=##,A ML^.7Q#;EW^NH)I3+X/&Q/#8MGB%S?G, :%+;*9-V1(>__7(@+PICHB,# ;\_ MDS'R!*L+^F_Y=K)=>#'^P(8F.X2PHWJI-E#JA?K3D0@A3=6'E=4* MQ#J!XHZ 8TKW''#5AAYOO*WROA?P^[DH? M=GEC5^#V!]J;UDH0Q"(*#!LRVQ9A:PUFAG[Y&OXF\N93OF-7=:D*EIN28\! M?J!K2%[HB3FY^<@D.@#X&XP>'"YE;<;UD C+^WBA#UH,6:KH':K.A3'L(?A% M_7/^)LI%H^^(-\AD8^I[RAES LT:\S-"EBA^E8906RD)VQ\63;:6!0!%!01% M]^9VAR4)R/L]7L& X6Z%G)PR>I+/W L65J2K1"LF4ZF(,N*RR4C4IZYK D6E MX&DP@V)9YB<6)-(R%[R+-$UVUI_X/N#Y4@718<@QO,2MYB3%5/4ZF6EWZE3M MKP=^=9G]BFNM0L1GE M(_M7^J3M"JQR3POZT\W_%U%E%P')PVXYY'^AN09VD?F4UC:(MM59#!Q.#C6. MZW&,E>$[RGFH2XDRF8B,'KF:KL#!*$;[K$)8&V,Q2YX]HS['YNU\/&XPY0(Z MF2B;F/13,V!X2:H>]SEMPWO9?N5SJR(*.A8__GEG3__]?Y*Y;-]:=OG1L8)UMPA?F@R6#,NOQ[]TN^'Y M%(**X4SQT>?KL+')_F9 55MJ4]DJD*W>J S8M]-&T([*-VS.V@1BLOGV4(F4 M-'.%;P>E9%@?E>A\4HW_FQ/)Z:X=A-R$U&9MG*$S+5C-!L9.0%&C@CR<)<5. M\<]]3DLOAT&?=Z 6Q[OFS6JOMXCG1$Y!&83'1@[O1D^;78A5AOS<.YMC,SVW M^2.Y#+$&HK?)"W'/1.H",-VPJ@%,ZS*LTAJE:RF?;+#K!-X91'*.^:SXC7+8 M3/C\[;E9I,\1*?%?/HA5'@>Z8BLFBOO, Q4?[SL*J5M.\);8-(B$/?#GU*W& M'[Q2H&".> *LCP4*QC*R4#&?,V)C$(&,+.HFLKR]*45ZF/+'/!?5'D;KD+G, M_3ZU%!J$3#/3WO-^SVC ??(-$MMU7!/RI?:( M2^<'-I 9KQ8JJRI'R")<,T!7TG3KXC4?] ^IEI1#^B:*B5(T.*JYK/^=1ZO0 MQ0%V;1G+BY"X+HPU#^/UA6PQWX!\ZM3S+$ M==?\]K2!MYG:?, @C7H&(*Z=XQT8TAG)$6$NFYSVN2<;YA>%'T!;=E M;.S,>UW[[R63C__WO$_.5[R$7.53@]HH,K%#@['Q=R2FCPJLQA=AL;U\U*8@ M5#O-1']SVK4GR=^-]5=%K?^NA]&GNG_AKPG"K9FX'9V8RFUDIM9,+)157])\ M6+=$UV?X$]% ZT1!+HNP3J2?QDS?XK4=15TULA^Y"(NGR38IWC?1.3BXUY\R M?(K=0L70_DG@0\Q^]\ILS64O5*;LM]S*1")&.,@9#A7BFO@[H,U 31O:%6K6 M1NC\H OW?=36*EQF2>450T#?0][+ =[QJD^1N_MY/E4M=UK$XQ%-$1&^!Z_^ MO-!05^;5@@OK2S;?-'.X69RL TLP(JU7KJ?OP\/9U,6ZO;)&YH<1/Z\J\: M1]B*$+NP'E1#]](D5V')]?K$,DM""T&8K=3YQ2KW_VK2;L378H:VT MJX*X86*[ R:/[T/N4M*-;Z-HF/WO/M^W[[NF64:85P7>N/01? ME>A;T!Y15++U;LK";PO,GC(G_2U,'&*E[E@S)%4^# Y[ M^:B9B4-I:$ODFS.>76?#X@XDA\EF8IM'"#]FSVMZI_Q*"\+(C[\ MS]O2]AWZ\_AOWSW=\>A_>3ALB&%9' U5!T#\*U#N^ M2!6?0[6"L)T+[V7P+K:,&,AYT< !O(ML59)1Y8Q08+LS3WX ]'A6LP5M!\YW MJ/VT/P@5O]M)0Q)Z(2ET^OXGOAW@D^T9%;VK MK60K??56QMG*8-O)V"6Y@W7\OK?GI]F/2@BL?:K+[+JZ>.Z+HE1 )+NMV0VY M:B,IUB\A!&@G3"F*=+KSB 9O\!D@/O&L7FM[LY8<4&2U_,K3*RZ/ M%O;OJ4@L.73[ +_Q5M^_K/\9!.B=-%FQQAZLREZ$*>[*&\8ZAOX?]MX\JJFT M2Q^-LX@0!@4%(2H@*D-*95 (I!01D8*@" @14A8J0PPI2Y @(5&064BIGZ!8 M$)5)9H4$%$(BA*$L"A$"08*0J109 NWO_[Z_FZON^Z\.FOM MK/R3Y+SK[/WLYWG/?O<6JC_6<[)07H12DI6\LI\0JU^KCL$UIEI'QHCK(>/. MNZ&7@(LIM9,>;D"',"-V=ZP)5;0YM:2JY+>&13U2( YXM&[.66%#&4)HJF.Z MP+(K'Y/&=#%%IPLU4"&UY$,05[0^=OV\Y;<&PG,FN%-O+0?M,O[*',/H*%W! MTXO^LH5DU.GBF(E#A41@)F(4N/ M.3]1TX-3&LK%ZI\RW?JBB0W1 4VNT=EK*?.TMFSLF>6Y^\0:B[?3\&1&S><"[9_#WP=EJF3U6WC1@(VK& MG'H$'S<.^-:V3.FK?G\*9;52ZZG3MP&T!)[$UA\C?P\8IG,B$-D4USO\/]!P MDF%KH?5;94@%*>I/*&K*O\^Z=KZL?_I)YANJKC"J<'?#G9#5$08"]YG*2@'5 MPWZC@5S^?#WA4>K89O,JWZ._MI=D7-QYK_ZZ@_FWD^\G_YS==NKU M-HQSS^Q_O>W'7T,&?WFU\H35UW[U1>:2-ZG? M<[#J:Z/+T&*:(!.32M=D?6?^;- .DVKHZMHWAQA>AOUPSUU6EJ[:@?UD0Z6" M@>*EL>:P$JSR##C -BA0NCS^8Y&Q#-LXBS)\,FD@9\2H!=(R[%L)DFED0'": M+$YA%R%D-+;>KYIF;OF7(YR& <<$7]IN<02&A8XM0RC="U4D>T;]DS\:@X^Z M[@2(;1T<;,C"M0KW>#ET'?T]E8"^R=&N51TBPT%B!V+#.ZA6))3!2Z.68<\Q M73WZ)VFG5'\6(HW>-]*^%>H8CIV-_+/(DX^R (G<./9&("U3T4^BD?],W3: C@")6F V$[#I#H4D.E?I?4,./#M\:6[:ZG1J/4 M6J7FWGCNUBY2&EKTF+H"%0^$<9=A6ZM=M92G0%I:]7G -1O,.4A>5T7"2VKN/A5, M"37GLQ$A+P=XK?GRZL=DMSZE2\6["8'AK6CDK*E@O47CS9"O'C/45"=.FW!$ M(=\'1%>";FU.EAE*7;!1W%E(UT5MI5J]#_ZDLGJ^LZO3R3H0]"C#35R;O4&. M+XZZ*HAN_*GIV,M'4TTF#=5EKO:[N MK;W,N<-4'UI0H)4!;^=#3HPIRW?R%MH6XO=# M"LM-U))(8%*G'\KI0"\55Y6Q0%D[0@=R;FVJ5:\_ M-70U%!9)*(..C*%U0B/B*);0;>E6&Y2%Z"\^ZG)%EUAA@_#,<4%-+)K27)_) MRXF7:\X&!Y/5<+.:I_;,RZ1F><*@:B=TMQ-M2+&:7(:MPDDPZ;'PX071L9<2 M;R]O8'XHU4X6Z,\ .!WT3(H>SU8V9^+686K67](PR*!JLO/*(M]61!3N ZFI MT\K+X6+9*C%'-O^/M;G*MQ!-TJOOC9&'1M\] B?,=2WFNKI,)-D4IKH;D MR+(CZQAF;6M->@W"MU\*5@7(ZSY5 MES+K-3-4.TAQKWY]_K(NB>]5^?I"0_)\DSN Z*"N'A5X+L/6E[53TR@'W];, M3;USFW"U!JA99,?JH-?XA/"#QSA]\RW&IY^]N*.9?O_]\%CPG^"+.X[;5:%J M#60&U*LVW)8F[EV&^0'K4L.7CGW9:#+$2BX1N5\"P=B=" UV4E45<.1$8:@;FC<]VPJ%=X;+# M"FVH]E53KU(?*R^ "B)<+96'&X!ZI1'HOY0]RJP>*RF-B@MNI-D_L1MV19#2 MVE1;^F(>V@_.DOU$6^9MM/F"'EEL-3Z W3]7M^(VV"P6RM1\;_5Q*$,"O\6I MZR.FXYXU=J!U)XA26IHIDLEGX0@ /I0]<*E:-]J],=W.Y=285[,U1'V%UOW( M/R4\O3]"M1XJS7_#4>?#$#!P!C.=0S8#';EH8$! [:@VEM9FJ.Q)1&[N?I*" MZV32F\S:^@CR:JN/ZI^@:Z,V RK%6="V6I3ELJH]>"AC5ND?)N'H0,E="X7[ M!N:=J9OQX9@^E)6X=L,U1!L]6671KX)[BN "XZXOJC[5'I"2;8+U5/?P8+:1XAE8-1#3WVL^F6 ['&W0]H MX[W3(>J%"UN6'E"R\ZI3&I0W+%?ZLS*[30W,CSFA9 M=D)[8*./H&<\Q=E^L+"@]%UK7!7^6NJ#HC.X*(,Q=X6S6N-X4G]:A@GB&4O. MXKS.99AFJV3T!+$.2W8%V[M>49Q?<+!VG/PNK[4KD>"LW+\>#$P_5AEI^(J(@,(D/BU5T-5>3#-H M6@ \"3DV0,ZB2(MDK8^3@:JU_:(SR/.Z0;U X'26XJPR M6 U%%\E!?=1SM)&B,RH^I%ME;J-P4/7O\OP(=#X4X\O#LMP;F_BVIJ>$6N9! M,D*0[8SY $4G2J^K=!*#YKZ>Z\%PVGHDPM M(;,:LA,_MB,(YP5N7!#P\RK?#;^6MUAZPY9T!EQA2AW0LI.XGM*?)X0K[2O( MX6H*'HO>0'*3G FB!_*4^R3K2[V:$\*3_HIL+/5REAWC^0Q&5]LR30YX\>=E MZ./L>I[2K1HK5.U6=5.!4[W#Q^#OJ%VF&DM/")=D%,>)Q:[.A\@L3KWK2W$! M_@SHT4',H&]B6T"][4WL9#%]/=Y@R/":")S-).,$F2G4V';@U@P0V5"X[7FR'QC.#;F*I6J5Y):+II;TJ'"5F!0G MOZQ6N;'2%J0\;Q!]L7?U)YQA;71@,(^,D]!6?VJ@Z_H795H1+-N#_]JY=1>/ MC+%(:6'D5E=L1?D]"7J(-W&?J_:Q&MW[^ZH/Q'>:*HT4M2+(:S?$Z3#H:@FK MC\)73R'@0VV+Q!0EGEKV^I'2E;BI5^Q-E:#E%JEWB9%E[,<2C Z$YF8Y/,F] M.O3=1+Y)*1TER-I*-)]&1U,AR_E>69=D-JE;0LNA[ .(K528<&Q4>1S:]R1X MM($&GC0?8&2?Z)FQ-T;J?)HHB;HZ4>I5ZE$1981+_]@O0YYO J:OV2M">Y]2 M:'W?;\P\*,XY^)-[SN[;9CEVQB?-W#>D5QS<4+'RZ388K.Q?']5O[B55_L!G M5J_S[6>A)7M8%N51&B85I!R>3]W O,TN?E"1]Y%9CX8!/F&/??LS1S-WUF"5 M?;8E9E"K1%[V:*HAX,N$8X&66G!W4/KH=0NR-6K0^0WB)"A^H?S>M S+5NU3 M&H)K>+T*'S7W3ZD=@XK: ^5YB\6"G&H)?/.4A._M%<2;F:VUC75&I]\5"$EE MKPK-7[[D#)D/*?=5X^5YZ-IE&)PI?#>BVI -: ]U!9KJ \(.W#HH[2@;R&T4 M<[8(W!VSV(;XN*M@=RTI\4G.1VQOFNI@77S53!B(2;&=6_(ZV= (+*3;(75P MD3]#5%],JA'E?.R?Z?_HD"KA3XY=($7;S.R( MRXRXX)%S9K3H=M"99&4?A8>NM^S$0>8+G05NDQW-57^\U#T(S3#<7HN MSQ#W3K K:8CFTNV^Z;NQ[DC1)XNFII= 5Z;-=*T]^N9B]<#S[K7E(F^/@'YS M&%-$,U:&J;%ENS*,I](AXP90)\$PE48+&-9AF 5P)0E!/150LB@NW3ZHQMZJ MY\#I>AX!-!EPDUTKRU+N*!$;@46)%U)*+RT.P0N07=T_\L0%Z321CHU>_.:=I;XOIVF,49WTBAQ M\/8)1L(3[.I)GM*1DJ:L+U;H+;YX@%6B*3[>6)"./=RB!67$#@RR(Y0% M-JO6WP [NT5IG0IU"L6H[S)%Z0>:O.=H4RP\+L0^#57N8P_8!G^43QI;[2Y+ M\#[R^XD%C@YJ19AN5KO!U!7I,BQ-7EMM0N4*QN>U<'?5?*+A);4W M.5N5ZZZ<9]L *1V3 APWX5&4PK)Q$.58P]7Z6U/N;2MF3M&V *.2E,Z"FL@F MV\:R^,;I>,4:B">G@AV]'70:@HEHYP@XDD*Z6$-E3%H5 CX;9%3#Q;/7D1?[ M;)D/31#?#Y"Q4@U;I8<$VZO]Z0N4W&$8G#^&.WP.3[3>_WZI^=0 )64I2[E* M D_AU.6]PJ056JK>AV#;T%HL=%%B7KN<[Q"ZBV?7' &7K\V26)GL7X;Y\ZQC M99K?$PX>"KB25/>A.#?=6S.A'VUDJ3)NA3[R7"H MJY2L!?6!5A@(([5)X!H4?@=\+)).X6OA)/W0MS,UL5:&^4.2-0-4('UBP2!/ MX#Y?,)C+J8P8"B5?MF$%:L9&\1(#PQ(OE ^/1!D1/M0\/I>P,,#OT4YW%JP_-U]E^_U2J>77J@5H9G@857M%MJF4Q=%[6_(!R M"5U7B8# FHA\CQ1C-U[U2-"0K26;KTN!"Z.";SS+?#^57YO&WCH:F>L8-VMX M:^[SY^Z?5RCB%8=5KW'URS"9FY@0QT48N6[[%&KKU'G/-B],@ATY: E2D[N/ M@*U4$48WQ/U*HEAS*O*WT658^VT9 5FSD2/@Y]]T#/SU/<59J0$IOG4T=P?] MW)9REF&7JJ\MPSKH==2,F0OU2_3EROYIN)81^$9>,%O0F7W&%JVGB%:6WR%/-F3DCRS#Y6>@>8+O0+G=H M#$:T9Z]J95OQ4,X28\?/@JE0TY5@NX'ISF0W9D,SS_8"!RALEI;74-Y7$TNP MG?+7Z$G3++!+;JP.SR32+Y@4)]LRT:S HTWP,15UL@:*9UE(M/Q\@()[S5VF M#ZE2S0(/]^?$U,+=+YM>1K!LSE6/DA(ZFVXU- T.I5G7V"C1$N-JZU4B-8,= M%^.F%]3W.1 :?*3\#K(!W5H%]'2*)ED;I-%L.1&U*7%-N%LRE!:X#@>E 6^& MU%]*FD?KDZX$YO2>Y3%#C(]!/95"Z&KW:8(7=^%J4^A+8GS1J)<\A#A_C3K< M+1Y9Y8?+0\CV+9"_95N(9[_J]-"LG5?U"H:Q[-Q\0G+\SRH+5J0% M/YR/U)+U=#9:YV=/-.=[WFJ@K*3TT%>A+RS#UGF)D-P%;+7TJTKBK\0>WF>!-6)%'KS?,*H?>:)FL=UF6M>S-V*[X. M*6RHK7884S(OM#S\L$#O0B\DEH4+(;%2FIU8KLB>+OY+9= MQDY<<[@A_EU2E_NQ35/F[.Y]V6ZDN\>>&6]M6]9([3OQO\X,A/^Y#$MQ70LX MRD9KR=Y0*RCTKH=N \)70B/7G4H+R!YP:]?K>4K>#\P4 '0L"_"IEPJWD0P( M38;9KF;02+M#/K\V_(I4T^5J=ZM*YVZ;_%LC@M@@LOM3-<7T(1V0GUTJI&B0 MVG 9= VEEIAZPQ%3\KH$ZNP5%Q3>5L=EZ($^,Z^T9\E=KMK],AL4XNG[3T8I MKP?4#"F%9TW&/OYC8?$B7;T\%\FWHICQ#QY=",AR7#8/W)5:=N#2Z8 /4H!6 M9V01G$:Q&E#M4+I#05+\IY[2%!"._;6W=FIL);@OA=(=M(+ %=+N4?9:.3B+7GC254(A%%MD$K1[[#< M?,?I*46TJDME"U&E\+3@<.5.BO806V/":>T#H+FK$ %\8!DT!12)M9!![+=S MQB'[A=X/CR6IQEL79UI*;3ZTOXG!:?8NPS;UT!^H>&C@&!U.Z>"L9_8*>/)C M2X_82%*<%#$]>U%-L(M>@-\**-08_ NDWT!MEH2$G\AYL]#N:@@(TV?F MFN]K4B]&&=7BT;*#FA9,:\4D!^#6(REK*6_H6LP7'U3O^7;JZ.6VA1Y2LZAYKXV]S"+M>FAST>"SY[N/03.+8,^S$4G]\U@FZ8G6X1(P2S\FL@O756 MCX0_P8\M"'Z/OFZ_Y'[2$KHBS7 [$R'4F:[)E;SY&@8\9^7Y\F.JG2:=:9LB M="<+#>XX9R5>Q,>[-CZY[IJX]( :#E]%Z49KH"R!AZV&P6/,=6EVWE;'V6!X M)M,X.ZS#U"QQ[] TOQ\G#/'>WRE=-3#G&!08E(X%+ 7/[>?M4[^%-(MH?#H]8T= ML]<%'1TEM]!ZK*WE$=>N5B:&+95$/B;EZAN4B^&Z/649V_&M8L[FB44'UJ_N M+JQ^S[*]K5>(#J^EL#ED2IY*>]!UB])I@&W2D*N"<0#DS1JECL \MSZBJ\W1 M2.LF>YOJ=6['J3^\#T;(+EKG]^F]&TG_<_UMV@%%*"7,^1<;B MY^4&_NH>&QF'OVSL[L(<9$P"O434#WT]&Y^"KXWW.]7=L?I*^#:K3YUNW)CT M=\*.Q6684E\HGV(U ]NHVBR_I]"55Z:N8$PUH01:7]]A;;H1U"Z/)5RBBK&3 M8W%*)XLG-,)K*!7*6/7"_%1M0H9']BS;3'D8LL(3I"%G']B/ M$EM#S4#T#:IX^\O(&ML+ [$M5ERCAH+'DTZ#?RZ<>IU8VUMJBC1F $?G(WR*3TZ")S]A7GEI.'+ 7T./7L;TS.]1A,JF!=^AP] MI9M#!WXCHJ7(29G@?" MY1=K=?#!]SIF&B4VT0E> M5E:>L02B+X?C<#4@X$@LH[XA"7GQWSC?R]G-4-$)M3J81^KAT<0$$P>=CR.> M/.1\2YCOR]RCC77].H+)Y9UXR_12="V=\?/>MOUFA"+OLL/4JJYRE97R6V7./;5CG7+5(Q,!?C)R M>I_81%/,Z1#J1SDA6A&:)#8^&RNQS/ N_%M_4*118S9+%W3S!7RRI2&>;_'] MI!.SWRM^P=KWIC'*8S,NF8,;^02\$ MUF&"!*D]L0S;KEX0AL')$=83.X0W$< IZK"4:R.-5^F1+ ,A=X4'R;SG&J@6 MM/8?F\9LZE^\:&SX4O*L;\[DVI>SG$&6>^GP6"CIBE]>VYCE($,6V,8VX4L: MOJ9):$I#,[D+5"1&Z"FW+15S+F $^AB>_7V;'X=8^_FNVGEG^B_J82>;;)FE M9Z-"OP-\FA^1:"?0PV,[ 7[SN:6'%1-.Q0%&A7<3B78.0X,S=,#[V\ECR[;: M;-6^ETOWR9>EN$U1P?-5P+!:#!2 @2?Z4 ,5[7?B0%JG:M%P2%FCU.OU^!L#NV7%7+X*W5\"J>1(*\U@&*%H17" M(/^*K_MJ7HIHMU1[WKH:00^/#%!Z-RX86"W#-!R*SI60,K>P/IQAXC2CG-X\ M^*55C+W)2IKI'RE=NHVR%(>$2\9ED0H?)9HY>(EMJNH+14(7$#=M2_6#27$2 MK=JV9=C* N, J%OLLDMZZ5F$RF5H?LG/HW[(O:6D+&>.LWHBU+E?W_WU#=C M6\3UO3MW;TA_M/_T@OJDSV_S6T_2JF9DC3W8F_?DOH]4T+IK# M5IA+"D(U%6[*=?5+Q:@5E4H+$)/-NB!&IZJL^YDN5ET&"'CL>N4A"7U3T)C' M1H-%NS%K4NV'9T!]YQ!-HJ7=[9.#V41['FG$+K*\60Q:II)_6/&Y EJ&=:(; MQ\HE1+AR(Y1=0]ZW=)ML61-5N!&D=>%6:4R[[E2]+;3L![5;Q+W#BH[/WST' M\MIJM4(;Y>ATU8$)OI.\1)H=91+&I6LC#C_KNP"RRS^PU?Z<9*3VZ8/S=*W0 MB&!B&WH3A/%_65?(AV_]A#9P-1\ET3 O\AV.SUMA,9M(>>V%.G<^#][WVA@W MMIG%&^US[[D%YF5SG"G;E,<@H3J)ND+"2,!+2A"F4_906]'L/:14.34-H2NJ M>\'A0.%4ZL\+@7D&\JOEEL/VQIA]M:A$D;']&=1AV$MP&7;=YDT=^;!XB;B( M!SB9J$-2HG8$!0FDOBPA/6P;V]5?%=L+)Z6YL1L'&(EXCX%J:?.S <:(PM.B MH;F^N2'WT*/"K5O-CZTV@JF.,_%H0:UJO;OB<(2A@3JK9;A^IU*#@![KJ)G# M.\3PM;_9FN>=[HN.Z<[ >0.(SFI-3%"LB^TR#$/WZ:.83UR+B4-$W.%WM0?# MDY9A[JZ6Y/5+M:X;H*G@I7JTZ%ZH!9#6SDE!,$IJ"L P"6)Z2#)AC6LS6DA7 M8LK.A')!2_&THU%MJLT)TI.V+XH$7 -/&2+&Z7<\' M>.C)@]B"E?UCQ_O:<$'O1R/S/%WNS?>PWM&!$SWH3C4GU>?)_1O D:."]W2M M0-_GWS'^3&YM:N!43W*T__:@;]L).KR6_-W=BN0-/G46S:^CGSO#*!J MW:#LVZ,)I9NX-EG(-&R=U:1T(^KL7'< "^DJ6VQD@DSI 1ITM1GEW*U+M2F<3[O MB>3,"JD3B3U7F1UD-6N[[:5&.HIB&>8U@V<^RFN>I]X_Z;YI_=_W052_H$5% MB.==V>@PG*F:EK9Z4\]5!_#$L^DHBZM-]"Y#>80R.;GV?<^G,'V)A*M"/J1WI=I5Y 7T"D+\,8\$YT:I-C!X*& MUIBC7P]D[^%9URC10*9+N"_HF,5H<3T=E):.BBL73IB:JID\-8 _>(> %D]? MD9^RR,)LC#02RG#2)C6''5:/HQ^Q$ M:RB9&X3X3N AHS&)4R>+NKZ9 U8=X&$=PW;Q5O@YP; M/=$V!QT>LH^TA//A+"_""3BJ@O)3E9@(>44O_4[DN4Z4I.840,-06QF?G@//[B MG=Y7IFB6TPVU%]G/Q,E_5?O980J7RKB#FXRC;S2#O*5>\LC>'/8&SPNBA*^V M%UF$(Q_'3ZK)Q8)J);_&WBKM;U'7<>_GX!W!W8(GU.GI:"72)56>99\!JJ7THT^-5"LP"CE"@@K\3X9 M:XR^(5QG:Y\=C%@!A0ES!5*Y%J"^RL9(3,8[-.%I=5/YN)LLO_)/W4_PFJ+*ZFC% M:: K;1X?P;0Y-2:9;6N*G:-L2U7U>WEA>]#>S^^8'/@!-W>0;]W: 1 M^6?(/A',D_\,?@^P;Q23LB1I;02_[Z%YX"=N4/\T,\&K-I.^KG:HT]2X[WP] M)U\P*F-%:N44B4Q.AG[NL.@C!Y9C7\<3-O6?8-\#D/)"R%)QC!37MKC01D= MQ(Z[$.V5 $VKB;&!^S<,SM,V3#BUI[ZQPFT1O-MZ'JBIR.]@5S_>]4"RFF=O MW(+ELG?5US,*B=KXC#(%PIUOJ$]('GV KKU[>2UHWS5$@R19+MU6;)G :;-V(DY%-_HS: M"E+:V?RQU_;+,&-2Z:2K&Q@5K!;FL1_P^<=[[/[W3K&9!6& M9^?BB.')KKNF"1P-!(XZFQK62BK./+4LWQ"4ONYZ4/ID9,2_*_K_:B7/6DI' M7YP59+6ZV@-I';BT_("BN;HP9___[> MM MJB5(7XW!'VI;:Z=4"]WV+9&AY^?7/NC*?7$?GO>"([G/J\VZQ+9=A7#LR MZ1EGZ0$'7YF %^J1-T%?@>.UJ:[:*GZH =#RM\L=4J0FV7Z@F 64W6#OA?;O MGI-AI(:MN)5GH0.^O/DM#[LHF@-$LGZU=VSQ(@DZN0Q;T[246KR?C(0>B.DC MM2)Y3G\704PT\MQ5*:V=?KF9N&L :4,^61Z)T)'56A=GCGOU,= :Y #PPV\. M0[F7FE:#1QN:,#,(F:;"A>R\5*(R>4]&06G$\A%- @8#HI-1X>+L(][KNI9A M&U'4Q\>'3 T@&B#M<)@<8F\!RU*16)G3Q3(">ZLXH<4R@#' W;F6_)& (,Y M3U&&(-[K[FLFU CPYZL9!2N_JAG]?F"LQ)$K\[3L@[GZJ?'!B_+.*:V#DRUL M"&RM-5;N&63#2$W+L*ZK5,8Q&A#7WI3;>+D:NCK;*7!,8]!N.8"1JIUO4?9/ M)YP29W-^['#1BD!L?T7B]1M6.2>C!!-"X^8?O)!3D7:MY68,WRN54M]O4S)^Q MX-EEZ+DX'VO(P01D^?!J9^PX.J&?'!H69#-+BOB)UAM.#M?6)X MU@!Y_ZMC5IFP)_QG\,[=L^YUQ][](S3_??NOBRHX-:[:@ ?2FF=R&%_]$5T MDFKGTBW7/:0?2%8>T&M)RRFQ++OVO:+_O)5?>('E":<[4Y8_\-[4Y"[#SH>< M'L86>!(T+BKV"K>H!FP6#CC>L=#]<%_VVOZQ^[^=XOH7"^SA,'M;E\*EM.D% M4/_5F&YSEA=$6TN_(,7<#)ZNR[HLGKV%@]M[(;>1K?D]?0TLA9U!Z,&W,3B9 MAE;!]"^1O^"P[\\(L1C[WY9AGB>_1Q0BZNQKJA5^D138$D-UH/M)*"E)X3V0 M)YIM<]&6+_@#Q&D@+%?1-K;?\9>H_&A:;"WY6O- %9.C!KX[*TH28$#!N="]S?UG1M@844/ MM1Q#>?,F%+5W?OARO[@/A:O\=#5OS(@W?ZCTH4>]]T5\KAM+-G.RR)X&-?FV@ M$^P+YZ90@VVBIOUQ8EP*8@/*JI2$?&6JR=,_ 2S#TN:*?W4CK+_C.1-=4Q-^ M!S_J%SB(O/AR8+Z%Z/>2-3C?$_IY(6"PEFAOW/WP0:)>YNY_J$G_=FA#A!9D MR7M!XG1"55 40I<3O@Q3&Y M(DA?7N6KZHMZP\JC%N\.8TD>[2H$?QZ/,0R=M'E";3OT:,HAP$"UHSD<&)%Z MR Z J\2<=B0MU(0).0,X,2Z]BKV#9"R/)7AX@3@:B@!:GD@2D_=(:3FAN]_. MSBI-2B9<5[]D.2TDLS=#3CC=^%#[9WVH< D&<=:[. @ZTC6CY7>"9]^\E=$3 M[E,W&#.5K(D)>QK,C8^TPO::##:S##7,O2U:_OSN_TK%R14KE6EUKKV_+?,S+&Q M-:#W/?G#"BBA VY24-V2%.740+-M64M?;>!PK:.Z2J<#,6&S:<573R!/I4&M M4CKVWVT5<&1"!9[4*+[';/?$ S-#DN(Q.*\S+2JW+XAT":(=35&&%T?TL :5N393(*\=BB;8*" M>&O]TS.>[*^69KKO0/3HSA4S3)O 4TW-@_;9IV3C \S$@,]?3@_,U,S.S$1; M3#_]1^AAQR\5HE7P'?3-X)-8O]-G.RV08DP=C. MW"9YK;?3G\D4PUD*$4S153)=YQOE"\9!F6ZG>6-"6F=5*U-B=W M4C7(0:7!S5T2F[4B,^9\]H"G'*Y'.O7!UJ[6,.*S=U&4P=VMA.)D3;DK7E(>TP&I^>3";:"CW9S3*OF7^N3FW\D>W>=?>*UKUY.O]OONN^'%9L4[T3&G)$#W&&5501G0/X6HW3 MQ&2B%FUZ2?&]T!O%-GG+#.7U57G4++$[]Y-.$[LIF5Y]?/?MD_U^)XE!>S9'R,-\TH,/.L M8_)B6I#>S-0N'U[,U!8]P1^=G6^&=S8RZAF-F0=MJA_E'/PQU2['[K0O;,WD MOY] \Z^&ZI9ZI+*H4N3-99B.T@JH[.Q3.D*T6@@3U*_<+'T9,S=H!C2F1\O, MLWP&QUX/MB>-_80F/>^Q:)AENJW^W/8K1RWAGWM,$'+ M,/#N]T!7N@JA="%J3US-59E <2+JYBF*,9\5$EUH[JH/X-+)\370FR^OV*N; M.7P4MBBQEOO\$[PX(DX/&Y7?\[%\T>H_:;[[Q5"&5UB0S9;J5+I10@V*3:0I M@35V81F60O8_MTU30EP!/?B15,7R%#"NG[V\:UKYNVWC&#XHR[7+%MW=&_G5TPQ>[RVMR#EBM_&#FFXZ-@CW:,$X^ M)!)NA$Y0]4(@ZO&&9VR0EE[#"I2T'"?23X.&Z;8$ZYB. 6;!"?$']L#%YWUV MU0ANT_'FPC-S5*V(?$2:'8/1%Y/HT#GRCWIX_<=4J_0+C2\R#XD*'5-)N]QS MMSZ^=\)ST_,7Y^\O/ \35+J;7+L-6+@[/VHQMZ3PYQSH4D MG"QE?_7L>UVU_NN3/7<>,=CYT' MS(K* T_YWUB="5/*H27U__*74CEXV5Z,/I0G)J9>8@HWO:-&37 ,V3IG@TAN M'8;2P&?7@TAW%6'?I^*TH7ZW\S;A_3/DL")2O?<^:Z0)XU=G*[GP6>\T2>U] M<"YN$]FXC[U[BJZG,L%(LV8-R:YI'4[N)6GIK,UAU1--EX+'4Z/GM1P^3>2/ M_K8H2Q&F5Q.M&51X55SPQY*-33%W5L5?;E?UH.OR;JD,R7X0LZ*Q';'Y$ZYN MSM4Y!"/_92GO/OL:E)6 M:]Y"P^M58Q/4D?Q+\JM-_-]L'[]H,"I,2[!HJ"UU:=?GFCZ^0#!_]D=F7V.E MFBYN5'5P&'G)Y$0@62SD"O74/Q#LT45=X2V!WQ#JJ<'EVNP/WA@/M<)QG9EM M=3U8R&US\G1LLKQI6_HV#'3(N'RE+))O8+H-A*>=:PYQG?RL::3(BWAO'/%^ MA>\[XZ3GIUZ9/MKG;ZZMX6_YJ+:0K47I06M3-D(T;>]]-MNRYOH#"?$W,)&*FW4NN?> ,.8MC$:S+U-K.TNBY M2<86D3>H(4BL.;L:.M#95-"8AKY8*U"("P;SDF,CYKTJ7WSL5ZVAO'4BRF/' MN2.<]"OK1[P RPZ3\+;NRV#8#W%]L398'XB^ID68P2ENDK*WD]'J>X5; ]T5 M"]LQ6A,46R PB]&<;=P>:L(G\,!--G35'. L&G MIFBZM"!T_$0=C]&\U:REZ6XK0A^U(JY\- C]3NEBGJ=1^MY3H:]Z+S1$>:KU ML@D;6"?;HW"-0M1[J#DG=?6<<#VIS*.E#G0OS (UU83AE8*N&T4Q!;M2+K$. MEQT5[,JN(&DK.L>,XXW;71WK^7>YJC5,'BK(:F0O'D&=6(:9V,/?>03W470H M V/[^2@WP+D]KNOH4@$Z4NNB%J8]='O"?5E9,P,R!,MC'GHMA2[#)-H/2@4^ M8VN@-*V;@-+S;=6N!G!K/T<#^ M_>3I>9^(Q[-KU-?///ND!-C3D"A21/N2O8Z\'_)" MR+^GKH9">W]HP6B/3!H4;DL[_>#C0&P"56MX.R".SX@?>;/3<\ ^"V,'1>\R> MCIOMC_JW2 MA!XHCD8V4/27GL;V' A2JZ=IG)2DTN@&_NB7J&1L&S(6PA"*>A^3$Z%W]L9> M9^:-0_RX0Q0]<)R+3/O9LYH4W7UZ,$^REE,%Y;5_!P6/M-*KYK_&@WI2:2T7 M">W>&!PW+1;1-:&N8TLEKMH1 DY7.0H@:<&#PZEHDS ^K/>N[9^ MX#,Q6TA>?DV ?5X2W\4J!/K;,DP[!H_%&488&=Z(K<9XPA1%TK(VG!;Y\K>F MSZFN>X"A9)1?F*1@@ZKM35?7&(+6SC:JXY]OO%R$SPL^2;*]0#\\P.ZI'/8L MPT5>*W:\^O/KLJA%?PF72NQ4=2/JNMK0[Q1B@S0@021/6Z(734#L(>:4>+5J M%\C)*$O:PD0:D.I/96Y!,^P+W'[/M#\C2<;T,R#KN1"#7DS?G,+8F/K$AG\^ M:=/+>Y8OCA<%C>>8K;[RP],G06'77^]+,?_YS?.M)?O*UY\G1^__YS2"VTKA M(YCP+,YY@L&X9"C#%0[=E32^)*,;7!P\*2N MOZ[ND2<[KU=45,#\?6'^,/7KIR=,9N/SAH:Z^B0KO-?!'4QFPXW5/X^,8#N? M'UZ][^F&V^YZUI>?7*_(W 1;@_EW\TO^%T-LH0RAGUE.]RGPG_A\NA%YJQF) M?J*NL)M+U2/ON2E[];>HB?:1+_CO X9KT?B"C@*%;+)>B2'YW;)R+O$QN MF*CIVQ^#+_"9^1@_PT3#27''!H.#/MX7&N<&\>2[,F&?>V]2UZA,R7#@0UEN*-\^Q*]];#]8EE[:V,AX 3KFH,(EQCU>[6-(<),\-S>7 M4#FU6##_WBFQ(.=!%!#9X!"0JRK[1YFUXB-BBTJ;[ +- PNAT#D0?3@+!]1P M-AT[WEX7-'G-IRQ\^\M^LKMX-/A=B3Q9$K+AZXZ!&)R@W.O5T>]+MM#%V7E!#8&#'+0.A%./9UE$?D?RRP,Q00YG1[ M-Q9MK%KQJ3'7P.G6+J%O'8/32&A]Q&I(G=0S"=JRI76VW6LROV_);F3 M>C/1%]'#S9V"E-1:*6)8(:)G,A/W7HDKB5+M@()$B6$!_3/O!/N:>?;.2]H) M,M=/S)2LQ-(WI/#1"Q&M7P@:F()E6)@Q4="VX,W?"0V#^ES5'LA?1-L,97'I MJY4XHO@UP74/^11U;#$I3+*N(]%G9G'VJ!=^RJ1QT5^88F>S81G6>=>M MC%27>,1%[S(BD_WUGW='=T.C@)>8+M,'>MN78>O9MM!/O1V%Z\ +#Y@#=HK' M=9)^\7ZYTYMLY^/TTJS\6[Y@S^<>D?)TKMX,%#KPBQC!&D%B3$ M FH'5 N3@ 4L\";Y";XA6%540=HE.&/.Q!B'N)6:K.(NEB@KRTC7I,%4W4FG MN,Q+,0]I:Z'T5>,X8Z4O$*C25#PA)H_A6_ #K\[LI;8R6>568&$Q4+PD7%>LLF5M%$WCT8*O*#,Z5[K!?FB[>WS1L9>!S:VS/_CGL[_05NQ[;*[P3)L M[V[)E_.1Q9_[_/Z\![(#!6N_(E9=:0AZMM]G[XG_A /]?]3@*#"M31WKD**= MLA*$9\U!\\LP*.#:M H)7,U^VAI^I2B2^#:^S);S=*RZ:/+V1)X@[G'?__:DHO^J;=Z2:9'KR=_-CSQU\,/]G1GG M<_1W9)C_JC5S>^N%?95Z.MT[?#4;SO\77/W_#OM_;SC]M_W_V_XOK>#Y;_MO M^Y^9U0>X[C+L=V[-,NQ=^.EE6/_$U.3B?\!"S=1E&'+05,WS5>XVCDN*V27D MRQK^BW_T1H;> J7VBQI*;_Q'8?3_G 4^)/\ <8%N$3^'O0,JD[H8OVI:D?,Q M? AUV+KAF@O#@19ITM[8]""CJLK,$UEM!D]P:?K]2T5[2/(:V%R^U6NVKI($ M'0!GCP_:JRFK4)]E"**/]=E;],UG>[3FS^>\))1&$?%:DT&A+;_5)1;&VX1G MDOB^[/.73A@(%(F&6#ZC5WLB+I]??T7NLK_5P*N9ODLB_&OJFI_:NP3_?LWF/_&F M]@ MC?F-" 2>!7=E%T-WNQKS&^BB:KCO@(TL%K,9%^'D,I0>6^FR]DVD <%G MW.MM%=$^X1,AP--F3A$T4^R?:GF.]W:%^X[M*SUA*^Y@8"L&[EQ;$:J1H/"C MO'&*+2RK&%,2(,+:Y"=1CH)C+R6Y8$ NV>3QI"#DS]QKI0^J21V61,T)HYP' M"9MR@[-SBRI'SKX+10[;2E)%Z;^O8Y\\VYNJC!3#MQ1_(7ET&*W+W,[,;(N? M(;M4OIMRN-U1@7W89 M-;6/F8 _HFG][#BP MU]MXW:VZ7R-633E9C?>$RVN6?D,=*!W!4ZRA;A%N781C=71#X7:PM*90&YCG MCMYT*-=ND<3T,^)-/X2(9[K(HK(+M(,'!2HT<="$^QEQFV+ZXM MT:'[#*%<*LY,!;LHM18NU@W,#<]6109[9X^5E$\:WJDRR'5*O*47$AH:@MFAH=52S3B%0=4<\=#['[2]>5!3 MV=][WNKOENW[A^G\D_./GNO MM==ZGF>??=:VJ(:HG=0L+D,KXM-/\!$=^A4UB=E(C?NHF1%Q_D2[';VO2^?H8>/@!SM,Y-LF M#P ],51=KW;?HWR-."YL9Y!GV*+M5"+&1]S9J>)4]M6V>#\]CA2,'.WES$>F4+3M=3E!DPJ!S@0:5'5A M(S!.Y&%/[35/EB/#+Q5WA7!7[F']*VYHG_'V+(K87^R/K#+K"-H\.5_HK.^6 M:'KNB;.^Z>/W.G*N*N]NW0TWNJ;EXN]O>'AOS*DBV7Q3_YQK!7*!".ZGYE=X MY,_*@DK<=$U\3BB4Y:LX1' N8,THJ12\=HIJL%3:GDSF*]+4_S;XU)1Y=B T MGY:L>J[OY98'D3GJ7$\IA+J^O&)?^@:,9EB+CE3S]>)>7@>+K@&?JF=TU1SX M3IG<;!@HY*M+(?&T["Z%>VR'^A^$%6^LW6TU JI([W94<\VGKV/GJ31FS0OS MVZO8O";JVX0O:5$A?V4$[4_A/\LP=G9(N_(P3][R_XG_>G4SCHC+&5M >4$B M&"8\!%+:ZS,0.HQ#X#VD.MZBE8\/::O/B.#HUR?.Q"\NM7EF79Z$5D4U$+1X M^.FZQL'\MT[]+RKRZ]+6/:)Z7A?_M]7E__$JG?09&_'V0?N\_^P]BNJ)"#/O M?/JAOBZQ,,OC<>D_0@,G[./\)K]M96V;OX5F"@,D'R+9;?*(..V(SM7XHZ*S M@U:7>\M$6VUD^5!TS9IVZ/YC#&+$JQQ7O#__T(WV0,/M=_;=NISZHO>PW,#E M"V@[@I.XC!0@A3S27BF*)QXD^ ,(U@KI_-NL@;/](I\WJ8I+G@WU(6?>DEU0 M(-?GVG24L=IC/_8L^8TY"WZ"A!_9QKZJ_*Y!<^?9/,15!$:30_DJZ%%(S M<5_3>A(W6A%02UG7_'-L?']7]OU\\;\'FP*^CZ>4<6R\/ 76;)OZI^U83. 6 MMI>7Q=LTG:@0/.?:7);3/K^D X]?/QZ)NWRQ[<&!7R)-Y%HG#P)SJ2*K/'QG MJ_9D-@^Y RQR&9 I(T5\K'-3DM!MF.KC/6PR87-I8'5O8-)L_]?^H**8JR.E M'=-KO'J9X>ES'6A-AJ;(;HB*5L(/=#(T@-5$N#LN.H++E)]:%"3S*,JC"P'J M0["[T)WMAHV":O^"[&32BGOW"61#W< C@+9(1 MU/7NV=(RQ\V'(6L;)N_M#\I@R0YP>A^.3&8JTT\ JZZW8I KZ>H^]L_SG=)?V* ]@/S9R)U_UP[>+((F?WY)K M.T 5QF)(I.FE)HK:Z-6);?E_C_GZ!&74]Z*N;]N?Y+>SWS#FH-_3T,Z+)^V? MOJ*3N.R5[0"4)RAX,T^1MS\J@H'DBODS%4UY^!.=OMI\1>;+JB=XMR5OO1VQ&:[LZM>5-;LM/6+8*G('M"-8S8;A@/2RT1!XMW>2UXIOFQN>VO,54^]6=.3K MIO[_U!?R=7Q#B 9AK_')UX X=MN47#=O2M$98Y,(-RD(T>"L)A)L%/-J[1Y) M]'OO.@U:87?(?ZY[:QT6/)QQQ^?^T?M*^SLZW:<1B11%QD&,E_8<"ZT+.G=R M''/6/F5&%8.(-F]D0KFIE?M!7_D)Z#3;K[ZGUV79).$O M]#V#1.RZ<'5#PGP-^KDVL:VZF%4+GO;.G IZ-"H^&\F/[3!@UFH5L43W=5IYG0!DC!2J/LR_QR,BN$E(I66&$8 M!+>@7(!?*WG-)J?X=5453S^DOL9?NOYV@+9RQ?<$JMYI8-G\2G__RK/'(;_[ M0=8C#U3F,KDEQ!U2",M9=AF36I'WI1!YED2Y$KP*!5)(K78\I2HII-4FW6(% M"CS^60[U1G31/U*(B]!80,[^+/KKFQ02=A)ZNN^_K+@X6_:A6&;M;=4M6U3H M ST69>=9.]U\7?T??WA]IR/ITY=E]5T:OT'V/S!\Q;@ ^@M_)W8AM(E'T(0= M(()/9B'4)'LQ1*5!0GB)\<-;#7SCN#*176%PUKG4L,/\3]E;)(H,NO!>_8WD M(DSDA'C1<5\N?M^CCJ_1/O]7TOY E>T-04TNFEQ!N,97:VN,>$2PN)6I.K7$:?)0S"P:XWCW M1(>'%T\:7G2X&1B"P=JUMZ_,G K9N@5.%H^[% MXR=Q:^Y_E7\QI V8>O(DG_?^U8+;FPILFJ=ZI1!^$>?9:Q '2 K?I9!DRJ_A MPO1=!,30FEV86S]M+$?S&B!$]W#%YV9YU4J+)#O]6+&2/+":1G=37]\,1U9Q7(VB&3.70BD]:YW >@/)-/@PW\RG=H!5H( MN3&MOZ>C\2-1-VJV6J-P77A\S;*>? %U)"I04%3]A&O6/=3XX9_^O$".9)A4 M&ST7C^#:U($MT^O R1K;I^!0Q5QR2Q_FX9;4DA[>"^S34_4#%ZVO&3(IY],^ M'?LGXL7YV0?VY%=OD63F+H:6R+OW:9L4LD.R#S3@(_RTC/@]R3>Q>V8?^P!KV[!;0Z._/PYE<(Q#S6*G^2,GPUX^S;K MP-XT5_\S.)LA1'#E:.?)9+<&ODU'.EFB7,VNR*OJ74-HAPAR=_9;E2X59T6A M= VN\MTQV@%%]R-^@0OJZKS"QJ^_*[=4>;_;%&(G27K7!_?B4E0Y4VA\&+IO M3:AK/3^*G@QJC*LH"<'BZZPCL[W?W_$SY=^?00Z:AGYT6^;I%.M Z>K?8(DD M'&FDLR5K8CV>?E/H)MH/%"5\9T$&J4JJX)N>T\/?OX6';%TK9O33D#53WCK9 M)MDA_VP!G )H;V-X=GWN.E5R;$NO'ALTC;+<7;ADJTD.[TFC[!3!*O&O.95Q MU/3=8*4[$/J2=Z\Y!VO*9F4P#E)<,GVBLAOT:0_O%C1A0HOJZT\&O'UHN+%+ M^>3>F&W_&/QY:OZ4[JF\K?];K.O_AZOR&5R6E@T4FZ20FSF7I!#WHLK2I?\F MU>?-=43,RU'L_WH /(^A)_M;0:$4PHR60@K6K3B][A,;S(^R$-SR_W5)]__] M=06V>G/@-BY<)T<&(574AN:W7WOIN1YE,'B3\A^K-=:<_(S;BM_[L:^?C]US M#2VJ40T RV\G@&MCN80VY=W16$WD;0L))_R95"E#"YVX' 1)I1 M_Y:4.NC81GTJ%;DKN_GJ.U7WT;MOOW>I_=%OUOSF=+')!Q+W"P4XW[-Q#"9J MAVY!_."POWMJSK-X^PV4G)K/1LC?*/+\.]#4W.3(QUS]V"<> V7 "VL3I14# M:G.&?ADLRN,+\0JZ0U$CW[O@P,UO?Y^]::SN&Z^YHWC0=2R+4M_96_IA(ZP_ MMG[46=#M2%)# .M(\$"@>(^FY+?T&*AH)4@*(3>26AP0\]/,;[L(RE+(7(@/ ME&]"W$OJG8EE ER91;[#_:40E:?QB/G-]C*POO$M9#ZX*X7$Q)/Z6DBS!\!]4LBGX70PJDBTRT*2)B^%''%N49+IM]/:+IZZ M@X-C+-5:CN[^'!_T6F%/M;O.45>=4H-\]1N7'Z,[*:W0G]/BZ?24YH(W698Q MU>81FG1MW(I3,W?E4HO]3J#C%UWO\C_VG7XXB. M\7Q_I#X3-B.%['S[E)7T(]KTQ^>UA8 _V]RW)G<=L;JS.[BF-4JIK)]TE77S MR*[%BU>S%(1GX3>M+D0=[\D@,/U9<)]G?!]3C[.U2^=S%2]GZ,>;IV \"TNC MD/Z(B2OE;A=*EM\8O??T.&:/[^ S^0M$C.(JISW%<0N7YCX M#3,()_./MD0)CSA#=NF#&W.AVT2W^46/Z :%/44LRRRK@M?*HV93K'35,10^ ME,TB&B9-O;.YU)X/EJ\07,5!(GVP'EB?J6?AMA%0H!0BP^K*U1L4#K2=>5/AJ.H\ES+%C[N^6: M(?*H%JHK=[M^0]TSYSM82QL5YT-$5Y$.GY+&G$XBT=KKEWOX86V9Q/WB.&:0 M3^!YMKTFP9F_^;4728FF*\BX%+SQ**..O\!;.MU$[_VNE&QMW8OA8#M>D/)$ MR/X;?1&^^$N715)^@K:EI\;.X!Y)(;CT^ @V6PK9AKA)XAB?!.5?@9'# MDR$F:&7PA5D>FV&-;Z"[_-GU+^AUC7]D@!0(4]Y='HYR&J;*CQD)[9:]!!'H M 6F"DNY"%W0[S2?'$\[T'*%T2MR+O1>W/#YU+%I!E-6 MP8U(.EESYG/^XRM#SX@14R+9H-;0(\CSXN0UM([#&^_%J>VK<+,W8--%@)FP M^B4FK]D[:SFQ:9P'4TE. &:(K4I)!.#V!Q4HPE M^/%D=L++\YSJBWR3#\H$,+NM)OC(DHT:="W34\]H&$NWDW',BS6/2AJJ^,\_ M>#2R5[9)(;\3/T!W,P/1:5._T*%EQ.Z-]#@80Q.3J]=/A^&F5W;8V8^ OYSP MT!]2>^=K"+0SN[G=[FX#GV.T[D:-X3.B;&(V>B<6ZC/J(_1F9M#;043GI.8P M76YF0LV);_-(Y%\T"49Y \/-N*VSV957?3F?V)%W!1%:J!Q!-=)^I#-GQSOV M!4MFU=C,R/88_,N[HSCC M# \3)\;P.X#4KJ2XH.QS/X.H#)*+7,ODL H7.8,%K,!!Y)ODD,%Q=@@_H. MEWO/U?OGGZG&< R]%Q>TC6@99+^BJ]Y$)U++U>7;^3(G/I$%E!'MV(K9P(4F M<'0:I5/Z.=ZJJ:%F@ $7F;RMHN9.'\A 11U<\W +N>J3\KL["<\_1&LKD-!D M]_J26MS"T\=.V>\5&8)=TTWH^"EJ9LM(!DE]7J-O N.9:]R7-Z3#VNBH#.1B M [SXFG%KE.WXY.4LI50ZHEBG*=I(JPM8&OF"S4)_8R#(;* M)):BK0/F_ME<27K%Z8U D>$W/)K5;R,@ID=;IT;()1/U' ,RUAOU"K@]RJ#S MN<$RXIY%*)#($I]@?V-)(7)[@C?.(FKEWC7_BIGV";L(?F]DY-SN0%"[7\]3 ME A^@>7(;<:?#J,F\;>OY]]5=;IN>KBV4W=VX2RWO[C*$Y8^AKW;K=.2MT MFWN9A^O "K,*@VMYN<9[+/]H6](_S'W^4#?DVYQDQR&"']^&6T1F^C'CL@!@ MKJV'PUEJ8RA$$Q96WCAP88\8*H!(<@"D\:(]N]V*^VAF]G9*W+M/>^R>D3A, M-6HR'K9"V[X\(DX&0EP&X0@@EGLNMK3=5+LB$1A[QW$JVM*RI7=1&Q?WO;N;"8D@:#"CAI+A("L$H<=3:M0?K.!&/<&R9 MJ-UO;HE406X"R"R[Y2:'PM>9Z!LU /;ADZ"X0<\^XL#X>$L@SFYBL&^, MPV&9=7_\6N62%[,%$Y#E=7M+VK&AG)$_U2\_?5XI_BNPV])VB-"(ZQW?*_S7GA-'C.EK\N@\Z<8,4#WRTQ*YGG=AZ;Y?VX"6X3JX 82/.2\GN/(%&Z"Y6?"B%&.;8F.MG4:YCS-H"0^\OV7X6]O*GNJ:(W* DD3A_>#M MS^+G1.N%@_JZI[L$,?1!\Y<*6D].V"&Y/0_*RXSN[O2_G!%M<.'J:)]?0/P% MG1.&+Q$O@R&B;>(<^\-@I4 F/V(>@V3)=C;/+L2;+[<\P8]PK^-G+M?BRA8U M-E)DD3)P:0!^BG<&N)(C'DF^(H4\.C1SN9]P:=I.Q[61/EQ4U2C+W['FEN#* MK[6\J*;TJ4B)C\Q7K[7-\WD]H#GL)QBX D.QBY&YV462CQO#)=C;^JXW!T3& M0@>"&[\H 3>+T3.ZVR\C2>.+ Z+N@[74(ZU/W P2F<5)$)&,9,=42\8:*:#<0SU M)R,EO4/4'//59>N( <[^5QDV)]UZKTW8U7]GX^XH#"I/H-R>HL;;]P >6@I[ MJCXF&U[L8,6[JCP?(F]UT7]@CQ97(6[UQ$DA=8@6G#K!&$Q^A0F;\EV(^(K7 M[% ;<;9N (0=B #2,G)7D-?[SU,H'??/]9+AJKJ&^#%TO_WHJV!WN[AEODVM MZ& =VU2B2;"NY=M1AWV-:(!2;#G=(?"/NJX[F(I3W E;,V].>$U@[;4\)BJA M .4<@.K4IKYE,D884(LCD]RRO"/WZ! M(,[ '827)=V3:CZG26JB.Z!?W@+'J6Y2:SA\Q:M#VRHS[CM2U:G%"!#4\QJ^ M/&5%VC=M?IXVXS*XAO(Y/>F<=KR\[W,J:F+EB]FJV703-5>G%%7\V]NZAOKG MQO5OZW,TK@;&!+W(S]+*]W]RT"] 9LJ^I#]#/I7;*Q$LJ: [#C#%6YS,YMHQ M8UZ!]V7\!+Z!+6- *:TJ"W[.6.WHX_G67\<\?MMQ5DO>U<#R8T< #)U ERB M0V>%%\4RF3^=2U+U81P0Z8O_MC^$3W\GV5[/_WB/,S=&WQHV@]0#37P 8E.( M&3T2*W@8#GMT>^WJ]\IJ\]R!)(_S:YE8QL/GNZ3H;ULO#H9YB* MC@_2E.(TK+,RVX11,"T\<4ZB/I$JLF%K9-I;9^FLQ[)4NK&%P9HF8II9MAGM M];IBZ0[-,M(C)I6R+.;/SEVO @FTG^(&+#$6#U@'#++LQO.7\QEV)JM"_ MH!4?N='/OC2@.G6IIII>-P4N34.WX2TD\N^%EJ!?RX:IO1*PWB&%C/9;5 M/9T6V&O4\6N["T1$6D,Z2OL0QU*P\4@62+L;Z2Y^V(MF&@>^^.^_MN M2LM<9O$J$Y6 *!:"JM2RJDRXB%IQ=M/;W"?9A_>[P+?,JDO+/!J\8?;#2L-O[TJN].D%F=(0I M7X00.60E(- M7_T5'^'%EPEO*HC5? CW*\;OWI!1:L7W8MJ$^6*( M@N^)X_H>3F/OTU8"-(8EY^6F_+6N+:/"(@^,;.L6V^ MD,$U*61/D.TM^Z. ^*/UNO+2Y![W[)'9(:I7_-=^Y KJ6$&58U/=U.^%/&7) M*#=]%SZD@Z'7)T)-KRH',4R ^H3;9FL^X9,:==EV MW?$O VUU>\_!>G:5\'0$.=(2F M?"%@\Z^"E//#W]^X&KST"JM,A9=BTR8!E\ ,^Y-S8V,!F"53#@5 MPBLG^E@/WT\=SUOTW5T+?&Q\=B3=1*(J;X>\Y!Y 'UKEG%0:F](4>8.!T[J7 MSO82;LZD*P;Y[AM>KERSTV%%1#Y3X/F@W?MO49,]ARR9BF-4SN3+0LS%J9'. MDD6-#+5K"ZM10?5/6T-O3L%8S"3F3HGY?"T^G8M+%T'Y2J=I#(H[?0BNP].% MM5EG:)=7V \5!!_%1'@A1CGE%9^%GMF1>QGUXXR[VQ]3NM)! YO$-68JZ1?[ M@Y(AA,J7?#;C*"$*G."-5>[&)T[ON T_P36)MG #<#)[*FEY1W4CWN4J)LU< MR639;F'78PK=RQ?3:EV-!I_8]##KG"K#A5JD%ADR^S%3F/)9/C W<X]^+Y2827(O=7^-#>ZX,[HN]R-]?BO,+>W/] MIQ1;M\ZO6-3@^#R?+0H++/">&$'[(@'EJR>BBRIC/ M:'"B75S;P7!LV"[TGS+8DT(Z>E(HU="5:BYZ3-X7=.?A4B@U%27 +]!8^P-, MX)'*5,C4KVN9_.;5I/#HWS[H%+DK:,&19I5QKP9AX2;-FL[\X-$%CGU^V=BB MWF[@WS_$?D(SPD7Q4U(P,T5[;@4MM &73K,)5TH(A@.2W2)/8*&.W@?'!6[- M3(IOF@[IT-+(YJBH+UXT+^,Z.9+)#?3R>RYBI\@4*+,5,54DYOA:EIYB M ]^J+JZ"U&HVC=B^R/F4RS!K;N"?41X;0:3@X(V16W,W40M@AWH)]-D/\2IY40]O 6+(5_/)[=05/&K[>?!,'=:?SY? M*=6JV4;PFC9,OU)F5G8G64SR(KM7:1>6WF%\._^$<[QB-N.W?ILZ4DL8Z5]W M<3)IF0_?+H44YG@_0 2+3&;0.\%ASN(J2YLBR&E^MH0-,QY9DT<<"DQQ*ZD] M3Z-&?% >R_( MJHA.I3T$V\&*NPBM8 U?7< ZG2>ODUQJY\SJ [^U;2#CUG)"7!A5C37,@? Q MW3F_OKES4[0Y0:8Y?FI9"4L,1,1'0S9:K"L0>P=2.-25R M&.%$-=#F[944 *PQ'X5^W]^'O?VJ__E-6D:_B9;*DWV?Z[L#1D27X,'[J\>GLN:;'_RS#/*D,^&_67%C=W$O_B5GQ0SLP3:R\G M_[U#62!:LGU%IAI[ MJF>_Z"!7G48=-/]>, Q;BVIR6=7>;6X>NKQB5G;C[01VEESS-FL6E6"NIH#; M<^/PWU[5CV_A)?H?,?[W[V+HCE<_A5XI7.@K./?W_:*+KP<#C=1?4?<=;W ] MT%Y'D/F(;^W5>LV.L&KS/(A[X-QS^[-V,&Q"N3=U\&!_OL<'E;"G3?3%2X_\ MM-PNN4)]+OP\ZJ!?"M$AS]_ET563([IC9T25_' M@4PIY$"0%!*?"8Y)(0Z5$E2NJA3R60'*_Q6D2&*_0D6'/B)^#$/Y1^#J4LAI MQD$II-54UA@E<$E=_<<)F5B%\>LE9+2H'FXDA7S01G +)-922*],!63,/6+^ M<'#^O_>)+#J+W$KJK4PB =DF.TNPDHA+]E2B%G/=M+7^'00 M0TIE?K>5]::!"Y.<[Y/!&"Y1"IE'[)/UH4R6T'-NRLRHUH+^;L*CB/0_D'X( MB-7_DZ&*C%-'?'P0QE]HK;N^U M8-XJCQ*4@&*A'GB"&UKY&@_E?9>!#"DX70,DM9-N",T+*H.9.U:(._&Q+;F[ MF_EF<=WQ):]/9]55EBBHH3"X&:#Y2VE4,0KS*;3B+\D[ @0L+2%< IK%P_4A M.%QY4.;"S2BK9SCU@N]AJ#(!&Z-6^T.M2K4S;,<))SVKK"/:9ZO:O_5T(GZX M()?EI)!;G0*9 P=LWNT0#5AVW;EO?S.IZTAORI&K;KF?RFX:'?/IL$AY:<4_ M_?NS0,U;/VY5/&U$U]YZ\4DNX6B98EC&Y9RSBC<=O5X>^O/NHE'W@7/J^\S\ M+N:XG/N[_X]T.-2T0,<51(M460+1(!-3*;?$_(5X8MSY)9%-^L5HD&##-SXU MB.7VAR-V8R0ZLMPP +8J6/GC/]$*ICH5$_FJPRU^M"J^16<):A03B4ZP[+9E MST^-&;L-6"$2$%4'!^\*3\Q@A:%!-C)E%%*7-/-/;H\@7)Q/"W%]]>T*O0%+ M\S#Q&,3^>]W2IDXCXLCSK$EC] .9>"B9JLYL@RF" RP$<$$*&?GRWI+),9E^ M#2Q-J7SW,!_HSN9IQGY/--&&=!M?$S#*:BBG M>2#86_%%X:(DF8L<,WY'DF'D0^9T#D63;J ZG_4=7=?Q/$_D#)BR?Y^8 J$= MP^A:N14;<7XAO/J(3:1U7IQ5NGQPC3/.O"3/=]0C*K!PL6\Q\ASE721Y^3-! M)MBW_MK(1Z<2U3#0FGJ6C^>8,Y@I1"]II[=TF?WVY?V:"7*[R%+[UY>5HMO\ MNJ(BUIT0NX[L0L*)JD&ZU>WJ[AT]/.9NT,LC:[;#S+%RA2BH_-@3CU"G;^4K M"9K!'_SZ=N\Q[WGT5NY;\3-[^3,X143R"OW1M.+S$E+JPJHW*=D\D')E1L.C(W2VTSKE_!U. MT2:15UY=Q0;46!#_97\[PH=U2G:)TYG3M6@%XC'0^;H"$"88[.,"QFW/L(CS M \M4IN;BI2#&[D'SO3&\+I>XO75\;"8+J1N\T?Q^J&(7GMPN?"0?AJW=",Q3 MFOLFV1XKO$: \W_6*OE=9 ?.E8T%H6E%*O_;T2D\<4YBK']\-C^;^8VZ&H.+R!WBV5RC)ELEC9G\,#UZM*(:[ M%@4U!B1KSLI2&WJL2?#YYQ'UHD# 9GE*-H>4J=D\I1:SG[^.Z=75<1A^ MA[@GZV'>L& =7<56Z$[.VJ+WKN6O^-9504Y%:F0_GK/K#7U AQ?O> M/GPWL:O/65]Y_C5!-K MCC)LN4V0I9BJRO95\?5<>&6Q%()K4$6/H 6-&<:N M!D\%(6"GX1].+?UG2.2-)8/\DD/_?' P.;COX195!4+#_]1$GF*R9 =*J#R/ MH"):$6H$+]"OZ&?AQ!#$HRR%GA2&BN@R<$EF"ZN9)6'/#H>(,J5-XV#V648? M;);*WUH]2.U1&I\*[G/FHI47_PS)J.G$BLL#2QQDCWHLIA(W?\5M:ZR<. M*KG^F9MO8%KX@\T;@>RU M"8/6#0T:#Z<1_^Z^U@O>< M@"00\^\]K< @MC']HR9.1\DC.5&=JAB$&LYL[_#395;QI0&3V[G M;TKF*2V+2T=$7L#Y@>\^(1[/YC>LJ(VXE.\)JY13G7#$[GSP@#C+YLV)U'4$]6#<3^%?.[>L \BW1:;'2LPD0WK&0$?J#"S! M%YK$(ZD1+,$KO$IU6.SL$-UZN""@?ZW!.&)>B"**]FVNQB O- M ^%BZ!?H"%20EBXH$S^1[!0%Y/*TZ.[E^-]T-3NK66HG9;"@3# Q *,Z=,QR M0Q+-RG%KJ?8S5P?T,^Z_MG4J*OKP]?A38SY9T#B()9C]1R2DA:-5W'7C04W#=IVO+^0D?,&V&MQYKZ9*'^9P*[^I1O]Y9B#J]&VGW;5OY;UF\JW[/ M-F^H@Z> 6.[<.PIY4@_T YBL>[Z[@?3X%8W)_D]#[A-HG^/?K!1PJ,& H^B0 M7/WA2FVLNP^;YIY8[9'M,GTG^]75;D49\G,JLGD>*,?8LYGG MR9,<<*0\S!9S#<>)QJLY8LT>3JL#G MN+((S]\V+"H7TNTKW>73)^^.)?PV2!^Q?S_7MFFM M:/DSO[-UBEKT;BH>J@O??3H(JDH_>).WK8PQA(NR3BZ9=8/$$?@#W1>FXHW%\0:.H=]TA(*!V3SPY9"GC"F=5"K]D_ M0.0@1G@=73+^&2,@3@X+-#($YUV!2VT1_0XA.W\_L]Y8)*.< >7(BTVW$J]X MR]+SA:9&!OVO6*/VB8_KJK5=)M5B)=F]%00MT)^/$VB!4D@T?[/30*@5(IZD M2$?R#=[YZF?I7%U+5P!9K5FW.!7/+'/<@C@A5]=^K&2RLLK_/J=Y>2#<=5GP M8Q5KBLZ"UJ8]YOD$2N2[A'^PN"3-]]-C7;C8R)R)B<4@;U]&8^J#)O'?V&RW M+/;E368S(4W9=F=\.*X*G*["=EQS>6CHJZ<+/:",5B_7"E&RK.IN;R9'%C2LLZPZ*O]@:Z>5[/^+S6E?D53; MB9>ED-\KVYBQJ_P+]MJ.,^A-2/X+D558&67KV)*M46?; 8(!)F)/V*)7)%S- MM6(TR"1:OR-3\_<6/ZO9[W&OLX[_\E,E;'DO+I%L)PZA:_52IN3L]=J!='?0 M%RO1"9')G%=OW9=@O_9@"U&3UPH?E[;C;FU\(9==\[$:JF@(#_0OF4+O?V/E M?J?8X0Y<"OF%H U> Y:X2B+-6!XTGK$;;W,:@)%A3'\G_I8-N?BRIV?[,J\- MLM_Q%[T$''_&F(E6N 8U:5%\^V5]TK?S4>7G>,>M=);&2A\H3>%400J+N+/7 MBJ0.LMJTC>,(L+RKUQ>S5A-$SF^NSF=I)!=>:QOP6=2N*"_IP=XL&D6=3C5K M'YIH.^^@7?O/8E[6-Q\E00*HQ8-I+!!_Z;YTO^4XG\)B&< MV!4IXLUQE5J0\;:4SE*F'-T^()M7F>+LQM\B41^F>VS]YPG[FN[-#7TB$ZZ/SL6A-;L R;:(,_5/1SC7 M.?BP4S%.J6N472$UHQCM*Q6SF+GF)Y]:5]\SIW,IU#,(768 (C;W -\YP6_( MWA@<.\E72H&CL+]2RE$WLE);O3' MF#?JO>'Y@Y6I*PP$OE*0+8M=+=%)D#E39P&.>8FS&*;XB/;(9$O3C2_UTR:K MJGB-U;9O\E$HDZ!0T47X"6A"Y8I9^5Y:-7/P2QGVRDHY[[E$QH9B@H)+7Y): MK)D!*Z$N67?[& KCBY6_*%<>Q:PWKHR=*1LW<=EWX#6P?0O_)!0#=O*8K'3R M5RMF"CTP;]X&4S@>@KP9$9E>TOF*8]L94>Y>B-J^MHT:Y:JKNG3ER>AMLXFA M_6^=;BA0R!0UHB[A.M!>E$K4 )=:T2KP?22S-HU<(T"FJIBJ\T_'O=UZ?;TK M\E_[^'"2FXX/Y371,!J\8?^@HK3CNXI%K;*NHF2##6Q/'[5P 7=0(VP@ZDK MV2ORX/.GNA7$V/X3^Q+S"%S#0^'(_BR*3'E[$"WB&&24T%HKZI1>1"] MSEM-D&P&]F3Y,U,(/GE@Y/KUJ+^^VUE<&+R1[,6^5?.P F?0^ST\<,@JT73E M>47H@ >U,2HD'#.[735SE[V>Z KHPT]V&0I'QA/A0$2;AX'K4"7<@K>=8%:Q MD"6*W,\,W.-1C,>U60LN]9BGEG-:PK9D-NZO5"C,WZ)YV-7N33O\MA2200%< M2,EFPBN8*1IE)8(7],6<@.7+"=*'&= @U>"*&C3H/)W^4*0[W1S%I; F;"?, M*U8LL1;.LG"M;WS.>+: *\>GK5YD6VVGZ;H%TA&NHJ/BA$#PBA!/P(FKX!9\ MF_/U0'HGCLRY1^9-Q;H6PK5OY=I5-0#][3-.S+K!O0-?',LSR:N?:]*$9^C# M-P9%?KR&F\,KR^';ERM.(FR)FU$C&!+P.VXE4YVJD17^#%%+(G_1/J8?WS]L M8"/3QO[930VC!E>Y*5WPVNOC;B>G3)]TFVA&^ G-@'5!R<]I#G9= .\#G3,] MK3@H..<6_X6WWLI0X<^1K5:P6.H/#=W3LY.=YP;-C9KK!C[?2I/PVJX[W.K9 MW8!/26SBZ[S+W0KTM.% &'N%PD5K+;RO #VE$,$?P#LVP2*2,"'?;AM&L!9G M8N=ZX9<*JZPWUN,K'=]A+['6E\R?EQD>]"]%H3%/)D;&97#0<@&.X#)CF?5% M(E4'H AL!-F6U6E493=! MEY7T0):CXU\G6HJ6UGM/]I56]"I-H!.9NXF[1!J]".XAL(D/;8$JP&T#-/I" M]([QK1]SLW6RZRZ^]_^9C<#+N%-&1:P],D6E/"R?=+36R"CHH)<$:Z];>5P:' MV4=0BQ'58R,>1N4?.G_OF+Q!(9. .UXL)7(&13!^#(>2"EA!#22] L MQG\ULYZ 7XCB&H%1?*4+Z:R(R+<7(NZ\:BG&U&4. .\' QT:?6"70K!^/CZ(@8N,X=,]K06D%=93[! MEZ_TKO+15U]O=[/!3.N-6WW@V:F3MY+>\V@YNS <1[U!O>K4N] 8FF<6&[\>Z=D[K](I]IM!I(ZO#=Q39[\LV)#XL+ MSSG1IJU8&B2%_#%W;NA[:7*3_ CJ3\/ZMX^/;OMT2AV,$OH%;7BDBS3\)-OK MBT&Y+XM!9"<_6'.XSGIX/9/O?0T41+FLAMY,W-^8-HQU/I\U81QQU9]! M?W*X,NPX,7#Z7N%4-5.D$<:#+5=.WZ\HE\@1V42E9K E7V17\TV)+-K./P3; M'L(X,K36)!]2*B"[DR^2-H&+[[E]9MB5L7/#]'UY#(KX!==L?XCBE*!7IJ\[ M2"T6S&4O,%T**5S=W2OW!=O=W?RSM[=UNN&[C=?2UA@ X4_ YZWZ! M?]J!5XZ!3URU+OSGTR2Z>9>@4/RWE?SJC@4!14>BY6J3OC]M[%T8,YD:%6W3 M&:%FBMW*C+%*3OZ+2M'LL>W2JB>S,AO_?DI&&Z&M?I3+8L8$S'F#IP@*Q ]) MOXU69,'BIG0DQNTST%2.Y9U:6:2B6C9FTXW)#.C2KS[#$;G;V:O8<.Z,F2+> MG%3W6[++):-G]RI@3"=F<.4#X@[Q:U)@>A)BJ\B_D./^&J2T;)37/;T[7.5J M$T]P]/,W8L>)7%\G*I?3I! R+3E*]_1@A[HA*J+VA6\_#W\+LG&('MB!H"+? M,G]V6A8OYW)!K=N[KURX'ZM": M?*G830)XO9(E/.4O=Y54).]\M=BY4791'408F,XG7P4[RWW=Q24\Z"[\ZB5^ M1T7 $#R\>-)RG3.5$*XD5Q^7VOZEW*I[8O(9YT[6M5U)$#&\W]Z,8,973/?G M*2F*G !$PG])U %V0CDM]7Z%*M?, MZ)IEEXK5H#SNCKYCA"6_72'?.O16XBF#KZ62;4, B/>:@8EVU9_N)YPH[ 0" MWY%H%;5<7*S7]L*@_FL8VXJ'/'1B9[;OR_\;17+96QN:!YY^TSZ7:GW > M&#MWP923>$\RX*WQ5+B9U'*>^"MQU/9<)J: H"VN>-4HSI78C;-P&*P?E[DG MI':^'T,\_.3+JE=U=?^-X0HJ;!M8U&;A?.L*50K9).O_E6?H)>+>TWE0*EI= M\*^9W^!;?(!X\=?\EST MWV8=-+_V8:RLP%!^*LCVRU->M,Y9OF)LM$;!JR6-WQ>U UY"_CP5Y?_[R^D& M\))&W+I 4H4'XYA<54!A-='R+[@_SW+ M\L<:U@EKP$+>M4H>"]&UYD2--17?YG F)X]^_? P,T+.7^A)_+B1V?8-\$*" M/X T(>\?YMM^$M>7@Q>RO/0.87_KTW,O5['\BZ;1$/W'D/Z+"LO+GD-[KP8> MY1@_->]I17/DI^M9,'E2"YYT"[D3A+5&XAY:4A)D 7]J!JWC/(V70KCJ#7R; MI/!L)(<(4PGA% A2!:CWX12U:_.">]J2VCW\X(VXMX\G?\"@*^X<4LM]B2Y> MCJNT7"X\@1=RD3%T8V"L70I10&"4MLS;;V(3%+C-:JWK$M6^3.Y<&S92U^)4 MME-U+=8&21N&JW.QIX<_#+9CM@XGWCSDP."H/H#V_=="$.C=HBB0*SR.GYF> M:T^70[3AXB0FE#;B9K!ANMG8@^+5NY9CTN9[8("NQ2N-CFAI]!CLOI,?0C2J M23\[?&.(<.1F6$39R:S04O6AF/+41=97A$C=;Z;@RU,N8M1!X$<=W-^?OM+ M9[8PY27[W(LZHQ7&?^[_'288O19=ZK?,.3>)[W@>7H%(HQ]YB32L=;USARMV MODZK2__X>/6VY%]Q 4-1=(0OMQS+CYT6RW(5W)JI0/UYO/K!?DOT-N^@C>@* M,G<,O0.\N#C7ZL&=L#UQ,_#5..BV[M9/@\J/7VW9F:7WLF"!G74_)NJ8+L1^ MO^S>W:0/QQD:I!$N'RV%>/[:@"YD6(+-0"=W['KG#'H//HKU;62ANVR*,XDV M\%W8.'J_B99SNF,$>=\OO_+Q8>S%+]MN;W;4ST[]YQT1*4M[.O"S<$U90JT MI) 4CX8F/;7,F9[$U+QC-@ZG^,@D*X?0[;=:LI<9OA&%-M&?%^TL)-LIY00_ M_MPR>1J18MU8U-JS"Y\]0ZR=82:B5>C^%;"$J3:&,9^1/X,E.0_ZL><&L"LK M5_&G68X###TPRB-1F\W*5?JI78X450]0H[PAXMU 93LS7@\.P$2FJ[_@A:W$ M8V#4O\&:\C/07T,R]$P T>,%F*GWJ_;B>;5%98\[11X[A]?K'EM,>(^W&]%[ M7\_WI,,F1L8[; M$=6+MF<.ZM;E<%?,6Y72I!#<*N2ZS,X(A(RZ[""U7&1L7]#X&F2_;W"%J$4< MGMJ9Q^RG_D/ <:>K'VE=B\6+.Y)$N<$OA*TE(6 M2MP7[)4'K5!36=\N&ML!%2$R",B45E!4A+3*H Q)*PT1$:*-B! A M+RI#B!AM0"*$1$4(@YA66VFA(2H"(D,<"+08$B !VJ81F24((8FV3)&]6PA; MDNR<>+Y3=>]WWJ]NW5OWUKWG5OG'JE3MVI7U_-;Z#<^S]UYKI2AV 7I'HM9@X,7+C\G@PLP%:0(J%/A!4E<#_6UR# ML4IPM8,80'?+0FKUV7AA"WN-VM,^W'K%QT[?YZ!>;E$;??< ;8]4D=(67I(? MI33X'^_JCY5L'DK@H:7=:ZF%RCW1SX"/.8^F&\Y][XYWJK\>A;GG=3:CY9:L M(?FJK?[/6Y:>R56O '$*+4*%(Z=RNSYFRB(<6QI/W3PX6.A\4\HRF#I'&'D& MR[9R>/X/ILT;@MLL])U:7R98]ZZW)QPS*LUR3H2MV,IR+>)^J4XCXH4<^%3< MTD7K^X(2+'2&(2Z"3IA["8;/8MV9238./V8$ M%?Z0*TO?/"UL//_S.Z+:Z*:\H1F=K44\=;C,,P#DA&=,6<<5 MNP$TO >*#1--5NEK@+AR"]VC8L!W-#>(X%U!L?K/= M +JPUV+T(6:+I:;KP?:?Z[F8ZU(MPOS8U&+NR.?%*V:66/'?I(1;9>K'FEI= M:66">/EZOO>7B*,QSJF\:"&/?Q]P_9VW/+J&S#<#_BI\5;%'%=TM9%E24R== M!9D[^<5I->&^TNF 0)_6Q$VOV/=)1.#RA-O"BB FO&I$E^Z=-7>3*:P E3Y] MK&3%"Z"@(ULV4.-E(RW=)?5/H4HA]H$_!RN*<&I@K1H<-TG1Y MO_53&(1O.WI[\+:89E[@<8W]*'[<6(>L[?$^R9/8UJK;N;O.F2M\QJ&-O][= MV6'0T"#46V/WM6IJ-].[>]BW5&.TB(P\[+N7?'/&UT.V+FM8O'_UNU+ND1V9OSG4?T/P. MFW>K](?A48_* .PWJ,RM\E&<+[?_]!GG4O @19.1#,@Z#A62TZQ8:P6B(PQF M_3YKWT-)^%>.%F&9K$4@ MJ06Z;)]!H6&OE''I?+]M&?10JE:%- M&YK3EXJ.N@W9VFA*^&9QB\KGTI$(=VG6K>2H;R;""[+_O@P[X=K<)K]HA35O MH-1_9$JR)ECDD=6@6B*CZ#REO02EXPTRC1X.Q&6J<>6C$XLZG43;6RZ.7]S, M?2!I'5QH/%-5)A%ZW]+D]QN"QPG'A?8[2]-^D559@HI]@Z]:(AI]=0E_SZA=V M!#J\81O1S-/EW0:1$QZQUW@DX,/A$JM[)V6<;R(GSQ?^79#B6MQ6T_3N\'2A MWXM227INV&VEHU-P0-/C0MF843+%98/\7\A;6D34[+!GD.9:TJS80AI)HYQ)DJR&A-**5@UF09AXDZ(O-,_DA4H%1G&%.[M=Y]_! MUMR>,_/ZJII]LBF?SS4JQJ0'48U!ZOA$)2-VN$BS;V@F="A+;'?N ND!5$5\ MWN=4&[TM/.ZTLZO3/O(//S]MV?1>V+ZN[$0J'MJ(;V>(K925@$,;/H^-PGA3 M51U#MDA0P[JL=I>&28%:EO3W#<0U!+)E5FGEWGL0):AIX P%=;P^=V4M.K.& MK8S_\V>OOF<57]X*6M4-H 7CU43@H"K0*A1NZ?\[H*UN@-]">92>,]3F_FI6 MJ5\>D)8/.@KK_9;0NK^C_;$<0;_^Y0A2#$KM!66J5L)]2HE178WGH:> H$5B M0YT5FH?6#@Y98EF\]=)I+6(M9'6H#RVCGJFA$-O,+"/R]BY[:?LD]D+R74E; M2GE\07THRE'W?RMY::!G!_%Q4+ZYB)SO!PN;M0AC==0X.G.Q_-%"@WF*9$U= MQ*[6A<+H1B(Q(L+_0@4U1=3(R55ON/\ %?.T9PYO.#EF\Y2;->+'2FF3-"#S MU&GWX+7YTXBDNZ3;A8(KF$WA+TOY12EE! :.OQ+ 9?"M(/Q> MP%VH(_-Q.C87FU5M$@0L9/$\*T9(A6ZW3E3_D[V]NL9X]\:PS;<).;]MO2&3 MD6IC+S@4^ELL??1U+X/_F^WJTF^JESI^4UV]T\+H\DJOM;AEMBO+[E_$KL-L M9K08,&)T,J O$HS-HE% !VE3EN#AV_B$<B,-=,B .+X+'QD:#9PW6(T MTD(=)#QV^6U+)D<]"JG<9,KQN/G;N_E?BA+8 MFX(O[=Y7XS]0XG,YL7)/T)EMU1O?.W0Y[EMW_'03[V\SQ!O5NQW&< MQAR5QX#00(H6L>W+Y@++:2MU7$D.4G31"1MJ$>\#Z7,]X5J$*![$P7G6'3JY M,H[]?)4UOS1#,.&C$]/-3U#J%YV++[#+!=(6XC?8B=_5NLK2PL@0? [&_5L7 MY(7R7*S,E:HC8[[73NIRZEF4NATUI:?'>,UYB]C M])R#&G0W:1%ZC'_*6?_5R)@R_B=DV'Y#'>Q[AB9:Q#%4SXY,%XZ&UC1:QS]H! M7JXC7^_'B /#4!G0!Z\DJ792'=O#4;F\8#DE!V6-SF/%=F_WUO0:W;\:F7;!S.;O?[II5[/8C?A=?;&P(]*45 M&($,8S#YM"O=_M6..]R#-GMZ6S4QAXX 0.6F;?P_\[<$EZX*..]N^ML[R=^A:A.&C,-T92Q5'P#R7]V2ZRK+S:.:"@:)8C%1B&=AK*B?FAO" M/V1ZI8/X=I21>@>'E-$6B>J]0?:4K)EZ$N#U(\]=G*PV]Z#?BTWXZ5L"JUQ MY@R'2CD*%N CTHT^?].PPS#7%>X#*G).-%Q+.-G,=WG:\#S/!Z1?F>EY&OG& MJBJ/T!E=N"4YW6SA2 \ZK#K9\1=*^02GR#L8U U\-X"3HV<40($R&_(%Q8,P MV@;"*J^R_?(./1?P!^:Z$EM3\2V2*X7H#%?&JFGW25-Q009*F!I3'"UEO!6[ MW2H[UB)5%;OC^+W.OY3FWMA$)O\ MR%617Q>J1=2Z'%I"_ M_5+Z=EC4%E^8UGBWU@^X> MAA4RI-[F8IG&0;8IKT/&!*:AGS0\JT19@">9M38]<[OK^3ISMX(SP?C&.2W" MD#Y(7#//6/V6FB>R14$O@>DC?4[#W.XEU$_CE+;\71V-]-+E#U+<"_UNWIT< M,QH8DAF(D YO%,FHS(:2/:]=I]O^\7*M)F^2H^?>FR[YO$ME!7=%;N1KN(QX M";0%F:,VY]"<>N'=DQ[F%S%&:@SH>WF"[LQN'O3 7]3+AK^E=@O7^&H1F:YX MZVD)LBZ=$@1T9SOI@)G%3297H7/J.FWV?7A)S&",E]/=4$98"@MR&+K*TQ]G MY)6@ =3, NC0@MD%5(_^X$[[ZZ(N!BF:'/]7)/QWK\7[V]C. M?$*[$#FCX6 T(A?1F S..=4%J.U14T1C#SN"-- M^CH/GVM""7?YGJL.,"Q-3TA\%%@A+ \3]1+MGZAP,Q4/U+N H9E/0%&+9*5A M]=@2(/0RS5L::#H-6X/(*_,+ED&WXAK M&.V,C4I;0,[L4 5'TGN)*[S,D^7=JR"Y3GRV:^Q:&],%;=B5U"&IY"K/@&5, M(B64DRUU*3X&-"M84?0(2HELBIO/WY'41#SRO"_!=;>+@C"S>*NFWU\YH(,: M+:4,"V0%:A."4@!Q0;E43Z@@RRIF(E2X]&N?9)Q+&(M)AZ-0$> NJF_,JJJ< M'-O4HUY^&G4$_'#)R[.2G/HYJZ.E:+[&L97O-%##D%J\8+>$NXQM4[DP6@XQ M3B2$_M ["Z-H42RY7@X-%[NIXPI]G=H.X.2I4T!F6T%>^=OXZQ/B6*&3@P_% M[%@\AT3V[#;/GE,8CAPP"G!N2"[?N^R?ML4EQ!L,;H7:F-F,6D]W(*'J.#.@ MG-P]S%"6 H,-";(BE TU='^= &#E>OF2DM>]3:VXZK4)SK>:=E^^FWU\;_>R&)+B^[Z-"X,6(08[H*RLTU[VP.I\9+E)^T-S&8*!+&%M2 M?8D%0%1L H);PH?:6'E^3"]ZG"_%G'^X5UDGI>[*A!JD/?57P+,QQ?:40;A$:*\A^I8 M:!3H.P:%CK-6C1P$B"@_F MA/=._XD=+R,^?B]19*KL_8&;+85Y:!&#V5A[2R[("AW[MO\GG3(PB4N-J7@@ MB8/M!SZ,%(#G6=530.>CXRZ'?&1[ZKK"/V>6<5O=)T-,EP"XF3[5\3%JWOBK M/+T.5I8684ZWHJ4!FUG14G8N"HG&&*H#^/W) O.))S:.AX;HNJ Y,>&A8;.\ M'&5I(^OG$TP. WP.IX4=UU+$@ M$G7C[Y[:644=U7D^;LXSW>_#G"P7 >L(X?@M,77FX5G8Z/J(\(Y6<[/%K.)E;".U@V$%AU0^Z]/S-X\?$7KX MF:7ST]/8TFU;EG[^I&.BG_.#90TS"P!%*A B5U,79*BKW6U=#C+[1MQEOBTD M%TU'CZL8"&IG@$=]167<&(K76U=?J!*)O=Q2S^LR\"/BJC-ESYZ6V.P*OM$W MB80<*==XGJ #O,H75+73UQ7\6/##H *S>BS<(';OD->.JN;-T">@\"3Y$94A M:CQ_LW9B,?/W7WPO5,07II#;_/0TY5JH"V + M==;10D&K#J:4H=[(-P985[R"94W!P2Q?J&V<8AQ_\RDU!=F@[?V,8E>,#OQI(<*)M2*Z:"G=5J$LL MP4TE+)FW^X]]3N>Q)QC#S+9"/X'J*-PCL*5Y-9J+L"/H]KYXV7L]5U231 ._+5W7E^UY)PM^W2!4R(YJ;1/YT#% MF&U]\ZPW8@W&7E$'CFL2]X)()L\3R>3J!Q2[ MBQ:/WDJV=WHXD7KI:5/]M31/U:8& ;>$$/""%*VB7\2N8HR7P$B(K=,38G"V M'3N\2XZ[K$Y^2%L&,D4)L3+TS*1J+Y0F% ]=4UNEDQ*CRDBA8Y90/D/JJ3\$ M463Z7>9!P#N00,W;!RASL+E)$FOGXLJI\(0A9K(388*C*Y5+7-$CYDJ)Y@Y] MYRCUC!:!@_15MF)J5=MYCX6K7M[5<>&L-DI>B7V_2]\]4N1:X&/3BIO5+5(. M,Y65P?.6.[)L)9-5I>2AKJ@'4&#R-*%(D;A/>RD>N(;"X[T\7 R&[=/P:]/SV*V09M4]I"/CVY2?HMGU[%G!L9M M@J7,YA?XRZG=69@M;WVDQ0'-)8UO$[M-\A#2V?-XEFJ[X_A8L]5D?@6S[G/GSUE=\ 6'O6< MDYL&;SUHNY#HI'FG7SZU>6@""SGAA)R<+T>Q,RXQC&"DV@O$M15QKF#K4)?H M6Z8QZX',6P,?N=@,N]>\[V],G2.YW387OU-./\+?#8_L+)],S1_,CW[XEFR^ M2.JM4_A]%"IOY"+4(YK[O#6ZI"UY@FM#,V$S0,""S=ROSD4@CT*42EH4P*\ M9G]L!#NR7 D,D\EZL2"3ZQG ,9ZDF]T,Z3VM]JZ<7K!TJ6)4Q#=>XT@)"9&] MW8']KLANRG :O-I<1:*_&C/JP<:PQ7G*-9IRNIW:!THIGZ0; !77,-80Y4?0 MB[_CZ>,&@KBXCF X,U3K>NG+^]$/EENZL\[G3"<9SK8%FLP3Q7H9B= M(_@BJ)09+0+=-DIL0+*L\C!.<5FI4JX>)ZU9V';_SAOB,>0 ML5OPJVFA9B;3QD128_T=Z]O*POI?7SNU<*\7XI^,=IQ;TW-<_."O/M$#W/:= M7F,'>ZH_59>T^)[_UZXU9T)SR_([0=>SOS[R&GO%=2#Y!CD;YS6>^R7:3+[% M?_=+3Y=NK.N?/[V=74IPZGJ*.@%.$<80W.#")9\%9=-BM0B?MWAX58L6\F9E M,P"30"U"MN7?$7.>3I3"&U'KM8C7"R9?GK!NFW?-'_D]G8_S"[X+^; M3?P/L^G$@>%6FA>4(I5DI7X#,81/7D5=$']4*L%>@F(?V&-'SKMC=\VB_8WL MVNY[65ND6:ZMY.]C?\ M[6]@9I=?;HW^_2!FZ1)FV946Z5:_:RB#?:N+M[GXYU/W6MGU?&B%;='U_U._7MO[L\9WGYASK6,.+ M[T(_?9!U0PXQ')7.J5KPC%@4"[NTKBL&.&0ADS>OK'-H"E]M2#-/VE6+U[\JFF\DU!C*!1%FO;,8R?. MY'[P8.4)SJ#%60O*>&BKW":T&5X+-HC05Q<%65Q'="8&"1"%LV;03*>L"G+> MGI2>*#HIK#<.(Y68OZ8(9)0:M[)'DXF2X6.!Y22GR;$IW=L70=^AL_TGNDT<2N=E)XN*5W0+ M84>0^.6C%.I0JRT:"M25_!547)OMUD%7_8[!** [+^IWHB')LC!LT@AR/ ZN MJ$P2_U9__B?)I.4A?WL^P2)ZD06O6E =(:/JW)N[OPE3'P8J6.I5X+0PTOQ9 M+WTSE=%!1/*BQS\]FA)O["CKDAN8'QY*LMGE.W":=NCZR/13\63HL^[2B*E= MDRE'0?VXF-]5?^N2_"O-+08)F8,Q[>/M!83*VQ :3&DF#A.-,9L)ZDU0%0E8 M:+-U@1+EW9GY\D#&82!]K(D#F1P UZ#6N*9;[2L9VJ]"BTX! UD-Y>$DCW+6 MHRG+6Q]KRN+@O5]6+T+IYW0_JWO@=7 G8[67@:R&>( IDV3RTD"/Z#>(+4AX)B^0U<7S:H2D\\F)RR=Y@SCE6>A*-52^E]B>AU0CM??>V'- MX'G@;6"RZ>L_0?]E9P_TEO[R9KCMS.'O47_AU,89LOHG*GM:DJ9,$(LV5KM" MD@=P)[P3XLBZC6FKH9M5:BOH05(5H1A-*!):>@]E.R.O&-Z+BI;/,A=3,L^, M'!O\5QVW%^WEOBRUX,VK*J_7]&)=6/IK$5&!1&43P!)RLB5Z/!_2.$=\>)+X*1DZF]E')H3>.U3K5B KK%][I-?GOU)QEG0ENZ6)A-K*CS"7V5'2^I+(N^AQ0*SC_,6 M\H!TW%&()%<41.I!-Z561?-WZD9]6OD;^SF*&O&6Y";L01XF@-:E"CI&[8!7 M/R&-8R]AERETOJQ%O!%33$C\W="0ZB"YQ(8'%+-%-;N$+YS5V''DI3$;\';Q M20[4.Q+<7QLUB!0??=\+9:@5T[WBT>)=P1>SQ82T(K+")#1W M1Y3,P"ZT]UU).S&'$8.Z*.%^4)M\\!_ F,89$> W[*?O\]\/E@+R@)YYM@%5 M3YD#Q1665S$N/*2>E_B#8Y72V2R,._ N9LI@[P>VC'AE?CD_/>:#7X_3W1*A M\,K2>8<6_EK@@_#+Z4TGFTN0O0E)Z%60^_>]7FAIC5G[CG4EM^[%'5U+*HS( M;#2\'CY,\%G]87N+^X[M_NZN&H8_T'XSI99(S4<\R M%LS.OCV.415EG]2\13?0%\2Y?SVA4@@W11[>M35NS%KH#('E&MW#\R>32=5A M_FLX)AW)Z_(_EIX:/N5D.I@R=+[!R+1P[,*)I/.C=Y%_LY7^X.,O$NP)@]NA MT)/AEZJ/ TP=%\B1&-!\Q[N_@21M*#W,%E*X7U,U@5HP?L6,V570>GHQY'8- M:3R?<;1OUK6N[U]P]V5TO6O96U#<,)VBV*2*CAM; J5SAFDHZ!R8*%]HJTGS M[4^:_89J)^6T4K+%RF*W%XRU?773W1;41M0:3B;-3CIBU?D'.CFMAAAZ65/W M@CR9U*D_Z?3^&#RE"V*48/P:XS'N*N,$Y3)]QP!].XY\$LR3GZF1CL:VT6T? M]YL?SFB!K8#BVY7(*UY.:2FDY.0'D61E"L8.Q%341$ZN49X(/#'B']"TS]O6 M<9B?V.N5'DW6)?!G(+X]3.T(>F.,XHD()]AL6!VDDRR'P?4\$W1>::]Z3Y6+ M0P1^#;)D6XE5;XW:!)F1%'%"%?[\ M=?*W-$)-8#F_2,HVG&YXH1B:VZFKC1,@;N92(B"'5^7(&6]FI>F-4)6H$#_3 M(V,DT3(GV:<+PE ML6I9/H=Y@]&R#6-'IF_4W(#-X5=C+M ZD--LNQ6*DJ8SFADF]E#F.-H(LA.: M':U\"%UR>>E2G"9:I&?#&P=<559Y*&Z<^0OE(P]*+77M25>\RV\XO*)FEZZ)$^YTW]R5K$"'*8 M)>OH0(D=0W@05SY[.7*GIHAN/ED8,OAEVU3BVOF *-!!MFZ0ZWPSY1&TT$%' M,O*M*9&CD@-+U5/F3,,R]-]Q:U_6B78X0=G MO+ <*L.O_SY0#%_G["V=E*QU45@)%_F9M:0*O_ZD*O0;XG"WG-$^*TXA/H:N MRX@72SPTA?155+^.T,;7_"^$CP*H!YT6MK::=L MCYG!A>0 B?6T3MYS1RU(EBF9/,G:]&$=6 _B"O6AQEBUN;GR9VCT(354%EW0 MBLK6(E:Y<)A\)'0]$2B5';=%#G@%/X!0X]ZW!JK(/T(A"=M/1RXTVSH\?3;( MU>/VS-:>5MQ_QO]U*I4BKM-E$4YXYFP.-EX".3C72/$K:3BPY ZP5.Y6(R?F M%<"KH2A0OTU)1P)JV!M:5^7KW=;-]'*M]'D8B2D>YQB-YCOL3].$_ODTN\A+ ME(G=HQYP>YM*BR*7S0N8-IZ@]\, M4X,# 'Q^G7YQP)&F/MX>[ZR;]H4-V2XC!&_LC\^Y_9P67LF?K]+2/6 "I8JS2!Y4 03(4%>\D%(-JAFSIU\=6DTM:K,U8__0YY(" ME+&8M5X^%1&XA]-'=\3G5TX._ASW6E,[&U+8^ZI5F<9XK7-78$2)@!SNJVDZ M@89[ [=+3%S8QE1T6P'=''HN[3:-&]L%N&>[!(:V+ XV@,QV> ^ S!WO\SI< M1CH[)<>]Z*2"T6C 5OUM. VBYWO4-39P!#5\4M;1/J^YPR!3AD\>8+83+;6(&*QU'-_S MM=K7JM3+62WA%.%"ZE5%!'9,D\VVT02UX'_)%FA36C^0TZ_0!.>(2\AT^5 M>'L>Z%5[CA,,?OI''Z_87W?,]4Y2T]8SKPI(T L I^P!LO++=;%TID*UFB[! MZ$-%(*NMQ(TMKR8^2X,66@5KYK'F8=.+G"Q7:IV!G1\/>$!'@D?S-7><\V0V M#-]>%VS.T/F@@WOS34;(9ZQA1A M+2&/41ZV(FRB)YSF"2(ONGB?&(D$'J 3E(%ZP3>#>OW*8DW=W6Y_(@12O,8M MV(_9BE'5KOBQS0![AC'>/2R7(V=N5;TLC5]D"=$K=#R%)EZ#\4K8N6I>8.I= M\OQ"57SCQR;Y*J<;"Z+POSFR"\[)6",/2;Q[X\?2JC\GL8/8AH69%K**2/\3 MM0[6MS\O;TO-NNKE#XCA\9%6%TF.K2E#P5YUN^GW9P+XU9/!6L4[@).-3JB) MG/?:(3,XX^B7>^&&[QB@::]1^>JH;HK("2^MR(?-(3LI/G>6_BWU!]JAUW,V M^AUC[J!A#3#;9JOWM 2K]VI1HAL'*@'? W]+?D9$&F$OP782*.]@72_%11^O M5WS8*^13?8/JN'H_I-9- 39&B\CXLE.FP@[@R-Z7E%73=O;PM],.0HE()FP" MI>WOYP9(5I.QEG."]1'$R+C%F4B#7EW:L:2&MM#W#_ WOA5DS8T:G.I%\W < MZK&EUW49R?\8+0*<;>[0/-3-N7_%"^@9R/0%8B^Z9%QX,!97D!K;TGW)++4B M@V=N\.H.3;$QGN\$)L^*B#FI'VM,SP/4R[/M]0NWSQ+BSB^:L2O@)T,; "VB M>#:1?225FTO2DZ?JMMM9],I1329YT=.>(?]^_ND.3ZNJR_1UO MWPAS[[3;]6+'],32+R<=F;>RUWAYILA8%J-3;HTA#T)_O-7KY2U#KXMO"(R- M/4,S)/ -V.S066A !%+RR6*[/8HH[ M% %226[D-] 3X%D$]!R\C,R.7%D'?FCE9%N:L1_%+>:WWXL9) (W J6#P "_ M(3:EZIBOVZWDJKTIB::]8Y-/)&''XE/,L#WIIDO4,W!?ZMQ31DN"(!IY]7RD M,72KBK8=B@+*,%;0;(<8W2K)+A1D\KQE74?Q+*71\-MI2T;6F>T53Y_\]Z?8 M_"?13J^N/_"YD.AV+^U,80.V!=T,! M,JN)$GW X2HMT*DBHP9C20OL?3>8K%^,\GGQK*\T;=9TXK92.=2P-O(M]Z]R M?9+9GW,CL$HG(O.(P&'6\&P[N[YB9@38)2?.5&[JUR*L=/(!V.?A0'KP6_F8 W]4D;&GE WT1XYMVF MVYLRN#V,,]WKZ:]USE?!HCE05)OI/6/ZFKNNZ$R,6R_M\#C'6OT=R,C0>3/E M*$5OZM"4QU^Z6CS?9.FXGN9UQCK?SN]9'X>^<6K(N*5BF+KS;$-XIF ZTW0) MI'/!962@HVT$]>8I?GA!SISY .Z24IB]^)P=851A>^S^U]^"UR[)BW^4AO(@N.YMX?/'CZ$A92+$4B7HRN-& MFJ\,KV-T^)DAT%-Y7U-4#@95U:J_@PJ M.^'7#V+,9TAGYS/;.ZI.3W#U3@/ MJ>(5)UX,TJVIS& +KM+O?R!.# WFB*RC!BH&7RB^5Y79];!W6P+C),Z*D.$ MLN4[T3: [)DAH,\'F(=O 2KIAVL4.SZ4(2NV.VR)RG;5:26,-W";17(=NE)[ MFHWC I(,'FK+<]"&Y],F+KE_@S"]:/W=!7R+4VR+H,%!A,V1&,$.U%UM>LU\ M!+L-M8J_EF8*/0>F17S+O@= 0;:+V6OU!; A AC*5^]XX%NEZ^KOF[53)7H] M&V_-)P.45E4$SF?OO6G)6O[F"TTW)6/L^I)&8X\ R0/3<8N_?%)[!\8L+@C=^9OZ M#@Z>I^_L=59'/VQ.XIA#;%$X=N[0M:<;]S-_VO]HXJQ?2'/T[F^-?M[;@K@F M=YGZCT]"'YY)4,PZ?:A[D>581'@87?^\X8[9_MB&8LNM]VZ[+S^5>VSXQ@__ M"KF>^_->5U?3)9\[.+H9EX0)[B\_L8>7[;XV_KBTG]F3S9R+SA)1K'D M3H9E!-R)K7-M$&:[.K*S@]764";J4L(<]79".,7"/C1X[4 U,Z*);DU]-*#TJF M&BTEKB,UZEV-@M*!>>Y(TWF4#;GPIPGQQ[+*:4O"''FEHXXO?:RQ-0R0PS MTL\]FEKTNY12.MSM5BJ/,'/4WT/)'%#'+*;MCV;B>53&42\]51#-IAX*EB:< M2 AMWU(8>R5IR\>Y1*! -@DRQ$XN>1;E3[G 1L@4&M0B#IO0__9V$W[_7%!R M]G5+PO9'?V!J[U_$KM(BXO&9V#J6>AVA+7(9%%H!675(GH7.^(Y+S'$RE@TT M*[M]*V64_B%/NZJP>H?Z9 MC@XNV-=+PZ:KECY2KX6(U6K3)DWQ1[7#*;;>+-_&'RC'ZX7Y)U:("=#Z.13D M=Q/WN/%IH;[&6Y'T\_6P>+.40U-NH4:^:0G)Z]X=?L7GZ"BH)?PG>PTCC@)M M8N;PT@"&R-8 RE3YP"+Z%M!W*(]OJ0Z$8DNG;+%0$4 YU#_X2JS"@4.M1,/P MMU##CSVNZ_9O'DC&,BW-JLK"IL*3/^2ULT[JU.'1Y^54QMP'$9%+:<4CH21J MUDK^%NK3L"@D24I<2EL+=3?\Z4]12Z'ZIUFMO681+9L)[C_G;-Q-. MGNVT+3L7\Q.NU^60GMQ=;12@#($D*@?Z*^S:.A8KT@2_E)K1031^#Y872(>Y M$;M"!F:2+&CH^W&5SG6%KEV:%H9"T6H M&'!7B1T4^W!LY%X_37-2*KC&#GA.YBS3*1U>U MR_;.HS$R,YC$<:6,QF]9\G!ZHWUVBGUN+7-9]/$5P9>7K%]FO7;EQUU!_V?/ M\OQ_N#G^VX* Z:G%SSXBQC_?30N4ZP>P>W@[QRFX)^M),&LA#&9WG6^SGB!SOFT>LO]2__;D;!?V]?V?]!H]V38SQ;) M$M6:*?9BA'U;R?K%T[-^6H@RM^\^>>#ER=@". M\C4]].W_5TMMOK;_?[7_*TNC4M5$ V/38W+0L-(2_4/VRM?&/[4=/M7Z/@<; M_-*A\":\KD-SL+%#,Z]%C,3=OY08('C_Y97S:CE<'G$27M0B%'6,UM^UB,J" M8UH$7Z!*,#UDW3O[F?'S?[Z* FJQ4]&#V%D./.)KJN?R B:^^]]?PZD=68MW MDEFJ:2VBOL=W29>S%E'P6>\_7?W/O1[^_BN6KUB^8OF*Y2N6KUB^8OF*Y2N6 MKUB^8OF*Y2N6KUB^8OF*Y2N6KUC^7\ R.F)@LLYB8/3$Q MV_U/^-O?\/^]-.J]'<,9AK>39WAS_M1.&@ M?KCS?S[_7__SQ_^[7C=.S[N71L<*^3T[Y8'E>$'DLQ]Z%_\TNJ[#76;\^\O- M5^/4LZ(QV8WY%-'(:P K((;'#_V?8?_M).B&G[3\/SAAW:SN?L! M*!C""]A.ZGH[N2%]\<$'\:.Z-+"'?N;)@37R:9693ZL!4VFUVKLM=4,4U,/I MA 7Q30,SZ-/3U2]T2[W9JF=N&IKF)/<>_"'GEB"<^-D9!,QJ#+W[#_@+W1!? MZH>+QA3_E/<&/\R](>]2;BT8"[TFS#ID;L#[#JOC9S4V5\1O_]IY\1S 6UA_1;FN&-8XJ^?=D( X0>ZV_B ]X4\ M=!A\0#Y9;S6_WRE^V("+X/RE6QN#V3SOG=TW\#RCCFF-\)./''9"V-DK<<\<!Z03LQP^9]SSU[MWTNY6P/P=]P'2NX5K//H?O@O7&>1!?-.B MUZ)8:+8NV+C/?$&47:1%Z$?K@7._=? :5.B.@1/!DTWG;#!@5EA>[66Y0'+1VTUL#_OAQ:[$P8DYX:'I\/\L91KS M(S1L9O$Q&"\_[70OST%K5J-5(WN"N$=SP_K*P/8'B'#AC4#SH?7TWD6K\FK0 M\7TD+RY%@HW! *!"3^T,?48_IC=F:[<9?]CY#)]VZ\V#^F[SE<@^I_(\C^Q- M1?;F:Y#]<'_.2.F-8-N@V\7&S'N+W_OAXT3Y$X<<_#B]::\[S:$Y8OW2>9X_,MWA@]AVVXCS7 MW6X'?QQ=O JK:Q[.*_+>>,R%0@6*"@X4CSE XK.GO%+R "3@QRYW?MI!H;WS M>2F/6V.<\QKV<\?9?--QSO%H4'(&S/>9W0L]ZSMMZDW2<8[GKCV^->A'7Z9\ MLCA<>AVL$POD%/#HX#@@_SZ\SZ#CB6-TJH/NQL=@+>S([T8^#H=\S+%_^3&P MU<^F;_D>.HI7/J18XYQDU>,/H$-V/@D=9B8N:!%XD9^0@HXPCR7Q:=6>8@5T MG[J1D0-5?J>^Y#9^/>#,-VA0+/<\X:3[:]9[.GNS>M.'G%?)-TW(?SWS>N#X M?HCZX&=U8-ALJ8Z0;N7L+]G!I%^LOI-$S! 6=P=1]=L=?1$@ M%P]FB#@&I3/RV66;"/W[(?7P\I@]Y@UH;F^(T,?RL8B5:"1GD+\_#V?,!@,SM*P>Y1KK' M=H" #/1%DRXW$%(,)R6.\_F-O. 8KG@E=D/BX@ -Y,)+B=0"M)0E_Z8[L402 M-$.;C#1\.]HTRT>;YKO09B4._LTU'<>SS$5WLNOFSB[\[)WV>SO H@ M-K3=M@P0!>(0RW2\RG*'PNAX!>(,RX!06:Y0&""\*D?(5?:7.!IL?@^TGQD< M/N121/5Z?I;TJYL*66-A[G&I5YTRUQMS=]G+),T7^T&R;YM_HOHU/=_UC9EE M)\GJ %E>@/Y@>4FP^)2V/-L*IGZ<-W>YFYZ<_?MLJR(Y^MX.1;,GA1I%;XBB MYMHH:I8"17/GLQI%;X>BUM&Z*(([-HVB4S\:8I*@=\_\Z1;(L)SY:JGU$J14 M5DX5 REEE$SY2*FN+"H$4@HK?0K (ZJY!0NPI:J)V%6C)X 3.:$GYW M6#8VMT85,N4+AN 8'0L6V.>0^F MFCQE@P?8@(W_F&A)8F"(:1PY&QUV% M(^;C53X;(9GO6=>UO#';'I2L3(R* F=S2UQ\VKS9IMJTIW9;=]YY+B:BU+ZLX* K@92Z.^H'W.:F/^V9#LOQCG:OK[80@^MRM75&L(CBR=MCFFNTOP$OUXYCO=PY5X-!C!:=U@IU!595Z#*:/G4USM@ M$UJ#W@T%T1_TSG@53:+R>-8(*D+,=A605(+@[0HB:E' ]S8A:H.1WQ5$U*(8 MT&U"U :#02N(J$7Y!]N$J TF(E0048N2%[8)41O,8B@EHG*]'D\VK:L.GO(] M%@7H8%<=-*T6O%A]4!4GBK%RV%H89+\]J"I*'8%*X*FBK5H+&:ZW\>;-SU.! M*@J& F@^Q03$RK&8%05&@4(P"PV0):I(Q9%1C'R_ D)BO=R3BJ.D8"DGA0;. MDR9SQ;&R>4NYT/!8BZ^4MZUPN1E,QC8N:O/A%]O&6X.N(GB#JX"B)^VHK4%4 M 0RJRJ'K*<5I:\"U>0VJ M.0K. +:0[%DS6\WVUDDA._'<>^:'O.^PQ6EDE<'3XC2R)^B@D?5&R&H>Q1\T MLMX36,KPVHUF%KOP)'TZ\/J(0PU3ZS?G5 ';1V9P*Y-:"RA-D$ATH'=Q<) M4&AS+6/KK>;A]K$G,D17HDI%>5/@AS>F.V0"(GYXP5T^CL952!"!V1S'G;;AX+(Y0("WT@FG "_],;,GUG4,3.#R&>" M0ZIKU&/5CYEWX7/7DE\G'C!C-_1-]([<\.#[E^D7YEJCL>E_S]&!@AMF,7YO M]AT5#KSX.;?3" MW'9:X.GMN^KV75';G:L MTN;,75R]5PJ\5[1*NNU[I:@:8N'V2NM([I76D=XK6[E76D?K[A6XHQC6U#// M*K2VIG=5Q4XIBJH;EGD/:RU2[V&MLY9Z#VOM5N]AK4N+/7SM>W9DA5=^C_GW MW&+Q+NYY@_#!])F\(.BXMKPDR&[)6S[F[O!J<.N;;C!@_M7@9\^SLP]4E\I+ M?&9WPFN/NV'7A=LKT?(.(9A'3 G")\GY>KMQA05)-N3R)=$Z:X'W2GDU4;U7 M*J\;%FNOE%CCTWM%ZV!OM%>P2)-6OXJR3;*KH36O8NX0K71M\0[1^M;3.T2K M6EN\0TJI99WZT?"4!Y8'Q)MJW];Z&R.'@)O?"H6P.DJI4[W7?JBL*J7W0Z4T MJ'?:#]55G/1^T/J2]D,5=RMLVFK06M*6^9KT+M"ZD?8GZ5U0%8WHRKWVV9@' M3+D(LSM!QKO=L+')7:S$S/R!YX]-UV)7?8(0&^$C=\61*JBAK2 EJONC' Z8?;B;?&Z2[$3O_Y__/@V;VC8'C[G<[+F M/WYXVS?%!/TP3]%7WO>;J/:]]AZNLC7RO+VV31: 4E!@#UP-.KZ/E;1QTC%L M.D.?T3>_\W#T,XP@^ W^B'P6R':?7[G9YXYL;F2ZTRK *M8;\LBBN@H\CS : M>RM6I=?(?(-R]QK[!<%^DNX3^J"L(!U5&L=I)/),8J"?Q>U MU"YJZ5VD=Q'*HC5W4:MPNZC'X#'V>V^CLFIK5=I&"U9>ZW3O8TMKZ+^S&5$6 MYUUE#U&+X[PKX\'E8L14]\"Q,(@IY2'?+UX +'>+3@?R)JS5F1=AI;+"J"!8 M*:,D6H"5ZHJA8F"E=#)(6@P7)H<;73SEK[8,4A;2W(2U#'H15JHH@XJ$E;+) MH"58J:0,*A!62B>#4'[##P,6()5-9R:3O**2B+26Q=/6\N@5<%-%J50\W)1- M-CV)FTI*J,+AII1R2H9'G_O>..\([PL;>'[L":4K>#_"0[TM$&8OI(V6>.^% MP,J*Q?(AL(RR\^4(K*Z +1T"2RF%MU3 %@DWI92=6RH6"X6;,DJ\3%+U%KFG MELQ;=\'>=FE%Q<5>9=2FU;&W97I58;%76<5K*\1J(1Q-!9:< M)UX$/_H3&-'TTAPG"/KB<]AXSL44ME[OKXCW^ZNF^IYXCF/V/9E!ZMI?87G< M@,79?BGI"M!KQQ_*!,%5TAM7H\,3<%QQ.^0MHQS&HH7KM]GI2/'U' ME?>!AG\%X9\RQ&>@_':&^/I07IY(:GF.-YS*"S3XMP#\+]?!JAZK?,F_"IY= 9RVN^5W_[:A_".]I.I?70ZWU0L9. SRLV-QZ4\W3F\C&SUC9M\EYBGO0P(I6-*I0/"YCE"7K>W"O* ]1NS M57'7+UCLJNWS(BSV^^QLJ84!+>!1X?3:@7< 5SL#+6>"$_DR1?TL71,(RPI' MH"C%EY1XSRL==(7I)S6"%A"@HMS@50%2.CY1:H 4E8-\96; 1IYC=\<3'U@L M7E5FZ^%9(%E"!,U)5@/*=G"3(@&EJ!SE//)=CDT0X+)S_DCM$+:-H2RF@>8G M*\%D.]A)@6#RKMSDW.3^;Z83L2_33A"P\,0Q@R -CAZS(I^'G 7TNP+&_.WQ MQU]@$4W?&DV_LGOF9("F+NFZH D&]'N[ @QI(1$3?.63\>4N^IPA+%F(%-X7 M+T6U^>)S :_QN7U00(D13B]8./+LKGO/@C"M:K\:"VQM!\264K-8G+"EX?]^ M\-_5\"\8_'+A4S@;7]^;9PJ9B^I+64LOCG2NL) MUOZYZCND-3ZW#PKO[Y^K,L1*Y*#8E&%1)OAKM&X!,#1'TWSD71T46PV72BC@ M,\4NKN ^,^3ND +JEM6\R%ZI7K%:Z8N9E_;^BDR?G7M>N.R%R57KO>RI#;$X MK_1J,. 6H_GEID7'93+@0QDWP;*DTL5S?Q^\SU2H:*U?H2)]QQMEYK\&@C1P MWM(UEP;!V\K5%X!@MQE_T&AX:S:RVUR7C21W%):-:."\-1M)0/"V;*3K6MZ8 MW9J/G0AL61\&FU;'3^&W(.06E6'()!*7OF97_L03#3QWZAMA(L6LEO5"_&C8 M5.:0<#D$>B& #ZO$>);I_"OR>6!SJ^2-DU8%PQ-SKS8L:/(X<'*?7@UZH6=] MCU6,WSRTY4^\\=ASZ9<*P&'AC*6.L6#.Y8;!C&\%YKC4C8._OZX_Y?DX*[T. M4VC E4F+68ZAKWS,0V9O*8@6S5ZC:"[IU3'=3(G!VP?O=N1%@>G:MTS0#J^I M@*A+3U7B9.EDRRWCGEKXWU#E=X<9M7=D^NR+&=#&F0#Y1+7$!].W;WW3A36\ M'4J:';R*JB"7:A1E5!!H^IU4#7RF>96&3IH9"U#%AVS(SG[ MR\AY[D5^95$E@@C6H(%&5+YG,390T(U&Y,O4M0M"L%E,)U-;J/1(6C+S=$F[ MF;EK!+T6@LK?BZ,T""IJ&XR7(:C$/:_+AJ#"MK5>'4$W+& 8"MJ!@6"HIT>5 MPLX>46.HE-Z]$J96H(:6=&^'LBV1?<5$6?FEX6HHVQ;Y6$B454!B]ICCH*GM MVA>F_YVAV;VMXO(I4FA9^4;XVA)!64!\E5]*KH"O;1&1Q<-7!>3CS\QEOND M43OVF+L\"#%[[IYMJY!67F:LB;5L$9T&15ECI2=V MWU.OW31W+9%:@HO)\,W8\!Z=XS/^3 M#JY]-F"^S^QL$'\%](4E0?P)+);20>L)L\CJP*1L[D2H4B4%$,\>+2>RF7WN M>V/14Y(TLZO!F>F[W!T&UTQ$OGV9YC\@4T-M/'&\*6.T#E>3F;3(TEOF;TC! M5"FV1334UGS1$%U^#\#6(;K@7H,-([H"FL.V(;JP6@?8'#T A!TY#,B<6U]T M_EO&,@F'EWS_!UDIKHU02B46U/]X>B26V+:J(Q$K;#1>>/QEQZQC$ MB0N#P*V5PAIX[P^\4GKM ME@E2#:*-@J@\WKIK%OKF]RP[#BL!C_4RF&1<%AI[7 9#K5Z6"0<5EH_ M[/QI/N;#<-6D]!Y,@P5?%B2DZ_.UA11^ LDKC'"-E/DEJZ0/^=YI1VVQ?OO< M3;#-_O"E0-I6!;4X0"J//[PW\J);_@:2_:.2[!^W$HLS=-UN>?YQ;7G^L1SR M?';W;+$47P_PVRR[VZ?]4;F M0Q5 ]IS:D@2K63)H7+T!KLI[FE)F7!7UU.35<%7BTY$2XZJPIR"O* H"^9PUS9_A@N"'5GAE=]C_CVWDKB(4S\:GO+ \NZ9/SV!)_B\'Z4J)[T'1VMJ2^-9 M>%PQ4B1O[95#>OGJ;\32:36+:.D4?0_IK;.-6V=36LGM=,*N!AT?5FQ(P=1) M8L709_3-[SP-HG.63;P*NTG+(]P?7BKPQ7D@8#/R96T%-"3R'"V6I M&[)QIH/I%(,N6X\2I+U' 718$ZK($Z-X@?#!])G^H MR1L^53 M+4D76T"WEW/9N92U/,JK[95'^^W;9$5$?WF/L#3Z*W(^MCGTE_C@3*._(J=R M;X_^C#-(JS_OOP46+X#6@0JS#[0BM%W[8'NUH:7[0*M$V[4/BJP7Q;3\F7E# MW\3^9Z9#,+:\R W]Z;=>^368A9/<^2QG>?RMI_6$9^"BW!*]J+@HL-Q<#1!;YWH15Q1Y>@@[\.3U9+5.>C9'*2I8"8*24\F4>(]65,IO' M2#EEC93._[JNM)11.LB_KK5\>08N*BM9-HJ+4LJ4-"ZJ*TTVB8MRRA'I:;ST MW&^5J#[S!$"48S4U7RU97H*4RHJ88B"EE+(F%RG5%3J%0$IAI8^DCCK ZEA_ M13S@>* 6'R'^^[;S]0OW>J$?6132WW4MSY]XOCF?6=:+^@'[*P(:G=W#_V'* M0*;71/;GA$_!?%M[\8:J70][<7^\L&WOBX.0D_R6]";T)_XK/KW$5<'3?_\6D ;ZL/S#%WIL>WL%B!< MC!MO;+KBMX#_AQVW\,Z=S__UM]9!\]./'R:95](338 MO;.3;S?=V^Y9S^AWUNE>7[SO9]EM.]G-DX;1;N[O':T,9SG!'D9R&*T4FN4/*P%:_NFP07B\A[OB'^HKGP@B MO\LC&5%H=Q4"2>+*B;^(9JMN^=0T=W/IL 8(#M\2!.=7-Q?&C\!$X:++: P, MV")EXQR5#?AOQW!-E-$VX\"\K&@L9>2.(1GS#1O,J"8YAFZK6?^56'7REL\: M:.L#[15A]::H,GZX,/WO8@Y7+ONG(2<"XEE-1:PTKL_Y7,D2"S/<$]>NKK^D,85_IU= ?QB'?[>8T./&=^Z1F\ZAFM?M@@+=W7[ M*&]7=UPW,IT;!LIEN-;N-G D9OC3#H>A@0(/L_2M\ZE[?&[94!RL[>VFB?A" _T [ MZ_.\;ORV4JOYIE++\XUPQ(P!#RS3,:;,] TP*9B]1)3MY8'^FBR.,V&-/!OU MQS9Z,>#>D6U.<3#,W?E\RBRRP\3B[+9J2\;6SAO;.4WN#WC<.7P3K"=Q\=/\ MCEM7 I<&$+!72BYB%M.XC")F-U]QQ(>2B^.MQ,S>&XB9]UJ95]T0MS>=RUX7 MYZ./6JZ[.;[M6I<7YS=2$NW-3_XR0W]>XMD<$GWGC, W1F&N<< M^"ILN%C:_0A(]ZTE#^+&^ M>]1N'LQS!QRIMD6+YO1HORES7(RY@WG,W; A#_"Y(3:_7 ]W/6OD>X@/YM>, MKFLUGJV"O8H[\4WYP0]GCZ85$OD,;V D9#/,P @FS,)S&]O@KL'#P#@9F3Y, M+_8,Z*VWOAMH/4QL?OQ2^#U7#1=S/#:CT/OT I5<4&U&^=MOSBI_S]B)+U,' MWW1S+N1XK<-YCI'Y MAA>.F&_\&?D\L#F5M -Q^ IROKASYVE^023PAZ;+_T-__[-<._EM0=)MW#1Z M#>-L/'&\*49N5!@562YD7'J-?Y:8>6Q*/.<8P1W;]C%@2/SSE;NLM>9I[/Y> MT_CB>Z;]8$YG&?P2-W6[NDHD/R.<3TS'8([.BD-^CXP0$)@NTTI0B&:#20%CF MJ0]5=*PGGK/_^MMAN_7Q4V"$S&&3$=QCN&3-U0R CA.AA\0 X]F$#6NS8^.' MQ5L_<_J-(J #MZV_V=NM]NQ6_Z?T\2Q\]7[ZU5\]$-_7.)7GV*5M,$SW#YM- M'4NVH5@RH9HU]M]Y!CW@CSX/.;S$I]W!?&8;D\@/(G0PAYX!5Z"9(8\GVS_T M_XDL%F-$.A8\Z74]J/-^S0*%'.3*B-VC?WPRLGN 2K 9S<9'6$Q#G!SN3(F/M6**YHW04/NH4_1;LG$LSL,V_C!YR.0/3;UAH M?/UZLH)G;J$3Y04F8N$-Q.&,@9B.6)Q3+D#NP\L7! N6ATI=U\;C.#!(IX8U M8H 3&.QW@PLZI"*V>&"8Q@.8IO7OKO< =&%F ,^UX8<@0O>3&1@V&W!7!'3= M1 X3A-UK[BNRII8$*-R8)W >ZUEX#I9S]/0[C.]7'%Y/CJY+@UN/5?_!@MD= MHKB@6.QEPTZOW6Q4[DAJ9/H=/^FDE$ ME]X;[XVJ8O1AQ"@** O48^.'EO26CX"!(D9MPW2<&*AI!/>9O ">_!1H4ZQ6 MZ1<(9/R9,C5L^-4=TJ43GUF,?!RMMG@>Y:T%Q@_P4)BN$41@Q@8C#Z-S#5&0 M VXTP]E-]V &\SN.;I:S^2=("==C%VA"'UH<;NZW\#*W MGO-# ". #U(8X0:Q1 /S&DI/>!@(&J3;T!CZWD,X4C\W0)@R&AG9-Y2L2M$: M>!;?;GY:-#[ZN?5)7?;D!8O'IRY$X2DO7C!6=:6TP( %].MMI1.D%8'&6Q]_ M;B*M0]VOX@.;#7&L\92+O;W;V'^SBA(;.A]?S'3W\I,H_1. YM#SIR_T0=$# M">"6?""ZH[[B)A$826T$\05=_.PD[6;CZ$V7[FACH1DK3?_-ZM/D3CZW5,"K M3EZ*UQ5GWVHTJ[9Q%^6-+^=@S<9^Q>C06< F5F8+;PN,@K.%=F/NQ*C\C&$O MKY#"O-AO'!5$ZK<7'Z&!&H.:_$\[[9TE0]R'93PL]A#?5OZ\>'CMQL>-#'#U M^(XJ*I^7>1:8UNBV5J/;*Y!&MYG5U_I<3[@W!"%B'X?X4WHOM'*WG?4YD > M?S_+/ZPH#'LZ*AY[*HX(SJE_I];S9UK.$[&:A:K<^BY61/$8];-&]1[*=.$8 M]:)!K1C__#K'I*_PU'<_OQ\L.2G''/1E 9I^-J:&(FF839&:H6=$@3AEA\&( MPNUA7!M:A:E@^ J^RYGBRQ\XO!I>:[@P70\/SN]Y0-XFUW0M;CIX*(]EZO#B M(#1=V_3MP,!:<]S.CP4W6KL_F/_,/S!?+=9%1WH\*](C%?TH R P@PX#'LPP M9%@C$%<'%@HKA<)PS2&%!<;E$,P@ ',0OU*+QP8#1F%$KBRN@7=RC"YR 1DH MJWS/,;Q[&$L"F"3V(@(2^C$L]II[J?SQGNGW37AL_>K185.*J_RAM6]\:_2P M9]+']@$FF_\3)Y[,4F8?]!V0KBE8#K@_%M%7$WBWB1(/Z,$PGA"^:X#M.&QF<5B#X*>=^FZV>XT;C6TOE+^#:@[$@S?M[GS> MK>VWCFJ'1X>UH[U]M5'4J-5.,?HFZF'1!$4V4,)RO(!T,'@*UKBRV)*5M%*I MV08] (0C=M-9%++X#(B_MW]?0/R<]7T X-1H'1+,V[5Y+2AN5Y2'!&I_2HGI M008*>0D,1$7*_.S1#5=12"HPK,,2;*CFOJH'\PG61+D:T'/2W7]3CT]W_FUC M[>@$5=W+\V6P^GS0JAU^W*WM[NW.(4GDWQ/9,H# _?@,"N4$FK\5A;!)[U<^ MYL!]7H=*1[76P5ZM=;242(YXX\SN268TMWE>J1K:1B3&Z=7)MXNSR]N>T;T\ MN;JYOKKI8._9+W\8-V?G9S=GER=G+^45BSJ4%"67?&]O-Z^=4JH9-+._3 &^ M8'>X%KN%-WYQ !/KZ4L,&/\$P>)'3*24IS52%^WT(,[T,N/X^'OD\M[CU C4 M+LEFO,0)+D9KKP./Q#\P>\4C?HA[Q!"M!XT+QN@G0#AMHY'G@%D6D.D/*F^K MW42](!:Y,)XEDF6^-=Q\0S:<>\.X1B-01OE3OLN2F<$.-'B*ZJ@0^(KN2"3/ MN :MP^AVNW'>CIS=36SHGL-Z&]@251&!G""A>(T-BH;/N/O\5B'/W-/%B.I_ MVMF[.^\L?).2$D5A"M+H-L[1>="UCU=WB^\W#MMOX%GWQL_'U MZ_7S0;K;V)T[VMP*E&(=6I3Z:R!UO['_%L? 1:',8K >Y(!5T6\]P**JY8"- M4C.NEA;(>MO"1(L.YC+M!G(?N\)!W=*B@W'QZ!6*\E)_T-5F]JQWCN*PMHDY M9/6^S\SO=7, ^_W8=!Y S]XQ/KS\W/)5R/&>KWP&]\L;Q 8*A].6O<4=<^<- M[DYP6X*-")8Y=EWRXG/Z+ZX- M'C-O]<4-K:VH8O$$E_)AL*-H\/GEH1]K?"']5?IZPUZ! MK!L ^XY+)ACQVS#8 A"_R"FHGXCFO'F<=_UJ MPZ]&S *CL&J<]Z!QN%_L->B&;"P#L1K;P80W2.P?36/DHZ/I;]W;LXN[UMV7 M;[WNY5FO=[>3#:ZB9]K,DDUICRG $_T[\!"53AC'4IG+[Z4![:1#$#7/?U^> MOT4L_4!S\X)P\XYFY^_(SH'N=ZW.W0T/OM^=FU;H^<$:+!UO,^1MFJUKMEXX MOK+?TGR]('S]B^;K[ZVF?[G[=GESUKOZ^MO9Z5WOMG-^?G=R=4%!G6LP^6^N MS\#BOV>VT0O- 9YGC%(Z^JSGZ.W/TW;NO9S]WOB)?/SD[ M.^U>_KP.8__*AJ9C 'NWKT?Q=\_?B\1?-WXO"W_];[=K*6^7\ _1L\W=^=7-W<_9SMW=[T[F\[5&LQ-7EW=E_?UO' M&A=E#K&(\LU\=211K,PXH]*&-;C"H=)#J;)+Q@76XO4#*L+6Q1*UOG$=^=;( M#$01,G$O%LV-?*X/[33C+R1#.SS4 F73 L4XT++DG67)P5WO[.O9R>W9Z=UY M][)S>=+M?+T[[=QVUI @_^\-"YA_S^S_;U7.GKY;LW?-WM^!O1]I]KYI]B[V MPD?-X]^9QW\$>^&R\_,9Q5'3F=VW7J\+A@)\^_6/7K=W=[Z6O3#79@,/\:(@ MX+(W1\?:HFT+7@,B(W)"NN1JPL1KM&&@)4?Q.-=14TN. M@D@.G6GY[J*C<_??WSJ7M]W;SFWWMS/\XZOZ+(,_UA =_XVUOCDV!+IG) 7@ M"T?]G8H$,3I]+PH-Z9G"G$TM&;1D*!QG:K7:6C040S0<:LGPSI+A,.4OZH%$ MD-9%[]OU]5?ZW+E90S(D9D+<0D4<*/2BR<2AO[%%SJD9FEH4:%%0.$ZD14%A M1,&1%@7O+ J.[DY^Z5S^?-:[ZUZB5=#Y^>9,BH/?N[>_W'5.3M80!2?4EQ*; MLI( +/ '/I,BH3?L;EO1S1*-?$+SU5_M]U12=<^%7S=\W?"\=> M6JT]S=\WS=^-HQ/-VM^;M9]@$L)9]^?+NW]]N^GV3KLGR.#7T>,3+PWF'Y@^ MDA(['\.87>-?D<\#FUNB[W(X,D-0]=D]-D'NNL&$63IN2,N$8K*DBLN$@E-_ MZTH'E)7,FI,6E9.^D%;;P?#2&ZH@A0AT)0+-]337TUQOBTQ_V;&AJ>W_]^[8 MT+P[[=ZW?3NSOY]=O*-0L//NR=G-UB/X.;Z:BU7@,^H-4_-.'MD5D1Q MX5># ;=4?8$3SY_@G_*72( 3;SQA;J"/_S2S+R:OT-_%Y=V;?ONL!K[_I MWOYQ=_7[)2C^OW2O[\ N.UT+^^^G%V>K5->0)8)FQI7#RYH_2,^P1H!)\P/ M3>X:7YC+P!S Z&[Q.UD%24D"65M@89$R+3ZT^"@<]]+BHSCB0W<,>G?QL1O+ MBINSKV0EH #IB;_.3N]NUTDD58*"9 #&AH "3)2X18':8K D9I,,1)N)Z,+ M#P)+ ZBDO4I:4A2046E)41Q)H7L/O;NDV+N[ONE>GG2O.U\QJ?3JV^5MY_+V M[OQLS>ZAW+7X!$R())'4.&=,%AQ@_CVW=!Z1YO\%9#\5Y_\%I[Z.*2P)F34G M+2HGU=$UI8PI_$TS/C=K?S]N[-__]+]TKWMY948O.N= M_+)6%,F(][DL)IA39=#H62-F1XXV^#7'+B G:K4.M"@HB"C0S8G>710<8'8Y M1IG_>M?[=G'1N?ECG9JR\%2CU:S_:O2B,4Q[JCF\YO"%8S"M5EYGH@^AV7<8 M?&OS^_7V=V:F_W@N)O0KW^^5^()6>Y('ZU=[Y\A7+YV80U;O^\S\7C<'(?./ M3>?!G 8[QH>7DV/30N,6-\V=-[C#VH!8+W8-:4'W4JBAO#O\/? M]:]75[_&7R:U[HW.Y:G1O3S]UKN%!V#/Q"44_#,*0CZ8?EIOS^\U]D'#*XRL MNAWQP.BX;@06] V;>'Z(]9=C/:MF>+X1SEU3,RQXG,G=0% 07O-@^G;=\;SO MH .(+X.X[']FQZ:&RT.@I#5#C)W/AMJGZ=MF+WK@,"P7QL:,,3-=>"ON=/SS M6Z/7,*Y]?H\YA4F+8N,K_#,D+@&S0,(8'2N4 0(4.R:&W6Z=J2>E;CY[M*B( M-=T#/[>.=O=JAAD8YABCRVPYY)HH:,3=>\^Y9T80]0.,14#_A,^#[\)G$;F6 M"&G#)S>,CN,8":V XE0?#Y[CIK[&=\(RA)[/+7C8P+2216"V09287R7N6DZ$ M6EGZ27YK:S4](8(S^"%F-OFE]4K_TF<-A@+-?(]W8>.+DW($_<9S0W/>18\]^ MR8 !C',>PAYQXK/?T M1K-?!Z.\R87 QMC\A3)O> !L"2INTUL '8LB0DVD"*GH"3: M=<)&)#/)Z /MF?_33G/'L)CC '.UX(GQW]+8I+^514MWH!;CF). ':L/GPQI MLC>;T@I=ZFL3%XLE>ACQD-7QW4C7!]^<++1B9Y"0KS8=J)5]:O6RV%AY+1V& M&3%U2:SCU12M51T(\T3:;>SN%H9(2S;0_YJ9^/]Z$45G#)#5=^.L.VI>]3:C MT-O@M'*TKG5>C_@!&7#PZ6DO6Z5W48: "Q;Y"?_D,L577H-"-I;_AFG?PQ3, MH="K4*^;C*8!MX)ZWPQ()QM/HI#>A5H<:#Y(A/_ZV_Y1LMW)437GIM*D+0S&C6D!>V14^ AY.;SZ(1PI[AUX@_ !S:%^%("! M'P2:59<59)I5:U:M675Y6+7/ F;ZUHC\E3:[9XXWH; R-H YAH$Q0!\67(B> M*A_5:=N/AH;- POKUTW1\3GTS;%T>,*%6OFN%A8U1]<<77/T<@C'PH'ZH%' 7!DF M+K)VZ?YJGNS\PRDEP6:[7'IX[ M59:$%@YEA;46#EHX:.%0#N& +'C&HYYQIR1A-2K[CKPN(N5.7I%D."+3A]G! MI<3A5?+9Q)R*I"3@_LCA?68Q3%8;^-Y8>'FR[TQG4DXB/XBPOC0*H(R\B)T] M7WS,U'3J%U-L9]/[*^+]/K4\@^%H*5)6_&LIHJ6(EB+ED2(+1 +^E+(A!I$4 M)S+O':[ &]U GA-8Y@3+%(@O;2Z3WH&E^S*O5;CW41"8P:A&_V_@[["B,BV9 MS!/_.Q.\.XB+"FA14%80:U&@18$6!>40!4\ERNKPG8K!2C-GS9PU\^FR(DSS:CKZ1YDQ/JE^.YL-E19#FPYH/:SY<'CZ<"NU6O9R,D%DC M%VZAS'^*UPZ LGS +6[ _PZ%>F=W)$T--,LOJS@U"Q> MLWC-XLO#XF<2>["-HZWJ-T9!DLBO\W$T!]<<7'-PS<'+Q,&_LZEA^Z!1^TDO M.^;CU#$<1?/HLJ)+\VC-HS6/+@>/IJX9<6CW$#,C7>J!Y)@/@>R8066V= 9. MF<&D6;)FR9HEEX,EJT9R+.3H;HY/%HD;+RAUDNI>%Z@<&W)7QVHWA0]Z1OKA M&-RGH@+E=UCU2D9ZUS+.])KLA 1, %WKL=,@<55<$A(!,E$>S!8WI+*(LI(N\$_9)0GK8L%$B6WC[9IU MEQ!TFG5KUJU9=WE8-^CD7)0[<43C"0Z>MWP6PR9WZ;5JM9.U2ZTFW<-='-$Q<.4UR+OZ=EMEJ7<^ MMW&:,)V1K^8S,8>LWO>9^;UN#F ZQZ;S8$Z#'>-#9MI+(;IHCOD[*7?*KSC' M'TUCY+/!3SM_N\4UO/,&=R=P)9IY,VB=A27 EOD.)VS2O>C?4_?&V]S\+(GX M,N*L+Z4V_,K%C&M%Z LM8V6&_]8X^5U4MW8]3.C&P&1G"A]&G-V+=CC4)*=& MHPBEN%NRQ_5,#HBD#INS S#NBX% MDYISD61F12F,"X?#?.Z05&+QH# M *?T2^N3T6>.]T"SF[\VD!?5A%<&9@%7T\H+"L(8 R9AD4-FZJ:WD,9+R*7> M)FAVX?D,3P]JE$Y*M5^0@(:9\661V#(GW(9W6"/3'5(57O>>^QX=.S1HC_@P M.>&:B@!$/DHYRG>"%_M#6;L]A!U%!\GPKUAW; ;""AZ0<"1Y6$Z;$13G/C, MYA;L#L=9^'B:D* 9+3\P5W4T\B1VL% ./&?1FC>,JZ7;P+ ]&CGP>LPLF$GT M30YHT%4GDW!-ZZ^("\\@ )\HX\,' +QR&,)?6?NO9OSIP5P-7'AXA& "HFEN MID@^KB@A!'4"W%]>H^H,](^$F8'^8.">@,VP*,.0 3F]/+MO*]LY-:&D"(J=*Y==;6!!*@)%R>/T>9[%X33P_M3E>+D5+(D"4]*$\ M4PX#-/WT38I94=TOO&,@6W9,N"O<38)M@C; L!8O-GSZ4V$11%+J48BNOHEB M.IK 7:E%32R8!I!YO=PGDH7D*2!S8CGL$P/)L! MX(Y,Q!XI)(C<*;%D8B(^N^< %FRNA9(M%AFH_L5TB^F?&ON"->#NB%@(W!_+ M1B%<24K0B9$?JSU,3 ?7!<;K8'<5O'$BUCWS]+?:61O<2[?S3%(J?@%-G,.L ML)(2;0EB7S!RF*H_304F(XC->/&%I(B.E3!!PR%Q18A[3S]/X4[:/3+&!D8H=1;"^:6;H MB&M1\U'B/+35^](N@BV)NS4$?C DP3]58G(8F8"\D F;S;1 CS"M*>YSQ56P MM"+2;Y85"6Z361+)1D!-51WR4:4733!K:=[%0/WN>@\. MLX>LE@_>VH)%2+9(O!S O&&*DL/&;S.-8(R,+C"1'@9N?+F90($ ?H=T%G0+ M&?$C(:'RL?S[K'R(52XT*7T\&\G@E+0O)2AJL&(X28;-0E#I$DM.@ "2\0&' M$=,RI9Y1>?WB"0?J.?T'UWUS'40RF=#HDWH,#>4<51K;JH]2ZEQ EB>:NM1U MDJ%DEQJ-)1IRU90^$RLZL]]$05KED5_"NJIO\SD<8 Z !N"%#SUK!%>W]PX^ MH1*/YG#7M1K2/B7.''@.[3%$1S_@-@=FV[OU[OSSLGMU=FS]69UUXMR'N-N3- M3^_=9S/WW1(R]ZM4'6ATR4FSCV1S2@<4;CCX($1]RIT,$M^DZG5]!H,B#Z-H M\9AR5AFPD7A JL\7$=B1Y*R-A(U-=\I*0&K(SJ* M>!:M(SIT1(>.Z"A'1(1%QJ+FYYN::FY>#FW<'R)G1!HA<=? $ MW!E]?Z"?FT[245*5V18'Z>(V&;X'S)S.8O%O>2R9+:N=?7X061:82\*,D-D\ MTHY0%:C0KJ$6EDF&CH@DO&=NQ.(38>X&T0#$#J>3X#@ 0D4#>7X2*PX/&O!0 M!AIJN5+&':'EBI8K6JZ40ZZ@7^ROR/1AJ,Y49EZZZ: \.L5R(HSW"5G:?G"F MZD!,A*>9-A9-P1,N&1J&I@*L5I24Q *QX>& /.N[YNQEQ*3F[)JS:\Y>#L[> M%4R7/6+,#W9I -)Y8ZQK%IQ"KQ*S,8\7.X!CU%*]@$5AQG M-2,2F*TE0!FQJR6 E@!: I1# JAB#1C5@QDE=+*+28AAY+M)3DT7D94:AYN>;EFI>7@Y=W5!YG7AHA:N>1 M2&O%EG..&>*<*44PFYV9;F$WQHR'B>^->8 :^]ASF!4YHCR):P#EXH.",8-W MVS*YE?(>F2/JKF2%0DW6X+$B2LF/Z+F4]ZE&%%?ZG8IR,.)&>K#-T*&5&H;* M,@ .PR*P6#))IE-YVD$5&F1&0R*\7O/ZQS D/A<_+HQ2$H6^.KEU M:J'J.6A'B',6M%L8YJ0GMSG\.]AM(\^S M96$=G+LV+\JX6;3(T2)'BYQRB)P34:..*GTF\B;6_T,L:AJ7ZA3^,N;ZP!.5 MY\@T4GEN2561"0PHJ5$=1%SP8_6URI+#8JE8@CG,^-Y$;3TJL:\E0!FQJR6 ME@!: I1# G20K;%@0J5PO2BDJG"BR+G!'4>4NI0EG(T1PXJ9H+D'$:NINHHD M%4ZN?NN>UEM'P.)=FXVY59/132[#.M/WJ7!7I)-')82QZ$:59>M4B6: M'-3B"E(U@V&16543%]AXB'86YK (VR24U6Q5IX%4H)F\8?: 1Q32HDJX%@B% MN)/!W"/CA@NRZ5?B#02YW/<]TZ[-=;N7+>46EM?*'UX0-[_!P9&OT!)!>_!\ M:?'-=.QI9O!I NJI[AV, U"-@YD M4S^T;:39ENYU<\]41D=+9)ZT>0S1%"U0J M:\HN\AD5'L9N1'T24C0K& \?.F_%I4!!BQNE0=3M/^IG M)^48FTT)\MDPN&J*DNKQ75,-Z9D+U@LUHX\C,CB51X-?77.H ME/[YT6$(>! [Z(!$#^$H:Q!)VT>(K%DK.%K!T0K.JRHXZZS\\L5=2_U9!"=H:A<7: MW&?2ZRV..54C5FI1,?(""<I2&Z6#Y%MRQU*]WS$/ITT\O#QWCFY.)[P$7:LSR)^V#*0]SU2J* M5E&TBE(.'PPZV$T1)SM?R!>](^@3P9/B=+^H),=D&'$;ZZYLB4MC7[LT2NW2 MV.0K%R)_O4'(E>Z#TK0V2IX)"8/;/^UG<[G[LA&QNMAO$E'>>Q8+H'Y9GMYZM[C+QA M#TN@.2,Z5YNA4',WR)?E24)\,0HQM.. %:>K2:HD3!&9)#JEJ.Q'&?"Z.EE6 MP/G&Z8+270APBGP"JZMF3$;3 $A1[YL!&&%Q@Y:X7">C@.P@E18*7!S[!=3I MD!QSB%SXWDE5[43+3:22SIS%I$@]F3B@/8BD'TI_A47A-G84B-N.65X0RM[U MG$Y2XJJG\"T-85%%'5%*SA=&94X5TX9QE6Y&$\^5!T84B"8Y?>Y-1B;0S2*H MP+W4#T$TNL$X-E&M3IPD628E V,[Y)"'D0R%PQN&2#*7"!#7$Z7C*U+>!"@] MW['%B.A,"0G-@3JN";2>R<@-F3D6[74<+.@-RD:0[:N35%GU5 V\=+&C^]ER MK0MS?.-S+._!-29\PE"0(XG%8F=V$;W+]L49&) 8R&P3R5S&['EN6?Y]=)N" MU!/T5-6LR)?4!^5HS%1_;^!*LN>&PQYKL*+N,!S!!I!%J^H8"^H&<2\.4Y3J M=BGZ,V(MD[( --+1N7COH'5F7ATB@E?(/P"410W"&6'V!"H6*<84>*8 M<"': 6I?R^J\,+X1@AV]:5,7SQH0%1LF(@&LWR:N 7TT:C1E0 MRT&,*_60-\-=B"]X$$T,QR0?.C]1/(F=F1Z767P3'X%'-HO,\N.B?WK"FS 8 M5>X+G/S<5/!9 2?C5FR.#02*BLY9G%^2IJOD)^*(F8KB'94$V1>3! : 3$> M+)J)7"^(^3-= >"Q@.K 0A7N45@ U&!ADD;VE#C# WE8'O,NP#]@@,GT3=HP M]?NSNILS8V8E)"2%:?9+E MLJ"2ZGGDHYC Z=3F2I;G#FB. $ =.TG8A0\#+L@$KQ:U894>D!YW2A%84"RV M873B'JBH<\#T+>'JER@3V=;O=!PD,^-3E4^H+ N3&(F;$<9-< 7BD]KV>%(1A$+- M&J0D85+M7@E%T?J*($LKU#"ZKM%NMELU>HB4@$ ^^-*8T2Q3JN08MF+D"Q44 M[FZJ-HXUE4=O2WW/B;5,B\*5$*@H3_^^UVXT#2"Y0TD.\,WNQW_48M:KIBP? MBS#"02)G8^D2.:;M97,TY(U8#H?J78HADL_/@9WG"-44J8J='6LB9P5G)VNC M"9X_P!+^*J*V1LT);!_X(?J0X+53&36EZM',#A=,\#FU/":>R.%/JU9B$C)> M*WX6\30'X(MN3'B"5*\P_]2-FZ)16TO\%6ZO1Q/!<6BH*OY845",6.COJ7-" M&9&&_$Q.1J'00 &&7 )L!EC!,.[+B0!)<>.DS%P6PT)&H4 A]4SE^* G''$" M*]XY^:V&)&2/Q /A"7]O-9NU9K/9,'Y'AF0;K:-FS6CM[XJYMW9;@HVD2@N) MN#6?R=JG,,3#)@#IX]$_Q#T?#_\1YQYYJ/'16P>>4!6FS(2A I>#^TZ9Q6@J MN[ 9Q)9 :(O'M)NM(Y1L5"6))"/M'-6BNI8EG<\H9P)F=;,55/6+) LOJB!$E MM*1! 2#Q1&%BB'ZN)&CN8]4=4<8![K: V>QC&T8/5"4ZJ&E^NL P22H\@E^T M/GX*C%,@310$^#(<7P>$W125;7C,.1BZ+A72Q2J-M.ATS8T\=(!+KN)027I@ M^].OH(&=R[:TG3@5"W?@-?,IQ0OD)8VF]4F<(R<=S[/I9$/3QQ-?P@LI4?E( MJZ:$S#@2LC 1G;^2<%D0,SYF IK49GC@@701QF/:M2#429G F*\U E,%.+M( M-7TT/'.5UM/(5YM]&1N3Y6_4TB!17*%44UL?T"H6 M+4ZB?HL&0""88W]ACDLL9DZD/P095Q.J4ZKM]+P[0BHUP,^>J(.\XC"?3 TG4/F!IUA#? MF'J55(,&3#U-B7]O:E)@> 590\9PP[AW;M=!3A\2KAPS<@'I9)&GW()JWZ/B M ""8UKT'5]AN*621(/1,4H>EOU=Z8Q2L,U[F/JP&$*5N.:8LF#C@?OHKX84D M_(GD:4ZKF_@P?29:48DMH!Y.W":#T>1ZDJ'BZ+?/J+E XEJ=,>X#A7(>;.,8G"D4\MQ40+ M2%E6C%RW#[1K2:'L7I[6C#HY.JB&<@CC8D+'27(P1"07*E]P>=I8)6<9C/]; MH]P:*3P*'/E_+13BQ6[B\[7VU;L<9!T(! *9T!$@,8 M7EO57^[_*<<"/)7Q>Q&[D*1_.,!/3&+P#^F!"]B@M6=F3@-DR\00T'"HGYDS'DQ%L7#6!@*%1GID!T9+D,8A@-T7. M&5H&BIA IIA*)Z_%_/SO+T!%_K*4IMO+Q="D",PYT8$8U M C.>)4PW"+SY,+?-C&-@WL-JX])BM0X1H 6L)(>'9XSM!Q;SGY6Y(G&?#%.< M8R[$CB>RN? \/VXLC!'<#/&,W\E(QLE)3;4N-5DZ1,CJN.12+ MQ@$S54K0#R5R&,6AE2>R'<43\EP_^6!I-2X MT+?_2&<;^6V$A%$1![N^E6VQF67L! 86*1)^)1ZG]$[)T+@$[9R0+_R#J*7A MFBM5V227IA.),W&*FR 70@8*M#GF2N *_>R+#QJ9Y]0OINALZ_T5\7X?!)]L M.PA+]N6B5Q-;4I:!%5[0!^';@%_%$VTC T VUWTV9;WF]*$-QI0!H4X3B&'0 M<3PJ=&!E@RXOV&QBA>#3/=POX@(_GO M^_O)@%=W7#0R75V2 M#C#PO>C.H[,H' @Z#LA9C5MCR 6]87GJMA?UXR\SJ@*&#V#5%CP/$!58Z-1; MN@!37F;I"C[)0+JS^GY?R3WL")%/*,%&;NKQ;^7T*4R.%EBCRGEGQT===)"T M^[%QE)PO_KW5/&RTDK\1Q7\_W&_LQXCG[@IG/K7DH GIC<[-.C+2.KDYY=D) MFLKR;*9]\(_90R-T "%8J6 =GMW T%J-=FJH[8/&PMD MQ0.L-<%Q6**0X9X4UV\0,KR[\=#8,1='5$(SYUB+$#CO*(+7JYXPN.(R[A7Q MZ/ !HZ/;ET4:$WBS\4TJHDSZNM,QNWF!"RHL;=:%6K[07%UM8A5DSV5]Z43. M921:PAY+F<;Y[I.J:!+G^^Z?]TGA7 C 5(X8D8(Z(UN?9A_340=RK_0\65]? MQ#!23(OT/\O=. ^[.1;W!.P;B6!== M+I1JP-R\G@#JS#"]:JE@V$S4CZ[*4%96I$6Y%N5:E%==E/_L"U>HS,XR*8[J MM<1Z1KRH,ZXUQ7;+0" MR,/5;O\C;:.N^J!F3::W<0P#$C'M?=D;:&$T? YZ?B+#_ E-90.@%6F>Q8]*5=B2XX#LKJ M0G,[2?B#0=BU(Q+L:]I(UGFW3HJKU=<:,HS>PS1D)(7 MZ,[G\A$FOH<'F7'Z5#B=R "=^'PKB!\VP+2M59ZV@>0RRI\:9%.H%B2/K;(Z MK=W62HN834)[YHG<*F_"4[M5KEN:FO8@R;$/U#A8@QC-E6A17#+4%L"DL=K$ M5MKY@M,TLEZR3*Y2W.]Z88]H13],PJ?439'U6:>LSQRE7#*_.'-])FN=$8-# M3UV@,DA345M36B9IO@@_I"_+$(V\*#!EN8TE230JX0\[!?29RP8\3"KK):/3 M.GU9=1*MTVN=7NOT%=/I+^:\+\]4[+^P*68%S1Y$99@_)I9A>V8E"&T1,BJ< M3-F,*U61*UVR; 1J)W.'LIO-;%VGN80S66 $,VJ?JBVRL+1(5H#'R6E#7P5I M@JX:=]!)DM&$/P[DH$]G4DA.NH+^@ANX8]>]*!29A_*T3(8,6I@P:HE3.A#+ M%9&7^I"JQ/)2'U+I0ZHMDI=KQINH9B4;D$):]F4L+(!%UBZ-7D68ZX6179C"OFN2M9R"KW8B5: M)&D95T2'_"H-ZI M'MK311EJ<_4KXC]260FI=(-L'0;*8$Y76$@E1,V6<9@K MO!"O<,98QOIW6"M.ALR($G RJ4"YN^+Y@^92#?5 F],E5@^T.:W-Z>JI![(( MNZD*GCYX_G<4\8F#-LV&R4DK)6RFQG2&TR>6)/!3$?Z8E64R^)):E"0E!X,I M&JTJ0#+)C<6$PI8RAF"Z:'I$_I\?TO#Z 14:$@1,*32D>HY=.A.Y99?H<+-*C.;=6"L M _6YL^*5X5 MSUCVL A2@09Q .W"L$!1)B.NAZ$29551KZQ':]5RZ#,1I;2^LE!&WF%%TKX* MT;#H6 H)@ZT\,DN)F]HVTS/+%'M7]49RJ*6() YOS)#:36""4VJ4Z"/?4P]AL+3P:C'*>=6'(Y/C9[1"1?@"=D3Q+SM1QXY>H#6YBB43_R\= ( M?.NGG6'3-5OAP/K/?M2F8;4:?TZ&.T;(0YSSCF$Z(?Z355+:S,.S80D7HO6Q?R0%()&',A;3,<3454P_ 'HF&9M,,"[+\VQ/R%I9)L M4:G,LE;8ZJI\S\IVYRU=]TSNWGMHUV<[7 8P#.;*[18[@!S>]TU_KK$@EM_@ MI#]D6OW9#/:?,*-)IE([73#K98U#L->2.VI)Q4(L<2G2>F:;><[WLT17#6C) MXTD8IS>A5R <>,?9<%'%/-$./(U[@I1=PU<;;7H*B? MFFK&B%]2WS+2A4!3FT@OB.FHIJ*I7H&J-Q^I,Q9%S8H.D+30J%H*YD]-9LQ[ M0*2IOL#N '6L+U?#RIS F]4/2*HZT8OT(9E#%BM,M:2S9'P+T<=[Y!;&P\I6 M+:E1XMX SLUTRR(GE&%@RXEK"A10B6S%ISX%),8DM2UE*(3<%R@$RA[TP)"5@+ M2(1UA;.S%8N>UQ2Z@V+5I[Y3-1&9G.[HA\^0BCG.%-D'X7M*Y85F407R%^X* M!M2E:CJ'*[P1MU+^=E-*.(S@820W^2)E'\>1[O6Q>%-6KU$- BNO#:_(^,JV M8S6_$X?SJ.-P3=1X]!*1(*6!-#_%CX+K-(R>L,@&D4CDQ H45%1CKM$)K*Q( M2"-N0J%\JDWK #D6MO7@CR*/KQ87=%"7*,-/='\+HB'ELE*YY4@6S,:&M"HK M5#C)<=R W&RV+K$=.:.@)O4V549"O@TG)T+R48)2G?\@GB?-3,X&B/'WW;B> M:P51U%%INHND$*4 *Y[?CVPL#ZWZ9=.:)JU\2=4( G,*[.B!ZD0#3%JB V$B MR5&5,:. R=9Z0?(XH>O#$SQ+U/HD9D*,'C:\B)$U#5",,>LDER5B^[[QA,0" M3$FV+!8)QP'QUED96:W.+X4RM9$C)7:JG40UWZ=K+E@56:CD^:,8XHF+& M\+H\O3S'38G%$F7#]<6MQ54GUXSM]P[--C:#A2^,Y(5L)0"XL+D5J]NFG]:* M^VS@^=$>!%$;X&ZWK(F5D^%ZD6V7;M*<$KI'(*:#1F MT2&2-/+TW.#)*GZD1X!E'9O0/ M:O1I*JC<$$;[/SY0B&G@QP]*G!$B!8)IY MS7P6[,R&<>7&S:9%(;WIHH4, M@1$Q"^&WMAG DYILC(_G@NY2R) QXT*! J1978Q\4GV+%.97<0Q\W'XIF MP-A0O9L9'SJL5=*1F,;,*T@)1P&0"J]/D59>X85S,CBPV<[D+ MRT0SJLU1%>USL><"AEX53R1O4PA7S)[&GLV4J4*?D8"B0:=\TCRO7P D(!!L M*]-7G7VRK^]'I!*X7@B/AY\FGD/>36^6!:%+#*]:\C1A=5/[<"R)$ZA.KRD% M*!97N=K5#&/%*8M>YI0NP5TLXXR^H#E(H,.+;%*1+?&6:EXE&:"AND@M9C." M/+BAB$LFK"4^"Q#\#M,@3:$MU)377C0IAJ>[V'Z M03:1OB%/IF&BU8:M9&UIO%.8@*IV$*O&0H$1LT$=)>8IN2^6/4AP^X,2D]*; M9>]W\JD&H*QD.G;,8C%5*RE4J;9D#Z18OSA.G!/RZ+WJA'%B6)JC+LZKXQ8!7GD_0THI<& MD>1^L.%#2@2R62C]J;+\6]J])RB/WN3<5BTL2/EM9_A@GS1Q"1 USE29.3L^ MW1&=C.$A\6R"E+@>84,K7W6;3J^>4&Z *:<+SC.SR7G956M"M7@3G@!KN M"(\\2AN8T!C[T\<;0(D1B2Y$7P9BL,83CD[$N"AAD/+Y!XLP*'6[M% C/S9U M(2/F-B]:W?@P&BC@$9=.-D^:02L@4VO!>#O6XCFD) @=0KF)(KI5)\Z8$GXM MXW"[LXCG.2 M285!*)NPJH 'AEWO&,4\J3;ODIU2$\ %E0<(R#P0/1P<>7@HM"+INGQR; M4B 68:<:!>0D%LH7LA<]-RL$1C#"@VA@3MX#L2G1C4^EK'E1B"DZHIL=OI;.,4,VE-5=B39H$YJ2[]\89OWG.XE7D]@J1;#K1 M]6T37=LK)+H>-/=3B:Y[S6 R0GL/.9'W&C-,$9Y+$N\#$_%-E[<=@]GF+&>N]\D.(";3B5KI^OUFG' M<7'M*.V'T'X([85>BP-L+PA^BRT"$<*13D+O:7^R$-,-J/3 M4)4E)PXT%M0-FSTA$!$;>1R.TM6Q.*@\V7@BYTB?X[WV.=[N2N=XJ8*U>T=' M;WN.5QBJS9_J+>^OD3W EGU,4#ZKQN6^;ZIB#A.?LY"2FZGV"VCTW7.? M"H_/U%X.?39&)R45(5I0@KF6[D*=C3SS&S%HE:)&J16 V1V)&EIXQK=1QU+<-W/7>19#2Q#U-@?&?3F=H-5+L= M"V"F!8%HW9>12);I6+)B@2KS( .?I9]!2579[SI;DC&))1'1)D%-5+BV<(#4 M0C$M;95;(AEI+=5K4OR46[X>A?=,V7HMLLJZV;3(TB)+BZQJB*RO: ;5*7#% MN%#A%6=)O=9%8BOCU!.&'4H+Y/.BVBM+&S5Q]=8\H2:*J;H!/$(FT?2G.97U M0X:)HV#@R=IC6;ZPHHRGZJ6,0#SX13KG5Z8KCED<6N)WWB MK/P_2P61JCY=HR8I@4POEJU!1)PA/AK8+I@XMJ@7(!N<9D473P8CG(.44T8W MJ]HMIJA#BK('7Q(%L 0#GS,73^S@WLF(LJJIL]@ >$UC>PKSW !.AB[/-'D7 M97VQG+KLHQA0[6MJ.!N7PYEM$:_2PPTK;L. 42Q17U4,I^P^C'HUXJC7/^%U ML.!!PS@'$YD]8DLVIEKTB?ZH$Y.R.%A@^;RORF8 P>%E]?^?O2]M;B,[LOTK M%>UN3RL&8'/1VGHS$=36EBU9LJAV>_RM %P U2I4P;600O_ZER!%OW"* JKOF>O*DY78=Y4-FF5#RI5[T2THF1D]>SFV>Z4O'AX=W4=:8 M!ZTK0+8W9"IO?HVK/Q1B<=<$HD-J\6JCM6XRI$7\J\P#WW^-<'B"?SRUG.)Z M WK2YF&6T'QTXG@?&,;'<, /9-APSJLDJ\66&AC!!:7 Q\%[!U)HM[B%CH[V M@-IO&%![@R=O6^"S (&,%;$?M*!748M^I]QK,\GGTYA^,C1UI?I*2<<&"_'H M;*-YSW8^BT=&^@/9YBU=TCW)1 25K5S7Q.IKR>%!P?=\7XI "_>6>;;1](%. MK?XFJ).32*H-8TH_#-N'V8V(&YPIG]+(S@\!TC8/_=OIP;.#?@I.MLOYZ,5 MH(V19NC:JX=-"SS_S"_-Z>@\*:$"GN1Q,>*^1V>G3QRCDD5MH@B03@'#=E1_ MK&@LT2:2]RSL9/F4^'XIFSJC Q!G]$5=M59L]PLQ']U2:V4-APX8"](RMSU* M-"6<$I\8UHE0.,B[Z:UXGIT>;\--V M3_G\$BN%20>/#X^/>D%C)/K9G/X8M7[CFAGV2!_&95V($4"_/HRXAU.-%IH) M>3NE2@ W-HXGA/W?O[][?'!H.[:S)C]Y\$//.;MV+BT0.\].#JD89+-,..> M*W2&*AD]BST$E4U)OB) P>I>+XT7CO&?O29X!5T?.?UY#OO>BO\1Q]IUZ2@1O+J\[(IIU&?Z,%T3\X <^O&,%B M2@8U9"P67GIX)3-,%EQX=+D^F*HAO)^2D13O<&>7F!:%KEDI 3)QIB/L!D! M%+"Q&)B6O8@>/.'##[N63,NBJN>XEX%KX9N%ZK7E)Y)9I"=EU74,8>.T]P&] M15 QO*1Q [_D#9OQF7N?.\[N.Y'KV6V[R;D3?7+RPV77-CP3B/2XI=%&J:"A MHM4XNLM/DH:0^@AVFFSPA?-8'^>V\K"QPK((W!8NK[0W+%D$WJSFK?.4XT:$;;,-5\Z2M[;]&?6H<(B[);!].3_YGHD0H-OF58UC=1 ]6=*= MP<4K3'#=8/[R>S0@ZJX#M_/2]M.X& 7R=PILQH1"\TC*_'$/2F MWQ\='N($:ER#CONCPQXIN!.9W=')D72)](^ XL?;<$!!QC]"JF+%%8)5(0\Z M/CQZA*Z]:"Y^H=EE&8OUSF3R/"(0];HXAS>P1UCY3\ZWD?.OX7(^2WH++HM MH71MP#RS82,K9UA)QI8(1QP(%B-**>'Z2EH04MO.]+[OU*1S]I,K>L1#G*>;A9#F\1?."D7&4_H(KAE _IAVTQL#GRMV[B;&=:C^UNW4G03 MM.$B?77+CE5DX/G9"#U0J7F]=9>1G[1E8PK#_]MGY#:C]RZE,Q(+MPQ"FLV M]3"OYZE%D5]N')>H2#AZ\!@)X*5P 4?3PV221-;;(?4EXDRT%"P5HJ,PFBU; MWPCQ1#C,+K7$>8?AT*0FZ&RH,[QJ#[ZKA+NVA@-R#7/FW4V8,Q^<>.;,X^-[ M.]L![\R8B,MX#A_[BA&]1253K-5E:9.HIZ@$*1-.?KY(LC@;(GOZ-,\D%\/? M><>$UOR5-PZ6P \\?OPWLXA>Q(S3BD[I*@D]-G)8;TV!H0)HRJ,Y>LP&6^SP M'MK%4A*ZA9G$!>>38;MQ]7RWU;>47/A\A%>PVE\3]@0HK!5D9PW,SS-@?@(N MO!V+8O\&03XV;>,]CO!5HRT.ER/"PI=@):!A>%.IW1E];6S8A5%0SY+]:](C MUT59<[_'/(K1YQ57Q'*OFV)6!DVUV,O()$@AV5E%1)60$.HJ?ZC" JV[%.^!>N^[\EF2[1& MSM[*^M]]WY/;>'^VH?:W_:/W4NKPLLGHP$7 M.XC&<1&35$8&[3\&.,8+81Y MUM89:8V%P/HP/I1*7N1%-26)(141K$L=Y*VL!\RRQ$]IZ9-A/)O'*$/:C:9: M1]?#,+&QQ?7M:I=/6J(UDO I65.H%Z9Y[X)>^7+3R:]9$VSW6=]&3? ;8-^O MX_E&PGXXC0ORS4U!DQ+QG.:6)8"E/NJM0#S''M0%'AUP# $O,G? /]OKJDQ MYCKF"@_R.U45JCD.HA? Q3/\-=880T^PXHQH'QM)_3;J7T/5T^!. MKS-6(0$>6$'U 5@X=7T@_6!=$>U@(72"267G([/U=;1:EQ9.NI MO9[:ZZD;;&%,-VE3-16G*=(Q#0VSWD+X+=3DR4??WKS]M79W8VTAO*?MOM*,/7(C,0YY+65:4:V/J,U[\8G3/\)]?'SD>0UOEB!S+8KJ>M)XVSW MO=U)';5/X^Q0&F>[[\\VZKV_)-52B\.U;_FY*U_#1-Y!6[^])W)[3^E.2OF] M)[+W1&Z)1'[Q_.U_;^1M "%9%]&X,$9IZD+\EH-A,9$%I'. 0A,*$,? 0R\9 M&*&SX@H^[@/;V0#6Q$6*@R?-7RM)OVM@J]$*XLOU?SV(WHQ!'"2A!>%^JFBHS\QC@TJ:"\\C;F$.N/653-@ M" 4>ITN/?*^O8*L+VRWBOKO;*^X;#A5;3U7 <0JI;^#G6!XKM'D(5N,*' MO3ZXO7=DKP_V^F"O#VX0"W<&3^DJ"B'#"&U+5[+=+U$0TB26:>.95CBV?=F9 M4"D?T+9JSQS'1:F"OR^][U9]*$_K[H4DG< G<:IZD1;MJF&@+Y*"DY/]EN=;=72;?WFNY5TEXE M[572#<+>IO%\,XU4EQJ#JJ8DCOLCH!-*[03@0,E,&(]'+H<#FX+?>BCHM3)- MOK"DWQ4>UY,]CVMP(MM78_MY7/<6QQ9*X;W%L;9F-F>>'W;$R^:F6J:C\C8*&+Z.\=--[))V*O] MXE;)7AMLX0W9:X.]-O@FM<&6^)\OT3211/,+( VE7_=FE<)QJZ4JX"-!492' MG8S,4FXL;A<'AU6\OO1*GX?_G.87EC304X YALCE$B[212"@SXM)G-$.1/4\ M]U^0'N,RGCT2?X_$W^NT/1)_C\3?GONSC7H22'S27*^X]R?Y*/P?;X)2LLW8 ME/0Q:.Z*%"-#"IE,+ZX4;2CMIATY(7M!S*2G:$-Y/)O0@>C_^UBAJ"P&> MZ(:8<%$VGP*:#.%,9(@C;2FH._*) M,B/J T<"+!TNT$Q-S(U\/.XKU(6;(RK@$E,;Q^>TJ5!=TIXZYU[MPSC]B=S) MF#8'C5!=A^J][W=[[_E.ZLF][[?W_6Z)3KN66@8HCFF@Y;@O\I*JF4_C4J)X MS<+HGF#V Z!EEU/I:@B@D!@W4\I7V1&T73T8>S-!<92B?HI(P$]*EX(EM\ #^[1)4$]W>2OFQ0H>0)E]7!)A4.#9(JPW4;I&YI MI5'X($PEHGAGON]Q02-"I[JAL;J_&7&UH\,,0"KL];%K-=HNLQ\DN=:2Z"NK M_&,RY+;7/=\>E/9KK]%OKY3;:_2]1M]K])O3Z->9PV/]RJK'QF7/F2^%_$SH MC0;GB?ITS1Z@S ")T?7X9:F#LXK*;0)F];4]:2 >EZSI>EP[P8Q;*2CON:LZ M%QE."B/TC.BM'@WJ2FP 4E6E-P0 B,67;1]V4[7+-E!O>)'7J>)K+V "#$ 7 M5I8)=(IP8$HY8+ *F)3.B:GV&9L;Z$09]&ME0Y[3;C7A'M->'.:\&U<35\@P=;9W*[+PZ5/35;/;*5'E>>I>'%A M_3==R60DS,"%V$]SG5?4YUKT_W.=5] M3G5K[L\VZNB.9G:_(GSY?DICFTSS6J*^S>9VT=LB'Y);]_/>.;JUAW$GA?G> M.=H[1[=$\+Y*SLTSAFU<)?U7E[0.8SH4V8@< 2[GFQ>(D+FVK,/2=95LNDZN MJOU<7 T6F0.>[KG'8OKVFY,)VKLZ(G_+H85T85S%FB^B1:SROD$LK1TZHQ?D M: XKCQB8Z@)D+0PD*:M2XX^F4,3)($$:"I_L(VZ=7E9P[[;WHGUEI?(%EVBO M5&Y2J=S&L[Z-2N5U;,JJR#]=H[!0AI@WV7E2Y!E &0YH(#DB1FM43GPC@*64 M*_R\>'0.S,+(/\KW0OYB,:E;TC/[15T@#86L&FHJHK_&60WNSN/#XV-:5:3: M_E,G!2W6O]Z?OHJ>)/F9:V_0BUYFPP/T:$.)1YPM1)N[<*)-],6IZLY%1#MY MG@R;K7/H,X>S!$-BT598? M+I"72Q-#UL-%DC*,AUEQZD(ZA=/KA>B4!P.CPQ\.SKXE^!;W )\5D??FF;0 M:7P(ES/ &$5A+PC\B)E,!VQEM*IBSJ7AJKXX9D*>>"1MPMM=(I;IA3KA4]]" M2_O7R.45LE>A8Z8EG7*Q[!>7< 33:))Y(M:%G+O%@T M)?IJP0VMZF*>EX:3ZZ:KVSNWIZ=UG[D%+F6!@]>E=+$*P-(Y7ZYU5F4\HQMB MAM-,KGPL0MR] @_F*Q_3!(>FYI2!2A @M8$.A.$K5[RDTPSB0YHF+9?\E;[> M2H6;,3T5%GOX'9N_D$6R7[8(=)_.3RPM\3@QZ:C4U:YQ\Z,QFDUR@WL ZY 7 M46<@J1A/5\4?N$4Q?X7^]^@0[SH^C!8F%L4S\&]T*XG) .X7%Q],=1!AAWEA MA@S+(U&G"\O.#*U=L)JR#G)LM-_DHO5T/,O.UHQDN($@E)[+2[MJSX8"#AF3 M.# T!)8OS"@]S"=<)<>@?]<:C;:]([&_%_NW7>S'ILCY0Q']@K"?IZGBQEG9> #Y-PU>2_F M;_4QW8OYO9C?B_G=$O.S9%CD@4%^!0E?@LDA!^54E4/.5],DB\9).D-<'2%V M6J2]Q+_5)W8O\?<2?R_Q=TOBYTG*)OTDOHJP'\95G"[*I 3MCZT(W4OW6WTZ M]])]+]WWTGVWI+LP^EQ!L,R-_60[H7\GLA MOQ?RNR7DAWE6HK@]HDE]8"C9),]'5XK=Y&,+YND!Z^5*S;^QIE!W]TVA@L/2 M/L?;WQ3J)E]YZS&KIR4WK;98O3R;Y(S8%YAF".Y3N'43(MI$H2YC%9G8:>@8 M+++HKW5F %D_9,@Z2PM&P7(3 6F$!T!F%$_H/U$P( 0:O]"3R^B?]&^!L[]Z M]92AHL+ )$!L>M4BBBO0(U?),.3."#FOE,)8[=M%-#<%%[O1:)=0V.MW]Q.! MV9\,P_ZL?6[57#^I2R!DRS6X\\L/[Q;!SL^!]S<7.W<]%9A;EQ9@O!I,2U.8 MMNHP7?_A#B"VTI("5KX:K2UI?[YC?!>M6-#B"!H,X,B@G,$ Z?IA>*GY""Z9 M;%*AO&,8SW$0^AA'5M*H>JYL@H:0<5?C*:U7-(Z3%!TO@>^E43TS]K%18>C6 M9\QBGF3GIJR8W15SYN&20"")@9JBUFAYE,*' QPSLYJC)(4^RN=SFDC-G+.0 M7'4I_+:*DE^STBQU&*5):!I;Q.^QZ7@]_6Q(0@_!(,W M$.@"N7>O4C;>2]Y42AD/;T',&RP,>@.EBQ5 N53A@#&)+ RN+@AF=U5Q?+FA M>>/7&14'P8E]+65(O^I8[N( MRT=5#IZ>4!"?IV6_I.6=S"9160S_Y[O) M818?5>/A'_?J8Q[6O8/?YY/O:)6;M0[&C\G7:3EV.%LT$GY..0A"];)'1RTA%=.-,VR-Y\OI,=@$[2 ]TQ4KX#3[D[PMUNWNFT1*VD!^_8;YTK^>XW42&3TP- MEGRMT0/=!7XF+5ALI1QM[5 )V3-3%UKE!Z-P-JMMF1HIYGC.Q7U2>740M2N- M3^L)R10LY%&7US9)2:NGX93"P8LY8[?0\LX>36,4JF-BS(GM'A9:Z!F803'*ZB)W"DA*5M<\_U#LQ>/# MHTM*6<#RSA$#ZCG M] ,2:/;L!))[7$LW#O_1:A?:'4(M3Q9N\;'A?WL3!1P-*X;,'J3*F8:R7^'A MAPP.:Q[9(9))C;6TK&'5UOQJI[+5VP>.A/;*X4G?W[MW<(BU2,%^$)W"^R!] M3R.BF__]T)984F8,]C, M8N']1:5U@1_')9='%+BU]B4QG[ONQZZ[A[I-S]1G;:T]@W%"(GZ1Y*XGQM*&[=RXD\H9#=E/0MY/W1>(D M'C%)>X-PQ(62F4&1*3F2TO1<]**L3#RBP4>3(K\0G0@?>IR3*FW9L[EMM+:& M\R7@1E)6I1%BY_RS,+Y.>CC76#9_N4E$$K2>L?PQG>9Y+U(F$36/T$RTKCA) M8&WV)0]/(R,:_\0,K4L=1+#C89&CD4S$/C_MQL2H6>%\86UF:NFAAK0)(/&1 ME,K(YC0/HM>PU):\.&^N'5":Y=I-'CWPQC$7-*G)AZ%AP\Z5^UG@G)$MUU)%\=T")T(4'(I+'AYBFT M(8\FGQ+.\H#\O7%2E;>%..EZ.F)L-\IPC]+=HW3W*-W=0NF^G $4@L2/T-JZ M:&)HN_^\R>NC4U6KC&'3IZ8+WVDW$88\AV%A)5"3"K>R_S*K 7:3;=&1&9OO M+.*$>07IO\FPG??KN<(28%V8P4(HX9FWCU1AJE'%IBK;$1;V?9NF'>GLL5=* M.Z24MOO^;*-2.G4^RRPN 8!0E8 0S<5F_15_#M5146<=BL6Y+N0]LQ?D549\ MGB>9'M%*" MP6.:A%U.^35P!@Z0RIAI_\H@SUP*R#_$A-JX;PK@O99F8%YY77H\0P"Y1WZ9 M-J;.)H+Z1^:7'CA.!D7.Y'#DH*?Q;(8!+LA2NC#N:SU4&=+@Z2#Z/T'R<$&" M\7^3?_?]*X=Q,:)%JM,974!ZK'Y3H-$US9.N,MY^$ $HI UC6FME>X>=_AY_ M!&S$K8EMC_:DP#&(3K,)#3G\@G[^.B_FM _17TB6TS :T M;LVGOWKUM!>=Q5D^3J*S@U/ZR1FM^/M$?__^272:I@E7UV,^[^,/9A1';QLG MHHR>:NLV+9#@]\I7#Z+?+#:5A)!QW7?DTYXB/1B56\4X&VG*R(X42(9:RH2D M>I,7 &>N2E([#O,1M1L OW 209[.X ^N3_7%0PXQP&@?#XUG:#3#TX9I]R:;XPIN/Y- 'IHZ0M70;"F8]H&#;8E1:."BS[N+C@J],M+A3ORRCE3 M*(QV#<1\?P]BWCD0\^<7M83&T^>=SJMLT[*O$XBGD3I&;KG=7)++1_& M[_[78_Y<%8B1YW!!SLCXPI$A:1UH))>:#O2U CXAISGF XP59YXMMI6+86?Q MJ($BU3>UB"*"][1U#[V)BUQ(>$+I#'*FJ'"*K WJ_'0-%520-+3TB_@CK;IM MA(HBW^C>X4_W#J/?LF;Q763M,8EJUV! MF%7TD6@NJ>V5"I5-M[6[DN5RAZWK63^O *Q_/6&AWM:GAO-D6#^SU_P9H3V9 MJ \2+KGE+_C_/=81]!&'Y'6P?WC'%_OPX,&]X(_OL5C-/SWQ*RJ#>GAX]Y6V2/_IAMK<,_SADKC 5:7;I^I"-:A7A(.N?6OT MV%EAMWR??E)MU-9)LV0T2LV:;7KZXL7ABZ?7KY.P MQE]'(7W>EGQ).L;NT-2G7JAKVRG16KN[#VNUS\U=D);VV?""7(OJV9JMNG]P MLDKAW.!&=:6>OZG[\LG:Y;H]GMW=A/7IB^TSI?'P. IIAG*JP8%AM].,1:1=Z MQBKP[=X-V4X=LW=#OMQ.'.^]D)O?A+T7L@6;L HE^]E:YO@SMD]E[,K=\ M)^X=W-L[,C>]"7M'9@LVX5U\;K)LJ9#B\U+J>S]D[X?<\ITX.3C:^R$WO0E[ M/V0+-D'*\/88JRVY 5MQZ+]!A7!W[S*$FR +;=?Y*Q7FK=0'*_D!KC3YH\,? M5ELQF.1Z6#S\T2BVER-)U M2',- &/P]8.M0)ZK65?N)?G@<1G]HX[I(_"GO>-OX3LO:'&CH\/^/UJM:+6# MV9F95_*2D\/@+6C'/?*UIV?/G^)9;D!W74>R76!&^RR]!F289 M6&?B-&+_KSRXE%U@0QJ"]OJ_S!SY S>?6J)!N)1DXD*))(2P0OB/Z$F. :_BB9))6T03M0;KV5:]9%LU?H$G:U7XYAHR!F$D],YPZHQ1.5]<".7TF: M#E:01'S)RW)#$#LEGFHM[7F+:T1IS%(=70] MX:,#%K*,R;6T;Y_O)H9KX@WMBRD-;M$7WA7?V9@[G1DR%-.4F5@2--XU]-(Z MYI[P&>WHB@7FMFYC.O<8E/:: \E6D:#57&R;J!5FB@!AZ1KO>6B:C%''A/,RKATF+:9854; M/#AVERR5I="PT1? '!=;%IEE0D%LA1UYNG"[W_)[W"K6GHGSDG'O8!.XO^07 MZ+;3H\4=QK4L4C>O'9C9@J7*F3.(;\ PSO#AO#"C9%B%;?OH/S-\8\95?;;5 M(B0'Q&/5'[!+ZJ\G28J:KNZ;H@P5>IET;K;!80]-'7Z8'<:]NWV,HGI$9 M5FG+OVGP"KV@LWA!=_%<6F:+7J!Y-+Y[ />6C:F"QP(I5Y=ET/&[2,H/+,?& MY+>(0ZM42TZ8S7D,35H_-Y9YRB>Y0*-N_()9@0\?OZ/'1B^DV2-?[6/^4TF. M=QHK]5^S\ZQ^Z[?FO$"29U@05G4!NDS>:T]$)5WH2_KC4!N)#N-RNJ)3>7/1 M>:1'CZ_U"C7,QJ]F*-(5 EO8;WGQ0784+(Y/&^1M:^VY(5'P=1,$;PN-YU*S4'FAZ+45;_1W!;?/][IUU/M>IC3WY:"]?#9/+W1TPMZ"- !G;/U M">I:G"I>F\),0#JK'30#X[P,9XOYJ"5D+WF'V Q,%A9Z9",XYLVJ$&)2F$\- M8MXR'ILJZ/ 6#VD8<16'#*/L(]29[4?,I+!+K)TXCIF(G+)"@[:)=$[.]:Q! MW6.Y1MXDY%$&J]'>FM:%\BNL.X/=X 9#=%QBM5MI"\?)2$P+;1 ;KO>%XPM< M>51VUB$X+3O65_=JP2:E.<_3<]AN:L>7QGS (<$1I M.-PY=8FGEAY6U+X1! MUO+!2KLFEFE0V*PW.30=MW6/NH]"&G@!MQ?=BF$>-#PY; \;L;K[%5LCNFOH M*EP%IKIH=_,QQ@>]ABT43IE5@)5W3+D:S6J6--ZYUB"\B. ?RSMAG^I>ERY% MC&B.11G5S*N;INUO.+N)_66!"S+QM'3Z5PH*=VZ^T8@>P2J3=>O!#K)M0 M:_JQM)R1%9>PN4<7QITV7I>ED\0R5@[B9DI+-B6E MUYC]^W539=+S83+GD:PZ/O03],?,R0/_:&T$/!?6A7.9.-#$O=03-!ZWBH2W MDQ:H)$/_CWQ.O\D26N"0=7U$MF9-ZV+TPD%46B)T'NJ,5$A"%ZS#VK<.Q(C& M=:KI[%'PTNX81,@1N%,;?;%,_ MBW/ZYL<$;_!M,C'1P]9H:9QG0VG8&V.YCIW9^.0<]GK M#H;Z#/\DCYF]NHCGR0AAPK %0*"VZ"L#TA*T#OUA&JN:'B=%^"=I'<+NPAN. M9B0:SA5:@%:M8M_,;5YEZ9TFM?N4AAH%KM1(D')Q,8($)N&(<$^ MV\N_/^M%?==+NZQH7%CTWYP3"ZNB'LP2V.7X.MHPI.KW64?TQ;-37EP8P:]/ M7[T_"O4V!^NPN[1&Z1BS/#X\/A:[@I[\>QA'.Y>LE?X%:C$[E: M,!%7V="^';7]6HWZRVC<&Q:I:?/GCX(%\EPRT)Z[(ERIA?1;\^?-]81'_;" M%1O'YZ2YH*;@G8M93>_NV,T@6\D+:0>\\3+R!$:GZ%"N=J-M5>9CEO1I7J2C"T3:EHU[F[GU7CI?ZB>OS^1LX2K3 Z7% MP84XK/B0O\_NCW^F6N-@C*-R!M?"1APY]@!,B*B900*Y+1?):QQV MRYUCY:0[/ST0_4LJ0WQ$JP2;R^ ?SUVF1M%?7K[H'Y-@FD\EF7CVYNSHI[^] M.SWKN76 !RK.F*0*K.JP6M]'3UXV-^M(@K2V)91=3HF50.6[=2T,"1E1D(T1 M:2R;MRG.-/U#5S&1C(LNCGX-T1O7> *9&'DH[X#-G/:6/+S.%UI1@!Q_H:XO M^7<*.^# CBEFI0TPN0/5"^*#L(R^OW?OX!!^;IJPUTU2EP:CWJ[(8%H1EX!: ME?H6=_W[XX,'=%3D63@?>=7 7+CGD7M;Y*7$D(($KVP]HRTO#$?7:(0D4'"3 M@J"9R[=E=.8J:>*$B7+7$!?P" ,W[/[BO0!G8/5Y(+ 6!;H1,71#P!_Y17^4 MUP/WQX96L'@.A/V2<6*@8_$Z2$VRH8RQV3#-;3UMG.W3UK4N2#OG:?_U@BRP MZ.P_=3(8V+.HJ2KM/>72TBK9>1L'<)N\@SGB%Y+.1'B61>YI/:&)Z!U> M$KC1),T'TE:O Q6T%-B3]>R(6?T[3J)7\<#VB@M-])C&1D\,+9K6;\C>;W"#!B+7=&,#*Z*5/8<-&30 M/:1[AS_8=#$]=(R+Y&*BR\O,WW3-SQK*057*KQDO]EF%(*'KRK82&B6RAQ_X MD?/I)+B_/SEYZ*0:C&1O'?4B_U^!9<=F&"2) @(Z0G\\J>4C470'6B]/V36E M:L?"JNAK=*\+)%Y=E9)];2_9CD7Y'NZC?-]FE&_KM-!R;.]FQM'L8<:]SLIZ M-HL+!X=>O=%%K,(O_S#M&!4J-Z8<3IT9JII3AY\3"8#V3O: M_! PG+(R<\8 ,NB!#:0D+\C+^*,1[$DRADO\?$NJF1\W1&NLK?]J3?N_;F'YVO5/:FV5U>6OQ]EY>'Q\__&GU\'MP/VY MJ5*XU:WLOOO?LZH@5[(N-)0_RT>&$R"<">$0P2:O9A4!./T:7"U'IT6)D-"O M3,)P.7ZYB?Y3"\ P",=!&TUB!<$A\9D(0+Y,@.?1J!XIG;J,$3IVZL\^O92, M%3".)K50=91S&(Y* "#7MZ]U RF;T+0+A4 "%CS#DLAHM&RM>Z([4I9]/0IN MNVM5MT+!?69Q]E[![;*"V^[[LXT*[KF6%KJB)!<"=MF@S33<.F^+]$>>3;CX M;IS6)AM*&DCPP0C=T]>;=94>#QV"6I;],P72B(/&GE,09X^K>*]M;NUMV6N; MO;;9:YO=TC8ON5AJ;$%^),;KK.0R(%NH.)S"(I*;^8&9)C'H*'HHO<\'1+92"SA;"D"W]I"!I[=]0+8J\ MA.5.KXU+P]4.3][_K1<,O@>KVM*&]5M@12G_=^.T4SH ZDK&P=6[SH[/:BX; M =\.^.X^T./BZ F_]N\O^G_^TZ-[=Q\_P1LY,T\G(^9LCX/BT\5](G9S3[ ^ M\";HE'Q@V#X X'3GRGI0+>:2*[%#.[";4NK#9V:4,!.)!KO\ZX/WJA(1:#R8 M)Z)1D9SK)0^2-4_Z&)-[F=:]U9F@H>'3X"QQ!$V9##[*KC\]???Z]"CZ\6E, MXIR9A(9%G<@1&>5X8Q_2AOY7E07+KJ,C@8""!B:#WJ''/ N_^/KTEU__YK]^ M1^#\3U\='48_ML;ZDSM#1X=WN*2%%\9P=?K$9(S G&.SH @1.'0'T 2;&ZSO M$.00(X9KQB&D/=!CF@G#V>G:M'5W82T4;S[>!#FY>599*VSXDG$Y(3K#R[5KKUX /_5+X]99D/ MA6) *CT"O3=3]URU:E4D$Z[AYR-1)55="5615O2OOW)2T9*/*] :E/98-?!Q[=%8F[JT5_W.)!T+7CQ_^]]2B3$#MTO&[$$%?BB%+QS4 M5;_(>;&HS:#E[%O\BZ^69/T F$P_33ZX4'!BE,11)[UHSXVAGLRWAQJ2*=DF M\*9UQB*'RVE^84::UF1+I5_5,XAO50"]",_4"AA7-;V"\,@F34O+G-@N+0\* MF[1^Y2*/%K0TY=?@#[NQ*E^L,/R(_.;_HM0J);#TZR(4<)W/;"^IQ M01^.!EI6Z!9V[!V>'>NO3?;' C5^0]@=\<)6B+M=IYTA=6V9B\QXC)HO)N@F M"^8\L8 H?B+Y-<&>>D_IS=.7_5?_=V+MGK6.F%A&=#-Z0J:*PQXK:V R(-^* MUF/ 'E-^'J7BX0%=7_-P_/"^K7E8 M&Y6TB[G\?Z,UPWFTT7".PN$QTN*3YP61@"#&);*(0QRB)>7+):*=+.3D*^3);R*OZ-?G MR7G.S^LS 0"I+ZYW_V@R*+5Q%?WX]-F_[@BRMCR(/NMH22^8ZY1&UV$F?SU) M='2XP=4_?G@<7/U[#S]3$GV"A#HZVDA"G03#O/OH&B345IRAY1#Z1BUY/B^" M_O[M+V?1G_]T_^AQ]*S/;!.$OAX-".9QA*+&WSDMC R+Y6N*L[(8$[+/__IWJ/'T?N7 MS_3]%7--5CR].!J1$28_D>^=/;/?*^<%/BL0#B'SG4S]LJ.H[=-# 8\N+PN\ MLI"Z&174X&P*%,OF.H6W%#Y=0-#@S$^KV9HZQBF05>3G>L*_^U]5&GJ1<]4, MGF8:SUX*=O4[],I;IU>B5_]W?/SHHAU&JD>^L:QX;G>P[/AP'RS;C6#9 M9@C$;SL,]L0LP*'GI8+E$+:R8[WY'!K'JP("V67MO)S\LC;O%<$_U[U&,Y!@ MFZB16XG>/7_:/PJDX):->=O6L'V,MFQX&M/:ME&))1$:#!(HTPCM.4HX\F$: M?XQ^9+Y&:S)8,B;SZN<,4B:56ZE":/CZ$>Z^<=W[D2Y>XCFT(19M2,H MM\(6N*XHQU4WX5-7_'HB;%OKU!YOX"T^.#X,O,7[7Y12Y#,#6;?..?R'=;ER M\ 3/T=FJY94]\=[;13(T#;_MFE;BRT<3;P$ [#WC"YBCMZPG$Z!!!?G@6.\D MC8&F7L(@W8#!2/<(@8UX:,RZ22X7>AKTOC#88YL MA'3(NG MO2 WEBXD3UD.<^U(T@DB7I6HVW.$;\(1_M40NY\LVJYB6(,%_&^, 5W&[:X+ MS=Q.N;T,W&U@&'H6$P"2:@5<-&5>('T0N,#J=6)\%<4!!$B:C)38^C\U_2>[ MN #*,O\ZYXA 0FY^0KPUSY2KF2UMP>:*9@$"C<%GDL2JF**>;&G;9BDJ\M2X M'@A@5;:752^-E2+2VU-:(RBIL_TF"1';8LF3MNI(N5Q@3N(;-S6S^,$;!BK:K"ZA-!HLY)*QL9A>M["Y" M1*6KP#0OZ?\7BY1[1O&Z*'14PK(,ES"E;]&6&CZ7EYR%@)%&>L+)Z5@Z$9ZW M]UE2%K5K)\F#"Z,UX>8R(*F49F)T5,VH/9I>@.=:=AA<@1.2 = \X( MU[\KURRW-*_L^8,#!.^_X:%"O-; M6_21K#4:Y5"PV@X>JY> .H^D9;'K8.%"/7IY@W13ZYBQE&<*QB;R+]@=J47Q M'55MK^E1+6U-W-DCQ14/N8:.=B2W125R\K3#)R;&423[F\"+ ,W_)0US.^O" M'.1PM=[G+CVL^UMW0I"(.W@L+H'&8(F=/1."9%QKWIX#?T:H:9F/^EIZXOY\ M+'\^OM-KWL%FO)">+5M,]HS0S.@6D( :)+G#A*IAY*&!S<>P1QRHS.#/8FNQ M]&*)0Y_<.^$2BC/^W[%M4<@&V.NGKX_YP[G\5QR-:)F@G\@X1A40S\)>DYX, M]&F>YL>']R(N+J5#A8,;Q$&1_+I"TO-+!#T?76?,\_\-BHYXWNV.>1X?[9.X MNY'$_81[=6,7:8.FB=<^B&=DOM%6SPUO0DNNLC FR])FX_I.V%^54GWKI1K) M?-97*W7/CZ?/WO9_2?,[HH5N%,?XK8$I3S;(.]V]'^2=CNX^7)%WVJ5]NH%K M\K(A'SIL+MA- !J3X'#VTAV0L9.YQ:*$/MF=Y6CF)IPAR-&0F8G+NA#7_/79 ML^C'UZ;,HS-PTB.J(MSV>VGR]:7)W4VDR<.@2.3HP;U;(DUNJ3_:2#VR@6&K MQ@0?-BGR"P!?O?"1J)%MO\M?*HP4N^?.K5WMF#D$"B33*"\M1]TH&7&H21[/ M'>MI6;E>DXRC03Y:1#+M*,U+Q/1YK(Q0LF5N_+B&124A3W9!T[B7G+=:VWYW;Z+8>[]W6W7!;M^GHWXI#L5J]W]ND[]6]H*3IY/[A M7KU?<[C9*9A5,>>X 1E25,?:('00@[XK88F[=WK7 W3M17D:SVE> W[>BV>G MGA[K[>F[M\$;0%%E$.B.R^C5__V=/OWW*3R 4[A"_Z9Q#>,[R'22&B?-7E3Z MR+B*/R9Q5)D4S7IAJY2)L(&].WW6/^&VMT+:=?K^74#:=8?_%H_B\]P]3;K. M^Z\XQ;[(#)V3$E/6 OJK 7B1.QER%+\=WRXM;TZL,*1N[J'P6"$))5ME/A@#*#N=ON&'>4[WH(%[ M(U5_SK!-B/,ZC9641SW[:EH :R:(@0 N9-O"HGHY!$+%24$6QACH6,$/D2,K M#XH_T)3)(1^:@Z@9U>31\A,%L!T/A_6L]B%.#T3K6>8[V_:<'2\@U*"M=LS7 M/-G[FKOA:WZ*.+G)/=F2ZCKQ%TI6W1IRY$"_=*45N[<04;,!W#CZ;N=21<880+#"W76G$)'J- \_&XK_S3M@S:IXVX MHJH9^Y#;)K:H7?.LR6H>1RFS@@O\OA<]_;^W)Z=W;? C6<;CDQ":!4$MSORX M#N)+G=E"3XA(9 WZ=$D/C"/I7#V*++2GYD9&[3:8(F^P3K(2KPU+93H M8$(6,EL0RJLL,6<3WNM@GFVQVT7Q*9MB/O)*1IE)>!4ET 8*:PTB?4M 6AO3 M[( CMPXT4[CZY>:E9%.BL1_8?M3@D-AJP9;Y\;KVG'PY *^7]LIUY@KA M^UFN"'_^3?NXR_'FP\5O&IAL..4(Y\B=,F& C<&U75;1Z;^?]8\>/+B'@&YK MKB(%W>PDM #@_%SQRI27KS7II:7G\J@68RE-Z M=-D5'H\3KO>T\\ >@Q6#U OCN1\K-)$8\8S9W7I=.Y M2X'?D/;N_=2$]2 VI] \6B67T=C>+KS+UF0QCW_D]O: %N4NXIXN> MY>F?P,CDYGRT1H\.?V@")U*I+8+F1*@QI\>A&CL#?S)GZQMZL#'^:PQ,W4Q0 MHUGS3N_NA,)R%N+]LY>N7$#4OXI'[5P@IH4PMGDS,T1$L$1FQ<^QWWBH 5U$ MJYZ];"ST2S ;T=[T&F+6'I8L5R'$]XX&YF6U-44"!V@F$ P<8-3G1*2::'M] M:5GJ+NI81A(E*VX*"K$\T6"KP%].#5,[>9=X7A?D<@E*AR=D*U*9MTD";=E2 M#BU\MO*RJO$M_^U+T1P9G=CP#="+=Z!"TZEK@:S!F,Q<3:)X;..:8]]=]4AJ M;7[QS@^AO+^);,6:#,^#33(\QR&Y\J,KHW"O& K=)W3V"9WMZ(1V]N;LZ*>_ MO3L]^ZKIG)O1FB\A_E,Z4!K\5H:7UV?L\K3X%N+(+XT"+?H6CXJ0:6;7N2 MD/6I2>J!QW@9'AVQ"R!Q.) M1&M=*!])BF!!7E1EDTSM@B/GS#Q3( NS)I 9!B]CK=[O;OHCV@1-\G@!=S>! M\A:^EFT(RBL7JF@A)")EA3+Z26&DWY17W,PP: .6(RU/PJX6S2Z[5U7FO+$S M@\ZXY=P,^3$]G-4:AFZ?AT*7IDB0.HFC'^DG]1SM2U^?N287KF_3G1[^[E)Z M99ZBZU,[YLZ!6''L&Z=0*-7LD?2'!='VK$:CTKH(HNUJC:N=SM(!%]^?+)I8 M@GC71<:,94R7Z<:?W; M=76V7DF9PM$0UF#<]D'>A:6&5K1YUXQ9^J K6J^$O':A)"@RB=$+"Z(5(PO7 M_%R4@+2CH9E\OPT[01<-$RU/ M(W!AL5+-@R'P9@E6SN:#G=1@MDS)>RI?9<"09@,-'#_NVR%WS$WE8ND6U,7! M($OUJ-1E@W/1[Y!JZX/H!5*:']$ZU7!V!*K>Y_KT:TR+I&4D!=GO)&(OO(E&#!W77._[4IIJV936N.#(S+%(N\_?]UH M"M\(&-,/_TJ:(Z85$JI+>+]#Y4+ZU_O35YC/F7MA+WJ9#0^TU $2W@(>\W.Z M[J4;&BA&^80CW5>B/^-6@Q_ZN0ER@OH[HEDVEMG+E^^[DX6[)X)%EJX M=II\\P,[WBZ$M32"4$F[C[R*/J5X;$.3U%&00#<$0:4YAY$9D_,Z\F&27TR6 MS^@6(+,9).5FO-:P&%OT??JP=I=GR'J.P+1(>A6]&^)5Q".2OLQTA15RI>2J M(JCA*:CXPFG%(2D#)X>YF^*9@]J(YE@AY,@?"*JG..UF!HV3HGJM49&*: M^I;1$B/2V4A/=@62R/ BA^)CU3*T%'/XR#;=X23PKUY)A Y+7):6;=,F',/A MA,1G?E3VW?I*B^ '_&%*1B^E.?I*JWC:8Y1KVOF:;ZP'&IN9/1)R:0$DCT4 ML2NG@$^-SX=RI+M!84V;@6"SD*:H=G8\6RPI>.%;TQ0]2'>T:APE/VE1@3Z+ M1G8NK1C8F8>DQN,A2R$+2Q$.9X-,&Y_J931%D0](GKC=X9"E>?HL&V$% M>I$/?S9D%=93W)K\-U/MF;I0;=K.$EJ"66=1N,?GTJ\7MUNX0%=],6;X30,N MDJP*5\N+5[O,SE>CTT4>ZL O4V!X2)]@D/H""%&9E0]Q;[6V<\,T0E_Y>H)C M2J;$4118SSVK(I8<4^!7;&][T3AL XP,@R4@^9&JZEXC;P[KSGD%39=BHO@B M&Q! F?^"M'O#+5D=;X%ML_3:*X-C-B^&"YE?&$O[\Y^X_^KAE6_>)_.WPD9D MT?W,T,D4S@5HK+^91?3>&I")N8+'VAU'9C-H,_:;T%7_Y%6YPAH\C=-AD$_Y M8!:JNCQ64/.2C9;I:L/>?,GF%[<&SXT$H^8Q7>N2'0L$GH;Q2 $-KIT#DX$4 MD,/B0V']IB192#R4UI0HQ9U!>I?!$+;3/"- C8'9Y>)WU4X%2(I M*=?83$M(.4;#"HS5#I7T M#Z"1#_D-B1C)C"DQ<.#Y;6<2;F0+0IMXQ]Z.*[O>(I7(;F@\'X7V5OJK40*@ M/B(="G=C/-!'A!KP1/=M]I]FY">EULRSDKK%.% M[OJ)@#AS3 VU'YO0:_S+X[KY>6I$*L96JEVA8O M^Q"<7(,'TYKA<1)IT/PSQPH0=B-#/@6@&P%T\@U]S!E02:&W59>?X23)H%;' M+ \'Q6>I-*WO2.C VLD^>DQ#^ F%#\DD&;DH@>/-G;7:(-@W,1"-7N"?\V,C MK;=2T]C^0(^.[C_6),PO/Q[=Z8).WW$0T.[!^93#=8R)"1_XY6:&[!G>>@% M)=)518&7V=MH>_5E]WIOO8J9X-1UE=K2$Y<&# M$RV=]XCVI;J A]V8==!20 2L'1D=%M4K;M1]]RM[!3YGY/?NW/GBT+L;!F7< MVX,RO@50QJ?$,:^WO]WG>4Q?AUWDX2;8T\-[ :G3TU.E:-VL7:>#O[V7P M;LC@6WZE;Q9\$(8/RCRM;?!X")2-@ZQI-B.,,"[Y)M8>7.^$]J)!G:0C*;GB M"CM$A.!YI30&A=.,\2/DBR8+).2KNA@(>-WB9%ZL^(+]AU3:N)7@4D&7K6LZ M.K'46?N_(LC T5JD$8+\31E-\PN)GK@'RTO)E\LFH+=KNXOB&Z*X?&C9;0(P MAZ2YW*(+44'&*5UQ.;BAFHNSE1*TX75Z\?SM?Q_P_Q67$Q=42P40E;4,.>1- MC4W!R AFS#7P0G17Z2%"1 VXP]#_?'7XG M:42T+K6=XKK*-[]IJ:GH+/5UJ:X* MR@WES__[J1I=ND0G!R?[6F_5^?M9YKNFNLEY2!NN,7/HF''R;L M\_?#B=S4I*Y&T;+T>IP=DI;.D5YSAG;X_C26;\4&=QZ&[@UH^D_?_2_W!0ZI M2DG*SPP40C(L-6H]3DRJ\?]!D7-ML04]CX/2_183PTH-RLW VWM*_Z? _X&8 MIO\E2;X7Z-MY(/<"?2_0]P)]:P4ZZE[H$3,VF"_RXL.8;&G/.3F6FD4GU9TH M%QP:)P='MD"&OH2F[562)G]8*%:LV29@*;.JG@7:PF9Y]P+^5A_0O8#?"_B] M@-]: ;^151\B9]*%0"&X4L1;^:-%1A,:EHK)DT^KGMQOQ?W>W%_J\6]C^7$]!_]63R? MVV+, /OH_UX"'XTJ%Q;=^-Y>?-_6X[<7WWOQO1??MUM\^_H8J5ON0,709XY% M2AA-AFE>V_(G2'63G2=%SF*]T51CC3S?(:37:0NUU0D!XCK1S"!8!8H+YN28 M:CFY"LXTNIYH #F.5? M)MWE MEN*M+;O]:HP$8!+:O\N:'; M5YCSQ$BK[7JT"*@]F%'M8S*3RJ.3'AWX )@R<8;7WITB"HM.M)#+OGZ'35I M/4&!!7T!LL@415[8#@!:[Z?M/$LNH', -5OXQ^4?EN(MW'%L:5%GF=2%.YJ: M!;-@%0G33SD<&E>26R(B^MB6A90FK$74CA9HEC/B,I0X"YX&[BZPGZ/A>J-^ M43"(EB(T]G@]GU_C=Y'(WI)$SIC);<.%T8[9,2A"E)I>3>TBWN MPI@/+%L\%Z^6?C71&G(+F*\=*[L$ 70$IU*I%X(+F4C!+^E!A-ZYRBTN9. \ M(0<0;#7TH#5#)Z&(:_9"VJBR18T0T.=)-WI;OTT[ 9:SY>VXR.L494#@=Q"N M-:5?DYK>YF[IL=G)VD"^S\U[S&A.W&X0+I?3E9P#EEZ+*7S"OA66$:A9 4I; MQKO-E:!)7B053IS?Q7% "UWR#@PK.0)VB1C4N];C;H)4M M4A;X*SV$MJA8]$&3,8J+4;BQ(&\8<^$="Q,YEO5P:,Q(YN^&[.A"?.:I3&S(PB1!&-G/YO)Z-85]3\G^6$Y>FC; MZ(<%:>O42I!<6)J&K2V0V7!WMET"R_&U<35\D3"#B MROFM:.])/T%T,[- $V8!L-\;TD+F,R[[[R#9:O#'^:8XEJ.^_?7*Q+-0?\2B M!7@6Z!51N/[@MN,>>\-R]^AV.9U@^[."49/)#A [DQRLHE)]P?\.OX.Y>Q"+58XMN'Y]#)EPLSXG)D29A_;],&9$M[W MI4-+PF ()?X^!SU4(7H4%[G(:0@SIA()RH"RT!.(*^=SFHQ-\*R5&";41)XUI\DTAAXO0ES=8.'DD)'2^62+ M9H6F#8C9RE0%>$S@$CNYBHML7\^YQ*I<.;^#Z'5#MT1MW>*[3/!QVK$R^P?[ M,OO=*+/_)'U_@R=O6QK0>,-AE%L"S2N*C.;5])&2?EP.WE$#SJ<\-CN6F.Y-,>XMV*VSF/7-V MF+.5/)D_FZ6:H7-=WMG,9PXW4VE[I("IN0<+-'1I>4HN;+@TAF8.-6#S)P6$ MD#BXQZ/3NLK_<7;Z[J=G9%$\G2X[^0'7AS(4-WXN9MPK^TZAF^CZJ_6(EX,# M81*XL4&."%4N4IT9.((XKXW$!L]B\A.U\C,8LY8@SY8:ED$^4W , M+H+C&;OU%@G)NPL=S>4]G,VW/._83VW38C/&N^C(=YW,!/8T><:5[PD9\DXN M4U3?6BZUZR*+NTGC;34]W*,-Z.'N/7@0M"8^6=6:>.NLZ%MPU^S=LK)8)5J4 MYL*"@6@#\\(WT@*+IL!,)%#"Z!*3+I0-:CFZ57F+>4F36F1%=\0#,5$87MWA M$&&8SMPDQ@F2/_RX-:,>:5#?-4BP5-IBRYN,\P(:];_3)EC=UE@Z[D>95!4")*4HN%Y$^FDJ(\KXAS/]X0A0FAU.6KU# M)L'U*O#4P=(F4@-4 $ $YEJ=5'9[7 ,L^@I-%3$WC9'S\92V(_)0[7BU902%&AV#M1\AT@U+]$D;=00/Q[0 ML^2!:RWH-UU%M)4G92^:]J+IJQZX/=:"O*("34:B.-,HP*,R46B=HTX)&?SEY33MC21W\Z&N9+T27WX7CQNVVG=B\>] M>/RJ!VYELG.-4+&I<<[?NL;PMHA!Z>4N%84KI-G!MU/?+&WPQIQH=25KTONYD3HGK:I5LN"502A[U^W##J(7@BVQH\-F*M5D1^1) M@E_-G2SK01#C2IJ]_M2/\>>3/IL(K:?UF8=15 /3U3UE1$ MELN-HU4HMV/8UX=[[.L>^_HM8U]G)B[K@O?62I HGJ DH.JP7FQ+6RLIH+>T M<,NC+3O@8.6P,-R0E%/>6X9&A3# ;K^I MV8(\/PT6H%ZHKY1$[FBANCLT8784A,OAVQ"FLTKCQFZ9."R-KW8;. ?1RXIM MX[# E0] \X%NU9&PXO>6^V3.S2:&"COW:KY7A0]]\$6#%Z.7Q2^[+T MV-L,PZ'-FMNX#8&Q/"[Q4H_ I5FZQ_ISZVH45P1>T:N1ADA2,QZ92]M[=ZEA MCZCOH%*PA:98FN6C2Z>2#WF@5NC-"ZO$A7V(I',"Y+]W*:P3C5,M,1)6 9!I M"GZC#[*<2P82FJ]XQ@ GM077[IW\]U,)>)"X;0I&6[/8@F>M=N(;L*P5T0A% M2[;8J$:&9$TRP((/Z/L0W190R>XD5\MGF%3/T^P$1IN(32X6IJU+Q13 \<)I MRQ-CRS/=!C=U-QZQX!8\L6+]W"<--63O]YR.-A=CBB2VI;A)N>9HX_('1WL. M#B@$85S=)FI\+.]91XE/]*L+M52-MP+02>(\F:?&K;(O&F8%ZP"*=MMDDEF< MY311FACJE*[)'Z+>II.D) MCI+:9A=\.((31+=CO@@+J!HZN!0Z,59$.XBUK0=5ZFT'6D;^CK;W#6'>SDIF MBT#(UQ*R7>GZYEEGI^'0$NF#1[8E(&H);P;%?S=0,5K/*F'DT_9D920]G;CY7DE@EETF7USZ0 MGM^T*E$?*45OEF(@\]>VI8ZUQ;<;,LU#-'!7@U)KK7:>.D^XXX[G@=\+S6&% ME!!FY-P;[9O$VI?)A.(23#1E#7:/QN%;+5;BIDWO\SQ=^ZWVP(PY/]G8GX.S MPK,7M>X95Z6PEJMR H:I#G;"*=;KX"3TG3I)FD^B-.>(P,SYWEZSNHC8/$1"5G6 [9<.7P8 M9Y-&C8I>GVDR9GUB,YTT'/I/T8$.R!.25EM\Y-@4HNYR52IX-4SIJ\^Z+SL6%D M-D\L0^N4M@2DE$%E>,@%W6/^-W8RW+Z5]%$Y%IP8+W:C1+L7,:,9_8!4E]L5 M/6/SBJD>O$/1W.WVDP8%?P$'$G>4OT[.:&UKZ[6(@+\TBN<\^>#86;ZHGJ_? MQZ]*N@ %/[_-EE[0T@8L?>$Y1,2HXG5&L"FH&$\R\ORLWT)ZY8-&723'J@Q9IT1CDKA]X+FK#BHZSCA D:+N&G ]EH4 M%XZ,+$AC@+B<]C$%'(49!C):)GH^S;2R5&"(@V:^O!%#D+"@(_% >L MV0">(]:>9VWV!#C925:;T(3*ESP!MW(R@QE:'O -L"S2*K=:X2ZM[UQWQF\C M!N'1'H/P#6,0MDK6;DO^^TTGQAOR/""0A+6 R 3"@*88)H$-%(19!VK>L]5A MTG0+2;JD%0AYIULXMJ!A)G/BH#A3D(D^<+NJ@8)Z[[:[B-\8-D.C)R_?_//E M*9AT'? HDPV[Y,D]P[/,Z=*7@$F84:]Z TILN<+$YUQAA8HBLAZ MACU]U!LR*P=%4L_\K[9LDYXNBKK$5+U*[VW9$&4MMVU0K_,4!WG;AO7JU=,M M&Q+N0DE6WC"/7H-_E43J%HYP>+!]@_I0Y>0Z_HO,^;>)"I0M&R1D[UE J_@V MK4M9S6AGT5>_*6R?$S@MJP%TV/3]M(Q*AC 93_\K&H@UX6OWK6<<.+/:0E'^ M@?_N5*7E0TJ3L;'/+ML/)]5%WEM6(\%V0.]NGXH]$34.6+& M=E#A^\B%YT8-U@8Z??WD^3O:W[^2XR" 1<21_9FMR9^EOGZ=D=.='L>_G+P<5MS=-U1 MM(5%" 1R+E#X+O5;DLA$O!L':50/=8^ YD@XJY@4TE:,89T%4W0.V6J5&*_M M36&!VSU!6V@BLB4#4"^#"#Q9X+:-%_)NOK^09N4D[&+#FT)UJ1$W0#/DQ3V( M,$@4H3P+V]W9D'(P1P^CX<2Y[7B&(S;)!=+"K3JZFHXTN:\0VFHB6'8X:?4, M,_5>S*>EKF[#O7L_[=($M@4>0C[_(=+-)JE\@[CPG/04*]:XQ9HI MJ@JD0\P,F*B$3S:N09&8RM:#";2K<27U'T&O1HN-;C?'6!W_[ 4QV)X'QO:T M?%YL#TEF.>_4WT#+NUBKVNWLK-'=D,P%12#7RE QMT4K-C@E%S=^"(IL2@9">F3^)%1 MZ"QZ<3K5JD!*P/_%%?(-S! 6FS:*2HW#"=9(^UQK8N=F8L*XXQ_,HC-Q&4O3 M&MNK4M,"'OW=WD?/G4V'="PXSG-$:F =,;)[H94!3J?1H>1^R?'85(YOGN^< M/4]#+4%P"5"N4F ST]\21:]T-/C2CM>2FS3_J>5T)K-!79323T"+:7PJ;QXO MM7IVDYM^#0]HXF"/;ULPN@QYY/J]LU]@F5*/FQ'RO6QZ( MI>96-3ZG6=3<[U9RILYS/ )?)<:ZYPD99?: M\0A@DXZD$#P;NK:+;,_KXOK^:J'=IIW#^!F_9MQ3^JQRA3AJ85J,]++09F!S MYG312BD=>H:#,+88?LE+_#4/HL/(@!#1MK1*_7H>?J'.&.:KS.B9=E5;)I35O1LX>3BQ_H6#F/ M'.U:H0AK!KHW!V?%:YA8$8'LXUE!/6BZ<*Z=NTWR"CAM0I41="6PSN,HUV\M M@L=ZR=[TX)P> J $W]*U+5>K4* MC8F%WIA0FPUC8+FG-Y1LUPV*%M MRU#4+!E/14\B$:[/H-Z3L;DP7 3#Y'+?0I_$Q$92D#(''60IAM%EP.-GIT4 D MUWIV[DH^<]JTS8#P;(.>>DL;B_70-JU\RYQTLB+)%W>_>';*+I&W^80B .7= MC),.Y%E=39D/W_!)1Z-.O1S24O'^"_G'F]B%$^]>"4[]Y0L%?&+6;8^*= *+NV_7B A=4:2 M\R+^CVR"BYL>'QX=<<\I2CH4VK)#,-[_MH2E5.KJ M4ATVUE*:2(NY$;?6]?593QQ,Z$!ZHNM/AA_1I_(#+0&V#W7A*&?Z])H6Y9RL MV2Y/:JGF*3!\?K00]-A5%)(P0)I*U0Y_[0X[,F2P05VR@>W9VS BZSSW2&?6 MA:\W2&:S6NT[";>Q_0?K(MY%[^97QAMS*,IN.*E?\2%BX84Q@;4,0M:>BP.Q M@0CD.I=#]2(-6Z.>&WCWH&&UZ;D\MK>"O\0FN]06T[B=N]261!_:>Q\>X#B: MU57-)6EZ=-TLX5]KG1K]BS/M8>6E%-:GK*%MR%W EM>=0OW. M&WC K@>-'@IQ-6S;'^YH:#=;NT_I4R4 ;K#@;L=[;CGZNAS#(N%>]O0=<6* M?/[<6")NG%YV7C+7@,I?5AFUPNZYD$%I%]#*$8=..MQC?6C)TZ I4)K(?L3! MN_V=<+?,GI??#+L*O+82N!)BG:4!:1,QE2R(A0AW"DH6I.2 W[STWMCVL-<7 MME$=XHNI!]>\%ZWQV/O;,:XL[)J.I3F(.B4DS@-(D_RUJR6LHMO'YP-=[]D: MM;EP7U"!:B+S00)^[%%U!7O$AUOVJ.D$I/3PBI-/UN77<$ FC=ECJ\='S?O# MFZ=7B/NR2@_=I9AP+_IK/(]]GN)YC=):^@-]*\]:YXS?D*G:EOK?4##:>Y,S M*0,(W5"!_GM.A@GI4<,N'\\PJ>A?_#0@H$:6)^0_M),!)B#DRSTW2K=D)U*7 M5C0V#H@53W;GV\>W;)X@*=!'$$#W%[81K6A9N6N#(3!7AC[@0,1Q[%E/-#.X M]K66JZOUM&4%S+R>&J:R=T8-F<8IWD$+Y6V@LUNW<%DL>+:5"8JGY&JR=1H8 MP/9N]#Q\A+48OLL_PW+K=SC/P#8'\'6.B%?5GJ3?^]/\HH7\PD5$9%U !C5? M?:L$?#XX5 $T&BY\1+5!3]$\S/P5IY+:=^5G,_>?K,0OD#G@SKF)QDEY_OP9 M>AM*+C26>K"%$P<];W7E/EG(;_3VC@UI62 7.PX[>,:\C,$"_EK&CJ-O[JK;19Y"PO8K[2DBOG"J MBGS!26<.=60P*X2K@/:\8D'+-]]93B[,7"@U@6";DE$?[/_@_T@FB9AUY"KU M1WD]<'_L-;@-.DX!GBPYIW<\JL2"U$LN*+ M!3[7_]3B9C'N/:F7;[B2% W^E11V)=HWP&F)DQF#4I:&WU""D8W;*TR]-2[\ ML)9<. ;4:[T4\DQQTIAV< FLOI8L0>LQ7E-U+H2(\HQ=78$):-=?SZ$67!!L MO?.T+IO #MZA]Z&NDW7GGA79(B!Q5FLRN8/$\VPX"'>0U8/4X-P^# !3)*TRB ?@7%%8ZV]P+]HQ79=9MC^A1/6<8"P;88P M6%+GI ]R'AY_:.L6>#XS^E4J +:20V)2ST(?&) ))>7,4OCF6>C4\'N34JF+ ME&J^Z\'-R"];V'9YN7%XQCEN$*P)N&Z]JX_P@>$HHU6^%OH0<8QK:9=%C^6E MO_NY]_C#: $')GR9V,J(P0[>HU\S@7QH4%/ZQ<5<;=U<3 F#PO(P7\JFL@'5 M)1LJ-&?4XG01QHU,#(>WHSV'35N -9?CURL,MJ77N$_:KSJ(GB<2HF;H, )6 M;M%:2V87E5],/B_)_AJ:Q$8YF%'&QP_]#X5E76^[O"=?)^]L<)Y_-)3:OZ$) M+4^27-K\B"1#3D(J&SIK+GC-VEJRVPC[.-K#/KX)V,>:1C/?=I?!4Y>- 2;= MAMA72:RQ&A3"("\)F-Z2(.6JG37BB&61U]\7!?(2&3VQ2H;&9B_M4#CNL&H\ M:UZCL5U4D>A 2Y=#^Y3':7",-) M#]B/Y9T=-!>[]Q6)W(97O^("LBBYF.;BS+07/0[ P,[38%F"?.%*XXF3SC*@ MIGG3?GXM24H. )-=5@LAIALK.TF=LW$I>?R5+8]Y*,FY0*%[7@"MA% MD9[(6CBJG(@,_?"!2R2_?,R:RY@D?-,*9_(\EJ8F7!;!:;1'$+S]%F-'U>IJG]6R0Q$C!2]W3XAK(AT]^^,QI?]G0OM3.A"$L M+@F@^[.$4UR]3"R7<>;=9\MK+)"&-5_P6'V^SRIY!K67M"X M-0>G;EC)KR' M;DO0FN0GW87H4D*R8B787N@%P?B.0& ^[EVV+Y%G;\U0!E)X":H23;JNJD?< M*)/#U'RLD4M&I-)U8-+\XKK4V]9."A.R5$O.CX\?-B)#HYIM4>BY/2R MO-.8PJG_)#C0:[8LS)!V!@C""+!L!5^^I1>B IAT@D31IB;0-U:KB%'*+VF8 MR1-.E<-4RM#B3?K$N9@HGE4+UW08?K0EFQ9"Q6")$>OZTI'[2>C08A6!9,(3 M^';W-KZH$OFT2S>*WLH(V+X8HH!TJ, I:>1G:5R"@+^M9IT#<.26Q=OHZV[4 M1NLCL!.9B$:,P"R)(MF#0Q<-$#D)*U/E+MM,<;CA'S2"&M)_],E6%=$]31F MU5K-N*KH;->5)6OFX]F>2K.WFZ36&)G$;%"\W2@-CB7F+$5]_M"%441,9^=E MV0O>41$;\S#\N2P3G-?:M9$=%XPUX=(5*QFA&?WY3P^/C]'8ZN'QT?'C,_NU M)5'%WSMZ_&F:Y39Q";T]Z__RSR?+8N5Z^F!LS?DC7?HZ7H@:O=>+CAX]NMNA M1I>-4J=-\0M_(D_]YZN-5I6F0!GCF(FT.#/S*E#ICUBEWV7#JE/9BVH-BI9= M=,!QQ%:;AA+^-S@/2^;3HKZ&\NKPPEC3Q-1]OA?I.N,\$M:6B,- M:"G"Q(S:6^2&C/NM8WB-'*W1M;-(=O!6]K0&AM]I0;7*HH'L]!PKP"X#,W1: MG&^O?4([- 6&X"D0F)9$@4-AC7F#>J\7-E'HQ?*Q6[K1US%:MJ2ZYMUOD.Y[FNAEQKM#Z=<4Q:";X2:JP M!2>56_#&6&'S^^1COPNN6<3 3.-T'!9CK!2H7;<7O;\LIJ"-W7$[,$Y;]2E17&L6L2=-]M.2^>W:Z,>U*! 9V)IG A= MK1P[C71O\ZVV\C@!GE\TD)I=0,T 'FK[+;M<-(/X<0[5WNQZE7>=6(_8&@7O M*ZP5WG*Z?=0%_>A2X-9*MC@?/.ZUG8M5#EJOY:%=IC<:HI[D=$,V*6<_ V(L M4ZE**[A2Q2A57K6+J3AA[(^$FHL]./\ [L?+DM-HG5T@]QMJ05DLG-)0%>[& M*2C=%?O..C1;V-4*-D>,G0XS?^>OX#JCR>H 6^OBBV:PW;)F0C(8)HBG[T]_19C4'^M4PU"'4D4JBN9LSX*]? :HE!W M)0K5NRP,M>+UJX(W<+M6!W ZST0KF$,J?UT(1'XC_JZ?9W>8Y^7KMZ=/WR^; M\)IF9?/]EQ37&SG0;-1W!1+Y\(.2EHGA_;:@@_(O5T#!S;'2QC?^<88.U_]X M_=/KU_Z/6-NG^6PPX9?$-9U8'F&:# I@@=38#1I4= :5'%1LQ83:CD$C0&,C M-C:&(X:BI'$U#+1Q_$G?WXX_72V2@U!APJ4$.Q/2:45S_!EUYGKGRK7C-?JE M5?&:9$5X]]J"-=UR9YN#-:T5W'E/U\O VX$KRSG&YKJS_JI%>EO5O^XQVZ&,] MS!OE_MU>VBL 8UPP\:M\J_";UF)=;LT2P(%[4I(]TN9/P?*7BC L'+M:^/"U M-D)H$32L 4VQ? DOKC'3T"/1!;*4>V59>]Z0!F%(VQ\:3M\R)62=)M]R,YUW'G#>$-/][!):-7%]'JF2!%INI W&XB7 9N?_ M4YW.:0&VU:G_(QVC>(J3L*I3P+IW3)"NH&YB: MEFDI5#E>Q5#+HK_&68WH[_'AT=V=EROK3,%/=KC7N]JX6QNYU=R'Y&O[T:L6 M8P?]Z-N(SSC9XS-V Y]Q6X,WFS1L^>H!I5=OWG9%D3X!PW#K@DF"[.!7#:0YNWVZWT9T0EY[9A1G]]C%&.(T9%0S MU04Z)WS*0>BM/R;63%Y5]HIN)]X(;-29N+/"=[N]NY%0T;L>&5F^Y@ET1)8? MH%9E:")S92\9R#FV3\([:Q>N,#.. ^&@,9?)JDC:99.YD6J7_\_>VW6Y;259 MHG^%J_M.C[P6,TN272Z[ZMY9*TN27>HNV5J2/7ZZ#R!YF$0)!-@ D2G6KY^( M'1'GQ ' 5,IEC3-3?.@N*TD"YS,^=^Q0;FLZ4/2-9:S/CK\P=_M#@^_HH4L5 M 'P/C,Z?) $3V2C!%8=L@M#03!R&!^]<_BHA>\3'^HU"C'C2;388C$XL24VL MQ5>EGE8]G=-/V$7]SNSC[8./1^RHWSSX^/& F,\Q"LFYJ&$X\K>(169*AA\X M88=\1#SR ];.IX]73I_:?RU>B>!/8CUKQF[*TR\?O."8O(O=9)\WMD9%WK?A MDK5Q%M?]@+3V>CU[,FV[55Z[YF%'W@4I3\O:UF2*D.R9#+4IJ?#4 [H;R7(? MQ(;>Y-.=\%D?B"M/KMH#C"O?=WS6+^CG@H*!"S)'#DP&J]&UAQ],>T4W].F? MCM*:I7,._M,LOS8=6OM-JF-N"*T=><5TB"GUJ4NA)KUXTO&>&=*S>-9R0T9_ MQPSRV[*@4Z:(I\S#H^9H4=LVT@5W(5E\^= M1,OT"@CHT4+?A-YEQUL'33Q@ZN&"67$ HT=+>WYB<^M&0"I0MTEOW@^\3?QR M1[_L<]?%3NZ"]Z*_Q21W=L&428F_=L$3G(, MT[]8!W,TN, >4^3B)8%=DB+MN16ECR-,S9&_/S[<$FD;!BR<+\9\O'&Q-;;P MVTBG!^]HW#Y"<;30YDY$*(Y&(SYU6$!12F,A\RF11=KT>()L\YA2EW9^Y>IF M$DR,XZJ0MC)B0!BM"OH8B,097Z94--HZT F_18"B6-T<@COY/J- M%,*='BWZLA3O@K4$+"[9O)Y&5PQY_'F:Z(JK*8!0HTF& 5,F#!+S$7.#9!76 M;-AGND9V3?N)_0G3F('Y%H('NIL]ZW*/DN&.Y0%]H?;SHP86[8/_JV[%;E MTNK#A9Q>3@>YI2_1J8BT82GI/[2 M5CLX-W,YY>_>O*\\YOY __F^8R<[&D9 MBIAS%SO I %H()M]!X>MBD'F\7L'IPL+0-/UXYCH8C/7;DW2+F,B$*!/;]I) MSWEBF6>('75]F';IN6ND7$,Q>7G&?=<-E8Z:_UE^HMLT?;4"1" 4W#.4^'6P9IZ'.X7S+B]FAFKPWE=D$R4DIA)D8I>U*V/O&G M"SZ9ZXAW4_$>N)ST?T?/\,./JF@K6)>MTP:F\P_K3]\8-CKGJ3.(:P/+?\[; MP,:,7X4UIQ,;'=D;RGZT(':T3_-9,DK7)?EGH9X=:"(N1.*[!1]M95],^OAU M;!NM)):63C)6DESA?=EA#4<)-A%9?7],&=+Z?=:+WNQPQ?LS+^M4!_6VYRB&'@X ^@O-RQ@1N-&@:%0/FCY+':YGE M+'CM',ZEBU=_<4TI?60\%5F9ACB6O.4&WV&7K M2RS&G:H?A(8FRDOGMY20O2+7QQ/RXM-V18^ER6C,[$P4ANVJ[WU$>I35\< 8 M:(?SE\:=OYKQZSZUY7Q)DJ3B5B\,7J*EIA/V21IP?O6[Y@O(?^&T^)7IX'U0 M\S?4&WC^&A@@'RK TO(-+,D"XP1=["-93O:)2<9J!;X:TNY.ICE2]SM,]>)SW_NBI/FO'-D7](,M>FG+8P!0>*F[9I.S&/]#/GZ M3]KN^?TW]<@GGD;ZPP))EZZ?'".ELKFT4[D43SP&'Q,,. ?6JY*/+,-L MYNK>1I P?FK1G,#:(5A1P9K#-.3QF)?"#\S.?@)E:85>A,UHD$1N;-FE2(PE M]Z_*IDJH?7A'?K)2DJ !3H"EW!XHF@RJ.+NH'/@VKXK#C'1RA^X#7^]M(:*D M%ZA!)V6I-*SU6N%I#?XH3A\VU>+@$6!U'847?-]5V/%VJ>5D=6--@CA!N^O M13O?/.=FL-0B49&SYU=TDE*X@EAX@'?YITUD2#'QU1G$J*AY)ZOR':Z$1T?P M)>QKLT-QT%%K><4N/GY;A?<2YJ-M7Y9\NM?E4NX$(!0LJSE6(U*??LV(#+H7 M'/#-(K4F)*2 1MM!2SAPV;<,7:&Q(%'"1T?2-OQ@0;7%P+VQO>F5S8++C#ES M;Y2\D=FA&<6:^O7)BR;;&+,[*KKX&O!Z<.2D:9V.TRF3]ND-&YJ]0R8Q3)BE MMKCYBE@60FUV46OT/MP9LM\3PA5"FD%,+?8,SEP:@F/3:ZYK]L>+[VF@H9*MNW["-.H5!XN"EPT# );(5>YH M?JG[*:Y@,;%X5H_0T2T&[R].5,M / ;M!'89TP]9\>%$J G!X7H2\CC"_)0V MP/:AD[Q7YS8@+JA1*OX;HT/P$+;\SF<7#$ZF+>XK<33U8' K2"Z=D/-?^9NU;)Z3?^>P5S8X7:NZ.5CI.#PRU\\<3:NQ-LK_9<)QT^:W3L_081T@)G!IAH\".09/J%D\>6/:31OLG MAC_\CKO)BXFZPW")G#2M E3]E($@1 EIJ=Z% 5S<_A@Y8V T,;V#Y@DX,=K> MY!PE^_&J[,Z*LRL>T@9,#>X]8E/;6P3]&PW0EG1^538X!=Y2B#Z;53MP.WA@ MF/>S)T_)_%M49;=)3+C8#YS/"QARWX5%"SX_M-1Y^A2*-AHX&X;5CVEGU(E@ MJXN]JO_V#(]2$0DIV*(]!#%$9#24%=\5NOY@^'/L^-A#5^J/8MIA^/DV>JBJSEY MEGU:D4_)T1*5#=^&:YX('8:K$,'5!N62"@RX-/3?:O=S;(FLI]1^Z)HD974X MD^/"/T@&L=\I*^:0?_CQFKLP"&GPA6ZX- W6?6=V]S$[./>O67#7-*>6IH,$ M?13A6IV,R=#Y'UIU0-C$PX(_ 9L!=\.2X5S5H%<(/V#,A$D/3>H;=PY=IZ\Q M]Z>/O_R&-G+124SG0.8XR]6MN0SPU;M/6B+].\KB8W)&@*O7_/\8KWI44DVI M,HZ@SE9M?RD0+BX#RHS/X;@J LB>(*\WZ85)D#=^?!4]3U1\J MS0*Y]\TA!#NR?(0U^D8O\I(&490GCQ_C4#=]O?J0Y&3L[Y(Q#4\>PU5>-2C5 M8* 4G/$;HG*#-N==< '!XWH@ 8M9*MJ%SJZ\%[^YW/4_T0W;WR"FH?[X$.A/ MHK2XQ7Y\Z#P\P-#4:P>49,3=K$(87A$A? 56?2N[904XXHIKZE#EN8!)*FGH MON72PI54AKTO8LY-BU&Q&0;1H\WZR8*YLQ\YT!.F0P5UT;;0N!HK,-<>,#T5 MM2QXJPI'6F2I6$9&A<"C99SQ,-S3,3;'RC+SY(L_+ ]P\W]2)(Q %Z.E8>)# MPL >)09(H?TB!0XC:C=5G MCX=H,@')T9,,5L9)=#8';V'1W5*+/KQ-SV)XNF\_T_6E"_1V+PB$O3L7,2@7 MR]W)I/SN^<49[/4K^A6$)5TR/,W"U6H/T[TCL_ R@DF+;%/C.CL(_W-^VNN6 M!<$S#>D:@%R%QD_\TS>T[99UO%@BW_KDVV^^8B6)2'#=I?)4'-U&NK[[UZMD MXX]I0LPPTU>LQM&$O90^[BP#U7^BV3>H#$[#5M'2[\0M)-V/$RJP<0L^\[>% ML$5"AI)0':SN(AP:CL'2@_9B:SSYZAAX,D([L0,%2;P?:^1RDU<*+V*_(=D^ M6/_:C1X>*?]2OAA-+ &&;;#I8D,0?E 8U?Y=':IF13!ZB,GQ-)(\2; MR:\6R+-2*$"A.+NA,WRUYEBS2'^<']>Q5X9=FCCG'2H76-$HU+(V@F JXT2AY6ZTM5!:9FF1@&E&==Z?F3],H\FYNK2\F$*[7B@ M*?V21L2 AR.#F:J[8 \Y^/,PGVU(^U\I(!KZGPMG!_'[?4X"5_1T(EO%(B1[ M6>^[EO4 20V 8!8'&K 4-BV N_CQE(6AIXQ]%:;)!%1%' MGXMN<7<@N>1SEL_'0D6;8C4( GWU[3$"L"2EAOB0 3NQHG8!=H$=T]1DIX%X]:< M5.66"Y6$6MQ@CDQ(ANPF#FN@RUZ+.!%2ZQ*#VH:"M3PG9M/9/_([S(,$B0 H M39*HLN&'RASY8M'D6 ^0%1%6APC,S C5,N-NA'#A1_\!.)^ILR5*#)4*_#>D M[!<(0<(/$!! QJ@]J&-BS5]V:"J^.(Q.C !(R)3AQ"JYUE5C('UW+L]GS\DQ M*[4J@=:1L^8="J#JX=&>C%,P_%/E_C]#'LDKR"O=[A2+NCL,0X(Q\2M#53W? MB*IV0XQY6Q)(!4V^Z/PE.Y]=5 P:NMS$DMUN'W;=K>_E. (YN0'BB1=;(%Z M:-K:I"C?];K?AI8#Y1%;UZG&U1J$L9\HZ09-(636F[>V=%??+C?M?_S[TZ^^ M_LL*Y8:V4?P,_:".0I1J''^( :/<),AISEU&8B6U""1^ MS&I;A#HPJ*BH?'ICI)\?&#+CZQ,RXV$@,^YK'<+-+7U^GS&]!9G MF[(NS"L1"(I$X2HQX!$.R?SQ)W]\/$6/\]UWV/-_^U_&^$,3YUJQRZI9(%]0 M()Z$55$X*KO.FEU-3I?\C&8@V/?4[";B;ZH@<--.]F+??P?/8P+4E>53&E4"=*%Z#O):+A&%HX5]R$7 M\2)P_SSF3#\?:8-+B4B_NYB%+]'Q4H*=L>1$Y_>7Y #J/?@ "=4!#JP@\&D! M&6A-IW6BSLPRU_,\JS[(8R= &!O650&7&H:LDDX/HBZ+LMEM"IKI,M (.=J5 M*A8T*EP;OZW:T:Y@)1ANO^($VQ5*\/S07@GS@'4 MB%^P>M$-FJAC/%(7$/^6K"O?&;KX8LVAPQBL*B6 MQ>7I/?HODUGK/'?E"LW'YT>J8^@%L,E] MH7DL G@KFLU1SS MMRRM1EB27PGYB6BR_6/BGAV1CZX6Y?B=>D %Z]^S$I#H_1O)RD<,@"[NA68^ M'[I]X5;"I3./Q./$P%T')N?FFL"]T/NLM)LG6\^5566K,DL8'/[ST2@>/S<" MBNFMK!$UDWD54,F%7>+[ .B!T40P[YB20RI5_SRG_Z=Q[[42/E[&.7/4+_%7 M(Q]3&L?_[B4[A2O<\%QB GQ7+-\54J(+9,AE 52TZ[>A; 3.NZ"(X*HM%\Q MJ+>4BEEZPK:94OFN-<&NZ?9G]C)2]#47&AJ!61NTJ#92!S3MWH12(YS_8U/* M\@V*+A&HB0I123[P\UW'3SOQQX.Q91WCL3?N:X$>E#!=4$9:0O5+GB^ES_GX M]/;H-E[#SIE"#C*3)=M5>!H)!X/JA-![;:(3J:>]-=&'N3L#1\K 7-;W##US0O9P,D7B%JA A@Y^X4YGU>/Y.Q-_LNX;[ MN\ K%8+%;DL7:$]F.BA'FRD_6O?"DTM.6A+JY.$9G@--<]F> MKC%=WBA&N9SHL..'0JJO0ZL,]]PF:(9!-FVD=F;)90V^,"+]@KH"C$**75_< M*F=(.T@*[;HK:$R(!0?.,X-J,,OE@%<%33YL1:)>&?\E@9B,'[-#TC>7\?$% M[&=)^I.OY2I4Q2'FFJRAC,Q]WZ_ NS>$$>H9TQ76''RQVK+5B.S5%=S'?] T ME >Q-MJLATY\>1%/C%+BI)WAS/)T)YU93>.!9)C4A(D]84M+-&,@:+=&/KD4 M=YNN.'.H9HQE7,\EH49.UBO(?!J'9]7@41(IL/V[YQ=_UOU:E5>V8[)955AS M.H<^TDIQLDM"^__]V^-_FRU#5=%E8GLG_GO'Z4[]MSY'?G&&&,6N"W^V__@+ MC6>UW]#6D7Z3-[3X_RM4E5W6=&B:77R,?%E. 0F@?3CC=_/67;?%[M]N>=BF MDUU?WS9IF1^_6Q\7VC9RP\YTL3ZVW-@GT_[?/^Q7'URD+\^__/+.+-(-=_1_ M#B;^/_^E%;TA2W?SA7>I5+SPKV207R*5/G*,'?8NR!3RRR9,'8GH+AM:3I9!MQ/2N.D-$Y*XWXHC170 M@P/?F!&I#?U !#)7IW:=HO6M\@O!]]G+'Y[#.][T-(4)OS'3'(!)A_6:L=U@ M<8##,/PI<@:*F*6M.FF!^WI^3UK@I 5.6N!^:($804(1BB^?\/%8Y!H0GELT M9*'#AG_YYJ]S]+H.G8: I0VVR7.T$%=1GW\"26^E$=998W62]_?UI)[D_4G> MG^3]_9#W&L.)S?VL3E* TU5UIF@!AC5/&^@,5C3LIA;6K8-VV0:*L5C&7AGC M? !X;@I)M'$K>6EA;RPC$W$E W0BGN3\%(DF=1).>O;Z-MKCH90F_>E4FG2O M2Y-.5LQ=E+\G*^9DQ9RLF-_4BOF8G;]YEJBK9&)&#!TX:H*"L>Q_HU#+>D)6TN6TB M&X*6U5@55X8]Q3P&,-,1L-T9?\9J +O/ *:"X71%(1.6X:/N"S7P\LMUBA+< M'\EPTJ\G_7K2K_O 2+0:HGW$]2F<=4MF%N='2N!3LW;5@[4.LI MUGM?S]])BI^D^$F*WP\I[L#<$%\T'EL>/G] MJ]?S0>5$;4^.7>: :W<3%'[>1,(HG@U*:BQB#HXZUS53)QD!D,(9R"1[UJXU MEN3)8W#*DT%*8+*N/RX@(!+W"Z);. M:9&A?OK^V6MK+@9^ELM6.RFG,L1B7W#"T^B6],4_,(;^I!+NYV$^J8232CBI MA/NA$G;%P8K#>[+B9^N@[ UH*\F.A&\:X<0SI#Z7P#J^"=,:EKB)S@!)>K#@*/"AX"&;$V[9J\-'MRW6,Y'BI-9,0/7 M_@MZ5)^2^*_*?7DI_WRKO*N(.KUY\>KM/#H 1Q]OE!AQM$G?: UNHE9+Q GG MM\4Y_CK*'SDT_RK#S\21_ BPQ&M7T?Q65N*!4_K\52HE$BL,BN"Z6,]=3))K MT$E/AXO#J,4.E%DL7GHT!@.(5VG%QD\ ^K4;,>_92\&BZB_+A#3TI^7?_A<3 M19?[MM%K*70N6;FY"^H.T,,XBWOLL9C"07CRN7G5KTN?$1S(0GE;EF= M,G^YF>N3;^!^VS?ORZ5;A8F683_E;#I3N]>-BOH-_Z-];Q6GHRN*0DU/0J2\ M>*,B_6-2]/N_OSY>T!\%8PM%]$R%]T9>L)-7->Y M4%@Q^92LFQP$[MP2C&7T*@B?'[.87\5LR+)H2;G3&M5R](0&T5X53Z2=8R[= MBL2A )QCX%P37'9I0I^.E>XNJ*B?=,:\5B_?_)7)-H64\($KJF>#>I"ROFHJ MS8%YGJXDB2=ND2?WD[)HY M'IEU/U)DE:WD2)?E3M9(&SKFXN)\-EQE:=('D1\)_/CII/MQ+0^Q=+]3(*=0 M;!Z9*Q8C]C4-[^U?R[8$>:]\J\&4269$T:JT;=)PN"VV0[I5$ U$CIZKOTYZ895^>SB\1#$.N%!O%WL2O00;NC?;/.B<)=0%NXTJ9Q M2EWS(2&KXNM3]:VZ,Y?WHC8IC>:VW.(-I.?6-9=Y'N/A;Z[QM;Z.Y&UC U+V MKMN4NYWL/LCHA4Q7^AQ M07\@;X[[$+HD4#YWT?YS\PKT1,MQ%I_@QGLR_U07!7:7-(*&U&3"RR\?GZW( M,K@N1.AI#^AD'VC#<6X*S2/E@ZB"\2@)"+^'5G'PR))E'+.7*$0$P5@;+(C, M 5\TFP0TZ<:[;UUJ1?.,Q;L1%C(;<2?/[^LV%%TC/?PVH:A(RZ 7'DFJ*1). M&IXNA8QW'L<&>LR"FPJ2+%^&M@:7)G9;K.9%T\?&*]Z\-RW O5SV7-P6N\R9 M"<)$REWP7"Z;IEJ!JI/UC;]G_ %.G?1>T.[C]C#S/TUH8]Q\.IAMN+J29I,T M"ECWV@U5IC*]F7,;0Y=-9LZ713?YH4O=[R)C)D0B+=<$+:U(/]'L=NO]N4&- M!OD7R]MO\LP:< Z-"OY0; HY-CZZQ#>D#MK 6II'ZPY;D^P2#5:2:EOGK'9D,]> MM!SR(-:DW$U3Y9LCX05=K0A5693XN$RY:,_3KN^8*0.OJ"\;\23=UV#&3.X* MCTM?!MIA?HX9NBC;\<(V_O2Z01-'"(N,PQGB^#N6_^\+#E?.$40*2VGN9+)> MSXCV>K>_6M]BZ,I4AP1Q]\"Z4WYS M*@&_UR7@#U;5WD M4E9=.LO*S;,L7FHH$DFP$)KQ1MWY[!>RKXY_5\RM+,YCUB#'HWBCV$K/ .WF MO&W#GGY2<7"%/*8KULT??!G/YM@+_5'#.\A.B9!Y>-T6$<[#4]-1.9\NF"#[ MGV @(T^M7':^M(QYQUX\L[8\@X ;HACFR"%1@$O!D7K]B/W_N!9Q"?+P5>:* M9QUEK!3[P?LKY!I:"W$SDWG1Q,@=GKXYCLN;OTYPP3D&.1_UK&,O@J%4%3=S M<#2TO(([,$I$9!@M-<>SW$?_2OL[%1F+74K(\W UY2575[,9@Z-)UI0;@9P7 M>F05BH[]_KKGQ@DBT>,3Q\,_'H7- [?3A]JK 3FH41FP$X(GV)DGEZ-.([$. M=.QG#= 1$KB)V;KXNR6"\>+7(#LH&BED,+B1,N15AC^7]V_!94X'H-RG$Y)N MY^!1*I 600,+QP6*;F-,%68"4>I-IU/>K)P7@:5BUS5+4 _*$_M:VN(%A@!* MKV-N0@6'2)S>C^ZS=.]N_H5>>S[8<[)AML$G(!HD#FGIQJ*:03V[/%/#JXFH MC_3Q2=:+(NA%L*D?.)]YSAT\OC3)5/_U??MT8@B(LP;;=P\#)7RE6V6 MRQXGOMQ+;%2#G:MDTT7QJ]?#3C3V5:Z;BWA*U)]FN]L/@Y[GLQ_WTLV,0Z*= M=DXZ-B$-%6R+%8K&>[>8@=.&V%UM?NS331H!,L "J6"DKD-]5;8-.OQ]JJMX M9_++M_9P7[RG+[(^N,#Q/&*BWVNQ%*9;] &PEH__@F9B(-5A M44\FW1P?//D+[+P-_L2W:)@MXGAE[)S&P6V.-TW<-K:&N(-PNC]0':8O6.^0 M ;(JI5LQ"<)PMM^@Y3 :%*[(]>)HN\BR6F1MAXBK1EOY.M;2#ZQH)731SK+J M);J)W.T9]P%CD5CR3C4Y\#!]-=&)L W2_8U12/EZ2B28PR-J5I1;,7M,X#7' MTFN=CPGS1!J]\C6YHFJ1#W\JD*R2FS0/[!#-Y-SBK=Y/,;6BC>1F*C>P-D@: M;0X=]PH3\S$MV:YO6>!UD.S(@IPM#F?\ORF ^&>0$)%VZ?GM-LU'W NS"F<6 M"T<.)OD'W>!%9+V07=)>DF%*MEK8\ZAD>[C*;/R1=]W"(:@^=[^+.-X5'WA72<+CY6R&4R+KI>DE#Z" D' M87% >J8L+FL$8M0TA)"!3N\QYRC:W@^+8Z0R8FL#+IJ]6,5XR;KX[1+!F 4A^#VF'L@N#U1PT M^G8/>& "YR=W&YI%9=E%H?=S:,]+I9L!74:-7OZ^,G7@LV-0]_ MI=LU)#W1\YJ\+#X=-!*)!?#W5MV4.:)'68TK_J9VJQ]Y\YVT&4TG)AIH)JVF M3:XY#P%1$JPNCK..=-?37BPKA_HEC\W0-WS)X_+9WDCC6/XUXNZCW\_ZG=(H MAH*,=G9&U[Y;+6(JK^'@/>5ARG]^J9ZJG(MF%7E%CB6%.&"M<](^>E,'U(3JE(2]""6OT&YT+:O."RS;RJR M36ON3UPLR-3?B6-,&JM8D&7?;>?L2= P%YK@)#W7AA3:V'&JL%@VJT--*[J$ MP2=9DX/5JHKI$5.)L^>2W='%&L.F?>8W <.'-E).-Z+)4!O-.SJM>QZ-'V+5 M7.(]N@"6HVD6G+]2 "B'CC2J$MN$#ML#H<23X489W^ MI[_N](O_=-/I'\6 $2@'V>0:+ )=R5IQ<,QEMR2SBGC5/!I09FK=HG-3A!7O M.=B\SSCZY14I[)A?*WS(20JN2Z6/R*(YG[WJJWVYH\$>.3%V---2#/!O^T:/ M[0 MIT4\J"ZHI0GVM,;F:0]/ZM$!\1:AMCO=@SE]B:9:Q8RU M7HU;[Q\#Q>U]66O$==_""BO5TBE MN^$MTO *X!:Y,ES.#)V7RV!U SHJ>&GQC!Y[_& &C*$[#QAP[Y*M M)QF^N4;&"K\Q1P4$;66,XM)92_V>^: B&"@("L44J#"BYZQ+CK$=N8NXR<&5G#84:3>G(1]<]D6NXW>3C(P=OR[:;))OCP#%L#VF;!(9).&&G@"1Y)&)@=!Y;';U"!.O J0):G.H0C9 KQ^9M M>D.J.;M^+=!X'%(%O\=%R+&#:TT'X&V+L"QPYC<.6"5CITEJZ13@33U)DLI$ M8P)TXEHA@PK0859?*P@-QHOF_$ZS[\T*)&DE9]Q+PVQ;DM]ZL!N>&1-=Q$&+ M(9_ )9*'HL"Q>W2).F<[@(_P-:\_%,(/?N M3G()-X,E72UMK-M4"+'$_#6=,]%2I8]5!4,3-]87I*##!"[)])/C5AJ])=[! MO&>K"[(. A8BD7,BM\4<7K(9[Z8(^&@)I1RS M4@[OQ+)!K?JZWRXDJ181.IJV3)BF^$,!62AOE*W9JEGVRO(V/.DQA:_X2U94 M72K@E_@Z(^\JH*U7C) QPCD'L/ZN*"N43G"V0C)DKH] M3P&"T5IJ^EUK;DNQC%9M<:W"V(8!@)9FBA_\/7S=DD4E*6165"ZQH>F:FWKA M39 @C-#^&2V">9/K5H*)+ G7,?,\X%D"2!=E]W;(YU)OKTZY#OA&(@:K?QBB M=_Z<7EJO,B![W^E_V6CH(BP=!D<=OJOCV9^,VHQ+1:ZO&2[ MN9BQ$D*\B&X;!R(U(;NLKDL3^91XR:7?.S'N%)KQ=A@?X!X6/>5$J]I MDD\#+>S<*(4$;P;2BX,*PB2"M9E+UDLQU7O]6K[Z[)X(/O_7\GO=.VE"=_6B MOZ292'[GZ>,GW\R=T:N4*;$K6_)&DT$P/,I&((..17!RO8XKMM M5:IJPXHK+AEH++.@^TXSSB<"3/-4*91EBN96*@@] M()6&'C.,\+SZ#SLD#"9M)/:^X>WJD@R8H72%X<, J01:NZ*9*3>56/DXEL6P:=+NOP5!_(#./UV M@78.P2]V:W?\W?_GR>,Y'?Q$N,4\3_R2^.A(C=F- :OW&YKRU>,3-.4$3;F+ MNN!N0E-H[ZU/H30M'*;X)30J\@7X/'4,?!PD9\^&_#R(EZA=VV$"^%], PIN!^B>1E=$ *>.YM1V1-?F(AMJ)DD3JI+LJ9E'W,2:K.F?^1 MY>I_]YQH@22=@%]RC\8L""M:8MC645YK#O*RV-D=0]5.MQ)%MKS:$#(CS8:O=%.71^GPJ 1UC$IOX[UU*Q'7G3M^R;O MBN6[XC(2=(.HLE(_ELT\J??(Z,<3'LG6*>:AD;<9I/8F%F35A$XK64B>739Y M*3!BX&5C.IZ=9ZY-Z#:A6J,6Z'/)PMY:%;Q&J51+UE+L9/!9Y*E^CO976H$W M!HU^09>=#NN%%@Z\?O/B8C[VI11\D..V$JME593; >BEK!7S784KCD7MXES)P'3%F'.+.9O?N6HZJ3(< MD6\>^"OD)/,]>*1J.^5CX_J5H( M]>JL69_M--ZU#=K^BMV&R MXV3+(8!'VUT'JFJFL+H'O^G/\RX!C0 0'MTJ80.W3QMJ>%+8E<#2[F+ MK*:=DO"<51*Z8E&IO8NOYF2*1*3#:C;H.R#QS8S[EX$QH6TEH)^FGE)S$J.= M!_*E-3EG6<\;@#XF:(E]4Y&68_%]+V^6X#AHEW.C9/ CI94%6.M1S MT+'Q8E_;G4&H3$*RKO8R%D88M5;NHU=QH(-_9PBKB6:)F M$A[SYM2TE:-P?SRQK%()SOAUD92:V\5F/GN6 MHNW23@M?LO@5LR8 (; 6P9"B(EH&-'GS8WA+XARB08>/">$=RFX%).D%2IO^ MFRY%8F\9/,%.=K8U17IY&IOK-?/)I,/],_XL?K\BTP?$8,A0%MO/Q0@T,5HF M=J9(02*)#9&?6)MFG5MTS,:GXH:#2LPT'&V"+L1'H"\!%I6]V?K2C('8?BB3 M+1E:AKR673Z4K/S<_8GK^"/ \C)B\AP\C(>T:$/8F2 M1EQA'R+TS"SHNK-"NGX,\4Q\^_%Q&=@)M3J(KRJPKDOMZL (H.'+O=K"EQA? M*\PU"EE*Y#6T9SG*4MTR;TIT07^%<^#6S3,Z.6/?_QDLS.)5S%W(.U)5,F(V MD<6*O7OJ[WW/)-K)+CC9!2>[X('8!7^=X"F:MA :)88Y1(TUQ7%D/N5\BG3* MIZ>'9]Z=&5APR#>Z+W)354US;>A(G MRC _!]!-D6\D^L+[,F8^C<(S Z,BWL3.O?4)&!ACQQ9Z8*%%:BJL;\>QU@BN M;*3<+I;S>'\];EGZG9(.&6RRHWV0M'5Q&13VE H-$-Q?KQ7TQ9%]CA?.$1N4 MYM!6SKALFZX[8R!9248#MLWSQI^L@_LOUT[6P,V0E7)O4CH: M Q?3=>R9Q[W+?ZL\^U#WG=/WF4(?E#[3]Z]1K84VB5[#>IVL:/MC*:LA$^W< M&'%+8?1O46@D %3FUC6&2B[53;U[E76[*+>= ?"1.RN14C+?>3CG+"ROR("N M?,](V?U&^I+N8O'.D\?V=R0,-0Q_TH;W^1Z?M.%)&YZTX0/1AKY<>]*J\$/U*V;'&T0C>V;=I%N2K%;MER76ZE_Y!? MCT>R+]X)J(S3"LLEW0,E[N"' C;=%C!!-#Y";S6&GBS+$$&%RK==VHLKCO7S M_*8:IC#.J0.OMCW&U

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

*F,,@5 M>>ML*O3B]8"S-D?^4BMD"FXBLLJ,@[5%1@OQ*\TD T_]X_[CI]\LFG7#1J^J M[!?GDKM=4[L(U7D;)JNL)RZY3V#L$C8J@'=JXK]RK@/V^570.S+U[>O"(?9 M[%J@P@]HG_+1E8QX5!JXF:$-$F\J3NCZWUN#)U0!-[K=V+RB5+[KY&F.C)HR M'6-V 9"*Z$. 95/5X:G,%(!=YZ1"/!NA0-53)L4C5I-+@+;07\AQN ^2M(_4 M%6HASGMJ!VN->GAC8KIPP4QP'H/<6YQF(HLK9_?Z+IF?E8#IQHP1,C^91'FF MB3\/UH8Z:&.+E5RZ.+20#3^-"IAB2I9#^/*97 KEAQ@87^BC!90A:U437NNQ97<-6X@HOKM<#G F)K:L4,6](N MDLX@EF0SF3>TJ0'7"D@L6KU=O-IH/]!/N39=EK*Q/!)&]G_6!W1(IE%+*YN9 M3VN#,72_"I;C"AV;,>NI1^?B$L6*7I&H6"3@U#![DV!;BKE0*IN?F3:\A:HL M^;;;Y_6]Z5&PT0,/-XNX$GMQSR6VH+[7H;9'9G 9L779<]1LQGZDP[2&$=E^ M+;%7 #>;V)+(L2.MAQ:N[W/3P !Q=0=(BO6PG7"6C-/J/.,0@XSL14;:KF/L M?X6X9[J4M#\W"=9'KZP M>D3EQ0B>@=-UL1(K,2U.T>(FPI\OIA SU!TS6\*6QZHU)!X]E ,U[+W(\QA7 M,3SX^"EMND9Y9R @&UVV-AP&] :*=1($W_#,PW>K;\YJO=88DS5UE7!?E,NC M4@W)/5RWX2MS []4(YC00.D=W/YS>D'+P,:P0BSA24-+E1C'-#\4:$/Y%=#J MFRA\+MB:9=UD)EI57YE!QF)YP!1@SR6RQP8@/?\6#JD\ZUCA5#O,Z^4FVV5% MW3ER)RRA-2^OBGD,4:#J<4VPT4\3:&VXZ.N54S*5E.\)M,Z)R7%L3+:S2<+5 M1J@Y-[+02G>F9J)4$VWT+/,BP30B6KIR%>LYA43$;/2,HZZ4$A3UHAH=Q."Z1(UM4AVS+Y01_13*1P M"B3^I9:->U,O;-KG0]W_F8V;S8[1W53VG6[NE!KO"TP?]P9UW(UL8&EP'RGA MM 8P =8URESIJG3+P\E3"L?14G@T:<&$8NNC[854L;,1#USWN,@-QM85]&KR7;6K& S!%$EN3+"_ +J M1I@U.;W#WF[Q%-!3J?)294X+NNBA/1EH)G30?&'-6L7#HLVXK/=(U_GV\X0= MTO&&G^,F9CS]L !#XD]U+.ECAXS"6_&@41XTFALTZKQ!W]%8M[QIRZZA*OBF M!#( R^K+?GQ?__7Y]?VYWAC)V8;.K10U#%INF0*8XT1=0Q/,(LU8>;;P4792&WB2Z&+S#HY.-5Q<:8K(^#/F4&87U'6Q@( M;,\2!L3;\^'S(^$?=%^4U=YP7[51@4],M*PE_#R$RA1X2="^9P M=5Z?+*H""S"USOQ!\6C58U?W#[0_&051W"$'B]$G^3G[;ZK#5*!Q[+ M A ? ]GFGC<*G%G[0 A_%H#>A98?PT@'&5MSA(*#"$U6Y@I%WE@.G=IE?NH1 MQ;-- 1WXK*SH4[_%$:2&Z3'9,NPTO5\J[PJ]4=4#@M8HRQ?;W<,/'<.L742- M>\68NYH+:QJ/30%=;)$[X80Z].\VR?/!58&@$L3SH;XZ?I%>_%(.W3_R$MQP M'CQQ:Y_(&F*$5(H[#,P)#L4KA[*;!E&2Z7PL)B^HFE=*)!O3+%U%-?AVO9S] M.4??6H=%SSI(LI,YAI)S<<&YSZ*(2/:E#U F:%9=9G;DK>,.Q?5^ECI"QS'1 M?J/:#NMQ* KRB7JS\^N2ZPFA) Y7(BM,EWYH^JED$#O4S4SFDVMM *K1*DPR M#@_H(0LF01Q;=/@Z#07=2MH5MYPQ36X+W4YR@+)^[D)O3)I_@SWDZQ0KY=I< M*5?C2CE2>GZ;6G_I=5P5.(([*A_6G)U]_[#H6S)2EC08315GJ,R[NT)-CF7G M)2C]U5+X2>-@@\!TAS<" =NB[RS6U_O:D2T/Q=8"E=2, WWYE;I:6+.%G!^7 M-9M9I1,%K^"J0@+AE,W$_0AC7G@K4$H;C+=L\*VL$_1'T>UC#]^[\',6-1@0 MJB,YO77B@G2UE 2RPBM0N8G8F4?@M$+DU#Q%$F?=!9M^N41$5L#XP$JGO_ V MC&%>H2/N8(&<_ #03J.YC F9+XF@*UA'E->XPZS.Y3A0[H*1 MD9#KF1U6(D MX_T6ZT56[Z,&65A'WL^NG#BT.8LH(4^M\!U7RBP!XA1B- M-8,4Y7@JB%LNSF$VIH &0^7YT/&O&*'X5P",_2 )O_UVF0^NFA$NDI F^[CL MA1=G4_-=0CY*?%?PUV@*2C7_GOHBD"/F-P,/5$HP_PE?DE>%(Z0JB!96%_WZ M/;*A8TOX*4L4'OB<3,/8*2Y_L8#[+')';_PU2I->DUO$1? F(QZX$M?S,8SG MN8S&6+ B$S- EG)UZ7Q!*K5A=P"$9.+$1?'Y'SAES7D'(\/"P#35Y78<=(1, M%\@]QJ,GYQ/8G4"V+93Y-,,?8%]EDYJUMQ ,?VN"X2\0KRQ%$[W- MQ_R-$7XX'O&GN;X*FV6XJ-9R"+EP9_;CM6R6%2JSL^A9==9*LE-E4UKE$)@M MQ)@9.[F=\"Y@U#2,6A$,C@&3+2D,S+T>Y&[[6G.)E6QN[59FM:WOH\('>8[U MX@36]FHT2%SF*M 6:W,%K0_A/F#5F=3D<_\_,.SI/O-+UFO*I(Z.-Q.%JHK( M^;@Y33&+P9AVYQ &#$$3"?3<8BNO3J*IO8V<;CU=J^9A86)>56?M M.H6[-P3Y,P3G/#,O.].>G4),+69G2\3,K8+FUKL"&RS'C6Y^\D86T6_]HAL?OWM:N&=MBX?$.[ M70Z[V&V#G2=%^M" XC\ L<# /L(][NQ MKSSH]U +8SM%P\,Y]=0@8*/4$Q2UHTRNVB%$%( =J[1*)AI=JDU.8"( MKK@X+M0 IT219&>^;S[P@69,N>92C<^#M-!GS;NC17&?7_S1MYL87O'<3#>% M_[L9K+:C>1DA59=&[EE[(DE#&HV\JJ04? M$)]%*?Y!4-YP_+A]#-+/9R\H[^798AMIZI$V98;*437C8/[GIN M78TS552[2Q@$9_9/8@GT*]AA 0->YRKPBK$[^9?WFJ!:OC%15US1NE)=D'5EJ".U$WI[A M!F5/%8N-5SQN.+_JV+B[?A!&18>E\-:J7AM\'G5K5PZY"4@7N>/5'0;Q>5WU MX15&'\4PR.O"3J,GM*#G-5IKRK#X?G84E;@[=K.!_,X@#CZ@./QDPCA5F_C6 MX2J(FE9!T+[P;'H 9:SB5Z3/4'=3T$#R!Q]QVXZD]V24P0?W!I2E+Z=;Y^BGDYT70?54]2U[ MI(>U7C>F7_^YNLZMC2*763*T3/(V, __RMK8L_H,F;I?JZ_.*/9RP5D9TE7; M97R^L?)#3%LWK'+]D?E$0CYI;ZIKL19!Y_XR5VU7->):58O%^&=E2"]UXL;- M[[K**LX#'ZH8)JL9OH?D4]3<(QGC>9QU-108:#,ZH^+J[+/=)_762D.]DS>1 MRBF1S]L:P]352S/NFVITBZ4!;E)66W!VEO2U;:,H_:'O2HQO#\'/!_[:CO-N MR^IL&;.G+TSF5FFN%!,U?D'<>2#@L=8J)P72A#=0XRDR-_MZF>S@4W.STN[7 MZC2-PUM]GN11 L$0V(A?I>C,7./XFY_/FF?.*)C-@$)3;+/Y]Q(R;.K?ZCGR M$^?H&R^3X+7^CY]@5F,Z%>=,2)G\AAC_+[:1B>\61SI:FL?(/Y:']&X:IL$Y MTG>*$W47^\NS)XO"7J=9A:+]51KM?[)G09H"Y;C*!5RE_46:']*;KSY[Y\'OG!D*(]GLLB M8\)Z+\>_QEP <)X*RV9-V(*IFTD0H-U4M0V2!2D_]@LX^V3AI:DAL?K\MA\ M%3!]J!3=S0H<#)FCB2*JI,B=*H>P2F76JD"$BX() XOW5=^$BXO?L)A*58PT MG#=J@+5D1LCX8;\)V^0"+#@?%4V2KBP#H*:!E"8M0($.C&+_7-E(-;-QG/W5CY*Z_-0S@67>$)/>3 M7+JNU2:3[054('U[^"SN),';.>&H"JF5*\.W_M'PK:NLRI-?G5Q:Y:J(7'X] M;Y'C>-D,3TDA,6,8"YXHSN1$EES9?)^8D4CQ&Y2Q,+,D\!GJB!\EZM5P/B%E M4-'J3&8%9_+)4312 4'&4PN\'E%C$>&!:ID%XYL@ZXD 'FBI1S,-:#.TRO%R ML+43Z-D8::KR6]-AAC,$Y)A[\5HXP6VU=.8!KK5XA#1^[MT*YJJY[&/I$XY>Q:8BZP$9 3ND>(- S9#6 MM8T/##? I)RF$$7*:LV&F,U(L!+K^6>8M'2!A01.4\B+RS]0$_+4&QKR-&FR M_'!NS5#.7A^_$7^Q/LE5N43;II56/2^MBB9Q%]Z,A1T-D8<4VN,JJT/M=_;S M[UR4 MY5/;SF$LDQQM@[#EUVL^ &)@-(\B7Q[^E*O$Y&KN!N<<75H #4?VOK M,Y'](RG9/;8".R:S4FJ[&0'IPS ]\9=R>M0;^UE3>_8J*GR5Y]'8INSL/5"D M%T5U -6KN/TSSV=M#0"&]6BU=[,=-VF[+;6-94$"C%&XQ(TN5J!KK-]K8XC! MQF5^OG7^<\53&4"RR&MU/5-F21A9^\1*"ZX=\/NL5RXV0T456;0LO95.B)G7 MK85\RA =9+89UA<+O#4V+31P8;T8L^49]K=WL MNGUQZK)QE7TU6G?]]9?1?!ZBP. %Y>K=Y1KO=N%6W>W&0I\+2Q5IEIE0"%F\ MNW<(N:GL+_B& M:#))@E2.6E3/GXE5248#.9%8EF[+SU:MAK_+-?QI+F/U<_MMU/@M?['[;A_&7\@;P,8J7 M4^$9_4.<&(R0F#]2OU&EP++Z7(=@,\O@IXJN3C8#!(OQDUT0 "96[QN1L52O7W[ M,T_I,MDA.FL4+U:QNDSXJ$B5/&65;V;X@,1"0I,(88SFU>M=,.\7XOMM-@3 M[P(_7LC+IQS8)SQ7$#)Q@$QH6(8WT>7(;J;5/QRX9U_\OTP$\=4O,B[U0P5/ M"KYL*EY67X1?J2#<#[EC@^&)23 VUVBD9]<'3'S>).>M'P!CL**'@JNTV";G M/^(4)6--AVDHVV4&&=KE\@$=Y!*!S_L.#'YTY-@L)-8" G]?$4?AP)V-Q1EF M>7@]7^C!5(?9L;5??*%BX9)L'(9N$L?:S\)OP.:%T^TQE3E5$ MJ-=LM!_ **OHWY8(YL<,3\ ML5&,9Y&/)\'"T?0RHNFE0)%E-K0T%*$[ [R1;DRP-!3 MA7Q19LU8(\W(%V5ZF!"J>=HJ:[(,BLN;RL9!&J^ZYNM)U-,J7HK:F(Q72!L> MK1)_,4Y^("<17!Y[F*FX?/^^^?[RA4S%\ZBH_OC#L:0Y>*L7)V+"(4(.AR$"P/+ \U!4& M22_()H,B-BPB)&!@DT$$")8'$C!PT(D*$BP0)&#@H!.?_OK"P$$GNMBPB)Q& MT\FC,/#:C3YM&*ZB27KGQX&SC",8*"_GTB=!?!N.@H1X1>6 MXV@]8B-!R&!3KFBQ1:*#!5NDTX>*+=*>/09=M]MCBT02&[9(C 5;I*I UL=WMC !JFZDL4&Z7FR/\?!I?>@>GOA@>=DD.H>GA)B=<;JK*YB M0]2-8X_[9*"2];3L<3\8 QJX@^:@=!O%(L.VA]%AVU,)J#C:L^>P\[;;ZK39 M]KSDGA\\4[Y\LU,E&#B"'4N_P:86.LI\]3D-+/.E5\\+9Z7O1EZ[[P[;7KF*DST/ MBL+'1HT.%FS4:H E&[5C&;7FP&V6U[3/1HVN\+%1HX,%&[4:8)E/4K%1.[RO M<^@.RAO4P3:-KNRQ3:-)6<,IKPC Y;KWI@R2&GHXU4<;O=%ENO^L@4AY(XE'2* M2+5Z'$HB"0PAGN2M_H*LIZXN!I=1DCK1Q%1)OR;7R59+&OWRMWV?2T_-M14) MG/8L#*OW984H=GQ_(0$#6QBV,(P36Y@*8L<6A@0,;&'8PC!.3TW*L(4AB!U; M&!(PL(7ATU]?&!X_C+B">2ZBV+"(D("!1]<3 8(O):>!TYYUSGPI(8@=VQP2 M,+#-(0($VYS3P(D#8:>+'=L<$C!P((Q/?WUAX$ 876Q81$KCQGZ^\FZOW>C3 MAN$JFJ1W?APXRS@:KT9IXOB+L9,$\6TX*H\5F^TWK6UGY40"!EEK5^_[7:OG M=LHCZ&0)H2TA;!_X]-<7!K8/."ZTV2R--X?1B( MZT-IQ#0L(+0%I);FH11:FAT^+.BH.B4D.H>/[V1]5#]]5&UA( H$RP,)&&35 M;;T=6*_M]CJE3?-@":$M(6PQB #!\D "!@YYB N&V^[VR2'# D("!@YYE Y! M_4(>[1:'/,K&@!"_KEUM^0+D.]()+%ABT02D#% MX9X]"^9(9,198D[(]%0>"X[B$$3*.[R9F:,X)U+N^]02[!^RK;G!/IV]AG:P;>@T\!RSQGJ?$UZ.(?DMCVO M7+W)#@A%V6.;1@<+MFDUP))MVK&Z83INKU4:H2W;-+JRQS:-#A9LTVJ Y9X# M&-FF/5A*T7=[@P';-(K8L$TCCD4IY#6<]]J-5*\\1AM69U569]46&Z*.'COM MU<$R7][,3OOA-6@]M],]N G^:%:.98JM%Z/#UJL>6'+(Z4CX#ERO7WX6A47J MA(Q7Y;'@2!)!I%H<2:()3'T)D]N=1HLV-K_&49(XRSB:A"FW[%! A&C#(=^- MJH,EEY@=*WG597I+JMAP&RICP3:M-EBR33N636N[G?[!@][9IE57]MBFT<&" M;5H-L.0C+%UHLR.FR]:H E!YR.Q>;:<=O](5NO^L@4 M1Y(XDG2*2+6&'$HB"0PAWNFM_H(LI*XN!I^60>RGXM6=X*]EL$B"Y#6Y1C=I MEJE,U]*"&+'-H<$#&QSB #!-N8\MMQE];?6 M7"V1@$%6V=7[9C=LNL-FAQPT+"$D8&#[P*>_OC"P?3B[Z'7?6CUW%:S-%8:EA#:$E)+^U *)\T.)Q:45)UR$1VO-/H9 MUD>GIX^J+0Q$@6!Y( &#++BMMP?;'KH=CH"7#@-1"6&+000(E@<2,'#,X^RB MU75;0X\<-"PA)&#@F$?I$-0OYM'K<,RC; QJP:Y+O_CRRI^)KX/*2['N;P%0 M[9*K2ZZEC2A_VUDCD8"!ZVK$':+E>MTF.6A80DC P/:!3W]]86#[<';A]=W^ MX767+"'5EA"V#WSZZPL#YR#.+CINN\OFH6P4B I(+ M@F!]5#]]5&UA( H$RP,)&+CL4I@+SVWW#BZ[9 FIMH2PQ2 "!,L#"1@XY'%V M\:KM=GL'MYJRA!P)AA_((<#ACM(AJ%^XX]SK<[RC;! (\5W:]96:35SM<8Y0 M'%]LZ<=B,ZM=A_EKL AB?X:5F/YX'B["1'PP#6^#LBJ5;6OQ A"=G.Q0J1K? MA0V/3J #57Y*]9/0JO3%I==QF^5QY.PE5K;*8]%BBU1#+-@BG3Y4;)'VI4AR M!\,!6R2*V+!%8BS8(E4%JOQX.;9(6\L!6J[GE<:IP1:)KFBQ1:+)OF$G?@[# MI=H)HFZ[-$H.5F=55F?5%ANB?AR[W"<#E:RN99?[09>[[S8[!U-0',U&LRJ/!8=Q""+5[7(8AR0PA.A67[CV MM]5OM+NTP?D2I?[,B98!5/PN;IS@KV6P2(*DK(IYMCXGT.1F:3K8U$*WF2]" MIX%EOA+K>>&L]DVIWW>;O7:YBI-]$(K"QT:-#A9LU&J )1NU8QFU5L=M#PZ. M_[%1JZ[PL5&C@P4;M1I@F4]9L5$[/%+< M6'+(Z4CXMGMN=U#:%%FV7J=HO2J/!8>2""+%H22BP-270KG=:;1H8_-;E"3. M)([FNI(Z6AQ<0V^D<7$+-;5PDQ\FP M0:N!$F2#5ATLV: =RZ#UFN[0Z[$]HP@.VS,2,!#5@6S/JH,E9[&.9<^Z3;?; MZK,]HP@.VS,2,#!AT*D@-6#>9YK G#K_6;7%AJB3QPY[=;#DHNEC.>SM@=OW M#FYU9/K.FCGB;+G8GU3;SI80@=FQS M2,# -H<($&QS3@,G#H2=+G9L"1>W09+.Q7)+X[]F$TYKVUD_D8!!EMO5 M^XKWRG/[@])Z2EE"RFXS9=- :]OK=O")PL"FX>RBXWJ'3Q=E :FV@+!YX--? M7Q@>'_RKGGEXU74'@R$Y:.HF(7QS>'TI7ODZ#FNJBTH_\/7>_CU- 2/ E#- M[6=U7Z_3SC> K&:YWC> 87ES*5D\:(L'&P4^]?6#@<-"9Q=MU^N5QJ[/ D); M0-@LU.O4UWO[.314-@+U%8 *,_?< MDU!?&+BPZ^S"\]QV]^#,/4M(M26$[0.?_OK"P/;A[*(U<%N]@U,[+"'5EA"V M#WSZZPL#IWB@9[#G#IL=?\SME(\ "P.J^ M/MM=^FGG*P"7_JK27W?8:I%#A@6$! QL%OC4UP\&C@R=77@#M]TYF$V*):3: M$L)VH5ZGOM[;S]&ALA&HKP"41O]KE_KJX0IJ;W/S%?#%EGXL-K':)<$?@/,[ M2%(G7(RB^<'5P,?!11K@%\"ETO[1=BT,"PL*HP)FQ"JSC'? M8TX&*EGMS?>8AS,]@WYIT\).S #52K+8$)6/ 1NBTX>* VI[$E#W2Z.?9C-$ M5Z[8#%'!X&3DHT:8<$B-)"PL*F1YKE^XTKW5;[2[M.W[ERCU9TZ43H/XB=7N MQ\&&K*T_*;_K.;MS-#:PJ84W&;Z;G@:6^>K#YX6STI=7K^GVV@??7X^C-T_& MZ:B5[+%-HX,%V[0:8,DV[5@!V8[;:Y7&%LLVC:[LL4VC@P7;M!I@F0_SLDT[ MO&J_U7:'@])F*+%1(\F+3MR>G43BI&:B42-,.,=($A86%7J8L DAZ3[S5:@Z M6.;K^ODJ='C*JN7V.Z5-"SPQ&U8KV6-;5CX&;,MJ@"6']8[%#N6Y@T%I_/5L MR^C*'MLR*AB_;G4:+MB7_+4H2YSH0 M?Q>H1@$G]?\*$G(MMSSJONRF]*UW&79]R\=ISPK)>E\I7WG-ICMHED:-LDO* M:B5$I9$YLGFAM>UL7DX#)S8O>Q4B]MS6\.!1S&Q=V+J99SV0BP +"ZK\]V\R7B-'#: MLXB\YI>(5M<=]CE$538.?(E@J\)6Y01PXM#4/E:EW6J20XY-2MD(L$FIUX&O M]_9S7*IL!.HK '5A7B=N@C^8 FHG^&L9+)+ >74=+())F#(/$@F$B#:-\NBO MDX$J7PG'[;O;X.MXW+M+$A@*S7!LCBA@P>;H]*%B<[0O\3E/\B )#)LCQH+- M456@XL'(^\'7.[B.FZU1=<6*N#4ZB>Q"S>2C1I@PL1%)6%A4Z&'")H2D=\P7 MF9.!*E]-SA>9K:5_K2'G>4@BPQ4';(+8!)TP5!Q+VS.6UN9@&DE@^"94=S-T M8O)1(TPXF$82%A:5&K*$=[Q<O;E/\>I,XL2I@6_+1\*&Y?KCE.S-NZ'RVX MY[:\@R?(5[>A[51"EFQ>JJ6VV+R^U^^3 8^M2-@)L7=BZ,$Y[ M)L#8NA1;%Z %'S"C7]DXL'4YC3A]=0]\O;>?Z9?*1H %@-5]?;:;+Q&G@1/3 M@N])"]X;'%S(75V3PI<(MBIL5=BJ<&CJ$*LR[/*XNK)!8)/")H6OY65;"D: M!>#EM[\NM. G5$#M^&D:A]>KU+^>!4X:B;]8C,1'XF@V$YOHA(LTB(,DY:XI M"J@1[0SE)MZ3@8KY6?>\*PY:W,5+$AGFD2 ! U']QJ;H9*!B4[1O,LSU^ATV M1A2Q86-$ @:B&HZ-T1&^\'GN>W.@&T116@H\(60-4@GD7*HF7S4"!.F M-R()"XL*/4S8A)!TD/DNFS*2(+#IHP$#&S*JH,E/5.V)\,5F[('35F_ZP[;!Y>]L"EC4\891Q:- M6F%2F'%D6,J&A46%'B9L0O@65!5OC-XM:$_V>+X%[1/0Z_9+8Y@_,?O%MR V M8:7K/C9AE3!A',@[%A5'\V B#C9?U=6?;,.H8' R\E$C3#B21Q(6%A6RW/E; M'3G93E#M-@&BS;4O/K*&M[W@!LJW2Z(X;98],E1$H2I]& [#P :%#0KCQ :E M&E"Q02$! QL4-BB,TR.28 P54:C8H)" @:4ISV0BP +"ZK\]V M\[WA-'#:K/]FJ(A"5;H!81C8D+ A8;'@ -1I0\6&A 0,;$CJ=>KKO?T<@"H; M@?($0&ZUWNDB,%ZBTOE'I.06/QV'M]N:ND;B-8+8?FFOE;VUM2VYU_Z^3.LV M[,.[BO>9QOJ%EOY-<'X=!_ZWU/[OS[Y,SY\?'@5WTDFLOLNN=C_B2 M?_>=:1Q,?C[[VQ< \6LT^7HI_E(L+!&_% =ZD0-S'(RBV$_#:/%:2%80ST+Q MZ+,+_*P331S]V;__"!\51\*_4)OXM,W9[P389Y3R5P[6Y+W3Z':^+UR$0OHZ MFHUMG,-42-7H,>?F$4?BWD)_/FF?.*)C-0.$)E6C^ MK50D_CNW$:_]51K]I.XP0I'-_&42O-;_\9.C%&FSJ?RVEV^>V#%XX>4&^=37 MF:UB:A140B$6!+OWYK-4[(^#L])J-]@,8Z0W@MB&DMP& MX6 ?NWHH;O\._-AY)Y8U=MX&HV!^'<02RK;G\J0?Q<)4=5CJ(+OS?UP%7<.N5?^\-2]>%==9Q'%<_H6 NQ]7)0)'E?"D8H?Y!LVEK M;X,.'EG!;CB[X1Q\9[U84;W((7=ZL-#3BZSVJ*J]WD%C8>JM]BZG_N(F8,5' M#AAZBH\=0M:,-=*,W[-2)(<)/:5(('9+&!I:6K!_O%1^;6 ED:EB1_OC"P?2 + M#4L("1C8/O#IKR\,>XY 8/O $E)3&-@^\.FO+PR/MP_/FA5E;%A$J,' !H)/ M?WUAD.R#?($@" U+" D8V#[PZ:\O#!Q@(@L-2P@)&-@^\.FO+PP<8**+#8O( M:?2D5 F#JVB2WOEQ:7VL;*9I;3OK(!(P#37U\8. U$%QL6$1(PL('@TU]?&+C. MF"PT+"$D8&#[P*>_OC!P@(DL-"PA)&!@^\"GO[XP<(")+C8L(A4D-/;:C3YM M&#XMSI=Q, ^3P$F>6'7,S4'<^7#*,'Q'#@$N*#N[Z'?<[G! #IJZ"0=1'<6F M@4\_FX::FH;NP&U['CEHZB8<1'44FP8^_;4T#9P%.KOP>FYKT"<'3=V$@ZB. MJJ5I&!TRPO<9_5=04G7*.[0&!X_@97W$^HBWG4]_Y5Q5+F@]N^BTW%Z'7=6R M82"JH]@T\.FOI6G@*,;9A==U>[T..6CJ)AQ$=50M30-',0_HB0-QD\NF^1>!R[D9ABX0.8Y[@^>V^SWR$'#$D("!K8/?/KK"P/; MA[.+H>L-6^2080$A 0.;!S[]]86!TP_B^N .!@=G'UA JBT@M30/!V4?GM&% MK5OVH=4\./O ^HCU$6\[G_YJPL"%E&<7?;?C'4P4P )2;0%A\\"GO[XP<#0# MHAG]/D=C[]U82! M*RJ1/Z#7:9.#AB6$! QL'_CTUQ<&#F?(<,;!_ $L(-46D%J:!PYGG&Q))>LC M>B653$]Y. Q_Q-$D2)(P6O@S)PGBVW 4).3JC6MI)H)_5@L M'T<"X0=R"-32,#"?0[F@G+>9SZ%L#(B:ZEKJH_*WG4\_"1BXEO+LHNLV6P=/ M^68!J;: L'G@TU]?&#B.<7;1<;OM@XD#6$"J+2"U- \V MG7@!=$Y.;*@4@N_"1F]FR2*LL4FB2:? MAIWQ.0R7:F>&RJ,,96W&VHRQ8 >[#E#)HEEVL$_%P6:985-30RS8U)P^5!S+ M.:7D DL,&YK:8L%W?[K8/&Q&'@5/M8-H5*XM+$UUI;!M-1M=VC!\B5+@KM6% MULLX&J]&:>+XBS$SVM*1#1+;;JDRV%2^:Q+%*5_(=CA4U;YH>FVWU>Z1 X]O MGR1@8!/#)H9Q8A/S%.R&+;?;/CB8R1:FVB+$%H8M#..T9\*,+4PA=JVFVV_R M':9L&(B*4"TM#'/:E*R26LQI4S8&K(]XV]GC/36<\M7([/$68M?KN7UF<2P= M!J(BQ!:&+0SCQ#&5)UU@NFY_R!:F;!B(BE M+0S'5,H%I3WDF$K9&!#B"7Z^ M>E7B&+R-5S?.VS 91;=!?$^NQZN6MJ'\;6=-1 (&GJ1-%AJ6$!(PL'W@TU]? M&-@^D(6&)80$#&P?^/37%P8>44@6&I80$C"P?>#37U\8'F\?*I@)(HH-BP@) M&-A \.FO+PRR?I8O$ 2A80DA 0/;!S[]]86! TQDH6$)(0$#VP<^_?6%@0-, M=+%A$:D@.Z[7;O1IPX %QV-=<,R$N'3$@<2VLU8B 0-7EIU=M#IN=] A!PU+ M" D8V#[PZ:\O#&P?SBZ\KMOM<5=[V3 0E1"V#WSZZPL#)X;.+H9NTQN20X8% MA 0,M30/3'I2+BC= 9.>E(T!ZR/>=C[]Q&#@.M>S"V_@#IH#T# MG_[ZPL#AC+.+5VVWU6F3@Z9N$O(#.01J:1HXE%$N*.=>GV,998- B,#5KI_4 M;.QJCW.$[/AB2S\6FUFK.LN1^*LXO%ZE8;0HJQ39-AC$P.&S1%CP7)R&M@\;&P>!4^U,W?_ZV^#EM=B:2(* M3OG2Q%:' A9\"3I]J&19,U^"V"2=-#ALDA@+-DG5@(KCP?G$!'J:7D8%,+ M;T!\IST-+/.%C\\+9Z4OO:V.VQN6QJC)W@==V6.;1@<+MFDUP))M6B58HMFF MT94]MFETL&";5@,L\Z%@MFE/8+;VVDTV:12A89-&'(M2B*-LEJC#<*EVWJL[ M+(U,BM49JS/&@CUTQG*C8)T]]!,E\V8V1+95=<:";54-L.1H4B6(Q>MIJTIC M$6[6//F@.W>7AW#]NSZNI0MF=TL&![5FU[=EC:BNW99K/J MT!VT>VS.*&+#YHPX%@?EN(Z#2V&.:T]Z(GX[#VVWG]#^K) TG M][L/JM<2_[;?O]/H=K[/O\<97T22]$T [?\31 M>#5*$\=?C)VK(+X-1^*9GV7Q,NS(<[WUH2]9@/TCWOO3XGP9!_,P"9Q$;4'C M[Z H]2MNGJ.S"^?+-'#"Q2@._ 3^P]1V.^+[G&CSD):<-'*"OT*Q>8L;W/.%>+.1V,QH'L2.D/F[=.KB+\2:[.^'X? M^+'CQ^)=;X*YV-'$&:]B>%0JEHB_#,1.CYVWP2B87XLGMCW7:35;GB-6-(KF M(-QC6,,#?]_$)>SW[.;CGNT-&W__$;;\HGK'ZQ]1DHHW/M;1FN8?MW:LQBL\ M3?K3XN^68L.=21S-LR.F'J%/6.("6'?!; ;_:Y\]\>15/)KZB?4I\\7)ZCH9 MQ>$R#:.%> 2L3=B'T50OUPD3\9^CZ&8A-GGLQ#Z<]7L'*.&=5.QP=1$WBG3N MA\)?6?B+4=!P'L1])^Q)P3.+L4_7'E.DBQ)_)IXK?CE:Q6#94;+%7]V&T2I! M.4T:3M%K; &W!J *HS@)DD0<=G_F),HHKJ'ZR[:6MR*G9A/\<5 $/HCNLNC+ ME2K6._Z@6MFA@HN>\827*;0N^Z[S99?9W"Y$L/A9 .K-B2:.[R3B](:3<"3. MA9,&H^E"?,'-O88#,/I/,$H!/'QN.O53 6,B;+1X#?%3VWB+KQ#B(X0/-&N1 MA&HY6RTC. Q"*_NSG)Z&%0J)P\]/[/6 *,^C<3"#7ZTM+GEF^=SJO!\@FT_R MWO<[(KMT[D-B5WB>\^^_\RP7?G['2@NO02O&&QN.C3BKNVGYPD M4D"N@QN4"V?FIP%Z@KE3;LF,<(M7N')QW#?.]T@<@]A__@-.P:O =X6[0QB9 M _N@5FTXEP4?V_^F()3*@RX_' UU(";B_*"'$(2WXF_%O\0?BA7Z-W& EQ3G M+DRGSJ\"],3YE_CW2FA*U_GMMTM7>9'F8/S7:A'@\U\"VC+NW6]A6M);/2VI MNO?LM[FI4)D/];#GO0YGZ]B[OMO9^N7C%<2G9_YU M)&Z*H*+,SN?MQ.\"%UPB/,^UW2 ,D,S%VE(P$?F'B>,$]A&[(-0.*"YXF%%="O>B34:EY/P9B)OU$CP_7&BTBHUVO0O%TR>SU2A= M@763/D40AQ%^7/U7[MHV#> Z)K9F)2Y;<2HN7L["!^6(3E[.Y3.OI-]HKB]R ML(1Q !?_ *YLXO7AD\+NWL3^'&X9(;@T"3P$_C3;J2AF![' 02R^EQVF*U[6 M0WSY)6SS$ ^74TL"-UYOS\AA/FUDCN?F >1'S9WH<1]K//9K]O.QUK7MKFO884]\K/Y^^(GH[%BW MN<.>8LRA<'3@5(FU'?:@;;=']!O!Q0*+\A$" F-?72G? V3^ML/S\%<6.ND/ M?\SQP_EAGPS&AWZC\/E&HV 6@&849VC-)Q$NRUTDM@PG6O=_2IQIX,_2Z8&[ MLGXWMYUQ[VBNXX#6_?PR2M!3^6RQ=SWE_1ZVP6NF1!4:R%RQ+-7X^:QYY@C4 MH:!G)& W_U9E'OCOG,U[[:_2Z"=5Z(%.US()7NO_^,E1Q2!-L9JSPUCCCD/O M]V+#M(O+3\@5;=6>D13W>[@FSI=B5Z[C\*7KYGHOR$2ZO3>FV6@_@%&FLI^] MD&Y#+6^#<+"/5WHH;O\&_^==SO^14&*\C>E*B<%U1*[2\JW.2]6G[@\+VZ27 ML$DDH#"VB81I\GJ-SK&& =3&=E$0L1?B_><-+]9I!PG*LRH]PD@14WG=1KO# M*N^132\08+Q-&IC4*5WSL7]^PAJR-C)#=/S3*8WR8B#IS9QD,66;5AM@V*:Q M?U\'7+%62_KWWK!T75AG'<=Q]1,*YG)@"-GM MXPMQ98"AIPKY0LR:L4::D2_$]# A5-FT5=9DL1,7,96-@S1>=:U7(E$UJS@J M:F,R7H5 LAFM$G\Q3GX@)Q%= 6QZ*63X,/2R<8R3*1X(%@@0,; [X]-<7!C8'5)!@@2 ! YL# M/OWUA:&+22-&HGPD6"!(P,#F@$]_?6'8TQR\5*J3L6$1H08#&P@^_?6%05(' M,A+E(\$"00(&-@=\^NL+ X>/J"#! D$"!C8'?/KK"P.'C^ABPR)R&FTDC\+ M:S?ZM&&XBB;IG1\'SC*.QJM1FN (9STPFESY/-OO*G'S KWJF82 N#2URR-1--HBJJ%I:!HJ\6'7*0'3ZI?%:L3YB?<3;7OO3 M3\]3W;-PM=*>JM=V>YT>.6CJ)AQ$=12;!C[]M30-',005P:WW>V30Z9NLD%4 M1=72,G 0HUQ0VBT.8I2-02WX55O]1KM+&X=?XRA)'+EHT#G_[ZPL $&G2Q81$A 0,;"#[]]86!RUC/+@9-., MPV04W0;Q/;E2>[;7W.%07QBX?.SLHM-U!QYWJY<- U$)8?O I[^^,+!]0+;N M7NO@5!!+2+4EA.T#G_[ZPL#YH+,+;^AZ0[X_E T#40FII7U@3I.2&Z69TZ1T M#&JOCW!KAWIG%0B78@.NX[ NN\V'G@0,7,UZ=M%JN8-FAQPT+"$D8*BEFUK^ MMO/I)P$#AS'.+MJ\73A?IH$3+D9QX"?P'T*/)*D339PXN T6*[%2L00GV?DM MSG@5B_/GI.)1]X$?.X'8G+'S-A@%\^L@=MJ>Z[2:+<_Q$_'X^5(\:.RDT4-_ MWW3NQ ?\-(W#ZQ4B"!_2:TU@D?Y2+.BO<.ZGP>S>^:[;Z,HS(#9Z%D8+>)]E M$"?18A',SN-@)OYN[ 1_+8-%$KCKGVXUVAN?CJ-[?Y;>Z\^(-\5%3 5:8J&) M/Q/KF(F=FB4N;LG:(X6 .M;3HA0^I9XEP/D1T+F _MLA_+0(_@D07RY,]5\ MW)GRAH\^4ZU&[PEGRBLXD4\^4YWM9\H5;S!)@M2YOG=\9QPH##9?J]EHV4\1 MN(HOQ*]#TYSZX6(N_FM]D9>?_O7A[;DW;#SKH26H29T;BVWZ8;4J00X#*'CQ&["QT#BQ4-OXB#!?XMO$<[MS+^. M8C^%'ZR]._ZM/Q=J5ZQLMAKKC?CEXU7^@QN&H9?W#'99E"(3T':V&Y1'V(#< M8T9"#8P1HU4*+Z)M2O$*/'9LCBD?S^_(M/-H[^_#K#FQVX[)/L[*X2=U#]&V M[%I.]I*G.RN#M7NP/(BYB_#WN<-V'SX.XI_/FF?.2#@($'<09\3\6T4J M\-^YQ;SV5VGTD_ST.:*W3(+7^C]^ELB[[P\(V MZ25L$@DHC&WJ43!-7J_1:650P1X7VB6V7<1$[(7RF+SAQ3KM($%Y5J5'&"FC M\KHD5%ZWT>ZPRGMD\3&$JV^3!L;E2M=\[)^?L(:LCL'1=6&<=QW'U$PKF+/3T(JL]JFI/]GZSVGL,K)=3 M?W$3L.(C!PP]Q<<.(46D6!L>$X+[[7E+[!P7?KW^\-'UM MM!V)+!0KO*HIO I+S DH0G;[^!)<&6#HJ4*^!%-$BK4A7X)KI@A/8THW%RN] M/ XO/+N$Q*[3Y**HCR*$>,-5O>]WF-7Q'#@$>V7UV,6RZP\-G7;%P5%M' ML6G@T\^FH::FH==Q>\,N.6CJ)AQ$=12;!C[]M30-/ 'Q[*+5##Y$0M'M744FP:.7+Q0;HTC%VL%D=ZR[!IB52/Y M(TZ3%#]5PR4K/$(VWE*C:$U>)S)?N7?H -E>HVE_\ G#F$/00@M_MGT.\\;0 MV^839M<.=\XXWCI3-J\LS3'^[,[_SXYLER1._OOC.-@\G/9W_[ @?^:S3Y>BG^$D;-@I"8(OQ:Z/XAGH7BT$& 4%G$8]6?-M&M_8^+U09NSWPE8F\);(0U9 M,*;^-#2U/@A$UJ\,![%5[;)+Q)9:-):=V!)/:C>](;4U@0]$;$F/]J,\5B\/ZH;'JOR41_@HWF#M0BF]@R*W MQ>ZXL[8G3(4S,GJ,/_&(G;SR9^*CL!,?_?A;@#OT3K[O45RQK>Z6NI=**95M M\C^?-<^<43"##MB16(CYM[KMX[]SBWGMK]+H)]5D+^[D,W^9!*_U?_SDJ)A MLZD",Z0(307Q.2$/61F:(,@]Z1])]+%QEAY6.-TWA,27'+*9LTVH# M#-LT]N_K@"L6LTC_GL"XF3KK.(ZKGU PE^/J9*"@->"'AWL?%F,JW?2P&TY? M\7'PG?5BO?0BA]SIP4)/+[+:HZKV>,+9 57^/.^1)C#T%!\[A!218FW(\QY9 M$5;; ]QWWTMJ_Z#@^_6/EZ:OC;8CD85BA5%54.95'&B377G%CD>*Z9Y+UF].(\_X.' M6IO0?\OUN@?7N[%P5%M'L6G@T\^FH::FP>N[_6&7'#1U$PZB.HI- Y_^6IH& MGAIX=M%QVUVV#&6C0%1%L67@H8$O$[O@H8&E8T!4&%@'\>FOI7KJ[9VV M/+?=ZY"#IF["051'L6G@TU]+T\"!B[.+5VVWVSNXUXF%XT@P'%P9QE:A6E:A M?D&+LC' M6JCWN&$C(-CGI"-@=V[_]X;%IX0/UO5YA%I[3ET60*\ZTE>H_6H M,R/V )=W^>E?']Z>>T/7$:^9AOY,/"R:3)(@=:[OQ>T) MP;\&BR#VY::^&<_#19B(#Z;A;7#40<'[&78>(LQ#A$ET$K_X]F]SPWB(L'4Q MX2'"/$3XM.$BU"K,PP[8)ITP%",>(EP]9(@P;7Q. M2$/61F:(,OGP$.&* ,E#A"N +MLTTL"P36/_O@ZX\A!A*O+$5IZ? M1!08>HJ/'4**2+$VY/E)K BK[0'NN^\\1)BUW:.NO 2R4*SPJJ;P*BPQ)Z ( MV>WC2W!E@*&G"OD23!$IUH9\":Z9(N0APH;18Y(DFE4:\;?R>3:/#!2H]+KN,TFDVN7#0-1'<6F M@4\_FX::FH:.YPZ& W+0U$TXB.HH-@U\^FMI&G@DS]E%J^5ZWL%-A"PLC$@*@RL@_CTU](]Y6'"PCWMN\W.P;W<+!S5UE%L&OCT MU](T<.3B[,+KN(,N![7+AH&HCF+3P)&+EXE<=#ERL582R0.%7WZ@\,W6*D5R M-O'M[K.,A9_&8O==^)@,@M&.#-W%"5IXBS$JI/$ MC^]A<=>K<#96HW7#!8R6=7QGN;J>A2/YYHM[\?A)[(LM7(W251QLF5#.UJ)M?_W*DSOQ:GTOR&*G\6?WU=TN/&S MG-8CS3C.CPE>/Z_-_<\KO,_.A_7SA^:)1_BA4ULX$QDF>V=CD,6^B;^&_Q(H MKA]B84/F<(A'T/H^ 47?LC-6XV'M&Z6=/V-&] H3VMVVFT=D-5NZ9G MTI.2N7F-K>?9$>5H M"%B(^=0AQJ>+PH?IULU<$43VRBZN/4O[C>(XP#:[U3AY5$T)VU M'FN]$\*!EM;CN,3C8>7YET2!.7&]5V&1.0%-.#Q:VJHVJ/)$=)*PL!H\*61H MJ4%V"-DAK PPA#)46P5.):TX&54V$&BR:IIWHD2T4!NSP6. Z6!Q"F. "RW% M\ZBH*#4M1M89X/BA8-Y$O9C%/D2:H@^2:S8]N-GO5FQW[EN?T! MS_4J&X:#'2FX7I,G)I2- E45Q8:!#W\-#4,?XQ;U-@RO MNNY@<'"VG(6C3K>%2@L"6PD2,-"S$L@;4&\C,>RTR<%2-\&@JI_83)" H6;2 M0,],\&7B[*+M>KTN.61X)EXM9N+-HB0I3L_O/?\.)H1E<[C&JT#/%8L#L3TP M!4M_R?XCW1Q8V_;2@;VGG<7!,@X2_(A9#3PV<4*Y'-@D'#OFC/QD"JN3H\[D MJ*]1$-Z*3TSB:(Y__4<@=M;Y8^J+'70NHW@9P12V:.$Z42Q_Z3KS(+X12Q#/ M_^C?RU6(9_FCD1#;=-M;XV>/\];>\)AO#8O]/9Q?KQ)K);M&F>7KNLS!WQ2- MG"KXODP%[#6;ZH6FL7ZCI7\3G%^+W?MV[D_$"[WV9W?^?7+F_/@X#5CTEN5( M^]]]9QH'DY_/_O8%--K7:/+U4OPEG!+Q2Z@O*>8!?N?7./,"/! R$&I2H6AG2BHY-3NV0 MV!7^8@+S*@#)4XPJ@"YW1=,&YO]G[VV;&[>1O>^O@O).SNU4<121>IY)5)4S MV>S)ULEFK\R<>^N\2M$49#%#DUH^V./KTU\-D-2#+7MH63:;P/]-,K8EDNA_ M=_\ $$#CI//N20?TF2XDT&> ND ?;V& /IR=A(G(S1ER*.#')IR0"2$=!@&V M"XD"?MT7%T0#T3HNW:&^/0KX=4E6%/#CK0]6'^"=-U8?F#UV5E,>F.K(>LUR$=>&4]S$L\75;4:V$J3,?SGL$ATX%,B )^ M1W3_4,"/H2Q(@YU2AE<:1(<0'4)CA&'TANK!@$,!/R9"H(!?VPJ@@!^K>+![ M]1<*^+WZL3S;DZ"6ZB2HZ_(D*&['5*(*AU6'@^+@7)1GJE5Q761X[86P+#:X9"J!@(8-ET< /%!A/G,W=J3,8'KW7 MU,#@0/6^5ZS>%QQX1?^\NGW^IOZ"& MNA:@*C;VQJ5<(\BLD:I0Y\>+)L]9?G'0F]1?=.@WRTSFXN*6OE\7);S__:K> MG?KZH->OO_W<9KNS_6:_<8<]=].FK[9F_^'?#'O>YKM?:\ECY?J:.3_OPFF_ MJ(5HU&KQ2QPD5Q)ER@P^PJ6S_>#6-W)@]2S*E+6[JA-EREC(P&@;!E?*L$YT M0(YU2CPVSLP@!]."$& M$Y&;D[)0IHQ-."$30CH, FP7$F7*NB\NB :B=5RZ0WU[E"GKDJPH4\9;'ZP^ MP#MOK#XP;QX*!7N.FX=JO;,.1"'O=4@'9+VNR\IBTAU9#UFO0SKPRGJ8EWBZ MK*A*P528CN<]@T.F YD09_5C>3:G/X6;TY]X'<6':@-6'8"(TT%1 MAZ96Q77ZHPD[96R+#:XI"F" \P,,5H+!<[P1ZI.UK0+7% 4PP/DM! /J":CZ M9(X[&[.3QK;@0'FRMA4 )5C(P(\2*$\V=YWI9,I.&-M"@VN& BA8R&!9-/ # M!8839_/!9,1.%]0FLZ(VV4(&J?0S72LKW']'W[A$F9\)^KQ:@;A01;,:U17S M\SP-+XJR0).JM!6+Y%JF?A2I1XK">/^)4C^7AZIGK9,T7R91F#R_>A9+>4B) M9\K3?YH\5?VSN_+4S[$0],V8;ONH&.+"C_PXD(Z@%!*L=KZ=D1[A,@RHI=&M M?HRW2O:W^H&JHFNY;O?FJLE2K-,DD'*1B66:7%5W#?/0C\2ZN(AT#;FEU,8@ M,_TL+]+"3V^KQL<+_05ZKBBY>4L/?> K/Q:7Y"+Z"XX@0ZE+1[=[I=QV'ER0 M(8L@5S7=[KOH?I/,K^FF/?&3_T7\]4X94&T2%$A] 881B]H7HPX%#@C8D0*/#6M@(H\,8J'NQ>_84" M;RT4>--'0>7^%R'KHZ N=HZ"XG6X(6HW6'6D) Y;15&?6I6A>_1B#T2&X0D* M6(#S PM68F$PQ!G<;6O -4$!"W!^"[& T@QG\S&JO+4M =?\A H^+&2P+!KX M80*EWN;GW@R32FV+T(G7#$:' 1#!0@9^B,!(@D82 PPE[JP*0)&WEV_S3]NB M6LLBBI33%;XN7N6KBEBJ3%==RNM_>A][8BD7J@R;+IR5Y7ZN2L0M9:J+A_E? MA)]E,L^1B1LO3D M*S\7?BJI^4L*7EV9BOY/-U W5C6R/A1YV9^#'0QDOWN?'31:8LY:_7:?(EO*+/D]W? M>--!;T#J1)'V9KK4&W94J]K80ZT17C7,GZCH46Q0)(>E_(?,;*6/59$\_E]!?D-IGR,UU*;M=GZ?IK_U;[CHJ!(B_H@O0$8;(@__X?[6M^ M_9CJ_F_5_1]YX#MF)!>/PJLP+VL!3OO?J.O0?:L[ZL?8-I >P1>79+]8>[\. M'M4@?4U1750HEUNJBGS:S$\47B4*/Z6 5K]:2)(J6>NZ?]MP^ZHGN*/>Z(XC M]/I/<(/74:]YC*N('J\/=7]XA7A&%OAW$::E37[\^$%0IR,,Q&38=\2V-J"D M.%,+%.8OWY M5/HJ%"XH(')5JE'?X2"J2EZHQ*S*8"9*P35=*PC7597'KT>->J8''?60D_;$ MK_N-74@""I&DY@1]@4+QBAA'\?A9>3'].M8^IO].\:*=4OVB;*K4S:Z0EM4M M;H1K]5='U0'U52N***/901=J[M](E3=\, M)KML>.-YO=F=ADUZDX>RQK^4QP5JC\9BMX?Q2$SOKWC>0/KQF*[K7K8S1''[ M;M6@55JW:$U>_/:"7/#S6W])#7KG1S?^;78FOGO:*.%0*]M)6]_[8D5=M!_. M_O))9>H_DN4?'^B3JKM*?U1KZO?47"C9M1N^T[TY59N8KJ*_JP*F_N[WWZFO MTAC"GY^D]&DS%[A3%O59<&E3DUVSM_@<]5A&)<):4":/UN\-!;-'JG(ELZ/=JU,JRC/;6#TD-Z.5O1_5#WJX*^/'A^9+5/;; MB9^]3M=#DR>]#?].4/'\$ ]WMQD]GX*O>_-.]@4]] 7-Z NRZGX^(_">ZB?' M.L7_*?R4O)O&Y+_KT;(>;/]6S@\D.HD?/OSWQDKIUDK)QDIBX>>^)H?T@Y6>952SK.JA MZZ]F]4"_G"&[0Y9]UM=S^ZHQY9S G4M3IWUSVGI76KPGT6L7ZZ4<^&[ M1OFZ-:CS$!5*-1EE\F8ETVKRAF[X8VG1W^4Z2?.>^*\PRY,T#.A7]8/KQB;Y MIL'DZVHNF3ZCY_[N-%/;Y\J_54^OAFG:'3<64J^VEF&F+J][*8F:J+X5"?TQ MK2SQ[)5^=$!)0I/KK3+ZK__%>5"]S^_UJM4E;9[A3+]#S^!T=U,7%,*<1I-^;,3RV M7?=]VWWOOWM^QJ#/X?R,R;0W_4K] XYG,XU?LB/VB?KF4OQ*?UQEXJ^J=]#Z M.4VL3M5X4>-WX?RE"C@MGK_42 )CJ/*@$!HTKP80%D;G=O2?.VUP])\UZ+@W MBF07,I;#A(4&>_WCAD%CMB;(:IPE^RC7^6Y:ZR.M\0NA]C5 6D-:ZY)D?R]B MB8S&0@IDM(YH@HS&6;)?U4IQC#U9:(&4UA%-D-(X2X89-59R(*MU1!-D-L%:UA[SD4)SKC!PO/WJCBZ=_1YOB=;:M[)DL &]Z>?G=8,#ABDN2ZJAC3' M4A:DN4XI@S3'7#6D.9:R(,UU2AFD.>:J(I)D?GQ(CNZOCV6OS-CQ !N^T9ON7P]5"BAK(=[$*)U(1 .'%0 ">#ZEJH $C 1 M N' 0060 *YOJ0H@ 1,A$ X<5 )X/J6J@ 2,!$"X#ZEJH $C 1POIP MZ,@6P"=IX YZ$]8R?$R6^8V?2K%.DT41Y)GPXX7(9'H=!C)CM_,)H#9WNQD7 M%=ZP$Z AHW#ZH(*%5/"&CC=M[8 7 MA ;K! 4JP/5!!3NIT!]Y[)2Q+#28)BA0 :X/*MA(A;$S&&*L@ 0%*C QNF6N M#RHP%(7&"K/1A)TREH4&TP0%*L#U004;J> YTW%K11T1&JP3%*@ UP<5;*1" MWYGU,8.$! 4J,#&Z9:X/*C 4Q1LX4Q=OF]DEJ-:JA.SM'3FNCIY9>TQ^2HM+ ML0BS(+F6Z6U;&Z^>7=S0Z&CAL@6N2?5"N_,:"Z4FC4M-6MTWF#CC_KC=A,>L M_B079=J-*["(BQ)@4>>5 HL:J3=R1I.C)R_!(F/C"BSBH@18U'FEP**&+)H, MCIXR!8N,C2NPB(L28%'GE0*+FK)H>O0"<+#(V+@"B[@H 19U7BFPJ)%Z4Z<_ M&8%%#)4!BZ $6&2$4F!1LW6-SFR M0L0!9UR4 ,[,EQ(X M.U&E=<]QO=8JH@!G;",/...B!'!FOI3 V8EP-G#ZQY\U IP9&WG &1!' M5=8@8YS-S[__CBXP?^95W&^KRW#;'(J.2#N;J^U.DRQ4*/L95GK,,#9(#K6ZH"R$!CAGX?;Z#9 MA4=K)7?V-KJ\0D$Y]AMB?DJ+2[$(LR"YENFM$1M@3N,C*#G(>_,@*@IV0JG] M';K/$LOD?HKK.L/)T4/8$U$1!0/Y!19@Q$4)P*CS2@%&S6#D.:YW])LVP,C8 MP *,N"@!&'5>*<"H,8S& \"(H32 $90 C(Q0"C!J!J.^TQ\=?0H.8&1L8 %& M7)0 C#JO%\$0V[_CU\&"1L7$%%G%1 BSJO%)@4<,SX-S9T>LLP2)CXPHL MXJ($6-1YI<"BQJ?.88Z.HS)@$90 BXQ0"BQJ."X:#:=@$4-E&!5D>NU-:=ZD M-QBQ%N=3DON1")(L%\E2I/):QH7,VMK'B8X#^ZW.3>HUHF?1"2D;UG1$U^-K M:U5FSK0_:S=GHN_!,/* ,RY* &?F2PF0S68><,90&N ,2@!G=D@)G)WLV!9O IQQE 8X@Q+ MF1U2 F7\MTSP,_*C*%V2&L_GY]]_1!>;/ MO(K[;749;AM#T05I9V.UW0F2A0IE#\/J#H0W70,;\6%T? -<'U+50 :YI[K]-L[<1WQP3H^@ :XOJ4J T*#/1A)TRB \.*@ -<'U+50 :5&FY2;_/3AGKX\/$LCOL=[]\ M]".ZOMKZ0H_]6:H:/$9L?,'>6^P,A KH.YQ8F9$SFQR][P7A871X@ QP?4M5 M !F(#*/1F)TP" \.*H ,<'U+50 9B R#Z='3C0@/H\,#9(#K6ZH"R$!D\ 9' M+U]#>!@='B #7-]2%4"&^= 9XSU#VR(P#0^0 :YOJ0H@PWS@S,88,R \0 8F M1H?KK95[V=O=4I=* MJFR\5RU)MVSMIV1,HW?!_$W&,O4CO0_&7UR%<9C1%_/P6AJQ&>8T_J+[$*_@ M+5T+8RZ[!Q^3!@7JV"BU7Z#N66*9W&=Q)\[D^ 75)R)D\WR'P *,;%,",.J\ M4H!1\X/FAH 10VD (R@!&!FA%#$8C9SIJ[?PBP(AM8 %&7)0 C#JO% M]#"]P?'O%@$C8P,+,.*B!>:4 HZ8P&DU;*S *&+$-+,"(BQ* 4>>5 HP: MJ3=S)AX&1AR5 8N@!%ADA%)@44,6C4<[ :^T(2^",;>0!9UR4 ,[,EQ(X.Q'. M^DX?DXTLI0'.H 1P9H>4P-F)*L^,G!%PQE(:X Q* &=V2 F(8C#!;C0ZC4.%T#'H]M2HN-Q&GG/ M/<\9N4?W/'! P0MJ\RU0UKX(3/,?4&:,E$#9B5 V&#KC"O3.=J ,* /*@#)("92U+>^YZSK3_M&[VH&R MUT)9:X4"'\ZFY:9 8\W_6[Z2J3BOR@!^*\(X2*[D.W8;HG67PU@5F.Y";]*5 ML"E7,96I83?!ZBX 4^DHPA! K:L N ND EP,4PZP(6#"H +X *9 !?#I -< M.*@ N ND EP,4PZP(6#"H +X *9 !?#I -<.*@ N ND EP,4PZP(6#"H + MX *9 !?#I -<.*@ N ND EP,4PZZ^'26OFQAR5Y]N8C=]";L);A7)4:^U9< M^F$LDEC(?Q=A?BO"^%IF^14]+;L]F:!_.WN:[>Z_&3!@'" M006P :YOJ0I@ ]C 10:6 0(VP/4M50%L !NXR, R0, &N+ZE*H -\W/7F4Q= M=LI8%A^M':D**G RNF5>SU0%4&%^/IRRD\6RX 2D(SL\WJF*@ )F$3B(@/+ M $;X/J6J@ VS(>..QJS$P;AP4$%D &N;ZD*( -QD.-E^DY?; F3^?I,/ M*S^^E"*,Q=(/4V7S0K+;B@5@8_^;I2H V//SB3/SCBY6A_AH^>4/J&!2/K+, MZYFJ "K,S\?>T;6X$1U@0A?MS30;6>;U3%4 $^;G0V?F'KU,#/$!*G31WDSS MD65>SU0%4&'N#9VI-V2G#.*#@PI US?4A6 AOG0F8SP9@'A 3(P,3I8,!.&<0'!Q6 !KB^I2H #?.I,QC-V F#\."@ L@ U[=4!9!A?CYP M^A.@@=/[Y]:*F.SM(*D+ %7FW:L!I!NU]E.RH]$[37Z)O\32&1L5(%$7)0 B3JO%$C4;$PTP>P< M1UU (B@!$AFA%$C42+WQ[.CM72"1'=6$7GOCES?I#4:LQ?F4Y'XDDGPETY-M M_CJ-2N@\,-Y0O)/JE$T/P@B]BTY(N=^[>%DU3>Y^Z%)(1Z_>/Q'9T -A=>HY M2,8^_8%DQD@)DIWJJ)3AT>M!YIQ5 8T@Q*@ MF1U2@F8G*T-P58 )8NVIMIQ@)8.B$3P-)H-[8SZ[=VW#/ K @ M8P$LW9()8&FR/7K8VH&9H JH@G0%JG1+)E"E 553#,6 MP-()F0"6KTLW<+P1L(+X 5N8&!ULZ81,8$NCDP+[?8^==);!!6,6)"QPI2LR M@2M-)L.&CGO\[B. A=-&HQ/M!7NUXF.\-?EEL\M(5&7'Q/F%C.4RS'$X, -] MF&Z+1=72KBB%JJ7-CO:=#+$YF:$N.&L#2H!$1B@%$C6Q<]0%)((2()$12H%$34^X XD8ZH(71 Q$8)K: *&N* 4(-7M!A'DYCK)@ M- 0E "(CE *(&JDW._HL"H#H58/*Q,)20[?7'['6X1\R%^?13G4I=GL@L;<; M>[LA4Y,^ /9V/U1):H*"'VW+@$-#D+$ EJ[(!+ TK22%HPX!%H"E?:,#+)V0 M"6!I6$EJ@M.H !: I7VC RR=D E@:0"6D8?ZA* *J-*^T4&53L@$JC2K)#6: MCMEI![ +/9E+("E$S(!+(TJ20$K;8O -'[ %K %,H$M1P]:ADY_#+A@S *N MM&]T<*43,H$KS2I)>1,L"N,$%FLJ275CNY':;23\/$_#BR+W+R(I\D3)97"S MZ6\!_25-HHA<1(1Q+E.9Y=B'W;XT3'?W8A]V5Y3"/NQF':.CRS9C'S;'$3@8 M9'QF X.ZHA08A,I9W94%#&(@ M/,!@9U12DPJ.'F+N_HUXZ@$"@$"H%"4 H4 M>NY(:(:Q$$=A0"$&(C#-;:!05Y0"A1I2:(@ZPAR% 848B, TMX%"75$*%&IX M*L;Q&P% (5 (% *%H!0H]$P*35Q0B*,PH! #$9CF-E"H*TJ!0DUGY% \F*,P MI]G0]MSMA8]M:%LDA=K+Y?5."*71L#=A+@&$=M0#$&(H!BQD@)BIE*L8$S'1U]GC,89FSZ!,BX* &0 60 68/7 M8LY@U ?)&$J#T1@#$0 Q8Z0$Q(R%F$OCL>-/E0;%7GG?YG=Z_QS]=A%>']]N MM__-?K._V6GF=)WO96^Z"]VLOD\9!^HJI>'+_7RE>C^<]<]$(*-(Z4-*;WZN ME-<_U[Y4ZDVVCOQU)M_5_W@O*I_H]ZMBNO>VJE*+-I"C02MO,4O\J2YN)',39_'OZ,:Z;U3PL%S)(4C\/D[B\X7_>RW>Z%6VTZ-RE;*!:-7]$ M=%.]?4_.!T0Y*"!]M3+:[A7V\_OAS^SK>O<;O\1!5"SHH?7>WK<7?B87(DBN MUC+.].V%GPG*K6'@Y_27,!;Y2HHR549)^\?SO8[ MX@92503=E=?U#NI[*.$W4^#48'/[@PHLJ[1NT=J_E&\O4NE_?NLOJ4'O_.C& MO\W.Q'=/P]R#6',;N=T)6_F]+U:I7/YP]I=/2L4_DN4?'^B3] '9>^Z[OD MVS*-0NW ^KLB68KZNQM/\>=/WC=_O N@0\ [19ZL0_ (6IZ6E_XLLCQ+AO6IG](HD6NT8/<[I=\)0X?T((_RZO95S([-U)(NVQ:'I. MY)2W?J<=[AE1]-7!WHD.Z7E.2?,'N?><\5Z+)&SWQ"N<$O<5)>CA%&Q_.!M0 MM#$XB&S:FXZ;G43V6F&SFY6?)>6QNGVB/I84O](?5YGX*SW>HO4SR%YCCHJ' M\>\'S=''B[W<.8LE;UXA(%BGLO:%T)RQE!\>!WQ,F[TSL08=/\E 7EW(M)1N MX#KL0L9RF+#08*][W#!HS-8$68VS9!_E.M]-:WVD-7XAU+X&2&M(:UV2[.]% M+ 62&HV#"@:E-[,U03+C+!FFU_AHP6B)(-?UYZR7 ML&$Q.AU@P.&*2Y+JJ&-,=2%J2Y3BF# M-,=<-:0YEK(@S75*&:0YYJHAS;&4!6FN4\H@S3%7C=+:J(\A#" MYE,/69V::PTUSG6YB:3(_'B1'5T)#ZO?F:'BY0KB'4*%03EJ[Q!_5D7L+&1# M^T:W//^PT*"LWOB4PHNF09JI, B.]C5X&2K Y'![UAJ "4R%07"TKP&8 +>W M4 ,P@:DP"([V-0 3X/86:@ F,!4&P=&^!F "W-Y"#< $IL(@.-K7 $R VUNH M 9C 5!@$1_L:'& " @&!8)\&H 1381 <[6N D0/'!W996C0 M%H:/R3*_\5/);A,5=HY@YQIG!+S<9DZPF:PLU !.8"F-Y M<)A8=&3N#"@Q%H;'"N-]GIXQEH6%']1'V>TC^*\ERN7CV_I&.[?/D8GV[ M-[-!!:#Z<64&3G\Z92<,PH.#"B #7-]2%4"&N>>,IT>_[T%X&!T>( -( ,3H\/U.:@ ,B@RN$?O0T=X&!T>( -$!,L#U+54!9" R#/LN.V$0'AQ4 !G@^I:J #(0&=P)RE@A/$ & M)D:'ZW-0 6109,"1DVV+P#0\0 :XOJ4J@ SS@3,=8C8)X0$R,#$Z7)^#"B # MD6$TP&P2P@-D8&)TN#X'%4 &1881Q@P(#Y"!B='A^AQ4 !GTF&'"3ACKPZ.U M(B9[.TK$19(N9%K;.$NB<"'*#PK=LK6?DC&-WGGRSS19RBP+D]B/1";3ZS"0 M65N[LG:(_0K:="UHN.R/>TR:VFYVIS<62I7T/XE8AO<0QK-V$]Y78FHWW2&N MP"+;E "+.J\46-2LYJ8SGH%%')4!BZ $6&2$4F!10Q9-O-;* (!%;.,*+.*B M!%C4>:7 HH9'Q7E3L(BC,F 1E "+C% *+&K*HN-/NP&+C(TKL(B+$F!1YY4" MBQK.T4VG1Z]N!(N,C2NPB(L28%'GE0*+&HZ+9H/6"OV 16SC"BSBH@18U'FE MP**&+!H-P2*.RMA1;\@=]":L9?A=7LNXD&*9)E[X9-ZR9ME]Y)VK,(H %R9& M!UPZ(1/@T@ N8V%'F8Q-BNW;XP3#*; (8Z+.J@(.00EPR BEP"%PJ+.J@$-0 APR0BEP"!SJK"K@$)0 MAXQ0"AS".Z).*P,600FPR BEP"*,B3JKBAVEMKQ^C_?NKD])[DAT&=,^TK#S&;C\HMKECFSMD:M(-PC9W5-SBJ@+3 M )< !?(!+@ 1=4W&I=!:8!!+@ +I )<#D: M+JBXQ4 %I@$$N ND EP><;(!16W6E>!:0 !+H +9 )?;V*]X:_)06 MEV(19D%R+=-;=MM+ ?IV=E_;G898J%!R'$*T+@3"@8,*( %X0'R,#$Z'!]#BJ #/.ITY_@/0/" V1@8G2X/@<50(:YY\P&8W;"(#PXJ R MP/4M50%D(#*X,[QG0'B #$R,#M?GH +(0&08C$$&=N'16@V1O4TE=?V=RL9[ M)7ATR]9^2L:T:?-)0)]*PXLB#Y.XK>U9.]Q^!86Z%CI<-LH])@TJC;%1:K_2 MV+/$,KF?X+I'UT@^$9*:)SM$%4ADFQ(@4>>5 HD:J?<6'&*H"C@$)< A(Y0" MA\"ASJH"#D$)<,@(I< A<*BSJH!#4 (<,D(I< @,4 H< H:<5$"-#-?2M#,@'IDH!G; MP /-N"@!FIDO)6AF0 TUT(QMX(%F7)0 S.$ M-+FW,1P[[O%;*%[J((('DZ5-0.=,12,91&I , M2H!D(!E(UI1DD^D0)&,H#4@&)4 RD PD:Z3LP'-<[^A-@""9L?D3)..B!$@& MDH%D7R?9P.D??S@+2&9L_@3)N"@!DH%D(-G79Q='SF2&,1E':3I.,I.C!F@S M1DJ@S=0@]6B0=OQ.0*#-V/R)01H7)4 RD PD^SK)U+)\+ %I(HW;>OZL=@%^ ME_MD'?KM(KQNWOCIG<8/>Z/!-_NM_V:O#1=)M-AM09B36P2[!NE_Q2)/:.Q/ MJW4\2]E!+MH^Y:TZZ;&4Y;YIU?Y,G[RG/):R)_GB\J[^_0T9_QV;S8\FF G^07T5YF> M(OM]-8SN^)BD.M"34+-)B '%&H-.QK0W'3>K+_Q:0=.Z M;C]F(EFVWE]XC7X #WLS.@O@X2%5"9A7B $NW6:F8UL-%FM2T>,(\3@09-IL MF&J-9#_)0%Y=R+24;N Z[$+(0YSI)A)HZ7'DATG54)B8ZS9)B)8R,%ZLWT%T9\V[P0FM=4.(^'+$ASG5(&:8ZY M:DAS+&5!FNN4,DASS%5#FF,I2\?3G.G3!TAKS.,':8VE+!U/:P8'#-)<%U6C M-,>N%B?2'-)51^.:]_G33$186C"_.\ MF !E81ZK:^I,1\[P^!+>" VC$Q2H -<'%2RDPF3L#-PI.V4L"PVF"0I4@.N# M"C928>J,O#$[92P+#:8)"E2 ZX,*=E+!=4?LE+$L-)@F*% !K@\J6$B%Z=@9 MC2?LE+$L-)@F*% !K@\J6$@%SW7&HQD[92P+#:8)"E2 ZX,*-E)AY+@NQ@I( M4* "$Z-;YOJ@ D-1O($S'>"]PAT5W-835+5[Y+OPQ[H^$W^P;Y9J]9>BO-3J/"G.X6[-JH_Q4C/:']?TN3+!._ZN=[ MI\SP))T/M6+[B+O6I><7 M>?*^VBU+3A3YZTR^J__Q7E1.W.]74$4!C+W=6H]NP-KW+3:]@-:/+# (.AW: M3(I#"G9T^[1*I12_TA]7F?@K/=ZB]2,+L,,41Q&P2V7M"V'A>)[S$3?*Q':C M \7E6]F W+TKDHP9DY6)3^7E?.<[$, MW9+.,@I_(GV9I1K25_M!TD;ZLL;!D9:ZJ!J+M(1ZQ$A?+"V.],5<-:0OEK*P M25\8/"+-&: :I;E^ZVD.Z0OIBZ4R2%_,54/Z:C](,'A$6D):XI>6,'A$^F)I M<:0OYJHA?;&4Y81+\E[NV.5#Y_<9M,+K8[+,;\CQQ#I-%D609\*/%R*3Z748 MR.S)!P]WI^&E\Y7_%9?ZM.7RX=F=_&WAR87M&]UML([=IE(%3&6:--MQ8'5! M@\F4G6R6U?GXAIT 8 J8 IG E*.9,F G&Y@"IMB7K,"43L@$IC1@"DIQ@BE@ M2OM&!U,Z(1.8@KDO_@J *4A68$I79 )3,$[AKP"8@F0%IG1%)C#EZ])-C]Z; M"Z: *5VT-]-D!:9T0B8PI0%3/':R@2E@BGW)"DSIA$Q@2@.F8-T7)Z94^Z6^ MR_V+2-)O%^'U0Z[X9Y'EX?+V<6>=S^5^SSE+U*>1)\?ON??B87XD-RM99QYN=A$K][\C:E0RW:/NYNAJ++5D;5 M-JZRPP]G_3,1R$CM^PS(*S<_5UZJ?]Y[F'=^D2?OJ]Q"OA3YZTR^J__Q7E2^ MW.]7>,:I]'M[%1_=?KCO9VQ U?KI-@9EO3Z:]Z1@[K_=T^[1* MI12_TA]7F?@K/=ZB]7W8V%_= EP>[KT=VE_](@'!.I6U+X2%,P."H0:+KG&2JFK- >N,8..UK@%X; MDEF7)/M5%7+^7@E4-W;W5A^HT1=IN".M^N3$9)A!HZ5',AJ'=$$68VS9)B!XZ6'06G-X*A!HNN<9)B!XZ""0>G-;$V0 MS#A+AAFXCL_ M;;TD.NZ=M9+X[#(G8L2G+&$)>[O=7&QHP_O.-FB=A07,RRM M&1PP2'-=5 UICJ4L2'.=4@9ICKEJ2',L94&:ZY0R2'/,54.:8RD+TERGE$&: M8ZX:I;D^TAP[69#F.J4,TAQSU9#F6,J"--3YBH4%9<.'VK#4 $Y@*@^!H7X,#3$ @(!#LTP"48"H,@J-]#3!R@-M; MJ &8P%08!$?[&H )<'L+-0 3F J#X&A? S !;F^A!F "4V$0'.UK@#<,#$1 M(+2O 2C!5!@$1_L:8.0 M[=0 S"!J3"6!T=']B$^28%Q;SHZ* *7?0T?DBP7 MR5*D\EK&A"/8@F;?QLK[P+5'@RJ2$$PL$&%4 "N+ZE*H $3(1 .'!0 M 22 ZUNJ DC 1 B$ P<50 *XOJ4J@ 1,A$ X<% !)(#K6ZH"2,!$"(0#!Q5 M KB^I2J !$R$0#AP4 $D@.M;J@)(P$0(A ,'%4 "N+ZE*H $3(2P/AQ,+!_B M#GH3UC)\3);YC9]*L4Z311'DF?#CA5+%W":7GE?^5V0RO0X#F;';[O7<+@G[ MO45V;[/CHL(;=@(\?0-JJFYUBOVG7$093&?L9+$L+IAF)PQ4X?I @HU(F(W9 MR6)97##-3D "7!](L!$)4X^=+);%!=/L!"3 ]8$$"Y'@>9@X0G8"$I@8W3+7 M!Q(8BN*.,$I =@(2F!C=,M<'$AB*XHXQ2D!V A*8&-TRUP<2&(KB>D-VLE@6 M%TRS$Y UP<2+$3"=,1.%C[VCEX7C. P.CC !;B^I2J "_/Q\>]X$!Q&!P>X ->W5 5P83X93-G) M@N#@H *X ->W5 5P83[TP 4$![C Q.AP?0XJ@ MS;X+W"P@.<(&)T>'Z'%0 M%^;>H,].%@0'!Q7 !;B^I2J "W-WZK*3!<'!005P :YOJ0K@PMP=X_T"N^ P ML>(*^[H7O\M,^FFP4H56Q$)>RRA97]%3LMMM!6!CBYNE*@#8<\]Q1Q-VPB \ M.*@ ,L#U+54!9%!D./[E#\+#Z/ &>#ZEJH ,LQ=9^;AU!B$!\C Q.AP?0XJ M@ Q$!N_X#28(#Z/# V2 ZUNJ L@PGXX'[&1!<'!0 5R ZUNJ K@PG^+M<]L2 M, T.< &N;ZD*X,)\ZJ&>(8(#7&!B=+@^!Q7 A?FHC_<+[(+#Q'HE[#>8?/0C MNK[:74*/_5GF9 =V6Z_ :NQWLU0%L'H^&."0 0'N,#$Z'!]#BJ "_/!!(>* M(3C !29&A^MS4 %XP,3H<'T. M*H +(]PL(#G"!B='A^AQ4 !?F[OCHTTD0'$8'![@ U[=4!7!A[KHH8&!VNST$%<&$^._IH$L0&NRTES]WEL[=_1%PDZ4*FM8VS) H7HOR@T"U; M^RD9T^A])G^3L4S]2.\T\1=781QF],4\O)9M;<3:8?8K"-2UR.&R)>XQ:6J[ MV9WC6"A5\O\D8IG<1Q@XLU%K)Y@UBJG==(>X HML4P(LZKQ28%$C]89.?]K: MJ6E@$=NX HNX* $6=5XIL*CAN&CQ;(QJ/62I4 M9&S3Y[-!9G+0@&S&2 FRF1JD$Z??WB&9(!O;](DA&A&G&5AJ0#60#V1J<.S;QCCX#$V0S-GUBB,9%"8 ,( /(&FS.GTQ:*YW=*9"Y MK:?/:DOD=[E/UJ'?+L+KA_PTH.;(=+?QKK<^Y+A[S?_FZPTL3=&O;7%*3^P/ MJXV%J[1NT=J_E&\O4NE_?NLOJ4'O_.C&O\W.Q'=/4_U0*^^TY)54_=X7JU0N M?SC[RR>EXA_)\H\/]$EZL(S^2)X=[ZFYD$&2ZMV'[RCN9!J%=.FSN?ZN2):B M_N[WWZFODD_X\R?OSCS>!7:=M.5;[OC^GT66A\O;Q[/T]$XN&/9&PV\./E;L>M&F55G26J1+S#V?],Q'( M*%*IEY+XYNN?]Q[OG5_DR?LJK5-*C?QU)M_5_W@OJM3?[U=%F'GM\VYX M ,F#"?;]%ZW_HU^LP\C,_H$)&'9Q]*WKQ"0+!.9>T+H3EC M*3\\#OB8-IO!L08=/\E 7EW(M)1NX#KL0L9RF+#08*][W#!HS-8$68VS9!_E M.M]-:WVD-7XAU+X&QZ0U@Z,&B:YSDOV]B*5 >N,8..UK@%X;DEF7)/O53X.5 MP!B48^2TKP&R&;)9ER2K9]:0T-I6 @FM(YH@H7&6#)-JO/0P**T9'#5(=)V3 M#)-J'%0P*+V9K0F2&6?),*G&0@9&JP2Y+D%GO8H-Z]&Y*,$9-UB-KDXIZ!]? M[O)DZ\\YE;OD(4O'TYK! 8,TUT75D.98RH(TUREED.:8JX8TQU(6I+E.*8,T MQUPUI#F6LB#-=4H9I#GFJE&:ZR/-L9,%::Y3RB#-,5<-:8ZE+$ASG5(&:8ZY M:DAS+&5!FNN4,DASS%5#FF,I"Z,EC0^O,<7!ASR$L/G@0U8'YUI#C?,P%ODJ M*3(_7F3?L@L(K'X_#A4??OZY__.'UT*%03GJWNG^QX3#BUG?0CZT;W3+PLU !.8 M"H/@:%\#O&%@( ("H7T-0 FFPB XVM< (P>XO84:@ E,A;$\.#JR]_!)"HQ[ MT]%!$;CL:_B09+E(EB*5US(N9';TOA+L.S1IL^W M5 60@(D0" <.*H $<'U+50 )F B!<."@ D@ U[=4!9" B1 (!PXJ@ 1P?4M5 M F8"&%].)A8,L0=]":L9?B8+/,;/Y5BG2:+(L@SX<<+I8JY32X]K_ROR&1Z M'08R8[?=Z[E=$O9[B^S>9L=%A3?L!'CZ!M14W>H4^T^YB#)VV:EB65@P34X8 MI\+U000+B3 :LU/%LK!@FIQ !+@^B& A$<93=JI8%A9,DQ.( -<'$2PDPA1C M!"0G$(&)T2US?1"!H2CC"3M5+ L+ILD)1(#K@P@V$L%CIXIE8<$T.8$(<'T0 MP4(B#/$> *_)06EV(19D%R+=-; M=AO& &CLTK-4!5!Z/CUZ)@^Q871L/%[=V+@X8*H"8H&#"N#$W.T?O2P,P6%T M< 4'%1 +'!0 :"8N\>O%D-P&!T< 4'%1 +'%0 *.;> %-/" Z\D6!B=+@^ M!Q7 A;GG8:8)P8$!!%<5$ L<5 HYIY[] HS!(?1P0%0<% !LZ.@ K@P]SR\ M7T!P@ M,C [7YZ "N(#WSNU+P#0XP 6XOJ4J@ MSK]]G)PN"@X,*X ) :6P "W!]2U4 %N:#(3M5K(^-UHJ4[&T<$1=)NI!I;>,L MB<*%*#\H=,O6?DK&-'J#R=]D+%,_TEM,_,55&(<9?3$/KV5;.[!VF/T* G4M M/-D:5/$M9L\7Y=D4 (8 \: L6SE] M%_.,')4!R* $0 :0 60-QV.MU=D!QM@F3[PN8RL-N :N@6L-N-9:65%PC6WR MQ/",BQ+ &# &C'T=8Y.CM^-;A3&W]>19;8+\+O?).O3;17C=O/'3.XT?]D;# M;_9;_\U>&RZ2:+';@C GMPAV#=+_BD6>T-C_4_AI+M/H5OPNKV5<2/&)!%]D M=_<6[@3BGT66A\O;QT-1!=-N&\M6/Z$-IU;UM_CM.I57829%EBSS&_)KD59- M#C.1%1=_RH"CJZKMY>$4!J3X9D"V3*_H6 M&5W>^%%&5Z-+''A6/Z5F7LHK,F;FZ$]13-)M=MJ0RB"YC,FZ"T%/[8N,;D+1 MO$[".!=AK&XK>^*_DBRG3]PSPF5*MK]*Z#?T=W^A'EE]AQYW+=,P6634%IG1 M[>7"$7XFY)>0_(":4;N;-,3 M'^N[7OED;AG[<2#W6Q+YZE9TJ4/REI?7M1VC++G3]-17CW%;F4 YD$ROZN82 M%E3\*B5\TE![2$]\6LE4DDFEL]$@$_2\"UG_0$W8>)^^N[/]67Y94TR131WU MG8UOTE?\VD97_BT%5RXNJ'575W(14NOH$>FF$<51:=.Z^4K:K2/UQ&]%JL19 MRDS=PX^VXNQZN5!VR6_78:!CC[Z@(O3MA78GLI2CKEDW%UN"CH!IN6Q5(N2CLG\66BC%9=ES+ 6GE#3_R4%I=B$6:!,O?MMA';.RS3 MY*JV ^E9_6MS7]54\J:0OJ@:HH0BOP_"91@(@ESD$W3U!FY!F4_2@\7*^"13 M5"RTC(MKY3WU=__SUX^[7[N6&W-IF4F)/Y-4)2OZ+*4B:FNJF+U_J]*:54!O M&Y?E_B4%U*_U!-M%V$4D4>3=Y>9_0ZD MMLE8998@H+ZH3ILW(?%4N7+]Y^I+^OIK&FP$MQI!-S**U/\?>HXB5@] OWLH MZDJ^J\A8J,2Y4 Y]H3.^>J#2J=6%?!7YT6Y0]\0]RUSXD0X"L?*OY<&$M,_^ M*NEFJW"99R51-*_H^;YL$YJ.W:K?$!=7%V15C3.RH+K(W;;7T*@_5*=2B\/];FI!5?M5/:FKH*TI_ MI2]UJ^]FV[+O8YDW2G>=A-7U/4,:*B;;UQR)RI*I]OT MB'>>Q*G30$#]2N6Y:7+K1WE(SZAN0?Y:=K J1*[N]('W\U*Q)L"KJ*"DI3I_ M"N=9EJA35W;"_5#O]$[7K.[S[?3+/I1PCBB![1F/KJ9Z4Q1_,:6'91'IMI;A MJ/*%NEQ"]O-UE[OL^VZ:L]COL5P4U/.GJ+4G''_;6.:OY>$PQL;DIJ'5*3C9 MSNAT&T6+K=,\.>;H"S3\C67TMG;?S:W"^#J)KNN^/8V34V*Z^LZ"8B)*UB5+ MMD,9LN1GJ9[6J9_R0/5ZQ2/JIJM8+3GTX???=!COCYG(S=6X*E7#A3O^7O5" MR^ZP[J?NC'%V&A?H@%-7JB)))2<-ZZKO7PY3=2R3056 WN2KJB6Q?[G!HKK$ M)L@VS[MSWY+"*;4N%A>W^J*;(55IY JL54>E4>L><>9 *9ONA:ZW/C19>BAT M'W/=.UY^RE66_5'5H%5:MVA--GY[03;\_-9?4H/>^=&-?YN=B>^>-M=XJ)7M MQ.OWOEC1$/6'L[]\4CVQ/Y+E'Q\2-3V09_3'C%QB3TT:G5>=U'?EL)Y<3!W] MI7MQY"?U=[__3GUU_OUW_OS)AX =[P*[4Z,OE%7;P,B>#*W#K):6Q4,16=4< MBSBOL/JM^"6F,< 6KY4;FD;9LM&R;G18-OI1JE;C8CWLJJ=\*6*7?IBJ]SIJ M@M4/XY*+$7%(WL.;_'>A9G$(LC2B*R=AB%__"*\(-8[X-4G7-(9VQ,=54GP* M]75^IPNHD;"^8#W )'*L$V)PS97JLEGN?]8CPK#.B6E9 D[LLEINIA?ZU >D8@Z2<0QB&@&$3L X4:! M]U0_.=8I/LI+W;?^)58?+6?I3DV50:]=J*BI^F421KW)NI58B:(N 2+GV0@]2S@P'6$U_?*__;+H9/7=V<]\5%*\8\D ME\(=J82O(. 7B["FE%JL4;[&"-5;JE"]?\GI%R5RU#W5@H&\?#.S^SBIO/13 M_89"7;)ZX!/,,GC,E*J]L9R@42^JPEQ-T%#Z"=7HET9TI$01Z''X9BA)QM(= M!C)=D:JQK)[%+H=^@5S7<])/'#>K'QN.G37*_Z?WL2?^]N./_ZSGJ7KUY,B] M)]3SWGN_T*\VMU/B82J#G+HQ=U^%EE-;:L"L?U,Y0H^B5XV3;T6@QL#Z[5PF M[]^11M9)4/=[]/O:RI&V\^2;,7OY@NO^O?:O6KXYDWIVFCILNJV.'M-'FTF% MS92EMA*% 5DPR+=J).FE'X?_MYP4Z#T[^;#SZ0^2+*A>^>J)"@KV4@PUY[@G M2/G6Y:Z]-U,K.U_?=G.KKJ]^\[,CP9[OW@L3U0'>F57=>>7S,O'1*[&Y;4;] M1E2_+M5!35*NMMZHN\ [BS94S_-4=T'2Z41KO3PCY9\);,W1,_;K*T MFDW>+&=05I6Y'@[X^_F>XBLL#;A(]I2OO_*P_AH+ZR*ED44YBZZ^D:D%)IN0 M)($U*O1;IG33UG*VFBY[Z/7P,_NM=_I"U;*L\LG+A6T_G/7/1""C2"U=HV?9 M_%PMBM,_[SW,.[_(D_?5LCC]WG"=R7?U/]Z+:NE3WN@KI28: M;>'9'R@]9_U>BT,G#BO/W=Y@V&()G7M]]P/+*9\@SDF5H$=1H[,?SER*MO87 M, _[O?Y7I*K-]EIA\Q7AM#C3EQR!_2]!5_QU;X112DG#C-97*;_&ZF,>,K K MP,(4,TP3'9##18D-#X59-A# )%>,G M.!Y.>[KO;^=1XKF%Y)]&"G-2 M5+TZJEI?E+T[-B)>3( 70L3SS,WF;??+F?UU$A%D^(H,?34NY'*R%J1!A+"3 M 7R ]]LK _C 5AI$" L9]$L3A$/K.B <6,@ 8+"5QOH(ZHS#=QT,'R\(!K."HRGCL3 8C?M)8%AR,%OJ=8".\2R&[>:G>W(YPV=\>SH[L&)LAZO/61LM&DWM$ D M/EJ 2 9(!2(U>_$U_V Y3-@GD\%LN^H)3FH=%V+5EBP=<_D_L1U$2^+EVTB!"6,B R40>.B < M6,@ 8+"5QOH(,7%UX[@W'?'6X7>923\-5L*/%V(AKV64K-5"1WYSY1CJX16% MO3* W//S6=^9]8?\M+$L1([>,0W&R'"F V8 M F2A@V61P%4&P&)^/I@Y0PPD6M?A-)N;&:\$Y#_]]]&/Z'9J[H^>^[/,R1#\ MIL8QNL,;"7ME +#GYY[GN*.C-R4C1-H>W8$-AB4ERQR?JPQ@P_S(V"T=T"!EY'&"X#N*V7=_3[J/?6M@X #7!\:V4 &^;G0]>9 MSJ;\M+$L1#BR 1. +'2P+!*XR@!8S,^]B=,?XGCSMG7 TK_6)3C_[R3+OA67 M?AB+)!;RWT68WXHPOI99_IP=P%CK8=A[(\M2$U<90._YN>M,IJU5=4:$,%[J M 33 \:V5 6B8#QVW?_0<( +$\ #!1" /'1 .+&0 +^:SX='E0! >. /0J)G M#RL_OI0BC,72#U-E] *+ -L/!AYFMSXG\9 !R)Z[KC,880U@VS)PC1#P =YO MKPS@P]R;.MX811[;EH%KA& .D(<." <6,@ 8\YDS\U"'OFT5["@*S'\6\)OT1Q-^RB! 6,@ /,#[[94!>)A[CC?":HZV M5> :()CWXZ$#PH&%#. %#2>F$ZP5;UL%1JO_]B;YQ$62+F1:&SE+HG AR@\* MW;*UGY(U39\,#)(K*7+_B\S:FB'?'=Z]@BB="QTZ8VG.69C8=4&OTG M4^LVPRB)I3",%E0^-K&Z2(J+2 JO]^(#IUT# M7R31XIE2';W-.HFU@_JY7(A8YB)*LJ,G5T^CS,$1[>L)PSADN+P2JK511CT( MHM+:K 2ACC;(#L[L-469TT(!MYF@)MAD;IN?>R!FW=U _V/;4 MTCO?Y3Y9AGZ["*\?/.ZH[I9_WVO[-_>G70PU\U!9'MO2_PW\7 MX2+,;QWQP5^'N1^)WV66%&E ]U!UKW\FIR/?H=_2!U.IJM[H"=GG6&!\QP"# M'HU*#XC_A/:?4/Q_2;'RKZ7PQ2K,\B2]%N[[4A<)%X&74A4S%P'>'UW9E35B#798A"]3DI;J6?"DGF6WQ/,1G72NP; M\6R^N5;Y>.4%/;&'OWW1AF![AD+/PB*JR+2,_(+228( M<_6=1V_[QAOT>WU!C0@>=^D 8TZ\I+->4F,. 3+^4J?J; M<@GU]V42D7>])?^Y\XG2:^@I?!%)\E.ZUY>0*NO+I(ER_R&$CW] M(RK*QU=?UA\LUO0_/TL9'%)X1++S0N*WK4CTX#O1J5H?7A'?E*-?W.JK7_D4]7FQ MD*4IPRLMREV3:4.J#S3XUAU+;(WF!ZM07I?Y57_OGI&74F8JE,R*H:]E(*60 M4^JDY*4.TL9"U*K/4E-Y)WS4U=Z,)K/>:)-^'C%9(-6)+GMT]M:'.IJ'>-W2 MSJS^I&K0*JU;M/8OY=N+5/J?W_I+:M [/[KQ;[,S\=W3NFB'6MF.6WQ/]$WE M\H>SOWQ2 O^1+/_X0)]4VM,?=]FC+[J0095.WJET*T^!R_Q>)G>9$6/J54MZ\S2%]GD(!Z:!69 M'^)HE9B#Y.HJ46U)@L\*P8(&/)1\;S02%\(=../QT)GTAR);4=;7>6;W.\+/ M";1W+T[L#[0#OG$GO7Y?$'C*[VN(%I&&$-U,+778P(V0791YS.O/>N,ZCQ$G M56Q3)VQ1!/J+VM5O5-Z+*Z@4=6Y4CQ9FV8;DFR>27]8RIDZK&O<1=@A917:R M#AH[!R7'^+&XI$<7[N2^6_B/=9[NN<#(\49]ASJX1WK >'R$!PR\T:MXP,LH MSV9,1W[PJ^Y,#7>Z%TOJ?"DG*&(:J*74C2-A9+0D72Y5/U3C1'4F<]TK4]W1 MG^EZXN/;0>49?J1[CH463-M76SJ34:1&3LH2)!=U_]0P("YT!T>-)0^ZCT/R M2[J$&CU6OUC(=9+1F)RR6OV=5%"?DYJLNN%)>O\NF\&&\*^JGC-=YB+?&V"4 MO>=0;5Y-RO^OBS0KU-A6-82<@BY]E:1RXS29V3+7 M'6!]2;IQW4'OB0=[>7&RVW=3';X+*>,RX+1SZXO4=C?=36E >2$C-0XHQS-? MR _K84"Z,^^S MF:$@G2/I9Z7:,;5/>$-RF#A?52.L9:&_7%]P[R+ZVMUDN;; 97Z MZ((N$25K'=AR2<*H@%*7"Z@5(5U<78V0J/*GON#]T5YI>7UO2L;756S=>:24 M7#Y/QE0KJ'%#_2*J7>_K#]1HV ;\O/J,F1 MNHT'1^U3,Z>O"_"%6L$)'57R@7+\(@%XNB3)(K-5%'5E3^4I#E MT]PG4]_664XYY.9>ZD;T1)>7"O4%_6+O"9^0PQJ.1]GEL'5$7%)]F#R,Z!E* M"QV=R\C]5MH3TI ^0$W82V6;P-11O>]-V[CLB7^%E$@H!:QE4%+N4+#HP%,> MMTDYJAL@+V]K_PE6"?4/4\E<*IRN'Y6^H,4H+5@:.X?5F' MVXH"]F:;[L.\C$#J@*SI3E\HUBK#J3Z"3 /E\[KJ5!UTVK.J![? IZKHK7*6 MCMY,2NIT+PA49'>%K3+!)&G9XUE2CXCZ0O%E3_P2;Z.4_D7XNME<:O<*FZ\X MM>!QDJO;:I]4"<,/,UF:?O-9G1]U?\@/U%1^_=E"NX(:%$01/<)275(Y:A'O M7VWG_G5FIN]=RE@Q>N\%0DSI*LM4=Y"^?*42D'HCD*0EJNY-0*M?A?$U0:?. MMA28N3+V0\TC7UM3;TXU4-UI6431K5-GT*2@/AEU0\ML?E&04]-GG+MWK.RB M6I/$9^*U_=^"KE+OUK"BGU8&5:V%Y.V[6*3!IJT>^S<"$W[%0J MBW"Y&UTWU43]3G=()9!,4T0C4;VU45V'3==EVT52V>P$$Z_,NYZ_Z5Y(3!\. M\D*Y( UC+VM9#_?>J\[:KJU4KU#N?5?/?0R\GK<=Q&K!2AAL)E]TITO]II1A MYP+WWHIY_<'$V:%!K>%VZ),HEV*FA0OV(Z/:.IY.+BW]0ET6, MQ7_\9>JY[GOQ00W+\^TT_P?==(KV0+&N E.PNPUF&U";L2A]=;VFSFPU=_ + M_59,R[Y(F(D?X[C0[W%UMU>9)XR5_N6 -I51J96"V!?"K+J'UBTK4Z..%)48 M;G70$7VHO[,P?>CURY[4U3R1AKQV(/T:;4D:O]5O7OW+5):S C>J7^$KPZ>+ MMZKK<*MFEPK574FN55K2 JC$6JCA>7(CT[(KN[V$\GY*Y"0JQ4@<7A57]0AA M)Q!JS\P3RI&9>#/>O%X5JK.C^::>3[\9SJJ)(O5+_0[R;EORW0?0SZ.\/5/# M<;_TGF#CIZ8K_R^YVYG;6"6K7[67'R2#4*=.][YJ])7:?_C]-T'$6:@!BY)Z M;YA)PX@@(DT#';TTL%5#1/*,I=0S#)&$]ODO4\&WO M'JH1"?4OZ$IJ)C"KIIU2]9URI)3)33;/Q"+1\5SYF>X];ARMH$?U,[FC=WDU M7P_?*?(CS6#5C:&OZ9D=/6/H5#T4]5:[6),7#OKD:K?JF4(U2T6==QJJJ?MN MVJ&:(9=J6FD'S3KEJ)Q'$KW=N>$N C8309G8M2Y\W0@OH*0=E)4?W+ M\FEJ"7;Z]WI@7"Z4V#[EO>AYZGLF-G'R_44JOGOL%4$G7Z9.\3+5C)>I77A_ M.[VS#%*#L-E20"V]&A^%P5-' ML_Z9(#)&:OTM-6'S<[6R5_^\]S#O_")/WE=K>_4$U3J3[^I_O!?U:NY^=>YW M)P^4?9 ]SSX)H8M;-TP]P$_;>_K*&>.@%/1PBG@_G+D4;NV?PC/L]_I?T6J[ M)/=UXN8K)X@TE_)8W?Y7C<[_JI?CWEOZW/I1/*^QAX*'#&8=7/XB\<(ZTP$Z M;*380,?CP!S7/6;_G]U,4N]*6F,C"+_$=%4[ %G*E4;FRCUS)3A8> MN7+WQ(\NY$K&VB%3=EU6M3$8OM"O%Y=;CY6YSF) M;@TVSO6JIJ3(_'B1M5:AX[%CPL"*%DZA?QHK3#KKZ1]JE:MZXW]>9'IYY+?U MTDU]H,=V;?-V-PF_4]E>C2-=?#&.W5P:P87X^F+K.I+T=*(@1QG# )" +'2R+!*XR@!;S\]' F8Y& M_+2Q+$1.,Q-XFBJ1S]H[;Y(HF^G!W06"VW. VU\@R'4W?1I972O8>+,1D?//KY4*>-6-Z.QD:;=R *0^&@!(!D@%8#42+[1 MT'6\R1!(XB@.#R3M'B;Q-"09'3E<$Q\8U1FIP*AF!WA,G?$4B&*I#:-3/!Z; M@UTDA3HDW.N=< SE#GH3WN*H:=CSA0Q25;3H6U6%2O]+K=?4L[-E*=,#]053 MJ>HP!JI A_I[V\=9'1@4OX2@G0LU+B^U9YX5O9(CM[=\<+O=%]'2:-[ M*^>3F3/RV)TX]F#"M"KN6EM:!)0!969J"909BS)W,G8&+KMCAH&R]G/H(Y/# M#7EF=.0 <.9H"< 9&Z;G(]?Q!@ <2W$.K>S]3A=[I-]6M1]/7&I[YWF?7D'T M0/N?T-K?'C@^\Z4:V4IYT9^*5+50%0K5U>'EX?ISJJX\_??0B:+E@0/^>ITF M7T)5SSJZ%6\F%$^;(N_UY/8ZI;^GU"HUFUU$^CK+-+D2LVZ- MH@J@QYF^:?6D=(.Z<4[U6_7!A535U MHCSI;"ZJ2L:Z[CE9I3?=/&EIT5B_2LAO=V^A"Y>'F0@B/\O"9:A,JIIZ_\R( MVY[XL#6DJC"[XP)9)BL+1:%_$4:E.VP6F)?&6=YUC>'6,^X5&'\XG%3PC->' M6-?1:.H_$$T;\]TQFSO>D9:LJJQ+XMQ=TG_PFO5KIL5."-X-DB;:UH'X-8E' MLYZW>=;M+1>%5$7KM9]5[[U4P-.G]W+%0BYEFJI2]_):QBIHZ5/EC>_>9[@3 MF.3/=0E[NHEJSJ:2O;@)\Y7XSU\_.F4\N]Y.#J"+GS24'T\H/?%I)?4+O](" M9.-4"NI,Y*$?1:J.\Y(LKY6D%NPE1LIAQQ7K(J6P5U% GR'3 M?99Z_"4R&="SEI!6,4%_?3QC^7GU^Z%"NCJYEFNGH1N^SOU$\K'IS0Y% ]=8A&J-3<7 M15[)M"SB15:FWG]*\Z-"K_WHF0EQEV=*\#U%B;T6"G,]%$FH.)Z45#H14&_OS M_NGG-'+?:/_1T-T9/SY9@3#+"KI9&?$*L]2UODJJ&;6Z+QW&H:(W MI8<+"DW-W&421W_I(:],Z/;OS; M[$Q\][1W.8=:V8['?>^+%D+[J009+J M,?$[ZN3*- KITF=S_5WE'_5W-Z-9_]Z(]BCC-'.!W;?WS\H2TP<>8[>_/Z;3S%1^EG24PVS&]?8::BE5#XFXQI@$D#2$D_LJ$\MSLIF^B*264;?H.\OJ?WTA271B.ZB[J2,L$HR->(D[Q^ECNW7J3%I1J8!^K;M_4=LI[X+QJL)ZF2BPR_O=H5#?3+JU&K M%_1GHJHL!_-YH10CZ"6+$W1 .*66#VK I2SQ8Q D1:R'>/],J/^E^*[G5G:T M_7NQN+S:[#,Z]-6_4OM5G\.XLN-G<@[("O?2.D[ MI&J:BNY"+?7+8**OZ[LMPB6)11]W1%9<_*GFFZYE^4UUHTA^$7_6*JJW9;F* M'&I!=1/U2.H98[D[(5>+*OR+I,CU!R3UQX.\',#G.KMMFA[&*ZD6O%#<%M1I MI+:'<4_\1A&Y?=S_^,O4*LOI%Y4%RNRC4[C.(I1 U7(=_<) 29TN5,>WG+#[ MG]['GOC;CS_^4[^9JS[JUU-^N7Y9]]5;UMJIZ9.-A?_<"ZRMO4N;EJ965J<[ MDO.H1'VEG%"WOWSQX.R_?*V37:G\YG5(Z4!ZNC*(DDQE-0631/NSGID]_!8C M;&C/S0V4Z;1;JSBAI*K2[K^D5J><9MTTD8RWVN9C]:0TM""3.^)SG-P0?IN'UMW?:M/5(8KKM:E&R;IUENI MW;\IEZ5V7B;J]F2"4/D=74R]A*.+Z;8\Y '4CD@E,:W3]MU3$*9!<46&5Z,R M1Y-O1^O2@J67EH%:3;51H(:ZD==A5D9,O+V7(T+RIICZ/BJ*:4002;V)M#+E MU\6G+DVV+C-.O6I .YMN8_WX>[=LTK'=G:X[F[_&2[)6 /.O51B5KK#;FWJ( M-@N9!31@+]6Y2O1O*,]&ZL=_4+@)3^@4Z[[? _@AR%CT^1"=?ZJVR=1]4I8C5 7XC*AP90*A7KPZVB;Q57?IN[H:@IE M&P(IBI_K'7_*%&/)%5\*\1\J7"CK%?VS>_=D "9J+PI4QI6;YM1 M-4S?9*D#?VN5\JENY,[7'M)BUU84XZBY4HN**#J;G&\=\7-U^G[VV;H^07E M[G[YBGI-'3)9?_3Z6^'34P>*Y <_N!G;/.41E .>TZ4?\J14>>Z->C^?AQFU MT7_@\CUA7$K9A?9VU+2!E1KI$(ZCL!RE[:M8*;4=EAR02YG^BF!&G6-]O3(P M+XE*>\NCSMUO-Y%'%U$30G0)_;BJ [T7D(XX][YM_ !?\9?%]]M$L^P0'__X,:OSNPPGS7 MP\_F>IQ?&TX-HJH5>*)8$^W(>FO_MLRD96*^XP++[53HW@AN?Z"NYE:6X1>] MO'_Q@#OJ\69]J'^2>#Y?CJ^I"NPL-#WM\F(G= M!Z@"H/KZ=B(TU,%-#G91OHM;57.RVWR@K)MFY?01#0*+_\?>NS>WC21KWE\% MH9Z98T= :H)WVMV.D&5Y1KMN26NYY[SG+P=$EBR,(4 -@+Z<3_]6%0 2%"B* M! 'Q ?CL[O1:-@4"^%4^F77)3#=>J'S@OM3RZ7?'=?62IIX3RSENLG:CYL_) M"K:,BD,9- M]716\:_/2*YV)ES^R,N,A_TK-0 M3SKR,+0#-1>=* -:6#1(546MZTJM64)FXTGBFMN1._<+'T4HYV#CN/K31!)W M?7VD3JWX?%$CP0]^QNL/=W?JG(,<)?(VY8N3U\PLXRP$?>G1]W#!7D,9:4AE ME7*I!E *1.\5NZZ9(I@',]'/^WA_.%ZE>96\^XGS+7W[\8M7TY(X[RW>;(Z3 MYWX_:!T88ZGN*CU.7F[VA>)7^X;61)EBVDG8_N3)F M$O/L,O&']00IGYGW:!KEVHO7:Y%/3AW8T\A??Q2X0BVX'B9OZM5ZVP-+-TB7 MI$WFWU#[J ?RAE;,2O_KP5/_UU:O<\6.ZVHCSNR-ZR]\F\LZU0^RJX=*5/&1 M++$GOUX-G6&[W7^=D=='AE"#S6?A]3T">.E@6 [@X6G4>%TJ#9Y5=H*,>/62 M6?"(]AO?_>"KX0I;A^PRKI!1L,-/ZHWU9OJC:K>\1G65'LOU2EWPS*3/[3C)8KXAXXQ$_9(;1M0EFL]KBC+ ME&7*,JHLWSANOS-=M-%K#^EK(N)<17% MYR1.IX'>Y F,_V/+;Z5RUWGH4;FIW%1N5.5>KLEW]G]F>ITYY?"H5)O4ZD8, M-FHUM9I:C:K5RS<=;6_RZ^*.9.#_M%UUKGQV#&@]06Y*5FEIPDB2;I"Y$8W^J-,3FQ M'SOZ?+LSUC/X[*$'E4FD\FV.BL>.]3P:GASB=#R5'))L-.JCG)D\A:1L?X#9VMK<[HIT?TY^>%_O4D@S%FJ$)'G0-O9\^'2V#CV\/I_2P#66-01WZ3!/-DM)F+ MYX.3=&MM^FE6>6S+=N"I@ERSA$W]*O6KFMU2FBCOJZ=-7IOZX\U454J)7VEJ MU:F@SQ(#\H*D!N"M%-+%R@)R:IB 3>JV!'JDVD;@A%]G"5MI=0]UVVH I^]X MR;?HM#P]9F:)I^D+\8,XD3USR/YO_7EE-%,W&QC-?TQKB,_+L^J+/RA-DAD[ MZ<.KRC+A\N)?[5D)-W7UN!B85/A9YG45R2B/%T]\CF04XVI6-><11= I.OE, M@UDBTI-Y*Z^49,S49.9Q">O3=R/O(BM;# M%$&EHK-$OHFNZRM_]9%'-6<%]%A^ M.K-/_]H3-_90Z_6E%Q/3U+_%7CQ3>>%!J)*I!:'M(TU^5V\S3A*-=WTR%19, M79O[\-Z=AK/Z(5G5\J\5K*3BP_TTBF]M7K!)YQ3I''IY*^HYXCM5EJCJ 'US M)BJU_;&1ERG/I$1>!ZN9W#?E9*6NW86J4K N>1YG2:2YG$D:;K:<@\Z\C9+2 M_[,2#XF$3<.%NA4+6U_*W/3EO@C_BYR]RG&B H9,'MXL,5?W3HC9I/HKGUF_ M&.T1W-"?>Z.$:3R@EF4CJD=;6F%C8D?V[!8=M5+KZ43XI*I6+#OR=2:)^:&N M>Z5K&NIW*>]]3OQ778X]6WV[&>>02KU7L<6*\2"? M5OZ5$][JQPWB2AMI*:GEQ;KB0C2Q.NAB+>(N\8+QR(J]7_J>9X-"7S^VWLF" M]2YYM<4RF6J07WBR/ =II8BOREI]93PI\>M,G+2=365\K$QI-KY5)Y*Y#YC+ MZ:H8=2$M-S-W^AG7[TC%5"4YIQ77Y "_UKF!CZ4YKR_6CVCT@EO0X:DR)C4@ MTW?QR"_:BSXQCN!5=N%U1N0G\^NON-:L]-,\E3"5GKR[L)?)I::.+[SHT0%<[>QY)&RD7HVG]45WI=(AZBJ,-Y,4A;&$PZP$B* B[, M/)(',6=AAGSGAVFZ]TPW]#TM+$5D+CYO\1%[]5 LU'92%!X6?$EKH7G990W] M*F?U&O/)N0^G$>DG=%^S[KQ]CYI2S(M?QW'-_XK SW8P>C2A4Q>.>/0U9J6T MC'F'47UMIEV4K;G2+6'>ZE%TDFT)T[@:A]F'2VK&98=9MC=.QO4L5(P0TM+] MGT+$/4JFKBI\& \8U:8G_5?I_^305\4Z%VJSV]_CJC5.F#3LB ?H)/XI#K=F M!K-V6;*92\@TMM*16:834NK^LC>B)&GNHQ+KUK5SXI)F\P7)MZXM'^)J?.N[ MRLWH:QRFD>R=/Q'ND7&:O,\E.J<7AR3$0[7I_5#3M:^X#DGB MS6/CB2._;[Z*YO2\)_7BQ85H,G>@YWVI2U&+?U_7U(EZN+55+"HM*E0]B-+B>?YW;T$$5?0EL80B[26JER)U_.CJ6:X?.K-& M0(F92J.11A;$^/3W9MYS>!O7C-:K\ O3?U7?SDDF*7="1(LCQ'5NQ.-O6\<@ MZNFF\AUGONTAR?D G]BJ H2J'3HKPS-?L\R_OR36CV]?K97,>ANHX2_?C;KQ M165+!ZV8K#MF]%/H0#0N9)JTCKR_=W4H&L[6G^.-#SO[TN9E8#*/GWW!@?@B MOR.]Z^S8NTG)+YCAM=1VI6.S-1!]=SIBG/N2!43IP^D!G_K'!;<8O_Z%*JEQ M#Q--Y\@HI^(]MGJKLD+QY11WM2_R90''=UN:56_T=]/HM_ZN3:@W^'L94>V\ MW.PB,?F%A@S3^Z;\;W>D/]0_:O6J7L"OY7E'B^<=:WW>L3$SG'5/!3U#+)IS M6&IE?[Z,Y*4'+U+7DUV$>-"\^-&>I>DJ2BHMZ<[,L2ZKN. MQ\E.L?RB2;RR MKG9@E/-_\&79SDVS70GMW^3HEX-XML"R4.8[#7OC$MWIRHETT&FQ7%4I-Z[5 M_>C3)#/2TBI ([5A^"B4L"_49PY\SU>[W'>Q##2K^_F5C'&2.M4%ZD\+-Q3? MXWU^S\C7GXZKMF9;"^@5N''
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�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

%/)=;S..7;!9&[F'?>*D9- V<>ZIH9R* M94(W)QA!J"-'[3D.LH248SF\,+O@LO]*"[C3).RN49VZ<=HK%Q5K.1XHFBY0 M)CD>QC*V7@6K>6678V3E1V$D=X8RI'*%9R4PER^OVJI(ZB M8$'8>"G^R(SM6]8U 3P]F>:/UGM='H/ V"I3L:Y6RAN2* 1E #3G%?6YO%UI MV$8C&A^#H=94'[VCMP4OLKNF@!H9Y[GT69,!2J+*H?R"U"ONN+L5N&97VI4_ M'.&B7V8\%=+F2^*D@X%B/! GQW:, 3#R*!4V/82$X)SU'IC=]FH-2*E,4!WS MO*'SD#R>1Y8C6'H"B(6R^X73-2.=3)BO"/E3C!Y=M@3N'8K0R1)^.1)2T M.Z@S^JC1;]Y&.ZN7N3G"V[Y"D]B(WXJ2MP,M2%Y8/P%' K3/)HCJIY]ZG0(8E MFN"(&BG\7ROS9+D\.E^KRCV;XT-L6U6.15>WD,04:9IH$D]+O%:\#PW5"=$W MK&.K(^=M6_^&5SNBUT:_HW]PE/@==56>%1@\QO(3^RW!X;+G;RKR-:_ MF2)*.MD0)'+5H)N7N#>9850TA7GMJJ 89759S5*H>\R_"N7H2WU>(\>,Z[2J MEE%V;44''Z0RHR80=O ICI1T:Z6TE5W@7M[5_6!-CW),%Y^I!_@8LC.- M!+[V">91F0UJ3B(S42+W^YRQ1F@?V3BGDR>T]"VP^\B^S27O.2^==<]SCPVG M<91"%WG-4^["^ 7X7HA5T>KX)P#X::OC%^MXDTA@7VQJ&1R,AV M6$E &6ZX,@+?.H]:4*>./^EC3*/N9EK'P38?Y M66)34J!^A!O+*ZUGN=3$[$X:K\G91^I" 0AK.-VAI"@H8*N ^A$PCD[%37%Z M'C$(B[&08E/V(U36_]WT9.GT01U(G/!L]2J=#L#O(]U9CKYB[G?2+%/0 M-WK5_WP18RZI(IG.SQSJKOU0 MU]V#'OT9V(K]"*#[^K\O0^(WW?*?3U=7E?^>=3B]*(FW!R,"E MT7Q7G]P:U4H;!H:E,-T@[NT=';+?A$K9R2F8#/KLM ;OYC5LXJ<@BNX^9F>C M]X!/_F>4?.VPJW_B'/SC5_LGAR>]!O/,!XQK7TOJ?ON%^WQ\=I^HQO/NY>.J M/3CZ\L?[[WT&_LWOQ.N8AE@FDT3<1AXX;E.WC,HIKK*=MJ863>'S\2('6QSLKK;?! M*VZ!_'Q /MJT)6_M^958A^*?;9AMNYG_99NPB*5LD/8XRPW(X;4GD&X/RJSZ ML LR!Y:]HJN74(@;N"58,]BK,P=WM^MOFD6"&:\'.?&VL3*DE:+-D*(MRAJ' MLJWUFZXI,I8EHJ7?)M-OB[+&H6QK1<[G1(8IN^)C<=92<),IN$59XU#6.OCM M^EL]]C#2X+WO)T*I5HDU6B*V*&LYYP[7' M%8SY6 M>E$%$ED,/AL>EW-_&,^C8OQ^F59".Q$7/$$]0.C74*8S$P'F P@%^OE*Q/ZZ M^^J'#:2U!YU2889XF$.\]1&Y]AC%I("XGO.0 <15:6@$?IX_)**KB5;_]\8< M[Z4'ZN,A.#1!'#ZF*?=&9G0#SCC$8>:!BLSIL?1U-+AC5M8#8?;)>.Q)E<2R M]'%E#M\:Z+'S)79ZDG&RS#6\>MW>Z?=&9?WPIOOZI#S^H&3C';_N]E[A[X5% M6/K]5:][^L;Y?0DWT6R,\*GJ7#]6=@_OO(8V=.<5-">C_I([5/6;AIGN5V9N M2"(\&4NEOJ;1KU7M$)"UJHU]J* MNZM*]R_7OU8'MFGC5/@M@[0,TDP&H2EK^G"P 4,*U^=3W.)45?>H9G-R+-$[ MCCL9T%+W"UQ-XZX_V%H^#K%R%1KMC]= M*NQ5>7GS9C[?ZY2%M=[XS(3H"M--C]2=_- ]?GU'I*[Z>ROE-CQH;*D0!:'Q MVEZ,/'RQ2"N<]L)40T2>S3MQ\$>:! *N:+6-#";&S,/<,PH4/^\$H>LDO D$1+MW2J M+E?Z)$7?E!?(\($.G5R_,&II_V-18<&SEZ?0.9@PR0 MB2<9>]%X+%-S;&7=R;SS#JA,A(J=HS.EPL(37:6@](DQ[@$D*C\ F@E=CJ*$ ME^'A]4)UG_]@W)*K"BE3S&9CZ.%:G@&,-PMDLXW3K44L' C(SJJF,T"2:U)M0+P=H/T[/5H;; M74I_P?Y[K[N]30.!K>OZ-!A(3]Q]KF(#MWL?.NE\N!&6$UA\!< M0^ 8T\SF+7ETK^Z!\PEG!=*NONC]A"<^!7/J^%'-W=AZ;^N"U,1&("5AZ;0+ M"NR(Y!;L2,42C/SAX \Z>#321YN:K\KGU798?UH-('5F@DRFC+0FV-1QRY32 M>7U*"MP"!;[YD<#0P:@S)X:IBU6&"TNCGP,>3GGU@Y-%A3\$J[24Z= O2F.E&_OH M#&%@D!+#/#U,YG2^/3!X2KV0E]P;8< <:",&\A"V]S(_,CT1GD#. 95BCNJ& MY7GZK'2UX*STCG.V.@F_9X&J>[#[8U%<%L,;;+;(;!J@NJHX-XDA%T'K=!-O MK<5SU&"+QU0P/;1E4VU\ULFQ$3?93920W(.=^)3.(OV!A%JMZELL4Y^%MZO+ M? J1^1X$V2#A'NX"2%[I@7'P_RR@M0R2:$P0,B/BK#F) A!G& '\B'F.+HNL.%Q9/",<8SXE MW6M@E?)OHMSC?RT(Z.SU#%6[S]6+!M"9==<:V@B2.M 4,P=H5Q8^V (#MGVF M^046)VZ%20W#%\>'<,&4!@NJ#.["JULAOJX0/VZP$/\I2@9"VOSBKZ%F BUT M?T4;X4(HE4N$:^U@/J;(_ZCEBR;7O.+!901/<"64<6OGE*^P78X5, . C@^7 M 8?L$>78_P@;C]!#P3(>W*T8QT$T%4"?O@1W M)\7:'=2GE$2$?SOX$6D#%#R5& $J_%NI(E2)97UIL&1*?\(4HP_$?^85JF.? MJXJWP9_%TY7S>"*QR4@"C2&3" LEQRTCMU_E54^$#4VV./6FU3LKZ)V3!NL= M&__3M6%1 8L ?9BT=%@?"'P*;C:8QC6*U_+\* M_Y\VF?^U&0%$R36Q@6?H/P?[6_LF<1:DB@55 X)5N\:2U+OO:]A-$$/@-IOSME5$=!]<[S;WV.7 M@?[XE%8+SU1$JPN-!W M&K#*D4:S$6>!>TXZI(*0>8#'E0:2]V6@0S#&=@0&!7]14K%/:(@OSWEQ#YP\ M14G93F[NP7(.X#W:'Y76 5MJK[.T!8:Q,$1N0C5E#C!/_HB.*>:6OF#<-A-4 MOHP_]GYX\XI:"?D8ZX_\3BGKAE?EWBZ&MFZY#&K-Y)FEMX)X-4'<;[ @_@V( M ;VQ)T@VW\D-'3Q2"R1?8,[D0A&DLZK O5]%:$OI\L@]!<6#5(Y!M#G,38D( MD XRQ,0CA&* (H^^S),!.B.> MZ4BO#N7"!?LDZS 8 X+52+Y:*SJ70;']CO9D,KU4@88R+H#-8WZB.$@,7^?P MX;VJZ5?GW$:PZ3V(TT=_QG?!7>, [3YUY@,,[?TOAI0^(F$]6HV@U#:";E57 M$-DSXF'@#6#4C D;E,A*!7^'7Y84!Y>S0WS1:,DYD ME%<; )^)6\K_\V^625"Y3PHI9K*;])A4FT64/.0SNT0@H&V!%I>P,@?%28+2 M @@SSOI '<"K2*F:;WG?9@L=^"2]+]?&'\(@TR;R: M.N,G8XF\!N;] _/"S/D.SU*R]-YFI]DU#]#6*P#^:&72FA'&@FO;7\]&F%HW MQF6E".A_:+P$5*PS\NEY@'8M@@ TU?Y%A(5(CV?!U!9\_:1S];/L8X56A+;# M3*$!V"-!YFL@@V4Y')4 G5>)U0GA"16(Y>SK<37"FMM8A*8*(N:R-H!7-9G( MIM+R&O ^B\R9&1@FP.[FN^RJR4TTAM' ,54>"/24*M!5=+#6AV;]U6TT HW' M0Y,!M/-$I<#H.#T64/7C(N@V.;$V4VL;C3@Y_>&CSL[X4GX*_(,9=F[[2BX2^ M"M:J4!VXKM,$DWT_R(Z*@U]1 M1A%-YZL8.P*NIB2 M)LQ&S9GL!LG7U:9,TT-V](;NS,O6]7 M[E%;,\@0OR*[SMFN-+]245N>B"I:7^ +,,*YSKJ$8ABET@1>0#;IT$2>="F) M1> 4BJ$R=$F4"!;EX;Q11-FZA)9S&P7@R Y@MP$1 94V@["50GQU91UZ\?2 M%F /YPQ>M0M/ M0/NDX64S;#=-''D*@4:5[P"=]CJ$DB@S5^X'SRFT3IAP]"(3O..-Z[LB5^?/ -@7F M;B3XI>SISO#OO$W^GH&A.9BN=K3P@_#GPD4L">KGF@LLC-Z BX?U_W>9%K M5,T\%6VG/@:E0+F6.D!9.499]0%T^7]8]( 692LZ7FO"P)@ SJF@$LSBRI0= MJ[-FCV3&*(!KI,Z8V3OOJ"$205Z%85W/[Y$Y?;O<;Z4!S!-8TK H",IABH@H MVJ/G.'.+B\F+,_+J5\:5KLG%SBXZ3AA^'8J07#\P:=,B@EF^QN1AW!WE%NM8 MAG*&."@ ?R1^($FOL?1Q'!^U@<*3S/M9)*7E^@> M7B?OP@&+22BF>F(\-QG[.:)EGJ-9EBQULS7@A85=<[?_G:<7;88>MV?S)%K+ M1%Y&<8&.R=R/<[T&( 5UC?,GM%K1:1=LSP;6*B?YYF29W+T:V3D3I72VTG#F M\%9F#G=D4EG$Z/*VHI>=C &KOTH%QH]7C?+LU2#\8?]TOP=4BGIOG 5#"BOK"T@4P'V+@\5KV?#/SIOU;;E6$-[5,SA; M(:$; Z7NHLIS^MKX@ ?G,M&Q!-RNW#'W1;RY_\O8K]#/7G'0<:"($%=EN1Q M+$U2'HXM2D%2,SL;&^$H=!>(MAK=F#Y(83[]YE%7'P !$A !&A.[SR+0J*XC M*\]?9O[XWRE4_.WJPV_BT^>??SL[%L_V]O?_^?QX?__DZH2_>-$] MZ(FK3"9Y5$1I(N/]_=/S9^+9L"C&;_?W;V]ON[?/NVEVO7]UL3\L1O&+_3A- M<]4-B_#93__COW[$S^B_2H;XWR(J8@7_R,/K;$]][1V\^OWPQ:LN/ 9?[IMO M?]PWS__WWIXX_T4S*.KI.W670]+-[]+(,OUUE:)N%>D,9I]O:[]_2_=R.974?)7C\M MBG3T]F!'OPEW>#-"GV;A4.^K:?QN$[/=P!_8^_SJ/_ MJ+<]_#'].9"C*)Z\O8I&*A?GZE9COTY!ZTKLM@F'W_'9##NS!*KE76$6=)T%W-"F>>BSW"9S]]G_3S\;O:'*:^ M4<^*=F[V)&K;4H['*@MDKI:^_U/V^D?\O+*>4 5I)O&6OX6;HK(X@I-Z]M.% MRHLL"@H5BLLB#;Z(SPF0WM%UIM0(UB+>?[P0YQ_/]SYW+[OBT]'%U=GQV:>C M\ZO+'_?Q%3]-W[I8#8K%KN#K[JLW:TBA8J<8*O']=S\<'AZ\FWMCC]/16"83 MO4WTZ]Z[73%4F>I/Q#7,I\@%#CQ(XSB]A?>)S)U%3F=1PEGD8EQF>0F/BR(5 M^/?AP>&!./UW&143G!_L7'2CQ*=8)ETF9_Z_5S VT.XH%S()19 F(?%X^+,H M9#"$E^!<8$R9*2'C'/XAQC(K<%*92@?UF[FLHWWLJ_F(]#4W\9RG110HD0[$ M+T@HE;L61C>"=N"OS_ S'2O33#$;XZ[.#9R)0<9R/90!49?\>RS T M?^LI\"]0:L9RG*NWYA_OA-![B&]XV^OV7O[EW6T4%D,X'-A">F>&_RE%P;,^$^9U>%)UEGL91* ZZKU^."V&$ MLGE G__,9V@Q,Y\@A:+]D6>SI52-YOSMP[^K1(@?/"(9GLL1T5:F@F@<(9>_ M%X?[!,PB@A$<@1HN]Q8IU=' G_%D%^=RVTOQJ)>"&*TXD87:4N^6>C>->L_+ M41^L9V+JK4KDSJ+<_>+R'V@FPOR&9>D(Z(!F .33IX4Y#"P=B1 MA;B!.R.BT4B%$?#_>"+2A$PSHG<1;F7"EN0WD.0=?:.%GY?]/U1 3@0D=_0W MY.@%*.,M<6^)>^.(^Q^:AB\+=%EMU?9E4/$^^9'@LS"ZF3Z]5]7IO5J%!_Y> M;WQD0O29Z7I[Z5X>S/#15;[<*'<6Q=1!$N0C56-'$C$_,B_J)3(UDE."3,A&G<$(1:KC>$QTAT^Z8$[^U1+OC+C#!H^-5KH9P0NRD-,I$#NI&/HC@M5$B!B4K&WB2&J$BAG!&1=HXW-NH&&(T8:R]1OA]E",2A9$)%%WHZ"!# M.F9L20IJ#>)'A&)\2JZ",HL*F$_W&]I%;,G(LDAG&$%L+TVW@VK?SQ"/:\5; MO\7DU@F=-9\&\W1V86XKPQ@3_4SL_W0)6R&+,J.;6P%N?%/"685R^J<_VB)3 MJA!'80C,.J\>:);>MJM03V?3?IZ\77C?[H(#*%#9 M4UO>%68-O-TR@WF8P3$H7?N7A2S4_O^-QJ#BA6ICU&W[BLU(9^ -GQ>?C//W M[8GZFM=B2;T?]^7"W'%]IO_BX/#EJ\/#UV_V;I[_O_.CWT\^7.)B,#W)NAK& M\EKM]3,EO^S) 9S/6QG?RDE>CYL\A$37A6FLH:H^G_C]]AD_&\V([DKA@0'$ M>9KH%!ZG^^=/:1/F%I= B&DVQF]@OZYL?LRQS8]97RKUWOA'F1?18+)@]HOG ML+IKZW7J(_E09ASK#C\N\"V[\Y]7K K8L#WMY'G+:ZX<83.IDZ92/UEZ!0@N MRUL:#'#*CONZWW-$%%1S/9U:-1]=S7I5?>2C6YF%Y+!KN[CYHBNI#]]( K-^ MOFKJ66_^TX$A@K@,V8$\$>CBXS3D]E?C M0+4Y(S2Y]_I=#H^529%-](@PE8C=U7*,_NOH:R/K;8?F;E#1JSMLLPT//58+ MPL9-T8O3)VLW87IF8#7#9V6KQ5L3+XL MA>&0"C(5**1O$ $B'TKV;6*D(TU,<.)_'F"! ]@J]!*42HR!8NC1#F^=8X[? M9M^.>7;$)I=&->48AC0A.[TLV+=%V;F.SOE'<&>.]U8-J:@AAYNDAFCHV-+5 M#0Y##J6.(R,KDP',-:3 (;%RI,8Z;O)NYO=MKFA]7BOA;4? <0:9#+2V0RPI M1T%6QO3R09:.C/H21P&M!S<".156DH!;)*_A%V7N-)WFAM(9](%C(OW"@V%Z MFUCQJ?"5A;@=IK$O3/'TJE.%PTSA[13(QQD'%*XEYPF-U,9Y?,YZ&\$L0A4# MJ\Y:M4Y4ZY1A]B3A^G"(N*LXM H[50[O\] &CQO+"8E!O5>%_*JJ!10N%6VZ M>-VF)MMQ>=*P=7K>L'DM$7+9OC6NH .MRNP/IA%U1+_D&P&34S=*A]GA@^<' M\, DI\!Z";_"IQ?CQ2U%&?ZTC/CY)C'B]VDV4)$)SGY.F.J9CWY&V7ZL\MRR M@$N5W0!;7"K;/F,.P@1I\2$^J0=*YHJ,1K@44\ ^8DASH0DL](XIV-X1-]NS7/ZM@IM? 44)[R",Z9W]3&T-1@ M@%P&5%.9-R?78#S^%O+$AQ)^"QLU*#,"TY#*F[>:066%7/1N5U@9;=](3GC4 MOE()PWCP]*HCLF4\Q_R8!E8NBMN(;$GB&/- 86DIF@,(:\+UJ-$X3B<**#", MP+8H$,N$,I&"JO#?#OZ)IP]"FB!7L-GA392C5R*MRCQ]#AH*!68X&.1TP_0K M\HX9-W=O@W^ZT7-O>"*BVV$$5(370)EM\6P@LI-SBP*C_6;"K)<%FL>]N?; M-V"9*-7'*3(ECU=TIOJ'\D(698X78/1X!^G3!69)1M^$5./!#J)D6_E#9,U4]=P MZC$P%O.59K/(=8GIF 4@IT*F=SM4-"CQX4+$$I6X 4I5S=JC!,/I(3X 2@G& MR6 4&)P)E]A@+&]SHW/^4691'D:L4MTB_VC;&4WU-*I*KD%SI7\ZFU3/ONW< MO!?CHG@;A33^#I/03=ZB$.B>=P,7>1OE<%>^HN\@MV=AU.6*SP0&#A5O%4JN M2?.$VF9F_1#&RK$"JWK[7,XY49BE*5\X$$W1 >$C>#1]G'NA2&_O3X@L$K:' M0/^/TE#LJ.YUEV>G/\'!]/[2B"<% C@T(( EQLW;!,JZ! L?<1[WEB*#=OFG ML> [+JQB&'[]3:@/@EG:E'@D!5K>".I'C*Y6(9D;D#;]@YBJ83QYX\;UDGDSR-T,ZC98W26C;U?& M8KG=#]-7TQPPJ6]#@'1NY%SAW].&;_JGG2.ZW4^?;X-]#[A0KS;I0GVJL5(V M39=\GRI&-?Q1C\VTS@&$*2B@XXGS<<$O!V661/FP/>RB0X@5:;"HA^M;H-NW ML9G6>_-ZD^[-N4V:6PK0I1YUD4&@QH7AT&2]-1Q.\-"7)+TE_1(4/%I'7L@D M9"P'^30X2/)V12R\][+[_(?ETF)]HQZ-&G=DJ_EZ+Y*K/V-8'/FU9.P?U:+&*5A-(@P0"Y'Y"G$<'@^9JLJ<^[KZ&H%*/JKK< H=PV+)W5B@3X]\8?8WN()5*0=/FK+ZJZ4LF_=O=48D MLZ_$4!!5TK%TQ@'/- ADSG@3_#-,54XF8( V7]-!;#/Y&WB[04FTJ''$.N1$ MEF=?)6J V$N@V#A2I?L20\OHO!-;6ENZP:*)P;@'F&28-&J!#PP:Z]]%)T2KI?RGX4(R:C MRGG:H_$V -]X&IU#C,_LQUJ/LL'=.0*3%9K?,0')+:DO3NJ#%>OPU1"=K[Y[ M=(_ULAS=;WG6?0[R>N4\BXWF&7[4FM.*U5?SFRA!8#+#L_$SSBI!X(5$2PK1 M68;CD!%&6O,XEH'2^(H$M2CC7"8XV0@_I%W87OU[4,QP,RAF!K&81"[MG4., MU%?4KE58H8YZS+]S-X/90/#)\Z6 3^YU93;D?M2IU&$],+6 4'W1B!#/"$H- M9!R4,4LGBDV!(9YA-*F#1AP5!8L0BNT!!?&;$*X?/#5!<&H^BO(( W MPKH0/)C9/)?5S*85CEQ_>"N;[\%IH]5QV@9LDYS:85/3!P7K%LM))M<=\8W8 MLW%1R;R&_(?][VB<+'R1Z+PBG#+/S9!^&_1*@U$YO.S0Y@,,-I=]>$F$7KN: M7V1+M(L3[1^K50^T]\N2#F=D8*!I0NBY=HJ,,+R/,1W$!B<&2\II=9B=*Q-M M+H.E'')B.]V$0&6%!-URZQ"Y%RU\61TM)*D(8AF-&.%.;>Y)L '/J>APB#27 M(TK=9/\$K#G7]L2@D@9FN5M+4JB/ZI\; SW#W[93R]*Z'>(57AZ@>H-1;O?$)95\*E]"9E/=!/X+ MAY-@J&PHDVNX"_CC05QBW(O(LJ^*6X(I3J&P. 6U6@1EEBG0D:TN@65OJ 8. M)>N<8#7JS*&^)"4%,A++%Q?H1TTMS%*.L(Y-+L*2$)2@FOC)RZQ6%(:[5$>@ M+V%KU+]+_!)4=F5&G2*'9*"1GU1!P@T\=Z&V;<&KQ[J//VP2B.9*?A4?)&[ M:D=4F,YR5+,D,2O!QD6#G7N(/K09N)S M29G2UVSA@3W2:A%.4JA1+LQ?30BIW?#I84L4ZC$<,Q8'<$$^3A4%(1GZ'[9@ M5'=6?GA ^'L7>H5GN-[EG6+$/A7N[I)/3X"MWD;\"2HZ"$%2K!&Q-B,8410S M6GZHX@8^]@Y>H6LB6+WOPY2O]Y0-4H79XYIJJ0O_4!+;L M@FV?LBBU5;E 8*H;,C7E5R/M\!+?NI?K&D'$G0I=8P)+\,B&F.!DYH(XGC5$ M42_((BH_D(Q+X&@!7 @D&5VBHF]J[M0D0]5LU?9VR\L\YL'^+)LK2NW+,LD0 M(TRGI*94K?E7E9?YYK?.>M21" H%V#&M'C).857-LA':':&^JJ#4W!:&("[> M+*N[.CJRQ>&.'DI&;05UU9.,2;_8_'CTRLS/A17,E=9:-B6]Q"4ZO\Z\^[6\ MZLO,Z$9*\=IU@!-##@]&P :DD_"K,S5K&.31JN"CUQ:W'1@@Y0H&Z&TB&8:H[<$XM^0C[0%?[ M[BVLV3UC.:E7[F]R*<8WN"*+ON?$F^&DXRE@5OE+*_;9PV_JU4.'J)N8.OV2 M]Z)E 55@>A4Q[K!;Q1 ,E^MAA?_;TUQR^4,PZQ\Z#"C.%,2V6B]=E4JH>RRC MUNSM>B9BTPCO>)$P),TF135,^;H9OX")3A <9F(VJOS0[5G#\YKNZ:3-=)@3 MTT#8.ND>^NZ5B?_6I/][2\RF,VH@HS@W$ [MO13HQ .J(4B$IY^U>/]PN ;I M+D<*:+)_L G'0G%0YN3#YM(^Y.'6Q;H]4%UF2CB@<]?Z&DV0N3W O'",LD'] M?_KR)%;KN5"#'WXX>/GJX,6;![N^WFQ2\/A$%E)\RD"S"AY,\%4-J'GCN6QF M''U1+- -RU0^PVPJ1ERT4YE\CYL()L .'N?::I0?-87HWW VM@IB:3+4,-Z5 MVX;-IIIHI;H*0E&U DIW,L]U:9_6*)?*8YC)6U]>F#.[XP"\ MV@P^:6BM9VB+5N,[,R5#':"")0/!$B I3(/2Q$G)J:#Z>=0$2,T?E[:!.:HB M9]8F8VZXPZNR]00\H%,L;P=EG.@XN;=6[X;OB([M46_?) M*X!KZLG16RK$C@IHU0K:I;":G0"KKQ3I%S[%T FB\>,DSSJ6==,7[V61B=DY[OI'] M,$CR.KIQ& 3O-+M+OL"/ZY3]_KO>JX-W_']7J!,\4GU:*_:/3L\^?OY-YL4% M)A2"*?,)[*Z?T?-,WVC_!\)Z?)G8$->+"NAG/Q'K.W8DBISHPHN9WY@.%%TQ M#R,MLW2LP-CXG. ULNB(N6?S6;^M"C6QPY[";4A'42".8&LZ1EO5@,Q?X>:$ M8$JWEM)<:$-:)U$-\IC"VZIAI':<<,^ .^0%%=R588@%RI'K]UZ^.! _9ZD, M;S%_ZO %/"W>QRGR::2U?Z79%_/ZJ4T.= @,\&JDL"B3!.&I\QB(V M-!S6JO16?9@*E*EPU2G6CE-/;(@.NP_XI4<]\(A/2Q6!"ZS+NM>/LJ(K#E^+ M7TX^7>""/F7IH"M.0!(-NT%7_$U%7U+Q=YC+1'R02:2RM"-.?CD1)ZHL\@!& M_$5AQ5;XIQR Y/W^N\.7A^\R 4JE2N##LOB/^&74_UM'O,]DF0Q3+$J*6_&\ M(WYX>?C\!_$)LS/ O $;2:^D-G.PG-G5P,$PF#S"9F)!LAIFUQWQO/YW>+T7 MNM=V0[4P0UY[OH4Q]27S(5+_C_7%U5T,/N? !"W[\:A+Z!N.9=(P2Y;*'A4F MJ4Q3.LI.3J2I4;6+/E>ZN5@G7:0]F?\,,#(PY&4&3(>S2F1,[M@_TKX@7W>GAB)G?S=Z"DSKDF$TS@6YSZNM M23M8*I_\*.AKQ\8^8XNWJG5(<2[U^HL(-(4>] !W(,9_J:\J"^!0X9^F29CM MA(,; K?L*ZX MA>4BWHZ&4$+._J0"\"\?.2E\VZ3 [S40 :$3Z1)+E.$H2DB9X11SZ@8BKPUP MTF)IX>ZG >>A3\E&J2>ZD.ZP>J_?6CL?6+RP&0I?1GE'Y\R9R$9GBAY'8K,6 M:HERAL!JI3#W4HB\>5"#%\*DXA? N7!05RJ))*7W+O-Z\Q($ O5V4;+B'I"V M6ZDJZ/G,VQQ;';%SN,M6G>]UKQOBU7J:E0W#V3_?U<:VV;Z&+Z.HFLSMV*G$I. M9$6= IOZBVN6T14:^\#)^]7&?8RI0!N""C-HSVAC]J;"'! [;0)-EIQUJ?%8 M\G/T0U9"I:UG M--T)G*\^+P00H;10WOO=!T_3+Z_?[0E,#MOCNWL]H*D$ZT M!=4A\R\F&8Z[P+76KM6S9Z,0^7::?='M73SCA32V)N__ MW+V$^ZWIGE.L_88N;2:3Q\N!N#,+E.&A7!D #Q7"4;#:O@*='X'/[K%^S MSWKY&K ?!2+JM)1(;L4:-@LIQ/RR)M),R9^:B@)?:XZ=,I2+%&F8L.:AG=DB MHQ9]TVLDA*#EC%OZ !5GB;RMPUD<%K@JEHAJ4;T@UB MR:ZS,!U[>W#ZF9LDYCFG*3TQXKV7YEL_HP<2Z1SLXAB9CX75/ W#]JAEJZ!$=#!5$>K.<&QN M*.VTH=[?]*:#WM\*E"30 C]!U;?D M60A MX)8M >7!82J)K^*$+$5R$,RH"\4!'#2Y'-(<)M!AFT1/ M$A=@FB-7H#M(P>@BLHS9BL93'")L.J;SBF'18R1/>=X@RQVWN*H/1-1Q'"MG1V- ME*058XXU*5N]8IP2GX$+"C^.QI'2C3UP)G#TWI@.Y^^#VYY4M.'5-M+P2/.H MU%S(E57W)TN3< M*APG41[$::XK&WXR!K47O)QMS)/M[GI2-[R$)+IR(9; MQ,.H#,H%KW/($04SG%0TZV3H60^73I?_,.T;$H/).$:;!:OF!<:1RL&Q$Y5$K+3^TV)2+<%^FJ8)^RTB M7'' FB+CJ%GWW[K]RR9R+4OMUH #Z=6ZA[/;4@PI M@(8H-17J@1A"3-5F?&5-@\*#&M%[S,X&A[-VK/=4W.-*!>]=G*V?9IC"BFSL M$NO0BQZPAS%JK,DU:Y[PMWY(L[_F)U30?I(]?N,=('VEYCC]_T:KS MUABOS]MZW8/7?S&?\!C\T?KHR0O[S/J36K]30_#D[0?[3>-##/G=1+*5DN": M N_68Y%H)_LIM,$\?TKJ*YJ $:8?VT2*EIP,TP,SP9X$#NUP4@MXI6-=_3WW MG%K-C!X/,H@7"*U1@@R:"&;596=3@[Z5O_E!?8KI[PW*H//5@L72Y'H'FY0G M]P&4;!6#_J'2\N$%,?^DA7 BJ4:V1FW(P9K>&ZJM& MIC)5Z935QQ[$H,455J7S',%>9\[5 MSBD-"U4LQ:[*U5?K7.:&6R!+?>-UWO9D>D:V4?X0*>UE?-")H5 QNFF ,.M, M:C1U:*P2W:?%M8@F?[YV^(/T\E=Y-PN90]C\B?C'1I4C/$_%44CJQH7UV?V2 M+:'>18.FO9"C@VL8NYF* MO(TB!*0!M$BUW2W#K4-T#'*AW ZXOY=::PW"JP M'\T7G/MQ=I2+HZY ]7EDFGJ8.@CXU9W]7V:6MVV 6'1]F:HQ[^PMJEO2J$QQ MZ^6V>)M$<>/*+N5I-M?"38)NX;9/E[RN5UE>(6K["=_^]O[=:WK[?\%*+@G2 MP6_D2PK%/U12JJ7??;KLW':\B6NQ[3VN:38L@-B2=#V&(P949B&9B5:/H&BD MOJZ4.$G!+B!DK%6*R44F%!T,4V DV/4.OD/O!=R<<:SLC_%3%+;H2LL+:;(^ MV=&C)2/S"XY$^BU[S"1DM2>.KF8^E$G[]-BKXR=DQ,"&KEV+OS#*QZ69"?47 M\DIP49<>^Y<-<5;: >GY$2^ WRHT)V'[M'T*AV K3->Q^_[/4+OJHY>QKRM: MDWV-.YNCRZ>ZYMI1V!Q7RP%Y-;3/9KEIXF@ P[\E-V 7+%'$!_R$YC M+]>!X'A6C_?L;",;6=RB%US7#]5@IA$U23*1/X8YH1X/O">G[.DQE6L'"1^4 MA,3%3J;FM?!O;A^A_\!8G;I.BTB;-WY7,SV1K@!##LP ?(48I:%+'L< $YI& M+J>FNC6F(]NMI$IQ&D=4P7_5?V)R!3BDB#J =B>XIJZ\9+B\SAENMJSI/MKA M!"*=OT(Y.UF:1,$NAT6Q>A]&,+$@ _>7H[HZ!"5A2KIKRI5((9I:159R(UC9 MOFZC"7(!GRV#6I1!J4UB4)?429LA&(6R1:?XM7@]K],TQ M5#*?7$+;1;C.V+BG*#4&E M&)6Z"1"]TS:[]2>7@U3++.YS3G-? MQ@X0U&Y3^C8DPJ<']5?>HK*2I_:-K-2 &3_O&_QUMUBIU/(*,SJV;M3%>,A@ MDWC(L8L^GUKYA98^N_&1I"HPHY5Y5T=8< K(D'+N4B!)5#& _.G:P3(QE@^3 M-(5ARNW^]27?_-YE] MML$)#,&-/S4( W]+:C2'2EW1N([X-RCR%5>!7T37PVBT]$AMCXA6:W"PCJSM M;C^?T%<_]$"(Y6!CI]K"W.^-/O9[W!&D1)FH0WUMN)C:Z@;>O+DPD;:KX*?4 M9J7#D9^.=1%S"TGJ,:^3%R.NH&\[SNL;S^$CW7A49&5,G4==CJ3CICI/_-(- MAQSJU(SG4K,ME.7R]-CVK'+MY?F@.&)&)55B/Q^SGX83XK%VQ](^JC0VXCM& MLN(5:N=MK"27);2D>5-X._#?!;GGLR[F#S.S[&]1BE5?9!_45HU]5!1;T M-9<<0N!IN!U(-W/'XAM@[BB?UIO55'=UQ#3Q:=\Z$^&(C$#CV&$[X03N/=Q8MIU#=9)LE: (4=&T2;@'K8Q=XBNWM6NN"VD+56^>9E 8<:WR)+<1!C)UMQC>P(#@ M#X\7$-Q4;:15[9BBHH V$FV6-D)E)?8NQV#: X?EPE_Y,AHE-ACJ0PJ,Z4^25(<_WP* W8"'(P'6:?E@_!Y9),\_0NI%-)16RN% & MD,18M[VH"C=?JH98AWR$.8M.XM9 1=R-N6T7*KFQOOI#^V,!E'YEO1NET_R: M3CE[#2@F%A4EGAUZMIJ6_S8(MK!9^\S M&U7KND.IV,:A4TT62!8N9Y-89Q('=ZC6Y&0:L%XG%9 9.@5AWYGO>D?%P^XK MSU87,HE:ZJB@[*/*GTL)LX^+F6>-/NP&X-[E&] M8NQ.H5)8SEV)A#W.TF'4CYBTN6='W XKH]SYYMH)!A+:G)/ZMRG6KN(ZH?5M MZ+*+5FBO%2)H6FH$$3R_K^Q$#6($J^.'7*S&[&#S%<9V]"*Z_JTV-<4&L.CT M5E>E4)H[4%U]?89%-![#6\S!N>&TSRJ0I9G%R+OGB/0I22M )N#YN2IG=<0Z MDF.!]@H8UE=S,R.2R%9\UFY$SI_0^H%9=F547RU@Y$,TZ!VMJ# MW?>]B^<:X^<3O<$H8L\*= T/!L!0B5$;*&*]'Q;7A_,7B.I6)/W:/@97F$ZO M\4NV$&P7QEX9==!'&NI/FB^8*>46R?+2R5S>_0]J(:?9[]ZJ:XNJ:_$FJ6MM M9'KDP &K,=9F(Q%L-B-W)?':F?H>A'?,,_';/J*7;>48YPZ"#XAO4:S'@SPS MOO K,$@7R:O $N!"LBV%REG.5;RGW6F\;)P-1M=/NAI/D2XM0L+5A&>LSPF& MI27 &NJ0B8JKIE*+I[D%-[NH$ Q* E!B&IC-(K.)G?V(@\"Z9%/+,"2!8"0_ MKPUEX$ZPC?=N7V-:'F'TS3$0: M,!:9-L?(@+%%PR^;T*OTQWXF]I]60.G-L@-*\Y[J8QYCTRIZE'E?[P0YQ_/]PBR\NGHXNKL^.S3T?G5Y8ITS$>F#SDFM\A_4/J3 M1"_1"C(>(V-UFR)AC="KC:;LH!#4MJ'YT$)X/% %Q;S BC;(1&Z@=)U8=\BH M@F?69HL?DEG-]NL][:=QZ.^H[S.:[X06V/PKJT(=VVC7TR(OSDFT 4_;-,O% MVY0/Y]/>A]QWZ[>&!$D?8Y20 \VV%.KDSD#:@:K[!0DJ2]H2J,6"X[;+PQTX M7]0T10"S^8]*A!V;W4+2AFMKU1#PK9@N2+O@-%#TE7'F <)_8,:HS.YP\1?/ MB09*.^GE%$1!F!H!\$PIA=UIM4I-RX[<+S'J9ARPB];# )O)DPZDP+7ZO"UG1,J!(T2KUVM:TG2T4XB>?H/%*CGS?1F+;:>\T5\'08Q'GJ MBO3G2V\>L4:L0<@X3]WU]_V5GDM(][W6_:(Q9)GKMM>.J%H\4$@\9'22(PF] M9CKJ,C5^VO %^!-R94+Y!\Z'V6EB9&T/;^NQU@:N?IN>#;5BMXQ('/8J\[FD,B+DO29#&BZ6Q@5SRQ$]@P%U@D">4G6M(N."MY:QKGAB;Y'9 M+DY[Q&HKB?8AN[7#=^YF:K<_U2S)TS)C'&+U[*J9XG5/P:R"3>A 5HT):&\M MG#F6M:%NX[=#Y0D!C%P;AF^_J1"%BN-\5BQ\:N_!IW7_SIQSO-/8Y@87QKH6 M*B$L+/R52,J.,Y7?D6(L*&F66SD*2NP@F4=%J>,=LRBS5CR-FE!:P 8*K9R* M\M_C0:LO\[.!6H1[CNERU^BN0L^TYQHCY/(XHU1C3#U2A&VV5=OH M4J1BF-[JRQ6K&ZX8[N)5]L8U&F615\ELI.Y?'LGX+W>.-MB:(D/K]9^V,Q-7 /2G46I5_)KQ7E# MY%I3U_MAI+,9?WA^M'=L' ]G"6CM2N (1P0)(8.VE)DM4+5'O+,5DF3K:EF170C)<'B15( MSYS>W48_5U[-RH%V=%4/M%YGO)[,CIHT*#.F]0-2V.'!0:\CCB[/CDUM<+-Z38TY?',2C9XB/BG,3Q1]%[L0\BZ* KCIQ_+E2@M\0&@E//.2D1 MWXLX#O$1M2-Q8K+>;=L(-#!PZG75=DMKRZ U+\F6'1)W4-L4E3SQ3]+HY"WN MCDQA^TC4=2.OF>J \&"(L<;%20U.@A\K18Z=H\\GO8,.$):K@&L;PP\P*F_5 M[_IC:4&>^X]E6>&GCW#_7^U,Y3T,5/9P, M(CSV6DU^"V#SRG]BW3SKD97UG'>_Z36&=]MS]TSR8\&.1!,#I IT5@>84KCG M#D@>+M;'HI&R@TD$KI:65_1G-NM\"%'=,P[40F8+$-5I8EN(%0)KNO-Q@[2X MB@I0Z#!U*E3V&W/N2LB;-,I$7 I5D.:8@>"*]1DK'(I5!2".B?;?#TPV":=? ME?A\F7&%/ZRP7G@'CG4O(H'T_OUWA\^?OROX/RSU1O JE?#QHO?X&J:9JZ[X M;=JD>87\ 6>(1*9]F< 0@CMHBH$D"8R7$V88'\ PLI._?&Y]_S&_?V6>>\U M/*HQ?JY&5+CJKE*?VI@WT3(&@EBY8R00:B#B/F M.GL'(^-5F]UT&OJM>WCX#W_K_GQE++?WF4J 76* "AM(PPRP0Q3U MTZ-4%"HE_J<4EN]UK1GTG13[&,\IX8<7U@!9W- 9PEW.V5 AH=C>@LKUAGQ/ M56N:(G:$85O=KI$DHRF+0Q8!@9VI,2*5IN-YYV+'$Z;4GD9_SATY4%JF8Y5P MTRK,\(%_Z40P$H! I1,ELUW.\X7_EV";9NJS2\G U,7Y/.V*YV]ZK^JUP;U( M4\1.*1PO4T69U=Q!#8]NA>L]^^FL,!V+VCM2ZX05FQKHNRXTJ9O-DGBNG'^B MS]89EWYRM"[(/R6#AM2*2N]<,+"\G!B=$U3&-.Z 4IBQA)0"VY/2DIYB/9U> M;P6QAZ=J"OYR>O'AZ/Q?3]T6G*5-K(41N RXQ>:I-$OPWP&?1 T$'6D,0/I* M_7M!@ %C?O[JQ;O>8>?EP0%*-DYJY1*COX!V#]Q1AQ6"+,WS/>X6+<:2480D MZ/K&-P42"<1D,70P$!Y"O-=5]'Y&\;=SIPSY&=>?HZS4"VRVBJRY)^N)D,Y? M1C4L7'D[4N08Y53W^MDFFG=-[RB.,>,,@8T?5!S2KV%QF$2/3D1 ,0>:&TO9IIZV#VF'9KI#I_9I$-Y-O76Z_;RW3%$U5B;?JCX85=3$?$ZBK"?.W=[>=OMVX&YH:@*S,Q?TU!L9 MQ:92/-S5H:$+*@+))G]7+(RN>AK^^0=JL7=D@+ZG_SFD3:7OX[SU!F(EPYPA M+OJ.Z-*6*JP"^$PNN.32+.,4^(BOI,(%P':5&6FJ4]S?B5*Z^@L1$4H39 @?Q,F!# M.:?%X>"P48-,CK!+69V-DMJ<*>15&ZAU.[K@0G2LFL/J>#5UOPEE$N0%]5I "V'@ M-JX.&'J( ZB@\BZ^;ZOT_3F^*X>LXMM\S154FH3U%7$_894JP)D MKX?D67,F< _E^6Z>8!VWR:3FN#4N6?))>M]Z/N:YDFE6 M1BF,,N._=>ILOI@?]BEI;G]R/0ICL$GX#;?F04'M-5.EUMSZ/Z%6YG Q_+T0 M'^T-L5Q+3$N5"?4('>0T87KK?4 UUC =E\JP$E;N+*/V0*:46&OFD\\+*45% MU_VJ_=;O>]J2=:RU%;KUNK9CKB=!^#[,TM,JB2N*JVLCX9 C+IT'C_>FFK8W M:6%9K BXD('8P9*-'8V&F%9*4A5!=[?3-N^^POA77JU2Q$K3-2?Q9+J,'6V* MG\/C:R[3DK&?5ACI\-OT95CWK);'F8>EU/OP@.D>H$=9BY!K-B''Y71A>I]O MJ:\1&D/:A$)+#VT\SE)MY0:9#VF#5;_+H=QDS^ M,KV@Y.-,]K[FQ$99Z&METTB1R!&L[O=@_#N._GOO]]Z; RP,*N?7B?\N05-Z M@N9.^^[T>'>VME#5F2/VQ7SNG+JCHRV'1L<23:*:K@^A?35U3PR1GZ[ <@)& MS*@/@N5Y+Z]WMV&M0(^!A_ M=T#+7MG9S'IN@-P\EW0JC&!F3NO'SU=_$[]^O#A=<=!O/<3NG?*B<91K[R_; M/&Q<56(L5GV\#F*:3][,*/"/'8WU4ZWQOC8\N!&:BP)W_7KHJB@ZXAG+) M=A]/&0_8E[%M4UH9Q8!D?KWXIT ,HI:)5*4'\Y% B-\@:@A,Z!&=3I0TXIR[ MIK<5O6T/>[-273"-/))5W%%7W+'#]6-]BE+SL5,X-TH>SF)!NH/2KW#.83I: MS\U>9Z-HC@SD3:JIMU"FV@>)+3U::\9<53BJK>Q=8.8KW.RS0FD"19P-F&%! M>J- :G,CLC'6Z\,V1BC4&C_C+#WX*:%6-8C&M; R<:\ZF@7^AB?^!O_Z(/^ M7[B UP4&HDJNNW@,!YG"U%IQZ[-([V\?+H[K&/4=TVNH,"!:IQA4OK)@6OO] M;' ^.[[U[F.!UU"-$@PIXA*^*#6V'T6<(VYWQ:2;VVV1US)*? ,TI9T"*:EON?W""2/@KY"SA ? B>Q;UYT&8L6#SD:=U3,%!PEZE'C,%\ MVXZ:K='62@A;:)V/6][B$KX5^QHL!TIF%Q$OM8_&"^RJ=^(7QE6 MT7N^\V77#&<1A$=!L=O",AH=?QIIGEY91IW\Z^A[U@4WR'2MTFI_E)=YB:." M&HJ)(P;OARM"@M6\PYL'<9G(]C'S"UN*.*W5,C[3VB&J2IU%)J'W_,T!YJS8 MNE*H:^M_?N[^VK5IJ-6#-#ODK4(++.9N^>K]FL16JNN#=[CWV@_#XW1;S.DKS, M&-&<)AQ\)6/5*B\+^6Y TIP=3^_W]CC[H76I-9O5KA$+H."@D+JS:^4CSO5J MO>E]6M=-Y^A!DH=]-B433J X^K=\RMJQS80=>K7+YK=1";TH:_,MU>!=ZO.R;=\03\M+OCTZ=$E58QFKJ=:D^+NZ.O*YM$\6'!P3NGN,]3^FHA F""AJ(2TP& M!%6VR,K@3Y+_^1@Z(!>?Y): UNE*A3%UZI7GS*5.]O*KLMJ*I 9 J Y1#%"Z MGC)&#)GO33%M&Q7VM7>P&&9I>4W@7VFIH)82*G/MJ<_?KB,Y+.8_ M?-U]]>91SW]'[E;8G)ZKZSG^[*?/8QWN]0Y2,SXZSS&HP[I2I77\'1(AI8-J M7R$^;)EEW"]+:Z_V?"F_HR3\U_0,8.Q"1MZ_>K2\,(4&B4ZI*U7[S"35<\]+ M='9&NOHKMUH">D0PFT782&P75"C4>;3DU1CK4G MW3MENZ4[MO_:[(7B%JYBB33NKHT7H85GW,U^45RP!;,TCMO+1R+3ZF@FEM4; M^Q#M\3[M=FPHI$(,AD*)7"W;"E402;(X$K145LZ, 9A".!1TFUE['_%<49\;8-2HQG MI;>:;95]]GMRX7ML8H;Y_K)2-4?"*6:)FA!Z!"F$JOU,X8O3PEM5MICHTLOD M]'.H&*/2BJ/984,;,>1H$"]/$[<6UZ;T+]XX5,E&5D'PJB:0?&8WA$1P33^> M5-#!$9<-ULS8UNCWUZH9O\^\ZTO9\,L1+'PY;*IF7NMWH8I]4 MGY>88()UJ?FV80].[LG2)K,JQ.V3 @[I>"Q%WNR8XQ360-/D>#'_/9OPDVH4 MG"+5;'"4Q-6I,5Q;!?8:37:X=H4+>IC:7?V(@[/DB(=5FZ)=]5:=Y@I4$V%DP)ID.Z4=1-*.$ 'X(JN,Q'M>9Q[P"XL2$/KQ6.'X^E#*XWSU_H MGU[@DGH'_9=[/2!6E(&C,KZ6KIXR<03XW;*K<3SZW;QJJ*OIT\S&W56)R#/9Y[/JD^J6?1J MF5CVU;C/-R.4\]*$D)._.&M'^N$'?E," 4>T<3I_/"B M;=NR*V!BKYIJ!N9&D8ETX:X9!'_]XIE.YI%?/FO[9>^7KHNN+E!7\!E(#1+- M7GL-K^G]W$"N:SN,!%F8ZXMVBI1>,#AQ--QI%S,ZX:&DDUBW3G'T]T2**2=N M))B0X<';[-=*L)Q0[HZ$UB()&ZDN6[1(LVHFBG("7(>-'UMCP;4[!RLT' E& M6H6X1O;+'ROZ$<+ OIQ5QSBA;!$.:0(*7<$Q M:3"M'/)>,RPI-N.CHJ/3.;^+Z8AJU R\H.VGG:_K'IE)@WRD\D'S2^VW4[: MK5!B*_W;MGU%8P*1D-CZ9V@4!=OI]*G22(S18#I2E% C"%3;MV]W/L-M M9R[R($C-)P;IU4%PW&CE:A(Z,Z7&(P9H)*0!Z,1I."@"QE2*(\HGRWJ*"2GK MF1^=.+DC.254N0 +$\.I@K"\::$Y)3HV[F!@<.QXTA8$S0HY"26$@8/0Z47W MNG]]>^(4("]%YP)>!_G[2^.LM4%193#667W5*+9A/1>71C+0\9%*,^A,1"*K M2N236*_$M].AL5:'30UQ]&;?E/!SGY*/LPF>:M$J"% JH02C! 6I1AFM4BS- M5%OSF&IP+382I^N 6)4Z6$HM(T'!J^VQN[_\? +L397KS15.( \G592H M.M'[7%:N]G;Q:W.N5!(A-G?JG2^9U:-7Q@3GWS.W52R#YQ0Q?IM*J@B-;$9F M$[ >-_E96J1HNXWGU;G?D^>U@RB6KPZ:1\E?[4,VN39"Y '/#%S6Y'B+7@N-4TP@-(@H\@GKE MJKE5KUR5Y867E[4+U>3:Z$L,I[C^XGH(G5L0Z(RJ2,Q +E"?)E0#J1VHIM8F MR/2D6;@XJG'['M%V#(S,5\W+FAT;=5574_;,!1]1]I_N&0:VJ0F M;I/RL32K!"TPM%(JR(3V-#F)TUI*[,AV6\JOWW52IHXA1K6'L2?']^/<#6(OTU.X7-\.8+)UY/1Q0 3!%Y&'Z%W7A?$Y#*18,&68@L6^U_9\[[ -KFL#$IFM M<-V)*M!F5;!/CF%WQJ4%GXI0\>G,]$JJIERXB31&EF&[^FDQLJJW=087&1,F M;+_KY5(8=\EL;IC((FL,.2UYL0J/%:=%8]'\GH4="]!L;?E02%5B0 UI[+'E M:$"K8$W4@B( UH%UH-,_O9OQA!OP Z\3D:K_M)04R3'U2(O_ZL1@HS16!IG# M!7*H6$T$KMF4:^3/,IC,DX*G<)RF^MW#WH9ZF.JA6>1>N%_I_&60;KN MIY%@4#$7J5255-2^!9"L0+$# M_W@(5&3-=C\X.NA^ (P^P[IPXQ[5OF?A-M!L^OYF>F ;(N<*4Y$H5LXP*8,S MEJ@Y52OPNRWPV[[?@B4W,XS2%?;N0:#5*PO>Y.1<4)'B06\*0?2G^UO3MA@L MSQ&1+YA@NH[G]NKBTVG1C9(%2'S,-M ;I@CE;7G_MQR:F)=,PY@MX5J65#P> M'Z>_)Q)=]5Y*PE;<9+!)ZE^/+M$$ODPNSV$TFCQ][UXS^PF.0X'CU((KO !2 M-,_*;R/\C#!_:V%;#$=$UG_=B*S_[C\ 4$L#!!0 ( !R"6%2]AWA!*@D M (M4 1 #,Q,5\Q,BYH=&WMG%]SXC@2P-^W:K]#+U,[E50! M!I+,[$$F50PA.]1EDQ0A=[-/5\(2H(JPO)(,83_]=0?FH5VM8LW#P M-NK;N+$?Q <+/?H&F9+#J&[D<'3=X?-4F JJ6^]KQ1?[K:+XTRJ2(O5(FS%3 M:>..YFR !5@:B51JPHQDV"-D@H6#]N=/G8^='NQ4R]5O,JC'E%X<\/*(G[9T MB-T(LSFF;K6[O\4NA?'[7.H[K!2=7>+;4/SY!"J>SP[NC@Y;'>A]ZD-YVB- M;J?7:9__.'9H?VY]:I[\WH9FJT>37_W7SFX1FN?0/#P]Z[4/8=%0: !_D>Q4 M:B3K;=+L?FR>M,]+IY^/VW_.6ZE5*K5O8Z.G_>$C=^D7]?B,2<@F,#/N5\U+ MIPA=-I[!$9[A10@1,G(P S=BKKZYHUJ<%2XGX*^'#P4E!JZ 18[UE8"^-ER8 M#X5* 8>ME(U9**/A]7',.)\?STV05BF%6BD66U&??VG 5'(WJEKXWI2#I1HJYIF%/#XL(#%S/IOG0IO[L[!2L9$K76 MIOZ&)4ZO;E0E'-Y,I\')'WP\)S_8)?XK4E\8"KN MG3:LFIEJL86L6L7_/2#SC-E<;JX#(S818,1$BJG@Z.JEA684)4Q!5\3:.- 1 M'*%)H%HI_1OT ,[#D7G[IK;[KD$>49@B=**PW%B>9_QGZ!]Y5_Q$QYN[W^]] M;>;N]Y6YWUKN?M?:_7YD%ITN>EA\Z+[$NTL)/A3%U N;U/URC2U$VD&([3(9 M 8MFD$3.) (58$Z,\0F;_#*#,1ZA%14,6(A%!O18.G ZE;LC$(E06,O,C$3& M[%)@OPMM6BSCJ QVJ6B"J0\2"*4)DS&*15@=-4$G#.@DPA'8A/[=U)\*([)& M: !C:95@Y,?10[L1#M#&(O0*4KLQJJ8Y#G."U3CT9XMFR/&R ?=>CI=7AI>= M'"^;B1+<_[]LUO MM>K[ALUPD2T5T+.]'@PD'F[9;>^6.\",\ ! AR[)?Z(U05CRI=*.J :)C3&T MH?"&CKFTH=(VP7H4]!BM4A+$1H>"8[&%+73\7"!)4N_>O@I'+!H*:&(\T4T4 M2OB5M;TMD6KA5];H*#V4M!84I02B]H&"C@4PI: @75;N:'"KHP%V1.-[MKX&QS!.4(>MDAL1Q!:XV@0V'1V.B)?:;I:4P4*0D6LL2N M7H6R47V!+C_K*(5F"ZX8# MQ2R0HI,2@Q[4Q6HE.7->T;Z57.($TP!DFH;SX5M$+2664F.>NM;GT7QPHZU MA1P&4U0I9@BO,%&,8C($;_U!0EBV(3U!=_HE%O.J)Q1 M/R:C^CFC-HA1*P<:=U"U>HBR,K&0R2 MK"^5=#/*NMW7+7'30\7S(D7>+=&%E2 ?\EUE XH3$R.OK,\2ACAEW"O@UX2& M(A*&*<06GA$Q\9!$DLBE:$)NRABCKAQ.FW#GYG!Z97 *GA_>LMGD58$2,>FZ[J]'7B'M9@E;B.74L+ M6K(:/+V# /KSQ3"/5Y%: O5I4.,Y3C;@7LMQ\LIPPG.37%Q):][0ZUM9A.?W(C;\]CK:>>?W1:=Z;:=:C9B]SOY1U.*!)K@/Y[P]LE!K!DI> M"I7MM5N2+WZUB38>8FOBK7.&Y0Q[V2'MY0Q;:X9]\;8&_\,9/B=@\2:^H'!G MD4(WH09QY!D9P3OK1M?:L81+IXV]3L+Y FQR/)8X:>*18*ZOF?$1$Y>HGV]D M"UF%L9.EV P_Z;*8 U;\E4A4W\,TB4*_*V\[W[VP";=A3II71II\]\)ZDZ:I M%- :C420T&8PVE862H%N/TN@7>\BF IV21FQ=(W$Y\3\ZH[_3<]\=_2S8)(M M^*=;\>X)21C'BE9<1R0/@B=;$\(JAFR*W/-I.6N+8),Q7C%H&C^8+!*\=Q_Y MZM'*\OL&Z%KTDW_W_0,O\R(;>CF/F7<:LZ$H]=%@ER4V0$O7F9JRF6TL0>>? M?]E.SM:S*::#41E-^+$ 3I[VQ-%AF*<:ST3.#9Z4BGL2"[17>D\8LD/^]<>"MQ,G^_ MT7UO H)#G.$Z'(F^2>AWS[7=(M0JM1J\Q)"^Q(@OP?$5,;ZW1/%;A$I/9GXM M2$7NH_W#1J*Q92ID)>>THQ4JY?=[L8/Y[9;#:9HL M@ZVS=,<6.K0[)[?O&&[M?-HWCS;V@^R-G?M!]FK0_P-02P,$% @ '()8 M5.=R%+,A"0 @E0 !$ !S9&=R+65X,S$R7S$Q+FAT;>V<47/B.!* W[?J M_H.6J9U*J@ #26;V(),J!L@.=SF2(J1N]NE*M@2H(EM>289A?_UURX80( F9 MR>[ Q'D(6&Y)K9;=']V2??IS^[(U^/VJ0SX-_G-!KFX^7G1;I%#RO/\>M3RO M/6BG)X[+E2H9:!H9886*J/2\3J] "F-KX[KG3:?3\O2HK/3(&_2]L0WEL2>5 M,KS,+"N<_>.G4RQSGYPR_+3"2@Y?#!OI$O]R5*W]KUHM@Q2<\^8G3[VY^,^E M$NG]1EHJFG!MN2:3DW*E7"N_KY!2"05\Q6;P^=-I3(R=2?ZA$%(]$E')5]:J ML%Z);2,KL2IVAY9_L241,1[9>N67QE!%MC2DH9"S^D"$W) >GY*^"FF4GC/B M3UZOUJ!FX>QMY)NX<>K%9TL]N@:I%*.HKL5HO.CP>2I,.=:M^TJRY7ZK(/ZT MBJA(/5(ZI#)MW.*<#:$ 2B.>2DVH%A1Z))E@X:SS^5/W8W= CJKEVE\RJ,>4 M7A[PZHB?MG0 W7"]/Z9N=?J#[GFWU1QT+WOD\IQ<];N]5O>J>4'.N[TF?(5O ME^<@T>G_.*.^NNE?WS1[ S*X)/V;B\XUJ1[14O7X@!Z29J]-JB=UDV_.^AVKG\<.W0^MSXU>[]U2+,UP,FO_O/HN$B:UZ39OKP:=-ID MV5!@ '>1'%5J*.MLTNQ_;/8ZUZ7+SQ>=W^>MU"J51V[;;['1T_[PD;OTJWI\ MQB1D$Y@9]YOFI5LD_U).!Z M1MU7KN9WZU.PE2%!:Z7K;VABU?9&E=S"_53*K'3763:C+=#2U^*QWPSP"X?M MB56><>E^BP$+9Z^-G/W^\K<;RUWOSOM?C]2 TX7/&PX([=P=TG.1KR8 M>F&=NE^FH(5(61) NU1$A$8SDD16)QP4H):'\ L;_3(E(1R!%249T@"*-%&A ML,2J5&Y-(.(!-X;J&8J$])9#OTMM&BACH QT*7&"L0\4"(0.DA#$(J@.FH 3 M)N D@C$Q"?Z[JS_EFF>-X !"822GZ,?!0]LQ#-#$/' *8KLQJ*88#',"U1CQ M9\MFR/&R!_=>CI=7AI>C'"_[B1=.AB("!XXLN'/816 +B,-IO71>1&A+-Q3X M'LB$09L A27O7 2@""UG) :?CCA"3$EYQYO,U9N5K@%IS"VF%%$BD2 D%% M M>=!CU:R90$L58!9U!LR $X?L:! M)*EW[WP)QC0:<=*$>**?2)!PBVLG!SS5PBVNX5%Z*' Y*$H)A.T3##J6P)2" M G79NJ/AO8Z&T!&.$*2/'(M8.+ MXW>!SG*PI+FDCB%9@NN. \4LD,*3 H(>T,4H*1BU3E'?""9@@G$ (DW#N? M MPI82@ZDQ1UWC\F@NN%&&@T(6@BFL%%. 5Y!(BC$9#,LI<9=B@QIIPFXYSPC? M?(Z"$#9!?<[V.N66,RIGU(_)*#]GU!XQ:NM 8PU5VX5PVH<[-X?3 M*X-3D,-II^'4@9E(7)2!GIL/ASRP8@(^UVQ87%FD^+:(FM+#S>LMCD50$2(> MDZ[J^"JQ#VNP35Q'%](6 'T:V'B.DSVXUW*4:$@SDV%02)1K^^E-#:T&JHC(5R?.(' MVC(!-/1'0MT#DPZ\<_NB4[T.4ZW&U"RR?QBU M.*!QYL(Y9X\LU)H1*6ZYS/;:K<@7O]E$>P^Q'?'6.<-RAKWLD$YRANTTP[YZ M6X-[<(;-"5B\BR\PW%FFT%VH@1QY1D9P;=UHH1U-F+!*FT42SA5 DV$H8-+X M(\&HL9L72-Q.7$ MW.J.>Z9GOCOZ63#)%OS3K7@;0A+*H*+ABXCD0?!D:T)01:--@7LN+6=,D9@D MA"L&3.,&DT6"&_>1;Q^MK+YO *]%-_GK[Q]XF7?9X/MY]+S3F(YXR0>#W9;H M$"Q=IW)*9Z:Q IV__WT[.5MSMN9LS7==_%UL?<[\/&-.O@^&HQD9:@B8B@!% M[L(\P*I[0#7C;S%-[8EHHN2$8WXO A"DS]GJ+#+D82S5C,/9Z5BEL2"]1W>@ M\8LD/],BJ55J-?(2(_H:&[X$QK>D M^,D*Q.\!*CV9N34O%=D$^X>-A&/+5,A*KG%#*ZF4WY_$ELSOODSQ1TR;':(Y MW/%]6V/!=[Q^3GU-O#//>/??E+7$A*\RWKZ9X>V;ZKM*HS46?$C.%Q[K,DV0 MD8.K=)<6%*V=/%PSU<[YL;\\PCCULA=UGGK9&T'_#U!+ P04 " <@EA4 M_V%Q @D% #O& $ '-D9W(M97@S,C%?."YH=&WM66USVD80_IZ9_H>- M//'8,^@-;,<1A!DBY(:I"PS(;?*I<\'P[3M7QN^;7?#;CEQ9#DN MA)*D.5-,I(3;=M WP)@IE7FVO5PNK67#$G)JAR-[IN;\R.9"Y-1*5&*T?WC1 MTK+B3DFB[XHI3O%+GDRE2:\:=?>W4PN5<,I>S[7LM?9+TX3^C^"+]))*125< M'EN.5;=>.V":6B$2R0KO+UH9Y&K%Z5M#T2ME$LZFJ2?9=*::TYV+5$B*X;%"I8F-%6>\ZHY$:DREU2O]2+!DU(P(7/&5U[(YC2'/EW"2,Q) M6L[E[ _JN74T50ZU(UXJY)SPTKC2 $Y0@-*4EEJ71#*".T*E:+2#JQF+F()& MW7);=M;^]OM\;=LXA^!#X%V'OEP#%J!&,\.D8C2\Z_1#" ;BG M<&&-+=^"<> 7B]W&L5.#SA@ZW<$P#+HWU-=*;YP3O4OX/H!Q9_2NTP_&YN## M>? 1.GZH9^J.4]^"=^2B$S1!+(-];623HN8@)I1&!,9D93FYN"*TQ5T8J5G=%IJQ?P" MHY8YUCJ:$I,)B[$;H<(XGLG]O?K123-AZ93*&O32V((#O61_[[1>=YJ^F&.UWN<2,!>K$J)CUY&DFVSR&8JD!639X+* UK!MP!H MM%M:=1W7_;M*0F,AB7[NRPW?D?C35 I\L,W-,)XDI -VV+*U>OONI']G-7XC MBW?DXHMYPZ455)L6JF5.\;E#YP'IW#:G^SF)X[*58YS02=,%X3"BF9!(%2F< M(1S@.N9/:T:I^CX@?L5XPO(85ZPHD4"Q2R?0I3&=1T@D#;>&5%-W;_!&:?J: M-B8+SI$UT"A'TL#>J6:%64E_7S!)Y]CU\X*1K@GP@!P"[GTM.#Y(#DM*S-!& MK/MY[9K^:+R0>,9'R\%5/"/(96L.=-\TCLIE\\+M)I TV:Y6O$A]T4;QCOSQ M(.JJAKJ6/??8:IR^VMGIYCNDLBW4-F#]]SWF_QR5[1"5_ZGL6ZAL-USVG(K\ M^7$92S44A2?(*:DB3+_8L+0@@XK4)H1)I)Q,TER32TU/$\X!EU'$C2/UY!F2 M2UZK^"TE::SE:# I?B_23*&U%KSD)I'1,OI\BR2M'?/)T[X:/]V.3_,FWL6" M\.",1G)!Y KJ1\5II@Y/A>$N*/^>C'^\1?@WV*R+5ETMQN37]ZPD",9Q8SNTKM/R(&G/GCWW/=]*U%^V!ZW) MAV$'WD]^N8#AY;N+7@L,T[9_K;9LNSUI%Q,GEN/"1)(D8XJ)A'#;[O0-,&*E M4M^VE\NEM:Q:0L[LR;^[CH5<.&>O)^OVFOVE:4+_1VB)Y(I*125SQ)=L%JO:G,@92\Q *"7FOI-N*$JD^3!?P9*()LIW M7M6F(E'FDNJU?B!X5!"F9,[XRI^P.WT\:7G0K13"H?Y]5? M.;'M\;9;+LHR&H=)D*6UO\>J6['^K/CKH7]DK%N=T:37[;6:D]Z@#X,N#$>] M?JLW;%Y M]=OXB,^#;K(T1GA]AB-+YO]"4P&X+Z!2VMLM2P8=UKY8K=ZZE2@ M.89F>S"<=-HWV-=,Y\Z9UC)YWX%Q<_2NV>^,S<%O%YT/T&Q-](SG.+M)WWN* MOYK0!VE\;9V=OWIPPLIDEXGXIAP.%S);( F4V$X+#76K*M-",B"12!6-(-UB M7S/IM(@IJ)C"F,B )#0S!]>'!&\]S:BTQ3TFRRD=N[1AB*FFP A2@V)31 MK*(MBED&'Q.QY#2:4:V1*']/V7E,243L"O*=_=;@=*H,)"D2< J!D!B'MX9C MH .<9RD)T>_-."51M!ZO[2Z6F*'@G*09]=T@F\)H-&H:]:U7_?O*A$-A21ZWQ<* MWY'PXTP*W-CFMAM/XM(1.Z[;FKUQ=]*_LQJ_D<4[$PHJF0"!4)=#$.H$U#.@\02*IN!:'&>(&BB4(VA@[U1Q+E;2 M/Q9,TCEV_2Q'I T 'I%C0-T;PNE1=%Q 8HHR0MW/*QOXH^%"XB$?)7>NPY@@ MEJTQT#VOGA3+YKG9-2!)M%NM>)'ZHH7B'?'C0=!5#G4M^^ZI57WS:F^GF^\0 MRG:BMA76?]\V_^>@;(]1^1_*O@7*]H-ESZG(GQ^6L42'(K<$,251A.D7&Y;D M8%""VI0PB9"32III<*GH:<(YX#**<>,(/5F*X))52GQ+2!)J.@J,\@]&&BDT MUX(7V"126GB?[8"DM6<\>=I7XZ?3^#1OXFTL"!^Z-) +(E?@G>2G&0^>*H;[ M@/Q[(O[I#N#?0+-BLNR =L'RI8/!W4'2OI4FE)2QX"P"QWI]FBI8[^G2\'L> ML/3X9JPUX0GKIQY(L!MV9L-/@G*XH(' X^VG+?AX5/">6Q@.#]PSI]:*&9U" M=]-,!^7'IJ.A9$A)D71K\OA6J/YSG;-NE_\%U.WR3X<_ 5!+ 0(4 Q0 ( M !R"6%3L\B9+QT *1! 6 " 0 !G,&YA,71F8WHU M=3(P,# P,#$N:G!G4$L! A0#% @ '()85#""/VU/CP 2)T !8 M ( !^T &C5U,C P,# P,BYJ<&=02P$"% ,4 M" <@EA4GIG^V\FN "?M0 %@ @ %^T 9S!N83%T9F-Z M-74R,# P,# S+FIP9U!+ 0(4 Q0 ( !R"6%0TD(GX,Z$ ,W. 6 M " 7M_ 0!G,&YA,71F8WHU=3(P,# P,#0N:G!G4$L! A0#% M @ '()85 _&)!YD@ Y*P !8 ( !XB " &C5U,C P,# P-2YJ<&=02P$"% ,4 " <@EA4#F_GUGQ% 2:0 %@ M @ &/LP( 9S!N83%T9F-Z-74R,# P,# V+FIP9U!+ 0(4 Q0 M ( !R"6%0+F1;S]K@! #-X @ 6 " 3_Y @!G,&YA,71F M8WHU=3(P,# P,#C5U,C P,# P."YJ<&=02P$"% ,4 M " <@EA4H6KJ>L$\ !820 %@ @ %*X00 9S!N83%T M9F-Z-74R,# P,# Y+FIP9U!+ 0(4 Q0 ( !R"6%2.#9[$RU$ %= 6 M " 3\>!0!G,&YA,71F8WHU=3(P,# P,3 N:G!G4$L! A0# M% @ '()85">\O^*K0@ U$X !8 ( !/G % &C5U,C P,# Q,2YJ<&=02P$"% ,4 " <@EA4WB+OC_NL "FQ@ M%@ @ $=LP4 9S!N83%T9F-Z-74R,# P,#$R+FIP9U!+ 0(4 M Q0 ( !R"6%3GR*DV!"0 .LH 6 " 4Q@!@!G,&YA M,71F8WHU=3(P,# P,3,N:G!G4$L! A0#% @ '()85-YFZF_E+P 0C8 M !8 ( !A(0& &C5U,C P,# Q-"YJ<&=02P$" M% ,4 " <@EA44PSBJ/ # @#D8@( %@ @ &=M 8 9S!N M83%T9F-Z-74R,# P,#$U+FIP9U!+ 0(4 Q0 ( !R"6%34&XZK:] ! %H! M @ 6 " <&X" !G,&YA,71F8WHU=3(P,# P,38N:G!G4$L! M A0#% @ '()85/&U.K-HZ@, $/0$ !8 ( !8(D* &

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�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